PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA	WOS
J	RUIJS, MBM; KEYSER, A; GABREELS, FJM; NOTERMANS, SLH				RUIJS, MBM; KEYSER, A; GABREELS, FJM; NOTERMANS, SLH			SOMATOSENSORY-EVOKED POTENTIALS AND COGNITIVE SEQUELAE IN CHILDREN WITH CLOSED HEAD-INJURY	NEUROPEDIATRICS			English	Article						SOMATOSENSORY EVOKED POTENTIAL; CLOSED HEAD-INJURY; COGNITIVE SEQUELAE	BRAIN-STEM RESPONSES; POSTTRAUMATIC AMNESIA; COMA; DYSFUNCTION; ADOLESCENTS; PROGNOSIS; SYMPTOMS	In search of a prognostic indicator for residual cognitive function loss in children after closed head-injury, the somatosensory evoked potential P300 has been studied in a prospective follow-up study of 17 patients with mild and moderately severe head-injuries. The P300 response was measured in the acute phase after patients regained consciousness. In addition the duration of coma and of post-traumatic amnesia were recorded. An age-matched control group of 20 healthy children supplied age-related normative evoked potential data. During a two-years follow-up period the presence of residual disorders in various faculties was evaluated at fixed time intervals after discharge. Correlation analyses revealed that, where the duration of coma and of post-traumatic amnesia qualify as general predictors of sequelae, the long-latency somatosensory evoked potential P300 correlated specifically with long-term deficits in the field of school performance.	CATHOLIC UNIV NIJMEGEN,ST RADBOUD HOSP,DEPT CHILD NEUROL,6500 HB NIJMEGEN,NETHERLANDS; CATHOLIC UNIV NIJMEGEN,ST RADBOUD HOSP,DEPT CLIN NEUROPHYSIOL,6500 HB NIJMEGEN,NETHERLANDS		RUIJS, MBM (corresponding author), CATHOLIC UNIV NIJMEGEN,ST RADBOUD HOSP,INST NEUROL,POB 9101,6500 HB NIJMEGEN,NETHERLANDS.						BENNA P, 1982, ITAL J NEUROL SCI, V3, P281, DOI 10.1007/BF02043575; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; DELATORRE JC, 1978, EXP NEUROL, V60, P304, DOI 10.1016/0014-4886(78)90085-7; DRAKE ME, 1987, CLIN EVOKED POTENTIA, V5, P19; GREENBERG RP, 1981, J NEUROSURG, V55, P227, DOI 10.3171/jns.1981.55.2.0227; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; HUME AL, 1981, ANN NEUROL, V10, P411, DOI 10.1002/ana.410100503; JENNETT B, 1975, LANCET, V1, P480; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LINDSAY KW, 1981, J NEUROL NEUROSUR PS, V44, P796, DOI 10.1136/jnnp.44.9.796; NEWLON PG, 1982, J NEUROSURG, V57, P168, DOI 10.3171/jns.1982.57.2.0168; NOSEWORTHY JH, 1981, ARCH NEUROL-CHICAGO, V38, P275, DOI 10.1001/archneur.1981.00510050041004; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; PFURTSCHELLER G, 1985, ELECTROEN CLIN NEURO, V62, P88, DOI 10.1016/0168-5597(85)90020-6; RAPPAPORT M, 1981, CLIN ELECTROENCEPHAL, V12, P167, DOI 10.1177/155005948101200403; ROWE MJ, 1980, ARCH NEUROL-CHICAGO, V37, P679, DOI 10.1001/archneur.1980.00500600027002; RUIJS MBM, 1992, DEV MED CHILD NEUROL, V34, P885; RUIJS MBM, 1990, CLIN NEUROL NEUROSUR, V92, P323, DOI 10.1016/0303-8467(90)90058-D; RUIJS MBM, 1993, EUR J PEDIATR, V152, P844, DOI 10.1007/BF02073384; SCHOENHUBER R, 1986, NEUROSURGERY, V19, P532, DOI 10.1227/00006123-198610000-00006; Schoenhuber R, 1983, J Neurosurg Sci, V27, P157; SCHOENHUBER R, 1985, EVOKED POTENTIALS NE, P237; TEASDALE G, 1974, LANCET, V2, P81; WERNER RA, 1991, ARCH PHYS MED REHAB, V72, P31; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; ZENTNER J, 1988, EEG-EMG-Z ELEK ELEKT, V19, P267	26	7	7	0	3	HIPPOKRATES VERLAG GMBH	STITTGART	PO BOX 30 05 04 RUDIGERSTRASSE 14, 70469 STITTGART, GERMANY	0174-304X			NEUROPEDIATRICS	Neuropediatrics	DEC	1993	24	6					307	312		10.1055/s-2008-1071562			6	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	MP787	WOS:A1993MP78700003	8133975				2022-02-06	
J	Lovell, M; Collins, M; Bradley, J				Lovell, M; Collins, M; Bradley, J			Return to play following sports-related concussion	CLINICS IN SPORTS MEDICINE			English	Article							NEUROPSYCHOLOGICAL TEST-PERFORMANCE; HIGH-SCHOOL; CEREBRAL CONCUSSION; RECOVERY; IMPAIRMENT; INJURY	This article provides a review of current important issues in the management of athletes who have sustained a concussion during athletic competition. Recent research in the area of concussion management is reviewed with specific reference to the sideline evaluation of concussion and the follow-up of the athlete during the recovery period. The use of neuropsychological testing in sports is also reviewed. A systematic protocol for the management of sports related concussion is presented.	Univ Pittsburgh, Ctr Med, Sports Med Concuss Program, Dept Orthopaed Surg, Pittsburgh, PA 15215 USA; Natl Football League Neuropsychol Testing Program, Pittsburgh, PA 15215 USA; Natl Hockey League Neuropsychol Testing Program, Pittsburgh, PA 15215 USA; Team Phys, Pittsburgh, PA 15215 USA		Bradley, J (corresponding author), Univ Pittsburgh, Ctr Med, Sports Med Concuss Program, Dept Orthopaed Surg, 200 Delafield Rd,Suite 410, Pittsburgh, PA 15215 USA.	bradleyjp@msx.upmc.odu					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barth JT, 1989, MILD HEAD INJURY, P257; Bergschneider M, 2003, J NEUROSURG, V86, P241; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, VIn: Vol 12, P386; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; LOVELL MR, 2000, NEUROLOGIC ATHLETIC, P109; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; PICKLES W, 1950, NEW ENGL J MED, V242, P607, DOI 10.1056/NEJM195004202421602; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Schnirring L, 2001, PHYSICIAN SPORTSMED, V29, P11; WOJYTS ED, 1999, AM J SPORTS MED, V27, P676	36	91	93	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JUL	2004	23	3					421	+		10.1016/j.csm.2004.04.001			22	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	843DT	WOS:000223056700010	15262380	Green Published			2022-02-06	
J	McDonald, S; Flanagan, S; Martin, I; Saunders, C				McDonald, S; Flanagan, S; Martin, I; Saunders, C			The ecological validity of TASIT: A test of social perception	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; CLOSED-HEAD-INJURY; PERFORMANCE SURVEY SCHEDULE; POSITIVE BEHAVIOR SUBSCALE; FRONTAL-LOBE DAMAGE; RIGHT-HEMISPHERE; EXECUTIVE DYSFUNCTION; LANGUAGE DISORDERS; CLINICAL TOOL; IMPAIRMENT	The Awareness of Social Inference Test (TASIT) comprises videoed vignettes in three parts assessing (1) emotion recognition, (2) the ability to understand when a conversational inference such as sarcasm is being made, and (3) the ability to differentiate between different kinds of counterfactual comments (lies and sarcasm). Many adults with traumatic brain injuries perform poorly on TASIT relative to normal control subjects. However, the extent to which poor performance on TASIT predicts poor social functioning is unknown. In this study 21 adults with chronic traumatic brain injuries were tested on TASIT. The TBI participants were video-recorded during a spontaneous encounter with a confederate. Their social behaviour was subsequently rated using the Behavioural Referenced Rating System of Intermediate Social Skills-Revised (BRISS-R). In addition a relative or carer was asked to complete the Social Performance Survey Schedule (SPSS). There were significant associations between TASIT and different aspects of spontaneous social behaviour, in particular, the use of humour and partner-directed behaviour. No correlation was found between TASIT performance and the SPSS either Positive or Negative behaviours. These results confirm that failure to recognise social cues on TASIT translates into observable and reliable difficulties in spontaneous social situations.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia		McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	s.mcdonald@unsw.edu.au	McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			ADAMOVICH BLB, 1984, CLIN APHASIOLOGY, V14, P124; ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; BEEMAN M, 1993, BRAIN LANG, V44, P80, DOI 10.1006/brln.1993.1006; BIHRLE AM, 1986, BRAIN COGNITION, V5, P399, DOI 10.1016/0278-2626(86)90042-4; BLONDER LX, 1991, BRAIN, V114, P1115, DOI 10.1093/brain/114.3.1115; BOROD JC, 1990, J COMMUN DISORD, V23, P247, DOI 10.1016/0021-9924(90)90003-H; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROWNELL HH, 1986, BRAIN LANG, V27, P310, DOI 10.1016/0093-934X(86)90022-2; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; CICONE M, 1980, CORTEX, V16, P145, DOI 10.1016/S0010-9452(80)80029-3; FINGERET AL, 1983, PSYCHOL REP, V53, P1175, DOI 10.2466/pr0.1983.53.3f.1175; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Holland A., 1982, CLIN APH P C, P345; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kibby MY, 1998, ARCH CLIN NEUROPSYCH, V13, P523, DOI 10.1016/S0887-6177(97)00038-3; KINSELLA G, 1991, J NEUROL NEUROSUR PS, V54, P422, DOI 10.1136/jnnp.54.5.422; LALANDE S, 1992, BRAIN LANG, V42, P165, DOI 10.1016/0093-934X(92)90123-V; LEVIN HS, 1981, BRAIN LANG, V12, P360, DOI 10.1016/0093-934X(81)90025-0; LOHMAN T, 1989, APHASIOLOGY, V3, P685, DOI 10.1080/02687038908249036; LOWE MR, 1985, BEHAV MODIF, V9, P193, DOI 10.1177/01454455850092004; LOWE MR, 1978, BEHAV THER, V9, P535, DOI 10.1016/S0005-7894(78)80126-9; LOWE MR, 1982, PSYCHOL REP, V50, P83, DOI 10.2466/pr0.1982.50.1.83; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; MCDONALD S, 1993, APHASIOLOGY, V7, P535, DOI 10.1080/02687039308248629; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; MCDONALD S, 1986, BRAIN LANG, V29, P68, DOI 10.1016/0093-934X(86)90034-9; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; McDonald S., 2002, AWARENESS SOCIAL INF; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Moriyama Y, 2002, ALCOHOL CLIN EXP RES, V26, P1239, DOI 10.1097/01.ALC.0000026103.08053.86; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Pearce S, 1998, BRAIN COGNITION, V38, P150, DOI 10.1006/brcg.1998.1018; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PRIGATANO GP, 1982, J PERCEPTUAL MOTOR S, V54, P859; Ready RE, 2001, CLIN NEUROPSYCHOL, V15, P314, DOI 10.1076/clin.15.3.314.10269; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; Sbordone RJ, 2001, NEUROREHABILITATION, V16, P199; SCOTT S, 1984, J NEUROL NEUROSUR PS, V47, P840, DOI 10.1136/jnnp.47.8.840; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; Tate RL, 2003, NEUROPSYCHOL REHABIL, V13, P43, DOI 10.1080/09602010244000372; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; TOMPKINS CA, 1985, BRAIN LANG, V24, P185, DOI 10.1016/0093-934X(85)90130-0; WALLANDER JL, 1985, BEHAV ASSESS, V7, P137; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WEYLMAN ST, 1989, BRAIN LANG, V36, P580, DOI 10.1016/0093-934X(89)90087-4; Wilson, 1993, APPL PREV PSYCHOL, V2, P209, DOI DOI 10.1016/S0962-1849(05)80091-5; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889	54	91	93	1	24	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUL	2004	14	3					285	302		10.1080/09602010343000237			18	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	829WZ	WOS:000222083400002					2022-02-06	
J	Adibhatla, RM; Hatcher, JF; Dempsey, RJ				Adibhatla, RM; Hatcher, JF; Dempsey, RJ			Phospholipase A(2), hydroxyl radicals, and lipid peroxidation in transient cerebral ischemia	ANTIOXIDANTS & REDOX SIGNALING			English	Article							TUMOR-NECROSIS-FACTOR; TRAUMATIC BRAIN-INJURY; CDP-CHOLINE; FOREBRAIN ISCHEMIA; ARACHIDONIC-ACID; NEURONAL DEATH; CYTOSOLIC PHOSPHOLIPASE-A(2); POSTISCHEMIC REPERFUSION; NERVOUS-SYSTEM; GERBIL BRAIN	Phospholipid degradation is an important promoter of neuronal death after transient cerebral ischemia. Phospholipid hydrolysis by phospholipase A(2) (PLA(2)) after transient cerebral ischemia releases arachidonic acid. Arachidonic acid metabolism results in formation of reactive oxygen species, lipid peroxides, and toxic aldehydes (malondialdehyde, 4-hydroxynonenal, and acrolein). Citicoline (cytidine-5'-diphosphocholine), an intermediate in phosphatidylcholine synthesis, has undergone 13 phase III clinical trials for stroke, and is being evaluated for treatment of Alzheimer's and Parkinson's diseases. Here we examined the effect of citicoline on PLA(2) activity in relationship to attenuating hydroxyl radical (OH.) generation and lipid peroxidation after transient forebrain ischemia in gerbil. High Ca2+ dependency (millimolar range) of PLA(2) activity suggests that secretory PLA(2) is the predominant isoform in membrane and mitochondria. Citicoline attenuated the increase in PLA(2) activity in both membrane and mitochondrial fractions. In vitro, citicoline and its components choline and cytidine had no effect on the PLA(2) activity. Thus, citicoline is not a "direct PLA(2) inhibitor." Citicoline also significantly attenuated loss of cardiolipin and arachidonic acid release from phosphatidylcholine and phosphatidylethanolamine. Transient cerebral ischemia resulted in significant formation of OH. and malondialdehyde, and citicoline significantly attenuated their formation. These results suggest that citicoline provides neuroprotection by attenuating the stimulation of PLA(2).	Univ Wisconsin, Ctr Clin Sci, Dept Neurol Surg, Madison, WI 53792 USA; Univ Wisconsin, Cardiovasc Res Ctr, Madison, WI 53792 USA; Vet Adm Hosp, Madison, WI 53705 USA		Adibhatla, RM (corresponding author), Univ Wisconsin, Ctr Clin Sci, Dept Neurol Surg, H4-330,600 Highland Ave, Madison, WI 53792 USA.	adibhatl@neurosurg.wise.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042008] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS42008] Funding Source: Medline		Adibhatla R.H., 1999, RRD NEUROCHEMISTRY 2, V2, P533; Adibhatla RM, 2002, BRAIN RES, V938, P81, DOI 10.1016/S0006-8993(02)02447-2; Adibhatla RM, 2003, J NEUROSCI RES, V73, P308, DOI 10.1002/jnr.10672; Adibhatla RM, 2002, J NEUROSCI RES, V70, P133, DOI 10.1002/jnr.10403; Adibhatla RM, 2002, J NEUROCHEM, V80, P12; Adibhatla RM, 2001, STROKE, V32, P2376, DOI 10.1161/hs1001.096010; ADIBHATLA RM, 2002, NEUROLOGY; ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; Anthonsen MW, 2001, J BIOL CHEM, V276, P30527, DOI 10.1074/jbc.M008481200; ARRIGONI E, 1987, BIOCHEM PHARMACOL, V36, P3697, DOI 10.1016/0006-2952(87)90022-0; Basavarajappa BS, 1997, ALCOHOL CLIN EXP RES, V21, P1199, DOI 10.1097/00000374-199710000-00007; Baskaya MK, 2000, J NEUROSURG, V92, P448, DOI 10.3171/jns.2000.92.3.0448; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Chan CY, 2001, IEEE T INTELL TRANSP, V2, P1, DOI 10.1109/6979.911080; Chi SI, 2000, NEUROSCIENCE, V100, P475, DOI 10.1016/S0306-4522(00)00317-1; CLARK MA, 1988, BIOCHEM J, V250, P125, DOI 10.1042/bj2500125; Clemens JA, 1996, STROKE, V27, P527, DOI 10.1161/01.STR.27.3.527; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; Davalos A, 2002, STROKE, V33, P2850, DOI 10.1161/01.STR.0000038691.03334.71; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Esterbauer H, 1996, PATHOL BIOL, V44, P25; FRESTA M, 1994, J PHARM PHARMACOL, V46, P974, DOI 10.1111/j.2042-7158.1994.tb03252.x; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HALL ED, 1997, PRIMER CEREBROVASCUL, P200; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; Jentzsch AM, 1996, FREE RADICAL BIO MED, V20, P251, DOI 10.1016/0891-5849(95)02043-8; Kasner SE, 1997, ANN EMERG MED, V30, P642, DOI 10.1016/S0196-0644(97)70084-2; KATSUKI H, 1995, PROG NEUROBIOL, V46, P607, DOI 10.1016/0301-0082(95)00016-O; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kirkland RA, 2002, NEUROSCIENCE, V115, P587, DOI 10.1016/S0306-4522(02)00512-2; Kishimoto K, 1999, NEUROSCIENCE, V92, P1061, DOI 10.1016/S0306-4522(99)00051-2; Kontos HA, 2001, STROKE, V32, P2712, DOI 10.1161/hs1101.098653; Kruman I, 1997, J NEUROSCI, V17, P5089; Krupinski J, 2002, NEUROPHARMACOLOGY, V42, P846, DOI 10.1016/S0028-3908(02)00032-1; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Mallampalli RK, 2000, J BIOL CHEM, V275, P9699, DOI 10.1074/jbc.275.13.9699; McCabe DR, 1997, J CHROMATOGR B, V691, P23, DOI 10.1016/S0378-4347(96)00416-1; Mir C, 2003, J MOL NEUROSCI, V20, P53, DOI 10.1385/JMN:20:1:53; Murakami M, 2002, J BIOCHEM, V131, P285, DOI 10.1093/oxfordjournals.jbchem.a003101; NAKAHARA I, 1992, J NEUROSURG, V76, P244, DOI 10.3171/jns.1992.76.2.0244; Nau R, 2002, TRENDS NEUROSCI, V25, P38, DOI 10.1016/S0166-2236(00)02024-5; Nevalainen TJ, 1997, J HISTOCHEM CYTOCHEM, V45, P1109, DOI 10.1177/002215549704500808; Plataras C, 2003, Z NATURFORSCH C, V58, P277; Rao AM, 2000, J NEUROCHEM, V75, P2528, DOI 10.1046/j.1471-4159.2000.0752528.x; Rao AM, 1999, NEUROCHEM RES, V24, P1225, DOI 10.1023/A:1020916905312; Rao AM, 1999, J NEUROSCI RES, V58, P697, DOI 10.1002/(SICI)1097-4547(19991201)58:5<697::AID-JNR11>3.0.CO;2-B; Rao AM, 2001, BRAIN RES, V893, P268, DOI 10.1016/S0006-8993(00)03280-7; Ribardo DA, 2001, J BIOL CHEM, V276, P5467, DOI 10.1074/jbc.M006690200; RORDORF G, 1991, J NEUROSCI, V11, P1829; Saito K, 1996, NEUROSCI LETT, V206, P149, DOI 10.1016/S0304-3940(96)12460-5; Sastry PS, 2000, J NEUROCHEM, V74, P1, DOI 10.1046/j.1471-4159.2000.0740001.x; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SCIAMANNA MA, 1993, ARCH BIOCHEM BIOPHYS, V305, P215, DOI 10.1006/abbi.1993.1414; Secades JJ, 2002, METHODS FIND EXP SB, V24, P1; Seeds MC, 1998, BBA-LIPID LIPID MET, V1389, P273, DOI 10.1016/S0005-2760(97)00151-3; Shimoyama Y, 2001, BIOL PHARM BULL, V24, P1004, DOI 10.1248/bpb.24.1004; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Sobrado M, 2003, NEUROSCIENCE, V118, P107, DOI 10.1016/S0306-4522(02)00912-0; Stephenson D, 1999, GLIA, V27, P110, DOI 10.1002/(SICI)1098-1136(199908)27:2<110::AID-GLIA2>3.0.CO;2-C; Uchida K, 1999, TRENDS CARDIOVAS MED, V9, P109, DOI 10.1016/S1050-1738(99)00016-X; Walton M, 1997, MOL BRAIN RES, V50, P165, DOI 10.1016/S0169-328X(97)00181-2; Woo CH, 2000, J BIOL CHEM, V275, P32357, DOI 10.1074/jbc.M005638200; Wu YL, 1998, J IMMUNOL, V160, P5929; Yang HC, 1999, ANAL BIOCHEM, V269, P278, DOI 10.1006/abio.1999.4053; Ying WH, 1999, J NEUROCHEM, V73, P1549, DOI 10.1046/j.1471-4159.1999.0731549.x; Zhang YP, 1999, J BIOL CHEM, V274, P27726, DOI 10.1074/jbc.274.39.27726	67	91	97	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1523-0864	1557-7716		ANTIOXID REDOX SIGN	Antioxid. Redox Signal.	OCT	2003	5	5					647	654		10.1089/152308603770310329			8	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	735FF	WOS:000186101200019	14580322				2022-02-06	
J	Iyer, LV; Haley, SM; Watkins, MP; Dumas, HM				Iyer, LV; Haley, SM; Watkins, MP; Dumas, HM			Establishing minimal clinically important differences for scores on the Pediatric Evaluation of Disability Inventory for inpatient rehabilitation	PHYSICAL THERAPY			English	Article						clinical importance; minimal clinically important difference; Pediatric Evaluation of Disability Inventory; responsiveness	QUALITY-OF-LIFE; SELECTIVE DORSAL RHIZOTOMY; TRAUMATIC BRAIN INJURY; VISUAL ANALOG SCALES; CONSTRUCT-VALIDITY; CEREBRAL-PALSY/; MOTOR FUNCTION; HEALTH-STATUS; CHILDREN; PROGRAM	Background and Purpose. Standardized pediatric assessment tools such as the Pediatric Evaluation of Disability Inventory (PEDI) numerically quantify changes during rehabilitation through test scores, but they are unable to provide client-specific information regarding important changes in function. The purpose of this study was to identify the smallest change in PEDI scores during inpatient rehabilitation that was considered to be a minimal clinically important difference (MCID) by physical therapists and other clinicians. Subjects and Methods. A retrospective review was done of the medical charts of 53 children and youth (1-19 years of age) discharged from an inpatient rehabilitation hospital. Fifteen clinicians (5 physical therapists, 6 occupational therapists, and 4 speech and language pathologists) who were masked to the PEDI scores provided ratings of the magnitude of functional changes during inpatient rehabilitation using a Likert scale and a visual analog scale (VAS). Ratings by clinicians were reduced to 4 categories, including the MCID, and compared with PEDI change scores. Results. The MCIDs ranged from 6 to 15 points ((X) over bar =11.5, 95% confidence interval= +/- 2.8) for all PEDI scales. Likert scale and VAS ratings were correlated (tau=.73-.80). Discussion and Conclusion. Across all scales, PEDI change scores on the order of about 11% (0-100 scale) appear to be meaningful to clinicians during a child's or adolescent's inpatient rehabilitation. These data can serve as a starting point for interpreting group and individual changes on the PEDI during physical therapy intervention in inpatient rehabilitation.	Boston Univ, Ctr Rehabil Effectiveness, Boston, MA 02215 USA; Boston Univ, Sargent Coll Hlth & Rehabil Sci, Boston, MA 02215 USA; Warbasse Nursery Sch, Brooklyn, NY USA; MGH Inst Hlth Profess, Post Profess Grad Program Phys Therapy, Boston, MA USA; Franciscan Childrens Hosp, Res Ctr Children Special Hlth Care Needs, Boston, MA USA; Rehabil Ctr, Boston, MA USA		Haley, SM (corresponding author), Boston Univ, Ctr Rehabil Effectiveness, 635 Commonwealth Ave, Boston, MA 02215 USA.	smhaley@bu.edu					American Physical Therapy Association, 2001, GUID PHYS THER PRACT; Bedell GM, 2002, BRAIN INJURY, V16, P659, DOI 10.1080/02699050210128924; Clarke PRF, 1964, B BRIT PSYCHOL SOC, V17, P55; COSTER WJ, 1994, AM J OCCUP THER, V48, P211, DOI 10.5014/ajot.48.3.211; DUDGEON BJ, 1994, ARCH PHYS MED REHAB, V75, P46; Dumas Helene M, 2002, Pediatr Phys Ther, V14, P85, DOI 10.1097/00001577-200214020-00004; Dumas Helene M., 2001, Physical and Occupational Therapy in Pediatrics, V21, P7; Dumas HM, 2002, AM J PHYS MED REHAB, V81, P661, DOI 10.1097/00002060-200209000-00005; FELDMAN AB, 1990, PHYS THER, V70, P602, DOI 10.1093/ptj/70.10.602; Fragala MA, 2002, BRAIN INJURY, V16, P149, DOI 10.1080/02699050110103328; GUYATT GH, 1987, J CHRON DIS, V40, P1129, DOI 10.1016/0021-9681(87)90080-4; Haley S, 1992, PEDIAT EVALUATION DI; Haley SM, 2001, PHYS THER, V81, P1425, DOI 10.1093/ptj/81.8.1425; HALEY SM, 1991, PEDIATRIC PHYSICAL T, V3, P177; Hays RD, 2000, PHARMACOECONOMICS, V18, P419, DOI 10.2165/00019053-200018050-00001; Jacobson NS, 1999, J CONSULT CLIN PSYCH, V67, P300, DOI 10.1037/0022-006X.67.3.300; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; JAESCHKE R, 1990, CONTROL CLIN TRIALS, V11, P43, DOI 10.1016/0197-2456(90)90031-V; Ketelaar M, 2001, PHYS THER, V81, P1534, DOI 10.1093/ptj/81.9.1534; Liang MH, 2000, MED CARE, V38, P84, DOI 10.1097/00005650-200009002-00013; LIPSEY MW, 1983, PSYCHOL BULL, V94, P152, DOI 10.1037/0033-2909.94.1.152; McAuliffe CA, 1998, PEDIAT PHYS THER, V10, P23; MCHORNEY CA, 1995, QUAL LIFE RES, V4, P293, DOI 10.1007/BF01593882; Nichols DS., 1996, PEDIATR PHYS THER, V8, P15, DOI DOI 10.1097/00001577-199600810-00004; Nordmark E, 2000, DEV MED CHILD NEUROL, V42, P245, DOI 10.1017/S0012162200000426; Osoba D, 1998, J CLIN ONCOL, V16, P139, DOI 10.1200/JCO.1998.16.1.139; Rasch G., 1960, PROBABILISTIC MODELS; Reid DT, 1993, PHYSICAL OCCUPATIONA, V13, P57, DOI [10.1080/J006v13n0404, DOI 10.1080/J006V13N04_04]; REVILL SI, 1976, ANAESTHESIA, V31, P1191, DOI 10.1111/j.1365-2044.1976.tb11971.x; Russell D, 1998, DEV MED CHILD NEUROL, V40, P693; Schneider JW, 2001, DEV MED CHILD NEUROL, V43, P601, DOI 10.1017/S0012162201001098; Singer AJ, 1998, ACAD EMERG MED, V5, P1007, DOI 10.1111/j.1553-2712.1998.tb02781.x; *SPSS INC, 1999, STAT PROGR SOC SCI V; SUNDBERG KB, 1992, INTERRATER RELIABILI; Tokcan Gul, 2003, Pediatr Phys Ther, V15, P16, DOI 10.1097/01.PEP.0000050765.71924.6C; Wright BD., 1982, RATING SCALE ANAL; Wright FV, 1993, CAN J REHABIL, V7, P41; Wyrwich KW, 1999, MED CARE, V37, P469, DOI 10.1097/00005650-199905000-00006; Ziviani Jenny, 2001, Physical and Occupational Therapy in Pediatrics, V21, P91	39	91	94	0	9	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0031-9023	1538-6724		PHYS THER	Phys. Ther.	OCT	2003	83	10					888	898		10.1093/ptj/83.10.888			11	Orthopedics; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Rehabilitation	805XQ	WOS:000220399400002	14519060	Bronze			2022-02-06	
J	Chen, SHA; Kareken, DA; Fastenau, PS; Trexler, LE; Hutchins, GD				Chen, SHA; Kareken, DA; Fastenau, PS; Trexler, LE; Hutchins, GD			A study of persistent post-concussion symptoms in mild head trauma using positron emission tomography	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CEREBRAL GLUCOSE-METABOLISM; LATE WHIPLASH SYNDROME; BRAIN-INJURY; TECHNETIUM-99M-HMPAO SPECT; POSTCONCUSSION SYMPTOMS; WORKING-MEMORY; BLOOD-FLOW; PET; ABNORMALITIES; DEPRESSION	Background: Complaints of persistent cognitive deficits following mild head trauma are often uncorroborated by structural brain imaging and neuropsychological examination. Objective: To investigate, using positron emission tomography (PET), the in vivo changes in regional cerebral uptake of 2-[F-18]fluoro-2-deoxy-D-glucose (FDG) and regional cerebral blood flow (rCBF) in patients with persistent symptoms following mild head trauma. Methods: Five patients with mild head trauma and five age and education matched healthy controls were imaged using FDG-PET to measure differences in resting regional cerebral glucose metabolism. Oxygen-15 labelled water ((H2O)-O-15)-PET was also used to measure group differences in rCBF changes during a spatial working memory task. In addition, neuropsychological testing and self report of dys-executive function and post-concussion symptoms were acquired to characterise the sample. Results: There was no difference between patients and controls in normalised regional cerebral FDG uptake in the resting state in frontal and temporal regions selected a priori. However, during the spatial working memory task, patients had a smaller increase in rCBF than controls in the right prefrontal cortex. Conclusions: Persistent post-concussive symptoms may not be associated with resting state hypometabolism. A cognitive challenge may be necessary to detect cerebral changes associated with mild head trauma.	Stanford Sch Med Radiol, Lucas MRS Imaging Ctr, Stanford, CA 94305 USA		Chen, SHA (corresponding author), Stanford Sch Med Radiol, Lucas MRS Imaging Ctr, 1201 Welch Rd MC 5488, Stanford, CA 94305 USA.		Kareken, David/Z-1960-2019; Chen, SH Annabel/F-3742-2011	Chen, SH Annabel/0000-0002-1540-5516; Kareken, David/0000-0003-0855-8300			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Altrocchi PH, 1996, NEUROLOGY, V46, P278; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BAXTER LR, 1985, ARCH GEN PSYCHIAT, V42, P441; BAXTER LR, 1989, ARCH GEN PSYCHIAT, V46, P243; BENCH CJ, 1992, PSYCHOL MED, V22, P607, DOI 10.1017/S003329170003806X; Bicik I, 1998, NEUROLOGY, V51, P345, DOI 10.1212/WNL.51.2.345; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BRITTAIN JL, 1991, CLIN NEUROPSYCHOL, V5, P163, DOI DOI 10.1080/13854049108403300; CONNERS CK, 1995, MULTI HLTH SYSTEMS S; DELIS D, 1987, CALIFORNIA VERBAL LE; Derogatis L. R., 1975, SYMPTOM CHECKLIST 90; DOLAN RJ, 1992, J NEUROL NEUROSUR PS, V55, P768, DOI 10.1136/jnnp.55.9.768; DREVETS WC, 1992, J NEUROSCI, V12, P3628; DUVERNOY HM, 1995, HUMAN BRAIN SURFACE; Fastenau PS, 2002, EXTENDED COMPLEX FIG; Gold S, 1997, NEUROIMAGE, V5, P280, DOI 10.1006/nimg.1997.0268; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Grace J, 1999, ASSESSMENT, V6, P269, DOI 10.1177/107319119900600307; GRAY BG, 1992, J NUCL MED, V33, P52; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Heaton R.K., 1981, WISCONSIN CARD SORTI; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; HURWITZ TA, 1990, CAN J PSYCHIAT, V35, P684, DOI 10.1177/070674379003500807; ICHISE M, 1994, J NUCL MED, V35, P217; JACOBS A, 1994, J NUCL MED, V35, P942; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A, P432; LONG CJ, 1986, SOUTHERN MED J, V79, P728, DOI 10.1097/00007611-198606000-00020; MARTINOT JL, 1990, AM J PSYCHIAT, V147, P1313; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Mesulam M. M., 1985, PRINCIPLES BEHAV NEU, V3, P125; Mild Traumatic Brain Injury Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; NORMAN MA, IN PRESS J CLIN EXP; Osterrieth PA, 1994, ARCH PSYCHOL, V30, P286; Otte A, 1997, J NEUROL NEUROSUR PS, V63, P368, DOI 10.1136/jnnp.63.3.368; Radanov BP, 1999, J NEUROL NEUROSUR PS, V66, P485, DOI 10.1136/jnnp.66.4.485; RUFF RM, 1994, BRAIN INJURY, V8, P197; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Talairach J., 1988, COPLANAR STEREOTAXIC; Taylor L, 1991, COMPENDIUM NEUROPSYC; Trahan DE, 1988, CONTINUOUS VISUAL ME; Wechsler D., 1997, WECHSLER INTELLIGENC; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wolfson, 1993, HALSTEAD REITAN NEUR	50	91	92	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAR	2003	74	3					326	332		10.1136/jnnp.74.3.326			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	651YC	WOS:000181350400013	12588917	Green Published, Bronze			2022-02-06	
J	Oertel, M; Kelly, DF; Lee, JH; McArthur, DL; Glenn, TC; Vespa, P; Boscardin, WJ; Hovda, DA; Martin, NA				Oertel, M; Kelly, DF; Lee, JH; McArthur, DL; Glenn, TC; Vespa, P; Boscardin, WJ; Hovda, DA; Martin, NA			Efficacy of hyperventilation, blood pressure elevation, and metabolic suppression therapy in controlling intracranial pressure after head injury	JOURNAL OF NEUROSURGERY			English	Article						hyperventilation therapy; induced-hypertension therapy; pressure autoregulation; metabolic suppression therapy; propofol; transcranial Doppler ultrasonography; traumatic brain injury; vasoreactivity	TRAUMATIC BRAIN INJURY; CEREBRAL PERFUSION-PRESSURE; CARBON-DIOXIDE REACTIVITY; PROPOFOL ANESTHESIA; PROLONGED HYPERVENTILATION; MODERATE HYPERVENTILATION; BURST SUPPRESSION; BARBITURATE COMA; AUTOREGULATION; HYPERTENSION	Object. Hyperventilation therapy, blood pressure augmentation, and metabolic suppression therapy are often used to reduce intracranial pressure (ICP) and improve cerebral perfusion pressure (CPP) in intubated head-injured patients. In this study, as part of routine vasoreactivity testing, these three therapies were assessed in their effectiveness in reducing ICP. Methods. Thirty-three patients with a mean age of 33 +/- 13 years and a median Glasgow Coma Scale (GCS) score of 7 underwent a total of 70 vasoreactivity testing sessions from postinjury Days 0 to 13. After an initial Xe-133 cerebral blood flow (CBF) assessment, transcranial Doppler ultrasonography recordings of the middle cerebral arteries were obtained to assess blood flow velocity changes resulting from transient hyperventilation (57 studies in 27 patients), phenylephrine-induced hypertension (55 studies in 26 patients), and propofol-induced metabolic suppression (43 studies in 21 patients). Changes in ICP, mean arterial blood pressure (MABP), CPP, PaCO2, and jugular venous oxygen saturation (SjvO(2)) were recorded. With hyperventilation therapy, patients experienced a mean decrease in PaCO2 from 35 +/- 5 to 27 +/- 5 mm Hg and in ICP from 20 +/- 11 to 13 +/- 8 min Hg (p < 0.001). In no patient who underwent hyperventilation therapy did SjvO(2) fall below 55%. With induced hypertension, MABP in patients increased by 14 5 mm Hg and ICP increased from 16 +/- 9 to 19 +/- 9 mm Hg (p = 0.001). With the aid of metabolic suppression, MABP remained stable and ICP decreased from 20 +/- 10 to 16 +/- 11 mm Hg (p < 0.001). A decrease in ICP of more than 20% below the baseline value was observed in 77.2, 5.5, and 48.8% of hyperventilation, induced-hypertension, and metabolic suppression tests, respectively (p < 0.001 for all comparisons). Predictors of an effective reduction in ICP included a high PaCO2 for hyperventilation, a high study GCS score for induced hypertension, and a high PaCO2 and a high CBF for metabolic suppression. Conclusions. Of the three modalities tested to reduce ICP, hyperventilation therapy was the most consistently effective, metabolic suppression therapy was variably effective, and induced hypertension was generally ineffective and in some instances significantly raised ICP. The results of this study suggest that hyperventilation may be used more aggressively to control ICP in head-injured patients, provided it is performed in conjunction with monitoring of SjvO(2).	Univ Calif Los Angeles, Sch Med, Brain Injury Res Ctr, Cerebral Blood Flow Lab, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Ctr Hlth Sci, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Med & Mol Pharmacol, Los Angeles, CA 90024 USA; Harbor UCLA Med Ctr, Torrance, CA 90509 USA; Inst Educ, Torrance, CA USA		Kelly, DF (corresponding author), 200 UCLA Med Plaza,Suite 504,Box 718224, Los Angeles, CA 90095 USA.		McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314; Martin, Neil/0000-0002-6565-4131; Glenn, Thomas/0000-0003-4273-3408	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30308] Funding Source: Medline		ALKIRE MT, 1995, ANESTHESIOLOGY, V82, P393, DOI 10.1097/00000542-199502000-00010; Allen CH, 1998, CRIT CARE CLIN, V14, P485, DOI 10.1016/S0749-0704(05)70012-9; ARTRU AA, 1992, J NEUROSURG ANESTH, V4, P99, DOI 10.1097/00008506-199204000-00005; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bouma G J, 1995, New Horiz, V3, P384; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BRICOLO AP, 1981, J NEUROSURG, V55, P397, DOI 10.3171/jns.1981.55.3.0397; BROWN FD, 1979, J NEUROSURG, V50, P423, DOI 10.3171/jns.1979.50.4.0423; Bullock MR, 1996, J NEUROTRAUM, V13, P699; Bullock MR, 1996, J NEUROTRAUM, V13, P693; COHEN PJ, 1964, ANESTHESIOLOGY, V25, P186; Cormio M, 1999, J NEUROTRAUM, V16, P927, DOI 10.1089/neu.1999.16.927; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; Doyle PW, 1999, BRIT J ANAESTH, V83, P580, DOI 10.1093/bja/83.4.580; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; Goblet W, 1977, Neurochirurgia (Stuttg), V20, P35; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; KLINGELHOFER J, 1992, STROKE, V23, P962, DOI 10.1161/01.STR.23.7.962; Lang EW, 2000, BRIT J NEUROSURG, V14, P117; LASSEN NA, 1990, REV NEUROL, V146, P620; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; Letarte PB, 1999, ACT NEUR S, V75, P45; LUNDBERG N, 1960, ACTA PSYCHIATRICA  S, V149, P1; MARSHALL LF, 1978, J NEUROSURG, V48, P169, DOI 10.3171/jns.1978.48.2.0169; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MATTA BF, 1995, BRIT J ANAESTH, V74, P159, DOI 10.1093/bja/74.2.159; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MUIZELAAR JP, 1988, J NEUROSURG, V69, P923, DOI 10.3171/jns.1988.69.6.0923; Newell DW, 1996, NEUROSURGERY, V39, P35, DOI 10.1097/00006123-199607000-00008; NEWMAN MF, 1995, ANESTH ANALG, V81, P452, DOI 10.1097/00000539-199509000-00004; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PICKARD JD, 1993, J NEUROL NEUROSUR PS, V56, P845, DOI 10.1136/jnnp.56.8.845; ROBERTS I, 2000, COCHRANE DATABASE SY, V136, DOI UNSP CD000033; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; RODENBERG FH, 1976, J NEUROSURG, V44, P347; ROSENBERG AA, 1988, STROKE, V19, P1365, DOI 10.1161/01.STR.19.11.1365; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; ROWED DW, 1975, ARCH NEUROL-CHICAGO, V32, P369, DOI 10.1001/archneur.1975.00490480035003; SADOSHIMA S, 1980, BRAIN RES, V189, P115, DOI 10.1016/0006-8993(80)90011-6; Schneider GH, 1998, ACT NEUR S, V71, P62; SHAPIRO HM, 1974, J NEUROSURG, V40, P90, DOI 10.3171/jns.1974.40.1.0090; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Steinmeier R, 1996, STROKE, V27, P2236, DOI 10.1161/01.STR.27.12.2236; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; Stover JF, 1998, EUR J CLIN PHARMACOL, V54, P529, DOI 10.1007/s002280050508; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; TEASDALE G, 1974, LANCET, V2, P81; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Todd MM, 1996, J NEUROSURG ANESTH, V8, P296, DOI 10.1097/00008506-199610000-00007; UNTERBERG AW, 1997, J TRAUMA S, V42, P32; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; Wodey E, 1999, BRIT J ANAESTH, V82, P516, DOI 10.1093/bja/82.4.516; Woodman T, 1996, NEUROTRAUMA, P519	64	91	99	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	NOV	2002	97	5					1045	1053		10.3171/jns.2002.97.5.1045			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	613BC	WOS:000179109800012	12450025				2022-02-06	
J	Besenski, N				Besenski, N			Traumatic injuries: imaging of head injuries	EUROPEAN RADIOLOGY			English	Article						CT; MR; head injury; linear translation; diffuse axonal injury	BRAIN-STEM LESIONS; MECHANISM; MRI	Due to the forces of acceleration, linear translation, as well as rotational and angular acceleration, the brain undergoes deformation and distortion depending on the site of impact of traumatizing force direction, severity of the traumatizing force, and tissue resistance of the brain. Linear translation of accereration in a closed-head injury can run along the shorter diameter of the skull in latero-lateral direction causing mostly extra-axial lesions (subdural hematoma,epidural hematoma, subarachnoidal hemorrhage) or quite pronounced coup and countercoup contusions. Contusions are considerably less frequently present in medial or paramedial centroaxial blows (fronto-occipital or occipito-frontal). The centroaxial blows produce a different pattern of lesions mostly in the deep structures, causing in some cases a special category of the brain injury, the diffuse axonal injury (DAI). The brain stem can also be damaged, but it is damaged more often in patients who have suffered centroaxial traumatic force direction. Computed tomography and MRI are the most common techniques in patients who have suffered brain injury Computed tomography is currently the first imaging technique to be used after head injury, in those settings where CT is available. Using CT, scalp, bone, extra-axial hematomas, and parenchymal injury can be demonstrated. Computed tomography is rapid and easily performed also in monitored patients. It is the most relevant imaging procedure for surgical lesions. Computed tomography is a suitable method to follow the dynamics of lesion development giving an insight into the corresponding pathological development of the brain injury. Magnetic resonance imaging is more sensitive for all posttraumatic lesions except skull fractures and subarachnoidal hemorrhage, but scanning time is longer, and the problem with the monitoring of patients outside the MRI field is present. If CT does not demonstrate pathology as can adequately be explained to account for clinical state, MRI is warranted. Follow-up is best done with MRI as it is more sensitive to parenchymal changes. In routine MR protocol gradient-recalled-echo sequences should be included at any other time after a traumatic event since they are very sensitive in detection of hemosiderin as well as former hematoma without hemosiderin. The MR signal intensity varies depending on sequences and time scanning after trauma.	Univ Zagreb, Croatian Inst Brain Res, HR-10002 Zagreb, Croatia		Besenski, N (corresponding author), Univ Zagreb, Croatian Inst Brain Res, Salata 12, HR-10002 Zagreb, Croatia.	nada.besenski@hiim.hr					BESENSKI N, 1992, NEURORADIOLOGY, V34, P126, DOI 10.1007/BF00588158; BESENSKI N, 1995, NEURORADIOLOGY, V37, P207; Besenski N, 1996, NEURORADIOLOGY, V38, pS36; BESENSKI N, 1992, NEUROL CROATICA, V41, P33; Braun M, 2000, ANN FR ANESTH, V19, P296; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GEAN AD, 1994, IMAGING HEAD TRAUMA, P76; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gentry LR, 1991, NEUROIMAG CLIN N AM, V1, P411; GRCEVIC N, 1988, SCAND J REHABIL ME S, V17, P1; GRCEVIC N, 1984, INVESTIGATIONS NEURO; HASHIMOTO T, 1993, NEUROSURG REV, V16, P291, DOI 10.1007/BF00383839; Hoelper BM, 2000, ACTA NEUROCHIR SUPPL, V76, P21; JADROSANTEL D, 1989, NEUROIMAGING, V2, P263; KIRCKPATRICK JB, 1988, FORENSIC NEUROPATHOL, P276; Leestma JE, 1988, FORENSIC NEUROPATHOL, P409; LINDENBERG R, 1960, ARCH PATHOL, V69, P440; LINDENBERG R, 1957, ARCH PATHOL, V63, P23; MACPHERSON BCM, 1990, CLIN RADIOL, V42, P321, DOI 10.1016/S0009-9260(05)82145-2; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; PAVIC D, 1994, NEUROL CROATICA, V43, P3; ROSS PS, 1989, PEDIATR EMERG CARE, V5, P216; SELLIER K, 1963, Hefte Unfallheilkd, V76, P1; Shibata Y, 2000, CLIN NEUROL NEUROSUR, V102, P124, DOI 10.1016/S0303-8467(00)00095-0; SICCARDI D, 1991, SURG NEUROL, V35, P455, DOI 10.1016/0090-3019(91)90179-D; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Tatalovic-Osterman L, 1991, Neurol Croat, V40, P231; Wardlaw JM, 2000, NEURORADIOLOGY, V42, P81, DOI 10.1007/s002340050019; ZIMMERMAN RA, 1978, RADIOLOGY, V126, P403, DOI 10.1148/126.2.403	32	91	102	0	3	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0938-7994	1432-1084		EUR RADIOL	Eur. Radiol.	JUN	2002	12	6					1237	1252		10.1007/s00330-002-1355-9			16	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	562LC	WOS:000176197400002	12042929				2022-02-06	
J	Dennis, M; Guger, S; Roncadin, C; Barnes, M; Schachar, R				Dennis, M; Guger, S; Roncadin, C; Barnes, M; Schachar, R			Attentional-inhibitory control and social-behavioral regulation after childhood closed head injury: Do biological, developmental, and recovery variables predict outcome?	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						closed-head injury; childhood; attention; behavior	TRAUMATIC BRAIN-INJURY; PSYCHIATRIC-DISORDERS; CHILDREN; ADOLESCENTS; MILD; PERFORMANCE; SEQUELAE; AGE; AVAILABILITY; ADJUSTMENT	Attentional-inhibitory control and social-behavioral regulation are two outcome domains commonly impaired after childhood closed head injury (CHI). We compared neuropsychological tests of attentional-inhibitory control (vigilance, selective attention, response modulation) and social discourse and intentionality (inferencing, figurative language, and speech acts) with parent ratings of attention and behavioral regulation in relation to four injury-related variables: age at CHI, time since CHI, CHI injury severity, and frontal lobe injury moderated by CHI severity. Participants were 105 school-aged children in the chronic stage of CHI, divided into mild, moderate, and severe injury severity groups, and further subdivided according to frontal lobe injury. Outcome indices were imperfectly correlated in the group as a whole, although several relations between neurocognitive tests and parent ratings were observed within CHI subgroups. Different domains of cognitive function had different predictors. For attentional-inhibitory control, age at injury and time since injury were most predictive of outcome; for social discourse, predictors were injury severity and frontal lobe injury moderated by injury severity. Variability in cognitive outcome after childhood CHI is not random, but appear, related to age, time, and biological features of the injury.	Hosp Sick Children, Dept Psychiat, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Univ Toronto, Dept Pediat, Toronto, ON, Canada; Univ Toronto, Dept Psychiat, Toronto, ON, Canada; Hosp Sick Children, Dept Psychol, Toronto, ON, Canada		Dennis, M (corresponding author), Hosp Sick Children, Dept Psychol Res, Room 6278A,555 Univ Ave, Toronto, ON M5G 1X8, Canada.	mdennis@sickkids.on.ca		Schachar, Russell/0000-0002-2015-4395	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2R01NS 21889-16] Funding Source: Medline		Achenbach T., 1991, INTEGRATIVE GUIDE 19; ACKERMAN BP, 1990, CHILD DEV, V61, P230; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; ANDERSON V, 1982, P 7 ANN BRAIN IMP C, P360; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BARKLEY RA, 1991, J ABNORM CHILD PSYCH, V19, P149, DOI 10.1007/BF00909976; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; Barnes MA, 2001, BRAIN LANG, V76, P253, DOI 10.1006/brln.2000.2385; Barnes MA, 1996, J EXP CHILD PSYCHOL, V61, P216, DOI 10.1006/jecp.1996.0015; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; BEUN RJ, 1994, J PRAGMATICS, V21, P191, DOI 10.1016/0378-2166(94)90019-1; Bohnert AM, 1997, DEV NEUROPSYCHOL, V13, P477, DOI 10.1080/87565649709540688; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BURG JS, 1995, BRAIN INJURY, V9, P395, DOI 10.3109/02699059509005779; CAMPBELL TF, 1990, J SPEECH HEAR DISORD, V55, P567, DOI 10.1044/jshd.5503.567; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M, 2000, SCI PRACT NEUROPSYCH, P3; Dennis M, 2000, APHASIOLOGY, V14, P391, DOI 10.1080/026870300401423; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P89; Dennis M., 2000, J INT NEUROPSYCH SOC, V6, P132; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; Fletcher JM, 2000, SCI PRACT NEUROPSYCH, P25; GORDON M, 1988, GORDON DIAGNOSTIC SY; Gordon M, 1983, GORDON DIAGNOSTIC SY; GRANT I, 1987, NEUROBEHAVIORAL RECO, P232; GRONWALL D, 1997, J INT NEUROSCIENCE, V53, P171; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; HAPPE FGE, 1993, COGNITION, V48, P101, DOI 10.1016/0010-0277(93)90026-R; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; Kufera J. A., 1997, AM J SPEECH-LANG PAT, V6, P66, DOI 10.1044/1058-0360.0602.66; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 2000, J CLIN EXP NEUROPSYC, V22, P1, DOI 10.1076/1380-3395(200002)22:1;1-8;FT001; Manly T., 1999, TEST EVERYDAY ATTENT; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; MCKOON G, 1992, PSYCHOL REV, V99, P440, DOI 10.1037/0033-295X.99.3.440; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; NORUSIS MJ, 1997, SPSS WINDOWS RELEASE; Oakhill J, 1993, EDUC PSYCHOL REV, V5, P223, DOI 10.1007/BF01323045; Overweg-Plandsoen WCG, 1999, EUR J PEDIATR, V158, P249, DOI 10.1007/s004310051061; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Searle John R., 1969, SPEECH ACTS ESSAY PH; SINGER M, 1992, MEM COGNITION, V20, P539, DOI 10.3758/BF03199586; Sokol DK, 1996, BRAIN INJURY, V10, P439, DOI 10.1080/026990596124296; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Timmermans SR, 1991, COGNITIVE REHABILITA, V9, P26; Verger K, 2000, BRAIN INJURY, V14, P495; Wechsler D., 1974, WECHSLER INTELLIGENC; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Wiig EH, 1985, TEST LANGUAGE COMPET; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; [No title captured]; [No title captured]	79	91	93	0	10	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2001	7	6					683	692		10.1017/S1355617701766040			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	471YE	WOS:000170955600004	11575590				2022-02-06	
J	Goldbaum, O; Richter-Landsberg, C				Goldbaum, O; Richter-Landsberg, C			Stress proteins in oligodendrocytes: differential effects of heat shock and oxidative stress	JOURNAL OF NEUROCHEMISTRY			English	Article						heat shock proteins; heme oxygenase; iron chelator; myelin forming cells; oxidative stress	CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN INJURY; HEME OXYGENASE-1 HO-1; MULTIPLE-SCLEROSIS; BIOCHEMICAL-PROPERTIES; REACTIVE OXYGEN; CELL-DEATH; IRON; EXPRESSION; ACTIVATION	Heat shock proteins (HSP) or stress proteins serve as biomarkers to identify the contribution of stress situations underlying the pathogenesis of degenerative diseases of the CNS. We have analyzed by immunoblot technique the constitutive and inducible occurance of stress proteins in cultured rat brain oligodendrocytes subjected to heat shock or oxidative stress exerted by hydrogen peroxide, or a combination of both. The data demonstrate that oligodendrocytes constitutively express HSP32, HSP60 and the cognate form of the HSP70 family of proteins, HSC70. After heat shock, HSP25, alphaB-crystallin and HSP70 were up-regulated, while after oxidative stress the specific induction of HSP32 and alphaB-crystallin was observed. HSP32 represents heme oxygenase 1 (HO-1), a small stress protein with enzymatic activity involved in the oxidative degradation of heme which participates in iron metabolism. The presence of the iron chelators phenanthroline or deferoxamine (DFO), which previously has been shown to protect oligodendrocytes from oxidative stress-induced onset of apoptosis, caused a marked stimulation of HSP32 without affecting HSP70. This indicates that DFO possibly exerts its protective role by directly influencing the antioxidant capacity of HO-1. In summary, HSP in oligodendrocytes are differentially stimulated by heat stress and oxidative stress. Heme oxygenase-1 has been linked to inflammatory processes and oxidative stress, its specific up-regulation after oxidative stress in oligodendrocytes suggests that it is an ideal candidate to investigate the involvement of oxidative stress in demyelinating diseases.	Univ Oldenburg, Dept Biol Mol Neurobiol, D-2611 Oldenburg, Germany		Richter-Landsberg, C (corresponding author), Univ Oldenburg, Dept Biol Mol Neurobiol, POB 2503, D-2611 Oldenburg, Germany.						Aquino DA, 1997, J NEUROPATH EXP NEUR, V56, P664; BAJRAMOVIC JJ, 1997, J NEUROIMMUNOL, V78, P142; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; BIRNBAUM G, 1995, SPRINGER SEMIN IMMUN, V17, P107; Boccaccio GL, 1996, J NEUROSCI RES, V45, P647; BOELENS WC, 1995, MOL BIOL REP, V21, P75, DOI 10.1007/BF00986495; Brosnan CF, 1996, J NEUROPATH EXP NEUR, V55, P389, DOI 10.1097/00005072-199604000-00001; CHARLES J, 1994, TRENDS NEUROSCI, V17, P135, DOI 10.1016/0166-2236(94)90085-X; Chen K, 2000, J NEUROCHEM, V75, P304, DOI 10.1046/j.1471-4159.2000.0750304.x; Connor JR, 1996, GLIA, V17, P83, DOI 10.1002/(SICI)1098-1136(199606)17:2<83::AID-GLIA1>3.0.CO;2-7; Dwyer BE, 1996, MOL BRAIN RES, V38, P251, DOI 10.1016/0169-328X(95)00341-O; Elbirt KK, 1999, P ASSOC AM PHYSICIAN, V111, P438, DOI 10.1111/paa.1999.111.5.438; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; GALEY JP, 1997, ANTIOXIDANTS DIS MEC, P147; GELMAN BB, 1995, J NEUROPATH EXP NEUR, V54, P477, DOI 10.1097/00005072-199507000-00001; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Hartsfield CL, 1998, FASEB J, V12, P1675, DOI 10.1096/fasebj.12.15.1675; Head MW, 2000, NEUROPATH APPL NEURO, V26, P304, DOI 10.1046/j.1365-2990.2000.00269.x; ITOH H, 1995, J BIOL CHEM, V270, P13429, DOI 10.1074/jbc.270.22.13429; Jelinski SE, 1999, BRAIN RES, V815, P150, DOI 10.1016/S0006-8993(98)01053-1; Kvam E, 2000, FREE RADICAL BIO MED, V28, P1191, DOI 10.1016/S0891-5849(00)00205-7; Leist M, 1998, EXP CELL RES, V239, P183, DOI 10.1006/excr.1997.4026; Lucchinetti CF, 1996, BRAIN PATHOL, V6, P259, DOI 10.1111/j.1750-3639.1996.tb00854.x; Ludwin SK, 1997, J NEUROPATH EXP NEUR, V56, P111, DOI 10.1097/00005072-199702000-00001; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MCMORRIS FA, 1981, EXP CELL RES, V133, P395, DOI 10.1016/0014-4827(81)90332-3; NEUHOFF V, 1979, H-S Z PHYSIOL CHEM, V360, P1657, DOI 10.1515/bchm2.1979.360.2.1657; NOWAK TS, 1994, HEAT SHOCK PROTEINS, P55; Pedchenko TV, 1998, J NEUROIMMUNOL, V84, P188, DOI 10.1016/S0165-5728(97)00256-7; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Raine CS, 1996, LAB INVEST, V75, P109; Richter-Landsberg C, 1999, J NEUROSCI RES, V56, P259, DOI 10.1002/(SICI)1097-4547(19990501)56:3<259::AID-JNR5>3.0.CO;2-N; Richter-Landsberg C, 1998, EXP CELL RES, V244, P218, DOI 10.1006/excr.1998.4188; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; Schipper HM, 2000, EXP GERONTOL, V35, P821, DOI 10.1016/S0531-5565(00)00148-0; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Sharp FR, 1999, TRENDS NEUROSCI, V22, P97, DOI 10.1016/S0166-2236(98)01392-7; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Smith KJ, 1999, BRAIN PATHOL, V9, P69; Stuhlmeier KM, 2000, EUR J BIOCHEM, V267, P1161, DOI 10.1046/j.1432-1327.2000.01112.x; Thorburne SK, 1996, J NEUROCHEM, V67, P1014; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANNOORT JM, 1995, NATURE, V375, P798, DOI 10.1038/375798a0; Vollgraf U, 1999, J NEUROCHEM, V73, P2501, DOI 10.1046/j.1471-4159.1999.0732501.x; [No title captured]	45	91	94	0	7	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	SEP	2001	78	6					1233	1242		10.1046/j.1471-4159.2001.00507.x			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	474LF	WOS:000171107900005	11579132	Bronze			2022-02-06	
J	Chan, RCK				Chan, RCK			Base rate of post-concussion symptoms among normal people and its neuropsychological correlates	CLINICAL REHABILITATION			English	Article							MILD HEAD-INJURY; QUESTIONNAIRE; RELIABILITY; PREDICTION; MODERATE	Objective: To explore the base rate of symptoms similar to those of post-concussion symptoms (PCS) among a group of participants without head injury. The effect of subjective complaints upon cognitive functioning was also examined. Design: A cross-sectional study. Participants: A total of 85 participants without head injury, other identifiable neurological diseases or psychiatric diseases were recruited. Outcome measures: These included Rivermead Post-concussion Symptoms Checklist, Cognitive Failures Questionnaire, Colour Trails Test, Stroop Word-Colour Test, Paced Auditory Serial Addition Test, Symbol Digits Modality Test, Word Fluency Test, Design Fluency Test, Digits Forward and Backward Span Test, and Modified Six Elements Test. Results: A relatively high proportion of the participants reported symptoms similar to those of patients with PCS. These included longer time to think (65.9%), forgetfulness (58.9%), poor concentration (58.9%), fatigue easily (53.5%), and sleep disturbances (50.6%). Gender effect was not significant for either the individual item or the total score of the Rivermead Post-concussion Symptoms Checklist. Moreover, there was no difference found between low symptom reporters and high symptom reporters in terms of attention, working memory, mental fluency, and strategy allocation. Conclusion: The base rates of symptoms were consistent with previous studies among the nonclinical groups. However, persons reporting a high score of concussion-like symptoms did not perform less well than those reporting a low score of symptoms in attention, working memory, mental fluency and strategy allocation.	Univ Hong Kong, Queen Mary Hosp, Dept Psychiat, Lab J2, Hong Kong, Hong Kong, Peoples R China		Chan, RCK (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Psychiat, Lab J2, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.		Chan, Raymond CK/B-6717-2009	Chan, Raymond CK/0000-0002-3414-450X			BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Burgess PW., 1996, BEHAV ASSESSMENT DYS; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Gronwall D, 1974, PSYCHOL EFFECTS CONC; JONESGOTMAN M, 1991, EPILIPSIA, V32, P41; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; MARSH NV, 1995, BRAIN INJURY, V9, P553, DOI 10.3109/02699059509008214; MCMORDIE WR, 1988, CLIN NEUROPSYCHOL, V2, P198; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; Miller W., 1992, PHYSICAL MED REHABIL, V6, P547; ODONNELL WE, 1993, J CLIN PSYCHOL, V49, P372, DOI 10.1002/1097-4679(199305)49:3<372::AID-JCLP2270490311>3.0.CO;2-K; Ryan LM, 1999, ARCH CLIN NEUROPSYCH, V14, P42, DOI 10.1093/arclin/14.1.42a; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); VANZOMEREN AH, 1984, CLOSED HEAD INJURY P; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3	21	91	95	0	5	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.	JUN	2001	15	3					266	273		10.1191/026921501675253420			8	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	437EN	WOS:000168977900006	11386396				2022-02-06	
J	Wallesch, CW; Curio, N; Kutz, S; Jost, S; Bartels, C; Synowitz, H				Wallesch, CW; Curio, N; Kutz, S; Jost, S; Bartels, C; Synowitz, H			Outcome after mild-to-moderate blunt head injury: effects of focal lesions and diffuse axonal injury	BRAIN INJURY			English	Article							TRAUMA	Primary objective: A comparison of the effects of focal and diffuse axonal injury in mild-to-moderate traumatic brain injury (TBI). Research design: In a prospective longitudinal study of 138 consecutive patients suffering from TBI who were admitted to the Magdeburg University Hospital, 60 could be assessed neuropsychologically 8-31 days after trauma and 18-45 weeks later. Methods and procedures: GCS, CT-analysis, comprehensive neuropsychological assessment. Main results: The initial GCS-score was significantly correlated with outcome impairments of semantic fluency and memory in the Wechsler Similarities and in two clinical scales (Neurobehavioural Rating Scale, Frontal Lobe Score). The presence of CT-signs of DAI corresponded with deficits in tasks of response selection and suppression, the presence of focal contusions with results in the clinical scales, reaching significance for behavioural deficits with frontal contusions. Improvements between first and second assessments were pronounced in patients with signs of DAI. Conclusions: The data indicate that traumatic DAI results in mainly transient neuropsychological deficits. Focal frontal contusions result in more relevant deficits at outcome that affect behaviour and, thus, impair rehabilitation prognosis. It is concluded that even in clinically 'mild' TBI, prognosis and rehabilitation requirements should be established by early imaging and post-acute neuropsychological assessment.	Univ Magdeburg, Dept Neurol, D-39120 Magdeburg, Germany; Univ Magdeburg, Div Neuropsychol, D-39120 Magdeburg, Germany; Univ Magdeburg, Dept Neurosurg, D-39120 Magdeburg, Germany		Wallesch, CW (corresponding author), Univ Magdeburg, Dept Neurol, Leipziger Str 44, D-39120 Magdeburg, Germany.	wallesch@medizin.uni-magdeburg.de					BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; DELIS DC, 1988, J CONSULT CLIN PSYCH, V56, P123, DOI 10.1037/0022-006X.56.1.123; ETTLIN T, 1999, SCI PRACT NEUROPSYCH, P233; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gennarelli TA, 1994, HEAD INJURY, P137; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KESSLER J, 1988, DEMENZTEST; KRAMER J, 1977, KURZE ANLEITUNG ZUM; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; MCFIE J, 1975, ASSESSMENT ORGANIC I; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; OSWALD WD, 1995, NURNBERGER ALTERSINV; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; TEASDALE G, 1974, LANCET, V2, P81; WALLESCH CW, IN PRESS J NEUROTRAU; Wechsler, 1997, WECHSLER ADULT INTEL; ZIMMERMANN P, 1995, NEUROPSYCHOLOGISCHE	25	91	95	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2001	15	5					401	412		10.1080/02699050010005959			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	431TW	WOS:000168648700003	11350654				2022-02-06	
J	Kirkendall, DT; Jordan, SE; Garrett, WE				Kirkendall, DT; Jordan, SE; Garrett, WE			Heading and head injuries in soccer	SPORTS MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; FOOTBALL PLAYERS; CONTACT-SPORTS; CONCUSSION; DAMAGE; PERFORMANCE; GUIDELINES; RETURN	In the world of sports, soccer is unique because of the purposeful use of the unprotected head for controlling and advancing the ball. This skill obviously places the player at risk of head injury and the game does carry some risk. Head injury can be a result of contact of the head with another head (or other body parts), ground, goal post, other unknown objects or even the ball. Such impacts can lead to contusions, fractures, eye injuries, concussions or even, in rare cases, death. Coaches, players, parents and physicians are rightly concerned about the risk of head injury in soccer, Current research shows that selected soccer players have some degree of cognitive dysfunction. It is important to determine the reasons behind such deficits. Purposeful heading has been blamed, but a closer look at the studies that focus on heading has revealed methodological concerns that question the validity of blaming purposeful heading of the ball. The player's history and age (did they play when the ball was leather and could absorb significant amounts of water), alcohol intake. drug intake. learning disabilities, concussion definition and control group use/composition are all factors that cloud the ability to blame purposeful heading. What does seem clear is that a player's history of concussive episodes is a more likely explanation for cognitive deficits. While it is likely that the subconcussive impact of purposeful heading is a doubtful factor in the noted deficits, it is unknown whether multiple subconcussive impacts might have some lingering effects. In addition, it is unknown whether the noted deficits have any affect on daily life. Proper instruction in the technique is critical because if the ball contacts an unprepared head (as in accidental head-ball contacts), the potential for serious injury is possible. To further our understanding of the relationship of heading, head injury and cognitive deficits, we need to: learn more about the actual impact of a ball on the head, verify the exposure to heading at all ages and competitive levels, determine stable estimates of concussive injury rates across the soccer spectrum, conduct prospective longitudinal studies on soccer players focusing on exposure, injury and cognition, and determine the minimum safe age to begin instruction on the skill of heading. Only then will we be able to speak with some authority on the issue of heading and head injuries in soccer.	Univ N Carolina, Dept Orthopaed, Chapel Hill, NC 27599 USA; US Soccer Federat, Chicago, IL USA; Neurol Associates W Los Angeles, Santa Monica, CA USA		Kirkendall, DT (corresponding author), Univ N Carolina, Dept Orthopaed, CB 7055, Chapel Hill, NC 27599 USA.						Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; BEERS SR, 1994, J LEARN DISABIL, V27, P315, DOI 10.1177/002221949402700508; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; BUCHSBAUM DG, 1991, ANN INTERN MED, V115, P774, DOI 10.7326/0003-4819-115-10-774; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, VIn: Vol 12, P386; Delaney JS, 1999, CLIN J SPORT MED, V9, P121; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Frith U, 1998, SCAND J PSYCHOL, V39, P191, DOI 10.1111/1467-9450.393078; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; Holbourn AHS, 1943, LANCET, V2, P438; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; HUGENHOLTZ H, 1982, CAN MED ASSOC J, V127, P827; JENNET B, 1971, SCI FDN NEUROLOGY; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; JOSEPH J, 2001, SOCCER MAY HAZARDOUS; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; LEVENDUKSY TA, SCI FOOTBALL, P385; LOHNES JH, 1994, SPORTS INJURIES MECH; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Luhtanen P., 1994, FOOTBALL SOCCER; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Maroon JC, 1999, SPORTS-RELATED CONCUSSION, P3; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MATTHEWS WB, 1972, BRIT MED J, V2, P326, DOI 10.1136/bmj.2.5809.326; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; Murphy, 1988, SCI FOOTBALL, P394; Neiman J, 1998, ALCOHOL CLIN EXP RES, V22, p346S, DOI 10.1111/j.1530-0277.1998.tb04389.x; *NFL SUBC MILD TRA, 1996, STAT REP MEM; Nigg JT, 1998, J ABNORM PSYCHOL, V107, P468, DOI 10.1037/0021-843X.107.3.468; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PARKINSON D, 1997, MAYO CLIN P, V52, P492; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Reilly TT, 1976, J HUM MOV STUD, V2, P87; Report of the Sports Medicine Committee, 1990, GUID MAN CONC SPORTS; Roberts AH, 1969, BRAIN DAMAGE BOXERS; Ruff RM, 1999, BRAIN INJURY, V13, P943; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SCHNEIDER K, 1988, INT J SPORT BIOMECH, V4, P358, DOI 10.1123/ijsb.4.4.358; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; STONER LJ, 1980, BIOM S P 1980 OCT BL; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; VICTOR M, 1989, WERNICKE KORSAKOFF R; Warren WL, 1998, CLIN SPORT MED, V17, P13, DOI 10.1016/S0278-5919(05)70057-0; 2000, SPORTS ILLUSTRA 0320, V92, P12	60	91	91	1	26	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0112-1642	1179-2035		SPORTS MED	Sports Med.		2001	31	5					369	386		10.2165/00007256-200131050-00006			18	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	429FD	WOS:000168504600006	11347686				2022-02-06	
J	Rao, VLR; Dogan, A; Bowen, KK; Todd, KG; Dempsey, RJ				Rao, VLR; Dogan, A; Bowen, KK; Todd, KG; Dempsey, RJ			Antisense knockdown of the glial glutamate transporter GLT-1 exacerbates hippocampal neuronal damage following traumatic injury to rat brain	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						antisense ODN; controlled cortical impact injury; glutamate uptake; hippocampus; knockdown; neuronal death	CONTROLLED CORTICAL IMPACT; OXIDE SYNTHASE EXPRESSION; IN-VIVO; EXTRACELLULAR GLUTAMATE; CELL-DEATH; ISCHEMIA; RELEASE; INHIBITION; SUBTYPE; EXCITOTOXICITY	Traumatic injury to rat brain induced by controlled cortical impact (CCI) results in chronic neuronal death in the hippocampus. In the normal brain, glutamate transporters actively clear the glutamate released synaptically to prevent receptor overactivation and excitotoxicity. Glutamate transporter 1 (GLT-1) is the most abundant and active glutamate transporter, which mediates the bulk of glutamate uptake. CCI injury significantly decreased GLT-1 mRNA (by 49-66%, P < 0.05) and protein (by 29-44%, P < 0.05) levels in the ipsilateral hippocampus, compared with either the respective contralateral hippocampus or the sham-operated control, 24-72 h after the injury, CCI injury in rats infused with GLT-1 antisense oligodeoxynucleotides (ODNs) exacerbated the hippocampal neuronal death and mortality, compared with the GLT-1 sense/random ODN-infused controls. At 7 days after the injury, hippocampal neuronal numbers were significantly lower in the CAI (reduced by 32%, P < 0.05), CA2 (by 45%, P < 0.01), CA3 (by 68%, P < 0.01) and dentate gyrus (by 31%, P < 0.05) in GLT-1 antisense ODN-infused rats, compared with the GLT-1 sense/random ODN-infused controls. This study suggested a role for GLT-1 dysfunction in promoting the hippocampal neuronal death after traumatic brain injury.	Univ Wisconsin, Dept Neurol Surg, Madison, WI 53706 USA; Univ Wisconsin, Cardiovasc Res Ctr, Madison, WI USA; Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Madison, WI 53792 USA; Univ Alberta, Dept Psychiat, Edmonton, AB, Canada		Rao, VLR (corresponding author), Univ Wisconsin, Dept Neurol Surg, Madison, WI 53706 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS28000, NS31220] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS028000, P01NS031220] Funding Source: NIH RePORTER		Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; Chan H, 2000, NEUROCHEM INT, V37, P243, DOI 10.1016/S0197-0186(00)00026-7; CHOI DW, 1997, PRIMER CEREBROVASCUL, P187; COCCIA C, 1999, SOC NEUR ABSTR, V25; Danbolt NC, 1998, PROG BRAIN RES, V116, P23, DOI 10.1016/S0079-6123(08)60428-8; Di X, 1999, J NEUROTRAUM, V16, P195, DOI 10.1089/neu.1999.16.195; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; ERECINSKA M, 1987, BIOCHEM PHARMACOL, V36, P3547, DOI 10.1016/0006-2952(87)90001-3; Figiel M, 2000, J NEUROSCI, V20, P3596, DOI 10.1523/JNEUROSCI.20-10-03596.2000; Fujita H, 1999, J CEREBR BLOOD F MET, V19, P604, DOI 10.1097/00004647-199906000-00003; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; Kanai Y, 1997, NEUROTRANSMITTER TRA, P171; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Knecht K, 1997, NEUROSCI LETT, V229, P201, DOI 10.1016/S0304-3940(97)00444-8; Koura SS, 1998, ACT NEUR S, V71, P244; Lievens JC, 1997, MOL BRAIN RES, V50, P181, DOI 10.1016/S0169-328X(97)00182-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Manzoni C, 1997, PHARMACOL RES, V35, P149, DOI 10.1006/phrs.1997.0129; Martin LJ, 1997, ANN NEUROL, V42, P335, DOI 10.1002/ana.410420310; Massieu L, 1997, J NEUROCHEM, V69, P1151; MASSIEU L, 1995, J NEUROCHEM, V64, P2262; MASSIEU L, 1999, J NEUROCHEM S, V73; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Miller HP, 1997, J NEUROCHEM, V68, P1564; Mukhin A, 1996, J NEUROSCI, V16, P6012; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Obrenovitch TP, 1999, ANN NY ACAD SCI, V890, P273, DOI 10.1111/j.1749-6632.1999.tb08004.x; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Rao VLR, 1999, J NEUROTRAUM, V16, P865, DOI 10.1089/neu.1999.16.865; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2000, NEUROCHEM INT, V36, P531, DOI 10.1016/S0197-0186(99)00153-9; RAO VLR, 1999, J NEUROCHEM S, V73; Robinson MB, 1998, NEUROCHEM INT, V33, P479, DOI 10.1016/S0197-0186(98)00055-2; Roettger V, 1996, NEUROSCIENCE, V75, P677, DOI 10.1016/0306-4522(96)00314-4; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Sanchez-Carbente MD, 1999, J NEUROCHEM, V72, P129; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Seal RP, 1999, ANNU REV PHARMACOL, V39, P431, DOI 10.1146/annurev.pharmtox.39.1.431; Seki Y, 1999, STROKE, V30, P433, DOI 10.1161/01.STR.30.2.433; Shioda S, 1998, ANN NY ACAD SCI, V865, P111, DOI 10.1111/j.1749-6632.1998.tb11169.x; Simantov R, 1999, J NEUROCHEM, V73, P1828; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; SUN FY, 1995, BRAIN RES, V693, P163, DOI 10.1016/0006-8993(95)00731-5; SUZUKI T, 1999, J NEUROTRAUM, V16, P973; SWANSON RA, 1995, J CEREBR BLOOD F MET, V15, P417, DOI 10.1038/jcbfm.1995.52; Swanson RA, 1997, J NEUROSCI, V17, P932; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Trotti D, 1996, J BIOL CHEM, V271, P5976, DOI 10.1074/jbc.271.11.5976; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wang Y, 1997, J NEUROSCI, V17, P4341; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; [No title captured]	63	91	97	0	0	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	JAN	2001	13	1					119	128		10.1046/j.1460-9568.2001.01367.x			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	394KJ	WOS:000166523000012	11135010				2022-02-06	
J	Stempien, L; Tsai, T				Stempien, L; Tsai, T			Intrathecal baclofen pump use for spasticity - A clinical survey	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						spasticity; intrathecal baclofen; brain injury; cerebral palsy; spinal cord injury; implantable pump	SEVERE SPINAL SPASTICITY; CEREBRAL-PALSY; GENERALIZED DYSTONIA; PROGRAMMABLE PUMP; BRAIN INJURY; FOLLOW-UP; INFUSION; ORIGIN; DELIVERY; REFLEX	Objective: To obtain information from continuous intrathecal baclofen infusion (CIBI) pump centers regarding specific clinical practices and experiences. Methods: A total of 115 centers were surveyed by mail. Results: Forty centers (35%) responded with information about 1002 test doses and 936 pump placements. Patient diagnoses included cerebral palsy, spinal cord injury, traumatic brain injury, and others. The average test dose was 50 mug. A total of 87% of trials were successful. The most common test dose complications were nausea/vomiting (2.6%) and sedation (2.2%). Pump placement complications included cerebrospinal fluid (CSF) collection (3.3%), constipation (2.9%), headache (2.4%), and CSF leak (2.2%). The most common long-term complications were catheter kink or migration (4%) and infection (1.2%). Improved daily activities including easier diapering, dressing, transfers, orthotic wear and comfort, and sitting tolerance were reported in the majority (>90%) of patients. Mixed results were reported for oral motor function and head, bladder, and bowel control. Conclusions: CIBI is an effective treatment for severe spasticity, with dramatic quality-of-life improvements and a small number of significant complications. Long-term benefits and complications need to be monitored in this complex population.	Univ Colorado, Rehabil Ctr, Childrens Hosp, Dept Rehabil Med, Denver, CO 80218 USA		Stempien, L (corresponding author), Univ Colorado, Rehabil Ctr, Childrens Hosp, Dept Rehabil Med, B285,1056 E 19th Ave, Denver, CO 80218 USA.						ABEL NA, 1994, ARCH PHYS MED REHAB, V75, P54; Albright AL, 1998, J NEUROSURG, V88, P73, DOI 10.3171/jns.1998.88.1.0073; Albright AL, 1996, J CHILD NEUROL, V11, P77, DOI 10.1177/088307389601100202; ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; AZOUVI P, 1993, J NEUROL NEUROSUR PS, V56, P515, DOI 10.1136/jnnp.56.5.515; Azouvi P, 1996, ARCH PHYS MED REHAB, V77, P35, DOI 10.1016/S0003-9993(96)90217-8; Becker R, 1997, J NEUROL, V244, P160, DOI 10.1007/s004150050067; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; Diederich NJ, 1997, MOVEMENT DISORD, V12, P1100, DOI 10.1002/mds.870120649; Dressler D, 1997, MOVEMENT DISORD, V12, P585, DOI 10.1002/mds.870120416; Gerszten PC, 1998, J NEUROSURG, V88, P1009, DOI 10.3171/jns.1998.88.6.1009; Gianino J M, 1998, J Neurosci Nurs, V30, P47; KROIN JS, 1984, EXP BRAIN RES, V54, P191; LATASH ML, 1989, EXP NEUROL, V103, P165, DOI 10.1016/0014-4886(89)90078-2; LAZORTHES Y, 1990, J NEUROSURG, V72, P393, DOI 10.3171/jns.1990.72.3.0393; LOUBSER PG, 1991, PARAPLEGIA, V29, P48, DOI 10.1038/sc.1991.7; MACDONELL RAL, 1989, J NEUROL NEUROSUR PS, V52, P1110, DOI 10.1136/jnnp.52.9.1110; Meythaler JM, 1997, J NEUROSURG, V87, P415, DOI 10.3171/jns.1997.87.3.0415; Middel B, 1997, J NEUROL NEUROSUR PS, V63, P204, DOI 10.1136/jnnp.63.2.204; Ordia JI, 1996, J NEUROSURG, V85, P452, DOI 10.3171/jns.1996.85.3.0452; PARKE B, 1989, ARCH PHYS MED REHAB, V70, P30; PENN RD, 1987, J NEUROSURG, V66, P181, DOI 10.3171/jns.1987.66.2.0181; PENN RD, 1992, J NEUROSURG, V77, P236, DOI 10.3171/jns.1992.77.2.0236; PENN RD, 1995, MOVEMENT DISORD, V10, P675, DOI 10.1002/mds.870100524; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; Zierski J, 1988, Acta Neurochir Suppl (Wien), V43, P94	26	91	96	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	NOV-DEC	2000	79	6					536	541		10.1097/00002060-200011000-00010			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	371WF	WOS:000165201700008	11083304				2022-02-06	
J	Drake, AI; Gray, N; Yoder, S; Pramuka, M; Llewellyn, M				Drake, AI; Gray, N; Yoder, S; Pramuka, M; Llewellyn, M			Factors predicting return to work following mild traumatic brain injury: A discriminant analysis	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognition; mild traumatic brain injury; occupational functioning; outcome; return to work	MINOR HEAD-INJURY; NEUROPSYCHOLOGICAL DEFICITS; RATING-SCALE; CONCUSSION; SYMPTOMS; SEQUELAE; RECOVERY; PROGRAM; COMA	Studies of mild traumatic brain injury (MTBI) suggest that most individuals recover rapidly and return to their everyday activities. However, a percentage of MTBI patients report persistent problems with cognitive, physical, and emotional symptoms. There is also evidence that some experience changes in occupational functioning following MTBI. The current study used a stepwise discriminant function analysis (DFA) to examine the role of injury severity variables, cognitive performance, and ratings of symptoms of TBI in predicting work status following MTBI. Subjects included 121 MTBI patients who were all active-duty military personnel. The stepwise DFA revealed that age and three cognitive variables (verbal memory, verbal fluency, and a speed test of planning and strategy) were predictive of work status 3-15 months following a documented MTBI, correctly classifying work status 68.8% of the time. A cross-validation DFA was conducted, with a 66.1% correct classification rate. These findings highlight the importance of cognitive impairments in identifying those at risk for occupational impairment following MTBI.	USN, Med Ctr, Dept Neurosci, Def & Vet Head Injury Program, San Diego, CA 92152 USA		Drake, AI (corresponding author), USN, Med Ctr, Dept Neurosci, Def & Vet Head Injury Program, San Diego, CA 92152 USA.						Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; Delis D.C., 1983, CALIFORNIA VERBAL LE; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; EKSTROM RB, 1976, MAP PLANNING TEST MA; EKSTRON RB, 1976, MAZE LERNING TEST MA; Fleming J, 1999, BRAIN INJURY, V13, P417; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Gentilini M., 1989, MILD HEAD INJURY; Grace J, 1999, ASSESSMENT, V6, P269, DOI 10.1177/107319119900600307; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; GRONWALL D, 1989, MILD HEAD INJURY; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hamsher K, 1983, VERBAL FLUENCY MULTI; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Heaton R.K., 1981, WISCONSIN CARD SORTI; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JENNETT B, 1989, MILD HEAD INJURY; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Levin H.S., 1989, MILD HEAD INJURY; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; Malec JF, 2000, J HEAD TRAUMA REHAB, V15, P670, DOI 10.1097/00001199-200002000-00006; PONSFORD J, 1994, BRIAN INJURY, V9, P1; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reitan RM, 1999, ARCH CLIN NEUROPSYCH, V14, P191, DOI 10.1016/S0887-6177(98)00012-2; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ruff R. M., 1989, MILD HEAD INJURY; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; RUTHERFORD WH, 1989, MILD HEAD INJURY; RYAN T V, 1992, Brain Injury, V6, P175, DOI 10.3109/02699059209029656; Spreen O., 1989, CLIN NEUROPSYCHOL, V3, P129, DOI [10.1080/13854048908403285, DOI 10.1080/13854048908403285]; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27	55	91	91	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	2000	15	5					1103	1112		10.1097/00001199-200010000-00004			10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	359DT	WOS:000089596800004	10970931				2022-02-06	
J	Lopez-Redondo, F; Nakajima, K; Honda, S; Kohsaka, S				Lopez-Redondo, F; Nakajima, K; Honda, S; Kohsaka, S			Glutamate transporter GLT-1 is highly expressed in activated microglia following facial nerve axotomy	MOLECULAR BRAIN RESEARCH			English	Article						glutamate transporter; GLT-1; microglia; astrocytes; facial nerve axotomy; facial nucleus; rat	AMYOTROPHIC-LATERAL-SCLEROSIS; RAT-BRAIN; MOTOR NEURONS; SPINAL-CORD; ASTROCYTES; NEUROTOXICITY; LOCALIZATION; HIPPOCAMPUS; EPILEPSY; ISCHEMIA	Glutamate transporters play an important role in the re-uptake of glutamate after its release from glutamatergic synapses. So far five of such transporters subtypes have been cloned from rodent and human brains. The densities of glutamate transporters are recognised to be developmentally regulated, but the role of glutamate transporters in the mechanisms underlying the occurrence of neuronal traumatic injury has not been widely Studied. Zn the present study quantitative Western blotting and immunohistochemical technique were employed to study the expression of GLT-1/EAAT2 in the facial nuclei of adult rats following unilateral facial nerve axotomy. The total content of GLT-1 protein decreased in the ipsilateral axotomised rat facial nucleus. However, activated microglia surrounding motoneurons showed high expression of GLT-1 after facial nerve axotomy. Parallel studies revealed that primary cultured microglial cells also showed GLT-1-immunoreactivity. To our knowledge, this is the first direct demonstration of the expression of GLT-1 protein in activated microglial cells, suggesting a neuroprotective role of microglia against glutamate excitotoxicity following nerve axotomy. (C) 2000 Elsevier Science B.V. All rights reserved.	Natl Inst Neurosci, Dept Neurochem, Kodaira, Tokyo 1878502, Japan; Soka Univ, Inst Life Sci, Div Neurochem, Hachioji, Tokyo 1928577, Japan		Kohsaka, S (corresponding author), Natl Inst Neurosci, Dept Neurochem, 4-1-1 Ogawahigashi, Kodaira, Tokyo 1878502, Japan.	kohsaka@ncnp.go.jp	Lopez-Redondo, Fernando/V-8224-2019	Lopez-Redondo, Fernando/0000-0002-3836-9239			ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Bristol LA, 1996, ANN NEUROL, V39, P676, DOI 10.1002/ana.410390519; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Choi I, 1997, GLIA, V20, P184, DOI 10.1002/(SICI)1098-1136(199707)20:3<184::AID-GLIA2>3.3.CO;2-U; DINGLEDINE R, 1990, TRENDS PHARMACOL SCI, V11, P334, DOI 10.1016/0165-6147(90)90238-4; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; GRAEBER MB, 1986, J NEUROCYTOL, V15, P363; GRAEBER MB, 1988, NEUROSCI LETT, V85, P317, DOI 10.1016/0304-3940(88)90585-X; Graeber MB, 1998, BRAIN RES, V813, P241, DOI 10.1016/S0006-8993(98)00859-2; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KONDO K, 1995, NEUROSCI LETT, V188, P140, DOI 10.1016/0304-3940(95)11408-O; LEHRE KP, 1995, J NEUROSCI, V15, P1835; LEKIEFFRE D, 1992, NEUROSCI LETT, V137, P78, DOI 10.1016/0304-3940(92)90303-O; LEVY LM, 1995, EUR J NEUROSCI, V7, P2036, DOI 10.1111/j.1460-9568.1995.tb00626.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Martin LJ, 1997, ANN NEUROL, V42, P335, DOI 10.1002/ana.410420310; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; Mennini T, 1998, J NEUROL SCI, V157, P31, DOI 10.1016/S0022-510X(98)00072-0; NAKAJIMA K, 1989, BIOMED RES-TOKYO, V10, P411; Nakajima K, 1998, GLIA, V24, P272, DOI 10.1002/(SICI)1098-1136(199811)24:3<272::AID-GLIA2>3.0.CO;2-4; NAKAJIMA K, 1992, J NEUROCHEM, V58, P1401, DOI 10.1111/j.1471-4159.1992.tb11356.x; Northington FJ, 1998, NEUROSCIENCE, V85, P1183, DOI 10.1016/S0306-4522(97)00673-8; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Robinson MB, 1998, NEUROCHEM INT, V33, P479, DOI 10.1016/S0197-0186(98)00055-2; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; SENBA E, 1991, BRAIN RES BULL, V26, P85, DOI 10.1016/0361-9230(91)90193-N; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; STREIT WJ, 1993, GLIA, V7, P68, DOI 10.1002/glia.440070112; Swanson RA, 1997, J NEUROSCI, V17, P932; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TORP R, 1995, EXP BRAIN RES, V103, P51; Yamada K, 1998, J NEUROSCI, V18, P5706	37	91	94	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	MAR 29	2000	76	2					429	435		10.1016/S0169-328X(00)00022-X			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	306ET	WOS:000086584900030	10762723				2022-02-06	
J	Borgens, RB; Shi, R				Borgens, RB; Shi, R			Immediate recovery from spinal cord injury through molecular repair of nerve membranes with polyethylene glycol	FASEB JOURNAL			English	Article						nerve fusion; nerve repair; neurotrauma	APPLIED ELECTRIC-FIELDS; FUNCTIONAL RECOVERY; GUINEA-PIGS; FUSION; HEMISECTION; MECHANISM; MODEL	A brief application of the hydrophilic polymer polyethylene glycol (PEG) swiftly repairs nerve membrane damage associated with severe spinal cord injury in adult guinea pigs. A 2 min application of PEG to a standardized compression injury to the cord immediately reversed the loss of nerve impulse conduction through the injury in all treated animals while nerve impulse conduction remained absent in all sham-treated guinea pigs. Physiological recovery was associated with a significant recovery of a quantifiable spinal cord dependent behavior in only PEG-treated animals. The application of PEG could be delayed for similar to 8 h without adversely affecting physiological and behavioral recovery which continued to improve for up to 1 month after PEG treatment.-Borgens, R. B., Shi, R. Immediate recovery from spinal cord injury through molecular repair of nerve membranes with polyethylene glycol.	Purdue Univ, Dept Basic Med Sci, Ctr Paralysis Res, Sch Vet Med, W Lafayette, IN 47907 USA		Borgens, RB (corresponding author), Purdue Univ, Dept Basic Med Sci, Ctr Paralysis Res, Sch Vet Med, W Lafayette, IN 47907 USA.						AHKONG QF, 1987, J CELL SCI, V88, P389; ALDEWINCKEL TL, 1982, BIOCHIM BIOPHYS ACTA, V689, P548; ASANO T, 1995, J NEUROTRAUM, V12, P993; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; BLIGHT AR, 1993, ADV NEUROL, V59, P91; BLIGHT AR, 1990, J COMP NEUOL, V60, P446; Borgens RB, 1999, J NEUROTRAUM, V16, P639, DOI 10.1089/neu.1999.16.639; BORGENS RB, 1986, J COMP NEUROL, V250, P157, DOI 10.1002/cne.902500203; BORGENS RB, 1987, SCIENCE, V238, P366, DOI 10.1126/science.3659920; BORGENS RB, 1993, RESTOR NEUROL NEUROS, V5, P305, DOI 10.3233/RNN-1993-55601; BORGENS RB, 1990, J COMP NEUROL, V296, P634, DOI 10.1002/cne.902960409; BORGENS RB, 1992, SPINAL CORD DYSFUNCT, V3, P110; Cheng HR, 1997, EXP NEUROL, V148, P544, DOI 10.1006/exnr.1997.6708; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P271, DOI 10.1007/BF01538965; FEHLINGS M, 1995, EXP NEUROL, V132, P123; Griffin John W., 1995, P375; Hannig J, 1999, INT J RADIAT BIOL, V75, P379, DOI 10.1080/095530099140555; Honmou Osamu, 1995, P480; Lee J, 1997, BIOCHEMISTRY-US, V36, P6251, DOI 10.1021/bi970404c; Lee Raphael C., 1993, Journal of Burn Care and Rehabilitation, V14, P528, DOI 10.1097/00004630-199309000-00007; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; LENTZ BR, 1994, CHEM PHYS LIPIDS, V73, P91, DOI 10.1016/0009-3084(94)90176-7; MASSENBURG D, 1993, BIOCHEMISTRY-US, V32, P9172, DOI 10.1021/bi00086a024; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Merchant FA, 1998, J SURG RES, V74, P131, DOI 10.1006/jsre.1997.5252; Moriarty LJ, 1998, J NEUROL SCI, V155, P121, DOI 10.1016/S0022-510X(97)00203-7; OLAGUE PH, 1980, P NATL ACAD SCI-BIOL, V77, P1701, DOI 10.1073/pnas.77.3.1701; PADANLAM JT, 1994, ANN NY ACAD SCI, V92, P111; Palmer JS, 1998, J UROLOGY, V159, P2136, DOI 10.1016/S0022-5347(01)63295-6; PONTECORVO G, 1975, SOMAT CELL GENET, V1, P397, DOI 10.1007/BF01538671; Shi R, 1999, J NEUROPHYSIOL, V81, P2406, DOI 10.1152/jn.1999.81.5.2406; SHI R, 1997, SOC NEUR ABSTR, V108, P16; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; THIERAULT E, 1988, J NEUROPHYSIOL, V60, P446; Tilcock C PS, 1979, BIOCHEMISTRY-US, V688, P645; YAWO H, 1985, J NEUROSCI, V5, P1626; Young Wise, 1993, Journal of Emergency Medicine, V11, P13	39	91	93	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2000	14	1					27	35		10.1096/fasebj.14.1.27			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	WOS:000084784700005	10627277				2022-02-06	
J	Cherian, L; Chacko, G; Goodman, JC; Robertson, CS				Cherian, L; Chacko, G; Goodman, JC; Robertson, CS			Cerebral hemodynamic effects of phenylephrine and l-arginine after cortical impact injury	CRITICAL CARE MEDICINE			English	Article						hypotension; intracranial hypertension; l-arginine; phenylephrine; traumatic brain injury; cortical impact injury	EXPERIMENTAL BRAIN INJURY; BLOOD-FLOW; ARTERIAL-PRESSURE; RATS; REDUCTION; SYNTHASE; VELOCITY; VOLUME; EDEMA	Objective: To determine the effects of a presser agent (phenylephrine and L-arginine) on the abnormal cerebral hemodynamics and on neurologic outcome after a severe cortical impact injury in rats. Design:Prospective, randomized study. Setting: University laboratory. Subjects: Male Long-Evans rats, weighing 300 to 400 g, fasted overnight. Interventions: The animals were anesthetized with isoflurane, and a severe cortical impact injury (velocity, 5 m/sec; deformation, 3 mm) was produced in the right parietal cortex. Five minutes after impact injury, one of the following three treatments were infused: 1 mL saline intravenously for 10 mins, 300 mg/kg L-arginine in 1 mL saline intravenously for 10 mins, or 0.3 mu g/kg/min phenylephrine intravenously for 3 hrs, Mean arterial pressure, intracranial pressure (ICP), cerebral perfusion pressure (CPP), and laser Doppler flow (IDF) at the impact site and in the contralateral parietal cortex were monitored for 3 hrs after the impact injury. Histologic examination of the brain was performed at 2 wks after injury in a separate group of L-arginine- and saline-treated animals. Measurements and Main Results: The immediate response to the impact injury was an increase in ICP, and a decrease in mean arterial pressure, CPP, and LDF, In the saline-treated animals, LDF decreased to <25% of the baseline values at the impact site and stayed at that level for the entire 3-hr monitoring period. On the contralateral side, LDF decreased initially and recovered gradually to approximately 50% of the preimpact baseline value. Infusion of both phenylephrine and L-arginine increased LDF back to near-baseline levels. However, phenylephrine increased ICP significantly, whereas ICP with L-arginine did not change. L-arginine treatment reduced the contusion volume from a median value of 5.28 mm(3) to 0.63 mm(3). Conclusions: Phenylephrine increased cerebral blood flow (CBF) by increasing CPP, L-arginine, however, increased CBF without changing CPP, The improvement in CBF was accompanied by a decrease in neurologic injury. Although the presser agents are used currently to increase CBF after traumatic brain injury, other strategies may also increase CBF without the potential adverse effects of induced hypertension.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA		Cherian, L (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline		Armstead WM, 1996, J NEUROSURG, V85, P901, DOI 10.3171/jns.1996.85.5.0901; ARNAL JF, 1995, J CLIN INVEST, V95, P2565, DOI 10.1172/JCI117957; BARIE PS, 1993, J TRAUMA, V35, P88, DOI 10.1097/00005373-199307000-00015; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Busto R, 1997, J NEUROTRAUM, V14, P35, DOI 10.1089/neu.1997.14.35; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DURWARD QJ, 1983, J NEUROSURG, V59, P803, DOI 10.3171/jns.1983.59.5.0803; ELLISON MD, 1989, STROKE, V20, P911, DOI 10.1161/01.STR.20.7.911; Golding EM, 1998, J NEUROTRAUM, V15, P635, DOI 10.1089/neu.1998.15.635; Henley CM, 1996, J NEUROTRAUM, V13, P487, DOI 10.1089/neu.1996.13.487; HU JG, 1994, NEUROSCI LETT, V175, P41, DOI 10.1016/0304-3940(94)91073-1; JING ZA, 1992, J TRAUMA, V33, P83, DOI 10.1097/00005373-199207000-00016; KIMURA M, 1994, STROKE, V25, P2227, DOI 10.1161/01.STR.25.11.2227; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; MACRAE IM, 1993, J CEREBR BLOOD F MET, V13, P276, DOI 10.1038/jcbfm.1993.34; Micieli G, 1997, J NEUROL SCI, V150, P71, DOI 10.1016/S0022-510X(97)05380-X; MORIKAWA E, 1994, STROKE, V25, P429, DOI 10.1161/01.STR.25.2.429; OKIYAMA K, 1994, J NEUROTRAUM, V11, P83, DOI 10.1089/neu.1994.11.83; PELLIGRINO DA, 1993, J CEREBR BLOOD F MET, V13, P80, DOI 10.1038/jcbfm.1993.10; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822, DOI 10.1152/ajpheart.1986.250.5.H822; TANAKA K, 1991, NEUROSCI LETT, V127, P129, DOI 10.1016/0304-3940(91)90911-C; TREVISANI GT, 1994, J TRAUMA, V37, P452, DOI 10.1097/00005373-199409000-00021; WADA K, 1997, ABSTR J NEUR, V14, P760	29	91	93	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	1999	27	11					2512	2517		10.1097/00003246-199911000-00031			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258AA	WOS:000083814800030	10579273				2022-02-06	
J	Stuss, DT; Binns, MA; Carruth, FG; Levine, B; Brandys, CE; Moulton, RJ; Snow, WG; Schwartz, ML				Stuss, DT; Binns, MA; Carruth, FG; Levine, B; Brandys, CE; Moulton, RJ; Snow, WG; Schwartz, ML			The acute period of recovery from traumatic brain injury: posttraumatic amnesia or posttraumatic confusional state?	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; acute recovery; posttraumatic amnesia; posttraumatic confusional state; attention; memory	SEVERE HEAD-INJURY; COGNITIVE SEQUELAE; PRACTICAL SCALE; EARLY INDEXES; COMA; ORIENTATION; PREDICTORS; PTA	Object. The goal of this study was to characterize more fully the cognitive changes that occur during the period of acute recovery after traumatic brain injury (TBI). Methods. The pattern of performance recovery on attention and memory tests was compared with the results of the Galveston Orientation and Amnesia Test (GOAT). Tests of memory and attention were administered serially to a hospitalized group of patients with TBI of varying severity. The tests differed in their level of complexity and/or requirement for more effortful or strategic processing. The authors found a regular pattern to recovery. As expected, ability to perform on simpler tests was recovered before performance on more effortful ones. The ability to recall three words freely after a 24-hour delay (the operational definition in this study of return to continuous memory) was recovered last, later than normal performance on the GOAT. Ability to perform simple attentional tasks was recovered before the less demanding memory task (recognition); ability to perform more complex attentional tasks was recovered before the free recall of three words after a 24-hour delay. This recovery of attention before memory was most notable and distinct in the group with mild TBI. Conclusions. The period of recovery after TBI, which is currently termed posttraumatic amnesia, appears to be primarily a confusional state and should be labeled as such. The authors propose a new definition for this acute recovery period and argue that the term posttraumatic confusional state should be used, because it more appropriately and completely characterizes the early period of recovery after TBI.	Baycrest Ctr Geriatr Care, Rotman Res Inst, N York, ON M6A 2E1, Canada; Univ Toronto, Dept Med Neurol, Toronto, ON, Canada; Univ Toronto, Dept Psychol, Toronto, ON, Canada; Univ Toronto, Dept Surg Neurosurg, Toronto, ON, Canada; Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; St Michaels Hosp, Toronto, ON, Canada		Stuss, DT (corresponding author), Baycrest Ctr Geriatr Care, Rotman Res Inst, 3560 Bathurst St, N York, ON M6A 2E1, Canada.		Binns, Malcolm/AAQ-9195-2020; Levine, Brian/O-2725-2019; Levine, Brian/G-4328-2010	Binns, Malcolm/0000-0001-9998-6612; Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ALEXANDER MP, 1982, PSYCHIAT ASPECTS NEU, P219; ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; ARTIOLA I, 1980, J NEUROL NEUROSUR PS, V43, P377; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BENSON DF, 1976, NEUROLOGY, V26, P147, DOI 10.1212/WNL.26.2.147; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BROOKS D N, 1974, Cortex, V10, P224; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; CORRIGAN J D, 1992, Brain Injury, V6, P155, DOI 10.3109/02699059209029653; COURVILLE CB, 1937, PATHOLOGY CENTRAL NE; CROVITZ HF, 1983, CORTEX, V19, P407, DOI 10.1016/S0010-9452(83)80009-4; DANIEL WF, 1987, CORTEX, V23, P169, DOI 10.1016/S0010-9452(87)80030-8; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; GASQUOINE P G, 1991, Brain Injury, V5, P169, DOI 10.3109/02699059109008087; GEFFEN GM, 1991, NEUROREPORT, V2, P105, DOI 10.1097/00001756-199102000-00010; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; HASLAM C, 1994, BRAIN INJURY, V8, P519, DOI 10.3109/02699059409151004; JACKSON RD, 1989, ARCH PHYS MED REHAB, V70, P33; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Katz D, 1992, J HEAD TRAUMA REHAB, V72, P1, DOI [10.1097/00001199-200501000-00008, DOI 10.1097/00001199-200501000-00008]; KATZ DI, 1994, HDB NEUROREHABILITAT, P493; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LIPOWSKI ZJ, 1990, DELIRIUM ACTURE CONF; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; O'Shanick G J, 1986, Adv Psychosom Med, V16, P173; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; RICHARDSON JTE, 1984, COGN NEUROPSYCHOL, V3, P217; SAS Institute, 1990, SAS STAT US GUID VER; Schwartz ML, 1998, CAN J NEUROL SCI, V25, P108, DOI 10.1017/S0317167100033709; SHORES EA, 1989, J NEUROL NEUROSUR PS, V52, P126, DOI 10.1136/jnnp.52.1.126-a; STUSS DT, 1995, NEUROLOGY, V45, P1251, DOI 10.1212/WNL.45.7.1251; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; Symonds CP, 1943, LANCET, V1, P7; TEASDALE G, 1974, LANCET, V2, P81	44	91	92	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	APR	1999	90	4					635	643		10.3171/jns.1999.90.4.0635			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	180CD	WOS:000079366700003	10193606				2022-02-06	
J	Fox, GB; Fan, L; LeVasseur, RA; Faden, AI				Fox, GB; Fan, L; LeVasseur, RA; Faden, AI			Effect of traumatic brain injury on mouse spatial and nonspatial learning in the Barnes circular maze	JOURNAL OF NEUROTRAUMA			English	Article						Barnes circular maze; brain trauma; cognition; controlled cortical impact	MORRIS WATER MAZE; CONTROLLED CORTICAL IMPACT; CLOSED-HEAD INJURY; COGNITIVE DEFICITS; CEREBRAL-ISCHEMIA; CORTEX LESIONS; RATS; HIPPOCAMPAL; MICE; PERFORMANCE	Controlled cortical impact (CCI) is a relatively new model of traumatic brain injury in the mouse, which, in combination with behavioral and histological methods, has potential for elucidating underlying mechanisms of neurodegeneration using genetically altered animals. Previously, we have demonstrated impaired spatial learning in a water maze task following CCI injury at a moderate level. There are many difficulties associated with this task, however, such as stress, physical demand, and the multiple trials over days required for satisfactory training. As a potential alternative to the water maze, we adapted the Barnes circular maze to our mouse model and assessed spatial/non-spatial learning following injury. Mice were trained to locate a dark tunnel, hidden beneath one of 40 holes positioned around the perimeter of a large, flat, plastic disk, brightly illuminated by four overhead halogen lamps. Sham-operated animals rapidly acquired this task, exhibiting reduced latency to find the tunnel and a more efficient search strategy as compared with injured mice. This difference was not due to visuomotor deficits, as all mice performed equally well in a cued version of the same task. These results demonstrate spatial learning impairment following CCI injury in a task that offers an efficient alternative to the water maze.	Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA		Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, 3970 Reservoir Rd NW,Rm EP-04, Washington, DC 20007 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR 306634] Funding Source: Medline		BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Compton DM, 1997, NEUROBIOL LEARN MEM, V68, P117, DOI 10.1006/nlme.1997.3793; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hardman R, 1997, BRAIN RES, V758, P187, DOI 10.1016/S0006-8993(97)00223-0; Hodges H, 1996, COGNITIVE BRAIN RES, V3, P167, DOI 10.1016/0926-6410(96)00004-3; Kraemer PJ, 1996, BRAIN RES BULL, V39, P17, DOI 10.1016/0361-9230(95)02028-4; Levin H.S., 1996, TRAUMATIC BRAIN INJU, P105; Logue SE, 1997, BEHAV NEUROSCI, V111, P104, DOI 10.1037/0735-7044.111.1.104; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MOSER MB, 1994, P NATL ACAD SCI USA, V91, P12673, DOI 10.1073/pnas.91.26.12673; NAGAHARA AH, 1995, BEHAV NEUROSCI, V109, P3, DOI 10.1037/0735-7044.109.1.3; Nelson A, 1997, BEHAV BRAIN RES, V85, P93, DOI 10.1016/S0166-4328(96)00167-2; NETTO CA, 1993, NEUROSCIENCE, V54, P69, DOI 10.1016/0306-4522(93)90384-R; Ohta H, 1997, NEUROSCIENCE, V79, P1039, DOI 10.1016/S0306-4522(97)00037-7; Owen AJ, 1997, BRAIN RES, V770, P115, DOI 10.1016/S0006-8993(97)00789-0; Ragozzino ME, 1998, J NEUROSCI, V18, P1595; Rogers DC, 1997, PHARMACOL BIOCHEM BE, V56, P747, DOI 10.1016/S0091-3057(96)00430-3; Rusakov DA, 1997, NEUROSCIENCE, V80, P69, DOI 10.1016/S0306-4522(97)00125-5; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Vorhees CV, 1997, DRUG CHEM TOXICOL, V20, P387, DOI 10.3109/01480549709003895; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yamada K, 1996, J PHARMACOL EXP THER, V276, P460; Yonemori F, 1996, J CEREBR BLOOD F MET, V16, P973, DOI 10.1097/00004647-199609000-00022	38	91	92	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	1998	15	12					1037	1046		10.1089/neu.1998.15.1037			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	148FW	WOS:000077495200004	9872460				2022-02-06	
J	Wrathall, JR; Li, W; Hudson, LD				Wrathall, JR; Li, W; Hudson, LD			Myelin gene expression after experimental contusive spinal cord injury	JOURNAL OF NEUROSCIENCE			English	Article						myelin; spinal cord injury; mRNA; proteolipid protein; myelin basic protein; protein zero; myelin transcription factor 1; in situ hybridization; Western analysis; immunocytochemistry	TRANSCRIPTION FACTOR-1 MYT1; DNA-BINDING PROTEIN; ZINC-FINGER; BASIC-PROTEIN; RAT-BRAIN; OLIGODENDROCYTES; APOPTOSIS; AXONS; CAT; REMYELINATION	After incomplete traumatic spinal cord injury (SCI), the spared tissue exhibits abnormal myelination that is associated with reduced or blocked axonal conductance. To examine the molecular basis of the abnormal myelination, we used a standardized rat model of incomplete SCI and compared normal uninjured tissue with that after contusion injury. We evaluated expression of mRNA for myelin proteins using in situ hybridization with oligonucleotide probes to proteolipid protein (PLP), the major protein in central myelin; myelin basic protein (MBP), a major component of central myelin and a minor component of peripheral myelin; and protein zero (PO), the major structural protein of peripheral myelin, as well as myelin transcription factor 1 (MYT1). We found reduced expression of PLP and MBP chronically after SCI in the dorsal, lateral, and ventral white matter both rostral and caudal to the injury epicenter. Detailed studies of PLP at 2 months after injury indicated that the density of expressing cells was normal but mRNA per cell was reduced. In addition, PO, normally restricted to the peripheral nervous system, was expressed both at the epicenter and in lesioned areas at least 4 mm rostral and caudal to it. Thus, after SCI, abnormal myelination of residual axons may be caused, at least in part, by changes in the transcriptional regulation of genes for myelin proteins and by altered distribution of myelin-producing cells. In addition, the expression of MYT1 mRNA and protein seemed to be upregulated after SCI in a pattern suggesting the presence of undifferentiated progenitor cells in the chronically injured cord.	Georgetown Univ, Dept Cell Biol, Div Neurobiol, Washington, DC 20007 USA; NINDS, Lab Dev Neurogenet, Bethesda, MD 20892 USA		Wrathall, JR (corresponding author), Georgetown Univ, Dept Cell Biol, Div Neurobiol, 3900 Reservoir Rd, Washington, DC 20007 USA.			Li, Wen/0000-0002-5543-4899	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA051008] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35647, NS28130, R01 NS035647] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035647, P01NS028130] Funding Source: NIH RePORTER		Armstrong RC, 1997, J NEUROPATH EXP NEUR, V56, P772; ARMSTRONG RC, 1995, GLIA, V14, P303, DOI 10.1002/glia.440140407; ARMSTRONG RC, 1992, J NEUROSCI, V12, P1538; BALENTINE JD, 1978, LAB INVEST, V39, P254; Bhat RV, 1996, GLIA, V17, P169; BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1; BLIGHT AR, 1983, NEUROSCIENCE, V10, P1471, DOI 10.1016/0306-4522(83)90128-8; BLIGHT AR, 1989, J NEUROL SCI, V91, P15, DOI 10.1016/0022-510X(89)90073-7; BLIGHT AR, 1993, ADV NEUROL, V59, P91; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRESNAHAN JC, 1978, J NEUROL SCI, V37, P59, DOI 10.1016/0022-510X(78)90228-9; BUNGE MB, 1994, EXP NEUROL, V127, P76, DOI 10.1006/exnr.1994.1082; BUNGE RP, 1993, ADV NEUROL, V59, P75; CARSON JH, 1983, DEV BIOL, V96, P485, DOI 10.1016/0012-1606(83)90185-9; COOK JL, 1992, NEUROSCI LETT, V137, P56, DOI 10.1016/0304-3940(92)90297-K; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DEFERRA F, 1985, CELL, V43, P721, DOI 10.1016/0092-8674(85)90245-4; EIDELBERG E, 1977, EXP NEUROL, V56, P312, DOI 10.1016/0014-4886(77)90350-8; FOLLESA P, 1994, MOL BRAIN RES, V22, P1, DOI 10.1016/0169-328X(94)90026-4; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; GLEDHILL RF, 1973, EXP NEUROL, V38, P472, DOI 10.1016/0014-4886(73)90169-6; GRIFFITHS IR, 1983, J NEUROL SCI, V58, P335, DOI 10.1016/0022-510X(83)90093-X; HANSEBOUT RR, 1993, J NEUROTRAUM, V10, P1, DOI 10.1089/neu.1993.10.1; HAYES KC, 1994, J NEUROTRAUM, V11, P433, DOI 10.1089/neu.1994.11.433; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUDSON LD, 1990, SEMIN NEUROSCI, V2, P483; HUDSON LD, 1997, MOL SIGNALING REGULA, P182; Kim JG, 1997, J NEUROSCI RES, V50, P272, DOI 10.1002/(SICI)1097-4547(19971015)50:2<272::AID-JNR16>3.0.CO;2-A; KIM JG, 1992, MOL CELL BIOL, V12, P5632, DOI 10.1128/MCB.12.12.5632; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Liu XZ, 1997, J NEUROSCI, V17, P5395; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mocchetti I, 1996, EXP NEUROL, V141, P154, DOI 10.1006/exnr.1996.0149; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; NOBLE LJ, 1989, EXP NEUROL, V103, P34, DOI 10.1016/0014-4886(89)90182-9; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; Peters A., 1991, FINE STRUCTURE NERVO, V3rd ed.; Richardson WD, 1997, DEV NEUROSCI-BASEL, V19, P58, DOI 10.1159/000111186; Rosenberg LJ, 1997, J NEUROTRAUM, V14, P823, DOI 10.1089/neu.1997.14.823; Salgado-Ceballos H, 1998, BRAIN RES, V782, P126; SHIBABUDDIN LS, 1997, EXP NEUROL, V148, P577; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; Teng YD, 1997, J NEUROSCI, V17, P4359; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7; ZELLER NK, 1985, J NEUROSCI, V5, P2955	46	91	93	0	6	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	NOV 1	1998	18	21					8780	8793					14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	132ED	WOS:000076616600023	9786985				2022-02-06	
J	Stiell, IG; Wells, GA; Vandemheen, K; Laupacis, A; Brison, R; Eisenhauer, MA; Greenberg, GH; MacPhail, I; McKnight, RD; Reardon, M; Verbeek, R; Worthington, J; Lesiuk, H				Stiell, IG; Wells, GA; Vandemheen, K; Laupacis, A; Brison, R; Eisenhauer, MA; Greenberg, GH; MacPhail, I; McKnight, RD; Reardon, M; Verbeek, R; Worthington, J; Lesiuk, H			Variation in ED use of computed tomography for patients with minor head injury	ANNALS OF EMERGENCY MEDICINE			English	Article							ACUTE ANKLE INJURIES; TRAUMATIC INTRACRANIAL HEMATOMA; CLINICAL DECISION RULES; ACUTE KNEE INJURIES; SUBDURAL-HEMATOMA; SELECTION CRITERIA; DELAYED DIAGNOSIS; CT SCANS; RADIOGRAPHY; MANAGEMENT	Study objective: To determine the frequency of utilization, yield for brain injury, incidence of missed injury, and variation in the use of computed tomography (CT) for ED patients with minor head injury. Methods: This retrospective health records survey was conducted over a 12-month period in the EDs at seven Canadian teaching institutions. Included in this review were adult patients who sustained acute minor head injury, defined as witnessed loss of consciousness or amnesia and a Glasgow Coma Scale score of 13 or greater. Data were collected by research assistants who were trained to select cases and abstract data in a standardized fashion according to a resource manual. Subsequently, patient eligibility was reviewed by the study coordinator and principal investigator. Results: Of the 1,699 patients seen, 521 (30.7%) were referred for CT, and 418 (79.8%) of these scans were negative for any type of brain injury. Overall, 105 (6.2%) of these patients sustained acute brain injury, including 9 (.5%) with an epidural hematoma. Cochran's Q test for homogeneity demonstrated significant variation between the seven centers for rate of ordering CT (P<.0001), from a low of 15.9% to a high of 70.4%. All five cases of ''missed'' hematoma occurred at the institutions with the highest acid third highest rates of CT use. After controlling for possible differences in case severity and patient characteristics at each hospital, logistic regression analysis revealed that five of seven hospitals were significantly associated with use of CT (respective odds ratios [OR], .4, .5, .5, 3.2, and 4.7). Three of the centers (two with the highest ordering rates) showed significant heterogeneity in the ordering of CT among their attending staff physicians, from a low of 6.5% to a high of 80.0%. Conclusion: There was considerable variation among institutions and individual physicians in the ordering of CT for patients with minor head injury. Although emergency physicians were selective when ordering CT, the yield of radiography was very low at all hospitals. None of the cases of ''missed'' intracranial hematoma came from the lowest ordering institutions, indicating that patients may be managed safely with a selective approach to CT use, These findings suggest great potential for more standardized and efficient use of CT of the head, possibly through the use of a clinical decision rule.			Stiell, IG (corresponding author), OTTAWA CIVIC HOSP,LOEB RES INST,CLIN EPIDEMIOL UNIT,DIV EMERGENCY MED,1053 CARLING AVE,OTTAWA,ON K1Y 4E9,CANADA.		Reardon, Michael/ABF-8880-2021	Stiell, Ian/0000-0002-2583-6408			*AM COLL SURG, 1993, ADV TRAUM LIF SUPP I; ANIS AH, 1995, ANN EMERG MED, V26, P422, DOI 10.1016/S0196-0644(95)70108-7; BELL RS, 1971, NEW ENGL J MED, V284, P236, DOI 10.1056/NEJM197102042840504; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; CARTER A, 1992, CAN MED ASSOC J, V147, P1649; Cook L S, 1994, Acad Emerg Med, V1, P227; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DEITCH D, 1989, NEUROLOGY, V39, P985, DOI 10.1212/WNL.39.7.985; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DUUS BR, 1993, BRIT J SURG, V80, P988, DOI 10.1002/bjs.1800800817; DUUS BR, 1994, ANN EMERG MED, V23, P1279, DOI 10.1016/S0196-0644(94)70352-3; FEINSTEIN AR, 1985, ARCH INTERN MED, V145, P1257, DOI 10.1001/archinte.145.7.1257; Feinstein AR, 1987, CLINIMETRICS; GALBRAITH S, 1976, BMJ-BRIT MED J, V1, P1438, DOI 10.1136/bmj.1.6023.1438; Goel V, 1996, PATTERNS HLTH CARE O, V2nd; GRAHAM ID, 1996, MED DECIS MAKING, V16, P469; GUTMAN MB, 1992, J NEUROSURG, V77, P9, DOI 10.3171/jns.1992.77.1.0009; *HLTH SERV RES GRO, 1992, CAN MED ASSOC J, V146, P467; ISCOE NA, 1994, CAN MED ASSOC J, V150, P345; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; LEVITT MA, 1994, ANN EMERG MED, V23, P1143; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; Long A E, 1985, Emerg Med Clin North Am, V3, P437; MADDEN C, 1995, ACAD EMERG MED, V2, P248, DOI 10.1111/j.1553-2712.1995.tb03217.x; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; McCaig L F, 1994, Adv Data, P1; MCDONALD CJ, 1994, JAMA-J AM MED ASSOC, V271, P872, DOI 10.1001/jama.271.11.872; MENDELOW AD, 1979, BRIT MED J, V1, P1240, DOI 10.1136/bmj.1.6173.1240; MIKHAIL MG, 1992, AM J EMERG MED, V10, P24, DOI 10.1016/0735-6757(92)90119-I; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; MILLER JD, 1986, NEUROSURG REV, V9, P135, DOI 10.1007/BF01743065; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; MORAN SG, 1994, AM SURGEON, V60, P533; *NAT CTR HLTH STAT, 1994, NAT HOSP AMB MED CAR; PITTS LH, 1991, ANN EMERG MED, V20, P1387, DOI 10.1016/S0196-0644(05)81089-3; REINUS WR, 1993, ANN EMERG MED, V22, P1148, DOI 10.1016/S0196-0644(05)80981-3; RICHLESS LK, 1993, AM J EMERG MED, V11, P327, DOI 10.1016/0735-6757(93)90161-4; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; ROSEN P, 1992, EMERGENCY MED CONCEP; SCHYNOLL W, 1993, AM J EMERG MED, V11, P321, DOI 10.1016/0735-6757(93)90160-D; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SERVADEI F, 1993, SURG NEUROL, V39, P269, DOI 10.1016/0090-3019(93)90003-J; SERVADEI F, 1995, J TRAUMA, V39, P696, DOI 10.1097/00005373-199510000-00015; SERVADEI F, 1988, SURG NEUROL, V30, P364, DOI 10.1016/0090-3019(88)90199-1; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; SNOEY ER, 1994, ANN EMERG MED, V23, P1127, DOI 10.1016/S0196-0644(94)70115-6; STEIN SC, 1993, ANN EMERG MED, V22, P1193, DOI 10.1016/S0196-0644(05)80989-8; STEIN SC, 1993, BRAIN INJURY, V7, P425, DOI 10.3109/02699059309029685; STEIN SC, 1991, ANN EMERG MED, V20, P1286, DOI 10.1016/S0196-0644(05)81066-2; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; STIELL I, 1995, BRIT MED J, V311, P594, DOI 10.1136/bmj.311.7005.594; STIELL IG, 1992, CAN MED ASSOC J, V147, P1671; STIELL IG, 1993, JAMA-J AM MED ASSOC, V269, P1127, DOI 10.1001/jama.269.9.1127; STIELL IG, 1992, ANN EMERG MED, V21, P384, DOI 10.1016/S0196-0644(05)82656-3; STIELL IG, 1995, ACAD EMERG MED, V2, P966, DOI 10.1111/j.1553-2712.1995.tb03123.x; Stiell IG, 1996, JAMA-J AM MED ASSOC, V275, P611, DOI 10.1001/jama.275.8.611; STIELL IG, 1994, JAMA-J AM MED ASSOC, V271, P827, DOI 10.1001/jama.271.11.827; STIELL IG, 1995, ANN EMERG MED, V26, P405, DOI 10.1016/S0196-0644(95)70106-0; STIELL IG, 1991, THESIS U OTTAWA OTTA; TAHERI PA, 1993, ARCH SURG-CHICAGO, V128, P289; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; TINTINALLI JE, 1992, EMERGENCY MED COMPRE; VOSS M, 1995, BRIT MED J, V311, P1395, DOI 10.1136/bmj.311.7017.1395; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WENNBERG JE, 1984, HLTH AFF MILLWOOD, V4, P6; YEALY D M, 1991, Emergency Medicine Clinics of North America, V9, P707	73	91	91	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	JUL	1997	30	1					14	22		10.1016/S0196-0644(97)70104-5			9	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	XG890	WOS:A1997XG89000003	9209219				2022-02-06	
J	Kelly, DF; Kordestani, RK; Martin, NA; Nguyen, T; Hovda, DA; Bergsneider, M; McArthur, DL; Becker, DP				Kelly, DF; Kordestani, RK; Martin, NA; Nguyen, T; Hovda, DA; Bergsneider, M; McArthur, DL; Becker, DP			Hyperemia following traumatic brain injury: Relationship to intracranial hypertension and outcome	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; intracranial hypertension; cerebral blood flow; cerebral vasoreactivity; hyperemia	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; PRESSURE; METABOLISM; AUTOREGULATION; VASOREACTIVITY; CIRCULATION; MANAGEMENT	The role of posttraumatic hyperemia in the development of raised intracranial pressure (ICP) has important pathophysiological and therapeutic implications. To determine the relationship between hyperemia (cerebral blood flow (CBF) > 55 ml/100 g/minute), intracranial hypertension (ICP > 20 mm Hg), and neurological outcome, 193 simultaneous measurements of ICP and CBF (xenon-133 method) were obtained in 59 patients with moderate and severe head injury. Hyperemia was associated with an increased incidence of simultaneous intracranial hypertension compared to nonhyperemic CBF measurements (32.2% vs. 21.6%, respectively; p < 0.059). However, in 78% of blood flow studies in which ICP was greater than 20 mm Hg. CBF was less than or equal to 55 ml/100 g/minute. At least one episode of hyperemia was documented in 34% of patients, all of whom had a Glasgow Coma Scale (GCS) score of 9 or below. In 12 individuals with hyperemia without simultaneous intracranial hypertension, ICP was greater than 20 mm Hg for an average of 11 +/- 16 hours and favorable outcomes were seen in 75% of patients. In contrast, in eight individuals with hyperemia and at least one episode of hyperemia-associated intracranial hypertension, ICP was greater than 20 mm Hg for an average of 148 +/- 84 hours (p < 0.001), and a favorable outcome was seen in only one patient (p < 0.001). Compared to the remainder of the cohort, patients with hyperemia-associated intracranial hypertension were distinctive in being the youngest, exhibiting the lowest GCS scores (all less than or equal to 6), and having the highest incidence of effaced basilar cisterns and intractable intracranial hypertension. In the majority of individuals with hyperemia-associated intracranial hypertension, their clinical profile suggests the occurrence of a severe initial insult with resultant gross impairment of metabolic vasoreactivity and pressure antoregulation. In a minority of these patients, however, high CBF may be coupled to a hypermetabolic state, given their responsiveness to metabolic suppressive therapy. In patients with hyperemia but without intracranial hypertension, elevated CBF is also likely to be a manifestation of appropriate coupling to increased metabolic demand consistent with a generally favorable outcome. This study supports the concept that there are multiple etiologies of both elevated blood flow and intracranial hypertension after head injury.	UNIV CALIF LOS ANGELES, SCH MED, CEREBRAL BLOOD FLOW LAB, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, BRAIN INJURY RES CTR, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, BRAIN RES INST, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MOL & MED PHARMACOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT EPIDEMIOL, LOS ANGELES, CA 90024 USA		Kelly, DF (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DIV NEUROSURG, BOX 957039, ROOM 18-218A NPI, LOS ANGELES, CA 90095 USA.		McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314; Martin, Neil/0000-0002-6565-4131	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30308] Funding Source: Medline		AASLID R, 1987, STROKE, V18, P771, DOI 10.1161/01.STR.18.4.771; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; *ASS ADV AUT MED, 1990, ABBR INJ SCALE 1990; BERGSNEIDER M, 1995, J CEREB BLOOD FLO S1, V15, pS26; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1975, LANCET, V1, P480; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KLINGELHOFER J, 1992, STROKE, V23, P962, DOI 10.1161/01.STR.23.7.962; KURODA Y, 1992, J NEUROSURG, V76, P471, DOI 10.3171/jns.1992.76.3.0471; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; MARION DW, 1993, J NEUROSURG, V78, pA347; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARMAROU A, 1992, J NEUROTRAUMA S1, V49, pS327; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; Miller J D, 1993, Acta Neurochir Suppl (Wien), V57, P152; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; Ritter A M, 1994, Neurosurg Clin N Am, V5, P633; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SAKAS DE, 1995, J NEUROSURG, V83, P277, DOI 10.3171/jns.1995.83.2.0277; SHALMON E, 1994, INTRACRANIAL PRESSUR, V9, P357; SIOUTOS PJ, 1995, NEUROSURGERY, V36, P943, DOI 10.1227/00006123-199505000-00009; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	43	91	94	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	1996	85	5					762	771		10.3171/jns.1996.85.5.0762			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	VP489	WOS:A1996VP48900004	8893712				2022-02-06	
J	Carey, ME				Carey, ME			Analysis of wounds incurred by US Army Seventh Corps personnel treated in corps hospitals during Operation Desert Storm, February 20 to March 10, 1991	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	7th International Symposium of Weapons Traumatology and Wound Ballistics	SEP 20-23, 1994	ST PETERSBURG, RUSSIA	Russian Acad Med Sci, Fed Minister Hlth & Med Ind, Moscow, Mayer St Petersburg		trauma; combat; hemorrhage; brain wounds; missile injury; Operation Desert Storm	VIETNAM	One hundred and forty-three soldiers who received ballistic injury were actively treated at U.S. Army Seventh Corps hospitals during Operation Desert Storm, Ninety-five percent were wounded by fragments, 5% by bullets, Many had wounds of several body parts, including 17.3% who received a head wound; 4.3% a neck wound; 5.8% a chest wound; 9.3% an abdominal wound; and 90% who had extremity wounds, Three hospital deaths occurred-a 2.1% mortality rate, Only two soldiers sustained a brain wound; in both, the missile entered below the skull area protected by the Kevlar helmet, One brain-wounded individual was treated and lived; the other died from hemorrhage and shock from concomitant traumatic lower-extremity amputations, The current U.S. helmet appears to provide significant protection from fragmenting ordnance as does the armored vest. Hemorrhage from proximal extremity wounds caused hospital deaths, Treatment of such wounds will have to be improved to reduce future combat mortality.			Carey, ME (corresponding author), LOUISIANA STATE UNIV,MED CTR,DEPT NEUROSURG,USA RESERVE,MED CORPS,1542 TULANE AVE,NEW ORLEANS,LA 70112, USA.						BEEBE GW, 1952, BATTLE CASUALTIES, P165; BEEBE GW, 1952, BATTLE CASUALTIES, P178; BELLAMY RF, 1984, MIL MED, V149, P55; BOWEN TE, 1988, EMERGENCY WAR SURG, P5; BURNS BD, 1942, 350 RC BRIT MIN SUPP; CAREY ME, 1987, MIL MED, V152, P1; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; HEATON LD, 1966, CURR PROB SURG, P5; MAUGHON JS, 1970, MIL MED, V135, P8, DOI 10.1093/milmed/135.1.8; OUGHTERSON AW, 1962, WOUND BALLISTICS, P290; REISTER FA, 1973, BATTLE CASUALTIES ME, P35; REISTER FA, 1975, MED STAT WORLD WAR 2, P21; REISTER FA, 1973, BATTLE CASUALTIES ME, P43; SYNDER HGE, 1962, WOUND BALLISTICS, P484; UHORCHAK JM, CASUALTY DATA ASSESS; WHELAN TJ, 1968, ADV SURG, V3, P249; 1970, EVALUATION WOUND DAT, V1	17	91	94	0	3	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	1996	40	3		S			S165	S169		10.1097/00005373-199603001-00036			5	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	UB897	WOS:A1996UB89700040	8606402				2022-02-06	
J	KREGOR, PJ; SONG, KM; ROUTT, MLC; SANGEORZAN, BJ; LIDDELL, RM; HANSEN, ST				KREGOR, PJ; SONG, KM; ROUTT, MLC; SANGEORZAN, BJ; LIDDELL, RM; HANSEN, ST			PLATE FIXATION OF FEMORAL-SHAFT FRACTURES IN MULTIPLE INJURED CHILDREN	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							EXTERNAL FIXATION; FEMUR FRACTURES; ADOLESCENT; TRACTION	A study was done of twelve patients (seven boys and five girls) who, because of multiple injuries or a head injury, had been managed with compression plating of a unilateral or bilateral femoral-shaft fracture at a level-I trauma center from 1986 through 1990. The patients had a total of fifteen fractures. The average age at the time of the injuries was eight years (range, five years to nine years and eleven months). There were nine closed fractures and six open fractures; three of the open fractures were Grade I; two, Grade II; and one, Grade IIIA, according to the criteria of Gustilo et al. Each patient had an average of three associated injuries. All fifteen fractures had healed clinically and radiographically at an average of eight weeks (range, six to twelve weeks) after the operation. There were no infections. Anatomical alignment was obtained in fourteen limbs. One fracture healed with 13 degrees of anterior angulation. The compression plates were removed at an average of ten months (range, three to twenty-four months) after the index operation. At the latest follow-up evaluation (average, twenty-six months; range, eleven to fifty-seven months), no patient had restriction of activities due to the femoral fracture. Scanograms revealed overgrowth of the injured femur averaging 0.9 centimeter (range, 0.3 to 1.4 centimeters) in seven patients who had an uninjured contralateral femur. We believe that plate fixation of the femur is a good treatment option for children who have a femoral shaft fracture and a major head injury or multiple injuries, or both.	HARBORVIEW MED CTR,DEPT ORTHOPAED,SEATTLE,WA 98104; CHILDRENS HOSP & MED CTR,SEATTLE,WA 98105								ALLEN BL, 1977, J TRAUMA, V17, P8; ARONSON J, 1992, J PEDIATR ORTHOPED, V12, P157, DOI 10.1097/01241398-199203000-00003; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BELLAMY R, 1974, J TRAUMA, V14, P1021, DOI 10.1097/00005373-197412000-00004; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; DAMERON TB, 1959, J BONE JOINT SURG AM, V41, P1201, DOI 10.2106/00004623-195941070-00004; FRY K, 1976, J TRAUMA, V16, P371, DOI 10.1097/00005373-197605000-00008; GIBSON JMC, 1960, J BONE JOINT SURG BR, V42, P425; GLENN JN, 1973, J TRAUMA, V13, P958, DOI 10.1097/00005373-197311000-00004; GRATZ RR, 1979, J TRAUMA, V19, P551, DOI 10.1097/00005373-197908000-00001; GUSTILO RB, 1984, J TRAUMA, V24, P742, DOI 10.1097/00005373-198408000-00009; GUTTMANN GG, 1988, J PEDIATR ORTHOPED, V8, P699, DOI 10.1097/01241398-198811000-00014; HUMBERGER FW, 1969, J BONE JOINT SURG AM, VA 51, P499, DOI 10.2106/00004623-196951030-00007; IRANI RN, 1976, J BONE JOINT SURG AM, V58, P945, DOI 10.2106/00004623-197658070-00009; KIRBY RM, 1981, J PEDIATR ORTHOPED, V1, P193, DOI 10.1097/01241398-198110000-00010; KIRSCHENBAUM D, 1990, J PEDIATR ORTHOPED, V10, P588, DOI 10.1097/01241398-199009000-00003; MANN DC, 1986, J PEDIATR ORTHOPED, V6, P651, DOI 10.1097/01241398-198611000-00002; PETERSEN EA, 1974, ACTA ORTHOP SCAND, V45, P321, DOI 10.3109/17453677408989152; PORAT S, 1986, J TRAUMA, V26, P81, DOI 10.1097/00005373-198601000-00015; REEVES RB, 1990, J PEDIATR ORTHOPED, V10, P592, DOI 10.1097/01241398-199009000-00004; SHIH HN, 1989, J TRAUMA, V29, P498, DOI 10.1097/00005373-198904000-00014; STAHELI LT, 1977, CLIN ORTHOP RELAT R, P162; Staheli LT, 1984, FRACTURES CHILDREN, V3, P845; TIMMERMAN LA, 1993, J ORTHOP TRAUMA, V7, P331, DOI 10.1097/00005131-199308000-00008; TOLO VT, 1983, J PEDIATR ORTHOPED, V3, P435, DOI 10.1097/01241398-198309000-00004; WARD WT, 1992, J PEDIATR ORTHOPED, V12, P626; ZIV I, 1984, J TRAUMA, V24, P432, DOI 10.1097/00005373-198405000-00011; ZIV I, 1983, J BONE JOINT SURG BR, V65, P276, DOI 10.1302/0301-620X.65B3.6841395	28	91	96	0	0	JOURNAL BONE JOINT SURGERY INC	NEEDHAM	20 PICKERING ST, NEEDHAM, MA 02192	0021-9355			J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	DEC	1993	75A	12					1774	1780		10.2106/00004623-199312000-00006			7	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	MN144	WOS:A1993MN14400006	8258547				2022-02-06	
J	SCHMOKER, JD; ZHUANG, J; SHACKFORD, SR				SCHMOKER, JD; ZHUANG, J; SHACKFORD, SR			HYPERTONIC FLUID RESUSCITATION IMPROVES CEREBRAL OXYGEN DELIVERY AND REDUCES INTRACRANIAL-PRESSURE AFTER HEMORRHAGIC-SHOCK	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	21ST ANNUAL MEETING OF THE WESTERN TRAUMA ASSOC	FEB 23-MAR 02, 1991	JACKSON HOLE, WY	W TRAUMA ASSOC			SMALL-VOLUME RESUSCITATION; LACTATED RINGERS SOLUTION; SEVERELY INJURED PATIENTS; WATER-CONTENT; SALINE; BRAIN; NACL; PULMONARY; TRAUMA; MODEL	Prospective clinical studies have shown that hypotension from hemorrhage contributes to increased morbidity and mortality in patients with traumatic brain injury. It is implied that poorer outcome is the result of secondary brain injury from impaired cerebral oxygen delivery (cO2del). We studied the early and late effects of hypertonic sodium lactate (HSL: 500 mOsm/L) resuscitation on mean arterial pressure (MAP), cardiac output (CO), systemic oxygen delivery (sO2del), cerebral perfusion pressure (CPP), intracranial pressure (ICP), cO2del, cerebral blood flow (CBF), serum osmolality, and cortical water content (CWC) in a porcine model of hemorrhagic shock. Swine were randomized to receive a bolus (4 mL/kg) of either lactated Ringer's solution (LR: 274 mOsm/L) or HSL after shock, followed by either LR or HSL to return MAP to baseline levels. Shed blood was returned 1 hour after resuscitation, and all animals were studied for 24 hours. Control animals were instrumented only. The HSL resuscitation significantly increased cO2del and CBF for 24 hours postresuscitation when compared with LR. The ICP in the HSL-treated animals was significantly lower throughout the postresuscitation phase when compared with the LR-treated animals (p < 0.05). The CWC was significantly lower in the HSL-treated animals (p < 0.05). We attribute these effects to hypertonic dehydration of both the brain parenchyma and the cerebrovascular endothelium. These data suggest that by decreasing ICP and improving cO2del after shock, HSL could decrease secondary brain injury when brain injury and shock occur together.	UNIV VERMONT,COLL MED,DEPT SURG,BURLINGTON,VT 05405						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1-R01-NS 28637-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS028637] Funding Source: NIH RePORTER		DUCEY JP, 1989, J TRAUMA, V29, P1510, DOI 10.1097/00005373-198911000-00010; EISENBERG HM, 1983, INTRACRANIAL PRESSUR, V5, P549; GAZITUA S, 1969, AM J PHYSIOL, V217, P1216, DOI 10.1152/ajplegacy.1969.217.4.1216; GAZITUA S, 1971, AM J PHYSIOL, V220, P384, DOI 10.1152/ajplegacy.1971.220.2.384; GUNNAR WP, 1986, ANN SURG, V204, P686, DOI 10.1097/00000658-198612000-00012; HOLCROFT JW, 1987, ANN SURG, V206, P279, DOI 10.1097/00000658-198709000-00006; KRAMER GC, 1986, SURGERY, V100, P239; MANINGAS PA, 1987, CRIT CARE MED, V15, P1121, DOI 10.1097/00003246-198712000-00009; MANINGAS PA, 1986, ANN EMERG MED, V15, P1131, DOI 10.1016/S0196-0644(86)80852-6; MAZZONI MC, 1988, AM J PHYSIOL, V255, pH629, DOI 10.1152/ajpheart.1988.255.3.H629; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; NAKAYAMA S, 1984, CIRC SHOCK, V13, P149; NELSON SR, 1971, J APPL PHYSIOL, V30, P268, DOI 10.1152/jappl.1971.30.2.268; NERLICH M, 1983, CIRC SHOCK, V10, P179; NEWFIELD P, 1980, CRIT CARE MED, V8, P254, DOI 10.1097/00003246-198004000-00123; OSTRUP RC, 1987, J NEUROSURG, V67, P206, DOI 10.3171/jns.1987.67.2.0206; Pasztor E, 1973, STROKE, V4, P556, DOI 10.1161/01.STR.4.4.556; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; PROUGH DS, 1986, J NEUROSURG, V64, P627, DOI 10.3171/jns.1986.64.4.0627; READ RC, 1960, CIRC RES, V8, P538, DOI 10.1161/01.RES.8.3.538; SCHMOKER J, 1991, Journal of Trauma, V31, P1038, DOI 10.1097/00005373-199107000-00091; SEELIG JM, 1986, INTRACRANIAL PRESSUR, V6, P675; SHACKFORD SR, 1989, J TRAUMA, V29, P894, DOI 10.1097/00005373-198906000-00035; SHACKFORD SR, 1987, ARCH SURG-CHICAGO, V122, P523; SHACKFORD SR, 1987, SURG GYNECOL OBSTET, V164, P127; SHACKFORD SR, 1988, SURGERY, V104, P553; SHACKFORD SR, IN PRESS J NEUROSURG; SHIGENO T, 1982, J NEUROSURG, V57, P99, DOI 10.3171/jns.1982.57.1.0099; TRAVERSO LW, 1986, J TRAUMA, V26, P168, DOI 10.1097/00005373-198602000-00014; VELASCO IT, 1980, AM J PHYSIOL, V239, pH664, DOI 10.1152/ajpheart.1980.239.5.H664; WALSH J, 1990, SURG FORUM, V49, P56; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011; 1985, INJURY AM, P18	34	91	92	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1991	31	12					1607	1613		10.1097/00005373-199112000-00007			7	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	GW885	WOS:A1991GW88500007	1749030				2022-02-06	
J	SARNO, MT				SARNO, MT			THE NATURE OF VERBAL IMPAIRMENT AFTER CLOSED HEAD-INJURY	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article											SARNO, MT (corresponding author), NYU,SCH MED,INST REHABIL MED,NEW YORK,NY 10016, USA.			sarno, martha/0000-0001-7649-8691			Benson D. F., 1967, CORTEX MILANO, V3, P373, DOI DOI 10.1016/S0010-9452(67)80025-X; Benton A.L., 1967, CORTEX, V3, P32, DOI [10.1016/s0010-9452(67)80005-4, DOI 10.1016/S0010-9452(67)80005-4]; BENTON AL, 1969, J NEUROL SCI, V9, P39, DOI 10.1016/0022-510X(69)90057-4; BOLLER F, 1966, BRAIN, V89, P815, DOI 10.1093/brain/89.4.815; CAIRNS H, 1941, J ROY ARMY MED CORPS, V76, P12; GESCHWIND N, 1971, NEW ENGL J MED, V284, P654, DOI 10.1056/NEJM197103252841206; Geschwind N, 1964, Int J Neurol, V4, P207; Goldstein K, 1942, EFFECTS BRAIN INJURI; GROHER M, 1977, J SPEECH HEAR RES, V20, P212, DOI 10.1044/jshr.2002.212; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; Luria A.R., 1970, TRAUMATIC APHASIA; Newcombe F., 1969, MISSILE WOUNDS BRAIN; Norman Geschwind, 1967, CORTEX, V3, P97; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Poeck K., 1966, CORTEX, V2, P222, DOI 10.1016/S0010-9452(66)80005-9; SCHILLER F, 1947, J NEUROL NEUROSUR PS, V10, P183, DOI 10.1136/jnnp.10.4.183; Spreen O., 1969, NEUROSENSORY CTR COM; Teuber H-L, 1969, LATE EFFECTS HEAD IN, P13; THOMSEN IV, 1977, SCAND J REHABIL MED, V9, P73; THOMSEN IV, 1975, J NEUROL NEUROSUR PS, V38, P713, DOI 10.1136/jnnp.38.7.713; THOMSEN IV, 1976, ACTA NEUROL SCAND, V54, P219, DOI 10.1111/j.1600-0404.1976.tb04798.x; THOMSEN IV, 1976, FOLIA PHONIATR, V28, P363; [No title captured]; [No title captured]	25	91	93	1	6	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.		1980	168	11					685	692		10.1097/00005053-198011000-00008			8	Clinical Neurology; Psychiatry	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	KQ844	WOS:A1980KQ84400008	7441232				2022-02-06	
J	Shin, JH; Yan, Y; Bai, WB; Xue, YG; Gamble, P; Tian, LM; Kandela, I; Haney, CR; Spees, W; Lee, Y; Choi, M; Ko, J; Ryu, H; Chang, JK; Pezhouh, M; Kang, SK; Won, SM; Yu, KJ; Zhao, JN; Lee, YK; MacEwan, MR; Song, SK; Huang, YG; Ray, WZ; Rogers, JA				Shin, Jiho; Yan, Ying; Bai, Wubin; Xue, Yeguang; Gamble, Paul; Tian, Limei; Kandela, Irawati; Haney, Chad R.; Spees, William; Lee, Yechan; Choi, Minseok; Ko, Jonathan; Ryu, Hangyu; Chang, Jan-Kai; Pezhouh, Maryam; Kang, Seung-Kyun; Won, Sang Min; Yu, Ki Jun; Zhao, Jianing; Lee, Yoon Kyeung; MacEwan, Matthew R.; Song, Sheng-Kwei; Huang, Yonggang; Ray, Wilson Z.; Rogers, John A.			Bioresorbable pressure sensors protected with thermally grown silicon dioxide for the monitoring of chronic diseases and healing processes	NATURE BIOMEDICAL ENGINEERING			English	Article							TEMPERATURE-COEFFICIENT; BIOFLUID BARRIERS; ELECTRONICS; LAYERS; DISSOLUTION; CHALLENGES; ULTRATHIN; TISSUE	Pressures in the intracranial, intraocular and intravascular spaces are clinically useful for the diagnosis and management of traumatic brain injury, glaucoma and hypertension, respectively. Conventional devices for measuring these pressures require surgical extraction after a relevant operational time frame. Bioresorbable sensors, by contrast, eliminate this requirement, thereby minimizing the risk of infection, decreasing the costs of care and reducing distress and pain for the patient. However, the operational lifetimes of bioresorbable pressure sensors available at present fall short of many clinical needs. Here, we present materials, device structures and fabrication procedures for bioresorbable pressure sensors with lifetimes exceeding those of previous reports by at least tenfold. We demonstrate measurement accuracies that compare favourably to those of the most sophisticated clinical standards for non-resorbable devices by monitoring intracranial pressures in rats for 25 days. Assessments of the biodistribution of the constituent materials, complete blood counts, blood chemistry and magnetic resonance imaging compatibility confirm the biodegradability and clinical utility of the device. Our findings establish routes for the design and fabrication of bioresorbable pressure monitors that meet requirements for clinical use.	[Shin, Jiho; Lee, Yechan; Choi, Minseok; Ko, Jonathan; Ryu, Hangyu] Univ Illinois, Dept Chem & Biomol Engn, Urbana, IL USA; [Shin, Jiho; Lee, Yechan; Choi, Minseok; Ko, Jonathan; Ryu, Hangyu; Chang, Jan-Kai; Won, Sang Min; Zhao, Jianing] Univ Illinois, Frederick Seitz Mat Res Lab, Urbana, IL USA; [Yan, Ying; Gamble, Paul; MacEwan, Matthew R.; Ray, Wilson Z.] Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63130 USA; [Bai, Wubin; Xue, Yeguang; Huang, Yonggang; Rogers, John A.] Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA; [Bai, Wubin; Rogers, John A.] Northwestern Univ, Ctr Biointegrated Elect, Evanston, IL 60208 USA; [Xue, Yeguang; Huang, Yonggang] Northwestern Univ, Dept Mech Engn, Evanston, IL 60208 USA; [Xue, Yeguang; Huang, Yonggang] Northwestern Univ, Dept Civil & Environm Engn, Evanston, IL 60208 USA; [Tian, Limei] Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL USA; [Kandela, Irawati] Northwestern Univ, Dev Therapeut Core, Evanston, IL USA; [Haney, Chad R.] Northwestern Univ, Ctr Adv Mol Imaging, Evanston, IL USA; [Spees, William; Song, Sheng-Kwei] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Biomed Magnet Resonance Lab, St Louis, MO USA; [Spees, William; Song, Sheng-Kwei] Washington Univ, Sch Med, Hope Ctr Neurol Disorders, St Louis, MO USA; [Chang, Jan-Kai] Univ Illinois, Dept Mat Sci & Engn, Urbana, IL USA; [Pezhouh, Maryam] Northwestern Univ, Feinberg Sch Med, Northwestern Med, Evanston, IL USA; [Kang, Seung-Kyun] Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Daejeon, South Korea; [Won, Sang Min] Univ Illinois, Dept Elect & Comp Engn, Urbana, IL USA; [Yu, Ki Jun] Yonsei Univ, Sch Elect & Elect Engn, Seoul, South Korea; [Zhao, Jianing] Univ Illinois, Dept Mech Sci & Engn, Urbana, IL USA; [Lee, Yoon Kyeung] Seoul Natl Univ, Dept Mat Sci & Engn, Seoul, South Korea; [Rogers, John A.] Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Biomed Engn, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Chem, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Mech Engn, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Elect Engn & Comp Sci, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Neurol Surg, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, Feinberg Sch Med, Evanston, IL 60208 USA		Ray, WZ (corresponding author), Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63130 USA.; Rogers, JA (corresponding author), Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, Ctr Biointegrated Elect, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Biomed Engn, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Chem, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Mech Engn, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Elect Engn & Comp Sci, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Neurol Surg, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, Feinberg Sch Med, Evanston, IL 60208 USA.	rayz@wudosis.wustl.edu; jrogers@northwestern.edu	Xue, Yeguang/B-8696-2015; Haney, Chad R/A-3909-2008; Rogers, John/L-2798-2016; Huang, Yonggang/B-6998-2009; huang, yonggang/O-6236-2019; Bai, Wubin/AAG-2382-2020	Xue, Yeguang/0000-0002-1968-5092; Haney, Chad R/0000-0001-5981-2925; Bai, Wubin/0000-0003-2872-5559; Lee, Yoon Kyeung/0000-0001-5160-1015; Tian, Limei/0000-0002-1931-8567; Lee, Yechan/0000-0002-4744-267X; WANG, KE/0000-0003-2004-2745	Ryan Fellowship; Northwestern University International Institute for Nanotechnology; Beckman Institute Postdoctoral Fellowship at UIUC; Cancer Center Support grant (National Cancer Institute) [P30 CA060553]; National Research Foundation of KoreaNational Research Foundation of Korea [NRF-2017M1A2A2048880, NRF-2018M3A7B4071109]; Yonsei University [RMS2 2018-22-0028]; NSFNational Science Foundation (NSF) [1400169, 1534120, 1635443]	J.S. thanks G. Mensing and J. Maduzia at the Micro-Nano-Mechanical Systems Cleanroom (University of Illinois at Urbana-Champaign) for assistance with process development. J. S. acknowledges support from True Phantom Solutions Inc. with the preparation of brain phantoms for MRI compatibility tests. Y.X. acknowledges support from the Ryan Fellowship and the Northwestern University International Institute for Nanotechnology. L.T. acknowledges support from a Beckman Institute Postdoctoral Fellowship at UIUC. I.K. acknowledges support from Cancer Center Support grant no. P30 CA060553 (National Cancer Institute) awarded to the Robert H. Lurie Comprehensive Cancer Center. K.J.Y. acknowledges support from the National Research Foundation of Korea (grant nos. NRF-2017M1A2A2048880 and NRF-2018M3A7B4071109) and Yonsei University Future-leading Research Initiative of 2017 (grant no. RMS2 2018-22-0028). Y.H. acknowledges support from the NSF (grant nos. 1400169, 1534120 and 1635443).	[Anonymous], 2010, POSTCR SUBD PRESS MO; Boutry CM, 2012, PHILOS T R SOC A, V370, P2418, DOI 10.1098/rsta.2011.0439; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Camino G, 2001, POLYMER, V42, P2395, DOI 10.1016/S0032-3861(00)00652-2; Chamis AL, 2001, CIRCULATION, V104, P1029, DOI 10.1161/hc3401.095097; Comittee for the update of the Guide for the care and use of laboratory animals, 2011, GUIDE CARE USE LAB A, V8, P1; Dunn JF, 2009, MAGN RESON MED, V61, P222, DOI 10.1002/mrm.21803; Fang H, 2016, P NATL ACAD SCI USA, V113, P11682, DOI 10.1073/pnas.1605269113; Gelabert-Gonzalez M, 2006, ACTA NEUROCHIR, V148, P435, DOI 10.1007/s00701-005-0683-3; Haddad SH, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-12; Hall-Stoodley L, 2004, NAT REV MICROBIOL, V2, P95, DOI 10.1038/nrmicro821; Hwang SW, 2015, NANO LETT, V15, P2801, DOI 10.1021/nl503997m; Hwang SW, 2014, ADV MATER, V26, P3905, DOI 10.1002/adma.201306050; Hwang SW, 2012, SCIENCE, V337, P1640, DOI 10.1126/science.1226325; Jiang GQ, 2010, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/neuro.20.002.2010; Johanson CE, 2008, FLUIDS BARRIERS CNS, V5, DOI 10.1186/1743-8454-5-10; KANDA Y, 1982, IEEE T ELECTRON DEV, V29, P64, DOI 10.1109/T-ED.1982.20659; Kang SK, 2016, NATURE, V530, P71, DOI 10.1038/nature16492; Kang SK, 2015, ADV FUNCT MATER, V25, P1789, DOI 10.1002/adfm.201403469; Kang SK, 2014, ADV FUNCT MATER, V24, P4427, DOI 10.1002/adfm.201304293; Lee CH, 2015, ADV FUNCT MATER, V25, P5100, DOI 10.1002/adfm.201502192; Lee G, 2017, ADV ENERGY MATER, V7, DOI 10.1002/aenm.201700157; Lee YK, 2017, ACS NANO, V11, P12562, DOI 10.1021/acsnano.7b06697; Lee YK, 2017, ACS APPL MATER INTER, V9, P42633, DOI 10.1021/acsami.7b15302; Lund E., 2000, MRS P, V657; Luo MD, 2014, J MICROELECTROMECH S, V23, P4, DOI 10.1109/JMEMS.2013.2290111; Maitinez-Manas RM, 2000, J NEUROL NEUROSUR PS, V69, P82, DOI 10.1136/jnnp.69.1.82; Moghimi SM, 1998, ADV DRUG DELIVER REV, V32, P45, DOI 10.1016/S0169-409X(97)00131-2; NORTON P, 1978, SOLID STATE ELECTRON, V21, P969, DOI 10.1016/0038-1101(78)90296-4; Polikov VS, 2005, J NEUROSCI METH, V148, P1, DOI 10.1016/j.jneumeth.2005.08.015; Sawyer-Glover AM, 2000, J MAGN RESON IMAGING, V12, P92, DOI 10.1002/1522-2586(200007)12:1<92::AID-JMRI11>3.0.CO;2-7; Sit AJ, 2009, J GLAUCOMA, V18, P272, DOI 10.1097/IJG.0b013e3181862490; Tao H, 2014, P NATL ACAD SCI USA, V111, P17385, DOI 10.1073/pnas.1407743111; Wang Q, 2005, SENSOR ACTUAT A-PHYS, V120, P468, DOI 10.1016/j.sna.2005.01.036; Yu KJ, 2016, NAT MATER, V15, P782, DOI [10.1038/NMAT4624, 10.1038/nmat4624]; Yu L, 2014, SENSORS-BASEL, V14, P20620, DOI 10.3390/s141120620; Zacchetti L, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1137-9	37	90	90	35	164	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2157-846X			NAT BIOMED ENG	Nat. Biomed. Eng	JAN	2019	3	1					37	46		10.1038/s41551-018-0300-4			10	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	HG6VH	WOS:000455123800010	30932064		Y	N	2022-02-06	
J	Ahmedani, BK; Peterson, EL; Hu, Y; Rossom, RC; Lynch, F; Lu, CY; Waitzfelder, BE; Owen-Smith, AA; Hubley, S; Prabhakar, D; Williams, LK; Zeld, N; Mutter, E; Beck, A; Tolsma, D; Simon, GE				Ahmedani, Brian K.; Peterson, Edward L.; Hu, Yong; Rossom, Rebecca C.; Lynch, Frances; Lu, Christine Y.; Waitzfelder, Beth E.; Owen-Smith, Ashli A.; Hubley, Samuel; Prabhakar, Deepak; Williams, L. Keoki; Zeld, Nicole; Mutter, Elizabeth; Beck, Arne; Tolsma, Dennis; Simon, Gregory E.			Major Physical Health Conditions and Risk of Suicide	AMERICAN JOURNAL OF PREVENTIVE MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE PATIENTS; PREVENTION; MANAGEMENT; SYMPTOMS; VETERANS; PAIN	Introduction: Most individuals make healthcare visits before suicide, but many do not have a diagnosed mental health condition. This study seeks to investigate suicide risk among patients with a range of physical health conditions in a U.S. general population sample and whether risk persists after adjustment for mental health and substance use diagnoses. Methods: This study included 2,674 individuals who died by suicide between 2000 and 2013 along with 267,400 controls matched on year and location in a case-control study conducted in 2016 across eight Mental Health Research Network healthcare systems. A total of 19 physical health conditions were identified using diagnostic codes within the healthcare systems' Virtual Data Warehouse, including electronic health record and insurance claims data, during the year before index date. Results: Seventeen physical health conditions were associated with increased suicide risk after adjustment for age and sex (p < 0.001); nine associations persisted after additional adjustment for mental health and substance use diagnoses. Three conditions had a more than twofold increased suicide risk: traumatic brain injury (AOR = 8.80, p < 0.001); sleep disorders; and HIV/AIDS. Multimorbidity was present in 38% of cases versus 15.5% of controls, and represented nearly a twofold increased risk for suicide. Conclusions: Although several individual conditions, for example, traumatic brain injury, were associated with high risk of suicide, nearly all physical health conditions increased suicide risk, even after adjustment for potential confounders. In addition, having multiple physical health conditions increased suicide risk substantially. These data support suicide prevention based on the overall burden of physical health. (C) 2017 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.	[Ahmedani, Brian K.; Hu, Yong; Williams, L. Keoki; Zeld, Nicole; Mutter, Elizabeth] Henry Ford Hlth Syst, Ctr Hlth Policy & Hlth Serv Res, Detroit, MI 48202 USA; [Ahmedani, Brian K.; Prabhakar, Deepak] Henry Ford Hlth Syst, Behav Hlth Serv, Detroit, MI 48202 USA; [Peterson, Edward L.; Hu, Yong] Henry Ford Hlth Syst, Publ Hlth Sci, Detroit, MI 48202 USA; [Rossom, Rebecca C.] HealthPartners Inst, Bloomington, MN USA; [Lynch, Frances] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA; [Lu, Christine Y.] Harvard Med Sch, Dept Populat Med, Boston, MA USA; [Lu, Christine Y.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA; [Waitzfelder, Beth E.] Kaiser Permanente Hawaii, Ctr Hlth Res, Honolulu, HI USA; [Owen-Smith, Ashli A.] Georgia State Univ, Sch Publ Hlth, Atlanta, GA 30303 USA; [Owen-Smith, Ashli A.; Tolsma, Dennis] Kaiser Permanente Georgia, Ctr Clin & Outcomes Res, Atlanta, GA USA; [Hubley, Samuel] Univ Colorado, Dept Family Med, Denver, CO 80202 USA; [Williams, L. Keoki] Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI 48202 USA; [Beck, Arne] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA; [Simon, Gregory E.] Kaiser Permanente Washington, Seattle, WA USA		Ahmedani, BK (corresponding author), Henry Ford Hlth Syst, LMSW, 1 Ford Pl,3A, Detroit, MI 48202 USA.	bahmeda1@hfhs.org	Rossom, Rebecca/R-7103-2019	Prabhakar, Deepak/0000-0003-4237-162X; Rossom, Rebecca/0000-0002-9531-914X; Hubley, Samuel/0000-0001-7188-6003; Mutter, Elizabeth/0000-0003-1779-6300	National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH103539, U19MH092201]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH103539, U19MH092201] Funding Source: NIH RePORTER	This project was supported by Award Numbers R01MH103539 and U19MH092201 from the National Institute of Mental Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH. All authors have contributed to and have approved the final submitted manuscript.	Ahmedani BK, 2015, MED CARE, V53, P430, DOI 10.1097/MLR.0000000000000335; Ahmedani BK, 2014, AM J PREV MED, V47, pS222, DOI 10.1016/j.amepre.2014.05.038; Ahmedani BK, 2014, J GEN INTERN MED, V29, P870, DOI 10.1007/s11606-014-2767-3; Bernert RA, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0554-4; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Bruce ML, 2004, JAMA-J AM MED ASSOC, V291, P1081, DOI 10.1001/jama.291.9.1081; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Cavanagh JTO, 2003, PSYCHOL MED, V33, P395, DOI 10.1017/S0033291702006943; CDC, 2014, CDC NAT HLTH REP HIG; Curtin Sally C., 2016, INCREASE SUICIDE US; Go AS, 2008, CIRC-CARDIOVASC QUAL, V1, P138, DOI 10.1161/CIRCOUTCOMES.108.801654; Gunnell D, 2012, BRIT J PSYCHIAT, V201, P233, DOI 10.1192/bjp.bp.111.104422; Hogan MF, 2016, HEALTH AFFAIR, V35, P1084, DOI 10.1377/hlthaff.2015.1672; HORNBROOK MC, 2005, J NATL CANC I MONOGR, V35, P12, DOI DOI 10.1093/JNCIMONOGRAPHS/LGI033; Howe CQ, 2015, PHYS MED REH CLIN N, V26, P283, DOI 10.1016/j.pmr.2014.12.003; Ilgen MA, 2013, JAMA PSYCHIAT, V70, P692, DOI 10.1001/jamapsychiatry.2013.908; Ilgen MA, 2010, ARCH GEN PSYCHIAT, V67, P1152, DOI 10.1001/archgenpsychiatry.2010.129; Juurlink DN, 2004, ARCH INTERN MED, V164, P1179, DOI 10.1001/archinte.164.11.1179; Kuo CJ, 2010, AM J PSYCHIAT, V167, P1092, DOI 10.1176/appi.ajp.2010.09101455; Mann JJ, 2005, JAMA-J AM MED ASSOC, V294, P2064, DOI 10.1001/jama.294.16.2064; McCarthy JF, 2015, AM J PUBLIC HEALTH, V105, P1935, DOI 10.2105/AJPH.2015.302737; McDowell AK, 2011, MAYO CLIN PROC, V86, P792, DOI 10.4065/mcp.2011.0076; National Center for Health Statistics, 2010, INT CLASS DIS; O'Connor E, 2013, ANN INTERN MED, V158, P741, DOI 10.7326/0003-4819-158-10-201305210-00642; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Organization WH, 2012, INT CLASS DIS 10 REV; Research Prioritization Task Force National Action Alliance for Suicide Prevention, 2014, PRIOR RES AG SUIC PR PRIORITIZED RES AGEN; Robson A, 2010, PSYCHO-ONCOLOGY, V19, P1250, DOI 10.1002/pon.1717; Rossom RC, 2016, PSYCHIAT SERV, V67, P830, DOI 10.1176/appi.ps.201600068; St Sauver JL, 2013, MAYO CLIN PROC, V88, P56, DOI 10.1016/j.mayocp.2012.08.020; Swanson JW, 2015, JAMA-J AM MED ASSOC, V314, P2229, DOI 10.1001/jama.2015.15566; The Joint Commission, 2016, SENT EV AL 56 DET TR; Tinetti ME, 2012, JAMA-J AM MED ASSOC, V307, P2493, DOI 10.1001/jama.2012.5265; Tran T, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-76; U.S. department of health and human services office of the surgeon general and national action alliance for suicide prevention, 2012, 2012 NAT STRAT SUIC; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; Webb RT, 2012, ARCH GEN PSYCHIAT, V69, P256, DOI 10.1001/archgenpsychiatry.2011.1561; While D, 2012, LANCET, V379, P1005, DOI 10.1016/S0140-6736(11)61712-1	38	90	91	2	22	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0749-3797	1873-2607		AM J PREV MED	Am. J. Prev. Med.	SEP	2017	53	3					308	315		10.1016/j.amepre.2017.04.001			8	Public, Environmental & Occupational Health; Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; General & Internal Medicine	FE0QI	WOS:000407924400013	28619532	Green Accepted	Y	N	2022-02-06	
J	Fol, R; Braudeau, J; Ludewig, S; Abel, T; Weyer, SW; Roederer, JP; Brod, F; Audrain, M; Bemelmans, AP; Buchholz, CJ; Korte, M; Cartier, N; Muller, UC				Fol, Romain; Braudeau, Jerome; Ludewig, Susann; Abel, Tobias; Weyer, Sascha W.; Roederer, Jan-Peter; Brod, Florian; Audrain, Mickael; Bemelmans, Alexis-Pierre; Buchholz, Christian J.; Korte, Martin; Cartier, Nathalie; Mueller, Ulrike C.			Viral gene transfer of APPs alpha rescues synaptic failure in an Alzheimer's disease mouse model	ACTA NEUROPATHOLOGICA			English	Article						Alzheimer; Gene therapy; Amyloid precursor protein; APPs alpha; Synaptic plasticity; Spines; Behavior; Microglia; AAV	AMYLOID-PRECURSOR-PROTEIN; CEREBROSPINAL-FLUID LEVELS; TRAUMATIC BRAIN-INJURY; A-BETA; SECRETED FORMS; MESSENGER-RNA; MEMORY; EXPRESSION; MICE; ACTIVATION	Alzheimer's disease (AD) is characterized by synaptic failure, dendritic and axonal atrophy, neuronal death and progressive loss of cognitive functions. It is commonly assumed that these deficits arise due to beta-amyloid accumulation and plaque deposition. However, increasing evidence indicates that loss of physiological APP functions mediated predominantly by neurotrophic APPs alpha produced in the non-amyloidogenic alpha-secretase pathway may contribute to AD pathogenesis. Upregulation of APPs alpha production via induction of alpha-secretase might, however, be problematic as this may also affect substrates implicated in tumorigenesis. Here, we used a gene therapy approach to directly overexpress APPs alpha in the brain using AAV-mediated gene transfer and explored its potential to rescue structural, electrophysiological and behavioral deficits in APP/PS1a dagger E9 AD model mice. Sustained APPs alpha overexpression in aged mice with already preexisting pathology and amyloidosis restored synaptic plasticity and partially rescued spine density deficits. Importantly, AAV-APPs alpha treatment also resulted in a functional rescue of spatial reference memory in the Morris water maze. Moreover, we demonstrate a significant reduction of soluble A beta species and plaque load. In addition, APPs alpha induced the recruitment of microglia with a ramified morphology into the vicinity of plaques and upregulated IDE and TREM2 expression suggesting enhanced plaque clearance. Collectively, these data indicate that APPs alpha can mitigate synaptic and cognitive deficits, despite established pathology. Increasing APPs alpha may therefore be of therapeutic relevance for AD.	[Fol, Romain; Braudeau, Jerome; Audrain, Mickael; Cartier, Nathalie] INSERM U1169 MIRCen CEA, F-92265 Fontenay Aux Roses, France; [Fol, Romain; Braudeau, Jerome; Audrain, Mickael; Bemelmans, Alexis-Pierre; Cartier, Nathalie] Univ Paris Saclay, Univ Paris 11, F-91400 Orsay, France; [Fol, Romain; Audrain, Mickael] Univ Paris 05, F-75006 Paris, France; [Bemelmans, Alexis-Pierre] Commissariat Energie Atom & Energies Alternat CEA, DSV, Inst Imagerie Biomed I2BM, Mol Imaging Res Ctr MIRCen, F-92260 Fontenay Aux Roses, France; [Abel, Tobias; Brod, Florian; Buchholz, Christian J.] CNRS, UMR 9199, Neurodegenerat Dis Lab, F-92260 Fontenay Aux Roses, France; [Ludewig, Susann; Korte, Martin] Paul Ehrlich Inst, Mol Biotechnol & Gene Therapy, D-63225 Langen, Germany; [Korte, Martin] TU Braunschweig, Inst Zool, Div Cellular Neurobiol, Braunschweig, ME, Germany; [Korte, Martin] AG NIND, Helmholtz Ctr Infect Res, Inhoffenstr 7, D-38124 Braunschweig, Germany; [Weyer, Sascha W.; Roederer, Jan-Peter; Mueller, Ulrike C.] Heidelberg Univ, Dept Bioinformat & Funct Genom, Inst Pharm & Mol Biotechnol, Neuenheimer Feld 364, D-69120 Heidelberg, Germany		Cartier, N (corresponding author), INSERM U1169 MIRCen CEA, F-92265 Fontenay Aux Roses, France.; Cartier, N (corresponding author), Univ Paris Saclay, Univ Paris 11, F-91400 Orsay, France.; Muller, UC (corresponding author), Heidelberg Univ, Dept Bioinformat & Funct Genom, Inst Pharm & Mol Biotechnol, Neuenheimer Feld 364, D-69120 Heidelberg, Germany.	nathalie.cartier@inserm.fr; u.mueller@urz.uni-heidelberg.de	Bemelmans, Alexis-Pierre/H-4476-2019; Audrain, Mickael/L-9894-2016; Brod, Florian/AAF-3193-2021; cartier, nathalie/C-3103-2012	Bemelmans, Alexis-Pierre/0000-0001-7605-5225; Audrain, Mickael/0000-0001-9941-7380; Brod, Florian/0000-0003-4779-3733; cartier, nathalie/0000-0003-2298-5261; Braudeau, Jerome/0000-0002-9920-4112	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [MU 1457/9-1, MU 1457/9-2, KO 1674/3-1, KO 1674/3-2]; ERA-Net Neuron [01EW1305A]; LOEWE Center for Cell and Gene Therapy Frankfurt - Hessisches Ministerium fur Wissenschaft und Kunst [III L 4-518/17.004 (2010)]	This work was supported by the Deutsche Forschungsgemeinschaft Grants (MU 1457/9-1, 9-2 to UCM; KO 1674/3-1, 3-2 to MK), the ERA-Net Neuron (01EW1305A to CJB, NC and UCM), and the LOEWE Center for Cell and Gene Therapy Frankfurt funded by Hessisches Ministerium fur Wissenschaft und Kunst (III L 4-518/17.004 (2010)) to CJB.	Abramov E, 2009, NAT NEUROSCI, V12, P1567, DOI 10.1038/nn.2433; Ahmed RR, 2010, J NEUROCHEM, V112, P1045, DOI 10.1111/j.1471-4159.2009.06528.x; Almkvist O, 1997, ARCH NEUROL-CHICAGO, V54, P641, DOI 10.1001/archneur.1997.00550170111022; Anderson JJ, 1999, NEUROSCIENCE, V93, P1409, DOI 10.1016/S0306-4522(99)00244-4; Aurnhammer C, 2012, HUM GENE THER METHOD, V23, P18, DOI 10.1089/hgtb.2011.034; Austin S. A., 2008, P13, DOI 10.1007/978-0-387-73894-9_2; Aydin D, 2012, EXP BRAIN RES, V217, P423, DOI 10.1007/s00221-011-2861-2; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Bell KFS, 2008, NEUROBIOL AGING, V29, P554, DOI 10.1016/j.neurobiolaging.2006.11.004; Berger A, 2015, MOL THER, V23, P918, DOI 10.1038/mt.2015.11; Billings LM, 2005, NEURON, V45, P675, DOI 10.1016/j.neuron.2005.01.040; Bodles AM, 2005, NEUROBIOL AGING, V26, P9, DOI 10.1016/j.neurobiolaging.2004.02.022; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Bour A, 2004, NEUROBIOL LEARN MEM, V81, P27, DOI 10.1016/S1074-7427(03)00071-6; Caille I, 2004, DEVELOPMENT, V131, P2173, DOI 10.1242/dev.01103; Casanova F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094919; Claasen AM, 2009, NEUROSCI LETT, V460, P92, DOI 10.1016/j.neulet.2009.05.040; Copanaki E, 2010, MOL CELL NEUROSCI, V44, P386, DOI 10.1016/j.mcn.2010.04.007; Corrigan F, 2012, J NEUROCHEM, V122, P208, DOI 10.1111/j.1471-4159.2012.07761.x; Cousins SL, 2013, J NEUROCHEM, V126, P554, DOI 10.1111/jnc.12280; Cousins SL, 2009, J NEUROCHEM, V111, P1501, DOI 10.1111/j.1471-4159.2009.06424.x; Dobrowolska JA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089998; Doody RS, 2013, NEW ENGL J MED, V369, P341, DOI 10.1056/NEJMoa1210951; Drummond ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059166; Endres K, 2012, EXP BRAIN RES, V217, P343, DOI 10.1007/s00221-011-2885-7; Frank S, 2008, GLIA, V56, P1438, DOI 10.1002/glia.20710; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; Furukawa K, 1998, NEUROSCIENCE, V83, P429, DOI 10.1016/S0306-4522(97)00398-9; Furukawa K, 1996, NATURE, V379, P74, DOI 10.1038/379074a0; Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; Heneka MT, 2013, NATURE, V493, P674, DOI 10.1038/nature11729; Hick M, 2015, ACTA NEUROPATHOL, V129, P21, DOI 10.1007/s00401-014-1368-x; Hoe HS, 2012, CNS NEUROSCI THER, V18, P47, DOI 10.1111/j.1755-5949.2010.00221.x; Hoey SE, 2009, J NEUROSCI, V29, P4442, DOI 10.1523/JNEUROSCI.6017-08.2009; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Ishida A, 1997, NEUROREPORT, V8, P2133, DOI 10.1097/00001756-199707070-00009; Jankowsky JL, 2004, HUM MOL GENET, V13, P159, DOI 10.1093/hmg/ddh019; Jay TR, 2015, J EXP MED, V212, P287, DOI 10.1084/jem.20142322; Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103; Kamphuis W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042823; Klevanski M, 2014, MOL CELL NEUROSCI, V61, P201, DOI 10.1016/j.mcn.2014.06.004; Kogel D, 2012, EXP BRAIN RES, V217, P471, DOI 10.1007/s00221-011-2932-4; LANNFELT L, 1995, NAT MED, V1, P829, DOI 10.1038/nm0895-829; Lassek M, 2013, J NEUROCHEM, V127, P48, DOI 10.1111/jnc.12358; Lee KJ, 2010, NEUROSCIENCE, V169, P344, DOI 10.1016/j.neuroscience.2010.04.078; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; Leyssen M, 2005, EMBO J, V24, P2944, DOI 10.1038/sj.emboj.7600757; Li ZW, 1996, P NATL ACAD SCI USA, V93, P6158, DOI 10.1073/pnas.93.12.6158; Lichtenthaler SF, 2011, J NEUROCHEM, V117, P779, DOI 10.1111/j.1471-4159.2011.07248.x; Lu B, 2013, NAT REV NEUROSCI, V14, P401, DOI 10.1038/nrn3505; Marcello E, 2007, J NEUROSCI, V27, P1682, DOI 10.1523/JNEUROSCI.3439-06.2007; Meziane H, 1998, P NATL ACAD SCI USA, V95, P12683, DOI 10.1073/pnas.95.21.12683; Mileusnic R, 2004, EUR J NEUROSCI, V19, P1933, DOI 10.1111/j.1460-9568.2004.03276.x; Milosch N, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.352; Miners JS, 2011, J NEUROPATH EXP NEUR, V70, P944, DOI 10.1097/NEN.0b013e3182345e46; Mucke L, 1996, ANN NY ACAD SCI, V777, P82, DOI 10.1111/j.1749-6632.1996.tb34405.x; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; Nhan HS, 2015, ACTA NEUROPATHOL, V129, P1, DOI 10.1007/s00401-014-1347-2; Obregon D, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1781; Pennanen L, 2006, GENES BRAIN BEHAV, V5, P369, DOI 10.1111/j.1601-183X.2005.00165.x; Prokop Stefan, 2013, Acta Neuropathol, V126, P461; Prox J, 2012, EXP BRAIN RES, V217, P331, DOI 10.1007/s00221-011-2952-0; Ramirez MJ, 2001, BRAIN RES, V907, P222, DOI 10.1016/S0006-8993(01)02580-X; Ring S, 2007, J NEUROSCI, V27, P7817, DOI 10.1523/JNEUROSCI.1026-07.2007; ROCH JM, 1994, P NATL ACAD SCI USA, V91, P7450, DOI 10.1073/pnas.91.16.7450; Roozendaal B, 2001, NAT NEUROSCI, V4, P1169, DOI 10.1038/nn766; Savonenko A, 2005, NEUROBIOL DIS, V18, P602, DOI 10.1016/j.nbd.2004.10.022; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Shankar GM, 2007, J NEUROSCI, V27, P2866, DOI 10.1523/JNEUROSCI.4970-06.2007; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; Spires-Jones T, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/319836; Suh J, 2013, NEURON, V80, P385, DOI 10.1016/j.neuron.2013.08.035; Tang W, 2009, J NEUROSCI, V29, P8621, DOI 10.1523/JNEUROSCI.0359-09.2009; Taylor CJ, 2008, NEUROBIOL DIS, V31, P250, DOI 10.1016/j.nbd.2008.04.011; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; Vassar R, 2014, J NEUROCHEM, V130, P4, DOI 10.1111/jnc.12715; Villemagne VL, 2013, LANCET NEUROL, V12, P357, DOI 10.1016/S1474-4422(13)70044-9; Wang YM, 2015, CELL, V160, P1061, DOI 10.1016/j.cell.2015.01.049; Wang ZL, 2009, J NEUROSCI, V29, P10788, DOI 10.1523/JNEUROSCI.2132-09.2009; Weyer SW, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-36; Weyer SW, 2011, EMBO J, V30, P2266, DOI 10.1038/emboj.2011.119; Wilhelm BG, 2014, SCIENCE, V344, P1023, DOI 10.1126/science.1252884; Xiong HQ, 2011, NEUROSCI BULL, V27, P221, DOI 10.1007/s12264-011-1015-7; Yang L, 2009, J NEUROSCI, V29, P15660, DOI 10.1523/JNEUROSCI.4104-09.2009	87	90	92	0	51	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	FEB	2016	131	2					247	266		10.1007/s00401-015-1498-9			20	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	DB5DT	WOS:000368535000006	26538149				2022-02-06	
J	Nelson, LD; LaRoche, AA; Pfaller, AY; Lerner, EB; Hammeke, TA; Randolph, C; Barr, WB; Guskiewicz, K; McCrea, MA				Nelson, Lindsay D.; LaRoche, Ashley A.; Pfaller, Adam Y.; Lerner, E. Brooke; Hammeke, Thomas A.; Randolph, Christopher; Barr, William B.; Guskiewicz, Kevin; McCrea, Michael A.			Prospective, Head-to-Head Study of Three Computerized Neurocognitive Assessment Tools (CNTs): Reliability and Validity for the Assessment of Sport-Related Concussion	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Concussion; Sport; Computerized testing; ANAM; Axon Sports; ImPACT	TEST-RETEST RELIABILITY; FALSE DISCOVERY RATE; BASE-LINE; HIGH-SCHOOL; NEUROPSYCHOLOGICAL ASSESSMENT; COGNITIVE IMPAIRMENT; ONLINE VERSION; IMPACT; RECOVERY; SENSITIVITY	Limited data exist comparing the performance of computerized neurocognitive tests (CNTs) for assessing sport-related concussion. We evaluated the reliability and validity of three CNTsANAM, Axon Sports/Cogstate Sport, and ImPACTin a common sample. High school and collegiate athletes completed two CNTs each at baseline. Concussed (n=165) and matched non-injured control (n=166) subjects repeated testing within 24 hr and at 8, 15, and 45 days post-injury. Roughly a quarter of each CNT's indices had stability coefficients (M=198 day interval) over .70. Group differences in performance were mostly moderate to large at 24 hr and small by day 8. The sensitivity of reliable change indices (RCIs) was best at 24 hr (67.8%, 60.3%, and 47.6% with one or more significant RCIs for ImPACT, Axon, and ANAM, respectively) but diminished to near the false positive rates thereafter. Across time, the CNTs' sensitivities were highest in those athletes who became asymptomatic within 1 day before neurocognitive testing but was similar to the tests' false positive rates when including athletes who became asymptomatic several days earlier. Test-retest reliability was similar among these three CNTs and below optimal standards for clinical use on many subtests. Analyses of group effect sizes, discrimination, and sensitivity and specificity suggested that the CNTs may add incrementally (beyond symptom scores) to the identification of clinical impairment within 24 hr of injury or within a short time period after symptom resolution but do not add significant value over symptom assessment later. The rapid clinical recovery course from concussion and modest stability probably jointly contribute to limited signal detection capabilities of neurocognitive tests outside a brief post-injury window. (JINS, 2016, 22, 24-37)	[Nelson, Lindsay D.; LaRoche, Ashley A.; Pfaller, Adam Y.; Lerner, E. Brooke; Hammeke, Thomas A.; McCrea, Michael A.] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Hammeke, Thomas A.; McCrea, Michael A.] Clement J Zablocki VA Med Ctr, Milwaukee, WI USA; [Randolph, Christopher] Loyola Univ, Sch Med, Maywood, IL 60153 USA; [Barr, William B.] NYU, Sch Med, New York, NY USA; [Guskiewicz, Kevin] Univ N Carolina, Chapel Hill, NC USA		Nelson, LD (corresponding author), 8701 West Watertown Plank Rd, Milwaukee, WI USA.	linelson@mcw.edu		LaRoche, Ashley/0000-0003-0197-0853; Barr, William/0000-0001-7711-7758	U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-12-1-0004]; Clinical and Translational Science Institute [1UL1-RR031973 (-01)]; National Center for Advancing Translational Sciences, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [8UL1TR000055]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000055] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR031973] Funding Source: NIH RePORTER	This work was supported by the U.S. Army Medical Research and Materiel Command under award number W81XWH-12-1-0004. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army. The REDCap electronic database service used for the study was supported by the Clinical and Translational Science Institute grant 1UL1-RR031973 (-01) and by the National Center for Advancing Translational Sciences, National Institutes of Health grant 8UL1TR000055. The manuscript's contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The authors have no conflicts of interest to report.	Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Benjamini Y, 2001, ANN STAT, V29, P1165; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Bruce J, 2014, CLIN NEUROPSYCHOL, V28, P14, DOI 10.1080/13854046.2013.866272; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Chelune G.J., 1993, NEUROPSYCHOLOGY, V7, P41, DOI [10.1037/0894-4105.7.1.41, DOI 10.1037/0894-4105.7.1.41]; Cole WR, 2013, ARCH CLIN NEUROPSYCH, V28, P732, DOI 10.1093/arclin/act040; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Crawford JR, 2007, NEUROPSYCHOLOGY, V21, P419, DOI 10.1037/0894-4105.21.4.419; Derogatis L.R., 2001, BRIEF SYMPTOM INVENT; Dettwiler A, 2014, J NEUROTRAUM, V31, P180, DOI 10.1089/neu.2013.2983; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Eckner JT, 2011, J ATHL TRAINING, V46, P409; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Green P., 2003, GREENS MED SYMPTOM V; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Helmick K., 2006, DEFENSE VETERANS BRA; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; LaRoche AA, 2016, CLIN J SPORT MED, V26, P33, DOI 10.1097/JSM.0000000000000192; Lichtenstein JD, 2014, AM J SPORT MED, V42, P479, DOI 10.1177/0363546513509225; Louey AG, 2014, ARCH CLIN NEUROPSYCH, V29, P432, DOI 10.1093/arclin/acu020; MacDonald J, 2015, CLIN J SPORT MED, V25, P367, DOI 10.1097/JSM.0000000000000139; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Meehan WP, 2012, PEDIATRICS, V129, P38, DOI 10.1542/peds.2011-1972; Mondello S, 2014, MED RES REV, V34, P503, DOI 10.1002/med.21295; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Moser RS, 2015, APPL NEUROPSYCH-CHIL, V4, P41, DOI 10.1080/21622965.2013.791825; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Nakayama Y, 2014, AM J SPORT MED, V42, P2000, DOI 10.1177/0363546514535901; Nelson L.D., J ATHLETIC IN PRESS; Nelson LD, 2015, AM J SPORT MED, V43, P2018, DOI 10.1177/0363546515587714; Nelson LD, 2013, NEUROPSYCHOL REV, V23, P285, DOI 10.1007/s11065-013-9240-7; Prichep LS, 2013, J HEAD TRAUMA REHAB, V28, P266, DOI 10.1097/HTR.0b013e318247b54e; Rahman-Filipiak AAM, 2013, NEUROPSYCHOL REV, V23, P314, DOI 10.1007/s11065-013-9241-6; Randolph C, 2005, J ATHL TRAINING, V40, P139; Register-Mihalik JK, 2013, J HEAD TRAUMA REHAB, V28, P274, DOI 10.1097/HTR.0b013e3182585d37; Register-Mihalik JK, 2012, J ATHL TRAINING, V47, P297, DOI 10.4085/1062-6050-47.3.13; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Resch JE, 2013, NEUROPSYCHOL REV, V23, P335, DOI 10.1007/s11065-013-9242-5; Rousson V, 2002, STAT MED, V21, P3431, DOI 10.1002/sim.1253; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P499, DOI 10.1093/arclin/act034; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schretlen DJ, 2008, J INT NEUROPSYCH SOC, V14, P436, DOI 10.1017/S1355617708080387; Segalowitz SJ, 2007, NEUROREHABILITATION, V22, P243; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI64, DOI 10.1136/bjsm.2005.019620; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Vincent AS, 2012, MIL MED, V177, P248, DOI 10.7205/MILMED-D-11-00156; WechslerD, 2001, WECHSLER TEST ADULT; Weir JP, 2005, J STRENGTH COND RES, V19, P231, DOI 10.1519/15184.1; Yuh Esther L, 2014, Neurosurgery, V75 Suppl 4, pS50, DOI 10.1227/NEU.0000000000000491; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413	69	90	90	0	15	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2016	22	1					24	37		10.1017/S1355617715001101			14	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	DA1XW	WOS:000367590300003	26714883	Green Accepted, Green Submitted, Bronze			2022-02-06	
J	Tisherman, SA; Schmicker, RH; Brasel, KJ; Bulger, EM; Kerby, JD; Minei, JP; Powell, JL; Reiff, DA; Rizoli, SB; Schreiber, MA				Tisherman, Samuel A.; Schmicker, Robert H.; Brasel, Karen J.; Bulger, Eileen M.; Kerby, Jeffrey D.; Minei, Joseph P.; Powell, Judy L.; Reiff, Donald A.; Rizoli, Sandro B.; Schreiber, Martin A.			Detailed Description of All Deaths in Both the Shock and Traumatic Brain Injury Hypertonic Saline Trials of the Resuscitation Outcomes Consortium	ANNALS OF SURGERY			English	Article						clinical trial; hemorrhagic shock; mortality; trauma; traumatic brain injury	EPIDEMIOLOGY	Objective: To identify causes and timing of mortality in trauma patients to determine targets for future studies. Background: In trials conducted by the Resuscitation Outcomes Consortium in patients with traumatic hypovolemic shock (shock) or traumatic brain injury (TBI), hypertonic saline failed to improve survival. Selecting appropriate candidates is challenging. Methods: Retrospective review of patients enrolled in multicenter, randomized trials performed from 2006 to 2009. Inclusion criteria were as follows: injured patients, age 15 years or more with hypovolemic shock [systolic blood pressure (SBP) <= 70 mm Hg or SBP 71-90 mm Hg with heart rate >= 108) or severe TBI [Glasgow Coma Score (GCS) <= 8]. Initial fluid administered was 250 mL of either 7.5% saline with 6% dextran 70, 7.5% saline or 0.9% saline. Results: A total of 2061 subjects were enrolled (809 shock, 1252 TBI) and 571 (27.7%) died. Survivors were younger than nonsurvivors [30 (interquartile range 23) vs 42 (34)] and had a higher GCS, though similar hemodynamics. Most deaths occurred despite ongoing resuscitation. Forty-six percent of deaths in the TBI cohort were within 24 hours, compared with 82% in the shock cohort and 72% in the cohort with both shock and TBI. Median time to death was 29 hours in the TBI cohort, 2 hours in the shock cohort, and 4 hours in patients with both. Sepsis and multiple organ dysfunction accounted for 2% of deaths. Conclusions: Most deaths from trauma with shock or TBI occur within 24 hours from hypovolemic shock or TBI. Novel resuscitation strategies should focus on early deaths, though prevention may have a greater impact.	[Tisherman, Samuel A.] Univ Maryland, Baltimore, MD 21201 USA; [Schmicker, Robert H.; Bulger, Eileen M.; Powell, Judy L.] Univ Washington, Seattle, WA 98195 USA; [Brasel, Karen J.] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Kerby, Jeffrey D.; Reiff, Donald A.] Univ Alabama Birmingham, Birmingham, AL USA; [Minei, Joseph P.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Rizoli, Sandro B.] St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Schreiber, Martin A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA		Tisherman, SA (corresponding author), Univ Maryland, R Adams Cowley Shock Trauma Ctr, 22 S Greene St, Baltimore, MD 21201 USA.	stisherman@umm.edu	Tisherman, Samuel A./AAK-9377-2020	Tisherman, Samuel A./0000-0003-3810-3729	University of Washington Data Coordinating Center [5U01 HL077863]; University of Iowa [HL077865]; Medical College of WisconsinGeneral Electric [HL077866]; University of WashingtonUniversity of Washington [HL077867]; University of PittsburghUniversity of Pittsburgh [HL077871]; St Michael's Hospital [HL077872]; Oregon Health and Science University [HL077873]; University of Alabama at Birmingham [HL077881]; Ottawa Hospital Research Institute [HL077885]; University of Texas SW Medical Center/Dallas [HL077887]; National Heart, Lung and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [5U01 HL077863, HL077865, HL077866, HL077867, HL077871, HL077872, HL077873, HL077881, HL077885, HL077887, HL077908]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); US Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); Canadian Institutes of Health Research (CIHR)-Institute of Circulatory and Respiratory HealthCanadian Institutes of Health Research (CIHR); Defence Research and Development Canada; Heart, Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; American Heart AssociationAmerican Heart Association; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL077872, U01HL077867, U01HL077873, U01HL077871, U01HL077908, U01HL077887, U01HL077885, U01HL077881, U01HL077866, U01HL077865, U01HL077863] Funding Source: NIH RePORTER	The authors have no conflicts of interest to declare. The Resuscitation Outcomes Consortium is supported by a series of cooperative agreements to 10 regional clinical centers and 1 Data Coordinating Center (5U01 HL077863-University of Washington Data Coordinating Center, HL077865-University of Iowa, HL077866-Medical College of Wisconsin, HL077867-University of Washington, HL077871-University of Pittsburgh, HL077872-St Michael's Hospital, HL077873-Oregon Health and Science University, HL077881-University of Alabama at Birmingham, HL077885-Ottawa Hospital Research Institute, HL077887-University of Texas SW Medical Center/Dallas, HL077908 University of California San Diego) from the National Heart, Lung and Blood Institute in partnership with the National Institute of Neurological Disorders and Stroke, US Army Medical Research and Material Command, The Canadian Institutes of Health Research (CIHR)-Institute of Circulatory and Respiratory Health, Defence Research and Development Canada, the Heart, Stroke Foundation of Canada, and the American Heart Association. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung and Blood Institute or the National Institutes of Health. The original trials are registered with clinicaltrials.gov as: NCT00316004 and NCT00316017.	BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; Bulger EM, 2011, ANN SURG, V253, P431, DOI 10.1097/SLA.0b013e3181fcdb22; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2001, DOI 10.1089/neu.2013.3047; Davidson GH, 2011, JAMA-J AM MED ASSOC, V305, P1001, DOI 10.1001/jama.2011.259; Demetriades D, 2005, J AM COLL SURGEONS, V201, P343, DOI 10.1016/j.jamcollsurg.2005.05.003; Dewar DC, 2013, J TRAUMA ACUTE CARE, V74, P774, DOI 10.1097/TA.0b013e31827a6e69; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Gilchrist Julie, 2012, Morbidity and Mortality Weekly Report, V61, P270; Hartholt KA, 2012, AM J PUBLIC HEALTH, V102, pS207, DOI 10.2105/AJPH.2011.300288; Hu GQ, 2009, AM J PREV MED, V37, P188, DOI 10.1016/j.amepre.2009.04.023; Hu GQ, 2010, INJURY PREV, V16, P26, DOI 10.1136/ip.2009.023481; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; McGwin G, 2009, J TRAUMA, V66, P526, DOI 10.1097/TA.0b013e3181623321; Meislin H, 1997, J TRAUMA, V43, P433, DOI 10.1097/00005373-199709000-00008; Minei JP, 2010, ANN SURG, V252, P149, DOI 10.1097/SLA.0b013e3181df0401; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Stewart RM, 2003, J TRAUMA, V54, P66, DOI 10.1097/00005373-200301000-00009; TRUNKEY DD, 1983, SCI AM, V249, P28, DOI 10.1038/scientificamerican0883-28	19	90	93	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	MAR	2015	261	3					586	590		10.1097/SLA.0000000000000837			5	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	CB3WK	WOS:000349559900058	25072443	Green Accepted			2022-02-06	
J	Mirza, MA; Ritzel, R; Xu, Y; McCullough, LD; Liu, FD				Mirza, Mehwish A.; Ritzel, Rodney; Xu, Yan; McCullough, Louise D.; Liu, Fudong			Sexually dimorphic outcomes and inflammatory responses in hypoxic-ischemic encephalopathy	JOURNAL OF NEUROINFLAMMATION			English	Article						Hypoxic-ischemic encephalopathy; Neonate; Inflammation; Infarct; Microglia	TRAUMATIC BRAIN-INJURY; EXPERIMENTAL STROKE; TESTOSTERONE SURGE; NEONATAL STROKE; IMMATURE MOUSE; MICROGLIA; SEX; MICE; INFANTS; GENDER	Background: Neonatal hypoxic-ischemic encephalopathy (HIE) is an important cause of motor and cognitive impairment in children. Clinically, male infants are more vulnerable to ischemic insults and suffer more long-term deficits than females; however, the mechanisms underlying this sex difference remain elusive. Inflammatory processes initiated by microglial activation are fundamental in the pathophysiology of ischemia. Recent studies report a sexual dimorphism in microglia numbers and expression of activation markers in the neonatal brain under normal conditions. How these basal sex differences in microglia affect HIE remains largely unexplored. This study investigated sex differences in ischemic outcomes and inflammation triggered by HIE. We hypothesize that ischemia induces sex-specific brain injury in male and female neonates and that microglial activation and inflammatory responses play an important role in this sexual dimorphism. Methods: Male and female C57BL6 mice were subjected to 60-min Rice-Vanucci modeling (RVM) at post-natal day 10 (P10) to induce HIE. Stroke outcomes were measured 1, 3, 7, and 30 days after stroke. Microglial activation and inflammatory responses were evaluated by flow cytometry and cytokine analysis. Results: On day 1 of HIE, no difference in infarct volumes or seizure scores was seen between male and female neonates. However, female neonates exhibited significantly smaller infarct size and fewer seizures compared to males 3 days after HIE. Females also had less brain tissue loss and behavioral deficits compared to males at the chronic stage of HIE. Male animals demonstrated increased microglial activation and up-regulated inflammatory response compared to females at day 3. Conclusions: HIE leads to an equivalent primary brain injury in male and female neonates at the acute stage that develops into sexually dimorphic outcomes at later time points. An innate immune response secondary to the primary injury may contribute to sexual dimorphism in HIE.	[Mirza, Mehwish A.; Ritzel, Rodney; Xu, Yan; McCullough, Louise D.; Liu, Fudong] Univ Connecticut, Ctr Hlth, Dept Neurosci, Farmington, CT 06030 USA; [McCullough, Louise D.] Univ Connecticut, Ctr Hlth, Dept Neurol, Farmington, CT 06030 USA		Liu, FD (corresponding author), Univ Connecticut, Ctr Hlth, Dept Neurosci, 263 Farmington Ave, Farmington, CT 06030 USA.	fliu@uchc.edu	McCullough, Louise/R-2824-2019	Ritzel, Rodney/0000-0002-0160-2930	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS050505, NS055215]; American Heart AssociationAmerican Heart Association [12SDG9030000]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055215, F31NS083244, R01NS050505] Funding Source: NIH RePORTER	This work was supported by the NIH/NINDS (grants NS050505 and NS055215 to Louise D MCCULLOUGH), and by the American Heart Association (grant 12SDG9030000 to Fudong LIU). We thank Kathryn Bentivegna for her assistance with flow cytometry.	Arnold AP, 2009, FRONT NEUROENDOCRIN, V30, P1, DOI 10.1016/j.yfrne.2008.11.001; Cheong JLY, 2009, SEMIN FETAL NEONAT M, V14, P267, DOI 10.1016/j.siny.2009.07.009; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Comi AM, 2004, PEDIATR NEUROL, V31, P254, DOI 10.1016/j.pediatrneurol.2004.04.010; CORBIER P, 1992, ARCH INT PHYSIOL BIO, V100, P127, DOI 10.3109/13813459209035274; Courties G, 2014, J AM COLL CARDIOL, V63, P1556, DOI 10.1016/j.jacc.2013.11.023; Crain JM, 2013, J NEUROSCI RES, V91, P1143, DOI 10.1002/jnr.23242; Crain JM, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-24; DELBIGIO MR, 1994, NEUROPATH APPL NEURO, V20, P144, DOI 10.1111/j.1365-2990.1994.tb01173.x; Deng H, 2003, STROKE, V34, P2495, DOI 10.1161/01.STR.0000091269.67384.E7; Denker SP, 2007, J NEUROCHEM, V100, P893, DOI 10.1111/j.1471-4159.2006.04162.x; Di Napoli M, 2014, NEUROINFLAMMATION NE, P199, DOI [10.1007/978-1-4939-1071-7_11, DOI 10.1007/978-1-4939-1071-7_11]; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Enzmann G, 2013, ACTA NEUROPATHOL, V125, P395, DOI 10.1007/s00401-012-1076-3; Foster-Barber A, 2001, DEV NEUROSCI-BASEL, V23, P213, DOI 10.1159/000046146; Galasso JM, 2000, NEUROREPORT, V11, P231, DOI 10.1097/00001756-200002070-00002; Golomb MR, 2004, J CHILD NEUROL, V19, P493, DOI 10.1177/08830738040190070301; Hesp BR, 2007, EPILEPSY RES, V76, P103, DOI 10.1016/j.eplepsyres.2007.07.003; Hill CA, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/867531; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; Ikegami S, 2001, CLIN ENDOCRINOL, V55, P789, DOI 10.1046/j.1365-2265.2001.01416.x; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Kadam SD, 2009, BEHAV BRAIN RES, V197, P77, DOI 10.1016/j.bbr.2008.08.003; Kalay S, 2014, EXP THER MED, V7, P734, DOI 10.3892/etm.2014.1470; Knox R, 2013, NEUROBIOL DIS, V51, P113, DOI 10.1016/j.nbd.2012.10.024; Koellhoffer EC, 2013, TRANSL STROKE RES, V4, P390, DOI 10.1007/s12975-012-0230-5; Kohman RA, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-114; Konkle ATM, 2011, ENDOCRINOLOGY, V152, P223, DOI 10.1210/en.2010-0607; Lai MC, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/609813; Lauterbach MD, 2001, NEUROPSYCHOLOGY, V15, P411, DOI 10.1037/0894-4105.15.3.411; Lee Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/297241; Lenz KM, 2013, J NEUROSCI, V33, P2761, DOI 10.1523/JNEUROSCI.1268-12.2013; Li XL, 2004, EXP NEUROL, V187, P94, DOI 10.1016/j.expneurol.2004.01.004; Liu FD, 2013, ACTA PHARMACOL SIN, V34, P1121, DOI 10.1038/aps.2013.89; Liu FD, 2012, NEUROCHEM INT, V61, P1255, DOI 10.1016/j.neuint.2012.10.003; Liu FD, 2012, AGE, V34, P157, DOI 10.1007/s11357-011-9214-8; Liu F, 2009, J NEUROSCI METH, V179, P1, DOI 10.1016/j.jneumeth.2008.12.028; Manwani B, 2013, EXP NEUROL, V249, P120, DOI 10.1016/j.expneurol.2013.08.011; Mirza MA, 2013, BRAIN RES BULL, V98, P111, DOI 10.1016/j.brainresbull.2013.07.011; Oertelt-Prigione S, 2012, AUTOIMMUN REV, V11, pA479, DOI 10.1016/j.autrev.2011.11.022; Oygur N, 1998, ARCH DIS CHILD-FETAL, V79, pF190, DOI 10.1136/fn.79.3.F190; Patel Anita R, 2013, Int J Physiol Pathophysiol Pharmacol, V5, P73; Peruzzotti-Jametti L, 2014, NEUROSCIENCE, V283, P210, DOI 10.1016/j.neuroscience.2014.04.036; Petrone AB, 2014, AGING DIS, V5, P340, DOI 10.14336/AD.2014.0500340; Raz S, 2010, J INT NEUROPSYCH SOC, V16, P169, DOI 10.1017/S1355617709991147; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Rosenzweig JM, 2014, FRONT PEDIATR, V2, DOI 10.3389/fped.2014.00108; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; Traa BS, 2008, PEDIATR RES, V64, P81, DOI 10.1203/PDR.0b013e318174e70e; Turtzo LC, 2008, CEREBROVASC DIS, V26, P462, DOI 10.1159/000155983; Venna VR, 2012, ACTA NEUROPATHOL, V124, P425, DOI 10.1007/s00401-012-0990-8; Vexler ZS, 2006, CLIN NEUROSCI RES, V6, P293, DOI 10.1016/j.cnr.2006.09.008; Vogelgesang A, 2014, ACTA NEUROL SCAND, V129, P1, DOI 10.1111/ane.12165; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Ward IL, 2003, HORM BEHAV, V43, P531, DOI 10.1016/S0018-506X(03)00061-8; White TE, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-282; Wu YW, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.09.022	58	90	96	0	13	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	FEB 20	2015	12								32	10.1186/s12974-015-0251-6			10	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	CD3FA	WOS:000350962200001	25889641	Green Published, gold			2022-02-06	
J	Didehbani, N; Cullum, CM; Mansinghani, S; Conover, H; Hart, J				Didehbani, Nyaz; Cullum, C. Munro; Mansinghani, Sethesh; Conover, Heather; Hart, John, Jr.			Depressive Symptoms and Concussions in Aging Retired NFL Players	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Concussion; Depression; Cognition; Aging; Football; NFL	PROFESSIONAL FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; POSTCONCUSSION SYMPTOMS; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; EARLY ADULTHOOD; UNITED-STATES; HIGH-SCHOOL; IMPACT	We examined the relationship between a remote history of concussions with current symptoms of depression in retired professional athletes. Thirty retired National Football League (NFL) athletes with a history of concussion and 29 age-and IQ-matched controls without a history of concussion were recruited. We found a significant correlation between the number of lifetime concussions and depressive symptom severity using the Beck Depression Inventory II. Upon investigating a three-factor model of depressive symptoms (affective, cognitive, and somatic; Buckley et al., 2001) from the BDI-II, the cognitive factor was the only factor that was significantly related to concussions. In general, NFL players endorsed more symptoms of depression on all three Buckley factors compared with matched controls. Findings suggest that the number of self-reported concussions may be related to later depressive symptomology (particularly cognitive symptoms of depression).	[Didehbani, Nyaz; Mansinghani, Sethesh; Conover, Heather; Hart, John, Jr.] Univ Texas Dallas, Ctr BrainHlth, Dallas, TX 75230 USA; [Cullum, C. Munro] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA		Didehbani, N (corresponding author), Ctr BrainHlth, 2200 W Mockingbird Lane, Dallas, TX 75235 USA.	nyaz.didehbani@utdallas.edu	Cullum, C. Munro/AAC-2496-2019	Cullum, C. Munro/0000-0001-9706-5465; Didehbani, Nyaz/0000-0001-6121-5759; Mansinghani, Sethesh/0000-0001-5861-3764	National Institute of Health/National Institute of AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG12300-19]	This work was partially funded by the National Institute of Health/National Institute of Aging (P30 AG12300-19).	Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; Buckley TC, 2001, J SUBST ABUSE TREAT, V20, P197, DOI 10.1016/S0740-5472(00)00169-0; Casson IR, 2008, NEUROL CLIN, V26, P217, DOI 10.1016/j.ncl.2007.11.005; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Dave D., 2006, SO EC J SO EC ASS, DOI DOI 10.2307/27751397; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Delis D.C., 2000, CALIFORNIA VERBAL LE; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Garden N, 2010, NEUROPSYCHOLOGY, V24, P168, DOI 10.1037/a0017431; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Horn S, 2009, AM J PHYS MED REHAB, V88, P192, DOI 10.1097/PHM.0b013e318198b622; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Kaplan E, 1983, BOSTON NAMING TEST; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kraut MA, 2006, COGN BEHAV NEUROL, V19, P177, DOI 10.1097/01.wnn.0000213922.41008.22; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Penninx BWJH, 1998, JAMA-J AM MED ASSOC, V279, P1720, DOI 10.1001/jama.279.21.1720; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Schwenk TL, 2007, MED SCI SPORT EXER, V39, P599, DOI 10.1249/mss.0b013e31802fa679; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; Turner AP, 2000, BRIT J SPORT MED, V34, P332, DOI 10.1136/bjsm.34.5.332; Wechsler D., 2011, WECHSLER ABBREVIATED; Wechsler D., 2008, WECHSLER ADULT INTEL; Weir DR., 2009, NATL FOOTBALL LEAGUE; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	48	90	91	4	83	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2013	28	5					418	424		10.1093/arclin/act028			7	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	186CN	WOS:000322019600004	23644673	Green Published, Bronze			2022-02-06	
J	Meffre, D; Labombarda, F; Delespierre, B; Chastre, A; De Nicola, AF; Stein, DG; Schumacher, M; Guennoun, R				Meffre, D.; Labombarda, F.; Delespierre, B.; Chastre, A.; De Nicola, A. F.; Stein, D. G.; Schumacher, M.; Guennoun, R.			DISTRIBUTION OF MEMBRANE PROGESTERONE RECEPTOR ALPHA IN THE MALE MOUSE AND RAT BRAIN AND ITS REGULATION AFTER TRAUMATIC BRAIN INJURY	NEUROSCIENCE			English	Article						membrane progesterone receptor (mPR); neurons; astrocytes; oligodendrocytes; microglia; traumatic brain injury (TBI)	BINDING-PROTEIN 25-DX; NONCLASSICAL MECHANISMS; NEUROPROTECTIVE FACTOR; PLASMA-MEMBRANE; SEXUAL-BEHAVIOR; EXPRESSION; NEUROSTEROIDS; HYPOTHALAMUS; ESTRADIOL; HORMONE	Progesterone has been shown to exert pleiotropic actions in the brain of both male and females. In particular, after traumatic brain injury (TBI), progesterone has important neuroprotective effects. In addition to intracellular progesterone receptors, membrane receptors of the hormone such as membrane progesterone receptor (mPR) may also be involved in neuroprotection. Three mPR subtypes (mPR alpha, mPR beta and mPR gamma) have been described and mPR alpha is best characterized pharmacologically. In the present study we investigated the distribution, cellular localization and the regulation of mPR alpha in male mouse and rat brain. We showed by reverse transcription-PCR that mPR alpha is expressed at similar levels in the male and female mouse brain suggesting that its expression may not be influenced by steroid levels. Treatment of males by estradiol or progesterone did not modify the level of expression of mPR alpha as shown by Western blot analysis. In situ hybridization and immunohistochemistry analysis showed a wide expression of mPR alpha in particular in the olfactory bulb, striatum, cortex, thalamus, hypothalamus, septum, hippocampus and cerebellum. Double immunofluorescence and confocal microscopy analysis showed that mPR alpha is expressed by neurons but not by oligodendrocytes and astrocytes. In the rat brain, the distribution of mPR alpha was similar to that observed in mouse brain; and after TBI, mPR alpha expression was induced in oligodendrocytes, astrocytes and reactive microglia. The wide neuroanatomical distribution of mPR alpha suggests that this receptor may play a role beyond neuroendocrine and reproductive functions. However, in the absence of injury its role might be restricted to neurons. The induction of mPR alpha after TBI in microglia, astrocytes and oligodendrocytes, points to a potential role in mediating the modulatory effects of progesterone in inflammation, ion and water homeostasis and myelin repair in the injured brain. (c) 2012 IBRO. Published by Elsevier Ltd. All rights reserved.	[Meffre, D.; Labombarda, F.; Delespierre, B.; Chastre, A.; Schumacher, M.; Guennoun, R.] INSERM, UMR 788, F-94276 Le Kremlin Bicetre, France; [Meffre, D.; Labombarda, F.; Delespierre, B.; Chastre, A.; Schumacher, M.; Guennoun, R.] Univ Paris 11, F-94276 Le Kremlin Bicetre, France; [Labombarda, F.; De Nicola, A. F.] Univ Buenos Aires, Lab Neuroendocrine Biochem, Inst Biol & Med Expt, RA-1053 Buenos Aires, DF, Argentina; [Labombarda, F.; De Nicola, A. F.] Univ Buenos Aires, Dept Human Biochem, RA-1053 Buenos Aires, DF, Argentina; [Stein, D. G.] Emory Univ, Sch Med, Dept Emergency Med, Brain Res Lab, Atlanta, GA USA		Guennoun, R (corresponding author), INSERM, UMR 788, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	rachida.guennoun@inserm.fr	Stein, Donald/AAJ-5139-2020; Labombarda, Fabien/AAE-7747-2020; Schumacher, Michael/G-3581-2013; Guennoun, Rachida/F-2420-2011	Schumacher, Michael/0000-0001-6117-5371; Guennoun, Rachida/0000-0002-9219-7300; MEFFRE, Delphine/0000-0002-9204-2245	Government of France (INSERM/CONICET); Government of Argentina (INSERM/CONICET)	We thank Philippe Leclerc for confocal microscopy. This work was partly supported by a cooperative program between the Governments of France and Argentina (INSERM/CONICET).	Ashley RL, 2006, ENDOCRINOLOGY, V147, P4151, DOI 10.1210/en.2006-0002; Auger CJ, 2006, J NEUROENDOCRINOL, V18, P187, DOI 10.1111/j.1365-2826.2005.01400.x; Balasubramanian B, 2008, ENDOCRINOLOGY, V149, P5509, DOI 10.1210/en.2008-0712; Balasubramanian B, 2008, ENDOCRINOLOGY, V149, P5518, DOI 10.1210/en.2008-0713; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; BROWN TJ, 1987, J NEUROSCI, V7, P2529; Cekic M, 2010, NEUROTHERAPEUTICS, V7, P81, DOI 10.1016/j.nurt.2009.10.017; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Coirini H, 2002, NEUROSCIENCE, V113, P883, DOI 10.1016/S0306-4522(02)00224-5; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; de Sousa FL, 2010, BEHAV BRAIN RES, V212, P84, DOI 10.1016/j.bbr.2010.03.050; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; Falkenstein E, 2000, EUR J CLIN INVEST, V30, P51, DOI 10.1046/j.1365-2362.2000.0300s3051.x; Feeser VR, 2011, J NEUROIMMUNOL, V237, P4, DOI 10.1016/j.jneuroim.2011.06.007; Frye CA, 2001, HORM BEHAV, V40, P226, DOI 10.1006/hbeh.2001.1674; Garcia-Ovejero D, 2002, J COMP NEUROL, V450, P256, DOI 10.1002/cne.10325; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Gibson CL, 2009, NEUROSCIENTIST, V15, P324, DOI 10.1177/1073858409333069; Gomez C, 2002, PHARMACOL BIOCHEM BE, V72, P543, DOI 10.1016/S0091-3057(02)00722-0; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Greco B, 2001, ENDOCRINOLOGY, V142, P5172, DOI 10.1210/en.142.12.5172; Guennoun R, 2008, BRAIN RES REV, V57, P493, DOI 10.1016/j.brainresrev.2007.05.009; GUENNOUN R, 1995, MOL BRAIN RES, V30, P287, DOI 10.1016/0169-328X(95)00016-L; Gunn BG, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00131; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hosie AM, 2006, NATURE, V444, P486, DOI 10.1038/nature05324; Hussain R, 2011, ENDOCRINOLOGY, V152, P3820, DOI 10.1210/en.2011-1219; Hwang JY, 2009, CELL CALCIUM, V45, P233, DOI 10.1016/j.ceca.2008.10.006; Intlekofer KA, 2011, NEUROSCIENCE, V176, P86, DOI 10.1016/j.neuroscience.2010.12.033; Intlekofer KA, 2011, NEUROSCIENCE, V172, P55, DOI 10.1016/j.neuroscience.2010.10.051; KE FC, 1990, J NEUROCHEM, V54, P467, DOI 10.1111/j.1471-4159.1990.tb01895.x; Krebs CJ, 2000, P NATL ACAD SCI USA, V97, P12816, DOI 10.1073/pnas.97.23.12816; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Labombarda F, 2003, J NEUROCHEM, V87, P902, DOI 10.1046/j.1471-4159.2003.02055.x; Labombarda F, 2010, NEUROSCIENCE, V166, P94, DOI 10.1016/j.neuroscience.2009.12.012; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2000, J STEROID BIOCHEM, V73, P159, DOI 10.1016/S0960-0760(00)00064-9; LAN NC, 1991, J NEUROCHEM, V57, P1818, DOI 10.1111/j.1471-4159.1991.tb06388.x; Liu B, 2009, J NEUROENDOCRINOL, V21, P993, DOI 10.1111/j.1365-2826.2009.01920.x; MCEWEN BS, 1994, EXP GERONTOL, V29, P431, DOI 10.1016/0531-5565(94)90022-1; Meffre D, 2007, ENDOCRINOLOGY, V148, P2505, DOI 10.1210/en.2006-1678; Meffre D, 2005, J NEUROCHEM, V93, P1314, DOI 10.1111/j.1471-4159.2005.03127.x; Meffre D, 2007, J STEROID BIOCHEM, V104, P293, DOI 10.1016/j.jsbmb.2007.03.003; Meyer C, 1996, EUR J BIOCHEM, V239, P726, DOI 10.1111/j.1432-1033.1996.0726u.x; Mong JA, 2004, MOL PSYCHIATR, V9, P550, DOI 10.1038/sj.mp.4001493; Peluso JJ, 2005, BIOL REPROD, V73, P261, DOI 10.1095/biolreprod.105.041061; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Pfaff Donald W., 1994, P107; Phelps SM, 1998, HORM BEHAV, V34, P294, DOI 10.1006/hbeh.1998.1485; ProTECT-III, 2011, PROTECT 3 PROGESTERO; RAMIREZ VD, 1987, J STEROID BIOCHEM, V27, P589, DOI 10.1016/0022-4731(87)90358-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Rupprecht R, 2003, PSYCHONEUROENDOCRINO, V28, P139, DOI 10.1016/S0306-4530(02)00064-1; Sakamoto H, 2001, J NEUROSCI, V21, P6221, DOI 10.1523/JNEUROSCI.21-16-06221.2001; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Schmidt BMW, 2000, FRONT NEUROENDOCRIN, V21, P57, DOI 10.1006/frne.1999.0189; Schneider JS, 2003, P NATL ACAD SCI USA, V100, P2951, DOI 10.1073/pnas.0130100100; Schumacher M, 2007, ENDOCR REV, V28, P387, DOI 10.1210/er.2006-0050; Selmin O, 1996, CARCINOGENESIS, V17, P2609, DOI 10.1093/carcin/17.12.2609; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Sleiter N, 2009, ENDOCRINOLOGY, V150, P3833, DOI 10.1210/en.2008-0774; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Stein DG, 2010, AM J ROENTGENOL, V194, P20, DOI 10.2214/AJR.09.3407; SyNAPSe, 2011, RAND DOUBL BLIND PLA; Tang YT, 2005, J MOL EVOL, V61, P372, DOI 10.1007/s00239-004-0375-2; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Thomas P, 2004, MED CHEM RES, V13, P202, DOI 10.1007/s00044-004-0026-6; Thomas P, 2007, ENDOCRINOLOGY, V148, P705, DOI 10.1210/en.2006-0974; TISCHKAU SA, 1993, P NATL ACAD SCI USA, V90, P1285, DOI 10.1073/pnas.90.4.1285; Toran-Allerand CD, 2002, J NEUROSCI, V22, P8391; TOWLE AC, 1983, J STEROID BIOCHEM, V18, P135, DOI 10.1016/0022-4731(83)90079-1; Vongher JM, 1999, PHARMACOL BIOCHEM BE, V64, P777, DOI 10.1016/S0091-3057(99)00140-9; Wang DD, 2008, PROG NEUROBIOL, V86, P342, DOI 10.1016/j.pneurobio.2008.09.015; WITT DM, 1995, PHYSIOL BEHAV, V57, P307, DOI 10.1016/0031-9384(94)00247-3; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100; Zuloaga DG, 2012, ENDOCRINOLOGY	87	90	92	0	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	FEB 12	2013	231						111	124		10.1016/j.neuroscience.2012.11.039			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	087EN	WOS:000314744200011	23211561				2022-02-06	
J	De Beaumont, L; Tremblay, S; Poirier, J; Lassonde, M; Theoret, H				De Beaumont, Louis; Tremblay, Sebastien; Poirier, Judes; Lassonde, Maryse; Theoret, Hugo			Altered Bidirectional Plasticity and Reduced Implicit Motor Learning in Concussed Athletes	CEREBRAL CORTEX			English	Article						GABA system; neurophysiology; paired associative stimulation; sports concussion; synaptic plasticity; TMS	LONG-TERM POTENTIATION; TRAUMATIC BRAIN-INJURY; TRANSCRANIAL MAGNETIC STIMULATION; GABA(B) RECEPTOR AGONIST; THETA-BURST STIMULATION; COGNITIVE IMPAIRMENT; UNAFFECTED HEMISPHERE; CORTICAL INHIBITION; SPORTS CONCUSSION; CORTEX	Persistent motor/cognitive alterations and increased prevalence of Alzheimer's disease are known consequences of recurrent sports concussions, the most prevalent cause of mild traumatic brain injury (TBI) among youth. Animal models of TBI demonstrated that impaired learning was related to persistent synaptic plasticity suppression in the form of long-term potentiation (LTP) and depression (LTD). In humans, single and repeated concussive injuries lead to lifelong and cumulative enhancements of gamma-aminobutyric acid (GABA)-mediated inhibition, which is known to suppress LTP/LTD plasticity. To test the hypothesis that increased GABAergic inhibition after repeated concussions suppresses LTP/LTD and contributes to learning impairments, we used a paired associative stimulation (PAS) protocol to induce LTP/LTD-like effects in primary motor cortex (M1) jointly with an implicit motor learning task (serial reaction time task, SRTT). Our results indicate that repeated concussions induced persistent elevations of GABA(B)-mediated intracortical inhibition in M1, which was associated with suppressed PAS-induced LTP/LTD-like synaptic plasticity. This synaptic plasticity suppression was related to reduced implicit motor learning on the SRTT task relative to normal LTP/LTD-like synaptic plasticity in unconcussed teammates. These findings identify GABA neurotransmission alterations after repeated concussions and suggest that impaired learning after multiple concussions could at least partly be related to compromised GABA-dependent LTP/LTD synaptic plasticity.	[De Beaumont, Louis; Tremblay, Sebastien; Lassonde, Maryse; Theoret, Hugo] Univ Montreal, Dept Psychol, Ctr Rech Neuropsychol & Cognit CERNEC, Montreal, PQ H2V 2S9, Canada; [De Beaumont, Louis; Poirier, Judes] McGill Univ, Douglas Mental Hlth Univ Inst, Montreal, PQ H4H 1R3, Canada; [Lassonde, Maryse; Theoret, Hugo] CHU St Justine, Montreal, PQ H3S 2G5, Canada		Theoret, H (corresponding author), Univ Montreal, Dept Psychol, Ctr Rech Neuropsychol & Cognit CERNEC, Montreal, PQ H2V 2S9, Canada.	hugo.theoret@umontreal.ca		Tremblay, Sebastien/0000-0001-6251-9797; Theoret, Hugo/0000-0002-7458-8797	Canadian Institute of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Fonds de la recherche en sante du Quebec (FRSQ)Fonds de la Recherche en Sante du Quebec	Canadian Institute of Health Research (CIHR) awarded to M.L. and H.T.; Fonds de la recherche en sante du Quebec (FRSQ) awarded to H.T. and M.L.	Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Antal A, 2004, EUR J NEUROSCI, V19, P2888, DOI 10.1111/j.1460-9568.2004.03367.x; Barone FC, 1998, STROKE, V29, P1937, DOI 10.1161/01.STR.29.9.1937; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; Bigler ED, 1996, J LEARN DISABIL-US, V29, P515, DOI 10.1177/002221949602900507; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bruel-Jungerman E, 2007, NEUROSCIENTIST, V13, P492, DOI 10.1177/1073858407302725; Cheeran B, 2008, J PHYSIOL-LONDON, V586, P5717, DOI 10.1113/jphysiol.2008.159905; Cirillo J, 2009, J PHYSIOL-LONDON, V587, P5831, DOI 10.1113/jphysiol.2009.181834; Classen J, 1998, J NEUROPHYSIOL, V79, P1117, DOI 10.1152/jn.1998.79.2.1117; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Daskalakis ZJ, 2002, ARCH GEN PSYCHIAT, V59, P347, DOI 10.1001/archpsyc.59.4.347; Dave KR, 2005, J NEUROSCI RES, V82, P665, DOI 10.1002/jnr.20674; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Delvendahl I, 2010, CLIN NEUROPHYSIOL, V121, P594, DOI 10.1016/j.clinph.2009.09.034; Fatemi SH, 2000, MOL PSYCHIATR, V5, P654, DOI 10.1038/sj.mp.4000783; Fitzgerald PB, 2003, PSYCHIAT RES, V118, P197, DOI 10.1016/S0165-1781(03)00094-5; Frantseva MV, 2008, CEREB CORTEX, V18, P990, DOI 10.1093/cercor/bhm151; Fregni F, 2005, NEUROREPORT, V16, P1551, DOI 10.1097/01.wnr.0000177010.44602.5e; Fregni F, 2006, STROKE, V37, P2115, DOI 10.1161/01.STR.0000231390.58967.6b; Fritsch B, 2010, NEURON, V66, P198, DOI 10.1016/j.neuron.2010.03.035; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Garvey MA, 2001, CLIN NEUROPHYSIOL, V112, P1451, DOI 10.1016/S1388-2457(01)00581-8; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Hummel F, 2005, BRAIN, V128, P490, DOI 10.1093/brain/awh369; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Kim YH, 2006, STROKE, V37, P1471, DOI 10.1161/01.STR.0000221233.55497.51; Kim YH, 2004, NEUROSCI LETT, V367, P181, DOI 10.1016/j.neulet.2004.05.113; Kleim JA, 2006, NAT NEUROSCI, V9, P735, DOI 10.1038/nn1699; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kuramoto N, 2007, NEURON, V53, P233, DOI 10.1016/j.neuron.2006.12.015; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liepert J, 1997, J NEURAL TRANSM, V104, P1207, DOI 10.1007/BF01294721; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P669; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McDonnell MN, 2007, EXP BRAIN RES, V180, P181, DOI 10.1007/s00221-006-0849-0; McDonnell MN, 2006, EXP BRAIN RES, V173, P86, DOI 10.1007/s00221-006-0365-2; McNamara RK, 1996, PHARMACOL BIOCHEM BE, V53, P303, DOI 10.1016/0091-3057(95)02025-X; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MOTT DD, 1991, SCIENCE, V252, P1718, DOI 10.1126/science.1675489; Nakagawa Y, 1997, BRAIN RES, V766, P101, DOI 10.1016/S0006-8993(97)00529-5; NIELSEN J, 1993, EUR J APPL PHYSIOL O, V66, P116, DOI 10.1007/BF01427051; Nitsche MA, 2003, J COGNITIVE NEUROSCI, V15, P619, DOI 10.1162/089892903321662994; PASCUALLEONE A, 1994, SCIENCE, V263, P1287, DOI 10.1126/science.8122113; PASCUALLEONE A, 1995, J NEUROPHYSIOL, V74, P1037, DOI 10.1152/jn.1995.74.3.1037; Perez MA, 2007, J NEUROSCI, V27, P1045, DOI 10.1523/JNEUROSCI.4128-06.2007; Perez-Pinzon MA, 2007, COMP BIOCHEM PHYS A, V147, P291, DOI 10.1016/j.cbpa.2006.08.032; Petersen RC, 2005, NEW ENGL J MED, V352, P2379, DOI 10.1056/NEJMoa050151; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; RAJJI TK, 2010, BRAIN STIMU IN PRESS; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Rioult-Pedotti MS, 1998, NAT NEUROSCI, V1, P230, DOI 10.1038/678; Rioult-Pedotti MS, 2000, SCIENCE, V290, P533, DOI 10.1126/science.290.5491.533; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Sanes JN, 2000, ANNU REV NEUROSCI, V23, P393, DOI 10.1146/annurev.neuro.23.1.393; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Stefan K, 2004, J NEUROPHYSIOL, V92, P66, DOI 10.1152/jn.00383.2003; Stefan K, 2000, BRAIN, V123, P572, DOI 10.1093/brain/123.3.572; Talelli P, 2007, CLIN NEUROPHYSIOL, V118, P333, DOI 10.1016/j.clinph.2006.10.014; Tang TTT, 2009, P NATL ACAD SCI USA, V106, P21395, DOI 10.1073/pnas.0910499106; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Tremblay S, 2011, J NEUROTRAUM, V28, P493, DOI 10.1089/neu.2010.1615; Willingham DB, 2000, MEM COGNITION, V28, P366, DOI 10.3758/BF03198552; WILLINGHAM DB, 1989, J EXP PSYCHOL LEARN, V15, P1047, DOI 10.1037/0278-7393.15.6.1047; Wolters A, 2003, J NEUROPHYSIOL, V89, P2339, DOI 10.1152/jn.00900.2002; Ziemann U, 1998, ELECTROMYOGR MOTOR C, V109, P321, DOI 10.1016/S0924-980X(98)00023-X; Ziemann U, 2004, J NEUROSCI, V24, P1666, DOI 10.1523/JNEUROSCI.5016-03.2004; ZIEMANN U, 1993, NEUROSCI LETT, V156, P167, DOI 10.1016/0304-3940(93)90464-V; Ziemann U, 2008, BRAIN STIMUL, V1, P60, DOI 10.1016/j.brs.2007.08.003	89	90	92	0	51	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1047-3211	1460-2199		CEREB CORTEX	Cereb. Cortex	JAN	2012	22	1					112	121		10.1093/cercor/bhr096			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	863TI	WOS:000298190500010	21572090	Bronze			2022-02-06	
J	Tobinick, E; Kim, NM; Reyzin, G; Rodriguez-Romanacce, H; DePuy, V				Tobinick, Edward; Kim, Nancy M.; Reyzin, Gary; Rodriguez-Romanacce, Helen; DePuy, Venita			Selective TNF Inhibition for Chronic Stroke and Traumatic Brain Injury An Observational Study Involving 629 Consecutive Patients Treated with Perispinal Etanercept	CNS DRUGS			English	Article							TUMOR-NECROSIS-FACTOR; MONTREAL COGNITIVE ASSESSMENT; MENTAL-STATE-EXAMINATION; TRIALS COMPARING PLACEBO; FACTOR-ALPHA INHIBITOR; LONG-TERM SAFETY; ALZHEIMERS-DISEASE; TARGETED ETANERCEPT; RAPID IMPROVEMENT; NATURAL-HISTORY	Background Brain injury from stroke and traumatic brain injury (TBI) may result in a persistent neuroinflammatory response in the injury penumbra. This response may include microglial activation and excess levels of tumour necrosis factor (TNF). Previous experimental data suggest that etanercept, a selective TNF inhibitor, has the ability to ameliorate microglial activation and modulate the adverse synaptic effects of excess TNF. Perispinal administration may enhance etanercept delivery across the blood-CSF barrier. Objective The objective of this study was to systematically examine the clinical response following perispinal administration of etanercept in a cohort of patients with chronic neurological dysfunction after stroke and TBI. Methods After approval by an independent external institutional review board (IRB), a chart review of all patients with chronic neurological dysfunction following stroke or TBI who were treated open-label with perispinal etanercept (PSE) from November 1, 2010 to July 14, 2012 at a group medical practice was performed. Results The treated cohort included 629 consecutive patients. Charts of 617 patients following stroke and 12 patients following TBI were reviewed. The mean age of the stroke patients was 65.8 years +/- 13.15 (range 13-97). The mean interval between treatment with PSE and stroke was 42.0 +/- 57.84 months (range 0.5-419); for TBI the mean interval was 115.2 +/- 160.22 months (range 4-537). Statistically significant improvements in motor impairment, spasticity, sensory impairment, cognition, psychological/behavioural function, aphasia and pain were noted in the stroke group, with a wide variety of additional clinical improvements noted in individuals, such as reductions in pseudobulbar affect and urinary incontinence. Improvements in multiple domains were typical. Significant improvement was noted irrespective of the length of time before treatment was initiated; there was evidence of a strong treatment effect even in the subgroup of patients treated more than 10 years after stroke and TBI. In the TBI cohort, motor impairment and spasticity were statistically significantly reduced. Discussion Irrespective of the methodological limitations, the present results provide clinical evidence that stroke and TBI may lead to a persistent and ongoing neuroinflammatory response in the brain that is amenable to therapeutic intervention by selective inhibition of TNF, even years after the acute injury. Conclusion Excess TNF contributes to chronic neurological, neuropsychiatric and clinical impairment after stroke and TBI. Perispinal administration of etanercept produces clinical improvement in patients with chronic neurological dysfunction following stroke and TBI. The therapeutic window extends beyond a decade after stroke and TBI. Randomized clinical trials will be necessary to further quantify and characterize the clinical response.	[Tobinick, Edward; Kim, Nancy M.; Reyzin, Gary] Inst Neurol Recovery, Los Angeles, CA 90095 USA; [Tobinick, Edward; Kim, Nancy M.; Reyzin, Gary] Inst Neurol Recovery, Newport Beach, CA USA; [Tobinick, Edward; Rodriguez-Romanacce, Helen] Inst Neurol Recovery, Boca Raton, FL USA; [DePuy, Venita] Bowden Analyt, Apex, NC USA		Tobinick, E (corresponding author), Inst Neurol Recovery, 100 UCLA Med Plaza,Suites 205-210, Los Angeles, CA 90095 USA.	nrimed@gmail.com		Tobinick, Edward/0000-0001-7614-499X	Institute of Neurological Recovery(R) (INR(R))	Funding for the study was provided by the Institute of Neurological Recovery (R) (INR (R)). Edward Tobinick, Nancy M. Kim, Gary Reyzin, Helen Rodriguez-Romanacce and Venita DePuy played an important role in the acquisition, analysis and interpretation of the data, wrote the manuscript, made substantive suggestions for revision and approved the final submitted version. Venita DePuy performed the statistical analyses. Edward Tobinick was responsible for the conception and planning of the work that led to the manuscript. The authors acknowledge the general assistance of Lynna Sim, Daniel Gendler, Shea Sullivan and Young Hee Jennifer Kim. Edward Tobinick is the named inventor and receives royalties from multiple issued and pending US and international patents assigned to TACT IP LLC that describe perispinal administration of etanercept for the treatment of stroke and other methods of use of etanercept and other biologics for the treatment of neurological disorders. These patents include, but are not limited to, US patents 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306 and Australian patent 758,523. The INR (R) is a private medical practice that has licensed the TACT IP LLC patents. Nancy Kim, Helen Rodriguez-Romanacce and Gary Reyzin are INR (R) employees. Venita DePuy received payment for her authorship contributions.	Antoniou C, 2011, J EUR ACAD DERMATOL, V25, P1113, DOI 10.1111/j.1468-3083.2010.03820.x; Arnason BGW, 1999, NEUROLOGY, V53, P457, DOI 10.1212/wnl.53.3.457; Atkinson HH, 2007, J GERONTOL A-BIOL, V62, P844, DOI 10.1093/gerona/62.8.844; Bains JS, 2007, TRENDS NEUROSCI, V30, P417, DOI 10.1016/j.tins.2007.06.007; Balakrishnan Preethi, 2008, Curr Treat Options Cardiovasc Med, V10, P216, DOI 10.1007/s11936-008-0023-z; BANKS WA, 1995, NEUROIMMUNOMODULAT, V2, P161, DOI 10.1159/000096887; BATSON OV, 1957, AMER J ROENTGENOL RA, V78, P195; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Belarbi K, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-23; Benucci Maurizio, 2012, Acta Biomed, V83, P72; Buchhave P, 2010, NEUROBIOL AGING, V31, P1877, DOI 10.1016/j.neurobiolaging.2008.10.012; Butchart J, 2012, CNS NEUROSCI THER, V18, P64, DOI 10.1111/j.1755-5949.2011.00245.x; Cavanagh C, 2011, FUTUR NEUROL, V6, P757, DOI 10.2217/FNL.11.50; Cheng X, 2010, J ALZHEIMERS DIS, V19, P621, DOI 10.3233/JAD-2010-1253; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Chou SHY, 2012, J INVEST MED, V60, P1054, DOI 10.2310/JIM.0b013e3182686932; Christensen MC, NEUROCRIT CARE; CLARK IA, 1994, PARASITOL TODAY, V10, P410, DOI 10.1016/0169-4758(94)90237-2; CLARK IA, 1993, Q J MED, V86, P217; Clark I, 2012, PHARMACOL REV, V64, P1004, DOI 10.1124/pr.112.005850; Clark IA, 2007, CYTOKINE GROWTH F R, V18, P335, DOI 10.1016/j.cytogfr.2007.04.002; Clark IA, 2010, PHARMACOL THERAPEUT, V128, P519, DOI 10.1016/j.pharmthera.2010.08.007; Clausen BH, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-46; Cohen SP, 2009, ANESTHESIOLOGY, V110, P1116, DOI 10.1097/ALN.0b013e3181a05aa0; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Creutzfeldt CJ, 2012, J GEN INTERN MED, V27, P853, DOI 10.1007/s11606-011-1966-4; Cumming TB, 2011, STROKE, V42, P2642, DOI 10.1161/STROKEAHA.111.619486; DeMonaco HJ, 2006, PHARMACOTHERAPY, V26, P323, DOI 10.1592/phco.26.3.323; Dong YH, 2010, J NEUROL SCI, V299, P15, DOI 10.1016/j.jns.2010.08.051; ELLIOTT MJ, 1994, LANCET, V344, P1125, DOI 10.1016/S0140-6736(94)90632-7; Esposito E, 2011, TRENDS PHARMACOL SCI, V32, P107, DOI 10.1016/j.tips.2010.11.009; Felger JC, FRONT NEUROENDOCRINO; Flansbjer UB, 2005, J REHABIL MED, V37, P75, DOI 10.1080/16501970410017215; Frankola KA, 2011, CNS NEUROL DISORD-DR, V10, P391; Furrer E, 2009, J NEUROIMMUNOL, V215, P65, DOI 10.1016/j.jneuroim.2009.08.005; Genovese T, 2006, J PHARMACOL EXP THER, V316, P1006, DOI 10.1124/jpet.105.097188; Giuliani F, 2009, BRAIN RES BULL, V80, P302, DOI 10.1016/j.brainresbull.2009.07.009; Gladman DD, 2011, J RHEUMATOL, V38, P1355, DOI 10.3899/jrheum.100698; Glasziou P, 2007, BMJ-BRIT MED J, V334, P349, DOI 10.1136/bmj.39070.527986.68; Gottlieb AB, 2011, J DRUGS DERMATOL, V10, P289; Griffin WST, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-3; Halassa MM, 2007, TRENDS MOL MED, V13, P54, DOI 10.1016/j.molmed.2006.12.005; Harrison JE, 2000, BRIT J CLIN PSYCHOL, V39, P181, DOI 10.1348/014466500163202; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Hrobjartsson A, 2004, J INTERN MED, V256, P91, DOI 10.1111/j.1365-2796.2004.01355.x; Hrobjartsson A, 2011, J CLIN EPIDEMIOL, V64, P1223, DOI 10.1016/j.jclinepi.2011.01.008; Hrobjartsson A, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003974.pub3; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Jiang H, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-69; Johanson CE, 2005, PHARM RES-DORDR, V22, P1011, DOI 10.1007/s11095-005-6039-0; Kato K, 2009, NEUROSCIENCE, V160, P492, DOI 10.1016/j.neuroscience.2009.02.038; Kato K, 2010, J NEUROSCI RES, V88, P360, DOI 10.1002/jnr.22202; Kaushal V, 2008, J NEUROSCI, V28, P2221, DOI 10.1523/JNEUROSCI.5643-07.2008; Kerensky TA, 2012, EXPERT OPIN DRUG SAF, V11, P121, DOI 10.1517/14740338.2012.633509; Klareskog L, 2011, CLIN EXP RHEUMATOL, V29, P238; Klit H, 2009, LANCET NEUROL, V8, P857, DOI 10.1016/S1474-4422(09)70176-0; Kuhn T.S., 1962, STRUCTURE SCI REVOLU; Lang L, 2005, GASTROENTEROLOGY, V129, P1813, DOI 10.1053/j.gastro.2005.10.046; Langdon PC, 2007, J CLIN NEUROSCI, V14, P630, DOI 10.1016/j.jocn.2006.04.009; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Langhorne P, 2009, LANCET NEUROL, V8, P741, DOI 10.1016/S1474-4422(09)70150-4; Linde K, 2011, PHILOS T R SOC B, V366, P1905, DOI 10.1098/rstb.2010.0383; Macrez R, 2011, LANCET NEUROL, V10, P471, DOI 10.1016/S1474-4422(11)70066-7; Marchand F, 2009, EUR J PAIN, V13, P673, DOI 10.1016/j.ejpain.2008.08.001; McNaull BBA, 2010, GERONTOLOGY, V56, P3, DOI 10.1159/000237873; Miller A, 2011, EXPERT REV NEUROTHER, V11, P1077, DOI [10.1586/ERN.11.68, 10.1586/ern.11.68]; Nadeau S, 1999, NEUROSCIENCE, V93, P1449, DOI 10.1016/S0306-4522(99)00225-0; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Nathoo N, 2011, NEUROSURGERY, V69, P1007, DOI 10.1227/NEU.0b013e3182274865; Neurex, 2012, M ROL TNF BRAIN DYSF; Ohtori S, 2012, SPINE, V37, P439, DOI 10.1097/BRS.0b013e318238af83; Pardridge William M, 2005, NeuroRx, V2, P3; Pariser DM, 2012, J AM ACAD DERMATOL, V67, P245, DOI 10.1016/j.jaad.2011.07.040; Patel M, 2003, CLIN REHABIL, V17, P158, DOI 10.1191/0269215503cr596oa; Patel M, 2001, STROKE, V32, P122, DOI 10.1161/01.STR.32.1.122; Patel MD, 2002, J AM GERIATR SOC, V50, P700, DOI 10.1046/j.1532-5415.2002.50165.x; Paty DW, 1998, CAN J NEUROL SCI, V25; Pearce JMS, 2006, EUR NEUROL, V56, P136, DOI 10.1159/000095706; Pendlebury ST, 2010, STROKE, V41, P1290, DOI 10.1161/STROKEAHA.110.579888; Pilcher Maria, 2012, Nurs Stand, V26, P39; Price CJS, 2006, STROKE, V37, P1749, DOI 10.1161/01.STR.0000226980.95389.0b; Rossi D, 2011, CNS DRUGS, V25, P641, DOI 10.2165/11593090-000000000-00000; Rotar M, 2011, NEUROUROL URODYNAM, V30, P1315, DOI 10.1002/nau.21013; Schweizer TA, 2012, J NEUROL SCI, V316, P137, DOI 10.1016/j.jns.2012.01.003; Shen CH, 2011, ANESTH ANALG, V113, P184, DOI 10.1213/ANE.0b013e318217f7eb; Shen CH, 2011, ANESTH ANALG, V112, P454, DOI 10.1213/ANE.0b013e3182025b15; Shi JQ, 2011, BRAIN RES, V1368, P239, DOI 10.1016/j.brainres.2010.10.053; Shichita T, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00132; SKILBECK CE, 1983, J NEUROL NEUROSUR PS, V46, P5, DOI 10.1136/jnnp.46.1.5; Smith Mark, 2012, Nurs Stand, V26, P35; Smith T, 2007, CAN J PSYCHIAT, V52, P329, DOI 10.1177/070674370705200508; Sobel R K, 2001, US News World Rep, V131, P59; Stellwagen D, 2006, NATURE, V440, P1054, DOI 10.1038/nature04671; Sumbria RK, 2012, J CEREBR BLOOD F MET, V32, P1933, DOI 10.1038/jcbfm.2012.97; TANCREDI V, 1992, NEUROSCI LETT, V146, P176, DOI 10.1016/0304-3940(92)90071-E; Tarkowski E, 1999, J CLIN IMMUNOL, V19, P223, DOI 10.1023/A:1020568013953; Tarkowski E, 2003, J NEUROL NEUROSUR PS, V74, P1200, DOI 10.1136/jnnp.74.9.1200; Tobinick E, 2004, CURR MED RES OPIN, V20, P1075, DOI 10.1185/030079903125004286; Tobinick E, 2007, CURR ALZHEIMER RES, V4, P550, DOI 10.2174/156720507783018217; Tobinick Edward, 2006, MedGenMed, V8, P25; Tobinick Edward, 2006, MedGenMed, V8, P53; Tobinick E, 2012, CURR ALZHEIMER RES, V9, P99, DOI 10.2174/156720512799015073; Tobinick E, 2011, CNS DRUGS, V25, P145, DOI 10.2165/11588400-000000000-00000; Tobinick E, 2010, EXPERT REV NEUROTHER, V10, P985, DOI 10.1586/ERN.10.52; Tobinick E, 2009, CNS DRUGS, V23, P713, DOI 10.2165/11310810-000000000-00000; Tobinick Edward, 2008, Medscape J Med, V10, P135; Tobinick E, 2009, DRUG DISCOV TODAY, V14, P168, DOI 10.1016/j.drudis.2008.10.005; Tobinick EL, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-27; Tobinick EL, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-2; Tobinick Edward L, 2009, BMC Res Notes, V2, P28; Tobinick EL, 2009, DRUG NEWS PERSPECT, V22, P119, DOI 10.1358/dnp.2009.22.2.1303818; Tobinick EL, 2003, CLIN THER, V25, P2279, DOI 10.1016/S0149-2918(03)80219-9; Tobinick EL, 2003, SWISS MED WKLY, V133, P170; Tobinick EL, 2003, CLIN THER, V25, P1211, DOI 10.1016/S0149-2918(03)80077-2; Toglia J, 2011, ARCH PHYS MED REHAB, V92, P792, DOI 10.1016/j.apmr.2010.12.034; Toole James F, 2004, J Stroke Cerebrovasc Dis, V13, P99, DOI 10.1016/j.jstrokecerebrovasdis.2004.03.005; Tweedie D, 2007, CURR ALZHEIMER RES, V4, P378, DOI 10.2174/156720507781788873; Tweedie D, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-106; Vakhnina N V, 2009, Neurosci Behav Physiol, V39, P719, DOI 10.1007/s11055-009-9198-3; Vandenbroucke JP, 2001, ANN INTERN MED, V134, P330, DOI 10.7326/0003-4819-134-4-200102200-00017; vanOosten BW, 1996, NEUROLOGY, V47, P1531, DOI 10.1212/WNL.47.6.1531; Vender R, 2011, J DRUGS DERMATOL, V10, P396; WADE DT, 1983, J NEUROL NEUROSUR PS, V46, P521, DOI 10.1136/jnnp.46.6.521; WADE DT, 1985, J NEUROL NEUROSUR PS, V48, P7, DOI 10.1136/jnnp.48.1.7; Wang G, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/825364; Watanabe K, 2011, EUR SPINE J, V20, P1877, DOI 10.1007/s00586-011-1854-y; Wolinsky H, 2008, EMBO REP, V9, P416, DOI 10.1038/embor.2008.65; Wong GK, J NEUROL NEUROSURG P; Zanella JM, 2008, SPINE, V33, P227, DOI 10.1097/BRS.0b013e318162340a; Zhou QH, 2011, J PHARMACOL EXP THER, V339, P618, DOI 10.1124/jpet.111.185876; Zivin JA, 2010, TPA STROKE STORY CON	131	90	91	0	22	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1172-7047	1179-1934		CNS DRUGS	CNS Drugs		2012	26	12					1051	1070		10.1007/s40263-012-0013-2			20	Clinical Neurology; Pharmacology & Pharmacy; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	057PT	WOS:000312576200003	23100196				2022-02-06	
J	Nilsson, AL; Tennant, A				Nilsson, Asa Lundgren; Tennant, Alan			PAST AND PRESENT ISSUES IN RASCH ANALYSIS: THE FUNCTIONAL INDEPENDENCE MEASURE (FIM (TM)) REVISITED	JOURNAL OF REHABILITATION MEDICINE			English	Article						outcome assessment; patient; physiopathology; psychometrics; Rasch; Functional Independence Measure	TRAUMATIC BRAIN-INJURY; MEASUREMENT MODEL; DEPRESSION SCALE; STROKE PATIENTS; CEREBRAL-PALSY; REHABILITATION; IMPAIRMENT; DISABILITY; CATEGORIES; INTERVAL	Objective: To review the development of Rasch analysis by examining the history of its application to the Functional Independence Measure (FIM (TM)), and highlighting current issues in the approach. Methods: All Rasch-based papers concerning the FIM (TM) were reviewed for their analytical strategy and results. Four analytical pathways were identified that accommodated the majority of these strategies. Data derived from secondary analysis of 340 in-patients undergoing rehabilitation following stroke, measured on the FIM (TM) Motor Scale, were fitted to the Rasch measurement model according to these 4 pathways, with 2 additional pathways to accommodate recent developments. Results: In the analytical pathway, where items are not re-scored, the fit to the Partial Credit parameterization was better than the Rating Scale version. Fit improved following re-scoring of disordered thresholds. When local dependency was accommodated by 4 testlets, the Partial Credit, re-scored testlet version achieved adequate summary fit with no misfit among items, and unidimensionality. All other pathways required item deletion. Conclusion: The current study has shown that the FIM (TM) Motor Scale, as applied to a stroke rehabilitation sample, satisfies Rasch model expectations and the unidimensionality assumptions, having accommodated local dependency issues, and by using the partial credit parameterization with re-scored categories. Other analytical pathways gave less ideal solutions, and are consistent with the wide range of solutions found for the scale over the years. Consequently, the development of the Rasch approach in health outcomes can be traced in the history of analysis of the FIM (TM), and that development continues to this day.	[Nilsson, Asa Lundgren] Univ Gothenburg, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, S-41345 Gothenburg, Sweden; [Tennant, Alan] Univ Leeds, Dept Rehabil Med, Fac Med & Hlth, Leeds, W Yorkshire, England		Nilsson, AL (corresponding author), Univ Gothenburg, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, Per Dubbsgatan 14, S-41345 Gothenburg, Sweden.						ANDRICH D, 1978, PSYCHOMETRIKA, V43, P561, DOI 10.1007/BF02293814; Andrich D, 1985, TEST DESIGN DEV PSYC; Andrich D., 2010, RUMM 2030; Andrich D., 1988, RASCH MODELS MEASURE; BECH P, 1981, ACTA PSYCHIAT SCAND, V63, P290, DOI 10.1111/j.1600-0447.1981.tb00676.x; BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; Cantagallo A, 2006, BRAIN INJURY, V20, P913, DOI 10.1080/02699050600832742; Chira-Adisai W, 2001, Electromyogr Clin Neurophysiol, V41, P79; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P355, DOI 10.1016/S0003-9993(95)80661-X; Dallmeijer AJ, 2005, J REHABIL MED, V37, P346, DOI 10.1080/16501970510038284; Ehlan AH, 2010, RES ISSUES PHYS REHA, P89; Glass CA, 2009, J REHABIL MED, V41, P723, DOI 10.2340/16501977-0398; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; Grimby G, 1996, ARCH PHYS MED REHAB, V77, P1109, DOI 10.1016/S0003-9993(96)90131-8; Guttman L., 1950, MEASUREMENT PREDICTI, P60; Hagquist C, 2009, INT J NURS STUD, V46, P380, DOI 10.1016/j.ijnurstu.2008.10.007; HALEY SM, 1994, J CLIN EPIDEMIOL, V47, P671, DOI 10.1016/0895-4356(94)90215-1; Heinemann Allen W, 1994, Top Stroke Rehabil, V1, P1; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Holland PW, 1993, DIFFERENTIAL ITEM FU; Itzkovich M, 2002, SPINAL CORD, V40, P396, DOI 10.1038/sj.sc.3101315; Johnston MV, 2006, BRAIN INJURY, V20, P391, DOI 10.1080/02699050500487795; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Lange R, 2002, PERS INDIV DIFFER, V33, P937, DOI 10.1016/S0191-8869(01)00203-3; Leonard C T, 1998, J Stroke Cerebrovasc Dis, V7, P145, DOI 10.1016/S1052-3057(98)80142-0; LEWINE RRJ, 1983, SCHIZOPHRENIA BULL, V9, P368, DOI 10.1093/schbul/9.3.368; Linacre J, 1994, RASCH MEAS T, V7, P328; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; LUCE RD, 1964, J MATH PSYCHOL, V1, P1, DOI 10.1016/0022-2496(64)90015-X; Lundgren-Nilsson A, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-55; Marais Ida, 2008, J Appl Meas, V9, P200; MASTERS GN, 1982, PSYCHOMETRIKA, V47, P149, DOI 10.1007/BF02296272; NANDAKUMAR R, 1993, J EDUC MEAS, V30, P293, DOI 10.1111/j.1745-3984.1993.tb00428.x; New PW, 2007, J SPINAL CORD MED, V30, P225, DOI 10.1080/10790268.2007.11753930; Newby Van A, 2009, J Appl Meas, V10, P348; Nilsson AL, 2005, ACTA NEUROL SCAND, V111, P264, DOI 10.1111/j.1600-0404.2005.00404.x; Pallant JF, 2007, BRIT J CLIN PSYCHOL, V46, P1, DOI 10.1348/014466506X96931; Rasch G., 1960, PROBABILISTIC MODELS; Rosenberg R, 1979, Ugeskr Laeger, V141, P3232; SILVERSTEIN B, 1992, ARCH PHYS MED REHAB, V73, P507; Smith Everett V Jr, 2002, J Appl Meas, V3, P205; Smith R M, 1998, J Outcome Meas, V2, P66; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; Tennant A, 1996, BRIT J RHEUMATOL, V35, P574; Tennant A, 2004, MED CARE, V42, P37, DOI 10.1097/01.mlr.0000103529.63132.77; Tennant A., 2006, RASCH MEAS T, V20, P1048; Tennant A, 2007, ARTHRIT RHEUM-ARTHR, V57, P1358, DOI 10.1002/art.23108; Teresi JA, 2007, QUAL LIFE RES, V16, P43, DOI 10.1007/s11136-007-9186-4; Teresi JA, 2006, MED CARE, V44, pS152, DOI 10.1097/01.mlr.0000245142.74628.ab; Tesio L, 2008, EUR J PHYS REHAB MED, V44, P365; Thurstone LL, 1928, AM J SOCIOL, V33, P529, DOI 10.1086/214483; Tsuji T, 1995, AM J PHYS MED REHAB, V74, P432, DOI 10.1097/00002060-199511000-00007; Tur BS, 2009, DEV MED CHILD NEUROL, V51, P732, DOI 10.1111/j.1469-8749.2008.03255.x; Velozo CA, 2007, J REHABIL RES DEV, V44, P467, DOI 10.1682/JRRD.2006.06.0068; WAINER H, 1987, J EDUC MEAS, V24, P185, DOI 10.1111/j.1745-3984.1987.tb00274.x; Wang Wen-Chung, 2008, J Appl Meas, V9, P387; Werner RA, 1996, AM J PHYS MED REHAB, V75, P114, DOI 10.1097/00002060-199603000-00006; WRIGHT BD, 1989, ARCH PHYS MED REHAB, V70, P857; [No title captured]	59	90	90	0	13	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	OCT	2011	43	10					884	891		10.2340/16501977-0871			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	844KF	WOS:000296745400003	21947180	gold			2022-02-06	
J	Redell, JB; Zhao, J; Dash, PK				Redell, John B.; Zhao, Jing; Dash, Pramod K.			Altered Expression of miRNA-21 and Its Targets in the Hippocampus After Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						miR-21; Tiam1; TBI; apoptosis; ontology	EXCHANGE FACTOR TIAM1; GENE-EXPRESSION; MICRORNA-21 TARGETS; CELL-DEATH; IN-VIVO; INVASION; GROWTH; RAC; ACTIVATION; ONTOLOGY	Traumatic brain injury (TBI) initiates many different signaling cascades throughout the brain that impact both pathophysiological and neuroprotective processes. Cellular mechanisms that can modulate these processes may play an important role in determining the nature and extent of the damage suffered after TBI and therefore influence overall outcome after injury. MicroRNAs (miRNAs) are an important class of noncoding regulatory RNAs providing an epigenetic mechanism for the regulation of protein expression levels of target genes. We report that miR-21 expression is significantly up-regulated in the hippocampus after rodent TBI, with expression levels peaking by 3 days postinjury and returning to near sham levels by 15 days postinjury. In situ localization of miR-21 transcripts indicates widespread expression in normal brain, with a pronounced increase in expression after TBI evident throughout the cortex and hippocampus, including the dentate gyrus and CA3 cell layer. We used a combination of the miRanda, TargetScan, and PicTar prediction algorithms to identify 99 potential target genes that possess miR-21 binding sites within their 3' untranslated regions. Analysis of these genes' annotated Gene Ontology molecular function and biological process terms revealed an overrepresentation of genes involved in enzyme-linked receptor signaling, transcriptional regulation, and developmental processes. These results suggest that increased miR-21 expression in the hippocampus may influence multiple components of TBI pathophysiology. (C) 2010 Wiley-Liss, Inc.	[Redell, John B.; Zhao, Jing; Dash, Pramod K.] Univ Texas Med Sch, Dept Neurobiol & Anat, Houston, TX 77225 USA		Dash, PK (corresponding author), Univ Texas Med Sch, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu		Dash, Pramod/0000-0001-6746-1002	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; American Heart AssociationAmerican Heart Association; Mission Connect/TIRR Foundation; Gillson Longenbaugh Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS078596] Funding Source: NIH RePORTER	Contract grant sponsor: National Institutes of Health; Contract grant sponsor: American Heart Association; Contract grant sponsor: Mission Connect/TIRR Foundation; Contract grant sponsor: Gillson Longenbaugh Foundation.	Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Baek D, 2008, NATURE IN PRESS; Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Birukova AA, 2007, FASEB J, V21, P2776, DOI 10.1096/fj.06-7660com; Birukova AA, 2007, EXP CELL RES, V313, P2504, DOI 10.1016/j.yexcr.2007.03.036; Bond M, 2002, J BIOL CHEM, V277, P13787, DOI 10.1074/jbc.M111507200; Carson JP, 2005, J MICROSC-OXFORD, V217, P275, DOI 10.1111/j.1365-2818.2005.01450.x; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen XY, 2005, NAT CELL BIOL, V7, P262, DOI 10.1038/ncb1226; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Corsten MF, 2007, CANCER RES, V67, P8994, DOI 10.1158/0008-5472.CAN-07-1045; Cottonham CL, 2010, J BIOL CHEM IN PRESS; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Floyd CL, 2007, PROG BRAIN RES, V161, P61, DOI 10.1016/S0079-6123(06)61005-4; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Fujita S, 2008, J MOL BIOL, V378, P492, DOI 10.1016/j.jmb.2008.03.015; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Grossmann S, 2007, BIOINFORMATICS, V23, P3024, DOI 10.1093/bioinformatics/btm440; Guillemot L, 2008, MOL BIOL CELL, V19, P4442, DOI 10.1091/mbc.E08-06-0558; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Ji RR, 2007, CIRC RES, V100, P1579, DOI 10.1161/CIRCRESAHA.106.141986; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009; Kloosterman WP, 2006, NAT METHODS, V3, P27, DOI 10.1038/NMETH843; Knezevic H, 2008, J BIOL CHEM IN PRESS; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kunda P, 2001, J NEUROSCI, V21, P2361, DOI 10.1523/JNEUROSCI.21-07-02361.2001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Malliri A, 2004, J BIOL CHEM, V279, P30092, DOI 10.1074/jbc.M401192200; Marquez RT, 2010, AM J PHYSIOL-GASTR L, V298, pG535, DOI 10.1152/ajpgi.00338.2009; Matsuo N, 2003, MOL CELL NEUROSCI, V24, P69, DOI 10.1016/S1044-7431(03)00122-2; Meng F, 2006, GASTROENTEROLOGY, V130, pA429; Mertens AEE, 2005, J CELL BIOL, V170, P1029, DOI 10.1083/jcb.200502129; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Minard ME, 2004, BREAST CANCER RES TR, V84, P21, DOI 10.1023/B:BREA.0000018421.31632.e6; Post S, 2008, ONCOGENE, V27, P2128; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Sathyan P, 2007, J NEUROSCI, V27, P8546, DOI 10.1523/JNEUROSCI.1269-07.2007; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Stark A, 2005, CELL, V123, P1133, DOI 10.1016/j.cell.2005.11.023; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Talotta F, 2008, ONCOGENE IN PRESS; Tolias KF, 2005, NEURON, V45, P525, DOI 10.1016/j.neuron.2005.01.024; Tolias KF, 2007, P NATL ACAD SCI USA, V104, P7265, DOI 10.1073/pnas.0702044104; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Yaylaoglu MB, 2005, DEV DYNAM, V234, P371, DOI 10.1002/dvdy.20441; Zavadil J, 2007, CELLS TISSUES ORGANS, V185, P157, DOI 10.1159/000101316; Zhang H, 2006, ONCOGENE, V25, P6101, DOI 10.1038/sj.onc.1209634; Zhang HY, 2006, NAT CELL BIOL, V8, P227, DOI 10.1038/ncb1368; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24; Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200	66	90	92	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	FEB	2011	89	2					212	221		10.1002/jnr.22539			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	696QL	WOS:000285456400009	21162128	Green Accepted			2022-02-06	
J	Krueger, F; Pardini, M; Huey, ED; Raymont, V; Solomon, J; Lipsky, RH; Hodgkinson, CA; Goldman, D; Grafman, J				Krueger, Frank; Pardini, Matteo; Huey, Edward D.; Raymont, Vanessa; Solomon, Jeffrey; Lipsky, Robert H.; Hodgkinson, Colin A.; Goldman, David; Grafman, Jordan			The Role of the Met66 Brain-Derived Neurotrophic Factor Allele in the Recovery of Executive Functioning after Combat-Related Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article							BDNF VAL66MET POLYMORPHISM; ACTIVITY-DEPENDENT SECRETION; FAMILY-BASED ASSOCIATION; PENETRATING HEAD-INJURY; CARD SORTING TEST; FACTOR GENE; ALZHEIMERS-DISEASE; NEURONAL DEVELOPMENT; MEMORY PERFORMANCE; RECEPTOR SORTILIN	Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family, promotes survival and synaptic plasticity in the human brain. The Val66Met polymorphism of the BDNF gene interferes with intracellular trafficking, packaging, and regulated secretion of this neurotrophin. The human prefrontal cortex (PFC) shows lifelong neuroplastic adaption implicating the Val66Met BDNF polymorphism in the recovery of higher-order executive functions after traumatic brain injury (TBI). In this study, we examined the effect of this BDNF polymorphism on the recovery of executive functioning after TBI. We genotyped a sample of male Vietnam combat veterans consisting of a frontal lobe lesion group with focal penetrating head injuries and a non-head-injured control group for the Val66Met BDNF polymorphism. The Delis-Kaplan Executive Function System as a standardized psychometric battery was administrated to examine key domains of executive functions. The results revealed that the Met allele but not the hypothesized Val allele promotes recovery of executive functioning. Overall, the Met66 carriers in the lesion group performed as well as the Met66 carriers in the control group. The Met66 allele accounted for 6.2% of variance for executive functioning independently of other significant predictors including preinjury intelligence, left hemisphere volume loss, and dorsolateral PFC volume loss. The findings point to different mechanisms of the Val66Met BDNF gene in complex phenotypes under normal and pathological conditions. Abetter understanding of these mechanisms could be instrumental in the development and application of effective therapeutic strategies to facilitate recovery from TBI.	[Krueger, Frank] George Mason Univ, Dept Mol Neurosci, Fairfax, VA 22030 USA; [Krueger, Frank; Raymont, Vanessa; Grafman, Jordan] Natl Inst Neurol Disorders & Stroke, Cognit Neurosci Sect, NIH, Bethesda, MD 20892 USA; [Hodgkinson, Colin A.; Goldman, David] NIAAA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA; [Pardini, Matteo] Univ Genoa, Dept Neurosci Ophthalmol & Genet, I-16132 Genoa, Italy; [Huey, Edward D.] Study Alzheimers Dis & Memory Disorders, Litwin Zucker Res Ctr, Manhasset, NY 11030 USA; [Raymont, Vanessa] Johns Hopkins Univ, Dept Radiol, Baltimore, MD 21287 USA; [Lipsky, Robert H.] Inova Fairfax Hosp, Dept Neurosci, Falls Church, VA 22042 USA		Krueger, F (corresponding author), George Mason Univ, Dept Mol Neurosci, Fairfax, VA 22030 USA.	fkrueger@gmu.edu; grafmanj@ninds.nih.gov	Majid, Salma/AAT-2616-2020; Pardini, Matteo/F-8414-2010; Goldman, David/F-9772-2010	Majid, Salma/0000-0002-1724-5405; Pardini, Matteo/0000-0002-4740-1982; Goldman, David/0000-0002-1724-5405; Grafman, Jordan H./0000-0001-8645-4457; Hodgkinson, Colin/0000-0002-5365-8119; Lipsky, Robert/0000-0001-7753-1473	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); U.S. Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [ZIAAA000301] Funding Source: NIH RePORTER	This work was supported by the National Institute of Neurological Disorders and Stroke intramural research program and a project grant from the U.S. Army Medical Research and Material Command administrated by the Henry M. Jackson Foundation (Vietnam Head Injury Study Phase III: a 30 year postinjury follow-up study). We are grateful to all the Vietnam veterans who participated in this study. Without their long-term commitment to improving the health care of veterans, this study could not have been completed. We thank the National Naval Medical Center for their support and provision of their facilities. We are grateful to S. Bonifant, B. Cheon, C. Ngo, A. Greathouse, K. Reding, and G. Tasick for their invaluable help with the testing of participants and organization of this study. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, the Department of Defense, or the U. S. Government.	Al-Shawi R, 2008, EUR J NEUROSCI, V27, P2103, DOI 10.1111/j.1460-9568.2008.06152.x; Bamdad MJ, 2003, BRAIN INJURY, V17, P1011, DOI 10.1080/0269905031000110553; Bath KG, 2006, COGN AFFECT BEHAV NE, V6, P79, DOI 10.3758/CABN.6.1.79; Beste C, 2010, NEUROSCIENCE, V166, P178, DOI 10.1016/j.neuroscience.2009.12.022; Binder DK, 2004, GROWTH FACTORS, V22, P123, DOI 10.1080/08977190410001723308; Boone KB, 1998, ARCH CLIN NEUROPSYCH, V13, P585, DOI 10.1016/S0887-6177(97)00074-7; CATHOMAS F, 2010, INT J NEUROPSYCHOPH, V19, P1; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Chen ZY, 2006, SCIENCE, V314, P140, DOI 10.1126/science.1129663; Chen ZY, 2004, J NEUROSCI, V24, P4401, DOI 10.1523/JNEUROSCI.0348-04.2004; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; COHEN J, 1988, STAT POWER ANAL BEHA, pR21; DELIS DC, 2001, DELISKAPLAN EXECUTIV; Dempster E, 2005, AM J MED GENET B, V134B, P73, DOI 10.1002/ajmg.b.30150; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Erickson KI, 2008, FRONT HUM NEUROSCI, V2, DOI 10.3389/neuro.09.011.2008; Frustaci A, 2008, NEUROPSYCHOBIOLOGY, V58, P163, DOI 10.1159/000182892; Gao BL, 2000, J NEUROPSYCH CLIN N, V12, P385, DOI 10.1176/appi.neuropsych.12.3.385; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; Gratacos M, 2007, BIOL PSYCHIAT, V61, P911, DOI 10.1016/j.biopsych.2006.08.025; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; Harrington AW, 2004, P NATL ACAD SCI USA, V101, P6226, DOI 10.1073/pnas.0305755101; Harris SE, 2006, MOL PSYCHIATR, V11, P505, DOI 10.1038/sj.mp.4001799; Ho BC, 2007, AM J PSYCHIAT, V164, P1890, DOI 10.1176/appi.ajp.2007.05111903; Ho BC, 2006, ARCH GEN PSYCHIAT, V63, P731, DOI 10.1001/archpsyc.63.7.731; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Huey ED, 2009, NEUROLOGY, V72, P453, DOI 10.1212/01.wnl.0000341781.39164.26; Jansen P, 2007, NAT NEUROSCI, V10, P1449, DOI 10.1038/nn2000; Joober R, 2002, ARCH GEN PSYCHIAT, V59, P662, DOI 10.1001/archpsyc.59.7.662; Karnik MS, 2010, PSYCHIAT RES, V178, P425, DOI 10.1016/j.psychres.2009.09.008; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Kunugi H, 2001, MOL PSYCHIATR, V6, P83, DOI 10.1038/sj.mp.4000792; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LING G, 2008, EXPLOSION BLAST RELA, P91; Lu B, 2003, NEURON, V39, P735, DOI 10.1016/S0896-6273(03)00538-5; Lu B, 2005, NAT REV NEUROSCI, V6, P603, DOI 10.1038/nrn1726; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; Montag C, 2009, PSYCHOL MED, V39, P1831, DOI 10.1017/S0033291709005509; Neves-Pereira M, 2002, AM J HUM GENET, V71, P651, DOI 10.1086/342288; Nykjaer A, 2004, NATURE, V427, P843, DOI 10.1038/nature02319; Oroszi G, 2006, ANN RHEUM DIS, V65, P1330, DOI 10.1136/ard.2006.051623; Pezawas L, 2004, J NEUROSCI, V24, P10099, DOI 10.1523/JNEUROSCI.2680-04.2004; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Raymont V, 2008, BRAIN, V131, P543, DOI 10.1093/brain/awm300; Riemenschneider M, 2002, MOL PSYCHIATR, V7, P782, DOI 10.1038/sj.mp.4001073; Romanczyk TB, 2002, EUR J NEUROSCI, V15, P269, DOI 10.1046/j.0953-816x.2001.01858.x; Rybakowski JK, 2003, BIPOLAR DISORD, V5, P468, DOI 10.1046/j.1399-5618.2003.00071.x; Rybakowski JK, 2006, MOL PSYCHIATR, V11, P122, DOI 10.1038/sj.mp.4001765; Sambataro F, 2010, MOL PSYCHIATR, V15, P116, DOI 10.1038/mp.2009.64; Sen S, 2003, NEUROPSYCHOPHARMACOL, V28, P397, DOI 10.1038/sj.npp.1300053; Sklar P, 2002, MOL PSYCHIATR, V7, P579, DOI 10.1038/sj.mp.4001058; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Strauss J, 2004, NEUROMOL MED, V5, P181, DOI 10.1385/NMM:5:3:181; Stuss D., 2002, PR FRONTAL LOBE FUNC, P392, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0025; Tan YL, 2005, SCHIZOPHR RES, V77, P355, DOI 10.1016/j.schres.2005.03.012; Teng HK, 2005, J NEUROSCI, V25, P5455, DOI 10.1523/JNEUROSCI.5123-04.2005; Tettamanti G, 2010, GENE, V450, P85, DOI 10.1016/j.gene.2009.07.023; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; *US DEP DEF, 1960, AFQT7A US DEP DEF; Ventriglia M, 2002, MOL PSYCHIATR, V7, P136, DOI 10.1038/sj.mp.4000952; Volosin M, 2006, J NEUROSCI, V26, P7756, DOI 10.1523/JNEUROSCI.1560-06.2006; Wechsler D., 1997, WECHSLER MEMORY SCAL; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; Zivadinov R, 2007, HUM MOL GENET, V16, P2659, DOI 10.1093/hmg/ddm189	70	90	93	0	13	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JAN 12	2011	31	2					598	606		10.1523/JNEUROSCI.1399-10.2011			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	705MR	WOS:000286139100021	21228168	Green Published, Green Accepted, Bronze			2022-02-06	
J	Daneshvar, DH; Baugh, CM; Nowinski, CJ; McKee, AC; Stern, RA; Cantu, RC				Daneshvar, Daniel H.; Baugh, Christine M.; Nowinski, Christopher J.; McKee, Ann C.; Stern, Robert A.; Cantu, Robert C.			Helmets and Mouth Guards: The Role of Personal Equipment in Preventing Sport-Related Concussions	CLINICS IN SPORTS MEDICINE			English	Article						Concussion; Equipment; Helmet; Headgear; Mouth guard; Face shield; Sport	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL FOOTBALL; FOR-DISEASE-CONTROL; ICE HOCKEY; HEAD-INJURIES; PROFESSIONAL FOOTBALL; NECK INJURIES; PROTECTIVE EQUIPMENT; AMERICAN FOOTBALL; SPINE INJURIES	Millions of athletes in the United States experience concussions annually. Although helmets and mouth guards have decreased the risk of catastrophic head injuries, their protective effects on concussions are less clear. This article evaluates the current literature on the effect of equipment on concussions. Understanding the role that these equipment play in preventing concussions is complicated by many factors, such as selection bias in nonrandomized studies, variations in playing style, and risk compensation in sports with mandatory protective equipment. Improving coach and player education about proper concussion management, encouraging neck-strengthening exercises, and minimizing high-risk impacts may reduce concussions in sports.	[Daneshvar, Daniel H.; Baugh, Christine M.; Nowinski, Christopher J.; McKee, Ann C.; Stern, Robert A.; Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurol, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA; [Nowinski, Christopher J.; Cantu, Robert C.] Sports Legacy Inst, Boston, MA 02118 USA; [Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Surg, Concord, MA 01742 USA; [Cantu, Robert C.] Brigham & Womens Hosp, Dept Neurosurg, Neurol Sports Injury Ctr, Boston, MA 02115 USA		Daneshvar, DH (corresponding author), Boston Univ, Sch Med, Dept Neurol, Ctr Study Traumat Encephalopathy, 72 E Concord St,B7800, Boston, MA 02118 USA.	ddanesh@bu.edu	Baugh, Christine/AAG-2324-2020; , Bob/ABA-8507-2020	Baugh, Christine/0000-0002-9340-6338; Daneshvar, Daniel/0000-0003-3691-9513; Stern, Robert/0000-0002-5008-077X	Boston University Alzheimer's Disease Center [NIA P30 AG13846, 0572063345-5]; National Operating Committee on Standards; National Collegiate Athletic Association; National Federation of State High School Associations; American Football Coaches Association; Sports Legacy Institute; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER	This work was supported by the Boston University Alzheimer's Disease Center NIA P30 AG13846, supplement 0572063345-5, the National Operating Committee on Standards for Athletic Equipment, the National Collegiate Athletic Association, the National Federation of State High School Associations, the American Football Coaches Association, and the Sports Legacy Institute.	Abu-Zidan FM, 2007, EMERG MED AUSTRALAS, V19, P366, DOI 10.1111/j.1742-6723.2007.00967.x; ADA, 2006, J AM DENT ASSOC, V137, P1712; [Anonymous], 2006, MED SCI SPORT EXER, V38, P395, DOI 10.1249/01.mss.0000202025.48774.31; Asplund C, 2009, BRIT J SPORT MED, V43, P993, DOI 10.1136/bjsm.2009.060152; Barbic D, 2005, CLIN J SPORT MED, V15, P294, DOI 10.1097/01.jsm.0000171883.74056.21; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Barth JT, 2001, J ATHL TRAINING, V36, P253; BENNETT T, 1977, NFLS OFFICIAL ENCY H, P1; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Benson Brian W, 2005, Med Sport Sci, V49, P86, DOI 10.1159/000085393; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; Berg P, 2007, HEALTH PROMOT INT, V22, P191, DOI 10.1093/heapro/dam020; Biasca N, 2002, BRIT J SPORT MED, V36, P410, DOI 10.1136/bjsm.36.6.410; BISHOP PJ, 1984, AM J SPORT MED, V12, P233, DOI 10.1177/036354658401200313; BROGLIO SP, 2010, MED SCI SPORTS EXERC, V14, P13; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Buller DB, 2003, J TRAUMA, V55, P939, DOI 10.1097/01.TA.0000078694.53320.CA; CANTU R, 2010, J NEUROTRAUM, V27, P50; Cantu RC, 2009, BRIT J SPORT MED, V43, P981, DOI 10.1136/bjsm.2009.067728; Cantu RC, 2003, NEUROSURGERY, V52, P846, DOI 10.1227/01.NEU.0000053210.76063.E4; Cantu RC, 1998, CLIN SPORT MED, V17, pXI, DOI 10.1016/S0278-5919(05)70055-7; CANTU RC, J PHYS MED IN PRESS; CLARKE KS, 1979, MED SCI SPORT EXER, V11, P138; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Crisco JJ, 1997, MED SCI SPORT EXER, V29, P26, DOI 10.1097/00005768-199701000-00005; Cusimano MD, 2010, BRIT J SPORT MED, V44, P781, DOI 10.1136/bjsm.2009.070573; DALY PJ, 1990, SPORTS MED, V10, P122, DOI 10.2165/00007256-199010020-00005; Danis R P, 2000, Inj Prev, V6, P232, DOI 10.1136/ip.6.3.232; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dick R, 2007, J ATHL TRAINING, V42, P255; Drew LB, 2004, NEUROCRIT CARE, V1, P385, DOI 10.1385/NCC:1:3:385; Durkin MS, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.6.e74; Faul M, 2010, TRAUMATIC BRAIN INJU; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Finch C, 2003, J SCI MED SPORT, V6, pV, DOI 10.1016/S1440-2440(03)80001-4; Finkelstein E., 2006, INCIDENCE EC BURDEN; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gwin JT, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000249; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; Haileyesus T, 2007, INJURY PREV, V13, P202, DOI 10.1136/ip.2006.014019; HEINTZ WD, 1975, PHYSICIAN SPORTSMED, V3, P61; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Janda DH, 2003, CLIN ORTHOP RELAT R, P20, DOI 10.1097/01.blo.0000057789.10364.e3; Kahanov Leamor, 2005, Res Sports Med, V13, P77, DOI 10.1080/15438620590956025; Kis M, 2004, CAN J NEUROL SCI, V31, P499, DOI 10.1017/S031716710000370X; Labella CR, 2002, MED SCI SPORT EXER, V34, P41, DOI 10.1097/00005768-200201000-00007; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levy AS, 2002, J TRAUMA, V53, P695, DOI 10.1097/00005373-200210000-00013; Levy ML, 2004, NEUROSURGERY, V55, P649, DOI 10.1227/01.NEU.0000134598.06114.89; Levy ML, 2004, NEUROSURGERY, V55, P656, DOI 10.1227/01.NEU.0000134599.01917.AA; Levy ML, 2004, NEUROSURGERY, V55, P661; Lincoln AE, 2007, AM J SPORT MED, V35, P207, DOI 10.1177/0363546506293900; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Marshall SW, 2005, INT J EPIDEMIOL, V34, P113, DOI 10.1093/ije/dyh346; Marshall SW, 2003, JAMA-J AM MED ASSOC, V289, P568, DOI 10.1001/jama.289.5.568; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; McIntosh A, 2004, BRIT J SPORT MED, V38, P46, DOI 10.1136/bjsm.2002.003103; McIntosh AS, 2009, MED SCI SPORT EXER, V41, P306, DOI 10.1249/MSS.0b013e3181864bee; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2005, BRIT J SPORT MED, V39, P314, DOI 10.1136/bjsm.2005.018200; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2007, DENT TRAUMATOL, V23, P14, DOI 10.1111/j.1600-9657.2006.00488.x; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Mueller BA, 2008, EPIDEMIOLOGY, V19, P270, DOI 10.1097/EDE.0b013e318163567c; Mueller FO, 1982, CATASTROPHIC SPORT I; Myers Thomas J., 1993, Bio-Medical Materials and Engineering, V3, P15; Naunheim R, 2002, J TRAUMA, V53, P691, DOI 10.1097/00005373-200210000-00012; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; Nicholls RL, 2004, SPORTS MED, V34, P17, DOI 10.2165/00007256-200434010-00003; Norton K, 2001, BRIT J SPORT MED, V35, P418, DOI 10.1136/bjsm.35.6.418; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pettersen JA, 2002, BRIT J SPORT MED, V36, P19, DOI 10.1136/bjsm.36.1.19; REID SE, 1971, SURG GYNECOL OBSTETR, V133, P929; Rihn JA, 2009, SPORTS MED, V39, P697, DOI 10.2165/11315190-000000000-00000; ROBEY JM, 1971, J AMER MED ASSOC, V217, P184, DOI 10.1001/jama.217.2.184; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Sawyer RJ, 2010, HEALTH PROMOT PRACT, V11, P34, DOI 10.1177/1524839907309377; Scheiman S, 2010, ACCIDENT ANAL PREV, V42, P758, DOI 10.1016/j.aap.2009.11.005; Singh GD, 2009, DENT TRAUMATOL, V25, P515, DOI 10.1111/j.1600-9657.2009.00808.x; STEPHENS K, 2004, STANDARD DROP TEST M; Stevens ST, 2006, J SCI MED SPORT, V9, P238, DOI 10.1016/j.jsams.2006.03.025; Stuart MJ, 2002, AM J SPORT MED, V30, P39, DOI 10.1177/03635465020300012001; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; Thompson DC, 2000, COCHRANE DB SYST REV, V2; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; Torg J S, 1999, Am J Orthop (Belle Mead NJ), V28, P128; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; VIANO DC, 1993, CLIN J SPORT MED, V4, P217; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; WILLIAMS M, 1991, ACCIDENT ANAL PREV, V23, P119, DOI 10.1016/0001-4575(91)90043-5; Winters JE, 2001, J ATHL TRAINING, V36, P339; Wisniewski JF, 2004, DENT TRAUMATOL, V20, P143, DOI 10.1111/j.1600-4469.2004.00259.x; Withnall C, 2005, BRIT J SPORT MED, V39, pI40, DOI 10.1136/bjsm.2005.019174; *XEN, 2010, XEN INN; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44; 2006, J AM DENT ASS, V137, P1731	112	90	94	2	71	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JAN	2011	30	1					145	+		10.1016/j.csm.2010.09.006			20	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	691XR	WOS:000285114800014	21074089	Green Accepted			2022-02-06	
J	Tan, M; Zhu, JC; Du, J; Zhang, LM; Yin, HH				Tan, Min; Zhu, Jing-Ci; Du, Jiang; Zhang, Li-Mei; Yin, Hua-Hua			Effects of probiotics on serum levels of Th1/Th2 cytokine and clinical outcomes in severe traumatic brain-injured patients: a prospective randomized pilot study	CRITICAL CARE			English	Article							VENTILATOR-ASSOCIATED PNEUMONIA; CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; NOSOCOMIAL INFECTIONS; DOUBLE-BLIND; SYNBIOTICS; BACTERIA; PROPHYLAXIS; PREBIOTICS; THERAPY	Introduction: Traumatic brain injury (TBI) is associated with a profound immunological dysfunction manifested by a severe shift from T-helper type 1 (Th1) to T-helper type 2 (Th2) response. This predisposes patients to infections, sepsis, and adverse outcomes. Probiotic bacteria have been shown to balance the Th1/Th2 cytokines in allergic murine models and patients. For the present study, we hypothesized that the enteral administration of probiotics would adjust the Th1/Th2 imbalance and improve clinical outcomes in TBI patients. Methods: We designed a prospective, randomized, single-blind study. Patients with severe TBI and Glasgow Coma Scale scores between 5 and 8 were included, resulting in 26 patients in the control group and 26 patients in the probiotic group. All patients received enteral nutrition via a nasogastric tube within 24 to 48 hours following admission. In addition, the probiotic group received 10(9) bacteria of viable probiotics per day for 21 days. The associated serum levels of Th1/Th2 cytokines, Acute Physiology and Chronic Health Evaluation (APACHE) II and Sequential Organ Failure Assessment (SOFA) scores, nosocomial infections, length of ICU stay, and 28-day mortality rate were studied. Results: The patients responded to viable probiotics, and showed a significantly higher increase in serum IL-12p70 and IFN gamma levels while also experiencing a dramatic decrease in IL-4 and IL-10 concentrations. APACHE II and SOFA scores were not significantly affected by probiotic treatment. Patients in the probiotic group experienced a decreased incidence of nosocomial infections towards the end of the study. Shorter ICU stays were also observed among patients treated with probiotic therapy. However, the 28-day mortality rate was unaffected. Conclusions: The present study showed that daily prophylactic administration of probiotics could attenuate the deviated Th1/Th2 response induced by severe TBI, and could result in a decreased nosocomial infection rate, especially in the late period.	[Tan, Min] Affiliated Hosp N Sichuan Med Coll, Dept Nursing, Nanchong 637000, Sichuan, Peoples R China; [Tan, Min; Zhu, Jing-Ci; Zhang, Li-Mei; Yin, Hua-Hua] Third Mil Med Univ, Sch Nursing, Chongqing 400038, Peoples R China; [Du, Jiang] Affiliated Hosp N Sichuan Med Coll, Dept Gen Surg, Nanchong 637000, Sichuan, Peoples R China		Zhu, JC (corresponding author), Third Mil Med Univ, Sch Nursing, Chongqing 400038, Peoples R China.	zhujingci2009@163.com			11th 5-year research program of the People's Liberation Army of China [09MA009]	The present work was funded in part by the 11th 5-year research program of the People's Liberation Army of China under Grant No. 09MA009. The authors highly appreciate the great editing effort in the final version of the manuscript by Mr Lawrence Huang and Mr Leon Sun in the National Cancer Institute of the United States. They also would like to thank all staff at the Department of Neurosurgery, Affiliated Hospital of North Sichuan Medical College for their corporation during the study, and the Institute of Rheumatology and Immunology at North Sichuan Medical College for the support in experimental techniques.	Alberda C, 2007, AM J CLIN NUTR, V85, P816, DOI 10.1093/ajcn/85.3.816; Amaral ACKB, 2005, INTENS CARE MED, V31, P243, DOI 10.1007/s00134-004-2528-6; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Artis D, 2008, NAT REV IMMUNOL, V8, P411, DOI 10.1038/nri2316; Barraud D, 2010, INTENS CARE MED, V36, P1540, DOI 10.1007/s00134-010-1927-0; Bengmark S, 2001, CLIN NUTR, V20, P11, DOI 10.1054/clnu.2000.0111; Besselink MGH, 2008, LANCET, V371, P651, DOI 10.1016/S0140-6736(08)60207-X; Camargo LFA, 2004, CRIT CARE, V8, pR422, DOI 10.1186/cc2965; Christensen HR, 2002, J IMMUNOL, V168, P171, DOI 10.4049/jimmunol.168.1.171; Delgado S, 2008, J APPL MICROBIOL, V104, P1119, DOI 10.1111/j.1365-2672.2007.03642.x; DIPIRO JT, 1995, ARCH SURG-CHICAGO, V130, P1159; Dziedzic T, 2004, CRIT CARE, V8, P266, DOI 10.1186/cc2828; Fukushima Y, 2007, BRIT J NUTR, V98, P969, DOI 10.1017/S0007114507764723; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Ghadimi D, 2008, IMMUNOBIOLOGY, V213, P677, DOI 10.1016/j.imbio.2008.02.001; Giamarellos-Bourboulis EJ, 2009, J TRAUMA, V67, P815, DOI 10.1097/TA.0b013e31819d979e; Hart AL, 2004, GUT, V53, P1602, DOI 10.1136/gut.2003.037325; Husebye E, 2001, AM J PHYSIOL-GASTR L, V280, pG368, DOI 10.1152/ajpgi.2001.280.3.G368; Isakow W, 2007, CHEST, V132, P286, DOI 10.1378/chest.06-2156; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Knight DJW, 2009, INTENS CARE MED, V35, P854, DOI 10.1007/s00134-008-1368-1; Kotzampassi K, 2006, WORLD J SURG, V30, P1848, DOI 10.1007/s00268-005-0653-1; McNaught CE, 2005, CLIN NUTR, V24, P211, DOI 10.1016/j.clnu.2004.08.008; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Miller AC, 2007, J TRAUMA, V63, P1407, DOI 10.1097/TA.0b013e31815b839e; Mohamadzadeh M, 2005, P NATL ACAD SCI USA, V102, P2880, DOI 10.1073/pnas.0500098102; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; Morrow LE, 2010, AM J RESP CRIT CARE, V182, P1058, DOI 10.1164/rccm.200912-1853OC; Morrow LE, 2008, CRIT CARE, V12, DOI 10.1186/cc6927; Nylen ES, 2001, BEST PRACT RES CL EN, V15, P553, DOI 10.1053/beem.2001.0169; Schiavi E, 2011, ALLERGY, V66, P499, DOI 10.1111/j.1398-9995.2010.02501.x; Schultz MJ, 2011, CRIT CARE, V15, DOI 10.1186/cc9963; Siempos II, 2010, CRIT CARE MED, V38, P954, DOI 10.1097/CCM.0b013e3181c8fe4b; Spindler-Vesel A, 2007, JPEN-PARENTER ENTER, V31, P119, DOI 10.1177/0148607107031002119; Sudo N, 2002, CLIN EXP ALLERGY, V32, P1112, DOI 10.1046/j.1365-2222.2002.01430.x; Takahashi N, 2006, BIOSCI BIOTECH BIOCH, V70, P2013, DOI 10.1271/bbb.60260; Watkinson PJ, 2007, CLIN NUTR, V26, P182, DOI 10.1016/j.clnu.2006.07.010; Whelan K, 2010, AM J CLIN NUTR, V91, P687, DOI 10.3945/ajcn.2009.28759; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Wolvers D, 2010, J NUTR, V140, p698S, DOI 10.3945/jn.109.113753	41	90	109	1	18	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2011	15	6							R290	10.1186/cc10579			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	969VJ	WOS:000306087200084	22136422	gold, Green Published			2022-02-06	
J	Tefertiller, C; Pharo, B; Evans, N; Winchester, P				Tefertiller, Candace; Pharo, Beth; Evans, Nicholas; Winchester, Patricia			Efficacy of rehabilitation robotics for walking training in neurological disorders: A review	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						gait; locomotor training; multiple sclerosis; neurological disorders; rehabilitation; robotics; spinal cord injury; stroke; traumatic brain injury; walking	BODY-WEIGHT SUPPORT; SPINAL-CORD-INJURY; ELECTROMECHANICAL GAIT TRAINER; ASSISTED TREADMILL WALKING; SUBACUTE STROKE PATIENTS; MULTIPLE-SCLEROSIS; HEMIPARETIC PATIENTS; LOCOMOTOR THERAPY; MECHANIZED GAIT; MUSCLE-ACTIVITY	Robotic technologies are becoming more prevalent for treating neurological conditions in clinical settings. We conducted a literature search of original articles to identify all studies that examined the use of robotic devices for restoring walking function in adults with neurological disorders. We evaluated and rated each study using either the Physiotherapy Evidence Database scale for randomized controlled trials (RCTs) or the Downs and Black scale for non-RCTs. We reviewed 30 articles (14 RCTs, 16 non-RCTs) that examined the effects of locomotor training with robotic assistance in patients following stroke, spinal cord injury (SCI), multiple sclerosis (MS), traumatic brain injury (TBI), and Parkinson disease (PD). This review supports that locomotor training with robotic assistance is beneficial for improving walking function in individuals following a stroke and SCI. Gait speed and endurance were not found to be significantly different among patients with motor incomplete SCI after a variety of locomotor training approaches. Limited evidence demonstrates that locomotor training with robotic assistance is beneficial in populations of patients with MS, TBI, or PD. We discuss clinical implications and decision making in the area of gait rehabilitation for neurological dysfunction.	[Tefertiller, Candace; Pharo, Beth; Evans, Nicholas] Shepherd Ctr, Atlanta, GA USA; [Winchester, Patricia] Mercy Reg Med Ctr, Durango, CO USA		Tefertiller, C (corresponding author), Craig Hosp, 3425 S Clarkson St, Englewood, CO 80113 USA.	ctefertillerc@craighospital.org	Evans, Nicholas/AAT-1330-2020				ALAIMO MA, 1984, J APPL PHYSIOL, V56, P1608, DOI 10.1152/jappl.1984.56.6.1608; Backus D, 2008, TOPICS SPINAL CORD I, V14, P23, DOI DOI 10.1310/SCI1401-23; Barbeau H, 2003, ARCH PHYS MED REHAB, V84, P1458, DOI 10.1016/S0003-9993(03)00361-7; Barbeau H, 1998, ANN NY ACAD SCI, V860, P377, DOI 10.1111/j.1749-6632.1998.tb09063.x; Beer S, 2008, MULT SCLER J, V14, P231, DOI 10.1177/1352458507082358; Behmran AL, 2000, PHYS THER, V80, P688, DOI 10.1093/ptj/80.7.688; Behrman AL, 2005, PHYS THER, V85, P1356, DOI 10.1093/ptj/85.12.1356; Behrman AL, 2006, PHYS THER, V86, P1406, DOI 10.2522/ptj.20050212; Brown TH, 2005, J HEAD TRAUMA REHAB, V20, P402, DOI 10.1097/00001199-200509000-00002; Colombo G, 2000, J REHABIL RES DEV, V37, P693; Colombo G, 2001, SPINAL CORD, V39, P252, DOI 10.1038/sj.sc.3101154; Dietz V, 2002, BRAIN, V125, P2626, DOI 10.1093/brain/awf273; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Eng Janice J, 2007, Top Spinal Cord Inj Rehabil, V13, P1, DOI 10.1310/sci1301-1; Field-Fote Edelle C, 2005, J Neurol Phys Ther, V29, P127; Forlander DA, 1999, CLIN REHABIL, V13, P97, DOI 10.1191/026921599675502264; Freivogel S, 2008, BRAIN INJURY, V22, P625, DOI 10.1080/02699050801941771; Gardner MB, 1998, PHYS THER, V78, P361, DOI 10.1093/ptj/78.4.361; Giesser B, 2007, MULT SCLER, V13, P224, DOI 10.1177/1352458506070663; Hesse S, 2000, J REHABIL RES DEV, V37, P701; Hesse S, 1999, CLIN REHABIL, V13, P401, DOI 10.1191/026921599673896297; Hesse S, 2000, ARCH PHYS MED REHAB, V81, P1158, DOI 10.1053/apmr.2000.6280; Hesse S, 2004, SPINAL CORD, V42, P346, DOI 10.1038/sj.sc.3101595; Hesse S, 2001, Curr Atheroscler Rep, V3, P287, DOI 10.1007/s11883-001-0021-z; Hesse Stefan, 2003, Adv Neurol, V92, P423; Hicks AL, 2005, SPINAL CORD, V43, P291, DOI 10.1038/sj.sc.3101710; Hidler J, 2009, NEUROREHAB NEURAL RE, V23, P5, DOI 10.1177/1545968308326632; Hornby TG, 2008, STROKE, V39, P1786, DOI 10.1161/STROKEAHA.107.504779; Hornby TG, 2005, PHYS THER, V85, P52, DOI 10.1093/ptj/85.1.52; Husemann B, 2007, STROKE, V38, P349, DOI 10.1161/01.STR.0000254607.48765.cb; Israel JF, 2006, PHYS THER, V86, P1466, DOI 10.2522/ptj.20050266; Krewer C, 2007, GAIT POSTURE, V26, P372, DOI 10.1016/j.gaitpost.2006.10.003; KURTZKE JF, 1994, ANN NEUROL, V36, pS73, DOI 10.1002/ana.410360717; Lam T, 2008, SPINAL CORD, V46, P246, DOI 10.1038/sj.sc.3102134; Lam T, 2008, NEUROREHAB NEURAL RE, V22, P438, DOI 10.1177/1545968308315595; Lamontagne A, 2004, STROKE, V35, P2543, DOI 10.1161/01.STR.0000144685.88760.d7; Lewek MD, 2009, PHYS THER, V89, P829, DOI 10.2522/ptj.20080180; Lo AC, 2008, NEUROREHAB NEURAL RE, V22, P661, DOI 10.1177/1545968308318473; LOVELY RG, 1990, BRAIN RES, V514, P206, DOI 10.1016/0006-8993(90)91417-F; LOVELY RG, 1986, EXP NEUROL, V92, P421, DOI 10.1016/0014-4886(86)90094-4; Mayr A, 2007, NEUROREHAB NEURAL RE, V21, P307, DOI 10.1177/1545968307300697; McCain KJ, 2008, ARCH PHYS MED REHAB, V89, P684, DOI 10.1016/j.apmr.2007.09.050; Mehrholz J, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006676.pub2; Miyai I, 2002, ARCH PHYS MED REHAB, V83, P1370, DOI 10.1053/apmr.2002.34603; Miyai I, 2000, ARCH PHYS MED REHAB, V81, P849, DOI 10.1053/apmr.2000.4439; Moreh E, 2009, J REHABIL MED, V41, P88, DOI 10.2340/16501977-0279; Morrison Sarah A, 2007, J Neurol Phys Ther, V31, P50; Moseley AM, 2002, AUST J PHYSIOTHER, V48, P43, DOI 10.1016/S0004-9514(14)60281-6; Neckel ND, 2008, J NEUROENG REHABIL, V5, DOI 10.1186/1743-0003-5-19; Nooijen CFJ, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-36; Peurala SH, 2005, ARCH PHYS MED REHAB, V86, P1557, DOI 10.1016/j.apmr.2005.02.005; Pohl M, 2007, CLIN REHABIL, V21, P17, DOI 10.1177/0269215506071281; Pohl M, 2003, ARCH PHYS MED REHAB, V84, P1760, DOI 10.1016/S0003-9993(03)00433-7; Protas EJ, 2001, ARCH PHYS MED REHAB, V82, P825, DOI 10.1053/apmr.2001.23198; Querry RG, 2008, J REHABIL RES DEV, V45, P175, DOI 10.1682/JRRD.2007.02.0028; Riener R, 2005, MED BIOL ENG COMPUT, V43, P2, DOI 10.1007/BF02345116; Scherer M, 2007, BRAIN INJURY, V21, P93, DOI 10.1080/02699050601149104; Schwartz I, 2009, PM&R, V1, P516, DOI 10.1016/j.pmrj.2009.03.009; SMITH JL, 1983, BIRTH DEFECTS-ORIG, V19, P357; Sullivan KJ, 2007, PHYS THER, V87, P1580, DOI 10.2522/ptj.20060310; Tong RK, 2006, ARCH PHYS MED REHAB, V87, P1298, DOI 10.1016/j.apmr.2006.06.016; Tong RKY, 2006, PHYS THER, V86, P1282, DOI 10.2522/ptj.20050183; Visintin M, 1998, STROKE, V29, P1122, DOI 10.1161/01.STR.29.6.1122; Werner C, 2002, STROKE, V33, P2895, DOI 10.1161/01.STR.0000035734.61539.f6; Wernig A, 1998, SPINAL CORD, V36, P744, DOI 10.1038/sj.sc.3100670; WEST SP, 1986, EXP NEUROL, V91, P174, DOI 10.1016/0014-4886(86)90035-X; Westlake KP, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-18; Winchester P, 2005, NEUROREHAB NEURAL RE, V19, P313, DOI 10.1177/1545968305281515; Winchester Patricia, 2006, Phys Med Rehabil Clin N Am, V17, P159, DOI 10.1016/j.pmr.2005.10.008; Winchester P, 2009, J SPINAL CORD MED, V32, P63, DOI 10.1080/10790268.2009.11760754; Wirz M, 2005, ARCH PHYS MED REHAB, V86, P672, DOI 10.1016/j.apmr.2004.08.004	71	90	94	1	42	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2011	48	4					387	416		10.1682/JRRD.2010.04.0055			30	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	774GB	WOS:000291372200008	21674390	Bronze			2022-02-06	
J	Bell, RS; Mossop, CM; Dirks, MS; Stephens, FL; Mulligan, L; Ecker, R; Neal, CJ; Kumar, A; Tigno, T; Armonda, RA				Bell, Randy S.; Mossop, Corey M.; Dirks, Michael S.; Stephens, Frederick L.; Mulligan, Lisa; Ecker, Robert; Neal, Christopher J.; Kumar, Anand; Tigno, Teodoro; Armonda, Rocco A.			Early decompressive craniectomy for severe penetrating and closed head injury during wartime	NEUROSURGICAL FOCUS			English	Article						decompressive craniectomy; penetrating head injury; blast injury; Glasgow Outcome Scale	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; WOUNDS	Object. Decompressive craniectomy has defined this era of damage-control wartime neurosurgery. Injuries that in previous conflicts were treated in an expectant manner are now aggressively decompressed at the far-forward Combat Support Hospital and transferred to Walter Reed Army Medical Center (WRAMC) and National Naval Medical Center (NNMC) in Bethesda for definitive care. The purpose of this paper is to examine the baseline characteristics of those injured warriors who received decompressive craniectomies. The importance of this procedure will be emphasized and guidance provided to current and future neurosurgeons deployed in theater. Methods. The authors retrospectively searched a database for all soldiers injured in Operations Iraqi Freedom and Enduring Freedom between April 2003 and October 2008 at WRAMC and NNMC. Criteria for inclusion in this study included either a closed or penetrating head injury suffered during combat operations in either Iraq or Afghanistan with subsequent neurosurgical evaluation at NNMC or WRAMC. Exclusion criteria included all cases in which primary demographic data could not be verified. Primary outcome data included the type and mechanism of injury, Glasgow Coma Scale (GCS) score and injury severity score (ISS) at admission, and Glasgow Outcome Scale (GOS) score at discharge, 6 months, and 1-2 years. Results. Four hundred eight patients presented with head injury during the study period. In this population, a total of 188 decompressive craniectomies were performed (154 for penetrating head injury, 22 for closed head injury, and 12 for unknown injury mechanism). Patients who underwent decompressive craniectomies in the combat theater had significantly lower initial GCS scores (7.7 +/- 4.2 vs 10.8 +/- 4.0, p < 0.05) and higher ISSs (32.5 +/- 9.4 vs 26.8 +/- 11.8, p < 0.05) than those who did not. When comparing the GOS scores at hospital discharge, 6 months, and 1-2 years after discharge, those receiving decompressive craniectomies had significantly lower scores (3.0 +/- 0.9 vs 3.7 +/- 0.9, 3.5 +/- 1.2 vs 4.0 +/- 1.0, and 3.7 +/- 1.2 vs 4.4 +/- 0.9, respectively) than those who did not undergo decompressive craniectomies. That said, intragroup analysis indicated consistent improvement for those with craniectomy with time, allowing them, on average, to participate in and improve from rehabilitation (p < 0.05). Overall, 83% of those for whom follow-up data are available achieved a 1-year GOS score of greater than 3. Conclusions. This study of the provision of early decompressive craniectomy in a military population that sustained severe penetrating and closed head injuries represents one of the largest to date in both the civilian and military literature. The findings suggest that patients who undergo decompressive craniectomy had worse injuries than those receiving craniotomy and, while not achieving the same outcomes as those with a lesser injury, did improve with time. The authors recommend hemicraniectomy for damage control to protect patients from the effects of brain swelling during the long overseas transport to their definitive care, and it should be conducted with foresight concerning future complications and reconstructive surgical procedures. (DOI: 10.3171/2010.2.FOCUS1022)	[Bell, Randy S.; Mossop, Corey M.; Dirks, Michael S.; Stephens, Frederick L.; Mulligan, Lisa; Neal, Christopher J.; Armonda, Rocco A.] Univ Hlth Sci, Uniformed Serv, Bethesda, MD USA; [Bell, Randy S.; Mulligan, Lisa; Ecker, Robert; Neal, Christopher J.; Kumar, Anand; Armonda, Rocco A.] USN, Med Ctr, Dept Neurosurg, Bethesda, MD 20814 USA; [Tigno, Teodoro; Armonda, Rocco A.] Walter Reed Army Med Ctr, Dept Neurosurg, Washington, DC 20307 USA; [Mossop, Corey M.; Dirks, Michael S.; Stephens, Frederick L.; Armonda, Rocco A.] Natl Capital Consortium Neurosurg Program, Washington, DC USA		Bell, RS (corresponding author), NAVMED MPT&E, 8901 Wisconsin Ave, Bethesda, MD 20889 USA.	randy.s.bell@us.army.mil			University of Texas, Medical Branch	The authors are thankful for the service of all neurosurgeons deployed during OIF and OEF. They also thank Dr. Alexander H. Vo, Ph. D., from the University of Texas, Medical Branch, for his support with statistical analysis.	Aarabi B, 1998, NEUROSURGERY, V42, P500, DOI 10.1097/00006123-199803000-00014; Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Bell RS, 2010, NEUROSURGERY, V66, P66, DOI 10.1227/01.NEU.0000361285.50218.A8; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; BELLAMY RF, 1984, MIL MED, V149, P55; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; Cushing H, 1918, BRIT J SURG, V5, P558; HAGAN RE, 1971, J NEUROSURG, V34, P132, DOI 10.3171/jns.1971.34.2part1.0132; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Kim KA, 2005, NEUROSURGERY, V57, P737, DOI [10.1227/01.NEU.0000175727.76530.94, 10.1227/01.NEU.0000164174.07281.F9]; Manley GT, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS.JUNE09.INTRO; MATSON D, 1958, MANAGEMENT ACUTE CRA, V1; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; NAKAGAWA M, 2004, RSMC TOKYO TYPHOON C, V7, P10	17	90	97	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	MAY	2010	28	5							E1	10.3171/2010.2.FOCUS1022			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	589ZU	WOS:000277193600001	20568925				2022-02-06	
J	Englander, J; Bushnik, T; Oggins, J; Katznelson, L				Englander, Jeffrey; Bushnik, Tamara; Oggins, Jean; Katznelson, Laurence			Fatigue after traumatic brain injury: Association with neuroendocrine, sleep, depression and other factors	BRAIN INJURY			English	Article						Brain injuries; rehabilitation; fatigue; neuroendocrine systems	ANEURYSMAL SUBARACHNOID HEMORRHAGE; DISABILITY RATING-SCALE; QUALITY-OF-LIFE; 1ST 2 YEARS; MULTIPLE-SCLEROSIS; SEVERITY SCALE; LONG-TERM; HYPOPITUITARISM; INVENTORY; REHABILITATION	Objective: Define associations between post-traumatic brain injury (TBI) fatigue and abnormalities in neuroendocrine axes, sleep, mood, cognition and physical functioning. Design: Survey. Setting: Large community hospital-based rehabilitation centre. Participants: Convenience sample of 119 individuals at least 1 year post-TBI. Outcome measures: Multidimensional Assessment of Fatigue (MAF); Fatigue Severity Scale (FSS); neuroendocrine assessments-growth hormone (GH) reserve, thyroid, cortisol and testosterone levels; visual analogue pain rating; Pittsburgh Sleep Quality Index; Beck Depression Inventory-II; Disability Rating Scale; Craig Handicap Assessment and Reporting Technique; Neurobehavioural Functioning Inventory. Results: Fifty-three per cent reported fatigue on the MAF and one-third on the FSS; 65% were found to have moderate/severe GH deficiency; 64% had adrenal insufficiency (low fasting cortisol); 12% had central hypothyroidism; and 15% of men had testosterone deficiency. Pituitary dysfunction did not correlate with fatigue or other symptoms. Predictors of MAF total scores were female gender, depression, pain and self-assessed memory deficits. Predictors of FSS scores were depression, self-assessed motor deficits and anti-depressant usage. Conclusions: Robust correlates of fatigue were gender, depression, pain and memory and motor dysfunction. Investigation of post-TBI fatigue should include screening for depression, pain and sleep disturbance. There was no correlation between pituitary dysfunction and fatigue; however, the relatively high prevalence of hypothyroidism and adrenal dysfunction suggests screening for these hormone deficiencies.	[Englander, Jeffrey] Santa Clara Valley Med Ctr, PM&R, San Jose, CA 95128 USA; [Bushnik, Tamara] Santa Clara Valley Med Ctr, Rehabil Res, San Jose, CA 95128 USA; [Oggins, Jean] Consulting & Res Evaluat Serv, San Francisco, CA USA; [Katznelson, Laurence] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA; [Katznelson, Laurence] Stanford Univ, Dept Neurosurg, Sch Med, Stanford, CA 94305 USA		Bushnik, T (corresponding author), NYU, Langone Med Ctr, Rusk Inst Rehabil Res, 400 E 34th St,RR115A, New York, NY 10010 USA.	tamara.bushnik@nyumc.org	Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604; Bushnik, Tamara/0000-0003-3328-257X; Katznelson, Laurence/0000-0001-8115-5714	U.S. Department of Education, Office of Special Education and Rehabilitative Services, National Institute on Disability and Rehabilitation ResearchUS Department of Education [H133A020524]	This research was funded in part by a grant from the U.S. Department of Education, Office of Special Education and Rehabilitative Services, National Institute on Disability and Rehabilitation Research (Grant # H133A020524) and by a supplement grant from Pfizer Pharmaceuticals Inc. for neuroendocrine testing.	Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Baum HBA, 1996, J CLIN ENDOCR METAB, V81, P84, DOI 10.1210/jc.81.1.84; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; BELZA BL, 1995, J RHEUMATOL, V22, P639; BOGARO SR, 2005, J HEAD TRAUMA REHAB, V5, P416; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bormann J, 2001, J Assoc Nurses AIDS Care, V12, P75, DOI 10.1016/S1055-3290(06)60146-5; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P25, DOI 10.1097/01.HTR.0000308718.88214.bb; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Centers for Disease Control and Prevention, 1998, BEH RISK FACT SURV S; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Dijkers MPJM, 2008, J HEAD TRAUMA REHAB, V23, P3, DOI 10.1097/01.HTR.0000308716.80590.6b; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; FRYER LJ, 1987, J HEAD TRAUMA REHAB, V2, P51, DOI DOI 10.1097/00001199-198709000-00007; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Grady C, 1998, NURS RES, V47, P227, DOI 10.1097/00006199-199807000-00008; Jha A, 2008, J HEAD TRAUMA REHAB, V23, P52, DOI 10.1097/01.HTR.0000308721.77911.ea; JONES SL, 1994, CLIN ENDOCRINOL, V41, P123, DOI 10.1111/j.1365-2265.1994.tb03793.x; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kleinman L, 2000, QUAL LIFE RES, V9, P499, DOI 10.1023/A:1008960710415; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PACKER TL, 1994, ARCH PHYS MED REHAB, V75, P1122, DOI 10.1016/0003-9993(94)90088-4; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rothman MS, 2007, J NEUROPSYCH CLIN N, V19, P363, DOI 10.1176/appi.neuropsych.19.4.363; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schwartz CE, 1996, ARCH PHYS MED REHAB, V77, P165, DOI 10.1016/S0003-9993(96)90162-8; Srinivasan L, 2009, BRAIN INJURY, V23, P639, DOI 10.1080/02699050902970778; Substance Abuse and Mental Health Services Administration, NAT HOUS SURV DRUG A; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Widmer IE, 2005, J CLIN ENDOCR METAB, V90, P4579, DOI 10.1210/jc.2005-0354; Winstead-Fry P, 1998, J Nurs Meas, V6, P111	42	90	93	0	22	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	12					1379	1388		10.3109/02699052.2010.523041			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	667NR	WOS:000283200800001	20961172				2022-02-06	
J	Monetta, L; Grindrod, CM; Pell, MD				Monetta, Laura; Grindrod, Christopher M.; Pell, Marc D.			Irony comprehension and theory of mind deficits in patients with Parkinson's disease	CORTEX			English	Article						Fronto-striatal mechanisms; Nonliteral language; Neurogenic language impairment; Parkinson's disease; Pragmatics; Theory of mind	WORKING-MEMORY DEFICITS; TRAUMATIC BRAIN-INJURY; SENTENCE COMPREHENSION; METAPHOR COMPREHENSION; EXECUTIVE DYSFUNCTION; DAMAGED INDIVIDUALS; PROCESSING SPEED; VERBAL FLUENCY; ADULTS; COMMUNICATION	Many individuals with Parkinson's disease (PD) are known to have difficulties in understanding pragmatic aspects of language. In the present study, a group of eleven non-demented PD patients and eleven healthy control (HC) participants were tested on their ability to interpret communicative intentions underlying verbal irony and lies, as well as on their ability to infer first- and second-order mental states (i.e., theory of mind). Following Winner et al. (1998), participants answered different types of questions about the events which unfolded in stories which ended in either an ironic statement or a lie. Results showed that PD patients were significantly less accurate than HC participants in assigning second-order beliefs during the story comprehension task, suggesting that the ability to make a second-order mental state attribution declines in PD. The PD patients were also less able to distinguish whether the final statement of a story should be interpreted as a joke or a lie, suggesting a failure in pragmatic interpretation abilities. The implications of frontal lobe dysfunction in PD as a source of difficulties with working memory, mental state attributions, and pragmatic language deficits are discussed in the context of these findings. (C) 2009 Elsevier Srl. All rights reserved.	[Monetta, Laura] Univ Laval, Dept Readaptat, Ctr Rech Robert Giffard, Quebec City, PQ G1V 0A6, Canada; [Grindrod, Christopher M.] Univ Illinois, Dept Speech & Hearing Sci, Champaign, IL USA; [Monetta, Laura; Pell, Marc D.] McGill Univ, Sch Commun Sci & Disorders, Montreal, PQ, Canada		Monetta, L (corresponding author), Univ Laval, Dept Readaptat, Ctr Rech Robert Giffard, Pavillon F Vandry,1050 Ave Med, Quebec City, PQ G1V 0A6, Canada.	laura.monetta@rea.ulaval.ca	Monetta, Laura/AAK-7657-2020; Pell, Marc D./AAL-3121-2021	Pell, Marc D./0000-0002-9947-1552	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); CIHR Institute of AgingCanadian Institutes of Health Research (CIHR); Fonds de la recherche en sante du QuebecFonds de la Recherche en Sante du Quebec; McGill University	This research was financed by an operating grant from the Canadian Institutes of Health Research (to MDP) and by a CIHR Institute of Aging postdoctoral fellowship (to LK. The senior author is grateful for support from the Fonds de la recherche en sante du Quebec (Chercheur-boursier junior 2 award) and McGill University (William Dawson Chair). We are particularly indebted to Marie Desmarteau for her help in running the study.	Angwin AJ, 2005, COGNITIVE BRAIN RES, V25, P78, DOI 10.1016/j.cogbrainres.2005.04.008; Barkley RA, 2001, NEUROPSYCHOL REV, V11, P1, DOI 10.1023/A:1009085417776; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Berg E, 2003, CLIN LINGUIST PHONET, V17, P63, DOI 10.1080/0269920021000055540; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Brown P, 1998, LANCET, V351, P1801, DOI 10.1016/S0140-6736(97)11225-9; BROWN RG, 1991, BRAIN, V114, P215; Brownell H, 1998, RIGHT HEMISPHERE LANGUAGE COMPREHENSION, P309; CALNE DB, 1992, ANN NEUROL, V32, pS125, DOI 10.1002/ana.410320721; Champagne M, 2004, BRAIN LANG, V91, P172, DOI 10.1016/j.bandl.2004.06.089; Channon S, 2007, NEUROPSYCHOLOGIA, V45, P1725, DOI 10.1016/j.neuropsychologia.2006.12.021; Cheang HS, 2008, SPEECH COMMUN, V50, P366, DOI 10.1016/j.specom.2007.11.003; Collins P, 2000, BEHAV NEUROSCI, V114, P3, DOI 10.1037/0735-7044.114.1.3; Culbertson W. C., 2001, TOWER LONDON DX TOL; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; Dara C, 2008, BRAIN RES, V1188, P100, DOI 10.1016/j.brainres.2007.10.034; Demakis George J, 2007, Dis Mon, V53, P152, DOI 10.1016/j.disamonth.2007.04.005; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Dubois B, 1997, J NEUROL, V244, P2, DOI 10.1007/pl00007725; Eviatar Z, 2006, NEUROPSYCHOLOGIA, V44, P2348, DOI 10.1016/j.neuropsychologia.2006.05.007; Friederici AD, 2003, NEUROPSYCHOLOGY, V17, P133, DOI 10.1037/0894-4105.17.1.133; Gabrieli JDE, 1996, NEUROPSYCHOLOGY, V10, P322, DOI 10.1037/0894-4105.10.3.321; Gallagher HL, 2003, TRENDS COGN SCI, V7, P77, DOI 10.1016/S1364-6613(02)00025-6; Gernsbacher MA, 2001, J MEM LANG, V45, P433, DOI 10.1006/jmla.2000.2782; Gibbs RW., 2000, METAPHOR SYMBOL, V15, P5, DOI [10.1080/10926488.2000.9678862, DOI 10.1080/10926488.2000.9678862]; Grossman M, 2003, NEUROLOGY, V60, P775, DOI 10.1212/01.WNL.0000044398.73241.13; Grossman M, 2002, NEUROPSYCHOLOGY, V16, P174, DOI 10.1037//0894-4105.16.2.174; HAPPE FGE, 1993, COGNITION, V48, P101, DOI 10.1016/0010-0277(93)90026-R; Henry JD, 2004, J INT NEUROPSYCH SOC, V10, P608, DOI 10.1017/S1355617704104141; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Lee C, 2003, BRAIN LANG, V85, P347, DOI 10.1016/S0093-934X(03)00063-4; LESLIE AM, 1994, COGNITION, V50, P211, DOI 10.1016/0010-0277(94)90029-9; Lewis SJG, 2003, NEUROPSYCHOLOGIA, V41, P645, DOI 10.1016/S0028-3932(02)00257-9; LIEBERMAN P, 1990, J NERV MENT DIS, V178, P360, DOI 10.1097/00005053-199006000-00003; Martin I, 2004, J AUTISM DEV DISORD, V34, P311, DOI 10.1023/B:JADD.0000029553.52889.15; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; Mattis S, 1988, DEMENTIA RATING SCAL; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McNamara P, 2003, BRAIN LANG, V84, P414, DOI 10.1016/S0093-934X(02)00558-8; Monetta L, 2008, J NEUROLINGUIST, V21, P400, DOI 10.1016/j.jneuroling.2007.11.002; Monetta L, 2007, BRAIN LANG, V101, P80, DOI 10.1016/j.bandl.2006.06.007; Monetta L, 2008, J NEUROPSYCHOL, V2, P415, DOI 10.1348/174866407X216675; Mutter SA, 2006, Q J EXP PSYCHOL, V59, P1556, DOI 10.1080/17470210500343546; Natsopoulos D, 1997, CORTEX, V33, P463, DOI 10.1016/S0010-9452(08)70230-2; Owen AM, 2000, EXP BRAIN RES, V133, P33, DOI 10.1007/s002210000398; Pell MD, 2003, COGN AFFECT BEHAV NE, V3, P275, DOI 10.3758/CABN.3.4.275; Pell MD, 2006, BRAIN LANG, V97, P123, DOI 10.1016/j.bandl.2005.08.010; PITCAIRN TK, 1990, BRIT J DISORD COMMUN, V25, P85; Reynolds WM, 1995, HAMILTON DEPRESSION; Saltzman J, 2000, J INT NEUROPSYCH SOC, V6, P781, DOI 10.1017/S1355617700677056; Shamay-Tsoory SG, 2005, NEUROPSYCHOLOGY, V19, P288, DOI 10.1037/0894-4105.19.3.288; STEMMER B, 1994, BRAIN LANG, V47, P1, DOI 10.1006/brln.1994.1040; TAYLOR AE, 1986, BRAIN, V109, P845, DOI 10.1093/brain/109.5.845; TOMPKINS CA, 1994, J SPEECH HEAR RES, V37, P896, DOI 10.1044/jshr.3704.896; Troyer AK, 1998, NEUROPSYCHOLOGIA, V36, P499, DOI 10.1016/S0028-3932(97)00152-8; Walsh K. W., 1985, UNDERSTANDING BRAIN; Warrington E, 1984, RECOGNITION MEMORY T, V1; White T., 1996, COLOR TRAILS TEST PR; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889	60	90	95	0	33	ELSEVIER MASSON	MILANO	VIA PALEOCAPA 7, 20121 MILANO, ITALY	0010-9452			CORTEX	Cortex	SEP	2009	45	8			SI		972	981		10.1016/j.cortex.2009.02.021			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	473LD	WOS:000268206700009	19371867				2022-02-06	
J	Galluzzi, L; Morselli, E; Kepp, O; Kroemer, G				Galluzzi, Lorenzo; Morselli, Eugenia; Kepp, Oliver; Kroemer, Guido			Targeting post-mitochondrial effectors of apoptosis for neuroprotection	BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS			English	Article; Proceedings Paper	International Symposium on Mitchondrial Physiology and Pathology	JUN, 2008	Bari, ITALY			Apoptosis-inducing factor (AIF); Caspases; Endonuclease G (EndoG); Ischemia; Omi/HtrA2; Permeability transition pore complex (PTPC); Smac/Diablo	FOCAL CEREBRAL-ISCHEMIA; PERMEABILITY TRANSITION PORE; TRAUMATIC BRAIN-INJURY; NEURONAL CELL-DEATH; NEONATAL HYPOXIA-ISCHEMIA; SPINAL-CORD-INJURY; OXYGEN-GLUCOSE DEPRIVATION; CYTOCHROME-C RELEASE; ACTIVATING FACTOR-I; X-LINKED INHIBITOR	Mitochondrial membrane permeabilization (MMP) is commonly regarded as the "point-of-no-return" in the cascade of events that delineate the intrinsic pathway of apoptosis. MMP leads to the functional impairment of mitochondria and to the release into the cytosol of toxic proteins that are normally confined within the mitochondrial intermembrane space. These include direct activators of caspases and caspase-independent effectors of the cell death program. MMP has been implicated in a plethora of pathophysiological settings. In particular, MMP contributes to both the immediate and delayed phases of cell loss that follow acute neuronal injury by ischemia/reperfusion or trauma. Although preventing MMP a priori would be the most desirable therapeutic choice, prophylactic interventions are rarely (if ever) achievable in the treatment of stroke and trauma patients. Conversely, interventions that block the post-mitochondrial phase of apoptosis (if administered within the first few hours after the accident) hold great promises for the development of novel neuroprotective strategies. In animal models of acute neuronal injury, the inhibition of caspases, apoptosis-inducing factor (AIF) and other apoptotic effectors can confer significant neuroprotection. Our review recapitulates the results of these studies and proposes novel strategies of inhibiting post-mitochondrial apoptosis in neurons. (C) 2008 Elsevier B.V. All rights reserved.	[Kroemer, Guido] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; Univ Paris 11, F-94805 Villejuif, France		Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, PR1 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Galluzzi, Lorenzo/AAG-6432-2019; Galluzzi, Lorenzo/AAG-6294-2019; Galluzzi, Lorenzo/K-2709-2012; Galluzzi, Lorenzo/AAH-3286-2021; KROEMER, Guido/B-4263-2013; Kepp, Oliver/N-2763-2017	Galluzzi, Lorenzo/0000-0003-2257-8500; KROEMER, Guido/0000-0002-9334-4405; Kepp, Oliver/0000-0002-6081-9558			Abou-Sleiman PM, 2006, NAT REV NEUROSCI, V7, P207, DOI 10.1038/nrn1868; Baines CP, 2007, NAT CELL BIOL, V9, P550, DOI 10.1038/ncb1575; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Blomgren K, 2003, BIOCHEM BIOPH RES CO, V304, P551, DOI 10.1016/S0006-291X(03)00628-4; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Bredesen DE, 2005, CELL DEATH DIFFER, V12, P1031, DOI 10.1038/sj.cdd.4401680; BRENNER BM, 2000, J RENIN ANGIOITENS A, V1, P329; Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609; Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004; Butcher SP, 1997, J NEUROSCI, V17, P6939; Cain K, 2002, BIOCHIMIE, V84, P203, DOI 10.1016/S0300-9084(02)01376-7; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Cheung ECC, 2005, J NEUROSCI, V25, P1324, DOI 10.1523/JNEUROSCI.4261-04.2005; Clark RSB, 2007, J CEREBR BLOOD F MET, V27, P316, DOI 10.1038/sj.jcbfm.9600338; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Culmsee C, 2005, J NEUROSCI, V25, P10262, DOI 10.1523/JNEUROSCI.2818-05.2005; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.00220.x; David KK, 2006, CELL DEATH DIFFER, V13, P1147, DOI 10.1038/sj.cdd.4401787; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Elibol B, 2001, NEUROSCIENCE, V105, P79, DOI 10.1016/S0306-4522(01)00159-2; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Fan YF, 2006, NEUROCHEM INT, V48, P50, DOI 10.1016/j.neuint.2005.07.008; Ferrer I, 2003, J NEUROPATH EXP NEUR, V62, P329, DOI 10.1093/jnen/62.4.329; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.0.CO;2-Y; Galiegue S, 2003, CURR MED CHEM, V10, P1563, DOI 10.2174/0929867033457223; Galluzzi L, 2008, ONCOGENE, V27, P4633, DOI 10.1038/onc.2008.114; Galluzzi L, 2008, CELL DEATH DIFFER, V15, P1113, DOI 10.1038/cdd.2008.28; Galluzzi L, 2007, CELL DEATH DIFFER, V14, P1237, DOI 10.1038/sj.cdd.4402148; Galluzzi L, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000018; Galluzzi L, 2007, NAT CELL BIOL, V9, P487, DOI 10.1038/ncb0507-487; Gao YQ, 2005, J CEREBR BLOOD F MET, V25, P694, DOI 10.1038/sj.jcbfm.9600062; Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950; Garrido C, 2004, CURR OPIN CELL BIOL, V16, P639, DOI 10.1016/j.ceb.2004.09.008; Genovese T, 2007, SHOCK, V27, P258, DOI 10.1097/01.shk.0000239775.41022.54; Gibson ME, 2001, MOL MED, V7, P644, DOI 10.1007/BF03401871; Gill R, 2002, J CEREBR BLOOD F MET, V22, P420, DOI 10.1097/00004647-200204000-00006; Golstein P, 2007, TRENDS BIOCHEM SCI, V32, P37, DOI 10.1016/j.tibs.2006.11.001; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Guan QH, 2006, NEUROSCIENCE, V139, P609, DOI 10.1016/j.neuroscience.2005.11.067; Han BH, 2002, J BIOL CHEM, V277, P30128, DOI 10.1074/jbc.M202931200; Hao ZY, 2005, CELL, V121, P579, DOI 10.1016/j.cell.2005.03.016; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hetz C, 2005, J BIOL CHEM, V280, P42960, DOI 10.1074/jbc.M505843200; Hisatomi T, 2002, CURR EYE RES, V24, P161, DOI 10.1076/ceyr.24.3.161.8305; Hisatomi T, 2001, AM J PATHOL, V158, P1271, DOI 10.1016/S0002-9440(10)64078-3; Hisatomi T, 2008, J CLIN INVEST, V118, P2025, DOI 10.1172/JCI34267; Honarpour N, 2001, P NATL ACAD SCI USA, V98, P9683, DOI 10.1073/pnas.171283198; Houde C, 2004, J NEUROSCI, V24, P9977, DOI 10.1523/JNEUROSCI.3356-04.2004; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; Joza N, 2005, MOL CELL BIOL, V25, P10261, DOI 10.1128/MCB.25.23.10261-10272.2005; Kalinowska M, 2005, APOPTOSIS, V10, P821, DOI 10.1007/s10495-005-0410-9; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Katoh I, 2004, J BIOL CHEM, V279, P15515, DOI 10.1074/jbc.M311819200; Kermer P, 2000, MOL BRAIN RES, V85, P144, DOI 10.1016/S0169-328X(00)00256-4; Kim I, 2007, ARCH BIOCHEM BIOPHYS, V462, P245, DOI 10.1016/j.abb.2007.03.034; Kim R, 2005, BIOCHEM BIOPH RES CO, V333, P336, DOI 10.1016/j.bbrc.2005.04.161; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kowaltowski AJ, 1996, FEBS LETT, V378, P150, DOI 10.1016/0014-5793(95)01449-7; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; KROEMER G, 2008, CELL DEATH IN PRESS; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kugler S, 2000, CELL DEATH DIFFER, V7, P815, DOI 10.1038/sj.cdd.4400712; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kuida K, 2000, INT J BIOCHEM CELL B, V32, P121, DOI 10.1016/S1357-2725(99)00024-2; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Lalier L, 2007, APOPTOSIS, V12, P887, DOI 10.1007/s10495-007-0749-1; Lamkanfi M, 2007, CELL DEATH DIFFER, V14, P44, DOI 10.1038/sj.cdd.4402047; Le DA, 2002, P NATL ACAD SCI USA, V99, P15188, DOI 10.1073/pnas.232473399; Lee BI, 2005, NEUROSCI LETT, V386, P23, DOI 10.1016/j.neulet.2005.05.058; Lee SH, 2004, STROKE, V35, P2195, DOI 10.1161/01.STR.0000136150.73891.14; Leonard JR, 2002, J NEUROPATH EXP NEUR, V61, P673, DOI 10.1093/jnen/61.8.673; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Lin KM, 2001, CIRCULATION, V103, P1787, DOI 10.1161/01.CIR.103.13.1787; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; Lotocki G, 2003, J CEREBR BLOOD F MET, V23, P1129, DOI 10.1097/01.WCB.0000086938.68719.E0; Ma JY, 1998, BRIT J PHARMACOL, V124, P756, DOI 10.1038/sj.bjp.0701871; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Martins LM, 2004, MOL CELL BIOL, V24, P9848, DOI 10.1128/MCB.24.22.9848-9862.2004; Marzo I, 1998, FEBS LETT, V427, P198, DOI 10.1016/S0014-5793(98)00424-4; Matsumori Y, 2005, J CEREBR BLOOD F MET, V25, P899, DOI 10.1038/sj.jcbfm.9600080; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Mattson MP, 2003, TRENDS MOL MED, V9, P196, DOI 10.1016/S1471-4914(03)00046-7; Modjtahedi N, 2006, TRENDS CELL BIOL, V16, P264, DOI 10.1016/j.tcb.2006.03.008; Mondragon L, 2008, J MED CHEM, V51, P521, DOI 10.1021/jm701195j; Morita-Fujimura Y, 1999, J CEREBR BLOOD F MET, V19, P634, DOI 10.1097/00004647-199906000-00006; Morrison RS, 1996, J NEUROSCI, V16, P1337; Mouw G, 2002, METAB BRAIN DIS, V17, P143, DOI 10.1023/A:1019921904378; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Ness JM, 2006, BRAIN RES, V1099, P150, DOI 10.1016/j.brainres.2006.04.132; Okada H, 2002, MOL CELL BIOL, V22, P3509, DOI 10.1128/MCB.22.10.3509-3517.2002; Ota K, 2002, J BIOCHEM, V131, P131, DOI 10.1093/oxfordjournals.jbchem.a003067; Penninger JM, 2003, NAT CELL BIOL, V5, P97, DOI 10.1038/ncb0203-97; Perfettini JL, 2005, TRENDS CELL BIOL, V15, P179, DOI 10.1016/j.tcb.2005.02.005; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Pinton P, 2006, CELL DEATH DIFFER, V13, P1409, DOI 10.1038/sj.cdd.4401960; Pirianov G, 2007, J CEREBR BLOOD F MET, V27, P1022, DOI 10.1038/sj.jcbfm.9600413; Plesnila N, 2004, J CEREBR BLOOD F MET, V24, P458, DOI 10.1097/00004647-200404000-00011; Plesnila N, 2002, EUR SURG RES, V34, P37, DOI 10.1159/000048885; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Pospisilik JA, 2007, CELL, V131, P476, DOI 10.1016/j.cell.2007.08.047; Qin ZH, 2001, J BIOL CHEM, V276, P8079, DOI 10.1074/jbc.M007028200; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Robey RB, 2006, ONCOGENE, V25, P4683, DOI 10.1038/sj.onc.1209595; Rodrigues CMP, 2003, P NATL ACAD SCI USA, V100, P6087, DOI 10.1073/pnas.1031632100; Rodrigues CMP, 2003, BIOCHEMISTRY-US, V42, P3070, DOI 10.1021/bi026979d; Rodrigues TMP, 2002, J CEREBR BLOOD F MET, V22, P463, DOI 10.1097/00004647-200204000-00010; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Ruchalski K, 2006, J BIOL CHEM, V281, P7873, DOI 10.1074/jbc.M513728200; Saito A, 2004, MOL BRAIN RES, V127, P89, DOI 10.1016/j.molbrainres.2004.05.012; Saito A, 2004, STROKE, V35, P1443, DOI 10.1161/01.STR.0000128416.28778.7a; Saito A, 2003, J CEREBR BLOOD F MET, V23, P1010, DOI 10.1097/01.WCB.0000080702.47016.FF; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Scherz-Shouval R, 2007, TRENDS CELL BIOL, V17, P422, DOI 10.1016/j.tcb.2007.07.009; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Schlattner U, 2006, BBA-MOL BASIS DIS, V1762, P164, DOI 10.1016/j.bbadis.2005.09.004; Schulz JB, 1998, CELL DEATH DIFFER, V5, P847, DOI 10.1038/sj.cdd.4400420; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; Shibata M, 2002, NEUROREPORT, V13, P1985, DOI 10.1097/00001756-200210280-00031; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Siegelin MD, 2005, NEUROCHEM INT, V46, P41, DOI 10.1016/j.neuint.2004.07.009; Strauss KM, 2005, HUM MOL GENET, V14, P2099, DOI 10.1093/hmg/ddi215; Sun HW, 2006, SPECTROSC SPECT ANAL, V26, P950; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Tajeddine N, 2008, ONCOGENE, V27, P4221, DOI 10.1038/onc.2008.63; Tamura M, 2005, GLIA, V51, P312, DOI 10.1002/glia.20212; Tehranian R, 2008, J NEUROTRAUM, V25, P755, DOI 10.1089/neu.2007.0441; Trapp T, 2003, MOL CELL NEUROSCI, V23, P302, DOI 10.1016/S1044-7431(03)00013-7; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944; Vande Walle L, 2007, J PROTEOME RES, V6, P1006, DOI 10.1021/pr060510d; Vaux DL, 2003, CELL, V115, P251, DOI 10.1016/S0092-8674(03)00851-1; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Verhagen AM, 2001, GENOME BIOL, V2; Verrier F, 2003, ANN NY ACAD SCI, V1010, P126, DOI 10.1196/annals.1299.022; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Wang XY, 2004, NEUROBIOL DIS, V16, P179, DOI 10.1016/j.nbd.2004.01.014; Weaver JGR, 2005, J CLIN INVEST, V115, P1828, DOI 10.1172/JCI22954; West T, 2006, NEUROBIOL DIS, V22, P523, DOI 10.1016/j.nbd.2005.12.017; Wiessner C, 1999, NEUROSCI LETT, V268, P119, DOI 10.1016/S0304-3940(99)00392-4; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Xu DG, 1999, J NEUROSCI, V19, P5026; Xu DG, 1997, NAT MED, V3, P997, DOI 10.1038/nm0997-997; Yakovlev AG, 2001, J NEUROSCI, V21, P7439, DOI 10.1523/JNEUROSCI.21-19-07439.2001; Yamashita D, 2004, NEUROREPORT, V15, P2719; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Zamzami N, 2005, CELL DEATH DIFFER, V12, P1478, DOI 10.1038/sj.cdd.4401682; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; Zhang JH, 2003, P NATL ACAD SCI USA, V100, P15782, DOI 10.1073/pnas.2636393100; Zhao H, 2003, J NEUROCHEM, V85, P1026, DOI 10.1046/j.1471-4159.2003.01756.x; Zhao YG, 2003, J BIOL CHEM, V278, P2356, DOI 10.1074/jbc.M209681200; Zhu C, 2007, CELL DEATH DIFFER, V14, P775, DOI 10.1038/sj.cdd.4402053; Zhu CL, 2007, J EXP MED, V204, P1741, DOI 10.1084/jem.20070193; Zhu CL, 2003, J NEUROCHEM, V86, P306, DOI 10.1046/j.1471-4159.2003.01832.x; Zoratti M, 2005, BBA-BIOENERGETICS, V1706, P40, DOI 10.1016/j.bbabio.2004.10.006	178	90	101	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0005-2728	0006-3002		BBA-BIOENERGETICS	Biochim. Biophys. Acta-Bioenerg.	MAY	2009	1787	5			SI		402	413		10.1016/j.bbabio.2008.09.006			12	Biochemistry & Molecular Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Biophysics	451MX	WOS:000266475400016	18848916	Bronze			2022-02-06	
J	Appelberg, KS; Hovda, DA; Prins, ML				Appelberg, K. Sofia; Hovda, David A.; Prins, Mayumi L.			The Effects of a Ketogenic Diet on Behavioral Outcome after Controlled Cortical Impact Injury in the Juvenile and Adult Rat	JOURNAL OF NEUROTRAUMA			English	Article						behavior; ketone metabolism; Morris water maze; traumatic brain injury	TRAUMATIC BRAIN-INJURY; KETONE-BODY UTILIZATION; OXYGEN SPECIES PRODUCTION; BETA-HYDROXYBUTYRATE; GLUCOSE-UTILIZATION; METABOLISM; BODIES; CORTEX; ENZYMES; MCT1	The ketogenic diet has been shown to have unique properties that make it a more suitable cerebral fuel under various neuropathological conditions (e.g., starvation, ischemia, and traumatic brain injury (TBI). Recently, age-dependent ketogenic neuroprotection was shown among postnatal day 35 (PND35) and PND45 rats after TBI, but not in PND17 and PND65 animals (Prins et al., 2005). The present study addresses the therapeutic potential of a ketogenic diet on motor and cognitive deficits after TBI. PND35 and PND75 rats received sham or controlled cortical impact (CCI) surgery and were placed on either standard (Std) or ketogenic (KG) diet for 7 days. Beam walking and the Morris water maze (MWM) were used to assess sensory motor function and cognition, respectively. PND35 CCI Std animals showed significantly longer traverse times than sham and CCI KG animals at the beginning of motor training. Footslip analysis revealed better performance among the sham and the CCI KG animals compared to the CCI Std group. In the MWM PND35 CCI KG animals showed significantly shorter escape latencies compared to CCI Std-fed animals. During the same time period there was no significant difference between sham animals and CCI KG animals. The therapeutic effect of the ketogenic diet on beam walking and cognitive performance was not observed in PND75 animals. This finding supports our theory about age-dependent utilization and effectiveness of ketones as an alternative fuel after TBI.	[Appelberg, K. Sofia; Hovda, David A.; Prins, Mayumi L.] Univ Calif Los Angeles, Dept Neurosurg, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Hovda, David A.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, David Geffen Sch Med, Los Angeles, CA 90095 USA		Prins, ML (corresponding author), Univ Calif Los Angeles, Dept Neurosurg, David Geffen Sch Med, Room NPI 18-228,Box 957039, Los Angeles, CA 90095 USA.	mprins@mednet.ucla.edu	Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739	UCLA Brain Injury Research Center;  [NS052406]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052406] Funding Source: NIH RePORTER	This work was supported by NS052406 and the UCLA Brain Injury Research Center.	Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; BOOTH RFG, 1980, J NEUROCHEM, V34, P17, DOI 10.1111/j.1471-4159.1980.tb04616.x; CREMER JE, 1976, BIOCHIM BIOPHYS ACTA, V448, P633, DOI 10.1016/0005-2736(76)90120-6; DAHLQUIST G, 1976, PEDIATR RES, V10, P910, DOI 10.1203/00006450-197611000-00002; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Gerhart DZ, 1997, AM J PHYSIOL-ENDOC M, V273, pE207, DOI 10.1152/ajpendo.1997.273.1.E207; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Hasselbalch SG, 1996, AM J PHYSIOL-ENDOC M, V270, pE746, DOI 10.1152/ajpendo.1996.270.5.E746; HAWKINS RA, 1971, BIOCHEM J, V122, P13, DOI 10.1042/bj1220013; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; KASHIWAYA Y, 1994, J BIOL CHEM, V269, P25502; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; Leino RL, 2001, NEUROCHEM INT, V38, P519, DOI 10.1016/S0197-0186(00)00102-9; Leino RL, 1999, DEV BRAIN RES, V113, P47, DOI 10.1016/S0165-3806(98)00188-6; LOCKWOOD EA, 1971, BIOCHEM J, V124, P249, DOI 10.1042/bj1240249; Lust WD, 2003, METAB BRAIN DIS, V18, P195, DOI 10.1023/A:1025503115837; Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065; MARIE C, 1990, METAB BRAIN DIS, V5, P65, DOI 10.1007/BF01001047; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Massieu L, 2003, NEUROSCIENCE, V120, P365, DOI 10.1016/S0306-4522(03)00266-5; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Murphy P, 2006, EXP NEUROL, V201, P84, DOI 10.1016/j.expneurol.2006.03.024; NEHLIG A, 1991, NEUROSCIENCE, V40, P871, DOI 10.1016/0306-4522(91)90018-J; NEHLIG A, 1987, NEUROCHEM RES, V12, P641, DOI 10.1007/BF00971014; OWEN OE, 1967, J CLIN INVEST, V46, P1589, DOI 10.1172/JCI105650; PAGE MA, 1971, BIOCHEM J, V121, P49, DOI 10.1042/bj1210049; Piot-Grosjean O, 2001, NEUROBIOL DIS, V8, P1082, DOI 10.1006/nbdi.2001.0450; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Prins M, 2007, J NEUROTRAUM, V24, P1267; Prins ML, 2008, J CEREBR BLOOD F MET, V28, P1, DOI 10.1038/sj.jcbfm.9600543; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Rho JM, 1999, EPILEPSY RES, V37, P233, DOI 10.1016/S0920-1211(99)00068-6; ROBERTSON C, 1992, STROKE, V23, P564, DOI 10.1161/01.STR.23.4.564; SATO K, 1995, FASEB J, V9, P651, DOI 10.1096/fasebj.9.8.7768357; SAUDUBRAY JM, 1981, J PEDIATR-US, V98, P904, DOI 10.1016/S0022-3476(81)80583-5; SOKOLOFF L, 1973, ANNU REV MED, V24, P271, DOI 10.1146/annurev.me.24.020173.001415; Statler KD, 2006, BRAIN RES, V1076, P216, DOI 10.1016/j.brainres.2005.12.106; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; SUTTON RL, 1994, ACTA NEUROCHIR, P446; SUTTON RL, 1989, BEHAV NEUROSCI, V103, P837, DOI 10.1037/0735-7044.103.4.837; Suzuki M, 2001, JPN J PHARMACOL, V87, P143, DOI 10.1254/jjp.87.143; Vannucci RC, 2000, SEMIN PERINATOL, V24, P107, DOI 10.1053/sp.2000.6361; Vannucci SJ, 2003, AM J PHYSIOL-ENDOC M, V285, pE1127, DOI 10.1152/ajpendo.00187.2003; Veech RL, 2001, IUBMB LIFE, V51, P241; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhao Q, 2004, PEDIATR RES, V55, P498, DOI 10.1203/01.PDR.0000112032.47575.D1; Ziegler DR, 2005, PHYSIOL BEHAV, V84, P421, DOI 10.1016/j.physbeh.2005.01.003; Ziegler DR, 2003, NEUROCHEM RES, V28, P1793, DOI 10.1023/A:1026107405399	53	90	90	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2009	26	4					497	506		10.1089/neu.2008.0664			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	430OV	WOS:000264999300003	19231995	Green Published			2022-02-06	
J	Froelich, M; Ni, QH; Wess, C; Ougorets, I; Hartl, R				Froelich, Matteus; Ni, Quanhong; Wess, Christian; Ougorets, Igor; Hartl, Roger			Continuous hypertonic saline therapy and the occurrence of complications in neurocritically ill patients	CRITICAL CARE MEDICINE			English	Article						hypertonic saline; intracranial pressure; deep vein thrombosis; hypernatremia; sodium; intensive care; complications; renal failure; renal dysfunction; neurosurgery; deep vein thrombosis; treatment; traumatic brain injury; traumatic brain injury	POSTTRAUMATIC INTRACRANIAL HYPERTENSION; DURAL SINUS THROMBOSIS; TRAUMATIC BRAIN INJURY; INTENSIVE-CARE-UNIT; CEREBRAL-BLOOD-FLOW; SODIUM-CHLORIDE; HEMORRHAGIC-SHOCK; RENAL-FAILURE; HEAD-INJURY; MANNITOL	Objective: To evaluate potential side effects of continuous hypertonic 3% saline (CHS) as maintenance fluid in patients with brain injury. Methods: Retrospective chart analysis of prospectively collected data. Patients. Patients admitted to the neurosurgical Intensive care unit for >4 days with traumatic brain injury, stroke, or subarachnoid hemorrhage with a Glasgow Coma Scale <9 and elevated intracranial pressure (ICP) or at risk of developing elevated ICP were included. Based on physician preference, one group was treated with 3% CHS at a rate of 1.5 mL/kg/bw as maintenance fluid. The other group received 0.9% normal saline (NS). Two percent saline was used in the CHS group to wean patients off 3% CHS or when sodium was above 155. Data on serum sodium, blood urea nitrogen, creatinine, ICP, infection rate, length of stay, rates of deep vein thrombosis, and pulmonary emboli and dural thrombosis were collected prospectively. Results: One hundred seven patients in the CHS group and 80 in the NS group met the inclusion criteria. The incidence of moderate hypernatremia (Na >155 mmol/L) and severe hypernatremia (Na >160 mmol/L) was significantly higher in the CHS therapy group than in the NS group. No significant relationship between CHS infusion and renal dysfunction was found. Moderate and severe hypernatremia was associated with a higher risk of elevated blood urea nitrogen and creatinine levels. Acute renal failure was not seen in these patients. A total of 53.3% in the CHS group and in 16.3% in the NS group (p < 0.0001) had raised ICP (>25 mm Hg), consistent with the physicians decision to use CHS in patients with elevated ICP. Conclusions. CHS therapy was not associated with an increased rate of infection, deep vein thrombosis, or renal failure. However, there was a significant risk of developing hypernatremia. We conclude that CHS administration in patients with severe injuries is safe as long as sodium levels are carefully monitored. (Crit Care Med 2009; 37:1433-1441)	[Froelich, Matteus] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Froelich, Matteus; Wess, Christian; Ougorets, Igor; Hartl, Roger] Karolinska Inst, Div Clin CNS Res, Neurosurg Sect, Stockholm, Sweden; [Froelich, Matteus; Wess, Christian; Ougorets, Igor; Hartl, Roger] New York Presbyterian Hosp, Dept Neurol Surg, Weill Cornell Med Coll, New York, NY USA; [Ni, Quanhong] New York Presbyterian Hosp, Dept Publ Hlth, Weill Cornell Med Coll, New York, NY USA		Hartl, R (corresponding author), Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.	roger@hartlmd.net					Abbott R, 2005, BRIT MED J, V331, P829, DOI 10.1136/bmj.331.7520.829; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS40; Aiyagari V, 2006, J CRIT CARE, V21, P163, DOI 10.1016/j.jcrc.2005.10.002; [Anonymous], 2007, J NEUROTRAUMA S1, V24, pS14; Bergada I, 2004, HORM RES, V61, P108, DOI 10.1159/000075374; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; BICKELL WH, 1991, SURGERY, V110, P529; Bulger EM, 2007, ANN SURG, V245, P635, DOI 10.1097/01.sla.0000251367.44890.ae; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; Coimbra R, 1997, J TRAUMA, V42, P602, DOI 10.1097/00005373-199704000-00004; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Detry O, 2006, WORLD J GASTROENTERO, V12, P7405, DOI 10.3748/wjg.v12.i46.7405; Di Cera E, 2003, CHEST, V124, p11S, DOI 10.1378/chest.124.3_suppl.11S; Dziedzic T, 2003, CLIN NEUROL NEUROSUR, V105, P87, DOI 10.1016/S0303-8467(02)00106-3; FINBERG L, 1963, JAMA-J AM MED ASSOC, V184, P187, DOI 10.1001/jama.1963.03700160063009; Gemma M, 1997, J NEUROSURG ANESTH, V9, P329, DOI 10.1097/00008506-199710000-00007; GERBER JG, 1979, AM J PHYSIOL, V237, pF441, DOI 10.1152/ajprenal.1979.237.6.F441; GOLDMAN JA, 1972, AM J OBSTET GYNECOL, V112, P1132, DOI 10.1016/0002-9378(72)90193-7; Gondim FDA, 2005, J NEUROSURG, V103, P444; GRANT PJ, 1985, THROMB RES, V40, P393, DOI 10.1016/0049-3848(85)90274-9; GROSS D, 1989, J TRAUMA, V29, P79, DOI 10.1097/00005373-198901000-00016; Hartl R, 1997, ACT NEUR S, V70, P126; Hartl R, 1997, J TRAUMA, V42, pS41, DOI 10.1097/00005373-199705001-00008; HARTL R, 1995, SHOCK, V3, P274; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; Hartl Roger, 2004, Curr Neurol Neurosci Rep, V4, P481, DOI 10.1007/s11910-004-0073-x; Heit JA, 2000, ARCH INTERN MED, V160, P809, DOI 10.1001/archinte.160.6.809; Himmelseher S, 2007, CURR OPIN ANESTHESIO, V20, P414, DOI 10.1097/ACO.0b013e3282eff9ea; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; HUANG PP, 1995, ANN SURG, V221, P543, DOI 10.1097/00000658-199505000-00012; Huang SJ, 2006, SURG NEUROL, V65, P539, DOI 10.1016/j.surneu.2005.11.019; HUDAK ML, 1989, AM J PHYSIOL, V257, pH912, DOI 10.1152/ajpheart.1989.257.3.H912; Junger WG, 1998, J CLIN INVEST, V101, P2768, DOI 10.1172/JCI1354; Kamijo Y, 2003, J TOXICOL-CLIN TOXIC, V41, P359, DOI 10.1081/CLT-120022003; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; KRAUSZ MM, 1992, ARCH SURG-CHICAGO, V127, P93; Kuroda T, 1997, BURNS, V23, P338, DOI 10.1016/S0305-4179(96)00134-9; Laureno R, 1997, ANN INTERN MED, V126, P57, DOI 10.7326/0003-4819-126-1-199701010-00008; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; Munar F, 2000, J NEUROTRAUM, V17, P41, DOI 10.1089/neu.2000.17.41; Murphy N, 2004, HEPATOLOGY, V39, P464, DOI 10.1002/hep.20056; Ng KFJ, 2002, BRIT J ANAESTH, V88, P475, DOI 10.1093/bja/88.4.475; Palevsky PM, 1996, ANN INTERN MED, V124, P197, DOI 10.7326/0003-4819-124-2-199601150-00002; Perez-Perez AJ, 2002, AM J NEPHROL, V22, P573, DOI 10.1159/000065279; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Pinto FCG, 2006, J TRAUMA, V60, P758, DOI 10.1097/01.ta.0000214581.89316.73; Polderman KH, 1999, CRIT CARE MED, V27, P1105, DOI 10.1097/00003246-199906000-00029; PRIEN T, 1993, ZBL CHIR, V118, P257; PRIEN T, 1993, ZENTRALBL CHIR, V118, P264; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Qureshi AI, 2002, NEUROSURGERY, V50, P749, DOI 10.1097/00006123-200204000-00012; Qureshi AI, 1998, J NEUROSURG ANESTH, V10, P188, DOI 10.1097/00008506-199807000-00010; Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032; Raghavan M, 2006, NEUROCRIT CARE, V4, P179, DOI 10.1385/NCC:4:2:179; REED RL, 1991, J TRAUMA, V31, P8, DOI 10.1097/00005373-199101000-00002; Ruttmann TG, 1998, BRIT J ANAESTH, V80, P612, DOI 10.1093/bja/80.5.612; Ruttmann TG, 1996, BRIT J ANAESTH, V76, P412, DOI 10.1093/bja/76.3.412; Schwarz S, 1998, STROKE, V29, P1550, DOI 10.1161/01.STR.29.8.1550; Schwarz S, 2002, STROKE, V33, P136, DOI 10.1161/hs0102.100877; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; SHACKFORD SR, 1994, J TRAUMA, V37, P899, DOI 10.1097/00005373-199412000-00005; Suarez JI, 1999, J NEUROSURG ANESTH, V11, P178, DOI 10.1097/00008506-199907000-00004; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; Takefuji S, 2007, EXP NEUROL, V204, P88, DOI 10.1016/j.expneurol.2006.09.025; Tseng MY, 2007, J NEUROSURG, V107, P274, DOI 10.3171/JNS-07/08/0274; Tyagi R, 2007, NEUROSURG REV, V30, P277, DOI 10.1007/s10143-007-0091-7; Valadka AB, 2000, CRIT CARE MED, V28, P1245, DOI 10.1097/00003246-200004000-00069; VASSAR MJ, 1993, J TRAUMA, V34, P622, DOI 10.1097/00005373-199305000-00003; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Vikrant Sanjay, 2007, Clin Exp Nephrol, V11, P88, DOI 10.1007/s10157-006-0449-0; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; Wilder DM, 2002, THROMB RES, V107, P255, DOI 10.1016/S0049-3848(02)00335-3	76	90	94	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2009	37	4					1433	1441		10.1097/CCM.0b013e31819c1933			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	426HQ	WOS:000264699000036	19242317				2022-02-06	
J	Sumowski, JF; Chiaravalloti, N; DeLuca, J				Sumowski, James F.; Chiaravalloti, Nancy; DeLuca, John			Cognitive reserve protects against cognitive dysfunction in multiple sclerosis	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Multiple sclerosis; Cognitive reserve; Intelligence; Processing speed; Memory; Cognition	RELAPSING-REMITTING MS; INFORMATION-PROCESSING EFFICIENCY; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; NEUROPSYCHOLOGICAL IMPAIRMENT; MEMORY; EDUCATION; ATROPHY; RISK; PERFORMANCE	Cognitive reserve theory helps to explain the neuropsychological expression of neurologic disease (e. g., Alzheimer's disease; Stern, 2006). Multiple sclerosis (MS) is a neurologic disease characterized by information processing inefficiency and verbal learning and memory deficits. The current study is the first to investigate whether higher cognitive reserve moderates the relationship between MS and cognitive functioning. A word-reading proxy of premorbid intelligence was used to estimate cognitive reserve for 58 persons with MS and 43 healthy controls. Dependent measures of simple processing efficiency, complex information processing efficiency, and verbal learning and memory were administered. There were significant Group x Cognitive Reserve interactions for complex information processing efficiency and verbal learning and memory, such that persons with MS demonstrated deficits relative to controls at lower, but not higher, levels of reserve. No such interaction was found for simple processing efficiency. The protective influence of higher cognitive reserve against disease-related cognitive deficits is discussed.	[Sumowski, James F.; Chiaravalloti, Nancy; DeLuca, John] Neuropsychol & Neurosci Lab, Kessler Fdn Res Ctr, W Orange, NJ 07052 USA; [Sumowski, James F.; Chiaravalloti, Nancy; DeLuca, John] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; [DeLuca, John] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ 07103 USA		Sumowski, JF (corresponding author), Neuropsychol & Neurosci Lab, Kessler Fdn Res Ctr, 300 Execut Dr,Suite 010, W Orange, NJ 07052 USA.	jsumowski@kesslerfoundation.net		Chiaravalloti, Nancy/0000-0003-2943-7567	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 HD07522 and RO1 HD38249]; Sclerosis Society [MB0003]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD038249] Funding Source: NIH RePORTER	This project was supported by National Institutes of Health (NIH) Grants RO1 HD07522 and RO1 HD38249, as well as a MB0003 fellowship training grant from the National Multiple Sclerosis Society.	Alexander GE, 1997, AM J PSYCHIAT, V154, P165; [Anonymous], 1993, NEUROPSYCHOLOGY, V7, P364, DOI [DOI 10.1037/0894-4105.7.3.364, 10.1037/0894-4105.7.3.364]; Archibald CJ, 2000, J CLIN EXP NEUROPSYC, V22, P686, DOI 10.1076/1380-3395(200010)22:5;1-9;FT686; Ball JD, 2007, CLIN NEUROPSYCHOL, V21, P422, DOI 10.1080/13854040600582577; Basso MR, 2000, J CLIN EXP NEUROPSYC, V22, P208, DOI 10.1076/1380-3395(200004)22:2;1-1;FT208; Beatty WW, 1995, J NEUROL REHABIL, V9, P167; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Benedict RHB, 2007, MULT SCLER, V13, P722, DOI 10.1177/1352458507075592; Benedict RHB, 2007, SEMIN NEUROL, V27, P78, DOI 10.1055/s-2006-956758; Benedict RHB, 2006, ARCH NEUROL-CHICAGO, V63, P1301, DOI 10.1001/archneur.63.9.1301; Benedict RHB, 2004, ARCH NEUROL-CHICAGO, V61, P226, DOI 10.1001/archneur.61.2.226; Benedict RHB, 2002, CLIN NEUROPSYCHOL, V16, P381, DOI 10.1076/clin.16.3.381.13859; Bennett DA, 2003, NEUROLOGY, V60, P1909, DOI 10.1212/01.WNL.0000069923.64550.9F; Bermel RA, 2006, LANCET NEUROL, V5, P158, DOI 10.1016/S1474-4422(06)70349-0; Bleecker ML, 2007, NEUROLOGY, V69, P470, DOI 10.1212/01.wnl.0000266628.43760.8c; Bobholz JA, 2006, NEUROLOGY, V67, P1640, DOI 10.1212/01.wnl.0000242885.71725.76; Bobholz JA, 2003, CURR OPIN NEUROL, V16, P283, DOI 10.1097/00019052-200306000-00006; Bonnet MC, 2006, J NEUROL SCI, V251, P23, DOI 10.1016/j.jns.2006.08.002; Chiaravalloti ND, 2003, J CLIN EXP NEUROPSYC, V25, P489, DOI 10.1076/jcen.25.4.489.13878; CRYSTAL H, 1988, NEUROLOGY, V38, P1682, DOI 10.1212/WNL.38.11.1682; Cutter GR, 1999, BRAIN, V122, P871, DOI 10.1093/brain/122.5.871; DeLuca J, 1998, J CLIN EXP NEUROPSYC, V20, P376, DOI 10.1076/jcen.20.3.376.819; DELUCA J, 1993, ARCH NEUROL-CHICAGO, V50, P301, DOI 10.1001/archneur.1993.00540030065016; DELUCA J, 1994, J CLIN EXP NEUROPSYC, V16, P183, DOI 10.1080/01688639408402629; DeLuca J., 2008, INFORM PROCESSING SP; Dufouil C, 2003, NEUROLOGY, V60, P831, DOI 10.1212/01.WNL.0000049456.33231.96; Elkins JS, 2006, NEUROLOGY, V67, P435, DOI 10.1212/01.wnl.0000228246.89109.98; Farmer JE, 2002, DEV NEUROPSYCHOL, V22, P455, DOI 10.1207/S15326942DN2202_2; Feinstein A, 2006, J NEUROL SCI, V245, P63, DOI 10.1016/j.jns.2005.08.020; GOLDSTEIN FC, 1992, ARCH NEUROL-CHICAGO, V49, P1060, DOI 10.1001/archneur.1992.00530340080021; Goverover Y, 2007, MULT SCLER, V13, P636, DOI 10.1177/1352458506072984; Grabner RH, 2006, BRAIN RES BULL, V69, P422, DOI 10.1016/j.brainresbull.2006.02.009; Grabner RH, 2007, NEUROIMAGE, V38, P346, DOI 10.1016/j.neuroimage.2007.07.041; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HAUSER SL, 1983, NEW ENGL J MED, V308, P173, DOI 10.1056/NEJM198301273080401; Hohol MJ, 1997, ARCH NEUROL-CHICAGO, V54, P1018, DOI 10.1001/archneur.1997.00550200074013; Iezzoni LI, 2007, MULT SCLER J, V13, P534, DOI 10.1177/1352458506071356; KATZMAN R, 1988, ANN NEUROL, V23, P138, DOI 10.1002/ana.410230206; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; KESSLER HR, 1992, INT J NEUROSCI, V62, P17, DOI 10.3109/00207459108999754; Korneck B, 2003, BRAIN RES BULL, V61, P321, DOI 10.1016/S0361-9230(03)00095-9; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lazeron RHC, 2005, MULT SCLER J, V11, P524, DOI 10.1191/1352458505ms1201oa; Lengenfelder J, 2006, ARCH CLIN NEUROPSYCH, V21, P229, DOI 10.1016/j.acn.2005.12.001; Lopez OL, 2003, ARCH NEUROL-CHICAGO, V60, P1394, DOI 10.1001/archneur.60.10.1394; Nyenhuis D L, 1995, J Int Neuropsychol Soc, V1, P291; O'Brien A, 2007, ARCH CLIN NEUROPSYCH, V22, P933, DOI 10.1016/j.acn.2007.07.002; Parmenter BA, 2007, MULT SCLER J, V13, P52, DOI 10.1177/1352458506070750; PEYSER JM, 1990, ARCH NEUROL-CHICAGO, V47, P94, DOI 10.1001/archneur.1990.00530010120030; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Price JL, 1999, ANN NEUROL, V45, P358, DOI 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; RAO SM, 1991, NEUROLOGY, V41, P692, DOI 10.1212/WNL.41.5.692; Richards M, 2003, J CLIN EXP NEUROPSYC, V25, P614, DOI 10.1076/jcen.25.5.614.14581; Rosti E, 2007, J INT NEUROPSYCH SOC, V13, P791, DOI 10.1017/S1355617707071019; Rosti E, 2007, APPL NEUROPSYCHOL, V14, P101, DOI 10.1080/09084280701319938; Sanfilipo MP, 2006, NEUROLOGY, V66, P685, DOI 10.1212/01.wnl.0000201238.93586.d9; SATZ P, 1993, J ACQ IMMUN DEF SYND, V6, P503; Scarmeas N, 2001, NEUROLOGY, V57, P2236, DOI 10.1212/WNL.57.12.2236; Sepulcre J, 2006, MULT SCLER J, V12, P187, DOI 10.1191/1352458506ms1258oa; Siegert RJ, 2005, J NEUROL NEUROSUR PS, V76, P469, DOI 10.1136/jnnp.2004.054635; Simon JH, 1999, NEUROLOGY, V53, P139, DOI 10.1212/WNL.53.1.139; Smith A., 1982, SYMBOL DIGIT MODALIT; STERN Y, 1992, ANN NEUROL, V32, P371, DOI 10.1002/ana.410320311; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Stern Y, 2006, ALZ DIS ASSOC DIS, V20, pS69, DOI 10.1097/00002093-200607001-00010; Stevens J.P, 2009, APPL MULTIVARIATE ST; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Thornton AE, 1997, NEUROPSYCHOLOGY, V11, P357, DOI 10.1037/0894-4105.11.3.357; Tombaugh TN, 2006, ARCH CLIN NEUROPSYCH, V21, P53, DOI 10.1016/j.acn.2005.07.006; US Census Bureau, 2006, AM COMM SURV PERC PE; Verghese J, 2003, NEW ENGL J MED, V348, P2508, DOI 10.1056/NEJMoa022252; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; Wilkinson G.S., 1993, WIDE RANGE ACHIEVEME; Wilson RS, 2002, JAMA-J AM MED ASSOC, V287, P742, DOI 10.1001/jama.287.6.742	77	90	90	1	11	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2009	31	8					913	926		10.1080/13803390902740643			14	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	520GT	WOS:000271830800002	19330566				2022-02-06	
J	Cloots, RJH; Gervaise, HMT; van Dommelen, JAW; Geers, MGD				Cloots, R. J. H.; Gervaise, H. M. T.; van Dommelen, J. A. W.; Geers, M. G. D.			Biomechanics of traumatic brain injury: Influences of the morphologic heterogeneities of the cerebral cortex	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						traumatic brain injury; brain tissue; cerebrum; cerebral cortex; inhomogeneities; finite element model	DIFFUSE AXONAL INJURY; MECHANICAL-BEHAVIOR; DYNAMIC-RESPONSE; WHITE-MATTER; HEAD; MODEL; STRETCH; TISSUE; ACCELERATION; DAMAGE	Traumatic brain injury (TBI) can be caused by accidents and often leads to permanent health issues or even death. Brain injury criteria are used for assessing the probability of TBI, if a certain mechanical load is applied. The currently used injury criteria in the automotive industry are based on global head kinematics. New methods, based on finite element modeling, use brain injury criteria at lower scale levels, e.g., tissue-based injury criteria. However, most current computational head models lack the anatomical details of the cerebrum. To investigate the influence of the morphologic heterogeneities of the cerebral cortex, a numerical model of a representative part of the cerebral cortex with a detailed geometry has been developed. Several different geometries containing gyri and sulci have been developed for this model. Also, a homogeneous geometry has been made to analyze the relative importance of the heterogeneities. The loading conditions are based on a computational head model simulation. The results of this model indicate that the heterogeneities have an influence on the equivalent stress. The maximum equivalent stress in the heterogeneous models is increased by a factor of about 1.3-1.9 with respect to the homogeneous model, whereas the mean equivalent stress is increased by at most 10%. This implies that tissue-based injury criteria may not be accurately applied to most computational head models used nowadays, which do not account for sulci and gyri.	[Cloots, R. J. H.; Gervaise, H. M. T.; van Dommelen, J. A. W.; Geers, M. G. D.] Eindhoven Univ Technol, Mat Technol Inst, NL-5600 MB Eindhoven, Netherlands		Cloots, RJH (corresponding author), Eindhoven Univ Technol, Mat Technol Inst, POB 513, NL-5600 MB Eindhoven, Netherlands.	r.j.h.cloots@tue.nl	Geers, Marc G.D./E-4385-2014	Geers, Marc G.D./0000-0002-0009-6351			Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Al-Bsharat A. S., 1999, STAPP CAR CRASH J, V43, P321; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; Bradshaw DRS, 2001, J BIOMECH, V34, P85, DOI 10.1016/S0021-9290(00)00135-4; Brands Dave W A, 2002, Stapp Car Crash J, V46, P103; CLAESSENS M, 1997, STAPP CAR CRASH J, V41, P315; Cotter CS, 2002, INT J NUMER METH FL, V40, P303, DOI 10.1002/fld.287; DIMASI FP, 1995, STAPP CAR CRASH C P, V39; Engel DC, 2005, NEUROPHARMACOLOGY, V49, P985, DOI 10.1016/j.neuropharm.2005.05.021; Floyd CL, 2005, GLIA, V51, P35, DOI 10.1002/glia.20183; Garo A, 2007, BIORHEOLOGY, V44, P51; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Goldsmith Werner, 2005, Critical Reviews in Biomedical Engineering, V33, P105, DOI 10.1615/CritRevBiomedEng.v33.i2.20; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; Henn H.W., 1998, TEACH MATH APPL, V17, P162, DOI 10.1093/teamat/17.4.162.; Ho J, 2007, J BIOMECH, V40, P3006, DOI 10.1016/j.jbiomech.2007.02.011; Hrapko M, 2006, BIORHEOLOGY, V43, P623; HRAPKO M, 2007, P IRCOBI C ZUR SWITZ, P143; Jin Xin, 2006, Stapp Car Crash J, V50, P637; King AI, 2000, ANNU REV BIOMED ENG, V2, P55, DOI 10.1146/annurev.bioeng.2.1.55; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kouznetsova V, 2001, COMPUT MECH, V27, P37, DOI 10.1007/s004660000212; LAURET C, EXPT SETUP OPT UNPUB; LEONOV AI, 1976, RHEOL ACTA, V15, P85, DOI 10.1007/BF01517499; Lind NM, 2007, NEUROSCI BIOBEHAV R, V31, P728, DOI 10.1016/j.neubiorev.2007.02.003; Mai JK, 1997, ATLAS HUMAN BRAIN; MAO H, 2006, STAPP CAR CRASH C P, V50; Miller R.T., 1998, STAPP CAR CRASH J, P155; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison Barclay 3rd, 2003, Stapp Car Crash J, V47, P93; Nishimoto T, 2000, JSAE REV, V21, P117, DOI 10.1016/S0389-4304(99)00079-X; Nolte J., 2002, HUMAN BRAIN INTRO IT; OMMAYA AK, 1994, INT J IMPACT ENG, V15, P535, DOI 10.1016/0734-743X(94)80033-6; Peters GWM, 1997, J NON-NEWTON FLUID, V68, P205, DOI 10.1016/S0377-0257(96)01511-X; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Raul JS, 2006, INT J LEGAL MED, V120, P212, DOI 10.1007/s00414-005-0018-1; Shen F, 2006, J BIOMECH ENG-T ASME, V128, P797, DOI 10.1115/1.2264393; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Takhounts Erik G, 2003, Stapp Car Crash J, V47, P107; Versace J, 1971, SAE TECHNICAL PAPER, DOI [10.4271/710881, DOI 10.4271/710881]; WELKER W, 2007, COMP MAMMALIAN BRAIN; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; WOOD JL, 1971, J BIOMECH, V4, P1, DOI 10.1016/0021-9290(71)90010-8; Zhou C, 1995, P STAPP CAR CRASH J, V39, P121, DOI DOI 10.4271/952714; [No title captured]	47	90	91	0	14	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JUL	2008	36	7					1203	1215		10.1007/s10439-008-9510-3			13	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	307KQ	WOS:000256318200011	18465248	hybrid, Green Published			2022-02-06	
J	Belli, A; Sen, J; Petzold, A; Russo, S; Kitchen, N; Smith, M				Belli, A.; Sen, J.; Petzold, A.; Russo, S.; Kitchen, N.; Smith, M.			Metabolic failure precedes intracranial pressure rises in traumatic brain injury: a microdialysis study	ACTA NEUROCHIRURGICA			English	Article						glutamate; glycerol; ICP; lactate; pyruvate ratio; microdialysis; traumatic brain injury	SEVERE HEAD-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; MEMBRANE PHOSPHOLIPID DEGRADATION; POSITRON-EMISSION-TOMOGRAPHY; INTRACEREBRAL MICRODIALYSIS; MITOCHONDRIAL DYSFUNCTION; CEREBRAL METABOLISM; N-ACETYLASPARTATE; SUBSTRATE DELIVERY; ENERGY-METABOLISM	Background: Cerebral microdialysis (MD) is able to detect markers of tissue damage and cerebral ischaemia and can be used to monitor the biochemical changes subsequent to head injury. In this prospective, observational study we analysed the correlation between microdialysis markers of metabolic impairment and intracranial pressure (ICP) and investigated whether changes in biomarker concentration precede rises in ICP. Methods: MD and ICP monitoring was carried out in twenty-five patients with severe TBI in Neurointensive care. MD samples were analysed hourly for lactate:pyruvate (LP) ratio, glutamate and glycerol. Abnormal values of microdialysis variables in presence of normal ICP were used to calculate the risk of intracranial hypertension developing within the next 3h. Findings: An LP ratio > 25 and glycerol > 100 mu mol/L, but not glutamate > 12 mu mol/L, were associated with significantly higher risk of imminent intracranial hypertension (odds ratio: 9.8, CI 5.8-16.1; 2.2, CI 1.6-3.8; 1.7, CI 0.6-3, respectively). An abnormal LP ratio could predict an ICP rise above normal levels in 89% of cases, whereas glycerol and glutamate had a poorer predictive value. Conclusions: Changes in the compound concentrations in microdialysate are a useful tool to describe molecular events triggered by TBI. These changes can occur before the onset of intracranial hypertension, suggesting that biochemical impairment can be present before low cerebral perfusion pressure is detectable. This early warning could be exploited to expand the window for therapeutic intervention.	[Belli, A.] Southampton Univ Hosp, Div Clin Neurosci, Southampton SO16 6YD, Hants, England; [Sen, J.; Russo, S.; Kitchen, N.] UCL Natl Hosp Neurol & Neurosurg, Victor Horsley Dept Neurosurg, London WC1N 3BG, England; [Smith, M.] UCL Natl Hosp Neurol & Neurosurg, Dept Neuroanaesthesia, London WC1N 3BG, England; [Petzold, A.] Inst Neurol, Dept Neuroimmunol, London WC1N 3BG, England		Belli, A (corresponding author), Southampton Univ Hosp, Div Clin Neurosci, Tremona Rd, Southampton SO16 6YD, Hants, England.	a.belli@soton.ac.uk	Petzold, Axel/C-1090-2009; Smith, Martin/B-2616-2009; Belli, Antonio/I-3799-2015	Petzold, Axel/0000-0002-0344-9749; Belli, Antonio/0000-0002-3211-9933	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0701458] Funding Source: Medline		Belli A, 2006, J NEUROCHEM, V96, P861, DOI 10.1111/j.1471-4159.2005.03602.x; Budd SL, 1996, J NEUROCHEM, V67, P2282; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Clausen T, 2005, J NEUROSURG, V103, P233, DOI 10.3171/jns.2005.103.2.0233; Dohmen C, 2005, BRAIN RES, V1037, P43, DOI 10.1016/j.brainres.2004.12.046; Fiskum G, 2004, J NEUROSURG ANESTH, V16, P108, DOI 10.1097/00008506-200401000-00025; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; HILLERED L, 1983, J CEREBR BLOOD F MET, V3, P207, DOI 10.1038/jcbfm.1983.28; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; HILLERED L, 1985, J CEREBR BLOOD F MET, V5, P259, DOI 10.1038/jcbfm.1985.33; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Hutchinson PJA, 2000, ACT NEUR S, V76, P431; Johnston Andrew J, 2002, Curr Opin Crit Care, V8, P121, DOI 10.1097/00075198-200204000-00006; Kim H, 1996, STROKE, V27, P114, DOI 10.1161/01.STR.27.1.114; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Murphy PS, 1999, MAGNET RESON MED, V42, P1155, DOI 10.1002/(SICI)1522-2594(199912)42:6<1155::AID-MRM21>3.0.CO;2-N; Nilsson OG, 1999, NEUROSURGERY, V45, P1176, DOI 10.1097/00006123-199911000-00032; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; REHNCRONA S, 1979, STROKE, V10, P437, DOI 10.1161/01.STR.10.4.437; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Robertson CS, 1998, NEUROL RES, V20, pS91; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Schinder AF, 1996, J NEUROSCI, V16, P6125; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Skjoth-Rasmussen J, 2004, J NEUROSURG, V100, P8, DOI 10.3171/jns.2004.100.1.0008; Smith AB, 2003, ORG LETT, V5, P1, DOI 10.1021/ol0202520; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; White RJ, 1996, J NEUROSCI, V16, P5688; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yau YH, 2000, J NEUROSURG, V93, P1072, DOI 10.3171/jns.2000.93.6.1072; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003	44	90	95	0	7	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	MAY	2008	150	5					461	470		10.1007/s00701-008-1580-3			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	299GS	WOS:000255744700006	18421408				2022-02-06	
J	Kemp, SPT; Hudson, Z; Brooks, JHM; Fuller, CW				Kemp, Simon P. T.; Hudson, Zoe; Brooks, John H. M.; Fuller, Colin W.			The epidemiology of head injuries in English professional rugby union	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						elite rugby; head injury; concussion; risk factors	AGREEMENT STATEMENT; CONCUSSION; FOOTBALL; PLAYERS; LEAGUE; PERFORMANCE; PROJECT; SEASONS; SPORTS	Objectives: To undertake a detailed epidemiological study of head injuries sustained by professional rugby union players in order to define their incidence, nature, severity, and causes. Design: A 3-season prospective cohort design. Setting: 13 English Premiership rugby union clubs. Participants: 757 male rugby union players. Main Outcome Measures: Anatomical location, diagnosis, severity (number of days unavailable for training and match play), injury incident, and incidence of match and training injuries (injuries/1000 player-hours). Risk Factors: Playing position, use of headgear, and activity. Results: The overall incidence of match head injury was 6.6 injuries/1000 player-hours, and each injury resulted, on average, in 14 days lost-time. The overall incidence of match concussions was 4.1 injuries/1000 player-hours resulting, on average, in 13 days lost-time. Concussion was the third most common match injury for all players. A large proportion of the players (48%) were able to return to play safely within 7 days. Match concussions were most commonly associated with tackling head-on (28%), collisions (20%), and being tackled head-on (19%). The midfield backs were the playing position at the greatest risk of sustaining a concussion. Only 42% of players were removed from the field of play immediately after a concussion. Foul play was reported by the player to be associated with match head injury in 17% of cases. Mouthguard and headgear usage was associated with a reduced incidence of concussive injury. The overall incidence of training head injury was 0.05 injuries/1000 player-hours, and the overall incidence of training concussions was 0.02 injuries/1000 player-hours. Conclusions: The results showed that rugby union players were exposed to a high risk of noncatastrophic head injury and concussion, particularly whilst tackling and being tackled head-on. In all, 48% of players sustaining a concussion were able to return to play in less than 7 days. The clinical challenge when assessing the potentially concussed player during a game is compounded by the current regulations regarding the permanent replacement of injured players. Injury prevention strategies should be focussed on minimizing the risk and force of direct contact to the head in the tackle.	[Kemp, Simon P. T.; Brooks, John H. M.] Rugby Football Union, Twickenham TW1 1DS, England; [Hudson, Zoe] Royal London Hosp, Ctr Sports & Exercise Med, London E1 1BB, England; [Fuller, Colin W.] Univ Nottingham, Ctr Sports Med, Nottingham NG7 2RD, England		Brooks, JHM (corresponding author), Rugby Football Union, Rugby House,Rugby Rd, Twickenham TW1 1DS, England.	johnbrooks@rfu.com		Brooks, John/0000-0003-2935-7858; Kemp, Simon/0000-0002-3250-2713			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265; Best JP, 2005, BRIT J SPORT MED, V39, P812, DOI 10.1136/bjsm.2004.016402; Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Blignaut J B, 1987, Br J Sports Med, V21, P5; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Brooks JHM, 2005, BRIT J SPORT MED, V39, P767, DOI 10.1136/bjsm.2005.018408; Brooks JHM, 2005, BRIT J SPORT MED, V39, P288, DOI 10.1136/bjsm.2004.013391; COLLIE A, 2005, COGSPORT ERL USER MA; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; DURIE RM, 2000, NZ J SPORTS MED, V28, P84; Duthie G, 2003, SPORTS MED, V33, P973, DOI 10.2165/00007256-200333130-00003; Finch CF, 2001, BRIT J SPORT MED, V35, P89, DOI 10.1136/bjsm.35.2.89; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; Fuller CW, 2007, CLIN J SPORT MED, V17, P177, DOI 10.1097/JSM.0b013e31803220b3; Gabbett TJ, 2005, AM J SPORT MED, V33, P428, DOI 10.1177/0363546504268407; Gabbett TJ, 2000, BRIT J SPORT MED, V34, P98, DOI 10.1136/bjsm.34.2.98; Grindel Scott H, 2003, Curr Sports Med Rep, V2, P18, DOI 10.1249/00149619-200302000-00005; *INT RUGB BOARD, LAW GAM; Jones SJ, 2004, BRIT J SPORT MED, V38, P159, DOI 10.1136/bjsm.2002.002584; KIRKWOOD BR, 2003, ESSENTIAL MED STAT, pCH16; Levy ML, 2004, NEUROSURGERY, V55, P649, DOI 10.1227/01.NEU.0000134598.06114.89; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Marshall SW, 2002, INT J EPIDEMIOL, V31, P587, DOI 10.1093/ije/31.3.587; Marshall SW, 2001, J ATHL TRAINING, V36, P334; McCrory P, 2001, BRIT J SPORT MED, V35, P81, DOI 10.1136/bjsm.35.2.81; McCrory P, 2004, BRIT J SPORT MED, V38, DOI 10.1136/bjsm.2003.006338; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; MCCRORY P, 2003, RUGBY FOOTBALL UNION; McCrory PR, 2000, MED J AUSTRALIA, V172, P217, DOI 10.5694/j.1326-5377.2000.tb123912.x; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2005, BRIT J SPORT MED, V39, P314, DOI 10.1136/bjsm.2005.018200; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; MCINTOSH AS, 1996, J SCI MED SPORT, V2; Orchard J, 2002, BRIT J SPORT MED, V36, P39, DOI 10.1136/bjsm.36.1.39; ORCHARD J, ORCHARD SPORTS INJUR; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pickett W, 2005, BRIT J SPORT MED, V39, P226, DOI 10.1136/bjsm.2004.013169; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; *RUGB FOOTB UN, 2004, COACH CONT RUGB; Targett SGR, 1998, CLIN J SPORT MED, V8, P280, DOI 10.1097/00042752-199810000-00005; VANMECHELEN W, 1992, SPORTS MED, V14, P82, DOI 10.2165/00007256-199214020-00002	44	90	91	3	63	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2008	18	3					227	234		10.1097/JSM.0b013e31816a1c9a			8	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	298SG	WOS:000255706800002	18469563				2022-02-06	
J	Warner, KJ; Cuschieri, J; Copass, MK; Jurkovich, GJ; Bulger, EM				Warner, Keir J.; Cuschieri, Joseph; Copass, Michael K.; Jurkovich, Gregory J.; Bulger, Eileen M.			The impact of prehospital ventilation on outcome after severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	65th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 28-30, 2006	New Orleans, LA	Amer Assoc Surg Trauma		prehospital; intubation; traumatic brain injury; hyperventilation; outcome; target ventilation	RAPID-SEQUENCE INTUBATION; SEVERE HEAD-INJURY; HEMORRHAGIC-SHOCK; ENDOTRACHEAL INTUBATION; CEREBRAL OXYGENATION; HYPERVENTILATION; HYPOVENTILATION; MODERATE; HYPOXIA; PERILS	Background: Prehospital intubation has been challenged on the grounds that it predisposes to hyperventilation, which is detrimental after traumatic brain injury (TBI), and impairs venous return in patients with hypovolemia. We sought to determine the incidence of hyperventilation among a cohort of trauma patients undergoing prehospital intubation and the impact of ventilation on outcome after severe TBI. Methods: Data were prospectively collected for all intubated trauma patients transported directly from the field for a period of 14 months (n = 574). An arrival P-CO2 < 30 mm Hg was termed severe hypocapnea and considered a marker of hyperventilation. Patients with a P-CO2 > 45 mm Hg were considered severely hypercapneic. Targeted ventilation was defined as a P-CO2 between 30 and 35 rum Hg based on the Brain Trauma Foundation guidelines. Results: The rate of severe hypocapnea was 18 % and women were more likely to be hyperventilated (p < 0.05). Patients with severe hypercapnia had higher Injury Severity Scores and were more likely hypotensive, hypoxic, and acidodic (p < 0.05). Patients in the targeted ventilation range were less likely to die than were those outside the range even after excluding the severe hypercapnea group (odds ratio, 0.57; 95% confidence interval, 0.33-0.99). This effect was even greater among patients with isolated TBI (odds ratio, 0.31; 95% confidence interval, 0.10-0.96). Conclusion: Targeted prehospital ventilation is associated with lower mortality after severe TBI.	Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Emergency Serv, Seattle, WA 98104 USA		Bulger, EM (corresponding author), Univ Washington, Harborview Med Ctr, Dept Surg, Box 35976,325 9th Ave, Seattle, WA 98104 USA.	ebulger@u.washington.edu					Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2005, J EMERG MED, V29, P391, DOI 10.1016/j.jemermed.2005.04.012; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2005, NEUROCRIT CARE, V2, P165, DOI 10.1385/NCC:2:2:165; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2004, J TRAUMA, V56, P808, DOI 10.1097/01.TA.0000100217.05066.87; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Davis K, 2005, EUR J WOMENS STUD, V12, P5, DOI 10.1177/1350506805048851; Deakin CD, 2004, J TRAUMA, V57, P65, DOI 10.1097/01.TA.0000103984.70306.22; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; Marion DW, 2000, J TRAUMA, V48, P1032; Pepe PE, 2005, CURR OPIN CRIT CARE, V11, P212, DOI 10.1097/01.ccx.0000163650.80601.24; Stocchetti N, 2005, CHEST, V127, P1812, DOI 10.1378/chest.127.5.1812; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wright J, FIM TM	20	90	91	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2007	62	6					1330	1336		10.1097/TA.0b013e31804a8032			7	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	179YM	WOS:000247326600002	17563643				2022-02-06	
J	Ract, C; Le Moigno, S; Bruder, N; Vigue, B				Ract, Catherine; Le Moigno, Sophie; Bruder, Nicolas; Vigue, Bernard			Transcranial Doppler ultrasound goal-directed therapy for the early management of severe traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						brain injuries; hypoxia-ischemia; brain; transcranial Doppler ultrasonography; time management; critical care	CEREBRAL PERFUSION-PRESSURE; BLOOD-FLOW-VELOCITY; SEVERE HEAD-INJURY; COMPUTERIZED-TOMOGRAPHY; MODERATE; CARE	Objective: To evaluate the usefulness of early transcranial Doppler ultrasound (TCD) goal-directed therapy after severe traumatic brain injury initiated before invasive cerebral monitoring is available. Design: Prospective, observational clinical study. Setting: Surgical intensive care unit, university hospital. Patients and participants: Twenty-four severely brain-injured patients. Interventions: All patients had TCD measurements immediately on admission (T0) and when invasive cerebral monitoring was available (T1). TCD was considered abnormal when two out of three measured values were outside the following limits: Vm < 30 cm/s, Vd < 20 cm/s, PI > 1.4. When admission TCD was abnormal, attending physicians modified treatment to increase cerebral perfusion pressure. Measurements and results: Admission TCD was performed 18 +/- 11 min (T0) after admission, whereas cerebral inasive monitoring was available 242 +/- 116 min (T1) after admission. At T0, 11 (46%) patients had abnormal TCD values (group 1) and 13 had normal TCD values (group 2); mean arterial pressure was comparable between groups. All group 1 patients received mannitol and/or norepinephrine. At T1, mean arterial pressure was increased compared to admission in group 1 (105 +/- 17 mmHg vs. 89 +/- 15 mmHg, p < 0.05) and only two patients had still an abnormal TCD. Although group 1 patients had higher intracranial pressure than those of group 2 (32 +/- 13 mmHg vs. 22 +/- 10 mmHg, p < 0.01), both cerebral perfusion pressure and jugular venous oxygen saturation were comparable between the groups. Conclusions: The use of TCD at hospital admission allows identification of severely brain-injured patients with brain hypoperfusion. In such high-risk patients, early TCD goal-directed therapy can restore normal cerebral perfusion and might then potentially help in reducing the extent of secondary brain injury.	Ctr Hosp Univ Bicetre, AP HP, F-94275 Le Kremlin Bicetre, France; Ctr Hosp Bretagne Atlantique, Dept Anesthesie Reanimat, Vannes, France; Ctr Hosp Univ Timone, Dept Anesthesie Reanimat, Marseille, France		Vigue, B (corresponding author), Ctr Hosp Univ Bicetre, AP HP, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.	bernard.vigue@bct.aphp.fr					AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHAN KH, 1992, J NEUROL NEUROSUR PS, V55, P787, DOI 10.1136/jnnp.55.9.787; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Czosnyka M, 1998, J NEUROSURG, V88, P802, DOI 10.3171/jns.1998.88.5.0802; CZOSNYKA M, 1994, NEUROSURGERY, V35, P287, DOI 10.1227/00006123-199408000-00015; DeWitt D S, 1995, New Horiz, V3, P376; Ducrocq X, 1998, J NEUROL SCI, V159, P145, DOI 10.1016/S0022-510X(98)00158-0; Gabriel Edward J., 2002, Journal of Neurotrauma, V19, P111; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Hlatky R, 2001, SEMIN RESP CRIT CARE, V22, P3, DOI 10.1055/s-2001-13835; Jaffres P, 2005, INTENS CARE MED, V31, P785, DOI 10.1007/s00134-005-2630-4; Jennett B., 1997, HEAD INJURY, P439; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kirkpatrick PJ, 1997, HEAD INJURY, P243; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McQuire JC, 1998, J NEUROSURG, V89, P526, DOI 10.3171/jns.1998.89.4.0526; Revell M, 2002, EMERG MED J, V19, P494, DOI 10.1136/emj.19.6.494; Rouxel JPM, 2004, ANN FR ANESTH, V23, P6, DOI 10.1016/j.annfar.2003.09.021; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Trabold F, 2004, INTENS CARE MED, V30, P108, DOI 10.1007/s00134-003-2057-8; TUOR UI, 1986, AM J PHYSIOL, V251, pH824, DOI 10.1152/ajpheart.1986.251.4.H824; van Santbrink H, 2002, ACTA NEUROCHIR, V144, P1141, DOI 10.1007/s00701-002-1012-8; Vigue B, 1999, INTENS CARE MED, V25, P445, DOI 10.1007/s001340050878; Voulgaris SG, 2005, MED SCI MONITOR, V11, pCR49; 1999, ANN FR ANESTH REANIM, V18, P36	31	90	95	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	APR	2007	33	4					645	651		10.1007/s00134-007-0558-6			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149TS	WOS:000245170300011	17325830				2022-02-06	
J	Fan, Y; Liu, ZY; Weinstein, PR; Fike, JR; Liu, JL				Fan, Yang; Liu, Zhengyan; Weinstein, Philip R.; Fike, John R.; Liu, Jialing			Environmental enrichment enhances neurogenesis and improves functional outcome after cranial irradiation	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						cognitive impairment; dentate gyrus; gerbil; memory; neural precursor cells; radiation injury	INDUCED COGNITIVE DYSFUNCTION; EARLY-ONSET STIMULATION; TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; HIPPOCAMPAL NEUROGENESIS; DENTATE GYRUS; ADULT NEUROGENESIS; NEURONAL DIFFERENTIATION; NEUROTROPHIN LEVELS; CELL-PROLIFERATION	Radiation therapy is a widely used treatment for brain tumors but it can cause delayed progressive cognitive decline and memory deficits. Previous studies suggested that this neurocognitive dysfunction might be linked to the impairment of hippocampal neurogenesis. However, little is known regarding how to reduce the cognitive impairment caused by radiation therapy. To investigate whether environmental enrichment (EE) promotes neurogenesis and cognitive function after irradiation, irradiated gerbils were housed in EE for 2 months and evaluated by neurobehavioral testing for learning and memory function, and immunohistochemical analysis for neurogenesis. Our results demonstrated that even relatively low doses (5-10 Gy) of irradiation could acutely abolish precursor cell proliferation in the dentate gyrus by more than 90%. This reduction in precursor proliferation was persistent and led to a significant decline in the granule cell population 9 months later. EE housing enhanced the number of newborn neurons and increased residual neurogenesis. EE also significantly increased the total number of immature neurons in the dentate gyrus. Furthermore, irradiated animals after EE housing showed a significant improvement in spatial learning and memory during the water-maze test and in rotorod motor learning over a 5-day training paradigm. In conclusion, EE has a positive impact on hippocampal neurogenesis and functional recovery in irradiated adult gerbils. Our data suggest that there is still a considerable amount of plasticity remaining in the hippocampal progenitor cells in adult animals after radiation injury, which can become a target of therapeutic intervention for radiation-induced cognitive dysfunction.	Univ Calif San Francisco, Dept Neurol Surg 112C, San Francisco, CA 94121 USA; San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA; Fudan Univ, HuaShan Hosp, Dept Neurosurg, Shanghai 200433, Peoples R China		Liu, JL (corresponding author), Univ Calif San Francisco, Dept Neurol Surg 112C, 4150 Clement St, San Francisco, CA 94121 USA.	jialing.liu@ucsf.edu	Liu, Jialing/A-8627-2012	Liu, Jialing/0000-0003-4420-4382	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS40469, R21 NS051576, R01 NS46051] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046051, R01NS040469, R21NS051576] Funding Source: NIH RePORTER		Abayomi OK, 1996, ACTA ONCOL, V35, P659, DOI 10.3109/02841869609083995; Bauer S, 2005, J CELL BIOL, V171, P641, DOI 10.1083/jcb.200505072; Berman RF, 1996, ALCOHOL, V13, P209, DOI 10.1016/0741-8329(95)02049-7; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Bruel-Jungerman E, 2005, EUR J NEUROSCI, V21, P513, DOI 10.1111/j.1460-9568.2005.03875.x; Bruel-Jungerman E, 2006, J NEUROSCI, V26, P5888, DOI 10.1523/JNEUROSCI.0782-06.2006; Byrne TN, 2005, CURR OPIN NEUROL, V18, P662, DOI 10.1097/01.wco.0000191511.52745.99; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Coq JO, 1998, EXP BRAIN RES, V121, P191, DOI 10.1007/s002210050452; CROSSEN JR, 1994, J CLIN ONCOL, V12, P627, DOI 10.1200/JCO.1994.12.3.627; Deisseroth K, 2004, NEURON, V42, P535, DOI 10.1016/S0896-6273(04)00266-1; Diamond MC, 2001, AN ACAD BRAS CIENC, V73, P211, DOI 10.1590/S0001-37652001000200006; Dorr W, 1997, INT J RADIAT BIOL, V72, P635, DOI 10.1080/095530097142780; During Matthew J., 2006, Current Alzheimer Research, V3, P29, DOI 10.2174/156720506775697133; Faverjon S, 2002, NEUROLOGY, V59, P1356, DOI 10.1212/01.WNL.0000033588.59005.55; Ge SY, 2006, NATURE, V439, P589, DOI 10.1038/nature04404; Gobbo OL, 2004, BEHAV BRAIN RES, V152, P231, DOI 10.1016/j.bbr.2003.10.017; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; Kanzawa T, 2006, ONCOGENE, V25, P3638, DOI 10.1038/sj.onc.1209414; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; Kempermann G, 2002, ANN NEUROL, V52, P135, DOI 10.1002/ana.10262; Klein M, 2002, LANCET, V360, P1361, DOI 10.1016/S0140-6736(02)11398-5; Komitova M, 2005, STROKE, V36, P1278, DOI 10.1161/01.STR.0000166197.94147.59; Laack NN, 2004, SEMIN ONCOL, V31, P702, DOI 10.1053/j.seminoncol.2004.07.013; Lazic SE, 2006, EUR J NEUROSCI, V23, P1829, DOI 10.1111/j.1460-9568.2006.04715.x; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; Lehmann K, 2005, EUR J NEUROSCI, V21, P3205, DOI 10.1111/j.1460-9568.2005.04156.x; Lichtenwalner RJ, 2006, J CEREBR BLOOD F MET, V26, P1, DOI 10.1038/sj.jcbfm.9600170; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; Madsen TM, 2003, NEUROSCIENCE, V119, P635, DOI 10.1016/S0306-4522(03)00199-4; Maegele M, 2005, J NEUROTRAUM, V22, P772, DOI 10.1089/neu.2005.22.772; Maegele M, 2005, EUR J NEUROSCI, V21, P2406, DOI 10.1111/j.1460-9568.2005.04070.x; Martin SJ, 2002, HIPPOCAMPUS, V12, P609, DOI 10.1002/hipo.10107; Matsumori Y, 2006, NEUROBIOL DIS, V22, P187, DOI 10.1016/j.nbd.2005.10.015; Meltzer LA, 2005, TRENDS NEUROSCI, V28, P653, DOI 10.1016/j.tins.2005.09.007; Meshi D, 2006, NAT NEUROSCI, V9, P729, DOI 10.1038/nn1696; Mizumatsu S, 2003, CANCER RES, V63, P4021; Monje ML, 2003, CURR OPIN NEUROL, V16, P129, DOI 10.1097/00019052-200304000-00002; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Pham TM, 1999, BEHAV BRAIN RES, V103, P63, DOI 10.1016/S0166-4328(99)00019-4; Raber J, 2004, ANN NEUROL, V55, P381, DOI 10.1002/ana.10853; Raber J, 2004, RADIAT RES, V162, P39, DOI 10.1667/RR3206; Rampon C, 2000, NAT NEUROSCI, V3, P238, DOI 10.1038/72945; Rola R, 2004, RADIAT RES, V162, P442, DOI 10.1667/RR3234; Rola R, 2004, EXP NEUROL, V188, P316, DOI 10.1016/j.expneurol.2004.05.005; ROMAN DD, 1995, INT J RADIAT ONCOL, V31, P983, DOI 10.1016/0360-3016(94)00550-8; Steiner B, 2006, EXP NEUROL, V199, P291, DOI 10.1016/j.expneurol.2005.11.004; Suh SW, 2005, DIABETES, V54, P500, DOI 10.2337/diabetes.54.2.500; Surma-aho O, 2001, NEUROLOGY, V56, P1285, DOI 10.1212/WNL.56.10.1285; Tada E, 2000, NEUROSCIENCE, V99, P33, DOI 10.1016/S0306-4522(00)00151-2; Tozuka Y, 2005, NEURON, V47, P803, DOI 10.1016/j.neuron.2005.08.023; Uberti D, 2001, MOL BRAIN RES, V93, P81, DOI 10.1016/S0169-328X(01)00180-2; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Winocur G, 2006, HIPPOCAMPUS, V16, P296, DOI 10.1002/hipo.20163; Wojtowicz JM, 2006, HIPPOCAMPUS, V16, P261, DOI 10.1002/hipo.20158; Wong CS, 2004, MOL INTERV, V4, P273, DOI 10.1124/mi.4.5.7; Yoneoka Y, 1999, BRIT J RADIOL, V72, P1196, DOI 10.1259/bjr.72.864.10703477; Young D, 1999, NAT MED, V5, P448, DOI 10.1038/7449; Zhu SW, 2006, BEHAV BRAIN RES, V169, P10, DOI 10.1016/j.bbr.2005.11.024	64	90	98	0	8	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	JAN	2007	25	1					38	46		10.1111/j.1460-9568.2006.05269.x			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	128TQ	WOS:000243682100004	17241265				2022-02-06	
J	Knowles, SB; Marshall, SW; Bowling, JM; Loomis, D; Millikan, R; Yang, JZ; Weaver, NL; Kalsbeek, W; Mueller, FO				Knowles, Sarah B.; Marshall, Stephen W.; Bowling, J. Michael; Loomis, Dana; Millikan, Robert; Yang, Jinzhen; Weaver, Nancy L.; Kalsbeek, William; Mueller, Frederick O.			A prospective study of injury incidence among North Carolina high school athletes	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						athletic injuries; incidence; prospective studies; risk; sports; wounds and injuries	DISCRETIONARY PROTECTIVE EQUIPMENT; RISK-FACTORS; FOOTBALL; SPORTS; PATTERNS; CONCUSSION; COLLEGIATE; HEALTH; WOMEN; MEN	Sports-related injuries are an issue of concern in high school sports athletes. A prospective cohort study of injury risk factors was conducted from 1996 to 1999 among varsity high school athletes in 12 sports in 100 North Carolina high schools. Data were collected by trained school personnel. Unadjusted and adjusted incidence rates and rate ratios were estimated using Poisson regression models. The overall rate of injury was 2.08 per 1,000 athlete-exposures (95% confidence interval (CI): 1.79, 2.41). At 3.54 per 1,000 athlete-exposures (95% CI: 2.87, 4.37), football had the highest rate of injury of all sports. The adjusted rate ratio for athletes with a history of injury, compared with those without a prior injury, was 1.94 (95% CI: 1.69, 2.22). The injury rate rose with each year of playing experience (rate ratio = 1.06, 95% CI: 1.01, 1.12). In a subanalysis restricted to gender-comparable sports, boys had a higher rate of injury than did girls (rate ratio = 1.33, 95% CI: 0.99, 1.79). All other factors did not appear to be independent predictors of the injury rate. The influence of prior injury suggests that proper rehabilitation and primary prevention of the initial injury are important strategies for injury control.	Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA; Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA; Univ N Carolina, Sch Med, Dept Orthoped, Chapel Hill, NC USA; Univ N Carolina, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, Chapel Hill, NC USA; Univ N Carolina, Sch Publ Hlth, Dept Biostat, Chapel Hill, NC USA; Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; St Louis Univ, Sch Publ Hlth, Dept Behav Sci & Hlth Educ, St Louis, MO 63103 USA; Univ Iowa, Coll Publ Hlth, Dept Community & Behav Hlth, Iowa City, IA USA		Knowles, SB (corresponding author), Palo Alto Med Fdn, Res Inst, 795 El Camino Real,Ames Bldg, Palo Alto, CA 94301 USA.	knowless@pamfri.org	Loomis, Dana/AAE-3988-2019; Yang, Jingzhen/N-4786-2014	Loomis, Dana/0000-0003-3297-5200; Marshall, Stephen/0000-0002-2664-9233			ARENDT E, 1995, AM J SPORT MED, V23, P694, DOI 10.1177/036354659502300611; Arnason A, 2004, AM J SPORT MED, V32, p5S, DOI 10.1177/0363546503258912; Boden BP, 2003, AM J SPORT MED, V31, P881, DOI 10.1177/03635465030310062501; *CDCP, 1996, SURG GEN REP PHYS AC; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P736; DELEE JC, 1992, AM J SPORT MED, V20, P575, DOI 10.1177/036354659202000515; *DIV NUTR PHYS ACT, 2005, BMI BOD MASS IND BMI; GARRICK JG, 1978, PEDIATRICS, V61, P465, DOI 10.1542/peds.61.3.465; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hagel BE, 2003, AM J EPIDEMIOL, V157, P825, DOI 10.1093/aje/kwg050; Jones BH, 2000, AM J PREV MED, V18, P71, DOI 10.1016/S0749-3797(99)00169-5; Knapik JJ, 2001, MED SCI SPORT EXER, V33, P946, DOI 10.1097/00005768-200106000-00014; LEVY P, 1999, SAMPLING POPULATIONS; MCLAIN LG, 1989, PEDIATRICS, V84, P446; *NAT FED STAT HIGH, 2005, PART SETS REC 6 STRA; *NAT FED STAT HIGH, 2005, 2003 2004 PART SUMM; Olson O C, 1979, Phys Sportsmed, V7, P75, DOI 10.1080/00913847.1979.11710899; Pate RR, 2000, ARCH PEDIAT ADOL MED, V154, P904, DOI 10.1001/archpedi.154.9.904; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Powell JW, 1999, J ATHL TRAINING, V34, P277; Powell JW, 2000, AM J SPORT MED, V28, P385, DOI 10.1177/03635465000280031801; PRAGER BI, 1989, AM J SPORT MED, V17, P681, DOI 10.1177/036354658901700516; PRITCHETT JW, 1980, AM J SPORT MED, V8, P197, DOI 10.1177/036354658000800310; PRITCHETT JW, 1982, J BONE JOINT SURG AM, V64, P240, DOI 10.2106/00004623-198264020-00015; *RES TRIANL I, 2001, SUDAAN US MAN REL 8; ROBEY JM, 1971, J AMER MED ASSOC, V217, P184, DOI 10.1001/jama.217.2.184; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Schulz MR, 2004, AM J SPORT MED, V32, P396, DOI 10.1177/0363546503261715; Stocker B D, 1997, J Ky Med Assoc, V95, P458; Turbeville SD, 2003, AM J SPORT MED, V31, P974, DOI 10.1177/03635465030310063801; Weaver NL, 1999, MED SCI SPORT EXER, V31, P176, DOI 10.1097/00005768-199901000-00027; Yang JZ, 2005, AM J PUBLIC HEALTH, V95, P1996, DOI 10.2105/AJPH.2004.050807; Yang JZ, 2005, AM J EPIDEMIOL, V161, P511, DOI 10.1093/aje/kwi077	33	90	92	1	11	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262	1476-6256		AM J EPIDEMIOL	Am. J. Epidemiol.	DEC 15	2006	164	12					1209	1221		10.1093/aje/kwj337			13	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	115DK	WOS:000242714800009	17012366				2022-02-06	
J	Williams, AJ; Hartings, JA; Lu, XCM; Rolli, ML; Tortella, FC				Williams, Anthony J.; Hartings, Jed A.; Lu, Xi-Chun M.; Rolli, Michael L.; Tortella, Frank C.			Penetrating ballistic-like brain injury in the rat: Differential time courses of hemorrhage, cell death, inflammation, and remote degeneration	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; inflammation; military injury; models of injury; traumatic brain injury	CONTROLLED CORTICAL IMPACT; CEREBRAL-ARTERY OCCLUSION; LATERAL FLUID PERCUSSION; MISSILE HEAD-INJURY; NEURONAL DEGENERATION; AXONAL INJURY; INTRACEREBRAL HEMORRHAGE; NEUROBEHAVIORAL OUTCOMES; NONCONVULSIVE SEIZURES; THERAPEUTIC WINDOW	Acute and delayed cerebral injury was assessed in a recently developed rat model of a penetrating ballistic-like brain injury (PBBI). A unilateral right frontal PBBI trajectory was used to induce survivable injuries to the frontal cortex and striatum. Three distinct phases of injury progression were observed. Phase I (primary injury, 0-6 h) began with immediate (< 5 min) intracerebral hemorrhage (ICH) that reached maximal volumetric size at 6 h (27.0 +/- 2.9 mm(3)). During Phase II (secondary injury, 6-72 h), a core lesion of degenerate neurons surrounding the injury track expanded into peri-lesional areas to reach a maximal volume of 69.9 +/- 6.1 mm(3) at 24 h. The core lesion consisted of predominately necrotic cell death and included marked infiltration of both neutrophils (24 h) and macrophages (72 h). Phase III (delayed degeneration, 3-7 days) involved the degeneration of neurons and fiber tracts remote from the core lesion including the thalamus, internal capsule, external capsule, and cerebral peduncle. Overall, different time courses of hemorrhage, lesion evolution, and inflammation were consistent with complementary roles in injury development and repair, providing key information about these mediators of primary, secondary, and delayed brain injury development. The similarities/differences of PBBI to other focal brain injury models are discussed.	Walter Reed Army Inst Res, Dept Appl Neurobiol, Silver Spring, MD 20910 USA		Williams, AJ (corresponding author), Walter Reed Army Inst Res, Dept Appl Neurobiol, 503 Robert Grant Ave Bldg 503,Rm 2A40, Silver Spring, MD 20910 USA.	anthony.williams@na.amedd.army.mil		Hartings, Jed/0000-0001-8583-3471			ADAMS JH, 1982, INJURY, V13, P444, DOI 10.1016/0020-1383(82)90105-X; Al-Abdulla NA, 2002, NEUROSCIENCE, V115, P7, DOI 10.1016/S0306-4522(02)00363-9; ALLEN IV, 1982, INJURY, V14, P183, DOI 10.1016/0020-1383(82)90057-2; AWASTHI D, 1991, SURG NEUROL, V36, P441, DOI 10.1016/0090-3019(91)90157-5; BELLAMY R, 1998, TXB MILITARY MED 1, V5, P107; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; BOYA J, 1986, ACTA ANAT, V127, P142; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; BUTLER EG, 1945, J NEUROSURG, V2, P358, DOI 10.3171/jns.1945.2.4.0358; Butler TL, 2002, BRAIN RES, V929, P252, DOI 10.1016/S0006-8993(01)03371-6; CAREY ME, 1989, J NEUROSURG, V71, P754, DOI 10.3171/jns.1989.71.5.0754; Carey ME, 1990, J NEUROTRAUM, V7, P13, DOI 10.1089/neu.1990.7.13; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Church AJ, 2005, J NEUROTRAUM, V22, P277, DOI 10.1089/neu.2005.22.277; CLARK RK, 1994, BRAIN RES BULL, V35, P387, DOI 10.1016/0361-9230(94)90119-8; CLARK RK, 1993, BRAIN RES BULL, V31, P565, DOI 10.1016/0361-9230(93)90124-T; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CLEMEDSON CJ, 1973, Z RECHTSMED, V73, P103, DOI 10.1007/BF01882332; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; CROCKARD HA, 1977, J NEUROSURG, V46, P776, DOI 10.3171/jns.1977.46.6.0776; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; Dreier JP, 2000, J NEUROSURG, V93, P658, DOI 10.3171/jns.2000.93.4.0658; Emerich DF, 2002, EXP NEUROL, V173, P168, DOI 10.1006/exnr.2001.7835; FREYTAG E, 1963, ARCH PATHOL, V76, P215; Fujita T, 1998, ACTA NEUROCHIR, V140, P275, DOI 10.1007/s007010050095; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hartings JA, 2003, J NEUROSCI, V23, P11602; Hartings JA, 2005, J NEUROTRAUM, V22, P1201; Hartings JA, 2003, EXP NEUROL, V179, P139, DOI 10.1016/S0014-4886(02)00013-4; Hotz GA, 2000, BRAIN INJURY, V14, P649; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287; IIZUKA H, 1990, STROKE, V21, P790, DOI 10.1161/01.STR.21.5.790; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; KIERNAN JA, 1999, HIST HISTOCHEMICAL M; Kotwica Z, 1989, Zentralbl Neurochir, V50, P68; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; Li Y, 1998, J NEUROL SCI, V156, P119, DOI 10.1016/S0022-510X(98)00036-7; Lu XCM, 2001, NEUROPATH APPL NEURO, V27, P481, DOI 10.1046/j.1365-2990.2001.00357.x; Marin R, 2003, PHYSIOL BEHAV, V80, P167, DOI 10.1016/j.physbeh.2003.06.001; Martins RS, 2003, SURG NEUROL, V60, P98, DOI 10.1016/S0090-3019(03)00302-1; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MOSHANG E, 2003, MODEL PENETRATING TR; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pantoni L, 1998, ARTERIOSCL THROM VAS, V18, P503, DOI 10.1161/01.ATV.18.4.503; PERSSON L, 1976, VIRCHOWS ARCH B, V22, P21; Pintar F A, 2001, Biomed Sci Instrum, V37, P429; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Sapsford W, 2003, J R Army Med Corps, V149, P5; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith Wade S, 2004, J Vasc Interv Radiol, V15, pS3; Soares HD, 1995, J NEUROSCI, V15, P8223; Stanimirovic D, 2000, BRAIN PATHOL, V10, P113; Sunami K, 1989, Neurol Med Chir (Tokyo), V29, P975, DOI 10.2176/nmc.29.975; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Volgas DA, 2005, INJURY, V36, P380, DOI 10.1016/j.injury.2004.08.038; Wada K, 1999, NEUROSURGERY, V45, P601, DOI 10.1097/00006123-199909000-00031; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WEI H, 2006, ADV TECHN APPL COMB; Williams AJ, 2000, J PHARMACOL EXP THER, V294, P378; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2004, STROKE, V35, P1186, DOI 10.1161/01.STR.0000125721.10606.dc; Williams AJ, 2004, J PHARMACOL EXP THER, V311, P220, DOI 10.1124/jpet.104.069146; Williams AJ, 2003, J CEREBR BLOOD F MET, V23, P75, DOI 10.1097/01.WCB.0000039285.37737.C2; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Wu JM, 2002, BRAIN RES, V953, P45, DOI 10.1016/S0006-8993(02)03268-7; Zafonte RD, 2001, ARCH PHYS MED REHAB, V82, P306, DOI 10.1053/apmr.2001.18226; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496; Zauner A, 1996, ACT NEUR S, V67, P40; Zhang FY, 2002, J NEUROSURG, V97, P963, DOI 10.3171/jns.2002.97.4.0963	74	90	90	0	6	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2006	23	12					1828	1846		10.1089/neu.2006.23.1828			19	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	120AP	WOS:000243056100010	17184192				2022-02-06	
J	van Baalen, B; Odding, E; van Woensel, MPC; van Kessel, MA; Roebroeck, ME; Stam, HJ				van Baalen, B.; Odding, E.; van Woensel, M. P. C.; van Kessel, M. A.; Roebroeck, M. E.; Stam, H. J.			Reliability and sensitivity to change of measurement instruments used in a traumatic brain injury population	CLINICAL REHABILITATION			English	Article							FUNCTIONAL ASSESSMENT SCALES; HEALTH SURVEY SF-36; RATING-SCALE; HEAD-INJURY; FOLLOW-UP; REHABILITATION; COMMUNITY; SEVERITY; RECOVERY; OUTCOMES	Objective: To compile a minimum data set for the follow-up of traumatic brain injury patients from discharge from hospital to one year post injury to assess functioning and participation in the physical, cognitive and psychosocial domains, and in quality of life. Design: Repeated questionnaire interviews by two observers to establish interobserver reliability of the measurement instruments at discharge and at one year post injury, as well as their sensitivity to change over time in traumatic brain injury patients. Setting: Department of neurosurgery of an academic hospital, department of a rehabilitation centre, and at the patients' homes in the Netherlands. Subjects: The study at discharge included 25 patients aged 18-50 years with a moderate to severe traumatic brain injury (Glasgow Coma Scale score 3-14), whereas the one year post injury study included 14 patients aged 19-51 years. Main (outcome) measures: Physical domain: Barthel Index (BI), Functional Independence Measurement (FIM), Glasgow Outcome Scale (GOS), GOS Extended (GOSE). Cognitive domain: Disability Rating Scale (DRS), Functional Assessment Measurement (FAM), Levels of Cognitive Functioning Scale (LCFS), Neurobehavioural Bating Scale (NRS). Psychosocial domain: Community Integration Questionnaire (CIQ), Employability Rating Scale (ERS), Frenchay Activity Index (FAI), Multi Health Locus of Control (MHLC), Rehabilitation Activities Profile (RAP), Social Support List (SSL), Supervision Rating Scale (SRS), Wimbledon Self Reporting Rating Scale (WSRS). Quality of life: Coop/Wonca Charts (Coop), Rand SF-36 (Rand-36), Sickness Impact Profile-68 (SIP-68). Results: At both discharge and at one year post injury, in the physical domain the FIM showed excellent squared weighted kappa (SWK ranging from 0.75 to 0.80), and intraclass correlation coefficient (ICC ranging from 0.75 to 0.92), and a relatively small standard error of measurement (SEM 3.22) and smallest detectable difference (SDD 8.92). In the cognitive domain the FAM and the NRS showed excellent SWK, and ICC, and a relatively small SEM and SDD. In the psychosocial domain the FAI showed excellent SWK (0.89), and ICC (0.87), and a relatively small SEM (2.64) and SDD (7.31). For quality of life, at both discharge and at one year post injury the SIP-68 and the Coop showed excellent SWK (0.87), and ICC (0.89), and a relatively small SEM (3.79) and SDD (10.51). At both time points SWK and ICC ranged from 0.80 to 0.89, SEM ranged from 1.47 to 1.98, and the SDD was 4.07. Conclusions: An example of a reliable minimum data set that is also able to detect changes over time is: the FIM, the FAM and the Coop for the early stages in recovery, extended with the NRS, the FAI, and the SIP-68 later in recovery, thereby covering all relevant domains after traumatic brain injury.	Univ Med Ctr Rotterdam, Erasmus MC, Dept Rehabil Med, NL-3000 CA Rotterdam, Netherlands; Rijndam Rehabil Ctr, Rotterdam, Netherlands		van Baalen, B (corresponding author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Rehabil Med, POB 2040, NL-3000 CA Rotterdam, Netherlands.	j.t.m.vanbaalen@erasmusmc.nl					Beckerman H, 2001, QUAL LIFE RES, V10, P571, DOI 10.1023/A:1013138911638; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P255, DOI 10.1053/apmr.2003.50092; Collin C, 1988, Int Disabil Stud, V10, P61; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Coughlan AK, 1988, CLIN REHABIL, V2, P207, DOI DOI 10.1177/026921558800200305; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; DEBRUIN AF, 1994, J CLIN EPIDEMIOL, V47, P407, DOI 10.1016/0895-4356(94)90162-7; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Donaghy S, 1998, ARCH PHYS MED REHAB, V79, P1231, DOI 10.1016/S0003-9993(98)90267-2; Fleiss J.L., 1981, STAT METHODS RATES P; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Geertzen JHB, 1998, ACTA ORTHOP SCAND, V69, P4, DOI 10.1080/17453674.1998.11744780; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; HOLBROOK M, 1983, AGE AGEING, V12, P166, DOI 10.1093/ageing/12.2.166; JELLES F, 1995, J CLIN EPIDEMIOL, V48, P407, DOI 10.1016/0895-4356(94)00152-G; JENNETT B, 1975, LANCET, V1, P480; Johnston M V, 1994, Arch Phys Med Rehabil, V75, pSC1; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, pSC27; JOHNSTON MV, 1996, MED REHABILITATION T, P197; KONIGZAHN C, 1997, CROSS CULTURAL HLTH, P48; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MacDermid Joy C, 2004, J Hand Ther, V17, P165, DOI 10.1197/j.jht.2004.02.005; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; Norman, 1995, HLTH MEASUREMENT SCA; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Roebroeck ME, 1998, ARCH PHYS MED REHAB, V79, P442, DOI 10.1016/S0003-9993(98)90147-2; Sacket DL, 1991, CLIN EPIDEMIOLOGY BA; SAHGAL V, 1989, SCAND J REHABIL MED, V21, P71; Schreuders TAR, 2003, PHYS THER, V83, P806, DOI 10.1093/ptj/83.9.806; Smidt N, 2002, ARCH PHYS MED REHAB, V83, P1145, DOI 10.1053/apmr.2002.33728; Smith J, 1998, CANADIAN J REHABILIT, V11, P131; Teasdale GM, 1997, ACTA NEUROCHIR, V139, P797, DOI 10.1007/BF01411397; Turner-Stokes L, 1999, CLIN REHABIL, V13, P273, DOI 10.1191/026921599670005973; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; VANBALEN HGG, 1996, CLIN REHABIL, V10, P259; VANSONDEREN E, 1997, SOCIALE STEUN LIJST; WALLSTON KA, 1978, HEALTH EDUC QUART, V6, P160, DOI 10.1177/109019817800600107; Ware J.E., 1993, SF 36 HLTH SURVEY MA; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zasler ND, 1997, ARCH PHYS MED REHAB, V78, pS12, DOI 10.1016/S0003-9993(97)90150-7	60	90	93	0	7	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	AUG	2006	20	8					686	700		10.1191/0269215506cre982oa			15	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	077DN	WOS:000240008000005	16944826				2022-02-06	
J	Leblanc, J; De Guise, E; Gosselin, N; Feyz, M				Leblanc, Joanne; De Guise, Elaine; Gosselin, Nadia; Feyz, Mitra			Comparison of functional outcome following acute care in young, middle-aged and elderly patients with traumatic brain injury	BRAIN INJURY			English	Article						elderly; traumatic brain injury; acute care; outcome	CLOSED-HEAD INJURY; OLDER-ADULTS; NEUROBEHAVIORAL CONSEQUENCES; PRACTICAL SCALE; MORTALITY; COMA; DISCHARGE; SEVERITY; RECOVERY; SEQUELAE	Primary objective: To compare functional physical and cognitive outcome of patients in three age groups with mild, moderate and severe traumatic brain injury (TBI) at discharge from acute care. Research design: Retrospective database review. Methods and procedures: Scores on the Extended Glasgow Outcome Scale (GOSE) and on the FIM (TM) instrument,(1) discharge destination and length-of-stay (LOS) were gathered and compared for 2327 patients with TBI admitted to a level 1 trauma hospital from 1997-2003 divided into three age groups; 971 patients between 18-39 years, 672 between 40-59 years and 684 aged 60-99 years. Main outcomes and results: Relative to younger adults with similar TBI severity, elderly patients showed worse outcome on the GOSE and FIM (TM) instrument (physical and cognitive ratings) and longer LOS. No difference was observed between the young and middle-aged groups except for cognitive FIM (TM) ratings and LOS for severe TBI. A higher percentage of elderly patients went to in-patient rehabilitation, to long-term care facilities or died compared to young and middle-aged patients. A higher number of young and middle-aged patients were discharged home. Conclusions: Further development of services in early rehabilitation as well as post-rehabilitation geared to the specific needs of the elderly patient with TBI is required as the population ages.	McGill Univ, Montreal Gen Hosp, Ctr Hlth, Traumat Brain Injury Program, Montreal, PQ H3G 1A4, Canada; Univ Montreal, Montreal, PQ, Canada		Leblanc, J (corresponding author), McGill Univ, Montreal Gen Hosp, Ctr Hlth, Traumat Brain Injury Program, Local D13-124,1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	joanne.leblanc@mcgill.ca					ADEKOYA N, 2002, SURVEILLANCE SUMMARI, V51, P1; AharonPeretz J, 1997, BRAIN INJURY, V11, P871; AMACHER AL, 1987, NEUROSURGERY, V20, P954; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Chan L, 2001, ARCH PHYS MED REHAB, V82, P1151, DOI 10.1053/apmr.2001.24892; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; *COMM MED ASP AUT, 1971, JAMA-J AM MED ASSOC, V215, P277; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; DAVIS CS, 1988, J AM GERIATR SOC, V36, P225, DOI 10.1111/j.1532-5415.1988.tb01805.x; ENGLANDER J, 1999, REHABILITATION ADULT, P453; Ferrell Richard B, 2002, Curr Psychiatry Rep, V4, P354; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Gan BK, 2004, ANN ACAD MED SINGAP, V33, P63; GOLDSTEIN FC, 1995, J HEAD TRAUMA REHAB, V10, P57, DOI 10.1097/00001199-199502000-00007; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; Goldstein FC, 1999, J NEUROPSYCH CLIN N, V11, P38, DOI 10.1176/jnp.11.1.38; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; Harris C, 2003, J AM COLL SURGEONS, V197, P711, DOI 10.1016/S1072-7515(03)00729-4; Hawkins ML, 2003, AM SURGEON, V69, P497; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Kuhne CA, 2005, WORLD J SURG, V29, P1476, DOI 10.1007/s00268-005-7796-y; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; MALKMUS D, 1979, REHABILITATION HEAD; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; RAKIER A, 1995, BRAIN INJURY, V9, P187, DOI 10.3109/02699059509008191; Rapoport MJ, 2001, BRAIN INJURY, V15, P857, DOI 10.1080/02699050110065303; Rapoport MJ, 2000, BRAIN INJURY, V14, P749; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reeder KP, 1996, J HEAD TRAUMA REHAB, V11, P22, DOI 10.1097/00001199-199606000-00006; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Ritchie PD, 2000, J CLIN NEUROSCI, V7, P301, DOI 10.1054/jocn.1999.0198; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; ROY CW, 1986, INJURY, V17, P220, DOI 10.1016/0020-1383(86)90222-6; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TEASDALE G, 1974, LANCET, V2, P81; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Wilson J A, 1987, Brain Inj, V1, P183, DOI 10.3109/02699058709034456; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	49	90	94	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2006	20	8					779	790		10.1080/02699050600831835			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	081ZO	WOS:000240356300001	17060145				2022-02-06	
J	Loscher, W; Schmidt, D				Loescher, Wolfgang; Schmidt, Dieter			New horizons in the development of antiepileptic drugs: Innovative strategies	EPILEPSY RESEARCH			English	Article; Proceedings Paper	3rd Workshop on New Horizons in the Development of Antiepileptic Drugs	NOV 30-DEC 01, 2005	Washington, DC			epilepsy; seizures; drug resistance; drug targets; neurodegeneration; inflammation; epileptogenesis	TEMPORAL-LOBE EPILEPSY; LONG-TERM POTENTIATION; LITHIUM-PILOCARPINE MODEL; SYNAPTIC VESICLE PROTEIN; AMYGDALA-KINDLING MODEL; TRAUMATIC BRAIN-INJURY; SPONTANEOUS RECURRENT SEIZURES; ABC TRANSPORTER SUPERFAMILY; NMDA-RECEPTOR ANTAGONISTS; MAXIMAL ELECTROSHOCK TEST	The past decades have brought many advances to the treatment of epilepsy. However. despite the continued development and release of new antiepileptic drugs, many patients have seizures that do not respond to drug therapy or have related side effects that preclude continued use. Even in patients in whom pharmacotherapy is efficacious, current antiepileptic drugs do not seem to affect the progression or the underlying natural history of epilepsy. Furthermore. there is currently no drug available which prevents the development of epilepsy, e.g. after head trauma or stroke. Thus. there are at least four important goals for the future: (1) development of better antiepileptic ("anti-ictal") drugs with higher efficacy and tolerability to stop seizures compared to current medications; (2) better understanding of processes leading to epilepsy. thus allowing to create therapies aimed at the prevention of epilepsy in patients at risk; (3) development of disease-modifying therapies. interfering with progression of epilepsy, and (4) improved understanding of neurobiological mechanisms of pharmacoresistance, allowing to develop drugs for reversal or prevention of drug resistance. The third Workshop on New Horizons in the Development of Antiepileptic Drugs explored these four goals for improved epilepsy therapy, with a focus on innovative strategies in the search for better anti-ictal drugs, for novel drugs for prevention of epilepsy or its progression, and for drugs overcoming drug resistance in epilepsy. In this conference review, the current status of antiepileptic therapies under development is critically assessed. and innovative approaches for future therapies are highlighted.	Univ Vet Med Hannover, Dept Pharmacol Toxicol & Pharm, D-30559 Hannover, Germany; Epilepsy Res Grp, Berlin, Germany		Loscher, W (corresponding author), Univ Vet Med Hannover, Dept Pharmacol Toxicol & Pharm, Bunteweg 17, D-30559 Hannover, Germany.	wolfgang.loescher@tiho-hannover.de			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [Z01NS002732] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [Z01 NS002732-19] Funding Source: Medline		AARTS JHP, 1984, BRAIN, V107, P293, DOI 10.1093/brain/107.1.293; Adamec R, 2005, BEHAV BRAIN RES, V159, P73, DOI 10.1016/j.bbr.2004.10.004; Agrawal M, 2003, CHEM ENG PROG, V99, P9; Altaha R, 2002, CURR PHARM DESIGN, V8, P1707, DOI 10.2174/1381612023394043; Altrock WD, 2003, NEURON, V37, P787, DOI 10.1016/S0896-6273(03)00088-6; Arikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7; Arroyo S, 2003, EPILEPSY BEHAV, V4, P457, DOI 10.1016/j.yebeh.2003.07.011; Asarnow RF, 1997, DEV MED CHILD NEUROL, V39, P430; Bailet LL, 2000, EPILEPSIA, V41, P426, DOI 10.1111/j.1528-1157.2000.tb00184.x; Barbarosie M, 2000, J NEUROPHYSIOL, V83, P1115, DOI 10.1152/jn.2000.83.3.1115; Barbarosie M, 1997, J NEUROSCI, V17, P9308; Barton ME, 2003, EPILEPSY RES, V56, P17, DOI 10.1016/j.eplepsyres.2003.08.001; Barton ME, 2001, EPILEPSY RES, V47, P217, DOI 10.1016/S0920-1211(01)00302-3; Bates SE, 2001, J BIOENERG BIOMEMBR, V33, P503, DOI 10.1023/A:1012879205914; Begley CE, 2000, EPILEPSIA, V41, P342, DOI 10.1111/j.1528-1157.2000.tb00166.x; Belliotti TR, 2005, J MED CHEM, V48, P2294, DOI 10.1021/jm049762l; Bender RA, 2004, ADV EXP MED BIOL, V548, P213; BERENBAUM MC, 1989, PHARMACOL REV, V41, P93; Berg AT, 2003, NEUROLOGY, V60, P186, DOI 10.1212/01.WNL.0000031792.89992.EC; Bi GQ, 2001, ANNU REV NEUROSCI, V24, P139, DOI 10.1146/annurev.neuro.24.1.139; Bialer M, 1999, EPILEPSY RES, V34, P1, DOI 10.1016/S0920-1211(98)00108-9; Bialer M, 2002, EPILEPSY RES, V51, P31, DOI 10.1016/S0920-1211(02)00106-7; Bialer M, 2004, EPILEPSY RES, V61, P1, DOI 10.1016/j.eplepsyres.2004.07.010; Bialer M, 2001, EPILEPSY RES, V43, P11, DOI 10.1016/S0920-1211(00)00171-6; Binder DK, 1999, J NEUROSCI, V19, P4616; Binder DK, 1999, J NEUROSCI, V19, P1424; Binnie C D, 1991, Adv Neurol, V55, P113; Binnie CD, 2003, LANCET NEUROL, V2, P725, DOI 10.1016/S1474-4422(03)00584-2; BINNIE CD, 1992, EPILEPSY RES, P71; Bittigau P, 2002, P NATL ACAD SCI USA, V99, P15089, DOI 10.1073/pnas.222550499; Bjornaes H, 2001, SEIZURE-EUR J EPILEP, V10, P250, DOI 10.1053/seiz.2000.0503; Borowicz KK, 1996, EPILEPSIA, V37, P618, DOI 10.1111/j.1528-1157.1996.tb00625.x; Borowicz KK, 2003, POL J PHARMACOL, V55, P735; BOROWICZ KK, 1995, EUR J PHARMACOL, V281, P319, DOI 10.1016/0014-2999(95)00266-N; Borowicz KK, 1999, EUR J PHARMACOL, V380, P67, DOI 10.1016/S0014-2999(99)00541-5; Borowicz KK, 2002, EPILEPSIA, V43, P956, DOI 10.1046/j.1528-1157.2002.34301.x; BOURGEOIS BFD, 1983, ANN NEUROL, V14, P438, DOI 10.1002/ana.410140407; Brandt C, 2005, EPILEPSIA, V46, P60; Brandt C, 2004, EPILEPSIA, V45, P1488, DOI 10.1111/j.0013-9580.2004.16904.x; Brandt C, 2003, EPILEPSY RES, V55, P83, DOI 10.1016/S0920-1211(03)00114-1; Brandt C, 2003, NEUROSCIENCE, V118, P727, DOI 10.1016/S0306-4522(03)00027-7; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Brown JP, 1998, J BIOL CHEM, V273, P25458, DOI 10.1074/jbc.273.39.25458; BROWNING RA, 1985, FED PROC, V44, P2425; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; Burger H, 2004, BLOOD, V104, P2940, DOI 10.1182/blood-2004-04-1398; Buzsaki G, 1996, CEREB CORTEX, V6, P81, DOI 10.1093/cercor/6.2.81; Buzsaki G, 1998, J SLEEP RES, V7, P17, DOI 10.1046/j.1365-2869.7.s1.3.x; Cendes F, 2005, CURR OPIN NEUROL, V18, P173, DOI 10.1097/01.wco.0000162860.49842.90; Chaperon F, 2003, BEHAV PHARMACOL, V14, P477, DOI 10.1097/01.fbp.0000091471.79060.ed; Chenard BL, 1999, CURR PHARM DESIGN, V5, P381; CHIASSON BJ, 1995, MOL BRAIN RES, V29, P191, DOI 10.1016/0169-328X(94)00250-I; Chrobak JJ, 2000, HIPPOCAMPUS, V10, P457, DOI 10.1002/1098-1063(2000)10:4<457::AID-HIPO12>3.0.CO;2-Z; Clayton DA, 2001, NEUROBIOL AGING, V22, P165, DOI 10.1016/S0197-4580(00)00196-2; Coenen AML, 2003, BEHAV GENET, V33, P635, DOI 10.1023/A:1026179013847; Colbert CM, 1997, J NEUROSCI, V17, P6512; Cortez MA, 2001, NEUROLOGY, V56, P341, DOI 10.1212/WNL.56.3.341; Crowder KM, 1999, P NATL ACAD SCI USA, V96, P15268, DOI 10.1073/pnas.96.26.15268; Cunningham MO, 2004, EUR J NEUROSCI, V20, P1566, DOI 10.1111/j.1460-9568.2004.03625.x; CZUCZWAR SJ, 1995, EUR J PHARMACOL, V281, P327, DOI 10.1016/0014-2999(95)00268-P; Czuczwar SJ, 1998, EUR J PHARMACOL, V359, P103, DOI 10.1016/S0014-2999(98)00632-3; CZUCZWAR SJ, 1982, EUR J PHARMACOL, V83, P335, DOI 10.1016/0014-2999(82)90273-4; Czuczwar SJ, 1996, METAB BRAIN DIS, V11, P143, DOI 10.1007/BF02069501; D'Ambrosio R, 2004, PHARMACOL THERAPEUT, V103, P95, DOI 10.1016/j.pharmthera.2004.05.004; Dalby NO, 1997, NEUROSCI LETT, V229, P135; Danysz W, 2005, IDRUGS, V8, P755; Dean M, 2001, J LIPID RES, V42, P1007; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Donevan SD, 2000, MOL PHARMACOL, V58, P614, DOI 10.1124/mol.58.3.614; Dooley DJ, 2000, J PHARMACOL EXP THER, V295, P1086; Dooley DJ, 2000, NEUROSCI LETT, V280, P107, DOI 10.1016/S0304-3940(00)00769-2; Dooley DJ, 2002, SYNAPSE, V45, P171, DOI 10.1002/syn.10094; DZIKI M, 1992, EUR J PHARMACOL, V222, P273, DOI 10.1016/0014-2999(92)90866-3; Ebert U, 2000, NEUROPHARMACOLOGY, V39, P1893, DOI 10.1016/S0028-3908(00)00039-3; Ebert U, 2002, EPILEPSIA, V43, P86, DOI 10.1046/j.1528-1157.43.s.5.39.x; Ebert U, 1997, EUR J PHARMACOL, V322, P179, DOI 10.1016/S0014-2999(97)00084-8; Eichenbaum H, 1999, BEHAV BRAIN RES, V103, P123, DOI 10.1016/S0166-4328(99)00044-3; Eid T, 2004, J NEUROPATH EXP NEUR, V63, P73, DOI 10.1093/jnen/63.1.73; Elkind NB, 2005, CANCER RES, V65, P1770, DOI 10.1158/0008-5472.CAN-04-3303; Emilien G, 1998, INT J CLIN PHARM TH, V36, P181; Engel J, 2001, EPILEPSIA, V42, P796, DOI 10.1046/j.1528-1157.2001.10401.x; Errante LD, 2003, SEIZURE-EUR J EPILEP, V12, P300, DOI 10.1016/S1059-1311(02)00295-9; Errante LD, 2002, EPILEPSY RES, V49, P203, DOI 10.1016/S0920-1211(02)00034-7; Eskazan E, 2002, EPILEPSIA, V43, P1115, DOI 10.1046/j.1528-1157.2002.35601.x; FARWELL JR, 1985, EPILEPSIA, V26, P395, DOI 10.1111/j.1528-1157.1985.tb05670.x; Fehrenbacher JC, 2003, PAIN, V105, P133, DOI 10.1016/S0304-3959(03)00173-8; Fink K, 2002, NEUROPHARMACOLOGY, V42, P229, DOI 10.1016/S0028-3908(01)00172-1; French JA, 2004, NEUROLOGY, V62, P1252, DOI 10.1212/01.WNL.0000123693.82339.FC; Friedl M, 1999, BRAIN RES, V821, P117, DOI 10.1016/S0006-8993(99)01083-5; Fulda S, 2001, SLEEP MED REV, V5, P423, DOI 10.1053/smrv.2001.0157; Galanopoulou AS, 2005, EPILEPSIA, V46, P107, DOI 10.1111/j.1528-1167.2005.01007.x; GALE K, 1992, J CLIN NEUROPHYSIOL, V9, P264, DOI 10.1097/00004691-199204010-00007; Galvis-Alonso OY, 2004, NEUROSCIENCE, V125, P787, DOI 10.1016/j.neuroscience.2004.01.042; Garcia CC, 2004, J MED GENET, V41, P183, DOI 10.1136/jmg.2003.013680; GARCIACAIRASCO N, 1983, BRAZ J MED BIOL RES, V16, P171; Gilad R, 1996, ARCH NEUROL-CHICAGO, V53, P1149, DOI 10.1001/archneur.1996.00550110089017; Glien M, 2002, EPILEPSIA, V43, P350, DOI 10.1046/j.1528-1157.2002.18101.x; Gloveli T, 2003, NEUROBIOL DIS, V13, P203, DOI 10.1016/S0969-9961(03)00039-1; GODDARD GV, 1969, EXP NEUROL, V25, P295, DOI 10.1016/0014-4886(69)90128-9; Golarai G, 1996, J NEUROPHYSIOL, V75, P343, DOI 10.1152/jn.1996.75.1.343; GOLDLUST A, 1995, EPILEPSY RES, V22, P1, DOI 10.1016/0920-1211(95)00028-9; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Grabenstatter HL, 2005, EPILEPSIA, V46, P8, DOI 10.1111/j.0013-9580.2005.13404.x; Gravius A, 2005, BEHAV PHARMACOL, V16, P113, DOI 10.1097/00008877-200503000-00007; Greenberg DA, 2005, AM J HUM GENET, V76, P139, DOI 10.1086/426735; Gu J, 2004, EUR J NEUROSCI, V19, P334, DOI 10.1111/j.0953-816X.2003.03106.x; Han KJ, 2000, ACTA HAEMATOL-BASEL, V104, P174, DOI 10.1159/000046511; Hannesson DK, 2004, EPILEPSY RES, V58, P145, DOI 10.1016/j.eplepsyres.2004.01.004; Hannesson DK, 2000, NEUROSCI BIOBEHAV R, V24, P725, DOI 10.1016/S0149-7634(00)00033-6; Harkin LA, 2002, AM J HUM GENET, V70, P530, DOI 10.1086/338710; Harty TP, 2000, EPILEPSY RES, V39, P47, DOI 10.1016/S0920-1211(99)00108-4; He XP, 2002, J NEUROSCI, V22, P7502; Hellmich HL, 2005, ANESTHESIOLOGY, V102, P806, DOI 10.1097/00000542-200504000-00017; Helmstaedter C, 2003, ANN NEUROL, V54, P425, DOI 10.1002/ana.10692; Hernandez TD, 1997, TRENDS PHARMACOL SCI, V18, P59, DOI 10.1016/S0165-6147(96)01027-9; Hesdorffer DC, 2001, ANN NEUROL, V50, P458, DOI 10.1002/ana.1136; Hinz B, 2001, EUR J CELL BIOL, V80, P615, DOI 10.1078/0171-9335-00196; Hirai H, 2001, EUR J NEUROSCI, V14, P73, DOI 10.1046/j.0953-816x.2001.01630.x; Holmes GL, 1998, ANN NEUROL, V44, P845, DOI 10.1002/ana.410440602; Holmes GL, 1997, EPILEPSIA, V38, P12, DOI 10.1111/j.1528-1157.1997.tb01074.x; Holmes GL, 1999, J COMP NEUROL, V404, P537, DOI 10.1002/(SICI)1096-9861(19990222)404:4<537::AID-CNE9>3.0.CO;2-#; Hoover RC, 2004, J NEUROTRAUM, V21, P501, DOI 10.1089/089771504774129847; Hovinga CA, 2002, EXPERT OPIN INV DRUG, V11, P1387, DOI 10.1517/13543784.11.10.1387; Hovorka J, 1997, EPILEPSY RES, V28, P225, DOI 10.1016/S0920-1211(97)00048-X; Huang YF, 2002, J NEUROSCI, V22, P8422; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; Illmer T, 2004, LEUKEMIA, V18, P401, DOI 10.1038/sj.leu.2403257; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; Isoherranen N, 2001, EPILEPSIA, V42, P831, DOI 10.1046/j.1528-1157.2001.042007831.x; Jokeit H, 2002, PROG BRAIN RES, V135, P455; Jung HY, 1997, J NEUROSCI, V17, P6639; Kali S, 2004, NAT NEUROSCI, V7, P286, DOI 10.1038/nn1202; Kaneko S, 2002, NEUROSCI RES, V44, P11, DOI 10.1016/S0168-0102(02)00065-2; KASTELEIJNNOLSTTRENITE DGA, 1988, EPILEPSY RES, V2, P111, DOI 10.1016/0920-1211(88)90027-7; Khalilov I, 2003, NAT NEUROSCI, V6, P1079, DOI 10.1038/nn1125; Klitgaard H, 1998, EUR J PHARMACOL, V353, P191, DOI 10.1016/S0014-2999(98)00410-5; Klodzinska A, 1999, POL J PHARMACOL, V51, P543; Klugbauer N, 2003, J BIOENERG BIOMEMBR, V35, P639, DOI 10.1023/B:JOBB.0000008028.41056.58; Kohling R, 1998, BRAIN, V121, P1073, DOI 10.1093/brain/121.6.1073; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; KREINDLER A, 1958, J NEUROPHYSIOL, V21, P430, DOI 10.1152/jn.1958.21.5.430; Kuzniecky R, 2002, NEUROLOGY, V58, P368, DOI 10.1212/WNL.58.3.368; LEBER PD, 1989, EPILEPSIA, V30, pS57, DOI 10.1111/j.1528-1157.1989.tb05816.x; LEITE JP, 1995, EPILEPSY RES, V20, P93, DOI 10.1016/0920-1211(94)00070-D; Leith CP, 1999, BLOOD, V94, P1086; LEMOS T, 1995, EXP BRAIN RES, V102, P423; Leonard GD, 2003, ONCOLOGIST, V8, P411, DOI 10.1634/theoncologist.8-5-411; Lerma J, 1997, TRENDS NEUROSCI, V20, P9, DOI 10.1016/S0166-2236(96)20055-4; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; LOEWE S, 1953, ARZNEIMITTEL-FORSCH, V3, P285; LOISEAU P, 1983, ANN NEUROL, V13, P642, DOI 10.1002/ana.410130610; Lombroso CT, 1997, EPILEPSIA, V38, P797, DOI 10.1111/j.1528-1157.1997.tb01467.x; Loscher W, 2005, NAT REV NEUROSCI, V6, P591, DOI 10.1038/nrn1728; Louie K, 2001, NEURON, V29, P145, DOI 10.1016/S0896-6273(01)00186-6; Luker GD, 1997, J NUCL MED, V38, P369; Luszczki J, 2003, PHARMACOL BIOCHEM BE, V75, P319, DOI 10.1016/S0091-3057(03)00081-9; Luszczki JJ, 2006, EPILEPSIA, V47, P10, DOI 10.1111/j.1528-1167.2006.00364.x; Luszczki JJ, 2005, EUR J PHARMACOL, V515, P54, DOI 10.1016/j.ejphar.2005.03.046; Luszczki JJ, 2005, NEUROPSYCHOPHARMACOL, V30, P958, DOI 10.1038/sj.npp.1300602; Luszczki JJ, 2004, EPILEPSIA, V45, P895, DOI 10.1111/j.0013-9580.2004.05104.x; Luszczki JJ, 2003, NEUROPSYCHOPHARMACOL, V28, P1817, DOI 10.1038/sj.npp.1300243; Luszczki JJ, 2003, EPILEPSIA, V44, P1003, DOI 10.1046/j.1528-1157.2003.10003.x; Luszczki JJ, 2003, EPILEPSIA, V44, P489, DOI 10.1046/j.1528-1157.2003.32702.x; Lynch BA, 2004, P NATL ACAD SCI USA, V101, P9861, DOI 10.1073/pnas.0308208101; Maquet P, 2001, SCIENCE, V294, P1048, DOI 10.1126/science.1062856; MARESCAUX C, 1987, EXP NEUROL, V97, P160, DOI 10.1016/0014-4886(87)90290-1; Marson A, 2005, LANCET, V365, P2007, DOI 10.1016/S0140-6736(05)66694-9; Massa R, 2001, NEUROLOGY, V57, P1071, DOI 10.1212/WNL.57.6.1071; Massey PV, 2004, J NEUROSCI, V24, P7821, DOI 10.1523/JNEUROSCI.1697-04.2004; Matsuzaka T, 2001, EPILEPSIA, V42, P9, DOI 10.1046/j.1528-1157.42.s6.2.x; Matveeva EA, 2003, J NEUROCHEM, V84, P621, DOI 10.1046/j.1471-4159.2003.01589.x; McAllister AK, 1996, NEURON, V17, P1057, DOI 10.1016/S0896-6273(00)80239-1; MCNAMARA JO, 1988, NEUROPHARMACOLOGY, V27, P563, DOI 10.1016/0028-3908(88)90176-1; MEENCKE HJ, 1983, J NEUROL, V230, P171, DOI 10.1007/BF00313628; MELDRUM B, 1985, CLIN SCI, V68, P113, DOI 10.1042/cs0680113; Minichiello L, 2002, NEURON, V36, P121, DOI 10.1016/S0896-6273(02)00942-X; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; MORUZZI G, 1995, J NEUROPSYCH CLIN N, V7, P251; MOSHE SL, 1984, DEV BRAIN RES, V13, P305, DOI 10.1016/0165-3806(84)90165-2; Nabbout R, 2003, J CLIN NEUROPHYSIOL, V20, P393, DOI 10.1097/00004691-200311000-00002; Narkilahti S, 2003, NEUROPHARMACOLOGY, V44, P1068, DOI 10.1016/S0028-3908(03)00115-1; NEVANDER G, 1985, ANN NEUROL, V18, P281, DOI 10.1002/ana.410180303; Neyens LGJ, 1999, EPILEPSY RES, V34, P85, DOI 10.1016/S0920-1211(98)00118-1; NGouemo P, 1997, BRAIN RES, V761, P217, DOI 10.1016/S0006-8993(97)00322-3; Nielsen EO, 1999, J PHARMACOL EXP THER, V289, P1492; Northcott E, 2005, EPILEPSIA, V46, P924, DOI 10.1111/j.1528-1167.2005.62304.x; NOYER M, 1995, EUR J PHARMACOL, V286, P137, DOI 10.1016/0014-2999(95)00436-O; Olney JW, 2004, TRENDS PHARMACOL SCI, V25, P135, DOI 10.1016/j.tips.2004.01.002; Parsons CG, 1998, DRUG NEWS PERSPECT, V11, P523, DOI 10.1358/dnp.1998.11.9.863689; Patel MK, 2000, BRIT J PHARMACOL, V130, P1731, DOI 10.1038/sj.bjp.0703530; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; Pellock JM, 1999, EPILEPSIA, V40, pS57, DOI 10.1111/j.1528-1157.1999.tb00920.x; PENNELL PB, 1995, NEUROLOGY, V45, P456, DOI 10.1212/WNL.45.3.456; Perucca E, 2003, EPILEPSIA, V44, P41, DOI 10.1046/j.1528-1157.44.s4.1.x; Perucca E, 2002, EUR J PAIN, V6, P35, DOI 10.1053/eujp.2001.0320; Perucca E, 2001, CNS DRUGS, V15, P609, DOI 10.2165/00023210-200115080-00004; Perucca E, 1998, EUR J CLIN PHARMACOL, V54, P1, DOI 10.1007/s002280050411; Petroff OAC, 2001, EPILEPSIA, V42, P543, DOI 10.1046/j.1528-1157.2001.18800.x; Pitkanen A, 2005, EPILEPSY RES, V63, P27, DOI 10.1016/j.eplepsyres.2004.10.003; Pitkanen A, 2004, EXPERT OPIN PHARMACO, V5, P777, DOI 10.1517/eoph.5.4.777.30162; Postma T, 2000, EPILEPSIA, V41, P1514; Potschka H, 1999, EUR J PHARMACOL, V374, P175, DOI 10.1016/S0014-2999(99)00311-8; Prakriya M, 2000, NEURON, V26, P671, DOI 10.1016/S0896-6273(00)81203-9; Pyle RA, 2000, J BIOL CHEM, V275, P17195, DOI 10.1074/jbc.M000674200; Reid KH, 2001, NEUROSCI LETT, V308, P29, DOI 10.1016/S0304-3940(01)01973-5; Reigada D, 2003, P NATL ACAD SCI USA, V100, P3485, DOI 10.1073/pnas.0336914100; Reis J, 2002, EPILEPSIA, V43, P1149, DOI 10.1046/j.1528-1157.2002.09902.x; Remy S, 2003, ANN NEUROL, V53, P469, DOI 10.1002/ana.10473; Rigoulot MA, 2003, EPILEPSIA, V44, P529, DOI 10.1046/j.1528-1157.2003.50502.x; Robey R, 1999, BLOOD, V93, P306, DOI 10.1182/blood.V93.1.306.401k42_306_314; Roch C, 2002, EPILEPSIA, V43, P1129, DOI 10.1046/j.1528-1157.2002.17802.x; Roch C, 2002, EPILEPSIA, V43, P325, DOI 10.1046/j.1528-1157.2002.11301.x; RODIN E, 1971, ELECTROEN CLIN NEURO, V30, P62, DOI 10.1016/0013-4694(71)90205-7; RODIN EA, 1986, DEV MED CHILD NEUROL, V28, P25; ROGAWSKI MA, 1990, PHARMACOL REV, V42, P223; Roopra A, 2001, Mol Interv, V1, P219; Roth T, 2001, SLEEP MED, V2, P379, DOI 10.1016/S1389-9457(01)00071-5; Roth Thomas, 2003, Clin Cornerstone, V5, P5, DOI 10.1016/S1098-3597(03)90031-7; RUNDFELDT C, 1993, J PHARMACOL EXP THER, V266, P216; Sakaeda T, 2003, PHARMACOGENOMICS, V4, P397, DOI 10.1517/phgs.4.4.397.22747; Sanchez RM, 2001, J NEUROSCI, V21, P8154, DOI 10.1523/JNEUROSCI.21-20-08154.2001; Schachter SC, 2000, EXPERT OPIN INV DRUG, V9, P871, DOI 10.1517/13543784.9.4.871; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Schivell AE, 1996, J BIOL CHEM, V271, P27770, DOI 10.1074/jbc.271.44.27770; Schmidt D, 2005, EPILEPSIA, V46, P858, DOI 10.1111/j.1528-1167.2005.54904.x; SCHWINDT PC, 1995, J NEUROPHYSIOL, V74, P2220, DOI 10.1152/jn.1995.74.5.2220; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Shen B, 1996, HIPPOCAMPUS, V6, P685; SHEWMON DA, 1988, ELECTROEN CLIN NEURO, V69, P319, DOI 10.1016/0013-4694(88)90004-1; Shimoyama M, 2000, PAIN, V85, P405, DOI 10.1016/S0304-3959(99)00283-3; Sillanpaa M, 1998, NEW ENGL J MED, V338, P1715, DOI 10.1056/NEJM199806113382402; Sills GJ, 2003, EPILEPSIA, V44, P886, DOI 10.1046/j.1528-1157.2003.04203.x; SILVER JM, 1991, ANN NEUROL, V29, P356, DOI 10.1002/ana.410290404; SILVERMAN RB, 1991, J MED CHEM, V34, P2295, DOI 10.1021/jm00111a053; Sparreboom A, 2003, DRUG RESIST UPDATE, V6, P71, DOI 10.1016/S1368-7646(03)00005-0; Sperber EF, 1999, DEV BRAIN RES, V116, P59, DOI 10.1016/S0165-3806(99)00075-9; Spigelman I, 1998, NEUROSCIENCE, V86, P109, DOI 10.1016/S0306-4522(98)00028-1; Spooren W, 2003, BEHAV PHARMACOL, V14, P257, DOI 10.1097/01.fbp.0000081783.35927.8f; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Stables James P., 2003, Epilepsia, V44, P1472, DOI 10.1111/j.0013-9580.2003.32803.x; Stables James P., 2002, Epilepsia, V43, P1410, DOI 10.1046/j.1528-1157.2002.06702.x; Stafstrom CE, 2002, INT REV NEUROBIOL, V49, P391; STALEY KJ, 1995, SCIENCE, V269, P977, DOI 10.1126/science.7638623; Steckler T, 2005, BEHAV BRAIN RES, V164, P52, DOI 10.1016/j.bbr.2005.05.010; Stefani A, 1998, NEUROPHARMACOLOGY, V37, P83, DOI 10.1016/S0028-3908(97)00189-5; Stephen LJ, 2002, SEIZURE-EUR J EPILEP, V11, P349, DOI 10.1053/seiz.2002.0711; Stratton SC, 2003, EPILEPSY RES, V53, P95, DOI 10.1016/S0920-1211(02)00254-1; SUMANCHAUHAN N, 1993, EUR J PHARM-MOLEC PH, V244, P293, DOI 10.1016/0922-4106(93)90155-3; SUTULA T, 1987, BRAIN RES, V420, P109, DOI 10.1016/0006-8993(87)90245-9; SVEINBJORNSDOTTIR S, 1993, EPILEPSY RES, V16, P165, DOI 10.1016/0920-1211(93)90031-2; TAYLOR CP, 1993, EPILEPSY RES, V14, P11, DOI 10.1016/0920-1211(93)90070-N; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; THURLOW RJ, 1993, EUR J PHARM-MOLEC PH, V247, P341, DOI 10.1016/0922-4106(93)90204-M; Trinka E, 2004, J NEUROL, V251, P1235, DOI 10.1007/s00415-004-0521-1; Tromp SC, 2003, J CHILD NEUROL, V18, P407, DOI 10.1177/08830738030180060501; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Volk HA, 2005, BRAIN, V128, P1358, DOI 10.1093/brain/awh437; Wakamoto H, 2000, BRAIN DEV-JPN, V22, P246, DOI 10.1016/S0387-7604(00)00121-2; Walker MC, 1996, NEUROLOGY, V46, P912, DOI 10.1212/WNL.46.4.912; Walker MC, 1997, NEUROLOGY, V49, P333, DOI 10.1212/WNL.49.2.333; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; Wang MH, 1999, BIOCHEM J, V342, P313, DOI 10.1042/0264-6021:3420313; Weglage J, 1997, DEV MED CHILD NEUROL, V39, P646; Westphalen RI, 2003, J PHARMACOL EXP THER, V304, P1188, DOI 10.1124/jpet.102.044685; White H S, 1998, Adv Neurol, V76, P29; White HS, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s7.10.x; Williams J, 1998, SEIZURE-EUR J EPILEP, V7, P223, DOI 10.1016/S1059-1311(98)80040-X; WILSON MA, 1994, SCIENCE, V265, P676, DOI 10.1126/science.8036517; Wirrell E, 2001, EPILEPSIA, V42, P760, DOI 10.1046/j.1528-1157.2001.02401.x; Wirrell EC, 1996, NEUROLOGY, V47, P912, DOI 10.1212/WNL.47.4.912; Wirrell EC, 1997, ARCH PEDIAT ADOL MED, V151, P152, DOI 10.1001/archpedi.1997.02170390042008; Wlaz P, 1998, EUR J PHARMACOL, V342, P39, DOI 10.1016/S0014-2999(97)01452-0; Wlaz P, 1997, EPILEPSIA, V38, P1167, DOI 10.1111/j.1528-1157.1997.tb01212.x; Wong M, 2003, EXP NEUROL, V183, P87, DOI 10.1016/S0014-4886(03)00099-2; WONG MW, 1987, RAPID COMMUN MASS SP, V1, P3; Wong N D, 2001, Prev Cardiol, V4, P109, DOI 10.1111/j.1520-037X.2001.00570.x; Xu T, 2001, NAT CELL BIOL, V3, P691, DOI 10.1038/35087000; Zhang Y, 2004, J NEUROSCI, V24, P5239, DOI 10.1523/JNEUROSCI.0992-04.2004; Zhang Y, 2002, MOL THER, V6, P67, DOI 10.1006/mthe.2002.0633; Zupanc ML, 2003, EXPERT OPIN PHARMACO, V4, P2039, DOI 10.1517/14656566.4.11.2039	281	90	96	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211	1872-6844		EPILEPSY RES	Epilepsy Res.	JUN	2006	69	3					183	272		10.1016/j.eplepsyres.2006.03.014			90	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	062DO	WOS:000238925000001	16835945	Green Accepted			2022-02-06	
J	Pullela, R; Raber, J; Pfankuch, T; Ferriero, DM; Claus, CP; Koh, SE; Yamauchi, T; Rola, R; Fike, JR; Noble-Haeusslein, LJ				Pullela, Ramadevi; Raber, Jacob; Pfankuch, Timothy; Ferriero, Donna M.; Claus, Catherine P.; Koh, Seong-Eun; Yamauchi, Toshihiro; Rola, Radoslaw; Fike, John R.; Noble-Haeusslein, Linda J.			Traumatic injury to the immature brain results in progressive neuronal loss, hyperactivity and delayed cognitive impairments	DEVELOPMENTAL NEUROSCIENCE			English	Article						traumatic brain injury; immature brain; cognitive function; delayed cell loss	HEAD-INJURY; ADULT-RAT; REGIONAL VULNERABILITY; SUPEROXIDE-DISMUTASE; SOCIAL-INTERACTION; ANIMAL-MODELS; MOUSE-BRAIN; TIME-COURSE; CELL LOSS; CHILDREN	The immature brain may be particularly vulnerable to injury during critical periods of development. To address the biologic basis for this vulnerability, mice were subjected to traumatic brain injury at postnatal day 21, a time point that approximates that of the toddler-aged child. After motor and cognitive testing at either 2 weeks (juveniles) or 3 months (adults) after injury, animals were euthanized and the brains prepared for quantitative histologic assessment. Brain-injured mice exhibited hyperactivity and age-dependent anxiolysis. Cortical lesion volume and subcortical neuronal loss were greater in brain-injured adults than in juveniles. Importantly, cognitive decline was delayed in onset and coincided with loss of neurons in the hippocampus. Our findings demonstrate that trauma to the developing brain results in a prolonged period of pathogenesis in both cortical and subcortical structures. Behavioral changes are a likely consequence of regional-specific neuronal degeneration. Copyright (c) 2006 S. Karger AG, Basel.	Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; Oregon Hlth & Sci Univ, Dept Behav Neurosci, ONPRC, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Neurol, ONPRC, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Div Neurosci, ONPRC, Portland, OR 97201 USA		Noble-Haeusslein, LJ (corresponding author), 521 Parnassus Ave,Room C-224, San Francisco, CA 94143 USA.	noblelj@itsa.ucsf.edu	Rola, Radoslaw/AAQ-5587-2021; Rola, Radoslaw/V-6749-2018	Rola, Radoslaw/0000-0003-0613-6593; Rola, Radoslaw/0000-0003-0613-6593	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050159] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS050159, R21NS41246] Funding Source: Medline		Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Conti AC, 1998, J NEUROSCI, V18, P5663; Crack PJ, 2001, J NEUROCHEM, V78, P1389, DOI 10.1046/j.1471-4159.2001.00535.x; de Bilbao F, 2000, EUR J NEUROSCI, V12, P921, DOI 10.1046/j.1460-9568.2000.00984.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Durkin MS, 1998, NEUROSURGERY, V42, P300, DOI 10.1097/00006123-199802000-00052; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Gonzalez LE, 2000, BRAIN RES, V887, P7, DOI 10.1016/S0006-8993(00)02931-0; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; HAHN YS, 1988, CHILD NERV SYST, V4, P34; Hicks R. R., 2000, Journal of Neurotrauma, V17, P969; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; Jessberger S, 2003, EUR J NEUROSCI, V18, P2707, DOI 10.1111/j.1460-9568.2003.02986.x; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kesner RP, 2000, CURR OPIN NEUROBIOL, V10, P260, DOI 10.1016/S0959-4388(00)00067-2; Konrad K, 2003, COGNITIVE BRAIN RES, V16, P425, DOI 10.1016/S0926-6410(03)00057-0; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Lacroix L, 2000, BEHAV NEUROSCI, V114, P1119, DOI 10.1037//0735-7044.114.6.1119; Lassalle JM, 2000, NEUROBIOL LEARN MEM, V73, P243, DOI 10.1006/nlme.1999.3931; Lehnung M, 2001, CHILD NEUROPSYCHOL, V7, P59, DOI 10.1076/chin.7.2.59.3129; Levin ED, 1998, BEHAV GENET, V28, P381, DOI 10.1023/A:1021673703129; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LISTER RG, 1990, PHARMACOL THERAPEUT, V46, P321, DOI 10.1016/0163-7258(90)90021-S; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Max JE, 2003, J INT NEUROPSYCH SOC, V9, P815, DOI 10.1017/S1355617703960012; Mesulam MM, 1998, BRAIN, V121, P1013, DOI 10.1093/brain/121.6.1013; MICHAUD LJ, 1993, PEDIATR CLIN N AM, V40, P553; Mizuguchi M, 1999, AM J PATHOL, V155, P1713, DOI 10.1016/S0002-9440(10)65486-7; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; Nacher J, 2001, EUR J NEUROSCI, V14, P629, DOI 10.1046/j.0953-816x.2001.01683.x; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Peterson BS, 2000, ARCH GEN PSYCHIAT, V57, P364, DOI 10.1001/archpsyc.57.4.364; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; RADCLIFFE J, 1994, INT J DEV NEUROSCI, V12, P327, DOI 10.1016/0736-5748(94)90081-7; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Rangel A, 2003, BRAIN RES, V992, P96, DOI 10.1016/j.brainres.2003.08.038; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.1289/ehp.00108s3511; Rustay NR, 2003, BEHAV BRAIN RES, V141, P237, DOI 10.1016/S0166-4328(02)00376-5; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Shah AA, 2003, BRAIN RES, V969, P183, DOI 10.1016/S0006-8993(03)02299-6; SLOTNICK BM, 1975, STEREOTAXIC ATLAS MO; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Solanto MV, 2002, BEHAV BRAIN RES, V130, P65, DOI 10.1016/S0166-4328(01)00431-4; StubleyWeatherly L, 1996, BRAIN RES, V716, P29, DOI 10.1016/0006-8993(95)01589-2; SUTHERLAND RJ, 1983, BEHAV BRAIN RES, V7, P133, DOI 10.1016/0166-4328(83)90188-2; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Vasa RA, 2004, BIOL PSYCHIAT, V55, P208, DOI 10.1016/S0006-3223(03)00708-X; WEINGARTEN J, 1999, PSYCHOSURGERY HUMAN; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; ZILLES K, 1985, RAT NERVOUS SYSTEM, V1, P375	68	90	94	0	13	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					396	409		10.1159/000094166			14	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600017	16943663				2022-02-06	
J	Wade, SL; Michaud, L; Brown, TM				Wade, SL; Michaud, L; Brown, TM			Putting the pieces together - Preliminary efficacy of a family problem-solving intervention for children with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; child adjustment; communication skills; family adaptation; problem solving	PREDICTORS; ADOLESCENTS; SKILLS	Objective: To describe a family-centered problem-solving intervention (FPS) for pediatric traumatic brain injury (TBI), and to assess the efficacy of the intervention in a randomized clinical trial. Participants: Families of 32 school-aged children with moderate to severe TBI randomly assigned to FPS or usual care (UC) group. Main Outcome Measures: Child Behavior Checklist, Brief Symptom Inventory, Conflict Behavior Questionnaire. Intervention: Seven-session problemsolving/skill-building intervention delivered over a 6-month period for the participating families. Results: Parents in the FPS group reported significantly greater improvements in their children in internalizing symptoms, anxiety/depression, and withdrawal than did parents in the UC comparison group. Conclusions: FPS holds promise for reducing child behavior problems, the most common and persistent sequelate of TBI.	Childrens Hosp, Med Ctr, Div Pediat Phys Med & Rehabil, Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA		Wade, SL (corresponding author), Childrens Hosp, Med Ctr, Div Pediat Phys Med & Rehabil, Dept Pediat, 333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org					ACHENBACH TM, 1991, MANUAL CHILD BEAHV C; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; Cohen J., 2013, STAT POWER ANAL BEHA; D'Zurilla T.J., 1999, PROBLEM SOLVING THER, V2nd edn; Derogatis LR., 1982, BRIEF SYMPTOM INVENT; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Horwitz SM, 2001, PSYCHIAT SERV, V52, P1088, DOI 10.1176/appi.ps.52.8.1088; Jacobs R, 2002, CHILD NEUROPSYCHOL, V8, P93, DOI 10.1076/chin.8.2.93.8726; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; JENNETT B, 1975, LANCET, V1, P480; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Nezu AM, 1998, HELPING CANC PATIENT; OBRIEN RG, 1985, PSYCHOL BULL, V97, P316, DOI 10.1037/0033-2909.97.2.316; Patterson G.R., 1992, ANTISOCIAL BOYS, VVolume 4; Patterson GeraldR., 1988, STRESS COPING DEV CH, P235; Robin AL, 1989, NEGOTIATING PARENT A; SANDERS MR, 1989, J CLIN CHILD PSYCHOL, V18, P72, DOI 10.1207/s15374424jccp1801_9; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; SINGER GHS, 1994, J HEAD TRAUMA REHAB, V9, P38, DOI DOI 10.1097/00001199-199412000-00006; WADE S, 1995, J PEDIATR PSYCHOL, V20, P737, DOI 10.1093/jpepsy/20.6.737; Wade SL, 2004, J CONSULT CLIN PSYCH, V72, P776, DOI 10.1037/0022-006X.72.5.776; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Ylvisaker M., 1998, COLLABORATIVE BRAIN	25	90	90	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2006	21	1					57	67		10.1097/00001199-200601000-00006			11	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	004WW	WOS:000234784300006	16456392				2022-02-06	
J	Casha, S; Yu, WR; Fehlings, MG				Casha, S; Yu, WR; Fehlings, MG			FAS deficiency reduces apoptosis, spares axons and improves function after spinal cord injury	EXPERIMENTAL NEUROLOGY			English	Article						spinal cord injury; FAS; apoptosis; oligodendrocyte; neuroprotection	TRAUMATIC BRAIN-INJURY; NEURONAL CELL-DEATH; COMPRESSION TRAUMA; WALLERIAN DEGENERATION; CONTUSION INJURY; GLIAL APOPTOSIS; UP-REGULATION; GRADED MODEL; IN-VITRO; RAT	After spinal cord injury (SCI), apoptosis of neurons and oligodendrocytes is associated with axonal degeneration and loss of neurological function. Recent data have suggested a potential role for FAS death receptor-mediated apoptosis in the pathophysiology of SCI. In this study, we examined the effect of FAS deficiency on SCI in vitro and in vivo. FAS(Lpr/lpr) mutant mice and wildtype background-matched mice were subjected to a T5-6 clip compression SCI, and complementary studies were done in an organotypic slice culture model of SCI. Post-traumatic apoptosis in the spinal cord, which was seen in neurons and oligodendrocytes, was decreased in the FAS-deficient mice both in vivo and in vitro particularly in oligodendrocytes. FAS deficiency was also associated with improved locomotor recovery, axonal sparing and preservation of oligodendrocytes and myelin. However, FAS deficiency did not result in a significant increase in surviving neurons in the spinal cord at 6 weeks after injury, likely reflecting the importance of other cell death mechanisms for neurons. We conclude that inhibition of the FAS pathway may be a clinically attractive neuroprotective strategy directed towards oligodendroglial and axonal preservation in the treatment of SCI and neurotrauma. (c) 2005 Elsevier Inc. All rights reserved.	Toronto Western Hosp, Krembil Neurosci Ctr, Spinal Program, Toronto, ON M5T 2S8, Canada; Univ Toronto, Inst Med Sci, Dept Surg, Toronto, ON M5T 2S8, Canada		Fehlings, MG (corresponding author), Toronto Western Hosp, Krembil Neurosci Ctr, Spinal Program, 399 Bathurst St, Toronto, ON M5T 2S8, Canada.	Michael.fehlings@uhn.on.ca		Fehlings, Michael/0000-0002-5722-6364			Abe Y, 1999, J NEUROTRAUM, V16, P945, DOI 10.1089/neu.1999.16.945; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bjartmar C, 1999, J NEUROCYTOL, V28, P383, DOI 10.1023/A:1007010205037; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DEMJEN D, 2004, NAT MED, V7, P7; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Ghirnikar RS, 2001, J NEUROSCI RES, V64, P582, DOI 10.1002/jnr.1110; Gillardon F, 1999, NEUROSCIENCE, V93, P1219, DOI 10.1016/S0306-4522(99)00292-4; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Joshi M, 2002, J NEUROTRAUM, V19, P175, DOI 10.1089/08977150252806947; Joshi M, 2002, J NEUROTRAUM, V19, P191, DOI 10.1089/08977150252806956; Katoh K, 1996, NEUROSCI LETT, V216, P9; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; Kim GM, 2001, J NEUROSCI, V21, P6617, DOI 10.1523/JNEUROSCI.21-17-06617.2001; Krassioukov AV, 2002, BRAIN RES PROTOC, V10, P60, DOI 10.1016/S1385-299X(02)00180-0; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; Li GL, 1999, ACTA NEUROPATHOL, V98, P473, DOI 10.1007/s004010051112; Li GL, 2000, ACTA NEUROPATHOL, V100, P75, DOI 10.1007/s004010051195; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Li XM, 2000, RESTOR NEUROL NEUROS, V17, P203; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lou J, 1998, SPINAL CORD, V36, P683, DOI 10.1038/sj.sc.3100632; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; Morita-Fujimura Y, 1999, J CEREBR BLOOD F MET, V19, P634, DOI 10.1097/00004647-199906000-00006; Nakahara S, 1999, J NEUROPATH EXP NEUR, V58, P442, DOI 10.1097/00005072-199905000-00003; Nakatsuru S, 1999, PATHOL INT, V49, P974, DOI 10.1046/j.1440-1827.1999.00979.x; Ray SK, 2000, NEUROCHEM RES, V25, P1191, DOI 10.1023/A:1007631826160; Ray SK, 2000, BRAIN RES, V867, P80, DOI 10.1016/S0006-8993(00)02260-5; Saito N, 2000, J NEUROTRAUM, V17, P173, DOI 10.1089/neu.2000.17.173; Sakurai M, 1998, BRAIN RES, V797, P23, DOI 10.1016/S0006-8993(98)00290-X; Sakurai M, 2000, STROKE, V31, P200, DOI 10.1161/01.STR.31.1.200; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; Schmidt M, 2001, J IMMUNOL, V166, P1344, DOI 10.4049/jimmunol.166.2.1344; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; Siegel RM, 2000, NAT IMMUNOL, V1, P469, DOI 10.1038/82712; Silvestris F, 2000, MOL MED, V6, P509, DOI 10.1007/BF03401791; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Ugolini G, 2003, J NEUROSCI, V23, P8526; Vidal S, 1998, J CLIN INVEST, V101, P696, DOI 10.1172/JCI1817; Wada S, 1999, J NEUROSURG, V91, P98, DOI 10.3171/spi.1999.91.1.0098; Warden P, 2001, EXP NEUROL, V168, P213, DOI 10.1006/exnr.2000.7622; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yin XH, 1998, J NEUROSCI, V18, P1953, DOI 10.1523/jneurosci.18-06-01953.1998; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Yoshino O, 2004, SPINE, V29, P1394, DOI 10.1097/01.BRS.0000129894.34550.48; Zurita M, 2001, J NEUROSURG, V94, P257, DOI 10.3171/spi.2001.94.2.0257	51	90	100	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	DEC	2005	196	2					390	400		10.1016/j.expneurol.2005.08.020			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	987WG	WOS:000233547700020	16202410				2022-02-06	
J	Iverson, GL; Gaetz, M; Lovell, MR; Collins, MW				Iverson, GL; Gaetz, M; Lovell, MR; Collins, MW			Relation between subjective fogginess and neuropsychological testing following concussion	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						concussion; neuropsychological testing; sports		The purpose of this study was to examine the relation between the subjective report of feeling foggy at one-week post concussion and acute neuropsychological outcome. The outcome variables were derived from a computerized neuropsychological screening battery, Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT). Participants were I 10 high school students who sustained a sports-related concussion and were evaluated 5-10 days post injury (M = 6.8 days). Athletes were divided into two groups on the basis of self-reported fogginess. The first group reported no fogginess (it = 91), whereas the second group reported experiencing some degree of fogginess (n = 19) on a 6-point scale. The athletes with persistent fogginess experienced a large number of other post-concussion symptoms, compared to the athletes with no reported fogginess. In addition, the athletes with persistent fogginess had significantly slower reaction times, reduced memory performance, and slower processing speed. Thus, athletes with any degree of self-reported fogginess at one-week post injury are likely to have adverse effects from their concussions in multiple domains.	Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2B4, Canada; Riverview Hosp, Vancouver, BC V6T 2B4, Canada; Univ Fraser Valley, Abbotsford, BC, Canada; Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA		Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2B4, Canada.	giverson@interchange.ubc.ca		Iverson, Grant/0000-0001-7348-9570			Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027	3	90	92	1	7	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	OCT	2004	10	6					904	906		10.1017/S1355617704106139			3	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	862PB	WOS:000224502000013	15637782				2022-02-06	
J	Reeves, TM; Prins, ML; Zhu, JP; Povlishock, JT; Phillips, LL				Reeves, TM; Prins, ML; Zhu, JP; Povlishock, JT; Phillips, LL			Matrix metalloproteinase inhibition alters functional and structural correlates of deafferentation-induced sprouting in the dentate gyrus	JOURNAL OF NEUROSCIENCE			English	Article						deafferentation; collateral sprouting; synaptogenesis; matrix metalloproteinase; extracellular matrix; synaptic plasticity	ENTORHINAL CORTEX LESION; LONG-TERM POTENTIATION; TRAUMATIC BRAIN-INJURY; EXCITATORY SYNAPTIC TRANSMISSION; CENTRAL-NERVOUS-SYSTEM; CURRENT SOURCE-DENSITY; RAT FASCIA-DENTATA; ADULT-RAT; EXTRACELLULAR-MATRIX; HIPPOCAMPAL CA1	Molecules comprising the extracellular matrix (ECM), and the family of matrix metalloproteinases (MMPs) that regulate them, perform essential functions during neuroplasticity in both developing and adult nervous systems, including substrate guidance during neuritogenesis and the establishment of boundaries for axonal terminal fields. MMP proteolysis of ECM molecules may perform a permissive or inductive role in fiber remodeling and synaptogenesis initiated by deafferentation. This study examined functional and structural effects of MMP inhibition during the early phases of deafferentation-induced sprouting, characterizing components of the degeneration/proliferation cycle that may be dependent on MMP activity. Adult rats received unilateral lesions of the entorhinal cortex to induce collateral sprouting of the crossed temporodentate fiber pathway. This was followed by intraventricular infusion of the MMP inhibitor FN-439 (2.9 mg/kg) or saline vehicle. After 7 d postlesion, rats underwent in vivo electrophysiological recording or histological processing for electron microscopic analysis. Lesioned rats receiving vehicle exhibited normal sprouting and synaptogenesis, with the emergence of the capacity for long-term potentiation (LTP) within the sprouting pathway, and the successful clearance of degenerating terminals with subsequent synaptic proliferation. In contrast, lesioned rats receiving the MMP inhibitor failed to develop the capacity for LTP and showed persistent cellular debris. Current source density analysis also revealed an FN-439-induced disruption of the current sink, normally localized to the middle region of the granule cell dendrites, corresponding to the terminal field of the crossed temporodentate fibers. These results establish a role for MMP-dependent processes in the deafferentation/sprouting cycle.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat & Neurobiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Anesthesiol, Richmond, VA 23298 USA; Univ Calif Los Angeles, Div Neurosurg, Los Angeles, CA 90095 USA		Reeves, TM (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat & Neurobiol, 1217 E Marshall St,Room 740,Box 980709, Richmond, VA 23298 USA.		Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS044372, R56NS044372, R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS020193, NS44372, R56 NS044372, NS20193, R01 NS044372] Funding Source: Medline		Amaral David G., 1995, P443; Amet LEA, 2001, MOL CELL NEUROSCI, V17, P1014, DOI 10.1006/mcne.2001.0998; Anan H, 1996, J ENDODONT, V22, P668, DOI 10.1016/S0099-2399(96)80061-6; Bukalo O, 2001, NEUROSCIENCE, V104, P359, DOI 10.1016/S0306-4522(01)00082-3; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; BURDETTE LJ, 1995, BRAIN RES, V680, P53, DOI 10.1016/0006-8993(95)00231-E; Canning KJ, 1997, HIPPOCAMPUS, V7, P643, DOI 10.1002/(SICI)1098-1063(1997)7:6<643::AID-HIPO6>3.3.CO;2-L; Chang HP, 2001, NEUROSCIENCE, V102, P289, DOI 10.1016/S0306-4522(00)00478-4; CHOI BH, 1994, MICROSC RES TECHNIQ, V28, P193, DOI 10.1002/jemt.1070280304; COTMAN CW, 1981, PHYSIOL REV, V61, P684, DOI 10.1152/physrev.1981.61.3.684; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; DAVIS L, 1988, J COMP NEUROL, V267, P190, DOI 10.1002/cne.902670204; Deller T, 1996, NEUROSCIENCE, V71, P651, DOI 10.1016/0306-4522(95)00475-0; Deller T, 1997, NEUROSCIENCE, V81, P829, DOI 10.1016/S0306-4522(97)00194-2; Deller T, 1997, PROG NEUROBIOL, V53, P687, DOI 10.1016/S0301-0082(97)00044-0; DESMOND NL, 1983, BRAIN RES, V265, P21, DOI 10.1016/0006-8993(83)91329-X; DISCENNA PG, 1994, HIPPOCAMPUS, V4, P569, DOI 10.1002/hipo.450040506; ERB DE, 1991, EXP BRAIN RES, V83, P253; Fillmore HL, 2001, J NEURO-ONCOL, V53, P187, DOI 10.1023/A:1012213604731; Forster E, 1997, NEUROSCIENCE, V80, P731, DOI 10.1016/S0306-4522(97)00054-7; FROTSCHER M, 1988, ADV ANAT EMBRYOL CEL, V111, P2; Fujimura M, 1999, BRAIN RES, V842, P92, DOI 10.1016/S0006-8993(99)01843-0; GAGE FH, 1988, EXP NEUROL, V102, P2, DOI 10.1016/0014-4886(88)90073-8; Haas CA, 1997, NEUROSCIENCE, V81, P33, DOI 10.1016/S0306-4522(97)00187-5; Haas CA, 1999, J NEUROSCI, V19, P9953; Johnston D, 1995, FDN CELLULAR NEUROPH; KIGASAWA K, 1995, JPN J OPHTHALMOL, V39, P35; Komai S, 2000, EUR J NEUROSCI, V12, P1479, DOI 10.1046/j.1460-9568.2000.00035.x; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; Lauri SE, 1999, J NEUROSCI, V19, P1226; Lee MY, 1997, J NEUROSCI, V17, P1137; LEUNG LS, 1994, BRAIN RES, V650, P75; LEUNG LS, 1995, J NEUROPHYSIOL, V73, P2392, DOI 10.1152/jn.1995.73.6.2392; LOESCHE J, 1977, BRAIN RES BULL, V2, P31, DOI 10.1016/0361-9230(77)90022-3; LOMO T, 1971, EXP BRAIN RES, V12, P46; Lukes A, 1999, MOL NEUROBIOL, V19, P267, DOI 10.1007/BF02821717; MATTHEWS DA, 1976, BRAIN RES, V115, P23, DOI 10.1016/0006-8993(76)90820-9; MATTHEWS DA, 1976, BRAIN RES, V115, P1, DOI 10.1016/0006-8993(76)90819-2; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; ODAKE S, 1994, BIOCHEM BIOPH RES CO, V199, P1442, DOI 10.1006/bbrc.1994.1392; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; PHILLIPS LL, 1990, MOL BRAIN RES, V8, P249, DOI 10.1016/0169-328X(90)90024-8; PHILLIPS LL, 1994, NEUROSCIENCE, V58, P503, DOI 10.1016/0306-4522(94)90076-0; RAMIREZ JJ, 1984, BEHAV BRAIN RES, V13, P53, DOI 10.1016/0166-4328(84)90029-9; Ramirez JJ, 1996, P NATL ACAD SCI USA, V93, P15512, DOI 10.1073/pnas.93.26.15512; REEVES TM, 1987, BEHAV NEUROSCI, V101, P179; Reeves TM, 1997, NEUROSCIENCE, V77, P431, DOI 10.1016/S0306-4522(96)00486-1; REEVES TM, 1995, EXP BRAIN RES, V106, P248; REEVES TM, 1986, EXP BRAIN RES, V65, P167; RICHARDSON TL, 1987, J NEUROPHYSIOL, V58, P981, DOI 10.1152/jn.1987.58.5.981; STEWARD O, 1983, J COMP NEUROL, V214, P370, DOI 10.1002/cne.902140403; STEWARD O, 1976, EXP BRAIN RES, V26, P423; STEWARD O, 1976, SCIENCE, V194, P426, DOI 10.1126/science.982024; Steward O., 1991, CEREB CORTEX, V9, P81; Steward O., 1994, NEUROBIOLOGY CENTRAL, P266; Uhm JH, 1998, GLIA, V22, P53, DOI 10.1002/(SICI)1098-1136(199801)22:1<53::AID-GLIA5>3.0.CO;2-9; Vaillant C, 1999, J NEUROSCI, V19, P4994; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; WHITE G, 1990, J NEUROPHYSIOL, V64, P1186, DOI 10.1152/jn.1990.64.4.1186; WILSON R C, 1981, Journal of Neurophysiology (Bethesda), V46, P339; WILSON RC, 1981, J NEUROPHYSIOL, V46, P324, DOI 10.1152/jn.1981.46.2.324; WYSS JM, 1981, J COMP NEUROL, V199, P495; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Yong VW, 1998, TRENDS NEUROSCI, V21, P75; Yuan W, 2002, NEUROSCIENCE, V114, P1091, DOI 10.1016/S0306-4522(02)00347-0; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.ne.12.030189.000305	67	90	95	0	6	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	NOV 12	2003	23	32					10182	10189					8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	742UH	WOS:000186536100002	14614076				2022-02-06	
J	Michaelson, P; Michaelson, M; Jaric, S; Latash, ML; Sjolander, P; Djupsjobacka, M				Michaelson, P; Michaelson, M; Jaric, S; Latash, ML; Sjolander, P; Djupsjobacka, M			Vertical posture and head stability in patients with chronic neck	JOURNAL OF REHABILITATION MEDICINE			English	Article						neck pain; whiplash injury; work-related myalgia; single-blind method; posture; balance; head stabilization; proprioception	SUSPECTED CERVICAL ORIGIN; LOW-BACK-PAIN; WHIPLASH INJURIES; ARM MOVEMENTS; DISORDERS; DIZZINESS; BALANCE; MUSCLES; CAT	Objective: To evaluate postural performance and head stabilization of patients with chronic neck pain. Design: A single-blind comparative group study. Subjects: Patients with work-related chronic neck pain (n=9), with chronic whiplash associated disorders (n=9) and healthy subjects (n=16). Methods: During quiet standing in different conditions (e.g. 1 and 2 feet standing, tandem standing, and open and closed eyes) the sway areas and the ability to maintain the postures were measured. The maximal peak-to-peak displacement of the centre of pressure and the head translation were analysed during predictable and unpredictable postural perturbations. Results: Patients with chronic neck pain, in particular those with whiplash-associated disorders, showed larger sway areas and reduced ability to successfully execute more challenging balance tasks. They also displayed larger sway areas and reduced head stability during perturbations. Conclusion: The results show that disturbances of postural control in chronic neck pain are dependent on the aetiology, and that it is possible to quantify characteristic postural disturbances in different neck pain conditions. It is suggested that the dissimilarities in postural performance are a reflection of different degrees of disturbances of the proprioceptive input to the central nervous system and/or of the central processing of such input.	So Lapland Res Dept, SE-91232 Vilhelmina, Sweden; Univ Gavle, Ctr Musculoskeletal Res, Gavle, Sweden; Umea Univ, Dept Surg & Perioperat Sci, Div Sports Med, S-90187 Umea, Sweden; Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; Saxnasgardens Rehabil Ctr, Marsfjall, Sweden; Univ Delaware, Human Performance Lab, Newark, DE 19716 USA		Sjolander, P (corresponding author), So Lapland Res Dept, Postgatan 7, SE-91232 Vilhelmina, Sweden.	per.sjolander@vilhelmina.se	salimi, mehdi/D-1192-2009				Alund M, 1993, J Vestib Res, V3, P383; ARUIN AS, 1995, EXP BRAIN RES, V103, P323; ARUIN AS, 1995, EXP BRAIN RES, V106, P291; BRANDT T, 1991, VERTIGO ITS MULTISEN, P277; Branstrom H, 2001, ADV PHYSIOTHER, V3, P120; CORDO PJ, 1982, J NEUROPHYSIOL, V47, P287, DOI 10.1152/jn.1982.47.2.287; DIRNHOFER R, 1977, Z RECHTSMED, V79, P25; FITZRITSON D, 1991, J MANIP PHYSIOL THER, V14, P193; Graybiel A, 1966, Acta Otolaryngol, V61, P292, DOI 10.3109/00016486609127066; Hagg GM, 2000, EUR J APPL PHYSIOL, V83, P159, DOI 10.1007/s004210000274; Hodges PW, 1996, SPINE, V21, P2640, DOI 10.1097/00007632-199611150-00014; Johansson H, 1999, AM J IND MED, P104; JONSSON H, 1991, J SPINAL DISORD, V4, P251, DOI 10.1097/00002517-199109000-00001; Jull GA, 2000, J MUSCULOSKELET PAIN, V8, P143, DOI 10.1300/J094v08n01_12; Karlberg M, 1996, ARCH PHYS MED REHAB, V77, P874, DOI 10.1016/S0003-9993(96)90273-7; Karlberg M, 1996, J VESTIBUL RES-EQUIL, V6, P37; KARLBERG M, 1995, GAIT POSTURE, V3, P241; Lanska DJ, 2000, NEUROLOGY, V55, P1201, DOI 10.1212/WNL.55.8.1201; Latash ML, 1996, BEHAV BRAIN SCI, V19, P55, DOI 10.1017/S0140525X00041467; Luoto S, 1998, SPINE, V23, P2081, DOI 10.1097/00007632-199810010-00008; MASSION J, 1992, PROG NEUROBIOL, V38, P35, DOI 10.1016/0301-0082(92)90034-C; McPartland JM, 1997, J MANIP PHYSIOL THER, V20, P24; MUNRO BH, 1997, STAT METHODS HLTH CA, P162; NASHNER LM, 1976, EXP BRAIN RES, V26, P59; Ordway NR, 1997, SPINE, V22, P501, DOI 10.1097/00007632-199703010-00007; Pedersen J, 1997, PAIN, V70, P83, DOI 10.1016/S0304-3959(96)03305-2; Persson L, 1996, J VESTIBUL RES-EQUIL, V6, P439; ROSSITERFORNOFF JE, 1995, J GERONTOL A-BIOL, V50, pM291, DOI 10.1093/gerona/50A.6.M291; RUBIN AM, 1995, AM J OTOL, V16, P216; Serra L L, 1994, Acta Neurol (Napoli), V16, P262; Sjolander Per, 2002, J Electromyogr Kinesiol, V12, P167, DOI 10.1016/S1050-6411(02)00017-2; SRIVASTAVA M, 1996, REGRESSION ANAL THEO, P158; STONES MJ, 1987, ARCH PHYS MED REHAB, V68, P85; Thunberg J, 2001, PAIN, V91, P15, DOI 10.1016/S0304-3959(00)00415-2	34	90	92	0	13	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	OCT	2003	35	5					229	235		10.1080/16501970306093			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	712UP	WOS:000184817000006	14582555	gold			2022-02-06	
J	van Santbrink, H; Von der Brink, WA; Steyerberg, EW; Suazo, JAC; Avezaat, CJJ; Maas, AR				van Santbrink, H; Von der Brink, WA; Steyerberg, EW; Suazo, JAC; Avezaat, CJJ; Maas, AR			Brain tissue oxygen response in severe traumatic brain injury	ACTA NEUROCHIRURGICA			English	Article						traumatic brain injury; brain tissue PO2; cerebral oxygenation; arterial pO(2); hyperventilation; pathophysiology; ischemia; outcome; prognosis	SEVERE HEAD-INJURY; CEREBRAL BLOOD-FLOW; TRANSCRANIAL DOPPLER ULTRASOUND; PARTIAL-PRESSURE; INTRACRANIAL HYPERTENSION; PERFUSION-PRESSURE; COMATOSE PATIENTS; REACTIVITY; VELOCITY; SATURATION	Objective. To investigate clinical relevance and prognostic value of brain tissue oxygen response (TOR: response of brain tissue pO(2) to changes in arterial pO(2)) in traumatic brain injury (TBI). Patients and methods. In a prospective cohort study TOR was investigated in 41 patients with severe TBI (Glasgow Coma Score less than or equal to8) in whom continuous monitoring of brain tissue oxygen pressure (PbrO(2)) was performed. TOR was investigated each day over a five day period for 15 minutes by increasing FiO(2) on the ventilator setting. FiO(2) was increased directly from baseline to 1.0 for a period of 15 minutes under stable conditions (145 tests). In 34 patients the effect of decreasing PaCO2 was evaluated on TOR by performing the same test after increasing inspiratory minute volume on the ventilator setting to 20% above baseline. Arterial blood gas analysis was performed before and after changing ventilator settings. Multimodality monitoring. including PbrO(2) was performed in all patients. Outcome at six months was evaluated according to the Glasgow Outcome Scale. For statistical analysis the Mann-whitney U-test was used for ordinally distributed variables, and the Chi-square test for categorical variables. Predictive value of TOR was analyzed in a multivariable model. Results. 145 tests were available for analysis. Baseline PbrO(2) varied from 4.0 to 50 mmHg at PaO2 values of 73-237 mmHg. At FiO(2) settings of 1.0. PbrO(2) varied from 9.1-200 mmHg and PaO2 from 196-499 mmHg. Three distinct patterns of response were noted: response type A is characterized by a sharp increase in PbrO(2), reaching a plateau within several minutes; type B by the absence of a plateau, and type C by a short plateau phase followed by a subsequent further increase in PbrO(2). Patterns characterized by a stable plateau (type A), considered indicative of intact regulatory mechanisms, were seen more frequently from 48 hours after injury on. If present within the first 24 hours after injury such a response was related to more favorable outcome (p = 0.06). Mean TOR of all tests was 0.73 +/- 0.59 with an median TOR of 0.58. Patients with an unfavourable outcome had a higher TOR (1.03 +/- 0.60) during the first 24 hours, compared to patients with a favorable outcome (0.61 +/- 0.51; p = 0.02). Multiple logistic regression analysis supported the independent predictive value of tissue oxygen response for unfavorable outcome (odds ratio 4.8). During increased hyperventilation, mean TOR decreased substantially from 0.75 +/- 0.54 to 0.65 +/- 0.45 (p = 0.06; Wilcoxon test). Within the first 24 hours after injury a decrease in TOR following hyperventilation was significantly related to poorer outcome (p = 0.01). Conclusions. Evaluation of TOR affords insight in (disturbances in) oxygen regulation after traumatic brain injury, is of prognostic value and may aid in identifying patients at (increased) risk for ischemia.	Erasmus MC, Dept Neurosurg, NL-3015 GD Rotterdam, Netherlands; Erasmus MC, Ctr Clin Decis Sci, NL-3015 GD Rotterdam, Netherlands; Isala Klin, Dept Neurosurg, Zwolle, Netherlands; Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands		Maas, AR (corresponding author), Erasmus MC, Dept Neurosurg, Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands.	airmaas@erasmusmc.nl	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Steyerberg, Ewout/0000-0002-7787-0122			AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; AVEZAAT CJJ, 1979, J NEUROL NEUROSUR PS, V42, P687, DOI 10.1136/jnnp.42.8.687; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; CHAN KH, 1992, NEUROSURGERY, V30, P697; Charoenchai C., 1997, Australian Journal of Grape and Wine Research, V3, P2, DOI 10.1111/j.1755-0238.1997.tb00109.x; COHEN PJ, 1967, J APPL PHYSIOL, V23, P183, DOI 10.1152/jappl.1967.23.2.183; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; ELLINGSEN I, 1987, ACTA PHYSIOL SCAND, V129, P157, DOI 10.1111/j.1748-1716.1987.tb08054.x; Fandino J, 1999, ACTA NEUROCHIR, V141, P825, DOI 10.1007/s007010050383; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GROLIMUND P, 1988, LANCET, V1, P1173; Ince C, 1999, CRIT CARE MED, V27, P1369, DOI 10.1097/00003246-199907000-00031; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; KLINGELHOFER J, 1992, STROKE, V23, P962, DOI 10.1161/01.STR.23.7.962; LAMBERTSEN CJ, 1953, J APPL PHYSIOL, V5, P471, DOI 10.1152/jappl.1953.5.9.471; Longhi L, 2002, ACT NEUR S, V81, P315; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MAAS AIR, 1993, ACTA NEUROCHIR, P50; MAAS AIR, 1993, ICP 8, P233; Maas Andrew I.R., 2000, Curr Opin Crit Care, V6, P281, DOI 10.1097/00075198-200008000-00008; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; MARKWALDER TM, 1984, J CEREBR BLOOD F MET, V4, P368, DOI 10.1038/jcbfm.1984.54; MARMAROU A, 1992, J NEUROTRAUM, V9, pS327; MARMAROU A, 1993, ACTA NEUROCHIR, P18; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; MEIXENSBERGER J, 1993, ACTA NEUROCHIR, P58; MEIZENSBERGER J, 1993, ACTA NCUROCHIR WIE S, V59, P58; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 2000, ZBL NEUROCHIR, V61, P181, DOI 10.1055/s-2000-15598; MILLER JD, 1992, NEUROSURGERY, V30, P518; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; RINGELSTEIN EB, 1986, KLIN WOCHENSCHR, V64, P194, DOI 10.1007/BF01713462; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Rossi S, 2001, J NEUROTRAUM, V18, P163, DOI 10.1089/08977150150502596; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Shigemori M, 1992, Acta Neurochir Suppl (Wien), V55, P6; Siegemund M, 1999, INTENS CARE MED, V25, P1044, DOI 10.1007/s001340051011; STANDGAARD S, 1975, CEREBRAL CIRCULATION, P3; Suazo JAC, 2000, CRIT CARE MED, V28, P3268, DOI 10.1097/00003246-200009000-00024; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	50	90	90	0	4	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	JUN	2003	145	6					429	438		10.1007/s00701-003-0032-3			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	703GK	WOS:000184271500002	12836066				2022-02-06	
J	Maxwell, WL; Dhillon, K; Harper, L; Espin, J; MacIntosh, TK; Smith, DH; Graham, DI				Maxwell, WL; Dhillon, K; Harper, L; Espin, J; MacIntosh, TK; Smith, DH; Graham, DI			There is differential loss of pyramidal cells from the human hippocampus with survival after blunt head injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						adult head injury; blunt head injury; hippocampus; pyramidal neurons	UNBIASED STEREOLOGICAL ESTIMATION; TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD-FLOW; GERBIL HIPPOCAMPUS; NUMBER; RAT; VULNERABILITY; PATHOLOGY; ISCHEMIA; NEURONS	The experimental literature has shown that neurons within sub-fields of the hippocampus possess differential sensitivities to cell loss after different types of insult to the brain. In humans, after blunt head injury, differential neuronal responses between sub-fields of the hippocampus up to 72 hours after injury have been documented, But, in only a small part of the literature have data for alterations in real numbers of neurons been provided. In this study the hypothesis was tested that, after severe blunt head injury in humans, the total number of neurons within a defined volume of brain tissue differed between different sub-fields of the hippocampus and between groups of patients with differing post-traumatic survivals. Stereological methods were used to measure total cross-sectional area of sub-fields of the hippocampus taken at the level of the lateral geniculate nucleus and count numbers of neurons within each of the CA1, CA2, CA3, and CA4 sub-fields of the hippocampus in patients, The patients used in this study were categorized as follows: Group I (early) had survived for I week or less; Group 2 (late) survived 6 months or longer after fatal severe head injury; and Group 3 (controls) consisted of age-matched patients that had no history of head injury or disease prior to death. There was a significant loss in cross-sectional area in sub-fields CA3 and CA4 at I week or less after injury and in sub-field CA1 at 6 months and greater survival. There was no change in CA2. There was loss of neurons from within a predefined volume of brain tissue in sub-fields CA1, CA3, and CA4 one week or less after injury. But there was no loss in CA2. There was continued loss of neurons from sub-fields CA1 and CA4 between I week and 6 months and greater survival, but there was no loss of neurons in sub-fields CA2 and CA3 within the same period. These novel data show that after human severe head injury there is first an acute loss (I week or less survival) of pyramidal neurons in all hippocampal sub-fields except CA2. Second, there is an ongoing loss of neurons in sub-field CA1 and, most notably, in sub-field CA4, in patients surviving for more than 6 months. However, in neither group of patients is there loss of neurons from sub-field CA2.	Univ Glasgow, IBLS, Dept Anat, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, So Gen NHS Trust, Dept Neuropathol, Glasgow, Lanark, Scotland; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA		Maxwell, WL (corresponding author), Univ Glasgow, IBLS, Dept Anat, Thomson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	wmaxwell@bio.gla.ac.uk	smith, douglas/A-1321-2007		NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG12527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803, NS38104] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS038104, P50NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012527] Funding Source: NIH RePORTER		Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Benes FM, 2001, TRENDS NEUROSCI, V24, P11, DOI 10.1016/S0166-2236(00)01660-X; BONNEKOH P, 1990, ACTA NEUROPATHOL, V80, P18, DOI 10.1007/BF00294217; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; CAMMERMEYER JAN, 1961, ACTA NEUROPATHOL, V1, P245; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; de No RL, 1934, J PSYCHOL NEUROL, V46, P113; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; GUNDERSEN HJG, 1981, VIRCHOWS ARCH B, V37, P317, DOI 10.1007/BF02892580; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; HONAVAR M, 1997, GREENFIELDS NEUROPAT, P942; HOWARD CV, 1998, NUMBER ESTIMATION UN, P69; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; MATHIEU O, 1981, J MICROSC-OXFORD, V121, P75, DOI 10.1111/j.1365-2818.1981.tb01200.x; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; NG T, 1989, ACTA NEUROPATHOL, V78, P438, DOI 10.1007/BF00688181; PULSINELLI WA, 1985, PROG BRAIN RES, V63, P29; RAISMAN G, 1965, BRAIN, V88, P963, DOI 10.1093/brain/88.5.963; Shaw K, 2001, CLIN NEUROPATHOL, V20, P106; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; WEST MJ, 1994, LANCET, V344, P769, DOI 10.1016/S0140-6736(94)92338-8; WEST MJ, 1990, J COMP NEUROL, V296, P1, DOI 10.1002/cne.902960102; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; WILLIAMS RW, 1988, J COMP NEUROL, V278, P344, DOI 10.1002/cne.902780305; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	36	90	93	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAR	2003	62	3					272	279		10.1093/jnen/62.3.272			8	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	653QM	WOS:000181448400006	12638731	Bronze			2022-02-06	
J	Hartman, RE; Laurer, H; Longhi, L; Bales, KR; Paul, SM; McIntosh, TK; Holtzman, DM				Hartman, RE; Laurer, H; Longhi, L; Bales, KR; Paul, SM; McIntosh, TK; Holtzman, DM			Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease	JOURNAL OF NEUROSCIENCE			English	Article						Alzheimer's disease; amyloid; APP; traumatic brain injury; apoE; hippocampus	CLOSED-HEAD INJURY; TRANSGENIC MICE; E EPSILON-4; BETA-PROTEIN; PRECURSOR PROTEIN; E-DEFICIENT; ALLELE; NEURODEGENERATION; SUSCEPTIBILITY; ASSOCIATION	The epsilon4 allele of apolipoprotein E (APOE) and traumatic brain injury (TBI) are both risk factors for the development of Alzheimer's disease (AD). These factors may act synergistically, in that APOE4+ individuals are more likely to develop dementia after TBI. Because the mechanism underlying these effects is unclear, we questioned whether APOE4 and TBI interact either through effects on amyloid-beta (Abeta) or by enhancing cell death/tissue injury. We assessed the effects of TBI in PDAPP mice (transgenic mice that develop AD-like pathology) expressing human APOE3 (PDAPP: E3), human APOE4 (PDAPP: E4), or no APOE (PDAPP: E-/-). Mice were subjected to a unilateral cortical impact injury at 9-10 months of age and allowed to survive for 3 months. Abeta load, hippocampal/cortical volumes, and hippocampal CA3 cell loss were quantified using stereological methods. All of the groups contained mice with Abeta-immunoreactive deposits (56% PDAPP: E4, 20% PDAPP: E3, 75% PDAPP: E-/-), but thioflavine-S-positive Abeta (amyloid) was present only in the molecular layer of the dentate gyrus in the PDAPP: E4 mice (44%). In contrast, our previous studies showed that in the absence of TBI, PDAPP: E3 and PDAPP: E4 mice have little to no Abeta deposition at this age. After TBI, all of the Abeta deposits present in PDAPP: E3 and PDAPP: E-/- mice were diffuse plaques. In contrast to the effect of APOE4 on amyloid, PDAPP: E3, PDAPP: E4, and PDAPP: E-/- mice did not differ in the amount of brain tissue or cell loss. These data support the hypothesis that APOE4 influences the neurodegenerative cascade after TBI via an effect on Abeta.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alzheimers Dis Res Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Eli Lilly & Co, Lilly Res Labs, Neurosci Discovery Res, Indianapolis, IN 46285 USA; Indiana Univ, Dept Pharmacol Toxicol & Psychiat, Sch Med, Indianapolis, IN 46285 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA		Holtzman, DM (corresponding author), Washington Univ, Sch Med, Dept Neurol, 660 S Euclid Ave,Box 8111, St Louis, MO 63110 USA.		Hartman, Richard/C-5767-2008; Longhi, Luca/AAF-9903-2021	Hartman, Richard/0000-0001-9235-3169; Longhi, Luca/0000-0001-9894-8788	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG13956, P50 AG005681, AG05681, R37 AG013956, P01 AG011355, AG11355, R01 AG013956] Funding Source: Medline; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [T32 DA007261, DA07261] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS008803, NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R37AG013956, P50AG005681, P01AG011355, R01AG013956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA007261] Funding Source: NIH RePORTER		Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Buttini M, 1999, J NEUROSCI, V19, P4867; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; Fagan AM, 1998, EXP NEUROL, V151, P314, DOI 10.1006/exnr.1998.6818; Fagan AM, 2002, NEUROBIOL DIS, V9, P305, DOI 10.1006/nbdi.2002.0483; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Genis L, 2000, J NEUROSCI RES, V60, P559, DOI 10.1002/(SICI)1097-4547(20000515)60:4<559::AID-JNR15>3.0.CO;2-K; Gouras GK, 1997, ANN NEUROL, V41, P402, DOI 10.1002/ana.410410317; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Holtzman DM, 2001, J MOL NEUROSCI, V17, P147, DOI 10.1385/JMN:17:2:147; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; LECLERCQ PD, 2002, NEUROPATHOL APPL NEU, V28, P161; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Macfarlane DP, 1999, NEUROREPORT, V10, P3945, DOI 10.1097/00001756-199912160-00040; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Raby CA, 1998, J NEUROCHEM, V71, P2505; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Stone DJ, 1998, J NEUROSCI, V18, P3180; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sun YL, 1998, J NEUROSCI, V18, P3261; Tang MX, 1996, ANN NY ACAD SCI, V802, P6, DOI 10.1111/j.1749-6632.1996.tb32593.x; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Teter B, 2000, ALZHEIMERS REP, V3, P199; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Wisniewski T, 1997, NEUROBIOL DIS, V4, P313, DOI 10.1006/nbdi.1997.0147	40	90	92	0	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	DEC 1	2002	22	23					10083	10087					5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	619DE	WOS:000179458100004	12451108				2022-02-06	
J	Beschorner, R; Nguyen, TD; Gozalan, F; Pedal, I; Mattern, R; Schluesener, HJ; Meyermann, R; Schwab, JM				Beschorner, R; Nguyen, TD; Gozalan, F; Pedal, I; Mattern, R; Schluesener, HJ; Meyermann, R; Schwab, JM			CD14 expression by activated parenchymal microglia/macrophages and infiltrating monocytes following human traumatic brain injury	ACTA NEUROPATHOLOGICA			English	Article						traumatic brain injury; inflammation; immune response; CD14	TUMOR-NECROSIS-FACTOR; MICROGLIAL CELLS; DEPENDENT MECHANISMS; MONONUCLEAR-CELLS; NEGATIVE BACTERIA; GENE-EXPRESSION; UP-REGULATION; SOLUBLE CD14; EX-VIVO; LIPOPOLYSACCHARIDE	The immune response in the central nervous system (CNS) is under tight control of regulatory mechanisms, resulting in the establishment of immune privilege. CNS injury induces an acute inflammatory reaction, composed mainly of invading leukocytes and activated microglial cells/macrophages. The generation of this robust immune response requires binding of receptors such as CD14, a pattern recognition receptor of the immune system. CD14, a surface molecule of monocytic cells, is up-regulated after monocyte stimulation and is involved in cellular activation. To examine CD14 expression in human brain lesions we investigated sections of brains obtained at autopsy from 25 cases following closed traumatic brain injury (TBI) and 5 control brains by immunohistochemistry. Detection of CD14 in controls demonstrated constitutive expression by perivascular cells, but not in parenchymal microglial cells, equivalent to known expression pattern of ED2 in rats. Following TBI, numbers of CD14(+) cells in perivascular spaces and in the brain parenchyma increased in parallel within 1-2 days, both at the lesion and in adjacent perilesional areas. The number of CD14(+) cells in perivascular spaces and in the brain parenchyma reached maximum levels within 4-8 days and remained elevated until weeks after trauma. In contrast to activated parenchymal microglia/macrophages, resting parenchymal microglial cells lacked CD14. Thus, early CD14 expression constitutes an essential part of the acute inflammatory CNS response following trauma.	Heidelberg Univ, Inst Legal Med, Heidelberg, Germany; Univ Tubingen, Brain Res Inst, Sch Med, D-72076 Tubingen, Germany		Beschorner, R (corresponding author), Univ Tubingen, Brain Res Inst, Sch Med, Calwerstr 3, D-72076 Tubingen, Germany.	rudi.beschorner@med.uni-tuebingen.de	Beschorner, Rudi/M-6397-2014	Schwab, Jan/0000-0001-6784-4919; Beschorner, Rudi/0000-0003-1109-915X			Abe M, 1999, J NEUROL, V246, P358, DOI 10.1007/s004150050363; Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Antal-Szalmas P, 2000, CYTOMETRY, V41, P279, DOI 10.1002/1097-0320(20001201)41:4<279::AID-CYTO6>3.0.CO;2-B; ARDITI M, 1995, J IMMUNOL, V155, P3994; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Bauer J, 1996, HISTOCHEM J, V28, P83, DOI 10.1007/BF02331413; Becher B, 1996, GLIA, V18, P1; Becher B, 1996, J NEUROSCI RES, V45, P375; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P627, DOI 10.1007/s004010000232; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; Beyer M, 2000, GLIA, V31, P262, DOI 10.1002/1098-1136(200009)31:3<262::AID-GLIA70>3.0.CO;2-2; Bosco MC, 1997, J IMMUNOL, V159, P2922; Cauwels A, 1999, J IMMUNOL, V162, P4762; Chen KC, 1999, WIREL NETW, V5, P1, DOI 10.1023/A:1019157818476; DENTENER MA, 1993, J IMMUNOL, V150, P2885; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; Dick AD, 1997, AIDS, V11, P1699, DOI 10.1097/00002030-199714000-00006; DICKSON DW, 1991, LAB INVEST, V64, P135; Dufour A, 1996, J NEUROL, V243, P666, DOI 10.1007/BF00878667; Fearns C, 1998, SHOCK, V9, P157, DOI 10.1097/00024382-199803000-00001; Frevert CW, 2000, J IMMUNOL, V164, P5439, DOI 10.4049/jimmunol.164.10.5439; Galea E, 1996, J NEUROIMMUNOL, V64, P19, DOI 10.1016/0165-5728(95)00143-3; GRAEBER MB, 1990, TRENDS NEUROSCI, V13, P366, DOI 10.1016/0166-2236(90)90020-B; Graham DI, 1997, GREENFIELDS NEUROPAT, P197; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Guillemin G, 1997, J NEUROSCI RES, V49, P576, DOI 10.1002/(SICI)1097-4547(19970901)49:5<576::AID-JNR8>3.3.CO;2-O; Han JH, 1998, PROG CLIN BIOL RES, V397, P157; HICKEY WF, 1987, P NATL ACAD SCI USA, V84, P2082, DOI 10.1073/pnas.84.7.2082; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; Jersmann HPA, 2001, INFECT IMMUN, V69, P479, DOI 10.1128/IAI.69.1.479-485.2001; JORDAN FL, 1988, BRAIN RES REV, V13, P165, DOI 10.1016/0165-0173(88)90019-7; Kane JP, 1999, CIRCULATION, V99, P3210, DOI 10.1161/01.CIR.99.25.3210; Kennedy DW, 1997, BLOOD, V90, P986, DOI 10.1182/blood.V90.3.986.986_986_993; Kennedy DW, 1998, P NATL ACAD SCI USA, V95, P14944, DOI 10.1073/pnas.95.25.14944; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; KRUGER C, 1991, CLIN EXP IMMUNOL, V85, P297; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; KUSUNOKI T, 1995, J EXP MED, V182, P1673, DOI 10.1084/jem.182.6.1673; LASSMANN H, 1991, J NEUROSCI RES, V28, P236, DOI 10.1002/jnr.490280211; LASSMANN H, 1993, GLIA, V7, P19, DOI 10.1002/glia.440070106; LING EA, 1993, GLIA, V7, P9, DOI 10.1002/glia.440070105; LOPPNOW H, 1995, INFECT IMMUN, V63, P1020, DOI 10.1128/IAI.63.3.1020-1026.1995; Lucas R, 1997, J LEUKOCYTE BIOL, V61, P551, DOI 10.1002/jlb.61.5.551; Manigold T, 2000, CYTOKINE, V12, P1788, DOI 10.1006/cyto.2000.0783; MATO M, 1986, ACTA NEUROPATHOL, V72, P117, DOI 10.1007/BF00685972; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; Meng FY, 1997, J EXP MED, V185, P1661, DOI 10.1084/jem.185.9.1661; Mittelbronn M, 2001, ACTA NEUROPATHOL, V101, P249; Nadeau S, 2000, J NEUROSCI, V20, P3456, DOI 10.1523/JNEUROSCI.20-09-03456.2000; Nockher WA, 1999, J NEUROIMMUNOL, V101, P161, DOI 10.1016/S0165-5728(99)00141-1; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; PEUDENIER S, 1991, ANN NEUROL, V29, P152, DOI 10.1002/ana.410290207; Postler E, 2000, J NEUROIMMUNOL, V108, P244, DOI 10.1016/S0165-5728(00)00283-6; Prinz M, 1999, J NEUROPATH EXP NEUR, V58, P1078, DOI 10.1097/00005072-199910000-00006; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; Saito S, 2000, EUR J BIOCHEM, V267, P37, DOI 10.1046/j.1432-1327.2000.00956.x; Schimke J, 1998, P NATL ACAD SCI USA, V95, P13875, DOI 10.1073/pnas.95.23.13875; Schletter J, 1995, ARCH MICROBIOL, V164, P383, DOI 10.1007/BF02529735; Schluesener HJ, 1998, ACTA NEUROPATHOL, V96, P575, DOI 10.1007/s004010050938; Schluesener HJ, 1997, GLIA, V20, P365, DOI 10.1002/(SICI)1098-1136(199708)20:4<365::AID-GLIA8>3.0.CO;2-4; Selvi E, 2000, ANN RHEUM DIS, V59, P399, DOI 10.1136/ard.59.5.399; STREIT WJ, 1987, J NEUROCYTOL, V16, P249, DOI 10.1007/BF01795308; Streit Wolfgang J., 1995, P85; Su GL, 1999, J HEPATOL, V31, P435, DOI 10.1016/S0168-8278(99)80034-8; Su GL, 1995, CRIT REV IMMUNOL, V15, P201, DOI 10.1615/CritRevImmunol.v15.i3-4.10; Takeshita S, 1999, J INFECT DIS, V179, P508, DOI 10.1086/314600; THEELE DP, 1993, GLIA, V7, P5, DOI 10.1002/glia.440070104; Ulevitch RJ, 1999, NAT MED, V5, P144, DOI 10.1038/5504; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Ulevitch RJ, 1999, CURR OPIN IMMUNOL, V11, P19, DOI 10.1016/S0952-7915(99)80004-1; ULVESTAD E, 1994, J NEUROPATH EXP NEUR, V53, P492, DOI 10.1097/00005072-199409000-00008; VASS K, 1986, ACTA NEUROPATHOL, V70, P149, DOI 10.1007/BF00691433; Verbon A, 2001, J IMMUNOL, V166, P3599, DOI 10.4049/jimmunol.166.5.3599; Wang PY, 1999, J BIOL CHEM, V274, P23235, DOI 10.1074/jbc.274.33.23235; Wang PY, 1998, J BIOL CHEM, V273, P24309, DOI 10.1074/jbc.273.38.24309; WILLIAMS K, 1992, J NEUROPATH EXP NEUR, V51, P538, DOI 10.1097/00005072-199209000-00009; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; ZIEGLERHEITBROCK HWL, 1994, EUR J IMMUNOL, V24, P1937, DOI 10.1002/eji.1830240835	80	90	94	0	12	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	JUN	2002	103	6					541	549		10.1007/s00401-001-0503-7			9	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	557EE	WOS:000175894500002	12012085				2022-02-06	
J	Knoller, N; Levi, L; Shoshan, I; Reichenthal, E; Razon, N; Rappaport, ZH; Biegon, A				Knoller, N; Levi, L; Shoshan, I; Reichenthal, E; Razon, N; Rappaport, ZH; Biegon, A			Dexanabinol (HU-211) in the treatment of severe closed head injury: A randomized, placebo-controlled, phase II clinical trial	CRITICAL CARE MEDICINE			English	Article						head-trauma; HU-211; Glasgow Coma Scale; intracranial pressure; N-methyl-D-aspartate antagonist; antioxidant; anti-inflammatory	TRAUMATIC BRAIN INJURY; NEUROPROTECTANT; ANTAGONIST; MULTICENTER; EFFICACY; TERM; RAT	Objective: To establish the safety of intravenous dexanabinol in severe head injury. Design: Prospective, randomized, double-blind, placebo- (vehicle) controlled, multicenter, escalating dose study of a single administration of drug (48 or 150 mg) or vehicle (1 or 3 mL). Setting: All Israeli neurosurgical intensive care units (a total of six units). Patients: Sixty-seven patients, aged 16 - 65 yrs, Glasgow Coma Scale score of 4-8, injured within 6 hrs of treatment. Measurements and Main Results: Intracranial pressure, cerebral perfusion pressure, blood pressure, and heart rate were measured continuously in the intensive care unit, Adverse medical events were recorded and clinical outcome was assessed by the Glasgow outcome scale throughout a 6-month follow-up period. A highly significant reduction in the percentage of time with intracranial pressure >25, cerebral perfusion pressure <50, and systolic blood pressure <90 mm Hg was observed in the drug-treated group. The nature and incidence of adverse medical events were similar in the two groups. The percentage of patients achieving good neurologic outcome on the Glasgow outcome scale was 21% and 14% higher in the drug-treated group at 3 and 6 months, respectively. Statistical analysis of these differences by a logistic model using dose, entry Glasgow coma scale score, and computed tomograph as covariates yielded p values for the effect of treatment of .03 and .14 at 3 and 6 months, respectively. Conclusions: Dexanabinol was safe and well tolerated in severe head injury. The treated patients achieved significantly better intracranial pressure/cerebral perfusion pressure control without jeopardizing blood pressure. A trend toward faster and better neurologic outcome was also observed.	Chaim Sheba Med Ctr, Dept Neurosurg, Tel Hashomer, Israel; Rambam Med Ctr, Haifa, Israel; Hadassah Med Ctr, Dept Neurosurg, IL-91120 Jerusalem, Israel; Soroka Med Ctr, Dept Neurosurg, IL-84101 Beer Sheva, Israel; Ichilov Hosp, Dept Neurosurg, Tel Aviv, Israel; Beilinson Med Ctr, Dept Neurosurg, IL-49100 Petah Tiqwa, Israel; Pharmos Ltd, Rehovot, Israel		Knoller, N (corresponding author), Chaim Sheba Med Ctr, Dept Neurosurg, Tel Hashomer, Israel.		Rappaport, Zvi Harry/AAH-6024-2019	Rappaport, Zvi Harry/0000-0001-9479-3619			BAILEY I, 1992, Journal of Neurotrauma, V9, pS545; BELAYEV L, 1995, STROKE, V26, P2313, DOI 10.1161/01.STR.26.12.2313; BIEGON A, 1995, NEUROL RES, V17, P275, DOI 10.1080/01616412.1995.11740326; BIEGON A, 1993, AM SOC NEUR ABSTR, V19, P1485; Brewster ME, 1997, INT J CLIN PHARM TH, V35, P361; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; ESHHAR N, 1995, EUR J PHARMACOL, V283, P19, DOI 10.1016/0014-2999(95)00271-L; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; GALLILY R, 1997, J PHARMACOL EXP THER, V83, P1; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; MAIERHAUFF K, 1984, J NEUROSURG, V61, P97, DOI 10.3171/jns.1984.61.1.0097; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MECHOULAM R, 1988, EXPERIENTIA, V44, P762, DOI 10.1007/BF01959156; OTT I, 1998, NEUROINFLAMMATION ME, P221; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Yoles E, 1996, J NEUROTRAUM, V13, P49, DOI 10.1089/neu.1996.13.49; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538	24	90	93	1	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	MAR	2002	30	3					548	554		10.1097/00003246-200203000-00009			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531ZC	WOS:000174446300009	11990913				2022-02-06	
J	Shi, R; Pryor, JD				Shi, R; Pryor, JD			Pathological changes of isolated spinal cord axons in response to mechanical stretch	NEUROSCIENCE			English	Article						axon; membrane sealing; spinal cord injury; neurotrauma; elongation; nerve repair	CNS WHITE MATTER; NA+-CA2+ EXCHANGER; MORPHOMETRIC ANALYSIS; POLYETHYLENE-GLYCOL; CONDUCTION-BLOCK; IN-VITRO; INJURY; 4-AMINOPYRIDINE; MODEL; TETRODOTOXIN	White matter strips extracted from adult guinea-pig spinal cords were maintained in vitro and studied physiologically using a double sucrose gap technique and anatomically using a horseradish peroxidase assay. The amplitude of compound action potentials was monitored continuously before, during, and after elongation. Three types of conduction blocks resulting from stretch injury were identified: an immediate, spontaneously reversible component. which may result from a transient increase in membrane permeability and consequent disturbance of ionic distributions a second component that was irreversible within 30 60 min of recording, perhaps resulting from profound axolemmal disruption; and a third component, which may be due to perturbation of the myelin sheath, that was reversible with application of 100 muM of the potassium channel blocker, 4-aminopyridine. The intensity of the conduction deficits correlated with the extent of initial stretch over a Call range of severity. Stimulus-response data indicate that mechanical damage to axons in stretch was evenly distributed across the caliber spectrum, Morphological examinations revealed that a small portion of axons exhibited membrane damage at 2 min following stretch and appeared to be largely sealed at 30 min after injury. Further, in the entire length of the cord strip subjected to stretch. axons closer to the surface were found to be more likely to suffer membrane damage, which distinguished stretch injury from compression injury. In summary. we have developed an in vitro model of axonal stretch that provides the ability to monitor changes in the properties of central myelinated axons following stretch injury in the absence of pathological variables related to vascular damage. This initial investigation found no evidence of secondary deterioration of axons in the first 30 min after stretch in vitro, although there was evidence of both transient and lasting physiological and anatomical damage to axons and their myelin sheaths. (C) 2002 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Purdue Univ, Sch Vet Med, Dept Basic Med Sci, Ctr Paralysis Res,Inst Appl Neurol, W Lafayette, IN 47907 USA		Shi, R (corresponding author), Purdue Univ, Sch Vet Med, Dept Basic Med Sci, Ctr Paralysis Res,Inst Appl Neurol, W Lafayette, IN 47907 USA.						Agrawal SK, 1996, J NEUROSCI, V16, P545; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; BEMENT SL, 1969, EXP NEUROL, V24, P147, DOI 10.1016/0014-4886(69)90012-0; Blight A, 1988, J Am Paraplegia Soc, V11, P26; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; BLIGHT AR, 1989, BRAIN RES BULL, V22, P47, DOI 10.1016/0361-9230(89)90126-3; BLIGHT AR, 1986, NEUROSCIENCE, V19, P321, DOI 10.1016/0306-4522(86)90025-4; BOENING JA, 1989, NEUROSCIENCE, V33, P263, DOI 10.1016/0306-4522(89)90205-4; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; GOLDBERG WJ, 1986, J NEUROSCI, V6, P3144; GORDON TR, 1990, NEUROSCIENCE, V37, P829, DOI 10.1016/0306-4522(90)90112-H; KOESIS JD, 1986, NEUROBIOLOGY, V36, P117; Kuffler SW, 1984, NEURON BRAIN, V2nd; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Rosenberg LJ, 1996, BRAIN RES, V734, P349; Rosenberg LJ, 1999, J NEUROSCI, V19, P6122, DOI 10.1523/JNEUROSCI.19-14-06122.1999; Shi R, 1999, J NEUROPHYSIOL, V81, P2406, DOI 10.1152/jn.1999.81.5.2406; Shi R, 1997, NEUROSCIENCE, V77, P553, DOI 10.1016/S0306-4522(96)00477-0; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi R, 1996, J NEUROPHYSIOL, V76, P1572, DOI 10.1152/jn.1996.76.3.1572; Shi R, 2000, NEUROSCIENCE, V98, P157, DOI 10.1016/S0306-4522(00)00096-8; Shi RY, 2000, J NEUROPHYSIOL, V84, P1763, DOI 10.1152/jn.2000.84.4.1763; Shi RY, 1997, EXP NEUROL, V148, P495, DOI 10.1006/exnr.1997.6706; Smith DH, 1999, J NEUROSCI, V19, P4263; STYS PK, 1991, ANN NEUROL, V30, P375, DOI 10.1002/ana.410300309; STYS PK, 1992, J NEUROSCI, V12, P430; Teng YD, 1997, J NEUROSCI, V17, P4359; WAXMAN SG, 1991, TRENDS NEUROSCI, V14, P461, DOI 10.1016/0166-2236(91)90046-W; WEST DC, 1983, J PHYSIOL-LONDON, V337, P37, DOI 10.1113/jphysiol.1983.sp014610	31	90	97	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2002	110	4					765	777	PII S0306-4522(01)00596-6	10.1016/S0306-4522(01)00596-6			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	545YN	WOS:000175245300016	11934483				2022-02-06	
J	Masanic, CA; Bayley, MT; vanReekum, R; Simard, M				Masanic, CA; Bayley, MT; vanReekum, R; Simard, M			Open-label study of donepezil in traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						acetylcholinesterase inhibitor; brain injuries; memory; rehabilitation	VESICULAR ACETYLCHOLINE TRANSPORTER; HEAD-INJURY; REY-OSTERRIETH; MODERATE; HIPPOCAMPAL; COGNITION; PROTEIN; DISEASE	Objective: To determine preliminarily whether donepezil will improve memory, behavior, and global function after chronic traumatic brain injury (TBI). Design: Sixteen-week open-label study. Setting: Outpatient TBI rehabilitation program. Patients: Four patients with chronic, severe TBI. Interventions: Donepezil 5mg daily for 8 weeks followed by 10mg daily for 4 weeks. Main Outcome Measures: Memory measures included the Rey Auditory Verbal Learning Test (RAVLT), the Complex Figure Test (CFT), items from the Rivermead Behavioural Memory Test (RBMT), and a semantic fluency task. The Neuropsychiatric Inventory (NPI) evaluated behavior and affect. Function was assessed by using the FIM(TM) instrument and a clinical global impression of change. Results: On the RAVLT, the mean scores for learning and short- and long-term recall improved by 0.4, 1.04, and .83 standard deviations (SDs) above baseline respectively. On the CFT, the mean scores for short-term recall and long-term recall improved by 1.56 and 1.38 SDs above baseline, respectively. A positive trend was observed on the RBMT and on the NPI subscales. Conclusions: Donepezil may improve some aspects of memory and behavior in persons with chronic TBI. Randomized clinical trials are required to support these preliminary findings.	Hamilton Hlth Sci Corp, Div Phys Med & Rehabil, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Med, Hamilton, ON, Canada; Baycrest Ctr Geriatr Care, Dept Psychiat, Toronto, ON, Canada; Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, Toronto, ON, Canada; Univ Toronto, Div Geriatr Psychiat, Toronto, ON, Canada		Masanic, CA (corresponding author), Hamilton Hlth Sci Corp, Div Phys Med & Rehabil, Chedoke Campus,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.		Simard/Q-9675-2019	Simard/0000-0003-1257-8275; Bayley, Mark/0000-0001-7860-9463			Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CASEY MB, 1991, J CLIN EXP NEUROPSYC, V13, P600, DOI 10.1080/01688639108401074; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; CRAWFORD JR, 1989, J CLIN EXP NEUROPSYC, V11, P975, DOI 10.1080/01688638908400950; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DULEY JF, 1993, CLIN NEUROPSYCHOL, V7, P29, DOI DOI 10.1080/13854049308401885; Geffen Gina, 1990, Clin Neuropsychol, V4, P45, DOI 10.1080/13854049008401496; GOLDBERG E, 1982, Journal of Clinical Neuropsychology, V4, P219, DOI 10.1080/01688638208401131; GRANGER CV, 1986, GUIDE USE UNIFORM DA; KUEHN SM, 1992, ARCH CLIN NEUROPSYCH, V7, P445, DOI 10.1016/0887-6177(92)90157-I; Levin H S, 1986, Cent Nerv Syst Trauma, V3, P333; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Levy ML, 1999, GERONTOLOGY, V45, P15, DOI 10.1159/000052760; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McLean A Jr, 1987, Brain Inj, V1, P145, DOI 10.3109/02699058709034453; MITRUSHINA M, 1999, HDB NORMATIVE DATA N, P184; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Rey A., 1964, EXAMEN CLIN PSYCHOL; Rogers SL, 1998, ARCH INTERN MED, V158, P1021, DOI 10.1001/archinte.158.9.1021; Rogers SL, 1999, NEUROLOGY, V52, P218; Schneider LS, 1997, ALZ DIS ASSOC DIS, V11, pS22; Shao LF, 1999, J NEUROTRAUM, V16, P555, DOI 10.1089/neu.1999.16.555; Silver JM., 1994, NEUROPSYCHIATRY TRAU; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; Talland G.A, 1965, DERANGED MEMORY PSYC; Taverni JP, 1998, BRAIN INJURY, V12, P77; Taylor E. M., 1959, APPRAISAL CHILDREN C; vanReekum R, 1997, CAN J PSYCHIAT, V42, pS35; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO	38	90	92	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	2001	82	7					896	901		10.1053/apmr.2001.23833			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	450KV	WOS:000169742800005	11441374				2022-02-06	
J	Bondarenko, A; Chesler, M				Bondarenko, A; Chesler, M			Rapid astrocyte death induced by transient hypoxia, acidosis, and extracellular ion shifts	GLIA			English	Article						ischemia; BCECF; potassium; propidium iodide; extracellular pH	RAT SPINAL-CORD; PROPIDIUM IODIDE; INTRACELLULAR PH; NEURONAL DEATH; MEMBRANE INTEGRITY; SIMULATED ISCHEMIA; CALCIUM ACTIVITY; BRAIN ISCHEMIA; MOUSE NEURONS; CELL-DEATH	Death of astrocytes requires hours to days in injury models that use hypoxia, acidosis, or calcium paradox protocols. These methods do not incorporate the shifts in extracellular K+, Na+, Cl-, and Ca2+ that accompany acute brain insults. We studied astrocyte survival after exposure to hypoxic, acidic, ion-shifted Ringer (HAIR), with respective [Ca2+], [K+], [Na+], [Cl-], and [HCO3-] of 0.13, 65, 51, 75, and 13 mM (15% CO2/85% N-2, pH 6.6). Intracellular pH (pH(i)) was monitored with the fluorescent dye BCECF. Cell death was indicated by a steep fall in the pH-insensitive, 440-nm-induced fluorescence (F440) and was confirmed by propidium iodide staining. After 15-40-min HAIR exposure, reperfusion with standard Ringer caused death of most cultured (and acutely dissociated) astrocytes within 20 min. Cell death was not prevented if low Ca2+ was maintained during reperfusion. Survival fell with increased HAIR duration, elevated temperature, or absence of external glucose. Comparable durations of hypoxia, acidosis, or ion shifts alone did not lead to acute cell death, while modest loss was noted when acidosis was paired with either hypoxia or ion shifts. Severe cell loss required the triad of hypoxia, acidosis, and ion shifts. Intracellular pH was significantly higher in HAIR media, compared with solutions of low pH alone or with low pH plus hypoxia. These results indicate that astrocytes can be killed rapidly by changes in the extracellular microenvironment that occur in settings of traumatic and ischemic brain injury. GLIA 34:134-142, 2001. (C) 2001 Wiley-Liss, Inc.	NYU, Sch Med, Dept Physiol & Neurosci, New York, NY 10016 USA; NYU, Sch Med, Dept Neurosurg, New York, NY 10016 USA		Chesler, M (corresponding author), NYU, Sch Med, Dept Physiol & Neurosci, 550 1st Ave, New York, NY 10016 USA.		Bondarenko, Alexander I/B-3080-2013	Chesler, Mitchell/0000-0002-3189-8234	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS34906] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034906] Funding Source: NIH RePORTER		Back T, 1996, J CEREBR BLOOD F MET, V16, P202, DOI 10.1097/00004647-199603000-00004; BEVENSEE MO, 1995, J NEUROSCI METH, V58, P61, DOI 10.1016/0165-0270(94)00159-E; Bondarenko A, 2001, GLIA, V34, P143, DOI 10.1002/glia.1049; BONDARENKO A, 2000, SOC NEUR ABS, V26, P1893; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; CHESLER M, 1991, BRAIN RES, V556, P71, DOI 10.1016/0006-8993(91)90548-A; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Deitmer JW, 1996, PROG NEUROBIOL, V48, P73, DOI 10.1016/0301-0082(95)00039-9; DUGAN LL, 1995, J NEUROSCI, V15, P4545; Gido G, 1997, STROKE, V28, P206, DOI 10.1161/01.STR.28.1.206; GIFFARD RG, 1990, BRAIN RES, V530, P138, DOI 10.1016/0006-8993(90)90670-7; Giffard RG, 2000, J NEUROSCI, V20, P1001, DOI 10.1523/JNEUROSCI.20-03-01001.2000; GOLDMAN SA, 1989, J CEREBR BLOOD F MET, V9, P471, DOI 10.1038/jcbfm.1989.70; HANSEN AJ, 1985, PHYSIOL REV, V65, P101, DOI 10.1152/physrev.1985.65.1.101; HAUN SE, 1992, BRAIN RES, V593, P45, DOI 10.1016/0006-8993(92)91261-C; HERMAN B, 1988, FASEB J, V2, P146, DOI 10.1096/fasebj.2.2.3342967; IIJIMA T, 1992, J CEREBR BLOOD F MET, V12, P727, DOI 10.1038/jcbfm.1992.103; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; KELLEHER JA, 1993, STROKE, V24, P855, DOI 10.1161/01.STR.24.6.855; KIMELBERG HK, 1995, J CEREBR BLOOD F MET, V15, P409, DOI 10.1038/jcbfm.1995.51; KIMLEE MH, 1992, GLIA, V5, P56, DOI 10.1002/glia.440050109; KRAIG RP, 1985, BRAIN RES, V342, P281, DOI 10.1016/0006-8993(85)91127-8; KRAIG RP, 1987, J CEREBR BLOOD F MET, V7, P379, DOI 10.1038/jcbfm.1987.80; KRAIG RP, 1983, J NEUROPHYSIOL, V49, P831, DOI 10.1152/jn.1983.49.3.831; KRAIG RP, 1986, AM J PHYSIOL, V250, P348; Largo C, 1996, NEUROL RES, V18, P445; LITT L, 1985, J CEREBR BLOOD F MET, V5, P537, DOI 10.1038/jcbfm.1985.81; MACKLIS JD, 1990, J NEUROSCI METH, V31, P43, DOI 10.1016/0165-0270(90)90007-3; Matsuda T, 1996, EUR J NEUROSCI, V8, P951, DOI 10.1111/j.1460-9568.1996.tb01582.x; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MORIYA T, 1994, J NEUROTRAUM, V11, P255, DOI 10.1089/neu.1994.11.255; NEDERGAARD M, 1991, J NEUROSCI, V11, P2489; NEDERGAARD M, 1988, BRAIN RES, V449, P395, DOI 10.1016/0006-8993(88)91062-1; NEDERGAARD M, 1991, AM J PHYSIOL, V260, pR581, DOI 10.1152/ajpregu.1991.260.3.R581; NEDERGAARD M, 1986, J CEREBR BLOOD F MET, V6, P607, DOI 10.1038/jcbfm.1986.108; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Petito CK, 1998, J NEUROPATH EXP NEUR, V57, P231, DOI 10.1097/00005072-199803000-00004; PLUM F, 1983, NEUROLOGY, V33, P222, DOI 10.1212/WNL.33.2.222; Rose CR, 1997, J PHYSIOL-LONDON, V499, P573, DOI 10.1113/jphysiol.1997.sp021951; Rose CR, 1998, J NEUROSCI, V18, P3554; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; SMITH ML, 1986, J CEREBR BLOOD F MET, V6, P574, DOI 10.1038/jcbfm.1986.104; SOCHOCKA E, 1994, BRAIN RES, V638, P21, DOI 10.1016/0006-8993(94)90628-9; STEWART PA, 1978, RESP PHYSIOL, V33, P9, DOI 10.1016/0034-5687(78)90079-8; STOKES BT, 1983, EXP NEUROL, V80, P561, DOI 10.1016/0014-4886(83)90307-2; Swanson RA, 1997, GLIA, V21, P142, DOI 10.1002/(SICI)1098-1136(199709)21:1<142::AID-GLIA16>3.0.CO;2-S; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TSE FW, 1992, J NEUROSCI, V12, P1781; VONHANWEHR R, 1986, J NEUROCHEM, V46, P331; XU Y, 1991, STROKE, V22, P1303, DOI 10.1161/01.STR.22.10.1303; Ying WH, 1999, J NEUROCHEM, V73, P1549, DOI 10.1046/j.1471-4159.1999.0731549.x; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; YOUNG W, 1982, BRAIN RES, V253, P115, DOI 10.1016/0006-8993(82)90678-3; YU ACH, 1989, J CEREBR BLOOD F MET, V9, P20, DOI 10.1038/jcbfm.1989.3	55	90	93	1	10	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0894-1491			GLIA	Glia	APR 15	2001	34	2					134	142		10.1002/glia.1048			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	429NH	WOS:000168523500007	11307162				2022-02-06	
J	Cummins, RA				Cummins, RA			The subjective well-being of people caring for a family member with a severe disability at home: a review	JOURNAL OF INTELLECTUAL & DEVELOPMENTAL DISABILITY			English	Article							CHRONIC CHILDHOOD ILLNESS; TRAUMATIC BRAIN INJURY; WOMENS MULTIPLE ROLES; LIFE SATISFACTION; DISABLED-CHILDREN; MENTALLY-ILL; PSYCHOLOGICAL DISTRESS; DEPRESSED-PATIENTS; CYSTIC-FIBROSIS; SOCIAL SUPPORT	This review concerns the life quality of people caring for a relative with a severe disability within their family. It involves the balance between the advantages such care brings to the care recipient and the costs borne by the family. A brief history indicates that the forces that encourage family care are minimally concerned with family welfare. Moreover, an analysis of both qualitative and quantitative data indicates that primary caregivers are at considerable risk of high stress, clinical depression, and abnormally low subjective quality of life. It is concluded that increased public expenditure directed to the care of people with severe disability is urgently required.	Deakin Univ, Sch Psychol, Melbourne, Vic 3125, Australia		Cummins, RA (corresponding author), Deakin Univ, Sch Psychol, Melbourne, Vic 3125, Australia.			Cummins, Robert/0000-0001-9014-7193			AMMERMAN RT, 1988, J FAMILY VIOLENCE, V3, P53; Archbold P G, 1980, J Gerontol Nurs, V6, P79; BAUMANIS D, 1970, CAN MENT HEALTH, V18, P23; BAUMGARTEN M, 1992, J CLIN EPIDEMIOL, V45, P61, DOI 10.1016/0895-4356(92)90189-T; BENTELSPACHER CE, 1994, FAM SOC-J CONTEMP H, V75, P287, DOI 10.1177/104438949407500504; BERGWEGER M, 1996, CARING ELDERLY PAREN; Bethoux F, 1996, INT J REHABIL RES, V19, P291, DOI 10.1097/00004356-199612000-00001; Bindoff H.P., 1997, J FAM STUD, V3, P183; BOGGS EM, 1992, MENT RETARD, V30, P178; BOUMA R, 1990, J CLIN PSYCHOL, V46, P722, DOI 10.1002/1097-4679(199011)46:6<722::AID-JCLP2270460605>3.0.CO;2-6; BRANHOLM IB, 1992, SCAND J SOC MED, V20, P37; BRESLAU N, 1982, AM J DIS CHILD, V136, P682, DOI 10.1001/archpedi.1982.03970440026007; Browne G, 1996, Aust N Z J Ment Health Nurs, V5, P120; BURGENER SC, 1994, J RELIG HEALTH, V33, P175, DOI 10.1007/BF02354538; Christensen KA, 1998, HEALTH PSYCHOL, V17, P163, DOI 10.1037/0278-6133.17.2.163; Conoley JC, 1996, J LEARN DISABIL-US, V29, P662, DOI 10.1177/002221949602900610; Cummins R., 1997, COMPREHENSIVE QUALIT; Cummins RA, 1998, SOC INDIC RES, V43, P307, DOI 10.1023/A:1006831107052; CUMMINS RA, 1995, SOC INDIC RES, V35, P179, DOI 10.1007/BF01079026; Cummins RA, 1996, SOC INDIC RES, V38, P303, DOI 10.1007/BF00292050; CUMMINS RA, 2001, IN PRESS METHODOLOGI; DEIMLING GT, 1986, J GERONTOL, V41, P778, DOI 10.1093/geronj/41.6.778; Dyson LL, 1996, J LEARN DISABIL, V29, P280, DOI 10.1177/002221949602900306; FADDEN G, 1987, BRIT J PSYCHIAT, V150, P285, DOI 10.1192/bjp.150.3.285; FEINSTEIN C, 1986, ENTOURAGE, V1, P13; FENGLER AP, 1979, GERONTOLOGIST, V19, P175, DOI 10.1093/geront/19.2.175; GEORGE LK, 1986, GERONTOLOGIST, V26, P253, DOI 10.1093/geront/26.3.253; GOLODETZ A, 1969, MED CARE, V7, P385, DOI 10.1097/00005650-196909000-00006; Grant G, 1998, J INTELL DISABIL RES, V42, P58, DOI 10.1046/j.1365-2788.1998.00079.x; HALEY WE, 1987, PSYCHOL AGING, V2, P323, DOI 10.1037/0882-7974.2.4.323; Hatton C, 1998, BRIT J SOC WORK, V28, P821; HERRMAN H, 1994, QUALITY LIFE ASSESSM, P131; Hodapp RM, 1998, J INTELL DISABIL RES, V42, P331, DOI 10.1046/j.1365-2788.1998.00148.x; HOLROYD J, 1986, J CLIN PSYCHOL, V42, P552, DOI 10.1002/1097-4679(198607)42:4<552::AID-JCLP2270420403>3.0.CO;2-8; Jenkins JH, 1999, BRIT J PSYCHIAT, V174, P31, DOI 10.1192/bjp.174.1.31; JOHNSON L, 1999, AGE             1026, P11; KNIGHT RG, 1998, AUSTR NZ J PUBLIC HL, V22, P96; KROPF NP, 1993, J GERONTOL SOC WORK, V21, P25; Lawenius M, 1996, SOC BEHAV PERSONAL, V24, P195, DOI 10.2224/sbp.1996.24.2.195; LAWTON MP, 1975, J GERONTOL, V30, P85, DOI 10.1093/geronj/30.1.85; LUBETSKY MJ, 1995, MENT RETARD, V33, P251; MARSH DT, 1996, PSYCHIATR REHABIL J, V20, P1; MOHIDE EA, 1993, DEPRESSION SOCIAL EN, P289; MORONEY RM, 1983, HOME HEALTH CARE SER, V3, P188; Nirje B., 1976, CHANGING PATTERNS RE, P231; NIRJE B, 1970, J MENTAL SUBNORM DEC, P64; Rosenvinge H, 1998, INT J GERIATR PSYCH, V13, P8, DOI 10.1002/(SICI)1099-1166(199801)13:1<8::AID-GPS717>3.0.CO;2-7; Scheerenberger R. C., 1983, HIST MENTAL RETARDAT; SELZTER MM, 1995, J INTELLECTURAL DISA, V39, P408; SHANAS E, 1979, GERONTOLOGIST, V19, P169, DOI 10.1093/geront/19.2.169; SHERWOOD S, 1975, LONG TERM CARE HDB R, P3; Singer GHS, 1989, SUPPORT CAREGIVING F, P3; SINGHI PD, 1990, BRIT J MED PSYCHOL, V63, P173, DOI 10.1111/j.2044-8341.1990.tb01610.x; SMITH J, 1993, SOC PSYCH PSYCH EPID, V28, P11, DOI 10.1007/BF00797827; Spangenberg JJ, 1999, J PSYCHOL, V133, P253, DOI 10.1080/00223989909599738; Stainton T, 1998, J INTELLECT DEV DIS, V23, P57, DOI 10.1080/13668259800033581; Stengard E, 1997, NORD J PSYCHIAT, V51, P159, DOI 10.3109/08039489709109090; Stephens MAP, 1999, CURR DIR PSYCHOL SCI, V8, P149, DOI 10.1111/1467-8721.00035; Stuckey JC, 1996, GERONTOLOGIST, V36, P686, DOI 10.1093/geront/36.5.686; THOMPSON EH, 1982, FAM RELAT, V31, P379, DOI 10.2307/584170; TOWNSEND A, 1989, PSYCHOL AGING, V4, P393, DOI 10.1037/0882-7974.4.4.393; TRUTE B, 1995, J CHILD PSYCHOL PSYC, V36, P1225, DOI 10.1111/j.1469-7610.1995.tb01367.x; Tymchuk Alexander J., 1994, Australia and New Zealand Journal of Developmental Disabilities, V19, P111; Voepel-Lewis T, 1990, ANNA J, V17, P427; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Warfield ME, 1999, J DEV BEHAV PEDIATR, V20, P9, DOI 10.1097/00004703-199902000-00002; Weisz V, 1996, AM PSYCHOL, V51, P1239; Whitlatch CJ, 1997, J AGING HEALTH, V9, P222; WINEFIELD HR, 1993, SCHIZOPHRENIA BULL, V19, P619, DOI 10.1093/schbul/19.3.619; WINEFIELD HR, 1994, INT J STRESS MANAGE, V1, P283, DOI 10.1007/BF01857997; Winzer M., 1990, CHILDREN EXCEPTIONAL; Wolfensberger W., 1972, PRINCIPLE NORMALIZAT; WOOD V, 1969, J GERONTOL, V24, P465, DOI 10.1093/geronj/24.4.465; Yau MKS, 1999, BRIT J DEV DISABIL, V45, P38, DOI 10.1179/096979599799156028	74	90	90	0	11	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	1366-8250			J INTELLECT DEV DIS	J. Intellect. Dev. Dis.	MAR	2001	26	1					83	100		10.1080/13668250020032787			18	Education, Special; Rehabilitation	Social Science Citation Index (SSCI)	Education & Educational Research; Rehabilitation	461LB	WOS:000170364800006					2022-02-06	
J	Vanderploeg, RD; Crowell, TA; Curtiss, G				Vanderploeg, RD; Crowell, TA; Curtiss, G			Verbal learning and memory deficits in traumatic brain injury: Encoding, consolidation, and retrieval	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; PATTERNS; PERFORMANCE	The present study examined the nature of verbal memory deficits in individuals with traumatic brain injury (TBI) compared to healthy controls. The study was designed to control for methodological shortcomings of previous related research. Three groups of participants were used: (a) a head injured sample with moderate to severe traumatic brain injuries (N = 55), (b) a control sample matched on age and initial performance on CVLT Trial 5 and Sum of Trials 1 to 5 (N = 55), and (c) a control sample matched on age, education, and race, but not on initial CVLT learning performance (N = 55). Current findings indicate that: (a) rate of learning was comparable across groups, consistent with no encoding differences, (b) TBI patients have a significantly more rapid rate of forgetting of new information than either acquisition-matched or demographic-matched controls, consistent with consolidation problems in TBI, (c) TBI patients have less proactive interference than demographic-matched control participants, consistent with a consolidation problem in the TBI group, (d) TBI patients and acquisition-matched controls have comparably low rates of proactive interference, consistent with impaired acquisition in both of these groups, and (e) TBI patients and controls do not differ in the benefit experienced from semantic or recognition retrieval cues, consistent with no differences in retrieval processes. These data support an impaired consolidation hypothesis, rather than encoding or retrieval deficits, as the primary deficit underlying memory impairment in TBI.	Univ S Florida, James A Haley Vet Adm Med Ctr, Tampa, FL 33620 USA; Univ S Florida, Dept Psychiat, Tampa, FL 33620 USA; Univ S Florida, Dept Neurol, Tampa, FL 33620 USA; Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; Def & Vet Head Injury Program, Washington, DC USA		Vanderploeg, RD (corresponding author), James A Haley Vet Hosp, Psychiat Serv 116B, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Rodney.Vanderploeg@med.va.gov	Curtiss, Glenn/ABB-5566-2020				[Anonymous], 1988, JAMA, V259, P2701; Baum KM, 1996, CLIN NEUROPSYCHOL, V10, P340; BLACHSTEIN H, 1993, NEUROPSYCHOLOGY, V7, P530, DOI DOI 10.1037/0894-4105.7.4.530; Carlesimo GA, 1997, CORTEX, V33, P131, DOI 10.1016/S0010-9452(97)80009-3; Cohen J., 2013, STAT POWER ANAL BEHA; COOKE DL, 1995, J CLIN EXP NEUROPSYC, V17, P90, DOI 10.1080/13803399508406585; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; CROSSON B, 1989, CLIN NEUROPSYCHOL, V3, P29, DOI DOI 10.1080/13854048908404074; CURTIS G, IN PRESS J INT NEURO; Delis DC, 1987, CALIFORNIA VERBAL LE; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2708; ERICKSON RC, 1977, PSYCHOL BULL, V84, P1130, DOI 10.1037/0033-2909.84.6.1130; GOLDSTEIN FC, 1989, CORTEX, V25, P541, DOI 10.1016/S0010-9452(89)80016-4; Hart R. P., 1994, NEUROPSYCHOLOGY, V8, P325, DOI [10.1037/0894-4105.8.3.325, DOI 10.1037/0894-4105.8.3.325]; Kirk RE., 1995, EXPT DESIGN PROCEDUR, V3; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; MILLIS SR, 1994, J CLIN EXP NEUROPSYC, V16, P498, DOI 10.1080/01688639408402661; NOVACK TA, 1995, CLIN NEUROPSYCHOL, V9, P38; Numan B, 2000, J CLIN PSYCHOL, V56, P553, DOI 10.1002/(SICI)1097-4679(200004)56:4<553::AID-JCLP8>3.0.CO;2-Q; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PANIAK CE, 1989, J CLIN EXP NEUROPSYC, V11, P631, DOI 10.1080/01688638908400921; Postman Leo, 1971, WOODWORTH SCHOLSBERG, V3rd, P1019; Salazar AM, 2000, J HEAD TRAUMA REHAB, V15, P1081, DOI 10.1097/00001199-200010000-00002; Spencer J, 1998, CLIN NEUROPSYCHOL, V12, P296; Squire L. R., 1983, MEMORY CONSOLIDATION, P185; Squire LR., 1987, MEMORY BRAIN; VANDERPLOEG RD, 1990, ANN M AM PSYCH ASS B; Wechsler D, 1981, WECHSLER ADULT INTEL; Wilde MC, 1995, J CLIN EXP NEUROPSYC, V17, P849, DOI 10.1080/01688639508402434; ZOLAMORGAN SM, 1990, SCIENCE, V250, P288, DOI 10.1126/science.2218534; [No title captured]	35	90	91	0	14	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2001	23	2					185	195		10.1076/jcen.23.2.185.1210			11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	412QZ	WOS:000167567000005	11309672				2022-02-06	
J	Guhring, H; Gorig, M; Ates, M; Coste, O; Zeilhofer, HU; Pahl, A; Rehse, K; Brune, K				Guhring, H; Gorig, M; Ates, M; Coste, O; Zeilhofer, HU; Pahl, A; Rehse, K; Brune, K			Suppressed injury-induced rise in spinal prostaglandin E-2 production and reduced early thermal hyperalgesia in iNOS-deficient mice	JOURNAL OF NEUROSCIENCE			English	Article						nitric oxide; inducible nitric oxide synthase; zymosan; thermal hyperalgesia; paw edema; spinal microdialysis; L-NIL; RE-2047; prostaglandins; cyclooxygenase	NITRIC-OXIDE SYNTHASE; CYCLOOXYGENASE-2 MESSENGER-RNA; TRAUMATIC BRAIN INJURY; PERIPHERAL INFLAMMATION; SECONDARY HYPERALGESIA; JOINT INFLAMMATION; UP-REGULATION; SUBSTANCE-P; RAT; EXPRESSION	It is widely accepted that peripheral injury increases spinal inducible cyclooxygenase (COX-2) expression and prostaglandin E-2 (PGE(2)) formation as key mediators of nociceptive sensitization. Here, we used inducible nitric oxide synthase (iNOS) gene-deficient (iNOS-/-) mice to determine the contribution of iNOS-derived nitric oxide (NO) to this process. iNOS-/- mice exhibited reduced thermal hyperalgesia after zymosan injection. Spinal NO and PGE2 formation both remained at baseline levels, in contrast to wild-type (wt) mice. In wt mice reduced hyperalgesia similar to that seen in iNOS-/- mice was induced by local spinal, but not by systemic treatment with the iNOS inhibitor L-NIL, suggesting that the reduced heat sensitization in iNOS-/- mice was attributable to the lack of spinal rather than peripheral iNOS. Two additional observations indicate that the antinociceptive effects of iNOS inhibition are dependent on a loss of stimulation of PG synthesis. First, intrathecal injection of the COX inhibitor indomethacin, which exerted pronounced antinociceptive effects in wt mice, was completely ineffective in iNOS-/- mice. Second, treatment with the NO donor RE-2047 not only completely restored spinal PG production and thermal sensitization in iNOS-/- mice but also its sensitivity to indomethacin. In both types of mice induction of thermal hyperalgesia was accompanied by similar increases in COX-1 and COX-2 mRNA expression. The stimulation of PG production by NO therefore involves an increase in enzymatic activity, rather than an alteration of COX gene expression. These results indicate that NO derived from spinal iNOS acts as a fast inductor of spinal thermal hyperalgesia.	Dept Expt & Clin Pharmacol & Toxicol, D-91054 Erlangen, Germany; Dept Pharmaceut Chem, D-14195 Berlin, Germany		Guhring, H (corresponding author), Dept Expt & Clin Pharmacol & Toxicol, Fahrstr 17, D-91054 Erlangen, Germany.		ates, mehmet/P-4503-2019; Zeilhofer, Hanns Ulrich/A-4600-2008	ates, mehmet/0000-0002-8310-1979; Zeilhofer, Hanns Ulrich/0000-0001-6954-4629			Aley KO, 1998, J NEUROSCI, V18, P7008; AMIR S, 1991, EUR J PHARMACOL, V203, P125, DOI 10.1016/0014-2999(91)90800-6; Andrew D, 1999, J NEUROPHYSIOL, V82, P2649, DOI 10.1152/jn.1999.82.5.2649; Barker JE, 1998, BRAIN RES, V804, P1, DOI 10.1016/S0006-8993(98)00603-9; Beiche F, 1998, INFLAMM RES, V47, P482, DOI 10.1007/s000110050362; Beiche F, 1996, FEBS LETT, V390, P165, DOI 10.1016/0014-5793(96)00604-7; Bley KR, 1998, TRENDS PHARMACOL SCI, V19, P141, DOI 10.1016/S0165-6147(98)01185-7; BRUNE K, 1994, DRUGS, V5, P21; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chen XJ, 1999, J NEUROPHYSIOL, V81, P963, DOI 10.1152/jn.1999.81.3.963; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Deckert-Schluter M, 1998, J IMMUNOL, V160, P3427; DECKERTSCHLUTER M, 1995, IMMUNOLOGY, V85, P408; Dirig DM, 1999, BRIT J PHARMACOL, V126, P1333, DOI 10.1038/sj.bjp.0702427; Downen M, 1999, J NEUROPATH EXP NEUR, V58, P12, DOI 10.1097/00005072-199901000-00002; Ebersberger A, 1999, NEUROSCIENCE, V93, P775, DOI 10.1016/S0306-4522(99)00164-5; Ferreira SH, 1996, INFLAMM RES, V45, P499, DOI 10.1007/BF02311085; Goettl VM, 1996, PAIN, V67, P435, DOI 10.1016/0304-3959(96)03155-7; Gonzalez-Hernandez T, 1999, J NEUROSCI RES, V55, P198, DOI 10.1002/(SICI)1097-4547(19990115)55:2<198::AID-JNR7>3.0.CO;2-M; GREEN LC, 1981, SCIENCE, V212, P56, DOI 10.1126/science.6451927; HADDAD EB, 1995, EUR J PHARM-ENVIRON, V293, P287, DOI 10.1016/0926-6917(95)00032-1; Hamalainen MM, 1997, NEUROSCIENCE, V80, P821, DOI 10.1016/S0306-4522(97)00124-3; Hamilton LC, 1998, BRIT J PHARMACOL, V125, P335, DOI 10.1038/sj.bjp.0702077; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hay C, 1997, NEUROREPORT, V8, P1249, DOI 10.1097/00001756-199703240-00038; HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014-2999(80)90515-4; Ichitani Y, 1997, NEUROREPORT, V8, P2949, DOI 10.1097/00001756-199709080-00028; Inoue T, 1997, J NEUROL SCI, V153, P1, DOI 10.1016/S0022-510X(97)00188-3; KAWABATA A, 1994, BRIT J PHARMACOL, V112, P547, DOI 10.1111/j.1476-5381.1994.tb13108.x; Kress M, 1999, TRENDS PHARMACOL SCI, V20, P112, DOI 10.1016/S0165-6147(99)01294-8; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; Lauretti GR, 1999, ANESTHESIOLOGY, V90, P1528, DOI 10.1097/00000542-199906000-00005; Lawand NB, 1997, NEUROREPORT, V8, P895, DOI 10.1097/00001756-199703030-00016; Lee Sunhee C., 1996, Methods (Orlando), V10, P31, DOI 10.1006/meth.1996.0075; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MacNaughton WK, 1998, INT J RADIAT BIOL, V74, P255, DOI 10.1080/095530098141645; MALMBERG AB, 1993, PAIN, V54, P291, DOI 10.1016/0304-3959(93)90028-N; MELLER ST, 1994, NEUROPHARMACOLOGY, V33, P1471, DOI 10.1016/0028-3908(94)90051-5; MINAMI T, 1994, PAIN, V57, P217, DOI 10.1016/0304-3959(94)90226-7; MOORE WM, 1994, J MED CHEM, V37, P3886, DOI 10.1021/jm00049a007; Osborne MG, 1999, BRIT J PHARMACOL, V126, P1840, DOI 10.1038/sj.bjp.0702508; REHSE K, 1995, ARCH PHARM, V328, P71, DOI 10.1002/ardp.19953280113; Reichner JS, 1999, AM J PATHOL, V154, P1097, DOI 10.1016/S0002-9440(10)65362-X; Sahnoun Z, 1998, THERAPIE, V53, P315; SALVEMINI D, 1994, J CLIN INVEST, V93, P1940, DOI 10.1172/JCI117185; SALVEMINI D, 1995, J CLIN INVEST, V96, P301, DOI 10.1172/JCI118035; Salvemini D, 1997, CELL MOL LIFE SCI, V53, P576, DOI 10.1007/s000180050074; Shen T Y, 1977, Adv Drug Res, V12, P90; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Urban MO, 1999, PAIN, V81, P45, DOI 10.1016/S0304-3959(98)00265-6; Wei G, 1999, BBA-MOL BASIS DIS, V1455, P23, DOI 10.1016/S0925-4439(99)00051-4; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; YAKSH TL, 1993, AGENT ACTION SUPPL, V41, P89; Yamamoto T, 1997, NEUROREPORT, V8, P2179, DOI 10.1097/00001756-199707070-00018; Yang LC, 1996, PAIN, V67, P345, DOI 10.1016/0304-3959(96)03106-5; Zingarelli B, 1997, BRIT J PHARMACOL, V120, P357, DOI 10.1038/sj.bjp.0700892	56	90	94	0	2	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	SEP 1	2000	20	17					6714	6720		10.1523/JNEUROSCI.20-17-06714.2000			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	348VJ	WOS:000089006900044	10964977	Green Accepted, Bronze, Green Published			2022-02-06	
J	Schanke, AK; Sundet, K				Schanke, AK; Sundet, K			Comprehensive driving assessment: Neuropsychological testing and on-road evaluation of brain injured patients	SCANDINAVIAN JOURNAL OF PSYCHOLOGY			English	Article						brain damage; driver's license; neuropsychological tests; on-road driving	OLDER DRIVERS; ALZHEIMER; FITNESS; DISEASE; DAMAGE; STROKE	The study investigates the correspondence between neuropsychological test results and on-road driving performance among 55 patients with a CT-verified brain damage or documented neurological disorder (cerebrovascular accident: 43, traumatic brain injury: 5, multiple sclerosis: 4, other: 3). 5 patients showed unimpaired test profiles and passed the on-road evaluation. 18 patients showed severe neuropsychological deficits contrary to driving and were not recommended for on-road evaluation. Of the remaining 32 patients with some neuropsychological deficits, all 100% in the minor impaired group (n = 8) passed the driving evaluation, compared to 69% in the mildly impaired (n = 16) and 38% in the moderately impaired group (n = 8). Measures of reduced visuoconstructive ability, reaction time, visual attention, and awareness of cognitive impairments, were found to discriminate between groups, it is concluded that neuropsychological assessment of targeted functions provide an ecological valid prediction of driving skill after brain damage, but that on-road evaluation is needed as supplement in cases with ambiguous test findings.	Sunnaas Rehabil Hosp, N-1450 Nesoddtangen, Norway; Univ Oslo, Natl Hosp, Dept Psychosomat & Behav Med, Oslo, Norway		Schanke, AK (corresponding author), Sunnaas Rehabil Hosp, N-1450 Nesoddtangen, Norway.						ANDERSON W, 1989, CLIN NEUROPSYCHOL, V4, P327; BARR R, 1993, J AM GERIATR SOC, V41, P889, DOI 10.1111/j.1532-5415.1993.tb06199.x; Boake C., 1998, J INT NEUROPSYCH SOC, V4, P75; BROOKE MM, 1992, AM J PHYS MED REHAB, V71, P177, DOI 10.1097/00002060-199206000-00009; Brouwer WH, 1997, NEUROPSYCHOL REHABIL, V7, P177, DOI 10.1080/713755536; Colsher P L, 1993, Clin Geriatr Med, V9, P365; DICK JPR, 1984, J NEUROL NEUROSUR PS, V47, P496, DOI 10.1136/jnnp.47.5.496; Dobbs AR, 1998, ACCIDENT ANAL PREV, V30, P363, DOI 10.1016/S0001-4575(97)00110-3; FITTEN LJ, 1995, JAMA-J AM MED ASSOC, V273, P1360, DOI 10.1001/jama.273.17.1360; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fox G K, 1992, Disabil Rehabil, V14, P140; FRIEDLAND RP, 1988, ANN NEUROL, V24, P782, DOI 10.1002/ana.410240613; Gimse R, 1997, SCAND J PSYCHOL, V38, P165, DOI 10.1111/1467-9450.00023; Haselkorn JK, 1998, ARCH PHYS MED REHAB, V79, P738, DOI 10.1016/S0003-9993(98)90349-5; HOPEWELL CA, 1985, J CLIN EXP NEUROPSYC, V7, P148; JOHANSSON SL, 1993, J UROL PATHOL, V1, P69; JONES R, 1983, AM J OCCUP THER, V37, P754, DOI 10.5014/ajot.37.11.754; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; Lambert EW, 1992, COGNITIVE REHABI MAY, V10, P32; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LINGS S, 1992, ACTA NEUROL SCAND, V86, P33, DOI 10.1111/j.1600-0404.1992.tb08050.x; Lundberg C, 1998, ACCIDENT ANAL PREV, V30, P371, DOI 10.1016/S0001-4575(97)00111-5; Lundqvist A, 1997, APPL NEUROPSYCHOL, V4, P220, DOI 10.1207/s15324826an0404_3; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; MICHON JA, 1908, HUMAN BEHAV TRAFFIC, P485; *NAT HLTH SERV, 1997, GUID ISS HLTH CERT D; QUIGLEY FL, 1983, AM J OCCUPATIONAL TH, V26, P208; REBOK GW, 1994, ALZ DIS ASSOC DIS, V8, P228, DOI 10.1097/00002093-199408040-00002; SCHANKE AK, 1995, J NORWEGIAN MED ASS, V115, P1349; SHORE D, 1990, ARCH PHYSICAL MED RE, V62, P163; Stutts JC, 1998, ACCIDENT ANAL PREV, V30, P337, DOI 10.1016/S0001-4575(97)00108-5; SUNDET K, 1995, SCAND J PSYCHOL, V36, P47, DOI 10.1111/j.1467-9450.1995.tb00967.x; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; World Health Organization, 1980, INT CLASS IMP DIS HA	35	90	92	0	9	BLACKWELL PUBL LTD	OXFORD	108 COWLEY RD, OXFORD OX4 1JF, OXON, ENGLAND	0036-5564			SCAND J PSYCHOL	Scand. J. Psychol.	JUN	2000	41	2					113	121		10.1111/1467-9450.00179			9	Psychology, Multidisciplinary	Social Science Citation Index (SSCI)	Psychology	324VR	WOS:000087642500005	10870430				2022-02-06	
J	Skelton, RW; Bukach, CM; Laurance, HE; Thomas, KGF; Jacobs, WJ				Skelton, RW; Bukach, CM; Laurance, HE; Thomas, KGF; Jacobs, WJ			Humans with traumatic brain injuries show place-learning deficits in computer-generated virtual space	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							MORRIS WATER MAZE; HEAD-INJURY; TOPOGRAPHICAL DISORIENTATION; SPATIAL LOCALIZATION; STIMULUS-CONTROL; LOBE LESIONS; MEMORY; RATS; HIPPOCAMPUS; TASK	Spatial learning and memory has been linked to the hippocampus and temporal lobes and though these areas are often damaged in traumatic brain injury (TBI), spatial learning deficits after TBI have not received much attention. In the present study, a virtual environment was used to challenge people with TBI to solve a task comparable to the Morris water maze, which in turn has been shown to be highly sensitive to hippocampal and frontal lobe dysfunction in laboratory animals. A regular computer monitor was used to present 12 participants with TBI and 12 age- and sex-matched comparison participants with a computer-generated, three-dimensional "virtual arena maze,'' consisting of a large round arena within a very large square room. Participants were required to learn the place of an invisible target on the floor of the room based solely on distal cues on the walls of the room. Eight of the 12 participants with moderate to severe TBI showed substantial place-learning deficits in comparison to the uninjured participants. Performance in the virtual environment correlated with self-reported frequency of wayfinding problems in everyday life and with scores on a test of episodic memory, the Rivermead Behavioural Memory Task. These data confirm that deficits in spatial learning and memory follow TBI, and suggest that the virtual arena maze may provide a new method for objectively assessing them.	Univ Victoria, Dept Psychol, Victoria, BC V8W 3P5, Canada; Univ So Calif, Los Angeles, CA 90089 USA		Skelton, RW (corresponding author), Univ Victoria, Dept Psychol, Box 3050, Victoria, BC V8W 3P5, Canada.		Bukach, Cindy M/E-7057-2010; Skelton, Ronald/E-5605-2012; Thomas, Kevin Garth Flusk/AAA-8655-2020	Thomas, Kevin Garth Flusk/0000-0002-0807-6101			ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Astur RS, 1998, BEHAV BRAIN RES, V93, P185, DOI 10.1016/S0166-4328(98)00019-9; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; BOHBOT V, 1994, NEUR ABSTR, V20, P361; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; Cohen J., 2013, STAT POWER ANAL BEHA; CORKIN S, 1965, NEUROPSYCHOLOGIA, V3, P339, DOI 10.1016/0028-3932(65)90006-0; DAUM I, 1991, CORTEX, V27, P613, DOI 10.1016/S0010-9452(13)80010-X; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; EICHENBAUM H, 1990, J NEUROSCI, V10, P3531; Feigenbaum JD, 1996, NEUROPSYCHOLOGIA, V34, P163, DOI 10.1016/0028-3932(95)00107-7; GAGE FH, 1986, J NEUROSCI, V6, P2837; HABIB M, 1987, CORTEX, V23, P73, DOI 10.1016/S0010-9452(87)80020-5; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Jacobs WJ, 1998, LEARN MOTIV, V29, P288, DOI 10.1006/lmot.1998.1008; Jacobs WJ, 1997, LEARN MOTIV, V28, P521, DOI 10.1006/lmot.1997.0977; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Maguire EA, 1997, PHILOS T R SOC B, V352, P1475, DOI 10.1098/rstb.1997.0134; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; Maguire EA, 1996, NEUROPSYCHOLOGIA, V34, P993, DOI 10.1016/0028-3932(96)00022-X; MCDANIEL WF, 1991, BEHAV BRAIN RES, V44, P107, DOI 10.1016/S0166-4328(05)80245-1; MCNAMARA RK, 1993, BRAIN RES REV, V18, P33, DOI 10.1016/0165-0173(93)90006-L; MILNER B, 1970, BIOL MEM, V23, P31; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; Nadel L., 1991, Hippocampus, V1, P221, DOI 10.1002/hipo.450010302; OKeefe J., 1978, HIPPOCAMPUS COGNITIV; OLSEN GM, 1994, BEHAV NEUROSCI, V108, P681, DOI 10.1037/0735-7044.108.4.681; Paterson A, 1944, BRAIN, V67, P331, DOI 10.1093/brain/67.4.331; RAPPAPORT M, 1989, ARCH PHYSICAL MED RE, V70, P431; Reid I., 1995, NEUR ABSTR, V21, P1446; Rizzo AA, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199712000-00002; ROD MR, 1990, CAN J PSYCHOL, V44, P196, DOI 10.1037/h0084242; Sandstrom NJ, 1998, COGNITIVE BRAIN RES, V6, P351, DOI 10.1016/S0926-6410(98)00002-0; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; SKELTON RW, 1992, HIPPOCAMPUS, V2, P73, DOI 10.1002/hipo.450020110; Skelton RW, 1998, BEHAV BRAIN RES, V96, P13, DOI 10.1016/S0166-4328(97)00199-X; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH ML, 1989, NEUROPSYCHOLOGIA, V27, P71, DOI 10.1016/0028-3932(89)90091-2; SMITH ML, 1981, NEUROPSYCHOLOGIA, V19, P781, DOI 10.1016/0028-3932(81)90090-7; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SUZUKI S, 1980, LEARN MOTIV, V11, P1, DOI 10.1016/0023-9690(80)90018-1; TOLMAN EC, 1948, PSYCHOL REV, V55, P189, DOI 10.1037/h0061626; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO; Wilson PN, 1997, DISABIL REHABIL, V19, P213, DOI 10.3109/09638289709166530; [No title captured]; [No title captured]	52	90	90	0	9	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2000	22	2					157	175		10.1076/1380-3395(200004)22:2;1-1;FT157			19	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	310QF	WOS:000086838300001	10779831				2022-02-06	
J	Tate, RL				Tate, RL			Executive dysfunction and characterological changes after traumatic brain injury: Two sides of the same coin?	CORTEX			English	Article						frontal lobe; brain injury; cognition disorders	CARD SORTING TEST; CLOSED-HEAD INJURY; FRONTAL-LOBE LESIONS; COGNITIVE RISK-TAKING; TEMPORAL LOBECTOMY; PREFRONTAL CORTEX; RELATIVES VIEW; DESIGN FLUENCY; DAMAGE; INFORMATION	This study examined the capacity of neuropsychological variables indicative of dysfunction in the regulation of executive abilities (e.g. noncompliance with rules) to reflect changes in character associated with disturbances in regulatory abilities (e.g. impulsivity). A close relative of 30 participants with traumatic brain injury (TBI) was administered the Current Behaviour Scale (CBS) at admission (rating premorbid character) and six months posttrauma (rating current character). The TBI group was examined neuropsychologically at six months posttrauma, along with 30 nonbrain-damaged (NBD) participants. Significant increases in CBS factors, Loss of Emotional Control and Loss of Motivation, occurred in the TBI group posttrauma. Differences between TBI and NBD groups were found for most executive variables. Those TBI participants with impairments on the neuropsychological Rule Breaking variable showed significant posttrauma increases in Loss of Emotional Control. There was also a trend for individuals with frontal lesions to make rule-breaking and perseverative errors.	Univ Sydney, Dept Med, Rehabil Studies Unit, Royal Rehabil Ctr, Ryde, NSW 1680, Australia		Tate, RL (corresponding author), Univ Sydney, Dept Med, Rehabil Studies Unit, Royal Rehabil Ctr, POB 6, Ryde, NSW 1680, Australia.	state@med.usyd.edu.au					Al-Adawi S, 1998, NEUROPSYCHOLOGY, V12, P115, DOI 10.1037/0894-4105.12.1.115; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; Antonak R. F., 1993, J HEAD TRAUMA REHAB, V8, P87, DOI DOI 10.1097/00001199-199312000-00009; Axelrod Bradley N, 1992, Clin Neuropsychol, V6, P143, DOI 10.1080/13854049208401851; Barcelo F, 1997, NEUROPSYCHOLOGIA, V35, P399, DOI 10.1016/S0028-3932(96)00096-6; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; Benson D.F., 1986, FRONTAL LOBES; Benton A., 1994, CONTRIBUTIONS NEUROP; BERMAN KF, 1995, NEUROPSYCHOLOGIA, V33, P1027, DOI 10.1016/0028-3932(95)00035-2; Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1988, Acta Neurochir Suppl (Wien), V44, P59; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess PW, 1996, CORTEX, V32, P241, DOI 10.1016/S0010-9452(96)80049-9; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; CROWE SF, 1992, J CLIN EXP NEUROPSYC, V14, P327, DOI 10.1080/01688639208402832; EAMES P, 1988, J HEAD TRAUMA REHAB, V3, P1; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; Fleming JM, 1996, BRAIN INJURY, V10, P1; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GAINOTTI G, 1993, NEUROPSYCHOL REHABIL, V3, P259, DOI 10.1080/09602019308401440; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; GOLDSTEIN FC, 1989, INTEGRATING THEORY P, P217; Grattan LM, 1989, NEUROPSYCHOLOGY, V3, P175, DOI 10.1037//0894-4105.3.3.175; GURNS S, 1994, BRAIN INJURY, V8, P413, DOI 10.3109/02699059409150993; Heaton PDRK., 1993, WISCONSIN CARD SORTI; HECAEN H, 1964, FRONTAL GRANULAR COR, P335; HECK ET, 1986, J CLIN EXP NEUROPSYC, V8, P313, DOI 10.1080/01688638608401321; JONESGOTMAN M, 1977, NEUROPSYCHOLOGIA, V15, P653, DOI 10.1016/0028-3932(77)90070-7; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; Kertesz A., 1982, W APHASIA BATTERY; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; KINSELLA G, 1991, J NEUROL NEUROSUR PS, V54, P422, DOI 10.1136/jnnp.54.5.422; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Lishman W. A., 1987, ORGANIC PSYCHIAT; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; Luria A.R., 1973, WORKING BRAIN; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2d; Luria AR, 1969, HDB CLINICAL NEUROLO, P725; MACNIVEN E, 1993, BRAIN INJURY, V7, P241, DOI 10.3109/02699059309029676; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MILLER L, 1985, NEUROPSYCHOLOGIA, V23, P359, DOI 10.1016/0028-3932(85)90022-3; MILLER L, 1985, NEUROPSYCHOLOGIA, V23, P371, DOI 10.1016/0028-3932(85)90023-5; MILLER LA, 1992, NEUROPSYCHOLOGIA, V30, P69, DOI 10.1016/0028-3932(92)90015-E; Milner B., 1964, FRONTAL GRANULAR COR, P313; Moore W S, 1995, Cardiovasc Surg, V3, P109, DOI 10.1016/0967-2109(95)90882-6; MOUNTAIN MA, 1993, CLIN NEUROPSYCHOL, V7, P108, DOI 10.1080/13854049308401893; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; Prigatano G. P., 1987, COMMUNITY REENTRY HE, P1; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Sichez-Auclair N, 1988, Acta Neurochir Suppl (Wien), V44, P54; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; STUSS DT, 1992, J CONSULT CLIN PSYCH, V60, P349, DOI 10.1037/0022-006X.60.3.349; TATE RL, 1987, SCAND J REHABIL MED, V19, P13; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; Tate RL, 1998, NEUROPSYCHOL REHABIL, V8, P1, DOI 10.1080/713755554; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Varney NR, 1996, ARCH CLIN NEUROPSYCH, V11, P345, DOI 10.1016/0887-6177(95)00015-1; Varney NR., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI [10.1097/00001199-199303000-00005, DOI 10.1097/00001199-199303000-00005]; VILKKI J, 1992, J CLIN EXP NEUROPSYC, V14, P518, DOI 10.1080/01688639208402841; Walsh KW., 1991, UNDERSTANDING BRAIN; Wood R. L., 1987, BRAIN INJURY REHABIL; [No title captured]; [No title captured]	72	90	92	0	15	ELSEVIER MASSON, CORPORATION OFFICE	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	FEB	1999	35	1					39	55		10.1016/S0010-9452(08)70784-6			17	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	177MY	WOS:000079214900003	10213533				2022-02-06	
J	Walter, HJ; Berry, M; Hill, DJ; Cwyfan-Hughes, S; Holly, JMP; Logan, A				Walter, HJ; Berry, M; Hill, DJ; Cwyfan-Hughes, S; Holly, JMP; Logan, A			Distinct sites of insulin-like growth factor (IGF)-II expression and localization in lesioned rat brain: Possible roles of IGF binding proteins (IGFBPs) in the mediation of IGF-II activity	ENDOCRINOLOGY			English	Article							HUMAN CEREBROSPINAL-FLUID; CENTRAL-NERVOUS-SYSTEM; AUTORADIOGRAPHIC LOCALIZATION; SELECTIVE AFFINITY; PITUITARY-GLAND; MESSENGER-RNAS; CHOROID-PLEXUS; RECEPTOR; SERUM; HYBRIDIZATION	Although expression of the IGF-II has been demonstrated within the central nervous system (CNS), past studies have failed to reveal its precise roles or responses subsequent to a traumatic injury. To demonstrate that IGF-II, IGFBP, and IGF receptor (-R) expression alters in response to a penetrating CNS injury, we used the techniques of ribonuclease protection assay, in situ hybridization, immunohistochemistry, Western blotting, and RIA. Under normal physiology, IGF-II expression is restricted to the mesenchymal support structures of the brain, including the choroid plexus, where its expression is coincident with that of IGFBP-2. Between 1-7 days post lesion (dpl), in the acute phase following a penetrant wound to the CNS, IGF-II and IGF-IIR protein, but not messenger RNA, were colocalized, with IGF-I, IGF-IR, and IGFBP-1, -2, -3, and -6, to neurons, macrophages, astrocytes, and microglia within the damaged tissue. Within the cerebrospinal fluid (CSF), levels of IGF-II peptide increased to peak at 7 dpl. IGFBP-2, -3, and -6 were also observed within the CSF, with IGFBP-2 predominating and exhibiting an increase in binding efficiency from 7-10 dpl. In the chronic phase of injury (7-14 dpl), an increase in both IGF-II, IGF-IIR and IGFBP-5 messenger RNA and protein was observed specifically and focally in the marginal astrocytes forming the limiting glial membrane of the wound. Thus, our evidence suggests that there are two mechanisms of action for IGF-II within the injured rat brain. During the acute phase, the secretion of IGF-II from the choroid plexus into the CSF is up-regulated, resulting in increased transport of the peptide to the wound. In the CSF, transported IGF-II is complexed to IGFBP-2 and essentially demonstrates an endocrine mode of action with a balance of locally produced IGFBPs modulating its bioactivity in the wound. Later in the wounding response, levels of IGF-II decline in the CSF and the wound neuropil, possibly with the aid of increased IGFBP-5 levels that may help to locally sequester and down-regulate IGF-II activity. Hence, in the chronic phase of the injury response, IGF-II reasserts itself to a predominantly autocrine/paracrine role restricted to the mesenchymal support structures, including the glia limitans, which may help reestablish and maintain tissue homeostasis.	Univ Birmingham, Queen Elizabeth Med Ctr, Dept Med, Wolfson Res Labs, Birmingham B15 2TH, W Midlands, England; Guys Hosp, UMDS, Dept Anat & Cell Biol, London SE1 9RT, England; Lawson Res Inst, Dept Med Physiol & Paediat, London, ON N6A 4V2, Canada; Univ Bristol, Dept Surg, Bristol BS2 8HW, Avon, England		Logan, A (corresponding author), Univ Birmingham, Queen Elizabeth Med Ctr, Dept Med, Wolfson Res Labs, Birmingham B15 2TH, W Midlands, England.	a.logan@bham.ac.uk	Hill, David J/G-3302-2011	Hill, David J/0000-0002-2490-5678; Logan, Ann/0000-0003-3215-5042	Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		Ausubel FM., 1992, SHORT PROTOCOLS MOL, V4th; AYERLELIEVRE C, 1991, DEVELOPMENT, V111, P105; BERRY M, 1998, MONOGRAPH THERAPEUTI, P1; BERRY MM, 1997, GRAYS ANATOMY, P1202; BOHANNON NJ, 1988, BRAIN RES, V444, P205, DOI 10.1016/0006-8993(88)90931-6; BRAR AK, 1993, J NEUROSCI RES, V35, P103, DOI 10.1002/jnr.490350112; CARONI P, 1990, J CELL BIOL, V110, P1307, DOI 10.1083/jcb.110.4.1307; CAUSIN C, 1988, BIOCHEM J, V252, P795, DOI 10.1042/bj2520795; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Clemmons David R., 1997, Cytokine and Growth Factor Reviews, V8, P45, DOI 10.1016/S1359-6101(96)00053-6; CONOVER CA, 1986, BIOCHEM BIOPH RES CO, V139, P501, DOI 10.1016/S0006-291X(86)80019-5; COUCE ME, 1992, ENDOCRINOLOGY, V131, P1636, DOI 10.1210/en.131.4.1636; DEKEYSER J, 1994, SYNAPSE, V17, P196, DOI 10.1002/syn.890170309; DELHANTY PJD, 1993, GROWTH REGULAT, V3, P8; GARGOSKY SE, 1992, ENDOCRINOLOGY, V131, P3051, DOI 10.1210/en.131.6.3051; GIRBAU M, 1989, P NATL ACAD SCI USA, V86, P5868, DOI 10.1073/pnas.86.15.5868; HASELBACHER G, 1982, ENDOCRINOLOGY, V110, P1822, DOI 10.1210/endo-110-5-1822; HILL DJ, 1991, J DEV PHYSIOL, V15, P91; HILL DJ, 1990, EARLY HUM DEV, V21, P49, DOI 10.1016/0378-3782(90)90110-5; Hill J M, 1988, Peptides, V9 Suppl 1, P181, DOI 10.1016/0196-9781(88)90242-2; HOSSENLOPP P, 1986, FEBS LETT, V208, P439, DOI 10.1016/0014-5793(86)81065-1; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAR S, 1993, J COMP NEUROL, V333, P375, DOI 10.1002/cne.903330306; KIESS W, 1987, J BIOL CHEM, V262, P12745; KIESS W, 1987, P NATL ACAD SCI USA, V84, P7720, DOI 10.1073/pnas.84.21.7720; KNUSEL B, 1990, J NEUROSCI, V10, P558; LESNIAK MA, 1988, ENDOCRINOLOGY, V123, P2089, DOI 10.1210/endo-123-4-2089; LOGAN A, 1994, ENDOCRINOLOGY, V135, P2255, DOI 10.1210/en.135.5.2255; Logan Ann, 1994, Progress in Growth Factor Research, V5, P379, DOI 10.1016/0955-2235(94)00008-9; MCKELVIE PA, 1992, J NEUROPATH EXP NEUR, V51, P464, DOI 10.1097/00005072-199207000-00009; MULLER HL, 1994, J CLIN ENDOCR METAB, V79, P428, DOI 10.1210/jc.79.2.428; NILSSON C, 1992, BRAIN RES REV, V17, P109, DOI 10.1016/0165-0173(92)90011-A; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; OCRANT I, 1990, ENDOCRINOLOGY, V127, P1260, DOI 10.1210/endo-127-3-1260; OCRANT I, 1993, ANN NY ACAD SCI, V692, P44; OCRANT I, 1988, ENDOCRINOLOGY, V123, P1023, DOI 10.1210/endo-123-2-1023; REINHARDT RR, 1994, ENDOCRINOLOGY, V135, P1753, DOI 10.1210/en.135.5.1753; ROGERS SA, 1988, P NATL ACAD SCI USA, V85, P4037, DOI 10.1073/pnas.85.11.4037; ROGHANI M, 1989, FEBS LETT, V255, P253, DOI 10.1016/0014-5793(89)81101-9; ROTWEIN P, 1988, P NATL ACAD SCI USA, V85, P265, DOI 10.1073/pnas.85.1.265; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; STEEDMAN HF, 1957, NATURE, V179, P1345, DOI 10.1038/1791345a0; STENVERS KL, 1994, J COMP NEUROL, V339, P91, DOI 10.1002/cne.903390109; TSENG LYH, 1989, MOL ENDOCRINOL, V3, P1559, DOI 10.1210/mend-3-10-1559; VALENTINO KL, 1988, ENDOCRINOLOGY, V122, P2753, DOI 10.1210/endo-122-6-2753; Walter HJ, 1997, ENDOCRINOLOGY, V138, P3024, DOI 10.1210/en.138.7.3024; WERNER H, 1989, P NATL ACAD SCI USA, V86, P7451, DOI 10.1073/pnas.86.19.7451; WERTHER GA, 1989, J NEUROENDOCRINOL, V1, P369, DOI 10.1111/j.1365-2826.1989.tb00131.x	48	90	91	0	1	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0013-7227	1945-7170		ENDOCRINOLOGY	Endocrinology	JAN	1999	140	1					520	532		10.1210/en.140.1.520			13	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	149VH	WOS:000077626500067	9886865	Bronze			2022-02-06	
J	Gillen, R; Tennen, H; Affleck, G; Steinpreis, R				Gillen, R; Tennen, H; Affleck, G; Steinpreis, R			Distress, depressive symptoms, and depressive disorder among caregivers of patients with brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							DISABILITY RATING-SCALE; SEVERE HEAD-INJURY; RELATIVES; FAMILY; PERSONALITY; INTERVIEW; RECOVERY; VALIDITY	Objective: To examine the prevalence and correlates of major depression in caregivers of individuals with moderate to severe traumatic brain injuries. Design: Repeated-measures design involving structured diagnostic interview and self-report of psychological distress administered on two occasions separated by 6 months. Setting: Three acute care rehabilitation hospitals. Subjects: Fifty-nine caregivers (39 mothers and 20 spouses) of individuals with moderate to severe brain injuries recruited from previous inpatient rosters. AU caregivers were currently residing with the person with traumatic brain injury. Main Outcome Measure: The Diagnostic Interview Schedule-Revised [DIS-R] was utilized to assess depression. The Symptom Checklist 90-Revised (SCL 90-R) measured general psychological distress. Results: Forty-seven percent of caregivers initially met diagnostic criteria for depression, and 43% met criteria 6 months later. Nearly two thirds of those who were Initially depressed continued to be depressed 6 months later, and 17% of those who were not depressed initially subsequently met criteria for depression. The best predictor of depression was a previous (pre-brain injury) depressive episode. Neither time since injury nor injury severity predicted diagnostic status, and spouses were no more likely to be depressed than were mothers. The SCL 90-R, including its depression scale, showed high specificity but low sensitivity in predicting diagnostic status. Conclusions: The prevalence of major depression is high in caregivers of individuals with brain injuries. Because depression may interfere with the capacity to provide care and contribute to the rehabilitation process, it is important for clinicians to carefully assess both the current and preaccident affective status of primary caregivers.	Sunnyview Hosp & Rehabil Ctr, Dept Psychol, Schenectady, NY 12308 USA; Univ Connecticut, Ctr Hlth, Dept Community Med & Hlth Care, Farmington, CT USA; Univ Wisconsin, Dept Psychol, Milwaukee, WI 53201 USA		Gillen, R (corresponding author), Sunnyview Hosp & Rehabil Ctr, Dept Psychol, 1270 Belmont Ave, Schenectady, NY 12308 USA.						Affleck G, 1997, PSYCHOSOM MED, V59, P95; American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; ANHENSEL CS, 1987, J HEALTH SOC BEHAV, V28, P232; BOND M, 1984, CLOSED HEAD INJURY P; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS DN, 1984, CLOSED HEAD INJURY P; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Cadoret RJ, 1996, AM J PSYCHIAT, V153, P892; CAMPLAIR PS, 1990, COMMUNITY REINTEGRAT; Derogatis L., 1983, SCL 90R ADM SCORING; FAHY TJ, 1967, LANCET, V2, P475; FLEMING JM, 1994, ARCH PHYS MED REHAB, V75, P156; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; KAMEROW DB, 1990, DEPRESSION PRIMARY C; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; LEWINSOHN PM, 1993, J ABNORM PSYCHOL, V102, P110, DOI 10.1037/0021-843X.102.1.110; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; LUTZKY SM, 1994, PSYCHOL AGING, V9, P513, DOI 10.1037/0882-7974.9.4.513; MAUSSCLUM N, 1981, J NEUROSURG NURS, V3, P165; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MERIKANGAS KR, 1994, PSYCHOL MED, V24, P69, DOI 10.1017/S0033291700026842; Newmann JP, 1996, PSYCHOL AGING, V11, P112, DOI 10.1037/0882-7974.11.1.112; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Panting A, 1972, REHABILITATION, V38, P33; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; REDINBAUGH EM, 1995, PSYCHOL AGING, V10, P358, DOI 10.1037/0882-7974.10.3.358; RIMEL RW, 1983, REHABILITATION HEAD; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Robins LN, 1985, DIAGNOSTIC INTERVIEW; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; SCHULZ R, 1991, PSYCHOL AGING, V6, P569, DOI 10.1037/0882-7974.6.4.569; STEIN PN, 1992, REHABIL PSYCHOL, V37, P121, DOI 10.1037/0090-5550.37.2.121; TENNEN H, 1995, J PERS SOC PSYCHOL, V68, P870, DOI 10.1037/0022-3514.68.5.870; TENNEN H, 1995, J PERS SOC PSYCHOL, V68, P895, DOI 10.1037/0022-3514.68.5.895; TENNEN H, 1985, TEST CRITIQUES, P3; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; Wiseman EJ, 1996, J ADDICT DIS, V15, P43, DOI 10.1300/J069v15n02_04	42	90	91	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1998	13	3					31	43		10.1097/00001199-199806000-00004			13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	ZT046	WOS:000074042200004	9582177				2022-02-06	
J	Bareyre, F; Wahl, F; McIntosh, TK; Stutzmann, JM				Bareyre, F; Wahl, F; McIntosh, TK; Stutzmann, JM			Time course of cerebral edema after traumatic brain injury in rats: Effects of riluzole and mannitol	JOURNAL OF NEUROTRAUMA			English	Article						brain edema; fluid percussion; mannitol; rats; riluzole; traumatic brain injury	CLOSED-HEAD INJURY; AMYOTROPHIC-LATERAL-SCLEROSIS; BARRIER PERMEABILITY; GLUTAMATE RELEASE; CHANNEL BLOCKER; NMDA RECEPTORS; DAMAGE; CALCIUM; SODIUM; BLOOD	Brain trauma is the main cause of morbidity and mortality in young adults. One delayed events that occurs after a head trauma and compromises the survival of patients is cerebral edema. The present study examined first the occurrence of cerebral edema after a traumatic brain injury (TBI) induced by moderate fluid percussion in rats. Brain water content was measured from 1 h to 7 days posttrauma, in the hippocampus and cortex, on both ipsi-and contralateral hemispheres. Second, the effects of mannitol, an osmotic agent frequently used in the clinic, and riluzole, a neuroprotective compound, were investigated on regional edema formation. After TBI, the ipsilateral edema began early at 1-6 h, was maximal at 48 h and was resorbed by 5-7 days. No edema was observed in the contralateral hemisphere. Mannitol at 1 g/kg or vehicle was administered iv 15 min, 2 h and 4 h postinjury. At this dose, mannitol significantly attenuated the ipsilateral injured cortex edema measured at 6 h (p < 0.05). Riluzole at 4 and 8 mg/kg or vehicle was administered 15 min (IV) and 6 h, 24 h, and 30 h (SC) post-TBI. Riluzole at 4 x 4 mg/kg significantly reduced edema measured at 48 h, in the ipsilateral hippocampus (p < 0.05), whereas at 4 x 8 mg/kg, the reduction was observed in the hippocampus (p < 0.01) and the injured cortex (p < 0.05). Our results demonstrate that (1) cerebral edema begins early after the injury and is resorbed over 1 week; (2) mannitol could attenuate cerebral edema; and (iii) riluzole in addition to its neuroprotective effects reduces the brain edema. Thus, riluzole could be useful in human TBI treatment.	RHONE POULENC RORER SA,CTR NEURODEGENERAT DISORDERS,F-94400 VITRY SUR SEINE,FRANCE; UNIV PENN,DIV NEUROSURG,PHILADELPHIA,PA 19104								Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; BARBEITO L, 1996, J NEUROTRAUM, V13, P629; BENOIT E, 1991, PFLUG ARCH EUR J PHY, V419, P603, DOI 10.1007/BF00370302; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; Biros MH, 1996, AM J EMERG MED, V14, P27, DOI 10.1016/S0735-6757(96)90008-X; Bullock MR, 1996, J NEUROTRAUM, V13, P705; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEBONO MW, 1993, EUR J PHARMACOL, V235, P283, DOI 10.1016/0014-2999(93)90147-A; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOTOH O, 1985, STROKE, V16, P101, DOI 10.1161/01.STR.16.1.101; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; Hariri R J, 1994, Neurosurg Clin N Am, V5, P687; HATASHITA S, 1988, J CEREBR BLOOD F MET, V8, P552, DOI 10.1038/jcbfm.1988.96; HEBERT T, 1994, MOL PHARMACOL, V45, P1055; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Janis LS, 1996, NEUROSCI LETT, V214, P21, DOI 10.1016/S0304-3940(96)12873-1; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; LACOMBLEZ L, 1996, LANCET, V347, P1425, DOI DOI 10.1016/S0140-6736(96)91680-3; Mary V, 1995, NEUROSCI LETT, V201, P92, DOI 10.1016/0304-3940(95)12137-S; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; MCINTOSH T, 1988, NEUROL NEUR, V46, P653; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; Peluffo H, 1997, NEUROSCI LETT, V228, P207, DOI 10.1016/S0304-3940(97)00384-4; PETITO CK, 1979, J NEUROPATH EXP NEUR, V38, P222, DOI 10.1097/00005072-197905000-00003; Petty MA, 1996, EUR J PHARMACOL, V307, P149, DOI 10.1016/0014-2999(96)00235-X; PRATT J, 1992, NEUROSCI LETT, V140, P225, DOI 10.1016/0304-3940(92)90108-J; SANDERSON KL, 1996, J NEUROTRAUM, V13, P626; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHAPIRA Y, 1989, Neurological Research, V11, P169; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHAPIRA Y, 1988, J CEREBR BLOOD F MET, V8, P395, DOI 10.1038/jcbfm.1988.75; SHAPIRA Y, 1991, ANESTH ANAG, V68, P5247; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; SHOHAMI E, 1995, CRC S MEMBR, P235; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1988, CRIT CARE MED, V16, P954, DOI 10.1097/00003246-198810000-00006; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Stewart-Wallace AM, 1939, BRAIN, V62, P426, DOI 10.1093/brain/62.4.426; Stutzmann JM, 1996, NEUROREPORT, V7, P387, DOI 10.1097/00001756-199601310-00003; STUTZMANN JM, 1997, CNS DRUG REV, V3, P83; STUTZMANN JM, 1993, NEURODEGENER DIS, P205; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOMINAGA T, 1995, CENTRAL NERVOUS SYST, P85; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; VODDI MD, 1995, J NEUROTRAUM, V12, P146; VONBERENBERG P, 1994, ACTA NEUROCHIR, V60, pS531; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; WAHL F, 1993, EUR J PHARMACOL, V230, P209, DOI 10.1016/0014-2999(93)90804-Q; YAMASAKI Y, 1992, NEUROSCI LETT, V142, P45, DOI 10.1016/0304-3940(92)90616-F; YOUNG W, 1992, J NEUROTRAUM, V9, pS9	71	90	95	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	1997	14	11					839	849		10.1089/neu.1997.14.839			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	YK511	WOS:A1997YK51100003	9421455				2022-02-06	
J	Adelson, PD; Dixon, CE; Robichaud, P; Kochanek, PM				Adelson, PD; Dixon, CE; Robichaud, P; Kochanek, PM			Motor and cognitive functional deficits following diffuse traumatic brain injury in the immature rat	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	Fourteenth Annual Meeting of the Neurotrauma Society	NOV 15-16, 1996	WASHINGTON, DC	Neurotrauma Soc		function; head injury; immature rats	CONTROLLED CORTICAL IMPACT; FLUID-PERCUSSION MODEL; HEAD-INJURY; CHILDREN; ADOLESCENTS; MEMORY; CAT	To determine the motor and cognitive deficits following a diffuse severe traumatic brain injury (TBI) in immature Sprague Dawley rats (17 days), four groups of animals were injured at different severity levels using a new closed head weight drop model: (sham, severe injury [SI: 100 g/2 m], SH [SI + hypoxemia (30 min of an FiO(2) of 8% posttrauma)], and ultra severe injury [US: 150 g/2 m]). Latency on beam balance, grip test performance, and maintenance of body position on an inclined board were measured daily after injury to assess vestibulomotor function. Cognitive function was assessed on days 11-22 using the Morris water maze (MWM). Balance beam latency and inclined plane body position were reduced in both SI and SH rats (n = 20) (p < 0.05 vs. sham) (maximally at 24 h), and lasted 3-4 day postinjury; however, SH did not differ from SI. In the US group (n = 10), motor deficits were profound at 24 h (p < 0.05 vs. all other groups) and persisted for 10 days. The groups did not differ on grip test. In cognitive performance, there were no differences between sham, SI, and SH. US, however, produced significant cognitive dysfunction (vs. sham, SI, and SH), specifically, greater latencies to find the hidden platform through 22 days. Swim speeds were not significantly different between any of the injury groups and shams. These data indicate that (1) beam balance, inclined plane and MWM techniques are useful for assessing motor and cognitive function after TBI in immature rats; (2) SI produces motor but not cognitive deficits, which was not augmented by transient hypoxia; and (3) US created a marked but reversible motor deficit up to 10 days, and a sustained cognitive dysfunction for up to 22 days after TBI.	CHILDRENS HOSP PITTSBURGH,DEPT NEUROSURG,PITTSBURGH,PA 15213; CHILDRENS HOSP PITTSBURGH,DEPT ANESTHESIOL & CRIT CARE MED,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SAFAR CTR RESUSCITAT RES,PITTSBURGH,PA				Kochanek, Patrick M/D-2371-2015; Adelson, David/W-2083-2019	Kochanek, Patrick M/0000-0002-2627-913X; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033150, K08NS001809] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS01809, NS 33150] Funding Source: Medline		ADELSON PD, 1996, J NEUROSURG, V85, P134; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Biagas K. V., 1992, Society for Neuroscience Abstracts, V18, P1088; BOKSA P, 1995, PEDIATR RES, V37, P489, DOI 10.1203/00006450-199504000-00018; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; LEURSSEN TG, 1988, J NEUROSURG, V68, P409; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1985, CENTRAL NERVOUS SYST, P281; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MANSFIELD RT, 1995, J CEREB BLOOD FLOW M, V16, P244; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; VANNUCCI RC, 1988, STROKE, V19, P245, DOI 10.1161/01.STR.19.2.245; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	34	90	91	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	1997	14	2					99	108		10.1089/neu.1997.14.99			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	WN400	WOS:A1997WN40000004	9069441				2022-02-06	
J	Amirjamshidi, A; Rahmat, H; Abbassioun, K				Amirjamshidi, A; Rahmat, H; Abbassioun, K			Traumatic aneurysms and arteriovenous fistulas of intracranial vessels associated with penetrating head injuries occurring during war: Principles and pitfalls in diagnosis and management	JOURNAL OF NEUROSURGERY			English	Article						traumatic aneurysm; arteriovenous fistula; brain injury; cerebral angiography; cerebral hemorrhage; missile head wound	CRANIOCEREBRAL GUNSHOT WOUNDS; INTERNAL CAROTID-ARTERY; CEREBRAL-ARTERIES; BRAIN; EXPERIENCE; VIETNAM	In the early days of the war between Iran and Iraq, reports of the sudden deaths of soldiers who previously had survived a penetrating head injury suggested the possibility that a late complication, traumatic aneurysm (TA), could be the cause of this catastrophe. In response, the authors planned a prospective study to perform cerebral angiography in victims with penetrating head traumas, especially ill those who had artillery shells or bone fragments passing through areas of dense vasculature. Thirty-one TAs and arteriovenous fistulas were documented. Not all of the lesions, however, were deemed appropriate for surgical intervention. Six aneurysms (19.4%) healed spontaneously and shrank or disappeared on repeated serial angio rams. The authors present their cases and discuss the incidence of TAs, their nato ural course and behavior, and the special problems encountered in managing these interesting and potentially fatal complications of penetrating head injuries.	UNIV TEHRAN MED SCI, DR SHARIATI HOSP, TEHRAN, IRAN		Amirjamshidi, A (corresponding author), SINA HOSP, DEPT NEUROSURG, IMAM AVE, TEHRAN, IRAN.						AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; ACHRAM M, 1980, BRIT J RADIOL, V53, P1144, DOI 10.1259/0007-1285-53-636-1144; ACOSTA C, 1972, J NEUROSURG, V36, P531, DOI 10.3171/jns.1972.36.5.0531; AMAGASA M, 1986, Neurological Surgery, V14, P1585; ARAKI C, 1965, J NEUROSURG, V23, P64, DOI 10.3171/jns.1965.23.1.0064; ASARI S, 1977, J NEUROSURG, V46, P795, DOI 10.3171/jns.1977.46.6.0795; Ascroft PB, 1943, LANCET, V2, P211; BANK WO, 1978, AM J ROENTGENOL, V130, P975, DOI 10.2214/ajr.130.5.975; BARATHAM G, 1972, J NEUROL NEUROSUR PS, V35, P698, DOI 10.1136/jnnp.35.5.698; BARD LA, 1964, ARCH OPHTHALMOL-CHIC, V71, P332; BENOIT BG, 1973, J NEUROL NEUROSUR PS, V36, P127, DOI 10.1136/jnnp.36.1.127; BUCKINGHAM MJ, 1988, NEUROSURGERY, V22, P398, DOI 10.1227/00006123-198802000-00022; BURTON C, 1968, J NEUROSURG, V28, P468, DOI 10.3171/jns.1968.28.5.0468; CAMPBELL E, 1950, J NEUROPATH EXP NEUR, V9, P139, DOI 10.1097/00005072-195004000-00002; CAREY ME, 1972, SURG GYNECOL OBSTETR, V135, P386; COCKRILL HH, 1977, J NEUROSURG, V46, P377, DOI 10.3171/jns.1977.46.3.0377; COURVILLE C B, 1960, Bull Los Angel Neuro Soc, V25, P48; CRESSMAN MR, 1966, J NEUROSURG, V24, P102, DOI 10.3171/jns.1966.24.1.0102; CROMPTON MR, 1966, BRIT MED J, V1, P1138, DOI 10.1136/bmj.1.5496.1138; Dharker S R, 1975, Neurol India, V23, P207; DIAZ FG, 1979, J NEUROSURG, V50, P217, DOI 10.3171/jns.1979.50.2.0217; DITMORE M, 1980, NEUROSURGERY, V6, P293; DUFFY GP, 1969, BRIT J SURG, V56, P685, DOI 10.1002/bjs.1800560912; EICHLER A, 1969, J NEUROSURG, V31, P72, DOI 10.3171/jns.1969.31.1.0072; Endo S, 1974, No Shinkei Geka, V2, P329; FERRY DJ, 1972, J NEUROSURG, V36, P503, DOI 10.3171/jns.1972.36.4.0503; FLEISCHER A S, 1975, Surgical Neurology, V4, P233; FOX JL, 1983, INTRACRANIAL ANEURYS, V1, P523; HADDAD FS, 1978, CAN J SURG, V21, P233; HADDAD FS, 1991, NEUROSURGERY, V28, P1; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P199, DOI 10.1007/BF01808959; HIRSCH JF, 1962, NEURO-CHIR, V8, P189; HUBSCHMANN O, 1979, J TRAUMA, V19, P6, DOI 10.1097/00005373-197901000-00002; Iob I, 1983, J Neurosurg Sci, V27, P187; ITO H, 1975, NO TO SHINKEI, V27, P787; JACKSON FE, 1974, US NAVY MED, V63, P34; JAKOBSSON KE, 1984, ACTA NEUROCHIR, V71, P91, DOI 10.1007/BF01401153; KAUFMAN HH, 1980, NEUROSURGERY, V6, P181, DOI 10.1227/00006123-198002000-00011; KIRKPATRICK JB, 1978, J NEUROSURG, V49, P185, DOI 10.3171/jns.1978.49.2.0185; KUHN RA, 1964, J NEUROSURG, V21, P92, DOI 10.3171/jns.1964.21.2.0092; LAUN A, 1979, CEREBRAL ANEURYSMS A, P364; LAURENT JP, 1981, NEUROSURGERY, V9, P303, DOI 10.1227/00006123-198109000-00015; LILLARD PL, 1978, SURG NEUROL, V9, P79; MAKI Y, SAIGA IGOKU, V14, P92; Martin E M, 1986, J Neurosci Nurs, V18, P89; Marubayashi T, 1975, No Shinkei Geka, V3, P177; MEIROWSKY AM, 1954, JAMA-J AM MED ASSOC, V154, P666, DOI 10.1001/jama.1954.02940420028008; MELVILL RL, 1977, S AFR MED J, V51, P471; MENEZES AH, 1974, J NEUROSURG, V40, P544, DOI 10.3171/jns.1974.40.4.0544; MEZUE WC, 1991, NEUROSURGERY, V28, P428, DOI 10.1227/00006123-199103000-00015; MOORE D, 1979, SURG NEUROL, V11, P115; NOV AA, 1984, J NEURORADIOLOGY, V11, P3; OVERTON MC, 1966, J NEUROSURG, V24, P672, DOI 10.3171/jns.1966.24.3.0672; PARKINSON D, 1980, J NEUROSURG, V52, P11, DOI 10.3171/jns.1980.52.1.0011; PAUL GA, 1980, J NEUROSURG, V53, P101, DOI 10.3171/jns.1980.53.1.0101; PETTY J M, 1969, Journal of Neurosurgery, V30, P741, DOI 10.3171/jns.1969.30.6.0741; POZZATI E, 1982, J NEUROSURG, V57, P418, DOI 10.3171/jns.1982.57.3.0418; RAHIMIZADEH A, 1987, ACTA NEUROCHIR, V84, P93, DOI 10.1007/BF01418831; RAHMAT H, 1984, J NEUROSURG, V60, P630, DOI 10.3171/jns.1984.60.3.0630; RAIMONDI AJ, 1968, NEUROCHIRURGIA, V11, P219; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; ROBBINS JB, 1976, LARYNGOSCOPE, V86, P893, DOI 10.1288/00005537-197607000-00001; RUMBAUGH CL, 1970, RADIOLOGY, V96, P49, DOI 10.1148/96.1.49; SADAR ES, 1973, SURG GYNECOL OBSTET, V137, P59; SALAR G, 1978, J NEUROSURG, V49, P100, DOI 10.3171/jns.1978.49.1.0100; SARWAR M, 1976, RADIOLOGY, V120, P603, DOI 10.1148/120.3.603; SCHMIDT-VANDERHEYDEN W, 1971, Archiv fuer Psychiatrie und Nervenkrankheiten, V214, P10, DOI 10.1007/BF00344623; SCHORSTEIN J, 1947, BRIT J SURG S, V1, P96; SEDZIMIR CB, 1968, J NEUROSURG, V29, P636, DOI 10.3171/jns.1968.29.6.0636; SELDEN BS, 1988, ANN EMERG MED, V17, P247, DOI 10.1016/S0196-0644(88)80117-3; SHALLAT RF, 1981, NEUROSURGERY, V8, P569, DOI 10.1227/00006123-198105000-00010; SMALL J M, 1947, Br J Surg, V55, P62; SPETZLER RF, 1979, NEUROSURGERY, V4, P334, DOI 10.1227/00006123-197904000-00011; STEINMETZ H, 1988, SURG NEUROL, V30, P305, DOI 10.1016/0090-3019(88)90304-7; TEASDALE G, 1974, LANCET, V2, P81; UMEBAYASHI Y, 1970, Clinical Radiology, V21, P36, DOI 10.1016/S0009-9260(70)80136-2; VANDELLEN JR, 1980, SURG NEUROL, V13, P203; YONAS H, 1980, NEUROSURGERY, V7, P499, DOI 10.1227/00006123-198011000-00016	79	90	91	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	1996	84	5					769	780		10.3171/jns.1996.84.5.0769			12	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	UG540	WOS:A1996UG54000009	8622150				2022-02-06	
J	JACOBS, A; PUT, E; INGELS, M; BOSSUYT, A				JACOBS, A; PUT, E; INGELS, M; BOSSUYT, A			PROSPECTIVE EVALUATION OF TECHNETIUM-99M-HMPAO SPECT IN MILD AND MODERATE TRAUMATIC BRAIN INJURY	JOURNAL OF NUCLEAR MEDICINE			English	Article						TECHNETIUM-99M-HMPAO; TRAUMATIC BRAIN INJURY; SPECT	CEREBRAL BLOOD-FLOW; CLOSED-HEAD-INJURY; SEMIQUANTITATIVE ANALYSIS; COMPUTED-TOMOGRAPHY; INITIAL EXPERIENCE; PERFUSION; SEQUELAE; CT	We prospectively evaluated the contribution of Tc-99m-HMPAO SPECT in patients who have sustained acute, mild or moderate head trauma. Methods: Forty-two patients formed the first subgroup of moderate trauma (ModTr) and 25 patients formed the second subgroup of mild trauma (MilTr). All 67 patients underwent an initial SPECT (Tinit) within 4 wk after a closed cranial trauma. After a mean interval of 3 mo from the time of Tinit, all patients were clinically re-evaluated; those with an abnormal Tinit underwent a repeat SPECT (Trpt) as well. All SPECT studies were visually graded by agreement of three observers adjudging a score ranging from 0 (no lesions) to 4. Results: For the group as a whole (ModTr + MilTr), the following results could be derived: (1) in 32/33 Tinit negative cases, clinical symptoms had resolved; (2) the positive predictive value of Tinit was only 20/34 (59%); (3) the sensitivity for the repeat SPECT was 19/20 (95%). Conclusion: Our results show that: (1) SPECT alterations correlate well with the severity of the trauma; (2) a negative initial SPECT study is a reliable predictor of a favorable clinical outcome; (3) in cases with a positive initial SPECT, a follow-up consisting of a combination of SPECT and clinical data is necessary; (4) in patients suffering from postconcussive symptoms, SPECT offers an instrument to objectivate sequelae.	FREE UNIV BRUSSELS,DEPT NUCL MED,JETTE,BELGIUM		JACOBS, A (corresponding author), VIRGA JESSE HOSP,DEPT NUCL MED,STADSOMVAART 11,B-3500 HASSELT,BELGIUM.						ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; BECKER DP, 1988, CECIL TXB MED, P2239; BRITTON KE, 1991, RADIOACTIVE ISOTOPES IN CLINICAL MEDICINE AND RESEARCH, P235; DUCOURS JL, 1990, NUCL MED COMMUN, V11, P361, DOI 10.1097/00006231-199005000-00003; FUMEYA H, 1990, ACT NEUR S, V51, P283; GEORGE MS, 1991, NEUROACTIVATION NEUR, P29; GRAY BG, 1992, J NUCL MED, V33, P52; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; HOLBOURN AHS, 1943, LANCET, V2, P428; JACOBS A, 1993, NUCL MED COMMUN, V14, P702, DOI 10.1097/00006231-199308000-00011; JACOBS A, 1992, EUR J NUCL MED, V19, P728; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; PODREKA I, 1987, J NUCL MED, V28, P1657; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; ROPER SN, 1991, J NUCL MED, V32, P1684; RUTHERFORD WH, 1977, LANCET, V1, P1	20	90	91	0	0	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316	0161-5505			J NUCL MED	J. Nucl. Med.	JUN	1994	35	6					942	947					6	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	NP288	WOS:A1994NP28800006	8195879				2022-02-06	
J	TOULMOND, S; SERRANO, A; BENAVIDES, J; SCATTON, B				TOULMOND, S; SERRANO, A; BENAVIDES, J; SCATTON, B			PREVENTION BY ELIPRODIL (SL-82.0715) OF TRAUMATIC BRAIN-DAMAGE IN THE RAT - EXISTENCE OF A LARGE (18-H) THERAPEUTIC WINDOW	BRAIN RESEARCH			English	Article						BRAIN TRAUMA; ELIPRODIL; NEUROPROTECTION; N-METHYL-D-ASPARTATE RECEPTOR	D-ASPARTATE RECEPTOR; EXCITATORY AMINO-ACIDS; SPINAL-CORD INJURY; ANTI-ISCHEMIC AGENTS; NMDA RECEPTOR; CEREBRAL-ISCHEMIA; ANTAGONIST MK-801; POLYAMINE SITE; IFENPRODIL; RELEASE	The neuroprotective potential of eliprodil (SL 82.0715), an N-methyl-D-aspartate (NMDA) receptor antagonist acting at the polyamine modulatory site, in brain trauma was examined in a rat model of lateral fluid-percussion brain injury. The volume of the lesion was assessed histologically by measuring, at 7 days post-injury, the area of brain damage at 10 coronal planes. Eliprodil (10 mg/kg i.p.) when given 15 min, 6 h and 24 h after fluid percussion (1.6 atm) and then b.i.d. fpr the following 6 days, reduced by 60% the volume of cortical damage. A similar neuroprotection was obtained when the first administration of eliprodil was delayed by up to 12 h after the brain insult. Moreover, when the treatment with this compound was started at 18 h post-injury, cortical damage was still significantly reduced by 33%. Autoradiographic studies showed that eliprodil treatment (10 mg/kg, i.p.), initiated 15 min after the trauma, also caused a marked reduction of the loss of the neuronal marker omega1-2 (central benzodiazepine) binding sites and of the increase in the glial/macrophage marker peripheral type benzodiazepine binding sites in the cerebral cortex. In contrast, dizocilpine (a blocker of the cationic channel coupled to the NMDA receptor) when administered 6 h and 24 h after fluid percussion and then b.i.d. for the following 6 days induced a non significant reduction of the volume of the lesion at the highest tolerated dose (0.6 mg/kg i.p.). These results demonstrate the neuroprotective activity of eliprodil in experimental brain trauma using neuropathology as an endpoint and indicate that there is a very large time window for therapeutic intervention, consistent with the delayed nature of the neuronal loss, in this condition.	SYNTHELAB RECH LERS,DEPT BIOL,31 AV PAUL VAILLANT COUTURIER,F-92220 BAGNEUX,FRANCE								BENAVIDES J, 1990, BRAIN RES, V522, P275, DOI 10.1016/0006-8993(90)91472-S; BENAVIDES J, 1988, J PHARMACOL EXP THER, V245, P1033; BONDOLI A, 1989, RESUSCITATION, V9, P119; CARTER C, 1989, EUR J PHARMACOL, V164, P611, DOI 10.1016/0014-2999(89)90275-6; CARTER C, 1988, J PHARMACOL EXP THER, V247, P1222; CARTER CJ, 1990, J PHARMACOL EXP THER, V253, P475; CHOI DW, 1988, TRENDS NEUROSCI, V11, P165; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DANJOU P, 1991, BIOL PSYCHIAT, V2, P760; DIENEL GA, 1984, J NEUROCHEM, V42, P1053, DOI 10.1111/j.1471-4159.1984.tb12710.x; DUVAL D, 1992, NEUROSCI LETT, V137, P193, DOI 10.1016/0304-3940(92)90402-S; DUVERGER D, 1988, J CEREBR BLOOD F MET, V8, P449, DOI 10.1038/jcbfm.1988.86; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1989, J NEUROSURG, V70, P578; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; FAGE D, 1992, J NEUROCHEM, V58, P2170, DOI 10.1111/j.1471-4159.1992.tb10960.x; FOSTER AC, 1987, BRIT J PHARMACOL, V91, P403, DOI 10.1111/j.1476-5381.1987.tb10295.x; FOSTER AC, 1988, J NEUROSCI, V8, P4745; GILL R, 1987, J NEUROSCI, V7, P3343; GOMEZPINILLA F, 1989, EXP NEUROL, V104, P118, DOI 10.1016/S0014-4886(89)80004-4; GOTTI B, 1990, BRAIN RES, V522, P290, DOI 10.1016/0006-8993(90)91473-T; GOTTI B, 1988, J PHARMACOL EXP THER, V247, P1211; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LEWIS SJ, 1989, HYPERTENSION, V13, P759, DOI 10.1161/01.HYP.13.6.759; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; MCCULLOCH J, 1991, EXCITATORY AMINO ACI, P287; MCINTOSH T, 1989, J NEUROTRAUM, V4, P247; MCINTOSH T, 1988, NEUROL NEUR, V46, P653; MCINTOSH T, 1990, NEUROCHEM INT, V3, P14; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1992, FIDIA RES F S SERIES, V9, P247; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PARK CK, 1988, ANN NEUROL, V24, P543, DOI 10.1002/ana.410240411; Sanger D J, 1989, J Psychopharmacol, V3, P198, DOI 10.1177/026988118900300402; SANGER DJ, 1991, PSYCHOPHARMACOLOGY, V104, P27, DOI 10.1007/BF02244550; SANGER DJ, 1991, BEHAV PHARMACOL, V2, P57; SCATTON B, 1991, CEREBROVASC DIS, V1, P121, DOI 10.1159/000108829; SCATTON B, IN PRESS P MANSELL B; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SMITH D H, 1990, FASEB Journal, V4, pA400; SMITH DH, 1991, J CEREB BLOOD FLOW S, V11, P300; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; WAHL F, STROKE, V23, P267; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	57	90	90	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	AUG 20	1993	620	1					32	41		10.1016/0006-8993(93)90267-Q			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	LR731	WOS:A1993LR73100005	8402196				2022-02-06	
J	DUTREVOU, MD; VANDELLEN, JR; CAMINS, MB; CHANDLER, WF				DUTREVOU, MD; VANDELLEN, JR; CAMINS, MB; CHANDLER, WF			PENETRATING STAB WOUNDS TO THE BRAIN - THE TIMING OF ANGIOGRAPHY IN PATIENTS PRESENTING WITH THE WEAPON ALREADY REMOVED	NEUROSURGERY			English	Article						ANGIOGRAPHY; SLOT FRACTURE; STAB WOUND; TRAUMATIC ANEURYSM	TRAUMATIC INTRACRANIAL ANEURYSMS; CEREBRAL-ARTERIES; INJURY; HEAD	ANGIOGRAPHY IS ALWAYS necessary in patients with penetrating stab wounds to the head, to exclude unexpected vascular lesions. The most important, since they are seldom clinically evident, are traumatic aneurysms and arteriovenous fistulae. It has previously been proposed that carotid angiography should be delayed until the start of the second week, to allow for better visualization of these complications. However, traumatic aneurysms can rupture at any time after the injury, and the mortality resulting from a second hemorrhage is unacceptably high. A prospective study was undertaken in which 330 patients with penetrating stab wounds to the head underwent angiography as soon as possible after admission. In 250 of these patients (76%), the weapon had already been removed by the assailant, and there was radiological evidence of penetration of the dura. Of these 250, 130 patients underwent angiography within 7 days of the injury. Another 51 patients, who presented late, underwent angiography more than 7 days after the injury. The timing of angiography did not affect the identification of traumatic aneurysms,the incidence of which was 12% in both groups. Of the patients with cranial stabs and who required urgent evacuation of intracerebral hematomas, 10% had traumatic aneurysms that could be dealt with simultaneously. No patient in this series suffered a secondary hemorrhage. We conclude that it is neither necessary nor safe to delay angiography. In some patients, either because of vasospasm or 'cut-off" of a vessel, a second angiogram may be necessary to further elucidate a vascular abnormality that might not have been evident originally.	UNIV NATAL, FAC MED, DEPT NEUROSURG, DURBAN, SOUTH AFRICA								AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; ACOSTA C, 1972, J NEUROSURG, V36, P531, DOI 10.3171/jns.1972.36.5.0531; ASARI S, 1977, J NEUROSURG, V46, P795, DOI 10.3171/jns.1977.46.6.0795; BENOIT BG, 1973, J NEUROL NEUROSUR PS, V36, P127, DOI 10.1136/jnnp.36.1.127; BULLOCK R, 1985, SURG NEUROL, V24, P555, DOI 10.1016/0090-3019(85)90273-3; BURTON C, 1968, J NEUROSURG, V28, P468, DOI 10.3171/jns.1968.28.5.0468; CAROTHERS A, 1978, JAMA-J AM MED ASSOC, V239, P1151, DOI 10.1001/jama.239.12.1151; CRESSMAN MR, 1966, J NEUROSURG, V24, P102, DOI 10.3171/jns.1966.24.1.0102; De Villiers JC., 1975, HDB CLIN NEUROLOGY, V23, P477; DEVILLIERS JC, 1985, NEUROSURGERY, V17, P930, DOI 10.1227/00006123-198512000-00010; DUTREVOU M, 1991, INJURY, V22, P237, DOI 10.1016/0020-1383(91)90053-H; EICHLER A, 1969, J NEUROSURG, V31, P72, DOI 10.3171/jns.1969.31.1.0072; FERRY DJ, 1972, J NEUROSURG, V36, P503, DOI 10.3171/jns.1972.36.4.0503; FLEISCHER A S, 1975, Surgical Neurology, V4, P233; HADDAD FS, 1991, NEUROSURGERY, V28, P1; HANDA J, 1970, AMER J ROENTGENOL RA, V109, P127, DOI 10.2214/ajr.109.1.127; HERRING CJ, 1988, NEUROSURGERY, V23, P658, DOI 10.1227/00006123-198811000-00022; KIECK CF, 1984, J NEUROSURG, V60, P42, DOI 10.3171/jns.1984.60.1.0042; LUKIN R, 1974, NEURORADIOLOGY, V8, P1, DOI 10.1007/BF00339796; MCDONALD EJ, 1976, AM J ROENTGENOL, V126, P792, DOI 10.2214/ajr.126.4.792; MELVILL RL, 1977, S AFR MED J, V51, P471; MILLER P, 1987, NEUROSURGERY, V21, P92, DOI 10.1227/00006123-198707000-00021; MIZUKAMI M, 1982, NEUROSURGERY, V10, P301, DOI 10.1227/00006123-198203000-00001; PARENT AD, 1981, SURG NEUROL, V15, P229, DOI 10.1016/0090-3019(81)90151-8; PARKINSON D, 1980, J NEUROSURG, V52, P11, DOI 10.3171/jns.1980.52.1.0011; RUMBAUGH CL, 1970, RADIOLOGY, V96, P49, DOI 10.1148/96.1.49; SADAR ES, 1973, SURG GYNECOL OBSTET, V137, P59; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON JR, 1973, AM J ROENTGENOL, V118, P163, DOI 10.2214/ajr.118.1.163; VANDELLEN JR, 1978, SURG NEUROL, V10, P110; VILLIERS JCD, 1975, BRIT J OPHTHALMOL, V59, P52, DOI 10.1136/bjo.59.1.52; YAMAURA A, 1978, SURG NEUROL, V10, P327	32	90	90	1	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	NOV	1992	31	5					905	912		10.1227/00006123-199211000-00012			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	JX217	WOS:A1992JX21700012	1436415				2022-02-06	
J	BROOKE, MM; QUESTAD, KA; PATTERSON, DR; BASHAK, KJ				BROOKE, MM; QUESTAD, KA; PATTERSON, DR; BASHAK, KJ			AGITATION AND RESTLESSNESS AFTER CLOSED HEAD-INJURY - A PROSPECTIVE-STUDY OF 100 CONSECUTIVE ADMISSIONS	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						BRAIN INJURY; PSYCHOMOTOR AGITATION; STATISTICS	SCALE	Agitation and restlessness are two of the most striking and problematic behaviors for patients with traumatic brain injury (TBI), their caregivers, and their families. These behaviors are often treated with physical and chemical restraints which have potentially harmful side effects. There are, however, few prospective studies which clearly define agitation and restlessness in a representative sample of TBI patients. Subjects for this study were 100 consecutive patients with traumatic, closed head injury (CHI) admitted to a regional Level I Trauma Center with a Glasgow Coma Scale score of less than 8, who had more than one hour of coma, and who required more than one week of hospitalization. Agitation was defined as episodic motor or verbal behavior which interfered with patient care or clearly required physical or chemical restraints to prevent damage to persons or property. This variable was rated on the Overt Aggression Scale, a 16-item scale, in four categories: verbal aggression; physical aggression against objects; physical aggression against self; or physical aggression directed at others. Systematic direct observations, caregiver interviews, and chart reviews were used to determine the frequency and duration of agitation. Patients were also monitored for restlessness, which was defined as behavior that interfered with staff or required some action by staff, such as change of activity, but either did not meet the severity criteria for agitation, or was continuous. Only 11 of the 100 subjects exhibited episodic agitation which met the criteria. Eight subjects were agitated for one week, one for two weeks, one for three weeks, and one for four weeks. Only one subject went directly from being unresponsive to being agitated. Restlessness, however, occurred in 35 patients. The results suggest that agitation is not frequently or predictably a phase of recovery from head injury. The precise definition and expected duration of these behaviors should be considered carefully before potentially harmful treatment is prescribed.	UNIV WASHINGTON,SCH MED,DEPT REHABIL MED,SEATTLE,WA 98195		BROOKE, MM (corresponding author), TUFTS UNIV,SCH MED,DEPT REHABIL MED,136 HARRISON AVE,BOSTON,MA 02111, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR49-002570] Funding Source: Medline		CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MALKMUS D, 1980, REHABILITATION HEAD; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	7	90	90	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	1992	73	4					320	323		10.1016/0003-9993(92)90003-F			4	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	HM910	WOS:A1992HM91000003	1554303				2022-02-06	
J	LEVIN, HS; MEYERS, CA; GROSSMAN, RG; SARWAR, M				LEVIN, HS; MEYERS, CA; GROSSMAN, RG; SARWAR, M			VENTRICULAR ENLARGEMENT AFTER CLOSED HEAD-INJURY	ARCHIVES OF NEUROLOGY			English	Article									UNIV TEXAS,MED BRANCH,DIV NEURORADIOL,GALVESTON,TX 77550		LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01NS092314] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 07377-10, N01-NS-9-2314] Funding Source: Medline		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; BARRON SA, 1976, NEUROLOGY, V26, P1011, DOI 10.1212/WNL.26.11.1011; BOLLER FC, 1972, J NEUROL NEUROSUR PS, V35, P463, DOI 10.1136/jnnp.35.4.463; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; FRONT D, 1972, NEURORADIOLOGY, V4, P6, DOI 10.1007/BF00344802; GARDEUR D, 1979, J RADIOL ELEC MED N, V60, P79; Granholm L, 1972, Scand J Rehabil Med, V4, P31; GYLDENSTED C, 1977, NEURORADIOLOGY, V14, P183, DOI 10.1007/BF00496982; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; HAWKINS TD, 1976, CLIN RADIOL, V27, P279, DOI 10.1016/S0009-9260(76)80069-4; KASS B, 1978, ACTA NEUROL SCAND, V57, P19, DOI 10.1111/j.1600-0404.1978.tb04495.x; KISHORE PRS, 1978, NEURORADIOLOGY, V16, P261, DOI 10.1007/BF00395266; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; PENN RD, 1978, ANN NEUROL, V3, P216, DOI 10.1002/ana.410030306; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; SYNEK V, 1976, BRIT J RADIOL, V49, P233, DOI 10.1259/0007-1285-49-579-233; TEASDALE G, 1974, LANCET, V2, P81; VANDONGEN KJ, 1980, NEUROSURGERY, V7, P14, DOI 10.1227/00006123-198007000-00003; WEINBERGER DR, 1979, ARCH GEN PSYCHIAT, V36, P735	20	90	90	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.		1981	38	10					623	629		10.1001/archneur.1981.00510100051007			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ML870	WOS:A1981ML87000005	6975095				2022-02-06	
J	Liu, W; Rong, YL; Wang, JX; Zhou, Z; Ge, XH; Ji, CY; Jiang, DD; Gong, FY; Li, LW; Chen, J; Zhao, SJ; Kong, FQ; Gu, CJ; Fan, J; Cai, WH				Liu, Wei; Rong, Yuluo; Wang, Jiaxing; Zhou, Zheng; Ge, Xuhui; Ji, Chengyue; Jiang, Dongdong; Gong, Fangyi; Li, Linwei; Chen, Jian; Zhao, Shujie; Kong, Fanqi; Gu, Changjiang; Fan, Jin; Cai, Weihua			Exosome-shuttled miR-216a-5p from hypoxic preconditioned mesenchymal stem cells repair traumatic spinal cord injury by shifting microglial M1/M2 polarization	JOURNAL OF NEUROINFLAMMATION			English	Article						Spinal cord injury; Exosomes; Hypoxia; Microglia polarization; miR-216a-5p; TLR4 axis	CENTRAL-NERVOUS-SYSTEM; BLOOD-BRAIN-BARRIER; FUNCTIONAL RECOVERY; EXTRACELLULAR VESICLES; DELIVERY VEHICLES; THERAPY; PROMOTE; RAT; INFLAMMATION; PROTECTION	Background Spinal cord injury (SCI) can lead to severe motor and sensory dysfunction with high disability and mortality. In recent years, mesenchymal stem cell (MSC)-secreted nano-sized exosomes have shown great potential for promoting functional behavioral recovery following SCI. However, MSCs are usually exposed to normoxia in vitro, which differs greatly from the hypoxic micro-environment in vivo. Thus, the main purpose of this study was to determine whether exosomes derived from MSCs under hypoxia (HExos) exhibit greater effects on functional behavioral recovery than those under normoxia (Exos) following SCI in mice and to seek the underlying mechanism. Methods Electron microscope, nanoparticle tracking analysis (NTA), and western blot were applied to characterize differences between Exos and HExos group. A SCI model in vivo and a series of in vitro experiments were performed to compare the therapeutic effects between the two groups. Next, a miRNA microarray analysis was performed and a series of rescue experiments were conducted to verify the role of hypoxic exosomal miRNA in SCI. Western blot, luciferase activity, and RNA-ChIP were used to investigate the underlying mechanisms. Results Our results indicate that HExos promote functional behavioral recovery by shifting microglial polarization from M1 to M2 phenotype in vivo and in vitro. A miRNA array showed miR-216a-5p to be the most enriched in HExos and potentially involved in HExos-mediated microglial polarization. TLR4 was identified as the target downstream gene of miR-216a-5p and the miR-216a-5p/TLR4 axis was confirmed by a series of gain- and loss-of-function experiments. Finally, we found that TLR4/NF-kappa B/PI3K/AKT signaling cascades may be involved in the modulation of microglial polarization by hypoxic exosomal miR-216a-5p. Conclusion Hypoxia preconditioning represents a promising and effective approach to optimize the therapeutic actions of MSC-derived exosomes and a combination of MSC-derived exosomes and miRNAs may present a minimally invasive method for treating SCI.	[Liu, Wei; Rong, Yuluo; Wang, Jiaxing; Zhou, Zheng; Ge, Xuhui; Ji, Chengyue; Jiang, Dongdong; Gong, Fangyi; Li, Linwei; Chen, Jian; Zhao, Shujie; Kong, Fanqi; Gu, Changjiang; Fan, Jin; Cai, Weihua] Nanjing Med Univ, Dept Orthopaed, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China		Cai, WH (corresponding author), Nanjing Med Univ, Dept Orthopaed, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China.	caiwhsubmission@sina.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81974335]; Natural Science Foundation of Jiangsu ProvinceNatural Science Foundation of Jiangsu Province [BK20181490]; Jiangsu Province Six Talents Peak [TD-SWYY-010]; Wu Jieping Medical Foundation	This work was sponsored by the National Natural Science Foundation of China (Grant No.81974335), the Natural Science Foundation of Jiangsu Province (Grant No. BK20181490), the Jiangsu Province Six Talents Peak (Grant No. TD-SWYY-010), and the Wu Jieping Medical Foundation (Grant No.320-2745-16-117).	Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Ahuja CS, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.18; Ailawadi S, 2015, BBA-MOL BASIS DIS, V1852, P1, DOI 10.1016/j.bbadis.2014.10.008; Anderson JD, 2016, STEM CELLS, V34, P601, DOI 10.1002/stem.2298; Andras IE, 2016, TISSUE BARRIERS, V4, DOI 10.1080/21688370.2015.1131804; Anson CA, 1996, INT J REHABIL RES, V19, P55, DOI 10.1097/00004356-199603000-00006; Assinck P, 2017, NAT NEUROSCI, V20, P637, DOI 10.1038/nn.4541; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Bhanot Y, 2011, BRIT J NEUROSURG, V25, P516, DOI 10.3109/02688697.2010.550658; Boriachek K, 2018, SMALL, V14, DOI 10.1002/smll.201702153; Capiralla H, 2012, J NEUROCHEM, V120, P461, DOI 10.1111/j.1471-4159.2011.07594.x; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Crain JM, 2013, J NEUROSCI RES, V91, P1143, DOI 10.1002/jnr.23242; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; DeVivo MJ, 2012, SPINAL CORD, V50, P365, DOI 10.1038/sc.2011.178; EL Andaloussi S, 2013, ADV DRUG DELIVER REV, V65, P391, DOI 10.1016/j.addr.2012.08.008; Fan J, 2014, BRAIN RES, V1562, P76, DOI 10.1016/j.brainres.2014.03.019; Fernandez-Lizarbe S, 2009, J IMMUNOL, V183, P4733, DOI 10.4049/jimmunol.0803590; Francos-Quijorna I, 2016, GLIA, V64, P2079, DOI 10.1002/glia.23041; Gong Z, 2020, CURR STEM CELL RES T, V15, P321, DOI 10.2174/1574888X14666190823144424; Guo SC, 2017, THERANOSTICS, V7, P81, DOI 10.7150/thno.16803; Ha D, 2016, ACTA PHARM SIN B, V6, P287, DOI 10.1016/j.apsb.2016.02.001; Haney MJ, 2015, J CONTROL RELEASE, V207, P18, DOI 10.1016/j.jconrel.2015.03.033; Heiman A, 2014, BRAIN BEHAV IMMUN, V42, P232, DOI 10.1016/j.bbi.2014.06.203; Hessvik NP, 2018, CELL MOL LIFE SCI, V75, P193, DOI 10.1007/s00018-017-2595-9; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Hu XY, 2016, CIRC RES, V118, P970, DOI 10.1161/CIRCRESAHA.115.307516; Hu XY, 2014, STEM CELLS, V32, P2702, DOI 10.1002/stem.1784; Hu XY, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-303; Hua F, 2007, J IMMUNOL, V178, P7317, DOI 10.4049/jimmunol.178.11.7317; Huang JH, 2017, J NEUROTRAUM, V34, P3388, DOI 10.1089/neu.2017.5063; Huang RQ, 2019, AGING-US, V11, P7996, DOI 10.18632/aging.102314; Jain NB, 2015, JAMA-J AM MED ASSOC, V313, P2236, DOI 10.1001/jama.2015.6250; Jeong JO, 2011, CIRC RES, V108, P1340, DOI 10.1161/CIRCRESAHA.110.239848; Jha MK, 2016, BIOCHEM PHARMACOL, V103, P1, DOI 10.1016/j.bcp.2015.11.003; Kamerkar S, 2017, NATURE, V546, P498, DOI 10.1038/nature22341; Katsuda T, 2013, PROTEOMICS, V13, P1637, DOI 10.1002/pmic.201200373; Kawabata S, 2016, STEM CELL REP, V6, P1, DOI 10.1016/j.stemcr.2015.11.013; Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850; Kawikova I, 2015, BRAIN RES, V1617, P63, DOI 10.1016/j.brainres.2014.09.070; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Kishk NA, 2010, NEUROREHAB NEURAL RE, V24, P702, DOI 10.1177/1545968310369801; Kordelas L, 2014, LEUKEMIA, V28, P970, DOI 10.1038/leu.2014.41; Lankford KL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190358; Li LW, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12689; Li Y, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0648-5; Liu W, 2020, ACTA BIOMATER, V103, P196, DOI 10.1016/j.actbio.2019.12.020; Liu W, 2019, J NEUROTRAUM, V36, P469, DOI 10.1089/neu.2018.5835; Liu ZX, 2019, BIOCHEM BIOPH RES CO, V512, P367, DOI 10.1016/j.bbrc.2019.03.002; Lou GH, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.63; McDonald JW, 2002, LANCET, V359, P417, DOI 10.1016/S0140-6736(02)07603-1; Melo SA, 2014, CANCER CELL, V26, P707, DOI 10.1016/j.ccell.2014.09.005; Milane L, 2015, J CONTROL RELEASE, V219, P278, DOI 10.1016/j.jconrel.2015.06.029; Noelker C, 2013, SCI REP-UK, V3, DOI 10.1038/srep01393; Norenberg MD, 2004, J NEUROTRAUM, V21, P429, DOI 10.1089/089771504323004575; Nori S, 2011, P NATL ACAD SCI USA, V108, P16825, DOI 10.1073/pnas.1108077108; Orihuela R, 2016, BRIT J PHARMACOL, V173, P649, DOI 10.1111/bph.13139; Pan J, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0270-3; Pegtel DM, 2010, P NATL ACAD SCI USA, V107, P6328, DOI 10.1073/pnas.0914843107; Periyasamy P, 2018, MOL NEUROBIOL, V55, P3196, DOI 10.1007/s12035-017-0584-5; Qian DF, 2019, CELL CYCLE, V18, P3010, DOI 10.1080/15384101.2019.1667189; Qiu GG, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-1069-9; Rani S, 2015, MOL THER, V23, P812, DOI 10.1038/mt.2015.44; Rong YL, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1571-8; Rubio D, 2005, CANCER RES, V65, P3035, DOI 10.1158/0008-5472.CAN-04-4194; Siddall PJ, 2001, SPINAL CORD, V39, P63, DOI 10.1038/sj.sc.3101116; Su T, 2019, ACS NANO, V13, P2450, DOI 10.1021/acsnano.8b09375; Sun GD, 2018, MAT SCI ENG C-MATER, V89, P194, DOI 10.1016/j.msec.2018.04.006; Tanaka T, 2015, GLIA, V63, P595, DOI 10.1002/glia.22770; Thind A, 2016, J EXTRACELL VESICLES, V5, DOI 10.3402/jev.v5.31292; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; Vaccari JPD, 2016, J NEUROCHEM, V136, P39, DOI 10.1111/jnc.13036; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Varma AK, 2013, NEUROCHEM RES, V38, P895, DOI 10.1007/s11064-013-0991-6; Vergadi E, 2017, J IMMUNOL, V198, P1006, DOI 10.4049/jimmunol.1601515; Vlassov AV, 2012, BBA-GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017; Wang CY, 2019, FASEB J, V33, P5440, DOI 10.1096/fj.201801821R; Wood MJA, 2011, THER DELIV, V2, P1095, DOI 10.4155/TDE.11.83; Wortzel I, 2019, DEV CELL, V49, P347, DOI 10.1016/j.devcel.2019.04.011; Xiao CC, 2018, CIRC RES, V123, P564, DOI 10.1161/CIRCRESAHA.118.312758; Xiao Q, 2017, NEUROSCIENCE, V355, P61, DOI 10.1016/j.neuroscience.2017.04.050; Xiong Y, 2017, NEURAL REGEN RES, V12, P19, DOI 10.4103/1673-5374.198966; Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066; Yang TZ, 2015, PHARM RES-DORDR, V32, P2003, DOI 10.1007/s11095-014-1593-y; Yang XD, 2017, BRAIN BEHAV IMMUN, V64, P162, DOI 10.1016/j.bbi.2017.03.003; Yang Y, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.140; Young Wise, 1993, Journal of Emergency Medicine, V11, P13; Yu AY, 2017, IMMUNOL LETT, V182, P1, DOI 10.1016/j.imlet.2016.12.003; Zhao JX, 2019, CARDIOVASC RES, V115, P1205, DOI 10.1093/cvr/cvz040; Zhou X, 2014, NEURAL REGEN RES, V9, P1787, DOI 10.4103/1673-5374.143423; Zhou Y, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt194; Zhu JY, 2018, ARTIF CELL NANOMED B, V46, P1659, DOI 10.1080/21691401.2017.1388249; Zhuang XY, 2011, MOL THER, V19, P1769, DOI 10.1038/mt.2011.164	93	89	91	18	55	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	FEB 4	2020	17	1							47	10.1186/s12974-020-1726-7			22	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	KW6WO	WOS:000521323400001	32019561	Green Published, gold	Y	N	2022-02-06	
J	Ferreira, GC; McKenna, MC				Ferreira, Gustavo C.; McKenna, Mary C.			L-Carnitine and Acetyl-l-carnitine Roles and Neuroprotection in Developing Brain	NEUROCHEMICAL RESEARCH			English	Article						L-Carnitine; Acetyl-L-carnitine; Neuroprotection; Neonatal hypoxia-ischemia; Pediatric traumatic brain injury; Metabolism; Inborn errors of metabolism; Carnitine shuttle	PERFORMANCE LIQUID-CHROMATOGRAPHY; COA DEHYDROGENASE-DEFICIENCY; HYPOXIC-ISCHEMIC ENCEPHALOPATHY; MAGNETIC-RESONANCE-SPECTROSCOPY; ACETYLCHOLINE-RECEPTOR AGONIST; CENTRAL-NERVOUS-SYSTEM; C-13 NMR-SPECTROSCOPY; FATTY-ACID OXIDATION; FREELY MOVING RATS; ALPHA-LIPOIC ACID	L-Carnitine functions to transport long chain fatty acyl-CoAs into the mitochondria for degradation by beta-oxidation. Treatment with l-carnitine can ameliorate metabolic imbalances in many inborn errors of metabolism. In recent years there has been considerable interest in the therapeutic potential of l-carnitine and its acetylated derivative acetyl-l-carnitine (ALCAR) for neuroprotection in a number of disorders including hypoxia-ischemia, traumatic brain injury, Alzheimer's disease and in conditions leading to central or peripheral nervous system injury. There is compelling evidence from preclinical studies that l-carnitine and ALCAR can improve energy status, decrease oxidative stress and prevent subsequent cell death in models of adult, neonatal and pediatric brain injury. ALCAR can provide an acetyl moiety that can be oxidized for energy, used as a precursor for acetylcholine, or incorporated into glutamate, glutamine and GABA, or into lipids for myelination and cell growth. Administration of ALCAR after brain injury in rat pups improved long-term functional outcomes, including memory. Additional studies are needed to better explore the potential of l-carnitine and ALCAR for protection of developing brain as there is an urgent need for therapies that can improve outcome after neonatal and pediatric brain injury.	[Ferreira, Gustavo C.] Univ Fed Rio de Janeiro, Inst Med Biochem Leopoldo de Meis, Rio De Janeiro, Brazil; [Ferreira, Gustavo C.; McKenna, Mary C.] Univ Maryland, Sch Med, Dept Pediat, 655 W Baltimore St,BRB 13-019, Baltimore, MD 21201 USA; [McKenna, Mary C.] Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA		McKenna, MC (corresponding author), Univ Maryland, Sch Med, Dept Pediat, 655 W Baltimore St,BRB 13-019, Baltimore, MD 21201 USA.; McKenna, MC (corresponding author), Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA.	mmckenna@umaryland.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5P01 HD016596, P01 HD085928]; "Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro"Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ); Coordination for the Improvement of Higher Education Personnel (CAPES)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); National Council for Scientific and Technological Development (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD085928, P01HD016596] Funding Source: NIH RePORTER	The authors would like to gratefully acknowledge and thank Bruna Klippel Ferreira for her excellent effort in preparing Figs. 2 and 3, and Dr. Jaylyn Waddell and Dr. Susanna Scafidi for their very helpful suggestions. Research described from Dr. McKenna's laboratory was supported in part by NIH Grants 5P01 HD016596 and P01 HD085928. Dr. Ferreira's research is supported by the "Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro", Coordination for the Improvement of Higher Education Personnel (CAPES) and National Council for Scientific and Technological Development (CNPq).	Al-Majed AA, 2006, CLIN EXP PHARMACOL P, V33, P725, DOI 10.1111/j.1440-1681.2006.04425.x; Al-sharefi Ahmed, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2015-210727; Alves E, 2009, NEUROSCIENCE, V158, P514, DOI 10.1016/j.neuroscience.2008.10.041; ANGELINI C, 1987, CLIN BIOCHEM, V20, P1, DOI 10.1016/S0009-9120(87)80090-5; Aureli T, 1998, BRAIN RES, V796, P75, DOI 10.1016/S0006-8993(98)00319-9; Aureli T, 1999, EUR J BIOCHEM, V263, P287, DOI 10.1046/j.1432-1327.1999.00524.x; AURELI T, 1994, BRAIN RES, V643, P92, DOI 10.1016/0006-8993(94)90013-2; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Badve Monica S, 2015, N Z Med J, V128, P61; Barhwal K, 2008, J NEUROSCI RES, V86, P2705, DOI 10.1002/jnr.21722; BARNES CA, 1990, NEUROBIOL AGING, V11, P499, DOI 10.1016/0197-4580(90)90110-L; Bigford GE, 2014, ADV NUTR, V5, P394, DOI 10.3945/an.113.005264; Binienda ZK, 2006, NEUROSCI LETT, V410, P62, DOI 10.1016/j.neulet.2006.09.070; Bogaert YE, 2000, EXP NEUROL, V161, P115, DOI 10.1006/exnr.1999.7250; BOGAERT YE, 1994, FREE RADICAL BIO MED, V16, P811, DOI 10.1016/0891-5849(94)90197-X; Brekke EMF, 2014, J CEREBR BLOOD F MET, V34, P724, DOI 10.1038/jcbfm.2014.8; Cahova M, 2015, APPL PHYSIOL NUTR ME, V40, P280, DOI [10.1139/apnm-2014-0163, 10.1139/apnm-2014-016]; Calabrese V, 2006, J NUTR BIOCHEM, V17, P73, DOI 10.1016/j.jnutbio.2005.03.027; Calabrese V, 2005, J NEUROSCI RES, V79, P509, DOI 10.1002/jnr.20386; Calabrese V, 2003, NEUROCHEM RES, V28, P1321, DOI 10.1023/A:1024984013069; Catroppa C, 2012, J NEUROTRAUM, V29, P2539, DOI 10.1089/neu.2012.2403; Celestino-Soper PBS, 2012, P NATL ACAD SCI USA, V109, P7974, DOI 10.1073/pnas.1120210109; CERDAN S, 1990, J BIOL CHEM, V265, P12916; CHALMERS RA, 1984, PEDIATR RES, V18, P1325, DOI 10.1203/00006450-198412000-00021; Chavez-Valdez R, 2014, NEUROSCIENCE, V260, P106, DOI 10.1016/j.neuroscience.2013.12.023; Chiechio S, 2006, CURR NEUROPHARMACOL, V4, P233, DOI 10.2174/157015906778019509; Clark RH, 2014, PEDIATRICS, V134, pE37, DOI 10.1542/peds.2014-0329; Cruz F, 1998, J NEUROCHEM, V70, P2613; Czeredys M, 2008, BIOCHEM BIOPH RES CO, V376, P267, DOI 10.1016/j.bbrc.2008.08.122; Czeredys M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082105; DAVIES SEC, 1991, CLIN CHIM ACTA, V204, P263, DOI 10.1016/0009-8981(91)90237-7; de Paula S, 2009, PEDIATR RES, V65, P631, DOI 10.1203/PDR.0b013e31819ed5c8; Demarest TG, 2016, J BIOENERG BIOMEMBR, V48, P591, DOI 10.1007/s10863-016-9678-4; Demarest TG, 2016, J NEUROCHEM, V137, P714, DOI 10.1111/jnc.13590; DESIMONE R, 1991, INT J DEV NEUROSCI, V9, P39, DOI 10.1016/0736-5748(91)90071-S; Ebert D, 2003, J NEUROSCI, V23, P5928; El-Hattab AW, 2015, MOL GENET METAB, V116, P107, DOI 10.1016/j.ymgme.2015.09.004; Fatemi A, 2009, CLIN PERINATOL, V36, P835, DOI 10.1016/j.clp.2009.07.011; Faul M, 2010, TRAUMATIC BRAIN INJU; Ferreira GC, 2007, INT J DEV NEUROSCI, V25, P391, DOI 10.1016/j.ijdevneu.2007.05.009; Frye RE, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2012.143; Furukawa S, 2014, INT J DEV NEUROSCI, V37, P52, DOI 10.1016/j.ijdevneu.2014.06.011; Furukawa S, 2014, J PERINAT MED, V42, P379, DOI 10.1515/jpm-2013-0175; Furukawa S, 2014, BRAIN RES, V1562, P52, DOI 10.1016/j.brainres.2014.03.028; Gibson GE, 2015, J NEUROCHEM, V134, P86, DOI 10.1111/jnc.13096; Gold PE, 2003, NEUROBIOL LEARN MEM, V80, P194, DOI 10.1016/j.nlm.2003.07.003; Graham EM, 2008, AM J OBSTET GYNECOL, V199, P587, DOI 10.1016/j.ajog.2008.06.094; HASSEL B, 1995, J NEUROCHEM, V64, P2773; Higgins RD, 2011, J PEDIATR-US, V159, P851, DOI 10.1016/j.jpeds.2011.08.004; Hoffmann GF, 1996, NEUROPEDIATRICS, V27, P115, DOI 10.1055/s-2007-973761; Hori T, 2010, TOHOKU J EXP MED, V221, P191, DOI 10.1620/tjem.221.191; Hota KB, 2012, HIPPOCAMPUS, V22, P723, DOI 10.1002/hipo.20934; IMPERATO A, 1989, NEUROSCI LETT, V107, P251, DOI 10.1016/0304-3940(89)90826-4; Inazu M, 2006, J NEUROCHEM, V97, P424, DOI 10.1111/j.1471-4159.2006.03757.x; Inazu Masato, 2008, JAPANESE JOURNAL OF NEUROPSYCHOPHARMACOLOGY, V28, P113; Invernizzi F, 2001, J INHERIT METAB DIS, V24, P601, DOI 10.1023/A:1012476029536; Ishii T, 2000, JPN J PHARMACOL, V83, P119, DOI 10.1254/jjp.83.119; JANIRI L, 1991, J NEURAL TRANSM-GEN, V86, P135, DOI 10.1007/BF01250574; Januszewicz E, 2010, NEUROCHEM RES, V35, P743, DOI 10.1007/s11064-010-0131-5; Jones LL, 2010, PROG LIPID RES, V49, P61, DOI 10.1016/j.plipres.2009.08.004; Juul SE, 2014, CLIN PERINATOL, V41, P119, DOI 10.1016/j.clp.2013.09.004; Karakoc E, 2006, CLIN NEUROL NEUROSUR, V108, P794, DOI 10.1016/j.clineuro.2005.10.012; KAWAMURA N, 1988, ARCH BIOCHEM BIOPHYS, V264, P546, DOI 10.1016/0003-9861(88)90320-7; KIDOUCHI K, 1987, CLIN CHIM ACTA, V164, P261, DOI 10.1016/0009-8981(87)90300-7; Kim H, 2012, NEUROL SCI, V33, P1393, DOI 10.1007/s10072-012-0939-7; Kobayashi S, 2010, GERIATR GERONTOL INT, V10, pS99, DOI 10.1111/j.1447-0594.2010.00595.x; Kochanek PM, 2015, SEMIN NEUROL, V35, P83, DOI 10.1055/s-0035-1544237; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kochanek PM, 2010, DEV NEUROSCI-BASEL, V32, P335, DOI 10.1159/000323016; Kocsis K, 2015, J NEURAL TRANSM, V122, P867, DOI 10.1007/s00702-014-1343-7; Kolker S, 2011, J INHERIT METAB DIS, V34, P677, DOI 10.1007/s10545-011-9289-5; KUNNECKE B, 1993, NMR BIOMED, V6, P264, DOI 10.1002/nbm.1940060406; Kuratsune H, 1997, BIOCHEM BIOPH RES CO, V231, P488, DOI 10.1006/bbrc.1996.5919; Lamhonwah AM, 2008, BRAIN DEV-JPN, V30, P31, DOI 10.1016/j.braindev.2007.05.005; Limketkai BN, 2008, J GEN INTERN MED, V23, P210, DOI 10.1007/s11606-007-0473-0; LIU YB, 1993, FREE RADICAL BIO MED, V15, P667, DOI 10.1016/0891-5849(93)90171-P; LLOYDSTILL JD, 1993, ACTA PAEDIATR, V82, P145, DOI 10.1111/j.1651-2227.1993.tb12626.x; Longo N, 2006, AM J MED GENET C, V142C, P77, DOI 10.1002/ajmg.c.30087; Longo N, 2016, ANN NUTR METAB, V68, P5, DOI 10.1159/000448321; Madiraju Padma, 2009, Epigenetics, V4, P399; Marcovina SM, 2013, TRANSL RES, V161, P73, DOI 10.1016/j.trsl.2012.10.006; MARKOWSKA AL, 1990, NEUROBIOL AGING, V11, P491, DOI 10.1016/0197-4580(90)90109-D; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; MATSUISHI T, 1991, BIOCHEM MED METAB B, V45, P244, DOI 10.1016/0885-4505(91)90027-I; MATSUMOTO K, 1993, CLIN CHIM ACTA, V216, P135, DOI 10.1016/0009-8981(93)90146-U; McKenna MC, 2016, ADV NEUROBIOL, V13, P59, DOI 10.1007/978-3-319-45096-4_4; McKenna MC, 2015, NEUROCHEM RES, V40, P2527, DOI 10.1007/s11064-015-1600-7; McKenna MC, 2015, J NEUROCHEM, V134, P3, DOI 10.1111/jnc.13150; Mescka CP, 2013, INT J DEV NEUROSCI, V31, P21, DOI 10.1016/j.ijdevneu.2012.10.109; Miecz D, 2008, J NEUROCHEM, V104, P113, DOI 10.1111/j.1471-4159.2007.05024.x; MINKLER PE, 1993, J CHROMATOGR-BIOMED, V613, P203, DOI 10.1016/0378-4347(93)80135-Q; Mitsushima D, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3760; Morken TS, 2014, STROKE, V45, P2777, DOI 10.1161/STROKEAHA.114.005341; Muoio DM, 2012, CELL METAB, V15, P764, DOI 10.1016/j.cmet.2012.04.005; Nalecz KA, 1996, ACTA NEUROBIOL EXP, V56, P597; Nalecz Katarzyna A., 2004, Molecular Aspects of Medicine, V25, P551; Nasca C, 2013, P NATL ACAD SCI USA, V110, P4804, DOI 10.1073/pnas.1216100110; NOVAK M, 1988, J PEDIATR GASTR NUTR, V7, P220, DOI 10.1097/00005176-198803000-00011; NOVAK M, 1981, PEDIATRICS, V67, P95; Okun JG, 2002, BBA-MOL CELL BIOL L, V1584, P91, DOI 10.1016/S1388-1981(02)00296-2; Ori C, 2002, BRAIN RES, V951, P330, DOI 10.1016/S0006-8993(02)03290-0; Osredkar D, 2010, NEUROBIOL DIS, V38, P259, DOI 10.1016/j.nbd.2010.01.015; PANDE SV, 1971, J BIOL CHEM, V246, P402; Patel SP, 2012, NEUROSCIENCE, V210, P296, DOI 10.1016/j.neuroscience.2012.03.006; Phillis J. W., 2005, Critical Reviews in Neurobiology, V17, P161; Picconi B, 2006, NEUROPHARMACOLOGY, V50, P917, DOI 10.1016/j.neuropharm.2006.01.002; PIOVESAN P, 1995, INT J DEV NEUROSCI, V13, P13, DOI 10.1016/0736-5748(94)00070-J; POORTHUIS BJHM, 1993, CLIN CHIM ACTA, V216, P53, DOI 10.1016/0009-8981(93)90138-T; RASHED MS, 1995, PEDIATR RES, V38, P324, DOI 10.1203/00006450-199509000-00009; Rashidi-Nezhad A, 2014, BMC MED GENET, V15, DOI 10.1186/1471-2350-15-75; Rau TF, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0040881, 10.1371/journal.pone.0047877]; Reuter SE, 2012, CLIN PHARMACOKINET, V51, P553, DOI 10.2165/11633940-000000000-00000; Ribas GS, 2014, GENE, V533, P469, DOI 10.1016/j.gene.2013.10.017; Ricciolini R, 1998, J NEUROCHEM, V71, P2510; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Richards EM, 2006, FREE RADICAL BIO MED, V40, P1960, DOI 10.1016/j.freeradbiomed.2006.01.022; ROE CR, 1983, ARCH DIS CHILD, V58, P916, DOI 10.1136/adc.58.11.916; ROE CR, 1985, PEDIATR RES, V19, P459, DOI 10.1203/00006450-198505000-00011; ROE CR, 1984, J CLIN INVEST, V73, P1785, DOI 10.1172/JCI111387; ROSENTHAL RE, 1992, STROKE, V23, P1312, DOI 10.1161/01.STR.23.9.1312; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Sakai E, 2013, NEUROPEDIATRICS, V44, P218, DOI 10.1055/s-0032-1333439; Sarter M, 2003, NEUROBIOL LEARN MEM, V80, P245, DOI 10.1016/S1074-7427(03)00070-4; Scafidi S, 2010, DEV NEUROSCI-BASEL, V32, P480, DOI 10.1159/000323178; Scafidi S, 2010, J NEUROCHEM, V114, P820, DOI 10.1111/j.1471-4159.2010.06807.x; Scafidi S, 2009, J NEUROCHEM, V109, P189, DOI 10.1111/j.1471-4159.2009.05896.x; SCHMIDTSOMMERFELD E, 1989, J PEDIATR-US, V115, P577, DOI 10.1016/S0022-3476(89)80284-7; Schols L, 2005, J NEURAL TRANSM, V112, P789, DOI 10.1007/s00702-004-0216-x; Schuck PF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126606; Schuck PF, 2010, LIFE SCI, V87, P139, DOI 10.1016/j.lfs.2010.05.019; Shea TB, 2007, NEUROMOL MED, V9, P264, DOI 10.1007/s12017-007-8005-y; Shinohara M, 2011, BRAIN DEV-JPN, V33, P512, DOI 10.1016/j.braindev.2010.09.002; SHUG AL, 1975, AM J PHYSIOL, V228, P689, DOI 10.1152/ajplegacy.1975.228.3.689; Sitta A, 2011, CELL MOL NEUROBIOL, V31, P429, DOI 10.1007/s10571-010-9636-3; Smeland OB, 2012, NEUROCHEM INT, V61, P100, DOI 10.1016/j.neuint.2012.04.008; Smith AL, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/2585230; Spiekerkoetter U, 2010, J INHERIT METAB DIS, V33, P539, DOI 10.1007/s10545-010-9121-7; Stanley C A, 1995, Adv Pediatr, V42, P209; Stanley C.A., 2014, ONLINE METABOLIC MOL; Stanley CA, 2004, ANN NY ACAD SCI, V1033, P42, DOI 10.1196/annals.1320.004; STUMPF DA, 1980, PEDIATR RES, V14, P1127, DOI 10.1203/00006450-198010000-00008; Suchy J, 2009, NUTR RES, V29, P70, DOI 10.1016/j.nutres.2008.11.004; Szabo K, 2017, DRUG METAB PHARMACOK, V32, P165, DOI 10.1016/j.dmpk.2016.08.005; Tang SY, 2016, DEV NEUROSCI-BASEL, V38, P384, DOI 10.1159/000455041; Thomas RH, 2010, J NEUROCHEM, V113, P515, DOI 10.1111/j.1471-4159.2010.06614.x; Ueno Y, 2015, J CEREBR BLOOD F MET, V35, P382, DOI 10.1038/jcbfm.2014.210; Vaz FM, 2002, BIOCHEM J, V361, P417, DOI 10.1042/0264-6021:3610417; Vereczki V, 2006, J CEREBR BLOOD F MET, V26, P821, DOI 10.1038/sj.jcbfm.9600234; Neto EV, 2012, BRAZ J MED BIOL RES, V45, P546, DOI 10.1590/S0100-879X2012007500056; Virmani A, 2011, CURR NEUROPHARMACOL, V9, P195, DOI 10.2174/157015911795017182; Virmani MA, 2001, ANN NY ACAD SCI, V939, P162; Wainwright MS, 2006, STROKE, V37, P524, DOI 10.1161/01.STR.0000198892.15269.f7; Wainwright MS, 2003, PEDIATR RES, V54, P688, DOI 10.1203/01.PDR.0000085036.07561.9C; Walters JL, 2017, NEUROTOXICOL TERATOL, V60, P2, DOI 10.1016/j.ntt.2016.11.005; Waniewski RA, 1998, J NEUROSCI, V18, P5225, DOI 10.1523/JNEUROSCI.18-14-05225.1998; Wechsler B, 2005, J TRAUMA, V58, P940, DOI 10.1097/01.TA.0000162630.78386.98; WHITE HL, 1990, NEUROCHEM RES, V15, P597, DOI 10.1007/BF00973749; Wilson ADH, 2007, J PLAST RECONSTR AES, V60, P114, DOI 10.1016/j.bjps.2006.04.017; WOLFF JA, 1986, LANCET, V1, P289; Xu S, 2015, MAGN RESON MED, V74, P1530, DOI 10.1002/mrm.25537; Yang J, 2008, IEEE ENG MED BIO, P363, DOI 10.1109/IEMBS.2008.4649165; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yu ZP, 1997, N-S ARCH PHARMACOL, V355, P545, DOI 10.1007/PL00004981; Zaitone SA, 2012, PHARMACOL BIOCHEM BE, V100, P347, DOI 10.1016/j.pbb.2011.09.002; Zanelli SA, 2005, ANN NY ACAD SCI, V1053, P153, DOI 10.1196/annals.1344.013; Zhang R, 2012, INT J MOL SCI, V13, P2078, DOI 10.3390/ijms13022078; Zhang X, 2013, J MOL PHARM ORG PROC, DOI [10.4172/2329-9029.1000102, DOI 10.4172/2329-9029.1000102]; Zhang X, 2016, ANESTHESIOLOGY, V125, P133, DOI 10.1097/ALN.0000000000001154; Zou X, 2008, NEUROSCIENCE, V151, P1053, DOI 10.1016/j.neuroscience.2007.12.013	169	89	93	4	34	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	JUN	2017	42	6			SI		1661	1675		10.1007/s11064-017-2288-7			15	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	EW4GA	WOS:000402458800010	28508995	Green Accepted			2022-02-06	
J	Agoston, DV; Shutes-David, A; Peskind, ER				Agoston, Denes V.; Shutes-David, Andrew; Peskind, Elaine R.			Biofluid biomarkers of traumatic brain injury	BRAIN INJURY			English	Article						(that are not already included in title): mild traumatic brain injury (mTBI); cerebrospinal fluid (CSF)	NEURON-SPECIFIC ENOLASE; TIME-DEPENDENT CHANGES; TERMINAL HYDROLASE L1; CEREBROSPINAL-FLUID; INTRACRANIAL-PRESSURE; REVEALS COMPLEX; AXONAL INJURY; SERUM; S100B; SYSTEM	Primary objective: The purpose of this paper is to review the clinical and research utility and applications of blood, cerebrospinal fluid (CSF), and cerebral microdialysis biomarkers in traumatic brain injury (TBI). Research design: Not applicable. Methods and procedures: A selective review was performed on these biofluid biomarkers in TBI. Main outcome and results: Neurofilament heavy chain protein (NF-H), glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase-L1 (UCHL1), neuron-specific enolase (NSE), myelin basic protein (MBP), tau, and s100 beta blood biomarkers are elevated during the acute phase of severe head trauma but have key limitations in their research and clinical applications to mild TBI (mTBI). CSF biomarkers currently provide the best reflection of the central nervous system (CNS) pathobiological processes in TBI. Both animal and human studies of TBI have demonstrated the importance of serial sampling of biofluids and suggest that CSF biomarkers may be better equipped to characterize both TBI severity and temporal profiles. Conclusions: The identification of biofluid biomarkers could play a vital role in identifying, diagnosing, and treating the underlying individual pathobiological changes of TBI. CNS-derived exosomes analyzed by ultra-high sensitivity detection, methods have the potential to identify blood biomarkers for the range of TBI severity and time course.	[Agoston, Denes V.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD USA; [Agoston, Denes V.] Karolinska Inst, Dept Neurosci, Stockholm, Sweden; [Shutes-David, Andrew; Peskind, Elaine R.] Vet Affairs Puget Sound Hlth Care Syst, VA Northwest Network Mental Illness Res, Educ & Clin Ctr, Seattle, WA USA; [Shutes-David, Andrew] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA; [Peskind, Elaine R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA		Peskind, ER (corresponding author), VA Puget Sound Hlth Care Syst, 1660 So Columbian Way,5-116-MIRECC, Seattle, WA 98108 USA.	peskind@uw.edu			VA Puget Sound Health Care SystemUS Department of Veterans Affairs; Veterans AffairsUS Department of Veterans Affairs [I01RX000521, I01RX001612] Funding Source: NIH RePORTER	This material is the result of work supported with resources and the use of facilities at the VA Puget Sound Health Care System.	Agoston D.V., 2015, BRAIN NEUROTRAUMA MO; Ahmed F, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00114; Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; Ahmed F, 2013, BIOMACROMOLECULES, V14, P3850, DOI 10.1021/bm400938n; Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; Bedekovics T, 2016, BLOOD, V127, P1564, DOI 10.1182/blood-2015-07-656678; BENJAMINS JA, 1978, NEUROCHEM RES, V3, P137, DOI 10.1007/BF00964057; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Clay MB, 2013, J CHIROPR MED, V12, P230, DOI 10.1016/j.jcm.2012.11.005; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10210; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; Ercole A, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0614-3; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Gatson JW, 2014, J NEUROSURG, V121, P1232, DOI 10.3171/2014.7.JNS132474; Gyorgy A, 2011, J NEUROTRAUM, V28, P1121, DOI 10.1089/neu.2010.1561; Haqqani AS, 2007, J NEUROTRAUM, V24, P54, DOI 10.1089/neu.2006.0079; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hill CS, 2016, TRENDS NEUROSCI, V39, P311, DOI 10.1016/j.tins.2016.03.002; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hladky SB, 2016, FLUIDS BARRIERS CNS, V13, DOI 10.1186/s12987-016-0040-3; Hladky SB, 2014, FLUIDS BARRIERS CNS, V11, DOI 10.1186/2045-8118-11-26; Huang XJ, 2015, J NEUROTRAUM, V32, P1179, DOI 10.1089/neu.2015.3873; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Jessen NA, 2015, NEUROCHEM RES, V40, P2583, DOI 10.1007/s11064-015-1581-6; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnston M, 2002, NEWS PHYSIOL SCI, V17, P227, DOI 10.1152/nips.01400.2002; Kalani A, 2014, MOL NEUROBIOL, V49, P590, DOI 10.1007/s12035-013-8544-1; Karr JE, 2014, NEUROPSYCHOL REV, V24, P428, DOI 10.1007/s11065-014-9271-8; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kulbe JR, 2016, EXP NEUROL, V275, P334, DOI 10.1016/j.expneurol.2015.05.004; Lafrenaye AD, 2014, J CEREBR BLOOD F MET, V34, P1628, DOI 10.1038/jcbfm.2014.122; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Lescot T, 2010, J NEUROTRAUM, V27, P85, DOI 10.1089/neu.2009.0982; Li J, 2015, AM J EMERG MED, V33, P1191, DOI 10.1016/j.ajem.2015.05.023; Ling H, 2015, MOL CELL NEUROSCI, V66, P114, DOI 10.1016/j.mcn.2015.03.012; Logsdon AF, 2015, COMPR PHYSIOL, V5, P1147, DOI 10.1002/cphy.c140057; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Menon DK, 2015, NAT REV NEUROL, V11, P71, DOI 10.1038/nrneurol.2014.261; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Microdialysis-Principles UU, 1991, J INTERN MED, V230, P365, DOI [10.1111/j.1365-2796.1991.tb00459.x., DOI 10.1111/J.1365-2796.1991.TB00459.X]; Mitchell AJ, 2009, J NEUROL NEUROSUR PS, V80, P966, DOI 10.1136/jnnp.2008.167791; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Neselius S, 2015, KNEE SURG SPORT TR A, V23, P2536, DOI 10.1007/s00167-014-3066-6; Neselius S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099870; Newcombe VFJ, 2016, NEUROREHAB NEURAL RE, V30, P49, DOI 10.1177/1545968315584004; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Nwachuku EL, 2016, CLIN NEUROL NEUROSUR, V149, P1, DOI 10.1016/j.clineuro.2016.06.009; O'Bryant SE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028092; OTT L, 1987, JPEN-PARENTER ENTER, V11, P488, DOI 10.1177/0148607187011005488; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Peskind ER, 2015, JAMA NEUROL, V72, P1103, DOI 10.1001/jamaneurol.2015.1789; Pham N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012691; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Prins ML, 2016, J CHILD NEUROL, V31, P28, DOI 10.1177/0883073814549244; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Rosenthal G, 2008, J NEUROSURG, V108, P575, DOI 10.3171/JNS/2008/108/3/0575; Rostami E, 2013, RESP PHYSIOL NEUROBI, V189, P537, DOI 10.1016/j.resp.2013.08.010; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schroder C, 2013, J CANCER RES CLIN, V139, P1745, DOI 10.1007/s00432-013-1496-z; Shahim P, 2016, J NEUROTRAUM, V33, P1995, DOI 10.1089/neu.2014.3741; Shahim P, 2015, BRAIN INJURY, V29, P872, DOI 10.3109/02699052.2015.1018324; Sharma R, 2012, CURR NEUROL NEUROSCI, V12, P560, DOI 10.1007/s11910-012-0301-8; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Strathmann FG, 2014, CLIN BIOCHEM, V47, P876, DOI 10.1016/j.clinbiochem.2014.01.028; Tarasoff-Conway JM, 2015, NAT REV NEUROL, V11, P457, DOI 10.1038/nrneurol.2015.119; Thelin EP, 2014, NEUROCRIT CARE, V20, P217, DOI 10.1007/s12028-013-9916-0; Thelin EP, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1450-y; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; THOMAS D G T, 1978, Lancet, V1, P113; Tsilioni I, 2014, CLIN THER, V36, P882, DOI 10.1016/j.clinthera.2014.05.005; Ungerstedt U, 2004, CURR PHARM DESIGN, V10, P2145, DOI 10.2174/1381612043384105; Voss JD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0506-z; Wakeland W, 2005, ACT NEUR S, V95, P321; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Yang HH, 2015, INT J CLIN EXP PATHO, V8, P13957; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; ZELENIKA D, 1993, J NEUROCHEM, V60, P1574, DOI 10.1111/j.1471-4159.1993.tb03325.x; Zetterberg H, 2017, NEUROPATH APPL NEURO, V43, P194, DOI 10.1111/nan.12378; Zetterberg H, 2016, NAT REV NEUROL, V12, P563, DOI 10.1038/nrneurol.2016.127; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zetterberg H, 2009, BRAIN INJURY, V23, P723, DOI 10.1080/02699050903120399; Zhao BQ, 2007, STROKE, V38, P748, DOI 10.1161/01.STR.0000253500.32979.d1; Zurek J, 2012, ACTA NEUROCHIR, V154, P93, DOI 10.1007/s00701-011-1175-2	97	89	94	3	14	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	9			SI		1195	1203		10.1080/02699052.2017.1357836			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	FK0NN	WOS:000413176600006	28981341	hybrid			2022-02-06	
J	Xuan, WJ; Agrawal, T; Huang, LY; Gupta, GK; Hamblin, MR				Xuan, Weijun; Agrawal, Tanupriya; Huang, Liyi; Gupta, Gaurav K.; Hamblin, Michael R.			Low-level laser therapy for traumatic brain injury in mice increases brain derived neurotrophic factor (BDNF) and synaptogenesis	JOURNAL OF BIOPHOTONICS			English	Article						traumatic brain injury; transcranial low level light therapy; synaptogenesis; neurogenesis; BDNF; Synapsin-1	LIGHT THERAPY; INDUCED NEUROGENESIS; ISCHEMIC-STROKE; TERM; EXERCISE; MODERATE	Transcranial low-level laser (light) therapy (LLLT) is a new non-invasive approach to treating a range of brain disorders including traumatic brain injury (TBI). We (and others) have shown that applying near-infrared light to the head of animals that have suffered TBI produces improvement in neurological functioning, lessens the size of the brain lesion, reduces neuroinflammation, and stimulates the formation of new neurons. In the present study we used a controlled cortical impact TBI in mice and treated the mice either once (4 h post-TBI, 1-laser), or three daily applications (3-laser) with 810 nm CW laser 36 J/cm(2) at 50 mW/cm(2). Similar to previous studies, the neurological severity score improved in laser-treated mice compared to untreated TBI mice at day 14 and continued to further improve at days 21 and 28 with 3-laser being better than 1-laser. Mice were sacrificed at days 7 and 28 and brains removed for immunofluorescence analysis. Brain-derived neurotrophic factor (BDNF) was significantly up-regulated by laser treatment in the dentate gyrus of the hippocampus (DG) and the subventricular zone (SVZ) but not in the perilesional cortex (lesion) at day 7 but not at day 28. Synapsin-1 (a marker for synaptogenesis, the formation of new connections between existing neurons) was significantly upregulated in lesion and SVZ but not DG, at 28 days but not 7 days. The data suggest that the benefit of LLLT to the brain is partly mediated by stimulation of BDNF production, which may in turn encourage synaptogenesis. Moreover the pleiotropic benefits of BDNF in the brain suggest LLLT may have wider applications to neurodegenerative and psychiatric disorders.	[Xuan, Weijun] Guangxi Univ Chinese Med, Affiliated Coll & Hosp 1, Dept Otolaryngol, Nanning, Peoples R China; [Xuan, Weijun; Agrawal, Tanupriya; Huang, Liyi; Gupta, Gaurav K.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Xuan, Weijun; Agrawal, Tanupriya; Huang, Liyi; Gupta, Gaurav K.; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Huang, Liyi] Guangxi Med Univ, Affiliated Coll & Hosp 1, Dept Infect Dis, Nanning 530021, Peoples R China; [Gupta, Gaurav K.] Tufts Med Ctr, Dept Pathol & Lab Med, Boston, MA 02111 USA; [Hamblin, Michael R.] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA		Hamblin, MR (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.	hamblin@helix.mgh.harvard.edu	Hamblin, Michael R/H-2758-2019	Hamblin, Michael R/0000-0001-6431-4605; Agrawal, Tanupriya/0000-0002-7649-2828	US NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AI050875]; Air Force Office of Scientific ResearchUnited States Department of DefenseAir Force Office of Scientific Research (AFOSR) [FA9550-13-1-0068]; US Army Medical Research Acquisition Activity grant [W81XWH-09-1-0514]; US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-13-2-0067]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI050875] Funding Source: NIH RePORTER	This work was supported by US NIH grant R01AI050875, by Air Force Office of Scientific Research grant FA9550-13-1-0068, by US Army Medical Research Acquisition Activity grant W81XWH-09-1-0514 and by US Army Medical Research and Materiel Command grant W81XWH-13-2-0067.	Gomes LEA, 2012, PHOTOMED LASER SURG, V30, P642, DOI 10.1089/pho.2012.3242; Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Ambrogini P, 2013, BRAIN RES, V1534, P1, DOI 10.1016/j.brainres.2013.08.023; Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Avci P, 2014, LASER SURG MED, V46, P144, DOI 10.1002/lsm.22170; Avci P, 2013, LASER SURG MED, V45, P349, DOI 10.1002/lsm.22153; Barker JM, 2011, EUR J NEUROSCI, V34, P963, DOI 10.1111/j.1460-9568.2011.07823.x; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Chen A, 2013, BIOMED REP, V1, P167, DOI 10.3892/br.2012.48; Ferreira AFB, 2011, BRAIN RES, V1425, P111, DOI 10.1016/j.brainres.2011.10.004; Hashmi JT, 2010, PM&R, V2, pS292, DOI 10.1016/j.pmrj.2010.10.013; Huang YY, 2014, J BIOPHOTONICS, V7, P656, DOI 10.1002/jbio.201300125; Huang YY, 2012, J BIOPHOTONICS, V5, P827, DOI 10.1002/jbio.201200077; Huisa BN, 2013, INT J STROKE, V8, P315, DOI 10.1111/j.1747-4949.2011.00754.x; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323, DOI 10.1038/73888; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kokaia Z, 2006, CEREB CORTEX, V16, pI162, DOI 10.1093/cercor/bhj174; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Leeds PR, 2014, ACS CHEM NEUROSCI, V5, P422, DOI 10.1021/cn500040g; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Meng CB, 2013, J NEUROSCI, V33, P13505, DOI 10.1523/JNEUROSCI.0918-13.2013; Migliario M, 2014, LASER MED SCI, V29, P1463, DOI 10.1007/s10103-014-1556-x; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron A, 2012, J NEUROTRAUM, V29, P401, DOI 10.1089/neu.2011.2062; Parent JM, 2003, NEUROSCIENTIST, V9, P261, DOI 10.1177/1073858403252680; Quirk BJ, 2012, PHOTOMED LASER SURG, V30, P523, DOI 10.1089/pho.2012.3261; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Streeter J, 2004, MITOCHONDRION, V4, P569, DOI 10.1016/j.mito.2004.07.037; Vaynman SS, 2006, BRAIN RES, V1070, P124, DOI 10.1016/j.brainres.2005.11.062; Waterhouse EG, 2009, MOL CELL NEUROSCI, V42, P81, DOI 10.1016/j.mcn.2009.06.009; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Xuan WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053454; Zhang RL, 2008, NEUROPHARMACOLOGY, V55, P345, DOI 10.1016/j.neuropharm.2008.05.027; Zivin J. A., 2012, INT J STROKE, DOI [10.1111/j.1747-4949, DOI 10.1111/J.1747-4949]	41	89	94	3	24	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1864-063X	1864-0648		J BIOPHOTONICS	J. Biophotonics	JUN	2015	8	6					502	511		10.1002/jbio.201400069			10	Biochemical Research Methods; Biophysics; Optics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics; Optics	CK2VH	WOS:000356071500006	25196192	Green Accepted			2022-02-06	
J	Arciniegas, DB; Wortzel, HS				Arciniegas, David B.; Wortzel, Hal S.			Emotional and Behavioral Dyscontrol After Traumatic Brain Injury	PSYCHIATRIC CLINICS OF NORTH AMERICA			English	Article						Pathological laughing and crying; Affective lability; Irritability; Management; Aggression; Traumatic brain injury; Assessment; Disinhibition	CLOSED-HEAD-INJURY; SOCIAL COMMUNICATION-SKILLS; RANDOMIZED CONTROLLED-TRIAL; OF-THE-LITERATURE; AFFECTIVE INSTABILITY; COGNITIVE REHABILITATION; BORDERLINE PERSONALITY; AGGRESSIVE-BEHAVIOR; NEUROPSYCHIATRIC INVENTORY; POSTCONCUSSIVE SYMPTOMS	Emotional and behavioral dyscontrol are relatively common neuropsychiatric sequelae of traumatic brain injury and present substantial challenges to recovery and community participation. Among the most problematic and functionally disruptive of these types of behaviors are pathologic laughing and crying, affective lability, irritability, disinhibition, and aggression. Managing these problems effectively requires an understanding of their phenomenology, epidemiology, and clinical evaluation. This article reviews these issues and provides clinicians with brief and practical suggestions for the management of emotional and behavioral dyscontrol.	[Arciniegas, David B.; Wortzel, Hal S.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Beth K & Stuart C Yudofsky Div Neuropsychiat, Houston, TX 77030 USA; [Arciniegas, David B.] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX USA; [Arciniegas, David B.; Wortzel, Hal S.] Univ Colorado, Sch Med, Dept Psychiat, Neuropsychiat Serv, Aurora, CO USA; [Wortzel, Hal S.] VISN 19 MIRECC, Denver Vet Med Ctr, Denver, CO USA		Arciniegas, DB (corresponding author), TIRR Mem Hermann Res Ctr, 1333 Moursund St,Room 202, Houston, TX 77030 USA.	david.arciniegas@bcm.edu					Aboulafia-Brakha T, 2013, NEUROPSYCHOL REHABIL, V23, P216, DOI 10.1080/09602011.2012.747443; Alderman N, 2003, NEUROPSYCHOL REHABIL, V13, P211, DOI 10.1080/09602010244000327; Alderman N, 1997, BRAIN INJURY, V11, P503, DOI 10.1080/713802182; Alderman N, 1999, BRAIN INJURY, V13, P669; Allen MH, 2005, J PSYCHIAT PRACT S1, V11, P110; Allen Michael H, 2005, J Psychiatr Pract, V11 Suppl 1, P5, DOI 10.1097/00131746-200511001-00002; Alpert JE, 1997, PSYCHIAT CLIN N AM, V20, P453, DOI 10.1016/S0193-953X(05)70322-1; American Psychiatric Association, 2006, QUICK REF AM PSYCH A; American Psychiatric Association DSM-5 Task Force., 2013, DIAGNOSTIC STAT MANU, V5th, P624; American Psychiatric Association & DSM-5 Task Force, 2013, DIAGN STAT MAN MENT, VFifth; Arciniegas, 2000, Curr Treat Options Neurol, V2, P169; Arciniegas D B, 2000, Semin Clin Neuropsychiatry, V5, P290, DOI 10.1053/scnp.2000.9554; Arciniegas D. B., 2013, MANAGEMENT ADULTS TR; Arciniegas DB, 2008, CRIT CARE CLIN, V24, P737, DOI 10.1016/j.ccc.2008.06.001; Arciniegas DB, 2006, BEHAV NEUROL, V17, P25, DOI 10.1155/2006/460592; Arciniegas David B, 2011, Dialogues Clin Neurosci, V13, P325; Azouvi P, 1999, BRAIN INJURY, V13, P797, DOI 10.1080/026990599121188; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; BARRATT E. S., 1959, PERCEPT MOTOR SKILLS, V9, P191; Beresford TP, 2005, BRAIN INJURY, V19, P309, DOI 10.1080/02699050410001720121; Bickett AK, 2013, J HEAD TRAUMA REHABI; Block S H, 1987, Brain Inj, V1, P203, DOI 10.3109/02699058709034459; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Braden C, 2010, BRAIN INJURY, V24, P1298, DOI 10.3109/02699052.2010.506859; Brooks D. N., 1987, J HEAD TRAUMA REHAB, V2, P1; Bryant FB, 2001, J RES PERS, V35, P138, DOI 10.1006/jrpe.2000.2302; Cappa SF, 2005, EUR J NEUROL, V12, P665; Cappa SF, 2003, EUR J NEUROL, V10, P11, DOI 10.1046/j.1468-1331.2003.00537.x; Caracuel A, 2012, NEUROREHABILITATION, V30, P43, DOI 10.3233/NRE-2011-0726; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Monsalve BC, 2012, REV PSIQUIATR SALUD, V5, P160, DOI 10.1016/j.rpsm.2012.02.004; Cattelani R, 2010, NEUROPSYCHOL REV, V20, P52, DOI 10.1007/s11065-009-9125-y; Chahine LM, 2006, EPILEPSY BEHAV, V8, P610, DOI 10.1016/j.yebeh.2006.01.017; Chapman EH, 1999, J HEAD TRAUMA REHAB, V14, P521, DOI 10.1097/00001199-199912000-00002; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; Chow Tiffany W, 2005, Curr Psychiatry Rep, V7, P376, DOI 10.1007/s11920-005-0040-5; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; Corrigan JD, 2005, PSYCHOL ADDICT BEHAV, V19, P131, DOI 10.1037/0893-164X.19.2.131; Craig KJ, 2008, PSYCHIAT RES, V159, P367, DOI 10.1016/j.psychres.2007.03.002; Cummings JL, 2006, CNS SPECTRUMS, V11, P1; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; de Medeiros K, 2010, INT PSYCHOGERIATR, V22, P984, DOI 10.1017/S1041610210000876; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dimarco, 2002, EURA MEDICOPHYS, V38, P167; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Eames P, 2003, NEUROPSYCHOL REHABIL, V13, P241, DOI 10.1080/09602010244000435; Eames PG, 2001, BRAIN DAM B, P29; ELLIOTT FA, 1977, ANN NEUROL, V1, P489, DOI 10.1002/ana.410010516; Elovic EP, 2008, J HEAD TRAUMA REHAB, V23, P132, DOI 10.1097/01.HTR.0000314532.07530.e5; Ettenhofer ML, 2012, J INT NEUROPSYCH SOC, V18, P451, DOI 10.1017/S1355617711001895; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Fava M, 1997, PSYCHIAT CLIN N AM, V20, P427, DOI 10.1016/S0193-953X(05)70321-X; Ferguson SD, 2009, J PERS DISORD, V23, P230, DOI 10.1521/pedi.2009.23.3.230; Filley, 2013, BEHAV NEUROLOGY NEUR; Flanagan SR, 2009, PM&R, V1, P76, DOI 10.1016/j.pmrj.2008.10.013; Flashman LA, 2013, BEHAV NEUROLOGY NEUR, P604; GREEN RL, 1987, AM J PSYCHIAT, V144, P442; Gualtieri CT, 1991, J HEAD TRAUMA REHAB, V6, P90; Guay DRP, 2009, CLIN THER, V31, P1, DOI 10.1016/j.clinthera.2009.01.009; Guilmette TJ, 2004, ARCH CLIN NEUROPSYCH, V19, P183, DOI 10.1016/S0887-6177(03)00025-8; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hankin CS, 2011, J PSYCHIATR PRACT, V17, P170, DOI 10.1097/01.pra.0000398410.21374.7d; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Hart T, 2012, J HEAD TRAUMA REHAB, V27, P113, DOI 10.1097/HTR.0b013e31820e686c; HARVEY PD, 1989, J CLIN PSYCHOL, V45, P786, DOI 10.1002/1097-4679(198909)45:5<786::AID-JCLP2270450515>3.0.CO;2-P; Henry C, 2001, J PSYCHIATR RES, V35, P307, DOI 10.1016/S0022-3956(01)00038-3; Henry C, 2008, PSYCHIAT RES, V159, P1, DOI 10.1016/j.psychres.2005.11.016; Herrmann N, 2012, AM J GERIAT PSYCHIAT, V20, P789, DOI 10.1097/JGP.0b013e31823033f3; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Jamora CW, 2013, BRAIN INJURY, V27, P1134, DOI 10.3109/02699052.2013.804196; Johansson SH, 2008, BRAIN INJURY, V22, P999, DOI 10.1080/02699050802530573; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kant R, 1998, BRAIN INJURY, V12, P661, DOI 10.1080/026990598122223; Karol RL, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P1053; Kaufer DI, 2000, J NEUROPSYCH CLIN N, V12, P233, DOI 10.1176/jnp.12.2.233; Kilmer RP, 2006, REHABIL PSYCHOL, V51, P232, DOI 10.1037/0090-5550.51.3.232; Kim E, 2002, NEUROREHABILITATION, V17, P297; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kim E, 2006, J NEUROPSYCH CLIN N, V18, P547, DOI 10.1176/appi.neuropsych.18.4.547; Kim SH, 1999, J NERV MENT DIS, V187, P327, DOI 10.1097/00005053-199906000-00001; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Koenigsberg HW, 2002, AM J PSYCHIAT, V159, P784, DOI 10.1176/appi.ajp.159.5.784; Kolitz BP, 2003, ARCH PHYS MED REHAB, V84, P277, DOI 10.1053/apmr.2003.50100; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Lange RT, 2012, ARCH CLIN NEUROPSYCH, V27, P480, DOI 10.1093/arclin/acs059; Lauterbach EC, 2013, NEUROSCI BIOBEHAV R, V37, P1893, DOI 10.1016/j.neubiorev.2013.03.002; Leon-Carrion J, 2001, REV NEUROLOGIA, V33, P377, DOI 10.33588/rn.3304.2000196; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; LEWIN J, 1992, BRIT J PSYCHIAT, V161, P261, DOI 10.1192/bjp.161.2.261; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; Look AE, 2010, PERS INDIV DIFFER, V49, P187, DOI 10.1016/j.paid.2010.03.030; MacKinnon DF, 2006, BIPOLAR DISORD, V8, P1, DOI 10.1111/j.1399-5618.2006.00283.x; Maguen S, 2012, J REHABIL RES DEV, V49, P1115, DOI 10.1682/JRRD.2011.02.0015; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; McGrath J, 2000, BEHAV NEUROL, V12, P201, DOI 10.1155/2000/612185; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Mendez Mario F., 2009, V24, P168, DOI 10.1159/000197896; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; MICHALS ML, 1993, J CLIN PSYCHOPHARM, V13, P198; Moore SR, 1997, J NEUROL NEUROSUR PS, V63, P89, DOI 10.1136/jnnp.63.1.89; Morey, 1991, PERSONALITY ASSESSME; Muller U, 1999, BRAIN INJURY, V13, P805, DOI 10.1080/026990599121197; Mysiw WJ, 2006, BRAIN INJURY, V20, P905, DOI 10.1080/02699050600743972; Nakase-Thompson R, 2004, BRAIN INJURY, V18, P131, DOI 10.1080/0269905031000149542; *NAT CTR HLTH STAT, 2009, INT CLASS DIS; National Institute of Neurological Disorders and Stroke Common Data Elements Team, 2013, TRAUM BRAIN INJ COMM; Olney NT, 2011, BRAIN, V134, P3455, DOI 10.1093/brain/awr297; Pabis DJ, 1996, ANN PHARMACOTHER, V30, P278, DOI 10.1177/106002809603000312; Parmentier C, 2012, EUR PSYCHIAT, V27, P570, DOI 10.1016/j.eurpsy.2011.05.005; Pelegrin-Valero C, 2001, REV NEUROLOGIA, V32, P681, DOI 10.33588/rn.3207.2000180; Poeck K., 1969, HDB CLIN NEUROLOGY, P343; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rabins PV, 2007, CNS SPECTRUMS, V12, P17, DOI 10.1017/S1092852900025979; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; Rao V, 2009, J NEUROPSYCH CLIN N, V21, P420, DOI 10.1176/appi.neuropsych.21.4.420; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Rees RJ, 2007, NEUROREHABILITATION, V22, P229; Reich DB, 2009, INT CLIN PSYCHOPHARM, V24, P270, DOI 10.1097/YIC.0b013e32832d6c2f; Ripoll LH, 2012, CURR OPIN PSYCHIATR, V25, P52, DOI 10.1097/YCO.0b013e32834c3f19; ROBINSON RG, 1993, AM J PSYCHIAT, V150, P286; Scherer KR, 2004, SOC SCI INFORM, V43, P499, DOI 10.1177/0539018404047701; Scott LK, 2009, J NEUROS-PEDIATR, V3, P484, DOI 10.3171/2009.2.PEDS08292; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; Sherer M, 2005, ARCH PHYS MED REHAB, V86, P896, DOI 10.1016/j.apmr.2004.09.029; SIEVER LJ, 1991, AM J PSYCHIAT, V148, P1647; Silver JM, 2011, TXB TRAUMATIC BRAIN, VSecond; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Simon RI, 2008, TXB VIOLENCE ASSESSM, P161; Sink KM, 2005, JAMA-J AM MED ASSOC, V293, P596, DOI 10.1001/jama.293.5.596; SLOAN R L, 1992, Brain Injury, V6, P315, DOI 10.3109/02699059209034945; Solhan MB, 2009, PSYCHOL ASSESSMENT, V21, P425, DOI 10.1037/a0016869; Sorgi P, 1991, J Neuropsychiatry Clin Neurosci, V3, pS52; Spinella M, 2007, INT J NEUROSCI, V117, P359, DOI 10.1080/00207450600588881; Swartz JR, 1997, J CLIN PSYCHIAT, V58, P212, DOI 10.4088/JCP.v58n0506; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Tateno A, 2004, J NEUROPSYCH CLIN N, V16, P426, DOI 10.1176/appi.neuropsych.16.4.426; Teichner G, 1999, Rehabil Nurs, V24, P207; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; UDAKA F, 1984, ARCH NEUROL-CHICAGO, V41, P1095, DOI 10.1001/archneur.1984.04050210093023; Umene-Nakano W, 2013, GEN HOSP PSYCHIAT, V35, DOI 10.1016/j.genhosppsych.2012.05.002; van der Naalt J, 2000, BRAIN INJURY, V14, P781; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Villemure R, 2011, BRAIN INJURY, V25, P53, DOI 10.3109/02699052.2010.531881; Vos PE, 2012, EUR J NEUROL, V19, P191, DOI 10.1111/j.1468-1331.2011.03581.x; Votruba KL, 2008, J HEAD TRAUMA REHAB, V23, P65, DOI 10.1097/01.HTR.0000314525.93381.69; Walker AJ, 2010, BRAIN INJURY, V24, P517, DOI 10.3109/02699051003601721; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Wheaton P, 2011, J CLIN PSYCHOPHARM, V31, P745, DOI 10.1097/JCP.0b013e318235f4ac; Wheaton P, 2009, J CLIN PSYCHOPHARM, V29, P468, DOI 10.1097/JCP.0b013e3181b66f04; Willner P, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI 10.3310/hta17210; Willner P, 2013, BRIT J PSYCHIAT, V203, P288, DOI 10.1192/bjp.bp.112.124529; Wilson BA, 2008, ANNU REV CLIN PSYCHO, V4, P141, DOI 10.1146/annurev.clinpsy.4.022007.141212; Wilson SAK, 1924, J NEUROL PSYCHOPATHO, V4, P299; Wood RLL, 2013, BRAIN INJURY, V27, P253, DOI 10.3109/02699052.2012.743181; Wood RL, 2011, J HEAD TRAUMA REHAB, V26, P202, DOI 10.1097/HTR.0b013e318217b46d; Wood S, 2000, AM J GERIAT PSYCHIAT, V8, P75, DOI 10.1097/00019442-200002000-00010; Wortzel HS, 2008, CNS DRUGS, V22, P531, DOI 10.2165/00023210-200822070-00001; Wortzel HS, 2013, J AM ACAD PSYCHIATRY, V41, P274; Woyshville MJ, 1999, BIOL PSYCHIAT, V45, P261, DOI 10.1016/S0006-3223(98)00152-8; Wroblewski BA, 1997, BRAIN INJURY, V11, P37, DOI 10.1080/026990597123791; Yang CC, 2013, BRAIN INJURY, V27, P1008, DOI 10.3109/02699052.2013.794975; Yang CC, 2012, BRAIN INJURY, V26, P1185, DOI 10.3109/02699052.2012.666374; Yang CC, 2011, BRAIN IMPAIR, V12, P200; Yody BB, 2000, J HEAD TRAUMA REHAB, V15, P1041, DOI 10.1097/00001199-200008000-00006; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35; Yudofsky SC, 1985, PSYCHIATRY UPDATE, V4, P142; Zeilig G, 1996, BRAIN INJURY, V10, P591, DOI 10.1080/026990596124160	188	89	93	1	45	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0193-953X	1558-3147		PSYCHIAT CLIN N AM	Psychiatr. Clin. North Amer.	MAR	2014	37	1					31	+		10.1016/j.psc.2013.12.001			24	Psychiatry	Social Science Citation Index (SSCI)	Psychiatry	AD8UM	WOS:000333541200004	24529422				2022-02-06	
J	Danielyan, L; Beer-Hammer, S; Stolzing, A; Schafer, R; Siegel, G; Fabian, C; Kahle, P; Biedermann, T; Lourhmati, A; Buadze, M; Novakovic, A; Proksch, B; Gleiter, CH; Frey, WH; Schwab, M				Danielyan, Lusine; Beer-Hammer, Sandra; Stolzing, Alexandra; Schaefer, Richard; Siegel, Georg; Fabian, Claire; Kahle, Philipp; Biedermann, Tilo; Lourhmati, Ali; Buadze, Marine; Novakovic, Ana; Proksch, Barbara; Gleiter, Christoph H.; Frey, William H., II; Schwab, Matthias			Intranasal Delivery of Bone Marrow-Derived Mesenchymal Stem Cells, Macrophages, and Microglia to the Brain in Mouse Models of Alzheimer's and Parkinson's Disease	CELL TRANSPLANTATION			English	Article						Intranasal; Mesenchymal stem cells (MSCs); Macrophages; Alzheimer's disease; Parkinson's disease; Amyloid beta (A beta)	CENTRAL-NERVOUS-SYSTEM; AMYLOID-BETA; ALPHA-SYNUCLEIN; RAT MODEL; ERYTHROPOIETIN RECEPTOR; DOPAMINERGIC-NEURONS; COGNITIVE FUNCTIONS; IMMUNE-RESPONSE; TRANSGENIC MICE; STROMAL CELLS	In view of the rapid preclinical development of cell-based therapies for neurodegenerative disorders, traumatic brain injury, and tumors, the safe and efficient delivery and targeting of therapeutic cells to the central nervous system is critical for maintaining therapeutic efficacy and safety in the respective disease models. Our previous data demonstrated therapeutically efficacious and targeted delivery of mesenchymal stem cells (MSCs) to the brain in the rat 6-hydroxydopamine model of Parkinson's disease (PD). The present study examined delivery of bone marrow-derived MSCs, macrophages, and microglia to the brain in a transgenic model of PD [(Thyl)-h[A30P] alpha S] and an APP/PS1 model of Alzheimer's disease (AD) via intranasal application (INA). INA of microglia in naive BL/6 mice led to targeted and effective delivery of cells to the brain. Quantitative PCR analysis of eGFP DNA showed that the brain contained the highest amount of eGFP-microglia (up to 2.1 x 10(4)) after INA of lx 10(6) cells, while the total amount of cells detected in peripheral organs did not exceed 3.4x 10(3). Seven days after INA, MSCs expressing eGFP were detected in the olfactory bulb (OB), cortex, arnygdala, striatum, hippocampus, cerebellum, and brainstem of (Thyl)-h[A30P] alpha S transgenic mice, showing predominant distribution within the OB and brainstem. INA of eGFP-expressing macrophages in 13-month-old APP/PS1 mice led to delivery of cells to the OB, hippocampus, cortex, and cerebellum. Both MSCs and macrophages contained lba-1-positive population of small microglia-like cells and Iba-1-negative large rounded cells showing either intracellular amyloid beta (macrophages in APP/PS1 model) or alpha-synuclein [MS Cs in (Thyl)-h[A30P] alpha S model] immunoreactivity. Here, we show, for the first time, intranasal delivery of cells to the brain of transgenic PD and AD mouse models. Additional work is needed to determine the optimal dosage (single treatment regimen or repeated administrations) to achieve functional improvement in these mouse models with intranasal microglia/macrophages and MSCs. This manuscript is published as part of the International Association of Neurorestoratology (IANR) special issue of Cell Transplantation.	[Danielyan, Lusine; Lourhmati, Ali; Buadze, Marine; Proksch, Barbara; Gleiter, Christoph H.; Schwab, Matthias] Univ Tubingen, Eberhard Karls Univ Hosp & Clin, Dept Clin Pharmacol, D-72076 Tubingen, Germany; [Danielyan, Lusine; Beer-Hammer, Sandra; Lourhmati, Ali; Buadze, Marine; Novakovic, Ana; Proksch, Barbara; Gleiter, Christoph H.; Schwab, Matthias] Univ Tubingen, Interfac Ctr Pharmacogen & Drug Res, D-72076 Tubingen, Germany; [Beer-Hammer, Sandra; Novakovic, Ana] Univ Tubingen, Eberhard Karls Univ Hosp & Clin, Inst Expt & Clin Pharmacol & Toxicol, Dept Pharmacol & Expt Therapy, D-72076 Tubingen, Germany; [Stolzing, Alexandra; Fabian, Claire] Fraunhofer Inst Cell Therapy & Immunol, Dept Cell Therapy Stem Cell Biol, Leipzig, Germany; [Stolzing, Alexandra; Fabian, Claire] Fraunhofer Inst Cell Therapy & Immunol, Regenerat Unit, Leipzig, Germany; [Schaefer, Richard] Johann Wolfgang Goethe Univ Hosp, German Red Cross Blood Donor Serv Baden Wuttember, Inst Transfus Med & Immunohaematol, Dept Cell Therapeut & Cell Proc, Frankfurt, Germany; [Schaefer, Richard; Siegel, Georg] Univ Tubingen Hosp, Inst Clin & Expt Transfus Med IKET, Tubingen, Germany; [Kahle, Philipp] Univ Tubingen, Fac Med, Hertie Inst Clin Brain Res, Dept Neurodegenerat, D-72076 Tubingen, Germany; [Kahle, Philipp] Univ Tubingen, Fac Med, German Ctr Neurodegenerat Dis, D-72076 Tubingen, Germany; [Biedermann, Tilo] Univ Tubingen, Dept Dermatol, D-72076 Tubingen, Germany; [Frey, William H., II] Reg Hosp, Alzheimers Res Ctr, HealthPartners Ctr Memory & Aging, St Paul, MN USA; [Schwab, Matthias] Univ Tubingen, Dr Margarete FischerBosch Inst Clin Pharmacol, Stuttgart, Germany		Danielyan, L (corresponding author), Univ Tubingen, Eberhard Karls Univ Hosp & Clin, Dept Clin Pharmacol, Morgenstelle 8, D-72076 Tubingen, Germany.	lusine.danielyan@med.uni-tuebingen.de	Beer-Hammer, Sandra/AAK-4516-2020; Schwab, Matthias/ABH-7449-2020; Stolzing, Alexandra/S-4208-2019; Stolzing, Alexandra/O-7815-2016	Beer-Hammer, Sandra/0000-0001-6049-0257; Stolzing, Alexandra/0000-0002-2975-5736; Stolzing, Alexandra/0000-0002-2975-5736	Applied Clinical Research Program (AKF) [295-0-0]; Interfaculty Centre for Pharmacogenomics and Pharma Research (ICEPHA) grant from the Faculty of Medicine, University of Tubingen	We wish to thank Cornelia Grimmel (FACS core facility of the interdisciplinary center for clinical research of the University Hospital of Tubingen) and Claudia Muller for excellent technical assistance and advice on data analyses. This work was supported by Applied Clinical Research Program (AKF No. 295-0-0) and the Interfaculty Centre for Pharmacogenomics and Pharma Research (ICEPHA) grant from the Faculty of Medicine, University of Tubingen. W.H.F, L.D., and C.H.F own the patent on intranasal delivery of cells to the brain (Methods, pharmaceutical compositions, and articles of manufacture for administering therapeutic cells to the animal central nervous system. March 2009: WO/2009/035901). Authors declare no other conflict of interest for this work.	Arabpoor Zohreh, 2012, Adv Biomed Res, V1, P50, DOI 10.4103/2277-9175.100157; Assaraf MI, 2007, J NEUROPATH EXP NEUR, V66, P389, DOI 10.1097/nen.0b013e3180517b28; Avagyan H, 2009, J NEUROIMMUNOL, V210, P67, DOI 10.1016/j.jneuroim.2009.02.015; Balyasnikova IV, 2014, MOL THER, V22, P140, DOI 10.1038/mt.2013.199; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Barker RA, 1996, EXP NEUROL, V141, P79, DOI 10.1006/exnr.1996.0141; Beraud D, 2013, J NEUROIMMUNE PHARM, V8, P94, DOI 10.1007/s11481-012-9401-0; Blesch A, 1996, CLIN NEUROSCI, V3, P268; Bossolasco P, 2012, INT J NANOMED, V7, P435, DOI 10.2147/IJN.S27537; Calvo A, 2010, CNS NEUROL DISORD-DR, V9, P325, DOI 10.2174/187152710791292657; Camp DM, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-17; Chapman CD, 2013, PHARM RES-DORDR, V30, P2475, DOI 10.1007/s11095-012-0915-1; Chien YW, 1989, NASAL SYSTEMIC DRUG, P1; Coyne TM, 2007, TRANSPLANTATION, V84, P1507, DOI 10.1097/01.tp.0000288185.09601.4d; Coyne TM, 2006, STEM CELLS, V24, P2483, DOI 10.1634/stemcells.2006-0174; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Danielyan L, 2005, EUR J CELL BIOL, V84, P907, DOI 10.1016/j.ejcb.2005.07.001; Danielyan L, 2005, EUR J CELL BIOL, V84, P567, DOI 10.1016/j.ejcb.2004.12.030; Danielyan L, 2009, CELL DEATH DIFFER, V16, P1599, DOI 10.1038/cdd.2009.95; Danielyan L, 2011, REJUV RES, V14, P3, DOI 10.1089/rej.2010.1130; Danielyan L, 2009, EUR J CELL BIOL, V88, P315, DOI 10.1016/j.ejcb.2009.02.001; Dhuria SV, 2010, J PHARM SCI-US, V99, P1654, DOI 10.1002/jps.21924; Donega V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051253; Ehrenreich H, 2007, MOL PSYCHIATR, V12, P206, DOI 10.1038/sj.mp.4001907; El Khoury J, 2007, NAT MED, V13, P432, DOI 10.1038/nm1555; Fiala M, 2007, P NATL ACAD SCI USA, V104, P12849, DOI 10.1073/pnas.0701267104; FINSEN BR, 1991, J NEUROIMMUNOL, V32, P159, DOI 10.1016/0165-5728(91)90008-U; Fransson M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-112; FREY WH, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P329; Gonzalez FF, 2007, DEV NEUROSCI-BASEL, V29, P321, DOI 10.1159/000105473; Grathwohl SA, 2009, NAT NEUROSCI, V12, P1361, DOI 10.1038/nn.2432; Gutierrez-Fernandez M, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt159; Hawkes CA, 2009, P NATL ACAD SCI USA, V106, P1261, DOI 10.1073/pnas.0805453106; Hinze A, 2012, J INFLAMM-LOND, V9, DOI 10.1186/1476-9255-9-12; Hussain A A, 1989, Prog Clin Biol Res, V292, P261; Iwai M, 2007, STROKE, V38, P2795, DOI 10.1161/STROKEAHA.107.483008; Joyce N, 2010, REGEN MED, V5, P933, DOI 10.2217/RME.10.72; Kadota T, 2009, BRAIN RES, V1254, P120, DOI 10.1016/j.brainres.2008.11.094; Kahle PJ, 2001, AM J PATHOL, V159, P2215, DOI 10.1016/S0002-9440(10)63072-6; Karussis D, 2006, CLIN NEUROL NEUROSUR, V108, P250, DOI 10.1016/j.clineuro.2005.11.007; Kitada M, 2012, PARKINSONS DIS-US, V2012, DOI 10.1155/2012/873706; Koenigsknecht-Talboo J, 2008, J NEUROSCI, V28, P14156, DOI 10.1523/JNEUROSCI.4147-08.2008; Kozlowska H, 2007, STEM CELLS DEV, V16, P481, DOI 10.1089/scd.2007.9993; Lappalainen RS, 2008, NEUROSCI LETT, V440, P246, DOI 10.1016/j.neulet.2008.05.090; Lee HJ, 2010, J BIOL CHEM, V285, P9262, DOI 10.1074/jbc.M109.081125; Lee JK, 2010, STEM CELLS, V28, P329, DOI 10.1002/stem.277; Lee ST, 2012, J NEUROCHEM, V120, P115, DOI 10.1111/j.1471-4159.2011.07534.x; Liu Y, 2005, BRAIN, V128, P1778, DOI 10.1093/brain/awh531; Lochhead JJ, 2012, ADV DRUG DELIVER REV, V64, P614, DOI 10.1016/j.addr.2011.11.002; Lomoio S, 2012, J ALZHEIMERS DIS, V31, P285, DOI 10.3233/JAD-2012-112198; Lourhmati A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077182; Maurice T, 2013, J PSYCHOPHARMACOL, V27, P1044, DOI 10.1177/0269881113494939; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; McLaurin J, 2002, NAT MED, V8, P1263, DOI 10.1038/nm790; Neumann M, 2002, J CLIN INVEST, V110, P1429, DOI 10.1172/JC1200215777; Pendharkar AV, 2010, STROKE, V41, P2064, DOI 10.1161/STROKEAHA.109.575993; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; Ramot Y, 2010, NANOTOXICOLOGY, V4, P98, DOI 10.3109/17435390903470093; Reitz M, 2012, STEM CELL TRANSL MED, V1, P866, DOI 10.5966/sctm.2012-0045; Saresella M, 2014, J ALZHEIMERS DIS, V38, P403, DOI 10.3233/JAD-131160; Sargin D, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-27; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; SINDEN JD, 1992, CURR OPIN NEUROL NEU, V5, P902; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Steiner B, 2012, NEUROSCI LETT, V513, P25, DOI 10.1016/j.neulet.2012.01.078; Stemberger S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019808; Thorne RG, 2004, NEUROSCIENCE, V127, P481, DOI 10.1016/j.neuroscience.2004.05.029; Town T, 2008, NAT MED, V14, P681, DOI 10.1038/nm1781; Tuszynski MH, 2005, NAT MED, V11, P551, DOI 10.1038/nm1239; TUSZYNSKI MH, 1995, P NATL ACAD SCI USA, V92, P4621, DOI 10.1073/pnas.92.10.4621; van Velthoven CTJ, 2010, PEDIATR RES, V68, P419, DOI 10.1203/PDR.0b013e3181f1c289; Walker PA, 2009, STEM CELL REV REP, V5, P283, DOI 10.1007/s12015-009-9081-1; Wang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054296; Wei N, 2013, CELL TRANSPLANT, V22, P977, DOI 10.3727/096368912X657251; Wu Shuai, 2013, J Clin Cell Immunol, V4, DOI 10.4172/2155-9899.1000142; Xue YQ, 2010, GENE THER, V17, P83, DOI 10.1038/gt.2009.113; Yagi H, 2010, CELL TRANSPLANT, V19, P667, DOI 10.3727/096368910X508762; Yang B, 2013, STROKE, V44, P3463, DOI 10.1161/STROKEAHA.111.000821; Zaghi J, 2009, ACTA NEUROPATHOL, V117, P111, DOI 10.1007/s00401-008-0481-0	79	89	91	0	16	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2014	23			1			S123	S139		10.3727/096368914X684970			17	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Research & Experimental Medicine; Transplantation	AY9KT	WOS:000347869500014	25302802	Green Published			2022-02-06	
J	Crupi, R; Marino, A; Cuzzocrea, S				Crupi, R.; Marino, A.; Cuzzocrea, S.			n-3 Fatty Acids: Role in Neurogenesis and Neuroplasticity	CURRENT MEDICINAL CHEMISTRY			English	Article						n-3 fatty acids; dentate gyrus; neurogenesis; synaptic plasticity	DIETARY DOCOSAHEXAENOIC ACID; DENDRITIC SPINE DENSITY; TRAUMATIC BRAIN-INJURY; AGE-RELATED-CHANGES; EICOSAPENTAENOIC ACID; DOUBLE-BLIND; AMYLOID-BETA; NEURODEGENERATIVE DISEASES; HIPPOCAMPAL NEUROGENESIS; ALZHEIMERS-DISEASE	Omega-3 polyunsaturated fatty acids (PUFA) are essential unsaturated fatty acids with a double bond (C=C) starting after the third carbon atom from the end of the carbon chain. They are important nutrients but, unfortunately, mammals cannot synthesize them, whereby they must be obtained from food sources or from supplements. Amongst nutritionally important polyunsaturated n-3 fatty acids, alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are highly concentrated in the brain and have anti-oxidative stress, anti-inflammatory and antiapoptotic effects. They are involved in many bodily processes and may reportedly lead to neuron protection in neurological diseases. aged or damaged neurons and in Alzheimer's disease. Their effect in cognitive and behavioral functions and in several neurological and psychiatric disorders has been also proven. The dentate gyrus (DG), a sub-region of hippocampus, is implicated in cognition and mood regulation. The hippocampus represents one of the two areas in the mammalian brain in which adult neurogenesis occurs. This process is associated with beneficial effects on cognition, mood and chronic pharmacological treatment. The exposure to n-3 fatty acids enhances adult hippocampal neurogenesis associated with cognitive and behavioral processes, promotes synaptic plasticity by increasing long-term potentiation and modulates synaptic protein expression to stimulate the dendritic arborization and new spines formation. On this basis we review the effect of n-3 fatty acids on adult hippocampal neurogenesis and neuroplasticity. Moreover their possible use as a new therapeutic approach for neurodegenerative diseases is pointed out.	[Crupi, R.; Cuzzocrea, S.] Univ Messina, Policlin Univ, Sch Med, Inst Pharmacol, I-98123 Messina, Italy; [Marino, A.] Univ Messina, Sect Gen Physiol & Pharmacol, Dept Life Sci M Malpighi, I-98166 Messina, Italy; [Cuzzocrea, S.] Univ Manchester, Manchester M13 9PL, Lancs, England		Cuzzocrea, S (corresponding author), Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Torre Biol Policlin Univ Via C Valeria Gazzi, I-98100 Messina, Italy.	salvator@unime.it	Crupi, Rosalia/U-4364-2019	Crupi, Rosalia/0000-0002-7629-3132; Cuzzocrea, Salvatore/0000-0001-6131-3690			Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; Alonso M, 2004, LEARN MEMORY, V11, P172, DOI 10.1101/lm.67804; Baldelli P, 2007, J NEUROSCI, V27, P13520, DOI 10.1523/JNEUROSCI.3151-07.2007; Bate C, 2008, NEUROPHARMACOLOGY, V54, P934, DOI 10.1016/j.neuropharm.2008.02.003; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; Beltz BS, 2007, NEUROSCI LETT, V415, P154, DOI 10.1016/j.neulet.2007.01.010; Beltz BS, 2003, ARTHROPOD STRUCT DEV, V32, P39, DOI 10.1016/S1467-8039(03)00038-0; Bertrand PC, 2006, J NUTR, V136, P1570, DOI 10.1093/jn/136.6.1570; Bhatia HS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028451; Blanpied TA, 2004, BIOL PSYCHIAT, V55, P1121, DOI 10.1016/j.biopsych.2003.10.006; BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83; Bourre JM, 2006, J NUTR HEALTH AGING, V10, P386; Bousquet M, 2008, FASEB J, V22, P1213, DOI 10.1096/fj.07-9677com; Bremner JD, 2000, AM J PSYCHIAT, V157, P115, DOI 10.1176/ajp.157.1.115; Brenna JT, 2002, CURR OPIN CLIN NUTR, V5, P127, DOI 10.1097/00075197-200203000-00002; Calon F, 2004, NEURON, V43, P633, DOI 10.1016/j.neuron.2004.08.013; Calon F, 2007, PROSTAG LEUKOTR ESS, V77, P287, DOI 10.1016/j.plefa.2007.10.019; Cansev M, 2008, ALZHEIMERS DEMENT, V4, pS153, DOI 10.1016/j.jalz.2007.10.005; Cao DH, 2009, J NEUROCHEM, V111, P510, DOI 10.1111/j.1471-4159.2009.06335.x; Chalon S, 2001, LIPIDS, V36, P937, DOI 10.1007/s11745-001-0804-7; Chen G, 2000, J NEUROCHEM, V75, P1729, DOI 10.1046/j.1471-4159.2000.0751729.x; Chen H, 2003, AM J EPIDEMIOL, V157, P1007, DOI 10.1093/aje/kwg073; Chiu CC, 2008, PROG NEURO-PSYCHOPH, V32, P1538, DOI 10.1016/j.pnpbp.2008.05.015; Cline HT, 2001, CURR OPIN NEUROBIOL, V11, P118, DOI 10.1016/S0959-4388(00)00182-3; Connor WE, 2000, AM J CLIN NUTR, V71, p171S, DOI 10.1093/ajcn/71.1.171S; CRAWFORD MA, 1968, P ROY SOC MED, V61, P159, DOI 10.1177/003591576806100217; Crupi R, 2012, PREV MED, V54, pS103, DOI 10.1016/j.ypmed.2011.12.019; de Lau LML, 2005, NEUROLOGY, V64, P2040, DOI 10.1212/01.WNL.0000166038.67153.9F; Deneris ES, 2011, NEUROSCIENCE, V197, P17, DOI 10.1016/j.neuroscience.2011.08.061; Dyall SC, 2007, NEUROBIOL AGING, V28, P424, DOI 10.1016/j.neurobiolaging.2006.01.002; EATON SB, 1985, NEW ENGL J MED, V312, P283, DOI 10.1056/NEJM198501313120505; Fahy E, 2005, J LIPID RES, V46, P839, DOI 10.1194/jlr.E400004-JLR200; Freeman M P, 2000, Ann Clin Psychiatry, V12, P159, DOI 10.1023/A:1009069002816; Fujita S, 2001, BRIT J PHARMACOL, V132, P1417, DOI 10.1038/sj.bjp.0703970; Fukaya T, 2007, NEUROBIOL AGING, V28, P1179, DOI 10.1016/j.neurobiolaging.2006.05.023; Futerman AH, 1996, TRENDS NEUROSCI, V19, P144, DOI 10.1016/S0166-2236(96)80025-7; Candela CG, 2011, NUTR HOSP, V26, P323, DOI [10.1590/S0212-16112011000200013, 10.3305/nh.2011.26.2.5117]; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; Green KN, 2007, J NEUROSCI, V27, P4385, DOI 10.1523/JNEUROSCI.0055-07.2007; Green P, 1999, J LIPID RES, V40, P960; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Grosshans DR, 2002, NAT NEUROSCI, V5, P27, DOI 10.1038/nn779; Haastrup E, 2012, J NEUROIMMUNOL, V243, P69, DOI 10.1016/j.jneuroim.2011.12.006; Harzsch S, 1999, J NEUROSCI, V19, P3472; Hashimoto M, 2011, FOOD FUNCT, V2, P386, DOI 10.1039/c1fo00002k; Hashimoto M, 2009, J NUTR BIOCHEM, V20, P965, DOI 10.1016/j.jnutbio.2008.08.009; He CW, 2009, P NATL ACAD SCI USA, V106, P11370, DOI 10.1073/pnas.0904835106; Hibbeln JR, 1998, LANCET, V351, P1213, DOI 10.1016/S0140-6736(05)79168-6; Hibbeln JR, 1998, BIOL PSYCHIAT, V44, P243, DOI 10.1016/S0006-3223(98)00143-7; Jacobs BL, 2002, BRAIN BEHAV IMMUN, V16, P602, DOI 10.1016/S0889-1591(02)00015-6; KALTSCHMIDT B, 1993, MOL ASPECTS MED, V14, P171, DOI 10.1016/0098-2997(93)90004-W; Kan I, 2007, J LIPID RES, V48, P513, DOI 10.1194/jlr.C600022-JLR200; Kashiyae Y, 2009, NEUROSCI RES, V64, P143, DOI 10.1016/j.neures.2009.02.008; Kawakita E, 2006, NEUROSCIENCE, V139, P991, DOI 10.1016/j.neuroscience.2006.01.021; KELLEY VE, 1985, J IMMUNOL, V134, P1914; Kerchner GA, 2008, NAT REV NEUROSCI, V9, P813, DOI 10.1038/nrn2501; Kim HY, 2000, J BIOL CHEM, V275, P35215, DOI 10.1074/jbc.M004446200; KINSELLA JE, 1990, JPEN-PARENTER ENTER, V14, pS200, DOI 10.1177/014860719001400511; Lakhan SE, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-97; Lang-Lazdunski L, 2003, J VASC SURG, V38, P564, DOI 10.1016/S0741-5214(03)00473-7; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; Lim SN, 2010, PROSTAG LEUKOTR ESS, V83, P193, DOI 10.1016/j.plefa.2010.08.003; Lim SY, 2000, INT J VITAM NUTR RES, V70, P251, DOI 10.1024/0300-9831.70.5.251; Lukiw WJ, 2008, J NUTR, V138, P2510, DOI 10.3945/jn.108.096016; Maes M, 1996, J AFFECT DISORDERS, V38, P35, DOI 10.1016/0165-0327(95)00092-5; Matsuoka Y, 2011, BIOPSYCHOSOC MED, V5, DOI 10.1186/1751-0759-5-3; McGahon BM, 1999, NEUROBIOL AGING, V20, P655, DOI 10.1016/S0197-4580(99)00050-0; McGahon BM, 1999, NEUROSCIENCE, V94, P305, DOI 10.1016/S0306-4522(99)00219-5; Mills JD, 2011, NEUROSURGERY, V68, P474, DOI 10.1227/NEU.0b013e3181ff692b; Minogue AM, 2007, J NEUROCHEM, V103, P914, DOI 10.1111/j.1471-4159.2007.04848.x; Nakamura MT, 2003, PROSTAG LEUKOTR ESS, V68, P145, DOI 10.1016/S0952-3278(02)00264-8; Nemets H, 2006, AM J PSYCHIAT, V163, P1098, DOI 10.1176/appi.ajp.163.6.1098; Oertner TG, 2005, CELL CALCIUM, V37, P477, DOI 10.1016/j.ceca.2005.01.016; Orr SK., 2012, PROSTAGLANDINS LEUKO; Peet M, 1998, BIOL PSYCHIAT, V43, P315, DOI 10.1016/S0006-3223(97)00206-0; Peet M, 1996, PROSTAG LEUKOTR ESS, V55, P71, DOI 10.1016/S0952-3278(96)90148-9; Peet M, 2001, SCHIZOPHR RES, V49, P243, DOI 10.1016/S0920-9964(00)00083-9; Rapoport SI, 2001, J LIPID RES, V42, P678; Riedel M, 2011, J MOL NEUROSCI, V43, P290, DOI 10.1007/s12031-010-9439-5; Sahay A, 2007, NAT NEUROSCI, V10, P1110, DOI 10.1038/nn1969; Sakamoto T, 2007, BRAIN RES, V1182, P50, DOI 10.1016/j.brainres.2007.08.089; Samadikuchaksaraei A, 2007, J NEUROENG REHABIL, V4, DOI 10.1186/1743-0003-4-15; Shahbakhti H, 2004, PHOTOCHEM PHOTOBIOL, V80, P231, DOI 10.1562/2004-01-27-RA-066.1; Shrivastava R, 2005, NUTR NEUROSCI, V8, P317, DOI 10.1080/10284150500510242; Simopoulos AP, 2006, BIOMED PHARMACOTHER, V60, P502, DOI 10.1016/j.biopha.2006.07.080; Simopoulos A P, 1995, World Rev Nutr Diet, V77, P47; Simopoulos AP, 2000, POULTRY SCI, V79, P961, DOI 10.1093/ps/79.7.961; Simopoulos AP, 2008, EXP BIOL MED, V233, P674, DOI 10.3181/0711-MR-311; Song C, 1998, J AFFECT DISORDERS, V49, P211, DOI 10.1016/S0165-0327(98)00025-1; Song C, 2007, EXPERT OPIN INV DRUG, V16, P1627, DOI 10.1517/13543784.16.10.1627; Sprecher H, 2000, BBA-MOL CELL BIOL L, V1486, P219, DOI 10.1016/S1388-1981(00)00077-9; Stoll AL, 1999, ARCH GEN PSYCHIAT, V56, P407, DOI 10.1001/archpsyc.56.5.407; Strokin M, 2006, NEUROSCIENCE, V140, P547, DOI 10.1016/j.neuroscience.2006.02.026; Su HM, 2010, J NUTR BIOCHEM, V21, P364, DOI 10.1016/j.jnutbio.2009.11.003; Tanabe Y, 2004, CLIN EXP PHARMACOL P, V31, P700, DOI 10.1111/j.1440-1681.2004.04068.x; Venna VR, 2009, PSYCHONEUROENDOCRINO, V34, P199, DOI 10.1016/j.psyneuen.2008.08.025; Wada T, 2006, BIOL PHARM BULL, V29, P49, DOI 10.1248/bpb.29.49; Wang PY, 2010, J NUTR BIOCHEM, V21, P345, DOI 10.1016/j.jnutbio.2009.01.012; Ward RE, 2010, J NEUROTRAUM, V27, P1769, DOI 10.1089/neu.2010.1348; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Yamashima T, 2008, PROG NEUROBIOL, V84, P105, DOI 10.1016/j.pneurobio.2007.11.002; YOREK M, 1989, INVEST OPHTH VIS SCI, V30, P2087; Youdim KA, 2000, INT J DEV NEUROSCI, V18, P383, DOI 10.1016/S0736-5748(00)00013-7	105	89	91	0	91	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	0929-8673	1875-533X		CURR MED CHEM	Curr. Med. Chem.	AUG	2013	20	24					2953	2963		10.2174/09298673113209990140			11	Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Pharmacology & Pharmacy	179XU	WOS:000321556900002	23746276				2022-02-06	
J	Dashnaw, ML; Petraglia, AL; Bailes, JE				Dashnaw, Matthew L.; Petraglia, Anthony L.; Bailes, Julian E.			An overview of the basic science of concussion and subconcussion: where we are and where we are going	NEUROSURGICAL FOCUS			English	Article						concussion; subconcussion; traumatic brain injury; chronic traumatic encephalopathy; pathophysiology	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; FLUID-PERCUSSION INJURY; CLOSED-HEAD INJURY; AXONAL INJURY; DIFFUSION TENSOR; MITOCHONDRIAL DYSFUNCTION; MOUSE MODEL; COGNITIVE IMPAIRMENT; NEUROLOGIC FUNCTION	There has been a growing interest in the diagnosis and management of mild traumatic brain injury (TBI), or concussion. Repetitive concussion and subconcussion have been linked to a spectrum of neurological sequelae, including postconcussion syndrome, chronic traumatic encephalopathy, mild cognitive impairment, and dementia pugilistica. A more common risk than chronic traumatic encephalopathy is the season-ending or career-ending effects of concussion or its mismanagement. To effectively prevent and treat the sequelae of concussion, it will be important to understand the basic processes involved. Reviewed in this paper are the forces behind the primary phase of injury in mild TBI, as well as the immediate and delayed cellular events responsible for the secondary phase of injury leading to neuronal dysfunction and possible cell death. Advanced neuroimaging sequences have recently been developed that have the potential to increase the sensitivity of standard MRI to detect both structural and functional abnormalities associated with concussion, and have provided further insight into the potential underlying pathophysiology. Also discussed are the potential long-term effects of repetitive mild TBI, particularly chronic traumatic encephalopathy. Much of the data regarding this syndrome is limited to postmortem analyses, and at present there is no animal model of chronic traumatic encephalopathy described in the literature. As this arena of TBI research continues to evolve, it will be imperative to appropriately model concussive and even subconcussive injuries in an attempt to understand, prevent, and treat the associated chronic neurodegenerative sequelae. (http://thejns.org/doi/abs/10.3171/2012.10.FOCUS12284)	[Dashnaw, Matthew L.; Petraglia, Anthony L.] Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, NY 14642 USA; [Bailes, Julian E.] Univ Chicago, Pritzker Sch Med, Dept Neurosurg, NorthShore Univ Hlth Syst, Evanston, IL USA		Petraglia, AL (corresponding author), Univ Rochester, Med Ctr, Dept Neurosurg, 601 Elmwood Ave,Box 670, Rochester, NY 14642 USA.	anthony_petraglia@urmc.rochester.edu					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; ANDREW RD, 1991, J NEUROL SCI, V101, P7, DOI 10.1016/0022-510X(91)90013-W; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Conte V, 2004, J NEUROCHEM, V90, P758, DOI 10.1111/j.1471-4159.2004.02560.x; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DOEZEMA D, 1991, ANN EMERG MED, V20, P1281, DOI 10.1016/S0196-0644(05)81065-0; Engel S, 1996, Acta Neurochir Suppl, V66, P89; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859, DOI 10.1152/ajpheart.1997.272.6.H2859; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Hootman JM, 2007, J ATHL TRAINING, V42, P311; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Kalimo H, 1981, Acta Neuropathol Suppl, V7, P20; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Khuman J, 2011, J CEREBR BLOOD F MET, V31, P778, DOI 10.1038/jcbfm.2010.172; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Luther N, 2012, NEUROSURGERY, V71, pE558, DOI 10.1227/01.neu.0000417733.09300.04; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Maruta J, 2010, ANN NY ACAD SCI, V1208, P58, DOI 10.1111/j.1749-6632.2010.05695.x; MASUZAWA H, 1976, Neurologia Medico-Chirurgica, V16, P77, DOI 10.2176/nmc.16pt1.77; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCullough BJ, 2011, PHYS MED REH CLIN N, V22, P635, DOI 10.1016/j.pmr.2011.08.005; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Mills JD, 2011, NEUROSURGERY, V68, P474, DOI 10.1227/NEU.0b013e3181ff692b; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; Nakajima Y, 2010, TOHOKU J EXP MED, V221, P229, DOI 10.1620/tjem.221.229; NAKAMURA Y, 1990, BIOCHEM BIOPH RES CO, V169, P744, DOI 10.1016/0006-291X(90)90394-3; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; NIXON RA, 1993, BRAIN PATHOL, V3, P29, DOI 10.1111/j.1750-3639.1993.tb00723.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1973, J NEUROSURG, V39, P152, DOI 10.3171/jns.1973.39.2.0152; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.3.CO;2-G; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; ROSEN AS, 1990, NEUROSCIENCE, V38, P579, DOI 10.1016/0306-4522(90)90052-6; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; SALY V, 1993, J NEUROPHYSIOL, V69, P2200, DOI 10.1152/jn.1993.69.6.2200; SASS DJ, 1971, J BIOMECH, V4, P331, DOI 10.1016/0021-9290(71)90054-6; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Schwartzkroin PA, 1998, EPILEPSY RES, V32, P275, DOI 10.1016/S0920-1211(98)00058-8; SEKINO H, 1980, Neurologia Medico-Chirurgica, V20, P127; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Shultz SR, 2012, BEHAV BRAIN RES, V229, P145, DOI 10.1016/j.bbr.2011.12.015; Smith DW, 2012, NEUROSURGERY, V70, P740, DOI 10.1227/NEU.0b013e318235b991; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; Talavage TM, 2010, J NEUROTRAUMA; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YARNELL P, 1969, B NEW YORK ACAD MED, V45, P39; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	110	89	89	0	60	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	DEC	2012	33	6							E5	10.3171/2012.10.FOCUS12284			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	048GI	WOS:000311898500006	23199428	Bronze			2022-02-06	
J	Zonfrillo, MR; Master, CL; Grady, MF; Winston, FK; Callahan, JM; Arbogast, KB				Zonfrillo, Mark R.; Master, Christina L.; Grady, Matthew F.; Winston, Flaura K.; Callahan, James M.; Arbogast, Kristy B.			Pediatric Providers' Self-Reported Knowledge, Practices, and Attitudes About Concussion	PEDIATRICS			English	Article						concussion; mild traumatic brain injury; primary care; emergency medicine	TRAUMATIC BRAIN-INJURY; PRIMARY-CARE; SPORT; EDUCATION; SUPPORT; SCHOOL; PLAY; POPULATION; MANAGEMENT; COACHES	OBJECTIVE: To determine the self-reported practices and attitudes surrounding concussion diagnosis and management in a single, large pediatric care network. METHODS: A cross-sectional survey was distributed to pediatric primary care and emergency medicine providers in a single, large pediatric care network. For all survey participants, practices and attitudes about concussion diagnosis and treatment were queried. RESULTS: There were 145 responses from 276 eligible providers, resulting in a 53% response rate, of which 91% (95% confidence interval [CI]: 86%-95%) had cared for at least 1 concussion patient in the previous 3 months. A Likert scale from 1 "not a barrier" to 5 "significant barrier" was used to assess providers' barriers to educating families about the diagnosis of concussion. Providers selected 4 or 5 on the scale for the following barriers and frequencies: inadequate training to educate 16% (95% CI: 11%-23%), inadequate time to educate 15% (95% CI: 12%-24%), and not my role to educate 1% (95% CI: 0.4%-5%). Ninety-six percent (95% CI: 91%-98%) of providers without a provider decision support tool (such as a clinical pathway or protocol) specific to concussion, and 100% (95% CI: 94%-100%) of providers without discharge instructions specific to concussion believed these resources would be helpful. CONCLUSIONS: Although pediatric primary care and emergency medicine providers regularly care for concussion patients, they may not have adequate training or infrastructure to systematically diagnose and manage these patients. Specific provider education, decision support tools, and patient information could help enhance and standardize concussion management. Pediatrics 2012;130:1120-1125	[Zonfrillo, Mark R.; Winston, Flaura K.; Arbogast, Kristy B.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.; Callahan, James M.; Arbogast, Kristy B.] Childrens Hosp Philadelphia, Div Emergency Med, Philadelphia, PA 19104 USA; [Master, Christina L.; Grady, Matthew F.] Childrens Hosp Philadelphia, Sports Med & Performance Ctr, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.; Master, Christina L.; Grady, Matthew F.; Winston, Flaura K.; Callahan, James M.; Arbogast, Kristy B.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Winston, Flaura K.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA		Zonfrillo, MR (corresponding author), Childrens Hosp Philadelphia, Div Emergency Med, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	zonfrillo@email.chop.edu	Zonfrillo, Mark R./H-9403-2017	Zonfrillo, Mark R./0000-0002-0610-9563; Master, Christina/0000-0002-6717-4270; Arbogast, Kristy/0000-0002-1694-4562	Children's Hospital of Philadelphia Department of Pediatrics Chair's Initiative	This study was supported by The Children's Hospital of Philadelphia Department of Pediatrics Chair's Initiative.	Ahmed OH, 2010, DISABIL REHABIL, V32, P1877, DOI 10.3109/09638281003734409; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; *CDCP, HEADS CONC YOUTH SPO; Centers for Disease Control and Prevention, CONC MILD TBI; Creighton DW, 2010, CLIN J SPORT MED, V20, P379, DOI 10.1097/JSM.0b013e3181f3c0fe; Demorest RA, 2005, PEDIATRICS, V115, P28, DOI 10.1542/peds.2004-0266; Fiks AG, 2011, CURR PROB PEDIATR AD, V41, P60, DOI 10.1016/j.cppeds.2010.10.006; Fishbein M, 2006, J COMMUN, V56, pS1, DOI 10.1111/j.1460-2466.2006.00280.x; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Grady MF, 2010, CURR PROB PEDIATR AD, V40, P154, DOI 10.1016/j.cppeds.2010.06.002; Hajek CA, 2011, CHILD NEUROPSYCHOL, V17, P17, DOI 10.1080/09297049.2010.495058; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Kaye AJ, 2010, J TRAUMA, V68, P1396, DOI 10.1097/TA.0b013e3181cf7d1b; Langberg JM, 2009, EXPERT REV NEUROTHER, V9, P477, DOI [10.1586/ern.09.5, 10.1586/ERN.09.5]; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Mckinlay A, 2011, BRAIN INJURY, V25, P761, DOI 10.3109/02699052.2011.579935; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Mrazik M, 2011, CLIN J SPORT MED, V21, P315, DOI 10.1097/JSM.0b013e31821e2b78; Pleacher MD, 2006, BRIT J SPORT MED, V40, DOI 10.1136/bjsm.2005.019067; Power TJ, 2008, PEDIATRICS, V121, pE65, DOI 10.1542/peds.2007-0383; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Stevens Penelope K, 2010, J Trauma Nurs, V17, P178, DOI 10.1097/JTN.0b013e3181ff2789; Stevens PK, 2010, J TRAUMA NURS, V17, P183; Sullivan SJ, 2012, BRIT J SPORT MED, V46, P258, DOI 10.1136/bjsm.2010.080341; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; The National Football League, HLTH SAF CONC LEG ST; Walkinshaw E, 2011, CAN MED ASSOC J, V183, pE1047, DOI 10.1503/cmaj.109-3942	31	89	91	0	26	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	DEC	2012	130	6					1120	1125		10.1542/peds.2012-1431			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	087YZ	WOS:000314802000063	23147981				2022-02-06	
J	Dykiert, D; Der, G; Starr, JM; Deary, IJ				Dykiert, Dominika; Der, Geoff; Starr, John M.; Deary, Ian J.			Age Differences in Intra-Individual Variability in Simple and Choice Reaction Time: Systematic Review and Meta-Analysis	PLOS ONE			English	Article							LIFE-STYLE; PERFORMANCE VARIABILITY; COGNITIVE IMPAIRMENT; PUBLICATION BIAS; SEX-DIFFERENCES; HIGH-ALTITUDE; INCONSISTENCY; ATTENTION; HEALTH; SPEED	Background: Intra-individual variability in reaction time (RT IIV) is considered to be an index of central nervous system functioning. Such variability is elevated in neurodegenerative diseases or following traumatic brain injury. It has also been suggested to increase with age in healthy ageing. Objectives: To investigate and quantify age differences in RT IIV in healthy ageing; to examine the effect of different tasks and procedures; to compare raw and mean-adjusted measures of RT IIV. Data Sources: Four electronic databases: PsycINFO, Medline, Web of Science and EMBASE, and hand searching of reference lists of relevant studies. Study Eligibility: English language journal articles, books or book chapters, containing quantitative empirical data on simple and/or choice RT IIV. Samples had to include younger (under 60 years) and older (60 years and above) human adults. Study Appraisal and Synthesis: Studies were evaluated in terms of sample representativeness and data treatment. Relevant data were extracted, using a specially-designed form, from the published report or obtained directly from the study authors. Age-group differences in raw and RT-mean-adjusted measures of simple and choice RT IIV were quantified using random effects meta-analyses. Results: Older adults (60+ years) had greater RT IIV than younger (20-39) and middle-aged (40-59) adults. Age effects were larger in choice RT tasks than in simple RT tasks. For all measures of RT IIV, effect sizes were larger for the comparisons between older and younger adults than between older and middle-aged adults, indicating that the age-related increases in RT IIV are not limited to old age. Effect sizes were also larger for raw than for RT-mean-adjusted RT IIV measures. Conclusions: RT IIV is greater among older adults. Some (but not all) of the age-related increases in RT IIV are accounted for by the increased RT means.	[Dykiert, Dominika; Der, Geoff; Deary, Ian J.] Univ Edinburgh, Dept Psychol, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh, Midlothian, Scotland; [Der, Geoff] MRC, Social & Publ Hlth Sci Unit, Glasgow, Lanark, Scotland; [Starr, John M.] Univ Edinburgh, Geriatr Med Unit, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh, Midlothian, Scotland		Dykiert, D (corresponding author), Univ Edinburgh, Dept Psychol, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh, Midlothian, Scotland.	ddykiert@staffmail.ed.ac.uk	Deary, Ian J/C-6297-2009	Deary, Ian J/0000-0002-1733-263X; Dykiert, Dominika/0000-0002-6050-8223; Der, Geoff/0000-0002-8677-073X	UK Medical Research Council PhD studentshipUK Research & Innovation (UKRI)Medical Research Council UK (MRC); The University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative [G0700704/84698]; Biotechnology and Biological Sciences Research Council (BBSRC)UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC); Engineering and Physical Sciences Research Council (EPSRC)UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC); Economic and Social Research Council (ESRC)UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC); Medical Research Council (MRC)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MC_U130059823, G0700704, MC_UP_A540_1021] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_U130059823, G0700704, G0700704B, MC_UP_A540_1021] Funding Source: researchfish; Chief Scientist Office [SPHSU2] Funding Source: researchfish	Dominika Dykiert was supported by a UK Medical Research Council PhD studentship. The work was undertaken by The University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative (G0700704/84698). Funding from the Biotechnology and Biological Sciences Research Council (BBSRC), Engineering and Physical Sciences Research Council (EPSRC), Economic and Social Research Council (ESRC) and Medical Research Council (MRC) is gratefully acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adam M, 2006, SLEEP, V29, P55, DOI 10.1093/sleep/29.1.55; Anstey KJ, 1999, AGING NEUROPSYCHOL C, V6, P84, DOI 10.1076/anec.6.2.84.786; Anstey KJ, 2005, Q J EXP PSYCHOL-A, V58, P5, DOI 10.1080/02724980443000232; Bherer L, 2006, ACTA PSYCHOL, V123, P261, DOI 10.1016/j.actpsy.2006.01.005; Borenstein M., 2011, INTRO META ANAL, DOI DOI 10.1002/9780470743386; Brebner J., 1980, REACTION TIMES, P1; Bunce D, 2004, BRAIN COGNITION, V56, P320, DOI 10.1016/j.bandc.2004.08.006; Bunce D, 2008, J GERONTOL B-PSYCHOL, V63, pP67, DOI 10.1093/geronb/63.2.P67; Bunce D, 2012, ACCIDENT ANAL PREV, V49, P293, DOI 10.1016/j.aap.2012.01.001; Bunce D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013567; Bunce D, 2008, PSYCHOL AGING, V23, P848, DOI 10.1037/a0013678; Burton CL, 2006, J CLIN EXP NEUROPSYC, V28, P67, DOI 10.1080/13803390490918318; Cherbuin N, 2010, AM J GERIAT PSYCHIAT, V18, P723, DOI 10.1097/JGP.0b013e3181cdecf1; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Deary IJ, 2011, BEHAV RES METHODS, V43, P258, DOI 10.3758/s13428-010-0024-1; Deary IJ, 2005, AGING NEUROPSYCHOL C, V12, P187, DOI 10.1080/13825580590969235; Der G, 2006, PSYCHOL AGING, V21, P62, DOI 10.1037/0882-7974.21.1.62; Dixon RA, 2007, NEUROPSYCHOLOGY, V21, P381, DOI 10.1037/0894-4105.21.3.381; Duchek JM, 2009, NEUROPSYCHOLOGY, V23, P746, DOI 10.1037/a0016583; Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Dykiert D, 2012, DEV PSYCHOL, V48, P1262, DOI 10.1037/a0027550; Finkel D, 2007, EXP AGING RES, V33, P13, DOI 10.1080/03610730601006222; Fontani G, 2004, EUR J APPL PHYSIOL, V92, P452, DOI 10.1007/s00421-004-1108-3; FOZARD JL, 1994, J GERONTOL, V49, pP179, DOI 10.1093/geronj/49.4.P179; FOZARD JL, 1976, J GERONTOL, V31, P556, DOI 10.1093/geronj/31.5.556; Fredric M., 1986, METAANALYSIS QUANTIT; Gooch CM, 2009, AGING NEUROPSYCHOL C, V16, P285, DOI 10.1080/13825580802592771; Gorus E, 2006, AGING CLIN EXP RES, V18, P407, DOI 10.1007/BF03324837; Hendrickson AE, 1982, MODEL INTELLIGENCE, P151, DOI DOI 10.1007/978-3-642-68664-1_6; Hogan MJ, 2003, IRISH J PSYCHOL, V24, P161; Hultsch D. F., 2008, HDB AGING COGNITION, P491, DOI DOI 10.4324/9780203837665.CH10; Hultsch DF, 2002, J GERONTOL B-PSYCHOL, V57, pP101, DOI 10.1093/geronb/57.2.P101; Jackson JD, 2012, NEUROPSYCHOLOGIA, V50, P357, DOI 10.1016/j.neuropsychologia.2011.11.024; LAHTELA K, 1985, SCAND J PSYCHOL, V26, P357, DOI 10.1111/j.1467-9450.1985.tb01175.x; Li SC, 2009, PSYCHOL RES-PSYCH FO, V73, P777, DOI 10.1007/s00426-008-0190-2; MacDonald SWS, 2012, J NEUROSCI, V32, P8186, DOI 10.1523/JNEUROSCI.5474-11.2012; MacDonald SWS, 2003, PSYCHOL AGING, V18, P510, DOI 10.1037/0882-7974.18.3.510; Martin DM, 2009, NEUROPSYCHOLOGY, V23, P158, DOI 10.1037/a0014182; Maruff P, 2005, J SLEEP RES, V14, P21, DOI 10.1111/j.1365-2869.2004.00438.x; McAuley T, 2006, DEV NEUROPSYCHOL, V29, P447, DOI 10.1207/s15326942dn2903_4; McFarland RA, 1937, J COMP PSYCHOL, V23, P227, DOI 10.1037/h0056332; McFarland RA, 1937, J COMP PSYCHOL, V23, P191, DOI 10.1037/h0058262; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b2535, 10.1371/journal.pmed.1000217, 10.1016/j.ijsu.2010.02.007]; Obrist WD, 1953, J PSYCHOL, V35, P259, DOI 10.1080/00223980.1953.9712860; PIERSON WR, 1958, J GERONTOL, V13, P418, DOI 10.1093/geronj/13.4.418; Rakitin BC, 2006, J COGNITIVE NEUROSCI, V18, P376, DOI 10.1162/jocn.2006.18.3.376; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; Shammi P, 1998, AGING NEUROPSYCHOL C, V5, P1, DOI 10.1076/anec.5.1.1.23; Shipley BA, 2006, PSYCHOSOM MED, V68, P17, DOI 10.1097/01.psy.0000195867.66643.0f; Smulders FTY, 1997, BIOL PSYCHOL, V45, P217, DOI 10.1016/S0301-0511(96)05229-5; Sparrow WA, 2006, MOTOR CONTROL, V10, P201, DOI 10.1123/mcj.10.3.201; SPIRDUSO WW, 1978, J GERONTOL, V33, P26, DOI 10.1093/geronj/33.1.26; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; SURWILLO WW, 1963, ELECTROEN CLIN NEURO, V15, P1029, DOI 10.1016/0013-4694(63)90146-9; WAUGH NC, 1973, J GERONTOL, V28, P466, DOI 10.1093/geronj/28.4.466; West R, 2002, BRAIN COGNITION, V49, P402, DOI 10.1006/brcg.2001.1507; WILKINSON RT, 1989, J GERONTOL, V44, pP29, DOI 10.1093/geronj/44.2.P29; Williams BR, 2007, AGING NEUROPSYCHOL C, V14, P417, DOI 10.1080/13825580600584590; Williams BR, 2005, NEUROPSYCHOLOGY, V19, P88, DOI 10.1037/0894-4105.19.1.88; Yan JH, 1998, EXP AGING RES, V24, P155	62	89	91	1	47	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2012	7	10							e45759	10.1371/journal.pone.0045759			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	020KP	WOS:000309807700013	23071524	Green Published, gold			2022-02-06	
J	Master, CL; Gioia, GA; Leddy, JJ; Grady, MF				Master, Christina L.; Gioia, Gerard A.; Leddy, John J.; Grady, Matthew F.			Importance of 'Return-to-Learn' in Pediatric and Adolescent Concussion	PEDIATRIC ANNALS			English	Article							SPORT-RELATED CONCUSSION		[Master, Christina L.; Grady, Matthew F.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Master, Christina L.; Grady, Matthew F.] Univ Penn, Perelman Sch Med, Div Pediat Orthoped & Sports Med, Dept Surg, Philadelphia, PA 19104 USA; [Master, Christina L.; Grady, Matthew F.] Univ Penn, Perelman Sch Med, Div Pediat Orthoped & Sports Med, Dept Pediat, Philadelphia, PA 19104 USA; [Gioia, Gerard A.] George Washington Univ, Sch Med, Div Pediat Neuropsychol, Washington, DC 20052 USA; [Gioia, Gerard A.] George Washington Univ, Sch Med, Div Pediat Neuropsychol, SCORE Program,Childrens Natl Med Ctr, Washington, DC 20052 USA; [Gioia, Gerard A.] George Washington Univ, Sch Med, Dept Pediat, Washington, DC 20052 USA; [Gioia, Gerard A.] George Washington Univ, Sch Med, Dept Psychiat & Behav Sci, Washington, DC 20052 USA; [Leddy, John J.] SUNY Buffalo, UB Orthopaed & Sports Med, Buffalo, NY 14260 USA		Master, CL (corresponding author), Childrens Hosp Philadelphia, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	masterc@email.chop.edu		Master, Christina/0000-0002-6717-4270			DeMatteo CA, 2010, PEDIATRICS, V125, P327, DOI 10.1542/peds.2008-2720; Gioia GA, 2006, HEADS BRAIN INJURY Y; Gioia GA, 2010, J INT NEUROPSYCH SOC, V16, P178; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; Moser RS, 2012, J PEDIAT; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008	8	89	90	0	16	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086 USA	0090-4481	1938-2359		PEDIATR ANN	Pediatr. Annu.	SEP	2012	41	9					E180	E185		10.3928/00904481-20120827-09			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	082NM	WOS:000314398700002	22953975				2022-02-06	
J	Goeller, J; Wardlaw, A; Treichler, D; O'Bruba, J; Weiss, G				Goeller, Jacques; Wardlaw, Andrew; Treichler, Derrick; O'Bruba, Joseph; Weiss, Greg			Investigation of Cavitation as a Possible Damage Mechanism in Blast-Induced Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						blast wave; cavitation; Dynamic System Mechanics Advance Simulation (DYSMAS); improvised explosive device; shock tube tests; traumatic brain injury	MODEL; COLLAPSE; SHELL	Cavitation was investigated as a possible damage mechanism for war-related traumatic brain injury (TBI) due to an improvised explosive device (IED) blast. When a frontal blast wave encounters the head, a shock wave is transmitted through the skull, cerebrospinal fluid (CSF), and tissue, causing negative pressure at the contrecoup that may result in cavitation. Numerical simulations and shock tube experiments were conducted to determine the possibility of cranial cavitation from realistic IED non-impact blast loading. Simplified surrogate models of the head consisted of a transparent polycarbonate ellipsoid. The first series of tests in the 18-inch-diameter shock tube were conducted on an ellipsoid filled with degassed water to simulate CSF and tissue. In the second series, Sylgard gel, surrounded by a layer of degassed water, was used to represent the tissue and CSF, respectively. Simulated blast overpressure in the shock tube tests ranged from a nominal 10-25 pounds per square inch gauge (psig; 69-170 kPa). Pressure in the simulated CSF was determined by Kulite thin line pressure sensors at the coup, center, and contrecoup positions. Using video taken at 10,000 frames/sec, we verified the presence of cavitation bubbles at the contrecoup in both ellipsoid models. In all tests, cavitation at the contrecoup was observed to coincide temporally with periods of negative pressure. Collapse of the cavitation bubbles caused by the surrounding pressure and elastic rebound of the skull resulted in significant pressure spikes in the simulated CSF. Numerical simulations using the DYSMAS hydrocode to predict onset of cavitation and pressure spikes during cavity collapse were in good agreement with the tests. The numerical simulations and experiments indicate that skull deformation is a significant factor causing cavitation. These results suggest that cavitation may be a damage mechanism contributing to TBI that requires future study.	[Goeller, Jacques; Wardlaw, Andrew; Treichler, Derrick; O'Bruba, Joseph] Adv Technol & Res Corp, Columbia, MD 21046 USA; [Weiss, Greg] Appl Res Associates, Littleton, CO USA		Goeller, J (corresponding author), Adv Technol & Res Corp, 6650 Eli Whitney Dr, Columbia, MD 21046 USA.	jgoeller@atrcorp.com		Treichler, Derrick/0000-0002-3007-2967			Alley M.D., 2010, EXPT MODELING EXPLOS; Bailey MR, 2003, ACOUST PHYS+, V49, P369, DOI 10.1134/1.1591291; BENJAMIN TB, 1966, PHILOS TR R SOC S-A, V260, P221, DOI 10.1098/rsta.1966.0046; Brands D.W.A., 1999, P 43 STAPP CAR CRASH, P313; Brennen CE, 2002, J FLUID MECH, V472, P153, DOI 10.1017/S0022112002002288; Chafi S.M., 2007, P IMECE2007 NOV; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; ENGIN AE, 1978, AVIAT SPACE ENVIR MD, V49, P120; FROST D, 1986, J HEAT TRANS-T ASME, V108, P418, DOI 10.1115/1.3246940; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Gilchrist MD, 2000, COMPUT MECH, V26, P229, DOI 10.1007/s004660000179; GROSS AG, 1958, J NEUROSURG, V15, P548, DOI 10.3171/jns.1958.15.5.0548; HICKLING R, 1973, J BIOMECH, V6, P115, DOI 10.1016/0021-9290(73)90081-X; HICKLING R, 1964, PHYS FLUIDS, V7, P7, DOI 10.1063/1.1711058; Johnson E., 2006, 2006012368 SAE INT; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; LUBOCK P, 1980, J BIOMECH, V13, P1041, DOI 10.1016/0021-9290(80)90048-2; Matsumoto Y., 2003, RENAL STONE CO UNPUB; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; SUH C, 1972, J BIOMECH, V5, P181, DOI 10.1016/0021-9290(72)90054-1; van den Bosch E., 2000, DEV IMPROVED DUMMY H; Ward C, 1980, P 24 STAPP CAR CRASH; WARD JW, 1948, SCIENCE, V107, P349, DOI 10.1126/science.107.2779.349; Wardlaw A, 2010, IFMBE PROC, V32, P34, DOI 10.1007/978-3-642-14998-6_9; Wardlaw Jr A., 2002, P 73 SHOCK VIBR S; Wardlaw Jr A.B., 2003, 2500 NSWC IH TR; Young F.R., 1999, CAVITATION, P143; Zhang L., 2004, THEORY PRACTICE FINA, V126; Ziejewski M., 2009, 21 INT TECHN C ENH S; Ziejewski M., 2007, BRAIN INJ PROF, V4, P10	32	89	93	3	61	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2012	29	10					1970	1981		10.1089/neu.2011.2224			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	971YV	WOS:000306244400399	22489674				2022-02-06	
J	Czeiter, E; Mondello, S; Kovacs, N; Sandor, J; Gabrielli, A; Schmid, K; Tortella, F; Wang, KKW; Hayes, RL; Barzo, P; Ezer, E; Doczi, T; Buki, A				Czeiter, Endre; Mondello, Stefania; Kovacs, Noemi; Sandor, Janos; Gabrielli, Andrea; Schmid, Kara; Tortella, Frank; Wang, Kevin K. W.; Hayes, Ronald L.; Barzo, Pal; Ezer, Erzsebet; Doczi, Tamas; Buki, Andras			Brain Injury Biomarkers May Improve the Predictive Power of the IMPACT Outcome Calculator	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; IMPACT calculator; outcome; prognostic models; traumatic brain injury	SPECTRIN BREAKDOWN PRODUCTS; FIBRILLARY ACIDIC PROTEIN; C-TERMINAL HYDROLASE; CEREBROSPINAL-FLUID; PROGNOSTIC MODELS; HEAD-INJURY; DIAGNOSIS; CLASSIFICATION; DESIGN; SERUM	Outcome prediction following severe traumatic brain injury (sTBI) is a widely investigated field of research. A major breakthrough is represented by the IMPACT prognostic calculator based on admission data of more than 8500 patients. A growing body of scientific evidence has shown that clinically meaningful biomarkers, including glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase-L1 (UCH-L1), and alpha II-spectrin breakdown product (SBDP145), could also contribute to outcome prediction. The present study was initiated to assess whether the addition of biomarkers to the IMPACT prognostic calculator could improve its predictive power. Forty-five sTBI patients (GCS score <= 8) from four different sites were investigated. We utilized the core model of the IMPACT calculator (age, GCS motor score, and reaction of pupils), and measured the level of GFAP, UCH-L1, and SBDP145 in serum and cerebrospinal fluid (CSF). The forecast and actual 6-month outcomes were compared by logistic regression analysis. The results of the core model itself, as well as serum values of GFAP and CSF levels of SBDP145, showed a significant correlation with the 6-month mortality using a univariate analysis. In the core model, the Nagelkerke R-2 value was 0.214. With multivariate analysis we were able to increase this predictive power with one additional biomarker (GFAP in CSF) to R-2 = 0.476, while the application of three biomarker levels (GFAP in CSF, GFAP in serum, and SBDP145 in CSF) increased the Nagelkerke R-2 to 0.700. Our preliminary results underline the importance of biomarkers in outcome prediction, and encourage further investigation to expand the predictive power of contemporary outcome calculators and prognostic models in TBI.	[Czeiter, Endre; Kovacs, Noemi; Ezer, Erzsebet; Doczi, Tamas; Buki, Andras] Univ Pecs, Dept Neurosurg, Sch Med, H-7623 Pecs, Hungary; [Czeiter, Endre] Univ Pecs, Dept Anat, Sch Med, H-7623 Pecs, Hungary; [Mondello, Stefania; Gabrielli, Andrea; Hayes, Ronald L.] Univ Florida, Dept Anesthesiol, Gainesville, FL USA; [Wang, Kevin K. W.] Univ Florida, Ctr Neuroprote & Biomarkers Res, Dept Psychiat, McKnight Brain Inst, Gainesville, FL USA; [Mondello, Stefania; Hayes, Ronald L.] Banyan Biomarkers Inc, Dept Clin Programs, Ctr Innovat Res, Alachua, FL USA; [Wang, Kevin K. W.] Banyan Biomarkers Inc, Dept Diagnost Res & Dev, Ctr Innovat Res, Alachua, FL USA; [Sandor, Janos] Univ Debrecen, Div Biostat & Epidemiol, Fac Publ Hlth, H-4012 Debrecen, Hungary; [Schmid, Kara; Tortella, Frank] Walter Reed Army Inst Res, Dept Appl Neurobiol, Div Psychiat & Neurosci, Silver Spring, MD USA; [Barzo, Pal] Univ Szeged, Dept Neurosurg, Fac Med, Szeged, Hungary		Czeiter, E (corresponding author), Univ Pecs, Dept Neurosurg, Sch Med, 2 Ret St, H-7623 Pecs, Hungary.	endre.czeiter@gmail.com	Czeiter, Endre/B-1404-2009; Mondello, Stefania/A-1813-2012; Doczi, Tamas/C-5750-2009	Mondello, Stefania/0000-0002-8587-3614; Wang, Kevin/0000-0002-9343-6473	Department of DefenseUnited States Department of Defense [DAMD17-03-1-0772, DAMD17-03-1-0066]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS049175-01, R01-NS052831-01, R01-NS051431-01]; University of FloridaUniversity of Florida [N00014-06-1-1029]; Developing Competitiveness of Universities in the South Transdanubian Region [SROP-4.2.1.B-10/2/KONV-2010-0002]; MTA-PTE Clinical Neuroscience MR Research Group; ETT [269/2009]; Banyan Biomarkers, Inc.; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS051431, R01NS049175, R01NS052831] Funding Source: NIH RePORTER	This study was primarily sponsored by Department of Defense Award numbers DAMD17-03-1-0772 and DAMD17-03-1-0066; we also acknowledge additional funding support from the National Institutes of Health (R01-NS049175-01, R01-NS052831-01, and R01-NS051431-01), Navy grant no. N00014-06-1-1029 (University of Florida), and Developing Competitiveness of Universities in the South Transdanubian Region (SROP-4.2.1.B-10/2/KONV-2010-0002), as well as the MTA-PTE Clinical Neuroscience MR Research Group and ETT grant no. 269/2009.; Drs. Czeiter, Mondello, Kovacs, Gabrielli, Barzo, Ezer, and Buki are consultants for Banyan Biomarkers, Inc., and received consulting fees. Drs. Wang and Hayes own stock, receive royalties from, and are officers of Banyan Biomarkers Inc., and as such may benefit financially as a result of the outcomes of this research. No competing financial interests exist for Drs. Sandor, Schmid, Tortella, and Doczi.	Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Bratton SL, 2007, J NEUROTRAUMA S1, V24, pS45, DOI DOI 10.1089/NEU.2007.9989; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Farkas O, 2005, ACTA NEUROCHIR, V147, P855, DOI 10.1007/s00701-005-0559-6; Gong B, 2007, DRUG NEWS PERSPECT, V20, P365, DOI 10.1358/dnp.2007.20.6.1138160; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Menon DK, 2009, CURR OPIN CRIT CARE, V15, P437, DOI 10.1097/MCC.0b013e3283307a26; Middeldorp J, 2011, PROG NEUROBIOL, V93, P421, DOI 10.1016/j.pneurobio.2011.01.005; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Piazza O, 2007, PEDIATR NEUROSURG, V43, P258, DOI 10.1159/000103304; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schulz JB, 2008, J NEUROL, V255, P3, DOI 10.1007/s00415-008-5011-4; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2	39	89	95	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2012	29	9					1770	1778		10.1089/neu.2011.2127			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	954CN	WOS:000304924000006	22435839	Green Published			2022-02-06	
J	Burk, AM; Martin, M; Flierl, MA; Rittirsch, D; Helm, M; Lampl, L; Bruckner, U; Stahl, GL; Blom, AM; Perl, M; Gebhard, F; Huber-Lang, M				Burk, Anne-Maud; Martin, Myriam; Flierl, Michael A.; Rittirsch, Daniel; Helm, Matthias; Lampl, Lorenz; Bruckner, Uwe; Stahl, Gregory L.; Blom, Anna M.; Perl, Mario; Gebhard, Florian; Huber-Lang, Markus			EARLY COMPLEMENTOPATHY AFTER MULTIPLE INJURIES IN HUMANS	SHOCK			English	Article						Multiple injuries; complement; C5a; C3a; MAC; neutrophils	TRAUMA PATIENTS; C4B-BINDING PROTEIN; ACTIVATION; C5A; SEPSIS; GENERATION; PATHOPHYSIOLOGY; INHIBITION; SEVERITY; FAILURE	After severe tissue injury, innate immunity mounts a robust systemic inflammatory response. However, little is known about the immediate impact of multiple trauma on early complement function in humans. In the present study, we hypothesized that multiple trauma results in immediate activation, consumption, and dysfunction of the complement cascade and that the resulting severe "complementopathy" may be associated with morbidity and mortality. Therefore, a prospective multicenter study with 25 healthy volunteers and 40 polytrauma patients (mean injury severity score = 30.3 +/- 2.9) was performed. After polytrauma, serum was collected as early as possible at the scene, on admission to the emergency room (ER), and 4, 12, 24, 120, and 240 h post-trauma and analyzed for the complement profile. Complement hemolytic activity (CH-50) was massively reduced within the first 24 h after injury, recovered only 5 days after trauma, and discriminated between lethal and nonlethal 28-day outcome. Serum levels of the complement activation products C3a and C5a were significantly elevated throughout the entire observation period and correlated with the severity of traumatic brain injury and survival. The soluble terminal complement complex SC5b-9 and mannose-binding lectin showed a bi-phasic response after trauma. Key fluid-phase inhibitors of complement, such as C4b-binding protein and factor I, were significantly diminished early after trauma. The present data indicate an almost synchronical rapid activation and dysfunction of complement, suggesting a trauma-induced complementopathy early after injury. These events may participate in the impairment of the innate immune response observed after severe trauma.	[Burk, Anne-Maud; Flierl, Michael A.; Rittirsch, Daniel; Bruckner, Uwe; Perl, Mario; Gebhard, Florian; Huber-Lang, Markus] Univ Hosp Ulm, Dept Traumatol Hand Plast & Reconstruct Surg, D-89075 Ulm, Germany; [Martin, Myriam; Blom, Anna M.] Lund Univ, Skane Univ Hosp, Dept Lab Med, Malmo, Sweden; [Helm, Matthias; Lampl, Lorenz] Mil Hosp Ulm, Dept Anaesthesiol, Ulm, Germany; [Stahl, Gregory L.] Harvard Univ, Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anaesthesiol Perioperat & Pain Med,Sch Med, Boston, MA 02115 USA		Huber-Lang, M (corresponding author), Univ Hosp Ulm, Dept Traumatol Hand Plast & Reconstruct Surg, Steinhoevelstr 9, D-89075 Ulm, Germany.	markus.huber-lang@uniklinik-ulm.de	Blom, Anna M/B-9607-2009; Huber-Lang, Markus/AAJ-2209-2020	Blom, Anna M/0000-0002-1348-1734; Rittirsch, Daniel/0000-0002-1185-2431; Stahl, Gregory/0000-0002-4805-8119; Martin, Myriam/0000-0003-1526-8678	European Shock Society/Novo NordiskNovo Nordisk; Deutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG) [HU 823/2-2, HU 823/3-1, PE 908/2-1]; Swedish Research CouncilSwedish Research CouncilEuropean Commission; BMVg InSan I [0294-V-1299]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL056086, HL52886, HL099130, AI089781]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [RC1HL099130, R01HL052886, R29HL052886, R01HL056086, R56HL056086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R56AI089781, R01AI089781] Funding Source: NIH RePORTER	This work was supported by grants from the European Shock Society Award/Novo Nordisk 2006; the Deutsche Forschungsgemeinschaft (DFG HU 823/2-2, HU 823/3-1, PE 908/2-1); the Swedish Research Council; the BMVg InSan I 0294-V-1299; and the National Institutes of Health (HL056086, HL52886, HL099130, AI089781).	Amara U, 2010, J IMMUNOL, V185, P5628, DOI 10.4049/jimmunol.0903678; Amara U, 2010, SHOCK, V33, P568, DOI 10.1097/SHK.0b013e3181c799d4; Boldt J, 2000, CRIT CARE MED, V28, P445, DOI 10.1097/00003246-200002000-00026; Bossi F, 2004, J IMMUNOL, V173, P6921, DOI 10.4049/jimmunol.173.11.6921; Carlsson S, 2010, J BIOL CHEM, V285, P32038, DOI 10.1074/jbc.M110.148452; Chan RK, 2003, BRIT J SURG, V90, P1470, DOI 10.1002/bjs.4408; Demetriades D, 2004, J AM COLL SURGEONS, V198, P20, DOI 10.1016/j.jamcollsurg.2003.09.003; Dries D J, 1996, New Horiz, V4, P276; Fleming SD, 2008, J SURG RES, V150, P196, DOI 10.1016/j.jss.2008.02.010; Flierl MA, 2008, SHOCK, V29, P25, DOI 10.1097/shk.0b013e3180556a0b; FOSSE E, 1987, ACTA CHIR SCAND, V153, P325; Fosse E, 1998, INJURY, V29, P509, DOI 10.1016/S0020-1383(98)00113-2; Ganter MT, 2007, SHOCK, V28, P29, DOI 10.1097/shk.0b013e3180342439; Garcia de Frutos P, 1994, Blood, V84, P815; Gebhard F, 2008, LANGENBECK ARCH SURG, V393, P825, DOI 10.1007/s00423-008-0334-2; Gebhard F, 2000, LANGENBECK ARCH SURG, V385, P406, DOI 10.1007/s004230000152; Gerard C, 2003, NEW ENGL J MED, V348, P167, DOI 10.1056/NEJMcibr022995; Happonen KE, 2009, J IMMUNOL, V182, P1518, DOI 10.4049/jimmunol.182.3.1518; Hecke F, 1997, CRIT CARE MED, V25, P2015, DOI 10.1097/00003246-199712000-00019; HEIDEMAN M, 1984, J TRAUMA, V24, P1038, DOI 10.1097/00005373-198412000-00006; Huber-Lang M, 2001, J IMMUNOL, V166, P1193, DOI 10.4049/jimmunol.166.2.1193; Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419; Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037; Kohl J, 2006, IMMUNOL RES, V34, P157, DOI 10.1385/IR:34:2:157; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Liener UC, 2002, SHOCK, V17, P169, DOI 10.1097/00024382-200203000-00002; Martin M, 2009, J VASC SURG, V50, P100, DOI 10.1016/j.jvs.2008.12.033; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; MOORE FA, 1991, J TRAUMA, V31, P629, DOI 10.1097/00005373-199105000-00006; Napolitano LM, 1999, SURG CLIN N AM, V79, P1385, DOI 10.1016/S0039-6109(05)70084-0; Nilsson SC, 2007, MOL IMMUNOL, V44, P1835, DOI 10.1016/j.molimm.2006.10.005; Nordahl EA, 2004, P NATL ACAD SCI USA, V101, P16879, DOI 10.1073/pnas.0406678101; PARSONS PE, 1990, AM REV RESPIR DIS, V141, P98, DOI 10.1164/ajrccm/141.1.98; RISBERG B, 1986, CRIT CARE MED, V14, P917, DOI 10.1097/00003246-198611000-00001; ROUMEN RMH, 1995, CRIT CARE MED, V23, P474, DOI 10.1097/00003246-199503000-00010; Schaeffer V, 2007, SHOCK, V27, P623, DOI 10.1097/SHK.0b013e31802fa0bd; Sjoberg AP, 2009, TRENDS IMMUNOL, V30, P83, DOI 10.1016/j.it.2008.11.003; TENNENBERG SD, 1987, ARCH SURG-CHICAGO, V122, P26; WATKINS J, 1985, KLIN WOCHENSCHR, V63, P1019, DOI 10.1007/BF01737639; Younger JG, 2001, J APPL PHYSIOL, V90, P441, DOI 10.1152/jappl.2001.90.2.441; ZILOW G, 1992, CRIT CARE MED, V20, P468, DOI 10.1097/00003246-199204000-00006; Zimmermann T, 1989, Prog Clin Biol Res, V308, P291	42	89	92	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	APR	2012	37	4					348	354		10.1097/SHK.0b013e3182471795			7	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	910XH	WOS:000301681400003	22258234	Green Accepted			2022-02-06	
J	Huang, CL; Han, XN; Li, X; Lam, E; Peng, WG; Lou, NH; Torres, A; Yang, MX; Garre, JM; Tian, GF; Bennett, MVL; Nedergaard, M; Takano, T				Huang, Chunlan; Han, Xiaoning; Li, Xi; Lam, Eric; Peng, Weiguo; Lou, Nanhong; Torres, Arnulfo; Yang, Meixiang; Garre, Juan Mauricio; Tian, Guo-Feng; Bennett, Michael V. L.; Nedergaard, Maiken; Takano, Takahiro			Critical Role of Connexin 43 in Secondary Expansion of Traumatic Spinal Cord Injury	JOURNAL OF NEUROSCIENCE			English	Article							GAP-JUNCTION HEMICHANNELS; P2X(7) RECEPTOR; IMPROVES RECOVERY; MICROGLIAL CELLS; P2X7 RECEPTOR; ATP RELEASE; IN-VIVO; ASTROCYTES; EXPRESSION; BRAIN	Spinal cord injury (SCI) is often complicated by secondary injury as a result of the innate inflammatory response to tissue trauma and swelling. Previous studies have shown that excessive ATP release from peritraumatic regions contributes to the inflammatory response to SCI by activation of low-affinity P2X7 receptors. Because connexin hemichannels constitute an important route for astrocytic ATP release, we here evaluated the impact on post-traumatic ATP release of deletion of connexins (Cx30/Cx43) in astrocytes. In vivo bioluminescence imaging showed a significant reduction in ATP release after weight-drop injury in mice with deletion of Cx43 compared with Cx43-expressing littermates, both on a Cx30 knockout background. Moreover, astrogliosis and microglia activation were reduced in peritraumatic areas of those mice lacking Cx43; motor recovery was also significantly improved, and the traumatic lesion was smaller. Combined, these observations are consistent with a contribution by astrocytic hemichannels to post-traumatic ATP release that aggravates secondary injury and restrains functional recovery after experimental spinal cord injury. Connexins may thereby constitute a new therapeutic target in spinal cord injury.	[Takano, Takahiro] Univ Rochester, Med Ctr, Div Glial Dis & Therapeut, Ctr Translat Neuromed,Dept Neurosurg, Rochester, NY 14642 USA; [Garre, Juan Mauricio; Bennett, Michael V. L.] Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA		Takano, T (corresponding author), Univ Rochester, Med Ctr, Div Glial Dis & Therapeut, Ctr Translat Neuromed,Dept Neurosurg, 601 Elmwood Ave, Rochester, NY 14642 USA.	nedergaard@urmc.rochester.edu; takahiro_takano@urmc.rochester.edu		Takano, Takahiro/0000-0002-6235-6673	New York State Spinal Cord Injury Research Board; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32DE007202, NS50350, NS038073]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [R01DE022743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [T32DE007202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS075177, R01NS078167, R01NS038073] Funding Source: NIH RePORTER	This study was supported by the New York State Spinal Cord Injury Research Board and National Institutes of Health Grants T32DE007202, NS50350, and NS038073.	Abbracchio MP, 2009, TRENDS NEUROSCI, V32, P19, DOI 10.1016/j.tins.2008.10.001; Acarin L, 2000, EUR J NEUROSCI, V12, P3505, DOI 10.1046/j.1460-9568.2000.00226.x; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Bennett MVL, 2003, TRENDS NEUROSCI, V26, P610, DOI 10.1016/j.tins.2003.09.008; Bethea JR, 2000, PROG BRAIN RES, V128, P33; Collo G, 1997, NEUROPHARMACOLOGY, V36, P1277, DOI 10.1016/S0028-3908(97)00140-8; Cotrina ML, 2009, PURINERG SIGNAL, V5, P223, DOI 10.1007/s11302-009-9138-2; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Cronin M, 2008, MOL CELL NEUROSCI, V39, P152, DOI 10.1016/j.mcn.2008.06.005; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Di Virgilio F, 1999, PROG BRAIN RES, V120, P355; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Ferrari D, 2006, J IMMUNOL, V176, P3877, DOI 10.4049/jimmunol.176.7.3877; Garre JM, 2010, P NATL ACAD SCI USA, V107, P22659, DOI 10.1073/pnas.1013793107; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Iacobas DA, 2004, NEUROCHEM INT, V45, P243, DOI 10.1016/j.neuint.2003.12.008; Koizumi S, 2007, NATURE, V446, P1091, DOI 10.1038/nature05704; Lin JHC, 2008, J NEUROSCI, V28, P681, DOI 10.1523/JNEUROSCI.3827-07.2008; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; Matute C, 2007, J NEUROSCI, V27, P9525, DOI 10.1523/JNEUROSCI.0579-07.2007; Naus CCG, 2000, BRAIN RES REV, V32, P259, DOI 10.1016/S0165-0173(99)00087-9; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Parpura V, 2004, NEUROCHEM INT, V45, P259, DOI 10.1016/j.neuint.2003.12.011; Peng WG, 2009, P NATL ACAD SCI USA, V106, P12489, DOI 10.1073/pnas.0902531106; Popovich PG, 2008, NAT REV NEUROSCI, V9, P481, DOI 10.1038/nrn2398; Qiao F, 2006, AM J PATHOL, V169, P1039, DOI 10.2353/ajpath.2006.060248; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Theis M, 2003, J NEUROSCI, V23, P766; Theis M, 2001, GENESIS, V29, P1, DOI 10.1002/1526-968X(200101)29:1<1::AID-GENE1000>3.0.CO;2-0; Theriault E, 1997, J COMP NEUROL, V382, P199; Tozaki-Saitoh H, 2008, J NEUROSCI, V28, P4949, DOI 10.1523/JNEUROSCI.0323-08.2008; Wallraff A, 2006, J NEUROSCI, V26, P5438, DOI 10.1523/JNEUROSCI.0037-06.2006; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082	33	89	90	1	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 7	2012	32	10					3333	3338		10.1523/JNEUROSCI.1216-11.2012			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	905SV	WOS:000301295300008	22399755	Green Accepted, Bronze, Green Published			2022-02-06	
J	Berger, RP; Hayes, RL; Richichi, R; Beers, SR; Wang, KKW				Berger, Rachel P.; Hayes, Ronald L.; Richichi, Rudolph; Beers, Sue R.; Wang, Kevin K. W.			Serum Concentrations of Ubiquitin C-Terminal Hydrolase-L1 and alpha II-Spectrin Breakdown Product 145 kDa Correlate with Outcome after Pediatric TBI	JOURNAL OF NEUROTRAUMA			English	Article						alpha II-spectrin breakdown product; outcome; pediatric; traumatic brain injury; ubiquitin C-terminal hydrolase	TRAUMATIC BRAIN-INJURY; NEURON-SPECIFIC ENOLASE; ABUSIVE HEAD TRAUMA; CEREBROSPINAL-FLUID; S100B LEVELS; BIOMARKER CONCENTRATIONS; YOUNG-CHILDREN; COMA-SCALE; IDENTIFICATION; PREDICTION	Predicting outcome after pediatric traumatic brain injury (TBI) is important for providing information to families and prescribing rehabilitation services. Previously published studies evaluating the ability of serum biomarkers to predict outcome after pediatric TBI have focused on three markers: neuron-specific enolase (NSE), S100B, and myelin-basic protein (MBP), all of which have important limitations. The study objectives were to measure serum concentrations of two novel serum biomarkers, ubiquitin C-terminal hydrolase (UCH-L1) and alpha II-spectrin breakdown product 145 kDa (SBDP145), in children with TBI and healthy controls and to assess the ability of these markers to predict outcome as assessed by a dichotomous Glasgow Outcome Scale (GOS) score. We also sought to compare the predictive ability of UCH-L1 and SBDP145 to that of the clinical gold standard, the Glasgow Coma Scale (GCS) score, and to that of the well-accepted biomarkers NSE, S100B, and MBP. Serum UCH-L1 and SBDP145 concentrations were significantly greater in subjects than in controls. The increase in UCH-L1 and SBDP145 was exclusively seen in subjects with moderate and severe TBI; there was no increase after mild TBI. Both markers had a significant negative partial correlation with the GCS after controlling for age. Both UCH-L1 and SBDP145 were correlated with GOS, and this correlation was stronger than the correlations with NSE, S100B, or MBP. These results suggest that these two markers may be useful in assessing outcome after moderate and severe pediatric TBI.	[Berger, Rachel P.] UPMC, Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15224 USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Alachua, FL USA; [Richichi, Rudolph] Stat Anal & Measurement Consultants Inc, Lanexa, VA USA; [Beers, Sue R.] Western Psychiat Inst & Clin, Pittsburgh, PA USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Wang, Kevin K. W.] Univ Florida, Dept Neurosci, Gainesville, FL 32611 USA		Berger, RP (corresponding author), UPMC, Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	rachel.berger@chp.edu		Wang, Kevin/0000-0002-9343-6473	U.S. Department of DefenseUnited States Department of Defense [W81XWH-06-1-0517]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS052831, K23HD43843]; PCTRC of the University of Pittsburgh; Banyan Biomarkers Inc.; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD043843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052831] Funding Source: NIH RePORTER	This work is supported in part by U.S. Department of Defense Award #W81XWH-06-1-0517 (to R.L.H. and K.K.W.W.), National Institutes of Health R01NS052831 (to R.L.H. and K.K.W.W.), K23HD43843 (to R.P.B.), and the PCTRC of the University of Pittsburgh (to R.P.B.). We would like to thank Stefania Mondello for her assistance making the figure and Haley Stutz for her administrative assistance.; Kevin K.W. Wang and Ronald L. Hayes own stock, receive royalties from, and are officers of Banyan Biomarkers Inc., and as such may benefit financially as a result of the outcomes of this research or work reported in this publication. No competing financial interests exist for the other authors.	Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Bechtel K, 2009, PEDIATRICS, V124, pE697, DOI 10.1542/peds.2008-1493; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Berger R, 2009, PEDIATR CRIT CARE ME, V10, P260, DOI 10.1097/PCC.0b013e31819a376d; Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Berger RP, 2010, DEV NEUROSCI-BASEL, V32, P396, DOI 10.1159/000316803; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Blyth B., 2011, J NEUROTRAU IN PRESS; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Douglas-Escobar M, 2010, PEDIATR RES, V68, P531, DOI 10.1203/PDR.0b013e3181f85a03; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Fraser DD, 2011, PEDIATR CRIT CARE ME, V12, P319, DOI 10.1097/PCC.0b013e3181e8b32d; Guzel A, 2008, NEUROSURG REV, V31, P439, DOI 10.1007/s10143-008-0148-2; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Lewis SB, 2010, J NEUROSCI RES, V88, P1475, DOI 10.1002/jnr.22323; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Lo TYM, 2009, J NEUROTRAUM, V26, P1479, DOI [10.1089/neu.2008.0753, 10.1089/neu.2008-0753]; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Portela LVC, 2002, CLIN CHEM, V48, P950; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Sandler SJI, 2010, CHILD NERV SYST, V26, P205, DOI 10.1007/s00381-009-1009-1; Siman R, 2008, BRAIN RES, V1213, P1, DOI 10.1016/j.brainres.2008.03.034; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wiesmann M, 2010, ACTA NEUROL SCAND, V121, P178, DOI 10.1111/j.1600-0404.2009.01196.x; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6	37	89	94	0	12	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					162	167		10.1089/neu.2011.1989			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300019	22022780	Green Published			2022-02-06	
J	Struchen, MA; Davis, LC; Bogaards, JA; Hudler-Hull, T; Clark, AN; Mazzei, DM; Sander, AM; Caroselli, JS				Struchen, Margaret A.; Davis, Lynne Cole; Bogaards, Jay A.; Hudler-Hull, Terri; Clark, Allison N.; Mazzei, Diana M.; Sander, Angelle M.; Caroselli, Jerome S.			Making Connections After Brain Injury: Development and Evaluation of a Social Peer-Mentoring Program for Persons With Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						craniocerebral trauma; peer mentoring; social integration; traumatic brain injury	CLOSED-HEAD-INJURY; QUALITY-OF-LIFE; UCLA LONELINESS SCALE; FOLLOW-UP; INITIAL FINDINGS; PARENT PROGRAMS; DEPRESSION; SUPPORT; INDIVIDUALS; INTEGRATION	Objective: To describe the development and implementation of a social peer-mentoring program for persons with traumatic brain injury (TBI) and to explore whether this program yielded increased social functioning outcomes compared with wait-list (WL) controls. Design: Pilot randomized controlled study. Participants: Community-dwelling individuals with TBI (12 matched with social peer mentors and 18 completing the WL condition). Intervention: Trained social peer mentors (SPMs) were matched to partners with TBI (peer partners [PP]) to foster skill-building in planning of social activities and improving social communication abilities through phone contacts and joint participation in social events within the community over a 3-month period. Measures: Social Activity Interview, Center for Epidemiological Studies Depression Scale, UCLA Loneliness Scale, Satisfaction with Life Scale, 6-Item Interpersonal Support Evaluation List (baseline and postmentoring); weekly social activity data (1-month baseline, continuously collected during 3-month mentoring or WL period); satisfaction survey. Results: Both SPM and PP participants reported high satisfaction with the mentoring program. Statistically significant improvements in perceived social support after mentoring were observed for the mentored group than for WL participants; however, an increase in depressive symptoms was also observed. While significant improvements in social activity level and social network size were not found, a trend toward increased satisfaction with social life was present for mentored participants. Conclusions: Satisfaction ratings for the SPM program were uniformly high and selected positive findings encourage further investigation of social mentoring as an intervention to effect improvements in social integration. Small sample size and reduced "dosage" of mentor interactions were limitations of this pilot study. Benefits of and challenges to implementation of an SPM program are outlined.	[Struchen, Margaret A.; Davis, Lynne Cole; Hudler-Hull, Terri; Clark, Allison N.; Sander, Angelle M.; Caroselli, Jerome S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Struchen, Margaret A.; Davis, Lynne Cole; Bogaards, Jay A.; Hudler-Hull, Terri; Clark, Allison N.; Mazzei, Diana M.; Sander, Angelle M.] Brain Injury Res Ctr, Houston, TX USA; [Caroselli, Jerome S.] TIRR Mem Hermann, Dept Neuropsychol, Houston, TX USA; [Clark, Allison N.; Sander, Angelle M.] Harris Cty Hosp Dist, Dept Phys & Rehabil, Quentin Mease Community Hosp, Houston, TX USA		Struchen, MA (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1 Baylor Plaza, Houston, TX 77030 USA.	struchen@bcm.edu			National Institute on Disability and Rehabilitation Research, US Department of EducationUS Department of Education [H133B031117, H133B090023]	This work was supported by grants from the National Institute on Disability and Rehabilitation Research, US Department of Education (grant H133B031117, Rehabilitation Research and Training Center on Community Integration of Persons with Traumatic Brain Injury, and H133B090023, Rehabilitation Research and Training Center on Developing Strategies to Foster Community Integration and Participation for Individuals With Traumatic Brain Injury). The authors thank members of the Social Peer Mentor Working Committee for contributing to the development of measures, screening procedures, and training of peer mentors: DeLisa West, PhD, Niki Cannon, LaTricia Eckenrode, Patricia Backus, CCC-SLP, Shawn Jaffrey, CTRS, Melissa Gautreau, BS, and Lisa Keenan, PhD; Big Brothers Big Sisters of Greater Houston for assistance with developing mentor screening procedures, Sunil Kothari, MD, for his inspiration in designing this project, and Jason Ferguson for assistance with peer mentor training.	Akridge RL, 1991, P NAT FOR NAT I DIS; Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; Bay E, 2007, ARCH PSYCHIAT NURS, V21, P2, DOI 10.1016/j.apnu.2006.07.005; BERGLAND MM, 1991, REHABIL COUNS BULL, V35, P5; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; Cohen S., 1985, SOCIAL SUPPORT THEOR, P73, DOI [10.1007/978-94-009-5115-0_5, DOI 10.1007/978-94-009-5115-0_5]; Cornwall A, 1995, SOC SCI MED, V41, P1667, DOI 10.1016/0277-9536(95)00127-S; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; *CRAIG HOSP RES DE, 1999, CRAIG HAND ASS REP T; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; Devins G., 1985, TEST CRITIQUES, P144; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Fleming J., 1995, BRIT J OCCUPATIONAL, V58, P55, DOI [https://doi.org/10.1177/030802269505800204, DOI 10.1177/030802269505800204]; Fleminger S, 2003, NEUROPSYCHOL REHABIL, V13, P65, DOI 10.1080/09602010244000354; Folkman S., 1984, STRESS; Gee P, 2010, HONOLULU STAR B, V6; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; HARING TG, 1992, J APPL BEHAV ANAL, V25, P319, DOI 10.1901/jaba.1992.25-319; HARRICK L, 1994, BRAIN INJURY, V8, P439, DOI 10.3109/02699059409150995; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; Hoofien D, 2001, BRAIN INJURY, V15, P189; Izaute M, 2008, BRAIN INJURY, V22, P758, DOI 10.1080/02699050802366002; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Johnson K, 1998, BEHAV MODIF, V22, P502, DOI 10.1177/01454455980224004; KARPMAN T, 1985, J APPL REHABILITATIO, V0017, P00028; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; Kozloff R., 1987, J HEAD TRAUMA REHAB, V2, P14, DOI [DOI 10.1097/00001199-198709000-00004, 10.1097/00001199-198709000-00004]; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; Malec JF, 2010, ARCH PHYS MED REHAB, V91, P1087, DOI 10.1016/j.apmr.2010.04.002; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; McCauley SR, 2006, BRAIN INJURY, V20, P519, DOI 10.1080/02699050600676651; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Newsom JT, 1996, PSYCHOL AGING, V11, P34, DOI 10.1037/0882-7974.11.1.34; O'Brien J, 2006, MAKING DIFFERENCE GU; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODOM SL, 1986, J APPL BEHAV ANAL, V19, P59, DOI 10.1901/jaba.1986.19-59; ODOM SL, 1985, J APPL BEHAV ANAL, V18, P3, DOI 10.1901/jaba.1985.18-3; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; Radloff L, 1977, APPL PSYCH MEAS, V1, P283; Randall, 2004, ED PSYCHOL PRACTICE, V20, P353, DOI [10.1080/0266736042000314286, DOI 10.1080/0266736042000314286]; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; RUSSELL D, 1980, J PERS SOC PSYCHOL, V39, P472, DOI 10.1037/0022-3514.39.3.472; Russell DW, 1996, J PERS ASSESS, V66, P20, DOI 10.1207/s15327752jpa6601_2; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Santelli B, 1996, INFANT YOUNG CHILD, V9, P53, DOI 10.1097/00001163-199607000-00007; SANTELLI B, 1995, INFANT YOUNG CHILD, V8, P48, DOI 10.1097/00001163-199510000-00007; Seale GS, 2002, BRAIN INJURY, V16, P955, DOI 10.1080/02699050210155258; Seibert PS, 2002, BRAIN INJURY, V16, P837, DOI 10.1080/02699050210131939; SPSS, 2006, SPSS 15 0 WIND; Struchen MA, 2006, MAKING CONNECTIONS B; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; Wallace CA, 2000, BRAIN INJURY, V14, P549; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P1187; Whiteneck GG, 1992, GUIDE USE CHART CRAI; WILLIAMSON GM, 1992, PSYCHOL AGING, V7, P343, DOI 10.1037/0882-7974.7.3.343; Williamson GM, 2000, HEALTH PSYCHOL, V19, P339, DOI 10.1037//0278-6133.19.4.339	67	89	89	0	31	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2011	26	1					4	19		10.1097/HTR.0b013e3182048e98			16	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	703GA	WOS:000285965200002	21209559				2022-02-06	
J	Lippa, SM; Pastorek, NJ; Benge, JF; Thornton, GM				Lippa, Sara M.; Pastorek, Nicholas J.; Benge, Jared F.; Thornton, G. Matthew			Postconcussive Symptoms After Blast and Nonblast-Related Mild Traumatic Brain Injuries in Afghanistan and Iraq War Veterans	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Blast injury; Head injury; Concussion; Posttraumatic stress; Polytrauma; Neurobehavioral Symptom Inventory	POSTTRAUMATIC-STRESS-DISORDER; INDUCED NEUROTRAUMA; RAT-BRAIN; CONCUSSION; COMBAT; CARE; COMPLAINTS; METAANALYSIS; PERFORMANCE; MECHANISMS	Blast injury is common in current warfare, but little is known about the effects of blast-related mild traumatic brain injury (mTBI). Profile analyses were conducted investigating differences in self-reported postconcussive (PC) symptoms in 339 veteran outpatients with mTBI histories reporting current symptoms based on mechanism of injury (blast only, nonblast only, or both blast and nonblast), number of blast injuries, and distance from the blast. Veterans with any blast-related mTBI history were younger and reported higher posttraumatic stress symptoms than veterans with nonblast-related mTBI histories, with a marginally significant difference in posttraumatic stress symptom report between veterans reporting blast-related mTBI only and those reporting nonblast-related mTBI. The groups did not differ in terms of PC symptom severity or PC symptom cluster profiles. Among veterans with blast-related mTBI histories, PC symptom report did not vary by number of blast-related mTBIs or proximity to blast. Overall, posttraumatic stress symptoms accounted for a substantial portion of variance in PC symptom report. In veteran outpatients with remote mTBI histories who have enduring symptom complaints related to the mTBI, mechanism of injury did not clearly contribute to differential PC symptom severity or PC symptom cluster profile. Proximal rather than distal factors may be important intervention targets in returning symptomatic veterans with mTBI histories. (JINS, 2010, 16, 856-866.)	[Pastorek, Nicholas J.] Michael E DeBakey VA Med Ctr, ABPP CN, Houston, TX 77030 USA; [Lippa, Sara M.; Thornton, G. Matthew] Univ Houston, Dept Psychol, Houston, TX USA; [Pastorek, Nicholas J.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Benge, Jared F.] Baylor Coll Med, Menninger Dept Psychiat, Houston, TX 77030 USA		Pastorek, NJ (corresponding author), Michael E DeBakey VA Med Ctr, ABPP CN, 2002 Holcombe Blvd,RCL 117, Houston, TX 77030 USA.	nicholas.pastorek@va.gov		Benge, Jared/0000-0001-6201-3278; Pastorek, Nicholas/0000-0002-9290-380X	Department of Veterans AffairsUS Department of Veterans Affairs [B6812C]	The authors thank the Veterans who participated in this study. We also acknowledge the efforts of the Polytrauma Network Site team members at the Michael E. DeBakey VA Medical Center and the George E. Wahlen VA Medical Center for their assistance with data collection, especially Jennifer Romesser, Psy.D., and Maija Reblin, Ph.D. This material is based on work supported by the Office of Academic Affiliations, Department of Veterans Affairs. This work was supported in part by a Department of Veterans Affairs Center of Excellence grant (H.S.L., Grant number B6812C), Neurorehabilitation: Neurons to Networks Center for Rehabilitation Research. Dr. Pastorek had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The information in this manuscript and the manuscript itself has never been published either electronically or in print. No grant, pharmaceutical, or corporate funding was used in the preparation of this manuscript or collection of data. No conflicts of interest exist that might affect this manuscript. Portions of this study were previously presented at the Department of Veterans Affairs Evolving Paradigms II: The Journey Home Conference in Las Vegas, NV in September 2009.	American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; BRENNER LA, 2009, J HEAD TRAUMA REHABI; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Centers for Disease Control and Prevention, 2003, NAT CTR INJ PREV CON; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; *DEF BRAIN INJ CTR, 2009, BLAST REL MTBI FAQS; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; HOLLNAGEL H, 1980, Ugeskrift for Laeger, V142, P3071; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Jakupcak M, 2008, J NERV MENT DIS, V196, P425, DOI 10.1097/NMD.0b013e31817108ed; Kashdan TB, 2006, BEHAV RES THER, V44, P1609, DOI 10.1016/j.brat.2005.12.003; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; LEVIN JR, 1994, PSYCHOL BULL, V115, P153, DOI 10.1037/0033-2909.115.1.153; LOFTUS EF, 1992, APPL COGNITIVE PSYCH, V6, P93, DOI 10.1002/acp.2350060202; MAYO A, 2006, EMERGEN MED, V7, P40; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Tabacknick B.G., 2001, USING MULTIVARIATE S; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vasterling JJ, 2008, J REHABIL RES DEV, V45, P347, DOI 10.1682/JRRD.2007.05.0077; Weathers F.W., 1991, PTSD CHECKLIST MILIT; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; YEHUDA R, 1995, AM J PSYCHIAT, V152, P137	50	89	89	0	11	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2010	16	5					856	866		10.1017/S1355617710000743			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	670HA	WOS:000283410600015	20682086				2022-02-06	
J	Spain, A; Daumas, S; Lifshitz, J; Rhodes, J; Andrews, PJD; Horsburgh, K; Fowler, JH				Spain, Aisling; Daumas, Stephanie; Lifshitz, Jonathan; Rhodes, Jonathan; Andrews, Peter J. D.; Horsburgh, Karen; Fowler, Jill H.			Mild Fluid Percussion Injury in Mice Produces Evolving Selective Axonal Pathology and Cognitive Deficits Relevant to Human Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						axonal damage; cognition; memory; mild traumatic brain injury; white matter	SPATIAL NAVIGATION; UNMYELINATED AXONS; FLUORO-JADE; CONCUSSION; RAT; IMPAIRMENT; MODEL; ABNORMALITIES; VULNERABILITY; HIPPOCAMPUS	Mild traumatic brain injury (TBI) accounts for up to 80% of clinical TBI and can result in cognitive impairment and white matter damage that may develop and persist over several years. Clinically relevant models of mild TBI for investigation of neurobiological changes and the development of therapeutic strategies are poorly developed. In this study we investigated the temporal profile of axonal and somal injury that may contribute to cognitive impairments in a mouse model of mild TBI. Neuronal perikaryal damage (hematoxylin and eosin and Fluoro-Jade C), myelin integrity (myelin basic protein and myelin-associated glycoprotein), and axonal damage (amyloid precursor protein), were evaluated by immunohistochemistry at 4 h, 24 h, 72 h, 4 weeks, and 6 weeks after mild lateral fluid percussion brain injury (0.9 atm; righting time 167 +/- 15 sec). At 3 weeks post-injury spatial reference learning and memory were tested in the Morris water maze (MWM). Levels of damage to neuronal cell bodies were comparable in the brain-injured and sham groups. Myelin integrity was minimally altered following injury. Clear alterations in axonal damage were observed at various time points after injury. Axonal damage was localized to the cingulum at 4 h post-injury. At 4 and 6 weeks post-injury, axonal damage was evident in the external capsule, and was seen at 6 weeks in the dorsal thalamic nuclei. At 3 weeks post-injury, injured mice showed an impaired ability to learn the water maze task, suggesting injury-induced alterations in search strategy learning. The evolving localization of axonal damage points to ongoing degeneration after injury that is concomitant with a deficit in learning.	[Spain, Aisling; Horsburgh, Karen; Fowler, Jill H.] Univ Edinburgh, Ctr Cognit & Neural Syst, Edinburgh EH8 9JZ, Midlothian, Scotland; [Daumas, Stephanie] Univ Paris 06, Physiopathol Malad SNC, Paris, France; [Lifshitz, Jonathan] Univ Kentucky, Dept Anat & Neurobiol, Spinal Cord & Brain Injury Res Ctr, Dept Phys Med & Rehabil,Chandler Med Ctr, Lexington, KY 40536 USA; [Rhodes, Jonathan; Andrews, Peter J. D.] Univ Edinburgh, Dept Anaesthesia Crit Care & Pain Med, Intens Care Unit, Western Gen Hosp, Edinburgh EH8 9JZ, Midlothian, Scotland		Fowler, JH (corresponding author), Univ Edinburgh, Ctr Cognit & Neural Syst, 1 George Sq, Edinburgh EH8 9JZ, Midlothian, Scotland.	Jill.Fowler@ed.ac.uk	Spain, Aisling/E-5740-2012; Messier, Claude/A-2322-2008	Spain, Aisling/0000-0003-1292-967X; Messier, Claude/0000-0002-4791-1763; Fowler, Jill/0000-0003-3204-1221; Horsburgh, Karen/0000-0002-9620-3691; Daumas, Stephanie/0000-0001-7048-7617	Alzheimer's Society; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9200370] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0700704B, G9200370] Funding Source: researchfish; Royal Osteoporosis Society [128] Funding Source: researchfish	The support of the Alzheimer's Society is gratefully acknowledged.	Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Blanchet S, 2009, BRAIN INJURY, V23, P111, DOI 10.1080/02699050802649688; Browne KD, 2006, EXP NEUROL, V201, P301, DOI 10.1016/j.expneurol.2006.04.008; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cain DP, 2006, BEHAV BRAIN RES, V170, P241, DOI 10.1016/j.bbr.2006.02.023; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Conti AC, 1998, J NEUROSCI, V18, P5663; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; De Monte VE, 2006, BRAIN INJURY, V20, P1345, DOI 10.1080/02699050601082073; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; DOMESICK VB, 1970, BRAIN RES, V20, P19, DOI 10.1016/0006-8993(70)90150-2; FRANKLIN W, 1997, MOUSE BRAIN STEREOTA; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Holland MA, 2008, J NEUROTRAUM, V25, P140, DOI 10.1089/neu.2007.0312; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jortner BS, 2006, NEUROTOXICOLOGY, V27, P628, DOI 10.1016/j.neuro.2006.03.002; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Li SH, 2006, NEUROSCI LETT, V409, P182, DOI 10.1016/j.neulet.2006.09.054; Lifshitz Jonathan, 2009, P369, DOI 10.1007/978-1-60327-185-1_32; Lin CH, 2003, MOL PHARMACOL, V63, P44, DOI 10.1124/mol.63.1.44; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Livingstone SA, 2007, BEHAV BRAIN RES, V185, P21, DOI 10.1016/j.bbr.2007.07.015; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEUNIER B, 1988, INORG CHEM, V27, P161, DOI 10.1021/ic00274a032; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; SAPER CB, 1984, J COMP NEUROL, V222, P313, DOI 10.1002/cne.902220302; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Skelton RW, 2000, J CLIN EXP NEUROPSYC, V22, P157, DOI 10.1076/1380-3395(200004)22:2;1-1;FT157; Skelton RW, 1998, BEHAV BRAIN RES, V96, P13, DOI 10.1016/S0166-4328(97)00199-X; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Warburton EC, 2001, J NEUROSCI, V21, P7323, DOI 10.1523/JNEUROSCI.21-18-07323.2001; Warburton EC, 1999, BEHAV NEUROSCI, V113, P956, DOI 10.1037/0735-7044.113.5.956; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052	59	89	91	1	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2010	27	8					1429	1438		10.1089/neu.2010.1288			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	639OU	WOS:000280984900007	20528171				2022-02-06	
J	Fischer, M; Ruegg, S; Czaplinski, A; Strohmeier, M; Lehmann, A; Tschan, F; Hunziker, PR; Marsch, SC				Fischer, Michael; Rueegg, Stephan; Czaplinski, Adam; Strohmeier, Monika; Lehmann, Angelika; Tschan, Franziska; Hunziker, Patrick R.; Marsch, Stephan C.			Inter-rater reliability of the Full Outline of UnResponsiveness score and the Glasgow Coma Scale in critically ill patients: a prospective observational study	CRITICAL CARE			English	Article							TRAUMATIC BRAIN-INJURY; CONSCIOUSNESS; PREDICTION; VALIDATION; VALIDITY; LEVEL	Introduction: The Glasgow Coma Scale (GCS) is the most widely used scoring system for comatose patients in intensive care. Limitations of the GCS include the impossibility to assess the verbal score in intubated or aphasic patients, and an inconsistent inter-rater reliability. The FOUR (Full Outline of UnResponsiveness) score, a new coma scale not reliant on verbal response, was recently proposed. The aim of the present study was to compare the inter-rater reliability of the GCS and the FOUR score among unselected patients in general critical care. A further aim was to compare the inter-rater reliability of neurologists with that of intensive care unit (ICU) staff. Methods: In this prospective observational study, scoring of GCS and FOUR score was performed by neurologists and ICU staff on 267 consecutive patients admitted to intensive care. Results: In a total of 437 pair wise ratings the exact inter-rater agreement for the GCS was 71%, and for the FOUR score 82% (P = 0.0016); the inter-rater agreement within a range of +/- 1 score point for the GCS was 90%, and for the FOUR score 92% (P = ns.). The exact inter-rater agreement among neurologists was superior to that among ICU staff for the FOUR score (87% vs. 79%, P = 0.04) but not for the GCS (73% vs. 73%). Neurologists and ICU staff did not significantly differ in the inter-rater agreement within a range of +/- 1 score point for both GCS (88% vs. 93%) and the FOUR score (91% vs. 88%). Conclusions: The FOUR score performed better than the GCS for exact inter-rater agreement, but not for the clinically more relevant agreement within the range of +/- 1 score point. Though neurologists outperformed ICU staff with regard to exact inter-rater agreement, the inter-rater agreement of ICU staff within the clinically more relevant range of +/- 1 score point equalled that of the neurologists. The small advantage in inter-rater reliability of the FOUR score is most likely insufficient to replace the GCS, a score with a long tradition in intensive care.	[Fischer, Michael; Strohmeier, Monika; Lehmann, Angelika; Hunziker, Patrick R.; Marsch, Stephan C.] Univ Basel Hosp, Dept Med Intens Care, CH-4031 Basel, Switzerland; [Rueegg, Stephan; Czaplinski, Adam] Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland; [Tschan, Franziska] Univ Neuchatel, Dept Psychol, CH-2000 Neuchatel, Switzerland		Marsch, SC (corresponding author), Univ Basel Hosp, Dept Med Intens Care, Spitalstr, CH-4031 Basel, Switzerland.	smarsch@uhbs.ch					Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; BENZER A, 1991, LANCET, V338, P977, DOI 10.1016/0140-6736(91)91840-Q; Bland JM, 1997, BRIT MED J, V314, P572, DOI 10.1136/bmj.314.7080.572; Eken C, 2009, EUR J EMERG MED, V16, P29, DOI 10.1097/MEJ.0b013e32830346ab; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; Gill M, 2007, ANN EMERG MED, V49, P403, DOI 10.1016/j.annemergmed.2006.03.031; Iyer VN, 2009, MAYO CLIN PROC, V84, P694, DOI 10.1016/S0025-6196(11)60519-3; Kho ME, 2007, AM J CRIT CARE, V16, P378; LANDIS JR, 1977, BIOMETRICS, V33, P174; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; STANCZAK DE, 1984, J NEUROSURG, V60, P955, DOI 10.3171/jns.1984.60.5.0955; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; TEASDALE G, 1974, LANCET, V2, P81; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Wolf CA, 2007, MAYO CLIN PROC, V82, P435, DOI 10.4065/82.4.435	16	89	91	0	9	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2010	14	2							R64	10.1186/cc8963			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611LO	WOS:000278816800039	20398274	gold, Green Published			2022-02-06	
J	Madri, JA				Madri, J. A.			MODELING THE NEUROVASCULAR NICHE: IMPLICATIONS FOR RECOVERY FROM INJURY	JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY			English	Article; Proceedings Paper	13th International Congress of Histochemistry and Cytochemistry (ICHC 2008)	AUG 23-27, 2008	Gdansk, POLAND	Polish Soc Histochem & Cytochem		neurovascular niche; neural stem cell; hypoxia; endothelial cell; hydrogel; co-culture; recovery	NEURAL STEM-CELLS; ENDOTHELIAL GROWTH-FACTOR; BIRTH-WEIGHT INFANTS; NETWORKS IN-VIVO; VASCULAR NICHE; HIPPOCAMPAL NEUROGENESIS; AUTOCRINE FUNCTIONS; ANGIOGENIC FACTORS; S-NITROSYLATION; YOUNG ADULTHOOD	While survival from stroke, traumatic brain and spinal cord injuries, neurodegenerative diseases and hypoxia has improved over the past several years, treatments are limited and impacts of these injuries and diseases to patients, families and society can be devastating Recovery from these injuries is variable and involves in part an orchestrated angiogenesis and neurogenesis in the neurogenic zones (neurovascular niches) of the CNS In this focused review the roles of HIF-I alpha mediated responses to hypoxia in CNS neurovascular niches is discussed Using in vivo and in vitro murine models of sublethal hypoxia we mimicked the variable responses observed in the human population and correlated differences in baseline and hyoxia-induced induction of HIF-I alpha several downstream signaling components includind BDNF, VEGF, SDF-I, TrkB, Nrp-I, CXCR4 and NO with differences in survival as well as endothelial cell and neural stem cell survival and proliferation, providing insight into this important and timely problem and suggesting that optimizing of expression levels of some or all of these signaling components may have the potential of maximizing recovery following CNS injury.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA		Madri, JA (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St,POB 208023, New Haven, CT 06520 USA.				NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R37-HL28373, R01-HL51018] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS35476] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL051018, R37HL028373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS035476] Funding Source: NIH RePORTER		Antaya RJ, 2007, AM J DERMATOPATH, V29, P99, DOI 10.1097/01.dad.0000245636.39098.e5; Bassan H, 2006, PEDIATR NEUROL, V35, P85, DOI 10.1016/j.pediatrneurol.2006.03.005; Berchner-Pfannschmidt U, 2007, J BIOL CHEM, V282, P1788, DOI 10.1074/jbc.M607065200; Capela A, 2002, NEURON, V35, P865, DOI 10.1016/S0896-6273(02)00835-8; Chow J, 2001, DEV BRAIN RES, V130, P123, DOI 10.1016/S0165-3806(01)00220-6; Cooke RWI, 2006, ARCH DIS CHILD-FETAL, V91, pF293, DOI 10.1136/adc.2005.080192; Curristin SM, 2002, P NATL ACAD SCI USA, V99, P15729, DOI 10.1073/pnas.232568799; Doetsch F, 2003, CURR OPIN GENET DEV, V13, P543, DOI 10.1016/j.gde.2003.08.012; Dragun P, 2008, J PHYSIOL PHARMACOL, V59, P441; Fagel DM, 2006, EXP NEUROL, V199, P77, DOI 10.1016/j.expneurol.2005.04.006; Ford MC, 2006, P NATL ACAD SCI USA, V103, P2512, DOI 10.1073/pnas.0506020102; Hack M, 2002, NEW ENGL J MED, V346, P149, DOI 10.1056/NEJMoa010856; Iga J, 2007, PROG NEURO-PSYCHOPH, V31, P658, DOI 10.1016/j.pnpbp.2006.12.011; Kim H, 2004, J BIOL CHEM, V279, P33538, DOI 10.1074/jbc.M404115200; Li F, 2007, MOL CELL, V26, P63, DOI 10.1016/j.molcel.2007.02.024; LI Q, 2009, AM J PATHOL     1008; Li Q, 2008, J NEUROSCI RES, V86, P1227, DOI 10.1002/jnr.21597; Li Q, 2006, J NEUROSCI RES, V84, P1656, DOI 10.1002/jnr.21087; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; Martinez-Ruiz A, 2004, CARDIOVASC RES, V62, P43, DOI 10.1016/j.cardiores.2004.01.013; MENT LR, 1991, STROKE, V22, P390, DOI 10.1161/01.STR.22.3.390; MENT LR, 1995, DEV BRAIN RES, V84, P142, DOI 10.1016/0165-3806(94)00168-Y; Ment LR, 1997, IN VITRO CELL DEV-AN, V33, P684; MENT LR, 1992, STROKE, V23, P1132, DOI 10.1161/01.STR.23.8.1132; Ment LR, 1997, DEV BRAIN RES, V100, P52, DOI 10.1016/S0165-3806(97)00012-6; Mompeo B, 2003, J NEUROCYTOL, V32, P123, DOI 10.1023/B:NEUR.0000005597.28053.2a; Mucha K, 2007, J PHYSIOL PHARMACOL, V58, P165; Ogunshola OO, 2002, J BIOL CHEM, V277, P11410, DOI 10.1074/jbc.M111085200; Ogunshola OO, 2000, DEV BRAIN RES, V119, P139, DOI 10.1016/S0165-3806(99)00125-X; Ohab JJ, 2006, J NEUROSCI, V26, P13007, DOI 10.1523/JNEUROSCI.4323-06.2006; Oishi K, 2004, J PHARMACOL SCI, V96, P208, DOI 10.1254/jphs.FP0040373; Ozturk H, 2007, RENAL FAILURE, V29, P249, DOI 10.1080/08860220601166289; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Paul David A, 2006, BMC Pediatr, V6, P2, DOI 10.1186/1471-2431-6-2; Rauch MF, 2008, J BIOMAT SCI-POLYM E, V19, P1469, DOI 10.1163/156856208786140409; Saigal S, 2006, JAMA-J AM MED ASSOC, V295, P667, DOI 10.1001/jama.295.6.667; Scharfman H, 2005, EXP NEUROL, V192, P348, DOI 10.1016/j.expneurol.2004.11.016; Sharma A, 2008, PSYCHO-ONCOLOGY, V17, P66, DOI 10.1002/pon.1191; Sheldon RA, 1998, BRAIN RES, V810, P114, DOI 10.1016/S0006-8993(98)00892-0; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; Shen Q, 2008, CELL STEM CELL, V3, P289, DOI 10.1016/j.stem.2008.07.026; Tavazoie M, 2008, CELL STEM CELL, V3, P279, DOI 10.1016/j.stem.2008.07.025; Tsao PN, 2005, PEDIATR PULM, V39, P461, DOI 10.1002/ppul.20205; Tyson JE, 2005, JAMA-J AM MED ASSOC, V294, P371, DOI 10.1001/jama.294.3.371; Ward NL, 2007, J APPL PHYSIOL, V102, P1927, DOI 10.1152/japplphysiol.00909.2006; Ward NL, 2004, NEUROL RES, V26, P870, DOI 10.1179/016164104X3798; Warner-Schmidt JL, 2008, CURR OPIN PHARMACOL, V8, P14, DOI 10.1016/j.coph.2007.10.013; Warner-Schmidt JL, 2006, HIPPOCAMPUS, V16, P239, DOI 10.1002/hipo.20156; Wilson-Costello D, 2005, PEDIATRICS, V115, P997, DOI 10.1542/peds.2004-0221; Wurmser AE, 2004, NATURE, V430, P350, DOI 10.1038/nature02604; Wurmser AE, 2004, SCIENCE, V304, P1253, DOI 10.1126/science.1099344	51	89	97	0	12	POLISH PHYSIOLOGICAL SOC	GRZEGORZECKA	JAGIELLONIAN UNIV SCHOOL MED, INST PHYSIOLOGY, 31-531 KRAKOW, 16 GRZEGORZECKA, POLAND	0867-5910			J PHYSIOL PHARMACOL	J. Physiol. Pharmacol.	OCT	2009	60			4			95	104					10	Physiology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Physiology	562CK	WOS:000275026700013	20083857				2022-02-06	
J	Chaput, G; Giguere, JF; Chauny, JM; Denis, R; Lavigne, G				Chaput, Genevieve; Giguere, Jean-Francois; Chauny, Jean-Marc; Denis, Ronald; Lavigne, Gilles			Relationship among subjective sleep complaints, headaches, and mood alterations following a mild traumatic brain injury	SLEEP MEDICINE			English	Article						Mild traumatic brain injury; Sleep complaints; Headaches; Mood alterations; Symptoms; Risk factor; Irritability; Depression	CLOSED-HEAD-INJURY; POSTCONCUSSION SYMPTOMS; RECOVERY; SCALE	Background: Sleep complaints (e.g., frequent awakenings, nightmares), headaches and mood alterations (e.g., feeling depressed, irritable) can appear following a mild traumatic brain injury (MTBI). The objective of this retrospective study was to assess the relationships between the above symptoms. Our hypothesis was that sleep complaints might be among the risk factors for the development of headaches and mood alterations. Methods: The consecutive charts of 443 patients (68.2% males vs. 31.8% female; mean age of 46.9 years) diagnosed with MTBI were reviewed for past medical history and above symptoms using the Rivermead post-concussion symptom assessment questionnaire and self-report. Data were retrieved in 2 time courses: 10 days and 6 weeks. Results: For the 2 time Courses, the prevalence of subjective sleep complaints were 13.3% and 33.5%; headaches 46.8% and 39.3%; feeling depressed 9.5% and 20.4%; and feeling irritable 5.6% and 20.2%, respectively. Reports of sleep complaints at 6 weeks were 2.9 times (p = 0.004) more likely if such a symptom was reported at 10 days. Moreover, the presence of sleep complaints at 10 days is associated with concomitant headaches, depressive symptoms, and feeling irritable by 2.3, 9.9, and 12.2 times (p = 0.0001 and 0.014): and by 2.9, 6.3, and 4.8 times (p = 0.0001) at 6 weeks, respectively. Conclusions: Our results suggest that patients afflicted with sleep complaints are more likely to suffer from concomitant headaches, depressive symptoms, and irritability. (C) 2008 Elsevier B.V. All rights reserved.	[Chaput, Genevieve; Giguere, Jean-Francois; Chauny, Jean-Marc; Denis, Ronald; Lavigne, Gilles] Univ Montreal, Hop Sacre Coeur, Dept Surg, Div Trauma Res, Montreal, PQ H4J 1C5, Canada; [Chaput, Genevieve; Lavigne, Gilles] Univ Montreal, Fac Med Dent, Montreal, PQ H3C 3J7, Canada; [Chaput, Genevieve; Lavigne, Gilles] Univ Montreal, Fac Med, Montreal, PQ H3C 3J7, Canada		Lavigne, G (corresponding author), Univ Montreal, Hop Sacre Coeur, Dept Surg, Div Trauma Res, 5400 Blvd Gouin W, Montreal, PQ H4J 1C5, Canada.	gilles.lavigne@umontreal.ca	Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604	CIHR/Pain M2CCanadian Institutes of Health Research (CIHR); Hopital du Sacre-Coeur de Montreal (Canada); FRSQFonds de la Recherche en Sante du Quebec	This study was supported by a CIHR/Pain M2C Training grant, as well as trauma hospital funds from Hopital du Sacre-Coeur de Montreal (Canada) and FRSQ to the Research Center. Our sincere thanks to Ariane Demers of the Trauma team for her valuable help in accessing MTBI patient charts, and to jean Paquet for statistics.	ALVES WM, 1993, PHYS MED REHABIL, V6, P21; Bay Esther, 2007, J Neurosci Nurs, V39, P43; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Carroll LJ, 2004, J REHABIL MED, V36, P11, DOI 10.1080/16501960410023660; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chambers J, 1996, J TRAUMA, V41, P976, DOI 10.1097/00005373-199612000-00006; Chervin RD, 1999, NEUROLOGY, V52, P125, DOI 10.1212/WNL.52.1.125; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; KING N, 1995, J NEUROL, V242, P1432; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Kraus JCL, 2005, TXB TRAUMATIC BRAIN; LINDSAY JT, 1998, J NEUROTRAUM, V15, P573; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; McHugh T, 2006, BRAIN COGNITION, V60, P209; Mulhern S, 2006, J PSYCHOSOM RES, V61, P439, DOI 10.1016/j.jpsychores.2006.03.004; Olson LG, 1998, J SLEEP RES, V7, P248, DOI 10.1046/j.1365-2869.1998.00123.x; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8	29	89	91	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1389-9457	1878-5506		SLEEP MED	Sleep Med.	AUG	2009	10	7					713	716		10.1016/j.sleep.2008.07.015			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	487UI	WOS:000269301700004	19147402				2022-02-06	
J	Livingston, DH; Tripp, T; Biggs, C; Lavery, RF				Livingston, David H.; Tripp, Tovah; Biggs, Carina; Lavery, Robert F.			A Fate Worse Than Death? Long-Term Outcome of Trauma Patients Admitted to the Surgical Intensive Care Unit	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	67th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 24-27, 2008	Maui, HI	Amer Assoc Surg Trauma		Trauma; Outcomes; Critical care; Quality of life	QUALITY-OF-LIFE; MULTIPLE ORGAN FAILURE; 5-YEAR FOLLOW-UP; MAJOR TRAUMA; FUNCTIONAL OUTCOMES; BRAIN-INJURY; INPATIENT REHABILITATION; PHYSICAL IMPAIRMENT; RECOVERY PROJECT; ELDERLY-PATIENTS	Introduction: Trauma centers successfully save lives of severely injured patients who would have formerly died. However, survivors often have multiple complications and morbidities associated with prolonged intensive care unit (ICU) stays. Because the reintegration of patients into the society to lead an active and a productive life is the ultimate goal of trauma center care, we questioned whether our "success" may condemn these patients to a fate worse than death? Methods: Charts on all patients >= 18 years with ICU stay >= 10 days, discharged alive between June 1, 2002, and May 3 1, 2005, were reviewed. Patients with complete spinal cord injuries were excluded. Demographics, Injury Severity Score (ISS), presence of severe traumatic brain injury (TBI; Head Abbreviated Injury Scale [AIS] score = 4 or 5), presence of extremity fractures, need for operative procedures, ventilator days, complications, and discharge disposition were collected. Glasgow Outcome Scale score was calculated on discharge. Patients were contacted by phone to determine general health, work status, and using this data, Glasgow Outcome Scale score and a modified Functional Independence Measure (FIM) score were calculated. Results: Two hundred and forty-one patients met inclusion criteria. Thirty-three patients died postdischarge from the hospital and 39 were known to be alive from the electronic medical records but were unable to be contacted. Sixty-nine patients could not be tracked down and were ultimately considered as lost to follow-up. The remaining 100 patients who were successfully contacted participated in the study. Eighty-one percent were men with a mean age of 42 years, mean and median ISS of 28. Severe TBI was present in 50 (50%) patients. Mean and median follow-up was 3.3 years from discharge. At the time of follow-up, 92 (92%) patients were living at home, 5 in nursing homes, and 3 in assisted living, a shelter, or halfway house. FIM scores ranged from 6 to 12 with 55% reached a maximal FIM score of 12. One quarter of patients had FIM scores <= 10 and 10% had locomotion scores of <= 2 (very dependent). Seventy percent considered themselves to be less active. Seventy-six patients were either working or in full-time school before their trauma. Of the 24 patients not working preinjury, 12 were >= 55 years of age. At the time of follow-up, 37 patients (49%) were back to work or school. Severe TBI patients (57%, 21 of 37) were less likely to return to work when compared with 38% (12 of 38; p = 0.03) without severe TBI. There was no relationship with age, ISS, presence of any TBI, head AIS, presence of any extremity fracture, extremity AIS, or ventilator days in patients who did or did not return to work. Conclusions: These data demonstrate that ICU survivors >3 years after severe injury have significant impairments including inability to return to work or regain previous levels of activity and that the goal of reintegrating patients back into the society is not being met. Further studies better defining the limitations and barriers to improved quality of life are necessary. Survival, although important, is no longer a sufficient outcome to measure trauma center success.	[Livingston, David H.; Tripp, Tovah; Biggs, Carina; Lavery, Robert F.] Univ Med & Dent New Jersey, New Jersey Med Sch, Div Trauma, Dept Surg, Newark, NJ 07103 USA		Livingston, DH (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Div Trauma, Univ Hosp M234, 185 S Orange Ave, Newark, NJ 07103 USA.	livingst@umdnj.edu					Abelha Fernando J, 2007, BMC Surg, V7, P23, DOI 10.1186/1471-2482-7-23; Battistella FD, 1998, J TRAUMA, V44, P618, DOI 10.1097/00005373-199804000-00010; Braithwaite IJ, 1998, INJURY, V29, P55; Brenneman FD, 1997, J TRAUMA, V42, P778, DOI 10.1097/00005373-199705000-00004; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Delle Karth G, 2006, WIEN KLIN WOCHENSCHR, V118, P390, DOI 10.1007/s00508-006-0616-z; Dijkers MPJM, 1999, ARCH PHYS MED REHAB, V80, P867, DOI 10.1016/S0003-9993(99)90076-X; Dimopoulou I, 2004, AM J PHYS MED REHAB, V83, P171, DOI 10.1097/01.PHM.0000107497.77487.C1; Evans SA, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-8; Frick S, 2002, INTENS CARE MED, V28, P1405, DOI 10.1007/s00134-002-1434-z; FRUTIGER A, 1991, J TRAUMA, V31, P1216, DOI 10.1097/00005373-199109000-00004; FRUTIGER A, 1991, J TRAUMA, V31, P1225; Gabbe BJ, 2008, ANN SURG, V247, P854, DOI 10.1097/SLA.0b013e3181656d1e; Girotto JA, 2001, PLAST RECONSTR SURG, V108, P312, DOI 10.1097/00006534-200108000-00005; Grotz M, 1997, J TRAUMA, V42, P919, DOI 10.1097/00005373-199705000-00024; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Holtslag HR, 2007, INJURY, V38, P280, DOI 10.1016/j.injury.2006.10.026; Holtslag HR, 2007, J TRAUMA, V62, P919, DOI 10.1097/01.ta.0000224124.47646.62; Huang ME, 2000, AM J PHYS MED REHAB, V79, P327, DOI 10.1097/00002060-200007000-00003; Kaarlola A, 2006, CRIT CARE MED, V34, P2120, DOI 10.1097/01.CCM.0000227656.31911.2E; KING S, 2000, NEW YORKER      0619, P78; KONOPAD E, 1995, CRIT CARE MED, V23, P1653, DOI 10.1097/00003246-199510000-00008; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; MACKENZIE EJ, 1993, J TRAUMA, V34, P528, DOI 10.1097/00005373-199304000-00009; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MACKENZIE EJ, 1993, J TRAUMA, V34, P538; Mata GV, 1996, J TRAUMA, V41, P326, DOI 10.1097/00005373-199608000-00022; Meerding WJ, 2004, J TRAUMA, V56, P150, DOI 10.1097/01.TA.0000062969.65847.8B; Monneuse OJY, 2008, J AM COLL SURGEONS, V207, P179, DOI 10.1016/j.jamcollsurg.2008.01.021; Montuclard L, 2000, CRIT CARE MED, V28, P3389, DOI 10.1097/00003246-200010000-00002; Morris JA, 1999, J TRAUMA, V46, P771; MORRIS JA, 1991, J TRAUMA, V31, P827, DOI 10.1097/00005373-199106000-00014; MORRIS JA, 1991, J TRAUMA, V31, P833; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Niskanen M, 1999, CRIT CARE MED, V27, P1132, DOI 10.1097/00003246-199906000-00035; O'Dell MW, 1998, ARCH PHYS MED REHAB, V79, P1530, DOI 10.1016/S0003-9993(98)90414-2; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; PARKS J, 2007, J TRAUMA, V62, P267; Pirente N, 2007, LANGENBECK ARCH SURG, V392, P739, DOI 10.1007/s00423-007-0171-8; Redmill DA, 2006, INJURY, V37, P243, DOI 10.1016/j.injury.2005.11.014; Rivara FP, 2008, ARCH SURG-CHICAGO, V143, P282, DOI 10.1001/archsurg.2007.61; Sampalis JS, 2006, J TRAUMA, V60, P806, DOI 10.1097/01.ta.0000215103.62783.4d; Sluys K, 2005, J TRAUMA, V59, P223, DOI 10.1097/01.TA.0000173832.01547.CB; Soberg HL, 2007, J TRAUMA, V62, P461, DOI 10.1097/01.ta.0000222916.30253.ea; Ulvik A, 2008, ACTA ANAESTH SCAND, V52, P195, DOI 10.1111/j.1399-6576.2007.01533.x; Ulvik A, 2007, CRIT CARE, V11, DOI 10.1186/cc6111; Ulvik A, 2008, INTENS CARE MED, V34, P447, DOI 10.1007/s00134-007-0936-0; van der Sluis CK, 1998, INJURY, V29, P281, DOI 10.1016/S0020-1383(97)00199-X; Vles WJ, 2005, J TRAUMA, V58, P126, DOI 10.1097/01.TA.0000112342.40296.1F; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Watson WL, 2007, INJURY PREV, V13, P45, DOI 10.1136/ip.2005.010157; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Zatzick DF, 2007, PSYCHOL MED, V37, P1469, DOI 10.1017/S0033291707000943	53	89	89	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2009	67	2					341	348		10.1097/TA.0b013e3181a5cc34			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	482OL	WOS:000268898500026	19667888				2022-02-06	
J	Helmy, A; Carpenter, KLH; Skepper, JN; Kirkpatrick, PJ; Pickard, JD; Hutchinson, PJ				Helmy, Adel; Carpenter, Keri L. H.; Skepper, Jeremy N.; Kirkpatrick, Peter J.; Pickard, John D.; Hutchinson, Peter J.			Microdialysis of Cytokines: Methodological Considerations, Scanning Electron Microscopy, and Determination of Relative Recovery	JOURNAL OF NEUROTRAUMA			English	Article						albumin; cytokine; electron microscopy; microdialysis; relative recovery	BRAIN	Cerebral microdialysis is a monitoring technique with expanding clinical and research utility following traumatic brain injury. This study's aim was to determine the relative recovery for 12 cytokines using both crystalloid (CNS perfusion fluid) and colloid (CNS perfusion fluid supplemented with 3.5% human serum albumin) perfusate. Six CMA71 microdialysis catheters (nominal molecular weight cut-off 100 kDa) were perfused in vitro with either crystalloid or colloid and the relative recovery (%) determined for the cytokines as follows (crystalloid/colloid perfusate): IL-1 alpha (50.6/48), IL-1 beta (34.6/38.4), IL-1ra (21.9/38.4), IL-2 (17.1/52.8), IL-4 (26/56.7), IL-6 (9.8/25.5), IL-8 (47.7/73.4), IL-10 (2.9/8.7), IL-17 (14.4/43.7), TNF-alpha (4.4/31.2), MIP-1 alpha (31.8/55.6), and MIP-1 beta (31.9/50.1). The colloid perfusate significantly improved relative recovery for nine of these cytokines (p < 0.05), but not for IL-1 alpha, IL-1 beta, and IL-8. Relative recovery was related to apparent molecular weight of cytokine and to isoelectric point (pI), a surrogate marker of hydrophilicity. The mean fluid recovery for crystalloid and colloid perfusate was 92% and 145%, respectively. Scanning electron microscopy was utilized to investigate the ultrastructure of microdialysis membranes: (1) 20-kDa membrane, (2) 100-kDa membrane, and (3) ex vivo 100-kDa membrane. The 100-kDa membranes possessed multiple large cavities and the catheter examined after use in human brain clearly demonstrated cellular debris within the pores of the membrane. While colloid perfusate improves relative recovery, it causes a net influx of fluid into the microdialysis catheter, potentially dehydrating the extracellular space. This study is the first to systematically determine relative recovery in vitro for a wide range of cytokines. The two forms of perfusion fluid require direct comparison in vivo.	[Helmy, Adel] Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Addenbrookes Hosp, Cambridge CB2 0QQ, England; [Carpenter, Keri L. H.; Pickard, John D.; Hutchinson, Peter J.] Univ Cambridge, Wolfson Brain Imaging Ctr, Dept Clin Neurosci, Addenbrookes Hosp, Cambridge CB2 0QQ, England; [Skepper, Jeremy N.] Univ Cambridge, Multi Imaging Ctr, Dept Physiol Dev & Neurosci, Cambridge CB2 0QQ, England		Helmy, A (corresponding author), Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Addenbrookes Hosp, Box 167,Hills Rd, Cambridge CB2 0QQ, England.	adelhelmy@cantab.net	Helmy, Adel/AAS-3084-2020	Helmy, Adel/0000-0002-0531-0556; Carpenter, Keri/0000-0001-8236-7727	National Institute for Health; Royal College of Surgeons of England; Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship; Medical Research Council (Acute Brain Injury Programme Grant)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); National Institute for Health Research Biomedical Research Centre, CambridgeNational Institute for Health Research (NIHR); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390 ID 65883]; Academy of Medical Sciences/Health Foundation; University of Manchester; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G9439390, G0001237, G0802251] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0802251, G0001237, G9439390, G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2006-14-004] Funding Source: researchfish	We thank R. Doffinger, L. Ceron-Gutierrez, and L. Maskell for technical assistance. A. H. is supported by the National Institute for Health Research as an Academic Clinical Fellow, and by the Royal College of Surgeons of England as a Research Fellow. P.J.H. is supported by an Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship. K. L. H. C. is supported by the Medical Research Council (Acute Brain Injury Programme Grant) and the National Institute for Health Research Biomedical Research Centre, Cambridge. This study was supported by the Medical Research Council (grant no. G9439390 ID 65883), and the Academy of Medical Sciences/Health Foundation. We acknowledge our on-going collaboration with the University of Manchester on cytokine studies following acute brain injury (N. Rothwell, P. Tyrell, S. Hopkins, J. Galea, S. Hume).	Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; BUNGAY PM, 1990, LIFE SCI, V46, P105, DOI 10.1016/0024-3205(90)90043-Q; Clough GF, 2005, AAPS J, V7, pE686, DOI 10.1208/aapsj070369; Hamrin K, 2002, J APPL PHYSIOL, V92, P385, DOI 10.1152/jappl.2002.92.1.385; Helmy A, 2007, CURR MED CHEM, V14, P1525, DOI 10.2174/092986707780831113; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Maurer Martin H, 2003, Proteome Sci, V1, P7, DOI 10.1186/1477-5956-1-7; Mellergard P, 2008, NEUROSURGERY, V62, P151, DOI 10.1227/01.NEU.0000311072.33615.3A; Rosenbloom AJ, 2005, J NEUROSCI METH, V148, P147, DOI 10.1016/j.jneumeth.2005.04.018; Stahl M., 2002, Current Pharmaceutical Biotechnology, V3, P165, DOI 10.2174/1389201023378373; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Waelgaard L, 2006, SCAND J IMMUNOL, V64, P345, DOI 10.1111/j.1365-3083.2006.01826.x; Wang XD, 2007, ANAL CHEM, V79, P1816, DOI 10.1021/ac061503b; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X; Wisniewski N, 2001, J BIOMED MATER RES, V57, P513, DOI 10.1002/1097-4636(20011215)57:4<513::AID-JBM1197>3.0.CO;2-E	18	89	89	1	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2009	26	4					549	561		10.1089/neu.2008.0719			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	430OV	WOS:000264999300007	19196175				2022-02-06	
J	Vanderploeg, RD; Schwab, K; Walker, WC; Fraser, JA; Sigford, BJ; Date, ES; Scott, SG; Curtiss, G; Salazar, AM; Warden, DL				Vanderploeg, Rodney D.; Schwab, Karen; Walker, William C.; Fraser, Jamie A.; Sigford, Barbara J.; Date, Elaine S.; Scott, Steven G.; Curtiss, Glenn; Salazar, Andres M.; Warden, Deborah L.		Defense Vet Brain Injury Ctr Study	Rehabilitation of Traumatic Brain Injury in Active Duty Military Personnel and Veterans: Defense and Veterans Brain Injury Center Randomized Controlled Trial of Two Rehabilitation Approaches	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Cognition; Rehabilitation; Treatment outcome	COGNITIVE REHABILITATION; HEAD-INJURY; UNITED-STATES; RATING-SCALE; DISABILITY; INTERVENTION; INTENSITY; EFFICACY; MODERATE; OUTCOMES	Objectives: To determine the relative efficacy of 2 different acute traumatic brain injury (TBI) rehabilitation approaches: cognitive didactic versus functional-experiential and secondarily to determine relative efficacy for different patient subpopulations. Design: Randomized, controlled, intent-to-treat trial comparing 2 alternative TBI treatment approaches. Setting: Four Veterans Administration acute inpatient TBI rehabilitation programs. Participants: Adult veterans or active duty military service members (N=360) with moderate to severe TBI. Interventions: One and a half to 2.5 hours of protoco specific cognitive-didactic versus functional-experiential rehabilitation therapy integrated into interdisciplinary acute Commission for Accreditation of Rehabilitation Facilities-accredited inpatient TBI rehabilitation programs with another 2 to 2.5 hours daily of occupational and physical therapy. Duration of protocol treatment varied from 20 to 60 days depending on the clinical needs and progress of each participant. Main Outcome Measures: The 2 primary outcome measures were functional independence in living and return to work and/or school assessed by independent evaluators at 1-year follow-up. Secondary outcome measures consisted of the FIM, Disability Rating Scale score, and items from the Present State Exam, Apathy Evaluation Scale, and Neurobehavioral Rating Scale. Results: The cognitive-didactic and functional-experiential treatments did not result in overall group differences in the broad 1-year primary outcomes. However, analysis of secondary outcomes found differentially better immediate posttreatment cognitive function (mean +/- SD cognitive FIM) in participants randomized to cognitive-didactic treatment (27.3 +/- 6.2) than to functional treatment (25.6 +/- 6.0, t(332)=2.56, P=.01). Exploratory subgroup analyses found that younger participants in the cognitive arm had a higher rate of returning to work or school than younger patients in the functional arm, whereas participants older than 30 years and those with more years of education in the functional arm had higher rates of independent living status at 1 year posttreatment than similar patients in the cognitive arm. Conclusions: Results from this large multicenter randomized controlled trial comparing cognitive-didactic and functional-experiential approaches to brain injury rehabilitation indicated improved but similar long-term global functional outcome. Participants in the cognitive treatment arm achieved better short-term functional cognitive performance than patients in the functional treatment arm. The current increase in war-related brain injuries provides added urgency for rigorous study of rehabilitation treatments. (http://ClinicalTrials.gov ID# NCT00540020.)	[Vanderploeg, Rodney D.; Curtiss, Glenn] James A Haley Vet Affairs Med Ctr, Dept Mental Hlth & Behav Sci, Tampa, FL 33612 USA; [Vanderploeg, Rodney D.; Curtiss, Glenn] James A Haley Vet Affairs Med Ctr, Def & Vet Brain Injury Ctr, Tampa, FL 33612 USA; [Vanderploeg, Rodney D.; Curtiss, Glenn] Univ S Florida, Dept Psychiat & Behav Med, Tampa, FL USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Schwab, Karen; Fraser, Jamie A.; Warden, Deborah L.] Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20307 USA; [Schwab, Karen; Warden, Deborah L.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Walker, William C.] Hunter H McGuire Vet Affairs Med Ctr, Def & Vet Brain Injury Ctr, Richmond, VA USA; [Walker, William C.] Virginia Commonwealth Univ, Sch Med, Dept Phys Med & Rehabil, Richmond, VA USA; [Sigford, Barbara J.] Minneapolis Vet Affairs Med Ctr, Minneapolis, MN USA; [Date, Elaine S.] Vet Affairs Palo Alto Hlth Care Syst, Comprehens Rehabil Ctr, Palo Alto, CA USA; [Date, Elaine S.] Stanford Univ, Sch Med, Dept Orthopaed Surg, Stanford, CA 94305 USA; [Scott, Steven G.] James A Haley Vet Affairs Med Ctr, Polytrauma Rehabil Ctr, Phys Med & Rehabil Serv, Tampa, FL 33612 USA; [Scott, Steven G.] Univ S Florida, Coll Med, Dept Internal Med, Phys Med & Rehabil Sect, Tampa, FL 33612 USA; [Salazar, Andres M.] Oncovir Inc, Washington, DC USA		Vanderploeg, RD (corresponding author), James A Haley Vet Affairs Med Ctr, Dept Mental Hlth & Behav Sci, 116B,13000 N Bruce B Downs Blvd, Tampa, FL 33612 USA.	Rodney.Vanderploeg@va.gov	Curtiss, Glenn/ABB-5566-2020; Walker, William C/N-3162-2014				ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; Barrett AM, 2007, AM J PHYS MED REHAB, V86, P423, DOI 10.1097/PHM.0b013e31805ba039; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cifu DX, 2003, ARCH PHYS MED REHAB, V84, P1441, DOI 10.1016/S0003-9993(03)00272-7; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; Evans RW, 1992, J HEAD TRAUMA REHAB, V7, P24; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Giles GM, 2006, J HEAD TRAUMA REHAB, V21, P168, DOI 10.1097/00001199-200603000-00009; GILES GM, 1993, BRAIN INJURY REHABIL; GILES GM, 1999, REHABILITATION SEVER; Granger CV, 1998, ARCH PHYS MED REHAB, V79, P235, DOI 10.1016/S0003-9993(98)90000-4; HAFFEY WJ, 1991, J HEAD TRAUMA REHAB, V6, P24; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; Hamilton BB, 1987, REHABILITATION OUTCO, P137; Hartley L. L, 1995, COGNITIVE COMMUNICAT; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1990, ARCH NEUROL-CHICAGO, V47, P223, DOI 10.1001/archneur.1990.00530020131027; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Marin, 1996, Semin Clin Neuropsychiatry, V1, P304; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; *NAT CTR INJ PREV, 2008, TRAUM BRIN INJ; Novack TA, 1996, J HEAD TRAUMA REHAB, V11, P52, DOI 10.1097/00001199-199606000-00008; Prigatano G., 1989, TRAUMATIC BRAIN INJU, P175; PRIGATANO GP, 1994, J HEAD TRAUMA REHAB, V9, P91, DOI DOI 10.1097/00001199-199403000-00011; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUFF R M, 1990, Brain Injury, V4, P339, DOI 10.3109/02699059009026187; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Salazar AM, 2000, J HEAD TRAUMA REHAB, V15, P1081, DOI 10.1097/00001199-200010000-00002; SOHLBERE MM, 1989, INTRO COGNITIVE REHA; Sohlberg M., 2001, COGNITIVE REHABILITA; Sohlberg M.M., 1986, ATTENTION PROCESS TR; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; Sosin DM, 1996, BRAIN INJURY, V10, P47; Spilker B, 1991, GUIDE CLIN TRIALS; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vanderploeg RD, 2006, J HEAD TRAUMA REHAB, V21, P179, DOI 10.1097/00001199-200603000-00010; VOLPE BT, 1990, ARCH NEUROL-CHICAGO, V47, P220, DOI 10.1001/archneur.1990.00530020128026; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Wing JK, 1974, PRESENT STATE EXAMIN	49	89	89	1	29	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2008	89	12					2227	2238		10.1016/j.apmr.2008.06.015			12	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	385GY	WOS:000261803900001	19061734				2022-02-06	
J	Hokari, M; Kuroda, S; Shichinohe, H; Yano, S; Hida, K; Iwasaki, Y				Hokari, Masaaki; Kuroda, Satoshi; Shichinohe, Hideo; Yano, Shunsuke; Hida, Kazutoshi; Iwasaki, Yoshinobu			Bone marrow stromal cells protect and repair damaged neurons through multiple mechanisms	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						bone marrow stromal cell; neuron; differentiation; neurotrophin; regeneration; coculture	MESENCHYMAL STEM-CELLS; IN-VITRO DIFFERENTIATION; TRAUMATIC BRAIN-INJURY; MICE CEREBRAL INFARCT; SPINAL-CORD-INJURY; NEUROECTODERMAL DIFFERENTIATION; GENE-EXPRESSION; GROWTH-FACTOR; RAT; TRANSPLANTATION	A surprising shortage of information surrounds the mechanism by which bone marrow stromal cells (BMSC) restore lost neurologic functions when transplanted into the damaged central nervous system. To clarify the issue, the BMSC were cocultured with the neurons using two paradigms: the cell-mixing coculture technique and three-dimensional coculture technique. The green fluorescent protein (GFP)-expressing BMSC were cocultured with the PKH-26-labelled neurons, using cell mixing coculture technique. GFP-positive, PKH-26-negative cells morphologically simulated the neurons and significantly increased the expression of AP-2, Tuj-1, nestin, and GFAP GFP/nestin-positive, PKH-26-negative cells increased from 13.6% +/- 6.7% to 32.1 % +/- 15.5% over 7 days of coculture. They further enhanced Tuj-1 expression when cocultured with neurons exposed to 100 mu M of glutamate for 10 min. About 20-30% of GFP-positive cells became positive for PKH-26 through coculture with the neurons, but the doubly positive cells did not increase when cocultured with glutamate-exposed neurons. Alternatively, the BMSC significantly ameliorated glutamate-induced neuronal damage when cocultured with the three-dimensional coculture technique. The protective effect was more prominent when coculture was started prior to glutamate exposure than when coculture was started just after glutamate exposure. ELISA analysis revealed that the BMSC physiologically produce NGF, BDNF, SDF-1 alpha, HGF, TGF beta-1, and IGF-1 and significantly enhanced the production of NGF and BDNF when cocultured with glutamate-exposed neurons. These findings strongly suggest that the BMSC may protect and repair the damaged neurons through multiple mechanisms, including transdifferentiation, cell fusion, and production of growth factors. (C) 2007 Wiley-Liss, Inc.	[Hokari, Masaaki; Kuroda, Satoshi; Shichinohe, Hideo; Yano, Shunsuke; Hida, Kazutoshi; Iwasaki, Yoshinobu] Hokkaido Univ, Grad Sch Med, Dept Neurosurg, Kita Ku, Sapporo, Hokkaido 0608638, Japan		Kuroda, S (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Neurosurg, Kita Ku, N 15 W 7, Sapporo, Hokkaido 0608638, Japan.	skuroda@med.hokudai.ac.jp	Shichinohe, Hideo/G-5367-2012				Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bossolasco P, 2005, EXP NEUROL, V193, P312, DOI 10.1016/j.expneurol.2004.12.013; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Gao Q, 2005, NEUROSCIENCE, V136, P123, DOI 10.1016/j.neuroscience.2005.06.091; Garcia R, 2004, BIOCHEM BIOPH RES CO, V316, P753, DOI 10.1016/j.bbrc.2004.02.111; Hermann A, 2006, J NEUROSCI RES, V83, P1502, DOI 10.1002/jnr.20840; Hill WD, 2004, J NEUROPATH EXP NEUR, V63, P84, DOI 10.1093/jnen/63.1.84; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Jiang YH, 2003, P NATL ACAD SCI USA, V100, P11854, DOI 10.1073/pnas.1834196100; Jin KL, 2003, EXP NEUROL, V184, P78, DOI 10.1016/S0014-4886(03)00133-X; Jori FP, 2005, J CELL BIOCHEM, V94, P645, DOI 10.1002/jcb.20315; Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC; Kohyama J, 2001, DIFFERENTIATION, V68, P235, DOI 10.1046/j.1432-0436.2001.680411.x; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Kortesidis A, 2005, BLOOD, V105, P3793, DOI 10.1182/blood-2004-11-4349; Lee JB, 2004, BRAIN RES PROTOC, V14, P37, DOI 10.1016/j.brainresprot.2004.09.004; Lee JB, 2003, NEUROPATHOLOGY, V23, P169, DOI 10.1046/j.1440-1789.2003.00496.x; Lu P, 2004, J NEUROSCI RES, V77, P174, DOI 10.1002/jnr.20148; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Neuhuber B, 2005, BRAIN RES, V1035, P73, DOI 10.1016/j.brainres.2004.11.055; Neuhuber B, 2004, J NEUROSCI RES, V77, P192, DOI 10.1002/jnr.20147; Niikura T, 2004, J NEUROSCI RES, V77, P54, DOI 10.1002/jnr.20139; Poupot M, 2003, J IMMUNOL, V171, P2517, DOI 10.4049/jimmunol.171.5.2517; Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100; Rismanchi N, 2003, BRAIN RES, V991, P46, DOI 10.1016/j.brainres.2003.07.004; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Shichinohe H, 2004, BRAIN RES PROTOC, V13, P166, DOI 10.1016/j.brainresprot.2004.04.004; Shichinohe H, 2006, J NUCL MED, V47, P486; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; Spees JL, 2003, P NATL ACAD SCI USA, V100, P2397, DOI 10.1073/pnas.0437997100; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Tondreau T, 2004, DIFFERENTIATION, V72, P319, DOI 10.1111/j.1432-0436.2004.07207003.x; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wislet-Gendebien S, 2005, BRAIN RES BULL, V68, P95, DOI 10.1016/j.brainresbull.2005.08.016; Wislet-Gendebien S, 2005, STEM CELLS, V23, P392, DOI 10.1634/stemcells.2004-0149; Woodbury D, 2002, J NEUROSCI RES, V69, P908, DOI 10.1002/jnr.10365; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Yamaguchi S, 2006, BRAIN RES, V1087, P15, DOI 10.1016/j.brainres.2006.02.127; Yano S, 2005, BRAIN RES, V1065, P60, DOI 10.1016/j.brainres.2005.10.031; Yano S, 2005, J NEUROTRAUM, V22, P907, DOI 10.1089/neu.2005.22.907; Zhong C, 2003, NEUROSCI LETT, V342, P93, DOI 10.1016/S0304-3940(03)00255-6	46	89	102	0	10	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	APR	2008	86	5					1024	1035		10.1002/jnr.21572			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	284QD	WOS:000254720000007	18030676				2022-02-06	
J	Onyszchuk, G; He, YY; Berman, NEJ; Brooks, WM				Onyszchuk, Gregory; He, Yong-Yue; Berman, Nancy E. J.; Brooks, William M.			Detrimental effects of aging on outcome from traumatic brain injury: A behavioral, magnetic resonance imaging, and histological study in mice	JOURNAL OF NEUROTRAUMA			English	Article						age; blood-brain barrier dysfunction; geriatric brain injury; neurodegenerative disorders; traumatic brain injury	CONTROLLED CORTICAL IMPACT; PROSPECTIVE MULTICENTER TRIAL; COGNITIVE DEFICITS; INTRACEREBRAL HEMORRHAGE; GENE-EXPRESSION; TRANSGENIC MICE; OLDER-ADULTS; SPINAL-CORD; EDEMA; RECOVERY	Considerable evidence indicates that outcomes from traumatic brain injury (TBI) are worse in the elderly, but there has been little preclinical research to explore potential mechanisms. In this study, we examined the age-related effects on outcome in a mouse model of controlled cortical impact (CCI) injury. We compared the responses of adult (5-6 months old) and aged (21-24 months old) male mice following a moderate lateral CCI injury to the sensorimotor cortex. Sensorimotor function was evaluated with the rotarod, gridwalk and spontaneous forelimb behavioral tests. Acute edema was assessed from hyperintensity on T2-weighted magnetic resonance images. Blood-brain barrier opening was measured using anti-mouse immunoglobulin G (IgG) immunohistochemistry. Neurodegeneration was assessed by amino-cupric silver staining, and lesion cavity volumes were measured from histological images. Indicators of injury were generally worse in the aged than the adult mice. Acute edema, measured at 24 and 48 h post-injury, resolved more slowly in the aged mice (p < 0.01). Rotarod recovery (p < 0.05) and gridwalk deficits (p < 0.01) were significantly worse in aged mice. There was greater (P < 0.01 at 3 days) and more prolonged post-acute opening of the blood-brain barrier in the aged mice. Neurodegeneration was greater in the aged mice (p < 0.01 at 3 days). In contrast, lesion cavity volumes, measured at 3 days post-injury, were not different between injured groups. These results suggest that following moderate controlled cortical impact injury, the aged brain is more vulnerable than the adult brain to neurodegeneration, resulting in greater loss of function. Tissue loss at the impact site does not explain the increased functional deficits seen in the aged animals. Prolonged acute edema, increased opening of the blood-brain barrier and increased neurodegeneration found in the aged animals implicate secondary processes in age-related differences in outcome.	[Onyszchuk, Gregory; He, Yong-Yue; Brooks, William M.] Univ Kansas, Med Ctr, Hoglund Brain Imaging Ctr, Dept Neurol, Kansas City, KS 66160 USA; [Onyszchuk, Gregory; Berman, Nancy E. J.] Univ Kansas, Med Ctr, Steve Palermo Nerve Regenerat Lab, Kansas City, KS 66160 USA; [Onyszchuk, Gregory; Brooks, William M.] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA		Brooks, WM (corresponding author), Univ Kansas, Med Ctr, Hoglund Brain Imaging Ctr, Dept Neurol, MailStop 1052,3901 Rainbow Blvd, Kansas City, KS 66160 USA.	wbrooks@kumc.edu		brooks, william/0000-0001-6227-7636	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21 AG026482] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30 HD02528] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS039123] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD002528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG026482] Funding Source: NIH RePORTER		BARTKOWSKI HM, 1985, J TRAUMA, V25, P192, DOI 10.1097/00005373-198503000-00004; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; Benkovic SA, 2006, BRAIN RES, V1070, P215, DOI 10.1016/j.brainres.2005.11.065; Benn SC, 2004, NAT REV NEUROSCI, V5, P686, DOI 10.1038/nrn1477; Bilgen M, 2005, NEUROREHAB NEURAL RE, V19, P219, DOI 10.1177/1545968305278635; BRANTZAWADZKI M, 1984, AM J NEURORADIOL, V5, P125; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Dash PK, 2004, J NEUROTRAUM, V21, P1573, DOI 10.1089/0897715042441828; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; Felzien LK, 2001, BRAIN RES, V890, P137, DOI 10.1016/S0006-8993(00)03090-0; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Franceschi C, 2000, ANN NY ACAD SCI, V908, P244; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Franklin K.B., 1997, MOUSE BRAIN STEREOTA; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GALBRAITH S, 1987, BRIT MED J, V294, P325, DOI 10.1136/bmj.294.6568.325; Gong Y, 2005, ACT NEUR S, V95, P425; Gong Y, 2004, STROKE, V35, P2571, DOI 10.1161/01.STR.0000145485.67827.d0; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; He W., 2005, CURRENT POPULATION R; Helmy A, 2007, CURR MED CHEM, V14, P1525, DOI 10.2174/092986707780831113; Jones E.G., 1985, THALAMUS; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Leblanc N, 2006, BRAIN COGNITION, V60, P208; Li XL, 2004, EXP NEUROL, V187, P94, DOI 10.1016/j.expneurol.2004.01.004; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Mattson MP, 2006, NAT REV NEUROSCI, V7, P278, DOI 10.1038/nrn1886; Moor E, 2006, EXP GERONTOL, V41, P303, DOI 10.1016/j.exger.2005.12.006; Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Muessel MJ, 2002, MOL BRAIN RES, V103, P12, DOI 10.1016/S0169-328X(02)00158-4; Narayana PA, 2004, J NEUROSCI RES, V78, P749, DOI 10.1002/jnr.20275; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Sandhir R, 2004, NEUROSCI LETT, V369, P28, DOI 10.1016/j.neulet.2004.07.032; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Scholz M, 2007, MED RES REV, V27, P401, DOI 10.1002/med.20064; Schuhmann MU, 2002, ACTA NEUROCHIR SUPPL, V81, P213; Schwarcz A, 2001, MAGN RESON MED, V46, P1246, DOI 10.1002/mrm.1324; Shimamura M, 2004, MOL BRAIN RES, V122, P47, DOI 10.1016/j.molbrainres.2003.11.015; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Suo Z., 2004, Current Drug Targets - Inflammation and Allergy, V3, P105, DOI 10.2174/1568010043483953; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Tehranian R, 2006, BRAIN RES, V1101, P126, DOI 10.1016/j.brainres.2006.05.049; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; UNTERBERG A, 1994, ACTA NEUROCHIR, P431; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Zink Brian J., 1996, Emergency Medicine Clinics of North America, V14, P115	64	89	93	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2008	25	2					153	171		10.1089/neu.2007.0430			19	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	266RZ	WOS:000253456000008	18260798				2022-02-06	
J	Carone, DA				Carone, Dominic A.			Children with moderate/severe brain damage/dysfunction outperform adults with mild-to-no brain damage on the Medical Symptom Validity Test	BRAIN INJURY			English	Article						Effort testing; validity testing; mild traumatic brain injury; children; malingering	HEAD-INJURY; PERFORMANCE; SCALE; EXAGGERATION; CONCUSSION; CAPACITY; ISSUES	Primary objective: This study sought independent confirmation that the English computerized Medical Symptom Validity Test can be easily passed by children with moderate-to-severe brain injury/dysfunction (e.g. traumatic brain injury, stroke) and/or developmental disabilities. In addition, it was hypothesized that a higher percentage of such children would pass the MSVT compared to adults with mild traumatic brain injury or head injury (MTBI/HI) and would rate the task as easier. Methods: Thirty-eight children and 67 adults were administered the MSVT during an outpatient neuropsychological evaluation. Results: Two children (5%) failed the MSVT, whereas 14 (21%) of adults failed. Children performed significantly better on the MSVT and rated it as significantly easier compared to adults who failed the MSVT. There were no such differences when children were compared to adults who passed the MSVT. Conclusions: Findings independently validate the use of the MSVT with children and demonstrate symptom exaggeration in a sub-set of adult MTBI/HI patients.	[Carone, Dominic A.] SUNY Upstate Med Univ, Dept Phys Med & Rehabil, Neuropsychol Assessment Program, Syracuse, NY USA		Carone, DA (corresponding author), Univ Hosp, Neuropsychol Assessment Program, Dept Phys Med & Rehabil, 750 E Adams St, Syracuse, NY 13210 USA.	caroned@upstate.edu					American Psychological Association, 2017, ETH PRINC PSYCH COD; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Beck AT, 1993, BECK ANXIETY INVENTO; Blaskewitz N, 2008, ARCH CLIN NEUROPSYCH, V23, P379, DOI 10.1016/j.acn.2008.01.008; BRANDT J, 2001, VERBAL LEARNING TEST; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Chafetz MD, 2007, ARCH CLIN NEUROPSYCH, V22, P1, DOI 10.1016/j.acn.2006.10.003; CLARRIDGE C, MOTHER GETS 3 YEARS; Constantinou M, 2003, CHILD NEUROPSYCHOL, V9, P81, DOI 10.1076/chin.9.2.81.14505; DELIS DC, 2001, DELISKAPLAN EXECUTIV; Donders J, 2005, CHILD NEUROPSYCHOL, V11, P221, DOI 10.1080/09297040490917298; FAUST D, 1988, J CONSULT CLIN PSYCH, V56, P578, DOI 10.1037/0022-006X.56.4.578; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P, 2007, PHYS MED REHABILITAT, V18, pvi; Green P., 2003, GREENS WORD MEMORY T; Green P, 2004, GREENS MED SYMPTOM V; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; Greiffenstein MF, 2003, CLIN NEUROPSYCHOL, V17, P561, DOI 10.1076/clin.17.4.561.27937; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heubrock D, 2001, CHILD NEUROPSYCHOL, V7, P273, DOI 10.1076/chin.7.4.273.8738; Howe LLS, 2007, ARCH CLIN NEUROPSYCH, V22, P753, DOI 10.1016/j.acn.2007.06.003; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2006, APPL NEUROPSYCHOL, V13, P77, DOI 10.1207/s15324826an1302_3; Kaplan E., 2001, BOSTON NAMING TEST; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; LANGLOIS JA, 1997, MMWR-MORBID MORTAL W, V52, P1; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; Lu PH, 2002, CLIN NEUROPSYCHOL, V16, P90, DOI 10.1076/clin.16.1.90.8328; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Mantynen H, 2001, CHILD NEUROPSYCHOL, V7, P241, DOI 10.1076/chin.7.4.241.8739; MEYERS J, 1995, MEYERS SCORING SYSTE; Meyers JE, 1996, REY COMPLEX FIGURE R; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Polak A, 1999, DEV PSYCHOL, V35, P561, DOI 10.1037/0012-1649.35.2.561; Rey A., 1964, EXAMEN CLIN PSYCHOL; Richman J, 2006, J OCCUP ENVIRON MED, V48, P303, DOI 10.1097/01.jom.0000183482.41957.c3; SCHMITZ B, 1993, J PERS SOC PSYCHOL, V64, P1010, DOI 10.1037/0022-3514.64.6.1010; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sheslow DA, 2003, WIDE RANGE ASSESSMEN; Slick D.J., 1997, VICTORIA SYMPTOM VAL; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; TEASDALE G, 1974, LANCET, V2, P81; Tombaugh T.N., 1996, TEST MEMORY MALINGER; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	52	89	91	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	12					960	971	PII 905455478	10.1080/02699050802491297			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	371RV	WOS:000260849900007	19005888				2022-02-06	
J	Ofek, H; Defrin, R				Ofek, Hadas; Defrin, Ruth			The characteristics of chronic central pain after traumatic brain injury	PAIN			English	Article						traumatic brain injury; chronic pain; central pain; quantitative somatosensory testing	SPINAL-CORD-INJURY; CENTRAL NEUROPATHIC PAIN; SENSORY FUNCTION; PHARMACOLOGICAL-TREATMENT; MULTIPLE-SCLEROSIS; THRESHOLDS; MECHANISMS; RELIABILITY; THALAMUS; PATIENT	Central pain following traumatic brain injury (TBI) has not been studied in depth. Our purpose was to conduct a systematic study of patients with TBI suffering from chronic central pain, and to describe the characteristics of the central pain. Groups were TBI patients with (TBIP) and without central pain (TBINP) and healthy controls. TBI patients with other pain mechanisms were excluded from the study. Participants underwent quantitative somatosensory testing in the painful and pain-free body regions. Thresholds for warmth, cold, heat-pain, touch and graphesthesia were measured and pathologically evoked pain (allodynia, hyperpathia and wind-up pain) evaluated. Chronic pain was mapped and characterized. Chronic pain developed at a relatively late onset (6.6 +/- 9 months) was almost exclusively unilateral and reported as pricking, throbbing and burning. Although both TBIP and TBINP exhibited a significant reduction in thermal and tactile sensations compared to controls, thermal sensations in the painful regions of TBIP were significantly more impaired than pain-free regions in the same patients (p < 0.01) and in TBINP (p < 0.01). Painful regions also exhibited very high rates of allodynia, hyperpathia and exaggerated wind-up. The characteristics of the chronic pain resembled those of other central pain patients although TBIP displayed several unique features. The sensory profile indicated that damage to the pain and temperature systems is a necessary but not sufficient condition for the development of chronic central pain following TBI. Neuronal hyperexcitability may be a contributing factor to the chronic pain. (C) 2007 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	Tel Aviv Univ, Sackler Fac Med, Sch Hlth Profess, Dept Phys Therapy, IL-69978 Ramat Aviv, Israel; Loewenstein Hosp Rehabil Ctr, Raanana, Israel		Defrin, R (corresponding author), Tel Aviv Univ, Sackler Fac Med, Sch Hlth Profess, Dept Phys Therapy, IL-69978 Ramat Aviv, Israel.	rutidef@post.tau.ac.il	ofek, hadas/AAM-7017-2020				Alfano DP, 2000, ARCH CLIN NEUROPSYCH, V15, P831, DOI 10.1016/S0887-6177(00)80329-7; Barraquer-Bordas L, 1993, Neurologia, V8, P147; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BELLKROTOSKI J, 1987, J HAND SURG-AM, V12A, P155, DOI 10.1016/S0363-5023(87)80189-2; Beniczky S, 2005, J NEURAL TRANSM, V112, P735, DOI 10.1007/s00702-005-0300-x; BERIC A, 1988, PAIN, V34, P109, DOI 10.1016/0304-3959(88)90155-8; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BOIVIE J, 1989, PAIN, V37, P173, DOI 10.1016/0304-3959(89)90128-0; BOIVIE J, 1999, TXB PAIN, P871; Bowsher D, 1996, J NEUROL NEUROSUR PS, V61, P62, DOI 10.1136/jnnp.61.1.62; Bowsher D, 1998, NEUROLOGY, V51, P1352, DOI 10.1212/WNL.51.5.1352; CASEY KL, 1999, 9 WORLD C PAIN SEATT, P435; COOPER PR, 1993, HEAD INJURY, P1; COSGROVE JL, 1989, AM J PHYS MED REHAB, V68, P15, DOI 10.1097/00002060-198902000-00005; Defrin R, 2002, BRAIN, V125, P501, DOI 10.1093/brain/awf055; Defrin R, 2001, PAIN, V89, P253, DOI 10.1016/S0304-3959(00)00369-9; Defrin R, 1999, PAIN, V83, P275, DOI 10.1016/S0304-3959(99)00115-3; Ducreux D, 2006, BRAIN, V129, P963, DOI 10.1093/brain/awl016; Eide PK, 1996, J NEUROL NEUROSUR PS, V60, P411, DOI 10.1136/jnnp.60.4.411; Finnerup NB, 2005, PAIN, V118, P289, DOI 10.1016/j.pain.2005.08.013; Finnerup NB, 2003, BRAIN, V126, P57, DOI 10.1093/brain/awg007; Frese A, 2006, CLIN J PAIN, V22, P252, DOI 10.1097/01.ajp.0000173020.10483.13; FRUHSTORFER H, 1976, J NEUROL NEUROSUR PS, V39, P1071, DOI 10.1136/jnnp.39.11.1071; Gellman H, 1996, J HEAD TRAUMA REHAB, V11, P23, DOI 10.1097/00001199-199608000-00005; Greenspan JD, 2004, PAIN, V109, P357, DOI 10.1016/S0304-3959(04)00068-5; Hansson P, 2004, EUR J NEUROL, V11, P22, DOI 10.1111/j.1471-0552.2004.00793.x; Hulsebosch CE, 2005, CURR PHARM DESIGN, V11, P1411, DOI 10.2174/1381612053507864; Ivanhoe CB, 2004, J HEAD TRAUMA REHAB, V19, P29, DOI 10.1097/00001199-200401000-00004; JOHANSSON RS, 1980, BRAIN RES, V184, P343, DOI 10.1016/0006-8993(80)90803-3; KATZ N, 1989, AM J OCCUP THER, V43, P184, DOI 10.5014/ajot.43.3.184; Khoshyomn S, 2004, J TRAUMA, V56, P1131, DOI 10.1097/01.TA.0000071299.31349.D6; LAHUERTA J, 1990, PAIN, V42, P23, DOI 10.1016/0304-3959(90)91087-Y; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; LENZ FA, 1994, J NEUROPHYSIOL, V72, P1570, DOI 10.1152/jn.1994.72.4.1570; LENZ FA, 1987, PAIN, V31, P225, DOI 10.1016/0304-3959(87)90038-8; MELZACK R, 1971, ANESTHESIOLOGY, V34, P50; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Merskey H, 1994, CLASSIFICATION CHRON; Ness TJ, 1998, PAIN, V78, P139, DOI 10.1016/S0304-3959(98)00153-5; OCHOA JL, 1993, ANN NEUROL, V33, P465, DOI 10.1002/ana.410330509; Osterberg A, 2005, EUR J PAIN, V9, P531, DOI 10.1016/j.ejpain.2004.11.005; Pattany PM, 2002, AM J NEURORADIOL, V23, P901; Peyron R, 2000, PAIN, V84, P77, DOI 10.1016/S0304-3959(99)00190-6; PRICE DD, 1992, PAIN, V49, P163, DOI 10.1016/0304-3959(92)90139-3; Sherman Kristen Brewer, 2006, Phys Med Rehabil Clin N Am, V17, P473, DOI 10.1016/j.pmr.2005.11.007; Son BC, 2006, PAIN, V123, P210, DOI 10.1016/j.pain.2006.02.028; Svendsen KB, 2005, PAIN, V114, P473, DOI 10.1016/j.pain.2005.01.015; TASKER RR, 1992, J NEUROSURG, V77, P373, DOI 10.3171/jns.1992.77.3.0373; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; THURMAN D, 2001, HEAD TRAUMA BASIC PR; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; VERDUGO R, 1992, BRAIN, V115, P893, DOI 10.1093/brain/115.3.893; VESTERGAARD K, 1995, PAIN, V61, P177, DOI 10.1016/0304-3959(94)00140-A; VOGELBAUM MA, 1998, CLIN NEUROL, V3, P1; Walker WC, 2004, J HEAD TRAUMA REHAB, V19, P72, DOI 10.1097/00001199-200401000-00007; WILCOX GL, 1984, BRAIN RES BULL, V12, P143, DOI 10.1016/0361-9230(84)90227-2; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x; YARNITSKY D, 1990, PAIN, V40, P85, DOI 10.1016/0304-3959(90)91055-N	58	89	90	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	OCT	2007	131	3					330	340		10.1016/j.pain.2007.06.015			11	Anesthesiology; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology	220SU	WOS:000250178400015	17689190				2022-02-06	
J	Butcher, I; Maas, AIR; Lu, J; Marmarou, A; Murray, GD; Mushkudiani, NA; McHugh, GS; Steyerberg, EW				Butcher, Isabella; Maas, Andrew I. R.; Lu, Juan; Marmarou, Anthony; Murray, Gordon D.; Mushkudiani, Nino A.; McHugh, Gillian S.; Steyerberg, Ewout W.			Prognostic value of admission blood pressure in traumatic brain injury: Results from the IMPACT study	JOURNAL OF NEUROTRAUMA			English	Article						blood pressure; outcome; predictors; prognosis; traumatic brain injury	SEVERE HEAD-INJURY	Hypotension following traumatic brain injury (TBI) is recognized as an important secondary insult that is associated with adverse outcome. We aimed to describe the relationship between actual levels of admission blood pressure and Glasgow Outcome Scale (GOS) at 6 months. Individual patient data from the IMPACT database were available on systolic (N = 6801) and mean arterial (N = 6647) blood pressure. Regression models with restricted cubic spline functions were used to explore the shape of the relationships between blood pressure and outcome in unadjusted and adjusted analyses. Proportional odds methodology was applied to quantify the strength of the associations across the full range of the GOS. Analyses were performed to search for threshold values. A smooth U-shaped relationship was observed between systolic (SBP) and mean arterial (MABP) blood pressures and outcome, without any evidence of an abrupt threshold effect. Best outcomes were observed for values of SBP of the order of 135 mm Hg and for values of MABP of the order of 90 mm Hg. Both lower (OR 1.53; 95% CI: 1.31-1.80) and higher levels (OR 1.42; CI: 1.20-1.68) of SBP and lower (OR 1.30; CI 1.12-1.51) and higher levels of MABP (OR 1.45; CI 1.19-1.76) were associated with poorer outcome. These findings were consistent across studies. The relationship between high blood pressure level and poorer outcome largely disappeared on adjusted analysis. Current guidelines for the management of blood pressure in TBI focus on the avoidance of hypotension as defined by SBP < 90 mm, Hg. Our finding of a smooth relationship with improving outcome as SBP increases up to 135 nun Hg, while not supporting a strong causal inference, does suggest that current guidelines need to be reconsidered.	Univ Edinburgh, Sch Med, Edinburgh EH8 9AG, Midlothian, Scotland; Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands; Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands; Virginia Commonwealth Univ, Med Ctr, Dept Neurosurg, Richmond, VA USA		Butcher, I (corresponding author), Univ Edinburgh, Sch Med, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	Izzy.Butcher@ed.ac.uk	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Murray, Gordon/0000-0001-9866-4734; Steyerberg, Ewout/0000-0002-7787-0122; Lu, Juan/0000-0002-5389-7603	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-042691] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER		Bullock RM, 2000, J NEUROTRAUM, V17, P449; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Dutton RP, 2002, J TRAUMA, V52, P1141, DOI 10.1097/00005373-200206000-00020; Fowler R, 2002, EMERG MED CLIN N AM, V20, P953, DOI 10.1016/S0733-8627(02)00038-X; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; PRYSROBERTS C, 1984, MONITORING ANESTHESI, P79; Walia S, 2002, INJURY, V33, P339, DOI 10.1016/S0020-1383(02)00053-0	11	89	89	0	1	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2007	24	2					294	302		10.1089/neu.2006.0032			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	150AL	WOS:000245187900009	17375994				2022-02-06	
J	Buse, GJ				Buse, GJ			No holds barred sport fighting: a 10 year review of mixed martial arts competition	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							INJURIES; JUDO; CONCUSSION; KARATE	Objective: To identify the most salient medical issues that may be associated with mixed martial arts competition by determining the types and proportions of match stoppages. Methods: Publicly available video footage of 1284 men competing in 642 consecutive televised matches from November 1993 to November 2003 was reviewed to determine the reasons for which matches were stopped. Matches were sanctioned by either a United States or Japan based mixed martial arts organisation. Results: Of the 642 matches, 182 (28.3 +/- 3.4%) were stopped because of head impact, 106 (16.5 +/- 2.9%) because of musculoskeletal stress, 91 (14.1 +/- 2.7%) because of neck choke, 83 (12.9 +/- 2.6%) because of miscellaneous trauma, 173 (27.0 +/- 3.4%) because of expiration of match time, and seven ( 1.0 +/- 0.8%) because of disqualification, where the values in parentheses are percentages +/- 95% confidence interval. Conclusions: Blunt force to the head resulted in the highest proportion of match stoppages. Further research is warranted to delineate the morbidity associated with participation in mixed martial arts.	Cannon USAF Clin, Clovis, NM 88103 USA		Buse, GJ (corresponding author), Cannon USAF Clin, Clovis, NM 88103 USA.	george.buse@cannon.af.mil					Aotsuka A, 1990, Rinsho Shinkeigaku, V30, P1243; ARVANITIS J, 2003, PANKRATION TRADITION, P1; Birrer RB, 1996, AM J SPORT MED, V24, pS72, DOI 10.1177/036354659602406S21; Buckwalter JA, 2004, CLIN ORTHOP RELAT R, P7, DOI 10.1097/01.blo.0000131638.81519.de; Chang Eli L., 2002, International Ophthalmology Clinics, V42, P187; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; ESTWANIK J J, 1984, Physician and Sportsmedicine, V12, P123; Gartland S, 2005, CLIN J SPORT MED, V15, P34, DOI 10.1097/00042752-200501000-00007; Gartland S, 2001, BRIT J SPORT MED, V35, P308, DOI 10.1136/bjsm.35.5.308; GENTRY C, 2001, NO HOLDS BARRED EVOL, P1; Hainsworth R, 2004, CLIN AUTON RES, V14, P18, DOI 10.1007/s10286-004-1004-2; HEARN W, 1996, AM MED NEWS, V39, P11; Kelly JP, 1997, NEUROLOGY, V48, P581; Kochhar T, 2005, BRIT J SPORT MED, V39, P444, DOI 10.1136/bjsm.2004.011270; KOIWAI EK, 1987, J FORENSIC SCI, V32, P419; KUJALA UM, 1995, BRIT MED J, V311, P1465, DOI 10.1136/bmj.311.7018.1465; KURILOFF DB, 1989, ANN OTO RHINOL LARYN, V98, P824, DOI 10.1177/000348948909801014; Lundberg GD, 1996, JAMA-J AM MED ASSOC, V275, P1684, DOI 10.1001/jama.275.21.1684; McCarron MA, 1997, BRIT J SPORT MED, V31, P346, DOI 10.1136/bjsm.31.4.346; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Moriarity J, 2004, NEUROLOGY, V62, P1497, DOI 10.1212/WNL.62.9.1497; OLER M, 1991, J TRAUMA, V31, P251, DOI 10.1097/00005373-199131020-00017; OWENS RG, 1991, J SPORT MED PHYS FIT, V31, P627; POLIAKOFF MB, 1995, COMBAT SPORTS ANCIEN, P54; PORTER K, 1998, CHIPLEY MAN DIES INJ; RABADI MH, 2000, NEUROLOGIC ATHLETIC, P297; Rodriguez G, 1998, ITAL J NEUROL SCI, V19, P367, DOI 10.1007/BF02341784; SCHWARTZ ML, 1986, J NEUROSURG, V64, P248, DOI 10.3171/jns.1986.64.2.0248; Zazryn TR, 2003, BRIT J SPORT MED, V37, P448, DOI 10.1136/bjsm.37.5.448	29	89	90	0	32	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	FEB	2006	40	2					169	172		10.1136/bjsm.2005.021295			4	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	005NP	WOS:000234831400017	16432006	Green Published			2022-02-06	
J	Ariza, M; Serra-Grabulosa, JM; Junque, C; Ramirez, B; Mataro, M; Poca, A; Bargallo, N; Sahuquillo, J				Ariza, Mar; Serra-Grabulosa, Josep M.; Junque, Carme; Ramirez, Blanca; Mataro, Maria; Poca, Antonia; Bargallo, Nuria; Sahuquillo, Juan			Hippocampal head atrophy after traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						TBI; hippocampus; memory	HIGH INTRACRANIAL-PRESSURE; VERBAL MEMORY; VOLUME; AMYGDALA; DAMAGE; MRI; MORPHOLOGY; ANTERIOR; DEFICITS; FORNIX	Traumatic brain injury (TBI) causes hippocampal damage. The hippocampus can be macroscopically divided into the head, body and tail, which differ in terms of their sensitivity to excitability and also in terms of their cortical connections. We investigated whether damage also varies according to the hippocampal area involved, and studied the relationship of hippocampal reductions with memory performance. Twenty TBI patients and matched controls were examined. MRI measurements were performed separately for the hippocampal head, body and tail. Memory outcome was measured by Rey's auditory verbal learning test, Rey's complex figure test and a modified version of Warrington's facial recognition memory test. Group comparison showed that patients had bilateral hippocampal atrophy, mainly involving the hippocampal head. Moreover, TBI subjects showed verbal memory deficits which presented slight correlations with left hippocampal head atrophy. (c) 2005 Elsevier Ltd. All rights reserved.	Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, IDIBAPS, Dept Psychiat & Clin Psychol, Barcelona, Spain; Univ Autonoma Barcelona, Dept Neurosurg, Vall Hebron Univ Hosp, E-08193 Barcelona, Spain; Hosp Clin Barcelona, CDI, Dept Radiol, Barcelona, Spain		Junque, C (corresponding author), Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, IDIBAPS, Dept Psychiat & Clin Psychol, C Casanova,143, Barcelona, Spain.	cjunque@ub.edu	Poca, Maria A./B-8475-2008; Bargallo, Nuria/G-6854-2016; Mataro, Maria/B-4524-2011; Serra-Grabulosa, Josep M/S-8371-2019; Ariza, Mar/F-2754-2019; Sahuquillo, Juan/B-3577-2008; Junque, Carme/B-4400-2011; Serra-Grabulosa, Josep M/B-4655-2011	Poca, Maria A./0000-0002-3831-0536; Bargallo, Nuria/0000-0001-6284-5402; Mataro, Maria/0000-0002-9946-2656; Serra-Grabulosa, Josep M/0000-0002-4291-9432; Sahuquillo, Juan/0000-0003-0713-5875; Junque, Carme/0000-0002-6381-3063; Ariza, Mar/0000-0003-1020-6945			Baxendale SA, 1997, NEUROPSYCHOLOGIA, V35, P591, DOI 10.1016/S0028-3932(96)00123-6; Bernal F, 2000, EXP NEUROL, V161, P686, DOI 10.1006/exnr.1999.7293; Bernasconi N, 2003, BRAIN, V126, P462, DOI 10.1093/brain/awg034; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; BULLOCK MR, 2000, J NEUROTRAUM, V17, P1; Cavada C, 2000, CEREB CORTEX, V10, P220, DOI 10.1093/cercor/10.3.220; Duvernoy HM, 1988, HUMAN HIPPOCAMPUS; FREE SL, 1995, AM J NEURORADIOL, V16, P37; Gennarelli, 1998, Semin Clin Neuropsychiatry, V3, P160; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Gimenez M, 2004, NEUROIMAGE, V23, P869, DOI 10.1016/j.neuroimage.2004.07.029; Hackert VH, 2002, NEUROIMAGE, V17, P1365, DOI 10.1006/nimg.2002.1248; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hopkins RO, 2005, NEUROPSYCHOLOGY, V19, P233, DOI 10.1037/0894-4105.19.2.233; JACK CR, 1989, RADIOLOGY, V172, P549, DOI 10.1148/radiology.172.2.2748838; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Maguire EA, 2000, P NATL ACAD SCI USA, V97, P4398, DOI 10.1073/pnas.070039597; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Mishkin M, 1997, PHILOS T R SOC B, V352, P1461, DOI 10.1098/rstb.1997.0132; Mitrushina MN, 1999, HDB NORMATIVE DATA N; O'Driscoll GA, 2001, PSYCHIAT RES-NEUROIM, V107, P75, DOI 10.1016/S0925-4927(01)00095-6; Pruessner JC, 2000, CEREB CORTEX, V10, P433, DOI 10.1093/cercor/10.4.433; Pruessner JC, 2001, J NEUROSCI, V21, P194, DOI 10.1523/JNEUROSCI.21-01-00194.2001; Rey A., 1959, TEST COPIE REPROD ME; Sahuquillo J, 2002, NEUROCIRUGIA, V13, P78; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; SQUIRE LR, 1992, NEUROPSYCHOLOGY MEMO; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Wang L, 2003, NEUROIMAGE, V20, P667, DOI 10.1016/S1053-8119(03)00361-6; Warrington EK., 1984, WARRINGTON RECOGNITI	37	89	92	0	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia		2006	44	10					1956	1961		10.1016/j.neuropsychologia.2005.11.007			6	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	068VS	WOS:000239403200033	16352320				2022-02-06	
J	Livingston, DH; Lavery, RF; Mosenthal, AC; Knudson, MM; Lee, S; Morabito, D; Manley, GT; Nathens, A; Jurkovich, G; Hoyt, DB; Coimbra, R				Livingston, DH; Lavery, RF; Mosenthal, AC; Knudson, MM; Lee, S; Morabito, D; Manley, GT; Nathens, A; Jurkovich, G; Hoyt, DB; Coimbra, R			Recovery at one year following isolated traumatic brain injury: A Western Trauma Association prospective multicenter trial	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	35th Annnual Meeting of the Western-Trauma-Association	FEB 27-MAR 05, 2005	Jackson Hole, WY	Western Trauma Assoc		traumatic brain injury; multicenter trial; FIM score; outcomes	INPATIENT REHABILITATION; FUNCTIONAL OUTCOMES; HEAD-INJURY; AGE; MORTALITY; SEVERITY; HOSPITALIZATION; INDEPENDENCE; EPIDEMIOLOGY; MORBIDITY	Background: Age has been shown to be a primary determinant of survival following isolated traumatic brain injury (TBI). We have previously reported that patients >= 65 years who survived mild TBI have decreased functional outcome at 6 months compared with younger patients. The purpose of this study was to further investigate the effect of age on outcome at 1 year in all patients surviving isolated TBI. Methods: The Western Trauma Association multicenter prospective study included all patients sustaining isolated TBI defined as Abbreviated Injury Scale score for Head >= 3 with an Abbreviated Injury Scale score in any other body area <= 1. Outcome data included discharge disposition, Glasgow Outcome Scale score (1 = dead to 5 = full recovery) and modified Functional Independence Measure (FIM) score measuring feeding, expression, and locomotion (1 = total dependence to 4 = total independence) for each component at discharge and 1 year. Results: In all, 295 patients were enrolled with a follow-up of 82%, resulting in 241 study patients. An additional five patients died from non-TBI causes and were excluded. The mean and median times for the last follow-up in the 236 remaining patients were 307 and 357 days, respectively. Patients were divided into four age ranges: 18 to 29 years (n = 66),30 to 44 years (n = 54),45 to 59 years (n = 50), and >= 60 years (n = 65). More severe TBIs, as measured by admitting Glasgow Coma Scale (GCS), were observed in the youngest group compared with all others but there were no differences in mean GCS between the remaining three groups. There were no differences in neurosurgical intervention between the groups. Age was a major determinant in the outcome at discharge and last follow-up. Patients over 60 years discharged with a GOS <= 4 were less likely to improve at 1 year than all other groups (37% versus 63 to 85%; p <= 0.05). Patients between 18 and 29 years of age had the lowest mean Glasgow Outcome Scale and discharge FIM scores, which correlated with the low admission GCS. Despite the increased severity of TBI, this group had the best FIM score at 1 year. In contrast, patients older than 60 years had the least improvement and had a significantly lower final FIM score at 1 year compared with all other groups. Conclusion: Older patients following isolated TBI have poorer functional status at discharge and make less improvement at 1 year compared with all other patients. These worse outcomes occur despite what appears to be less severe TBI as measured by a higher GCS upon admission. Differences in outcome begin to appear even in patients between 45 and 59 years. Further investigations with more detailed outcome instruments are required to better understand the qualitative limitations of a patient's recovery and to devise strategies to maximize functional improvement following TBI. Age is an exceedingly important parameter affecting recovery from isolated TBI.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, New Jersey Trauma Ctr, Newark, NJ 07103 USA; Univ Calif San Francisco, Dept Surg, San Francisco Gen Med Ctr, San Francisco, CA 94143 USA; Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA; Univ Washington, Injury Prevent & Res Inst, Seattle, WA 98104 USA; Univ Calif San Diego, Dept Surg, La Jolla, CA 92093 USA		Livingston, DH (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, New Jersey Trauma Ctr, 185 S Orange Ave, Newark, NJ 07103 USA.		Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851			*AG HEALTHC RES PO, 1998, REH TRAUM BRAIN INJ; ANTONELLI M, 1994, CHEST, V105, P224, DOI 10.1378/chest.105.1.224; Arrich J, 2005, STROKE, V36, P310, DOI 10.1161/01.STR.0000152962.92621.b5; Breed ST, 2004, ARCH PHYS MED REHAB, V85, pS61, DOI 10.1016/j.apmr.2003.08.115; Butcher JL, 1996, J TRAUMA, V41, P4, DOI 10.1097/00005373-199607000-00002; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Holcomb JB, 2003, J AM COLL SURGEONS, V196, P549, DOI 10.1016/S1072-7515(02)01894-X; Huang ME, 2000, AM J PHYS MED REHAB, V79, P327, DOI 10.1097/00002060-200007000-00003; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; *NAT BUR HLTH STAT, 2004, US INT PROJ AG RAC H; O'Dell MW, 1998, ARCH PHYS MED REHAB, V79, P1530, DOI 10.1016/S0003-9993(98)90414-2; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Reeder KP, 1996, J HEAD TRAUMA REHAB, V11, P22, DOI 10.1097/00001199-199606000-00006; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; SAYWELL RM, 1989, J AM GERIATR SOC, V37, P625, DOI 10.1111/j.1532-5415.1989.tb01253.x; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; VANAALST JA, 1991, J TRAUMA, V31, P1096; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107	32	89	90	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2005	59	6					1298	1304		10.1097/01.ta.0000196002.03681.18			7	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	001DP	WOS:000234514100004	16394900				2022-02-06	
J	Holshouser, BA; Tong, KA; Ashwal, S				Holshouser, BA; Tong, KA; Ashwal, S			Proton MR spectroscopic imaging depicts diffuse axonal injury in children with traumatic brain injury	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							MAGNETIC-RESONANCE-SPECTROSCOPY; ACUTE HEAD-INJURY; IN-VIVO; ADOLESCENTS; MODERATE; INFANTS; MILD	BACKGROUND AND PURPOSE: Diffuse axonal injury (DAI) after traumatic brain injury (TBI) is important in patient assessment and prognosis, yet they are underestimated with conventional imaging techniques. We used MR spectroscopic imaging (MRSI) to detect DAI and determine whether metabolite ratios are accurate in predicting long-term outcomes and to examine regional differences in injury between children with TBI and control subjects. METHODS: Forty children with TBI underwent transverse proton MRSI through the level of the corpus callosum within 1-16 days after injury. T2-weighted, fluid-attenuated inversion recovery, and susceptibility-weighted MR imaging was used to identify voxels as normal-appearing or as nonhemorrhagic or hemorrhagic injury. Neurologic outcome was evaluated at 6-12 months after injury. Metabolite ratios for total (all voxels), normal-appearing, and hemorrhagic brain were compared and used in a logistic regression model to predict long-term outcome. Total and regional metabolite ratios were compared with control data. RESULTS: A significant decrease in N-acetylaspartate (NAA)/creatine (Cr) and increase in choline (Cho)/Cr (evidence of DAI) was observed in normal-appearing (P <.05) and visibly injured (hemorrhagic) brain (P <.001) compared with controls. In normal-appearing brain NAA/Cr decreased more in patients with poor outcomes (1.32 +/- 0.54) than in those with good outcomes (1.61 +/- 0.50, P =.01) or control subjects (1.86 +/- 0.1, P =.00). In visibly injured brains, ratios were similarly altered in all patients. In predicting outcomes, ratios from normal-appearing and visibly-injured brain were 85% and 67% accurate, respectively. CONCLUSION. MRSI can depict injury in brain that appears normal on imaging and is useful for predicting long-term outcomes.	Loma Linda Univ, Dept Radiol, Neuroradiol Sect, Sch Med, Loma Linda, CA 92350 USA; Loma Linda Univ, Div Child Neurol, Dept Pediat, Sch Med, Loma Linda, CA 92350 USA		Holshouser, BA (corresponding author), Loma Linda Univ, Med Ctr, MRI-B624,11234 Anderson St, Loma Linda, CA 92354 USA.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; ASHWAL S, 2004, PEDIATR RES, V56, P1; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHOE JS, 2001, 87 SCI ASS ANN M RAD; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; Danielsen ER, 2003, NEURORADIOLOGY, V45, P722, DOI 10.1007/s00234-003-1068-z; Ebel A, 2003, MAGN RESON IMAGING, V21, P113, DOI 10.1016/S0730-725X(02)00645-8; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Gorrie C, 2002, J NEUROTRAUM, V19, P1171, DOI 10.1089/08977150260337976; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Haseler LJ, 1997, PEDIATRICS, V99, P4, DOI 10.1542/peds.99.1.4; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; KREIS R, 1993, MAGNET RESON MED, V30, P424, DOI 10.1002/mrm.1910300405; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Li BSY, 2002, MAGNET RESON MED, V47, P439, DOI 10.1002/mrm.10081; Macmillan CSA, 2002, ACTA NEUROCHIR, V144, P853, DOI 10.1007/s00701-002-0966-x; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Pouwels PJW, 1999, PEDIATR RES, V46, P474, DOI 10.1203/00006450-199910000-00019; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Robertson NJ, 2001, PEDIATR RES, V50, P692, DOI 10.1203/00006450-200112000-00011; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; SHUTTER L, 2002, 1 JOINT S NAT INT NE; Signoretti S, 2002, ACT NEUR S, V81, P373; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Wild JM, 1999, MAGN RESON MATER PHY, V8, P109; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013	41	89	103	0	6	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	MAY	2005	26	5					1276	1285					10	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	928XV	WOS:000229306100052	15891197				2022-02-06	
J	Giza, CC; Griesbach, GS; Hovda, DA				Giza, CC; Griesbach, GS; Hovda, DA			Experience-dependent behavioral plasticity is disturbed following traumatic injury to the immature brain	BEHAVIOURAL BRAIN RESEARCH			English	Article						complex environment; development; enriched environment; experience-dependent plasticity; fluid percussion injury; Morris water maze; pediatric; traumatic brain injury	FLUID-PERCUSSION INJURY; LONG-TERM POTENTIATION; RAT CEREBRAL-CORTEX; EARLY CORTICAL DAMAGE; ENVIRONMENTAL ENRICHMENT; SECONDARY ISCHEMIA; STATUS EPILEPTICUS; COGNITIVE FUNCTION; SPATIAL MEMORY; AMINO-ACIDS	Traumatic brain injury (TBI) is most prevalent in children and young adults. The long-term effects of pediatric TBI include cognitive and behavioral impairments; however, over time, it is difficult to distinguish individual variability in intellect and behavior from sequelae of early injury. Postnatal day (PND) 19 rats underwent lateral fluid Percussion (FP) injury followed by rearing in either standard (STD) or enriched environment (EE) conditions. The hypothesis was that the traditional enhancement of cognitive functioning following EE rearing would be attenuated when this rearing is preceded by TBI at PND 19. Thirty days after injury, Morris water maze (MWM) acquisition and subsequent probe trial retention were used to assess the behavioral effects of injury on experience-dependent plasticity induced by housing in EE at two different time windows. MWM acquisition demonstrated improvements following early EE rearing in both sham and injured animals: however, the degree of improvement was greater for uninjured animals. When EE rearing was delayed for 2 weeks after injury, the injury effect was absent and the effect of rearing even stronger. Memory testing in the early EE groups using a delayed probe trial showed an effect of injury and housing, with the sham EE animals benefiting the most. After the delayed EE, sham EE animals again showed more probe target hits, while FPEE animals did not, demonstrating an enduring memory deficit. These data confirm that early TBI has effects on experience-dependent plasticity resulting in long-term neurobehavioral deficits. In addition, the ability to benefit from environmental stimulation following TBI is dependent upon time after injury. (C) 2004 Elsevier B.V. All rights reserved.	Univ Calif Los Angeles, Brain Injury Res Ctr, David Geffen Sch Med, Dept Surg,Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Brain Res, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pediat, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med & Mol Pharmacol, David Geffen Sch Med, Los Angeles, CA 90095 USA		Giza, CC (corresponding author), Univ Calif Los Angeles, Brain Injury Res Ctr, David Geffen Sch Med, Dept Surg,Div Neurosurg, Room 18-228 NPI,Mail Code 703919, Los Angeles, CA 90095 USA.	cgiza@mednet.ucla.edu; ggriesbach@mednet.ucla.edu; dhovda@mednet.ucla.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS002197, R01NS027544, R21NS048535, P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30308, R21 NS048535-01A1, R01 NS027544-09, K08 NS002197-03, NS02197, NS27544] Funding Source: Medline		Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; BENNETT EL, 1964, SCIENCE, V146, P610, DOI 10.1126/science.146.3644.610; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BURGESS JW, 1986, BEHAV BRAIN RES, V20, P1, DOI 10.1016/0166-4328(86)90096-3; Conti AC, 1998, J NEUROSCI, V18, P5663; CUMMINS RA, 1977, SCIENCE, V197, P692, DOI 10.1126/science.877587; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; DeWitt D S, 1995, New Horiz, V3, P376; DIAMOND MC, 1964, J COMP NEUROL, V123, P111, DOI 10.1002/cne.901230110; DIAMOND MC, 1976, J NEUROBIOL, V7, P75, DOI 10.1002/neu.480070108; DIAMOND MC, 1975, BEHAV BIOL, V14, P163, DOI 10.1016/S0091-6773(75)90161-3; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; GREENOUGH WT, 1973, EXP NEUROL, V41, P371, DOI 10.1016/0014-4886(73)90278-1; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; GURKOFF G, 2003, J NEUROTRAUMA, V20; Haas KZ, 2001, HIPPOCAMPUS, V11, P615, DOI 10.1002/hipo.1076; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; HATTORI H, 1990, PEDIATR NEUROL, V6, P219, DOI 10.1016/0887-8994(90)90111-D; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; IKONOMIDOU C, 1989, J NEUROSCI, V9, P2809; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; KOLB B, 1988, BEHAV BRAIN RES, V28, P259, DOI 10.1016/0166-4328(88)90129-5; KOLB B, 1987, BEHAV BRAIN RES, V26, P47, DOI 10.1016/0166-4328(87)90015-5; Kolb B, 1998, NEUROSCI BIOBEHAV R, V22, P143, DOI 10.1016/S0149-7634(97)00008-0; Kolb B, 2000, BRAIN RES, V882, P62, DOI 10.1016/S0006-8993(00)02828-6; Kolb B, 1991, CEREB CORTEX, V1, P189, DOI 10.1093/cercor/1.2.189; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Lado FA, 2000, MENT RETARD DEV D R, V6, P242, DOI 10.1002/1098-2779(2000)6:4<242::AID-MRDD3>3.3.CO;2-N; Malkasian D R, 1971, Int J Neurosci, V2, P161, DOI 10.3109/00207457109146998; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OSTEEN CL, 2002, J NEUROTRAUM, V19, P1384; OSTEEN CL, 2004, IN PRESS NEUROSCIENC; OSTEEN CL, 2000, RESTORATIVE NEUROL N, V16, P210; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Prins ML, 2003, DEV BRAIN RES, V140, P93, DOI 10.1016/S0165-3806(02)00588-6; Prins ML, 2001, J NEUROTRAUM, V18, P31, DOI 10.1089/089771501750055758; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Rosenzweig MR, 1996, BEHAV BRAIN RES, V78, P57, DOI 10.1016/0166-4328(95)00216-2; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Sankar R, 1998, J NEUROSCI, V18, P8382; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; TEES RC, 1990, DEV PSYCHOBIOL, V23, P427, DOI 10.1002/dev.420230505; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; VANGOOL WA, 1985, BEHAV NEURAL BIOL, V44, P454, DOI 10.1016/S0163-1047(85)90880-5; VENABLE N, 1988, BEHAV BRAIN RES, V31, P89, DOI 10.1016/0166-4328(88)90162-3; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Villablanca JR, 2000, NEUROSCIENCE, V95, P625; Weiner H. L., 2000, HEAD INJURY, P419; Williams BM, 2001, PHYSIOL BEHAV, V73, P649, DOI 10.1016/S0031-9384(01)00543-1; Yager JY, 1996, DEV BRAIN RES, V93, P143, DOI 10.1016/0165-3806(96)00026-0; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496	71	89	92	0	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	FEB 10	2005	157	1					11	22		10.1016/j.bbr.2004.06.003			12	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	889NY	WOS:000226450900002	15617766				2022-02-06	
J	Viano, DC; Pellman, EJ				Viano, DC; Pellman, EJ			Concussion in professional football: Biomechanics of the striking player - Part 8	NEUROSURGERY			English	Article						biomechanics; concussion; football; impact tolerances; neck injury; spearing; sport injury prevention	NECK-INJURY-REGISTRY; 4TH CERVICAL-VERTEBRAE; HYPEREXTENSION INJURIES; TACKLE FOOTBALL; SPINE INJURIES; 14-YEAR REPORT; HEAD; PATHOMECHANICS; QUADRIPLEGIA; FATALITIES	Objective: Concussive impacts in professional football were simulated in laboratory tests to determine the collision mechanics resulting in injury to the struck player and the biomechanics of the striking players, who were not concussed or neck-injured in the tackle. Methods: Twenty-seven helmet-to-helmet collisions were reconstructed in laboratory tests using Hybrid III dummies. The head impact velocity, direction, and kinematics matched game video. Translational and rotational head accelerations and six-axis upper neck loads and moments were used to evaluate how the striking player delivered the concussive blow. The neck injury criterion, Nij, was calculated to assess neck injury risks in the striking player. Results: The time-averaged impact force reached 6372 +/- 2486 N at 7.2 milliseconds because of 46.8 +/- 21.7 g head acceleration and 3524 +/- 1729 N neck compression force in the striking player. Fifty-seven percent of the load was contributed by neck compression. The striking players had their heads down and lined up in impact axis through their necks and torsos. This allowed momentum transfer with minimal neck bending and increased the effective mass of the striking player to 1.67 times that of the struck player at peak load. The impact caused 94.3 +/- 27.5 g head acceleration in the concussed players and 67.9 +/- 14.5 g without concussion (t = 2.06 , df = 25, P = 0.025). The striking player's Nij was greater than tolerance in 9 of 27 cases by exceeding the 4000 N neck compression limit. For these cases, the average neck compression force was 6631 +/- 997 N (range, 5210 - 8194 N). Nij was 1.25 +/- 0.16 for eight cases above the tolerance Nij = 1.0. In the NFL, striking players line up their heads, necks, and torsos to deliver maximum force is from acceleration of the striking player's head and torso load through the neck. Even though neck responses exceeded tolerance, no striking player experienced neck injury or concussion. A head-up stance at impact would reduce the torso inertial load in the collision and the risk of concussion in the struck player.	ProBiomech LLC, Bloomfield Hills, MI 48304 USA; Natl Football League, Mild Traumat Brain Injury Committee, New York, NY USA; ProHLTH Care Assoc LLP, Lake Success, NY USA		Viano, DC (corresponding author), ProBiomech LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net					ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; BACKAITIS SH, 1994, HYBRID 3 1 HUMAN LIK; Bandak, 1999, DEV IMPROVED INJURY; BISHOP PJ, 1986, 860201 SAE; Cantu RC, 2003, NEUROSURGERY, V52, P846, DOI 10.1227/01.NEU.0000053210.76063.E4; CARTER DR, 1980, AM J SPORT MED, V8, P302, DOI 10.1177/036354658000800502; DIMASI FP, 1995, HS808282 DOT; Duff J F, 1974, J Sports Med, V2, P175; FUNK FJ, 1975, CLIN ORTHOP RELAT R, P50, DOI 10.1097/00003086-197506000-00007; Gadd C. W, 1966, SAE TECHNICAL PAPER, DOI 10.4271/660793; Heck J F, 1996, J Athl Train, V31, P31; HECK J F, 1992, Journal of Athletic Training, V27, P120; Heck JF, 2004, J ATHL TRAINING, V39, P101; HECK JF, 1994, J ATHL TRAINING, V30, P63; Hodgson VR, 1980, P 24 STAPP CAR CRASH; HODGSON VR, 1983, 806434 DOT HS, P110; JARROD W, 2002, P 46 STAPP CAR CRASH; KING AI, 1995, BIOMEDICAL ENG HDB, P357; KLEINBERGER M, 1998, 19944059 NHTSA; KRAUS JF, 1984, ANNU REV PUBL HEALTH, V5, P163; Maroon J C, 1980, Clin Neurosurg, V27, P414; MCELHANEY J, 1979, SAE SP, V438; Mertz H J, 1978, Phys Sportsmed, V6, P95, DOI 10.1080/00913847.1978.11948406; MERTZ HJ, 1971, 15 STAPP CAR CRASH C; MUELLER FO, 1989, PHYSICIAN SPORTSMED, V17, P51, DOI 10.1080/00913847.1989.11709888; MUELLER FO, 1987, CLIN SPORT MED, V6, P185; *NCAA, 1976, FOOTB RUL CHANG RUL; NEWMAN JA, IN PRESS J BIOMECH; *NFSHSA, 1992, OFF FOOTB RUL, V15, P22; NIGHTINGALE RW, 1997, P 41 STAPP CAR CRASH, P451; *NOCSAE, 1996, 00196 NOCSAE; NUCKLEY DJ, 2002, P 46 STAPP CAR CRASH; Nusholtz G. S, 1981, P 25 STAPP CAR CRASH; NYQUIST GW, 1980, J BIOMECH ENG-T ASME, V102, P103, DOI 10.1115/1.3138204; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Pintar FA, 1998, SPINE, V23, P1957, DOI 10.1097/00007632-199809150-00007; PINTAR FA, 1995, P 39 STAPP CAR CRASH; SANCES A, 1981, P 25 STAPP CAR CRASH; Schneider RC., 1973, HEAD NECK INJURIES F; SHEA M, 1992, J ORTHOPAED RES, V10, P911, DOI 10.1002/jor.1100100621; *SOC AUT ENG, 1980, J855 SAE; *SOC AUT ENG, 1994, J1733 SAE; TORG JS, 1985, MED SCI SPORT EXER, V17, P295; TORG JS, 1979, JAMA-J AM MED ASSOC, V241, P1477, DOI 10.1001/jama.241.14.1477; TORG JS, 1985, JAMA-J AM MED ASSOC, V254, P3439, DOI 10.1001/jama.254.24.3439; TORG JS, 1990, AM J SPORT MED, V18, P50, DOI 10.1177/036354659001800109; TORG JS, 1987, CLIN SPORT MED, V6, P61; TORG JS, 1977, J BONE JOINT SURG AM, V59, P1015, DOI 10.2106/00004623-197759080-00003; TORG JS, 1987, CLIN SPORT MED, V6, P159; TORG JS, 1995, CLIN ORTHOP RELAT R, V321, P259; Yoganandan N, 1996, MED ENG PHYS, V18, P289, DOI 10.1016/1350-4533(95)00054-2	55	89	89	0	24	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	FEB	2005	56	2					266	278		10.1227/01.neu.0000150035.54230.3C			13	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	895UO	WOS:000226889400017	15670375				2022-02-06	
J	Hang, CH; Shi, JX; Tian, J; Li, JS; Wu, W; Yin, HX				Hang, CH; Shi, JX; Tian, J; Li, JS; Wu, W; Yin, HX			Effect of systemic LPS injection on cortical NF-kappa B activity and inflammatory response following traumatic brain injury in rats	BRAIN RESEARCH			English	Article						traumatic brain injury; NF-kappa B; proinflammatory cytokine; ICAM-1; apoptosis; inflammation; lipopolysaccharide	TUMOR-NECROSIS-FACTOR; INTERCELLULAR-ADHESION MOLECULE-1; ALPHA MESSENGER-RNA; CLOSED-HEAD INJURY; IMPACT INJURY; TNF-ALPHA; CEREBROSPINAL-FLUID; AXONAL INJURY; UP-REGULATION; CELL-DEATH	The aim of current study is to investigate the effect of systemic administration of lipopolysaccharide (LPS) on the temporal pattern of cortical nuclear factor kappa B (NF-kappaB) binding activity, inflammatory response and secondary damage in the injured brain following traumatic brain injury (TBI). Right parietal cortical contusion in rats was made by using weight-dropping method. The rats were randomly divided into sham, LPS, TBI and TBI-LPS groups, with LPS injected intraperitoneally. NF-kappaB binding activity, cytokines, intercellular adhesion molecule-1 (ICAM-1) and brain damage were detected by electrophoretic mobility shift assay (EMSA), enzyme-linked immunosorbent assay (ELISA), immunohistochemistry and terminal deoxynucleotidyl-transferase-mediated biotin-dUTP nick end labeling (TUNEL) apoptosis, respectively. The results showed that systemic administration of LPS following TBI could induce an immediate, strong and persistent upregulation of NF-kappaB, tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and ICAM-1 in the area surrounding the injured brain. As compared with rats of sham, LPS and TBI groups, NF-kappaB binding activity, TNF-alpha and IL-6 were significantly upregulated in the surrounding cortex of injured site as early as 3 h postinjury when challenged with LPS, kept at high level up to 7-days postinjury. ICAM-1 positive vessels and apoptotic TUNEL-positive cells in the injured brain were also significantly increased in TBI LPS rats. It was concluded that inflammatory response and secondary brain damage occurred in the injured brain could be highly exacerbated by endotoxemia. (C) 2004 Elsevier B.V. All rights reserved.	Nanjing Univ, Sch Clin Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Peoples R China; Nanjing Univ, Sch Life Sci, Nanjing 210093, Peoples R China; Nanjing Univ, Sch Clin Med, Jinling Hosp, Res Inst Gen Surg, Nanjing 210002, Peoples R China		Hang, CH (corresponding author), Nanjing Univ, Sch Clin Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Peoples R China.	hang1965@163.com					ANDERSSON J, 1992, IMMUNOL REV, V127, P69, DOI 10.1111/j.1600-065X.1992.tb01409.x; ARDITI M, 1995, J IMMUNOL, V155, P3994; Arvin B, 1995, ANN NY ACAD SCI, V765, P62, DOI 10.1111/j.1749-6632.1995.tb16561.x; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bohatschek M, 2001, EXP NEUROL, V172, P137, DOI 10.1006/exnr.2001.7764; BREDER CD, 1994, P NATL ACAD SCI USA, V91, P11393, DOI 10.1073/pnas.91.24.11393; Cai ZW, 2003, BRAIN RES, V975, P37, DOI 10.1016/S0006-8993(03)02545-9; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FROHMAN EM, 1989, J NEUROIMMUNOL, V23, P117, DOI 10.1016/0165-5728(89)90030-1; Gabriel C, 1999, MOL BRAIN RES, V65, P61, DOI 10.1016/S0169-328X(98)00330-1; GATTI S, 1993, BRAIN RES, V624, P291, DOI 10.1016/0006-8993(93)90090-A; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Grilli M, 1999, BIOCHEM PHARMACOL, V57, P1, DOI 10.1016/S0006-2952(98)00214-7; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184, DOI 10.1097/00004647-199902000-00010; HERY C, 1995, J NEUROIMMUNOL, V57, P101, DOI 10.1016/0165-5728(94)00168-N; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Isaksson J, 1997, ACTA NEUROPATHOL, V94, P16, DOI 10.1007/s004010050666; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Nadeau S, 2000, J NEUROSCI, V20, P3456, DOI 10.1523/JNEUROSCI.20-09-03456.2000; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.3.CO;2-G; RINK A, 1995, AM J PATHOL, V147, P1575; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N; Zhang J, 2001, J NEUROCHEM, V76, P855, DOI 10.1046/j.1471-4159.2001.00080.x; ZHANG RL, 1995, STROKE, V26, P1438, DOI 10.1161/01.STR.26.8.1438	45	89	98	1	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	NOV 5	2004	1026	1					23	32		10.1016/j.brainres.2004.07.090			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	865OU	WOS:000224713200003	15476694				2022-02-06	
J	Zinn, S; Stein, R; Swartzwelder, HS				Zinn, S; Stein, R; Swartzwelder, HS			Executive functioning early in abstinence from alcohol	ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH			English	Article						alcoholism; cognition disorders; memory disorders; abstinence; alcohol-induced disorders	ADDICTION SEVERITY INDEX; TRAUMATIC BRAIN-INJURY; FRONTAL-LOBE; NEUROPSYCHOLOGICAL PERFORMANCE; COGNITIVE IMPAIRMENT; MEMORY PERFORMANCE; FIGURAL FLUENCY; TEST-RETEST; RECOVERY; DEFICITS	Background: Executive dysfunction is among the cognitive impairments that may persist after abstinence in alcohol-dependent persons. The type(s) and extent of executive dysfunction early in abstinence have not been well characterized, but they may have important implications for the evolution of behavioral treatment strategies. Methods: To determine which aspects of executive functioning were impaired in early abstinence, we administered memory and executive function tests to veterans who successively presented for treatment at an outpatient substance abuse clinic. We then compared the neuropsychological performance of these recovering alcoholics (n = 27) with that of age-matched primary care outpatients (n = 18). We also examined group differences in self-evaluation of cognitive decline and evaluated associations between drinking history and cognitive impairment in the index group. Results: We found that the normal and alcohol-dependent groups differed on abstract reasoning, memory discrimination, and effectiveness on timed tasks. Patients in the alcohol-dependent sample were also more likely to perceive themselves as cognitively impaired. It is interesting to note that the duration of alcohol use did not relate to neuropsychological test performance, but recent quantity consumed and days of sobriety were associated with nonverbal abstract reasoning ability. Conclusions: Executive functions are impaired early in abstinence and should, therefore, be taken into account when early behavioral treatments are being developed.	Durham Vet Affairs MEd Ctr, Res & Dev, Durham, NC 27705 USA; Durham Vet Affairs MEd Ctr, Hlth Serv Res & Dev, Durham, NC 27705 USA; Durham Vet Affairs MEd Ctr, Mental Hlth Serv, Durham, NC 27705 USA; Duke Univ, Ctr Med, Dept Psychiat & Behav Sci, Durham, NC 27706 USA		Swartzwelder, HS (corresponding author), VA Med Ctr, 508 Fulton St,Bldg 16,Room 24, Durham, NC 27705 USA.	hss@duke.edu					ADAMS KM, 1993, ALCOHOL CLIN EXP RES, V17, P205, DOI 10.1111/j.1530-0277.1993.tb00750.x; ADAMS KM, 1986, J CLIN EXP NEUROPSYC, V8, P362, DOI 10.1080/01688638608401327; ALTERMAN AI, 1994, DRUG ALCOHOL DEPEN, V34, P201, DOI 10.1016/0376-8716(94)90157-0; Armitage SG, 1946, PSYCHOL MONOGR, V60, P1; BARONA A, 1986, INT J CLIN NEUROPSYC, V8, P169; Beatty WW, 2000, ALCOHOL CLIN EXP RES, V24, P149, DOI 10.1111/j.1530-0277.2000.tb04584.x; BECKER JT, 1984, J STUD ALCOHOL, V45, P339, DOI 10.15288/jsa.1984.45.339; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; BLENNERHASSETT R, 1993, J PSYCHOL MED, V10, P6; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; Brandt J, 1991, CLIN NEUROPSYCHOL, V5, P125, DOI [10.1080/13854049108403297, DOI 10.1080/13854049108403297]; CARLEN PL, 1984, CAN J NEUROL SCI, V11, P441, DOI 10.1017/S0317167100045972; CLIFFORD JS, 1986, J COUNS DEV, V65, P31, DOI 10.1002/j.1556-6676.1986.tb01225.x; COCCHI R, 1995, ITAL J INTELLECTIVE, V8, P197; Dao-Castellana MH, 1998, PSYCHOL MED, V28, P1039, DOI 10.1017/S0033291798006849; Dawson LK, 2000, J INT NEUROPSYCH SOC, V6, P12, DOI 10.1017/S1355617700611025; Demir B, 2002, PSYCHIAT RES-NEUROIM, V115, P115, DOI 10.1016/S0925-4927(02)00071-9; DESOTO CB, 1985, ALCOHOL CLIN EXP RES, V9, P505; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; DONOVAN DM, 1984, ALCOHOL CLIN EXP RES, V8, P470, DOI 10.1111/j.1530-0277.1984.tb05704.x; ECKARDT MJ, 1979, BIOL PSYCHIAT, V14, P943; ECKARDT MJ, 1995, AM J PSYCHIAT, V152, P53; Edwin D, 1999, HEPATOLOGY, V30, P1363, DOI 10.1002/hep.510300605; Gaffan D, 2002, J NEUROSCI, V22, P7288; Giancola PR, 1998, RECENT DEV ALCOHOL, V14, P227, DOI 10.1007/0-306-47148-5_10; Godding PR, 1992, PSYCHOL ADDICT BEHAV, V6, P34, DOI [10.1037/h0080602, DOI 10.1037/H0080602, DOI 10.1037/h0080602]; GRANT I, 1987, J CLIN PSYCHIAT, V48, P319; GRANT I, 1987, J CONSULT CLIN PSYCH, V55, P310, DOI 10.1037/0022-006X.55.3.310; HODGINS DC, 1992, J NERV MENT DIS, V180, P197; Ihara H, 2000, J NEUROL NEUROSUR PS, V68, P731, DOI 10.1136/jnnp.68.6.731; Jin H, 1998, J STUD ALCOHOL, V59, P640, DOI 10.15288/jsa.1998.59.640; KISH GB, 1980, J CLIN PSYCHOL, V36, P584, DOI 10.1002/jclp.6120360234; Kolitz BP, 2003, ARCH PHYS MED REHAB, V84, P277, DOI 10.1053/apmr.2003.50100; Kril JJ, 1997, NEUROSCIENCE, V79, P983, DOI 10.1016/S0306-4522(97)00083-3; Kubota M, 2001, J NEUROL NEUROSUR PS, V71, P104, DOI 10.1136/jnnp.71.1.104; Lange G, 2000, ARCH PHYS MED REHAB, V81, P89, DOI 10.1016/S0003-9993(00)90227-2; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; LOTFI J, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P2; Macciocchi S N, 1989, Arch Clin Neuropsychol, V4, P365, DOI 10.1016/0887-6177(89)90026-7; Mangels JA, 1996, NEUROPSYCHOLOGY, V10, P32, DOI 10.1037/0894-4105.10.1.32; Mann K, 1999, ALCOHOL ALCOHOLISM, V34, P567, DOI 10.1093/alcalc/34.4.567; MCCRADY BS, 1986, ALCOHOL CLIN EXP RES, V10, P145, DOI 10.1111/j.1530-0277.1986.tb05061.x; MCLELLAN AT, 1985, J NERV MENT DIS, V173, P412, DOI 10.1097/00005053-198507000-00005; MILLER L, 1991, J SUBST ABUSE TREAT, V8, P277, DOI 10.1016/0740-5472(91)90051-B; Moriyama Y, 2002, ALCOHOL CLIN EXP RES, V26, P1239, DOI 10.1097/01.ALC.0000026103.08053.86; Moscovitch M, 1997, NEUROPSYCHOLOGIA, V35, P1017, DOI 10.1016/S0028-3932(97)00028-6; Moselhy HF, 2001, ALCOHOL ALCOHOLISM, V36, P357, DOI 10.1093/alcalc/36.5.357; Munro CA, 2000, ALCOHOL CLIN EXP RES, V24, P1510, DOI 10.1111/j.1530-0277.2000.tb04569.x; Noel X, 2001, ARCH GEN PSYCHIAT, V58, P1152, DOI 10.1001/archpsyc.58.12.1152; PARSONS O A, 1983, Substance and Alcohol Actions-Misuse, V4, P175; PARSONS O A, 1986, Annals of Behavioral Medicine, V8, P13, DOI 10.1207/s15324796abm0802&3_3; Ratti MT, 2002, ACTA NEUROL SCAND, V105, P276, DOI 10.1034/j.1600-0404.2002.0o315.x; REED RJ, 1992, ALCOHOL CLIN EXP RES, V16, P677, DOI 10.1111/j.1530-0277.1992.tb00660.x; Rey A, 1993, CLIN NEUROPSYCHOL, V7, P3, DOI DOI 10.1080/13854049308401883; Rourke SB, 1999, J INT NEUROPSYCH SOC, V5, P234, DOI 10.1017/S1355617799533067; RUFF RM, 1994, ARCH CLIN NEUROPSYCH, V9, P41, DOI 10.1016/0887-6177(94)90013-2; RUFF RM, 1987, DEV NEUROPSYCHOL, V3, P37, DOI 10.1080/87565648709540362; SKINNER FK, 1989, ALCOHOL ALCOHOLISM, V24, P129, DOI 10.1093/oxfordjournals.alcalc.a044876; SMITH DE, 1991, ADDICT BEHAV, V16, P265, DOI 10.1016/0306-4603(91)90019-E; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; STOFFELMAYR BE, 1994, J SUBST ABUSE TREAT, V11, P373, DOI 10.1016/0740-5472(94)90048-5; Sullivan EV, 2000, ALCOHOL CLIN EXP RES, V24, P611, DOI 10.1111/j.1530-0277.2000.tb02032.x; TUCK RR, 1991, MED J AUSTRALIA, V155, P225, DOI 10.5694/j.1326-5377.1991.tb142226.x; Unkenstein A.E., 1991, CLIN NEUROPSYCHOL, V5, P24; VOLKOW ND, 1994, AM J PSYCHIAT, V151, P178; Wechsler D., 1997, WAIS 3 ADM SCORING M WAIS 3 ADM SCORING M; YOHMAN JR, 1985, ALCOHOL CLIN EXP RES, V9, P114, DOI 10.1111/j.1530-0277.1985.tb05530.x; ZINN S, 2002, J INT NEUROPSYCH SOC, V8, P205; [No title captured]	69	89	93	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0145-6008	1530-0277		ALCOHOL CLIN EXP RES	Alcoholism (NY)	SEP	2004	28	9					1338	1346		10.1097/01.ALC.0000139814.81811.62			9	Substance Abuse	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Substance Abuse	856VV	WOS:000224074300009	15365304	Green Published			2022-02-06	
J	Vitarbo, EA; Chatzipanteli, K; Kinoshita, K; Truettner, JS; Alonso, OF; Dietrich, WD				Vitarbo, EA; Chatzipanteli, K; Kinoshita, K; Truettner, JS; Alonso, OF; Dietrich, WD			Tumor necrosis factor alpha expression and protein levels after fluid percussion injury in rats: The effect of injury severity and brain temperature	NEUROSURGERY			English	Article						hyperthermia; hypothermia; inflammation; secondary injury; traumatic brain injury; tumor necrosis factor alpha	CLOSED-HEAD INJURY; TRANSIENT CEREBRAL-ISCHEMIA; TNF-ALPHA; MODERATE HYPOTHERMIA; CEREBROSPINAL-FLUID; POSTTRAUMATIC HYPOTHERMIA; INFLAMMATORY RESPONSE; CONVERTING ENZYME; CONTUSION; IL-6	OBJECTIVE: Tumor necrosis factor alpha (TNFalpha) is elevated in some models of traumatic brain injury (TBI). However, it is unclear how TNFalpha messenger ribonucleic acid (mRNA) expression and protein levels are affected by injury severity and posttraumatic temperature modification. This study determined the regional and temporal profile of TNFalpha levels after moderate and severe TBI and assessed the effects of posttraumatic hypothermia or hyperthermia on this proinflammatory cytokine. METHODS: Adult male Sprague-Dawley rats were subjected to sham procedures (no injury), moderate fluid-percussion TBI (1.8-2.2 atm), or severe fluid-percussion TBI (2.4-2.6 atm). After 1 to 72 hours of survival, animals were killed, and brain samples, cerebrospinal fluid, and serum were harvested for enzyme-linked immunosorbent assay quantification of TNFalpha levels. In a subsequent study, a 3-hour period of posttraumatic hypothermia (33degreesC) or hyperthermia (39.5degreesC) was applied, followed by immediate killing and cytokine assay. Another group was subjected to moderate TBI (1.8-2.2 atm), followed by killing at 15 minutes or at 1, 3, or 24 hours for TNFalpha reverse transcriptase-polymerase chain reaction analysis. RESULTS: A significant increase in TNFalpha mRNA and protein levels in cellular lysates of injured cortex and ipsilateral hippocampus was noted by I hour after TBI; it was sustained to 3 hours, followed by a rapid decline. Increased injury severity was associated with increased protein levels at remote injury sites and in the injured cerebral cortex at 72 hours. Posttraumatic hypothermia significantly reduced TNFalpha mRNA expression in the hippocampus compared with that in normothermic rats. In contrast, no temperature effects on TNFalpha protein levels were documented. CONCLUSION: Rapid and marked increase in TNFalpha mRNA expression and protein levels follows moderate and severe TBI. Injury severity and posttraumatic temperature play a modest but significant role on TNFalpha expression and protein levels. These findings suggest that the effects of posttraumatic temperature on histopathological and behavioral outcome primarily may involve secondary mediators that do not operate directly through their effect on TNFalpha.	Univ Miami, Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg,Neurotrauma Res Ctr, Miami, FL 33101 USA		Dietrich, WD (corresponding author), Univ Miami, Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg,Neurotrauma Res Ctr, POB 016960,R-48, Miami, FL 33101 USA.	ddietrich@miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291, NS42133] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, P50NS030291] Funding Source: NIH RePORTER		ABBAS AK, 1991, CELLULAR MOL IMMUNOL; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; DelZoppo GJ, 1997, ANN NY ACAD SCI, V823, P132; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1996, ADV NEUROL, V71, P177; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; Edwards AD, 1995, BIOCHEM BIOPH RES CO, V217, P1193, DOI 10.1006/bbrc.1995.2895; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Floyd RA, 1997, NEUROREPORT, V8, P915, DOI 10.1097/00001756-199703030-00020; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Hueber AO, 2003, CELL DEATH DIFFER, V10, P7, DOI 10.1038/sj.cdd.4401155; HUNT JS, 1992, CYTOKINE, V4, P340, DOI 10.1016/1043-4666(92)90076-4; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Karkkainen I, 2000, MOL CELL NEUROSCI, V15, P547, DOI 10.1006/mcne.2000.0848; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Portella G, 2000, ACT NEUR S, V76, P273; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Saito K, 1996, NEUROSCI LETT, V206, P149, DOI 10.1016/S0304-3940(96)12460-5; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Vink R, 2002, EXPERT OPIN INV DRUG, V11, P1375, DOI 10.1517/13543784.11.10.1375; Vitkovic L, 2000, J NEUROCHEM, V74, P457, DOI 10.1046/j.1471-4159.2000.740457.x; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Zhang ZL, 2000, J BIOL CHEM, V275, P15839, DOI 10.1074/jbc.M000604200	54	89	94	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	AUG	2004	55	2					416	424		10.1227/01.NEU.0000130036.52521.2C			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	844WJ	WOS:000223191500036	15271250				2022-02-06	
J	Singleton, RH; Povlishock, JT				Singleton, RH; Povlishock, JT			Identification and characterization of heterogeneous neuronal injury and death in regions of diffuse brain injury: Evidence for multiple independent injury phenotypes	JOURNAL OF NEUROSCIENCE			English	Article						cortex; fluorescence; hippocampus; horseradish peroxidase; neuron; necrosis; traumatic brain injury; diffuse brain injury	AMYLOID PRECURSOR PROTEIN; PLASMA-MEMBRANE DISRUPTIONS; AXONAL INJURY; HEAD-INJURY; HORSERADISH-PEROXIDASE; STRESS FAILURE; CYCLOSPORINE-A; FLUORO-JADE; CELL-DEATH; DAMAGE	Diffuse brain injury (DBI) is a consequence of traumatic brain injury evoked via rapid acceleration-deceleration of the cranium, giving rise to subtle pathological changes appreciated best at the microscopic level. DBI is believed to be comprised by diffuse axonal injury and other forms of diffuse vascular change. The potential, however, that the same forces can also directly injure neuronal somata in vivo has not been considered. Recently, while investigating DBI-mediated perisomatic axonal injury, we identified scattered, rapid neuronal somatic necrosis occurring within the same domains. Moving on the premise that these cells sustained direct somatic injury as a result of DBI, we initiated the current study, in which rats were intracerebroventricularly infused with various high-molecular weight tracers (HMWTs) to identify injury-induced neuronal somatic plasmalemmal disruption. These studies revealed that DBI caused immediate, scattered neuronal somatic plasmalemmal injury to all of the extracellular HMWTs used. Through this approach, a spectrum of neuronal change was observed, ranging from rapid necrosis of the tracer-laden neurons to little or no pathological change at the light and electron microscopic level. Parallel double and triple studies using markers of neuronal degeneration, stress, and axonal injury identified additional injured neuronal phenotypes arising in close proximity to, but independent of, neurons demonstrating plasmalemmal disruption. These findings reveal that direct neuronal somatic injury is a component of DBI, and diffuse trauma elicits a heretofore-unrecognized multifaceted neuronal pathological change within the CNS, generating heterogeneous injury and reactive alteration within both axons and neuronal somata in the same domains.	Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA		Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, Med Coll Virginia Campus,POB 980709, Richmond, VA 23298 USA.	jpovlish@hsc.vcu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32 NS007288, T32NS07288, R01 NS045824, NS045824] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007288, R01NS045824] Funding Source: NIH RePORTER		ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Barros LF, 2002, BIOL RES, V35, P209; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Clark RSB, 1997, J NEUROSCI, V17, P9172; CLARKE MSF, 1995, CIRC RES, V76, P927, DOI 10.1161/01.RES.76.6.927; Conti AC, 1998, J NEUROSCI, V18, P5663; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; Deurs B V, 1977, Brain Res, V124, P1; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Finnie JW, 2000, AUST VET J, V78, P775, DOI 10.1111/j.1751-0813.2000.tb10451.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Hardman JM, 2002, NEUROIMAG CLIN N AM, V12, P175, DOI 10.1016/S1052-5149(02)00009-6; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; KRISTENSSON K, 1977, ACTA NEUROPATHOL, V38, P143, DOI 10.1007/BF00688561; LIN CA, 2001, MASS COMMUNICATION S, V4, P19, DOI DOI 10.1207/S15327825MCS0401_03; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; MCNEIL PL, 1990, J CELL SCI, V96, P549; MCNEIL PL, 1989, GASTROENTEROLOGY, V96, P1238, DOI 10.1016/S0016-5085(89)80010-1; MCNEIL PL, 1992, AM J PATHOL, V140, P1097; McNeil PL, 2001, NAT CELL BIOL, V3, pE124, DOI 10.1038/35074652; McNeil PL, 2001, CELL TISSUE RES, V304, P141, DOI 10.1007/s004410000286; McNeil PL, 1997, J CELL BIOL, V137, P1, DOI 10.1083/jcb.137.1.1; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NICHOLSON C, 1993, BIOPHYS J, V65, P2277, DOI 10.1016/S0006-3495(93)81324-9; NOWAK TS, 1993, ANN NY ACAD SCI, V679, P142, DOI 10.1111/j.1749-6632.1993.tb18295.x; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Planas AM, 1997, PROG NEUROBIOL, V51, P607, DOI 10.1016/S0301-0082(97)00004-X; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Qian L, 1996, ACTA NEUROCHIR, V138, P90, DOI 10.1007/BF01411731; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RENNKE HG, 1979, J HISTOCHEM CYTOCHEM, V27, P1352, DOI 10.1177/27.10.41873; RINK A, 1995, AM J PATHOL, V147, P1575; Runnerstam M, 2001, J NEUROTRAUM, V18, P259, DOI 10.1089/08977150151070892; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Shigemori M, 1992, Acta Neurochir Suppl (Wien), V55, P37; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Terasaki M, 1997, J CELL BIOL, V139, P63, DOI 10.1083/jcb.139.1.63; TURNER PT, 1974, BRAIN RES, V74, P305, DOI 10.1016/0006-8993(74)90585-X; Vlahakis NE, 2000, J APPL PHYSIOL, V89, P2490, DOI 10.1152/jappl.2000.89.6.2490; Vlahakis NE, 2002, AM J RESP CRIT CARE, V166, P1282, DOI 10.1164/rccm.200203-207OC; WELINDER KG, 1979, EUR J BIOCHEM, V96, P483, DOI 10.1111/j.1432-1033.1979.tb13061.x; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YAMAGATA Y, 1994, ENZYME MICROB TECH, V16, P99, DOI 10.1016/0141-0229(94)90070-1; YAMAKI T, 1994, J NEUROTRAUM, V11, P613, DOI 10.1089/neu.1994.11.613; YU QC, 1992, AM J PATHOL, V141, P1349	70	89	89	1	2	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	APR 7	2004	24	14					3543	3553		10.1523/JNEUROSCI.5048-03.2004			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	810PE	WOS:000220715400010	15071102	Green Published, Bronze			2022-02-06	
J	Kuhtz-Buschbeck, JP; Hoppe, B; Golge, M; Dreesmann, M; Damm-Stunitz, U; Ritz, A				Kuhtz-Buschbeck, JP; Hoppe, B; Golge, M; Dreesmann, M; Damm-Stunitz, U; Ritz, A			Sensorimotor recovery in children after traumatic brain injury: analyses of gait, gross motor, and fine motor skills	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							HEAD-INJURIES; PURDUE PEGBOARD; PERFORMANCE; RELIABILITY; ADOLESCENTS; COORDINATION; CHILDHOOD; SEVERITY; COHORT; ADULTS	The recovery of gait, gross motor proficiency, and hand function was examined in 23 children (13 males, 10 females; age 4 years 7 months to 15 years 10 months) with traumatic brain injury (TBI) over five months of in patient rehabilitation. We used gait analysis, the Gross Motor Function Measure, the Developmental Hand Function Test, and the Purdue Pegboard test. Brain injury had been severe (initial Glasgow Coma Scale GCS <8) in 17 children and moderate (GCS 8-10) in six children. Compared with healthy control children of the same age and sex, repeated gait analyses in ambulatory children with brain injury showed significant reductions of velocity, stride length and cadence, and impaired balance. Spatiotemporal gait variables were correlated with Gross Motor Function Measure scores. Hand function tests revealed deficits in fine motor skills, speed, and coordination. Degree of impairment increased with trauma severity. Despite significant improvements, differences in gait velocity, stride length, and hand function of children with brain injuries and controls were still present about 8 months after TBI. Hand motor skills improved less than gait. Young age at injury was not associated with better recovery.	Univ Kiel, Inst Physiol, D-24098 Kiel, Germany; Mechernich Hosp, Dept Paediat, Mechernich, Germany; Neurol Rehabil Zentrum Kinder & Jugendliche Fried, Bremen, Germany		Kuhtz-Buschbeck, JP (corresponding author), Univ Kiel, Dept Physiol, Motor Control Lab, Olshaussenstr 40, D-24098 Kiel, Germany.		Kuhtz-Buschbeck, Johann/F-7745-2010	Kuhtz-Buschbeck, Johann P/0000-0002-4603-7103			Asikainen I, 1999, EUR J NEUROL, V6, P179, DOI 10.1111/j.1468-1331.1999.tb00011.x; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; Bowen JM, 1997, DEV MED CHILD NEUROL, V39, P17; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; Drouin LM, 1996, DEV MED CHILD NEUROL, V38, P1007; Emanuelson I, 1998, Pediatr Rehabil, V2, P65; Emanuelson IM, 1997, DEV MED CHILD NEUROL, V39, P502; Finger S, 1999, J Hist Neurosci, V8, P269, DOI 10.1076/jhin.8.3.269.1824; FORSSBERG H, 1991, EXP BRAIN RES, V85, P451; GARDNER RA, 1979, J CLIN CHILD PSYCHOL, V8, P156, DOI 10.1080/15374417909532912; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; GOWLAND C, 1995, PHYS THER, V75, P597, DOI 10.1093/ptj/75.7.597; HALEY SM, 1990, J HEAD TRAUMA REHAB, V5, P77; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JEBSEN R H, 1969, Archives of Physical Medicine and Rehabilitation, V50, P311; Johnk K, 1999, RESTOR NEUROL NEUROS, V14, P143; Kennard MA, 1936, AM J PHYSIOL, V115, P138, DOI 10.1152/ajplegacy.1936.115.1.138; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kuhtz-Buschbeck JP, 2003, ARCH PHYS MED REHAB, V84, P424, DOI 10.1053/apmr.2003.50017; LEMON RN, 1993, EXP PHYSIOL, V78, P263, DOI 10.1113/expphysiol.1993.sp003686; LOEWEN SC, 1988, PHYS THER, V68, P1077, DOI 10.1093/ptj/68.7.1077; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; MELCHERS P, 1991, KAUFMAN ASSESSMENT B; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PATLA AE, 1996, CLIN DISORDERS BALAN, P19; Preis S, 1997, DEV MED CHILD NEUROL, V39, P228; REDDON JR, 1988, PERCEPT MOTOR SKILL, V66, P503, DOI 10.2466/pms.1988.66.2.503; Rossi C, 1996, ARCH PHYS MED REHAB, V77, P1062, DOI 10.1016/S0003-9993(96)90069-6; RUSSELL DJ, 1989, DEV MED CHILD NEUROL, V31, P341; Stolze H, 1998, GAIT POSTURE, V7, P125, DOI 10.1016/S0966-6362(97)00043-X; SWAINE BR, 1992, ARCH PHYS MED REHAB, V73, P55; TAYLOR N, 1973, ARCH PHYS MED REHAB, V54, P129; VanderSchaaf PJ, 1997, PEDIATR NEUROL, V16, P306, DOI 10.1016/S0887-8994(97)00025-8; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Wallen MA, 2001, ARCH PHYS MED REHAB, V82, P642, DOI 10.1053/apmr.2001.22620	42	89	89	0	12	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	0012-1622			DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	DEC	2003	45	12					821	828		10.1017/S001216220300152X			8	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	750NW	WOS:000187003500007	14667074				2022-02-06	
J	Ruf, B; Heckmann, M; Schroth, I; Hugens-Penzel, M; Reiss, I; Borkhardt, A; Gortner, L; Jodicke, A				Ruf, B; Heckmann, M; Schroth, I; Hugens-Penzel, M; Reiss, I; Borkhardt, A; Gortner, L; Jodicke, A			Early decompressive craniectomy and duraplasty for refractory intracranial hypertension in children: results of a pilot study	CRITICAL CARE			English	Article						craniectomy; intensive care; pediatric; severe head injury	SEVERE HEAD-INJURY; HYPERTONIC SALINE; BRAIN-INJURY; PRESSURE; MANAGEMENT; HYPEREMIA	Introduction Severe traumatic brain injury (TBI) in childhood is associated with a high mortality and morbidity. Decompressive craniectomy has regained therapeutic interest during past years; however, treatment guidelines consider it a last resort treatment strategy for use only after failure of conservative therapy. Patients We report on the clinical course of six children treated with decompressive craniectomy after TBI at a pediatric intensive care unit. The standard protocol of intensive care treatment included continuous intracranial pressure (ICP) monitoring, sedation and muscle relaxation, normothermia, mild hyperventilation and catecholamines to maintain an adequate cerebral perfusion pressure. Decompressive craniectomy including dura opening was initiated in cases of a sustained increase in ICP > 20 mmHg for > 30 min despite maximally intensified conservative therapy (optimized sedation and ventilation, barbiturates or mannitol). Results In all cases, the ICP normalized immediately after craniectomy. At discharge, three children were without disability, two children had a mild arm-focused hemiparesis ( one with a verbal impairment), and one child had a spastic hemiparesis and verbal impairment. This spastic hemiparesis improved within 6 months follow-up ( no motor deficit, increased muscle tone), and all others remained unchanged. Conclusion These observational pilot data indicate feasibility and efficacy of decompressive craniectomy in malignant ICP rise secondary to TBI. Further controlled trials are necessary to evaluate the indication and standardization of early decompressive craniectomy as a 'second tier' standard therapy in pediatric severe head injury.	Univ Giessen, Univ Med Ctr, Dept Pediat, Giessen, Germany; Univ Giessen, Univ Med Ctr, Dept Neurosurg, Giessen, Germany; Univ Giessen, Univ Med Ctr, Dept Neuroradiol, Giessen, Germany		Ruf, B (corresponding author), Univ Giessen, Univ Med Ctr, Dept Pediat, Giessen, Germany.	bettina.ruf@paediat.med.uni-giessen.de		Jodicke, Andreas/0000-0003-4584-4875			BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Bruce DA, 2000, CHILD NERV SYST, V16, P755, DOI 10.1007/PL00013720; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Carter BG, 1999, INTENS CARE MED, V25, P722, DOI 10.1007/s001340050936; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Cruz J, 2002, NEUROSURGERY, V50, P774, DOI 10.1097/00006123-200204000-00017; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hieu PD, 1996, CHILD NERV SYST, V12, P270; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; LEVY DI, 1995, J NEUROSURG, V83, P453, DOI 10.3171/jns.1995.83.3.0453; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Munar F, 2000, J NEUROTRAUM, V17, P41, DOI 10.1089/neu.2000.17.41; Orliaguet GA, 1997, ANESTH ANALG, V85, P1218; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; REKATE HL, 2000, CHILD NERV SYST, V17, P632; SAKAS DE, 1995, J NEUROSURG, V83, P277, DOI 10.3171/jns.1995.83.2.0277; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; SIOUTOS PJ, 1995, NEUROSURGERY, V36, P943, DOI 10.1227/00006123-199505000-00009; Suzuki K., 1990, NAGOYA MED J, V34, P159; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	29	89	92	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	DEC	2003	7	6					R133	R138		10.1186/cc2361			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	751FL	WOS:000187042100002	14624687	Green Published, gold			2022-02-06	
J	Shirvan, A; Kimron, M; Holdengreber, V; Ziv, I; Ben-Shaul, Y; Melamed, S; Melamed, E; Barzilai, A; Solomon, AS				Shirvan, A; Kimron, M; Holdengreber, V; Ziv, I; Ben-Shaul, Y; Melamed, S; Melamed, E; Barzilai, A; Solomon, AS			Anti-semaphorin 3A antibodies rescue retinal ganglion cells from cell death following optic nerve axotomy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH CONE COLLAPSE; IN-VIVO; AXON GUIDANCE; ADULT-RATS; NEURONAL APOPTOSIS; MOLECULAR-BIOLOGY; TRANSGENIC MICE; III COLLAPSIN-1; HUMAN BRAIN; EXPRESSION	Damage to the optic nerve in mammals induces retrograde degeneration and apoptosis of the retinal ganglion cell (RGC) bodies. The mechanisms that mediate the response of the neuronal cells to the axonal injury are still unknown. We have previously shown that semaphorins, axon guidance molecules with repulsive cues, are capable of mediating apoptosis in cultured neuronal cells (Shirvan, A., Ziv, I., Fleminger, G., Shina, R., He, Z., Brudo, I., Melamed, E., and Brazilai, A. (1999) J. Neurochem. 73, 961-971). In this study, we examined the involvement of semaphorins in an in vivo experimental animal model of complete axotomy of the rat optic nerve. We demonstrate that a marked induction of type III semaphorin proteins takes place in ipsilateral retinas at early stages following axotomy, well before any morphological signs of RGC apoptosis can be detected. Time course analysis revealed that a peak of expression occurred after 2-3 days and then declined. A small conserved peptide derived from semaphorin 3A that was previously shown to induce neuronal death in culture was capable of inducing RGC loss upon its intravitreous injection into the rat eye. Moreover, we demonstrate a marked inhibition of RGC loss when axotomized eyes were co-treated by intravitreous injection of function-blocking antibodies against the semaphorin 3A-derived peptide. Marked neuronal protection from degeneration was also observed when the antibodies were applied 24 h post-injury. We therefore suggest that semaphorins are key proteins that modulate the cell fate of axotomized RGC. Neutralization of the semaphorin repulsive function may serve as a promising new approach for treatment of traumatic injury in the adult mammalian central nervous system or of opthalmologic diseases such as glaucoma and ischemic optic neuropathy that induce apoptotic RGC death.	Rabin Med Ctr, Dept Neurol, IL-49100 Petah Tiqwa, Israel; Rabin Med Ctr, Felsenstein Med Res Ctr, IL-49100 Petah Tiqwa, Israel; Sackler Sch Med, IL-49100 Petah Tiqwa, Israel; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, San Rothberg Glaucoma Ctr, Goldschleger Eye Res Inst, IL-69978 Tel Aviv, Israel		Shirvan, A (corresponding author), NST Ltd, 5 Odem St, IL-49170 Petah Tiqwa, Israel.		Solomon, Arieh/AAF-4361-2021				Adamus G, 1998, J AUTOIMMUN, V11, P523, DOI 10.1006/jaut.1998.0221; Bagnard D, 2001, J NEUROSCI, V21, P3332, DOI 10.1523/JNEUROSCI.21-10-03332.2001; Bagnard D, 1998, DEVELOPMENT, V125, P5043; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bonfanti L, 1996, J NEUROSCI, V16, P4186; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Chierzi S, 1998, VISION RES, V38, P1537, DOI 10.1016/S0042-6989(97)00332-5; Cuevas P, 1998, NEUROSCI LETT, V255, P1, DOI 10.1016/S0304-3940(98)00672-7; Delaire S, 1998, CELL MOL LIFE SCI, V54, P1265, DOI 10.1007/s000180050252; Djamgoz MBA, 1996, J NEUROSCI METH, V64, P237, DOI 10.1016/0165-0270(95)00109-3; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; FAN JH, 1993, J CELL BIOL, V121, P867, DOI 10.1083/jcb.121.4.867; Fujisawa H, 1998, CURR OPIN NEUROBIOL, V8, P587, DOI 10.1016/S0959-4388(98)80085-8; Fujita H, 2001, BRAIN RES, V914, P1, DOI 10.1016/S0006-8993(01)02765-2; Gagliardini V, 1999, MOL CELL NEUROSCI, V14, P301, DOI 10.1006/mcne.1999.0787; GARCIAVALENZUEL.E, 1994, EXP EYE RES, V61, P33; Giger RJ, 1998, J NEUROSCI RES, V52, P27, DOI 10.1002/(SICI)1097-4547(19980401)52:1<27::AID-JNR4>3.0.CO;2-M; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; HARLOW E, 1988, LAB MANUAL, P490; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hirsch E, 1999, BRAIN RES, V823, P67, DOI 10.1016/S0006-8993(99)01103-8; Isenmann S, 1999, CELL DEATH DIFFER, V6, P673, DOI 10.1038/sj.cdd.4400538; Isenmann S, 1998, EUR J NEUROSCI, V10, P2751, DOI 10.1046/j.1460-9568.1998.00325.x; Isenmann S, 1997, EXP NEUROL, V147, P28, DOI 10.1006/exnr.1997.6585; Jin Z, 1997, J NEUROSCI, V17, P6256; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; Kermer P, 1998, J NEUROSCI, V18, P4656; Koeberle PD, 1998, VISION RES, V38, P1505, DOI 10.1016/S0042-6989(97)00364-7; Kolodkin AL, 1998, PROG BRAIN RES, V117, P115; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Lafuente MP, 2001, INVEST OPHTH VIS SCI, V42, P2074; Lambiase A, 1997, GRAEF ARCH CLIN EXP, V235, P780, DOI 10.1007/BF02332863; Lazarov-Spiegler O, 1999, VISION RES, V39, P169, DOI 10.1016/S0042-6989(98)00089-3; Levin LA, 1999, SURV OPHTHALMOL, V43, pS98, DOI 10.1016/S0039-6257(99)00027-2; Lieberman AR., 1974, ESSAYS NERVOUS SYSTE, P71; Lucius R, 1997, MOL BRAIN RES, V48, P181, DOI 10.1016/S0169-328X(97)00170-8; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Mark MD, 1997, CELL TISSUE RES, V290, P299, DOI 10.1007/s004410050934; MEY J, 1993, BRAIN RES, V602, P304, DOI 10.1016/0006-8993(93)90695-J; Mordenti J, 1999, TOXICOL SCI, V52, P101, DOI 10.1093/toxsci/52.1.101; Nieto MA, 1996, NEURON, V17, P1039, DOI 10.1016/S0896-6273(00)80237-8; Ohguro H, 1999, INVEST OPHTH VIS SCI, V40, P3160; Pasterkamp RJ, 1999, MOL CELL NEUROSCI, V13, P143, DOI 10.1006/mcne.1999.0738; Pasterkamp RJ, 1998, EXP NEUROL, V153, P313, DOI 10.1006/exnr.1998.6886; PeinadoRamon P, 1996, INVEST OPHTH VIS SCI, V37, P489; Puschel AW, 1996, MOL CELL NEUROSCI, V7, P419, DOI 10.1006/mcne.1996.0030; RABACCHI SA, 1994, J NEUROSCI, V14, P5292; Schwartz M, 1996, J GLAUCOMA, V5, P427; Seigel G M, 1997, Mol Vis, V3, P14; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; Shirvan A, 2000, MOL BRAIN RES, V83, P81, DOI 10.1016/S0169-328X(00)00198-4; Shirvan A, 1999, J NEUROCHEM, V73, P961, DOI 10.1046/j.1471-4159.1999.0730961.x; So KF, 1998, VISION RES, V38, P1525, DOI 10.1016/S0042-6989(97)00226-5; Solomon AS, 1996, J NEUROSCI METH, V70, P21, DOI 10.1016/S0165-0270(96)00098-2; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Tanelian DL, 1997, NAT MED, V3, P1398, DOI 10.1038/nm1297-1398; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; THANOS S, 1995, J NEUROSCI, V15, P1057, DOI 10.1523/jneurosci.15-02-01057.1995; THANOS S, 1993, J NEUROSCI, V13, P455; Van Vactor D, 1999, CURR BIOL, V9, pR201; VarelaEchavarria A, 1997, NEURON, V18, P193, DOI 10.1016/S0896-6273(00)80261-5; Verma MJ, 1999, INVEST OPHTH VIS SCI, V40, P2465; VILLEGASPEREZ MP, 1988, J NEUROSCI, V8, P265; Xu XM, 1998, J BIOL CHEM, V273, P22428, DOI 10.1074/jbc.273.35.22428; Yamada T, 1997, P NATL ACAD SCI USA, V94, P14713, DOI 10.1073/pnas.94.26.14713; Yoshida H, 1998, J BIOL CHEM, V273, P9761, DOI 10.1074/jbc.273.16.9761; Yu HH, 1999, NEURON, V22, P11, DOI 10.1016/S0896-6273(00)80672-8	69	89	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49799	49807		10.1074/jbc.M204793200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	WOS:000180028900093	12376549	hybrid			2022-02-06	
J	Knoblach, SM; Nikolaeva, M; Huang, XL; Fan, L; Krajewski, S; Reed, JC; Faden, AI				Knoblach, SM; Nikolaeva, M; Huang, XL; Fan, L; Krajewski, S; Reed, JC; Faden, AI			Multiple caspases are activated after traumatic brain injury: Evidence for involvement in functional outcome	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; caspase; cysteine protease; mitochondria; neuron; trauma	SPINAL-CORD INJURY; CORTICAL IMPACT INJURY; NECROSIS-FACTOR-ALPHA; APOPTOTIC CELL-DEATH; CLOSED-HEAD INJURY; NEURONAL APOPTOSIS; CYTOCHROME-C; CEREBRAL-ISCHEMIA; GRANZYME-B; RAT-BRAIN	Caspase-3 is a cysteine protease that is strongly implicated in neuronal apoptosis. Activation of caspase-3 may be induced by at least two major initiator pathways: a caspase-8-mediated pathway activated through cell surface death receptors (extrinsic pathway), and a caspase-9-mediated pathway activated by signals from the mitochondria that lead to formation of an apoptosomal complex (intrinsic pathway). In the present studies, we compare the activation of caspases-3, -8, and -9 after lateral fluid-percussion traumatic brain injury (TBI) in rats. Inummoblot analysis identified cleaved forms of caspases-3 and -9, but not caspase-8, At 1, 12, and 48 h after injury. Immunocytochemistry specific for cleaved caspases-3 and -9 revealed their expression primarily in neurons. These caspases were also frequently localized in TUNEL-positive cells, some of which demonstrated morphological features of apoptosis. However, caspases-3 and -9 were also found in neurons that were not TUNEL-positive, and other TUNEL-positive cells did not show activated caspases. In contrast to caspases-3 or -9, caspase-8 expression was only minimally changed by injury. An increase in expression of this caspase was undetectable by immunoblotting methods, and appeared as positive immunostaining restricted to a few cells within the injured cortex. Treatment with the pan-caspase inhibitor z-VAD-fmk at 15 min after TBI improved performance on motor and spatial learning tests. These data suggest that several caspases may be involved in the pathophysiology of TBI and that pan-caspase inhibition strategies may improve neurological outcomes.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; Burnham Inst, La Jolla, CA 92037 USA		Knoblach, SM (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, EP-16,New Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036821, R01NS036537] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36821, NS36537] Funding Source: Medline		Allen JW, 1999, FASEB J, V13, P1875, DOI 10.1096/fasebj.13.13.1875; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Buki A, 2000, J NEUROSCI, V20, P2825; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Clark D, 1999, IEEE INTERNET COMPUT, V3, P13; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Conti AC, 1998, J NEUROSCI, V18, P5663; deTorres C, 1997, NEUROSCI LETT, V230, P1, DOI 10.1016/S0304-3940(97)00445-X; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; Fink K, 1998, J CEREBR BLOOD F MET, V18, P1071, DOI 10.1097/00004647-199810000-00003; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; HUANG X, 2000, SOC NEUROSCIENCE SOC; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kang SJ, 2000, J CELL BIOL, V149, P613, DOI 10.1083/jcb.149.3.613; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Krajewska M, 1997, CANCER RES, V57, P1605; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liao J, 2000, BIOTECHNIQUES, V28, P216, DOI 10.2144/00282bm05; Loddick SA, 1996, NEUROREPORT, V7, P1465, DOI 10.1097/00001756-199606170-00004; Lu J, 2000, NEUROSCI LETT, V290, P89, DOI 10.1016/S0304-3940(00)01307-0; Ma JY, 1998, BRIT J PHARMACOL, V124, P756, DOI 10.1038/sj.bjp.0701871; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; Mattson MP, 1998, EXP NEUROL, V153, P35, DOI 10.1006/exnr.1998.6863; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Namura S, 1998, J NEUROSCI, V18, P3659; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Paxinos G, 1986, RAT BRAIN STEREOTAXI; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; RINK A, 1995, AM J PATHOL, V147, P1575; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thomas DA, 2000, IMMUNITY, V12, P621, DOI 10.1016/S1074-7613(00)80213-7; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Velier JJ, 1999, J NEUROSCI, V19, P5932, DOI 10.1523/JNEUROSCI.19-14-05932.1999; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang XH, 1998, J BIOL CHEM, V273, P34278, DOI 10.1074/jbc.273.51.34278; Zhao X, 1999, NEUROCHEM RES, V24, P371, DOI 10.1023/A:1020933616351; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	69	89	93	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2002	19	10					1155	1170		10.1089/08977150260337967			16	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	605MJ	WOS:000178681400005	12427325				2022-02-06	
J	Singhal, A; Baker, AJ; Hare, GMT; Reinders, FX; Schlichter, LC; Moulton, RJ				Singhal, A; Baker, AJ; Hare, GMT; Reinders, FX; Schlichter, LC; Moulton, RJ			Association between cerebrospinal fluid interleukin-6 concentrations and outcome after severe human traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						human; inflammation; interleukin-1; interleukin-6; traumatic brain injury	TUMOR-NECROSIS-FACTOR; SEVERE HEAD-INJURY; SOMATOSENSORY-EVOKED-POTENTIALS; FOCAL CEREBRAL-ISCHEMIA; FACTOR-ALPHA; RAT-BRAIN; INFLAMMATORY RESPONSE; TNF-ALPHA; MESSENGER-RNA; BARRIER FUNCTION	Acute inflammation plays a significant role in the pathophysiology of traumatic brain injury (TBI). However, the specific relationships between inflammatory mediators and patient outcome following TBI have not been fully established. In this study, we measured plasma and cerebrospinal fluid interleukin-1 (IL-1) and interleukin-6 (IL-6) concentrations in 36 patients, following severe TBI. Patients were monitored with continuous measurements of somatosensory-evoked potentials (SSEP) to derive an established surrogate outcome measurement, the 96-h evoked potential (SSEP96). Clinical outcomes were assessed at 3 months using the Glasgow Outcome Scale (GOS). Peak cerebrospinal fluid (CSF) IL-1 and IL-6 concentrations were significantly higher than those observed in the plasma [median 6.5 pg/mL (range 1.4-25.0) vs. 3.0 (0.8-7.6) for IL-1, and 650 (130-7,214) vs. 253 (52-1,506) for IL-6, p < 0.001 for both]. Peak CSF IL-6 levels correlated with SSEP96 (r = 0.42; p = 0.0133), and peak CSF IL-6 levels were higher with improved GOS (p = 0.024). Multiple regression analysis identified that age (p = 0.0072), pupillary abnormality (p = 0.021), the presence of mass lesion (p = 0.023), and peak CSF IL-6 concentrations (p = 0.026) were all statistically significant predictors of clinical outcome following TBI. These results suggest that peak CSF IL-6 concentrations correlate with improved outcome following TBI. This finding helps to characterize the inflammatory reaction associated with TBI and may help to develop improved treatment strategies for patients with TBI.	St Michaels Hosp, Cara Phelan Ctr Trauma Res, Toronto, ON M5B 1W8, Canada; Univ Toronto, Dept Anaesthesia, Toronto, ON, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Univ Toronto, Dept Physiol, Toronto, ON, Canada; Toronto Western Res Inst, Cellular & Mol Biol Div, Toronto, ON, Canada		Baker, AJ (corresponding author), St Michaels Hosp, Cara Phelan Ctr Trauma Res, Rm 7086 Bond Wing,30 Bond St, Toronto, ON M5B 1W8, Canada.		Hare, Greg/AAM-5599-2021	Singhal, Ash/0000-0002-0061-9570			Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Ali C, 2000, J CEREBR BLOOD F MET, V20, P956, DOI 10.1097/00004647-200006000-00008; AMADO JA, 1995, METABOLISM, V44, P812, DOI 10.1016/0026-0495(95)90198-1; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bone RC, 1996, CRIT CARE MED, V24, P163, DOI 10.1097/00003246-199601000-00026; Brown JIM, 1998, NEUROSURGERY, V42, P1057, DOI 10.1097/00006123-199805000-00060; Carlson NG, 1999, J IMMUNOL, V163, P3963; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; D'Arcangelo G, 2000, EUR J NEUROSCI, V12, P1241, DOI 10.1046/j.1460-9568.2000.00011.x; Dawson DA, 1996, NEUROSCI LETT, V218, P41, DOI 10.1016/S0304-3940(96)13116-5; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; Ferrucci L, 1999, J AM GERIATR SOC, V47, P639, DOI 10.1111/j.1532-5415.1999.tb01583.x; Feuerstein G, 1998, CELL MOL NEUROBIOL, V18, P695, DOI 10.1023/A:1020226020062; Fisher J, 2001, J NEUROIMMUNOL, V119, P1, DOI 10.1016/S0165-5728(01)00342-3; Gebhard F, 2000, ARCH SURG-CHICAGO, V135, P291, DOI 10.1001/archsurg.135.3.291; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184, DOI 10.1097/00004647-199902000-00010; Hans VHJ, 1999, NEUROREPORT, V10, P409; Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2; Hermann DM, 1998, NEUROREPORT, V9, P1917, DOI 10.1097/00001756-199806010-00046; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Hudome S, 1997, PEDIATR RES, V41, P607, DOI 10.1203/00006450-199705000-00002; Kalabalikis P, 1999, INTENS CARE MED, V25, P288, DOI 10.1007/s001340050837; Kita T, 1997, INT J LEGAL MED, V110, P305, DOI 10.1007/s004140050093; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Lavine SD, 1998, J CEREBR BLOOD F MET, V18, P52, DOI 10.1097/00004647-199801000-00005; Lenzlinger PM, 2001, J NEUROTRAUM, V18, P479, DOI 10.1089/089771501300227288; Liu XH, 1999, J CEREBR BLOOD F MET, V19, P1099, DOI 10.1097/00004647-199910000-00006; MAEDA Y, 1994, J EXP MED, V180, P2297, DOI 10.1084/jem.180.6.2297; Martin C, 1997, CRIT CARE MED, V25, P1813, DOI 10.1097/00003246-199711000-00018; MartinAncel A, 1997, PEDIATRICS, V100, P789, DOI 10.1542/peds.100.5.789; Marz P, 1999, EUR J NEUROSCI, V11, P2995, DOI 10.1046/j.1460-9568.1999.00755.x; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; MOULTON R, 1991, J TRAUMA, V31, P676, DOI 10.1097/00005373-199105000-00012; Moulton RJ, 1998, CAN J NEUROL SCI, V25, pS7, DOI 10.1017/S031716710003465X; Nawashiro H, 1997, BRAIN RES, V778, P265, DOI 10.1016/S0006-8993(97)00981-5; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Penkowa M, 1999, GLIA, V25, P343; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Relton JK, 1996, EXP NEUROL, V138, P206, DOI 10.1006/exnr.1996.0059; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Savman K, 1998, PEDIATR RES, V43, P746; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Shuto T, 2001, NEUROREPORT, V12, P1081, DOI 10.1097/00001756-200104170-00043; Soares HD, 1995, J NEUROSCI, V15, P8223; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 1998, NEUROSCI LETT, V249, P123, DOI 10.1016/S0304-3940(98)00410-8; Stoll G, 2000, J NEURAL TRANSM-SUPP, P81; SZAFLARSKI J, 1995, STROKE, V26, P1093, DOI 10.1161/01.STR.26.6.1093; TARKOWSKI E, 1995, STROKE, V26, P1393, DOI 10.1161/01.STR.26.8.1393; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; TOWFIGHI J, 1995, ACTA NEUROPATHOL, V90, P375, DOI 10.1007/BF00315011; Uno H, 1997, J CEREBR BLOOD F MET, V17, P491, DOI 10.1097/00004647-199705000-00002; Vege A, 1998, ACTA PAEDIATR, V87, P819, DOI 10.1080/080352598750013563; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	73	89	99	1	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2002	19	8					929	937		10.1089/089771502320317087			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	585JC	WOS:000177520800003	12225653				2022-02-06	
J	Gao, H; Qiao, XX; Cantor, LB; WuDunn, D				Gao, H; Qiao, XX; Cantor, LB; WuDunn, D			Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells	ARCHIVES OF OPHTHALMOLOGY			English	Article							MESSENGER-RNA EXPRESSION; FIBROBLAST GROWTH-FACTOR; OPTIC-NERVE INJURY; IN-VIVO; SURVIVAL; DEGENERATION; ACTIVATION; RECEPTORS; NEURODEGENERATION; NEUROPROTECTION	Objectives: Brimonidine tartrate ophth, an alpha(2)-adrenergic agonist, is widely used as an antiglaucoma agent for lowering intraocular pressure. Recent studies suggest that brimonidine may be neuroprotective for retinal ganglion cells (RGCs) following optic nerve crush injury. Brain-derived neurotrophic factor (BDNF), a potent neuroprotective factor present in the RGCs, promotes RGC survival in culture and following optic nerve injury. We tested the hypothesis that a possible mechanism of brimonidine neuroprotection is through up-regulation of endogenous BDNF expression in the RGCs. Methods: A single dosage of brimonidine tartrate ophth solution (0.85-34muM) was injected intravitreally into Sprague-Dawley rat eyes. The fellow eyes of each animal were injected with balanced salt solution (BSS) and used as control eyes. To determine BDNF messenger RNA expression, animal eyes were enucleated and processed for in situ hybridization, or retinas were isolated and processed for Northern blot analysis using rat BDNF radiolabeled riboprobes. Results: In the control eyes injected with saline, BDNF was present in a minority of the RGCs. Two days after brimonidine injection, the number of BDNF-positive RGCs was increased from 55% to 166%, depending on brimonidine concentrations, when compared with those in the controls. In addition, the BDNF signal intensities in individual RGCs were elevated 50% in brimonidine-injected eyes compared with control eyes. Northern blot revealed a 28% increase of BDNF expression in the brimonidine group compared with the controls (P < .003). No significant difference was observed in BDNF receptor, trk B, expression between brimonidine, or BSS control groups. Conclusions: A single dose of a low concentration of intravitreal brimonidine is sufficient to significantly increase endogenous BDNF expression in RGCs. These results suggest that brimonidine neuroprotection may be mediated through up-regulation of BDNF in the RGCs. The BDNF should be further investigated regarding its role in the neuroprotective effects reported with brimonidine. Clinical Relevance: Brimonidine may be (potentially) used clinically as a neuroprotective agent in optic neuropathy, including glaucoma, and ischemic and traumatic optic neuropathy.	Indiana Univ, Sch Med, Dept Ophthalmol, Indianapolis, IN 46202 USA; Louisiana State Univ, Ctr Hlth Sci, Dept Anat & Cellular Biol, Shreveport, LA 71105 USA		Gao, H (corresponding author), Baylor Coll Med, Dept Ophthalmol, 6560 Fannin,Suite 2200, Houston, TX 77030 USA.						ALBLAS J, 1993, J BIOL CHEM, V268, P22235; Bautista RD, 1999, INT OPHTHALMOL CLIN, V39, P57, DOI 10.1097/00004397-199903930-00007; Berkowitz BA, 1998, INVEST OPHTH VIS SCI, V39, P391; Bullock R, 1995, ANN NY ACAD SCI, V765, P272, DOI 10.1111/j.1749-6632.1995.tb16584.x; Burke J, 1995, Ann N Y Acad Sci, V763, P78, DOI 10.1111/j.1749-6632.1995.tb32392.x; CARMIGNOTO G, 1989, J NEUROSCI, V9, P1263; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; DOBLE A, 1995, THERAPIE, V50, P319; Gao H, 1997, INVEST OPHTH VIS SCI, V38, P1840; GAO H, 1995, DEV BIOL, V169, P168, DOI 10.1006/dbio.1995.1135; Girkin CA, 2001, SURV OPHTHALMOL, V45, P379, DOI 10.1016/S0039-6257(00)00208-3; Greenfield DS, 1997, J GLAUCOMA, V6, P250; Hayashi T, 1999, NATURE, V397, P72, DOI 10.1038/16269; JOHNSON JE, 1986, J NEUROSCI, V6, P3031; Kent AR, 2001, OPHTHALMOLOGY, V108, P784, DOI 10.1016/S0161-6420(00)00654-0; LIU DX, 1994, J NEUROCHEM, V62, P37; MANSOURROBAEY S, 1994, P NATL ACAD SCI USA, V91, P1632, DOI 10.1073/pnas.91.5.1632; METSIS M, 1993, P NATL ACAD SCI USA, V90, P8802, DOI 10.1073/pnas.90.19.8802; MEY J, 1993, BRAIN RES, V602, P304, DOI 10.1016/0006-8993(93)90695-J; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; PEREZ MTR, 1995, NEUROSCI LETT, V183, P96, DOI 10.1016/0304-3940(94)11123-Z; PERRY VH, 1981, NEUROSCIENCE, V6, P931, DOI 10.1016/0306-4522(81)90174-3; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; QIAO X, 1994, INVEST OPHTH VIS SCI, V35, P1497; Qiao XO, 1996, J NEUROSCI, V16, P640; Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389; RICKMAN DW, 1995, VISUAL NEUROSCI, V12, P215, DOI 10.1017/S0952523800007896; SCHUMAN JS, 1996, SURV OPHTHALMOL S1, V41, P27; SCHWARTZ M, 1999, EUR J OPHTHALMOL, V9, P9; Thanos S, 1989, Fortschr Ophthalmol, V86, P172; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; Ugolini G, 1995, BRAIN RES, V704, P121, DOI 10.1016/0006-8993(95)01191-9; UNOKI K, 1994, INVEST OPHTH VIS SCI, V35, P907; Walters TR, 1996, SURV OPHTHALMOL, V41, pS19, DOI 10.1016/S0039-6257(96)82028-5; WEIBEL D, 1994, BRAIN RES, V642, P259, DOI 10.1016/0006-8993(94)90930-X; Wen R, 1996, J NEUROSCI, V16, P5986; Wheeler LA, 1999, EUR J OPHTHALMOL, V9, pS17, DOI 10.1177/112067219900901S09; Wilensky JT, 1996, SURV OPHTHALMOL, V41, pS3, DOI 10.1016/S0039-6257(96)82026-1; Yoles E, 1999, INVEST OPHTH VIS SCI, V40, P65; Yoles E, 1997, J NEUROTRAUM, V14, P665, DOI 10.1089/neu.1997.14.665; Yoles E, 1998, SURV OPHTHALMOL, V42, P367, DOI 10.1016/S0039-6257(97)00123-9	41	89	96	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0003-9950			ARCH OPHTHALMOL-CHIC	Arch. Ophthalmol.	JUN	2002	120	6					797	803					7	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	561MV	WOS:000176145500013	12049586				2022-02-06	
J	Stewart, WF; Schwartz, BS; Simon, D; Kelsey, K; Todd, AC				Stewart, WF; Schwartz, BS; Simon, D; Kelsey, K; Todd, AC			ApoE genotype, past adult lead exposure, and neurobehavioral function	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						apolipoprotein E; bone lead; cognitive function; neurobehavioral tests; X-ray fluorescence	AMYLOID PROTEIN DEPOSITION; RAT HIPPOCAMPAL-NEURONS; TRAUMATIC BRAIN-INJURY; E EPSILON 4; APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; INORGANIC LEAD; HEAD-INJURY; INDUCED NEUROTOXICITY; BONE-LEAD	Our objective in this study was to determine if the known relation between tibia bone lead levels and neurobehavioral test scores are influenced by the apolipoprotein E (ApoE) genotype. We collected data on 20 neurobehavioral tests in 529 former organolead workers who had an average of 16 years since last occupational exposure to lead. We used linear regression to model the relations between each of 20 neurobehavioral test scores and tibia lead, a binary variable for ApoE genotype (i.e., at least one epsilon4 allele vs. none), and an interaction term between tibia lead and the binary term for ApoE genotype. At the time of testing, former lead workers were an average of 57.6 years of age; 82% were younger than 65 years. In regression analysis, we observed one statistically significant and one borderline significant coefficient for ApoE genotype alone. Coefficients for the ApoE and tibia lead interaction term were negative in 19 of the 20 regression models. This indicates that the slope for the relation between tibia lead and each neurobehavioral test was more negative for individuals with at least one epsilon4 allele than for those who did not have an epsilon4 allele. Four of 19 negative coefficients for the interaction term were statistically significant (digit symbol, Purdue pegboard assembly, Purdue pegboard-dominant hand, complex reaction time); another three of the remaining 16 coefficients (symbol digit, trail-making A, Stroop) were borderline significant (i.e., p < 0.10). This study suggests that individuals may vary in susceptibility to the long-term effects of lead on the central nervous system (CNS). In particular, the persistent CNS effect of lead may be more toxic in individuals who have at least one ApoE-epsilon4 allele.	Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Div Occupat & Environm Hlth, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA; Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Mt Sinai Med Ctr, Dept Community & Prevent Med, New York, NY USA		Stewart, WF (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Room 6027,615 N Wolfe St, Baltimore, MD 21205 USA.	wstewart@jhsph.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P30ES000002, P42ES005947] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG010785] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG10785] Funding Source: Medline; NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P42 ES-05947, ES00002] Funding Source: Medline		Chen HH, 1998, BIOMED ENVIRON SCI, V11, P61; CORYSIECHTA DA, 1967, HDB NEUROTOXICOLOGY, P61; Derogatis L.R., 1994, SYMPTOM CHECKLIST 90, V3rd ed.; Finkelstein Y, 1998, BRAIN RES REV, V27, P168, DOI 10.1016/S0165-0173(98)00011-3; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GERHARDSSON L, 1993, ARCH ENVIRON HEALTH, V48, P147, DOI 10.1080/00039896.1993.9940813; Gong Zhaolong, 1995, Arhiv za Higijenu Rada i Toksikologiju, V46, P381; Gutowski M, 1998, TOXICOL LETT, V95, P195, DOI 10.1016/S0378-4274(98)00036-8; Harry GJ, 1996, TOXICOL APPL PHARM, V139, P84, DOI 10.1006/taap.1996.0145; HIXSON JE, 1990, J LIPID RES, V31, P541; Hu H, 1998, ENVIRON HEALTH PERSP, V106, P1, DOI 10.2307/3433626; Jones PM, 1998, GROUP DECIS NEGOT, V7, P249, DOI 10.1023/A:1008635500191; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KALA SV, 1995, NEUROTOXICOLOGY, V16, P297; KERN M, 1995, TOXICOL APPL PHARM, V134, P111, DOI 10.1006/taap.1995.1174; KONAT G, 1984, NEUROTOXICOLOGY, V5, P87; KONAT G, 1979, J NEUROCHEM, V32, P187, DOI 10.1111/j.1471-4159.1979.tb04526.x; Links JM, 2001, ENVIRON HEALTH PERSP, V109, P361, DOI 10.2307/3454895; MAESTRE G, 1995, ANN NEUROL, V37, P254, DOI 10.1002/ana.410370217; Marchioro M, 1996, J PHARMACOL EXP THER, V279, P143; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCCULLOUGH P, 1983, GEN LINEAR MODELS; Murphy KJ, 1995, TOXICOL LETT, V82-3, P271, DOI 10.1016/0378-4274(95)03561-3; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; NIKLOWITZ WJ, 1975, NEUROLOGY, V25, P927, DOI 10.1212/WNL.25.10.927; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Sahota A, 1997, ANN NEUROL, V42, P659, DOI 10.1002/ana.410420418; SCHWARTZ BS, 1993, AM J EPIDEMIOL, V137, P1006, DOI 10.1093/oxfordjournals.aje.a116757; Schwartz BS, 2000, NEUROLOGY, V55, P1144, DOI 10.1212/WNL.55.8.1144; SELVINTESTA A, 1994, NEUROTOXICOLOGY, V15, P389; SLOMIANKA L, 1989, NEUROTOXICOLOGY, V10, P177; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Southgate GS, 1998, J CHEM NEUROANAT, V14, P151, DOI 10.1016/S0891-0618(98)00026-X; Stewart WF, 1999, NEUROLOGY, V52, P1610, DOI 10.1212/WNL.52.8.1610; TIAN X, 1995, DEV BRAIN RES, V86, P268, DOI 10.1016/0165-3806(95)00038-F; Todd AC, 2000, ENVIRON HEALTH PERSP, V108, P383, DOI 10.2307/3454376; TODD AC, 1993, BASIC LIFE SCI, P299; TODD AC, 1992, ENVIRON RES, V57, P117, DOI 10.1016/S0013-9351(05)80073-8; WALSH TJ, 1984, NEUROTOXICOLOGY, V5, P67; WALSH TJ, 1986, NEUROTOXICOLOGY, V7, P21; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; Xu YZ, 1998, NEUROTOXICOL TERATOL, V20, P69, DOI 10.1016/S0892-0362(97)00072-X; Zaiser AE, 1997, NEUROSCI LETT, V239, P128, DOI 10.1016/S0304-3940(97)00895-1; Zhang HS, 1998, BIOMED ENVIRON SCI, V11, P81; ZIMMERMANN HP, 1988, MUTAT RES, V201, P293, DOI 10.1016/0027-5107(88)90018-8	47	89	92	0	2	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	MAY	2002	110	5					501	505		10.1289/ehp.02110501			5	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	552NL	WOS:000175626400025	12003753	Green Published, gold			2022-02-06	
J	Wang, XY; Mori, T; Jung, JC; Fini, ME; Lo, EH				Wang, XY; Mori, T; Jung, JC; Fini, ME; Lo, EH			Secretion of matrix metalloproteinase-2 and-9 after mechanical trauma injury in rat cortical cultures and involvement of MAP kinase	JOURNAL OF NEUROTRAUMA			English	Article						MAP kinase; mechanical injury; MMP; neuroprotection; primary cortical cultures; rats	ACTIVATED PROTEIN-KINASE; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; BLOOD-BRAIN-BARRIER; GENE KNOCK-OUT; IN-VITRO; MATRIX-METALLOPROTEINASE-9 EXPRESSION; INHIBITION; INTERLEUKIN-1; INCREASE	Matrix metalloproteinases (MMP) are involved in the pathophysiology of brain injury. We recently showed that knockout mice deficient in MMP-9 expression were protected against traumatic brain injury. However, the cellular sources of MMP activity after trauma remain to be fully defined. In this study, we investigated the hypothesis that resident brain cells secrete MMP after mechanical trauma injury in vitro, and mitogen-activated protein (MAP) kinase signal transduction pathways are involved in this response. Rat primary cortical neurons, astrocytes, and co-cultures were subjected to needle scratch mechanical injury, and levels of MMP-2 and MMP-9 in conditioned media were assayed by zymography. MMP-2 and MMP-9 were increased in cortical astrocytes and co-cultures, whereas only MMP-2 was increased in neurons. Western blots showed that phosphorylated extracellular signal regulated kinase (ERK1/2) and p38 were rapidly upregulated in co-cultures after mechanical injury. No change in phosphorylated c-jun N-terminal kinase (JNK) was observed. In-gel kinase assays confirmed this lack of response in the JNK pathway. Treatment with either 10 muM of U0126 (a MAP kinase/ERK1/2 kinase inhibitor) or 10 muM of SB203580 (a p38 inhibitor) had no detectable effect on MMP-2 and MMP-9 levels after mechanical injury. However, combination treatment with both inhibitors significantly reduced secretion of MMP-9. Herein, we demonstrate that (1) resident brain cells secrete MMP after mechanical injury, (2) astrocytes are the main source of MMP-9 activity, and (3) ERK and p38 MAP kinases are upregulated after mechanical injury, and mediate the secretion of MMP-9.	Harvard Univ, Med Sch, Det Neurol, Neuroprot Res Lab, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Neuroprot Res Lab, Dept Radiol, Boston, MA 02114 USA; Harvard Univ, Med Sch, Program Neurosci, Charlestown, MA USA; Tufts Univ, Sch Med, New England Eye Ctr, Vis Res Labs, Boston, MA USA; Massachusetts Gen Hosp, Neuroprot Res Lab, Dept Neurol, Boston, MA 02114 USA		Wang, XY (corresponding author), Harvard Univ, Med Sch, Det Neurol, Neuroprot Res Lab, MGH East 149-2322, Charlestown, MA 02129 USA.	wangxi@helix.mgh.harvard.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037074, R01NS038731, R01NS040529] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS37074, R01-NS38731, R01-NS40529] Funding Source: Medline		Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Anthony DC, 1998, J NEUROIMMUNOL, V87, P62, DOI 10.1016/S0165-5728(98)00046-0; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; BRIDGES RJ, 1992, NEUROPHARMACOLOGY, V31, P899, DOI 10.1016/0028-3908(92)90128-C; Cho A, 2000, ARTERIOSCL THROM VAS, V20, P2527, DOI 10.1161/01.ATV.20.12.2527; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Cuzner ML, 1999, J NEUROIMMUNOL, V94, P1, DOI 10.1016/S0165-5728(98)00241-0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Esparza J, 1999, BLOOD, V94, P2754, DOI 10.1182/blood.V94.8.2754.420k09_2754_2766; Esteve PO, 1998, BBA-MOL CELL RES, V1403, P85, DOI 10.1016/S0167-4889(98)00020-2; Fini ME, 1998, BIOL EXTRAC, P299; Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010; GOTTSCHALL PE, 1995, J NEUROCHEM, V64, P1513; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Harkness KA, 2000, BRAIN, V123, P698, DOI 10.1093/brain/123.4.698; Hartung HP, 2000, J NEUROIMMUNOL, V107, P140, DOI 10.1016/S0165-5728(00)00225-3; Heo JH, 1999, J CEREBR BLOOD F MET, V19, P624, DOI 10.1097/00004647-199906000-00005; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1089, DOI 10.1097/00004647-200007000-00008; Jiang Q, 2000, BRAIN RES, V857, P71, DOI 10.1016/S0006-8993(99)02364-1; Katano H, 1999, NEUROREPORT, V10, P2439, DOI 10.1097/00001756-199908200-00002; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; McCawley LJ, 2000, MOL PHARMACOL, V58, P145, DOI 10.1124/mol.58.1.145; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mengshol JA, 2000, ARTHRITIS RHEUM, V43, P801, DOI 10.1002/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-4; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Mun-Bryce S, 1998, J CEREBR BLOOD F MET, V18, P1163, DOI 10.1097/00004647-199811000-00001; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; Pagenstecher A, 1998, AM J PATHOL, V152, P729; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; Shah PT, 1997, NEUROSCIENCE, V79, P999, DOI 10.1016/S0306-4522(97)00013-4; Sugino T, 2000, J NEUROSCI, V20, P4506, DOI 10.1523/JNEUROSCI.20-12-04506.2000; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; Tsirka SE, 1997, J NEUROSCI, V17, P543; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Xu J, 2001, J NEUROSCI, V21, P92, DOI 10.1523/JNEUROSCI.21-01-00092.2001; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271	54	89	96	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2002	19	5					615	625		10.1089/089771502753754082			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	557PA	WOS:000175915900006	12042096				2022-02-06	
J	Paterson, B; Scott-Findlay, S				Paterson, B; Scott-Findlay, S			Critical issues in interviewing people with traumatic brain injury	QUALITATIVE HEALTH RESEARCH			English	Article								People with cognitive impairments often cannot effectively recall and articulate experiences, feelings, and perceptions, Therefore, interviewing them can be fraught with pragmatic and methodological difficulties. Given this situation, the authors' experience in a study oil the allocation of rehabilitative services to survivors of traumatic brain injury is discussed. Participants had physiological impairments affecting their ability to focus on interview questions. The authors discuss the unique challenges, including participants' recall of events, intolerance to stimuli, and image management and offer strategies for mitigating these concerns. The traditional view that reality is captured only in the subjective accounts of articulate people who can remember events in a precise and reflective manner is challenged.	Univ British Columbia, Sch Nursing, Vancouver, BC V5Z 1M9, Canada		Paterson, B (corresponding author), Univ British Columbia, Sch Nursing, Vancouver, BC V5Z 1M9, Canada.						Acton G J, 1999, J Gerontol Nurs, V25, P6; ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; BOWERS LJ, 1995, TOPICS CLIN CHIROPRA, V2, P94; BOWERS LJ, 1995, TOPICS CLIN CHIROPRA, V2, P86; Crowe M, 1998, J ADV NURS, V28, P339, DOI 10.1046/j.1365-2648.1998.00780.x; Docherty S, 1999, RES NURS HEALTH, V22, P177, DOI 10.1002/(SICI)1098-240X(199904)22:2<177::AID-NUR9>3.3.CO;2-8; GORDON N, 1997, NURSE RES, V5, P72; GRANT NK, 1993, J ADV NURS, V18, P2020, DOI 10.1046/j.1365-2648.1993.18122020.x; Gregory R J, 1998, J Psychosoc Nurs Ment Health Serv, V36, P28; Hertz R., 1995, QUALITATIVE INQUIRY, V1, P429, DOI [10.1177/107780049500100404, DOI 10.1177/]; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Holstein J.A., 1995, ACTIVE INTERVIEW; HUTCHINSON S, 1992, NURS RES, V41, P117; MEYER PH, 1998, CLIN APPL BOWEN FAMI, P69; NELSON K, 1993, MINN SYM CHILD PSYCH, V26, P1; Nochi M, 1998, QUAL HEALTH RES, V8, P665, DOI 10.1177/104973239800800507; PATERSON B, 1992, QUALITATIVE HLTH RES, V2, P99; RAMOS MC, 1989, RES NURS HEALTH, V12, P57, DOI 10.1002/nur.4770120109; Rolls C, 1997, Contemp Nurse, V6, P152; SARGEANT R, 2000, J COGNIT REHABIL, V18, P20; SCOTTFINDLAY S, 1998, THESIS U MANITOBA WI; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Thorne S, 1998, Image J Nurs Sch, V30, P173, DOI 10.1111/j.1547-5069.1998.tb01275.x; Thorne S E, 2000, Annu Rev Nurs Res, V18, P3; Torkelson Lynch R., 1995, J SPEC GROUP WORK, V20, P108, DOI [10.1080/01933929508411333, DOI 10.1080/01933929508411333]; Williams CC, 1999, PSYCHIATRY, V62, P61, DOI 10.1080/00332747.1999.11024853; WORTH A, 1993, J ADV NURS, V18, P1077, DOI 10.1046/j.1365-2648.1993.18071077.x	27	89	90	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1049-7323	1552-7557		QUAL HEALTH RES	Qual. Health Res.	MAR	2002	12	3					399	409		10.1177/104973202129119973			11	Public, Environmental & Occupational Health; Information Science & Library Science; Social Sciences, Interdisciplinary; Social Sciences, Biomedical	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; Information Science & Library Science; Social Sciences - Other Topics; Biomedical Social Sciences	523KM	WOS:000173952900009	11918104				2022-02-06	
J	Lee, JH; Kelly, DF; Oertel, M; McArthur, DL; Glenn, TC; Vespa, P; Boscardin, WJ; Martin, NA				Lee, JH; Kelly, DF; Oertel, M; McArthur, DL; Glenn, TC; Vespa, P; Boscardin, WJ; Martin, NA			Carbon dioxide reactivity, pressure autoregulation, and metabolic suppression reactivity after head injury: a transcranial Doppler study	JOURNAL OF NEUROSURGERY			English	Article						cerebral vasoreactivity; carbon dioxide reactivity; hyperventilation; intracranial hypertension; autoregulation; propofol; transcranial Doppler ultrasonography; traumatic brain injury	CEREBRAL BLOOD-FLOW; TRAUMATIC BRAIN INJURY; INTRACRANIAL HYPERTENSION; AUTO-REGULATION; PROPOFOL; CIRCULATION; HUMANS; VASOREACTIVITY; VELOCITY; HYPERVENTILATION	Object. Contemporary management of head-injured patients is based on assumptions about CO., reactivity, pressure autoregulation (PA), and vascular reactivity to pharmacological metabolic suppression. In this study, serial assessments of vasoreactivity of the middle cerebral artery (MCA) were per-formed using bilateral transcranial Doppler (TCD) ultrasonography. Methods. Twenty-eight patients (mean age 33 +/- 13 years, median Glasgow Coma Scale score of 7) underwent a total of 61 testing sessions during postinjury Days 0 to 13. The CO, reactivity (58 studies in 28 patients), PA (51 studies in 23 patients), and metabolic suppression reactivity (35 studies in 16 patients) were quantified for each cerebral hemisphere by measuring changes in MCA velocity in response to transient hyperventilation, arterial blood pressure elevation, or propofol-induced burst suppression, respectively. One or both hemispheres registered below normal vasoreactivity scores in 40%, 69%, and 97% of study sessions for CO, reactivity, PA, and metabolic suppression reactivity (p < 0.0001), respectively. Intracranial hypertension, classified as intracranial pressure (ICP) greater than 20 mm Hg at the time of testing, was associated with global impairment of CO, reactivity, PA, and metabolic suppression reactivity (p < 0.05). A low baseline cerebral perfusion pressure (CPP) was also predictive of impaired CO, reactivity and PA (p < 0.01). Early postinjury hypotension or hypoxia was also associated with impaired CO, reactivity (p < 0.05), and hemorrhagic brain lesions in or overlying the MCA territory were predictive of impaired metabolic suppression reactivity (p < 0.01). The 6-month Glasgow Outcome Scale score correlated with the overall degree of impaired vasoreactivity (p < 0.05). Conclusions. During the first 2 weeks after moderate or severe head injury, CO, reactivity remains relatively intact, PA is variably impaired, and metabolic suppression reactivity remains severely impaired. Elevated ICP appears to affect all three components of vasoreactivity that were tested, whereas other clinical factors such as CPP, hypotensive and hypoxic insults, and hemorrhagic brain lesions have distinctly different impacts on the state of vasoreactivity. Incorporation of TCD ultrasonography-derived vasoreactivity data may facilitate more injury- and time-specific therapies for head-injured patients.	Univ Calif Los Angeles, Div Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Cerebral Blood Flow Lab, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Epidemiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Div Neurosurg, Ctr Hlth Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Harbor Med Ctr, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Res & Educ Inst, Los Angeles, CA USA		Kelly, DF (corresponding author), Univ Calif Los Angeles, Div Neurosurg, Brain Injury Res Ctr, Room 18-218A NPI,Box 957039, Los Angeles, CA 90095 USA.	dfkelly@ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314; Glenn, Thomas/0000-0003-4273-3408; Martin, Neil/0000-0002-6565-4131	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30308] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308] Funding Source: NIH RePORTER		AASLID R, 1987, STROKE, V18, P771, DOI 10.1161/01.STR.18.4.771; AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; BAILIE GR, 1992, BRIT J ANAESTH, V68, P486, DOI 10.1093/bja/68.5.486; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bullock MR, 1996, J NEUROTRAUM, V13, P711; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Clark RSB, 1997, NEUROSURGERY, V41, P1284, DOI 10.1097/00006123-199712000-00010; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P222; Cormio M, 1999, J NEUROTRAUM, V16, P927, DOI 10.1089/neu.1999.16.927; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; Gelb A. W., 1993, Canadian Journal of Anaesthesia, V40, pA68; GOMEZ SM, 1990, STROKE, V21, P1746, DOI 10.1161/01.STR.21.12.1746; ILLIEVICH UM, 1993, ANESTH ANALG, V77, P155; JENNETT B, 1975, LANCET, V1, P480; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; KIRKHAM FJ, 1986, ULTRASOUND MED BIOL, V12, P15, DOI 10.1016/0301-5629(86)90139-0; KLINGELHOFER J, 1992, STROKE, V23, P962, DOI 10.1161/01.STR.23.7.962; Kochanek PM, 1997, ACT NEUR S, V70, P109; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; LARSEN FS, 1994, STROKE, V25, P1985, DOI 10.1161/01.STR.25.10.1985; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; LEE MW, 1994, J NEUROTRAUM, V11, P325, DOI 10.1089/neu.1994.11.325; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; Littell R.C., 1996, SAS SYSTEM MIXED MOD; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; MATTA BF, 1995, BRIT J ANAESTH, V74, P159, DOI 10.1093/bja/74.2.159; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Minassian AT, 1998, J NEUROSURG, V88, P996, DOI 10.3171/jns.1998.88.6.0996; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; Osborn A.G., 1994, DIAGNOSTIC NEURORADI, P117; PHILLIS J W, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P26; Raichle ME, 1972, STROKE, V3, P566, DOI 10.1161/01.STR.3.5.566; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SHAPIRO HM, 1974, J NEUROSURG, V40, P90, DOI 10.3171/jns.1974.40.1.0090; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; Strebel SP, 1998, ANESTHESIOLOGY, V89, P67, DOI 10.1097/00000542-199807000-00012; TEASDALE G, 1974, LANCET, V2, P81; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; VANHEMELRIJCK J, 1990, ANESTH ANALG, V71, P49; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383	61	89	91	1	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2001	95	2					222	232		10.3171/jns.2001.95.2.0222			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	459MP	WOS:000170254500007	11780891				2022-02-06	
J	Coplin, WM; Cullen, NK; Policherla, PN; Vinas, FC; Wilseck, JM; Zafonte, RD; Rengachary, SS				Coplin, WM; Cullen, NK; Policherla, PN; Vinas, FC; Wilseck, JM; Zafonte, RD; Rengachary, SS			Safety and feasibility of craniectomy with duraplasty as the initial surgical intervention for severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	Annual Meeting of the Association-of-Academic-Physiatrists	FEB, 1999	ORLANDO, FL	Assoc Acad Physiatrists		traumatic brain injury; craniectomy; brain swelling/edema; craniotomy; intracranial pressure; Glasgow Coma Scale; head injury; outcome; functional independence measure; Glasgow Outcome Scale; trauma	FUNCTIONAL INDEPENDENCE MEASURE; CLOSED-HEAD-INJURY; DECOMPRESSIVE CRANIECTOMY; INTRAVENTRICULAR HEMORRHAGE; HEMISPHERIC INFARCTION; CEREBRAL INFARCTION; MANAGEMENT; HEMICRANIECTOMY; MECHANISMS; CRANIOTOMY	Background: Decompressive craniectomy has historically served as a salvage procedure to control intracranial pressure after severe traumatic brain injury. We assessed the safety and feasibility of performing craniectomy as the initial surgical intervention. Methods: of 29 consecutive patients undergoing emergent decompression for severe traumatic brain injury with horizontal midline shift greater than explained by a removable hematoma, 17 had traditional craniotomy with or without brain resection and 12 underwent craniectomy. Results: The craniectomy group had lower Glasgow Coma Scale scores at surgery (median, 4 vs. 7; p = 0.04) and more severe radiographic injuries (using specific measures). Mortality, Glasgow outcome Scale scores, Functional Independence Measures, and length of stay in both the acute care setting and the rehabilitation phase were similar between the surgical groups, Conclusion Despite more severe injury severity, patients undergoing initial craniectomy had outcomes similar to those undergoing traditional surgery. A randomized evaluation of the effect of early craniectomy on outcome is warranted.	Wayne State Univ, Detroit Receiving Hosp, Dept Neurol, Detroit, MI USA; Wayne State Univ, Detroit Receiving Hosp, Dept Neurol Surg, Detroit, MI USA; Inst Rehabil, Dept Phys Med & Rehabil, Detroit, MI USA; Wayne State Univ, Med Ctr, Dept Radiol, Detroit, MI 48202 USA		Coplin, WM (corresponding author), Wayne State Univ, Sch Med, Dept Neurol, 4201 St Antoine,8D, Detroit, MI 48201 USA.	wcoplin@med.wayne.edu		Cullen, Nora/0000-0001-6359-9418	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038905] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1RO1-NS38905-01] Funding Source: Medline		ALDRICH EF, 1993, BRAIN SURG COMPLICAT, P1283; Bouma G J, 1995, New Horiz, V3, P384; Bullock R, 1995, GUIDELINES MANAGEMEN; Carter BS, 1997, NEUROSURGERY, V40, P1168, DOI 10.1097/00006123-199706000-00010; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; Coplin WM, 1998, STROKE, V29, P1573, DOI 10.1161/01.STR.29.8.1573; Cushing H, 1905, SURG GYNECOL OBSTET, V1, P297; Da Silva J A, 1976, Arq Neuropsiquiatr, V34, P232; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; DELASHAW JB, 1990, STROKE, V21, P874, DOI 10.1161/01.STR.21.6.874; DISCALA C, 1992, AM J PHYS MED REHAB, V71, P145, DOI 10.1097/00002060-199206000-00004; FISHER CM, 1994, SURG NEUROL, V41, P65, DOI 10.1016/0090-3019(94)90210-0; GAAB MR, 1990, ACT NEUR S, V51, P326; Gebel JM, 1998, STROKE, V29, P1799, DOI 10.1161/01.STR.29.9.1799; GERL A, 1980, Zentralblatt fuer Neurochirurgie, V41, P125; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; GRAEB DA, 1982, RADIOLOGY, V143, P91, DOI 10.1148/radiology.143.1.6977795; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P33, DOI 10.1097/00002060-199302000-00008; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; Jennett B, 1981, MANAGEMENT HEAD INJU; JENNETT B, 1992, PROGNOSIS NEUROLOGIC; KALIA KK, 1993, ARCH NEUROL-CHICAGO, V50, P1293, DOI 10.1001/archneur.1993.00540120010005; KARLEN J, 1987, NEUROCHIRURGIA, V30, P35; Keith R A, 1987, Adv Clin Rehabil, V1, P6; KERR FWL, 1968, MAYO CLIN PROC, V43, P852; KONDZIOLKA D, 1988, NEUROSURGERY, V23, P143, DOI 10.1227/00006123-198808000-00002; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; LEROUX PD, 1992, NEUROSURGERY, V31, P678, DOI 10.1227/00006123-199210000-00010; Lubillo S, 1999, J NEUROSURG, V91, P581, DOI 10.3171/jns.1999.91.4.0581; Marion DW, 1998, NEUROL CLIN, V16, P485, DOI 10.1016/S0733-8619(05)70073-6; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; PEREIRA WC, 1977, ARQ NEURO-PSIQUIAT, V35, P99, DOI 10.1590/S0004-282X1977000200002; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Prat R, 1998, ACTA NEUROCHIR, V140, P1257, DOI 10.1007/s007010050247; Qureshi AI, 2000, CRIT CARE MED, V28, P1556, DOI 10.1097/00003246-200005000-00049; RANSOHOFF J, 1971, J NEUROSURG, V34, P70, DOI 10.3171/jns.1971.34.1.0070; RENGACHARY SS, 1981, NEUROSURGERY, V8, P321, DOI 10.1227/00006123-198103000-00004; RIEKE K, 1995, CRIT CARE MED, V23, P1576, DOI 10.1097/00003246-199509000-00019; Schwab S, 1997, NEUROLOGY, V48, P412, DOI 10.1212/WNL.48.2.412; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; WRIGHT BC, 1992, RASCH ANAL BIG STEPS	52	89	95	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2001	50	6					1050	1059		10.1097/00005373-200106000-00013			10	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	442HD	WOS:000169278400017	11426120				2022-02-06	
J	Donnemiller, E; Brenneis, C; Wissel, J; Scherfler, C; Poewe, W; Riccabona, G; Wenning, GK				Donnemiller, E; Brenneis, C; Wissel, J; Scherfler, C; Poewe, W; Riccabona, G; Wenning, GK			Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPET study using (123)I-beta-CIT and (123)I-IBZM	EUROPEAN JOURNAL OF NUCLEAR MEDICINE			English	Article						head injury; single-photon emission tomography; nigrostriatal dysfunction; striatal dopamine transporter; striatal D2 receptor	HEALTHY-VOLUNTEERS; DOSIMETRY; RECOVERY; STATE	Structural imaging suggests that traumatic brain injury (TBI) may be associated with disruption of neuronal networks, including the nigrostriatal dopaminergic pathway. However, to date deficits in pre- and/or postsynaptic dopaminergic neurotransmission have not been demonstrated in TBI using functional imaging. We therefore assessed dopaminergic function in ten TBI patients using [(123)I]2-beta-carbomethoxy-3-beta-(4-iodophenyl)tropane (beta-CIT) and [(123)I]iodobenzamide (IBZM) single-photon emission tomography (SPET). Average Glasgow Coma Scale score (+/- SD) at the time of head trauma was 5.8 +/- 4.2. SPET was performed on average 141 days (SD +/- 42) after TBI. The SPET images were compared with structural images using cranial computerised tomography (CCT) and magnetic resonance imaging (MRI). SPET was performed with an ADAC Vertex dual-head camera. The activity ratios of striatal to cerebellar uptake were used as a semiquantitative parameter of striatal dopamine transporter (DAT) and D2 receptor (D2R) binding. Compared with age-matched controls, patients with TBI had significantly Lower striatal/cerebellar beta-CIT and IBZM binding ratios (P less than or equal to 0.01). Overall, the DAT deficit was more marked than the D2R loss. CCT and MRI studies revealed varying cortical and subcortical lesions, with the frontal lobe being most frequently affected whereas the striatum appeared structurally normal in all but one patient. Our findings suggest that nigrostriatal dysfunction may be detected using SPET following TBI despite relative structural preservation of the striatum. Further investigations of possible clinical correlates and efficacy of dopaminergic therapy in patients with TBI seem justified.	Univ Innsbruck Hosp, Dept Nucl Med, A-6020 Innsbruck, Austria; Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria		Donnemiller, E (corresponding author), Univ Innsbruck Hosp, Dept Nucl Med, Anichstr 35, A-6020 Innsbruck, Austria.			Wenning, Gregor/0000-0001-9077-1666; Scherfler, Christoph/0000-0002-4885-5265			Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kapucu LO, 1998, J NUCL MED, V39, P1703; KUIKKA JT, 1994, EUR J NUCL MED, V21, P53; LARUELLE M, 1994, J CEREBR BLOOD F MET, V14, P982, DOI 10.1038/jcbfm.1994.131; VERHOEFF NPLG, 1993, EUR J NUCL MED, V20, P747, DOI 10.1007/BF00180903; VERHOEFF NPLG, 1991, NUCL MED COMMUN, V12, P687, DOI 10.1097/00006231-199108000-00004; Wenning GK, 1999, MOVEMENT DISORD, V14, P366, DOI 10.1002/1531-8257(199903)14:2<366::AID-MDS1029>3.0.CO;2-D; Witte OW, 1998, CURR OPIN NEUROL, V11, P655, DOI 10.1097/00019052-199812000-00008; Zafonte RD, 1998, BRAIN INJURY, V12, P617	9	89	94	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0340-6997			EUR J NUCL MED	Eur. J. Nucl. Med.	SEP	2000	27	9					1410	1414		10.1007/s002590000308			5	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	352EN	WOS:000089201700021	11007526				2022-02-06	
J	Engel, S; Schluesener, H; Mittelbronn, M; Seid, K; Adjodah, D; Wehner, HD; Meyermann, R				Engel, S; Schluesener, H; Mittelbronn, M; Seid, K; Adjodah, D; Wehner, HD; Meyermann, R			Dynamics of microglial activation after human traumatic brain injury are revealed by delayed expression of macrophage-related proteins MRP8 and MRP14	ACTA NEUROPATHOLOGICA			English	Article						intracellular signalling; Ki-67; microglia activation; normal brain ischemia	CALCIUM-BINDING PROTEINS; LYMPHOCYTE CHEMOATTRACTANT FACTOR; CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS LESIONS; CLASS-II ANTIGENS; CD8(+) T-CELLS; HEAD-INJURY; RAT-BRAIN; CNS; ASTROCYTES	Human traumatic brain injury (TBI) is ideally suited for investigation of the kinetics of human microglial cell activation as the onset of lesion formation is precisely defined. The present study provides evidence of a distinct delay in macrophage/microglia response following TBI. Eighteen brains of patients who had survived TBI for 1 h to 6 months were analysed by immunohistology. Samples of contusional and non-contusional areas were studied using antibodies directed against antigens of microglia/macrophages [major histocompatibility complex class II, CD4, interleukin (IL)-16, macrophage-related protein (MRP) 8 and MRP14]. IL-16, a natural ligand to CD4, was expressed constitutively by numerous microglial cells in all cases throughout the brain. CD4 could be detected regularly on perivascular cells. MRP8 and MRP14, which are only expressed on activated macrophages and microglial cells, could be detected only within brains with a survival time of more than 72 h post TBI. In addition, proliferation of microglia detected by MIB-1 was not present until 72 h. This delayed expression of the activation markers MRP8 and MRP14 and the proliferation marker MIB-1 is comparable to experimental closed head injuries but strictly different from acute activation found in ischemic brains.	Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany; Univ Tubingen, Inst Legal Med, D-72076 Tubingen, Germany		Engel, S (corresponding author), Univ Tubingen, Inst Brain Res, Calwer Str 3, D-72076 Tubingen, Germany.			Mittelbronn, Michel/0000-0002-2998-052X			AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; AKIYAMA H, 1994, J NEUROIMMUNOL, V50, P195, DOI 10.1016/0165-5728(94)90046-9; BANATI RB, 1994, DEV NEUROSCI-BASEL, V16, P114, DOI 10.1159/000112098; Bernaudin M, 1998, EXP NEUROL, V150, P30, DOI 10.1006/exnr.1997.6728; BO L, 1994, J NEUROIMMUNOL, V51, P135, DOI 10.1016/0165-5728(94)90075-2; Bobryshev YV, 1996, PATHOL RES PRACT, V192, P260, DOI 10.1016/S0344-0338(96)80229-9; BRUCK W, 1995, ANN NEUROL, V38, P788, DOI 10.1002/ana.410380514; CENTER DM, 1995, J LAB CLIN MED, V125, P167; CENTER DM, 1982, J IMMUNOL, V128, P2562; Cruikshank W W, 1998, Int Rev Immunol, V16, P523, DOI 10.3109/08830189809043007; De la Riva I, 1990, REV ESPANOLA HERPETO, V4, P81; Deininger MH, 1998, HISTOCHEM CELL BIOL, V110, P425, DOI 10.1007/s004180050303; Engel S, 1996, ACT NEUR S, V66, P87; FABRY Z, 1994, IMMUNOL TODAY, V15, P218, DOI 10.1016/0167-5699(94)90247-X; FINSEN BR, 1993, GLIA, V7, P41, DOI 10.1002/glia.440070109; FLARIS NA, 1993, GLIA, V7, P34, DOI 10.1002/glia.440070108; GIULIAN D, 1994, NEUROCHEM INT, V25, P227, DOI 10.1016/0197-0186(94)90066-3; GOEBELER M, 1995, BIOCHEM J, V309, P419, DOI 10.1042/bj3090419; GRAEBER MB, 1988, J NEUROSCI RES, V21, P18, DOI 10.1002/jnr.490210104; Graham DI, 1997, GREENFIELDS NEUROPAT, P197; Heizmann CW, 1996, MOL CELLS, V6, P629; HICKEY WF, 1992, J NEUROPATH EXP NEUR, V51, P246, DOI 10.1097/00005072-199205000-00002; HILT DC, 1988, TRENDS BIOCHEM SCI, V13, P437; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/S0968-0004(06)80021-6; KETTENMANN H, 1990, J NEUROSCI RES, V26, P278, DOI 10.1002/jnr.490260303; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; Krautwald S, 1998, J IMMUNOL, V160, P5874; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kuruto-Niwa R, 1998, CELL STRUCT FUNCT, V23, P109, DOI 10.1247/csf.23.109; Laberge S, 1996, J IMMUNOL, V156, P310; LABERGE S, 1995, J IMMUNOL, V155, P2902; Lassmann H., 1997, Journal of Neural Transmission Supplement, V50, P183; MATIAZEK JW, 1997, J IMMUNOL, V158, P5; McKeever PE, 1998, J HISTOCHEM CYTOCHEM, V46, P585, DOI 10.1177/002215549804600504; Moller T, 1997, J NEUROSCI, V17, P615; PERRY VH, 1987, J EXP MED, V166, P1138, DOI 10.1084/jem.166.4.1138; Postler E, 1997, GLIA, V19, P27, DOI 10.1002/(SICI)1098-1136(199701)19:1<27::AID-GLIA3>3.0.CO;2-7; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; QI JF, 1995, J IMMUNOL, V155, P867; RAINE CS, 1994, J NEUROPATH EXP NEUR, V53, P328, DOI 10.1097/00005072-199407000-00002; RENAUD W, 1994, BIOCHEM BIOPH RES CO, V201, P1518, DOI 10.1006/bbrc.1994.1876; Rostworowski M, 1997, J NEUROSCI, V17, P3664; ROTH J, 1994, BIOCHEM J, V301, P655, DOI 10.1042/bj3010655; SASAKI A, 1992, NEUROPATH APPL NEURO, V18, P13, DOI 10.1111/j.1365-2990.1992.tb00761.x; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/0968-0004(96)10020-7; Schluesener HJ, 1996, J NEUROSCI RES, V44, P606; SCHLUESENER HJ, 1993, ACTA NEUROPATHOL, V86, P393, DOI 10.1007/BF00369453; SCHMID KW, 1995, HUM PATHOL, V26, P334, DOI 10.1016/0046-8177(95)90067-5; SIEVERS J, 1994, GLIA, V12, P245, DOI 10.1002/glia.440120402; Sorg C, 1992, Behring Inst Mitt, P126; STEVENS A, 1993, J NEUROL SCI, V118, P117, DOI 10.1016/0022-510X(93)90100-D; STREIT WJ, 1989, J NEUROIMMUNOL, V21, P117, DOI 10.1016/0165-5728(89)90167-7; Tanaka S, 1998, J NEUROSCI, V18, P6358; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; UNTERHARNSCHEID.F, 1993, PATHOLOGIE NERVENSYS, P396; Verkhratsky A, 1996, TRENDS NEUROSCI, V19, P346, DOI 10.1016/0166-2236(96)10048-5	58	89	93	0	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	SEP	2000	100	3					313	322		10.1007/s004019900172			10	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	336MW	WOS:000088307700011	10965802				2022-02-06	
J	Ashwal, S; Holshouser, BA; Shu, SK; Simmons, PL; Perkin, RM; Tomasi, LG; Knierim, DS; Sheridan, C; Craig, K; Andrews, GH; Hinshaw, DB				Ashwal, S; Holshouser, BA; Shu, SK; Simmons, PL; Perkin, RM; Tomasi, LG; Knierim, DS; Sheridan, C; Craig, K; Andrews, GH; Hinshaw, DB			Predictive value of proton magnetic resonance spectroscopy in pediatric closed head injury	PEDIATRIC NEUROLOGY			English	Article							TRAUMATIC BRAIN INJURY; CORTICAL IMPACT INJURY; NERVOUS-SYSTEM INJURY; SHAKEN BABY SYNDROME; ACETYL-L-ASPARTATE; N-ACETYLASPARTATE; COMPUTED-TOMOGRAPHY; AXONAL INJURY; HYPOXIC ENCEPHALOPATHY; H-1-NMR SPECTROSCOPY	We studied 26 infants (1-18 months old) and 27 children (18 months or older) with acute nonaccidental (n = 21) or other forms (n = 32) of traumatic brain injury using clinical rating scales, a 15-point MRI scoring system, and occipital gray matter short-echo proton MRS. We compared the differences between the acutely determined variables (metabolite ratios and the presence of lactate) and 6- to 12-month outcomes. The metabolite ratios were abnormal (lower NAA/Cre or NAA/Cho; higher Cho/Cre) in patients with a poor outcome. Lactate was evident in 91% of infants and 80% of children with poor outcomes; none of the patients with a good outcome had lactate. At best, the clinical variables alone predicted the outcome in 77% of infants and 86% of children, and lactate alone predicted the outcome in 96% of infants and 96% of children. No further improvement in outcome prediction was observed when the lactate variable was combined with MRI ratios or clinical variables. The findings of spectral sampling in areas of brain not directly injured reflected the effects of global metabolic changes. Proton MRS provides objective data early after traumatic brain injury that can improve the ability to predict long-term neurologic outcome. (C) 2000 by Elsevier Science Inc, All rights reserved.	Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Div Child Neurol, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Div Crit Care Med, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Div Forens Med, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Radiol, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Pediat Neurosurg, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Rehabil Med, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Pediat Surg, Loma Linda, CA 92350 USA		Ashwal, S (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, Coleman Pavil,11175 Campus St, Loma Linda, CA 92350 USA.						Aasly J, 1999, EPILEPSY RES, V35, P211, DOI 10.1016/S0920-1211(99)00011-X; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Adelson PD, 1999, TRAUMATIC BRAIN INJU, P283; ARNOLD DL, 1994, ANN NEUROL, V36, P76, DOI 10.1002/ana.410360115; Ashwal S, 1997, J HEAD TRAUMA REHAB, V12, P13, DOI 10.1097/00001199-199708000-00004; Ashwal S, 1997, ANN NEUROL, V41, P470, DOI 10.1002/ana.410410410; AULD KL, 1995, PEDIATR NEUROL, V12, P323, DOI 10.1016/0887-8994(95)00062-K; BECCA J, 1995, J PEDIATR, V126, P44; BECKER DP, 1990, NEUROLOGICAL SURGERY, P103; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; BIRKEN DL, 1989, NEUROSCI BIOBEHAV R, V13, P23, DOI 10.1016/S0149-7634(89)80048-X; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; BREITER SN, 1994, AM J NEURORADIOL, V15, P373; BURRI R, 1991, DEV NEUROSCI-BASEL, V13, P403, DOI 10.1159/000112191; CASSIDY M, 1993, NEUROPEPTIDES, V24, P271, DOI 10.1016/0143-4179(93)90015-3; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Cherian L, 1998, J NEUROTRAUM, V15, P307, DOI 10.1089/neu.1998.15.307; Cherian L, 1998, J NEUROTRAUM, V15, P1059, DOI 10.1089/neu.1998.15.1059; CHOE B, 1995, INVEST RADIOL, V8, P502; CHOI SC, 1996, NEUROTRAUMA, P779; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; Dubowitz DJ, 1998, AM J NEURORADIOL, V19, P1617; ENEVOLDSEN EM, 1977, CLIN NEUROL NEUROSUR, V80, P213; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; FRAHM J, 1989, MAGNET RESON MED, V11, P47, DOI 10.1002/mrm.1910110105; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; GENTRY LR, 1994, RADIOLOGY, V91, P1; Gotoh M, 1997, J NEUROCHEM, V69, P655; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GUTLING E, 1995, NEUROLOGY, V45, P915, DOI 10.1212/WNL.45.5.915; Haseler LJ, 1997, PEDIATRICS, V99, P4, DOI 10.1542/peds.99.1.4; HOLMES G, 1982, ELECTROEN CLIN NEURO, V53, P60, DOI 10.1016/0013-4694(82)90106-7; Holshouser BA, 2000, J MAGN RESON IMAGING, V11, P9, DOI 10.1002/(SICI)1522-2586(200001)11:1<9::AID-JMRI2>3.3.CO;2-Y; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; ICHISE M, 1994, J NUCL MED, V35, P217; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; JENNETT B, 1975, LANCET, V1, P480; KAUFMANN MA, 1992, RESUSCITATION, V23, P199, DOI 10.1016/0300-9572(92)90003-U; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kochanek PM, 1999, TRAUMATIC BRAIN INJU, P233; Koura SS, 1998, ACT NEUR S, V71, P244; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Kreis R, 1996, J CLIN INVEST, V97, P1142, DOI 10.1172/JCI118528; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; LIPPER MH, 1985, AM J ROENTGENOL, V144, P483, DOI 10.2214/ajr.144.3.483; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mcintosh TK, 1999, TRAUMATIC BRAIN INJU, P39; MEHTA V, 1995, MOL BRAIN RES, V31, P151, DOI 10.1016/0169-328X(95)00044-S; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; Miller SL, 1996, NEUROCHEM RES, V21, P615, DOI 10.1007/BF02527761; Murr R, 1996, ACTA NEUROCHIR, V138, P928, DOI 10.1007/BF01411281; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Novotny E, 1998, PEDIATR RES, V44, P1, DOI 10.1203/00006450-199807000-00001; Oehmichen M, 1998, FORENSIC SCI INT, V95, P67, DOI 10.1016/S0379-0738(98)00075-9; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; PRAYER L, 1993, ACTA RADIOL, V34, P593; RANGO M, 1995, MAGNET RESON MED, V33, P595, DOI 10.1002/mrm.1910330503; RIVEROS N, 1984, BRAIN RES, V299, P393, DOI 10.1016/0006-8993(84)90727-3; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P625, DOI 10.1001/archpedi.1990.02150300019014; ROSMAN P, 1999, PEDIAT NEUROLOGY PRI, P873; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; SAGER TN, 1995, J CEREBR BLOOD F MET, V15, P639, DOI 10.1038/jcbfm.1995.79; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; SUTTON LN, 1995, PEDIATR NEUROSURG, V22, P81, DOI 10.1159/000120881; TAYLOR DL, 1995, J NEUROCHEM, V65, P275; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21	80	89	92	0	2	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA	0887-8994			PEDIATR NEUROL	Pediatr. Neurol.	AUG	2000	23	2					114	125		10.1016/S0887-8994(00)00176-4			12	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	364AG	WOS:000089869400002	11020636				2022-02-06	
J	Beer, R; Franz, G; Schopf, M; Reindl, M; Zelger, B; Schmutzhard, E; Poewe, W; Kampfl, A				Beer, R; Franz, G; Schopf, M; Reindl, M; Zelger, B; Schmutzhard, E; Poewe, W; Kampfl, A			Expression of Fas and Fas ligand after experimental traumatic brain injury in the rat	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						apoptosis; Fas; Fas ligand; traumatic brain injury; TUNEL	TUMOR-NECROSIS-FACTOR; CORTICAL IMPACT INJURY; APOPTOTIC CELL-DEATH; CLOSED-HEAD INJURY; MULTIPLE-SCLEROSIS; MEMORY DEFICITS; MESSENGER-RNA; AMINO-ACIDS; TNF-ALPHA; RELEASE	Apoptotic cell death plays an important role in the cascade of neuronal degeneration after traumatic brain injury (TBI), but the underlying mechanisms are not fully understood. However, increasing evidence suggests that expression of Fas and its ligand (FasL) could play a major role in mediating apoptotic cell death in acute and chronic neurologic disorders. To further investigate the temporal pattern of Fas and Fast expression after experimental TBI in the rat, male Sprague Dawley rats were subjected to unilateral cortical impact injury. The animals were killed and examined for Fas and FasL protein expression and for immunohistologic analysis at intervals from 15 minutes to 14 days after injury. Increased Fas and FasL immunoreactivity was seen in the cortex ipsilateral to the injury site from 15 minutes to 72 hours after the trauma, respectively. Immunohistologic investigation demonstrated a differential pattern of Fas and FasL expression in the cortex, respectively: increased Fas immunoreactivity was seen in cortical astrocytes and neurons from 15 minutes to 72 hours after the injury. In contrast, increased expression of FasL was seen in cortical neurons, astrocytes, and microglia from 15 minutes to 72 hours after impact injury. Concurrent double-labeling examinations using terminal deoxynucleotidyl tranferase-mediated deoxyuridine-biotin nick end labeling identified Fas- and FasL-immunopostive cells with high frequency in the cortex ipsilateral to the injury site. In contrast, there was no evidence of Fas- and FasL-immunopositive cells in the hippocampus ipsilateral to the injury site up to 14 days after the trauma. Further, Fas and Fast immunoreactivity was absent in the contralateral cortex and hippocampus at all time points investigated. These results reveal induction of Fas and Fast expression in the cortex after TBI in the rat. Further, these data implicate an involvement of Fas and Fast in the pathophysiologic mechanism of apoptotic neurodegeneration after TBI. Last, these data suggest that strategies aimed to repress posttraumatic Fas- and Fast-induced apoptosis may open new perspectives for the treatment of TBI.	Univ Innsbruck Hosp, Dept Neurol, A-6020 Innsbruck, Austria; Univ Innsbruck Hosp, Dept Dermatol, A-6020 Innsbruck, Austria		Kampfl, A (corresponding author), Univ Innsbruck Hosp, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria.		Reindl, Markus/ABE-5880-2020	Reindl, Markus/0000-0003-2817-1402; Schmutzhard, Erich/0000-0003-3295-7491			AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Becher B, 1998, TRENDS NEUROSCI, V21, P114, DOI 10.1016/S0166-2236(97)01180-6; Bernassola F, 1999, CELL DEATH DIFFER, V6, P652, DOI 10.1038/sj.cdd.4400537; Bonetti B, 1997, ANN NEUROL, V42, P74, DOI 10.1002/ana.410420113; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Cheema ZF, 1999, J NEUROSCI, V19, P1754; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dowling P, 1996, J EXP MED, V184, P1513, DOI 10.1084/jem.184.4.1513; DSOUZA SD, 1996, J EXP MED, V181, P393; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fassbender K, 1999, J NEUROIMMUNOL, V93, P122, DOI 10.1016/S0165-5728(98)00210-0; Franz G, 1999, J NEUROCHEM, V73, P1615, DOI 10.1046/j.1471-4159.1999.0731615.x; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; GRAEBER MB, 1990, J NEUROIMMUNOL, V27, P121, DOI 10.1016/0165-5728(90)90061-Q; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kokaia Z, 1998, NEUROSCIENCE, V84, P1113, DOI 10.1016/S0306-4522(97)00579-4; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; Li YH, 1998, P NATL ACAD SCI USA, V95, P7748, DOI 10.1073/pnas.95.13.7748; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; MATSUYAMA T, 1995, MOL BRAIN RES, V34, P166, DOI 10.1016/0169-328X(95)00162-L; MATSUYAMA T, 1994, BRAIN RES, V657, P342, DOI 10.1016/0006-8993(94)90989-X; Matute-Bello G, 1999, J IMMUNOL, V163, P2217; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mincheff M, 1998, VOX SANG, V74, P113, DOI 10.1046/j.1423-0410.1998.7420113.x; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NISHIMURA T, 1995, ADV SPACE RES, V16, P137, DOI 10.1016/0273-1177(95)00393-S; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Park CH, 1998, BIOCHEM BIOPH RES CO, V252, P623, DOI 10.1006/bbrc.1998.9572; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; RAGHUPATHI R, 1997, J CEREB BLOOD FLOW M, V17, P494; RINK A, 1995, AM J PATHOL, V147, P1575; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Runic R, 1996, J CLIN ENDOCR METAB, V81, P3119, DOI 10.1210/jc.81.8.3119; Saas P, 1999, J IMMUNOL, V162, P2326; Shin SW, 1998, J NEUROCHEM, V71, P1773; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Tachibana O, 1996, ACTA NEUROPATHOL, V92, P431, DOI 10.1007/s004010050542; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Tarkowski E, 1999, STROKE, V30, P321, DOI 10.1161/01.STR.30.2.321; Vogt M, 1998, FEBS LETT, V429, P67, DOI 10.1016/S0014-5793(98)00562-6; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhao XR, 1998, J CEREBR BLOOD F MET, V18, P161, DOI 10.1097/00004647-199802000-00006	71	89	99	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2000	20	4					669	677		10.1097/00004647-200004000-00004			9	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	304CW	WOS:000086466000004	10779011	hybrid			2022-02-06	
J	Dikmen, SS; Machamer, JE; Winn, HR; Anderson, GD; Temkin, NR				Dikmen, SS; Machamer, JE; Winn, HR; Anderson, GD; Temkin, NR			Neuropsychological effects of valproate in traumatic brain injury - A randomized trial	NEUROLOGY			English	Article						traumatic brain injuries; valproate; phenytoin; neuropsychological side effects; double-blind method		Objectives: To examine the neuropsychological side effects of valproate (VPA) given to prevent posttraumatic seizures. Methods: In a randomized, double-masked, parallel group clinical trial, we compared the seizure prevention and neuropsychological effects of 1 or 6 months of VPA to 1 week of phenytoin. We studied 279 adult subjects who were randomized within 24 hours of injury and examined with a battery of neuropsychological measures at 1, 6, and 12 months after injury. We examined drug effects cross-sectionally at 1, 6, and 12 months and longitudinally by examining differential change from 1 to 6 months and from 6 to 12 months as a function of protocol-dictated changes in treatment. Results: No significant adverse or beneficial neuropsychological effects of VPA were detected. Conclusions: Valproate (VPA) appears to have a benign neuropsychological side effects profile, making it a cognitively safe antiepileptic drug to use for controlling established seizures or stabilizing mood. However, based on this study, VPA should not be used for prophylaxis of posttraumatic seizures because it does not prevent posttraumatic seizures, there was a trend toward more deaths in the VPA groups, and it did not have positive effects on cognition.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Pharm, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA		Dikmen, SS (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS19643] Funding Source: Medline		Armon C, 1996, NEUROLOGY, V47, P626, DOI 10.1212/WNL.47.3.626; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; DYER FN, 1973, MEM COGNITION, V1, P106, DOI 10.3758/BF03198078; Guerrini R, 1998, EPILEPSIA, V39, P27, DOI 10.1111/j.1528-1157.1998.tb01270.x; KIMURA D, 1963, ARCH NEUROL-CHICAGO, V8, P264, DOI 10.1001/archneur.1963.00460030048004; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Prevey ML, 1996, ARCH NEUROL-CHICAGO, V53, P1008, DOI 10.1001/archneur.1996.00550100086018; Reitan R.M., 1993, HALSTEADREITAN NEURO; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; TONNBY B, 1994, EPILEPSY RES, V19, P141, DOI 10.1016/0920-1211(94)90024-8; Vermeulen J, 1995, EPILEPSY RES, V22, P65, DOI 10.1016/0920-1211(95)00047-X; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D., 1955, MANUAL WECHSLER ADUL	15	89	89	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	FEB 22	2000	54	4					895	902		10.1212/WNL.54.4.895			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	284ZL	WOS:000085362700024	10690983				2022-02-06	
J	Oshiro, Y; Sakurai, Y; Sato, S; Kurahashi, N; Tanaka, T; Kikuchi, T; Tottori, K; Uwahodo, Y; Miwa, T; Nishi, T				Oshiro, Y; Sakurai, Y; Sato, S; Kurahashi, N; Tanaka, T; Kikuchi, T; Tottori, K; Uwahodo, Y; Miwa, T; Nishi, T			3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: Synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4-dihydro-5-methoxy-2(1H)-quinolinone and its derivatives	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; THYROTROPIN-RELEASING-HORMONE; ANTI-DEPRESSANT DRUGS; AFFECTIVE-DISORDERS; CEREBROPROTECTIVE AGENTS; STIMULATING ACTIVITY; BEHAVIORAL DESPAIR; SIGMA-RECEPTORS; CNS AGENTS; LIGANDS	To develop a novel antidepressant drug with central nervous system-stimulating activity, me prepared a series of 1-[w-(4-substituted phenyl-1-piperazinyl)alkyl]-3,4-dihydro-2(1H)-quinlinone derivatives and examined their activities by their effects at 30 and 100 mg/kg po on the sleeping time of mice anesthetized with halothane and on the time required for recovery from coma induced in mice by cerebral concussion. We examined their binding affinities for a receptors by evaluating their ability to inhibit [H-3]-1,3-di(o-tolyl)guanidine ([H-3]DTG) binding to the rat whole brain membrane in comparison with three putative a receptor agonists: 1,3-di(o-tolyl)guanidine (DTG, 66), (+)-1,2,3,4,5,6-hexahydro-6,11-dimethylmethano-3-benzazecin-8-ol (SKF10,047, 67), and (+)-1,2,3,4,5,6-hexahydro-6, 11-dimethyl-3(3 -methyl-2-butenyl)-2,6-methano-3-benzazecin-8-ol (pentazocine, 68). Among the series of derivatives, 1-3-[4-(3-chlorophenyl)-1-piperazinyl]-3p linone hydrochloride (34b) and its mesylate (34c), at a dose of 30 mg/kg po, reduced the sleeping time and the time for recovery from coma and they inhibited [H-3]DTG binding for a receptors. The putative a receptor agonists reduced the sleeping time and the time for recovery from coma whereas two a receptor antagonists, alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl) piperazinebutanol hydrochloride (BMY14802, 69) and cis-9-[3-(3,5-dimethyl-1-piperazinyl)propyl]carbazole dihydrochloride (rimcazole, 70), were inactive in the two tests. Preadministration of the putative a receptor antagonists 69 (3 mg/kg po) and 70 (30 mg/kg po) completely antagonized the actions of 34b and the a receptor agonists in the test for recovery from coma. These results suggested that 34b and 34c are a receptor agonists. Furthermore, a single administration of 1 and 10 mg/kg po 34b and 34c showed antidepressant-like activity by reducing the immobility time in the forced-swimming test with mice, while a tricyclic antidepressant, 10,11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine hydrochloride (imipramine, 1) (10 and 30 mg/kg po), did not reduce the time after a single administration. 1 reduced the time after repeated administration of 30 mg/kg po once a day for 4 days. The structure-activity relationship of the series of compounds is also discussed.	Otsuka Pharmaceut Co Ltd, Tokushima Inst New Drug Res 3, Kawauchi, Tokushima 7710192, Japan		Oshiro, Y (corresponding author), Otsuka Pharmaceut Co Ltd, Tokushima Inst New Drug Res 3, 463-10 Kagasuno, Kawauchi, Tokushima 7710192, Japan.						ABOUGHARBIA M, 1993, ANNU REP MED CHEM, V28, P1; ALEY KO, 1989, N-S ARCH PHARMACOL, V339, P306; BANNO K, 1988, CHEM PHARM BULL, V36, P4377; BANNO K, Patent No. 8149359; BLACKWELL B, 1981, DRUGS, V21, P201, DOI 10.2165/00003495-198121030-00002; BLACKWELL B, 1981, DRUGS, V21, P273, DOI 10.2165/00003495-198121040-00003; BORSINI F, 1986, EUR J PHARMACOL, V121, P265, DOI 10.1016/0014-2999(86)90498-X; Callahan AM, 1997, BIOL PSYCHIAT, V41, P264, DOI 10.1016/S0006-3223(97)00372-7; FERNANDEZ M, 1994, HETEROCYCLES, V38, P2615; HAVERA HJ, 1969, J MED CHEM, V12, P580, DOI 10.1021/jm00304a004; HEALY D, 1987, PSYCHOPHARMACOLOGY, V93, P271; ISHIKAWA H, 1989, CHEM PHARM BULL, V37, P2103; ITOH K, 1984, CHEM PHARM BULL, V32, P130; ITZHAK Y, 1990, LIFE SCI, V47, P1073, DOI 10.1016/0024-3205(90)90165-N; JANOWSKY DS, 1994, AM J MED GENET, V54, P335, DOI 10.1002/ajmg.1320540412; KIKUCHI T, UNPUB; Lancel M, 1996, NEUROPSYCHOPHARMACOL, V15, P63, DOI 10.1016/0893-133X(95)00157-9; LONDON JD, 1955, J CHEM SOC, P739; LONGONI B, 1993, J PHARMACOL EXP THER, V266, P153; LYSER D, 1994, ANNU REP MED CHEM, V29, P1; Maj Jerzy, 1996, Polish Journal of Pharmacology, V48, P379; MANAKA S, 1977, IGAKU NO AYUMI, V102, P867; Matsuno K, 1996, EUR J PHARMACOL, V312, P267, DOI 10.1016/0014-2999(96)00497-9; MATSUYAMA T, Patent No. 8541670; MAYER F, 1927, CHEM BER, V60, P858; MISZTAL S, 1992, MED CHEM RES, V2, P82; MIYAMOTO M, 1981, LIFE SCI, V28, P861, DOI 10.1016/0024-3205(81)90047-3; MOKROSZ JL, 1994, ARCH PHARM, V327, P529, DOI 10.1002/ardp.19943270811; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OSHIRO Y, 1991, J MED CHEM, V34, P2014, DOI 10.1021/jm00111a014; OSHIRO Y, 1991, J MED CHEM, V34, P2004, DOI 10.1021/jm00111a013; OTSUBO J, Patent No. 8242679; PINDER RM, 1993, MED RES REV, V13, P259, DOI 10.1002/med.2610130304; POLLARD CB, 1954, J AM CHEM SOC, V76, P1853, DOI 10.1021/ja01636a034; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; SCATTON B, 1987, J PHARMACOL EXP THER, V241, P251; SCHOENWALD RD, 1995, LIFE SCI, V56, P1275, DOI 10.1016/0024-3205(95)00073-9; SHIGEMATSU N, 1961, CHEM PHARM BULL, V9, P970; Shimidzu T, 1997, EUR J PHARMACOL, V338, P225, DOI 10.1016/S0014-2999(97)81925-5; SHONO T, 1981, J ORG CHEM, V46, P3719, DOI 10.1021/jo00331a027; Soares JC, 1996, DRUGS, V52, P477, DOI 10.2165/00003495-199652040-00001; Stocca G, 1996, PEPTIDES, V17, P1197, DOI 10.1016/S0196-9781(96)00128-3; TAMURA Y, 1970, CHEM IND-LONDON, P1435; TAMURA Y, 1972, YAKUGA ZASSHI, V92, P772, DOI 10.1248/yakushi1947.92.6_772; TAMURA Y, 1975, CHEM IND-LONDON, P922; TURNBULL MJ, 1976, BRIT J PHARMACOL, V58, P27, DOI 10.1111/j.1476-5381.1976.tb07689.x; WALKER JM, 1990, PHARMACOL REV, V42, P355; WETTSTEIN JG, 1991, PSYCHOPHARMACOLOGY, V104, P157, DOI 10.1007/BF02244171	48	89	91	0	9	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623			J MED CHEM	J. Med. Chem.	JAN 27	2000	43	2					177	189		10.1021/jm980333v			13	Chemistry, Medicinal	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Pharmacology & Pharmacy	279FP	WOS:000085034000006	10649973				2022-02-06	
J	Gosling, J; Oddy, M				Gosling, J; Oddy, M			Rearranged marriages: marital relationships after head injury	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; SEXUAL DYSFUNCTION; FOLLOW-UP; UNEMPLOYMENT; DAMAGE	An in depth study of 18 heterosexual couples investigated the quality of the marital and sexual relationships 1-7 years after the male partner had suffered a severe head injury. Both quantitative and qualitative methods were employed and the focus was on the perspective of the uninjured female partner. The female partners reported both marital and sexual satisfaction as lower following injury. They rated their current marital satisfaction as significantly less than their brain injured partners. The quantitative part of the study revealed major role changes experienced by the women, with many comparing their new role to that of a parent with total decision making responsibility. The incompatibility of this role with that of sexual partner was mentioned by many. A tendency for the males to express gratitude but not to communicate their feelings was described by many women. Most women were resigned to the expectation that there would be little change in the future and, for most, the only positive aspect of the relationship was a sense of commitment and continuing companionship. The implications of the findings for rehabilitation and couple therapy an discussed.	Ticehurst House & Unsted Pk Hosp, Brain Injury Rehabil Unit, Tiechurst TN5 7HU, E Sussex, England; St Thomas Hosp, Pain Management Unit, London, England		Oddy, M (corresponding author), Ticehurst House & Unsted Pk Hosp, Brain Injury Rehabil Unit, Tiechurst TN5 7HU, E Sussex, England.						ANDERSONPARENTE JK, 1990, COGNITIVE REHABI JAN, P22; AUBRY T, 1990, J COMMUNITY PSYCHOL, V18, P99, DOI 10.1002/1520-6629(199004)18:2<99::AID-JCOP2290180202>3.0.CO;2-Y; CREWE NM, 1988, ARCH PHYS MED REHAB, V69, P435; Elliott ML, 1996, BRAIN INJURY, V10, P703, DOI 10.1080/026990596123972; Gallie, 1985, NEW APPROACHES EC LI, P387; Garden F. H., 1990, J HEAD TRAUMA REHAB, V5, P52, DOI DOI 10.1097/00001199-199005020-00009; Goldberg D., 1992, GEN HLTH QUESTIONNAI; GRANT S, 1994, JOB STRESS CHANGING, P311, DOI DOI 10.1037/10165-020; HENWOOD K, 1995, PSYCHOLOGIST, V8, P115; JONES L, 1988, J DIVORCE, V12, P99; KOSTELJANETZ M, 1981, ACTA NEUROL SCAND, V63, P163; KRAVETZ S, 1995, BRAIN INJURY, V9, P131, DOI 10.3109/02699059509008186; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; LARSON JH, 1988, FAM RELAT, V33, P253; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; MATZ EA, 1995, J HEAD TRAUMA REHAB, V10, P1; MAUSSCLUM N, 1981, J NEUROSURGICAL NURS, V16, P36; MAY JL, 1988, J SEX MARITAL THER, V14, P253; MOROKOFF PJ, 1993, J SEX RES, V30, P43, DOI 10.1080/00224499309551677; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Panting A, 1972, REHABILITATION, V38, P33; Price J R, 1985, Rehabil Nurs, V10, P12; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; RUST J, 1986, GOLOMBEK RUST INVENT; RUST J, 1988, GOLONBOK RUST INVENT; Sandel ME, 1996, BRAIN INJURY, V10, P719, DOI 10.1080/026990596123981; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Watkins, 1995, J FAMILY STUDIES, V1, P103, DOI 10.5172/jfs.1.2.103; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183; Zencius A H, 1989, Brain Inj, V3, P199, DOI 10.3109/02699058909004553	35	89	90	0	6	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1999	13	10					785	796					12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	247TV	WOS:000083236800004	10576462				2022-02-06	
J	Goforth, PB; Ellis, EF; Satin, LS				Goforth, PB; Ellis, EF; Satin, LS			Enhancement of AMPA-mediated current after traumatic injury in cortical neurons	JOURNAL OF NEUROSCIENCE			English	Article						glutamate; traumatic brain injury; AMPA receptor; desensitization; excitotoxicity; cortex	AMINO-ACID RECEPTORS; DEPENDENT PROTEIN-KINASE; RAT HIPPOCAMPAL SLICES; CENTRAL NERVOUS-SYSTEM; STRETCH-INDUCED INJURY; BRAIN INJURY; GLUTAMATE RECEPTORS; KAINATE RECEPTORS; SYNAPTIC TRANSMISSION; NEOCORTICAL NEURONS	Overactivation of ionotropic glutamate receptors has been implicated in the pathophysiology of traumatic brain injury. Using an in vitro cell injury model, we examined the effects of stretch-induced traumatic injury on the AMPA subtype of ionotropic glutamate receptors in cultured neonatal cortical neurons. Recordings made using the whole-cell patch-clamp technique revealed that a subpopulation of injured neurons exhibited an increased current in response to AMPA. The current-voltage relationship of these injured neurons showed an increased slope conductance but no change in reversal potential compared with uninjured neurons. Additionally, the EC50 values of uninjured and injured neurons were nearly identical. Thus, current potentiation was not caused by changes in the voltage-dependence, ion selectivity, or apparent agonist affinity of the AMPA channel. AMPA-elicited current could also be fully inhibited by the application of selective AMPA receptor antagonists, thereby excluding the possibility that current potentiation in injured neurons was caused by the activation of other, nondesensitizing receptors. The difference in current densities between control and injured neurons was abolished when AMPA receptor desensitization was inhibited by the coapplication of AMPA and cyclothiazide or by the use of kainate as an agonist, suggesting that mechanical injury alters AMPA receptor desensitization. Reduction of AMPA receptor desensitization after brain injury would be expected to further exacerbate the effects of increased postinjury extracellular glutamate and contribute to trauma-related cell loss and dysfunctional synaptic information processing.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, Richmond, VA 23298 USA		Satin, LS (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol Toxicol, Box 980524, Richmond, VA 23298 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5 T32 NSO 7288-13, NS 27214] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007288, R01NS027214] Funding Source: NIH RePORTER		Arai A, 1998, BRAIN RES, V799, P230, DOI 10.1016/S0006-8993(98)00446-6; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; BERTOLINO M, 1993, RECEPTOR CHANNEL, V1, P267; Bleakman D, 1996, NEUROPHARMACOLOGY, V35, P1689, DOI 10.1016/S0028-3908(96)00156-6; BOXALL AR, 1995, NEUROCHEM RES, V20, P605, DOI 10.1007/BF01694543; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1987, J NEUROSCI, V7, P357; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; Dingledine R, 1999, PHARMACOL REV, V51, P7; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hamill OP, 1996, PHARMACOL REV, V48, P231; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hatt H, 1999, NATURWISSENSCHAFTEN, V86, P177, DOI 10.1007/s001140050593; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; HERRINGTON J, 1994, PULSE CONTROL V4 3 I; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; Jensen JB, 1998, NEUROCHEM INT, V32, P505, DOI 10.1016/S0197-0186(97)00130-7; JONAS P, 1992, J PHYSIOL-LONDON, V455, P143, DOI 10.1113/jphysiol.1992.sp019294; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KISKIN NI, 1986, NEUROSCI LETT, V63, P225, DOI 10.1016/0304-3940(86)90360-5; KOH JY, 1990, J NEUROSCI, V10, P693; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Ohno K, 1998, NEUROCHEM INT, V32, P265, DOI 10.1016/S0197-0186(97)00098-3; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; PATNEAU DK, 1991, NEURON, V6, P785, DOI 10.1016/0896-6273(91)90175-Y; PELLETIER MR, 1994, J NEUROPHYSIOL, V72, P1032, DOI 10.1152/jn.1994.72.2.1032; PERSSON K, 1995, AM J PHYSIOL-CELL PH, V269, pC1018, DOI 10.1152/ajpcell.1995.269.4.C1018; Povlishock JT, 1996, ACT NEUR S, V66, P81; RAMAN IM, 1992, NEURON, V9, P173, DOI 10.1016/0896-6273(92)90232-3; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Silver RA, 1996, J PHYSIOL-LONDON, V493, P167, DOI 10.1113/jphysiol.1996.sp021372; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632, DOI 10.1152/jn.1997.77.2.632; TRUSSELL LO, 1988, P NATL ACAD SCI USA, V85, P4562, DOI 10.1073/pnas.85.12.4562-a; Turski L, 1998, P NATL ACAD SCI USA, V95, P10960, DOI 10.1073/pnas.95.18.10960; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; VYKLICKY L, 1991, NEURON, V7, P971, DOI 10.1016/0896-6273(91)90342-W; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; WANG LY, 1994, J PHYSIOL-LONDON, V475, P431, DOI 10.1113/jphysiol.1994.sp020083; WEBER JT, 1997, J NEUROTRAUM, V14, P778; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Zauner A, 1996, ACT NEUR S, V67, P40; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; ZORUMSKI CF, 1990, NEURON, V5, P61, DOI 10.1016/0896-6273(90)90033-C	61	89	90	0	1	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	SEP 1	1999	19	17					7367	7374		10.1523/JNEUROSCI.19-17-07367.1999			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	233TL	WOS:000082442600016	10460243	Green Published, Bronze			2022-02-06	
J	Hanks, RA; Temkin, N; Machamer, J; Dikmen, SS				Hanks, RA; Temkin, N; Machamer, J; Dikmen, SS			Emotional and behavioral adjustment after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							BLUNT HEAD-INJURY; RELATIVES; SYMPTOMS; SEQUELAE; SCALE	Objectives: To examine emotional and behavioral adjustment and recovery over 1 year after traumatic brain injury (TBI), and to determine whether the difficulties, if present, are due to neurologic insult. Design: Longitudinal evaluation of adjustment from 1 month to 1 year after injury. Setting: Level I trauma center at a university hospital. Patients: One hundred fifty-seven consecutively hospitalized adults with TBI and 125 trauma controls with other system injuries evaluated at 1 and 12 months after injury. Main Outcome Measures: Katz Adjustment Scale (KAS). Results: The TBI group at 1 year follow-up demonstrated significant emotional and behavioral maladjustment, but such difficulties did not appear to be mediated by the brain injury, since the KAS scores for the TBI and trauma control groups were not significantly different. Those with moderate TBI reported greater difficulties than those with mild or severe injuries. Changes in adjustment over 1 year were common for both groups. Within the TBI group there was differential recovery: improvement in cognitive clarity, dysphoric mood, and emotional stability, but increased difficulties with anger management, antisocial behaviors, and self-monitoring, Conclusions: These results raise questions about commonly held beliefs that those with mild TBI report greater distress, and clarify some misconceptions regarding change in emotional and behavioral functioning over time. (C) 1999 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA		Hanks, RA (corresponding author), Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, Suite 555,261 Mack Ave, Detroit, MI 48201 USA.				AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [HS06497] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD33677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS19643] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01HS006497] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD033677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER		BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Burke J M, 1989, Brain Inj, V3, P35, DOI 10.3109/02699058909008071; Cicerone KD, 1997, BRAIN INJURY, V11, P643, DOI 10.1080/026990597123197; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; DIKMEN S, 1977, J NERV MENT DIS, V165, P247, DOI 10.1097/00005053-197710000-00004; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; GORAN DA, 1993, BRAIN INJURY, V7, P219, DOI 10.3109/02699059309029674; GRANT I, 1987, NEUROBEHAVIORAL RECO, P232; HOGARTY GE, 1971, ARCH GEN PSYCHIAT, V25, P470; JACKSON H F, 1992, Brain Injury, V6, P109, DOI 10.3109/02699059209029650; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; KATZ M, 1963, PSYCHOL REP S, V4, P503; KLONOFF PS, 1984, RATINGS KATZ ADJUSTM; LEININGER B E, 1991, Brain Injury, V5, P199, DOI 10.3109/02699059109008090; Levin H.S., 1989, MILD HEAD INJURY; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Prigatano G. P., 1987, COMMUNITY REENTRY HE, P1; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; STAMBROOK M, 1990, COGNITIVE REHABILITA, V8, P26; Stevens JP., 1996, APPL MULTIVARIATE ST; TEASDALE G, 1974, LANCET, V2, P81; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61	35	89	89	0	8	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	1999	80	9					991	997		10.1016/S0003-9993(99)90049-7			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	234ZZ	WOS:000082515400002	10488997				2022-02-06	
J	Hans, VHJ; Kossmann, T; Lenzlinger, PM; Probstmeier, R; Imhof, HG; Trentz, O; Morganti-Kossmann, MC				Hans, VHJ; Kossmann, T; Lenzlinger, PM; Probstmeier, R; Imhof, HG; Trentz, O; Morganti-Kossmann, MC			Experimental axonal injury triggers interleukin-6 mRNA, protein synthesis and release into cerebrospinal fluid	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						rat model; brain injury; interleukin-6; neuron; in situ hybridization; immunohistochemistry	TRAUMATIC BRAIN INJURY; GROWTH-FACTOR PRODUCTION; EXCITATORY AMINO-ACIDS; TUMOR NECROSIS FACTOR; CLOSED-HEAD INJURY; RAT-BRAIN; MONONUCLEAR PHAGOCYTES; CHOLINERGIC NEURONS; GENE-EXPRESSION; MESSENGER-RNA	Diffuse axonal injury is a frequent pathologic sequel of head trauma, which, despite its devastating consequences for the patients, remains to be fully elucidated. Here we studied the release of interleukin-6 (IL-6) into CSF and serum, as well as the expression of IL-6 messenger ribonucleic acid (mRNA) and protein in a weight drop model of axonal injury in the rat. The IL-6 activity was elevated in CSF within 1 hour and peaked between 2 and 4 hours, reaching maximal values of 82,108 pg/mL, and returned to control values after 24 hours. In serum, the levels of IL-6 remained below increased CSF levels and did not exceed 393 pg/mL. In sial hybridization demonstrated augmented IL-6 mRNA expression in several regions including cortical pyramidal cells, neurons in thalamic nuclei, and macrophages in the basal subarachnoid spaces. A weak constitutive expression of IL-6 protein was shown by immunohistochemical study in control brain. After injury, IL-6 increased at 1 hour and remained elevated through the first 24 hours, returning to normal afterward. Most cells producing IL-6 were cortical, thalamic, and hippocampal neurons as confirmed by staining for the neuronal marker NeuN. These results extend our previous studies showing IL-6 production in the cerebrospinal fluid of patients with severe head trauma and demonstrate that neurons are the main source of IL-6 after experimental axonal injury.	Univ Zurich Hosp, Dept Surg, Div Res, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland; Univ Bonn, Inst Anim Anat & Physiol, Dept Biochem, D-5300 Bonn, Germany; Univ Hosp, Inst Neuropathol, Bonn, Germany		Morganti-Kossmann, MC (corresponding author), Univ Zurich Hosp, Dept Surg, Div Res, Raemistr 100, CH-8091 Zurich, Switzerland.		Lenzlinger, Philipp/A-3822-2008	Morganti-Kossmann, Cristina/0000-0002-0807-2063			AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BENVENISTE EN, 1990, J NEUROIMMUNOL, V30, P201, DOI 10.1016/0165-5728(90)90104-U; BENVENISTE EN, 1995, HUMAN CYTOKINES THEI, P195; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CSUKA E, 1997, SHOCK S, V8, P6; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; FABRY Z, 1993, J NEUROIMMUNOL, V47, P23, DOI 10.1016/0165-5728(93)90281-3; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fiebich BL, 1995, J NEUROIMMUNOL, V63, P207, DOI 10.1016/0165-5728(95)00145-X; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; GADIENT RA, 1994, BRAIN RES, V637, P10, DOI 10.1016/0006-8993(94)91211-4; GADIENT RA, 1994, NEUROSCI LETT, V182, P243, DOI 10.1016/0304-3940(94)90807-9; GEHRMANN J, 1995, IMMUNE RESPONSES NER, P61; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1993, GLIA, V7, P102, DOI 10.1002/glia.440070116; HAMA T, 1991, NEUROSCIENCE, V40, P445, DOI 10.1016/0306-4522(91)90132-8; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARUO N, 1992, ENDOCRINOLOGY, V131, P710, DOI 10.1210/en.131.2.710; MATHIESEN T, 1993, J NEUROSURG, V78, P562, DOI 10.3171/jns.1993.78.4.0562; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; MORGANTIKOSSMAN.MC, 1995, IMMUNE RESPONSES NER, P159; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Paxinos G, 1986, RAT BRAIN STEROTAXIC; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; QIU ZH, 1995, J NEUROSCI, V15, P6688; Ringheim GE, 1995, J NEUROIMMUNOL, V63, P113, DOI 10.1016/0165-5728(95)00134-4; RINK A, 1995, AM J PATHOL, V147, P1575; ROTHWELL NJ, 1993, NEUROSCI BIOBEHAV R, V17, P217, DOI 10.1016/S0149-7634(05)80152-6; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHOBITZ B, 1993, EUR J NEUROSCI, V5, P1426, DOI 10.1111/j.1460-9568.1993.tb00210.x; SELMAJ KW, 1990, J IMMUNOL, V144, P129; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Skowronski EW, 1996, CELL DEATH DIFFER, V3, P171; Soares HD, 1995, J NEUROSCI, V15, P8223; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TEREBUH PD, 1992, AM J PATHOL, V140, P649; TOULMOND S, 1992, NEUROSCI LETT, V144, P49, DOI 10.1016/0304-3940(92)90713-H; Vallieres L, 1997, J NEUROCHEM, V69, P1668, DOI 10.1046/j.1471-4159.1997.69041668.x; VANDAMME J, 1987, J IMMUNOL, V139, P1867; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.iy.08.040190.001345; VONCOELLN R, 1995, DEV BRAIN RES, V89, P150, DOI 10.1016/0165-3806(95)00123-U; Wagner JA, 1996, J EXP MED, V183, P2417, DOI 10.1084/jem.183.6.2417; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAMADA M, 1994, BRAIN RES, V643, P173, DOI 10.1016/0006-8993(94)90023-X; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131	57	89	93	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	1999	19	2					184	194		10.1097/00004647-199902000-00010			11	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	185KZ	WOS:000079669300010	10027774	Bronze			2022-02-06	
J	Schumacher, PA; Eubanks, JH; Fehlings, MG				Schumacher, PA; Eubanks, JH; Fehlings, MG			Increased calpain I mediated proteolysis, and preferential loss of dephosphorylated NF200, following traumatic spinal cord injury	NEUROSCIENCE			English	Article						calpain; neurofilament; nerve tissue proteins; spinal cord injury	NEUROFILAMENT PROTEINS; BRAIN INJURY; RAT-BRAIN; FOREBRAIN ISCHEMIA; SECONDARY INJURY; PROTEASE CALPAIN; INHIBITOR; PHOSPHORYLATION; DEGRADATION; CALCIUM	We investigated the hypothesis that the Ca2+-activared protease calpain is involved in the pathophysiology of spinal cord injury, and is linked to the proteolytic degradation of cytoskeletal proteins. We report here that levels of calpain I (mu-calpain)-mediated spectrin breakdown products are increased by 15 min post-injury, with peak levels reached by 2 h post-injury. The dephosphorylated form of the neurofilament protein NF200 is substantially lost over the same time-period. A 35-g compressive injury was applied to the midthoracic rat spinal cord for 1 min, and animals were killed at 15 min, 1, 2, 4, 8, 16, and 24 h post-injury. Calpain I-mediated spectrin breakdown products accumulated post-injury, with peak levels reached at 2 h, Secondly, we have demonstrated a progressive loss of the 200,000 mol. wt neurofilament protein NF200, a cytoskeletal calpain substrate, which began within 1-2 h post-injury. Densitometric analyses confirmed that loss of NF200 is a substrate-specific phenomenon, since (i) dephosphorylated NF200 was preferentially lost while phosphorylated NF200 was relatively spared, and (ii) actin, which is not a substrate for calpain, was relatively spared following spinal cord injury. Finally, we demonstrated calpain I-mediated spectrin breakdown within NF200-positive neuronal processes post-injury. We conclude that the accumulation of spectrin breakdown products is temporally and spatially correlated with loss of dephosphorylated NF200 after spinal cord injury. (C) 1999 IBRO. Published by Elsevier Science Ltd.	Univ Toronto, Toronto Hosp, Western Div, Playfair Neurosci Unit, Toronto, ON M5T 2S8, Canada; Univ Toronto, Toronto Hosp, Western Div, Res Inst, Toronto, ON M5T 2S8, Canada		Fehlings, MG (corresponding author), Univ Toronto, Toronto Hosp, Western Div, Playfair Neurosci Unit, 399 Bathurst St, Toronto, ON M5T 2S8, Canada.			Fehlings, Michael/0000-0002-5722-6364; Eubanks, James/0000-0001-8595-2024			Agrawal SK, 1996, J NEUROSCI, V16, P545; Agrawal SK, 1997, J NEUROSCI, V17, P1055; ARAI A, 1990, BRAIN RES, V532, P63, DOI 10.1016/0006-8993(90)91742-Y; Banik N L, 1984, Cent Nerv Syst Trauma, V1, P131; BANIK NL, 1987, NEUROCHEM PATHOL, V7, P57, DOI 10.1007/BF02834292; BANIK NL, 1982, NEUROCHEM RES, V7, P1465, DOI 10.1007/BF00965089; BANIK NL, 1986, J NEUROL SCI, V73, P245, DOI 10.1016/0022-510X(86)90149-8; BARTUS RT, 1994, J CEREBR BLOOD F MET, V14, P537, DOI 10.1038/jcbfm.1994.67; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; BI XN, 1994, NEUROREPORT, V6, P61, DOI 10.1097/00001756-199412300-00017; CANER H, 1993, BRAIN RES, V607, P354, DOI 10.1016/0006-8993(93)91531-V; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; FEHLINGS MG, 1995, BRAIN RES, V677, P291, DOI 10.1016/0006-8993(95)00141-C; FEHLINGS MG, 1995, SPINE, V20, P2187, DOI 10.1097/00007632-199510001-00002; GEISLER N, 1987, FEBS LETT, V221, P403, DOI 10.1016/0014-5793(87)80964-X; GOLL DE, 1991, J BIOL CHEM, V266, P8501; GREENWOOD JA, 1993, J NEUROCHEM, V61, P191, DOI 10.1111/j.1471-4159.1993.tb03555.x; HAMAKUBO T, 1986, J NEUROSCI, V6, P3103, DOI 10.1523/jneurosci.06-11-03103.1986; HAPPEL RD, 1981, BRAIN RES, V211, P476, DOI 10.1016/0006-8993(81)90976-8; HAPPEL RD, 1984, NEUROSCI LETT, V49, P279, DOI 10.1016/0304-3940(84)90302-1; HAYES RL, 1995, J NEUROTRAUM, V12, P933, DOI 10.1089/neu.1995.12.933; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; HOFFMAN PN, 1985, J CELL BIOL, V101, P1332, DOI 10.1083/jcb.101.4.1332; KAKU Y, 1993, J CEREBR BLOOD F MET, V13, P402, DOI 10.1038/jcbfm.1993.54; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KISHIMOTO A, 1990, ADV SEC MESS PHOSPH, V24, P472; LI ZH, 1995, NEUROCHEM INT, V27, P425, DOI 10.1016/0197-0186(95)00024-3; Li ZH, 1996, NEUROCHEM RES, V21, P441, DOI 10.1007/BF02527708; LYNCH G, 1987, BRAIN RES BULL, V18, P809, DOI 10.1016/0361-9230(87)90220-6; MELLONI E, 1989, TRENDS NEUROSCI, V12, P438, DOI 10.1016/0166-2236(89)90093-3; NAKAMURA M, 1992, EXP BRAIN RES, V89, P31; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; PERLMUTTER LS, 1988, SYNAPSE, V2, P79, DOI 10.1002/syn.890020111; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; RIVLIN AS, 1979, J NEUROSURG, V50, P349, DOI 10.3171/jns.1979.50.3.0349; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SIMAN R, 1985, BRAIN RES, V347, P399, DOI 10.1016/0006-8993(85)90208-2; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; SUZUKI K, 1992, ANN NY ACAD SCI, V674, P218, DOI 10.1111/j.1749-6632.1992.tb27490.x; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767	49	89	93	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		1999	91	2					733	744		10.1016/S0306-4522(98)00552-1			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	190RA	WOS:000079977200032	10366029				2022-02-06	
J	Rzigalinski, BA; Weber, JT; Willoughby, KA; Ellis, EF				Rzigalinski, BA; Weber, JT; Willoughby, KA; Ellis, EF			Intracellular free calcium dynamics in stretch-injured astrocytes	JOURNAL OF NEUROCHEMISTRY			English	Article						astrocytes; intracellular free calcium; intracellular calcium stores; traumatic brain injury; signal transduction; inositol trisphosphate; glutamate	TRAUMATIC BRAIN INJURY; CEREBRAL ENERGY-METABOLISM; AMINO-ACID RECEPTOR; GLUTAMATE RECEPTORS; GLIAL-CELLS; NEURONS; STORES; FURA-2; MODEL; FLUORESCENCE	We have previously developed an in vitro model for traumatic brain injury that simulates a major component of in vivo trauma, that being tissue strain or stretch. We have validated our model by demonstrating that it produces many of the posttraumatic responses observed in vivo. Sustained elevation of the intracellular free calcium concentration ([Ca2+](i)) has been hypothesized to be a primary biochemical mechanism inducing cell dysfunction after trauma. In the present report, we have examined this hypothesis in astrocytes using our in vitro injury model and fura-2 microphotometry. Our results indicate that astrocyte [Ca2+](i) is rapidly elevated after stretch injury, the magnitude of which is proportional to the degree of injury. However, the injury-induced [Ca2+](i) elevation is not sustained and returns to near-basal levels by 15 min postinjury and to basal levels between 3 and 24 h after injury. Although basal [Ca2+](i) returns to normal after injury, we have identified persistent injury-induced alterations in calcium-mediated signal transduction pathways. We report here, for the first time, that traumatic stretch injury causes release of calcium from inositol trisphosphate-sensitive intracellular calcium stores and may uncouple the stores from participation in metabotropic glutamate receptor-mediated signal transduction events. We found that for a prolonged period after trauma astrocytes no longer respond to thapsigargin, glutamate, or the inositol trisphosphate-linked metabotropic glutamate receptor agonist trans-(1 S,3R)1-amino-1,3-cyclopentanedicarboxylic acid with an elevation in [Ca2+](i). We hypothesize that changes in calcium-mediated signaling pathways, rather than an absolute elevation in [Ca2+](i), is responsible for some of the pathological consequences of traumatic brain injury.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA		Rzigalinski, BA (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, POB 980613, Richmond, VA 23298 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-27214] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER		AMRUTHESH SC, 1993, J NEUROCHEM, V61, P150, DOI 10.1111/j.1471-4159.1993.tb03550.x; ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Castilho RF, 1996, MOL CELL BIOCHEM, V159, P105, DOI 10.1007/BF00420912; CHARLES AC, 1993, GLIA, V7, P134, DOI 10.1002/glia.440070203; CHARLES AC, 1994, DEV NEUROSCI-BASEL, V16, P196, DOI 10.1159/000112107; CONDORELLI DF, 1993, J NEUROCHEM, V60, P877, DOI 10.1111/j.1471-4159.1993.tb03232.x; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DELAHUNTY TM, 1992, BRAIN RES, V594, P307, DOI 10.1016/0006-8993(92)91140-A; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Elmoselhi AB, 1996, AM J PHYSIOL-CELL PH, V271, pC1652; FAROOQUI AA, 1994, J NEUROSCI RES, V38, P6, DOI 10.1002/jnr.490380103; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HANSSON E, 1995, FASEB J, V9, P343, DOI 10.1096/fasebj.9.5.7534736; HASSINGER TD, 1995, J NEUROBIOL, V28, P159, DOI 10.1002/neu.480280204; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HOLZWARTH JA, 1994, J NEUROSCI, V14, P1879; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; KIM WT, 1994, GLIA, V11, P173, DOI 10.1002/glia.440110211; KOSTYUK P, 1994, NEUROSCIENCE, V63, P381, DOI 10.1016/0306-4522(94)90537-1; KRIEGLER S, 1993, J NEUROSCI, V13, P4229, DOI 10.1523/jneurosci.13-10-04229.1993; Lamb RG, 1997, J NEUROCHEM, V68, P1904; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MCINTOSH TK, 1992, J NEUROTRAUM, V9, pS201; McIntosh TK, 1996, LAB INVEST, V74, P315; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; MILLER S, 1995, ANN NY ACAD SCI, V757, P460, DOI 10.1111/j.1749-6632.1995.tb17506.x; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; PALMER E, 1989, EUR J PHARMACOL, V166, P585, DOI 10.1016/0014-2999(89)90383-X; PECHAN PA, 1993, NEUROSCI LETT, V149, P182; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; PRASAD MR, 1994, J NEUROCHEM, V63, P773; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; RZIGALINSKI BA, 1996, J NEUROTRAUM, V13, P609; SCHOEPP DD, 1992, NEUROSCI LETT, V145, P100, DOI 10.1016/0304-3940(92)90213-Q; Schreiber D., 1995, P 1995 INT RES C BIO, P233; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632, DOI 10.1152/jn.1997.77.2.632; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; THASTRUP O, 1994, AGENTS ACTIONS, V43, P187, DOI 10.1007/BF01986687; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; Vernadakis A, 1996, PROG NEUROBIOL, V49, P185, DOI 10.1016/S0301-0082(96)00012-3; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WILLIAMS DA, 1990, CELL CALCIUM, V11, P75, DOI 10.1016/0143-4160(90)90061-X; YANO S, 1994, J BIOL CHEM, V269, P5428; YOUNG W, 1992, J NEUROTRAUM, V9, pS9; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	60	89	94	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0022-3042			J NEUROCHEM	J. Neurochem.	JUN	1998	70	6					2377	2385					9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	ZN457	WOS:000073647800016	9603202				2022-02-06	
J	Folkerts, MM; Berman, RF; Muizelaar, JP; Rafols, JA				Folkerts, MM; Berman, RF; Muizelaar, JP; Rafols, JA			Disruption of MAP-2 immunostaining in rat hippocampus after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						cytoskeleton; dendrite; microtubule; trauma	MICROTUBULE-ASSOCIATED PROTEIN-2; CEREBRAL-ISCHEMIA; CELL-DEATH; VULNERABILITY; MODEL; GROWTH; PATHOPHYSIOLOGY; FOREBRAIN; CALCIUM; SYSTEM	The effects of diffuse brain injury on dendritic morphology in rat hippocampus and cortex were examined in this study using the recently described impact acceleration model of traumatic brain injury (Marmarou et al., 1994). Dendritic structure was visualized using immunostaining of microtubule associated protein-2 (MAP-2). Brains were studied 24, 48, and 72 h after brain injury. Results from immunohistochemistry and light microscopy indicated a time-dependent disruption of dendritic cytoarchitecture in the CA1 subregion and in the hilus of the hippocampus but not in the dentate gyrus or CA3 subregion. Similar disruption was observed in the cortical mantle overlying the hippocampus. Although disruption of dendritic structure was observed at 24 h, the most severe damage was at 48 h after injury with evidence of at least partial recovery of MAP-2 immunostaining by 72 h. In the most severe damage, dendrites appeared to be fragmented, scattered, and unaligned, consisting of irregularly spaced and darkly stained swollen segments. A mixed pattern of immunostaining was observed in somata of hilar cells, with some appearing normal while others stained only faintly, appearing to have lost their typical polygonal shape. Semiquantitative rankings confirmed these qualitative findings. Immediate post-injury behavioral evaluations of injury severity were compared to the degree of disruption of MAP-2 immunostaining. The results of this study indicate that diffuse brain injury is associated not only with axonal damage but also with injury to dendrites.	Univ Calif Davis, Dept Neurol Surg, Neurotrauma Res Labs, Davis, CA 95616 USA; Wayne State Univ, Dept Cell Biol & Anat, Detroit, MI 48201 USA		Berman, RF (corresponding author), Univ Calif Davis, Dept Neurol Surg, Neurotrauma Res Labs, 1 Shields Ave, Davis, CA 95616 USA.						BERNHARDT R, 1984, J COMP NEUROL, V226, P203, DOI 10.1002/cne.902260205; BRAY D, 1978, P NATL ACAD SCI USA, V75, P5226, DOI 10.1073/pnas.75.10.5226; CACERES A, 1988, MOL BRAIN RES, V3, P233, DOI 10.1016/0169-328X(88)90046-0; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FISCHER I, 1991, EXP CELL RES, V194, P195, DOI 10.1016/0014-4827(91)90354-W; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Folkerts M. M., 1998, J NEUROTRAUM, V13, P610; FREUND TF, 1992, BRAIN RES BULL, V28, P27, DOI 10.1016/0361-9230(92)90227-O; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HSU M, 1993, J NEUROSCI, V13, P3964; INUZUKA T, 1990, STROKE, V21, P917, DOI 10.1161/01.STR.21.6.917; JENKINS LW, 1981, ACTA NEUROPATHOL, V55, P205, DOI 10.1007/BF00691320; JOHNSON GVW, 1992, J NEUROSCI RES, V33, P505, DOI 10.1002/jnr.490330402; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAGLOCZKY Z, 1995, NEUROSCIENCE, V66, P847, DOI 10.1016/0306-4522(94)00613-A; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MATESIC DF, 1994, J NEUROCHEM, V63, P1012; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; O'Neil BJ, 1996, CARDIAC ARREST SCI P, P84; PARNAVELAS JG, 1974, NATURE, V248, P71, DOI 10.1038/248071a0; Paxinos G, 1986, RAT BRAIN STEREOTAXI; POSTMANTUR RM, 1996, J NEUROPATHOL EXP NE, V55, P68; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; SATO M, 1990, ACTA NEUROPATHOL, V80, P527, DOI 10.1007/BF00294614; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TAKEDA M, 1991, ACTA NEUROPATHOL, V82, P346, DOI 10.1007/BF00296545; TOMIMOTO H, 1992, ACTA NEUROPATHOL, V84, P394; WINOCUR G, 1990, BEHAV BRAIN RES, V38, P145, DOI 10.1016/0166-4328(90)90012-4; YAMAMOTO K, 1986, BRAIN RES, V384, P1, DOI 10.1016/0006-8993(86)91212-6; YANAGIHARA T, 1990, ACTA NEUROPATHOL, V80, P499, DOI 10.1007/BF00294610	34	89	94	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	1998	15	5					349	363		10.1089/neu.1998.15.349			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	ZL515	WOS:000073441300005	9605349				2022-02-06	
J	Franzen, R; Schoenen, J; Leprince, P; Joosten, E; Moonen, G; Martin, D				Franzen, R; Schoenen, J; Leprince, P; Joosten, E; Moonen, G; Martin, D			Effects of macrophage transplantation in the injured adult rat spinal cord: A combined immunocytochemical and biochemical study	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						angiogenesis; axonal regeneration; CNS; macrophages; myelin; neural transplantation	CENTRAL-NERVOUS-SYSTEM; DELAYED WALLERIAN DEGENERATION; MYELIN-ASSOCIATED GLYCOPROTEIN; ROOT GANGLION NEURONS; NEURITE GROWTH; MONONUCLEAR PHAGOCYTES; AXONAL REGENERATION; TRAUMATIC INJURY; REACTIVE ASTROCYTES; SCHWANN-CELLS	Early and robust invasion by macrophages may be one of the reasons why axonal regeneration is more effective in the PNS than ill the CNS, Therefore, we have grafted autologous peritoneal macrophages labeled with fluorescent later; microspheres into spinal cord compression lesions, At various survival times, we have studied their effect on the expression, of neuronal (neurofilaments [NF], calcitonin gene-related peptide [CGRP], 5-hydroxytryptamine [5-HT]) and nonneuronal markers (myelin-associated: glycoprotein [MAG], glial fibrillary acidic protein [GFAP], laminin) by using semiquantitative Western blot and immunohistochemical techniques. After 1 month, we observed a significant decrease of the expression of MAG as well as an important invasion of the lesion site by neurites, chiefly peptidergic axons of presumed dorsal roof origin, in macrophage-grafted animals compared with controls, In addition, angiogenesis and Schwann cell infiltration were more pronounced after macrophage grafts, providing an increase in laminin, a favorable substrate for axonal regrowth. ;th. By using reverse transcription-polymerase, chain reaction (RT-PCR), mRNAs for tumor necrosis factor-alpha (TNF-alpha) were detected in the transplanted cells, whereas results were negative for nerve growth factor (NGF), neurotrophin-3 (NT-3), brain-derived neurotrophic factor (BDNF), ol acidic fibroblast growth factor (aFGF) and basic fibroblast growth factor (bFGF). Thus, macrophage grafts: may represent an interesting strategy to promote axonal regeneration in the CNS, Our study suggests that they may exert their beneficial effects by degrading myelin products, which inhibit axonal regrowth th, and bg promoting a permissive extracellular matrix containing notably laminin. No evidence for a direct synthesis of neurotrophic factors by the transplanted macrophages was found in this study, but resident glial cells could secrete such factors as a result of stimulation by macrophage-released cytokines. (C) 1998 Wiley-Liss, Inc.	Univ Liege, Expt Neuropathol Lab, Liege, Belgium; Univ Liege, Dept Neurol, Liege, Belgium; Univ Liege, Dept Human Physiol & Pathophysiol, Liege, Belgium; Univ Liege, Dept Neurosurg, Liege, Belgium; Univ Utrecht, Neurol Res Inst, Utrecht, Netherlands		Schoenen, J (corresponding author), CHU Sart Tilman, Expt Neuropathol Lab, Tour Pathol,1, B-4020 Liege, Belgium.	jschoenen@chu.ulg.ac.be		MARTIN, Didier/0000-0001-7325-4958; Leprince, pierre/0000-0002-7233-6553			ARAUJO DM, 1992, DEV BIOL, V133, P309; AVELLINO AM, 1995, EXP NEUROL, V136, P183, DOI 10.1006/exnr.1995.1095; BEDI KS, 1992, EUR J NEUROSCI, V4, P193, DOI 10.1111/j.1460-9568.1992.tb00867.x; BERNSTEIN JJ, 1985, BRAIN RES, V327, P135, DOI 10.1016/0006-8993(85)91507-0; BISBY MA, 1990, BRAIN RES, V530, P117, DOI 10.1016/0006-8993(90)90666-Y; BROWN MC, 1994, EUR J NEUROSCI, V6, P420, DOI 10.1111/j.1460-9568.1994.tb00285.x; CHAMAK B, 1994, J NEUROSCI RES, V38, P221, DOI 10.1002/jnr.490380213; CHEN S, 1993, J COMP NEUROL, V333, P449, DOI 10.1002/cne.903330310; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAHLIN LB, 1995, BRAIN RES, V679, P274, DOI 10.1016/0006-8993(95)00249-P; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; DAVID S, 1995, J NEUROSCI RES, V42, P594, DOI 10.1002/jnr.490420417; ELKABES S, 1995, J NEUROSCI, V16, P2505; FILBIN MT, 1995, CURR OPIN NEUROBIOL, V5, P588, DOI 10.1016/0959-4388(95)80063-8; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; FRYER HJL, 1986, ANAL BIOCHEM, V153, P262, DOI 10.1016/0003-2697(86)90090-4; GEORGE R, 1994, EXP NEUROL, V129, P225, DOI 10.1006/exnr.1994.1164; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GRIFFIN JW, 1992, J NEUROIMMUNOL, V40, P153, DOI 10.1016/0165-5728(92)90129-9; GUNDERSEN RW, 1979, SCIENCE, V206, P1079, DOI 10.1126/science.493992; GUTH L, 1983, TRENDS NEUROSCI, P20; HIKAWA N, 1993, NEUROREPORT, V5, P41, DOI 10.1097/00001756-199310000-00010; Hikawa N, 1996, CELL MOL NEUROBIOL, V16, P517, DOI 10.1007/BF02150231; JAFFE EA, 1985, BLOOD, V65, P79; Jelsma Tony N., 1994, Current Opinion in Neurobiology, V4, P717, DOI 10.1016/0959-4388(94)90015-9; KIEFER R, 1995, INT J DEV NEUROSCI, V13, P331; LazarovSpiegler O, 1996, FASEB J, V10, P1296, DOI 10.1096/fasebj.10.11.8836043; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LI Y, 1995, EXP NEUROL, V134, P102, DOI 10.1006/exnr.1995.1041; LIESI P, 1984, EMBO J, V3, P683, DOI 10.1002/j.1460-2075.1984.tb01867.x; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; LOTAN M, 1994, EXP NEUROL, V126, P284, DOI 10.1006/exnr.1994.1066; LUDWIN SK, 1992, J NEUROL SCI, V109, P140, DOI 10.1016/0022-510X(92)90160-M; LUDWIN SK, 1991, J NEUROPATH EXP NEUR, V50, P330; MALLAT M, 1989, DEV BIOL, V133, P309, DOI 10.1016/0012-1606(89)90322-9; MANSOUR H, 1990, J NEUROSCI RES, V25, P300, DOI 10.1002/jnr.490250306; MANTHORPE M, 1983, J CELL BIOL, V97, P1882, DOI 10.1083/jcb.97.6.1882; MARTIN D, 1991, NEUROSCI LETT, V124, P44, DOI 10.1016/0304-3940(91)90818-E; Martin D, 1996, J NEUROSCI RES, V45, P588; MARTIN D, 1992, J NEUROSCI RES, V32, P539, DOI 10.1002/jnr.490320409; MARTIN D, 1993, BRAIN RES BULL, V30, P507, DOI 10.1016/0361-9230(93)90285-J; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MCKEON RJ, 1995, EXP NEUROL, V136, P32, DOI 10.1006/exnr.1995.1081; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Ng WP, 1996, NEUROREPORT, V7, P861, DOI 10.1097/00001756-199603220-00005; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Ramon y Cajal, 1928, DEGENERATION REGENER; Reier P., 1983, SPINAL CORD RECONSTR, P163; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SempleRowland SL, 1995, J NEUROTRAUM, V12, P1003, DOI 10.1089/neu.1995.12.1003; SHIMOJO M, 1991, NEUROSCI LETT, V123, P229, DOI 10.1016/0304-3940(91)90937-O; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x	57	89	92	0	4	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	FEB 1	1998	51	3					316	327		10.1002/(SICI)1097-4547(19980201)51:3<316::AID-JNR5>3.3.CO;2-6			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	YV263	WOS:000071805700005	9486767				2022-02-06	
J	Reeves, TM; Lyeth, BG; Phillips, LL; Hamm, RJ; Povlishock, JT				Reeves, TM; Lyeth, BG; Phillips, LL; Hamm, RJ; Povlishock, JT			The effects of traumatic brain injury on inhibition in the hippocampus and dentate gyrus	BRAIN RESEARCH			English	Article						traumatic brain injury; paired-pulse inhibition; hippocampus; dentate gyrus; gamma-aminobutyric acid; rat	PAIRED-PULSE DEPRESSION; ACTIVITY-DEPENDENT DISINHIBITION; TRANSIENT CEREBRAL-ISCHEMIA; GABA-MEDIATED INHIBITION; RAT HIPPOCAMPUS; FASCIA-DENTATA; EXTRACELLULAR POTASSIUM; SYNAPTIC TRANSMISSION; COGNITIVE IMPAIRMENT; GLUCOSE-UTILIZATION	Changes in inhibitory neuronal functioning may contribute to morbidity following traumatic brain injury (TBI). Evoked responses to orthodromic paired-pulse stimulation were examined in the hippocampus and dentate gyrus at 2 and 15 days following lateral fluid percussion TBI in adult rats. The relative strength of inhibition was estimated by measuring evoked paired pulses in three afferent systems: the CA3 commissural input to the CA1 region of the hippocampus; the entorhinal cortical input to the ipsilateral CA1 area (temporoammonic system); and the entorhinal input to the ipsilateral dentate gyms (perforant path). In addition to quantitative electrophysiological estimates of inhibitory efficacy, levels of gamma-aminobutyric acid (GABA) were qualitatively examined with immunohistochemical techniques. Effects of TBI on paired-pulse responses were pathway-specific, and dependent on time postinjury. At 2 days following TBI, inhibition of population spikes was significantly reduced in the CA3 commissural input to CA1, which contrasted with injury-induced increases in inhibition in the dentate gyrus seen at both 2 and 15 days postinjury. Low-level stimulation, subthreshold for population spikes, also revealed changes in paired-pulse facilitation of field extracellular postsynaptic potentials (fEPSPs), which depended on fiber pathway and time postinjury. Significant injury-induced electrophysiological changes were almost entirely confined to the hemisphere ipsilateral to injury. Intensity of GABA immunobinding exhibited a regional association with electrophysiological indices of inhibition, with the most pronounced increases in GABA levels and inhibition found in the dentate gyrus. TBI-induced effects showed a regional pattern within the hippocampus which corresponds closely to inhibitory changes reported to follow ischemia and kindling. This degree of similarity in outcome following dissimilar injuries may indicate common mechanisms in the nervous system response to injury.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DIV NEUROSURG, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, DEPT PSYCHOL, RICHMOND, VA 23298 USA		Reeves, TM (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT ANAT, BOX 709, RICHMOND, VA 23298 USA.			Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587, K17NS001750, R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20193, NS01750, NS12587] Funding Source: Medline		ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; Brierly J, 1984, GREENFIELDS NEUROPAT, P125; CAVAZOS JE, 1994, J NEUROSCI, V14, P3106; CHANG HS, 1989, STROKE, V20, P1051, DOI 10.1161/01.STR.20.8.1051; CHANG HS, 1989, BRAIN RES, V505, P220, DOI 10.1016/0006-8993(89)91446-7; COLBERT CM, 1992, J NEUROPHYSIOL, V68, P1; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; DEJONGE M, 1987, BRAIN RES, V412, P318, DOI 10.1016/0006-8993(87)91139-5; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1992, ROLE OF NEUROTRANSMITTERS IN BRAIN INJURY, P213; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GLOBUS MYT, 1991, J NEUROCHEM, V57, P470, DOI 10.1111/j.1471-4159.1991.tb03775.x; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HAMM RJ, 1995, EXP NEUROL, V136, P143, DOI 10.1006/exnr.1995.1091; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAMM RJ, 1994, J NEUROSURG, V81, P267, DOI 10.3171/jns.1994.81.2.0267; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HERRON CE, 1985, NEUROSCI LETT, V61, P255, DOI 10.1016/0304-3940(85)90473-2; KAMPHUIS W, 1988, BRAIN RES, V440, P205, DOI 10.1016/0006-8993(88)90988-2; KAMPHUIS W, 1992, NEUROSCI LETT, V141, P101, DOI 10.1016/0304-3940(92)90344-7; KAPUR J, 1989, J NEUROPHYSIOL, V61, P417, DOI 10.1152/jn.1989.61.2.417; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KELLY PAT, 1982, J NEUROCHEM, V39, P613, DOI 10.1111/j.1471-4159.1982.tb07937.x; KELLY PT, 1983, BRAIN RES, V258, P338, DOI 10.1016/0006-8993(83)91162-9; KING GL, 1985, J NEUROPHYSIOL, V54, P1295, DOI 10.1152/jn.1985.54.5.1295; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MARU E, 1987, EXP NEUROL, V96, P46, DOI 10.1016/0014-4886(87)90167-1; MCNAUGHTON BL, 1982, J PHYSIOL-LONDON, V324, P249, DOI 10.1113/jphysiol.1982.sp014110; MOTT DD, 1993, J NEUROPHYSIOL, V69, P674, DOI 10.1152/jn.1993.69.3.674; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; ODELL DM, 1995, J NEUROSURG, V83, P878, DOI 10.3171/jns.1995.83.5.0878; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; REEVES TM, 1995, EXP BRAIN RES, V106, P248; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; ROCK DM, 1986, NEUROSCI LETT, V65, P265, DOI 10.1016/0304-3940(86)90272-7; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; Sloviter R S, 1991, Hippocampus, V1, P31, DOI 10.1002/hipo.450010105; SMITH ML, 1984, ACTA NEUROPATHOL, V64, P319, DOI 10.1007/BF00690397; THOMPSON SM, 1994, PROG NEUROBIOL, V42, P575, DOI 10.1016/0301-0082(94)90044-2; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P512, DOI 10.1152/jn.1989.61.3.512; THOMPSON SM, 1988, NEUROSCI LETT, V89, P49, DOI 10.1016/0304-3940(88)90479-X; TITULAER MNG, 1994, NEUROSCIENCE, V59, P817, DOI 10.1016/0306-4522(94)90286-0; TITULAER MNG, 1995, J NEUROCHEM, V64, P2615; TUFF LP, 1983, BRAIN RES, V277, P79, DOI 10.1016/0006-8993(83)90909-5; TUFF LP, 1983, BRAIN RES, V277, P91, DOI 10.1016/0006-8993(83)90910-1; ZHAO DC, 1991, BRAIN RES, V564, P220, DOI 10.1016/0006-8993(91)91457-C	51	89	91	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 16	1997	757	1					119	132		10.1016/S0006-8993(97)00170-4			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	XC521	WOS:A1997XC52100016	9200506				2022-02-06	
J	Wade, DT; Crawford, S; Wenden, FJ; King, NS; Moss, NEG				Wade, DT; Crawford, S; Wenden, FJ; King, NS; Moss, NEG			Does routine follow up after bead injury help? A randomised controlled trial	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						randomised controlled trial; head injury; follow up service	MINOR HEAD-INJURY; GENERAL HEALTH; CONCUSSION; SYMPTOMS; MILD; QUESTIONNAIRE; EPIDEMIOLOGY	Objective-To evaluate the Medical Disability Society's 1988 recommendation that ''every patient attending hospital after a head injury should be registered and offered an outpatient follow up appointment'' by determining whether offering a routine follow up service to patients presenting to hospital with a head injury of any severity affects outcome six months later. Design-A randomised controlled trial design with masked assessment of outcome. Setting-A mixed rural and urban health district with a population of about 560 000. Patients-1156 consecutive patients resident in Oxfordshire aged between 16 and 65 years presenting over 13 months to accident and emergency departments or admitted to hospital and diagnosed as having a head injury of any severity, including those with other injuries. Interventions-Patients were registered and randomised to one of two groups. Both groups continued to receive the standard service offered by the hospitals, The early follow up group were approached at 7-10 days after injury and offered additional information, advice, support, and further intervention as needed. AU randomised patients were approached for follow up assessment six months after injury by independent clinicians blind to their group. Main outcome measures-Validated questionnaires were used to elicit ratings of post-concussion symptoms (the Rivermead postconcussion symptoms questionnaire), and changes in work, relationships, leisure, social, and domestic activities (the Rivermead head injury follow up questionnaire). Results-The two groups were comparable at randomisation. Data was obtained at six months on 226 of 577 ''control'' patients and 252 of 579 ''trial'' patients (59% were lost to follow up). There were no significant differences overall between the trial and control groups at follow up, but subgroup analysis of the patients with moderate or severe head injuries (posttraumatic amnesia greater than or equal to one hour, or admitted to hospital), showed that those in the early intervention group had significantly fewer difficulties with everyday activities (P = 0.03). Conclusions-The results from the 41% of patients followed up do not support the recommendation of offering a routine follow up to all patients with head injury, but they do suggest that routine follow up is most Likely to be beneficial to patients with moderate or severe head injuries. Some of those with less severe injuries do continue to experience difficulties and need access to services. A further trial is under way to lest these conclusions.			Wade, DT (corresponding author), RIVERMEAD REHABIL CTR,OXFORD HEAD INJURY SERV,ABINGDON RD,OXFORD OX1 4XD,ENGLAND.			Wade, Derick/0000-0002-1188-8442			Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; ARTIOLA I, 1980, J NEUROL NEUROSUR PS, V43, P377; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN S, 1989, MILD HEAD INJURY; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GREENWOOD RJ, 1992, BRIT MED J, V308, P1199; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LENINGER B, 1990, J NEUROL NEUROSUR PS, V53, P293; MANDEL S, 1989, POSTGRAD MED, V85, P213; *MED DIS SOC, 1988, MAN TRAUM BRAIN INJ; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Moss NE, 1996, DISABIL REHABIL, V18, P169, DOI 10.3109/09638289609166296; Moss NE., 1994, CLIN REHABIL, V8, P149; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Smith A., 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002	29	89	90	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	1997	62	5					478	484		10.1136/jnnp.62.5.478			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	WX623	WOS:A1997WX62300009	9153604	Green Published, Bronze			2022-02-06	
J	CHAN, PH; EPSTEIN, CJ; LI, Y; HUANG, TT; CARLSON, E; KINOUCHI, H; YANG, G; KAMII, H; MIKAWA, S; KONDO, T; COPIN, JC; CHEN, SF; CHAN, T; GAFNI, J; GOBBEL, G; REOLA, E				CHAN, PH; EPSTEIN, CJ; LI, Y; HUANG, TT; CARLSON, E; KINOUCHI, H; YANG, G; KAMII, H; MIKAWA, S; KONDO, T; COPIN, JC; CHEN, SF; CHAN, T; GAFNI, J; GOBBEL, G; REOLA, E			TRANSGENIC MICE AND KNOCKOUT MUTANTS IN THE STUDY OF OXIDATIVE STRESS IN BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article						TRANSGENIC MICE; KNOCKOUT MUTANTS; FOCAL CEREBRAL ISCHEMIA; TRAUMA; SUPEROXIDE DISMUTASE; OXYGEN FREE RADICALS; CNS INJURY	CU/ZN-SUPEROXIDE-DISMUTASE; FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE; CORTICAL INFARCTION; OXYGEN RADICALS; NERVOUS-SYSTEM; BLOOD-FLOW; CELLS; NEUROTOXICITY; EDEMA	A rapid increase in the need to explore the molecular basis of cellular function and injury in the central nervous system has led neuroscientists to employ transgenic mouse technology. The successful making of transgenic mice (Tg) overexpressing human CuZn-superoxide dismutase (SOD-1) activity has made it possible to investigate the role of oxygen free radicals in ischemic and traumatic brain injury in a molecular fashion. It has been demonstrated that the 3-fold increase in SOD-1 transgene activity in SOD-1 Tg mice offers protection against cerebral ischemia and reperfusion in two different models of focal cerebral ischemia, as compared to nontransgenic wild-type littermates. Studies involving traumatic brain injury have also demonstrated that acute injuries, including brain edema and blood-brain barrier permeability, are significantly reduced in SOD-1 Tg mice. Furthermore, chronic neurological deficits, such as beam walking, beam balance, and body weight, are significantly improved in these transgenic animals following traumatic brain injury. In addition to the SOD-1 Tg mice being a useful tool for the study of CNS injury, targeted disruption of the mouse gene for mitochondrial manganese SOD (SOD-2) has been successful. These SOD-2 knockout mutant mice, in addition to the recently developed knockout mutants of neuronal nitric oxide synthase (NOS), are believed to offer a unique opportunity to elucidate the oxidative mechanisms in brain injury following stroke and trauma.			CHAN, PH (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT NEUROL & NEUROSURG,521 PARNASSUS AVE,SAN FRANCISCO,CA 94143, USA.		Copin, Jean-Christophe/K-6890-2012		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS014543, P01NS014543, R01NS025372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG008938] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG-08938] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-14543, NS-25372] Funding Source: Medline		AVRAHAM KB, 1988, CELL, V54, P823, DOI 10.1016/S0092-8674(88)91153-1; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; Chan P.H, 1988, CELLULAR ANTIOXIDANT, VVolume 3, P89; CHAN PH, 1994, ANN NY ACAD SCI, V738, P93; CHAN PH, 1990, STROKE, V21, P80; CHAN PH, 1993, NEUROREPORT, V5, P293, DOI 10.1097/00001756-199312000-00028; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; CHAN PH, 1994, BRAIN PATHOL, V4, P59; CHAN PH, 1992, NEW INSIGHTS ROLE OX, V7, P277; CHAN PH, 1983, BRAIN RES, V227, P329; CHAN PH, 1995, 19TH PRINC C CER DIS, P153; CHAN PH, 1993, PROG BRAIN RES, V96, P94; CHEN ST, 1986, STROKE, V17, P738, DOI 10.1161/01.STR.17.4.738; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DAWSON VL, 1993, J NEUROSCI, V13, P2651; EDWARDS RH, 1989, CELL, V58, P161, DOI 10.1016/0092-8674(89)90412-1; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; EPSTEIN CJ, 1992, GENE TRANSFER THERAP, P106; EPSTEIN CJ, 1994, P INT ROUND TABLE NE, P239; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HE YY, 1993, AM J PHYSIOL, V265, pH252, DOI 10.1152/ajpheart.1993.265.1.H252; HO YS, 1991, AM J RESP CELL MOL, V4, P278, DOI 10.1165/ajrcmb/4.3.278; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUANG TT, 1992, FASEB J, V6, P903, DOI 10.1096/fasebj.6.3.1740238; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; HUE RT, 1993, FREE RADICAL RES COM, V18, P195; IMAIZUMI S, 1990, STROKE, V21, P1312, DOI 10.1161/01.STR.21.9.1312; KIEDROWSKI L, 1991, J NEUROCHEM, V58, P335; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; KINOUCHI H, 1993, J CEREB BLOOD FLO S1, V13, pS30; KONTOS HA, 1985, CIRC RES, V57, P508, DOI 10.1161/01.RES.57.4.508; KORETSKY AP, 1992, AM J PHYSIOL, V262, pC261, DOI 10.1152/ajpcell.1992.262.2.C261; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; LEVANON D, 1985, EMBO J, V4, P77, DOI 10.1002/j.1460-2075.1985.tb02320.x; LI Y, 1995, IN PRESS NATURE GENE; LI Y, 1994, AM SOC BIOCH MOL BIO, V16; LIEMANHURWITZ J, 1982, P NATL ACAD SCI-BIOL, V79, P2808, DOI 10.1073/pnas.79.9.2808; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LIU TH, 1989, AM J PHYSIOL, V256, pH589, DOI 10.1152/ajpheart.1989.256.2.H589; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MATSUYAMA T, 1993, J CEREBR BLOOD F MET, V13, P135, DOI 10.1038/jcbfm.1993.16; MIKAWA S, 1995, JCBF M S S, V15, pS729; MIRAULT ME, 1994, ANN NY ACAD SCI, V738, P104; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; NAGAFUJI T, 1992, NEUROSCI LETT, V147, P159, DOI 10.1016/0304-3940(92)90584-T; PRADO R, 1993, J CEREBR BLOOD F MET, V13, P720, DOI 10.1038/jcbfm.1993.91; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; READHEAD C, 1987, CELL, V48, P703, DOI 10.1016/0092-8674(87)90248-0; ROSENFELD MG, 1988, ANNU REV NEUROSCI, V11, P353, DOI 10.1146/annurev.ne.11.030188.002033; SARAN M, 1990, FREE RADICAL RES COM, V10, P221, DOI 10.3109/10715769009149890; SHI YP, 1994, MAMM GENOME, V5, P337, DOI 10.1007/BF00356551; SIESJO BK, 1989, CEREB BRAIN METAB RE, V6, P303; TANAKA K, 1993, NEUROREPORT, V4, P267, DOI 10.1097/00001756-199303000-00010; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; XUE D, 1992, STROKE, V23, P894, DOI 10.1161/01.STR.23.6.894; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165; ZHANG FY, 1993, NEUROREPORT, V4, P559, DOI 10.1097/00001756-199305000-00024	64	89	91	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1995	12	5					815	824		10.1089/neu.1995.12.815			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	TE646	WOS:A1995TE64600005	8594209				2022-02-06	
J	JORGE, RE; ROBINSON, RG; STARKSTEIN, SE; ARNDT, SV				JORGE, RE; ROBINSON, RG; STARKSTEIN, SE; ARNDT, SV			INFLUENCE OF MAJOR DEPRESSION ON 1-YEAR OUTCOME IN PATIENTS WITH TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROSURGERY			English	Article						DEPRESSION; TRAUMATIC BRAIN INJURY; OUTCOME; RECOVERY; EMOTIONAL DISORDER; BEHAVIORAL DISORDER; TRAUMATIC COMA DATA BANK	SEVERE HEAD-INJURY; COMPUTERIZED-TOMOGRAPHY; RELATIVES VIEW; MOOD; SEQUELAE; COMA	The authors examine those factors that contributed to deterioration in social functioning, activities of daily living, or intellectual functioning during a 1-year period after traumatic brain injury (TBI). Fifty-two patients suffering an acute TBI were evaluated for existence and severity of mood disorders and impairment during their hospital stays and at 3-, 6-, and 12-month follow-up examinations. Patients whose scores on intellectual function, social function, or daily activities deteriorated during the 1-year period after trauma were considered to have a poor outcome. Eleven of 52 patients had a poor outcome in social function, which was associated with race, right-hemisphere lesions, intellectual impairment, and prolonged major depression. Seven of 52 patients had a poor outcome in daily activities, which was associated with a major depression of more than 6 months' duration and severity of Hamilton Depression Rating Scale scores. Eleven of these patients had a poor outcome in cognitive function, which was associated with cognitive impairment immediately after TBI. A major depression lasting more than 6 months was associated with deterioration of social functioning and activities of daily living during the 1-year period after TBI.	UNIV IOWA,COLL MED,DEPT PSYCHIAT,IOWA CITY,IA 52242; UNIV IOWA,MENTAL HLTH CLIN RES CTR,BIOSTAT CORE UNIT,IOWA CITY,IA; INST NEUROL INVEST RAUL CARREA,BUENOS AIRES,DF,ARGENTINA				Arndt, Stephan/A-6976-2013; Robinson, Robert/AAF-6191-2021	Arndt, Stephan/0000-0003-0783-8204; 			BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GRAFMAN J, 1986, BRAIN, V109, P1127, DOI 10.1093/brain/109.6.1127; GRANT I, 1987, NEUROBEHAVIORAL RECO, P232; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, AM J PSYCHIAT, V150, P916; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVINE DN, 1984, NEUROLOGY, V34, P577, DOI 10.1212/WNL.34.5.577; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; LISHMAN WA, 1988, BR J PSYCHITRY, V153, P1460; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; PARIKH RM, 1990, ARCH NEUROL-CHICAGO, V47, P785, DOI 10.1001/archneur.1990.00530070083014; Prigatano GP, 1985, NEUROPSYCHOLOGICAL R; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; TEASDALE G, 1974, LANCET, V2, P81; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1990, HDB CLIN NEUROLOGY, V13, P397; Wing J. K., 1974, MEASUREMENT CLASSIFI; [No title captured]	32	89	89	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	NOV	1994	81	5					726	733		10.3171/jns.1994.81.5.0726			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Surgery	PN296	WOS:A1994PN29600011	7931619				2022-02-06	
J	FAY, GC; JAFFE, KM; LIAO, SQ; MARTIN, KM; SHURTLEFF, HA; RIVARA, JB; WINN, HR; POLISSAR, NL				FAY, GC; JAFFE, KM; LIAO, SQ; MARTIN, KM; SHURTLEFF, HA; RIVARA, JB; WINN, HR; POLISSAR, NL			MILD PEDIATRIC TRAUMATIC BRAIN INJURY - A COHORT STUDY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							HEAD-INJURY; CHILDREN; SEQUELAE		CHILDRENS HOSP & MED CTR,DEPT REHABIL MED,4800 SANDY POINT WAY NE,SEATTLE,WA 98105; CHILDRENS HOSP & MED CTR,DEPT BEHAV SCI,SEATTLE,WA 98105; CHILDRENS HOSP & MED CTR,DEPT NEUROL SURG,SEATTLE,WA 98105; CHILDRENS HOSP & MED CTR,DEPT PEDIAT,SEATTLE,WA 98105; CHILDRENS HOSP & MED CTR,DEPT BIOSTAT,SEATTLE,WA 98105; CHILDRENS HOSP & MED CTR,SCH SOCIAL WORK,SEATTLE,WA 98105; UNIV WASHINGTON,CTR QUANTITAT SCI,SEATTLE,WA 98195; CHILDRENS HOSP & MED CTR,DEPT PSYCHIAT,SEATTLE,WA 98105					Shurtleff, Hillary/0000-0003-0959-2842	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49-CCR002299] Funding Source: Medline		ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; BIJUR PE, 1990, PEDIATRICS, V86, P337; BIJUR PE, 1986, AM J DIS CHILD, V140, P487, DOI 10.1001/archpedi.1986.02140190097036; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Bruininks R. H., 1984, SCALES INDEPENDENT B; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Conover W.J., 1998, PRACTICAL NONPARAMET; DELIS DC, 1989, CALIFORNIA VERBAL LE; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Edelbrock C., 1986, MANUAL TEACHERS REPO; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P740; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; LEVIN HS, 1979, CHILD BRAIN, V5, P281; Miller R. G., 1981, SIMULTANEOUS STAT IN; Reitan R.M., 1974, CLIN NEUROPSYCHOLOGY; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; TELZROW CF, 1987, J LEARN DISABIL, V20, P536, DOI 10.1177/002221948702000905; Wechsler D., 1974, WECHSLER INTELLIGENC; Wilkinson, 1984, WIDE RANGE ACHIEVEME; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; 1990, AM J DIS CHILD, V144, P627; 1985, ABBREVIATED INJURY S	29	89	89	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	1993	74	9					895	901					7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	LX551	WOS:A1993LX55100001	8379832				2022-02-06	
J	TAFT, WC; YANG, KY; DIXON, CE; CLIFTON, GL; HAYES, RL				TAFT, WC; YANG, KY; DIXON, CE; CLIFTON, GL; HAYES, RL			HYPOTHERMIA ATTENUATES THE LOSS OF HIPPOCAMPAL MICROTUBULE-ASSOCIATED PROTEIN-2 (MAP2) FOLLOWING TRAUMATIC BRAIN INJURY	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						CYTOSKELETON; MICROTUBULES; NEURONAL DEATH; PROTEASE; TEMPERATURE; TRAUMA	EXCITATORY AMINO-ACIDS; RAT-BRAIN; CALPAIN-I; FOREBRAIN ISCHEMIA; NEURONAL DAMAGE; TEMPERATURE; DEGRADATION; INHIBITOR; SPECTRIN; RELEASE	Traumatic brain injury (TBI) produces a tissue-specific decrease in protein levels of microtubule-associated protein 2 (MAP2), an important cross-linking component of the neuronal cytoskeleton. Because moderate brain hypothermia (30-degrees-C) reduces certain neurobehavioral deficits produced by TBI, we examined the efficacy of moderate hypothermia (30-degrees-C) in reversing the TBI-induced loss of MAP2 protein. Naive, sham-injured, and moderate (2.1 atm) fluid percussion-injured rats were assessed for MAP2 protein content 3 h post injury using quantitative immunoreactivity measurements. Parallel groups of sham-injured and fluid percussion-injured animals were maintained in moderate hypothermia (30-degrees-C), as measured by temporalis muscle temperature, for MAP2 quantitation 3 h post injury. No difference in MAP2 levels was observed between naive and sham-injured normothermic animals. Hypothermia alone had no effect on soluble MAP2 levels in sham-injured animals compared with normothermic sham-injured controls (88.0 +/- 7.3%; p > 0.10). Fluid percussion injury dramatically reduced MAP2 levels in he normothermic group (44.3 +/- 5.9%; p < 0.0005) compared with normothermic sham-injured controls. No significant reduction of MAP2 was seen in the hypothermic injured group (95.2 +/- 4.6%; compared with hypothermic sham-injured controls, p > 0.20). Although it is premature to infer any causal link, the data suggest that the attenuation of injury-induced MAP2 loss by hypothermia may contribute to its overall neuroprotective action.			TAFT, WC (corresponding author), UNIV TEXAS, HLTH SCI CTR, 6431 FANNIN, SUITE 7154, HOUSTON, TX 77030 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21458] Funding Source: Medline		AVILA J, 1992, LIFE SCI, V50, P327, DOI 10.1016/0024-3205(92)90433-P; BERNHARDT R, 1984, J COMP NEUROL, V226, P203, DOI 10.1002/cne.902260205; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CLASEN RA, 1968, ARCH NEUROL-CHICAGO, V19, P472, DOI 10.1001/archneur.1968.00480050042004; CLIFTON GL, 1992, J NEUROTRAUM, V9, pS487; CLIFTON GL, 1989, STROKE, V20, P1545, DOI 10.1161/01.STR.20.11.1545; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dustin P., 1984, MICROTUBULES; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HARA H, 1990, J PHARMACOL EXP THER, V255, P906; HARA H, 1990, J CEREBR BLOOD F MET, V10, P646, DOI 10.1038/jcbfm.1990.117; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HEIMANN R, 1985, J BIOL CHEM, V260, P2160; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; JOHNSON GVW, 1989, BIOCHEM BIOPH RES CO, V163, P1505, DOI 10.1016/0006-291X(89)91150-9; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; LYETH B G, 1991, Society for Neuroscience Abstracts, V17, P165; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MIYAZAWA T, 1992, J CEREBR BLOOD F MET, V12, P817, DOI 10.1038/jcbfm.1992.113; MURPHY DB, 1975, P NATL ACAD SCI USA, V72, P2696, DOI 10.1073/pnas.72.7.2696; NORWOOD WI, 1982, AM J PHYSIOL, V243, pC62, DOI 10.1152/ajpcell.1982.243.1.C62; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; RIEDERER B, 1985, P NATL ACAD SCI USA, V82, P6006, DOI 10.1073/pnas.82.17.6006; SELDEN SC, 1983, J BIOL CHEM, V258, P7064; SEUBERT P, 1987, SYNAPSE, V1, P20, DOI 10.1002/syn.890010105; Siesj? BK., 1978, BRAIN ENERGY METABOL; SIMAN R, 1985, BRAIN RES, V347, P399, DOI 10.1016/0006-8993(85)90208-2; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SIMAN R, 1989, J NEUROSCI, V9, P1579; TAFT W C, 1991, Society for Neuroscience Abstracts, V17, P164; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZIMMERMAN UJP, 1982, BIOCHEMISTRY-US, V21, P3977, DOI 10.1021/bi00260a012	45	89	91	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	1993	13	5					796	802		10.1038/jcbfm.1993.101			7	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	LT800	WOS:A1993LT80000008	8360286	Bronze			2022-02-06	
J	FERNAUDESPINOSA, I; NIETOSAMPEDRO, M; BOVOLENTA, P				FERNAUDESPINOSA, I; NIETOSAMPEDRO, M; BOVOLENTA, P			DIFFERENTIAL ACTIVATION OF MICROGLIA AND ASTROCYTES IN ANISOMORPHIC AND ISOMORPHIC GLIOTIC TISSUE	GLIA			English	Article						CNS INJURY; REACTIVE ASTROCYTES; IMMUNOCYTOCHEMISTRY	CENTRAL NERVOUS-SYSTEM; FIBRILLARY ACIDIC PROTEIN; ADULT-RAT-BRAIN; REACTIVE ASTROCYTES; WALLERIAN DEGENERATION; EXCITOTOXIC LESION; PRECURSOR PROTEIN; MAMMALIAN BRAIN; CELLS; ANTIBODIES	Reactive astrocytes and microglial cells are both involved in the formation of gliotic tissue. Using immunohistochemical markers, we have compared the response of both these cell types after two different kinds of damage in the brain: traumatic injury (anisomorphic gliosis) and neurotoxic induced lesion (isomorphic gliosis), in two distinct regions of the brain, the cortex and the hippocampus. We show that the time course and the relative contribution of astrocytes and microglial cells differ greatly in the two kinds of lesions. While in anisomorphic gliosis there is little activation of endogenous microglial cells independently of the brain region damaged, these cells contribute in large measure and for prolonged periods of time to the formation of isomorphic gliotic tissue. Astrocytes are quickly activated at the border of anisomorphic lesions, and after 3 days they already occupy an extensive portion of the brain parenchyma. However, after 1 month, they are found restricted to a thin strip at the lesion boundary. In contrast, after an isomorphic lesion, astrocytes become reactive around the site of neuronal cell loss but not at the site of the lesion itself. Only after 2 weeks do they totally invade the damaged region, persisting for at least 1 month. Such differences are observed independently of the brain region damaged. These results suggest that the cellular, and therefore the molecular, composition of gliotic tissue depends on the type of insult the CNS has suffered. (C) 1993 Wiley-Liss, Inc.	INST CAJAL,NEURAL PLASTIC GRP,C DOCTOR ARLE 37,E-28002 MADRID,SPAIN				Fernaud-Espinosa, Isabel/H-1875-2015	Fernaud-Espinosa, Isabel/0000-0003-2391-0704			AKIYAMA H, 1988, J NEUROSCI RES, V20, P147, DOI 10.1002/jnr.490200202; BIGNAMI A, 1976, NEUROPATH APPL NEURO, V2, P99, DOI 10.1111/j.1365-2990.1976.tb00488.x; BILLETT EE, 1984, BIOCHEM J, V221, P765, DOI 10.1042/bj2210765; BOVOLENTA P, 1992, PROG BRAIN RES, V94, P367; BOVOLENTA P, 1984, DEV BIOL, V102, P248, DOI 10.1016/0012-1606(84)90189-1; BOVOLENTA P, 1993, IN PRESS EUR J NEURO; BOYA J, 1986, ACTA ANAT, V127, P142; CALVO JL, 1991, BRAIN RES, V566, P333, DOI 10.1016/0006-8993(91)91720-L; CARD JP, 1988, NEURON, V1, P835, DOI 10.1016/0896-6273(88)90131-6; DAHL D, 1982, DIFFERENTIATION, V22, P185, DOI 10.1111/j.1432-0436.1982.tb01248.x; DENNISDONNINI S, 1984, NATURE, V307, P641; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; DRAGUNOW M, 1990, BRAIN RES, V527, P41, DOI 10.1016/0006-8993(90)91058-O; DUSART I, 1991, NEUROSCIENCE, V45, P541, DOI 10.1016/0306-4522(91)90269-T; GIULIAN D, 1991, J CELL BIOL, V112, P323, DOI 10.1083/jcb.112.2.323; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GIULIAN D, 1986, J CELL BIOL, V102, P803, DOI 10.1083/jcb.102.3.803; GOLDMAN JE, 1991, GLIA, V4, P149, DOI 10.1002/glia.440040206; GRAEBER MB, 1988, J NEUROCYTOL, V17, P573, DOI 10.1007/BF01189811; GRAEBER MB, 1988, NEUROSCI LETT, V85, P317, DOI 10.1016/0304-3940(88)90585-X; GRAEBER MB, 1988, J NEUROSCI RES, V21, P18, DOI 10.1002/jnr.490210104; GRAEBER MB, 1990, J NEUROIMMUNOL, V27, P121, DOI 10.1016/0165-5728(90)90061-Q; GREENFIELD JG, 1958, NEUROPATHOLOGY, P1; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; KETTENMANN H, 1984, NEUROSCI LETT, V52, P25, DOI 10.1016/0304-3940(84)90345-8; LANGAN TJ, 1992, BRAIN RES, V577, P200, DOI 10.1016/0006-8993(92)90275-E; MACVICAR BA, 1988, NEUROSCIENCE, V25, P721, DOI 10.1016/0306-4522(88)90272-2; MANSOUR H, 1990, J NEUROSCI RES, V25, P300, DOI 10.1002/jnr.490250306; MARTY S, 1991, NEUROSCIENCE, V45, P529, DOI 10.1016/0306-4522(91)90268-S; MCGEER PL, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P587; MILLER RH, 1986, J NEUROSCI, V6, P22; MORENOFLORES MT, 1993, GLIA, V7, P146, DOI 10.1002/glia.440070204; MURABE Y, 1981, CELL TISSUE RES, V218, P75; NADLER JV, 1978, NATURE, V271, P676, DOI 10.1038/271676a0; NIETOSAMPEDRO M, 1988, PHARM APPROACHES TRE, P331; NORTON WT, 1989, J NEUROSCI, V9, P769; OGAWA M, 1989, EXP NEUROL, V106, P187, DOI 10.1016/0014-4886(89)90093-9; OLNEY JW, 1978, KAINIC ACID TOOL NEU, P201; Paxinos G, 1986, RAT BRAIN STEREOTAXI; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; RAKIC P, 1981, TRENDS NEUROSCI, V4, P184, DOI 10.1016/0166-2236(81)90060-6; Reier P J, 1988, Adv Neurol, V47, P87; RIOHORTEGA DP, 1932, CYTOLOGY CELLULAR PA, V2, P481; ROBINSON AP, 1986, IMMUNOLOGY, V57, P239; SHAW G, 1981, EUR J CELL BIOL, V26, P68; SHIGEMATSU K, 1989, BRAIN RES, V501, P215, DOI 10.1016/0006-8993(89)90639-2; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SINGH VK, 1978, BRAIN RES, V155, P418, DOI 10.1016/0006-8993(78)91041-7; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; THOMAS WE, 1992, BRAIN RES REV, V17, P61; WILKIN GP, 1990, TRENDS NEUROSCI, V13, P43, DOI 10.1016/0166-2236(90)90065-I; WYLLIE DJA, 1991, J PHYSIOL-LONDON, V432, P235, DOI 10.1113/jphysiol.1991.sp018383; YONG VW, 1991, P NATL ACAD SCI USA, V88, P7016, DOI 10.1073/pnas.88.16.7016; [No title captured]	56	89	89	0	2	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012	0894-1491			GLIA	Glia	AUG	1993	8	4					277	291		10.1002/glia.440080408			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	LP872	WOS:A1993LP87200007	8406684				2022-02-06	
J	KARCZ, A; HOLBROOK, J; BURKE, MC; DOYLE, MJ; ERDOS, MS; FRIEDMAN, M; GREEN, ED; ISEKE, RJ; JOSEPHSON, GW; WILLIAMS, K				KARCZ, A; HOLBROOK, J; BURKE, MC; DOYLE, MJ; ERDOS, MS; FRIEDMAN, M; GREEN, ED; ISEKE, RJ; JOSEPHSON, GW; WILLIAMS, K			MASSACHUSETTS EMERGENCY-MEDICINE CLOSED MALPRACTICE CLAIMS - 1988-1990	ANNALS OF EMERGENCY MEDICINE			English	Article						MALPRACTICE; RISK MANAGEMENT		Study purpose: To describe the characteristics of malpractice claims against emergency physicians and to identify causes and potential preventability of such claims. Population: Malpractice claims closed in 1988, 1989, and 1990 against emergency physicians insured by the Massachusetts Joint Underwriters Association were compared with claims closed from 1980 to 1987 as investigated in our previous study. Methods: Retrospective review of malpractice claim files by board-certified emergency physicians. Results: The average indemnity and expense per claim were higher in the current study population than in our previous study population (P=.05). Claims in eight high-risk diagnostic areas (chest pain, abdominal pain, fractures, wounds, pediatric fever/meningitis, subarachnoid hemorrhage, aortic aneurysm, and epiglottitis) accounted for 50.8% of claims in this study and 55.5% of total monetary losses. Four claims in this study were related to two instances of failure of an emergency department radiograph follow-up system. The evaluation of patients who were intoxicated contributed to major monetary losses, especially in cases of fractures and head injury. Conclusion: Emergency physicians must have a particular awareness of their great risk exposure for missed myocardial infarction. Addition of dictation or voice-activated record generation systems, departmental protocols for radiograph follow-ups, and holding and re-evaluation of the intoxicated patient will help provide systems supports for reducing the liability of individual emergency physicians.			KARCZ, A (corresponding author), METROWEST MED CTR,DEPT EMERGENCY MED,FRAMINGHAM CAMPUS,FRAMINGHAM,MA 01701, USA.							0	89	90	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	MAR	1993	22	3					553	559		10.1016/S0196-0644(05)81941-9			7	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	KQ328	WOS:A1993KQ32800008	8442544				2022-02-06	
J	Xu, X; Yin, DP; Ren, HL; Gao, WW; Li, F; Sun, DD; Wu, YG; Zhou, S; Lyu, L; Yang, MC; Xiong, JH; Han, LL; Jiang, RC; Zhang, JM				Xu, Xin; Yin, Dongpei; Ren, Honglei; Gao, Weiwei; Li, Fei; Sun, Dongdong; Wu, Yingang; Zhou, Shuai; Lyu, Li; Yang, Mengchen; Xiong, Jianhua; Han, Lulu; Jiang, Rongcai; Zhang, Jianning			Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic updates brain injury	NEUROBIOLOGY OF DISEASE			English	Article						Traumatic brain injury; Neuroinflammation; NLRP3 inflammasome; Interleukin-1 beta; Microglia; MCC950	CEREBROSPINAL-FLUID; ACTIVATION; MICE; NEUROPROTECTION; DISRUPTION; DEFICITS; CORTEX	The nucleotide-binding oligomerization domain (NOD)-like receptor family pyrin domain containing 3 (NLRP3) inflammasome-mediated inflammatory response has emerged as a prominent contributor to the pathophysiological processes of traumatic brain injury (TBI). Recently, a potent, selective, small-molecule NLRP3 inflammasome inhibitor, MCC950, was described. Here, we investigated the effect of MCC950 on inflammatory brain injury and long-term neurological outcomes in a mouse model of TBI. Male C57/BL6 mice were subjected to TBI using the controlled cortical impact injury (CCI) system. Western blotting, flow cytometry, and immunofluorescence assays were utilized to analyze post-traumatic NLRP3 inflammasome expression and determine its cellular source. We found that NLRP3 inflammasome expression was significantly increased in the peri-contusional cortex and that microglia were the primary source of this expression. The effects of MCC950 on mice with TBI were then determined using post-assessments including analyses of neurological deficits, brain water content, traumatic lesion volume, neuroinflammation, blood-brain barrier (BBB) integrity, and cell death. MCC950 treatment resulted in a better neurological outcome after TBI by alleviating brain edema, reducing lesion volume, and improving long-term motor and cognitive functions. The therapeutic window for MCC950 against TBI was as long as 6 h. Furthermore, the neuroprotective effect of MCC950 was associated with reduced microglial activation, leukocyte recruitment, and pro-inflammatory cytokine production. In addition, MCC950 preserved BBB integrity, alleviated TBI-induced loss of tight junction proteins, and attenuated cell death. Notably, the efficacy of MCC950 was abolished in microglia-depleted mice. These results indicate that microglia-derived NLRP3 inflammasome may be primarily involved in the inflammatory response to TBI, and specific NLRP3 inflammasome inhibition using MCC950 may be a promising therapeutic approach for patients with TBI.	[Xu, Xin; Yin, Dongpei; Gao, Weiwei; Li, Fei; Sun, Dongdong; Wu, Yingang; Zhou, Shuai; Yang, Mengchen; Xiong, Jianhua; Jiang, Rongcai; Zhang, Jianning] Tianjin Med Univ, Dept Neurosurg, Gen Hosp, 154 Anshan Rd, Tianjin 300052, Peoples R China; [Xu, Xin; Yin, Dongpei; Ren, Honglei; Gao, Weiwei; Li, Fei; Sun, Dongdong; Wu, Yingang; Zhou, Shuai; Yang, Mengchen; Xiong, Jianhua; Han, Lulu; Jiang, Rongcai; Zhang, Jianning] Minist Educ & Tianjin City, Key Lab Postneuroinjury Neurorepair & Regenerat C, Tianjin Neurol Inst, 154 Anshan Rd, Tianjin 300052, Peoples R China; [Gao, Weiwei] Tianjin Huanhu Hosp, Dept Neurol, 6 Jizhao Rd, Tianjin 300350, Peoples R China; [Li, Fei] Tianjin Baodi Hosp, Dept Neurosurg, 8 Guangchuan Rd, Tianjin 301800, Peoples R China; [Lyu, Li] Tianjin Childrens Hosp, Dept Cardiovasc, 238 Longyan Rd, Tianjin 300074, Peoples R China		Jiang, RC; Zhang, JM (corresponding author), Tianjin Med Univ, Dept Neurosurg, Gen Hosp, 154 Anshan Rd, Tianjin 300052, Peoples R China.	jiang116216@163.com; jianningzhang@hotmail.com		Dongpei, Yin/0000-0003-2572-3689; Xu, Xin/0000-0003-3395-9923	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81330029, 81671380, 81502173, 81501055]; Natural Science Foundation of Tianjin CityNatural Science Foundation of Tianjin [17JCZDJC35900]; Tianjin Research Program of Application Foundation and Advanced Technology [16JCYBJC27200]; Tianjin Research Program [16PTSYJC00180]	The authors are grateful to Jing-fei Dong, Qiang Liu, Li Liu, Weiyun Cui, Fanglian Chen, and Lei Zhou from the Tianjin Neurological Institute for their excellent technical support. This work was supported by grants from the National Natural Science Foundation of China (grant 81330029, 81671380, 81502173, and 81501055), the Natural Science Foundation of Tianjin City (grant 17JCZDJC35900), the Tianjin Research Program of Application Foundation and Advanced Technology (grant 16JCYBJC27200), and the Tianjin Research Program (grant 16PTSYJC00180).	Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; da Fonseca ACC, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00362; Chen WQ, 2017, NAT MICROBIOL, V2, P1435, DOI 10.1038/s41564-017-0015-4; Cheng YJ, 2017, METAB BRAIN DIS, V32, P1133, DOI 10.1007/s11011-017-0003-7; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040; Gao L, 2017, INFLAMM RES, V66, P17, DOI 10.1007/s00011-016-0981-7; Gao WW, 2015, BRAIN RES, V1622, P230, DOI 10.1016/j.brainres.2015.04.035; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Gustin A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130624; Harrison JL, 2015, BRAIN BEHAV IMMUN, V47, P131, DOI 10.1016/j.bbi.2015.01.001; Irrera N, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00459; Ismael S, 2018, J NEUROTRAUM, V35, P1294, DOI 10.1089/neu.2017.5344; Jin WN, 2017, J CEREBR BLOOD F MET, V37, P2224, DOI 10.1177/0271678X17694185; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lee J, 2014, J TRAUMA ACUTE CARE, V77, P709, DOI 10.1097/TA.0000000000000445; Li MS, 2017, FASEB J, V31, P3278, DOI 10.1096/fj.201601377RR; Li MS, 2017, J CEREBR BLOOD F MET, V37, P2383, DOI 10.1177/0271678X16666551; Lin C, 2017, EXP NEUROL, V290, P115, DOI 10.1016/j.expneurol.2017.01.005; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Liu YL, 2017, ACTA PHARMACOL SIN, V38, P1445, DOI 10.1038/aps.2017.103; Ma J, 2016, INFLAMMATION, V39, P2094, DOI 10.1007/s10753-016-0446-8; Ma MW, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6057609; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Mortezaee K, 2018, J CELL PHYSIOL, V233, P5160, DOI 10.1002/jcp.26287; Mridha AR, 2017, J HEPATOL, V66, P1037, DOI 10.1016/j.jhep.2017.01.022; Netea MG, 2015, ANNU REV IMMUNOL, V33, P49, DOI 10.1146/annurev-immunol-032414-112306; Pan Y, 2014, BRAIN BEHAV IMMUN, V41, P90, DOI 10.1016/j.bbi.2014.04.007; Qian HH, 2017, MOL MED REP, V16, P3922, DOI 10.3892/mmr.2017.7079; Ren HL, 2018, STROKE, V49, P184, DOI 10.1161/STROKEAHA.117.018904; Sagulenko V, 2013, CELL DEATH DIFFER, V20, P1149, DOI 10.1038/cdd.2013.37; Simon DW, 2017, NAT REV NEUROL, V13, P572, DOI 10.1038/nrneurol.2017.116; Song LM, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00063; Szalay G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11499; Vaccari JPD, 2014, J CEREBR BLOOD F MET, V34, P369, DOI 10.1038/jcbfm.2013.227; van Hout GPJ, 2017, EUR HEART J, V38, P828, DOI 10.1093/eurheartj/ehw247; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wallisch JS, 2017, NEUROCRIT CARE, V27, P44, DOI 10.1007/s12028-017-0378-7; Wang XQ, 2014, NAT IMMUNOL, V15, P1126, DOI 10.1038/ni.3015; Wang ZX, 2016, MOL NEUROBIOL, V53, P1905, DOI 10.1007/s12035-015-9143-0; Wei X, 2016, J HUAZHONG U SCI-MED, V36, P576, DOI 10.1007/s11596-016-1628-1; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xu X, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0934-2; Yang L, 2017, METAB BRAIN DIS, V32, P1395, DOI 10.1007/s11011-017-9991-6; Yang XX, 2018, FASEB J, V32, P3336, DOI 10.1096/fj.201700833RR; Zhou KR, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/9238290; Zou P, 2018, MOL MED REP, V17, P3212, DOI 10.3892/mmr.2017.8241	48	88	93	4	42	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	SEP	2018	117						15	27		10.1016/j.nbd.2018.05.016			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GO8ZO	WOS:000440392100002	29859317				2022-02-06	
J	Szwajgier, D; Borowiec, K; Pustelniak, K				Szwajgier, Dominik; Borowiec, Kamila; Pustelniak, Katarzyna			The Neuroprotective Effects of Phenolic Acids: Molecular Mechanism of Action	NUTRIENTS			English	Article						cinnamic acids; benzoic acids; polyphenols; neuroprotection; neuroinflammation; central nervous system; neuron; glial cell; neurological disorder	CORD ISCHEMIA/REPERFUSION INJURY; MAJOR FOOD SOURCES; P-COUMARIC ACID; FERULIC ACID; CAFFEIC ACID; ROSMARINIC ACID; PHENETHYL ESTER; GALLIC ACID; CHLOROGENIC ACID; ELLAGIC ACID	The neuroprotective role of phenolic acids from food has previously been reported by many authors. In this review, the role of phenolic acids in ameliorating depression, ischemia/reperfusion injury, neuroinflammation, apoptosis, glutamate-induced toxicity, epilepsy, imbalance after traumatic brain injury, hyperinsulinemia-induced memory impairment, hearing and vision disturbances, Parkinson's disease, Huntington's disease, anti-amyotrophic lateral sclerosis, Chagas disease and other less distributed diseases is discussed. This review covers the in vitro, ex vivo and in vivo studies concerning the prevention and treatment of neurological disorders (on the biochemical and gene expression levels) by phenolic acids.	[Szwajgier, Dominik; Borowiec, Kamila; Pustelniak, Katarzyna] Univ Life Sci Lublin, Human Nutr & Sci Food Commod, Dept Biotechnol, PL-20704 Lublin, Poland		Borowiec, K (corresponding author), Univ Life Sci Lublin, Human Nutr & Sci Food Commod, Dept Biotechnol, PL-20704 Lublin, Poland.	dszwajgier@hotmail.com; kam.borowiec@gmail.com; kasia.pustus@wp.pl	Szwajgier, Dominik/ABD-6715-2021	Szwajgier, Dominik/0000-0002-2285-0669; Borowiec, Kamila/0000-0001-6795-8713	Ministry of Science and Higher Education of the Republic of PolandMinistry of Science and Higher Education, Poland [2339/B/P01/2010/38]; University of Life Sciences in Lublin; Polish Government	This scientific work was supported by the Ministry of Science and Higher Education of the Republic of Poland (Scientific Grant No. 2339/B/P01/2010/38) and the University of Life Sciences in Lublin, which is financed by the Polish Government.	Abou-Abbass H, 2016, ELECTROPHORESIS, V37, P1562, DOI 10.1002/elps.201500583; Akyol S, 2015, J INTERCULT ETHNOPHA, V4, P192, DOI 10.5455/jice.20150620024326; Alfredsson CF, 2015, BIOMED PHARMACOTHER, V76, P39, DOI 10.1016/j.biopha.2015.10.008; Alfredsson CF, 2014, BIOMED PHARMACOTHER, V68, P129, DOI 10.1016/j.biopha.2013.08.010; Alkis HE, 2015, INT J RADIAT RES, V13, P297, DOI 10.7508/ijrr.2015.04.002; Aseervatham GSB, 2016, BIOMED PHARMACOTHER, V82, P54, DOI 10.1016/j.biopha.2016.04.066; Ashafaq M., 2016, MOL NEUROBIOL; Ashafaq M, 2016, NEUROSCI LETT, V617, P94, DOI 10.1016/j.neulet.2016.02.001; Aswar M, 2016, INFLAMMOPHARMACOLOGY, V24, P181, DOI 10.1007/s10787-016-0272-5; [白俊鹏 Bai Junpeng], 2015, [中草药, Chinese Traditional and Herbal Drugs], V46, P163; Bak J, 2016, KOREAN J PHYSIOL PHA, V20, P279, DOI 10.4196/kjpp.2016.20.3.279; Balkhi HM, 2016, CNS NEUROL DISORD-DR, V15, P54, DOI 10.2174/1871527315666151110125435; Bhatt R, 2015, DRUG DELIV, V22, P931, DOI 10.3109/10717544.2014.880860; Blanchard HC, 2015, PROSTAG LEUKOTR ESS, V96, P25, DOI 10.1016/j.plefa.2015.01.002; Bourne LC, 1998, BIOCHEM BIOPH RES CO, V253, P222, DOI 10.1006/bbrc.1998.9681; Cao YD, 2016, INT J MOL MED, V38, P567, DOI 10.3892/ijmm.2016.2623; Cetin D, 2016, CYTOTECHNOLOGY, V68, P1361, DOI 10.1007/s10616-015-9896-3; Chang M X, 1993, Zhongguo Zhong Yao Za Zhi, V18, P300; Chang WC, 2015, FOOD RES INT, V77, P24, DOI 10.1016/j.foodres.2015.04.010; Chen JL, 2015, METAB BRAIN DIS, V30, P129, DOI 10.1007/s11011-014-9635-z; Chen SY, 2016, TROP J PHARM RES, V15, P241, DOI 10.4314/tjpr.v15i2.4; Coelho VR, 2016, N-S ARCH PHARMACOL, V389, P1195, DOI 10.1007/s00210-016-1281-z; Coelho VR, 2015, LIFE SCI, V122, P65, DOI 10.1016/j.lfs.2014.11.009; Crozier A, 2009, NAT PROD REP, V26, P1001, DOI 10.1039/b802662a; Andrade JMD, 2016, CHEM-BIOL INTERACT, V254, P135, DOI 10.1016/j.cbi.2016.06.005; Del Bo C, 2010, J AGR FOOD CHEM, V58, P2491, DOI 10.1021/jf903472x; Dong GC, 2015, MAT SCI ENG C-MATER, V49, P691, DOI 10.1016/j.msec.2015.01.030; Fang SQ, 2016, BIOMED PHARMACOTHER, V79, P254, DOI 10.1016/j.biopha.2016.02.018; Farbood Y, 2015, BASIC CLIN NEUROSCI, V6, P83; Fazili NA, 2015, BIOCHIMIE, V108, P178, DOI 10.1016/j.biochi.2014.11.011; Ferruzzi MG, 2009, J ALZHEIMERS DIS, V18, P113, DOI 10.3233/JAD-2009-1135; Fetoni AR, 2015, FREE RADICAL BIO MED, V85, P269, DOI 10.1016/j.freeradbiomed.2015.04.021; Ge LJ, 2015, ASIAN PAC J TROP MED, V8, P299, DOI 10.1016/S1995-7645(14)60334-5; Ginis Z, 2016, TOXICOL IND HEALTH, V32, P337, DOI 10.1177/0748233713500817; Grigoletto J, 2016, EPILEPSY BEHAV, V62, P27, DOI 10.1016/j.yebeh.2016.06.037; Grosso G, 2016, MATURITAS, V84, P11, DOI 10.1016/j.maturitas.2015.10.014; Grosso G, 2016, MOL NUTR FOOD RES, V60, P223, DOI 10.1002/mnfr.201500620; Grosso G, 2014, NUTRITION, V30, P1398, DOI 10.1016/j.nut.2014.04.012; dos Santos NAG, 2014, NEUROTOXICOLOGY, V45, P131, DOI 10.1016/j.neuro.2014.09.007; Gul Z, 2016, NEUROCHEM RES, V41, P2075, DOI 10.1007/s11064-016-1919-8; Guo YJ, 2015, LIFE SCI, V127, P12, DOI 10.1016/j.lfs.2015.01.036; Guven M, 2015, INFLAMMATION, V38, P2124, DOI 10.1007/s10753-015-0195-0; Guven M, 2015, INFLAMMATION, V38, P1986, DOI 10.1007/s10753-015-0179-0; Guven M, 2015, IRAN J BASIC MED SCI, V18, P356; Guven M, 2015, TURK J MED SCI, V45, P233, DOI 10.3906/sag-1402-71; Hajimoradi M, 2015, AVICENNA J PHYTOMEDI, V5, P288; He F, 2015, J CLIN NEUROSCI, V22, P83, DOI 10.1016/j.jocn.2014.05.038; HERRMANN K, 1989, CRIT REV FOOD SCI, V28, P315, DOI 10.1080/10408398909527504; Hsu SS, 2016, CHEM-BIOL INTERACT, V252, P61, DOI 10.1016/j.cbi.2016.04.010; Huang H, 2016, ACTA PHARMACOL SIN, V37, P1543, DOI 10.1038/aps.2016.88; Hwang ES, 2016, BIOCHEM BIOPH RES CO, V475, P44, DOI 10.1016/j.bbrc.2016.04.153; Ibero-Baraibar I, 2016, J NUTR, V146, p897S, DOI 10.3945/jn.115.222828; Ju DT, 2015, CHINESE J PHYSIOL, V58, P412, DOI 10.4077/CJP.2015.BAD340; Ju DT, 2015, AM J CHINESE MED, V43, P653, DOI 10.1142/S0192415X15500408; Khamse S, 2015, PHARM BIOL, V53, P1818, DOI 10.3109/13880209.2015.1010738; Khan M., 2015, CAFFEIC ACID BIOL PR; Khatri DK, 2016, INT J NUTR PHARM NEU, V6, P90, DOI [10.4103/2231-0738.179969, DOI 10.4103/2231-0738.179969]; Koh PO, 2015, NEUROSCI LETT, V588, P18, DOI 10.1016/j.neulet.2014.12.047; Kondo S, 2015, J FUNCT FOODS, V14, P758, DOI 10.1016/j.jff.2015.03.001; Lee AY, 2016, BIOMOL THER, V24, P338, DOI 10.4062/biomolther.2015.135; Lee CC, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/678487; Lenzi J, 2015, METAB BRAIN DIS, V30, P1453, DOI 10.1007/s11011-015-9725-6; Li GW, 2015, METAB BRAIN DIS, V30, P1505, DOI 10.1007/s11011-015-9704-y; Lin WC, 2015, IRAN J BASIC MED SCI, V18, P478; Liu HP, 2016, INT J CLIN EXP MED, V9, P12514; Liu QS, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600587; Liu XQ, 2016, NUTRITION, V32, P296, DOI 10.1016/j.nut.2015.09.009; Liu YM, 2017, PHYSIOL BEHAV, V169, P184, DOI 10.1016/j.physbeh.2016.12.003; Lowthian JA, 2016, CONTEMP CLIN TRIALS, V46, P60, DOI 10.1016/j.cct.2015.11.014; Luan HY, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-28; Mallik SB, 2016, NEUROSCI LETT, V632, P218, DOI 10.1016/j.neulet.2016.08.044; Mansouri MT, 2016, PHARM BIOL, V54, P1947, DOI 10.3109/13880209.2015.1137601; Margalef M, 2015, J NUTR BIOCHEM, V26, P987, DOI 10.1016/j.jnutbio.2015.04.006; Massocatto C. L., 2016, DIS ESOPHAGUS; Mattila P, 2006, J AGR FOOD CHEM, V54, P7193, DOI 10.1021/jf0615247; Mikami Y, 2015, LIFE SCI, V139, P69, DOI 10.1016/j.lfs.2015.08.005; Moghadas M, 2016, CELL J, V17, P659; Nagarajan S, 2015, PHARM BIOL, V53, P1591, DOI 10.3109/13880209.2014.993041; Naghizadeh B, 2015, DRUG RES, V65, P515, DOI 10.1055/s-0034-1377012; Neider D, 2016, NEUROPSYCH DIS TREAT, V12, P1711, DOI 10.2147/NDT.S107178; [宁巧庆 Ning Qiaoqing], 2016, [中草药, Chinese Traditional and Herbal Drugs], V47, P2497; Ojha S, 2015, DRUG DES DEV THER, V9, P5499, DOI 10.2147/DDDT.S90616; Oyagbemi Ademola Adetokunbo, 2016, Journal of Dietary Supplements, V13, P402, DOI 10.3109/19390211.2015.1103827; Pemminati S, 2015, INDIAN J PSYCHIAT, V57, pS125; Hung PV, 2016, CRIT REV FOOD SCI, V56, P25, DOI 10.1080/10408398.2012.708909; Fernandes FDP, 2014, BEHAV PHARMACOL, V25, P637, DOI 10.1097/FBP.0000000000000076; Qu L, 2016, AM J HEMATOL, V91, pE95; Rahbardar MG, 2017, BIOMED PHARMACOTHER, V86, P441, DOI 10.1016/j.biopha.2016.12.049; Ramanauskiene K, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1564257; RITSCHEL WA, 1989, METHOD FIND EXP CLIN, V11, P345; Roehrich ME, 2015, IMMUNOPHARM IMMUNOT, V37, P434, DOI 10.3109/08923973.2015.1081606; Rosinczuk J., 2015, BIOMED RES INT; Scalbert A, 2000, J NUTR, V130, p2073S, DOI 10.1093/jn/130.8.2073S; Scapagnini G, 2004, ANTIOXID REDOX SIGN, V6, P811, DOI 10.1089/ars.2004.6.811; Scapagnini G, 2002, MOL PHARMACOL, V61, P554, DOI 10.1124/mol.61.3.554; Semaming Y, 2015, APPL PHYSIOL NUTR ME, V40, P1078, DOI 10.1139/apnm-2015-0158; Sen HM, 2015, INFLAMMATION, V38, P1624, DOI 10.1007/s10753-015-0138-9; Shailasree S, 2015, MOL NEUROBIOL, V51, P119, DOI 10.1007/s12035-014-8700-2; Shan Y, 2016, J ALZHEIMERS DIS, V49, P829, DOI 10.3233/JAD-150486; Shang AJ, 2017, NUTR NEUROSCI, V20, P172, DOI 10.1080/1028415X.2015.1103460; Shen Y, 2016, CELL MOL BIOL, V62, P109; Song M, 2016, CELL MOL BIOL, V62, P50, DOI 10.14715/cmb/2016.62.6.9; Szwajgier D., 2017, CURR ALZHEI IN PRESS; Taram F, 2016, BRAIN RES, V1648, P69, DOI 10.1016/j.brainres.2016.07.028; Tarozzi A, 2007, NEUROSCI LETT, V424, P36, DOI 10.1016/j.neulet.2007.07.017; Thrash-Williams B, 2016, LIFE SCI, V154, P24, DOI 10.1016/j.lfs.2016.02.072; Tokmak M, 2015, INFLAMMATION, V38, P1969, DOI 10.1007/s10753-015-0177-2; Tresserra-Rimbau A, 2013, NUTR METAB CARDIOVAS, V23, P953, DOI 10.1016/j.numecd.2012.10.008; Tsai CF, 2015, INT J MOL SCI, V16, P5572, DOI 10.3390/ijms16035572; Tsai CP, 2015, J EPIDEMIOL, V25, P172, DOI 10.2188/jea.JE20140070; Tuzmen MN, 2015, TOXICOL MECH METHOD, V25, P120, DOI 10.3109/15376516.2014.997947; van de Kerkhof NWA, 2015, NEUROPSYCHOBIOLOGY, V71, P212, DOI 10.1159/000431095; Vauzour D, 2007, J AGR FOOD CHEM, V55, P2854, DOI 10.1021/jf063304z; Wang DJ, 2015, MOL NUTR FOOD RES, V59, P1025, DOI 10.1002/mnfr.201400544; Wang DL, 2016, ACTA CIR BRAS, V31, P143, DOI 10.1590/S0102-865020160020000010; Wang HY, 2015, NEUROCHEM RES, V40, P1655, DOI 10.1007/s11064-015-1646-6; Wang LY, 2016, MOL MED REP, V14, P3403, DOI 10.3892/mmr.2016.5586; Wu Jian-liang, 2015, Chinese Pharmacological Bulletin, V31, P97, DOI 10.3969/j.issn.1001-1978.2015.01.021; Wu JM, 2016, MOLECULES, V21, DOI 10.3390/molecules21030260; Wu K, 2014, J ETHNOPHARMACOL, V151, P1133, DOI 10.1016/j.jep.2013.12.027; Xu YX, 2015, NEUROCHEM INT, V91, P72, DOI 10.1016/j.neuint.2015.10.014; Xu Y, 2016, ONCOTARGET, V7, P20455, DOI 10.18632/oncotarget.7973; Yan JJ, 2001, BRIT J PHARMACOL, V133, P89, DOI 10.1038/sj.bjp.0704047; Yao Y, 2015, J ETHNOPHARMACOL, V162, P97, DOI 10.1016/j.jep.2014.12.047; Yi XY, 2017, J STROKE CEREBROVASC, V26, P352, DOI 10.1016/j.jstrokecerebrovasdis.2016.09.030; [尹雪 Yin Xue], 2015, [中草药, Chinese Traditional and Herbal Drugs], V46, P866; Zamora-Ros R, 2016, EUR J NUTR, V55, P1359, DOI 10.1007/s00394-015-0950-x; Zare K, 2015, METAB BRAIN DIS, V30, P205, DOI 10.1007/s11011-014-9604-6; Zhang LM, 2015, EXP THER MED, V9, P972, DOI 10.3892/etm.2014.2157; Zhang YJ, 2011, J ETHNOPHARMACOL, V136, P129, DOI 10.1016/j.jep.2011.04.023; Zhang ZJ, 2015, FREE RADICAL BIO MED, V84, P331, DOI 10.1016/j.freeradbiomed.2015.02.030; Zhao J, 2012, J NEUROTRAUM, V29, P1209, DOI 10.1089/neu.2011.1858	132	88	90	6	38	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2072-6643		NUTRIENTS	Nutrients	MAY	2017	9	5							477	10.3390/nu9050477			21	Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED)	Nutrition & Dietetics	EV8SU	WOS:000402054500055	28489058	Green Submitted, Green Published, gold			2022-02-06	
J	Woerman, AL; Aoyagi, A; Patel, S; Kazmi, SA; Lobach, I; Grinberg, LT; Mckee, AC; Seeley, WW; Olson, SH; Prusiner, SB				Woerman, Amanda L.; Aoyagi, Atsushi; Patel, Smita; Kazmi, Sabeen A.; Lobach, Iryna; Grinberg, Lea T.; McKee, Ann C.; Seeley, William W.; Olson, Steven H.; Prusiner, Stanley B.			Tau prions from Alzheimer's disease and chronic traumatic encephalopathy patients propagate in cultured cells	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						argyrophilic grain disease; corticobasal degeneration; Pick's disease; progressive supranuclear palsy; tauopathies	MICROTUBULE-ASSOCIATED PROTEIN; PAIRED HELICAL FILAMENTS; SHARE ANTIGENIC DETERMINANTS; FRONTOTEMPORAL DEMENTIA; TRANSGENIC MICE; NEUROFIBRILLARY TANGLES; PICKS-DISEASE; ABNORMAL PHOSPHORYLATION; BRAIN-INJURY; MOUSE-BRAIN	Tau prions are thought to aggregate in the central nervous system, resulting in neurodegeneration. Among the tauopathies, Alzheimer's disease (AD) is the most common, whereas argyrophilic grain disease (AGD), corticobasal degeneration (CBD), chronic traumatic encephalopathy (CTE), Pick's disease (PiD), and progressive supranuclear palsy (PSP) are less prevalent. Brain extracts from deceased individuals with PiD, a neurodegenerative disorder characterized by three-repeat (3R) tau prions, were used to infect HEK293T cells expressing 3R tau fused to yellow fluorescent protein (YFP). Extracts from AGD, CBD, and PSP patient samples, which contain four-repeat (4R) tau prions, were transmitted to HEK293T cells expressing 4R tau fused to YFP. These studies demonstrated that prion propagation in HEK cells requires isoform pairing between the infecting prion and the recipient substrate. Interestingly, tau aggregates in AD and CTE, containing both 3R and 4R isoforms, were unable to robustly infect either 3R-or 4R-expressing cells. However, AD and CTE prions were able to replicate in HEK293T cells expressing both 3R and 4R tau. Unexpectedly, increasing the level of 4R isoform expression alone supported the propagation of both AD and CTE prions. These results allowed us to determine the levels of tau prions in AD and CTE brain extracts.	[Woerman, Amanda L.; Aoyagi, Atsushi; Patel, Smita; Kazmi, Sabeen A.; Olson, Steven H.; Prusiner, Stanley B.] Univ Calif San Francisco, Inst Neurodegenerat Dis, Weill Inst Neurosci, San Francisco, CA 94143 USA; [Woerman, Amanda L.; Grinberg, Lea T.; Seeley, William W.; Olson, Steven H.; Prusiner, Stanley B.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Aoyagi, Atsushi] Daiichi Sankyo Co Ltd, Tokyo 1408710, Japan; [Lobach, Iryna] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Grinberg, Lea T.; Seeley, William W.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; [McKee, Ann C.] Boston Univ, Sch Med, Chron Traumat Encephalopathy Program, Alzheimers Dis Ctr, Boston, MA 02118 USA; [McKee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; [McKee, Ann C.] US Dept Vet Affairs, Vet Affairs Boston Healthcare Syst, Jamaica Plain, MA 02130 USA; [McKee, Ann C.] US Dept Vet Affairs, Med Ctr, Bedford, MA 01730 USA; [Prusiner, Stanley B.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA		Prusiner, SB (corresponding author), Univ Calif San Francisco, Inst Neurodegenerat Dis, Weill Inst Neurosci, San Francisco, CA 94143 USA.; Prusiner, SB (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.; Prusiner, SB (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	stanley.prusiner@ucsf.edu		Kazmi, Sabeen/0000-0002-3913-6170	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG002132, AG031220, AG023501, AG19724]; Daiichi SankyoDaiichi Sankyo Company Limited; Dana Foundation; Glenn Foundation; Sherman Fairchild Foundation; Tau Consortium; Consortium for Frontotemporal Dementia Research; Department of Veterans Affairs, National Institute of Neurological Disorders and Stroke, National Institute of Biomedical Imaging and Bioengineering [NS086559]; National Institute on Aging, Boston University Alzheimer's Disease Center [AG13846, 0572063345-5]; Concussion Legacy Foundation; Andlinger Foundation; World Wrestling Entertainment, Inc; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846, P01AG002132, P50AG023501, R37AG031220, P01AG019724] Funding Source: NIH RePORTER	We thank George A. Carlson for his thoughtful revisions and comments, and Brittany N. Dugger for microdissecting the CTE patient samples. This work was supported by NIH Grants AG002132 and AG031220, Daiichi Sankyo, Dana Foundation, Glenn Foundation, Sherman Fairchild Foundation, and a gift from the Rainwater Charitable Foundation. Control, AD, AGD, CBD, PiD, and PSP tissue samples were provided by the University of California, San Francisco, Neurodegenerative Disease Brain Bank, which is supported by NIH Grants AG023501 and AG19724 (to W.W.S.), Tau Consortium, and Consortium for Frontotemporal Dementia Research. CTE tissue samples were provided by the Boston University Alzheimer's Disease Center Chronic Traumatic Encephalopathy Center, which is supported by the Department of Veterans Affairs, National Institute of Neurological Disorders and Stroke, National Institute of Biomedical Imaging and Bioengineering (NS086559), National Institute on Aging, Boston University Alzheimer's Disease Center (AG13846; Supplement 0572063345-5), Concussion Legacy Foundation, Andlinger Foundation, and World Wrestling Entertainment, Inc. Additional control samples were provided by the University of Miami Brain Endowment Bank.	Ahmed Z, 2014, ACTA NEUROPATHOL, V127, P667, DOI 10.1007/s00401-014-1254-6; ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; BRION JP, 1985, ARCH BIOL, V96, P229; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; CARLSON GA, 1989, P NATL ACAD SCI USA, V86, P7475, DOI 10.1073/pnas.86.19.7475; CARLSON GA, 1994, P NATL ACAD SCI USA, V91, P5690, DOI 10.1073/pnas.91.12.5690; Clavaguera F, 2014, ACTA NEUROPATHOL, V127, P299, DOI 10.1007/s00401-013-1231-5; Clavaguera F, 2013, P NATL ACAD SCI USA, V110, P9535, DOI 10.1073/pnas.1301175110; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; Delacourte A, 1996, J NEUROPATH EXP NEUR, V55, P159, DOI 10.1097/00005072-199602000-00004; Dinkel PD, 2011, BIOCHEMISTRY-US, V50, P4330, DOI 10.1021/bi2004685; FLAMENT S, 1991, ACTA NEUROPATHOL, V81, P591, DOI 10.1007/BF00296367; FRASER H, 1973, J COMP PATHOL, V83, P29, DOI 10.1016/0021-9975(73)90024-8; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; Goedert M, 2015, SCIENCE, V349, DOI 10.1126/science.1255555; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Harada R, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6010007; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Iba M, 2015, ACTA NEUROPATHOL, V130, P349, DOI 10.1007/s00401-015-1458-4; Iba M, 2013, J NEUROSCI, V33, P1024, DOI 10.1523/JNEUROSCI.2642-12.2013; IQBAL K, 1986, LANCET, V2, P421; Jansen WJ, 2015, JAMA-J AM MED ASSOC, V313, P1924, DOI 10.1001/jama.2015.4668; Kfoury N, 2012, J BIOL CHEM, V287, P19440, DOI 10.1074/jbc.M112.346072; KIDD M, 1963, NATURE, V197, P192, DOI 10.1038/197192b0; Kim EJ, 2012, CEREB CORTEX, V22, P251, DOI 10.1093/cercor/bhr004; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; Kovacs GG, 2016, ACTA NEUROPATHOL, V131, P87, DOI 10.1007/s00401-015-1509-x; KSIEZAKREDING H, 1994, AM J PATHOL, V145, P1496; Lee VMY, 1999, NEURON, V24, P507, DOI 10.1016/S0896-6273(00)81106-X; Mackenzie IRA, 2010, ACTA NEUROPATHOL, V119, P1, DOI 10.1007/s00401-009-0612-2; Mair W, 2016, ANAL CHEM, V88, P3704, DOI 10.1021/acs.analchem.5b04509; Marquie M, 2015, ANN NEUROL, V78, P787, DOI 10.1002/ana.24517; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Morris M, 2015, NAT NEUROSCI, V18, P1183, DOI 10.1038/nn.4067; Nonaka T, 2010, J BIOL CHEM, V285, P34885, DOI 10.1074/jbc.M110.148460; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Peretz D, 2001, PROTEIN SCI, V10, P854, DOI 10.1110/ps.39201; POLLOCK NJ, 1986, LANCET, V2, P1211; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 2015, P NATL ACAD SCI USA, V112, pE5308, DOI 10.1073/pnas.1514475112; Prusiner SB, 2013, ANNU REV GENET, V47, P601, DOI 10.1146/annurev-genet-110711-155524; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Sander K, 2016, ALZHEIMERS DEMENT; Sanders DW, 2014, NEURON, V82, P1271, DOI 10.1016/j.neuron.2014.04.047; Serrano-Pozo A, 2016, J NEUROPATH EXP NEUR, V75, P516, DOI 10.1093/jnen/nlw026; Shively SB, 2016, LANCET NEUROL, V15, P944, DOI 10.1016/S1474-4422(16)30057-6; Stanford PM, 2004, J NEUROL, V251, P1098, DOI 10.1007/s00415-004-0489-x; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thomas SN, 2012, ACTA NEUROPATHOL, V123, P105, DOI 10.1007/s00401-011-0893-0; VONSATTEL JPG, 1995, J NEUROPATH EXP NEUR, V54, P42; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; Woerman AL, 2015, P NATL ACAD SCI USA, V112, pE4949, DOI 10.1073/pnas.1513426112; WOOD JG, 1986, P NATL ACAD SCI USA, V83, P4040, DOI 10.1073/pnas.83.11.4040; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010; Zhong Q, 2012, J BIOL CHEM, V287, P20711, DOI 10.1074/jbc.M112.364067; Zhukareva V, 2002, ANN NEUROL, V51, P730, DOI 10.1002/ana.10222; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	71	88	90	1	24	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	DEC 13	2016	113	50					E8187	E8196		10.1073/pnas.1616344113			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE6CQ	WOS:000389696700022	27911827	Green Published, Bronze			2022-02-06	
J	Wang, Y; Nelson, LD; LaRoche, AA; Pfaller, AY; Nencka, AS; Koch, KM; McCrea, MA				Wang, Yang; Nelson, Lindsay D.; LaRoche, Ashley A.; Pfaller, Adam Y.; Nencka, Andrew S.; Koch, Kevin M.; McCrea, Michael A.			Cerebral Blood Flow Alterations in Acute Sport-Related Concussion	JOURNAL OF NEUROTRAUMA			English	Article						arterial spin labeling; cerebral blood flow; concussion; MRI; recovery	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; FOOTBALL PLAYERS; HEAD-INJURY; HIGH-SCHOOL; PERFUSION; RECOVERY; MRI; AUTOREGULATION; RATS	Sport-related concussion (SRC) is a major health problem, affecting millions of athletes each year. While the clinical effects of SRC (e.g., symptoms and functional impairments) typically resolve within several days, increasing evidence suggests persistent neurophysiological abnormalities beyond the point of clinical recovery after injury. This study aimed to evaluate cerebral blood flow (CBF) changes in acute SRC, as measured using advanced arterial spin labeling (ASL) magnetic resonance imaging (MRI). We compared CBF maps assessed in 18 concussed football players (age, 17.8 +/- 1.5 years) obtained within 24 h and at 8 days after injury with a control group of 19 matched non-concussed football players. While the control group did not show any changes in CBF between the two time-points, concussed athletes demonstrated a significant decrease in CBF at 8 days relative to within 24 h. Scores on the clinical symptom (Sport Concussion Assessment Tool 3, SCAT3) and cognitive measures (Standardized Assessment of Concussion [SAC]) demonstrated significant impairment (vs. pre-season baseline levels) at 24 h (SCAT, p < 0.0001; SAC, p < 0.01) but returned to baseline levels at 8 days. Two additional computerized neurocognitive tests, the Automated Neuropsychological Assessment Metrics and Immediate Post-Concussion and Cognitive Testing, showed a similar pattern of changes. These data support the hypothesis that physiological changes persist beyond the point of clinical recovery after SRC. Our results also indicate that advanced ASL MRI methods might be useful for detecting and tracking the longitudinal course of underlying neurophysiological recovery from concussion.	[Wang, Yang; Nencka, Andrew S.; Koch, Kevin M.] Med Coll Wisconsin, Dept Radiol, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA; [Wang, Yang; Nencka, Andrew S.; Koch, Kevin M.] Med Coll Wisconsin, Dept Biophys, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA; [Nelson, Lindsay D.; LaRoche, Ashley A.; Pfaller, Adam Y.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Nelson, Lindsay D.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA		Wang, Y (corresponding author), Med Coll Wisconsin, Dept Radiol, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA.; Wang, Y (corresponding author), Med Coll Wisconsin, Dept Biophys, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA.	yangwang@mcw.edu	Koch, Kevin/AAD-6403-2021	LaRoche, Ashley/0000-0003-0197-0853	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000055] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000055] Funding Source: Medline		Alsop DC, 2015, MAGN RESON MED, V73, P102, DOI 10.1002/mrm.25197; Amin-Hanjani S, 2015, J CEREBR BLOOD F MET, V35, P312, DOI 10.1038/jcbfm.2014.203; [Anonymous], 2007, MMWR MORBID MORTAL W, V56, P733; Aslan S, 2010, MAGN RESON MED, V63, P765, DOI 10.1002/mrm.22245; Audenaert K., 2003, MED SCI MONITOR, V9, P112; Barr WB, 2012, BRAIN INJURY, V26, P58, DOI 10.3109/02699052.2011.608216; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Chen G, 2012, NEUROIMAGE, V60, P747, DOI 10.1016/j.neuroimage.2011.12.060; Chen YF, 2011, J MAGN RESON IMAGING, V33, P940, DOI 10.1002/jmri.22345; Choe MC, 2016, CURR PAIN HEADACHE R, V20, DOI 10.1007/s11916-016-0573-9; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Chow HM, 2013, P NATL ACAD SCI USA, V110, P10300, DOI 10.1073/pnas.1217691110; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Detre JA, 2009, CURR OPIN NEUROL, V22, P348, DOI 10.1097/WCO.0b013e32832d9505; Dijkhuizen RM, 2011, TRANSL STROKE RES, V2, P524, DOI 10.1007/s12975-011-0130-0; Doshi H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118061; Ellis Michael J., 2016, FRONTIERS NEUROLOGY, V7; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; Gardner AJ, 2015, BRIT J SPORT MED, V49, P1050, DOI 10.1136/bjsports-2014-093901; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859, DOI 10.1152/ajpheart.1997.272.6.H2859; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287, DOI 10.1152/ajpregu.1998.275.4.R1287; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Hammeke TA, 2013, J INT NEUROPSYCH SOC, V19, P863, DOI 10.1017/S1355617713000702; Hannawi Yousef, 2016, CURRENT NEUROLOGY NE, V16; Helmick K., 2006, DEFENSE VETERANS BRA; Iadecola C, 2007, NAT NEUROSCI, V10, P1369, DOI 10.1038/nn2003; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; King D, 2014, SPORTS MED, V44, P449, DOI 10.1007/s40279-013-0134-x; Kumar NS, 2014, AM J SPORT MED, V42, P2050, DOI 10.1177/0363546514539449; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Len TK, 2011, MED SCI SPORT EXER, V43, P2241, DOI 10.1249/MSS.0b013e3182249539; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Liu W, 2013, NMR BIOMED, V26, P651, DOI 10.1002/nbm.2910; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2014, PROG NEUROL SURG, V28, P112, DOI 10.1159/000358769; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McGoron Anthony J, 2008, BMC Med Imaging, V8, P4, DOI 10.1186/1471-2342-8-4; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Metting Z, 2014, BRAIN COGNITION, V86, P24, DOI 10.1016/j.bandc.2014.01.012; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; Nelson LD, 2015, AM J SPORT MED, V43, P2018, DOI 10.1177/0363546515587714; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Okonkwo OC, 2014, CEREB CORTEX, V24, P978, DOI 10.1093/cercor/bhs381; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Prabhu SP, 2011, CLIN SPORT MED, V30, P103, DOI 10.1016/j.csm.2010.09.003; RangeL-Castilla L, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E7; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schrader Harald, 2009, BMC Med Imaging, V9, P11, DOI 10.1186/1471-2342-9-11; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Strebel S, 1997, SURG NEUROL, V47, P128, DOI 10.1016/S0090-3019(96)00459-4; Tan CO, 2014, NEUROLOGY, V83, P1665, DOI 10.1212/WNL.0000000000000944; Vidorreta M, 2013, NEUROIMAGE, V66, P662, DOI 10.1016/j.neuroimage.2012.10.087; Wang DJJ, 2012, STROKE, V43, P1018, DOI 10.1161/STROKEAHA.111.631929; Wang JJ, 2003, MAGN RESON MED, V49, P796, DOI 10.1002/mrm.10437; Wang Y, 2016, J NEUROTRAUM, V33, P1227, DOI 10.1089/neu.2015.4072; Wang Y, 2015, DEV NEUROPSYCHOL, V40, P40, DOI 10.1080/87565641.2014.979927; Wang Y, 2011, NEUROIMAGE, V54, P1188, DOI 10.1016/j.neuroimage.2010.08.043; Wu WC, 2007, MAGN RESON MED, V58, P1020, DOI 10.1002/mrm.21403; Wu WC, 2010, MAGN RESON MED, V64, P1140, DOI 10.1002/mrm.22484; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yengo-Kahn AM, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15611; Zhang R, 2002, CIRCULATION, V106, P1814, DOI 10.1161/01.CIR.0000031798.07790.FE; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	79	88	88	0	41	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2016	33	13					1227	+		10.1089/neu.2015.4072			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DP2QY	WOS:000378336200389	26414315	Green Published			2022-02-06	
J	Mann, AP; Scodeller, P; Hussain, S; Joo, J; Kwon, E; Braun, GB; Molder, T; She, ZG; Kotamraju, VR; Ranscht, B; Krajewski, S; Teesalu, T; Bhatia, S; Sailor, MJ; Ruoslahti, E				Mann, Aman P.; Scodeller, Pablo; Hussain, Sazid; Joo, Jinmyoung; Kwon, Ester; Braun, Gary B.; Molder, Tarmo; She, Zhi-Gang; Kotamraju, Venkata Ramana; Ranscht, Barbara; Krajewski, Stan; Teesalu, Tambet; Bhatia, Sangeeta; Sailor, Michael J.; Ruoslahti, Erkki			A peptide for targeted, systemic delivery of imaging and therapeutic compounds into acute brain injuries	NATURE COMMUNICATIONS			English	Article							POROUS SILICON NANOPARTICLES; TRAUMATIC BRAIN; BARRIER DISRUPTION; CELL; SULFATE; MODELS; SILVER; EDEMA	Traumatic brain injury (TBI) is a major health and socio-economic problem, but no pharmacological agent is currently approved for the treatment of acute TBI. Thus, there is a great need for advances in this field. Here, we describe a short peptide (sequence CAQK) identified by in vivo phage display screening in mice with acute brain injury. The CAQK peptide selectively binds to injured mouse and human brain, and systemically injected CAQK specifically homes to sites of brain injury in mouse models. The CAQK target is a proteoglycan complex upregulated in brain injuries. Coupling to CAQK increased injury site accumulation of systemically administered molecules ranging from a drug-sized molecule to nanoparticles. CAQK-coated nanoparticles containing silencing oligonucleotides provided the first evidence of gene silencing in injured brain parenchyma by systemically administered siRNA. These findings present an effective targeting strategy for the delivery of therapeutics in clinical management of acute brain injuries.	[Mann, Aman P.; Scodeller, Pablo; Hussain, Sazid; Braun, Gary B.; She, Zhi-Gang; Kotamraju, Venkata Ramana; Ranscht, Barbara; Krajewski, Stan; Ruoslahti, Erkki] Sanford Burnham Prebys Med Discovery Inst, Canc Res Ctr, La Jolla, CA 92037 USA; [Scodeller, Pablo; Molder, Tarmo; Teesalu, Tambet] Univ Tartu, Inst Biomed & Translat Med, Canc Biol Lab, EE-50411 Tartu, Estonia; [Hussain, Sazid] AivoCode, La Jolla, CA 92037 USA; [Joo, Jinmyoung; Sailor, Michael J.] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; [Kwon, Ester; Bhatia, Sangeeta] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA; [Kwon, Ester; Bhatia, Sangeeta] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA; [Kwon, Ester; Bhatia, Sangeeta] MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; [Ruoslahti, Erkki] Univ Calif Santa Barbara, Ctr Nanomed, Santa Barbara, CA 93106 USA; [Ruoslahti, Erkki] Univ Calif Santa Barbara, Dept Cell Mol & Dev Biol, Santa Barbara, CA 93106 USA; [Joo, Jinmyoung] Univ Ulsan, Coll Med, Biomed Engn Res Ctr, Asan Med Ctr, Seoul 05505, South Korea		Ruoslahti, E (corresponding author), Sanford Burnham Prebys Med Discovery Inst, Canc Res Ctr, La Jolla, CA 92037 USA.; Ruoslahti, E (corresponding author), Univ Calif Santa Barbara, Ctr Nanomed, Santa Barbara, CA 93106 USA.; Ruoslahti, E (corresponding author), Univ Calif Santa Barbara, Dept Cell Mol & Dev Biol, Santa Barbara, CA 93106 USA.	ruoslahti@sbpdiscovery.org	Scodeller, Pablo/AAH-7694-2019; Sailor, Michael J/H-9044-2017	Scodeller, Pablo/0000-0003-0745-2467; Sailor, Michael J/0000-0002-4809-9826; Kwon, Ester/0000-0002-6335-9681	Defense Advanced Research Projects Agency (DARPA)United States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [HR0011-13-2-0017]; European Research CouncilEuropean Research Council (ERC)European Commission [291910]; Wellcome TrustWellcome TrustEuropean Commission [WT095077MA]; National Multiple Sclerosis Grant [RG-4666-A-2]; NSF SBIR Phase I grantNational Science Foundation (NSF)NSF - Directorate for Engineering (ENG) [1548490]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS047101]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA014051, P30CA030199] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047101] Funding Source: NIH RePORTER	We thank Drs Dieter Zimmermann and William Stallcup, for sharing reagents and for helpful discussions, and Guillermina Garcia for assistance in histology. We also thank Center for Neuroscience & Regenerative Medicine Brain Tissue Repository at the Uniformed Services University of the Health Sciences in Bethesda, MD for sharing human brain tissues. This work was supported by the Defense Advanced Research Projects Agency (DARPA) under Cooperative Agreement HR0011-13-2-0017. The findings and views expressed are those of the authors and do not reflect the official policy or position of the Department of Defense or the U.S. Government. T.T. was supported by grants from the European Research Council (No. 291910) and Wellcome Trust International Fellowship (WT095077MA). B.R. was funded by the National Multiple Sclerosis Grant RG-4666-A-2. S.H. was supported in part by NSF SBIR Phase I grant (1548490). UCSD School of Medicine Microscopy Core is supported by NINDS NS047101.	Asher RA, 2002, J NEUROSCI, V22, P2225, DOI 10.1523/JNEUROSCI.22-06-02225.2002; Bartlett DW, 2006, NUCLEIC ACIDS RES, V34, P322, DOI 10.1093/nar/gkj439; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Braun GB, 2014, NAT MATER, V13, P904, DOI [10.1038/NMAT3982, 10.1038/nmat3982]; Cai WB, 2008, NAT PROTOC, V3, P89, DOI 10.1038/nprot.2007.478; Chen YH, 2009, NAT MED, V15, P1215, DOI 10.1038/nm.2025; Chung K, 2013, NATURE, V497, P332, DOI 10.1038/nature12107; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Cunningham TL, 2014, J NEUROTRAUM, V31, P505, DOI 10.1089/neu.2013.2965; Dadosh T, 2009, MATER LETT, V63, P2236, DOI 10.1016/j.matlet.2009.07.042; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; Fan XM, 2007, PHARM RES-DORDR, V24, P868, DOI 10.1007/s11095-007-9238-z; Fukuda AM, 2013, GENES-BASEL, V4, P435, DOI 10.3390/genes4030435; Gu L, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3326; Hill JJ, 2012, P NATL ACAD SCI USA, V109, P9155, DOI 10.1073/pnas.1205697109; Hoffman JA, 2003, CANCER CELL, V4, P383, DOI 10.1016/S1535-6108(03)00273-3; Hussain S, 2014, SCI REP-UK, V4, DOI 10.1038/srep05232; Joo J, 2015, ACS NANO, V9, P6233, DOI 10.1021/acsnano.5b01594; Joo J, 2014, ADV FUNCT MATER, V24, P5688, DOI 10.1002/adfm.201400587; Kielian T, 2001, J IMMUNOL, V166, P4634, DOI 10.4049/jimmunol.166.7.4634; Kielian T, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-16; Krajewska M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024341; KUROIWA T, 1988, ACTA NEUROPATHOL, V76, P62, DOI 10.1007/BF00687681; Kwok JCF, 2012, INT J BIOCHEM CELL B, V44, P582, DOI 10.1016/j.biocel.2012.01.004; Lau LW, 2013, NAT REV NEUROSCI, V14, P722, DOI 10.1038/nrn3550; Nagahara AH, 2011, NAT REV DRUG DISCOV, V10, P209, DOI 10.1038/nrd3366; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Navarro JRG, 2013, ANALYST, V138, P583, DOI 10.1039/c2an36135c; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Park JH, 2009, NAT MATER, V8, P331, DOI [10.1038/NMAT2398, 10.1038/nmat2398]; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Pillai DR, 2009, J CEREBR BLOOD F MET, V29, P1846, DOI 10.1038/jcbfm.2009.106; Qin ZT, 2014, PART PART SYST CHAR, V31, P252, DOI 10.1002/ppsc.201300244; Ruoslahti E, 2002, NAT REV CANCER, V2, P83, DOI 10.1038/nrc724; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; Ruoslahti E, 2012, ADV MATER, V24, P3747, DOI 10.1002/adma.201200454; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Simberg D, 2007, P NATL ACAD SCI USA, V104, P932, DOI 10.1073/pnas.0610298104; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; STEWART PA, 1992, J NEUROSCI METH, V41, P75, DOI 10.1016/0165-0270(92)90125-W; Teesalu T, 2012, METHOD ENZYMOL, V503, P35, DOI 10.1016/B978-0-12-396962-0.00002-1; Teesalu T, 2009, P NATL ACAD SCI USA, V106, P16157, DOI 10.1073/pnas.0908201106; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407	44	88	91	9	77	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-1723			NAT COMMUN	Nat. Commun.	JUN	2016	7								11980	10.1038/ncomms11980			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ3NK	WOS:000379108800001	27351915	Green Published, Green Submitted, gold			2022-02-06	
J	Han, ZL; Chen, FL; Ge, XT; Tan, J; Lei, P; Zhang, JN				Han, Zhaoli; Chen, Fanglian; Ge, Xintong; Tan, Jin; Lei, Ping; Zhang, Jianning			miR-21 alleviated apoptosis of cortical neurons through promoting PTEN-Akt signaling pathway in vitro after experimental traumatic brain injury	BRAIN RESEARCH			English	Article						TBI; Neuron; miR-21; Apoptosis; PTEN; Akt	CELL APOPTOSIS; EXPRESSION; MICRORNA-21; PROTECTS; OVEREXPRESSION; INHIBITION; MECHANISM; RECOVERY; DAMAGE; STRESS	Traumatic brain injury (TBI) is a major cause of chronic disability and death in young adults worldwide. Multiple cellular, molecular and biochemical changes impact the development and outcome of TBI. Neuronal cell apoptosis, which is an important pathological change in secondary brain damage, is crucial to determine the functional recovery after TBI. miR-21, a widely-reported oncogene, which can reduce cell apoptosis in cancer, has been confirmed to be a pronounced up-regulated miRNA after TBI in animal model. Our study is designed to investigate whether miR-21 has the function of antiapoptosis in experimental TBI model in vitro and to explore the possible regulatory mechanism of miR-21 on neuronal apoptosis. The scratch cell injury was performed to mimic TBI-induced apoptosis in neurons, and miR-21 agomir/antagomir was transfected to up-/down-regulate the miR-21 level. Our data suggests that miR-21 can reduce the number of TUNEL-positive neurons. Meanwhile, miR-21 decreased the expression level of PTEN, and increased the phosphorylation of Akt significantly. In neurons transfected with miR-21 agomir, the expression of Bcl-2 was promoted while the caspase-3, caspase-9 and Bax level were down-regulated, which are crucially the downstream apoptosis-related proteins of PTEN-Akt signaling pathway. In conclusion, miR-21 can exert the function of reducing neuronal apoptosis through activating the PTEN-Akt signaling pathway. Our research provides new insights into the molecular mechanisms of neuronal apoptosis following TBI, which reminds that miR-21may be a potential therapeutic target for TBI treatment. (C) 2014 Published by Elsevier B.V.	[Han, Zhaoli; Chen, Fanglian; Ge, Xintong; Lei, Ping; Zhang, Jianning] Tianjin Med Univ, Tianjin Neurol Inst, Dept Neurosurg, Gen Hosp, Tianjin 300352, Peoples R China; [Tan, Jin; Lei, Ping] Tianjin Med Univ, Tianjin Inst Geriatr, Gen Hosp, Tianjin 300352, Peoples R China		Lei, P (corresponding author), Tianjin Med Univ, Tianjin Neurol Inst, Dept Neurosurg, Gen Hosp, Tianjin 300352, Peoples R China.	leiping1974@163.com	Ge, Xintong/X-4889-2019	Ge, Xintong/0000-0001-7153-952X	Tianjin Municipal Science and Technology Commission natural fund Project [13JCYBJC23700]; National Clinical Key Subject Construction Project of NHFPC Fund	This work was supported by Tianjin Municipal Science and Technology Commission natural fund Project (13JCYBJC23700) and National Clinical Key Subject Construction Project of NHFPC Fund.	Bao HJ, 2012, NEUROCHEM RES, V37, P2856, DOI 10.1007/s11064-012-0880-4; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Fluiter K, 2014, J IMMUNOL, V192, P2339, DOI 10.4049/jimmunol.1302793; Garcia-Junco-Clemente Pablo, 2014, Commun Integr Biol, V7, pe28358, DOI 10.4161/cib.28358; Glass C, 2011, MOL CELL BIOCHEM, V357, P135, DOI 10.1007/s11010-011-0883-5; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; Gwak HS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047449; Hong Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096212; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Ji Hui, 2013, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V25, P546, DOI 10.3760/cma.j.issn.2095-4352.2013.09.010; Kim GS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088962; Klawitter J, 2013, CARDIOVASC RES, V97, P66, DOI 10.1093/cvr/cvs302; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Liao CX, 2013, ONCOL RES, V21, P129, DOI 10.3727/096504013X13832473329999; Liu HZ, 2014, INT J MOL SCI, V15, P4007, DOI 10.3390/ijms15034007; Liu HX, 2014, NEUROSCI LETT, V569, P110, DOI 10.1016/j.neulet.2014.03.071; Liu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065431; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo XJ, 2013, ALCOHOL, V47, P481, DOI 10.1016/j.alcohol.2013.05.005; Ma YH, 2011, BRAIN RES BULL, V86, P441, DOI 10.1016/j.brainresbull.2011.07.007; Mao WF, 2014, INT J NEUROSCI, V124, P281, DOI 10.3109/00207454.2013.838236; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Ou YW, 2013, CANCER BIOL THER, V14, P45, DOI 10.4161/cbt.22627; Pan XA, 2010, CANCER BIOL THER, V10, P1224, DOI 10.4161/cbt.10.12.14252; Pont-Lezica Lorena, 2013, Methods Mol Biol, V1041, P55, DOI 10.1007/978-1-62703-520-0_7; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Ruan Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.47; Sabirzhanov B, 2012, J NEUROCHEM, V123, P542, DOI 10.1111/j.1471-4159.2012.07927.x; Shi L, 2010, BRAIN RES, V1352, P255, DOI 10.1016/j.brainres.2010.07.009; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Sun WF, 2014, INFLAMM RES, V63, P287, DOI 10.1007/s00011-013-0699-8; Tagawa H, 2013, CANCER SCI, V104, P801, DOI 10.1111/cas.12160; Truettner JS, 2013, BRAIN RES, V1533, P122, DOI 10.1016/j.brainres.2013.08.011; Umschwief G, 2010, J CEREBR BLOOD F MET, V30, P616, DOI 10.1038/jcbfm.2009.234; Wang GH, 2013, NEUROTHERAPEUTICS, V10, P124, DOI 10.1007/s13311-012-0157-2; Wang R, 2012, CHIN J INTEGR MED, V18, P934, DOI 10.1007/s11655-012-1297-z; Wei C, 2014, FREE RADICAL RES, V48, P282, DOI 10.3109/10715762.2013.865839; Wu FJ, 2013, J OLEO SCI, V62, P717, DOI 10.5650/jos.62.717; Wu XM, 2013, INT J CLIN EXP PATHO, V6, P1282; Xu XL, 2012, KIDNEY INT, V82, P1167, DOI 10.1038/ki.2012.241; Yang Q, 2014, MOL MED REP, V9, P2213, DOI 10.3892/mmr.2014.2068; Ye X, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004070; Yu D, 2014, J MOL NEUROSCI, V53, P242, DOI 10.1007/s12031-014-0293-8; Zeng J, 2013, EXP CLIN ENDOCR DIAB, V121, P425, DOI 10.1055/s-0033-1345169; Zhang H, 2013, INT J CLIN EXP MED, V6, P546; Zhao YB, 2012, EXP NEUROL, V237, P489, DOI 10.1016/j.expneurol.2012.07.004; Zou CS, 2013, NEUROCHEM INT, V62, P965, DOI 10.1016/j.neuint.2013.03.013	50	88	93	0	14	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 25	2014	1582						12	20		10.1016/j.brainres.2014.07.045			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AR1PM	WOS:000343357100002	25108037				2022-02-06	
J	King, LA; Horak, FB; Mancini, M; Pierce, D; Priest, KC; Chesnutt, J; Sullivan, P; Chapman, JC				King, Laurie A.; Horak, Fay B.; Mancini, Martina; Pierce, Donald; Priest, Kelsey C.; Chesnutt, James; Sullivan, Patrick; Chapman, Julie C.			Instrumenting the Balance Error Scoring System for Use With Patients Reporting Persistent Balance Problems After Mild Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain concussion; Brain injuries; Postural balance; Rehabilitation	SPORTS-RELATED CONCUSSION; HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; PARKINSONS-DISEASE; FOOTBALL PLAYERS; HEAD-INJURY; PERFORMANCE; ACCELEROMETER; IMPAIRMENT	Objective: To determine whether alterations to the Balance Error Scoring System (BESS), such as modified conditions and/or instrumentation, would improve the ability to correctly classify traumatic brain injury (TBI) status in patients with mild TBI with persistent self-reported balance complaints. Design: Cross-sectional study. Setting: Outpatient clinic. Participants: Subjects (n=13; age, 16.3 +/- 2y) with a recent history of concussion (mild TBI group) and demographically matched control subjects (n=13; age, 16.7 +/- 2y; control group). Interventions: Not applicable. Main Outcome Measures: Outcome measures included the BESS, modified BESS, instrumented BESS, and instrumented modified BESS. All subjects were tested on the noninstrumented BESS and modified BESS and were scored by visual observation of instability in 6 and 3 stance conditions, respectively. Instrumentation of these 2 tests used 1 inertial sensor with an accelerometer and gyroscope to quantify bidirectional body sway. Results: Scores from the BESS and the modified BESS tests were similar between groups. However, results from the instrumented measures using the inertial sensor were significantly different between groups. The instrumented modified BESS had superior diagnostic classification and the largest area under the curve when compared with the other balance measures. Conclusions: A concussion may disrupt the sensory processing required for optimal postural control, which was measured by sway during quiet stance. These results suggest that the use of portable inertial sensors may be useful in the move toward more objective and sensitive measures of balance control postconcussion, but more work is needed to increase sensitivity. (C) 2014 by the American Congress of Rehabilitation Medicine	[King, Laurie A.; Horak, Fay B.; Mancini, Martina; Priest, Kelsey C.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA; [Pierce, Donald] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent, Div Biostat, Portland, OR 97201 USA; [Chesnutt, James] Oregon Hlth & Sci Univ, Dept Sports Med, Portland, OR 97201 USA; [Chapman, Julie C.] DC Vet Affairs Med Ctr, War Related Illness & Injury Study Ctr, Washington, DC USA; [Sullivan, Patrick; Chapman, Julie C.] Georgetown Univ, Sch Med, Dept Neurol, Washington, DC USA		King, LA (corresponding author), Parkinson Ctr Oregon OP32, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	kingla@ohsu.edu	Priest, Kelsey/O-9359-2019	Priest, Kelsey/0000-0003-3929-8177; Mancini, Martina/0000-0002-4532-3984; King, Laurie/0000-0001-9802-4446	National Center for Medical Rehabilitation Research at the Eunice Kennedy Shriver National Institute of Child Health and Human Development; Center for Translation of Rehabilitation Engineering Advances and Technology [NIH R24HD065703]; Oregon Clinical and Translational Research Institute from the National Center for Advancing Translational Sciences at the National Institutes of Health [UL1TR000128, KL2TR000152]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD065703] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000128, KL2TR000152] Funding Source: NIH RePORTER	Supported by the National Center for Medical Rehabilitation Research at the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Center for Translation of Rehabilitation Engineering Advances and Technology (grant no. NIH R24HD065703); the Oregon Clinical and Translational Research Institute (grant nos. UL1TR000128 and KL2TR000152) from the National Center for Advancing Translational Sciences at the National Institutes of Health.	Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; [Anonymous], 2012, NIH BALANCE TOOLBOX; [Anonymous], 2013, APDM MOVEMENT MONITO; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2009, J ATHL TRAINING, V44, P497, DOI 10.4085/1062-6050-44.5.497; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Furman GR, 2013, AM J SPORT MED, V41, P1404, DOI 10.1177/0363546513484446; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Herdman SJ, 1994, CURR OPIN NEUROL, V13, P3; Horak F., 1996, HDB PHYSL EXERCISE R, DOI 10.1002/cphy.cp120107; Iverson GL, 2013, BRAIN INJURY, V27, P596, DOI 10.3109/02699052.2013.772237; Janes H, 2009, STATA J, V9, P17, DOI 10.1177/1536867X0900900102; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Mak MK, 2003, ARCH PHYS MED REHAB, V84, P683, DOI 10.1016/S0003-9993(03)04810-4; Mancini M, 2012, J BIOENG BIOMED SCI, VS1; Mancini M, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-59; Mancini M, 2011, PARKINSONISM RELAT D, V17, P557, DOI 10.1016/j.parkreldis.2011.05.010; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; Mulligan IJ, 2013, SPORTS HEALTH, V5, P22, DOI 10.1177/1941738112467755; Palmerini L, 2013, IEEE T NEUR SYS REH, V21, P664, DOI 10.1109/TNSRE.2012.2236577; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Spain RI, 2012, GAIT POSTURE, V35, P573, DOI 10.1016/j.gaitpost.2011.11.026; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Weiss A, 2011, PHYSIOL MEAS, V32, P2003, DOI 10.1088/0967-3334/32/12/009; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020; Wilkins JC, 2004, J ATHL TRAINING, V39, P156	36	88	88	2	30	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2014	95	2					353	359		10.1016/j.apmr.2013.10.015			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	AA2LW	WOS:000330927100021	24200875	Green Accepted			2022-02-06	
J	Liu, Q; Qiu, J; Liang, M; Golinski, J; van Leyen, K; Jung, JE; You, Z; Lo, EH; Degterev, A; Whalen, MJ				Liu, Q.; Qiu, J.; Liang, M.; Golinski, J.; van Leyen, K.; Jung, J. E.; You, Z.; Lo, E. H.; Degterev, A.; Whalen, M. J.			Akt and mTOR mediate programmed necrosis in neurons	CELL DEATH & DISEASE			English	Article						necroptosis; neuron; Akt; mTOR; RIPK1; RIPK3	CONTROLLED CORTICAL IMPACT; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; AUTOPHAGIC CELL-DEATH; MIXED LINEAGE KINASE; NF-KAPPA-B; TRANSCRIPTION FACTORS; INDUCED ACTIVATION; REACTIVE OXYGEN; RIP1 KINASE	Necroptosis is a newly described form of regulated necrosis that contributes to neuronal death in experimental models of stroke and brain trauma. Although much work has been done elucidating initiating mechanisms, signaling events governing necroptosis remain largely unexplored. Akt is known to inhibit apoptotic neuronal cell death. Mechanistic target of rapamycin (mTOR) is a downstream effector of Akt that controls protein synthesis. We previously reported that dual inhibition of Akt and mTOR reduced acute cell death and improved long term cognitive deficits after controlled-cortical impact in mice. These findings raised the possibility that Akt/mTOR might regulate necroptosis. To test this hypothesis, we induced necroptosis in the hippocampal neuronal cell line HT22 using concomitant treatment with tumor necrosis factor alpha (TNF alpha) and the pan-caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone. TNF alpha/zVAD treatment induced cell death within 4 h. Cell death was preceded by RIPK1-RIPK3-pAkt assembly, and phosphorylation of Thr-308 and Thr473 of AKT and its direct substrate glycogen synthase kinase-beta b, as well as mTOR and its direct substrate S6 ribosomal protein (S6), suggesting activation of Akt/mTOR pathways. Pretreatment with Akt inhibitor viii and rapamycin inhibited Akt and S6 phosphorylation events, mitochondrial reactive oxygen species production, and necroptosis by over 50% without affecting RIPK1-RIPK3 complex assembly. These data were confirmed using small inhibitory ribonucleic acid-mediated knockdown of AKT1/2 and mTOR. All of the aforementioned biochemical events were inhibited by necrostatin-1, including Akt and mTOR phosphorylation, generation of oxidative stress, and RIPK1-RIPK3-pAkt complex assembly. The data suggest a novel, heretofore unexpected role for Akt and mTOR downstream of RIPK1 activation in neuronal cell death.	[Liu, Q.; Qiu, J.; Liang, M.; Golinski, J.; Whalen, M. J.] Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Charlestown, MA 02129 USA; [Liu, Q.; Qiu, J.; Liang, M.; Golinski, J.; van Leyen, K.; Jung, J. E.; Lo, E. H.; Whalen, M. J.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA; [Liu, Q.; Qiu, J.; Liang, M.; Golinski, J.; van Leyen, K.; Jung, J. E.; Lo, E. H.; Whalen, M. J.] Massachusetts Gen Hosp, Ctr Neurosci, Charlestown, MA 02129 USA; [Liu, Q.] Fudan Univ, Shanghai Med Coll, Dept Anat Histol & Embryol, Shanghai 200433, Peoples R China; [Liang, M.] Fudan Univ, Huashan Hosp, Dept Rheumatol, Shanghai 200433, Peoples R China; [van Leyen, K.; Jung, J. E.; Lo, E. H.] Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Neurol, Charlestown, MA 02129 USA; [van Leyen, K.; Jung, J. E.; Lo, E. H.] Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Radiol, Charlestown, MA 02129 USA; [You, Z.; Degterev, A.] Tufts Univ, Sackler Sch Grad Biomed Sci, Dept Biochem, Boston, MA 02111 USA		Whalen, MJ (corresponding author), Massachusetts Gen Hosp, Dept Pediat Crit Care Med, 149 13th St, Charlestown, MA 02129 USA.	MWhalen@Partners.org	van Leyen, Klaus/C-9126-2013	van Leyen, Klaus/0000-0003-1032-3754	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5RO1NSO64545]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31371083]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049430] Funding Source: NIH RePORTER	This work was supported by NIH/NINDS 5RO1NSO64545 (MJW) and National Natural Science Foundation of China grant 31371083.	Aki T, 2003, ONCOGENE, V22, P8529, DOI 10.1038/sj.onc.1207197; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037; Christofferson DE, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.64; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; Friguls B, 2002, NEUROBIOL DIS, V11, P443, DOI 10.1006/nbdi.2002.0553; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Kalyanaraman B, 2012, FREE RADICAL BIO MED, V52, P1, DOI 10.1016/j.freeradbiomed.2011.09.030; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kilic E, 2005, FASEB J, V19, P2026, DOI 10.1096/fj.05-3941fje; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Kim YS, 2007, MOL CELL, V26, P675, DOI 10.1016/j.molcel.2007.04.021; Kitagawa H, 1999, NEUROSCI LETT, V274, P45, DOI 10.1016/S0304-3940(99)00676-X; Komandirov MA, 2011, J MOL NEUROSCI, V45, P229, DOI 10.1007/s12031-011-9499-1; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Laird MD, 2008, FREE RADICAL BIO MED, V45, P1103, DOI 10.1016/j.freeradbiomed.2008.07.003; Li F, 2003, BRAIN RES, V962, P21, DOI 10.1016/S0006-8993(02)03774-5; Li YL, 2008, NEUROSCI LETT, V447, P120, DOI 10.1016/j.neulet.2008.08.037; Los M, 2009, BIOESSAYS, V31, P492, DOI 10.1002/bies.200900005; Lu B, 2006, J IMMUNOL, V176, P6785, DOI 10.4049/jimmunol.176.11.6785; Maddika S, 2008, ONCOGENE, V27, P3060, DOI 10.1038/sj.onc.1210958; Maddika S, 2007, CELL PROLIFERAT, V40, P835, DOI 10.1111/j.1365-2184.2007.00475.x; Maddika S, 2008, J CELL SCI, V121, P979, DOI 10.1242/jcs.009530; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; McNamara CR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056576; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Nimbalkar D, 2003, CANCER RES, V63, P1034; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Northington FJ, 2011, J CEREBR BLOOD F MET, V31, P178, DOI 10.1038/jcbfm.2010.72; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; O'Donnell MA, 2012, IMMUNOL RES, V54, P214, DOI 10.1007/s12026-012-8321-7; Ohba N, 2004, NEUROSCI LETT, V359, P159, DOI 10.1016/j.neulet.2004.02.029; Park J, 2012, J CEREBR BLOOD F MET, V32, P330, DOI 10.1038/jcbfm.2011.131; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Rosenbaum DM, 2010, J NEUROSCI RES, V88, P1569, DOI 10.1002/jnr.22314; Shack S, 2003, MOL CELL BIOL, V23, P2407, DOI 10.1128/MCB.23.7.2407-2414.2003; Shioda N, 2007, NEUROSCIENCE, V148, P221, DOI 10.1016/j.neuroscience.2007.05.040; Song YS, 2008, J CEREBR BLOOD F MET, V28, P1917, DOI 10.1038/jcbfm.2008.80; Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031; Teng X, 2005, BIOORG MED CHEM LETT, V15, P5039, DOI 10.1016/j.bmcl.2005.07.077; van Leyen K, 2008, J NEUROSCI RES, V86, P904, DOI 10.1002/jnr.21543; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; Wang HY, 2009, BRAIN RES, V1297, P177, DOI 10.1016/j.brainres.2009.08.054; Wang ZG, 2012, CELL, V148, P228, DOI 10.1016/j.cell.2011.11.030; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Yamanaka K, 2011, J BIOL CHEM, V286, P24666, DOI 10.1074/jbc.M111.236273; Yigitkanli K, 2013, ANN NEUROL, V73, P129, DOI 10.1002/ana.23734; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308; Zhang XP, 2006, J CEREBR BLOOD F MET, V26, P915, DOI 10.1038/sj.jcbfm.9600238; Zhao J, 2012, P NATL ACAD SCI USA, V109, P5322, DOI 10.1073/pnas.1200012109	57	88	91	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	FEB	2014	5								e1038	10.1038/cddis.2014.69			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	AC0ZJ	WOS:000332223700041	24577082	Green Published, gold			2022-02-06	
J	Gao, K; Wang, CR; Jiang, F; Wong, AYK; Su, N; Jiang, JH; Chai, RC; Vatcher, G; Teng, JL; Chen, JG; Jiang, YW; Yu, ACH				Gao, Kai; Wang, Chen Ran; Jiang, Feng; Wong, Ann Yuen Kwan; Su, Na; Jiang, Jiao Hua; Chai, Rui Chao; Vatcher, Greg; Teng, Junlin; Chen, Jianguo; Jiang, Yu-Wu; Yu, Albert Cheung Hoi			Traumatic Scratch Injury in Astrocytes Triggers Calcium Influx to Activate the JNK/c-Jun/AP-1 Pathway and Switch on GFAP Expression	GLIA			English	Article						calcium wave; JNK; astrogliosis; glial fibrillary acidic protein; glial scar	FIBRILLARY ACIDIC PROTEIN; REACTIVE GLIOSIS; IN-VITRO; RAT-BRAIN; UP-REGULATION; GLIAL-CELLS; CULTURED ASTROCYTES; MMP-9 EXPRESSION; GENE-EXPRESSION; ASTROGLIOSIS	Astrocyte activation is a hallmark of central nervous system injuries resulting in glial scar formation (astrogliosis). The activation of astrocytes involves metabolic and morphological changes with complex underlying mechanisms, which should be defined to provide targets for astrogliosis intervention. Astrogliosis is usually accompanied by an upregulation of glial fibrillary acidic protein (GFAP). Using an in vitro scratch injury model, we scratched primary cultures of cerebral cortical astrocytes and observed an influx of calcium in the form of waves spreading away from the wound through gap junctions. Using the calcium blocker BAPTA-AM and the JNK inhibitor SP600125, we demonstrated that the calcium wave triggered the activation of JNK, which then phosphorylated the transcription factor c-Jun to facilitate the binding of AP-1 to the GFAP gene promoter to switch on GFAP upregulation. Blocking calcium mobilization with BAPTA-AM in an in vivo stab wound model reduced GFAP expression and glial scar formation, showing that the calcium signal, and the subsequent regulation of downstream signaling molecules, plays an essential role in brain injury response. Our findings demonstrated that traumatic scratch injury to astrocytes triggered a calcium influx from the extracellular compartment and activated the JNK/c-Jun/AP-1 pathway to switch on GFAP expression, identifying a previously unreported signaling cascade that is important in astrogliosis and the physiological response following brain injury.	[Gao, Kai; Wang, Chen Ran; Jiang, Feng; Wong, Ann Yuen Kwan; Su, Na; Jiang, Jiao Hua; Chai, Rui Chao; Vatcher, Greg; Yu, Albert Cheung Hoi] Peking Univ, Natl Hlth & Family Planning Commiss, Sch Basic Med Sci,Hlth Sci Ctr, Neurosci Res Inst,Minist Educ,Key Lab Neurosci,De, Beijing 100191, Peoples R China; [Teng, Junlin; Chen, Jianguo] Peking Univ, Coll Life Sci, Minist Educ, State Key Lab Biomembrane & Membrane Bioengn, Beijing 100191, Peoples R China; [Teng, Junlin; Chen, Jianguo] Peking Univ, Coll Life Sci, Minist Educ, Key Lab Cell Proliferat & Differentiat, Beijing 100191, Peoples R China; [Jiang, Yu-Wu] Peking Univ, Hosp 1, Dept Pediat, Beijing 100191, Peoples R China; [Yu, Albert Cheung Hoi] Peking Univ, Inst Syst Biomed, Lab Translat Med, Beijing 100191, Peoples R China		Yu, ACH (corresponding author), Peking Univ, Neurosci Res Inst, 38 Xue Yuan Rd, Beijing 100191, Peoples R China.	achy@hsc.pku.edu.cn	wang, chenran/N-6629-2013; Chai, Ruichao/AAF-3361-2020		Beijing Natural Science FoundationBeijing Natural Science Foundation [7091004]; National Basic Research Program of China (973 program)National Basic Research Program of China [2011CB504400]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30870818, 31070974, 31171009]; Foundation for Innovative Research Groups of the National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81221002]	Grant sponsor: Beijing Natural Science Foundation; Grant number: 7091004; Grant sponsor: National Basic Research Program of China (973 program); Grant number: 2011CB504400; Grant sponsor: National Natural Science Foundation of China; Grant numbers: 30870818, 31070974, and 31171009; Grant sponsor: Foundation for Innovative Research Groups of the National Natural Science Foundation of China; Grant number: 81221002.	Arcuino G, 2002, P NATL ACAD SCI USA, V99, P9840, DOI 10.1073/pnas.152588599; Bachetti T, 2010, ANN HUM GENET, V74, P506, DOI 10.1111/j.1469-1809.2010.00614.x; Baumgart EV, 2012, GLIA, V60, P343, DOI 10.1002/glia.22269; Buira SP, 2010, J NEUROCHEM, V115, P283, DOI 10.1111/j.1471-4159.2010.06928.x; Carbonell WS, 2003, J NEUROTRAUM, V20, P327, DOI 10.1089/089771503765172282; Cebolla B, 2006, J NEUROCHEM, V97, P1057, DOI 10.1111/j.1471-4159.2006.03804.x; Cebolla B, 2008, J NEUROSCI, V28, P6703, DOI 10.1523/JNEUROSCI.0215-08.2008; Chai RC, 2013, GLIA, V61, P1748, DOI 10.1002/glia.22555; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; Chen XQ, 2005, J CEREBR BLOOD F MET, V25, P338, DOI 10.1038/sj.jcbfm.9600032; Chun JT, 2004, EXP NEUROL, V185, P109, DOI 10.1016/j.expneurol.2003.09.019; Ciccarelli R, 2004, EUR J NEUROSCI, V20, P1514, DOI 10.1111/j.1460-9568.2004.03613.x; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; Du S, 1999, EXP NEUROL, V157, P96, DOI 10.1006/exnr.1999.7041; Ebrahimi F, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-89; El-Hage N, 2005, GLIA, V50, P91, DOI 10.1002/glia.20148; Eng DL, 1997, BRAIN RES, V778, P215, DOI 10.1016/S0006-8993(97)01093-7; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; FaberElman A, 1996, J CLIN INVEST, V97, P162, DOI 10.1172/JCI118385; Fiacco TA, 2006, GLIA, V54, P676, DOI 10.1002/glia.20396; Fields RD, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3147tr5; FINKBEINER S, 1992, NEURON, V8, P1101, DOI 10.1016/0896-6273(92)90131-V; Flint D, 2012, HUM MUTAT, V33, P1141, DOI 10.1002/humu.22094; Gadea A, 2008, J NEUROSCI, V28, P2394, DOI 10.1523/JNEUROSCI.5652-07.2008; GHIRNIKAR RS, 1994, J NEUROSCI RES, V38, P376, DOI 10.1002/jnr.490380403; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Ghirnikar RS, 1996, J NEUROSCI RES, V46, P727; GIMPL G, 1992, NEUROSCI LETT, V144, P139, DOI 10.1016/0304-3940(92)90735-P; Givogri MI, 2006, DEV NEUROSCI-BASEL, V28, P81, DOI 10.1159/000090755; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Gopalan SM, 2006, J BIOL CHEM, V281, P1956, DOI 10.1074/jbc.M510935200; GRAMSBERGEN JBP, 1994, BRAIN RES, V667, P216, DOI 10.1016/0006-8993(94)91499-0; Hassinger TD, 1996, P NATL ACAD SCI USA, V93, P13268, DOI 10.1073/pnas.93.23.13268; Hebert MA, 2000, ANN NY ACAD SCI, V914, P238, DOI 10.1111/j.1749-6632.2000.tb05200.x; Homkajorn B, 2010, NEUROSCI LETT, V486, P197, DOI 10.1016/j.neulet.2010.09.051; Hsuchou H, 2012, J MOL NEUROSCI, V47, P267, DOI 10.1007/s12031-012-9734-4; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Hwang J, 2010, J NEUROIMMUNOL, V226, P66, DOI 10.1016/j.jneuroim.2010.05.037; Jin MM, 2011, NEUROSCI BULL, V27, P389, DOI 10.1007/s12264-011-1944-1; Jung CS, 2007, BRAIN, V130, P3336, DOI 10.1093/brain/awm263; Kalman M, 2013, J EXP ZOOL PART B, V320, P351, DOI 10.1002/jez.b.22505; Kam AYF, 2007, CELL SIGNAL, V19, P2106, DOI 10.1016/j.cellsig.2007.06.005; Kaminska B, 2009, ANAT REC, V292, P1902, DOI 10.1002/ar.21047; Kanemaru K, 2013, P NATL ACAD SCI USA, V110, P11612, DOI 10.1073/pnas.1300378110; Katano H, 1999, NEUROREPORT, V10, P2439, DOI 10.1097/00001756-199908200-00002; Kleinman MT, 2008, TOXICOL LETT, V178, P127, DOI 10.1016/j.toxlet.2008.03.001; Kornyei Z, 2000, J NEUROSCI RES, V61, P421, DOI 10.1002/1097-4547(20000815)61:4<421::AID-JNR8>3.0.CO;2-4; Lanosa XA, 2007, IN VITRO CELL DEV-AN, V43, P186, DOI 10.1007/s11626-007-9038-0; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; Leung YKJ, 2010, EXP NEUROL, V221, P98, DOI 10.1016/j.expneurol.2009.10.006; Liedtke W, 1996, NEURON, V17, P607, DOI 10.1016/S0896-6273(00)80194-4; Lim JH, 2007, BRAIN RES, V1164, P1, DOI 10.1016/j.brainres.2007.06.020; Lin HW, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-15; Liu C, 2011, CELL MOL NEUROBIOL, V31, P259, DOI 10.1007/s10571-010-9616-7; Lu DC, 2011, J NEUROTRAUM; Lu J, 2013, P NATL ACAD SCI USA, V110, P10747, DOI 10.1073/pnas.1308950110; MacFarlane SN, 1997, J NEUROSCI, V17, P7316; Malhotra SK, 1997, CYTOBIOS, V89, P115; MASOOD K, 1993, J NEUROCHEM, V61, P160, DOI 10.1111/j.1471-4159.1993.tb03551.x; McCall MA, 1996, P NATL ACAD SCI USA, V93, P6361, DOI 10.1073/pnas.93.13.6361; Miller G, 2005, SCIENCE, V308, P778, DOI 10.1126/science.308.5723.778; Molnar T, 2011, BMC NEUROSCI, V3, P96; Morga E, 2009, GLIA, V57, P1741, DOI 10.1002/glia.20887; MOUMDJIAN RA, 1991, BRAIN RES, V547, P223, DOI 10.1016/0006-8993(91)90965-X; Nawashiro H, 1998, NEUROREPORT, V9, P1691, DOI 10.1097/00001756-199806010-00004; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; Newman EA, 1998, J NEUROSCI, V18, P4022; Nicole O, 2005, J NEUROSCI, V25, P4319, DOI 10.1523/JNEUROSCI.5200-04.2005; O'Toole DA, 2007, CELL MOL LIFE SCI, V64, P1303, DOI 10.1007/s00018-007-7106-y; Pan H, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/217580; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; PENNYPACKER KR, 1994, J NEUROSCI, V14, P3998; Perez-Ortiz JM, 2008, EUR J NEUROSCI, V27, P2453, DOI 10.1111/j.1460-9568.2008.06197.x; Puschmann TB, 2010, NEUROSIGNALS, V18, P152, DOI 10.1159/000321494; Raivich G, 2006, PROG NEUROBIOL, V78, P347, DOI 10.1016/j.pneurobio.2006.03.006; Ransom BR, 2012, METHODS MOL BIOL, V814, P3, DOI 10.1007/978-1-61779-452-0_1; Reyes RC, 2012, ASN NEURO, V4, P33, DOI 10.1042/AN20110059; Robel S, 2011, J NEUROSCI, V31, P12471, DOI 10.1523/JNEUROSCI.2696-11.2011; Robinson ESJ, 2005, J NEUROSCI METH, V147, P48, DOI 10.1016/j.jneumeth.2005.03.003; Saadoun S, 2005, J CELL SCI, V118, P5691, DOI 10.1242/jcs.02680; SARID J, 1991, J NEUROSCI RES, V28, P217, DOI 10.1002/jnr.490280209; Scemes E, 2006, GLIA, V54, P716, DOI 10.1002/glia.20374; SMITH ME, 1983, BRAIN RES, V264, P241, DOI 10.1016/0006-8993(83)90822-3; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Sriram K, 2004, J BIOL CHEM, V279, P19936, DOI 10.1074/jbc.M309304200; Theodoric N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047311; Tomobe YI, 1996, NEUROSCI LETT, V214, P57; van Weering HRJ, 2010, BRAIN BEHAV IMMUN, V24, P768, DOI 10.1016/j.bbi.2009.04.007; Verkhratsky A, 2006, ACTA PHARMACOL SIN, V27, P773, DOI 10.1111/j.1745-7254.2006.00396.x; VIJAYAN VK, 1990, MOL CHEM NEUROPATHOL, V13, P107, DOI 10.1007/BF03159912; Wang HH, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-84; Wang Y, 2002, CURR EYE RES, V24, P305, DOI 10.1076/ceyr.24.4.305.8408; Wu BY, 2000, J NEUROSCI RES, V62, P730, DOI 10.1002/1097-4547(20001201)62:5<730::AID-JNR13>3.0.CO;2-K; Wu CY, 2009, GLIA, V57, P1775, DOI 10.1002/glia.20890; Wu VW, 1998, J NEUROSCI RES, V51, P675, DOI 10.1002/(SICI)1097-4547(19980315)51:6<675::AID-JNR2>3.3.CO;2-N; Yang CZ, 2012, P NATL ACAD SCI USA, V109, P6963, DOI 10.1073/pnas.1118754109; Yoshii Y, 2011, NEUROSCI RES, V70, P321, DOI 10.1016/j.neures.2011.03.006; YU ACH, 1993, J NEUROSCI RES, V34, P295, DOI 10.1002/jnr.490340306; Yuan YM, 2012, BRIT J PHARMACOL, V166, P749, DOI 10.1111/j.1476-5381.2011.01804.x; Zhang ZJ, 2007, NAT CELL BIOL, V9, P945, DOI 10.1038/ncb1620; Zhu Z, 2007, GLIA, V55, P546, DOI 10.1002/glia.20476; Zorec R, 2012, ASN NEURO, V4, P103, DOI 10.1042/AN20110061	106	88	91	2	42	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	DEC	2013	61	12					2063	2077		10.1002/glia.22577			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	240RG	WOS:000326114100010	24123203				2022-02-06	
J	Cole, WR; Arrieux, JP; Schwab, K; Ivins, BJ; Qashu, FM; Lewis, SC				Cole, Wesley R.; Arrieux, Jacques P.; Schwab, Karen; Ivins, Brian J.; Qashu, Felicia M.; Lewis, Steven C.			TestRetest Reliability of Four Computerized Neurocognitive Assessment Tools in an Active Duty Military Population	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Reliability; Cognitive screening; Traumatic brain injury; Concussion; Military; NCAT	TRAUMATIC BRAIN-INJURY; TEST-RETEST RELIABILITY; REDICK CLINICAL UTILITY; IMPACT ASSESSMENT; CONCUSSION; NEUROPSYCHOLOGY; PERFORMANCE; MAYERS	Computerized neurocognitive assessment tools (NCATs) are increasingly used for baseline and post-concussion assessments. To date, NCATs have not demonstrated strong testretest reliabilities. Most studies have used non-military populations and different methodologies, complicating the determination of the utility of NCATs in military populations. The testretest reliability of four NCATs (Automated Neuropsychological Assessment Metrics 4 [ANAM4], CNS-Vital Signs, CogState, and Immediate Post-Concussion Assessment and Cognitive Test [ImPACT]) was investigated in a healthy active duty military sample. Four hundred and nineteen Service Members were randomly assigned to take one NCAT and 215 returned after approximately 30 days for retest. Participants deemed to have inadequate effort during one or both testing sessions, according to the NCATs scoring algorithms, were removed from analyses. Each NCAT had at least one reliability score (intraclass correlation) in the adequate range (.70.79), only ImPACT had one score considered high (.80.89), and no scores met very high criteria (.90.99). However, overall testretest reliabilities in four NCATs in a military sample are consistent with reliabilities reported in the literature and are lower than desired for clinical decision-making.	[Cole, Wesley R.; Arrieux, Jacques P.; Lewis, Steven C.] Womack Army Med Ctr, Ft Bragg, NC 28310 USA; [Cole, Wesley R.; Arrieux, Jacques P.; Lewis, Steven C.] DVBIC, Ft Bragg, NC USA; [Schwab, Karen; Ivins, Brian J.; Qashu, Felicia M.] DVBIC, Silver Spring, MD USA		Cole, WR (corresponding author), Womack Army Med Ctr, Dept Brain Injury Med, Ft Bragg, NC 28310 USA.	wesley.r.cole.ctr@mail.mil			Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs; Henry M. Jacskon Foundation; Womack Army Medical Center	This research was supported by the Defense and Veterans Brain Injury Center and conducted with the oversight and support of the Henry M. Jacskon Foundation and Womack Army Medical Center.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anderson T, 2006, PRACTICAL NEUROLOGY, V6, P342, DOI DOI 10.1136/JNNP.2006.106583; Bauer RM, 2012, ARCH CLIN NEUROPSYCH, V27, P362, DOI 10.1093/arclin/acs027; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Coldren RL, 2012, MIL MED, V177, P179, DOI 10.7205/MILMED-D-11-00278; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Department of Defense, 2012, DOD POL GUID MAN MIL; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Eckner JT, 2014, BRIT J SPORT MED, V48, P112, DOI 10.1136/bjsports-2012-091579; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Eonta SE, 2011, AVIAT SPACE ENVIR MD, V82, P34, DOI 10.3357/ASEM.2799.2011; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Gualtieri C Thomas, 2005, Am J Alzheimers Dis Other Demen, V20, P359; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Lange RT, 2010, J CLIN EXP NEUROPSYC, V32, P961, DOI 10.1080/13803391003645657; Leposavic I, 2010, PSYCHIAT DANUB, V22, P149; Lezak MD, 2012, NEUROPSYCHOLOGICAL A; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P287; Marx RG, 2003, J CLIN EPIDEMIOL, V56, P730, DOI 10.1016/S0895-4356(03)00084-2; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P435, DOI 10.1080/13803395.2012.667790; McCrea M., 2008, MILD TRAUMATIC BRAIN; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; Moritz S, 2003, APPL NEUROPSYCHOL, V10, P115, DOI 10.1207/S15324826AN1002_07; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Schatz P, 2002, J HEAD TRAUMA REHAB, V17, P395, DOI 10.1097/00001199-200210000-00003; Schatz P, 2012, J CLIN EXP NEUROPSYC, V34, P428, DOI 10.1080/13803395.2012.667789; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; US Army Traumatic Brain Injury Task Force, 2007, REP SURG GEN	42	88	88	0	22	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	NOV	2013	28	7					732	742		10.1093/arclin/act040			11	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	243AS	WOS:000326289300011	23819991	Bronze, Green Published			2022-02-06	
J	Galetta, MS; Galetta, KM; McCrossin, J; Wilson, JA; Moster, S; Galetta, SL; Balcer, LJ; Dorshimer, GW; Master, CL				Galetta, Matthew S.; Galetta, Kristin M.; McCrossin, Jim; Wilson, James A.; Moster, Stephen; Galetta, Steven L.; Balcer, Laura J.; Dorshimer, Gary W.; Master, Christina L.			Saccades and memory: Baseline associations of the King-Devick and SCAT2 SAC tests in professional ice hockey players	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Concussion; Sports; SCAT2; King-Devick test; Saccades; Memory	VISUAL SCREENING TOOL; CEREBRAL-DYSFUNCTION; EYE-MOVEMENTS; CONCUSSION; SPORT	Objective: The Sports Concussion Assessment Tool 2 (SCAT2) and King-Devick (K-D) tests have both been proposed as sideline tools to detect sports-related concussion. We performed an exploratory analysis to determine the relation of SCAT2 components, particularly the Standardized Assessment of Concussion (SAC), to K-D test scores in a professional ice hockey team cohort during pre-season baseline testing. We also examined changes in scores for two athletes who developed concussion and had rinkside testing. Methods: A modified SCAT2 (no balance testing) and the K-D test, a brief measure of rapid number naming, were administered to 27 members of a professional ice hockey team during the 2011-2012 pre-season. Athletes with concussion also underwent rinkside testing. Results: Lower (worse) scores for the SCAT2 SAC Immediate Memory Score and the overall SAC score were associated with greater (worse) times required to complete the K-D test at baseline. On average, for every 1-point reduction in SAC Immediate Memory Score, we found a corresponding increase (worsening) of K-D time score of 7.3 s (95% CI 4.9, 9.7, p<0.001, R-2 = 0.62, linear regression, accounting for age). For the overall SAC score, 1-point reductions were associated with K-D score worsening of 2.2 s (95% CI 0.6, 3.8, p = 0.01, R-2 = 0.25, linear regression). In two players tested rinkside immediately following concussion, K-D test scores worsened from baseline by 4.2 and 6.4 s. These athletes had no differences found for SCAT2 SAC components, but reported symptoms of concussion. Conclusion: In this study of professional athletes, scores for the K-D test, a measure for which saccadic (fast) eye movements are required for the task of rapid number naming, were associated with reductions in Immediate Memory at a pre-season baseline. Both working memory and saccadic eye movements share closely related anatomical structures, including the dorsolateral prefrontal cortex (DLPFC). A composite of brief rapid sideline tests, including SAC and K-D (and balance testing for non-ice hockey sports), is likely to provide an effective clinical tool to assess the athlete with suspected concussion. (c) 2013 Elsevier B.V. All rights reserved.	[Galetta, Matthew S.; Galetta, Kristin M.; Wilson, James A.; Moster, Stephen; Galetta, Steven L.; Balcer, Laura J.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Galetta, Steven L.; Balcer, Laura J.] Univ Penn, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Balcer, Laura J.] Univ Penn, Dept Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Dorshimer, Gary W.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [McCrossin, Jim] Philadelphia Flyers, Philadelphia, PA USA; [Master, Christina L.] Univ Penn, Dept Pediat, Perelman Sch Med, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Master, Christina L.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Sports Med, Philadelphia, PA 19104 USA		Balcer, LJ (corresponding author), NYU, Sch Med, Dept Neurol, 240 East 38th St,15th Floor, New York, NY 10016 USA.	msg8809@yahoo.com; kristingaletta@gmail.com; jmccrossin@comcast-spectator.com; jawilson@mail.med.upenn.edu; smoster@gmail.com; steven.galetta@nyumc.org; laura.balcer@nyumc.org; gary.dorshimer@uphs.upenn.edu; masterc@email.chop.edu		Master, Christina/0000-0002-6717-4270	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K24 EY 018136]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [K24EY018136] Funding Source: NIH RePORTER	This study was supported in part by NIH K24 EY 018136 (Dr. Balcer, funding for trainee research activities).	Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Dziemianowicz MS, 2012, CURR NEUROL NEUROSCI, V1-13; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Heitger MH, 2002, PROG BRAIN RES, V140, P433; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; Pierrot-Deseilligny C, 2003, BRAIN, V126, P1460, DOI 10.1093/brain/awg148; White OB, 2012, J NEURO-OPHTHALMOL, V32, P266, DOI 10.1097/WNO.0b013e3182688230	12	88	88	1	25	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	MAY 15	2013	328	1-2					28	31		10.1016/j.jns.2013.02.008			4	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	137VY	WOS:000318467500005	23499425				2022-02-06	
J	Mayer, AR; Ling, JM; Yang, Z; Pena, A; Yeo, RA; Klimaj, S				Mayer, Andrew R.; Ling, Josef M.; Yang, Zhen; Pena, Amanda; Yeo, Ronald A.; Klimaj, Stefan			Diffusion Abnormalities in Pediatric Mild Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article							AXONAL INJURY; HEAD-INJURY; COGNITIVE DEFICITS; CORPUS-CALLOSUM; CONCUSSION; CHILDREN; CHILDHOOD; RECOVERY; NEURODEGENERATION; NEUROPATHOLOGY	Pediatric mild traumatic brain injury (pmTBI) is the most prevalent neurological insult in children and is associated with both acute and chronic neurobehavioral sequelae. However, little is known about underlying pathophysiology and how injuries change as a function of recovery. Fractional anisotropy, axial diffusivity, and radial diffusivity were examined in 15 semi-acute pmTBI patients and 15 well-matched controls, with a subset of participants returning for a second visit. A novel analytic strategy was applied to capture spatially heterogeneous white matter injuries (lesions) in addition to standard analyses. Evidence of cognitive dysfunction after pmTBI was observed in the domains of attention (p = 0.02, d = -0.92) and processing speed (p = 0.05, d = -0.73) semi-acutely. Region of interest (ROI) and voxelwise analyses indicated increased anisotropic diffusion for pmTBI patients, with an elevated number of clusters with high anisotropy. Metrics of increased anisotropy were able to objectively classify pmTBI from healthy controls at 90% accuracy but were not associated with neuropsychological deficits. Little evidence of recovery in white matter abnormalities was observed over a 4-month interval in returning patients, indicating that physiological recovery may lag behind subjective reports of normality. Increased anisotropic diffusion has been previously linked with cytotoxic edema after TBI, and the magnitude and duration of these abnormalities appear to be greater in pediatric patients. Current findings suggest that developing white matter may be more susceptible to initial mechanical injury forces and that anisotropic diffusion provides an objective biomarker of pmTBI.	[Mayer, Andrew R.; Ling, Josef M.; Yang, Zhen; Pena, Amanda; Yeo, Ronald A.; Klimaj, Stefan] Lovelace Biomed & Environm Res Inst, Mind Res Network, Albuquerque, NM 87106 USA; [Mayer, Andrew R.; Yang, Zhen; Yeo, Ronald A.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA		Mayer, AR (corresponding author), Lovelace Biomed & Environm Res Inst, Mind Res Network, Pete & Nancy Domenici Hall,1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	amayer@mrn.org	Klimaj, Stefan/AAV-4060-2020; He, Robert/L-9441-2013; He, Hongbo/H-1815-2013		Mind Research Network Grant (Department of Energy Grant) [DE-FG02-99ER62764]	This research was supported by the Mind Research Network Grant (Department of Energy Grant DE-FG02-99ER62764) (A.R.M.).	Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Akpinar E, 2007, J COMPUT ASSIST TOMO, V31, P657, DOI 10.1097/RCT.0b013e318033df1a; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Babikian T, 2010, J NEUROTRAUM, V27, P473, DOI 10.1089/neu.2009.1058; Babikian T, 2009, PEDIATR NEUROL, V41, P406, DOI 10.1016/j.pediatrneurol.2009.06.002; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bayly PV, 2006, BRAIN RES, V1107, P70, DOI 10.1016/j.brainres.2006.05.102; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Faul M, 2010, TRAUMATIC BRAIN INJU; Galloway NR, 2008, J NEUROTRAUM, V25, P1153, DOI 10.1089/neu.2007.0494; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Giza CC, 2006, INDIAN J NEUROTRAUM, V3, P19; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Ling J, 2012, HUM BRAIN MAPP, V33, P50, DOI 10.1002/hbm.21192; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCauley SR, 2011, J NEUROTRAUM, V28, P503, DOI 10.1089/neu.2010.1555; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Mori S, 2007, AM J PSYCHIAT, V164, P1005, DOI 10.1176/appi.ajp.164.7.1005; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Reynolds C.R., 2004, BEHAV ASSESSMENT SYS, V2; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Rosenblum WI, 2007, J NEUROPATH EXP NEUR, V66, P771, DOI 10.1097/nen.0b013e3181461965; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Sotak CH, 2002, NMR BIOMED, V15, P561, DOI 10.1002/nbm.786; Sowell ER, 2002, DEV MED CHILD NEUROL, V44, P4, DOI 10.1017/S0012162201001591; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Storey P, 2007, MAGN RESON MED, V57, P614, DOI 10.1002/mrm.21132; Toga AW, 2006, TRENDS NEUROSCI, V29, P148, DOI 10.1016/j.tins.2006.01.007; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P319, DOI 10.1007/s11682-012-9174-3; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Yang Z, 2012, J NEUROTRAUM, V29, P2124, DOI 10.1089/neu.2012.2395; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082	61	88	89	0	18	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	DEC 12	2012	32	50					17961	17969		10.1523/JNEUROSCI.3379-12.2012			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	055GY	WOS:000312404700004	23238712	Bronze, Green Published			2022-02-06	
J	Lin, AP; Liao, HJ; Merugumala, SK; Prabhu, SP; Meehan, WP; Ross, BD				Lin, A. P.; Liao, H. J.; Merugumala, S. K.; Prabhu, S. P.; Meehan, W. P., III; Ross, B. D.			Metabolic imaging of mild traumatic brain injury	BRAIN IMAGING AND BEHAVIOR			English	Article						Spectroscopy; Single photon emissioncomputed tomography; Positron emission tomography; Mild traumatic brain injury; Metabolic imaging	MAGNETIC-RESONANCE-SPECTROSCOPY; POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL-BLOOD-FLOW; PROTON MR SPECTROSCOPY; TECHNETIUM-99M-HMPAO SPECT; HEAD-INJURY; COMPUTED-TOMOGRAPHY; SUBSTANCE-ABUSE; AXONAL INJURY; CONCUSSION	Traumatic brain injury results in a metabolic cascade of changes that occur at the molecular level, invisible to conventional imaging methods such as computed tomography or magnetic resonance imaging. Non-invasive metabolic imaging tools such as single photon emission computed tomography (SPECT), positron emission tomography (PET), and magnetic resonance spectroscopy (MRS) are the ideal methods for providing insight to these changes by measuring regional cerebral blood flow, glucose metabolism, and brain metabolite concentrations, respectively, after mild traumatic brain injury (mTBI). The purpose of this review is to provide an overview of the different methodologies and provide an up-to-date summary of recent findings with SPECT, PET, and MRS technologies, specifically after mTBI, as defined by standardized criteria. Given that the different physiological and pathological responses are heterogeneous, efforts will be made to separate studies at different time points after injury (acute, subacute, and chronic stages) as well as to the different types of mTBI such sports-related head injury where repetitive head injuries are much more common and may present a unique signature.	[Lin, A. P.; Liao, H. J.; Merugumala, S. K.; Ross, B. D.] Harvard Univ, Sch Med, Dept Radiol, Brigham & Womens Hosp, Boston, MA 02115 USA; [Prabhu, S. P.] Harvard Univ, Sch Med, Adv Image Anal Lab, Dept Radiol,Childrens Hosp Boston, Boston, MA 02115 USA; [Meehan, W. P., III] Harvard Univ, Sch Med, Sports Concuss Clin, Dept Med,Childrens Hosp Boston, Boston, MA 02115 USA; [Ross, B. D.] Huntington Med Res Inst, Pasadena, CA USA		Lin, AP (corresponding author), Harvard Univ, Sch Med, Dept Radiol, Brigham & Womens Hosp, Boston, MA 02115 USA.	aplin@partners.org	PRABHU, SANJAY/A-9947-2013	PRABHU, SANJAY/0000-0003-0871-115X	Department of Defense Psychological Health/Traumatic Brain Injury Research Program of the Office of the Congressionally Directed Medical Research Programs [W81XWH-10-1-0835]; National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [(R01 NS 078337)]; Center for Integration of Medicine (CIMIT) Innovation Grants; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD040128-06A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078337] Funding Source: NIH RePORTER	This work was supported in part by the Department of Defense Psychological Health/Traumatic Brain Injury Research Program of the Office of the Congressionally Directed Medical Research Programs (W81XWH-10-1-0835; APL, HL), by an National Institutes of Health/National Institute of Neurological Disorders and Stroke funded R01 (R01 NS 078337; APL), by the Center for Integration of Medicine (CIMIT) Innovation Grants (APL), and by an NIH training grant (T32 HD040128-06A1; WPM)	Abu-Judeh HH, 1998, J NUCL MED, V39, P1357; Amen DG, 2011, J PSYCHOACTIVE DRUGS, V43, P1, DOI 10.1080/02791072.2011.566489; Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Audenaert Kurt, 2003, Med Sci Monit, V9, pMT112; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bluml S, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P197, DOI 10.1007/0-387-32565-4_9; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Catafau AM, 2001, J NUCL MED, V42, P259; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Cimatti M, 2006, J Neurosurg Sci, V50, P83; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; GRAY BG, 1992, J NUCL MED, V33, P52; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Haseler LJ, 1997, PEDIATRICS, V99, P4, DOI 10.1542/peds.99.1.4; Hashimoto K, 2009, J REHABIL MED, V41, P661, DOI 10.2340/16501977-0388; Hattori N, 2009, J NUCL MED, V50, P1054, DOI 10.2967/jnumed.108.060368; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; ICHISE M, 1994, J NUCL MED, V35, P217; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Jacobs A, 1996, J NUCL MED, V37, P1605; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kirov I, 2007, BRAIN INJURY, V21, P1147, DOI 10.1080/02699050701630383; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LEONARD JP, 1986, J NUCL MED, V27, P1819; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lin A. P., 2010, 96 SCI ASS ANN M RAD; Lin Alexander, 2005, NeuroRx, V2, P197, DOI 10.1602/neurorx.2.2.197; Lin AP, 2003, MAGN RESON MATER PHY, V16, P29, DOI 10.1007/s10334-003-0004-x; Makoroff KL, 2005, PEDIATR RADIOL, V35, P668, DOI 10.1007/s00247-005-1441-7; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McDonald B. C., 2012, BRAIN IMAGING BEHAV; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Provenzano FA, 2010, NUCL MED COMMUN, V31, P952, DOI 10.1097/MNM.0b013e32833e37c4; ROBERTS MA, 1995, BRAIN INJURY, V9, P427, DOI 10.3109/02699059509008202; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Rushdie Salman., 2012, NEUROIMAGING FORENSI, P1; Sarmento E, 2009, HEADACHE, V49, P1345, DOI 10.1111/j.1526-4610.2009.01494.x; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Slobounov S. M., 2012, BRAIN IMAGING BEHAV; Umile EM, 1998, BRAIN INJURY, V12, P577; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; WOODS SW, 1992, J CLIN PSYCHIAT, V53, P20; Wortzel HS, 2008, J AM ACAD PSYCHIATRY, V36, P310; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578	64	88	91	2	43	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2012	6	2			SI		208	223		10.1007/s11682-012-9181-4			16	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	967LI	WOS:000305908900005	22684770				2022-02-06	
J	Bossu, P; Cutuli, D; Palladino, I; Caporali, P; Angelucci, F; Laricchiuta, D; Gelfo, F; De Bartolo, P; Caltagirone, C; Petrosini, L				Bossu, Paola; Cutuli, Debora; Palladino, Ilaria; Caporali, Paola; Angelucci, Francesco; Laricchiuta, Daniela; Gelfo, Francesca; De Bartolo, Paola; Caltagirone, Carlo; Petrosini, Laura			A single intraperitoneal injection of endotoxin in rats induces long-lasting modifications in behavior and brain protein levels of TNF-alpha and IL-18	JOURNAL OF NEUROINFLAMMATION			English	Article						Neuroinflammation; Lipopolysaccharide (LPS); Behavioral impairment; Cytokines; Hippocampus; Frontal cortex; Cerebellum	NECROSIS-FACTOR-ALPHA; CENTRAL-NERVOUS-SYSTEM; CLOSED-HEAD INJURY; ALZHEIMERS-DISEASE; COGNITIVE DECLINE; MICROGLIAL ACTIVATION; CYTOKINE TRANSCRIPTS; OBJECT RECOGNITION; INTERLEUKIN-18; LIPOPOLYSACCHARIDE	Background: Systemic inflammation might cause neuronal damage and sustain neurodegenerative diseases and behavior impairment, with the participation of pro-inflammatory cytokines, like tumor necrosis factor (TNF)-alpha and interleukin (IL)-18. However, the potential contribution of these cytokines to behavioral impairment in the long-term period has not been fully investigated. Methods: Wistar rats were treated with a single intraperitoneal injection of LPS (5 mg/ kg) or vehicle. After 7 days and 10 months, the animal behavior was evaluated by testing specific cognitive functions, as mnesic, discriminative, and attentional functions, as well as anxiety levels. Contextually, TNF-alpha and IL-18 protein levels were measured by ELISA in defined brain regions (that is, frontal cortex, hippocampus, striatum, cerebellum, and hypothalamus). Results: Behavioral testing demonstrated a specific and persistent cognitive impairment characterized by marked deficits in reacting to environment modifications, possibly linked to reduced motivational or attentional deficits. Concomitantly, LPS induced a TNF-a increase in the hippocampus and frontal cortex (from 7 days onward) and cerebellum (only at 10 months). Interestingly, LPS treatment enhanced IL-18 expression in these same areas only at 10 months after injection. Conclusions: Overall, these results indicate that the chronic neuroinflammatory network elicited by systemic inflammation involves a persistent participation of TNF-a accompanied by a differently regulated contribution of IL-18. This leads to speculation that, though with still unclear mechanisms, both cytokines might take part in long-lasting modifications of brain functions, including behavioral alteration.	[Bossu, Paola; Palladino, Ilaria; Angelucci, Francesco; Gelfo, Francesca; Caltagirone, Carlo] IRCCS, Fdn Santa Lucia, Rome, Italy; [Cutuli, Debora; Caporali, Paola; Laricchiuta, Daniela; De Bartolo, Paola; Petrosini, Laura] Fdn Santa Lucia, CERC, Rome, Italy; [Cutuli, Debora; Caporali, Paola; Laricchiuta, Daniela; De Bartolo, Paola; Petrosini, Laura] Univ Roma La Sapienza, Dipartimento Psicol, Rome, Italy		Bossu, P (corresponding author), IRCCS, Fdn Santa Lucia, Via Ardeatina 30600179, Rome, Italy.	p.bossu@hsantalucia.it	GELFO, FRANCESCA/AAC-6060-2022; De Bartolo, Paola/AAI-2695-2020; Bosso, Paola/E-4832-2014; Cutuli, Debora/K-1081-2016; Laricchiuta, Daniela/K-1080-2016; Caltagirone, Carlo/B-4930-2013; CAPORALI, PAOLA/K-8486-2016	De Bartolo, Paola/0000-0002-0557-3620; Bosso, Paola/0000-0002-1432-0078; Laricchiuta, Daniela/0000-0003-2237-2086; GELFO, FRANCESCA/0000-0002-3935-2164; CUTULI, Debora/0000-0003-4788-2461; CAPORALI, PAOLA/0000-0002-0112-3497	Italian Ministry of HealthMinistry of Health, Italy [RF07.96B]	Authors gratefully acknowledge the kind help of F. Foti and D. Saraulli in the various experimental procedures. This study received financial support from Italian Ministry of Health, Grant RF07.96B (PB).	Alboni S, 2011, BRAIN BEHAV IMMUN, V25, P483, DOI 10.1016/j.bbi.2010.11.011; Alboni S, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-9; Alkam T, 2008, BEHAV BRAIN RES, V189, P100, DOI 10.1016/j.bbr.2007.12.014; Barrientos RM, 2006, NEUROBIOL AGING, V27, P723, DOI 10.1016/j.neurobiolaging.2005.03.010; Barrientos RM, 2009, BRAIN BEHAV IMMUN, V23, P450, DOI 10.1016/j.bbi.2009.01.016; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; BLUTHE RM, 1992, BRAIN RES, V573, P318, DOI 10.1016/0006-8993(92)90779-9; Bossu P, 2008, BRAIN BEHAV IMMUN, V22, P487, DOI 10.1016/j.bbi.2007.10.001; Bossu P, 2010, CURR PHARM DESIGN, V16, P4213, DOI 10.2174/138161210794519147; BREDER CD, 1994, P NATL ACAD SCI USA, V91, P11393, DOI 10.1073/pnas.91.24.11393; Capuron L, 2011, PHARMACOL THERAPEUT, V130, P226, DOI 10.1016/j.pharmthera.2011.01.014; Carvey PM, 2003, FRONT BIOSCI S8, P26; Conti B, 1999, MOL BRAIN RES, V67, P46, DOI 10.1016/S0169-328X(99)00034-0; Culhane AC, 1998, MOL PSYCHIATR, V3, P362, DOI 10.1038/sj.mp.4000389; Cunningham C, 2008, BRAIN BEHAV IMMUN, V22, P1117, DOI 10.1016/j.bbi.2008.05.007; Cunningham C, 2009, BIOL PSYCHIAT, V65, P304, DOI 10.1016/j.biopsych.2008.07.024; Curran B, 2001, NEUROSCIENCE, V108, P83, DOI 10.1016/S0306-4522(01)00405-5; Dantzer R, 2001, BRAIN BEHAV IMMUN, V15, P7, DOI 10.1006/brbi.2000.0613; Dinarello CA, 2006, AM J CLIN NUTR, V83, p447S; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; Felderhoff-Mueser U, 2005, TRENDS NEUROSCI, V28, P487, DOI 10.1016/j.tins.2005.06.008; Foti F, 2011, CEREBELLUM, V10, P104, DOI 10.1007/s12311-010-0236-z; Frayling TM, 2007, J GERONTOL A-BIOL, V62, P73, DOI 10.1093/gerona/62.1.73; Gao HM, 2008, TRENDS IMMUNOL, V29, P357, DOI 10.1016/j.it.2008.05.002; GATTI S, 1993, BRAIN RES, V624, P291, DOI 10.1016/0006-8993(93)90090-A; Girault JA, 2004, ARCH NEUROL-CHICAGO, V61, P641, DOI 10.1001/archneur.61.5.641; Giuliani F, 2009, BRAIN RES BULL, V80, P302, DOI 10.1016/j.brainresbull.2009.07.009; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; Graybiel AM, 1997, SCHIZOPHRENIA BULL, V23, P459, DOI 10.1093/schbul/23.3.459; Hedtjarn M, 2002, J NEUROSCI, V22, P5910; Holmes C, 2003, J NEUROL NEUROSUR PS, V74, P788, DOI 10.1136/jnnp.74.6.788; Holmes C, 2009, NEUROLOGY, V73, P768, DOI 10.1212/WNL.0b013e3181b6bb95; Jacewicz M, 2009, FOLIA NEUROPATHOL, V47, P321; Jander S, 2002, J CEREBR BLOOD F MET, V22, P62, DOI 10.1097/00004647-200201000-00008; Janelsins MC, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-23; Jenkins TA, 2009, BEHAV BRAIN RES, V205, P355, DOI 10.1016/j.bbr.2009.07.014; Kakizaki Y, 1999, ENDOCR J, V46, P487, DOI 10.1507/endocrj.46.487; LAYE S, 1994, MOL BRAIN RES, V27, P157, DOI 10.1016/0169-328X(94)90197-X; Medeiros R, 2010, BEHAV BRAIN RES, V209, P165, DOI 10.1016/j.bbr.2010.01.040; Mrak RE, 2009, J ALZHEIMERS DIS, V18, P473, DOI 10.3233/JAD-2009-1158; Nguyen MD, 2004, J NEUROSCI, V24, P1340, DOI 10.1523/JNEUROSCI.4786-03.2004; Pepeu G, 2004, LEARN MEMORY, V11, P21, DOI 10.1101/lm.68104; Perry VH, 2007, NAT REV IMMUNOL, V7, P161, DOI 10.1038/nri2015; Pitossi F, 1997, J NEUROSCI RES, V48, P287, DOI 10.1002/(SICI)1097-4547(19970515)48:4<287::AID-JNR1>3.0.CO;2-7; Pitychoutis PM, 2009, NEUROSCIENCE, V159, P1216, DOI 10.1016/j.neuroscience.2009.01.072; Prinz M, 1999, J NEUROCHEM, V72, P2215, DOI 10.1046/j.1471-4159.1999.0722215.x; Puren AJ, 1998, J INFECT DIS, V178, P1830, DOI 10.1086/314481; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; Ricceri L, 2003, NEUROSCI BIOBEHAV R, V27, P377, DOI 10.1016/S0149-7634(03)00068-X; Rothwell NJ, 1996, PHARMACOL THERAPEUT, V69, P85, DOI 10.1016/0163-7258(95)02033-0; Sarter M, 2001, BRAIN RES REV, V35, P146, DOI 10.1016/S0165-0173(01)00044-3; Schmidt OI, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-13; Semmler A, 2007, EXP NEUROL, V204, P733, DOI 10.1016/j.expneurol.2007.01.003; Sifringer M, 2007, NEUROBIOL DIS, V25, P614, DOI 10.1016/j.nbd.2006.11.003; Sugama S, 2004, NEUROSCIENCE, V128, P451, DOI 10.1016/j.neuroscience.2004.07.020; Sugama S, 2002, BRAIN RES, V958, P1, DOI 10.1016/S0006-8993(02)03363-2; Sy HN, 2010, PHARMACOL BIOCHEM BE, V95, P158, DOI 10.1016/j.pbb.2009.12.020; Terrando N, 2010, P NATL ACAD SCI USA, V107, P20518, DOI 10.1073/pnas.1014557107; Weberpals M, 2009, J NEUROSCI, V29, P14177, DOI 10.1523/JNEUROSCI.3238-09.2009; Wheeler RD, 2000, MOL BRAIN RES, V77, P290, DOI 10.1016/S0169-328X(00)00069-3; Yaguchi T, 2010, BEHAV BRAIN RES, V206, P47, DOI 10.1016/j.bbr.2009.08.033; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008	62	88	90	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	MAY 29	2012	9								101	10.1186/1742-2094-9-101			12	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	013GB	WOS:000309292800001	22642744	Green Published, gold			2022-02-06	
J	Sink, EL; Beaule, PE; Sucato, D; Kim, YJ; Millis, MB; Dayton, M; Trousdale, RT; Sierra, RJ; Zaltz, I; Schoenecker, P; Monreal, A; Clohisy, J				Sink, Ernest L.; Beaule, Paul E.; Sucato, Daniel; Kim, Young-Jo; Millis, Michael B.; Dayton, Michael; Trousdale, Robert T.; Sierra, Rafael J.; Zaltz, Ira; Schoenecker, Perry; Monreal, Amy; Clohisy, John			Multicenter Study of Complications Following Surgical Dislocation of the Hip	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							ANTERIOR FEMOROACETABULAR IMPINGEMENT; FEMORO-ACETABULAR IMPINGEMENT; OSTEOCHONDROPLASTY; CLASSIFICATION; ARTHROSCOPY; HEAD	Background: Surgical hip dislocation enables complete exposure of the hip joint for treatment of various hip disorders. There is limited information regarding the complications associated with this procedure. Our purpose is to report the incidence of complications associated with surgical dislocation of the hip in a large, multicenter patient cohort. Methods: A retrospective, multicenter analysis of patients who had undergone surgical hip dislocation was performed. Patients who had undergone a simultaneous osteotomy were excluded. Complications were recorded, with specific assessment for osteonecrosis, trochanteric nonunion, femoral neck fracture, nerve injury, heterotopic ossification, and thromboembolic disease. We graded complications with a validated classification scheme that includes five grades based on the treatment required to manage the complication and any long-term morbidity. With this classification, a Grade-I complication is one that requires no change in the routine postoperative course, Grade II requires a change in outpatient management, Grade III requires invasive surgical or radiologic management, Grade IV is associated with long-term morbidity or is life-threatening, and Grade V results in death. Results: The study included 334 hips in 302 patients seen at eight different North American centers. There were eighteen complications (5.4%) that were classified as Grade I (not clinically relevant and required no deviation from routine postoperative care). There were six complications (1.8%) classified as Grade II (treated on an outpatient basis or with close observation and resolved). There were nine complications (2.7%) classified as Grade III (treatable and resolved with surgery or inpatient management). There was one complication (0.3%) classified as Grade IV (resulting in a long-term deficit). A total of thirty hips had one or more complications, for an overall incidence of 9%. Excluding heterotopic ossification, the complication rate was sixteen (4.8%) of 334. Conclusions: Surgical hip dislocation is a safe procedure with a low complication rate. Many of the complications were clinically unimportant heterotopic ossification. There were no cases of femoral head osteonecrosis or femoral neck fracture, and, with the exception of one sciatic neurapraxia that partially resolved, no other complication resulted in long-term morbidity.	[Sink, Ernest L.; Monreal, Amy] Childrens Hosp, Aurora, CO 80045 USA		Sink, EL (corresponding author), Childrens Hosp, 13123 E 16th Ave, Aurora, CO 80045 USA.	sinke@hss.edu		Beaule, Paul E./0000-0001-7667-9994			Beaule PE, 2007, J BONE JOINT SURG BR, V89B, P9, DOI 10.1302/0301-620X.89B1.18011; Beaule PE, 2007, J BONE JOINT SURG AM, V89A, P773, DOI 10.2106/JBJS.F.00681; Beck M, 2004, CLIN ORTHOP RELAT R, P67; BROOKER AF, 1973, J BONE JOINT SURG AM, VA 55, P1629, DOI 10.2106/00004623-197355080-00006; Byrd JWT, 2010, CLIN ORTHOP RELAT R, V468, P741, DOI 10.1007/s11999-009-0841-7; Clavien PA, 2009, ANN SURG, V250, P197, DOI 10.1097/SLA.0b013e3181b6dcab; Clohisy JC, 2010, J BONE JOINT SURG AM, V92A, P1697, DOI 10.2106/JBJS.I.00326; Clohisy JC, 2010, CLIN ORTHOP RELAT R, V468, P555, DOI 10.1007/s11999-009-1138-6; Davey JP, 1999, CLIN ORTHOP RELAT R, P33; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Espinosa N, 2006, J BONE JOINT SURG AM, V88A, P925, DOI 10.2106/JBJS.E.00290; Espinosa Norman, 2007, J Bone Joint Surg Am, V89 Suppl 2 Pt.1, P36, DOI 10.2106/JBJS.F.01123; Ganz R, 2001, J BONE JOINT SURG BR, V83B, P1119, DOI 10.1302/0301-620X.83B8.11964; Goldhahn S, 2009, J BONE JOINT SURG AM, V91A, P1847, DOI 10.2106/JBJS.H.01455; Larson CM, 2008, ARTHROSCOPY, V24, P540, DOI 10.1016/j.arthro.2007.11.007; Peters CL, 2006, J BONE JOINT SURG AM, V88A, P1735, DOI 10.2106/JBJS.E.00514; Philippon MJ, 2009, J BONE JOINT SURG BR, V91B, P16, DOI 10.1302/0301-620X.91B1.21329; Tannast M, 2010, OPER ORTHOPADE TRAUM, V22, P3, DOI 10.1007/s00064-010-3001-7	18	88	94	0	2	JOURNAL BONE JOINT SURGERY INC	NEEDHAM	20 PICKERING ST, NEEDHAM, MA 02192 USA	0021-9355			J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	JUN 15	2011	93A	12					1132	1136		10.2106/JBJSJ.00794			5	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	777LX	WOS:000291623400006	21571987				2022-02-06	
J	Beauchamp, MH; Ditchfield, M; Babl, FE; Kean, M; Catroppa, C; Yeates, KO; Anderson, V				Beauchamp, Miriam H.; Ditchfield, Michael; Babl, Franz E.; Kean, Michael; Catroppa, Cathy; Yeates, Keith O.; Anderson, Vicki			Detecting Traumatic Brain Lesions in Children: CT versus MRI versus Susceptibility Weighted Imaging (SWI)	JOURNAL OF NEUROTRAUMA			English	Article						child; CT; MRI; SWI; TBI	DIFFUSE AXONAL INJURY; HEAD-INJURY; MILD; PREDICTION; MODERATE; CLASSIFICATION; ADOLESCENTS; CHILDHOOD; SYMPTOMS; RULE	Cranial CT scans are at the center of decision making in brain injuries in children because of their speed and ability to detect surgically relevant lesions. However, alternative techniques, such as conventional MRI may have advantages in terms of radiation exposure and sensitivity to detect brain injury. Susceptibility-weighted imaging (SWI), a relatively novel MRI sequence, shows promise in terms of its sensitivity in detecting hemorrhagic lesions; however, its clinical potential remains uncertain. In this observational study of children (5-16 years of age) with traumatic brain injury (TBI) at a tertiary pediatric emergency department (ED) we compared the ability of detecting traumatic brain lesions on acute CT and MRI/SWI similar to 5 weeks post-injury based on detecting the presence or absence, extent, and type of traumatic brain lesions. We analyzed the results of 76 patients (53 male) after TBI (mean age 10.24 +/- 2.50 years, range 5.75-14.67 years). Glasgow Coma Score was 13-15 in 54 patients (71%), 9-12 in 13 patients (17%) and <8 in 9 patients (12%). CTs were completed in the ED; MRI and SWI were completed at a mean of 36.11 +/- 15.75 days post-injury. Detection of any lesions occurred on CT scan in 68%, on MRI in 54%, and on SWI in 86% of cases, and SWI detected additional lesions 30% of the time compared to CT and MRI. SWI may be more sensitive in detecting traumatic lesions than CT or MRI. This may be important for the ongoing management of TBIs and their prognosis.	[Anderson, Vicki] Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; [Beauchamp, Miriam H.] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Beauchamp, Miriam H.] Ste Justine Hosp, Res Ctr, Montreal, PQ, Canada; [Ditchfield, Michael] Monash Med Ctr, Melbourne, Vic, Australia; [Babl, Franz E.; Kean, Michael; Catroppa, Cathy; Anderson, Vicki] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Catroppa, Cathy; Anderson, Vicki] Univ Melbourne, Sch Behav Sci, Melbourne, Vic, Australia; [Yeates, Keith O.] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; [Yeates, Keith O.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA		Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au	Catroppa, Cathy/AAX-9458-2021; Yeates, Keith/AAJ-4223-2020	Catroppa, Cathy/0000-0002-9750-0436; Yeates, Keith/0000-0001-7680-2892	Victoria Neurotrauma Initiative [CO6E1]	We gratefully acknowledge the financial support of the Victoria Neurotrauma Initiative (No. CO6E1) and the research assistance of Ms. Louise Crossley.	Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Catroppa C, 2008, J CHILD NEUROL, V23, P486, DOI 10.1177/0883073807309773; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; COFFEY CE, 1991, AM PSYCHOP, P243; Colbert CA, 2010, RADIOLOGY, V256, P898, DOI 10.1148/radiol.10091842; Conners GP, 1999, PEDIATR EMERG CARE, V15, P241; Crowe L, 2010, ARCH DIS CHILD, V95, P1017, DOI 10.1136/adc.2009.174854; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; Gazelle GS, 2005, RADIOLOGY, V235, P361, DOI 10.1148/radiol.2352040330; Giza CC, 2001, J ATHL TRAINING, V36, P228; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Power T, 2007, BRAIN INJURY, V21, P279, DOI 10.1080/02699050701253095; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Suskauer SJ, 2009, DEV DISABIL RES REV, V15, P117, DOI 10.1002/ddrr.62; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Tong KA, 2008, AM J NEURORADIOL, V29, P9, DOI 10.3174/ajnr.A0786; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; VADE A, 1995, AM J ROENTGENOL, V165, P905, DOI 10.2214/ajr.165.4.7676990; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Woischneck D, 2003, CHILD NERV SYST, V19, P174, DOI 10.1007/s00381-002-0703-z; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu Z, 2010, AM J NEURORADIOL, V31, P1302, DOI 10.3174/ajnr.A2022; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Zhu GW, 2009, J INT MED RES, V37, P983, DOI 10.1177/147323000903700402	39	88	90	0	12	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2011	28	6					915	927		10.1089/neu.2010.1712			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	788PT	WOS:000292457600006	21501069				2022-02-06	
J	Chard, KM; Schumm, JA; McIlvain, SM; Bailey, GW; Parkinson, RB				Chard, Kathleen M.; Schumm, Jeremiah A.; McIlvain, Susan M.; Bailey, Gregory W.; Parkinson, R. Bruce			Exploring the Efficacy of a Residential Treatment Program Incorporating Cognitive Processing Therapy-Cognitive for Veterans With PTSD and Traumatic Brain Injury	JOURNAL OF TRAUMATIC STRESS			English	Article							POSTTRAUMATIC-STRESS-DISORDER	As the numbers of military personnel participating in the wars in Afghanistan and Iraq continue to grow, the percentage of individuals who return with both a traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD) also increases. Although there appears to be significant overlap in the symptoms resulting from PTSD and TBI, the best course of treatment remains an area of controversy. The authors present initial findings from a Veterans Administration residential program for comorbid PTSD and TBI. Forty-two participants completed a program comprising psychoeducational groups and cognitive skill building that was augmented with a modification of standard cognitive processing therapy. The results suggest that residential programs that incorporate this form of cognitive therapy can anticipate meaningful participation from patients, and that it may be an effective approach to treat PTSD in individuals with a history of TBI.	[Chard, Kathleen M.; Schumm, Jeremiah A.; McIlvain, Susan M.; Bailey, Gregory W.; Parkinson, R. Bruce] Cincinnati VA Med Ctr, PTSD & Anxiety Disorders Div, Cincinnati, OH 45220 USA; [Chard, Kathleen M.; Schumm, Jeremiah A.] Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45221 USA		Chard, KM (corresponding author), Cincinnati VA Med Ctr, PTSD & Anxiety Disorders Div, 3200 Vine St, Cincinnati, OH 45220 USA.	Kathleen.Chard@va.gov	Schumm, Jeremiah/I-9634-2019				Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Chard KM, 2005, J CONSULT CLIN PSYCH, V73, P965, DOI 10.1037/0022-006X.73.5.965; Chard KM, 2008, COGNITIVE PROCESSING; Department of Veterans Affairs and Department of Defense, 2009, VA DOD CLIN PRACT GU; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; First M., 1995, STRUCTURED CLIN INTE, V9, P92; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Monson CM, 2006, J CONSULT CLIN PSYCH, V74, P898, DOI 10.1037/0022-006X.74.5.898; Resick PA, 2002, J CONSULT CLIN PSYCH, V70, P867, DOI 10.1037//0022-006X.70.4.867; RESICK PA, 1992, J CONSULT CLIN PSYCH, V60, P748, DOI 10.1037/0022-006X.60.5.748; Resick PA, 2008, J CONSULT CLIN PSYCH, V76, P243, DOI 10.1037/0022-006X.76.2.243; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Twamley E. W., 2008, COGNITIVE SYMP UNPUB; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Weathers F., 1993, P ANN C INT SOC TRAU	24	88	88	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-9867	1573-6598		J TRAUMA STRESS	J. Trauma Stress	JUN	2011	24	3					347	351		10.1002/jts.20644			5	Psychology, Clinical; Psychiatry	Social Science Citation Index (SSCI)	Psychology; Psychiatry	773ZF	WOS:000291350300014	21626573				2022-02-06	
J	Meyers, JE; Volbrecht, M; Axelrod, BN; Reinsch-Boothby, L				Meyers, John E.; Volbrecht, Marie; Axelrod, Bradley N.; Reinsch-Boothby, Lorrie			Embedded Symptom Validity Tests and Overall Neuropsychological Test Performance	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Malingering; symptom validity testing; Meyers Neuropsychological Battery; Overall Test Battery Mean	BRAIN-INJURY; VALIDATION	A sample of 314 consecutive clinical and forensic referrals with mild traumatic brain injury was evaluated using the Meyers Neuropsychological Battery (MNB). A comparison was made of the test performance and performance on the embedded Symptom Validity Tests (SVTs) with a control for multicolinearity utilized. Using the nine embedded SVTs in the MNB, the incidence of poor effort fell at 26% of the total sample. Involvement in litigation was related to more failures on the individual SVTs. The correlation between failed effort measures and the Overall Test Battery Mean (OTBM) was consistently negative, regardless of litigation status, in that more failures were associated with lower OTBM scores. The correlation between the number of SVTs failed and the OTBM was -.77. Our results are similar to those presented by Green, Rohling, Lees-Haley, and Allen (2001); who reported a .73 correlation with the failure on the Word Memory Test and performance on the OTBM. The results of the current study also indicate that 50% of the variance in neuropsychological testing can be accounted by failures on internal SVTs.	[Meyers, John E.; Reinsch-Boothby, Lorrie] Meyers Neuropsychol Serv, Mililani, HI USA; [Volbrecht, Marie] Neuropsychol Consultants, Sioux Falls, SD USA; [Axelrod, Bradley N.] Vet Affairs Med Ctr, John D Dingell Dept, Detroit, MI USA		Meyers, JE (corresponding author), Meyers Neuropsychol Serv, Mililani, HI USA.	jmeyersneuro@yahoo.com					ANDREWS FM, 1981, GUIDE SELECTING STAT; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Boone K., 2007, ASSESSMENT FEIGNED C; BRANDT J, 1985, ANN NY ACAD SCI, V444, P502, DOI 10.1111/j.1749-6632.1985.tb37625.x; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; COHEN J, 1988, STAT POWER ANAL BEHA, pR21; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Green, 2003, WORD MEMORY TEST; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2010, CLIN NEUROPSYCHOL, V24, P137, DOI 10.1080/13854040902927546; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Kozel JJ, 1998, ARCH CLIN NEUROPSYCH, V13, P327, DOI 10.1016/S0887-6177(97)00036-X; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Meyers J E, 2001, Appl Neuropsychol, V8, P234, DOI 10.1207/09084280152829084; Meyers J E, 1996, Appl Neuropsychol, V3, P89, DOI 10.1207/s15324826an0302_8; Meyers J E, 1999, Appl Neuropsychol, V6, P208, DOI 10.1207/s15324826an0604_3; Meyers JE, 2004, ARCH CLIN NEUROPSYCH, V19, P637, DOI 10.1016/j.acn.2003.08.007; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P79, DOI 10.1016/S0887-6177(00)00105-0; Meyers JE., 1995, REY COMPLEX FIGURE T; Meyers JE, 1998, APPL NEUROPSYCHOL, V5, P120, DOI 10.1207/s15324826an0503_2; Reitan RM, 1985, HALSTEADREITAN NEURO; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Wechsler D., 1997, WAIS 3 ADM SCORING M WAIS 3 ADM SCORING M	28	88	88	0	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	FEB	2011	26	1					8	15		10.1093/arclin/acq083			8	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	709SU	WOS:000286462500002	21242283	Bronze			2022-02-06	
J	Galindo, LT; Filippo, TRM; Semedo, P; Ariza, CB; Moreira, C; Camara, NOS; Porcionatto, MA				Galindo, Layla T.; Filippo, Thais R. M.; Semedo, Patricia; Ariza, Carolina B.; Moreira, CarolineM.; Camara, Niels O. S.; Porcionatto, Marimelia A.			Mesenchymal Stem Cell Therapy Modulates the Inflammatory Response in Experimental Traumatic Brain Injury	NEUROLOGY RESEARCH INTERNATIONAL			English	Article							CENTRAL-NERVOUS-SYSTEM; STROMAL CELLS; MOUSE MODEL; HEAD-INJURY; CNS INJURY; TNF-ALPHA; EXPRESSION; CYTOKINES; SERUM; IL-6	Therapy with mesenchymal stem cells (MSCs) has showed to be promising due to its immunomodulatory function. Traumatic brain injury (TBI) triggers immune response and release of inflammatory mediators, mainly cytokines, by glial cells creating a hostile microenvironment for endogenous neural stem cells (NSCs). We investigated the effects of factors secreted by MSCs on NSC in vitro and analyzed cytokines expression in vitro in a TBI model. Our in vitro results show that MSC-secreted factors increase NSC proliferation and induce higher expression of GFAP, indicating a tendency toward differentiation into astrocytes. In vivo experiments showed that MSC injection at an acute model of brain injury diminishes a broad profile of cytokines in the tissue, suggesting that MSC-secreted factors may modulate the inflammation at the injury site, which may be of interest to the development of a favorable microenvironment for endogenous NSC and consequently to repair the injured tissue.	[Galindo, Layla T.; Filippo, Thais R. M.; Ariza, Carolina B.; Moreira, CarolineM.; Porcionatto, Marimelia A.] Univ Fed Sao Paulo, Dept Bioquim, Rua Tres Maio 100, BR-04044020 Sao Paulo, SP, Brazil; [Semedo, Patricia; Camara, Niels O. S.] Univ Sao Paulo, Dept Imunol, BR-05508000 Sao Paulo, SP, Brazil		Porcionatto, MA (corresponding author), Univ Fed Sao Paulo, Dept Bioquim, Rua Tres Maio 100, BR-04044020 Sao Paulo, SP, Brazil.	marimelia.bioq@epm.br	Porcionatto, Marimelia/C-3322-2012; Ariza, Carolina Batista/N-1334-2015; camara, niels/AAX-3269-2020	Porcionatto, Marimelia/0000-0001-6287-916X; camara, niels/0000-0001-5436-1248	FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2008/07570-9]; CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [573909/2008-3]; Grad Student's Fellowships	This paper was supported by FAPESP (Research Grant to M. A. Porcionatto (2008/07570-9); Grad Student's Fellowships to T. R. M. Filippo, C. B. Ariza, L. T. Galindo, C. M. Moreira); and CNPq (Research Fellowship and Research Grant (573909/2008-3) to M. A. Porcionatto).	Alexandre CS, 2009, STEM CELLS, V27, P682, DOI 10.1634/stemcells.2008-0496; Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Armstrong RJE, 2001, LANCET, V358, P1174, DOI 10.1016/S0140-6736(01)06260-2; Browne KD, 2006, EXP NEUROL, V201, P301, DOI 10.1016/j.expneurol.2006.04.008; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Campbell SJ, 2005, AM J PATHOL, V166, P1487, DOI 10.1016/S0002-9440(10)62365-6; Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886; Castellani C, 2010, HUM PATHOL, V41, P1566, DOI 10.1016/j.humpath.2009.12.017; Chiba S, 2004, J NEUROL SCI, V219, P107, DOI 10.1016/j.jns.2004.01.006; Coulson-Thomas YA, 2008, J NEUROSCI METH, V171, P19, DOI 10.1016/j.jneumeth.2008.01.030; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Edwards P, 2005, LANCET, V365, P1957; Farooqui AA, 2007, J NEUROCHEM, V101, P577, DOI 10.1111/j.1471-4159.2006.04371.x; Guo Y, 2005, STEM CELLS, V23, P1324, DOI 10.1634/stemcells.2005-0085; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Kamimura D, 2004, REV PHYSIOL BIOCH P, V149, P1, DOI 10.1007/s10254-003-0012-2; Karussis D, 2010, ARCH NEUROL-CHICAGO, V67, P1187, DOI 10.1001/archneurol.2010.248; Keilhoff G, 2006, CELL MOL NEUROBIOL, V26, P1235, DOI 10.1007/s10571-006-9029-9; Kojima T, 2010, STEM CELLS, V28, P545, DOI 10.1002/stem.306; Kokovay E, 2010, CELL STEM CELL, V7, P163, DOI 10.1016/j.stem.2010.05.019; Li JM, 2010, BRAIN RES, V1334, P65, DOI 10.1016/j.brainres.2010.03.080; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Mathieu P, 2010, J NEUROCHEM, V112, P1368, DOI 10.1111/j.1471-4159.2009.06548.x; McFarlin K, 2006, WOUND REPAIR REGEN, V14, P471, DOI 10.1111/j.1743-6109.2006.00153.x; Miller RH, 2010, DISCOV MED, V9, P236; Molina-Holgado E, 2010, J NEUROCHEM, V114, P1277, DOI 10.1111/j.1471-4159.2010.06849.x; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Murphy JM, 2003, ARTHRITIS RHEUM-US, V48, P3464, DOI 10.1002/art.11365; Nemeth K, 2010, P NATL ACAD SCI USA, V107, P5652, DOI 10.1073/pnas.0910720107; Nguyen BK, 2010, J CARDIOVASC TRANSL, V3, P547, DOI 10.1007/s12265-010-9171-0; Ohab JJ, 2008, NEUROSCIENTIST, V14, P369, DOI 10.1177/1073858407309545; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Paxinos GFK., 2001, MOUSE BRAIN STEREOTA, V2nd ed.; Pevny LH, 2010, INT J BIOCHEM CELL B, V42, P421, DOI 10.1016/j.biocel.2009.08.018; Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007-0637; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Robin AM, 2006, J CEREBR BLOOD F MET, V26, P125, DOI 10.1038/sj.jcbfm.9600172; Semedo P, 2009, STEM CELLS, V27, P3063, DOI 10.1002/stem.214; Semedo P, 2009, INT IMMUNOPHARMACOL, V9, P677, DOI 10.1016/j.intimp.2008.12.008; Shake JG, 2002, ANN THORAC SURG, V73, P1919, DOI 10.1016/S0003-4975(02)03517-8; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Si YL, 2011, AGEING RES REV, V10, P93, DOI 10.1016/j.arr.2010.08.005; Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122; Stumm R, 2007, J MOL ENDOCRINOL, V38, P377, DOI 10.1677/JME-06-0032; Szelenyi J, 2001, BRAIN RES BULL, V54, P329, DOI 10.1016/S0361-9230(01)00428-2; Townsend KP, 2005, FASEB J, V19, P1592, DOI 10.1096/fj.04-3620rev; van der Meulen AAE, 2009, NEUROPATH APPL NEURO, V35, P579, DOI 10.1111/j.1365-2990.2009.01036.x; Venetsanou K, 2007, EUR CYTOKINE NETW, V18, P206, DOI 10.1684/ecn.2007.0112; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126; Yoles E, 1998, EXP NEUROL, V153, P1, DOI 10.1006/exnr.1998.6811; Zhang M, 2007, FASEB J, V21, P3197, DOI 10.1096/fj.06-6558com; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	54	88	91	0	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-1852	2090-1860		NEUROL RES INT	Neurol. Res. Int.		2011	2011								564089	10.1155/2011/564089			9	Neurosciences	Emerging Sources Citation Index (ESCI)	Neurosciences & Neurology	V33DU	WOS:000215746900016	21766025	Green Submitted, Green Published, gold			2022-02-06	
J	Patel, AD; Gerzanich, V; Geng, ZH; Simard, JM				Patel, Ashish D.; Gerzanich, Volodymyr; Geng, Zhihua; Simard, J. Marc			Glibenclamide Reduces Hippocampal Injury and Preserves Rapid Spatial Learning in a Model of Traumatic Brain Injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Caspase-3; Glibenclamide; Hippocampus; Morris water maze; Rapid spatial learning; Sp1; Sulfonylurea receptor 1 (SUR1); Traumatic brain injury	MORRIS WATER MAZE; FACTOR-KAPPA-B; ISCHEMIC-STROKE; DENTATE GYRUS; CORTICAL CONTUSION; PATTERN SEPARATION; ATP CHANNELS; PLACE CELLS; HEAD TRAUMA; RAT	Cognitive disturbances after traumatic brain injury (TBI) are frequent, even when neuroimaging shows no overt hemorrhagic or other abnormality. Sulfonylurea receptor 1 (SUR1) plays a key role in various forms of CNS injury, but its role in hippocampal dysfunction after mild to moderate TBI is unknown. To assess the hypothesis that postinjury SUR1 upregulation in the hippocampus is associated with a later disturbance in learning, we studied a rat model of cortical impact TBI calibrated to avoid primary and secondary hemorrhage in the underlying hippocampus. The transcription factor, specificity protein 1, which regulates expression of SUR1 and caspase-3, was activated in the hippocampus 15 minutes after injury. Upregulation of SUR1 protein and of Abcc8 (which encodes SUR1) messenger RNA was evident by 6 hours. To assess the role of SUR1, injured rats were administered vehicle or a low dose of the specific sulfonylurea inhibitor glibenclamide for 1 week. At 2 weeks, the increase in activated caspase-3 in the hilus of glibenclamide-treated rats was half of that in vehicle-treated rats. Testing for rapid learning in a Morris water maze at 4 weeks showed significantly better performance in glibenclamide-treated rats; performance inversely correlated with Fluoro-Jade staining for degenerated neurons in the hilus. We conclude that glibenclamide may have long-term protective effects on the hippocampus after mild-to-moderate TBI.	[Patel, Ashish D.; Gerzanich, Volodymyr; Geng, Zhihua; Simard, J. Marc] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA		Simard, JM (corresponding author), Univ Maryland, Sch Med, Dept Neurosurg, 22 S Greene St,Suite S12D, Baltimore, MD 21201 USA.	msimard@smail.umaryland.edu			Department of Veterans Affairs (Baltimore, MD)US Department of Veterans Affairs	This work was supported by a grant to J.M.S. from the Department of Veterans Affairs (Baltimore, MD).	Aoyama N, 2002, BRAIN RES, V934, P117, DOI 10.1016/S0006-8993(02)02366-1; Bast T, 2009, PLOS BIOL, V7, P730, DOI 10.1371/journal.pbio.1000089; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Burgess N, 2002, NEURON, V35, P625, DOI 10.1016/S0896-6273(02)00830-9; Chen MK, 2001, J NEUROSCI, V21, P6512, DOI 10.1523/JNEUROSCI.21-17-06512.2001; Clausen F, 2005, NEUROSURGERY, V57, P154, DOI 10.1227/01.NEU.0000163412.07546.57; Corkin S, 2002, NAT REV NEUROSCI, V3, P153, DOI 10.1038/nrn726; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Dash PK, 2009, NEUROSCI LETT, V460, P103, DOI 10.1016/j.neulet.2009.04.028; Davis ME, 2004, J BIOL CHEM, V279, P163, DOI 10.1074/jbc.M307528200; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Gerlai R, 1996, NEUROBIOL LEARN MEM, V66, P143, DOI 10.1006/nlme.1996.0055; Gerzanich V, 2003, CIRC RES, V93, P805, DOI 10.1161/01.RES.0000097872.69043.A0; Gribble FM, 2003, DIABETOLOGIA, V46, P875, DOI 10.1007/s00125-003-1143-3; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hellmich HL, 2005, BRAIN RES, V1044, P144, DOI 10.1016/j.brainres.2005.02.054; Hernandez-Sanchez C, 1999, J BIOL CHEM, V274, P18261, DOI 10.1074/jbc.274.26.18261; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hoofien D, 2001, BRAIN INJURY, V15, P189; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee I, 2004, NEURON, V42, P803, DOI 10.1016/j.neuron.2004.05.010; Leutgeb JK, 2007, SCIENCE, V315, P961, DOI 10.1126/science.1135801; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Liu WF, 2002, J BIOL CHEM, V277, P8273, DOI 10.1074/jbc.M110768200; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; McHugh TJ, 2007, SCIENCE, V317, P94, DOI 10.1126/science.1140263; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Muller R, 1996, NEURON, V17, P813, DOI 10.1016/S0896-6273(00)80214-7; Nakashiba T, 2008, SCIENCE, V319, P1260, DOI 10.1126/science.1151120; O'Reilly RC, 2001, PSYCHOL REV, V108, P311, DOI 10.1037//0033-295X.108.2.311; OLTON DS, 1979, NEUROPSYCHOLOGIA, V17, P669, DOI 10.1016/0028-3932(79)90042-3; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; Rao V, 2002, PSYCHIAT CLIN N AM, V25, P43, DOI 10.1016/S0193-953X(03)00052-2; SASS KJ, 1990, NEUROLOGY, V40, P1694, DOI 10.1212/WNL.40.11.1694; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Simard JM, 2007, J CLIN INVEST, V117, P2105, DOI 10.1172/JCI32041; Simard JM, 2007, BBA-MOL BASIS DIS, V1772, P947, DOI 10.1016/j.bbadis.2007.03.004; Simard JM, 2010, J NEUROSURG, V113, P622, DOI 10.3171/2009.11.JNS081052; Simard JM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000522; Simard JM, 2010, STROKE, V41, P531, DOI 10.1161/STROKEAHA.109.572644; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Simard JM, 2009, J CEREBR BLOOD F MET, V29, P317, DOI 10.1038/jcbfm.2008.120; Simard JM, 2009, STROKE, V40, P604, DOI 10.1161/STROKEAHA.108.522409; Simard JM, 2006, NAT MED, V12, P433, DOI 10.1038/nm1390; SLOVITER RS, 1994, ANN NEUROL, V35, P640, DOI 10.1002/ana.410350604; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Thompson HJ, 2006, RESTOR NEUROL NEUROS, V24, P109; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Verstraeten SV, 2010, BBA-BIOMEMBRANES, V1798, P1739, DOI 10.1016/j.bbamem.2010.06.010; Whishaw IQ, 1996, HIPPOCAMPUS, V6, P513, DOI 10.1002/(SICI)1098-1063(1996)6:5<513::AID-HIPO4>3.0.CO;2-J; XIONG Y, 2010, J NEUROSURG     0521; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Yamada K, 2005, J MOL CELL CARDIOL, V38, P945, DOI 10.1016/j.yjmcc.2004.11.020; Zawar C, 1999, J PHYSIOL-LONDON, V514, P327	65	88	93	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	DEC	2010	69	12					1177	1190		10.1097/NEN.0b013e3181fbf6d6			14	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	686KN	WOS:000284695300001	21107131				2022-02-06	
J	Kemp, K; Hares, K; Mallam, E; Heesom, KJ; Scolding, N; Wilkins, A				Kemp, Kevin; Hares, Kelly; Mallam, Elizabeth; Heesom, Kate J.; Scolding, Neil; Wilkins, Alastair			Mesenchymal stem cell-secreted superoxide dismutase promotes cerebellar neuronal survival	JOURNAL OF NEUROCHEMISTRY			English	Article						bone marrow; mesenchymal stem cell; neurons; stem cell transplantation; superoxide dismutase; Purkinje cell	MARROW STROMAL CELLS; ACTIVATED PROTEIN-KINASE; TRAUMATIC BRAIN-INJURY; TUMOR-NECROSIS-FACTOR; P38 MAP KINASE; NITRIC-OXIDE; IN-VIVO; NEUROTROPHIC FACTOR; CORTICAL-NEURONS; C-JUN	P>It has been postulated that bone marrow-derived mesenchymal stem cells (MSCs) might be effective treatments for neurodegenerative disorders either by replacement of lost cells by differentiation into functional neural tissue; modulation of the immune system to prevent further neurodegeneration; and/or provision of trophic support for the diseased nervous system. Here we have performed a series of experiments showing that human bone marrow-derived MSCs are able to protect cultured rodent cerebellar neurons, and specifically cells expressing Purkinje cell markers, against either nitric oxide exposure or withdrawal of trophic support via cell-cell contact and/or secretion of soluble factors, or through secretion of soluble factors alone. We have demonstrated that MSCs protect cerebellar neurons against toxic insults via modulation of both the phosphatidylinositol 3-kinase/Akt and MAPK pathways and defined superoxide dismutase 3 as a secreted active antioxidant biomolecule by which MSCs modulate, at least in part, their neuroprotective effect on cerebellar cells in vitro. Together, the results demonstrate new and specific mechanisms by which MSCs promote cerebellar neuronal survival and add further evidence to the concept that MSCs may be potential therapeutic agents for neurological disorders involving the cerebellum.	[Kemp, Kevin; Hares, Kelly; Mallam, Elizabeth; Heesom, Kate J.; Scolding, Neil; Wilkins, Alastair] Univ Bristol, Inst Clin Neurosci, Multiple Sclerosis & Stem Cell Grp, Bristol, Avon, England		Kemp, K (corresponding author), Frenchay Hosp, MS Labs, Burden Ctr, 1st Floor, Bristol BS16 1JB, Avon, England.	kevin.kemp@bristol.ac.uk	Kemp, Kevin/B-9755-2017	Kemp, Kevin/0000-0003-1465-1309; Scolding, Neil/0000-0001-9177-1043	Ataxia UK; Ataxia UK [7160] Funding Source: researchfish	This work was carried out using a project grant from Ataxia UK.	Almeida RD, 2005, CELL DEATH DIFFER, V12, P1329, DOI 10.1038/sj.cdd.4401662; Arnhold S, 2006, EUR J CELL BIOL, V85, P551, DOI 10.1016/j.ejcb.2006.01.015; Asada S, 2007, CELL SIGNAL, V19, P519, DOI 10.1016/j.cellsig.2006.08.015; Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301-472X(01)00769-X; Beyth S, 2005, BLOOD, V105, P2214, DOI 10.1182/blood-2004-07-2921; Black IB, 2001, BLOOD CELL MOL DIS, V27, P632, DOI 10.1006/bcmd.2001.0423; Bossy-Wetzel E, 2004, NEURON, V41, P351, DOI 10.1016/S0896-6273(04)00015-7; Cao J, 2004, J BIOL CHEM, V279, P35903, DOI 10.1074/jbc.M402353200; Chen RW, 2007, NEUROSCI LETT, V422, P64, DOI 10.1016/j.neulet.2007.06.004; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Christofidou-Solomidou Melpo, 2006, Treat Respir Med, V5, P47, DOI 10.2165/00151829-200605010-00004; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Devine SM, 2000, CURR OPIN HEMATOL, V7, P358, DOI 10.1097/00062752-200011000-00007; Diem R, 2001, J NEUROSCI, V21, P2058, DOI 10.1523/JNEUROSCI.21-06-02058.2001; Du YL, 2008, EXP BIOL MED, V233, P881, DOI 10.3181/0712-RM-329; Eilers A, 1998, J NEUROSCI, V18, P1713; Encinas M, 2001, J NEUROSCI, V21, P1464, DOI 10.1523/JNEUROSCI.21-05-01464.2001; Enghild JJ, 1999, J BIOL CHEM, V274, P14818, DOI 10.1074/jbc.274.21.14818; Estevez AG, 1998, J NEUROSCI, V18, P923; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Goldberg JL, 2000, ANNU REV NEUROSCI, V23, P579, DOI 10.1146/annurev.neuro.23.1.579; HARRIS CA, 1991, J IMMUNOL, V147, P149; He F, 2008, COLLOID SURFACE B, V61, P290, DOI 10.1016/j.colsurfb.2007.09.009; Himes BT, 2006, NEUROREHAB NEURAL RE, V20, P278, DOI 10.1177/1545968306286976; Hokari M, 2008, J NEUROSCI RES, V86, P1024, DOI 10.1002/jnr.21572; Isele NB, 2007, NEUROCHEM INT, V50, P243, DOI 10.1016/j.neuint.2006.08.007; Ishikawa Y, 2003, MOL CELL NEUROSCI, V24, P451, DOI 10.1016/S1044-7431(03)00203-3; Jin KL, 2002, J NEUROCHEM, V80, P119, DOI 10.1046/j.0022-3042.2001.00678.x; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Klesse LJ, 1998, J NEUROSCI, V18, P10420; Lanza C, 2009, J NEUROCHEM, V110, P1674, DOI 10.1111/j.1471-4159.2009.06268.x; Le Blanc K, 2003, EXP HEMATOL, V31, P890, DOI 10.1016/S0301-472X(03)00110-3; Lin SZ, 2001, NEUROSCI LETT, V315, P61, DOI 10.1016/S0304-3940(01)02324-2; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Maitra B, 2004, BONE MARROW TRANSPL, V33, P597, DOI 10.1038/sj.bmt.1704400; NORDQUIST DT, 1988, J NEUROSCI, V8, P4780; Nozik-Grayck E, 2005, INT J BIOCHEM CELL B, V37, P2466, DOI 10.1016/j.biocel.2005.06.012; Park SY, 2002, MOL BRAIN RES, V107, P9, DOI 10.1016/S0169-328X(02)00421-7; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Ratnam DV, 2006, J CONTROL RELEASE, V113, P189, DOI 10.1016/j.jconrel.2006.04.015; Sayre LM, 2008, CHEM RES TOXICOL, V21, P172, DOI 10.1021/tx700210j; Sun XM, 2008, INT J DEV NEUROSCI, V26, P363, DOI 10.1016/j.ijdevneu.2007.11.005; Vaillant AR, 1999, J CELL BIOL, V146, P955, DOI 10.1083/jcb.146.5.955; Wang JY, 2003, J NEUROSCI RES, V72, P508, DOI 10.1002/jnr.10597; Wijesekera LC, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750-1172-4-3; Wilkins A, 2001, GLIA, V36, P48, DOI 10.1002/glia.1094; Wilkins A, 2005, J NEUROCHEM, V92, P1487, DOI 10.1111/j.1471-4159.2004.02981.x; Wilkins A, 2009, STEM CELL RES, V3, P63, DOI 10.1016/j.scr.2009.02.006; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamagishi S, 2003, MOL BRAIN RES, V119, P184, DOI 10.1016/j.molbrainres.2003.09.009; Zhang J, 2004, BRAIN RES, V1030, P19, DOI 10.1016/j.brainres.2004.09.061; Zhang J, 2006, J NEUROSCI RES, V84, P587, DOI 10.1002/jnr.20962; Zhao H, 2005, J NEUROSCI, V25, P9794, DOI 10.1523/JNEUROSCI.3163-05.2005	57	88	95	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	SEP	2010	114	6					1569	1580		10.1111/j.1471-4159.2009.06553.x			12	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	646NQ	WOS:000281549600004	20028455	Bronze			2022-02-06	
J	Sander, AM; Clark, A; Pappadis, MR				Sander, Angelle M.; Clark, Allison; Pappadis, Monique R.			What Is Community Integration Anyway?: Defining Meaning Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						community integration; participation; traumatic brain injury	ETHNIC-DIFFERENCES; REHABILITATION; OUTCOMES; PARTICIPATION; QUESTIONNAIRE; SATISFACTION; INDIVIDUALS; WORK; RACE; PERSPECTIVES	Full community integration, or participation in society, is the ultimate goal of rehabilitation and of research conducted in the field of rehabilitation for persons with traumatic brain injury (TBI). Community integration has been traditionally defined by 3 main areas: employment or other productive activity, independent living, and social activity. However, these have not always received equal weighting and attention in clinical or research efforts. Significant gaps remain in our understanding of factors that impact community integration and in our ability to intervene to improve participation for persons with TBI. This article describes 3 main challenges for researchers and rehabilitation professionals. First, a comprehensive meaning of community integration is needed, which includes the viewpoints and preferences of persons with TBI. Second, cultural competence in measurement and intervention is needed. Third, a thorough assessment of environmental factors impacting participation is needed and should be incorporated into research and treatment planning.	[Sander, Angelle M.; Clark, Allison; Pappadis, Monique R.] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX 77019 USA; [Sander, Angelle M.; Clark, Allison] Harris Cty Hosp Dist, Baylor Coll Med, Dept Phys Med & Rehabil, Waco, TX USA; [Pappadis, Monique R.] Univ Houston, Grad Coll SocialWork, Houston, TX USA		Sander, AM (corresponding author), TIRR Mem Hermann, Brain Injury Res Ctr, 2323 S Shepherd Dr,Ste 907, Houston, TX 77019 USA.	asander@bem.edu	Pappadis, Monique/Q-8639-2016	Pappadis, Monique/0000-0003-4742-4380	National Institute on Disability and Rehabilitation Research, US Department of EducationUS Department of Education [H133 B031117, H133A070043]	This work was supported by grants from the National Institute on Disability and Rehabilitation Research, US Department of Education (grants H133 B031117 and H133A070043).	Almeida J, 2009, SOC SCI MED, V68, P1852, DOI 10.1016/j.socscimed.2009.02.029; Arango-Lasprilla JC, 2008, ARCH PHYS MED REHAB, V89, P988, DOI 10.1016/j.apmr.2008.02.012; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Bier N, 2009, J HEAD TRAUMA REHAB, V24, P187, DOI 10.1097/HTR.0b013e3181a0b15a; BOAKE C, 1991, COGNITIVE REHABILITA, pR11; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Brandt EN, 1997, ENABLING AM ASSESSIN; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Christenson OD, 2006, J LEISURE RES, V38, P475, DOI 10.1080/00222216.2006.11950088; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Corrigan J D, 1994, NeuroRehabilitation, V4, P109, DOI 10.3233/NRE-1994-4207; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P445, DOI 10.1097/00001199-200411000-00003; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JA, 2008, ARCH PHYS MED REHAB, V89, P912, DOI 10.1016/j.apmr.2007.12.027; Craig Hospital Research Department, 2001, CRAIG HOSP INV ENV F; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Eames P, 1996, BRAIN INJURY, V10, P631, DOI 10.1080/026990596124061; FLOYD MF, 1994, J LEISURE RES, V26, P158, DOI 10.1080/00222216.1994.11969951; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Kamo Y, 2000, SOCIOL PERSPECT, V43, P211, DOI 10.2307/1389794; Kim HK, 1998, J COMP FAM STUD, V29, P313; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Malec JF, 2004, ARCH PHYS MED REHAB, V85, P1989, DOI 10.1016/j.apmr.2004.01.032; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; de la Plata CM, 2007, J HEAD TRAUMA REHAB, V22, P113, DOI 10.1097/01.HTR.0000265099.29436.56; Mascialino G, 2009, NEUROREHABILITATION, V24, P29, DOI 10.3233/NRE-2009-0451; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; Minnes P, 2003, BRAIN INJURY, V17, P149, DOI 10.1080/02699050301828; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pledger C, 2003, AM PSYCHOL, V58, P279, DOI 10.1037/0003-066X.58.4.279; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PRIGATANO GP, 1989, B MENNINGER CLIN, V53, P414; Rapport L, 2006, J HEAD TRAUMA REHAB, V21, P34, DOI 10.1097/00001199-200601000-00004; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Rosenthal M. Foreword, 1990, COMMUNITY INTEGRATIO, pxi; *RRTC COMM INT PER, T7 STAT OF THE SCI C; Saeki S, 2006, J REHABIL MED, V38, P333, DOI 10.1080/16501970600780245; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Sander AM, 2009, ARCH PHYS MED REHA E, V90, pE36; Sander AM, 2009, NEUROREHABILITATION, V24, P15, DOI 10.3233/NRE-2009-0450; Sarkisian N, 2006, FAM RELAT, V55, P331, DOI 10.1111/j.1741-3729.2006.00408.x; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Struchen M. A., 2005, REHABILITATION TRAUM, P88; *US DOE, 2000, LONG RANG PLAN 1999; Uysal S, 1998, J HEAD TRAUMA REHAB, V13, P57, DOI 10.1097/00001199-199812000-00007; Walker N, 2003, AM J PHYS MED REHAB, V82, P936, DOI 10.1097/01.PHM.0000098041.42394.9A; Whiteneck GG, 2004, J HEAD TRAUMA REHAB, V19, P191, DOI 10.1097/00001199-200405000-00001; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1994, BRAIN INJURY, V8, P647, DOI 10.3109/02699059409151017; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; World Health Organization, 2007, INT CLASS FUNCT DIS; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002	61	88	88	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2010	25	2					121	127		10.1097/HTR.0b013e3181cd1635			7	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	578EJ	WOS:000276276000007	20134333				2022-02-06	
J	Elkin, BS; Ilankovan, A; Morrison, B				Elkin, Benjamin S.; Ilankovan, Ashok; Morrison, Barclay, III			Age-Dependent Regional Mechanical Properties of the Rat Hippocampus and Cortex	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article							TRAUMATIC BRAIN-INJURY; VISCOELASTIC PROPERTIES; ARTICULAR-CARTILAGE; IN-VIVO; CORTICAL CONTUSION; STRESS-RELAXATION; ELASTIC-MODULUS; TISSUE; DEFORMATION; MODEL	Age-dependent outcomes following traumatic brain injury motivate the study of brain injury biomechanics in experimental animal models at different stages of development. Finite element models of the rat brain are used to better understand the mechanical mechanisms behind these age-dependent outcomes; however, age- and region-specific rat brain tissue mechanical properties are required for biofidelity in modeling. Here, we have used the atomic force microscope (A FM) to measure region-dependent mechanical properties for subregions of the cortex and hippocampus in P10, P17, and adult rats. Apparent elastic modulus increased nonlinearly with indentation strain, and a nonlinear Ogden hyperelastic model was used to fit the force-deflection data. Subregional heterogeneous distributions of mechanical properties changed significantly with age. Apparent elastic modulus was also found to increase overall with age, increasing by >100% between P10 and adult rats. Unconfined compression tests (epsilon = -0.3) were performed on whole slices of the hippocampus and cortex of P10, P17, and adult rats to verify the mechanical properties measured with the AFM. Mean apparent elastic modulus at an indentation strain of 30% from A FM measurements for each region and age correlated well with the long-term elastic modulus measured from 30% unconfined compression tests (slope not significantly different from 1, p>0.05). Protein, lipid, and sulfated glycosaminoglycan content of the brain increased with age and were positively correlated with tissue stiffness, whereas water content decreased with age and was negatively correlated with tissue stiffness. These correlations can be used to hypothesize mechanistic models for describing the mechanical behavior of brain tissue as well as to predict relative differences between brain tissue mechanical properties of other species, at different ages, and for different regions based on differences in tissue composition. [DOI: 10.1115/1.4000164]	[Elkin, Benjamin S.; Ilankovan, Ashok; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA		Elkin, BS (corresponding author), Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA.		Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864	National Highway Traffic Safety Administration (NHTSA); NSF Career Award of Kevin D. Costa [BES 0239138]	We would like to thank Evren U. Azeloglu and Kevin D. Costa for the enlightening discussions and help with AFM analysis, Van C. Mow for the use of the unconfined compression device, and Mohammed Shaik for the help with data collection. This work was supported by the National Highway Traffic Safety Administration (NHTSA) and funds for the AFM equipment came from the NSF Career Award of Kevin D. Costa (Grant No. BES 0239138).	ALVARADO MV, 1984, J NEUROSCI RES, V11, P13, DOI 10.1002/jnr.490110103; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Azeloglu EU, 2008, AM J PHYSIOL-HEART C, V294, pH1197, DOI 10.1152/ajpheart.01027.2007; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Bilston LE, 1997, BIORHEOLOGY, V34, P377, DOI 10.1016/S0006-355X(98)00022-5; BRANDS D. W. A., 2000, P STAPP CAR CRASH C, V44, P249; BRISCOE BJ, 1994, J PHYS D APPL PHYS, V27, P1156, DOI 10.1088/0022-3727/27/6/013; BRUCE DA, 1990, CURR PROBL PEDIATR, V20, P66; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Cheng S, 2007, J BIOMECH, V40, P117, DOI 10.1016/j.jbiomech.2005.11.004; Coats B, 2006, J BIOMECH, V39, P2521, DOI 10.1016/j.jbiomech.2005.07.020; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Costa KD, 2003, DIS MARKERS, V19, P139, DOI 10.1155/2004/482680; Costa KD, 1999, J BIOMECH ENG-T ASME, V121, P462, DOI 10.1115/1.2835074; Couper Z, 2008, BIOMECH MODEL MECHAN, V7, P105, DOI 10.1007/s10237-007-0079-9; Darling EM, 2007, BIOPHYS J, V92, P1784, DOI 10.1529/biophysj.106.083097; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; Del Bigio MR, 2008, FLUIDS BARRIERS CNS, V5, DOI 10.1186/1743-8454-5-12; DESOUZA SW, 1971, EXP NEUROL, V32, P431, DOI 10.1016/0014-4886(71)90009-4; Dimitriadis EK, 2002, BIOPHYS J, V82, P2798, DOI 10.1016/S0006-3495(02)75620-8; DIRESTA GR, 1991, J NEUROSCI METH, V39, P245, DOI 10.1016/0165-0270(91)90103-7; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HARDY WN, 2001, STAPP CAR CRASH J, V45, P368; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Huh JW, 2006, DEV NEUROSCI-BASEL, V28, P466, DOI 10.1159/000094172; Inouye LS, 2006, TALANTA, V70, P584, DOI 10.1016/j.talanta.2006.01.024; JOHNSON KL, 1970, J MECH PHYS SOLIDS, V18, P115, DOI 10.1016/0022-5096(70)90029-3; Katta J, 2008, P I MECH ENG H, V222, P1, DOI 10.1243/09544119JEIM325; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; KREIS R, 1993, MAGNET RESON MED, V30, P424, DOI 10.1002/mrm.1910300405; LAI WM, 1991, J BIOMECH ENG-T ASME, V113, P245, DOI 10.1115/1.2894880; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lei FL, 2007, J BIOMECH, V40, P936, DOI 10.1016/j.jbiomech.2006.03.014; Leterrier JF, 1996, J BIOL CHEM, V271, P15687, DOI 10.1074/jbc.271.26.15687; Levchakov A, 2006, J NEUROTRAUM, V23, P1570, DOI 10.1089/neu.2006.23.1570; LIKHITPANICHKUL M, 2007, P ASME 2007 SUMM BIO; Lin DC, 2007, EXPRESS POLYM LETT, V1, P576, DOI 10.3144/expresspolymlett.2007.79; Lin DC, 2009, BIOMECH MODEL MECHAN, V8, P345, DOI 10.1007/s10237-008-0139-9; Lippert SA, 2004, BIORHEOLOGY, V41, P681; Lopez-Picon FR, 2003, HIPPOCAMPUS, V13, P767, DOI 10.1002/hipo.10122; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Mahaffy RE, 2000, PHYS REV LETT, V85, P880, DOI 10.1103/PhysRevLett.85.880; Mahaffy RE, 2004, BIOPHYS J, V86, P1777, DOI 10.1016/S0006-3495(04)74245-9; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; MARGOLIS RU, 1975, BIOCHEMISTRY-US, V14, P85, DOI 10.1021/bi00672a014; Martinez A, 2002, J CHEMOMETR, V16, P41, DOI 10.1002/cem.669; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Miller K, 2005, J BIOMECH, V38, P153, DOI 10.1016/j.jbiomech.2004.03.004; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; MOW VC, 1980, J BIOMECH ENG-T ASME, V102, P73, DOI 10.1115/1.3138202; Nicolle S, 2005, BIORHEOLOGY, V42, P209; OBRIEN JS, 1965, J LIPID RES, V6, P537; OOHIRA A, 1986, J NEUROCHEM, V47, P588; OVERBEEK JTG, 1953, J COLL SCI IMP U TOK, V8, P593, DOI 10.1016/0095-8522(53)90048-8; PASCUCCI RC, 1988, INTENS CARE MED, V14, P185, DOI 10.1007/BF00717985; Pena A, 2005, ACT NEUR S, V95, P333; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.1289/ehp.00108s3511; Riu J, 1997, TRAC-TREND ANAL CHEM, V16, P211, DOI 10.1016/S0165-9936(97)00014-9; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Shreiber DI, 2009, BIOMECH MODEL MECHAN, V8, P311, DOI 10.1007/s10237-008-0137-y; Stolz M, 2004, BIOPHYS J, V86, P3269, DOI 10.1016/S0006-3495(04)74375-1; Sun DD, 2004, J BIOMECH ENG-T ASME, V126, P6, DOI 10.1115/1.1644562; Takhounts Erik G, 2003, Stapp Car Crash J, V47, P79; Takhounts Erik G, 2003, Stapp Car Crash J, V47, P107; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; WINICK M, 1968, PEDIATR RES, V2, P352, DOI 10.1203/00006450-196809000-00003; Xu G, 2009, BIOMECH MODEL MECHAN, V8, P253, DOI 10.1007/s10237-008-0131-4; YOFFE EH, 1984, PHILOS MAG A, V50, P813, DOI 10.1080/01418618408237539; ZENG K, 1992, J MATER SCI, V27, P3789, DOI 10.1007/BF00545457; Zhang JY, 2006, BIOMED SCI INSTRUM, V42, P501; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zhou C, 1995, P STAPP CAR CRASH J, V39, P121, DOI DOI 10.4271/952714	91	88	88	3	26	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	JAN	2010	132	1							011010	10.1115/1.4000164			10	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	550CW	WOS:000274106900010	20524748				2022-02-06	
B	Patel, V; Lund, C; Hatherill, S; Plagerson, S; Corrigall, J; Funk, M; Flisher, AJ		Blas, E; Kurup, AS		Patel, Vikram; Lund, Crick; Hatherill, Sean; Plagerson, Sophie; Corrigall, Joanne; Funk, Michelle; Flisher, Alan J.			Mental disorders: equity and social determinants	EQUITY, SOCIAL DETERMINANTS AND PUBLIC HEALTH PROGRAMMES			English	Article; Book Chapter							DEFICIT-HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; MIDDLE-INCOME COUNTRIES; CHILD SEXUAL-ABUSE; MAJOR DEPRESSION; RISK-FACTORS; HEALTH SURVEYS; ANTIDEPRESSANT TREATMENT; PSYCHIATRIC-DISORDER; FAMILY-ENVIRONMENT	As with most nonconummicable diseases, the etiology of mental disorders is multifactorial, with risk determined by an interaction of genetic, other biological, psychological and social determinants. The large variation in the prevalence of most mental disorders between and within countries suggests that the social determinants have particular salience. This chapter focuses on social determinants with emphasis on evidence from low- and middle-income countries, and gives particular attention to two examples of mental disorders: depression and attention deficit hyperactivity disorder (ADHD). These disorders were selected because they are each associated with a considerable burden, and there is a substantive evidence base that interventions for these disorders are effective and feasible. There are significantly increased rates of depression among low socioeconomic groups, and exposure to risk factors is disproportionately high in contexts characterized by social disadvantage where vulnerable groups are over represented. There is convincing evidence of an association between depression and stressful life events; exposure to violence and other crimes; chronic physical ill-health; low levels of educational attainment; conflict; disasters; stressful working environments; and female gender. Additionally, reasonable evidence implicates discrimination, income inequality, food insecurity, hunger, unemployment, toxins, urbanization, lack of housing, overcrowding, low social capital, poor sanitation and built environment, and minority ethnicity. Overall rates of mental health service use are generally lower amongst the disadvantaged. Low mental health literacy and stigma may reduce the ability of people with depression to use treatment services effectively. Further, depression is associated with negative physical health outcomes, including cardiovascular disease, type 2 diabetes mellitus, injuries, HIV/AIDS and various perinatal and reproductive conditions; consequences of these comorbidities may also show social gradients. While increased risk of ADHD is associated with lower socioeconomic status and lower parental education in high-income countries, research on ADHD from low- and middle-income countries is scarce and inconclusive. The expression of genetic susceptibility to ADHD appears to be moderated by environmental exposures. Fetal or neonatal hypoxia, traumatic brain injury, epilepsy and antiepileptic medications, and HIV infection are all associated with ADHD, and these exposures all show social gradients. Also, male gender appears to confer additional risk. Children with ADHD experience adverse academic outcomes. Put simply, mental disorders are inequitably distributed, as people who are socially and economically disadvantaged bear a disproportionate burden of mental disorders and their adverse consequences. A vicious cycle of disadvantage and mental disorder is the result of the dynamic interrelationship between them. This chapter reviews a wealth of evidence on interventions that can break this cycle, by addressing both upstream social determinants and vulnerabilities, and downstream health outcomes and consequences through a combination of population- and individual-level actions. A key goal is for health care systems to be responsive to the mental health needs of the population. Efforts to increase coverage of cost-effective interventions must explicitly target disadvantaged populations and health impact assessments of macroeconomic policies must consider mental health outcomes. Evidence from low- and middle-income countries remains relatively scarce and more contextual research is required to inform mental health policy and practice. In particular, research is needed regarding the impacts of social and economic change on mental disorder, and the mechanisms through which protective factors strengthen resilience and promote mental health. Longitudinal monitoring of population mental health is crucial for this purpose.									Aaron R, 2004, LANCET, V363, P1117, DOI 10.1016/S0140-6736(04)15896-0; Achenbach T, 1983, MANUAL CHILD BEHAV C; Ahmed SM, 2001, WORLD DEV, V29, P1957, DOI 10.1016/S0305-750X(01)00069-9; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Andrade LH, 2008, SOC PSYCH PSYCH EPID, V43, P45, DOI 10.1007/s00127-007-0263-3; [Anonymous], 1992, JAMA, V268, P3098; Araya R, 2003, J EPIDEMIOL COMMUN H, V57, P501, DOI 10.1136/jech.57.7.501; Ashenafi Y, 2001, East Afr Med J, V78, P308; BEISER M, 1994, INT J METHOD PSYCH, V4, P157; BHATIA MS, 1991, J CHILD PSYCHOL PSYC, V32, P297, DOI 10.1111/j.1469-7610.1991.tb00308.x; Bhugra D, 2004, BRIT J PSYCHIAT, V184, P10, DOI 10.1192/bjp.184.1.10; Biederman J, 1996, J AM ACAD CHILD PSY, V35, P343, DOI 10.1097/00004583-199603000-00016; Biederman J, 2005, BIOL PSYCHIAT, V57, P1215, DOI 10.1016/j.biopsych.2004.10.020; BIEDERMAN J, 1995, ARCH GEN PSYCHIAT, V52, P464; Biederman J, 2002, AM J PSYCHIAT, V159, P1556, DOI 10.1176/appi.ajp.159.9.1556; Biederman J, 2005, LANCET, V366, P237, DOI 10.1016/S0140-6736(05)66915-2; Bodnar LM, 2005, BIOL PSYCHIAT, V58, P679, DOI 10.1016/j.biopsych.2005.05.009; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P161, DOI 10.1001/archpsyc.55.2.161; BROMET EJ, 2002, PSYCHIAT SOC, P241; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Buitelaar JK, 2006, EUR CHILD ADOLES PSY, V15, P177, DOI 10.1007/s00787-005-0523-2; Chakraborty A, 2002, BRIT J PSYCHIAT, V180, P475, DOI 10.1192/bjp.180.6.475; Chandola T, 2001, HEALTH PLACE, V7, P105, DOI 10.1016/S1353-8292(01)00002-8; Chatterjee S, 2008, WORLD PSYCHIATRY, V7, P39; Chisholm D, 2007, LANCET, V370, P1241, DOI 10.1016/S0140-6736(07)61242-2; Christakis DA, 2004, PEDIATRICS, V113, P708, DOI 10.1542/peds.113.4.708; Chronis AM, 2003, J AM ACAD CHILD PSY, V42, P1424, DOI 10.1097/00004583-200312000-00009; Cohen A, 2006, ARCH GEN PSYCHIAT, V63, P50, DOI 10.1001/archpsyc.63.1.50; Cohen A, 2002, WORLD MENTAL HLTH CA; Cooper PJ, 2002, BRIT J PSYCHIAT, V180, P76, DOI 10.1192/bjp.180.1.76; CORRIGALL J, 2007, DECREASING BURDEN ME; Covey LS, 1998, J ADDICT DIS, V17, P35, DOI 10.1300/J069v17n01_04; De Silva MJ, 2005, J EPIDEMIOL COMMUN H, V59, P619, DOI 10.1136/jech.2004.029678; Demyttenaere K, 2004, JAMA-J AM MED ASSOC, V291, P2581, DOI 10.1001/jama.291.21.2581; DHADPHALE M, 1984, ACTA PSYCHIAT SCAND, V69, P151, DOI 10.1111/j.1600-0447.1984.tb02480.x; Dunn DW, 2003, DEV MED CHILD NEUROL, V45, P50, DOI 10.1017/S0012162203000094; Faraone Stephen V, 2003, World Psychiatry, V2, P104; FINKELHOR D, 1990, PROF PSYCHOL-RES PR, V21, P325, DOI 10.1037/0735-7028.21.5.325; FLAHERTY JA, 1988, J NERV MENT DIS, V176, P257; Flisher A. J, 2007, MONITORING CHILD WEL, P111; Flisher AJ, 1997, PSYCHOL MED, V27, P1145, DOI 10.1017/S0033291797005412; FLISHER AJ, 2007, J CHILD ADOLESCENT M, V19, P170; Froneberg B., 2003, AFRICAN NEWSLETTER O, V13, P32; Ghanizadeh A, 2005, J CHILD ADOLESC MENT, V17, P31, DOI 10.2989/17280580509486590; Goldberg D., 1978, MANUAL GEN HLTH QUES; Goodman R, 2000, BRIT J PSYCHIAT, V177, P534, DOI 10.1192/bjp.177.6.534; GUEVARA JP, 2007, EXPERT REV PHARM OUT, V3, P201; HARDING TW, 1980, PSYCHOL MED, V10, P231, DOI 10.1017/S0033291700043993; Heflin CM, 2005, SOC SCI MED, V61, P1971, DOI 10.1016/j.socscimed.2005.04.014; Heise L, 2002, INT J GYNECOL OBSTET, V78, pS5, DOI 10.1016/S0020-7292(02)00038-3; Herrman H, 2006, PROMOTING MENTAL HLT; HOSMAN CMH, 2005, EVIDENCE EFFECTIVE I; Hu TW, 2006, J MENT HEALTH POLICY, V9, P3; Hyman S, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P605; *I MED, 2001, NEUR PSYCH DEV MENT; JIN RL, 1995, CAN MED ASSOC J, V153, P529; Jorm AF, 1997, MED J AUSTRALIA, V166, P182, DOI 10.5694/j.1326-5377.1997.tb140071.x; Kaplan HI, 1994, KAPLAN SADOCKS SYNOP; Kashala E, 2005, Afr Health Sci, V5, P172; Kashala E, 2006, EUR CHILD ADOLES PSY, V15, P292, DOI 10.1007/s00787-006-0536-5; Kendall J, 2002, ADV NURS SCI, V25, P22, DOI 10.1097/00012272-200212000-00003; Kessler RC, 2002, PSYCHOL MED, V32, P959, DOI 10.1017/S0033291702006074; Kleinmann A., 2004, NEW ENGL J MED, V31, P10; Kurihara T, 2007, PSYCHIAT CLIN NEUROS, V61, P205, DOI 10.1111/j.1440-1819.2007.01642.x; LEIBSON CL, 2007, JAMA-J AM MED ASSOC, V285, P60; Linnet KM, 2003, AM J PSYCHIAT, V160, P1028, DOI 10.1176/appi.ajp.160.6.1028; London L, 2005, AM J IND MED, V47, P308, DOI 10.1002/ajim.20147; Lopez AD, 2006, GLOBAL BURDEN OF DISEASE AND RISK FACTORS, P1, DOI 10.1596/978-0-8213-6262-4; Lorant V, 2003, AM J EPIDEMIOL, V157, P98, DOI 10.1093/aje/kwf182; Lovisi GM, 2003, SOC PSYCH PSYCH EPID, V38, P493, DOI 10.1007/s00127-003-0666-8; MANN EM, 1992, AM J PSYCHIAT, V149, P1539; Marsella AJ, 1998, AM PSYCHOL, V53, P624, DOI 10.1037/0003-066X.53.6.624; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; McKee-Ryan FM, 2005, J APPL PSYCHOL, V90, P53, DOI 10.1037/0021-9010.90.1.53; Melfi CA, 1999, J HEALTH CARE POOR U, V10, P201; Mick E, 2002, J AM ACAD CHILD PSY, V41, P378, DOI 10.1097/00004583-200204000-00009; Mick E, 2002, J DEV BEHAV PEDIATR, V23, P16, DOI 10.1097/00004703-200202000-00004; Mollica RF, 2004, LANCET, V364, P2058, DOI 10.1016/S0140-6736(04)17519-3; Moussavi S, 2007, LANCET, V370, P851, DOI 10.1016/S0140-6736(07)61415-9; Nigg JT, 2006, WHAT CAUSES ADHD UND; Nolen-Hoeksema S, 2001, CURR DIR PSYCHOL SCI, V10, P173, DOI 10.1111/1467-8721.00142; Nozyce ML, 2006, PEDIATRICS, V117, P763, DOI 10.1542/peds.2005-0451; Olfson M, 2006, AM J PSYCHIAT, V163, P101, DOI 10.1176/appi.ajp.163.1.101; ORMEL J, 1993, AM J PUBLIC HEALTH, V83, P385, DOI 10.2105/AJPH.83.3.385; Paperwalla KN, 2004, MED CLIN N AM, V88, P1483, DOI 10.1016/j.mcna.2004.06.007; Patel V, 2004, BMJ-BRIT MED J, V328, P820, DOI 10.1136/bmj.328.7443.820; Patel V, 2003, LANCET, V361, P33, DOI 10.1016/S0140-6736(03)12119-8; Patel V, 2002, AM J PSYCHIAT, V159, P43, DOI 10.1176/appi.ajp.159.1.43; Patel V, 2001, BRIT MED BULL, V57, P33, DOI 10.1093/bmb/57.1.33; Patel V, 2006, ARCH GEN PSYCHIAT, V63, P404, DOI 10.1001/archpsyc.63.4.404; Patel V., 2001, POVERTY INEQUALITY H, P247; PATEL V, 2005, PROMOTING MENTAL HLT; Patel V, 2007, LANCET, V370, P991, DOI 10.1016/S0140-6736(07)61240-9; Patel V, 2007, INT J EPIDEMIOL, V36, P703, DOI 10.1093/ije/dym147; Patel V, 2007, LANCET, V369, P1302, DOI 10.1016/S0140-6736(07)60368-7; Patel V, 2007, TROP MED INT HEALTH, V12, P130, DOI 10.1111/j.1365-3156.2006.01756.x; Patel V, 2007, BRIT J PSYCHIAT, V190, P77, DOI 10.1192/bjp.bp.106.025692; Patel V, 2006, BRIT J PSYCHIAT, V189, P547, DOI 10.1192/bjp.bp.106.022558; Paykel ES, 1998, BRIT J PSYCHIAT, V173, P519, DOI 10.1192/bjp.173.6.519; Phillips MR, 2002, LANCET, V359, P835, DOI 10.1016/S0140-6736(02)07954-0; Pineda DA, 2003, INT J NEUROSCI, V113, P49, DOI 10.1080/00207450390161921; PRATINIDHI AK, 1999, INDIAN J PEDIATR, V59, P423; Pressman LJ, 2006, J AM ACAD CHILD PSY, V45, P346, DOI 10.1097/01.chi.0000192248.61271.c8; Prince M, 2007, LANCET, V370, P859, DOI 10.1016/S0140-6736(07)61238-0; RAPPLEY MD, 2007, NEW ENGL J MED, V352, P165; Ritsher JB, 2004, PSYCHIAT RES, V129, P257, DOI 10.1016/j.psychres.2004.08.003; Rodriguez A, 2005, J CHILD PSYCHOL PSYC, V46, P246, DOI 10.1111/j.1469-7610.2004.00359.x; Rohde LA, 1999, J AM ACAD CHILD PSY, V38, P716, DOI 10.1097/00004583-199906000-00019; Rohde LA, 2005, BIOL PSYCHIAT, V57, P1436, DOI 10.1016/j.biopsych.2005.01.042; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Rusch N, 2005, EUR PSYCHIAT, V20, P529, DOI 10.1016/j.eurpsy.2005.04.004; RUTTER M, 1975, BRIT J PSYCHIAT, V126, P493, DOI 10.1192/bjp.126.6.493; RUTTER M, 1976, PSYCHOL MED, V6, P313, DOI 10.1017/S003329170001388X; Saha S, 2005, PLOS MED, V2, P413, DOI 10.1371/journal.pmed.0020141; Samaan RA, 2000, J HEALTH CARE POOR U, V11, P100; Saraceno Benedetto, 2005, World Psychiatry, V4, P181; SARTORIUS N, 1996, BRIT J PSYCHIAT, pS38; Sartorius Norman, 2006, Psychol Health Med, V11, P383, DOI 10.1080/13548500600595418; Sartorius N, 2007, LANCET, V370, P810, DOI 10.1016/S0140-6736(07)61245-8; SAUGATA B, 1996, IND J CLIN PSYCHOL, V23, P184; Saxena S, 2006, BRIT J PSYCHIAT, V188, P81, DOI 10.1192/bjp.bp.105.011221; Saxena S, 2007, LANCET, V370, P878, DOI 10.1016/S0140-6736(07)61239-2; Scahill L, 1999, J AM ACAD CHILD PSY, V38, P976, DOI 10.1097/00004583-199908000-00013; Sirey JA, 2001, AM J PSYCHIAT, V158, P479, DOI 10.1176/appi.ajp.158.3.479; Spataro J, 2004, BRIT J PSYCHIAT, V184, P416, DOI 10.1192/bjp.184.5.416; STAVROULA L, 2004, WORK ORG STRESS; Stewart WF, 2003, JAMA-J AM MED ASSOC, V289, P3135, DOI 10.1001/jama.289.23.3135; Thomson H, 2003, J EPIDEMIOL COMMUN H, V57, P11, DOI 10.1136/jech.57.1.11; Tramontina S, 2001, CAN J PSYCHIAT, V46, P941, DOI 10.1177/070674370104601006; *US SUBST AB MENT, 1999, MENT HLTH REP SURG G; Vinokur A D, 2000, J Occup Health Psychol, V5, P32, DOI 10.1037/1076-8998.5.1.32; Wang PS, 2008, AM J PSYCHIAT, V165, P34, DOI 10.1176/appi.ajp.2007.07030502; Wang PS, 2007, LANCET, V370, P841, DOI 10.1016/S0140-6736(07)61414-7; Weich S, 2001, BRIT J PSYCHIAT, V178, P222, DOI 10.1192/bjp.178.3.222; Weich S, 1998, BMJ-BRIT MED J, V317, P115, DOI 10.1136/bmj.317.7151.115; Weissman MM, 1996, JAMA-J AM MED ASSOC, V276, P293, DOI 10.1001/jama.276.4.293; *WHO W PAC REG OFF, 2005, INT POV GEND HLTH PR; Wilcox CE, 2007, SOC SCI MED, V64, P1600, DOI 10.1016/j.socscimed.2006.11.032; World Health Organization, 2005, MENT HLTH INF SYST M; World Health Organization, 2001, WORLD HLTH REP 2001; World Health Organization, 2016, INT STAT CLASS DIS R; Wright A, 2005, MED J AUSTRALIA, V183, P18, DOI 10.5694/j.1326-5377.2005.tb06881.x; Wright A, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-215; Zimmerman FJ, 2005, HEALTH ECON, V14, P1197, DOI 10.1002/hec.1011	144	88	92	0	43	WORLD HEALTH ORGANIZATION	GENEVA	DISTRIBUTION & SALES SERVICE, 1211 27 GENEVA, SWITZERLAND			978-92-4-156397-0				2010							115	134					20	Public, Environmental & Occupational Health; Sociology	Book Citation Index – Social Sciences & Humanities (BKCI-SSH)	Public, Environmental & Occupational Health; Sociology	BPH11	WOS:000278839000007					2022-02-06	
J	Kohl, AD; Wylie, GR; Genova, HM; Hillary, FG; DeLuca, J				Kohl, A. D.; Wylie, G. R.; Genova, H. M.; Hillary, F. G.; DeLuca, J.			The neural correlates of cognitive fatigue in traumatic brain injury using functional MRI	BRAIN INJURY			English	Article						Cognitive fatigue; fMRI; fatigue; basal ganglia; traumatic brain injury	BASAL GANGLIA; HEAD-INJURY; ATTENTION DEFICITS; MENTAL FATIGUE; MEMORY; ACTIVATION; PERFORMANCE; ANATOMY; IMPACT; FMRI	Primary objective: The present study used fMRI (functional magnetic resonance imaging) to objectively assess cognitive fatigue in persons with traumatic brain injury (TBI). It was hypothesized that while performing a cognitive task, TBI participants would show increased brain activity over time, indicative of increased cerebral 'effort' which might manifest as the subjective feeling of cognitive fatigue. Methods and procedures: Functional MRI was used to track brain activity across time while 11 TBI patients with moderate-severe injury and 11 age-matched healthy controls (HCs) performed a modified Symbol Digit Modalities Task (mSDMT). Cognitive fatigue was operationally defined as a relative increase in cerebral activation across time compared to that seen in HCs. ROIs were derived from the Chauduri and Behan model of cognitive fatigue. Main outcomes and results: While performing the mSDMT, participants with a TBI showed increased activity, while HCs subsequently showed decreased activity in several regions including the middle frontal gyrus, superior parietal cortex, basal ganglia and anterior cingulate. Conclusions: Increased brain activity exhibited by participants with a TBI might represent increased cerebral effort which may be manifested as cognitive fatigue. Functional MRI appears to be a potentially useful tool for understanding the neural mechanisms associated with cognitive fatigue in TBI.	[Kohl, A. D.] Rutgers State Univ, Ctr Mol & Behav Neurosci, Newark, NJ USA; [Kohl, A. D.; Wylie, G. R.; Genova, H. M.; DeLuca, J.] Kessler Fdn, Res Ctr, W Orange, NJ USA; [Wylie, G. R.; Genova, H. M.; DeLuca, J.] UMDNJ Grad Sch Biomed Sci, Dept Phys Med & Rehabil, Newark, NJ USA; [Wylie, G. R.; Genova, H. M.; DeLuca, J.] UMDNJ New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ USA; [Hillary, F. G.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA		Wylie, GR (corresponding author), Kessler Med Rehabil Res & Educ Ctr, Neuropsychol & Neurosci Lab, 300 Execut Dr,Suite 10, W Orange, NJ 07052 USA.	gwylie@kmrrec.org	Hillary, Frank/AAN-8622-2021		National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1 R01 NS049176-01A2]; Henry H. Kessler foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049176] Funding Source: NIH RePORTER	This study was supported in part by a National Institute of Health grant (1 R01 NS049176-01A2) and by the Henry H. Kessler foundation.	AARONSON LS, 1999, IMAGE J NURSING SCH, V31, P41; ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P33, DOI 10.1097/01.HTR.0000308719.70288.22; Bandettini PA, 1997, HUM BRAIN MAPP, V5, P93; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Borgaro SR, 2004, BRAIN INJURY, V18, P685, DOI 10.1080/02699050310001646080; Centers for Disease Control and Prevention, 2001, INJ FACT BOOK 2001 2; Chaudhuri A, 2000, J NEUROL SCI, V179, P34, DOI 10.1016/S0022-510X(00)00411-1; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Christodoulou C, 2005, ISS CLIN COGN NEUROP, P19; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Cook DB, 2007, NEUROIMAGE, V36, P108, DOI 10.1016/j.neuroimage.2007.02.033; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; DeLuca J, 2008, J NEUROL SCI, V270, P28, DOI 10.1016/j.jns.2008.01.018; DeLuca J, 2005, ISS CLIN COGN NEUROP, P37; DeLuca J, 2005, ISS CLIN COGN NEUROP, P319; Dittner AJ, 2004, J PSYCHOSOM RES, V56, P157, DOI 10.1016/S0022-3999(03)00371-4; Duntley SP, 2005, ISS CLIN COGN NEUROP, P209; Elovic EP, 2005, ISS CLIN COGN NEUROP, P89; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Koch K, 2006, BRAIN RES, V1107, P140, DOI 10.1016/j.brainres.2006.06.003; Krupp LB, 1996, CURR OPIN NEUROL, V9, P456, DOI 10.1097/00019052-199612000-00011; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Leung HC, 2002, J COGNITIVE NEUROSCI, V14, P659, DOI 10.1162/08989290260045882; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Mulert C, 2005, INT J PSYCHOPHYSIOL, V56, P65, DOI 10.1016/j.ijpsycho.2004.10.002; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Petersen SE, 1998, P NATL ACAD SCI USA, V95, P853, DOI 10.1073/pnas.95.3.853; PRIGITANO GP, 1975, AWARENESS DEFICITS B; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; Riese H, 1999, NEUROPSYCHOL REHABIL, V9, P189, DOI 10.1080/713755600; Schwid SR, 2003, MULT SCLER, V9, P503, DOI 10.1191/1352458503ms946oa; Seger CA, 2006, NEUROSCIENTIST, V12, P285, DOI 10.1177/1073858405285632; Shomstein S, 2006, J NEUROSCI, V26, P435, DOI 10.1523/JNEUROSCI.4408-05.2006; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; Vuilleumier P, 2002, NAT NEUROSCI, V5, P491, DOI 10.1038/nn839; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	44	88	89	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	5					420	432	PII 910862632	10.1080/02699050902788519			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	439NL	WOS:000265633700006	19408165				2022-02-06	
J	Ding, K; de la Plata, CM; Wang, JY; Mumphrey, M; Moore, C; Harper, C; Madden, CJ; McColl, R; Whittemore, A; Devous, MD; Diaz-Arrastia, R				Ding, Kan; de la Plata, Carlos Marquez; Wang, Jun Yi; Mumphrey, Marysa; Moore, Carol; Harper, Caryn; Madden, Christopher J.; McColl, Roderick; Whittemore, Anthony; Devous, Michael D.; Diaz-Arrastia, Ramon			Cerebral Atrophy after Traumatic White Matter Injury: Correlation with Acute Neuroimaging and Outcome	JOURNAL OF NEUROTRAUMA			English	Article						MR imaging; post-traumatic atrophy; TBI	DIFFUSE AXONAL INJURY; BRAIN-INJURY; HEAD-INJURY; MULTIPLE-SCLEROSIS; CORPUS-CALLOSUM; MRI FINDINGS; RECOVERY; ROBUST; MILD; REGISTRATION	Traumatic brain injury (TBI) is a pathologically heterogeneous disease, including injury to both neuronal cell bodies and axonal processes. Global atrophy of both gray and white matter is common after TBI. This study was designed to determine the relationship between neuroimaging markers of acute diffuse axonal injury (DAI) and cerebral atrophy months later. We performed high-resolution magnetic resonance imaging (MRI) at 3 Tesla (T) in 20 patients who suffered non-penetrating TBI, during the acute (within 1 month after the injury) and chronic stage (at least 6 months after the injury). Volume of abnormal fluid-attenuated inversion-recovery (FLAIR) signal seen in white matter in both acute and follow-up scans was quantified. White and gray matter volumes were also quantified. Functional outcome was measured using the Functional Status Examination (FSE) at the time of the chronic scan. Change in brain volumes, including whole brain volume (WBV), white matter volume (WMV), and gray matter volume (GMV), correlates significantly with. acute DAI volume (r = -0.69, -0.59, -0.58, respectively; p < 0.01 for all). Volume of acute R-AIR hyperintensities correlates with volume of decreased FLAIR signal in the follow-up scans (r -0.86, p < 0.001). FSE performance correlates with acute hyperintensity volume and chronic cerebral atrophy (r = 0.53, p = 0.02; r = -0.45, p = 0.03, respectively). Acute axonal lesions measured by FLAIR imaging are strongly predictive of post-traumatic cerebral atrophy. Our findings suggest that axonal pathology measured as white matter lesions following TBI can be identified using MRI, and may be a useful measure for DAI-directed therapies.	[Ding, Kan; Mumphrey, Marysa; Moore, Carol; Harper, Caryn; Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [de la Plata, Carlos Marquez] Univ Texas Dallas, Ctr Brain Hlth, Richardson, TX 75083 USA; [de la Plata, Carlos Marquez] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [Wang, Jun Yi] Univ Texas Dallas, Dept Cognit & Neurosci, Richardson, TX 75083 USA; [Madden, Christopher J.] Univ Texas SW Med Ctr Dallas, Dept Neurol Surg, Dallas, TX 75390 USA; [McColl, Roderick; Whittemore, Anthony; Devous, Michael D.] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA		Diaz-Arrastia, R (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	ramon.diaz-arrastia@utsouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594; , Kan/0000-0003-3485-8200; McColl, Roderick/0000-0001-7022-100X	U.S. Department of EducationUS Department of Education [H133 A020526]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD48179, U01 HD42652]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER	The present study was supported by the U.S. Department of Education (grant NIDRR H133 A020526) and the National Institutes of Health (grants NIH R01 HD48179 and NIH U01 HD42652).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Anderson VM, 2007, J NEUROIMAGING, V17, P61, DOI 10.1111/j.1552-6569.2006.00081.x; Anderson VM, 2006, J MAGN RESON IMAGING, V23, P605, DOI 10.1002/jmri.20550; Ayala RR, 2008, NEUROLOGY, V70, pA362; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 2006, AM J PHYS MED REHAB, V85, P793, DOI 10.1097/01.phm.0000237873.26250.e1; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Jasperse B, 2007, J MAGN RESON IMAGING, V26, P881, DOI 10.1002/jmri.21101; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kinoshita T, 2005, EUR J RADIOL, V56, P5, DOI 10.1016/j.ejrad.2005.04.001; Langlois J, TRAUMATIC BRAIN INJU; LANGLOIS JA, 1997, MMWR-MORBID MORTAL W, V52, P1; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith SK, 2004, POPUL RES POLICY REV, V23, P1, DOI 10.1023/B:POPU.0000019918.24143.c9; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2002, NEUROIMAGE, V17, P479, DOI 10.1006/nimg.2002.1040; Smith SM, 2007, NEUROIMAGE, V36, P1200, DOI 10.1016/j.neuroimage.2007.04.035; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Stuss DT, 2000, NEUROLOGY, V54, P1337, DOI 10.1212/WNL.54.6.1337; Takaoka M, 2002, J NEUROL NEUROSUR PS, V73, P289, DOI 10.1136/jnnp.73.3.289; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Tong KA, 2008, AM J NEURORADIOL, V29, P9, DOI 10.3174/ajnr.A0786; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Weiss N, 2007, CRIT CARE, V11, DOI 10.1186/cc6107; Wilde EA, 2006, BRAIN INJURY, V20, P695, DOI 10.1080/02699050600744079	55	88	91	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2008	25	12					1433	1440		10.1089/neu.2008.0683			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	400IY	WOS:000262862500004	19072588	Green Published			2022-02-06	
J	Gao, X; Deng-Bryant, Y; Cho, W; Carrico, KM; Hall, ED; Chen, JH				Gao, Xiang; Deng-Bryant, Ying; Cho, Wongil; Carrico, Kimberly M.; Hall, Edward D.; Chen, Jinhui			Selective death of newborn neurons in hippocampal dentate gyrus following moderate experimental traumatic brain injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						traumatic brain injury; controlled cortical impact; cell death; dentate gyrus; Fluoro-Jade B	CONTROLLED CORTICAL IMPACT; GENERATED GRANULE CELLS; FLUORO-JADE-B; ADULT NEUROGENESIS; IN-VITRO; STEM-CELLS; SUBUNIT COMPOSITION; EXCITATORY ACTIONS; MOUSE MODEL; RAT	Memory impairment is one of the most significant residual deficits following traumatic brain injury (TBI) and is among the most frequent complaints heard from patients and their relatives. It has been reported that the hippocampus is particularly vulnerable to TBI, which results in hippocampus-dependent cognitive impairment. There are different regions in the hippocampus, and each region is composed of different cell types, which might respond differently to TBI. However, regional and cell type-specific neuronal death following TBI is not well described. Here, we examined the distribution of degenerating neurons in the hippocampus of the mouse brain following controlled cortical impact (CCI) and found that the majority of degenerating neurons observed were in the dentate gyrus after moderate (0.5 mm cortical deformation) CCI-TBI. In contrast, there were only a few degenerating neurons observed in the hilus, and we did not observe any degenerating neurons in the CA3 or CA1 regions. Among those degenerating cells in the dentate gyrus, about 80% of them were found in the inner granular neuron layer. Analysis with cell type-specific markers showed that most of the degenerating neurons in the inner granular neuron layer are newborn immature neurons. Further quantitative analysis shows that the number of newborn immature neurons in the dentate gyrus is dramatically decreased in the ipsilateral hemisphere compared with the contralateral side. Collectively, our data demonstrate the selective death of newborn immature neurons in the hippocampal dentate gyrus following moderate injury with CCI in mice. This selective vulnerability of newborn immature dentate neurons may contribute to the persistent impairment of learning and memory post-TBI and provide an innovative target for neuroprotective treatment strategies. (c) 2008 Wiley-Liss, Inc.	[Deng-Bryant, Ying; Hall, Edward D.; Chen, Jinhui] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Gao, Xiang; Deng-Bryant, Ying; Cho, Wongil; Carrico, Kimberly M.; Hall, Edward D.; Chen, Jinhui] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA		Chen, JH (corresponding author), Univ Kentucky, Dept Anat & Neurobiol, 741 S Limestone St, Lexington, KY 40536 USA.	jchen@uky.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072631, R21NS075733, R01NS046566] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01 NS046566, R21 NS075733, R21 NS072631, R01 NS046566] Funding Source: Medline		ALTMAN J, 1990, J COMP NEUROL, V301, P343, DOI 10.1002/cne.903010303; ALTMAN J, 1990, J COMP NEUROL, V301, P365, DOI 10.1002/cne.903010304; ALTMAN J, 1990, J COMP NEUROL, V301, P325, DOI 10.1002/cne.903010302; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Ben-Ari Y, 2002, NAT REV NEUROSCI, V3, P728, DOI 10.1038/nrn920; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Chen G, 1996, J PHYSIOL-LONDON, V494, P451, DOI 10.1113/jphysiol.1996.sp021505; Chen JH, 2004, P NATL ACAD SCI USA, V101, P16357, DOI 10.1073/pnas.0406795101; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; DAHLSTRAND J, 1992, J CELL SCI, V103, P589; DeRidder MN, 2006, NEUROBIOL DIS, V22, P165, DOI 10.1016/j.nbd.2005.10.011; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Flint AC, 1997, J NEUROSCI, V17, P2469; Forster E, 2006, NAT REV NEUROSCI, V7, P259, DOI 10.1038/nrn1882; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Ge SY, 2006, NATURE, V439, P589, DOI 10.1038/nature04404; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Gleeson JG, 1999, NEURON, V23, P257, DOI 10.1016/S0896-6273(00)80778-3; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; Gupta Y K, 2006, Indian J Physiol Pharmacol, V50, P7; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hellmich HL, 2005, BRAIN RES, V1044, P144, DOI 10.1016/j.brainres.2005.02.054; Isoniemi H, 2006, NEUROLOGY, V67, P756, DOI 10.1212/01.wnl.0000234140.64954.12; Jagasia R, 2006, TRENDS MOL MED, V12, P400, DOI 10.1016/j.molmed.2006.07.006; Jiang Taipeng, 2004, J Huazhong Univ Sci Technolog Med Sci, V24, P392; Kelly Kevin M, 2004, Epilepsy Curr, V4, P160, DOI 10.1111/j.1535-7597.2004.44015.x; Kempermann G, 2006, P NATL ACAD SCI USA, V103, P780, DOI 10.1073/pnas.0510291103; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; Kim JH, 2003, METHOD ENZYMOL, V365, P303; Koizumi H, 2006, NEURON, V49, P55, DOI 10.1016/j.neuron.2005.10.040; Korzhevskii D E, 2006, Neurosci Behav Physiol, V36, P857, DOI 10.1007/s11055-006-0098-5; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Liu YB, 1996, J NEUROPHYSIOL, V76, P1074, DOI 10.1152/jn.1996.76.2.1074; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Markgraf CG, 2001, J NEUROTRAUM, V18, P175, DOI 10.1089/08977150150502604; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; McCarthy MM, 2003, EXP NEUROL, V184, P40, DOI 10.1016/j.expneurol.2003.08.020; Mehrholz J, 2005, CLIN REHABIL, V19, P63, DOI 10.1191/0269215505cr824oa; Minino Arialdi M, 2006, Natl Vital Stat Rep, V54, P1; Mizumori SJY, 2001, REV NEUROSCIENCE, V12, P347; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Overstreet-Wadiche LS, 2006, HIPPOCAMPUS, V16, P208, DOI 10.1002/hipo.20152; Overstreet-Wadiche LS, 2006, J NEUROSCI, V26, P2326, DOI 10.1523/JNEUROSCI.4111-05.2006; Owens DF, 2002, NEURON, V36, P989, DOI 10.1016/S0896-6273(02)01136-4; Pandis C, 2006, NEUROSCIENCE, V140, P163, DOI 10.1016/j.neuroscience.2006.02.003; Payne JA, 2003, TRENDS NEUROSCI, V26, P199, DOI 10.1016/S0166-2236(03)00068-7; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Prigatano GP, 2005, ACT NEUR S, V93, P39; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Represa A, 2005, TRENDS NEUROSCI, V28, P278, DOI 10.1016/j.tins.2005.03.010; Rivera C, 2005, J PHYSIOL-LONDON, V562, P27, DOI 10.1113/jphysiol.2004.077495; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Sipila ST, 2005, J NEUROSCI, V25, P5280, DOI 10.1523/JNEUROSCI.0378-05.2005; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Snyder JS, 2001, J NEUROPHYSIOL, V85, P2423, DOI 10.1152/jn.2001.85.6.2423; Somogyi P, 2005, J PHYSIOL-LONDON, V562, P9, DOI 10.1113/jphysiol.2004.078915; Statler KD, 2006, DEV NEUROSCI-BASEL, V28, P354, DOI 10.1159/000094162; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; Taupin P, 2002, J NEUROSCI RES, V69, P745, DOI 10.1002/jnr.10378; Thomas CG, 2006, J NEUROPHYSIOL, V95, P1727, DOI 10.1152/jn.00771.2005; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Toni N, 2007, NAT NEUROSCI, V10, P727, DOI 10.1038/nn1908; Tovar KR, 1999, J NEUROSCI, V19, P4180; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Traub RD, 2004, ANNU REV NEUROSCI, V27, P247, DOI 10.1146/annurev.neuro.27.070203.144303; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Ye GL, 2005, DEV BRAIN RES, V155, P26, DOI 10.1016/j.devbrainres.2004.12.002; Ye GL, 2000, DEV BRAIN RES, V124, P33, DOI 10.1016/S0165-3806(00)00103-6; ZHANG TY, 2006, PSYCHOPHARM IN PRESS; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006	94	88	91	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	AUG 1	2008	86	10					2258	2270		10.1002/jnr.21677			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	331MB	WOS:000258015200013	18381764	Green Accepted			2022-02-06	
J	Lai, Y; Chen, Y; Watkins, SC; Nathaniel, PD; Guo, F; Kochanek, PM; Jenkins, LW; Szabo, C; Clark, RSB				Lai, Yichen; Chen, Yaming; Watkins, Simon C.; Nathaniel, Paula D.; Guo, Fengli; Kochanek, Patrick M.; Jenkins, Larry W.; Szabo, Csaba; Clark, Robert S. B.			Identification of poly-ADP-ribosylated mitochondrial proteins after traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						ADP-ribosyltransferase; controlled cortical impact; electron transport chain; poly(ADP-ribose) polymerase; poly(ADP-ribose) synthetase; proteomics	APOPTOSIS-INDUCING FACTOR; POLY(ADP-RIBOSE) PAR POLYMER; INDUCED CELL-DEATH; NAD(+) DEPLETION; HEAT-SHOCK; DAMAGE; DNA; GLYCOHYDROLASE; STRESS; MICE	Poly-ADP-ribosylation is a post-translational modification performed by poly(ADP-ribose) polymerases (PARP), involved in many diverse cellular functions including DNA repair, transcription, and long-term potentiation. Paradoxically, PARP over-activation under pathologic conditions including traumatic brain injury (TBI) results in cell death. We previously demonstrated that intra-mitochondrial poly-ADP-ribosylation occurs following excitotoxic and oxidative injury in vitro. Here we sought to identify mitochondrial proteins modified by poly-ADP-ribosylation after TBI in vivo. Poly-ADP-ribosylation within mitochondria from injured brain after experimental TBI in rats was first verified using western blot and immuno-electron microscopy. Poly-ADP-ribosylated mitochondrial proteins identified using a targeted proteomic approach included voltage-dependent anion channel-1, mitofilin, mitochondrial stress proteins, and the electron transport chain components F1F0 ATPase, cytochrome c oxidase, and cytochrome c reductase. To examine the functional consequences of mitochondrial poly-ADP-ribosylation, isolated rat brain mitochondria were exposed to conditions of nitrosative stress known to activate PARP. PARP activation-induced reductions in State 3 respiration were prevented by the PARP-1 inhibitor 5-iodo-6-amino-1,2-benzopyrone or exogenous poly(ADP-ribose) glycohydrolase. As the effects of PARP activation on mitochondrial respiration appear regulated by poly(ADP-ribose) glycohydrolase, a direct effect of poly-ADP-ribosylation on electron transport chain function is suggested. These findings may be of relevance to TBI and other diseases where mitochondrial dysfunction occurs.	[Lai, Yichen; Chen, Yaming; Nathaniel, Paula D.; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Safar Resuscitation Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Lai, Yichen; Chen, Yaming; Watkins, Simon C.; Nathaniel, Paula D.; Guo, Fengli; Kochanek, Patrick M.; Jenkins, Larry W.; Clark, Robert S. B.] Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; [Watkins, Simon C.; Guo, Fengli] Univ Pittsburgh, Safar Resuscitation Res, Dept Cell Biol & Physiol, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Safar Resuscitation Res, Dept Pediat, Pittsburgh, PA 15260 USA; [Szabo, Csaba] Univ Med & Dent New Jersey, Dept Surg, Newark, NJ 07103 USA; [Jenkins, Larry W.] Univ Pittsburgh, Safar Resuscitation Res, Dept Neurol Surg, Pittsburgh, PA USA		Clark, RSB (corresponding author), Univ Pittsburgh, Safar Resuscitation Res, Dept Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	clarkrs@ccm.upmc.edu	Watkins, Simon/ABG-2590-2021; Kochanek, Patrick M/D-2371-2015; Szabo, Csaba/ABG-2644-2021; Szabo, Csaba/D-1882-2013	Watkins, Simon/0000-0003-4092-1552; Kochanek, Patrick M/0000-0002-2627-913X; Lai, Yi-Chen/0000-0002-9450-5506	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD045968] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM060915] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, R01NS038620] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD045968, T32 HD40686] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM060915] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS38620, P50 NS30318] Funding Source: Medline		Andrabi SA, 2006, P NATL ACAD SCI USA, V103, P18308, DOI 10.1073/pnas.0606526103; BURZIO LO, 1981, BIOCHEM BIOPH RES CO, V103, P369, DOI 10.1016/0006-291X(81)91702-2; CARLSSON L, 1983, P NATL ACAD SCI-BIOL, V80, P4664, DOI 10.1073/pnas.80.15.4664; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Cohen-Armon M, 2004, SCIENCE, V304, P1820, DOI 10.1126/science.1096775; Cosi C, 1998, BRAIN RES, V809, P58, DOI 10.1016/S0006-8993(98)00829-4; Cozzi A, 2006, J CEREBR BLOOD F MET, V26, P684, DOI 10.1038/sj.jcbfm.9600222; Davidovic L, 2001, EXP CELL RES, V268, P7, DOI 10.1006/excr.2001.5263; Druzhyna N, 2000, DIABETES, V49, P1849, DOI 10.2337/diabetes.49.11.1849; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; Du XL, 2003, J CLIN INVEST, V112, P1049, DOI 10.1172/JCI200318127; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Fossati S, 2006, BIOCHEM CELL BIOL, V84, P703, DOI 10.1139/O06-083; Gieffers C, 1997, EXP CELL RES, V232, P395, DOI 10.1006/excr.1997.3539; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Halmosi R, 2001, MOL PHARMACOL, V59, P1497, DOI 10.1124/mol.59.6.1497; Hanai S, 2004, P NATL ACAD SCI USA, V101, P82, DOI 10.1073/pnas.2237114100; Hong SJ, 2004, TRENDS PHARMACOL SCI, V25, P259, DOI 10.1016/j.tips.2004.03.005; John GB, 2005, MOL BIOL CELL, V16, P1543, DOI 10.1091/mbc.E04-08-0697; Kim N, 2006, PROTEOMICS, V6, P1237, DOI 10.1002/pmic.200500291; Klaidman LK, 1996, NEUROSCI LETT, V206, P5, DOI 10.1016/0304-3940(96)12446-0; Koh DW, 2004, P NATL ACAD SCI USA, V101, P17699, DOI 10.1073/pnas.0406182101; Lai Y, 2005, J NEUROCHEM, V94, P360, DOI 10.1111/j.1471-4159.2005.03212.x; LAPLACA MC, 1998, J NEUROTRAUM, V15, P878; MASMOUDI A, 1993, BIOCHEM MOL BIOL INT, V29, P77; MASMOUDI A, 1988, J NEUROCHEM, V51, P188, DOI 10.1111/j.1471-4159.1988.tb04854.x; Navet R, 2007, J PROTEOME RES, V6, P25, DOI 10.1021/pr060064u; Nguewa PA, 2005, PROG BIOPHYS MOL BIO, V88, P143, DOI 10.1016/j.pbiomolbio.2004.01.001; NISSELBA.JS, 1969, ANAL BIOCHEM, V27, P212, DOI 10.1016/0003-2697(69)90025-6; Poitras MF, 2007, NEUROSCIENCE, V148, P198, DOI 10.1016/j.neuroscience.2007.04.062; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Saunders PA, 1997, J NEUROCHEM, V69, P1820; Scovassi AI, 2004, FASEB J, V18, P1487, DOI 10.1096/fj.04-1841rev; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; Virag L, 1998, J IMMUNOL, V161, P3753; Weeber EJ, 2002, J BIOL CHEM, V277, P18891, DOI 10.1074/jbc.M201649200; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Ying WH, 2005, J NEUROSCI RES, V79, P216, DOI 10.1002/jnr.20289; Ying WH, 2003, BIOCHEM BIOPH RES CO, V308, P809, DOI 10.1016/S0006-291X(03)01483-9; Yu SW, 2006, P NATL ACAD SCI USA, V103, P18314, DOI 10.1073/pnas.0606528103; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x	44	88	89	0	7	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	MAR	2008	104	6					1700	1711		10.1111/j.1471-4159.2007.05114.x			12	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	269DC	WOS:000253628700023	17996029				2022-02-06	
J	Soane, L; Kahraman, S; Kristian, T; Fiskum, G				Soane, Lucian; Kahraman, Sibel; Kristian, Tibor; Fiskum, Gary			Mechanisms of impaired mitochondrial energy metabolism in acute and chronic neuro degenerative disorders	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article; Proceedings Paper	7th International Conference on Brain Energy Metabolism	AUG 15-18, 2006	Ecole Polytech Fed Lausanne, Lausanne, SWITZERLAND		Ecole Polytech Fed Lausanne	PARP-1; nitric oxide; calcium; apoptosis; mitochondrial permeability transition	PERMEABILITY TRANSITION PORE; MAGNETIC-RESONANCE-SPECTROSCOPY; TRANSIENT FOCAL ISCHEMIA; TRAUMATIC BRAIN-INJURY; CYTOCHROME-C RELEASE; CELL-DEATH; CYCLOSPORINE-A; CYCLOPHILIN-D; CEREBRAL-ISCHEMIA; OXIDATIVE STRESS	Altered mitochondrial energy metabolism contributes to the pathophysiology of acute brain injury caused by ischemia, trauma, and neurotoxins and by chronic neurodegenerative disorders such as Parkinson's and Huntington's diseases. Although much evidence supports that the electron transport chain dysfunction in these metabolic abnormalities has both genetic and intracellular environmental causes, alternative mechanisms are being explored. These include direct, reversible inhibition of cytochrome oxidase by nitric oxide, release of mitochondrial cytochrome c, oxidative inhibition of mitochondrial matrix dehydrogenases and adenine nucleotide transport, the availability of NAD for dehydrogenase reactions, respiratory uncoupling by activities such as that of the permeability transition pore, and altered mitochondrial structure and intracellular trafficking. This review focuses on the catabolism of neuronal NAD and the release of neuronal mitochondrial NAD as important contributors to metabolic dysfunction. In addition, the relationship between apoptotic signaling cascades and disruption of mitochondrial energy metabolism is considered in light of the fine balance between apoptotic and necrotic neural cell death. (c) 2007 Wiley-Liss, Inc.	Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA		Fiskum, G (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, 685 W Baltimore St,MSTF 5-34, Baltimore, MD 21201 USA.	gfiskum@anes.umm.edu	Kristian, Tibor/I-5697-2019; Kristian, Tibor/U-6497-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD016596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007375, R21NS050653, R01NS034152] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD16596, P01 HD016596-240013, P01 HD016596] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS07375, T32 NS007375, NS34152, NS050653, R01 NS034152, R01 NS034152-12, R21 NS050653] Funding Source: Medline		Aksoy P, 2006, BIOCHEM BIOPH RES CO, V345, P1386, DOI 10.1016/j.bbrc.2006.05.042; Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; Albrecht J, 2006, HEPATOLOGY, V44, P788, DOI 10.1002/hep.21357; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; ALLEN KL, 1995, J NEUROCHEM, V64, P2222; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Barsoum MJ, 2006, EMBO J, V25, P3900, DOI 10.1038/sj.emboj.7601253; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Cai AL, 2006, EUR J NEUROSCI, V24, P2169, DOI 10.1111/j.1460-9568.2006.05110.x; CARSON DA, 1986, EXP CELL RES, V164, P273, DOI 10.1016/0014-4827(86)90028-5; Cereghetti GM, 2006, ONCOGENE, V25, P4717, DOI 10.1038/sj.onc.1209605; Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038; CHANG LH, 1992, J CEREBR BLOOD F MET, V12, P1030, DOI 10.1038/jcbfm.1992.140; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Delivani P, 2006, MOL CELL, V21, P761, DOI 10.1016/j.molcel.2006.01.034; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567; Dohm CP, 2006, J MOL NEUROSCI, V29, P1, DOI 10.1385/JMN:29:1:1; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; Dubinsky JM, 1999, BIOCHEM SOC SYMP, V66, P75, DOI 10.1042/bss0660075; Feldkamp T, 2004, AM J PHYSIOL-RENAL, V286, pF749, DOI 10.1152/ajprenal.00276.2003; Feng ZC, 1998, RESUSCITATION, V37, P33, DOI 10.1016/S0300-9572(98)00031-8; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0; Germain M, 2005, EMBO J, V24, P1546, DOI 10.1038/sj.emboj.7600592; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Hansson MJ, 2004, J BIOENERG BIOMEMBR, V36, P407, DOI 10.1023/B:JOBB.0000041776.31885.45; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; Jacobson J, 2005, J NEUROCHEM, V95, P388, DOI 10.1111/j.1471-4159.2005.03374.x; Kahraman S, 2007, NEUROCHEM RES, V32, P799, DOI 10.1007/s11064-006-9206-8; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; Kirkinezos IG, 2005, J NEUROSCI, V25, P164, DOI 10.1523/JNEUROSCI.3829-04.2005; Kosenko E, 2004, J NEUROCHEM, V89, P1101, DOI 10.1111/j.1471-4159.2004.02426.x; Kristal BS, 2004, J BIOENERG BIOMEMBR, V36, P309, DOI 10.1023/B:JOBB.0000041759.35731.70; Kristian T, 2004, CELL CALCIUM, V36, P221, DOI 10.1016/j.ceca.2004.02.016; Kuroda S, 1996, ACTA PHYSIOL SCAND, V156, P149, DOI 10.1046/j.1365-201X.1996.449170000.x; KURUP CKR, 1990, J BIOENERG BIOMEMBR, V22, P61; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Lindholm D, 2004, BIOCHEM BIOPH RES CO, V321, P753, DOI 10.1016/j.bbrc.2004.06.138; Luetjens CM, 2000, J NEUROSCI, V20, P5715; Mannella CA, 2006, BBA-MOL BASIS DIS, V1762, P140, DOI 10.1016/j.bbadis.2005.07.001; Marmarou A, 2005, ACT NEUR S, V95, P149; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; McBride HM, 2006, CURR BIOL, V16, pR551, DOI 10.1016/j.cub.2006.06.054; Muruganandham M, 2005, CLIN CANCER RES, V11, P3503, DOI 10.1158/1078-0432.CCR-04-1399; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Narasimhan P, 2003, MOL BRAIN RES, V113, P28, DOI 10.1016/S0169-328X(03)00062-7; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Ouyang YB, 1997, NEUROSCI RES COMMUN, V20, P167, DOI 10.1002/(SICI)1520-6769(199705)20:3<167::AID-NRC198>3.0.CO;2-3; Parone PA, 2006, BBA-MOL CELL RES, V1763, P522, DOI 10.1016/j.bbamcr.2006.04.005; Perez-Pinzon MA, 1998, J CEREBR BLOOD F MET, V18, P215, DOI 10.1097/00004647-199802000-00013; PerezPinzon MA, 1997, BRAIN RES, V754, P163, DOI 10.1016/S0006-8993(97)00066-8; Polster BM, 2001, J BIOL CHEM, V276, P37887; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Rostovtseva TK, 2005, J BIOENERG BIOMEMBR, V37, P129, DOI 10.1007/s10863-005-6566-8; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Schmidt-Kastner R, 2004, BRAIN RES, V1001, P133, DOI 10.1016/j.brainres.2003.11.065; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Sensi SL, 2004, CURR MOL MED, V4, P87, DOI 10.2174/1566524043479211; Seo YW, 2003, J BIOL CHEM, V278, P48292, DOI 10.1074/jbc.M308785200; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Sharpley MS, 2006, J BIOL CHEM, V281, P34803, DOI 10.1074/jbc.M607389200; Shuttleworth CW, 2003, J NEUROSCI, V23, P3196; Solenski NJ, 2002, STROKE, V33, P816, DOI 10.1161/hs0302.104541; Starkov AA, 2002, J NEUROCHEM, V83, P220, DOI 10.1046/j.1471-4159.2002.01153.x; Suh SW, 2003, J NEUROSCI, V23, P10681; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Tanaka S, 2005, J NEUROCHEM, V95, P179, DOI 10.1111/j.1471-4159.2005.03353.x; Tieu K, 2003, J CLIN INVEST, V112, P892, DOI 10.1172/JCI200318797; Tretter L, 2000, J NEUROSCI, V20, P8972; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Vesce S, 2005, J BIOL CHEM, V280, P38720, DOI 10.1074/jbc.M506575200; Vishwasrao HD, 2005, J BIOL CHEM, V280, P25119, DOI 10.1074/jbc.M502475200; Wallace DC, 2005, GENE, V354, P169, DOI 10.1016/j.gene.2005.05.001; Walter L, 2005, J BIOENERG BIOMEMBR, V37, P191, DOI 10.1007/s10863-005-6600-x; WELSH FA, 1982, J CEREBR BLOOD F MET, V2, P221, DOI 10.1038/jcbfm.1982.22; WOODFIELD K, 1988, BIOCHEM J, V336, P287; Yasuda O, 2006, J BIOL CHEM, V281, P23899, DOI 10.1074/jbc.M512610200; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Ying WH, 2006, FRONT BIOSCI-LANDMRK, V11, P3129, DOI 10.2741/2038; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697; YU T, 2006, FRONT BIOSCI, V103, P2653; Yu TZ, 2006, P NATL ACAD SCI USA, V103, P2653, DOI 10.1073/pnas.0511154103; Yuan H, 2007, CELL DEATH DIFFER, V14, P462, DOI 10.1038/sj.cdd.4402046; Zaidan E, 1999, J NEUROCHEM, V73, P2214; Zaidan E, 1996, NEUROSCI LETT, V218, P75, DOI 10.1016/S0304-3940(96)13128-1; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zanelli SA, 2006, J NEUROCHEM, V97, P724, DOI 10.1111/j.1471-4159.2006.03767.x; Zeng JY, 2007, J CEREBR BLOOD F MET, V27, P304, DOI 10.1038/sj.jcbfm.9600335; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	105	88	97	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	NOV 15	2007	85	15					3407	3415		10.1002/jnr.21498			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	231SW	WOS:000250970300022	17847081	Bronze, Green Accepted			2022-02-06	
J	Matheis, RJ; Schultheis, MT; Tiersky, LA; DeLuca, J; Millis, SR; Rizzo, A				Matheis, Robert J.; Schultheis, Maria T.; Tiersky, Lana A.; DeLuca, John; Millis, Scott R.; Rizzo, Albert			Is learning and memory different in a virtual environment?	CLINICAL NEUROPSYCHOLOGIST			English	Article						ecological validity; learning and memory; neuropsychological assessment; traumatic brain injury (TBI); virtual reality (VR)	TRAUMATIC BRAIN-INJURY; CARD SORTING TEST; ECOLOGICAL VALIDITY; NEUROPSYCHOLOGICAL TESTS; EXECUTIVE FUNCTION; REALITY; REHABILITATION; PERFORMANCE; RELIABILITY; MODERATE	It has been suggested that virtual reality may provide a medium for producing neuropsychological measures with greater ecological validity. The present study examined the usefulness of virtual reality (VR) to assess learning and memory in individuals with traumatic brain injury (TB). A total of 20 TBI participants were compared with 20 healthy controls on their ability to learn and recall 16 target items presented within a VR-based generic office environment. The results indicated that VR memory testing accurately distinguished the TBI group from controls. Additionally, non-memory-impaired TBI participants acquired targets at the same rate as HC participants. Finally, there was a significant relationship between the VR Office and a standard neuropsychological measure of memory, suggesting the construct validity of the task. These findings suggest that the VR Office provides a viable medium for measuring learning and memory. The present results provide provide preliminary support for the ecological validity of the VR Of can improve assessment of real-world functioning following TBI.	Fairleigh Dickinson Univ, Sch Psychol, Teaneck, NJ USA; Kessler Med Rehabil Res & Educ Corp, REAL, W Orange, NJ USA; Kessler Med Rehabil Res & Educ Corp, Neurosci Res, W Orange, NJ USA; Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Univ So Calif, Integrated Media Syst Ctr, Los Angeles, CA USA		Schultheis, MT (corresponding author), Drexel Univ, Dept Psychol, 3141 Chestnut St, Philadelphia, PA 19104 USA.	schultheis@drexel.edu		Schultheis, Maria/0000-0002-6558-548X			Benedict RHB, 1996, PSYCHOL ASSESSMENT, V8, P145, DOI 10.1037/1040-3590.8.2.145; Bennett TL, 2001, ARCH CLIN NEUROPSYCH, V16, P237, DOI 10.1016/S0887-6177(00)00082-2; Bowman ML, 1996, CLIN NEUROPSYCHOL, V10, P382, DOI 10.1080/13854049608406699; Brooks BM, 2004, BRAIN INJURY, V18, P391, DOI 10.1080/02699050310001619855; Buckwalter J G, 1997, Stud Health Technol Inform, V39, P17; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; Delis D, 1997, CALIFORNIA VERBAL LE; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Elkind JS, 2001, CYBERPSYCHOL BEHAV, V4, P489, DOI 10.1089/109493101750527042; Farias ST, 2003, ARCH CLIN NEUROPSYCH, V18, P655, DOI 10.1016/S0887-6177(02)00159-2; FRICK RW, 1984, MEM COGNITION, V12, P507, DOI 10.3758/BF03198313; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Heaton R.K., 1981, WISCONSIN CARD SORTI; Hooper HE., 1983, HOOPER VISUAL ORG TE; Kaplan E, 1983, BOSTON NAMING TEST; Kibby MY, 1998, ARCH CLIN NEUROPSYCH, V13, P523, DOI 10.1016/S0887-6177(97)00038-3; Ku J, 2003, CYBERPSYCHOL BEHAV, V6, P397, DOI 10.1089/109493103322278781; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Mayer RE, 1997, EDUC PSYCHOL-US, V32, P1, DOI 10.1207/s15326985ep3201_1; Moreno R, 1999, J EDUC PSYCHOL, V91, P358, DOI 10.1037/0022-0663.91.2.358; NEWNAN OS, 1978, PERCEPT MOTOR SKILL, V46, P635, DOI 10.2466/pms.1978.46.2.635; PIOK M, 2004, HALS NASEN OHREN HEI, V10, P443; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Riva G, 1997, ST HEAL T, V44, P71; Rizzo AA, 1997, ST HEAL T, V44, P123; Sbordone RJ, 1996, ECOLOGICAL VALIDITY; Schultheis MT, 2002, J HEAD TRAUMA REHAB, V17, P378, DOI 10.1097/00001199-200210000-00002; Schultheis MT, 2001, REHABIL PSYCHOL, V46, P296, DOI 10.1037/0090-5550.46.3.296; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Vakil E, 1996, BRAIN COGNITION, V31, P75, DOI 10.1006/brcg.1996.0026; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wechsler ., 1997, WECHSLER ADULT INTEL; Wechsler, 1999, WECHSLER ABBREVIATED; Zhang L, 2003, ARCH PHYS MED REHAB, V84, P1118, DOI 10.1016/S0003-9993(03)00203-X; Zhang L, 2001, AM J PHYS MED REHAB, V80, P597, DOI 10.1097/00002060-200108000-00010	36	88	89	1	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	JAN	2007	21	1					146	161		10.1080/13854040601100668			16	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	135UU	WOS:000244180200009	17366282				2022-02-06	
J	Wang, KKW; Larner, SF; Robinson, G; Hayes, RL				Wang, Kevin K. W.; Larner, Stephen F.; Robinson, Gillian; Hayes, Ronald L.			Neuroprotection targets after traumatic brain injury	CURRENT OPINION IN NEUROLOGY			English	Article						antagonist; hypothermia; inhibitor; neuroprotection; traumatic brain injury	RECEPTOR ANTAGONISTS; CELL-DEATH; PERMEABILITY TRANSITION; CALPAIN INHIBITORS; CASPASE INHIBITOR; CLINICAL-TRIALS; CYCLOSPORINE-A; RATS; ERYTHROPOIETIN; DISEASE	Purpose of review The scarcity of pharmacological neuroprotective treatments for traumatic brain injury is a concern being targeted on various fronts. This review examines the latest treatments under investigation. Recent findings In the last 12-18 months, no drug has completed phase III clinical trials as a clearly proven method to treat traumatic brain injury. While the drugs work in rodents, when they make it to clinical trial they have failed primarily due to negative side-effects. Those still in trial show promise, and even those rejected have undergone modifications and now show potential, e.g. second-generation N-methyl-D-aspartic acid and alpha-amino-3-hydroxy-methyl-4-isoxazolyl-propionic acid receptor antagonists, calpain inhibitors, and cyclosporine A analogues. Also, several drugs not previously given much attention, such as the antibiotic minocycline, estrogen and progesterone, and a drug already approved for other diseases, erythropoietin, are being examined. Finally, a treatment generating some controversy, but showing potential, is the application of hypothermia to the patients. Summary Clearly, finding treatments for traumatic brain injury is not going to be easy and is evidently going to require numerous trials. The good news is that we are closer to finding one or more methods for treating traumatic brain injury patients.	Univ Florida, McKnight Brain Inst, Dept Psychiat, Ctr Neuroproteom & Biomarkers Res, Gainesville, FL 32610 USA; Univ Florida, McKnight Brain Inst, Dept Neurosci, Ctr Traumat Brain Injury Studies, Gainesville, FL 32610 USA; Banyon Biomarkers Inc, Alachua, FL USA		Wang, KKW (corresponding author), Univ Florida, McKnight Brain Inst, Dept Psychiat, Ctr Neuroproteom & Biomarkers Res, 100 S Newell Dr,Box 100256, Gainesville, FL 32610 USA.	kwang@psychiatry.ufl.edu		Wang, Kevin/0000-0002-9343-6473			Belayev L, 2001, J NEUROTRAUM, V18, P1031, DOI 10.1089/08977150152693728; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Cai SX, 2006, CURR TOP MED CHEM, V6, P651, DOI 10.2174/156802606776894465; Carey ME, 1996, J TRAUMA, V40, pS165, DOI 10.1097/00005373-199603001-00036; Chen HSV, 2006, J NEUROCHEM, V97, P1611, DOI 10.1111/j.1471-4159.2006.03991.x; Cooper GJ, 1996, J TRAUMA, V40, pS105, DOI 10.1097/00005373-199603001-00024; Davies A R, 2005, Crit Care Resusc, V7, P238; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Dubal DB, 2006, ENDOCRINOLOGY, V147, P3076, DOI 10.1210/en.2005-1177; Furukawa T, 2003, J NEUROTRAUM, V20, P269, DOI 10.1089/089771503321532851; Han BH, 2002, J BIOL CHEM, V277, P30128, DOI 10.1074/jbc.M202931200; Hansson MJ, 2004, J BIOENERG BIOMEMBR, V36, P407, DOI 10.1023/B:JOBB.0000041776.31885.45; Hasselblatt M, 2006, J NEUROSURG ANESTH, V18, P132, DOI 10.1097/00008506-200604000-00007; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hoffman GE, 2006, ENDOCRINE, V29, P217, DOI 10.1385/ENDO:29:2:217; Irazuzta J, 2005, INTENS CARE MED, V31, P146, DOI 10.1007/s00134-004-2462-7; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kreuter M, 2004, ARCH IMMUNOL THER EX, V52, P141; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; KURTZKE JF, 1992, CLIN NEUROLOGY, V4, P80; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Linton SD, 2005, J MED CHEM, V48, P6779, DOI 10.1021/jm050307e; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Matucz E, 2004, BRAIN RES, V1019, P210, DOI 10.1016/j.brainres.2004.05.098; Mcilvoy LH, 2005, AACN ADV CRIT CARE, V16, P488, DOI 10.1097/00044067-200510000-00006; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; Ringger NC, 2004, J NEUROTRAUM, V21, P829, DOI 10.1089/0897715041526177; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Sairanen T, 2006, BRAIN, V129, P189, DOI 10.1093/brain/awh645; Seppelt I, 2005, Crit Care Resusc, V7, P233; Shirasaki Y, 2005, BIOORGAN MED CHEM, V13, P4473, DOI 10.1016/j.bmc.2005.04.059; Siren AL, 2006, BRAIN, V129, P480, DOI 10.1093/brain/awh703; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Tanaka Ken-ichi, 2004, Nihon Shinkei Seishin Yakurigaku Zasshi, V24, P71; THRUMAN DJ, 2001, HEAD TRAUMA BASIC PR, P327; Tsai PT, 2006, J NEUROSCI, V26, P1269, DOI 10.1523/JNEUROSCI.4480-05.2006; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Weiser T, 2002, CURR PHARM DESIGN, V8, P941, DOI 10.2174/1381612024607135; Wessely S, 1999, LANCET, V354, P936, DOI 10.1016/S0140-6736(98)08320-2; Yang W, 2003, BRIT J PHARMACOL, V140, P402, DOI 10.1038/sj.bjp.0705450; Yu DY, 2006, IUBMB LIFE, V58, P429, DOI 10.1080/15216540600791555; Yurkewicz L, 2005, J NEUROTRAUM, V22, P1428, DOI 10.1089/neu.2005.22.1428; Zhu M, 2006, NEUROSCIENCE, V141, P2019, DOI 10.1016/j.neuroscience.2006.05.011	60	88	91	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2006	19	6					514	519		10.1097/WCO.0b013e3280102b10			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	115XJ	WOS:000242766800002	17102687	Green Submitted			2022-02-06	
J	Bach, LJ; David, AS				Bach, Laura J.; David, Anthony S.			Self-awareness after acquired and traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							IMPAIRED AWARENESS; HEAD-INJURY; BEHAVIORAL LIMITATIONS; ALZHEIMERS-DISEASE; PREFRONTAL CORTEX; CLOSE RELATIVES; FRONTAL LOBES; RATING-SCALE; MIND; REHABILITATION	Self-awareness deficits are common after acquired and (traumatic) brain injury (ABI), particularly in social behaviour, yet the underlying cognitive and neuroanatomical structures supporting social self-awareness are not fully understood. This paper reviews the current literature on prevalence, type and severity of self-awareness deficits in ABI. Neuropsychological and neuroanatomical models are reviewed and theoretical frameworks are examined. We summarise results of a case-control comparison of 20 ABI patients with and 20 ABI patients without behavioural disturbance. Our research found that lack of social self-awareness predicts behavioural disturbance in acquired and traumatic brain injury independent of cognitive and executive function. Theory of mind ability was related to self-awareness and a possible role for metacognition and affective processes in self-awareness is discussed to account for social self-awareness deficits.	Maudsley Hosp & Inst Psychiat, Lishman Brain Injury Unit, London SE5 8AZ, England; Inst Psychiat, Dept Med Psychol, London, England		Bach, LJ (corresponding author), Maudsley Hosp & Inst Psychiat, Lishman Brain Injury Unit, Denmark Hill, London SE5 8AZ, England.	l.bach@iop.kcl.ac.uk	David, Anthony/O-1750-2019; David, Anthony S/C-1315-2011	David, Anthony/0000-0003-0967-774X; David, Anthony S/0000-0003-0967-774X			Agnew SK, 1998, AGING MENT HEALTH, V2, P7, DOI 10.1080/13607869856876; ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; BARONCOHEN S, 1989, J CHILD PSYCHOL PSYC, V30, P285, DOI 10.1111/j.1469-7610.1989.tb00241.x; Bechara A, 2004, BRAIN COGNITION, V55, P30, DOI 10.1016/j.bandc.2003.04.001; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; BRAMHAM J, 2006, EMOTIONAL SOCIAL FUN; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Clare L, 2004, J CLIN EXP NEUROPSYC, V26, P215, DOI 10.1076/jcen.26.2.215.28088; Cohen J., 2013, STAT POWER ANAL BEHA; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [DOI 10.1097/00001199-198909000-00008, 10.1097/00001199-198909000-00008]; Damasio AR, 1996, PHILOS T R SOC B, V351, P1413, DOI 10.1098/rstb.1996.0125; DAVID A, 1992, BRIT J PSYCHIAT, V161, P599, DOI 10.1192/bjp.161.5.599; DAVID AS, 1990, BRIT J PSYCHIAT, V156, P798, DOI 10.1192/bjp.156.6.798; DEATON AV, 1986, REHABIL PSYCHOL, V31, P231, DOI 10.1037//0090-5550.31.4.231; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fischer S, 2004, J INT NEUROPSYCH SOC, V10, P190, DOI 10.1017/S1355617704102051; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; FLEMING JM, 1999, P 21 ANN BRAIN IMP C; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Freeland J, 1996, MAGAZINE, V4, P32; Frith C, 1996, J PSYCHOPHARMACOL, V10, P9, DOI 10.1177/026988119601000103; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Happe F, 1999, COGNITION, V70, P211, DOI 10.1016/S0010-0277(99)00005-0; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; HORNAK J, 1996, J COGNITIVE NEUROSCI, V16, P463; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kraus JF, 1993, HEAD INJURY, P1; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; Lanham RA, 2000, J HEAD TRAUMA REHAB, V15, P1123, DOI 10.1097/00001199-200010000-00006; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; MALIA K, 1997, J COGNITIVE REHA MAY, P10; Markova IS, 2000, MEMORY DISORDERS IN PSYCHIATRIC PRACTICE, P204, DOI 10.1017/CBO9780511530197.011; McCrae RR, 1998, J PERS, V66, P285, DOI 10.1111/1467-6494.00013; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Newman AC, 2000, BRAIN INJURY, V14, P333; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1999, REHABIL PSYCHOL, V44, P145, DOI 10.1037/0090-5550.44.2.145; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P162; RANSEEN JD, 1990, INT J CLIN NEUROPSYC, V9, P145; Santos ME, 1998, BRAIN INJURY, V12, P759, DOI 10.1080/026990598122151; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; SCHACTER DL, 1990, J CLIN EXP NEUROPSYC, V12, P155, DOI 10.1080/01688639008400962; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Stuss DT, 2004, BRAIN COGNITION, V55, P69, DOI 10.1016/s0278-2626(03)00271-9; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; TYRER P, 1979, BRIT J PSYCHIAT, V135, P163, DOI 10.1192/bjp.135.2.163; VANREEKUM R, 1996, BRAIN INJURY, V10, P19; Weinstein E.A., 1955, DENIAL ILLNESS SYMBO	68	88	89	1	23	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	AUG	2006	16	4					397	414		10.1080/09602010500412830			18	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	078YU	WOS:000240143500004	16864479				2022-02-06	
J	Swartz, BE; Houser, CR; Tomiyasu, U; Walsh, GO; DeSalles, A; Rich, JR; Delgado-Escueta, A				Swartz, Barbara E.; Houser, Carolyn R.; Tomiyasu, Uwami; Walsh, Gregory O.; DeSalles, Antonio; Rich, J. Ronald; Delgado-Escueta, Antonio			Hippocampal cell loss in posttraumatic human epilepsy	EPILEPSIA			English	Article						temporal lobe epilepsy; traumatic brain injury; hippocampal sclerosis; dentate gyrus	TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; DENTATE GYRUS; HEAD TRAUMA; SURGICAL OUTCOMES; DUAL PATHOLOGY; NEURON LOSS; REORGANIZATION; RAT; PATHOGENESIS	Purpose: We performed this study to determine whether significant head trauma in human adults can result in hippocampal cell loss, particularly in hilar (polymorph) and CA3 neurons, similar to that observed in animal models of traumatic brain injury. We examined the incidence of hippocampal pathology and its relation to temporal neocortical pathology, neuronal reorganization, and other variables. Methods: Twenty-one of 200 sequential temporal lobectomies had only trauma as a risk factor for epilepsy. Tissue specimens from temporal neocortex and hippocampus were stained with glial fibrillary acidic protein (GFAP) and hematoxylin and eosin (H&E). Eleven hippocampal specimens had additional analysis of neuronal distributions by using cresyl violet and immunolabeling of a neuron-specific nuclear protein. Results: The median age at onset of trauma was 19 years, the median time between trauma and onset of seizures was 2 years, and the median epilepsy duration was 16 years. The length of the latent period was inversely related to the age at the time of trauma (r = 0.75; Spearman). The neocortex showed gliosis in all specimens, with hemosiderosis (n = 8) or heterotopias (n = 6) in some, a distribution differing from chance (p = 0.02; Fisher). Hippocampal neuronal loss was found in 94% of specimens, and all of these had cell loss in the polymorph (hilar) region of the dentate gyrus. Hilar cell loss ranged from mild, when cell loss was confined to the hilus, to severe, when cell loss extended into CA3 and CA1. Some degree of mossy fiber sprouting was found in the dentate gyrus of all 10 specimens in which it was evaluated. Granule cell dispersion (n = 4) was seen only in specimens with moderate to severe neuronal loss. Conclusions: Neocortical pathology was universally present after trauma. Neuronal loss in the hilar region was the most consistent finding in the hippocampal formation, similar to that found in the fluid-percussion model of traumatic head injury. These findings support the idea that head trauma can induce hippocampal epilepsy in humans in the absence of other known risk factors.	Hoag Mem Hosp, Epilepsy Ctr, Newport Beach, CA 92658 USA; VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA; VA Greater Los Angeles Healthcare Syst, Neurol Serv, Los Angeles, CA USA; VA Greater Los Angeles Healthcare Syst, Pathol Serv, Los Angeles, CA USA; Univ Calif Los Angeles, Calif Comprehens Epilepsy Program, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA USA		Swartz, BE (corresponding author), Hoag Mem Hosp, Epilepsy Ctr, 1 Hoag Dr,POB 6100, Newport Beach, CA 92658 USA.	BSwartz@Hoaghospital.org		Delgado-Escueta, Antonio V./0000-0002-1581-6999	Veterans AffairsUS Department of Veterans Affairs [I01BX000404] Funding Source: NIH RePORTER; BLRD VA [I01 BX000404] Funding Source: Medline		Annegers JF., 1996, TREATMENT EPILEPSY P, P165; BABB T, 1996, TREATMENT EPILEPSY P, P106; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Berg AT, 2003, NEUROLOGY, V60, P186, DOI 10.1212/01.WNL.0000031792.89992.EC; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bratz E, 1899, ARCH PSYCHIAT, V31, P820, DOI 10.1007/BF02047162; BRUTON CJ, 1988, MAUDSLEY MONOGRAPHS, V31; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; CENDES F, 1995, NEUROLOGY, V45, P2058, DOI 10.1212/WNL.45.11.2058; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; COURVILLE CB, 1958, TEMPORAL LOBE EPILEP, P220; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; EVANS JH, 1962, NEUROLOGY, V12, P665, DOI 10.1212/WNL.12.10.665; FALCONER MA, 1964, ARCH NEUROL-CHICAGO, V10, P233, DOI 10.1001/archneur.1964.00460150003001; FRENCH JA, 1993, ANN NEUROL, V34, P774, DOI 10.1002/ana.410340604; Fuerst D, 2003, ANN NEUROL, V53, P413, DOI 10.1002/ana.10509; GILMORE LF, 1979, ANN NEUROL, V4, P329; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; HARDIMAN O, 1988, NEUROLOGY, V38, P1041, DOI 10.1212/WNL.38.7.1041; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; HOUSER CR, 1990, BRAIN RES, V535, P195, DOI 10.1016/0006-8993(90)91601-C; HOUSER CR, 1990, J NEUROSCI, V10, P267; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; JOHANSEN FF, 1993, ACTA NEUROL SCAND, V88, P1; LEVESQUE MF, 1991, J NEUROSURG, V75, P364, DOI 10.3171/jns.1991.75.3.0364; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MANAKA S, 1981, FOLIA PSYCHIAT NEU J, V35, P301; MARGERISON JH, 1966, BRAIN, V89, P499, DOI 10.1093/brain/89.3.499; MARKS DA, 1995, NEUROLOGY, V45, P2051, DOI 10.1212/WNL.45.11.2051; Mathern G.W., 1997, EPILEPSY COMPREHENSI, P133; MATHERN GW, 1995, BRAIN, V118, P105, DOI 10.1093/brain/118.1.105; MATHERN GW, 1994, EPILEPSY RES, V19, P129, DOI 10.1016/0920-1211(94)90023-X; MEENCKE HJ, 1984, EPILEPSIA, V25, P8, DOI 10.1111/j.1528-1157.1984.tb04149.x; OBENAUS A, 1993, J NEUROSCI, V13, P4470; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PohlmannEden B, 1997, ACTA NEUROL SCAND, V95, P257, DOI 10.1111/j.1600-0404.1997.tb00206.x; ROBBINS RJ, 1991, ANN NEUROL, V29, P325, DOI 10.1002/ana.410290316; SAGAR HJ, 1987, ANN NEUROL, V22, P334, DOI 10.1002/ana.410220309; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Schottler F, 1998, J COMP NEUROL, V395, P29; Schuh LA, 1998, ARCH NEUROL-CHICAGO, V55, P1325, DOI 10.1001/archneur.55.10.1325; SLOVITER RS, 1994, ANN NEUROL, V35, P640, DOI 10.1002/ana.410350604; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; SWARTZ BE, 1990, EPILEPSY RES, V5, P146, DOI 10.1016/0920-1211(90)90031-P; SWARTZ BE, 1992, EPILEPSIA, V33, P624, DOI 10.1111/j.1528-1157.1992.tb02338.x; SWARTZ BE, 1990, EPILEPSY RES, V5, P61, DOI 10.1016/0920-1211(90)90066-5; Swartz BE, 1998, EPILEPSY RES, V29, P97, DOI 10.1016/S0920-1211(97)00070-3; Toth Z, 1997, J NEUROSCI, V17, P8106; WILLMORE LJ, 1992, NEUROL CLIN, V10, P869, DOI 10.1016/S0733-8619(18)30184-1; Wolf P, 2001, EPILEPSIA, V42, P573	53	88	97	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	AUG	2006	47	8					1373	1382		10.1111/j.1528-1167.2006.00602.x			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	071XB	WOS:000239636100015	16922884	Bronze			2022-02-06	
J	Tung, GA; Kumar, M; Richardson, RC; Jenny, C; Brown, WD				Tung, Glenn A.; Kumar, Monica; Richardson, Randal C.; Jenny, Carole; Brown, William D.			Comparison of accidental and nonaccidental traumatic head injury in children on noncontrast computed tomography	PEDIATRICS			English	Article						abuse; subdural hematoma; brain imaging; accidents; retinal hemorrhage	ACUTE SUBDURAL-HEMATOMA; SHAKEN IMPACT SYNDROME; YOUNG-CHILDREN; FINE-STRUCTURE; BABY SYNDROME; BRAIN-INJURY; CRANIAL MRI; CT FINDINGS; ABUSE; INFANTS	OBJECTIVE. Mixed-density convexity subdural hematoma and interhemispheric subdural hematoma suggest nonaccidental head injury. The purpose of this retrospective observational study is to investigate subdural hematoma on noncontrast computed tomography in infants with nonaccidental head injury and to compare these findings in infants with accidental head trauma for whom the date of injury was known. PATIENTS AND METHODS. Two blinded, independent observers retrospectively reviewed computed tomography scans with subdural hematoma performed on the day of presentation on 9 infant victims of nonaccidental head injury ( mean age: 6.8 months; range: 1 - 25 months) and on 38 infants ( mean age: 4.8 months; range: newborn to 34 months) with accidental head trauma (birth-related: 19; short fall: 17; motor vehicle accident: 2). RESULTS. Homogeneous hyperdense subdural hematoma was significantly more common in children with accidental head trauma ( 28 of 38 [74%]; nonaccidental head trauma: 3 of 9 [ 33%]), whereas mixed-density subdural hematoma was significantly more common in cases of nonaccidental head injury ( 6 of 9 [67%]; accidental head trauma: 7 of 38 [18%]). Twenty-two ( 79%) subdural hematomas were homogeneously hyperdense on noncontrast computed tomography performed within two days of accidental head trauma, one ( 4%) was homogeneous and isodense compared to brain tissue, one ( 4%) was homogeneous and hypodense, and four ( 14%) were mixed-density. There was no statistically significant difference in the proportion of interhemispheric subdural hematoma, epidural hematoma, calvarial fracture, brain contusion, or subarachnoid hemorrhage . CONCLUSIONS. Homogeneous hyperdense subdural hematoma is more frequent in cases of accidental head trauma; mixed-density subdural hematoma is more frequent in cases of nonaccidental head injury but may be observed within 48 hours of accidental head trauma. Interhemispheric subdural hematoma is not specific for inflicted head injury.	Rhode Isl Hosp, Dept Diagnost Imaging, Providence, RI 02903 USA; Rhode Isl Hosp, Dept Pediat, Providence, RI 02903 USA; Rhode Isl Hosp, Dept Neurol, Providence, RI 02903 USA; Brown Univ, Sch Med, Hasbro Childrens Hosp, Providence, RI 02912 USA		Tung, GA (corresponding author), Rhode Isl Hosp, Dept Diagnost Imaging, 593 Eddy St, Providence, RI 02903 USA.	gtung@lifespan.org		Richardson, Randal/0000-0003-3546-9266			Barnes PD, 2000, PEDIATR RADIOL, V30, P74, DOI 10.1007/s002470050018; BERGSTROM M, 1977, J COMPUT ASSIST TOMO, V1, P449, DOI 10.1097/00004728-197710000-00011; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Block R W, 1999, Curr Probl Pediatr, V29, P249; BROWN JK, 1993, DEV MED CHILD NEUROL, V35, P849; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; BRUCE DA, 1989, PEDIATR ANN, V18, P486; BRUCE DA, 1989, PEDIATR ANN, V18, P492; Case ME, 2001, AM J FOREN MED PATH, V22, P112, DOI 10.1097/00000433-200106000-00002; Chabrol B, 1999, CHILD ABUSE NEGLECT, V23, P217, DOI 10.1016/S0145-2134(98)00128-8; CHAN KH, 1990, CHILD NERV SYST, V6, P27, DOI 10.1007/BF00262262; Chen CY, 1999, NEURORADIOLOGY, V41, P711, DOI 10.1007/s002340050830; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Feldman KW, 2001, PEDIATRICS, V108, P636, DOI 10.1542/peds.108.3.636; FRIEDE RL, 1978, AM J PATHOL, V92, P69; GREENBERG J, 1985, NEUROSURGERY, V17, P48, DOI 10.1227/00006123-198507000-00008; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; Hart BL, 1996, AM J FOREN MED PATH, V17, P217, DOI 10.1097/00000433-199609000-00008; Hymel KP, 1997, PEDIATR RADIOL, V27, P743, DOI 10.1007/s002470050215; KAO MC, 1983, J NEUROSURG, V58, P246, DOI 10.3171/jns.1983.58.2.0246; KAUFMAN HH, 1980, J COMPUT ASSIST TOMO, V4, P557, DOI 10.1097/00004728-198008000-00034; Krous HF, 1999, PEDIATR DEVEL PATHOL, V2, P497, DOI 10.1007/s100249900156; Lee HK, 1997, INT SOCIOL, V12, P353, DOI 10.1177/026858097012003005; MOLLER A, 1979, RADIOLOGY, V130, P149; NEW PFJ, 1976, RADIOLOGY, V121, P635, DOI 10.1148/121.3.635; NORMAN D, 1977, RADIOLOGY, V123, P335, DOI 10.1148/123.2.335; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Sargent S, 1996, J FORENSIC SCI, V41, P314; SCHACHENMAYR W, 1978, AM J PATHOL, V92, P53; SCOTTI G, 1977, J NEUROSURG, V47, P311, DOI 10.3171/jns.1977.47.3.0311; SINAL SH, 1987, SOUTHERN MED J, V80, P1505, DOI 10.1097/00007611-198712000-00006; SMITH WP, 1981, AM J ROENTGENOL, V136, P543, DOI 10.2214/ajr.136.3.543; Vinchon M, 2005, J NEUROSURG, V102, P380, DOI 10.3171/ped.2005.102.4.0380; Vinchon M, 2004, J NEUROSURG, V101, P44, DOI 10.3171/ped.2004.101.2.0044; Vinchon M, 2002, PEDIATR NEUROSURG, V37, P245, DOI 10.1159/000066216; WILLIAMS RA, 1991, J TRAUMA, V31, P1350, DOI 10.1097/00005373-199110000-00005; Zimmerman R A, 1994, Neuroimaging Clin N Am, V4, P349; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687; ZIMMERMAN RA, 1978, NEURORADIOLOGY, V16, P39, DOI 10.1007/BF00395197; Zouros A, 2004, J NEUROSURG, V100, P512, DOI 10.3171/ped.2004.100.5.0512	43	88	90	0	5	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	AUG	2006	118	2					626	633		10.1542/peds.2006-0130			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	069IW	WOS:000239440600024	16882816				2022-02-06	
J	Suh, M; Kolster, R; Sarkar, R; McCandliss, B; Ghajar, J				Suh, Minah; Kolster, Rachel; Sarkar, Ranjeeta; McCandliss, Bruce; Ghajar, Jamshid		Cognitive Neurobiological Res Cons	Deficits in predictive smooth pursuit after mild traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						mild TBI; smooth pursuit eye movement; shearing injury; attention; executive function; variability; diffuse axonal injury (DAI)	HEAD-INJURY; EYE-MOVEMENTS; ATTENTION; MEMORY; INTEGRATION; MODULATION; SACCADES; MONKEY	Given that even mild traumatic brain injury (TBI) may produce extensive diffuse axonal injury (DAI), we hypothesized that mild TBI patients would show deficits in predictive smooth pursuit eye movements (SPEM), associated with impaired cognitive functions, as these processes are dependent on common white matter connectivity between multiple cerebral and cerebellar regions. The ability to predict target trajectories during SPEM was investigated in 21 mild TBI patients using a periodic sinusoidal paradigm. Compared to 26 control subjects, TBI patients demonstrated decreased target prediction. TBI patients also showed increased eye position error and variability of eye position, which correlated with decreased target prediction. In all subjects, average target prediction, eye position error and eye position variability correlated with scores related to attention and executive function on the California Verbal Learning Test (CVLT-II). However, there were no differences between TBI and control groups in average eye gain or intra-individual eye gain variability, or in performance on the Wechsler Abbreviated Scale of Intelligence (WASI), suggesting that the observed deficits did not result from general oculomotor impairment or reduced IQ. The correlation between SPEM performance and CVLT-II scores suggests that predictive SPEM may be a sensitive assay of cognitive functioning, including attention and executive function. This is the first report to our knowledge that TBI patients show impaired predictive SPEM and eye position variability, and that these impairments correlate with cognitive deficits. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	Weill Cornell Med Coll, Dept Neurol Surg, New York, NY 10021 USA; Weill Cornell Med Coll, Brain Trauma Fdn, New York, NY 10021 USA; Weill Cornell Med Coll, Sackler Inst, Dept Psychiat, New York, NY 10021 USA		Suh, M (corresponding author), Weill Cornell Med Coll, Dept Neurol Surg, New York, NY 10021 USA.	minah@med.cornell.edu					Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Barnes GR, 2005, EXP BRAIN RES, V160, P10, DOI 10.1007/s00221-004-1981-3; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bruce JM, 2003, NEUROPSYCHOLOGY, V17, P622, DOI 10.1037/0894-4105.17.4.622; Bublak P, 2000, J CLIN EXP NEUROPSYC, V22, P176, DOI 10.1076/1380-3395(200004)22:2;1-1;FT176; CANNON SC, 1987, J NEUROPHYSIOL, V57, P1383, DOI 10.1152/jn.1987.57.5.1383; Courchesne E, 1997, LEARN MEMORY, V4, P1, DOI 10.1101/lm.4.1.1; de Brouwer S, 2002, J NEUROPHYSIOL, V87, P1646, DOI 10.1152/jn.00432.2001; Delis D.C., 2000, CALIFORNIA VERBAL LE; Fukushima K, 2002, NATURE, V419, P157, DOI 10.1038/nature00953; FUKUSHIMA K, 1995, NEUROSCI RES, V22, P249, DOI 10.1016/0168-0102(95)00904-8; GERSHBERG FB, 1995, NEUROPSYCHOLOGIA, V33, P1305, DOI 10.1016/0028-3932(95)00103-A; Gottwald B, 2004, J NEUROL NEUROSUR PS, V75, P1524, DOI 10.1136/jnnp.2003.018093; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Han Y, 2004, BRAIN RES PROTOC, V14, P1, DOI 10.1016/j.brainresprot.2004.06.002; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Hetherington CR, 1996, BRAIN INJURY, V10, P473, DOI 10.1080/026990596124197; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hutton SB, 2005, EXP BRAIN RES, V163, P306, DOI 10.1007/s00221-004-2171-z; Kalashnikova L A, 2005, Neurosci Behav Physiol, V35, P773, DOI 10.1007/s11055-005-0123-0; Kettner RE, 1996, EXP BRAIN RES, V108, P221; KHURANA B, 1987, VISION RES, V27, P1603, DOI 10.1016/0042-6989(87)90168-4; KOWLER E, 1989, VISION RES, V29, P1049, DOI 10.1016/0042-6989(89)90052-7; LANGER T, 1985, J COMP NEUROL, V235, P1, DOI 10.1002/cne.902350102; LISBERGER SG, 1987, ANNU REV NEUROSCI, V10, P97, DOI 10.1146/annurev.ne.10.030187.000525; Machner B, 2005, NEUROREPORT, V16, P1507, DOI 10.1097/01.wnr.0000177015.75096.b6; Madelain L, 2003, J NEUROPHYSIOL, V90, P972, DOI 10.1152/jn.00869.2002; Mateer CA, 1996, J HEAD TRAUMA REHAB, V11, P1; Middleton FA, 2001, J NEUROSCI, V21, P700, DOI 10.1523/JNEUROSCI.21-02-00700.2001; Missal M, 2004, J NEUROPHYSIOL, V92, P1257, DOI 10.1152/jn.01255.2003; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Nagel M, 2006, NEUROIMAGE, V29, P1319, DOI 10.1016/j.neuroimage.2005.08.050; Nakamagoe K, 2000, SCIENCE, V288, P857, DOI 10.1126/science.288.5467.857; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Reynolds JH, 2004, ANNU REV NEUROSCI, V27, P611, DOI 10.1146/annurev.neuro.26.041002.131039; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Schmid A, 2001, NEUROREPORT, V12, P1409, DOI 10.1097/00001756-200105250-00023; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Stone LS, 2000, PERCEPTION, V29, P771, DOI 10.1068/p2979; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; WAESPE W, 1992, EXP BRAIN RES, V89, P311; Wechsler D., 2011, WECHSLER ABBREVIATED; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; Williams IM, 1997, J CLIN NEUROSCI, V4, P186, DOI 10.1016/S0967-5868(97)90072-2	47	88	88	0	13	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JUN 19	2006	401	1-2					108	113		10.1016/j.neulet.2006.02.074			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	050JB	WOS:000238082400022	16554121				2022-02-06	
J	Agha, A; Thompson, CJ				Agha, A; Thompson, CJ			Anterior pituitary dysfunction following traumatic brain injury (TBI)	CLINICAL ENDOCRINOLOGY			English	Article							GROWTH-HORMONE DEFICIENCY; BODY-COMPOSITION; HYPOGONADOTROPIC HYPOGONADISM; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; SPONTANEOUS-RECOVERY; ADULT PATIENTS; HEAD-INJURY; HYPOPITUITARISM; SEVERITY	Traumatic brain injury (TBI) is the commonest cause of death and disability in young adults living in industrialized countries. Several recent studies have convincingly shown that anterior hypopituitarism is a common complication of head trauma with a prevalence of at least 25% among long-term survivors. This is a much higher frequency than previously thought and suggests that most cases of post-traumatic hypopituitarism (PTHP) remain undiagnosed and untreated. These findings raise important questions about the potential contribution of PTHP to the high physical and neuropsychiatric morbidity seen in this group of patients. In this review, we examine the published reports on the neuroendocrine abnormalities in TBI patients and highlight new data that give novel insights into the natural history of this disorder. We discuss the potential contribution of PTHP to recovery and rehabilitation after injury and the need for the identification and the appropriate and timely management of hormone deficiencies to optimize patient recovery from head trauma, improve quality of life and avoid the long-term adverse consequences of untreated hypopituitarism.	Beaumont Hosp, Dept Endocrinol, Div Endocrinol & Diabet, Dublin 9, Ireland; RCSI, Sch Med, Dublin, Ireland		Agha, A (corresponding author), Beaumont Hosp, Dept Endocrinol, Div Endocrinol & Diabet, Beaumont Rd, Dublin 9, Ireland.	amaragha@yahoo.com					Agha A, 2005, QJM-INT J MED, V98, P463, DOI 10.1093/qjmed/hci075; Agha A, 2005, AM J PHYS MED REHAB, V84, P381, DOI 10.1097/01.PHM.0000156898.47097.93; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; ASA S, 2002, PITUITARY, P4; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; Benvenga S, 1997, J ENDOCRINOL INVEST, V20, P675, DOI 10.1007/BF03348031; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; BESHYAH SA, 1995, CLIN ENDOCRINOL, V42, P179, DOI 10.1111/j.1365-2265.1995.tb01860.x; BINNERTS A, 1992, AM J CLIN NUTR, V55, P918, DOI 10.1093/ajcn/55.5.918; BJORK S, 1989, ACTA PAEDIATR SCAND, P55; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Ceballos R, 1966, Ala J Med Sci, V3, P185; Cernak I, 1999, BRAIN INJURY, V13, P1005; CHIOLERO R, 1988, J TRAUMA, V28, P1368, DOI 10.1097/00005373-198809000-00011; CITTADINI A, 1994, AM J PHYSIOL, V267, pE219, DOI 10.1152/ajpendo.1994.267.2.E219; Colao A, 1999, J CLIN ENDOCR METAB, V84, P1919, DOI 10.1210/jc.84.6.1919; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Cryan E., 1918, DTSCH MED WOCHENSCHR, V44, P1261; CUNEO RC, 1991, J APPL PHYSIOL, V70, P695, DOI 10.1152/jappl.1991.70.2.695; CYTOWIC RE, 1986, NEW ENGL J MED, V314, P715; DANIEL PM, 1959, LANCET, V2, P927; DEBOER H, 1992, J CLIN ENDOCR METAB, V75, P833, DOI 10.1210/jc.75.3.833; Della Corte F, 1998, CRIT CARE MED, V26, P1419; EDWARDS OM, 1986, MEDICINE, V65, P281; EIHOLZER U, 1986, EUR J PEDIATR, V145, P128, DOI 10.1007/BF00441873; Escamilla RF, 1942, J CLIN ENDOCRINOL, V2, P65, DOI 10.1210/jcem-2-2-65; FEIBEL J, 1983, J CLIN ENDOCR METAB, V57, P1245, DOI 10.1210/jcem-57-6-1245; FLEISCHER AS, 1978, J NEUROSURG, V49, P650, DOI 10.3171/jns.1978.49.5.0650; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; HOLMES SJ, 1994, J CLIN ENDOCR METAB, V78, P669, DOI 10.1210/jc.78.3.669; Iglesias P, 1996, J ENDOCRINOL INVEST, V19, P320, DOI 10.1007/BF03347870; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KING LR, 1981, NEUROSURGERY, V9, P229, DOI 10.1227/00006123-198109000-00002; KLASBEEK WD, 1980, J NEUROSURG, V53, P519; Koiv L, 1997, ACTA NEUROL SCAND, V96, P52; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; LEE SC, 1994, BRAIN INJURY, V8, P571; LEVITAN D, 1984, AM J NEPHROL, V4, P99, DOI 10.1159/000166785; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Lissett CA, 2003, CLIN ENDOCRINOL, V59, P773, DOI 10.1046/j.1365-2265.2003.01884.x; Masel BE, 2004, GROWTH HORM IGF RES, V14, pS108, DOI 10.1016/j.ghir.2004.03.024; MATSUURA H, 1985, NEUROSURGERY, V16, P791, DOI 10.1227/00006123-198506000-00009; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; MCGAULEY GA, 1989, ACTA PAEDIATR SCAND, P70; McGregor K, 1997, SOC SCI MED, V45, P295, DOI 10.1016/S0277-9536(96)00345-0; MEROLA B, 1993, J CLIN ENDOCR METAB, V77, P1658, DOI 10.1210/jcem.77.6.8263155; *NIH, 1998, REH PERS TRAUM BRAIN, V16, P1; PIERUCCI G, 1971, Pathologica (Genoa), V63, P71; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; RUDMAN D, 1977, J CLIN ENDOCR METAB, V45, P747, DOI 10.1210/jcem-45-4-747; SPRATT DI, 1992, J CLIN ENDOCR METAB, V75, P1562, DOI 10.1210/jc.75.6.1562; TEASDALE G, 1974, LANCET, V2, P81; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; Van den Berghe G, 2003, ENDOCRIN METAB CLIN, V32, P385, DOI 10.1016/S0889-8529(03)00005-7; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x; WOOLF PD, 1988, AM J MED, V84, P201, DOI 10.1016/0002-9343(88)90414-7; World Health Organization, 1980, INT CLASS IMP DIS HA; YAUN XQ, 1991, NEUROENDOCRINOLOGY, V12, P209	66	88	95	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-0664	1365-2265		CLIN ENDOCRINOL	Clin. Endocrinol.	MAY	2006	64	5					481	488		10.1111/j.1365-2265.2006.02517.x			8	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	034PR	WOS:000236943600002	16649964	Bronze			2022-02-06	
J	Rahman, S; Robbins, TW; Hodges, JR; Mehta, MA; Nestor, PJ; Clark, L; Sahakian, BJ				Rahman, S; Robbins, TW; Hodges, JR; Mehta, MA; Nestor, PJ; Clark, L; Sahakian, BJ			Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia	NEUROPSYCHOPHARMACOLOGY			English	Article						orbitofrontal cortex; methylphenidate; risk-taking; decision-making; frontal variant frontotemporal dementia	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; TRAUMATIC BRAIN-INJURY; DECISION-MAKING; PREFRONTAL CORTEX; PARKINSONS-DISEASE; COGNITIVE INFLEXIBILITY; METABOLIC IMPAIRMENT; ALZHEIMERS-DISEASE; NORMAL VOLUNTEERS; CONTROLLED-TRIAL	The frontal variant of frontotemporal dementia is a significant neurological condition worldwide. There exist few treatments available for the cognitive and behavioural sequelae of fvFTD. Previous research has shown that these patients display risky decision-making, and numerous studies have now demonstrated pathology affecting the orbitofrontal cortex. The present study uses a within-subjects, double-blind, placebo-controlled procedure to investigate the effects of a single dose of methylphenidate (40 mg) upon a range of different cognitive processes including those assessing prefrontal cortex integrity. Methylphenidate was effective in 'normalizing' the decision-making behavior of patients, such that they became less risk taking on medication, although there were no significant effects on other aspects of cognitive function, including working memory, attentional set shifting, and reversal learning. Moreover, there was an absence of the normal subjective and autonomic responses to methylphenidate seen in elderly subjects. The results are discussed in terms of the 'somatic marker' hypothesis of impaired decision-making following orbitofrontal dysfunction.	Univ Cambridge, Sch Clin Med, Dept Psychiat, Cambridge, England; Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England; Univ Cambridge, Addenbrookes Hosp, Dept Neurol, Cambridge CB2 2QQ, England; Univ London, Inst Psychiat, London, England; MRC, Cognit & Brain Sci Unit, Cambridge, England		Sahakian, BJ (corresponding author), Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Psychiat, Cambridge CB2 2QQ, England.		Nestor, Peter/Y-6106-2018; Sahakian, Barbara/AAW-1198-2020; Mehta, Mitul/F-3960-2010	Nestor, Peter/0000-0002-5860-5921; Sahakian, Barbara/0000-0001-7352-1745; Clark, Luke/0000-0003-1103-2422; Robbins, Trevor/0000-0003-0642-5977	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_U105559861, G108/653, G0001354] Funding Source: Medline; Wellcome TrustWellcome TrustEuropean Commission [019407] Funding Source: Medline; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001354B] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MC_U105559861, G108/653] Funding Source: UKRI		ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Aron AR, 2003, BIOL PSYCHIAT, V54, P1465, DOI 10.1016/S0006-3223(03)00609-7; Bartzokis G, 2000, NEUROPSYCHOPHARMACOL, V22, P102, DOI 10.1016/S0893-133X(99)00077-9; Bechara A, 2003, ANN NY ACAD SCI, V985, P356, DOI 10.1111/j.1749-6632.2003.tb07094.x; BECHARA A, 2001, SOC NEUR ABSTR, V27; Bechara Antoine, 2003, J Gambl Stud, V19, P23, DOI 10.1023/A:1021223113233; Bettendorff L, 1997, J NEUROCHEM, V69, P2005; BOND A, 1974, BRIT J MED PSYCHOL, V47, P211, DOI 10.1111/j.2044-8341.1974.tb02285.x; BRUN A, 1994, J NEUROL NEUROSUR PS, V57, P416; Chatterjee A, 2002, J NEUROPSYCH CLIN N, V14, P461, DOI 10.1176/appi.neuropsych.14.4.461; Clark L, 2004, BRAIN COGNITION, V55, P41, DOI 10.1016/s0278-2626(03)00284-7; Clark L, 2003, NEUROPSYCHOLOGIA, V41, P1474, DOI 10.1016/S0028-3932(03)00081-2; Clarke HF, 2004, SCIENCE, V304, P878, DOI 10.1126/science.1094987; CONNERS CK, 1963, AM J PSYCHIAT, V120, P458, DOI 10.1176/ajp.120.5.458; Cools R, 2003, NEUROPSYCHOLOGIA, V41, P1431, DOI 10.1016/S0028-3932(03)00117-9; Coull JT, 1996, PSYCHOPHARMACOLOGY, V123, P239, DOI 10.1007/BF02246578; Crofts HS, 2001, CEREB CORTEX, V11, P1015, DOI 10.1093/cercor/11.11.1015; Damasio AR, 1996, PHILOS T R SOC B, V351, P1413, DOI 10.1098/rstb.1996.0125; Deakin J, 2004, J INT NEUROPSYCH SOC, V10, P590, DOI 10.1017/S1355617704104104; Deakin JB, 2004, PSYCHOPHARMACOLOGY, V172, P400, DOI 10.1007/s00213-003-1686-5; Diehl J, 2004, NEUROBIOL AGING, V25, P1051, DOI 10.1016/j.neurobiolaging.2003.10.007; Elliott R, 1997, PSYCHOPHARMACOLOGY, V131, P196, DOI 10.1007/s002130050284; ELLSBERG D, 1961, Q J ECON, V75, P643, DOI 10.2307/1884324; FALLON JH, 1978, J COMP NEUROL, V180, P501; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198; FRANCIS PT, 1993, DEMENTIA, V4, P172, DOI 10.1159/000107319; GILBERT JJ, 1988, ANN NEUROL, V24, P688, DOI 10.1002/ana.410240518; Gilman A. G., 1980, PHARM BASIS THERAPEU; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; HEISHMAN SJ, 1991, PSYCHOPHARMACOLOGY, V103, P436, DOI 10.1007/BF02244241; Hollerman JR, 1998, NAT NEUROSCI, V1, P304, DOI 10.1038/1124; Howell DC., 1997, STAT METHODS PSYCHOL, V4th ed; Ibach B, 2004, NEUROIMAGE, V23, P739, DOI 10.1016/j.neuroimage.2004.06.041; Kobayashi K, 1999, CLIN NEUROPATHOL, V18, P240; LACOCO D, 2004, J NEUROPSYCHIATRY CL, V16, P117; Lee ACH, 2003, EUR J NEUROSCI, V18, P1660, DOI 10.1046/j.1460-9568.2003.02883.x; Liu W, 2004, NEUROLOGY, V62, P742, DOI 10.1212/01.WNL.0000113729.77161.C9; MARIN RS, 1995, J NEUROPSYCH CLIN N, V7, P23; Mavaddat N, 2000, BRAIN, V123, P2109, DOI 10.1093/brain/123.10.2109; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; Mehta MA, 2000, J PSYCHOPHARMACOL, V14, P299, DOI 10.1177/026988110001400314; MENDEZ MF, 2003, DEMENTIA CLIN APPROA, P179; MULLER U, 2005, PSYCHOPHARMACOL 0414; Nagaoka S, 1995, PROG NEURO-PSYCHOPH, V19, P1251, DOI 10.1016/0278-5846(95)00264-2; OADES RD, 1987, BRAIN RES REV, V12, P117, DOI 10.1016/0165-0173(87)90011-7; OWEN AM, 1995, NEUROPSYCHOLOGY, V9, P126, DOI 10.1037/0894-4105.9.1.126; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Rahman S, 1999, BRAIN, V122, P1469, DOI 10.1093/brain/122.8.1469; RAHMAN S, 2000, EARLY ONSET DEMENTIA; Ratnavalli E, 2002, NEUROLOGY, V58, P1615, DOI 10.1212/WNL.58.11.1615; Rogers RD, 1999, NEUROPSYCHOPHARMACOL, V20, P322, DOI 10.1016/S0893-133X(98)00091-8; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; Salmon E, 2003, NEUROIMAGE, V20, P435, DOI 10.1016/S1053-8119(03)00346-X; SCHEELKRUGER J, 1971, EUR J PHARMACOL, V14, P47, DOI 10.1016/0014-2999(71)90121-X; Schultz W, 2002, NEURON, V36, P241, DOI 10.1016/S0896-6273(02)00967-4; Sjogren M, 1998, NEUROBIOL AGING, V19, P379, DOI 10.1016/S0197-4580(98)00086-4; Smith K, 2002, MANAGE SCI, V48, P711, DOI 10.1287/mnsc.48.6.711.194; SPARKS DL, 1991, ARCH NEUROL-CHICAGO, V48, P796, DOI 10.1001/archneur.1991.00530200032014; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; TANNOCK R, 1989, J ABNORM CHILD PSYCH, V17, P473, DOI 10.1007/BF00916508; Turner DC, 2003, PSYCHOPHARMACOLOGY, V168, P455, DOI 10.1007/s00213-003-1457-3; Volkow ND, 2005, J NEUROSCI, V25, P3932, DOI 10.1523/JNEUROSCI.0433-05.2005; Volkow ND, 1998, AM J PSYCHIAT, V155, P1325, DOI 10.1176/ajp.155.10.1325; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Williams SE, 1998, J HEAD TRAUMA REHAB, V13, P73, DOI 10.1097/00001199-199806000-00007	65	88	92	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X			NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	MAR	2006	31	3					651	658		10.1038/sj.npp.1300886			8	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	023QP	WOS:000236141600018	16160709	Green Accepted, Bronze			2022-02-06	
J	Cater, HL; Sundstrom, LE; Morrison, B				Cater, Heather L.; Sundstrom, Lars E.; Morrison, Barclay, III			Temporal development of hippocampal cell death is dependent on tissue strain but not strain rate	JOURNAL OF BIOMECHANICS			English	Article						tolerance criteria; traumatic brain injury; hippocampus; diffuse axonal injury; viscous criterion	IN-VITRO; MECHANICAL STRETCH; BRAIN-INJURY; TOLERANCE CRITERION; NEURONAL SURVIVAL; SLICE CULTURES; MODEL; CALCIUM; DEFORMATION; NEURODEGENERATION	Deformation of brain tissue in response to mechanical loading of the head is the root-cause of traumatic brain injury (TBI). Even below ultimate failure limits, deformation activates pathophysiological cascades resulting in delayed cell death. Injury response of soft tissues, such as the chest and spinal cord, is dependent on the product of deformation and velocity, a parameter termed the viscous criterion. We set out to test if hippocampal cell death could be predicted by a similar combination of strain and strain rate and if the viscous criterion was valid for hippocampus. Quantitative prediction of the brain's biological response to mechanical stimuli is difficult to achieve in animal models of TBI, so we utilized an in vitro model of TBI based on hippocampal slice cultures. We quantified the temporal development of cell death after precisely controlled deformations for 30 combinations of strain (0.05-0.50) and strain rate (0.1-50 s(-1)) relevant to TBI. Loading conditions for a subset of cultures were verified by analysis of highspeed video. Cell death was found to be significantly dependent on time-post injury, on strain magnitude, and to a lesser extent, on anatomical region by a repeated-measures, three-way ANOVA. The responses of the CA1 and CA3 regions of the hippocampus were not statistically different in contrast to some in vivo TBI studies. Surprisingly, cell death was not dependent on strain rate leading us to conclude that the viscous criterion is not a valid predictor for hippocampal tissue injury. Given the large data set and extensive combinations of biomechanical parameters, predictive mathematical functions relating independent variables (strain, region, and time post-injury) to the resultant cell death were defined. These functions can be used as tolerance criteria to equip finite element models of TBI with the added capability to predict biological consequences. (c) 2005 Elsevier Ltd. All rights reserved.	Univ Southampton, Div Clin Neurosci, Southampton SO16 7PX, Hants, England; Columbia Univ, Dept Biomed Engn, Neurotrauma & Repair Lab, New York, NY 10027 USA		Morrison, B (corresponding author), Univ Southampton, Div Clin Neurosci, Southampton SO16 7PX, Hants, England.	bm2119@columbia.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; Cater, Heather/0000-0002-8696-6070			Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; Brands D W, 2000, Stapp Car Crash J, V44, P249; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; *CDCP, 1999, TRAUM BRIAN INJ US R; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Gahwiler BH, 1997, TRENDS NEUROSCI, V20, P471, DOI 10.1016/S0166-2236(97)01122-3; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; KEARNEY P A, 1988, Journal of Neurotrauma, V5, P187, DOI 10.1089/neu.1988.5.187; King A. I., 2003, P IRCOBI C; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; Laurent VM, 2003, ANN BIOMED ENG, V31, P1263, DOI 10.1114/1.1616932; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; Lusardi TA, 2003, BIORHEOLOGY, V40, P401; LYMAN WD, 1992, BRAIN RES, V599, P34, DOI 10.1016/0006-8993(92)90849-5; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; Morrison B, 2002, BRIT J PHARMACOL, V137, P1255, DOI 10.1038/sj.bjp.0704986; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; MORRISON B, 2005, IN PRES J NEUROSCIEN; Morrison Barclay 3rd, 2003, Stapp Car Crash J, V47, P93; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Pringle AK, 1997, BRAIN RES, V755, P36, DOI 10.1016/S0006-8993(97)00089-9; Pringle AK, 1996, STROKE, V27, P2124, DOI 10.1161/01.STR.27.11.2124; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Shreiber D.I., 1997, STAPP CAR CRASH J, V41, P277; Shreiber DI, 1999, NEUROSCI LETT, V259, P5, DOI 10.1016/S0304-3940(98)00853-2; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; SUGIYAMA K, 1989, NEUROSCIENCE, V32, P779, DOI 10.1016/0306-4522(89)90298-4; SWANSON RA, 1993, J CEREBR BLOOD F MET, V13, P162, DOI 10.1038/jcbfm.1993.19; VIANO DC, 1988, J BIOMECH, V21, P387, DOI 10.1016/0021-9290(88)90145-5; VIBULSRETH S, 1987, BRAIN RES, V422, P303, DOI 10.1016/0006-8993(87)90937-1; Wang CCB, 2002, J BIOMECH ENG-T ASME, V124, P557, DOI 10.1115/1.1503795	47	88	88	0	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.		2006	39	15					2810	2818		10.1016/j.jbiomech.2005.09.023			9	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	111EH	WOS:000242433700009	16289515				2022-02-06	
J	Smith, DC; Modglin, AA; Roosevelt, RW; Neese, SL; Jensen, RA; Browning, RA; Clough, RW				Smith, DC; Modglin, AA; Roosevelt, RW; Neese, SL; Jensen, RA; Browning, RA; Clough, RW			Electrical stimulation of the vagus nerve enhances cognitive and motor recovery following moderate fluid percussion injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						fluid percussion; memory; norepinephrine; recovery of function; skilled reaching; traumatic brain injury; vagus nerve stimulation	TRAUMATIC BRAIN-INJURY; UNILATERAL SENSORIMOTOR CORTEX; NOREPINEPHRINE TURNOVER; FUNCTIONAL RECOVERY; LOCOMOTOR FUNCTION; PROMOTES RECOVERY; LOCUS-COERULEUS; AMPHETAMINE; VAGAL; EPILEPSY	Intermittent, chronically delivered electrical stimulation of the vagus nerve (VNS) is an FDA-approved procedure for the treatment of refractory complex/partial epilepsy in humans. Stimulation of the vagus has also been shown to enhance memory storage processes in laboratory rats and human subjects. Recent evidence suggests that some of these effects of VNS may be due to the activation of neurons in the nucleus locus coeruleus resulting in the release of norepinephrine (NE) throughout the neuraxis. Because antagonism of NE systems has been shown to delay recovery of function following brain damage, it is possible that enhanced release of NE in the CNS may facilitate recovery of function. To evaluate this hypothesis the lateral fluid percussion injury (LFP) model of traumatic brain injury was used and a variety of motor and cognitive behavioral tests were employed to assess recovery in pre-trained stimulated, control, and sham-injured laboratory rats. Two hours following moderate LFP, vagus nerve stimulation (30.0-sec trains of 0.5 mA, 20.0 Hz, biphasic pulses) was initiated. Stimulation continued in each animal's home cage at 30-min intervals for a period of 14 days, with the exception of brief periods when the animals were disconnected for behavioral assessments. Motor behaviors were evaluated every other day following LFP and tests included beam walk, locomotor placing, and skilled forelimb reaching. In each measure an enhanced rate of recovery and/or level of final performance was observed in the VNS-LFP animals compared to nonstimulated LFP controls. Behavior in the Morris water maze was assessed on days 11-14 following injury. Stimulated LFP animals showed significantly shorter latencies to rind the hidden platform than did controls. Despite these behavioral effects, neurohistological examination did not reveal significant differences in lesion extent, density of fluorojade positive neurons, reactive astrocytes or numbers of spared neurons in the CA3 subarea of the hippocampus, at least at the one time point studied 15 days post-injury. These results support the idea that vagus nerve stimulation enhances the neural plasticity that underlies recovery of function following brain damage and provides indirect support for the hypothesis that enhanced NE release may mediate the effect. Importantly, since VNS facilitated both the rate of recovery and the extent of motor and cognitive recovery, these findings suggest that electrical stimulation of the vagus nerve may prove to be an effective non-pharmacological treatment for traumatic brain injury.	So Illinois Univ, Sch Med, Dept Psychol, Brain & Cognit Sci Program, Carbondale, IL 62901 USA; So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA; So Illinois Univ, Sch Med, Dept Anat, Carbondale, IL 62901 USA		Smith, DC (corresponding author), So Illinois Univ, Sch Med, Dept Psychol, Brain & Cognit Sci Program, Carbondale, IL 62901 USA.	dcsmith@siu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS041551-02, R01 NS041551, R01 NS041551-03, R01 NS041551-01A1, R01 NS041551-04, NS 41551] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041551] Funding Source: NIH RePORTER		ARDELL JL, 1986, AM J PHYSIOL, V251, pH764, DOI 10.1152/ajpheart.1986.251.4.H764; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; BROWNING RA, 1987, NEUROTRANSMITTERS EP, P277; Bury SD, 2002, J NEUROSCI, V22, P8597; Clark KB, 1998, NEUROBIOL LEARN MEM, V70, P364, DOI 10.1006/nlme.1998.3863; CLARK KB, 1995, NEUROBIOL LEARN MEM, V63, P213, DOI 10.1006/nlme.1995.1024; Clark KB, 1999, NAT NEUROSCI, V2, P94, DOI 10.1038/4600; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Dietrich WD, 1996, NEUROTRAUMA, P1491; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; Feeney DM, 1998, RESTORATIVE NEUROLOGY, P35; FEENEY DM, 1985, BRAIN RES, V342, P352, DOI 10.1016/0006-8993(85)91135-7; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FEENEY DM, 1983, PSYCHOPHARMACOLOGY, V79, P67, DOI 10.1007/BF00433018; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; Fisher RS, 1999, NEUROLOGY, V53, P666, DOI 10.1212/WNL.53.4.666; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Friedberg MH, 1999, J NEUROPHYSIOL, V81, P2243, DOI 10.1152/jn.1999.81.5.2243; Gladstone DJ, 2000, CAN J NEUROL SCI, V27, P97; Goldstein LB, 1998, RESTORATIVE NEUROLOGY, P241; Goldstein LB, 1997, PHARMACOL BIOCHEM BE, V58, P1151, DOI 10.1016/S0091-3057(97)00324-9; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Groves DA, 2005, NEUROSCI BIOBEHAV R, V29, P493, DOI 10.1016/j.neubiorev.2005.01.004; Groves DA, 2005, NEUROSCI LETT, V379, P174, DOI 10.1016/j.neulet.2004.12.055; GUEDEL AE, 1920, INHALATIONAL ANESTHE, P10; Hassert DL, 2004, BEHAV NEUROSCI, V118, P79, DOI 10.1037/0735-7044.118.1.79; Hatton J, 2001, CNS DRUGS, V15, P553, DOI 10.2165/00023210-200115070-00005; HERMANN GE, 1985, J AUTONOM NERV SYST, V13, P1, DOI 10.1016/0165-1838(85)90002-5; Hernandez TD, 1997, NEUROLOGY, V48, P803, DOI 10.1212/WNL.48.4.803; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hoane MR, 1997, RESTOR NEUROL NEUROS, V11, P71, DOI 10.3233/RNN-1997-111208; Hoover RC, 2004, J NEUROTRAUM, V21, P501, DOI 10.1089/089771504774129847; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; JOBE PC, 1986, LIFE SCI, V39, P775, DOI 10.1016/0024-3205(86)90455-8; Jobe PC, 2003, EPILEPSY BEHAV, V4, pS14, DOI 10.1016/j.yebeh.2003.08.020; KASAMATSU T, 1976, SCIENCE, V194, P206, DOI 10.1126/science.959850; Kikuchi K, 2000, BRAIN RES, V860, P130, DOI 10.1016/S0006-8993(00)02034-5; Krahl S. E., 1994, Society for Neuroscience Abstracts, V20, P1453; Krahl SE, 1998, EPILEPSIA, V39, P709, DOI 10.1111/j.1528-1157.1998.tb01155.x; LEVIN BE, 1995, BRAIN RES, V674, P307, DOI 10.1016/0006-8993(95)00032-L; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; MARKLUND N, 2004, EXCITOTOXICITY NEURO, P189; Maynert E W, 1975, Adv Neurol, V13, P79; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Metz GAS, 2000, BEHAV BRAIN RES, V116, P111, DOI 10.1016/S0166-4328(00)00245-X; MEYER PM, 1963, J COMP PHYSIOL PSYCH, V56, P402, DOI 10.1037/h0049297; NARITOKU DK, 1995, EPILEPSY RES, V22, P53, DOI 10.1016/0920-1211(95)00035-9; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Queen SA, 1997, BRAIN RES, V777, P42, DOI 10.1016/S0006-8993(97)00717-8; ROOSEVELT RW, 2004, SOC NEUROSCI; ROOSEVELT RW, 2000, SOC NEUROSCI ABSTRAC; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Schachter SC, 1998, EPILEPSIA, V39, P677, DOI 10.1111/j.1528-1157.1998.tb01151.x; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; SMITH DC, 2005, NAT NEUR SOC S WASH; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Sutton RL, 2000, NEURAL PLAST, V7, P109, DOI 10.1155/NP.2000.109; SUTTON RL, 1989, BEHAV NEUROSCI, V103, P837, DOI 10.1037/0735-7044.103.4.837; SUTTON RL, 1987, J HEAD TRAUMA REHAB, V2, P50; TAKIGAWA M, 1977, BRAIN RES, V135, P217, DOI 10.1016/0006-8993(77)91027-7; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; Whishaw IQ, 2002, BEHAV BRAIN RES, V134, P323, DOI 10.1016/S0166-4328(02)00051-7; Whishaw IQ, 2004, J NEUROTRAUM, V21, P1584, DOI 10.1089/neu.2004.21.1584; WOODBURY DM, 1990, EPILEPSIA, V31, pS7, DOI 10.1111/j.1528-1157.1990.tb05852.x	79	88	102	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2005	22	12					1485	1502		10.1089/neu.2005.22.1485			18	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	000EA	WOS:000234442500010	16379585	Green Accepted			2022-02-06	
J	Lefebvre, H; Pelchat, D; Swaine, B; Gelinas, I; Levert, MJ				Lefebvre, H; Pelchat, D; Swaine, B; Gelinas, I; Levert, MJ			The experiences of individuals with a traumatic brain injury, families, physicians and health professionals regarding care provided throughout the continuum	BRAIN INJURY			English	Article						traumatic brain injuries; adaptation; relationships; uncertainty; continuity of care; care continuum; empowerment; social integration	SERVICE DELIVERY; EMPOWERMENT; REHABILITATION; MORTALITY; PARADOX; IMPACT; NEWS; BAD	Primary objective: To investigate the experiences of individuals who had sustained a traumatic brain injury, their families and the physicians and health professionals involved, from the critical care episodes and subsequent rehabilitation. Research design: Semi-structured interviews were conducted with individuals who had sustained a TBI (n=8) and their families (n=8) as well as with the health professionals (or service providers) (n=22) and physicians (n=9) who provided them care. Main outcomes and results: Results revealed the difficulties encountered by the different people involved, from the standpoint of the readjustment of the individual with the TBI and their family, the relationships among the various actors and the continuity of care. Conclusions: This study brings to light the importance of including the family and the person with a TBI in the care process by calling for their participation and by setting up suitable structures that prioritize a meaningful partnership among the key individuals.	Univ Montreal, ERIFAM, Montreal, PQ H3C 3J7, Canada; Montreal Ctr Interdisciplinary Res Rehabil, Montreal, PQ, Canada; Sacre Coeur Hosp, Res Ctr, Montreal, PQ, Canada; Montreal Rehabil Inst, Montreal, PQ, Canada; McGill Univ, Montreal, PQ, Canada; Jewish Rehabil Hosp, Montreal, PQ, Canada		Lefebvre, H (corresponding author), Univ Montreal, ERIFAM, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	helene.lefebvre@umontreal.ca					BARIBEAU C, 1996, REV SCI ED, V22, P3; Bouchard J., 1988, ED FAMILIALE, P157; Bouchard J., 1999, APPRENTISSAGE SOCIAL, V19, P47; BOURQUE C, 1999, CADRE REFERENCE CLIN; BURY JA, 1988, ED SANTE CONCEPT ENJ; Carson P, 1993, J Neurosci Nurs, V25, P165; Cohen M H, 1993, West J Nurs Res, V15, P77, DOI 10.1177/019394599301500106; DELLORTO AE, 1997, HEAD INJURY FAMILY L; DEMERS C, 2001, UNPUB A GIR C; DEPOMPEI R, 1994, TOP LANG DISORD, V15, P68, DOI 10.1097/00011363-199411000-00007; DUMONT C, 2003, THESIS LAVAL U; DUNST CJ, 1987, SCHOOL PSYCHOL REV, V16, P443; DUNST CJ, 1991, COLLABORATION PARENT, P25; DUNST CJ, 1988, ENABLING EMPOWERING; Elovic E, 1999, TOP SPINAL CORD INJ, V5, P1, DOI DOI 10.1310/V75J-RE76-20GH-X7BY; Fallowfield L, 2004, LANCET, V363, P312, DOI 10.1016/S0140-6736(03)15392-5; Folkman S., 1984, STRESS; Gadoury M, 2001, CADRE REFERENCE CLIN; GELINAS I, 1998, INNOVATIONS APPRENTI, P105; GENDRON S, 2002, THESIS U MONTREAL; Gervais M, 1999, ETUDE EXPLORATOIRE B; Glaser B., 1967, DISCOVERY GROUNDED T; Gregory RJ, 2001, DISABIL REHABIL, V23, P22, DOI 10.1080/09638280150211257; Guba E., 1985, NATURALISTIC INQUIRY; Habermas Jurgen, 1987, THEORIE AGIR COMMUNI, V1; HOBBES N, 1984, STRENGTHENING FAMILI; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kendall E, 2000, DISABIL REHABIL, V22, P435, DOI 10.1080/09638280050045901; Kosco M, 2000, Crit Care Nurs Q, V23, P60; Lawlor MC, 1998, AM J OCCUP THER, V52, P259, DOI 10.5014/ajot.52.4.259; Lefebvre H., 2002, FAMILLE SITUATION HA, P27; Marquis R, 1996, Am J Hosp Palliat Care, V13, P38, DOI 10.1177/104990919601300408; Merton R. K., 1990, FOCUSED INTERVIEW MA; Ministere de la Sante et des Services Sociaux, 1999, CONT SERV PERS AYANT; Mishel M H, 1997, Annu Rev Nurs Res, V15, P57; MUCCHIELLI A, 1996, DICT METHODES QUALIT; MURRELL KL, 1992, ORG DEV J, V10, P47; NOLTE ML, 2000, DISS ABSTR INT B, V60, P4000; PELCHAT D, 2001, REV INFIRMIERE QUEBE, V9, P26; PELCHAT D, 1998, REV CANADIENNE RECHE, V30, P99; PELCHAT D, 2003, RS3004 CQRS U MONTR; PELCHAT D, 2003, SR3537 CQRS U MONTR; Pires, 1997, RECHERCHE QUALITATIV; PIRES A, 1997, RECHERCHE QUALITATIV, P173; POUPART J., 1997, RECHERCHE QUALITATIV, P173; POURTOIS JP, 1999, ED POSTMODERNE; Ptacek J T, 2000, Crit Care Nurs Q, V23, P51; Ptacek JT, 1996, JAMA-J AM MED ASSOC, V276, P496; RANDOLPH WA, 1995, ORGAN DYN, V23, P19, DOI 10.1016/0090-2616(95)90014-4; RAPPAPORT J, 1981, AM J COMMUN PSYCHOL, V9, P1, DOI 10.1007/BF00896357; RISSEL C, 1994, HEALTH PROMOT INT, V9, P39, DOI 10.1093/heapro/9.1.39; Sampalis JS, 1997, J TRAUMA, V43, P288, DOI 10.1097/00005373-199708000-00014; SAMPALIS JS, 1995, J TRAUMA, V39, P232, DOI 10.1097/00005373-199508000-00008; SANDRINEBERTHON.B, 2000, ED PATIENT SECOURS M; SCHERZER BP, 1995, EVEIL, V1, P3; SCHUMACHER KL, 1994, J NURS SCHOLARSHIP, V26, P72; *STAT CAN, 1999, CAN INJ DAT MORT 199; STCHARLES D, 1998, INNOVATIONS APPRENTI, P97; STONGE M, 1998, COLLABORATION ENTRE; TOCHON Francois V., 1996, REV SCI ED, V22, P467, DOI DOI 10.7202/031889AR; VANDERMAREN JM, 1995, METHODES RECHERCHE E	61	88	88	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2005	19	8					585	597		10.1080/02699050400025026			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	933IS	WOS:000229622700003	16175812				2022-02-06	
J	Wolf, OT; Fujiwara, E; Luwinski, G; Kirschbaum, C; Markowitsch, HJ				Wolf, OT; Fujiwara, E; Luwinski, G; Kirschbaum, C; Markowitsch, HJ			No morning cortisol response in patients with severe global amnesia	PSYCHONEUROENDOCRINOLOGY			English	Article						amnesic patients; salivary cortisol; ambulatory sampling; circadian rhythm; morning cortisol increase	STRESS; BURNOUT; MEMORY; TIME	Activity of the hypothalamus pituitary adrenal (HPA) axis is characterized by a pronounced circadian rhythm. An acute increase in cortisol. levels occurs after awakening in the morning with continuously declining levels over the course of the remaining day. The morning cortisol increase probably reflects an activational response of the HPA axis aimed at preparing the body for the day. Some studies found patterns of enhanced or blunted waking cortisol responses observed under chronic stress, burnout, or post traumatic stress disorder. The present study wanted to characterize the morning cortisol. response and the circadian cortisol day profile in a sample of six mate patients with severe amnesia due to hypoxia, herpes simplex encephalitis or closed head injury. Age and gender matched relatives or friends served as controls. Cortisol was measured from saliva samples collected at home on two consecutive days. The patients were woken up in the morning by their partners or caregivers. The morning cortisol increase typically observed in healthy subjects and also observed in the control group was absent in the amnesic patients. In contrast, a normal circadian day profile was found in the amnesic patients, with a pronounced circadian cortisol decrease. Further studies are needed to understand the neurological or psychological mechanisms leading to a missing morning cortisol response in amnesic patients. (C) 2004 Elsevier Ltd. All rights reserved.	Univ Dusseldorf, Inst Expt Psychol, D-40225 Dusseldorf, Germany; Univ Bielefeld, D-4800 Bielefeld, Germany; Tech Univ Dresden, Dept Psychol, D-8027 Dresden, Germany		Wolf, OT (corresponding author), Univ Dusseldorf, Inst Expt Psychol, Geb 23-02,Ebene 01,Room 43,Univ Str 1, D-40225 Dusseldorf, Germany.	oliver.wolf@uni-duesseldorf.de	Fujiwara, Esther/F-8233-2011; Kirschbaum, Clemens/AAB-1752-2020	Fujiwara, Esther/0000-0003-4154-0145; Wolf, Oliver T./0000-0002-9320-2124			De Vente W, 2003, OCCUP ENVIRON MED, V60, P54, DOI 10.1136/oem.60.suppl_1.i54; Edwards S, 2001, PSYCHONEUROENDOCRINO, V26, P613, DOI 10.1016/S0306-4530(01)00015-4; Gold PW, 2002, BIOL PSYCHIAT, V52, P381, DOI 10.1016/S0006-3223(02)01480-4; Kunz-Ebrecht SR, 2004, PSYCHONEUROENDOCRINO, V29, P516, DOI 10.1016/S0306-4530(03)00072-6; Lupien SJ, 2001, BEHAV BRAIN RES, V127, P137, DOI 10.1016/S0166-4328(01)00361-8; MARKOWITSCH HJ, 1993, J CLIN EXP NEUROPSYC, V15, P627, DOI 10.1080/01688639308402586; Markowitsch HJ, 2003, NEUROIMAGE, V20, pS132, DOI 10.1016/j.neuroimage.2003.09.010; Mesulam M., 2000, PRINCIPLES BEHAV COG, P257; Nelson H.E., 1982, NATL ADULT READING T; Pruessner JC, 2003, PSYCHONEUROENDOCRINO, V28, P916, DOI 10.1016/S0306-4530(02)00108-7; Pruessner JC, 1997, LIFE SCI, V61, P2539, DOI 10.1016/S0024-3205(97)01008-4; Pruessner JC, 1999, PSYCHOSOM MED, V61, P197, DOI 10.1097/00006842-199903000-00012; Rohleder N, 2004, BIOL PSYCHIAT, V55, P745, DOI 10.1016/j.biopsych.2003.11.018; Roozendaal B, 2001, NAT NEUROSCI, V4, P1169, DOI 10.1038/nn766; Steptoe A, 2003, PSYCHOSOM MED, V65, P461, DOI 10.1097/01.PSY.0000035717.78650.A1; Tchiteya BM, 2003, PSYCHONEUROENDOCRINO, V28, P674, DOI 10.1016/S0306-4530(02)00050-1; Wust S, 2000, PSYCHONEUROENDOCRINO, V25, P707, DOI 10.1016/S0306-4530(00)00021-4	17	88	89	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4530			PSYCHONEUROENDOCRINO	Psychoneuroendocrinology	JAN	2005	30	1					101	105		10.1016/j.psyneuen.2004.05.001			5	Endocrinology & Metabolism; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry	858TL	WOS:000224214700011	15358447				2022-02-06	
J	Laverty, PH; Leskovar, A; Breur, GJ; Coates, JR; Bergman, RL; Widmer, WR; Toombs, JP; Shapiro, S; Borgens, RB				Laverty, PH; Leskovar, A; Breur, GJ; Coates, JR; Bergman, RL; Widmer, WR; Toombs, JP; Shapiro, S; Borgens, RB			A preliminary study of intravenous surfactants in paraplegic dogs: Polymer therapy in canine clinical SCI	JOURNAL OF NEUROTRAUMA			English	Article						canine paraplegia; P 188; paraplegia; polyethylene glycol; polymer; spinal cord injury; surfactant	SPINAL-CORD-INJURY; HIGH-DOSE METHYLPREDNISOLONE; MOLECULAR REPAIR; RECOVERY; 4-AMINOPYRIDINE; MEMBRANES	Hydrophilic polymers, both surfactants and triblock polymers, are known to seal defects in cell membranes. In previous experiments using laboratory animals, we have exploited this capability using polyethylene glycol (PEG) to repair spinal axons after severe, standardized spinal cord injury (SCI) in guinea pigs. Similar studies were conducted using a related co-polymer Poloxamer 188 (P 188). Here we carried out initial investigations of an intravenous application of PEG or P 188 (3500 Daltons, 30 70 w/w in saline; 2 mL/kg I.V. and 2 mL/kg body weight or 300 mL P 188 per kg, respectively) to neurologically complete cases of paraplegia in dogs. Our aim was to first determine if this is a clinically safe procedure in cases of severe naturally occurring SCI in dogs. Secondarily, we wanted to obtain preliminary evidence if this therapy could be of clinical benefit when compared to a larger number of similar, but historical, control cases. Strict entry criteria permitted recruitment of only neurologically complete paraplegic dogs into this study. Animals were treated by a combination of conventional and experimental techniques within similar to72 h of admission for spinal trauma secondary to acute, explosive disk herniation. Outcome measures consisted of measurements of voluntary ambulation, deep and superficial pain perception, conscious proprioception in hindlimbs, and evoked potentials (somatosensory evoked potentials [SSEP]). We determined that polymer injection is a safe adjunct to the conventional management of severe neurological injury in dogs. We did not observe any unacceptable clinical response to polymer injection; there were no deaths, nor any other problem arising from, or associated with, the procedures. Outcome measures over the 6-8-week trial were improved by polymer injection when compared to historical cases. This recovery was unexpectedly rapid compared to these comparator groups. The results of this pilot trial provides evidence consistent with the notion that the injection of inorganic polymers in acute neurotrauma may be a simple and useful intervention during the acute phase of the injury.	Purdue Univ, Ctr Paralysis Res, Dept Basic Med Sci, W Lafayette, IN 47907 USA; Purdue Univ, Sch Vet Med, Dept Vet Clin Sci, W Lafayette, IN 47907 USA; Vet Teaching Hosp, Coll Vet Med, Dept Small Anim Med & Surg, College Stn, TX USA; Indiana Univ, Med Ctr, Dept Neurosurg, Indianapolis, IN USA; Purdue Univ, Coll Engn, Dept Biomed Engn, W Lafayette, IN 47907 USA		Borgens, RB (corresponding author), Purdue Univ, Ctr Paralysis Res, Dept Basic Med Sci, 408 S Univ St, W Lafayette, IN 47907 USA.	cpr@purdue.edu					Blight AR, 1991, J NEUROTRAUM, V8, P103, DOI 10.1089/neu.1991.8.103; Borgens RB, 2000, FASEB J, V14, P27, DOI 10.1096/fasebj.14.1.27; Borgens RB, 1999, J NEUROTRAUM, V16, P639, DOI 10.1089/neu.1999.16.639; Borgens RB, 2004, J NEUROSCI RES, V76, P141, DOI 10.1002/jnr.20053; Borgens RB, 2002, J EXP BIOL, V205, P1; Borgens RB, 2001, NEUROSURGERY, V49, P370, DOI 10.1097/00006123-200108000-00021; Borgens RB, 2001, J NEUROSCI RES, V66, P1179; BORGENS RB, 1993, RESTOR NEUROL NEUROS, V5, P305, DOI 10.3233/RNN-1993-55601; BORGENS RB, 2003, ADV ANAT EMBRYOLOGY, P1; CARPENTER CP, 1971, TOXICOL APPL PHARM, V18, P35, DOI 10.1016/0041-008X(71)90312-7; COATES JR, 1995, VET SURG, V24, P128, DOI 10.1111/j.1532-950X.1995.tb01307.x; Coates JR, 2000, VET CLIN N AM-SMALL, V30, P77, DOI 10.1016/S0195-5616(00)50004-7; Duerstock BS, 2002, J EXP BIOL, V205, P13; HANSEBOUT RR, 1993, J NEUROTRAUM, V10, P1, DOI 10.1089/neu.1993.10.1; HANSEN H J, 1952, Acta Orthop Scand Suppl, V11, P1; HAYES KC, 1993, PARAPLEGIA, V31, P216, DOI 10.1038/sc.1993.40; HOERLEIN BF, 1979, J AM ANIM HOSP ASSOC, V15, P535; Lee Raphael C., 1993, Journal of Burn Care and Rehabilitation, V14, P528, DOI 10.1097/00004630-199309000-00007; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; Luo J, 2002, J NEUROCHEM, V83, P471, DOI 10.1046/j.1471-4159.2002.01160.x; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Maskarinec SA, 2002, BIOPHYS J, V82, P1453, DOI 10.1016/S0006-3495(02)75499-4; McNally HA, 2004, J NEUROCYTOL, V33, P251, DOI 10.1023/B:NEUR.0000030700.48612.0b; Palmer JS, 1998, J UROLOGY, V159, P2136, DOI 10.1016/S0022-5347(01)63295-6; Pointillart V, 2000, SPINAL CORD, V38, P71, DOI 10.1038/sj.sc.3100962; PRINCIPE ANDREW H., 1968, J FORENSIC SCI, V13, P90; SHAFFER CB, 1947, J AM PHARM ASSOC SCI, V36, P152, DOI 10.1002/jps.3030360507; SHAFFER CB, 1948, AM J PHYSIOL, V152, P93, DOI 10.1152/ajplegacy.1947.152.1.93; SHAPIRO S, 2004, IN PRESS J NEUROSURG; Shi R, 1999, J NEUROPHYSIOL, V81, P2406, DOI 10.1152/jn.1999.81.5.2406; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; Short DJ, 2000, SPINAL CORD, V38, P273, DOI 10.1038/sj.sc.3100986; SMYTH HF, 1947, J AM PHARM ASSOC SCI, V36, P157, DOI 10.1002/jps.3030360508; WORKING P, 1997, POLY ETHYLENE GLYCOL	34	88	91	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2004	21	12					1767	1777		10.1089/neu.2004.21.1767			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	877FY	WOS:000225554400008	15684768				2022-02-06	
J	Kreitschmann-Andermahr, I; Hoff, C; Saller, B; Niggemeier, S; Pruemper, S; Hutter, BO; Rohde, V; Gressner, A; Matern, S; Gilsbach, JM				Kreitschmann-Andermahr, I; Hoff, C; Saller, B; Niggemeier, S; Pruemper, S; Hutter, BO; Rohde, V; Gressner, A; Matern, S; Gilsbach, JM			Prevalence of pituitary deficiency in patients after aneurysmal subarachnoid hemorrhage	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM			English	Article							GROWTH-HORMONE DEFICIENCY; TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; INTRACRANIAL ANEURYSMS; LAMINA TERMINALIS; GH DEFICIENCY; DIAGNOSIS; HYPOPITUITARISM; EMBOLIZATION; MANAGEMENT	After aneurysmal subarachnoid hemorrhage (SAH), patients frequently present with persistent bodily, psychosocial, and cognitive impairments that resemble those of patients with untreated partial or complete pituitary insufficiency. Because of these similarities, the authors hypothesized that aneurysmal SAH may cause pituitary dysfunction. Pituitary function testing was performed in 40 aneurysmal SAH patients between 12 and 72 months after the SAH. A combined TRH-LHRH-arginine test and the insulin tolerance test were performed on two separate days. Only 18 of 40 (45%) of the tested patients had normal pituitary function. Five of 40 exhibited isolated severe GH deficiency (GHD), and an additional three of 40 had severe GHD plus corticotroph deficiency. Isolated corticotroph deficiency was seen in 13 of 40 patients, and one patient showed isolated thyrotroph deficiency. All but one patient with corticotroph insufficiency were female. Patients with severe GHD had gained significantly more weight since their SAH than patients without GHD and exhibited a significantly higher body mass index. None of the clinical parameters indicative of a poor neurological outcome in aneurysmal SAH were related to pituitary insufficiency. In summary, neuroendocrine dysfunction was identified in a substantial portion of patients with previous aneurysmal SAH and should be borne in mind as a potential long-term sequel of the illness.	Univ Hosp Aachen, Dept Neurosurg, D-52074 Aachen, Germany; Univ Hosp Aachen, Endocrine Outpatient Clin, D-52074 Aachen, Germany; Univ Hosp Aachen, Dept Internal Med 3, Dept Med Psychol & Sociol, D-52074 Aachen, Germany; Univ Hosp Aachen, Inst Clin Chem & Pathobiochem, D-52074 Aachen, Germany; Pfizer GmbH, D-76032 Karlsruhe, Germany		Kreitschmann-Andermahr, I (corresponding author), Univ Hosp Aachen, Dept Neurosurg, Pauwelsstr 30, D-52074 Aachen, Germany.	ilonka.kreitschmann@post.rwth-aachen.de					Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Biller BMK, 2002, J CLIN ENDOCR METAB, V87, P2067, DOI 10.1210/jcem.87.5.8509; Brabant G, 2003, HORM RES, V60, P53, DOI 10.1159/000071871; Brilstra EH, 2002, NEUROLOGIST, V8, P35, DOI 10.1097/00127893-200201000-00004; Brilstra EH, 1999, STROKE, V30, P470, DOI 10.1161/01.STR.30.2.470; Bulow B, 2002, CLIN ENDOCRINOL, V56, P183, DOI 10.1046/j.0300-0664.2001.01461.x; Dhillo WS, 2002, EUR J ENDOCRINOL, V146, P231, DOI 10.1530/eje.0.1460231; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Freda PU, 1998, J CLIN ENDOCR METAB, V83, P3808, DOI 10.1210/jc.83.11.3808; HIJDRA A, 1988, STROKE, V19, P1250, DOI 10.1161/01.STR.19.10.1250; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; HUTTER BO, 1995, BRIT J NEUROSURG, V9, P465, DOI 10.1080/02688699550041106; Hutter BO, 1999, ACT NEUR S, V72, P157; JENNETT B, 1975, LANCET, V1, P480; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Komotar RJ, 2002, NEUROSURGERY, V51, P1403, DOI 10.1097/00006123-200212000-00010; KOVACS KJ, 1993, P NATL ACAD SCI USA, V90, P7681, DOI 10.1073/pnas.90.16.7681; Kreitschmann-Andermahr I, 2003, J NEUROL NEUROSUR PS, V74, P1133, DOI 10.1136/jnnp.74.8.1133; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P772, DOI 10.1136/jnnp.72.6.772; Ronkainen A, 2001, STROKE, V32, P2850, DOI 10.1161/hs1201.099711; van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249; VANCE ML, 1994, NEW ENGL J MED, V330, P1651, DOI 10.1056/NEJM199406093302306; Wallymahmed ME, 1999, CLIN ENDOCRINOL, V51, P333	26	88	89	0	1	ENDOCRINE SOC	CHEVY CHASE	8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA	0021-972X			J CLIN ENDOCR METAB	J. Clin. Endocrinol. Metab.	OCT	2004	89	10					4986	4992		10.1210/jc.2004-0146			7	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	860EW	WOS:000224326300032	15472195				2022-02-06	
J	Stalnacke, BM; Tegner, Y; Sojka, P				Stalnacke, BM; Tegner, Y; Sojka, P			Playing soccer increases serum concentrations of the biochemical markers of brain damage S-100B and neuron-specific enolase in elite players: a pilot study	BRAIN INJURY			English	Article							MINOR HEAD-INJURY; POST-CONCUSSION SYMPTOMS; PROTEIN MEASUREMENTS; NEUROPSYCHOLOGICAL IMPAIRMENT; NEUROBIOCHEMICAL MARKERS; ICE HOCKEY; SPORTS; FOOTBALL; RELEASE; HISTORY	Primary objective: To analyse serum concentrations of two biochemical markers of brain tissue damage, S-100B and NSE (neurone-specific enolase), in male soccer players in connection to the game. Methods: Blood samples were taken in players before and after a competitive game and the numbers of headers and of trauma events during soccer play were assessed. Results: Both S-100B and NSE were significantly raised in serum samples obtained after the game in comparison with the pre-game values (S-100B: 0.118 +/- 0.040 mug L-1 vs 0.066 +/- 0.025 mug L-1 , p < 0.001; NSE: 10.29 +/- 2.16 mug L-1 vs 8.57 +/- 2.31 mug L-1 , p < 0.001). Only changes in S-100B concentrations (post-game minus pre-game values) were statistically significantly correlated to the number of headers (r = 0.428, p = 0.02) and to the number of other trauma events (r = 0.453, p = 0.02). Conclusion: Playing competitive elite soccer was found to cause increase in serum concentrations of S-100B and NSE. Increases in S-100B were significantly correlated to the number of headers, and heading may accordingly have contributed to these increases.	Umea Univ, Dept Community Med & Rehabil, Umea, Sweden; Umea Univ, Dept Surg & Perioperat Sci, Umea, Sweden; Lulea Univ Technol, Inst Hlth Sci, Boden, Sweden		Sojka, P (corresponding author), Umea Univ Hosp, Dept Community Med & Rehabil, Bldg 9A, S-90185 Umea, Sweden.	peter.sojka@clinphys.umu.se		Tegner, Yelverton/0000-0003-3628-0705			Autti T, 1997, LANCET, V349, P1144, DOI 10.1016/S0140-6736(05)63019-X; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Biberthaler P, 2002, EUR J MED RES, V7, P164; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Ergun R, 1998, NEUROL RES, V20, P418; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; HAIMOTO H, 1987, LAB INVEST, V57, P489; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; INGEBRIGTSEN T, 2003, 3 INT C BIOCH MARK B; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KRAUS JF, 1989, MILD MODERATE HEAD I, P9; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrory P, 1999, BRIT J SPORT MED, V33, P136, DOI 10.1136/bjsm.33.2.136; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; *NAT COLL ATHL ASS, INJ SURV SYST; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; SHARMA HS, 1991, NEUROSCI RES, V10, P211; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; Tegner Y, 1996, BRIT J SPORT MED, V30, P251, DOI 10.1136/bjsm.30.3.251; TOWNEND WJ, 2000, J NEUROL NEUROSUR PS, V73, P542; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Wills SM, 2001, BRAIN INJURY, V15, P645, DOI 10.1080/02699050010010502; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	62	88	89	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2004	18	9					899	909		10.1080/02699050410001671865			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	831FG	WOS:000222178700005	15223742				2022-02-06	
J	Chen, XH; Iwata, A; Nonaka, M; Browne, KD; Smith, DH				Chen, XH; Iwata, A; Nonaka, M; Browne, KD; Smith, DH			Neurogenesis and glial proliferation persist for at least one year in the subventricular zone following brain trauma in rats	JOURNAL OF NEUROTRAUMA			English	Article						brain trauma; neural progenitor cell; progressive neurodegeneration; subventricular zone; ventriculomegaly	ADULT-RAT; CELL-PROLIFERATION; DENTATE GYRUS; RODENT HIPPOCAMPUS; NUCLEAR ANTIGEN; GROWTH-FACTOR; EXPRESSION; INJURY; NEUROBLASTS; GENERATION	In several models of traumatic brain injury in rodents, remarkably progressive tissue loss and neuron death has been observed accompanied by expanding ventricles. Here, we explored potential cell proliferation in the subventricular zone (SVZ) in response to this progressive posttraumatic neurodegeneration. Four-month-old rats (n = 57) were subjected to parasagittal fluid-percussion brain injury or sham treatment (no injury), and their brains were harvested at 2 weeks, 2 months, 6 months, and 1 year (n = 6-8/group) after injury or sham treatment. Brain sections (6 mum) were stained with markers of cell proliferation, Ki-67, and proliferative cell nuclear antigen (PCNA) to detect mitotically active cells. In sham animals, we found a typical age-dependent decrease in Ki-67- and PCNA-labelled cells in the SVZ over the course of 1 year. However, in brain-injured animals, this decrease was reversed culminating in a sixfold increase in the number of cells staining with Ki-67 and a threefold increase in cells staining with PCNA by 1 year following injury compared to age-matched controls. Using double labeling, we also determined that many of the cells staining with Ki-67 or PCNA expressed markers selective for neurons (neurofilament protein) and glia (GFAP). These data suggest that there is a persistent proliferation of neurons and glia in the SVZ following brain trauma that does not diminish during aging as found in non-injured animals.	Univ Penn, Med Ctr, Dept Neurosurg, Philadelphia, PA 19104 USA		Smith, DH (corresponding author), Univ Penn, Med Ctr, Dept Neurosurg, 3320 Smith Walk,105 Hayden Hall, Philadelphia, PA 19104 USA.		smith, douglas/A-1321-2007		NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 21527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 08803, NS 38104] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS038104, P01NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K08AG021527] Funding Source: NIH RePORTER		Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Calza L, 1998, P NATL ACAD SCI USA, V95, P3209, DOI 10.1073/pnas.95.6.3209; COLTRERA MD, 1991, J HISTOCHEM CYTOCHEM, V39, P23, DOI 10.1177/39.1.1670579; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; GERDES J, 1984, J IMMUNOL, V133, P1710; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; KAPLAN MS, 1984, J NEUROSCI, V4, P1429; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kee N, 2002, J NEUROSCI METH, V115, P97, DOI 10.1016/S0165-0270(02)00007-9; Kempermann G, 1997, P NATL ACAD SCI USA, V94, P10409, DOI 10.1073/pnas.94.19.10409; Kornack DR, 2001, SCIENCE, V294, P2127, DOI 10.1126/science.1065467; Kuhn HG, 1996, J NEUROSCI, V16, P2027; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKeever PE, 1997, J NEUROPATH EXP NEUR, V56, P798; Parent JM, 2002, J NEUROSCI, V22, P3174, DOI 10.1523/JNEUROSCI.22-08-03174.2002; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Strom RC, 1998, J NEUROSCI, V18, P9948; Szele FG, 1996, J COMP NEUROL, V368, P439, DOI 10.1002/(SICI)1096-9861(19960506)368:3<439::AID-CNE9>3.0.CO;2-6; Thomaidou D, 1997, J NEUROSCI, V17, P1075, DOI 10.1523/jneurosci.17-03-01075.1997; Tropepe V, 1997, J NEUROSCI, V17, P7850; Weinstein DE, 1996, BRAIN RES, V743, P11, DOI 10.1016/S0006-8993(96)00979-1; YACHNIS AT, 1993, J COMP NEUROL, V334, P356, DOI 10.1002/cne.903340303	30	88	91	0	8	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2003	20	7					623	631		10.1089/089771503322144545			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	703KL	WOS:000184278500002	12908924				2022-02-06	
J	Andersson, EH; Bjorklund, R; Emanuelson, I; Stalhammar, D				Andersson, EH; Bjorklund, R; Emanuelson, I; Stalhammar, D			Epidemiology of traumatic brain injury: a population based study in western Sweden	ACTA NEUROLOGICA SCANDINAVICA			English	Article						traumatic brain injury; epidemiology; incidence	HEAD-INJURY	Background - This study on traumatic brain injury (TBI) is based on prospective and retrospective population based data from a head injury register in Boras. Methods - Data was collected from the hospital emergency unit, the discharge register, the regional neurosurgical clinic and the coroner's records during 1 year. This district is mixed urban and rural with a population of 138 000. Results - The 753 cases identified represent an incidence of 546 per 100 000 which includes deaths (0.7%), hospital admissions (67%) and attendance at the emergency department in patients not admitted (32%). Males (644 per 100 000), had 1.46 higher overall rate than females (442 per 100 000). The external causes were dominated by fall from same level (31%) and fall from different level (27%) followed by traffic accidents (16%) and persons hit by objects (15%). Conclusions - The incidence of TBI found in this study is high but well in accordance with earlier published Swedish studies.	Cent Hosp Boras, Dept Rehabil Med, Boras, Sweden; Sahlgrenska Univ Hosp, Dept Hlth Women & Children, Gothenburg, Sweden; Sahlgrenska Univ Hosp, Inst Clin Neurosci, Gothenburg, Sweden		Andersson, EH (corresponding author), Boras Lasarett, Dept Rehabil Med, SE-50182 Boras, Sweden.						ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; CARLSSON GS, 1986, THESIS GOTHENBURG U; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; Eker C, 2000, BRAIN INJURY, V14, P605; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; GRONWALL D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kelly JP, 1997, NEUROLOGY, V48, P581; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LONG CJ, 1986, SOUTHERN MED J, V79, P728, DOI 10.1097/00007611-198606000-00020; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774	17	88	94	0	5	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-6314			ACTA NEUROL SCAND	Acta Neurol. Scand.	APR	2003	107	4					256	259		10.1034/j.1600-0404.2003.00112.x			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	663MB	WOS:000182008400003	12675698				2022-02-06	
J	Heinemann, AW; Sokol, K; Garvin, L; Bode, RK				Heinemann, AW; Sokol, K; Garvin, L; Bode, RK			Measuring unmet needs and services among persons with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Conference on TBI in the 21st Century	DEC 02, 1999	BETHESDA, MD			brain injuries; health services; health services needs and demand; psychometrics; rehabilitation	HEAD-INJURY; LIFE; QUALITY; STATE	Objectives: (1) To develop a comprehensive list of needs and services appropriate for persons with traumatic brain injury (TBI); (2) to determine whether these needs and services formed unidimensional hierarchies from least common to most common; (3) to describe the relationship between unmet needs and services received; and (4) to estimate the extent to which a variety of demographic, injury, and service characteristics predict unmet needs. Design: Statewide mailed survey. Setting: Illinois communities. Participants: A total of 895 persons who had had a TBI recruited from Brain Injury Association members and rehabilitation service recipients. The median time post-TBI was 7 years; the median age was 37 years. Interventions: Not applicable. Main Outcome Measures: A 27-item instrument assessing service needs and utilization of services, and equal-interval measures of needs and services derived with Rasch analysis. Results: The most prevalent unmet needs were improving memory or problem-solving skills (51.9%), increasing income (50.5%), and improving job skills (46.3%). The instrument defined unidimensional and reliable constructs of needs and services. Persons with greater unmet needs tended to receive fewer services; to report lower life satisfaction and worse medical health and psychologic well-being since injury; to be younger, single, black, dependent in 1 or more daily activities; and to have more recent injuries. Conclusions: The results show the common pattern of unmet needs and services and emphasize the importance of comprehensive, statewide assessment of services and needs in developing policies.	Rehabil Inst Chicago, Ctr Rehabil Outcome Res, Chicago, IL 60611 USA; Northwestern Univ, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; Northwestern Univ, Inst Hlth Serv Res & Policy Studies, Chicago, IL 60611 USA; US Govt Accounting Off, Chicago, IL USA; Loyola Univ, Chicago, IL 60611 USA		Heinemann, AW (corresponding author), Rehabil Inst Chicago, Ctr Rehabil Outcome Res, 345 E Super St, Chicago, IL 60611 USA.	a-heinemann@northwestern.edu	Heinemann, Allen W/K-6283-2012; Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W/0000-0003-2782-7326; Heinemann, Allen W./0000-0003-2782-7326			Allen SM, 1997, MED CARE, V35, P1132, DOI 10.1097/00005650-199711000-00005; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Brzuzy S, 1997, SOC WORK HEALTH CARE, V26, P77, DOI 10.1300/J010v26n01_05; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; FLANAGAN JC, 1982, ARCH PHYS MED REHAB, V63, P56; FRIEMAN M, 1998, HLTH SERV RES 1, V33, P867; GORDON W, 1999, LIVING LIFE TBI PUBL; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; LINACRE JM, 2000, WINSTEPS PC COMPATIB; MCCAFFREY RJ, 1987, INT J CLIN NEUROPSYC, V9, P174; Mngadi S, 1992, J APPL REHABILITATIO, V23, P12, DOI 10.1891/0047-2220.23.2.12; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Patrick D, 1989, DISABLEMENT COMMUNIT; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Rasch Georg, 1980, PROBABILISTIC MODELS; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Wright B, 1982, RATING SCALE ANAL RA	23	88	89	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2002	83	8					1052	1059		10.1053/apmr.2002.34283			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	580QG	WOS:000177244800003	12161825				2022-02-06	
J	Castriotta, RJ; Lai, JM				Castriotta, RJ; Lai, JM			Sleep disorders associated with traumatic brain injury.	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Annual Meeting of the American-Academy-of-Physical-Medicine-and-Rehabilitation	NOV 12-13, 1999	WASHINGTON, D.C.	Amer Acad Phys Med & Rehabil		craniocerebral trauma; hypersomnia; rehabilitation; sleep apnea; obstructive; sleep-disordered breathing	POSTTRAUMATIC NARCOLEPSY; DAYTIME SLEEPINESS; APNEA; ACCIDENTS	Objectives: To investigate the frequency of sleep disorders in traumatic brain injury (TBI) patients with hypersomnia and to discern the relationship between posttraumatic sleep disorders and pretraumatic sleep symptoms. Design: Prospective cohort study using the criterion standard to diagnose sleep disorders in a consecutive sample of TBI patients. Setting: Academic medical center with level I trauma center, rehabilitative medicine services, and accredited sleep disorders center. Patients: Ten TBI patients with subjective excessive sleepiness. Intervention: Nocturnal polysomnography followed by Multiple Sleep Latency Test. Subjects who had overt sleep apnea on the first nocturnal polysomnography had a second nocturnal polysomnography with titration of nasal continuous positive airway pressure. Main Outcome Measures: Diagnosis of sleep-disordered breathing, narcolepsy, and posttraumatic hypersomnia. Results: A diagnosis of treatable sleep disorder was made in all 10 subjects. Sleep-disordered breathing was found in 7 subjects: overt obstructive sleep apnea (OSA) was diagnosed in 5 subjects, rapid eye movement-related OSA in 1, and upper airway resistance syndrome (UARS) in 1. Narcolepsy was diagnosed in 2 subjects, and the diagnosis of posttraumatic hypersomnia was made in 1 subject. Three subjects had symptoms of hypersomnia before their injury (1 each with narcolepsy, OSA, UARS), and 2 of these were driving a car at the time of injury. Conclusion: Treatable sleep disorders appear to be common in the sleepy TBI population, but may be largely undiagnosed and untreated.	Univ Texas, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Mem Hermann Hosp, Sleep Disorders Ctr, Houston, TX USA		Castriotta, RJ (corresponding author), Univ Texas, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, 6431 Fannin,Ste 1-266, Houston, TX 77030 USA.	Richard.J.Castriotta@uth.tmc.edu	Castriotta, Richard/B-1158-2009; Lang, Steven/AAE-8102-2021; Sanguansri, Luz/B-6630-2011	Lang, Steven/0000-0003-1669-9146; Sanguansri, Luz/0000-0003-1908-7604; Castriotta, Richard/0000-0003-3502-4558			CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; *CDCP, IN PRESS TRAUM INJ U; CHESNUT RM, 1999, AGENCY HLTH CARE HLT; DERDERIAN SS, 1988, CHEST, V94, P1023, DOI 10.1378/chest.94.5.1023; Engleman HM, 2000, SLEEP, V23, pS102; FINDLEY LJ, 1986, CHEST, V90, P686, DOI 10.1378/chest.90.5.686; Gill AW, 1941, LANCET, V1, P474; GOOD JL, 1989, J NEUROSURG, V71, P765, DOI 10.3171/jns.1989.71.5.0765; GREENBERG GD, 1987, SLEEP, V10, P254, DOI 10.1093/sleep/10.3.254; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; Horstmann S, 2000, SLEEP, V23, P383; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; LANKFORD DA, 1994, SLEEP, V17, pS25, DOI 10.1093/sleep/17.suppl_8.S25; LEGER D, 1994, SLEEP, V17, P84, DOI 10.1093/sleep/17.1.84; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; MONTPLAISIR J, 1992, SLEEP S6, V15, pS517; RECHSTHAFFEN A, 1968, BRAIN INFORMATION SE; Teran-Santos J, 1999, NEW ENGL J MED, V340, P847, DOI 10.1056/NEJM199903183401104; Young T, 1997, SLEEP, V20, P608, DOI 10.1093/sleep/20.8.608; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Young T, 1997, SLEEP, V20, P705, DOI 10.1093/sleep/20.9.705	22	88	90	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2001	82	10					1403	1406		10.1053/apmr.2001.26081			4	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	479NQ	WOS:000171410800009	11588744				2022-02-06	
J	Warrington, SA; Wright, CM				Warrington, SA; Wright, CM		ALSPAC Study Team	Accidents and resulting injuries in premobile infants: data from the ALSPAC study	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article						accident; burn; fall; injury	BURN INJURIES; CHILDREN FALL; BED; ABUSE; AGE	Background and aims-Little is known about injuries resulting from accidents in premobile infants. We aimed to describe the pattern of minor accidents in infants and their resulting injuries. Methods-The ALSPAC study collected data in successive postal questionnaires. At 6 months of age, parents were asked to describe any accident since birth. The type of fall, distance fallen, resulting injury, and help sought were independently coded. Burns were similarly coded. Results-A total of 11 466 responses were available. In 2554 children, 3357 falls were reported; 53% fell from beds or settees and 12% fell from arms or while being carried. Only 14% reported visible injury, of which 56% were bruises; 97% of injuries specified involved the head. Only 21 falls (<1%) resulted in concussion or fracture. A burn or scald occurred in 172 cases (1.5%). The main causes of scalds were hot drinks and water, with contact burns caused by radiators, cookers, and hot food. Conclusions-Falls in young infants are common while burns are rare. Injuries from falls are infrequent, predominantly trivial, and almost entirely confined to the head. Falls from beds and settees did not result in skull fractures. Serious injury was the result of complex accidents.	Univ Newcastle Upon Tyne, Dept Child Hlth, Community Child Hlth Unit, Newcastle Upon Tyne NE8 6ET, Tyne & Wear, England; Univ Bristol, ALSPAC Study Team, Bristol BS8 1TQ, Avon, England		Warrington, SA (corresponding author), 2 Beechfield Rd, Newcastle Upon Tyne NE3 4DR, Tyne & Wear, England.						BANCO L, 1994, PEDIATR EMERG CARE, V10, P98, DOI 10.1097/00006565-199404000-00010; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; CAFFEY J, 1974, PEDIATRICS, V54, P396; *CAPT CHILD ACC PR, 1992, NHS SOC COSTS CHILDR, P49; Carpenter RF, 1999, ARCH DIS CHILD, V80, P363, DOI 10.1136/adc.80.4.363; CARTER YH, 1993, BRIT J GEN PRACT, V43, P159; CHADWICK DL, 1991, J TRAUMA, V31, P1353, DOI 10.1097/00005373-199110000-00006; Cronin KJ, 1996, BURNS, V22, P221, DOI 10.1016/0305-4179(95)00109-3; DATUBOBROWN DD, 1989, BURNS, V15, P285, DOI 10.1016/0305-4179(89)90002-8; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; HELFER RE, 1977, PEDIATRICS, V60, P533; HOBBS CJ, 1984, ARCH DIS CHILD, V59, P246, DOI 10.1136/adc.59.3.246; JOFFE M, 1988, PEDIATRICS, V82, P457; KEMPE CH, 1962, JAMA-J AM MED ASSOC, V181, P105; KLEIN DM, 1981, CHILD ABUSE NEGLECT, P73; LINDBLAD BE, 1990, BURNS, V16, P254, DOI 10.1016/0305-4179(90)90134-I; LYONS TJ, 1993, PEDIATRICS, V92, P125; MADDOCKS GB, 1978, PUBLIC HEALTH, V92, P171, DOI 10.1016/S0033-3506(78)80120-6; MCCORMICK MC, 1981, AM J DIS CHILD, V135, P159, DOI 10.1001/archpedi.1981.02130260051015; NIMITYONGSKUL P, 1987, J PEDIATR ORTHOPED, V7, P184, DOI 10.1097/01241398-198703000-00014; PHILLIPS W, 1986, BURNS, V12, P343, DOI 10.1016/0305-4179(86)90105-1; RIVARA FP, 1988, PEDIATRICS, V81, P93; ROSSIGNOL AM, 1990, BURNS, V16, P41, DOI 10.1016/0305-4179(90)90204-A; SIMON PA, 1994, ARCH PEDIAT ADOL MED, V148, P394, DOI 10.1001/archpedi.1994.02170040060010; *STAT HLTH, 1992, HLTH NAT STRAT HLTH; STEWART G, 1993, PEDIATR EMERG CARE, V9, P199, DOI 10.1097/00006565-199308000-00004; Tarantino CA, 1999, PEDIATR EMERG CARE, V15, P5, DOI 10.1097/00006565-199902000-00002; *US DHEW PHS DIV P, 1970, 71R3 FY US DHEW PHS; WILLIAMS RA, 1991, J TRAUMA, V31, P1350, DOI 10.1097/00005373-199110000-00005; 1995, HLTH SURVEY ENGLAND, V1, pCH5	30	88	91	2	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888			ARCH DIS CHILD	Arch. Dis. Child.	AUG	2001	85	2					104	107		10.1136/adc.85.2.104			4	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	456WK	WOS:000170105600004	11466183	Green Submitted, Green Published, Bronze			2022-02-06	
J	Couch, JR; Bearss, C				Couch, JR; Bearss, C			Chronic daily headache in the posttrauma syndrome: Relation to extent of head injury	HEADACHE			English	Article						head injury; posttraumatic headache; chronic daily headache	EPIDEMIOLOGY; POPULATION; CONCUSSION; TRAUMA; BRAIN	Objective.-To evaluate the occurrence of continued intermittent headache and chronic daily headache in patients with head injury and the relationship between severity of the headache problem and intensity of the head injury, Background.-In the majority of patients with posttraumatic headache, the condition is self-limited, but a minority of patients may develop persistent headaches. The features of posttraumatic headache may vary, but the most distressing type is the chronic daily headache. This study evaluates occurrence of chronic daily headache in relation to the intensity of head injury. Methods.-All patients with head injury who were seen by the senior author (J.R.C.) in the Southern Illinois University Medical School (SIUMS) Neurology Clinic between 1980 and 1991 were identified from the SIUMS headache registry. Data on headache status before and after head injury was obtained, and patients with more than one headache per week before head injury were excluded. Each patient's headache status at the time of the clinic visit was classified as chronic daily headache (headache occurring at least 5 of 7 days for 6 months), intermittent migraine, or no headache. Head injury severity was graded by duration of loss of consciousness or amnesia as minimal (less than 5 minutes), mild (5 to 60 minutes), moderate (1 to 24 hours), or severe (more than 24 hours). Results.-There was an inverse relation between extent of head injury and occurrence of chronic daily headache. For minimal head injury (n = 54), 80% had chronic daily headache, and 11% had no headache, while for moderate/severe head injury (n = 23), only 27% had chronic daily headache, and 68% had no headache (P<,001, <chi>(2)) Conclusion.-This study suggests that the risk of developing posttraumatic chronic daily headache is greater for less severe head injury compared with moderate/severe head injury. The reason for this relation is unclear.	Univ Oklahoma, Hlth Sci Ctr, Dept Neurol, Oklahoma City, OK 73190 USA; So Illinois Univ, Sch Med, Carbondale, IL 62901 USA		Couch, JR (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Neurol, 711 Stanton L Young Blvd, Oklahoma City, OK 73190 USA.						Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Brenner C, 1944, J NEUROSURG, V1, P379, DOI 10.3171/jns.1944.1.6.0379; Cartlidge NEF, 1981, HEAD INJURY, P95; Castillo J, 1999, HEADACHE, V39, P190, DOI 10.1046/j.1526-4610.1999.3903190.x; COUCH JR, 1995, J NEUROL REHABIL, V9, P83; COUCH JR, 1998, HEADACHE, V38, P5; FRIEDMAN AP, 1969, LATE EFFECTS HEAD IN, V5, P55; GUTMAN E, 1943, LANCET, V1, P10; *HEAD CLASS COMM I, 1988, CEPHALALGIA S7, V8, P10; KAY DWK, 1971, LANCET, V2, P1052; KELLY R, 1981, J ROY SOC MED, V74, P242; MOSKOWITZ MA, 1984, ANN NEUROL, V16, P157, DOI 10.1002/ana.410160202; PACKARD RC, 1992, HEADACHE, V32, P496, DOI 10.1111/j.1526-4610.1992.hed3210496.x; PACKARD RC, 1994, J NEUROPSYCH CLIN N, V6, P229; RASKIN NH, 1987, HEADACHE, V27, P416, DOI 10.1111/j.1526-4610.1987.hed2708416.x; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Scher AI, 1998, HEADACHE, V38, P497, DOI 10.1046/j.1526-4610.1998.3807497.x; Schwartz BS, 1998, JAMA-J AM MED ASSOC, V279, P381, DOI 10.1007/s11916-010-0146-2; SIMONS DJ, 1946, PSYCHOSOM MED, V8, P227, DOI 10.1097/00006842-194607000-00001; SPEED WG, 1989, HEADACHE, V29, P643, DOI 10.1111/j.1526-4610.1989.hed2910643.x; Symonds CP, 1943, LANCET, V1, P7; TAYLOR AR, 1967, BRIT MED J, V3, P67, DOI 10.1136/bmj.3.5557.67; WELCH KMA, 1990, NEUROL CLIN, V8, P817, DOI 10.1016/S0733-8619(18)30319-0	25	88	91	0	1	BLACKWELL SCIENCE INC	MALDEN	350 MAIN ST, MALDEN, MA 02148 USA	0017-8748			HEADACHE	Headache	JUN	2001	41	6					559	564		10.1046/j.1526-4610.2001.041006559.x			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	447TC	WOS:000169587700007	11437891				2022-02-06	
J	Malaspina, D; Goetz, RR; Friedman, JH; Kaufmann, CA; Faraone, SV; Tsuang, M; Cloninger, CR; Nurnberger, JI; Blehar, MC				Malaspina, D; Goetz, RR; Friedman, JH; Kaufmann, CA; Faraone, SV; Tsuang, M; Cloninger, CR; Nurnberger, JI; Blehar, MC			Traumatic brain injury and schizophrenia in members of schizophrenia and bipolar disorder pedigrees	AMERICAN JOURNAL OF PSYCHIATRY			English	Article							NEUROLOGIC SIGNS; HEAD-INJURY; RELATIVES; DEPRESSION; PSYCHOSIS; GENOTYPE; SEQUELAE; FAMILY; ONSET	Objective: Schizophrenia following a traumatic brain injury could be a phenocopy of genetic schizophrenia or the consequence of a gene-environment interaction. Alternatively, traumatic brain injury and schizophrenia could be spuriously associated if those who are predisposed to develop schizophrenia have greater amounts of trauma for other reasons. The authors investigated the relationship between traumatic brain injury and psychiatric diagnoses in a large group of subjects from families with at least two biologically related first-degree relatives with schizophrenia, schizoaffective disorder, or bipolar disorder. Method: The Diagnostic Interview for Genetic Studies was used to determine history of traumatic brain injury and diagnosis for 1,275 members of multiplex bipolar disorder pedigrees and 565 members of multiplex schizophrenia pedigrees. Results: Rates of traumatic brain injury were significantly higher for those with a diagnosis of schizophrenia, bipolar disorder, and depression than for those with no mental illness. However, multivariate analysis of within-pedigree data showed that mental illness was related to traumatic brain injury only in the schizophrenia pedigrees. Independent of diagnoses, family members of those with schizophrenia were more likely to have had traumatic brain injury than were members of the bipolar disorder pedigrees. The members of the schizophrenia pedigrees also failed to show the gender difference for traumatic brain injury (more common in men than in women) that was expected and was present in the bipolar disorder pedigrees. Subjects with a schizophrenia diagnosis who were members of the bipolar disorder pedigrees land thus had less genetic vulnerability to schizophrenia) were less likely to have had traumatic brain injury (4.5%) than were subjects with schizophrenia who were members of the schizophrenia pedigrees land who had greater genetic vulnerability to schizophrenia) (19.6%). Conclusions: Members of the schizophrenia pedigrees, even those without a schizophrenia diagnosis, had greater exposure to traumatic brain injury com pared to members of the bipolar disorder pedigrees. Within the schizophrenia pedigrees, traumatic brain injury was associated with a greater risk of schizophrenia, consistent with synergistic effects between genetic vulnerability for schizophrenia and traumatic brain injury. Posttraumatic-brain-injury schizophrenia in mu[tip[ex schizophrenia pedigrees does not appear to be a phenocopy of the genetic disorder.	New York State Psychiat Inst, New York, NY 10032 USA; Columbia Univ, New York, NY 10027 USA; Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; Washington Univ, Dept Psychiat, St Louis, MO USA; NIMH, Bethesda, MD 20892 USA; Indiana Univ, Dept Psychiat, Indianapolis, IN 46204 USA		Malaspina, D (corresponding author), New York State Psychiat Inst, 722 W 168th St, New York, NY 10032 USA.		Faraone, Stephen/AAE-7334-2019; Cloninger, Claude/F-5357-2012; Faraone, Stephen V/O-7239-2018	Faraone, Stephen/0000-0002-9217-3982; Cloninger, Claude/0000-0003-3096-4807; Faraone, Stephen V/0000-0002-9217-3982; Nurnberger, John/0000-0002-7674-1767	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [U01MH046289, P20MH050727] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH-50727, MH-46289] Funding Source: Medline		ACHTE K, 1991, PSYCHOPATHOLOGY, V24, P309, DOI 10.1159/000284731; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; CLONINGER CR, 1994, AM J MED GENET, V54, P83, DOI 10.1002/ajmg.1320540202; CROW TJ, 1986, BRIT J PSYCHIAT, V149, P419, DOI 10.1192/bjp.149.4.419; CUMMINGS JL, 1985, BRIT J PSYCHIAT, V146, P184, DOI 10.1192/bjp.146.2.184; DAVISON K, 1983, PSYCHIAT DEV, V1, P1; Davison K, 1969, CURRENT PROBLEMS NEU, P113; DEMOL J, ENCEPHALE, V8, P17; FARMER AE, 1984, PSYCHIAT RES, V13, P109, DOI 10.1016/0165-1781(84)90054-4; FEDEROFF JP, 1991, AM J PSYCHIAT, V148, P1172; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GERSHON ES, 1987, ARCH GEN PSYCHIAT, V44, P314; GOETZ KL, 1986, J NERV MENT DIS, V74, P31; Gualtari CT, 1991, BRAIN INJURY, V5, P219; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; KENDLER KS, 1986, AM J PSYCHIAT, V143, P279; Kinney DK, 1999, SCHIZOPHR RES, V35, P99, DOI 10.1016/S0920-9964(98)00121-2; KINNEY DK, 1986, ARCH GEN PSYCHIAT, V43, P665; KINNEY DK, 1991, PSYCHIAT RES, V39, P45, DOI 10.1016/0165-1781(91)90007-C; Kraepelin E., 1919, DEMENTIA PRAECOX PAR; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; MAIER W, 1993, ARCH GEN PSYCHIAT, V50, P871; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NURNBERGER JI, 1994, ARCH GEN PSYCHIAT, V51, P849, DOI 10.1001/archpsyc.1994.03950110009002; OCALLAGHAN E, 1988, BRIT J PSYCHIAT, V153, P394, DOI 10.1192/bjp.153.3.394; PEARLSON GD, 1984, AM J PSYCHIAT, V141, P253; PLESS IB, 1995, PEDIATRICS, V95, P219; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; ROBINSON RG, 1988, AM J PSYCHIAT, V145, P172; RUTHERFORD WH, 1977, LANCET, V1, P1; SILVER JM, 1993, 146TH AM PSYCH ASS A, P250; TAYLOR MA, 1992, AM J PSYCHIAT, V149, P22; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; Violon A, 1988, Acta Neurochir Suppl (Wien), V44, P67; WILCOX JA, 1987, PSYCHIAT RES, V21, P303, DOI 10.1016/0165-1781(87)90013-8; WOODS BT, 1991, BIOL PSYCHIAT, V30, P806, DOI 10.1016/0006-3223(91)90236-F	41	88	92	0	15	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0002-953X			AM J PSYCHIAT	Am. J. Psychiat.	MAR	2001	158	3					440	446		10.1176/appi.ajp.158.3.440			7	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	408JL	WOS:000167323000016	11229986				2022-02-06	
J	Gilad, GM; Gilad, VH				Gilad, GM; Gilad, VH			Accelerated functional recovery and neuroprotection by agmatine after spinal cord ischemia in rats	NEUROSCIENCE LETTERS			English	Article						decarboxylated arginine; motoneurons; neuroprotective treatment; neurotrauma; transient ischemia; rat model	CLONIDINE-DISPLACING SUBSTANCE; NITRIC-OXIDE SYNTHASE; NEURONAL DAMAGE; BRAIN; POLYAMINES; INHIBITION; ARGININE; RECEPTOR; DECARBOXYLATION; ACCUMULATION	Treatment with agmatine, decarboxylated arginine, proved to be non-toxic and to exert neuroprotective effects in several models of neurotoxic and ischemic brain and spinal cord injuries. Here we sought to find out whether agmatine treatment would also prove beneficial in a rat spinal cord ischemia model (balloon occlusion of the abdominal aorta bellow the branching point of the left subclavian artery for 5 min). Agmatine was injected (100 mg/kg, i.p.) 5 min after beginning of re-perfusion and again once daily for the next 3 post-operative days. Motor performance ('combined motor score') was recorded for up to 17 days post-operative and motoneuron cell counts (in representative spinal cord sections) performed on the 17th post-operative day. Agmatine treatment was found to accelerate recovery of motor deficits and to prevent the loss of motoneurons in the spinal cord after transient ischemia. Together, the present and previous findings demonstrate that agmatine is an efficacious neuroprotective agent and that this naturally occurring non-toxic compound should be tried for therapeutic use after neurotrauma and in neurodegenerative diseases. (C) 2000 Published by Elsevier Science Ireland Ltd.	Assaf Harofeh Med Ctr, Lab Neurosci Res & Dev, IL-70300 Zerifin, Israel		Gilad, GM (corresponding author), Assaf Harofeh Med Ctr, Lab Neurosci Res & Dev, PO Beer Yaakov, IL-70300 Zerifin, Israel.		Gilad, Gad M/E-7193-2010				AriciogluKartal F, 1997, LIFE SCI, V61, P1775, DOI 10.1016/S0024-3205(97)00801-1; AUGUET M, 1995, JPN J PHARMACOL, V69, P285, DOI 10.1254/jjp.69.285; BREWER KL, 1998, SOC NEUR ABSTR, V24, P577; DIETRICH WD, 1991, ACTA NEUROPATHOL, V81, P615, DOI 10.1007/BF00296371; Fairbanks CA, 2000, P NATL ACAD SCI USA, V97, P10584, DOI 10.1073/pnas.97.19.10584; Galea E, 1996, BIOCHEM J, V316, P247, DOI 10.1042/bj3160247; GILAD GM, 1992, BIOCHEM PHARMACOL, V44, P401, DOI 10.1016/0006-2952(92)90428-L; GILAD GM, 1991, EXP NEUROL, V111, P349, DOI 10.1016/0014-4886(91)90102-I; Gilad GM, 1996, NEUROREPORT, V7, P1730, DOI 10.1097/00001756-199607290-00007; GILAD GM, 1993, MOL CHEM NEUROPATHOL, V18, P197, DOI 10.1007/BF03160034; Gilad GM, 1996, NEUROSCI LETT, V216, P33; GILAD GM, 1995, LIFE SCI, V58; HARA H, 1993, PROG NEUROBIOL, V40, P645, DOI 10.1016/0301-0082(93)90009-H; Kolesnikov Y, 1996, EUR J PHARMACOL, V296, P17, DOI 10.1016/0014-2999(95)00669-9; KOMORI Y, 1994, ARCH BIOCHEM BIOPHYS, V315, P213, DOI 10.1006/abbi.1994.1492; LI G, 1994, SCIENCE, V263, P966, DOI 10.1126/science.7906055; LORING RH, 1990, BRIT J PHARMACOL, V99, P207, DOI 10.1111/j.1476-5381.1990.tb14680.x; MARSALA M, 1994, J CEREBR BLOOD F MET, V14, P526, DOI 10.1038/jcbfm.1994.65; MARX M, 1995, NEPHRON, V69, P155, DOI 10.1159/000188432; MURAYAMA T, 1993, BIOCHEMISTRY-US, V32, P561, DOI 10.1021/bi00053a022; Olmos G, 1999, BRIT J PHARMACOL, V127, P1317, DOI 10.1038/sj.bjp.0702679; PFEIFFER B, 1981, H-S Z PHYSIOL CHEM, V362, P1331, DOI 10.1515/bchm2.1981.362.2.1331; PILETZ JE, 1995, J PHARMACOL EXP THER, V272, P581; PINTHONG D, 1995, BRIT J PHARMACOL, V115, P689, DOI 10.1111/j.1476-5381.1995.tb14988.x; REYNOLDS IJ, 1990, J PHARMACOL EXP THER, V255, P1001; Sastre M., 1995, Society for Neuroscience Abstracts, V21, P2059; SENER A, 1989, BIOCHEM PHARMACOL, V38, P327, DOI 10.1016/0006-2952(89)90044-0; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Takahashi K, 1997, J CEREBR BLOOD F MET, V17, P1137, DOI 10.1097/00004647-199711000-00001; VLASSARA H, 1994, LAB INVEST, V70, P138; WEITZEL G, 1980, H-S Z PHYSIOL CHEM, V361, P51, DOI 10.1515/bchm2.1980.361.1.51; Yang XC, 1999, J PHARMACOL EXP THER, V288, P544	32	88	90	0	2	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	DEC 22	2000	296	2-3					97	100		10.1016/S0304-3940(00)01625-6			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	383AP	WOS:000165859800009	11108990				2022-02-06	
J	Diaz-Arrastia, R; Agostini, MA; Frol, AB; Mickey, B; Fleckenstein, J; Van Ness, PC				Diaz-Arrastia, R; Agostini, MA; Frol, AB; Mickey, B; Fleckenstein, J; Van Ness, PC			Neurophysiologic and neuroradiologic features of intractable epilepsy after traumatic brain injury in adults	ARCHIVES OF NEUROLOGY			English	Article							TEMPORAL-LOBE EPILEPSY; HEAD-INJURY; POSTTRAUMATIC SEIZURES; RANDOMIZED TRIAL; PATHOLOGY; NEUROPROTECTION; LOCALIZATION; PREVENTION; LOBECTOMY; DAMAGE	Background: There is controversy regarding the precise mechanism by which epilepsy results after traumatic brain injury (TBI). Previous reports have suggested that mesial temporal lobe epilepsy may result from TBI only in young children, while neocortical epilepsy arises from TBI in later life. These conclusions were based on surgical series and may be biased because of patient selection. Objective: To determine the frequency of mesial temporal lobe as opposed to neocortical epilepsy in patients with intractable epilepsy resulting from TBI after the age of 10 years. Patients and Methods: We identified 23 patients with intractable epilepsy who had TBI after the age of 10 years, preceding the onset of epilepsy. Patients were studied by simultaneous videotape and scalp electroencephalographic recording of typical seizures; magnetic resonance imaging; neuropsychologic studies; and, when appropriate, intracarotid amobarbital testing. Two patients underwent anterior temporal lobectomies. Results: Of the 23 patients, 8 (35%) had mesial temporal lobe epilepsy, based on the finding of hippocampal sclerosis on a magnetic resonance imaging scan, consistent interictal and ictal electroencephalographic recordings, evidence of temporal lobe dysfunction on neuropsychologic testing, and characteristic seizure semiology. Two of these patients underwent anterior temporal lobectomies with clinical benefit, and hippocampal sclerosis was confirmed pathologically. In 2 cases, patients were not treated surgically because of bilateral temporal lobe dysfunction noted on intracarotid amobarbital testing. Eleven patients had neocortical epilepsy; 1 had primary generalized epilepsy; and, in 3, the site of seizure onset was not localized. Conclusions: Mesial temporal lobe epilepsy can result from TBI in adolescents and adults as well as in children, and can often be bilateral and associated with multifocal injury. This information may be useful in developing prophylactic therapy for posttraumatic epilepsy.	Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Neurosurg, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Neuroradiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Neuropathol, Dallas, TX 75235 USA		Diaz-Arrastia, R (corresponding author), Univ Texas, SW Med Ctr, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Diaz-Arrastia, Ramon/0000-0001-6051-3594	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012297, R03AG016450] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R03AG16450, R01AG12297] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [KO8NS01763] Funding Source: Medline		Ajmone-Marsan Cosimo, 1993, P313; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Annegers JF., 1996, TREATMENT EPILEPSY P, P165; Arrowsmith JE, 1998, STROKE, V29, P2357, DOI 10.1161/01.STR.29.11.2357; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; CASCINO GD, 1992, EPILEPSY RES, V11, P51, DOI 10.1016/0920-1211(92)90021-K; CAVENESS WF, 1963, J NEUROSURG, V20, P570, DOI 10.3171/jns.1963.20.7.0570; COOK MJ, 1992, BRAIN, V115, P1001, DOI 10.1093/brain/115.4.1001; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; COURVILLE CB, 1958, TEMPORAL LOBE EPILEP, P220; DUNCAN JS, 1987, NEUROLOGY, V37, P405, DOI 10.1212/WNL.37.3.405; EVANS JH, 1962, NEUROLOGY, V12, P665, DOI 10.1212/WNL.12.10.665; FRENCH JA, 1993, ANN NEUROL, V34, P774, DOI 10.1002/ana.410340604; GRAHAM DI, 1996, NEUROLOGY TRAUMA, P53; HAUSER WA, 1984, NEUROLOGY, V34, P746, DOI 10.1212/WNL.34.6.746; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; KRAUS JF, 1996, NEUROLOGY TRAUMA, P3; KUZNIECKY J, 1995, MAGNETIC RESONANCE I, P107; MARGERISON JH, 1966, BRAIN, V89, P499, DOI 10.1093/brain/89.3.499; MARKS DA, 1995, NEUROLOGY, V45, P2051, DOI 10.1212/WNL.45.11.2051; MATHERN GW, 1994, EPILEPSY RES, V19, P129, DOI 10.1016/0920-1211(94)90023-X; MCNAMARA JO, 1989, EPILEPSIA, V30, pS13, DOI 10.1111/j.1528-1157.1989.tb05809.x; Pitkanen A, 1999, EPILEPSY RES, V33, P67, DOI 10.1016/S0920-1211(98)00074-6; Prince D A, 1999, Adv Neurol, V79, P665; RISINGER MW, 1989, NEUROLOGY, V39, P1288, DOI 10.1212/WNL.39.10.1288; Rushing EJ, 1997, AM J FOREN MED PATH, V18, P335, DOI 10.1097/00000433-199712000-00004; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Schuh LA, 1998, ARCH NEUROL-CHICAGO, V55, P1325, DOI 10.1001/archneur.55.10.1325; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; WILLMORE LJ, 1990, EPILEPSIA, V31, P67; Yang Y, 1998, BRAIN RES, V804, P169, DOI 10.1016/S0006-8993(98)00410-7	35	88	91	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	NOV	2000	57	11					1611	1616		10.1001/archneur.57.11.1611			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	370NM	WOS:000165129200007	11074793	Bronze			2022-02-06	
J	Neumann-Haefelin, T; Witte, OW				Neumann-Haefelin, T; Witte, OW			Periinfarct and remote excitability changes after transient middle cerebral artery occlusion	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						focal cerebral ischemia; middle cerebral artery occlusion; reperfusion; penumbra; diaschisis; electrophysiology	INDUCED CORTICAL INFARCTS; LONG-TERM POTENTIATION; TRAUMATIC BRAIN INJURY; ACUTE STROKE; NEURONAL HYPEREXCITABILITY; INTRAVENOUS THROMBOLYSIS; RAT-BRAIN; IN-VITRO; ISCHEMIA; RECOVERY	Transient middle cerebral artery (MCA) occlusion results in substantially smaller cortical infarcts than permanent MCA occlusion if reperfusion is initiated within the first few hours. Only little information is available on the long-term functional outcome of the cortical regions "salvaged" by early reperfusion. To address this issue we examined basic electrophysiologic parameters in vitro using standard extracellular recording techniques at 7 and 28 days after transient MCA occlusion (1- and 2-hour ischemia) in rats. Both neocortical areas ipsi- and contralateral to MCA occlusion were systematically mapped to delineate the extent of periinfarct and remote alterations. In the periinfarct region we found a significant reduction of field potential amplitudes up to 3 mm when measuring from the infarct border at 7 days and up to 7 mm at 28 days. Paired-pulse inhibition, an indicator of GABAergic transmission, was only moderately impaired in this region at 7 days and not significantly different from control at 28 days. Remote effects were observed both ipsi- and contralaterally. Ipsilaterally they were restricted to a region close to the midline (presumably motor cortex) and were most likely attributable to the degeneration of corticostriatal connections. The extent of the contra lateral excitability changes was clearly related to the size of the neocortical infarcts with large infarcts resulting in the widespread reduction of field potential amplitudes and an impairment of paired-pulse inhibition. The results show that there is a relatively large periinfarct region with decreased overall excitability after transient MCA occlusion which is Likely to have a profound effect on perilesional processes involved in functional recovery. Remote excitability changes may contribute to the functional deficit and are probably related to deafferentation.	Univ Dusseldorf, Neurol Klin, D-40225 Dusseldorf, Germany		Witte, OW (corresponding author), Univ Dusseldorf, Neurol Klin, Moorenstr 5, D-40225 Dusseldorf, Germany.		Witte, Otto/P-4127-2018; Neumann-Haefelin, Tobias/AAC-3915-2020	Witte, Otto/0000-0003-2101-4105; 			ANDREWS RJ, 1991, STROKE, V22, P943, DOI 10.1161/01.STR.22.7.943; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Becker KJ, 1998, CURR OPIN NEUROL, V11, P45, DOI 10.1097/00019052-199802000-00008; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Bolay H, 1998, STROKE, V29, P1988, DOI 10.1161/01.STR.29.9.1988; BuchkremerRatzmann I, 1996, STROKE, V27, P1105, DOI 10.1161/01.STR.27.6.1105; CharriautMarlangue C, 1996, J CEREBR BLOOD F MET, V16, P186, DOI 10.1097/00004647-199603000-00002; Chollet Francois, 1994, Current Opinion in Neurobiology, V4, P226, DOI 10.1016/0959-4388(94)90077-9; del Zoppo GJ, 1998, J NEUROL NEUROSUR PS, V65, P1, DOI 10.1136/jnnp.65.1.1; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DOMANN R, 1993, NEUROSCI LETT, V155, P69, DOI 10.1016/0304-3940(93)90675-B; Eysel UT, 1997, ADV NEUROL, V73, P195; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; Garcia JH, 1996, STROKE, V27, P761, DOI 10.1161/01.STR.27.4.761; Garcia JH, 1997, NEUROLOGY, V49, pS27, DOI 10.1212/WNL.49.5_Suppl_4.S27; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hagemann G, 1998, ANN NEUROL, V44, P255, DOI 10.1002/ana.410440217; Hossmann KA, 1996, CEREBROVAS BRAIN MET, V8, P195; HOSSMANN KA, 1994, ANN NEUROL, V36, P557, DOI 10.1002/ana.410360404; HURWITZ BE, 1991, STROKE, V22, P648, DOI 10.1161/01.STR.22.5.648; Koizumi J, 1986, JPN J STROKE, V8, P1, DOI DOI 10.3995/JSTROKE.8.1; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; LUHMANN HJ, 1995, EUR J NEUROSCI, V7, P180, DOI 10.1111/j.1460-9568.1995.tb01054.x; Luhmann HJ, 1996, PROG NEUROBIOL, V48, P131, DOI 10.1016/0301-0082(95)00042-9; Lyden PD, 1997, NEUROLOGY, V49, P14, DOI 10.1212/WNL.49.1.14; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MIES G, 1983, STROKE, V14, P22, DOI 10.1161/01.STR.14.1.22; MIES G, 1991, J CEREBR BLOOD F MET, V11, P753, DOI 10.1038/jcbfm.1991.132; Mittmann T, 1998, NEUROSCIENCE, V85, P15, DOI 10.1016/S0306-4522(97)00638-6; MITTMANN T, 1994, NEUROSCIENCE, V60, P891, DOI 10.1016/0306-4522(94)90270-4; MIYAZAKI S, 1993, NEUROL RES, V15, P249; MORI E, 1992, STROKE, V23, P712, DOI 10.1161/01.STR.23.5.712; NEDERGAARD M, 1988, ACTA NEUROL SCAND, V77, P81, DOI 10.1111/j.1600-0404.1988.tb05878.x; Neumann-Haefelin T, 1998, NEUROSCIENCE, V87, P871, DOI 10.1016/S0306-4522(98)00124-9; NEUMANNHAEFELIN T, 1995, NEUROSCI LETT, V193, P101, DOI 10.1016/0304-3940(95)11677-O; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; OBRENOVITCH TP, 1995, CEREBROVAS BRAIN MET, V7, P1; Qu M, 1998, NEUROSCIENCE, V85, P29, DOI 10.1016/S0306-4522(97)00656-8; Qu MS, 1998, BRAIN RES, V813, P374, DOI 10.1016/S0006-8993(98)01063-4; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Reinecke S, 1999, NEUROSCI LETT, V261, P85, DOI 10.1016/S0304-3940(99)00014-2; Schiene K, 1996, J CEREBR BLOOD F MET, V16, P906, DOI 10.1097/00004647-199609000-00014; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; URBAN L, 1989, J NEUROSCI, V9, P3966; von Monakow C., 1914, DIASCHISIS LOKALISAT, P26; Witte OW, 1998, CURR OPIN NEUROL, V11, P655, DOI 10.1097/00019052-199812000-00008; Witte OW, 1997, ADV NEUROL, V73, P207; Witte OW, 1997, TRENDS NEUROSCI, V20, P348	50	88	88	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2000	20	1					45	52		10.1097/00004647-200001000-00008			8	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	281PJ	WOS:000085169600008	10616792	Bronze			2022-02-06	
J	Xiong, Y; Peterson, PL; Lee, CP				Xiong, Y; Peterson, PL; Lee, CP			Effect of N-acetylcysteine on mitochondrial function following traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						N-acetylcysteine; neuroprotection; rat brain mitochondria; reduced glutathione; traumatic brain injury	TRANSIENT FOREBRAIN ISCHEMIA; NERVOUS-SYSTEM TRAUMA; LIPID-PEROXIDATION; ENDOTHELIAL-CELLS; HEAD-INJURY; GLUTATHIONE; ANTIOXIDANT; BARRIER; CALCIUM; REPERFUSION	Efficacy of N-acetylcysteine (NAC) in traumatic brain injury (TBI)-induced mitochondrial dysfunction was evaluated following controlled cortical impact injury in rats, Respiratory function and calcium transport of rat forebrain mitochondria from injured and uninjured hemispheres were examined, NAC significantly restored mitochondrial electron transfer, energy coupling capacity, calcium uptake activity and reduced calcium content absorbed to brain mitochondrial membranes when examined 12 h post-TBI if NAC was administered i.p. 5 min before injury or 30 min or 1 h postinjury, Glutathione (reduced form, GSH) levels in brain tissues were decreased at all time points examined over a 14-day observation period, while mitochondrial GSH levels significantly decreased only at 3 days and 14 days following TBI, NAC treatment given within 1 h greatly restored brain GSH levels from 1 h to 14 days and mitochondrial GSH levels from 12 h to 14 days post-TBI, NAC did not show protective effects when given 2 h postinjury, Our data indicate that NAC administered postinjury at an early stage can effectively restore TBI-induced mitochondrial dysfunction and the protective effect of NAC may be related to its restoration of GSH levels in the brain.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA		Lee, CP (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield St, Detroit, MI 48201 USA.	cplee@med.wayne.edu		Xiong, Ye/0000-0001-9770-6031			ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Banaclocha MM, 1997, BRAIN RES, V762, P256, DOI 10.1016/S0006-8993(97)00493-9; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; COOPER AJL, 1980, J NEUROCHEM, V35, P1242, DOI 10.1111/j.1471-4159.1980.tb07882.x; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; CORCORAN GB, 1986, J PHARMACOL EXP THER, V238, P54; COSSARIZZA A, 1995, EXP CELL RES, V220, P232, DOI 10.1006/excr.1995.1311; COTGREAVE I, 1991, BIOCHEM PHARMACOL, V42, P13, DOI 10.1016/0006-2952(91)90674-T; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; FUKUZAWA K, 1995, TRANSPLANTATION, V59, P6, DOI 10.1097/00007890-199501150-00002; GRAMMAS P, 1993, FREE RADICAL BIO MED, V14, P553, DOI 10.1016/0891-5849(93)90113-9; GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTER KK, 1994, J BIOENERG BIOMEMBR, V26, P471, DOI 10.1007/BF00762732; Hall ED, 1996, ACT NEUR S, V66, P107; Hall ED, 1996, J NEUROSCI RES, V44, P293, DOI 10.1002/(SICI)1097-4547(19960501)44:3<293::AID-JNR10>3.0.CO;2-6; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; HALL ED, 1987, J PHARMACOL EXP THER, V242, P137; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; Hartl R, 1997, ACT NEUR S, V70, P240; HOVDA DA, 1994, ACTA NEUROCHIR, P521; Hsiang JNK, 1997, ACTA NEUROCHIR, V139, P464, DOI 10.1007/BF01808884; JAIN A, 1991, P NATL ACAD SCI USA, V88, P1913, DOI 10.1073/pnas.88.5.1913; Kelly G S, 1998, Altern Med Rev, V3, P114; KNUCKEY NW, 1995, STROKE, V26, P305, DOI 10.1161/01.STR.26.2.305; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KOSOWER NS, 1983, FUNCTIONS GLUTATHION, P307; Lee C. P., 1993, V2, P41; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; Martinez M, 1995, MECH AGEING DEV, V84, P77, DOI 10.1016/0047-6374(95)01644-F; MCINTOSH TK, 1995, J HEAD TRAUMA REHAB, V10, P1; MCLELLAN LI, 1995, CARCINOGENESIS, V16, P2099, DOI 10.1093/carcin/16.9.2099; MEISTER A, 1995, BIOCHIM BIOPHYS ACTA, V1271, P273; MEREDITH MJ, 1982, J BIOL CHEM, V257, P3747; MIQUEL J, 1995, EUR J PHARM-ENVIRON, V292, P333, DOI 10.1016/0926-6917(95)90041-1; MOLDEUS P, 1986, RESPIRATION, V50, P31, DOI 10.1159/000195086; PHELPS DT, 1992, AM J RESP CELL MOL, V7, P293, DOI 10.1165/ajrcmb/7.3.293; REHNCRONA S, 1980, J NEUROCHEM, V34, P477, DOI 10.1111/j.1471-4159.1980.tb11170.x; SCHINETTI ML, 1989, CARDIOVASC RES, V23, P76, DOI 10.1093/cvr/23.1.76; SCIAMANNA MA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P223, DOI 10.1016/0167-4889(92)90180-J; SIMS NR, 1991, J NEUROCHEM, V56, P1836, DOI 10.1111/j.1471-4159.1991.tb03438.x; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; TRABER J, 1992, BIOCHEM PHARMACOL, V43, P961, DOI 10.1016/0006-2952(92)90599-E; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	54	88	90	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	1999	16	11					1067	1082		10.1089/neu.1999.16.1067			16	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	260MM	WOS:000083954500005	10595823				2022-02-06	
J	Dixon, CE; Kraus, MF; Kline, AE; Ma, XC; Yan, HQ; Griffith, RG; Wolfson, BM; Marion, DW				Dixon, CE; Kraus, MF; Kline, AE; Ma, XC; Yan, HQ; Griffith, RG; Wolfson, BM; Marion, DW			Amantadine improves water maze performance without affecting motor behavior following traumatic brain injury in rats	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						brain injury; amantadine; dopamine; rat	SENSORIMOTOR CORTEX INJURY; CLOSED-HEAD-INJURY; METHYLPHENIDATE TREATMENT; DOUBLE-BLIND; WORKING-MEMORY; RECOVERY; AMPHETAMINE; AGONIST; ABLATION; IMPACT	Amantadine, a dopamine agonist, is reported to have beneficial effects on the neurobehavioral sequelae of clinical brain injury. However, there are currently no published laboratory reports on its use in the assessment of functional or histopathological outcome following experimental traumatic brain injury (TBI). To this end, we examined the effects of daily amantadine treatment on functional recovery (motor and Morris water maze performance) and hippocampal neuronal survival following controlled cortical impact (CCI) injury (4 meters/sec, 2.7 mm tissue deformation). Male Sprague-Dawley rats were pretrained on motor performance tasks (beam balance and beam walking) one day prior to injury and tested on post-operative days 1-5. Additionally, all subjects were trained on the Morris water maze on post-operative days 14-18. Beginning one day after CCI injury or sham surgery, animals were injected once daily for 18 days with either amantadine (10 mg/kg, i.p.) or saline. The amantadine treatment regimen was ineffective in promoting motor recovery and increasing survival of hippocampal neurons in both the CA1 and CA3 regions following TBI, but did show improved swim latencies during the five days of water maze testing (Day 14 vs. Day 18, p < 0.01) when compared to saline controls. Mean (+/- SE) swim latencies on Day 18 were 15.12 +/- 2.8, 13.25 +/- 4. 18, 70.83 +/- 11.1, and 38.5 +/- 3.55 sec for the sham/saline, sham/amantadine, injured/saline, and injured/amantadine treatment groups, respectively. Thus, while the daily administration of amantadine exhibited a neutral effect on motor behavior, it produced a modest attenuation of water maze performance deficits. This latter finding is consistent with published clinical data suggesting a beneficial effect on functional outcome with amantadine therapy.	Univ Pittsburgh, Ctr Med, Dept Neurosurg, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15213 USA		Dixon, CE (corresponding author), Univ Pittsburgh, Ctr Med, Dept Neurosurg, Brain Trauma Res Ctr, 3434 5th Ave,Suite 201, Pittsburgh, PA 15260 USA.	edixon@neuronet.pitt.edu	Marion, Donald/AAR-5749-2021				ALLEN RM, 1983, CLIN NEUROPHARMACOL, V6, pS64; AOKI FY, 1988, CLIN PHARMACOKINET, V14, P35, DOI 10.2165/00003088-198814010-00003; ARNSTEN AFT, 1994, PSYCHOPHARMACOLOGY, V116, P143, DOI 10.1007/BF02245056; BAK IJ, 1972, J NEURAL TRANSM, V33, P45, DOI 10.1007/BF01244727; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; BOND M, 1984, CLOSED HEAD INJURY P; BOYESON MG, 1993, AM J PHYS MED REHAB, V72, P286, DOI 10.1097/00002060-199310000-00007; BOYESON MG, 1992, BRAIN RES BULL, V29, P435, DOI 10.1016/0361-9230(92)90080-H; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1992, BEHAV NEUROSCI, V106, P964, DOI 10.1037/0735-7044.106.6.964; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; COPE DN, 1994, J HEAD TRAUMA REHAB, V9, P1, DOI 10.1097/00001199-199409000-00003; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOBKIN BH, 1993, ANN NEUROL, V33, P313, DOI 10.1002/ana.410330315; Feeney DM, 1998, RESTORATIVE NEUROLOGY, P35; FEENEY DM, 1993, J NEURAL TRANSP PLAS, V4, P199, DOI 10.1155/NP.1993.199; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; FEENEY DM, 1998, CEREBROVASC DIS, P620; GIANUTSOS G, 1985, EUR J PHARMACOL, V110, P357, DOI 10.1016/0014-2999(85)90564-3; Goldstein L B, 1990, Restor Neurol Neurosci, V1, P311, DOI 10.3233/RNN-1990-1501; GOLDSTEIN LB, 1991, RESTOR NEUROL NEUROS, V3, P41, DOI 10.3233/RNN-1991-3105; Goldstein LB, 1997, PHARMACOL BIOCHEM BE, V58, P1151, DOI 10.1016/S0091-3057(97)00324-9; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Grade C, 1998, ARCH PHYS MED REHAB, V79, P1047, DOI 10.1016/S0003-9993(98)90169-1; GRELAK RP, 1970, SCIENCE, V169, P203, DOI 10.1126/science.169.3941.203; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1989, MILD HEAD INJURY, P153; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HERRMANN EC, 1960, P SOC EXP BIOL MED, V103, P625, DOI 10.3181/00379727-103-25617; Hornyak J E, 1997, Pediatr Rehabil, V1, P15; HOVDA DA, 1989, BEHAV NEUROSCI, V103, P574, DOI 10.1037/0735-7044.103.3.574; JENNETT B, 1990, HDB CLIN NEUROLOGY, V57, P1; Kimberg DY, 1997, NEUROREPORT, V8, P3581, DOI 10.1097/00001756-199711100-00032; KLINE AE, 1994, PHARMACOL BIOCHEM BE, V48, P773, DOI 10.1016/0091-3057(94)90345-X; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1991, J NEUROL SCI, V103, pS39; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LUCIANA M, 1992, J COGNITIVE NEUROSCI, V4, P58, DOI 10.1162/jocn.1992.4.1.58; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MOONEY GF, 1993, ARCH PHYS MED REHAB, V74, P153; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; NISHINO K, 1991, FUNCTIONAL NEUROSURG, V30, P116; PARKER SA, 1976, ACTA NEUROCHIR, V34, P71, DOI 10.1007/BF01405864; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Schmanke T, 1997, J NEUROTRAUM, V14, P459, DOI 10.1089/neu.1997.14.459; SCHWAB RS, 1969, J AMER MED ASSOC, V208, P1168, DOI 10.1001/jama.208.7.1168; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH ML, 1995, NEUROSCIENCE, V67, P679, DOI 10.1016/0306-4522(95)00076-U; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; Steele TD, 1996, ANN NY ACAD SCI, V777, P427, DOI 10.1111/j.1749-6632.1996.tb34457.x; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Von Voigtlander P F, 1971, Science, V174, P408, DOI 10.1126/science.174.4007.408; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; WROBLEWSKI BA, 1994, J HEAD TRAUMA REHAB, V9, P19, DOI 10.1097/00001199-199409000-00004; Zafonte RD, 1998, BRAIN INJURY, V12, P617	67	88	88	0	8	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		1999	14	4					285	294					10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	218EP	WOS:000081540500005	12671249				2022-02-06	
J	Meredith, W; Rutledge, R; Fakhry, SM; Emery, S; Kromhout-Schiro, S				Meredith, W; Rutledge, R; Fakhry, SM; Emery, S; Kromhout-Schiro, S			The conundrum of the Glasgow Coma Scale in intubated patients: A linear regression prediction of the Glasgow Verbal Score from the Glasgow Eye and Motor Scores	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	57th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma and the Japanese-Society-for-Acute-Medicine	SEP 24-27, 1997	WAIKOLOA, HAWAII	Amer Assoc Surg Trauma, Japanese Soc Acute Med			HEAD-INJURED PATIENTS; TRAUMATIC BRAIN INJURY; INTENSIVE-CARE UNIT; INTRACRANIAL HYPERTENSION; COMPUTERIZED-TOMOGRAPHY; ACUTE PHYSIOLOGY; RISK-FACTORS; APACHE-II; SEVERITY; MORTALITY	Background: The Glasgow Coma Scale (GCS), which is the foundation of the Trauma Score, Trauma and Injury Severity Score, and the Acute Physiology and Chronic Health Evaluation scoring systems, requires a verbal response. In some series, up to 50% of injured patients must be excluded from analysis because of lack of a verbal component for the GCS. The present study extends previous work evaluating derivation of the verbal score from the eye and motor components of the GCS. Methods: Data were obtained from a state trauma registry for 24,565 unintubated patients. The eye and motor scores were used in a previously published regression model to predict the verbal score: Derived Verbal Score = -0.3756 + Motor Score * (0.5713) + Eye Score * (0.4233). The correlation of the actual and derived verbal and GCS scales were assessed. In addition the ability of the actual and derived GCS to predict patient survival in a logistic regression model were analyzed using the PC SAS system for statistical analysis. The predictive power of the actual and the predicted GCS were compared using the area under the receiver operator characteristic curve and Hosmer-Lemeshow goodness-of-fit testing. Results: A total of 24,085 patients were available for analysis. The mean actual verbal score was 4.4 +/- 1.3 versus a predicted verbal score of 4.3 +/- 1.2 (r = 0.90, p = 0.0001). The actual GCS was 13.6 +/- 3.5 versus a predicted GCS of 13.7 +/- 3.4 (r = 0.97, p = 0.0001). The results of the comparison of the prediction of survival in patients based on the actual GCS and the derived GCS shaw that the mean actual GCS was 13.5 + 3.5 versus 13.7 + 3.4 in the regression predicted model. The area under the receiver operator characteristic curve for predicting survival of the two values was similar at 0.868 for the actual GCS compared with 0.850 for the predicted GCS. Conclusions: The previously derived method of calculating the verbal score from the eye and motor scores is an excellent predictor of the actual verbal score. Furthermore, the derived GCS performed better than the actual GCS by several measures. The present study confirms previous work that a very accurate GCS can be derived in the absence of the verbal component.	Univ N Carolina, Dept Surg, Chapel Hill, NC 27599 USA; N Carolina Baptist Hosp, Chapel Hill, NC USA; N Carolina Trauma Registry, Chapel Hill, NC USA		Rutledge, R (corresponding author), Univ N Carolina, Dept Surg, Campus Box 7210,Burnett Womack, Chapel Hill, NC 27599 USA.	rrutledg@med.unc.edu					ANTONELLI M, 1994, CHEST, V105, P224, DOI 10.1378/chest.105.1.224; BASTOS PG, 1993, CRIT CARE MED, V21, P1459, DOI 10.1097/00003246-199310000-00012; BENESCH CG, 1993, ARCH NEUROL-CHICAGO, V50, P1309, DOI 10.1001/archneur.1993.00540120024008; BRATTON SL, 1994, ARCH PEDIAT ADOL MED, V148, P167, DOI 10.1001/archpedi.1994.02170020053008; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Chan Betty, 1993, Journal of Emergency Medicine, V11, P579, DOI 10.1016/0736-4679(93)90312-U; Ellis A, 1992, Intensive Crit Care Nurs, V8, P94, DOI 10.1016/0964-3397(92)90037-K; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; GENSEMER IB, 1989, ANN EMERG MED, V18, P9, DOI 10.1016/S0196-0644(89)80303-8; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; GOTT PS, 1991, ARCH NEUROL-CHICAGO, V48, P1267, DOI 10.1001/archneur.1991.00530240071024; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; Hill DA, 1997, J TRAUMA, V42, P62, DOI 10.1097/00005373-199701000-00011; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JOHNSON SB, 1992, J TRAUMA, V33, P95, DOI 10.1097/00005373-199207000-00018; KARKELA J, 1992, CRIT CARE MED, V20, P378; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KLAUBER MR, 1984, J NEUROSURG, V61, P695, DOI 10.3171/jns.1984.61.4.0695; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LANGFITT TW, 1978, J NEUROSURG, V48, P673, DOI 10.3171/jns.1978.48.5.0673; LANZA DC, 1990, ANN OTO RHINOL LARYN, V99, P38, DOI 10.1177/000348949009900106; LEE H, 1992, CRIT CARE MED, V20, P1555, DOI 10.1097/00003246-199211000-00013; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; MARGULIES DR, 1994, AM SURGEON, V60, P387; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MENEGAZZI JJ, 1993, J TRAUMA, V34, P46, DOI 10.1097/00005373-199301000-00008; METZ CA, 1993, CRIT CARE MED, V21, P1844, DOI 10.1097/00003246-199312000-00010; NISKANEN M, 1991, CRIT CARE MED, V19, P1465, DOI 10.1097/00003246-199112000-00005; OSULLIVAN MG, 1994, J NEUROSURG, V80, P46, DOI 10.3171/jns.1994.80.1.0046; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; ROCCA B, J TRAUMA, V29, P299; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; Rutledge R, 1996, J TRAUMA, V41, P514, DOI 10.1097/00005373-199609000-00022; SANO K, 1994, NEUROL RES, V16, P23; SCHWARTZ ML, 1991, J TRAUMA, V31, P962, DOI 10.1097/00005373-199107000-00013; SEGATORE M, 1992, HEART LUNG, V21, P548; STARMARK JE, 1988, J NEUROSURG, V69, P692, DOI 10.3171/jns.1988.69.5.0692; TEASDALE G, 1974, LANCET, V2, P81; TERES D, 1982, CRIT CARE MED, V10, P86, DOI 10.1097/00003246-198202000-00004; TUHRIM S, 1991, ANN NEUROL, V29, P658, DOI 10.1002/ana.410290614; TURAZZI S, 1984, ACTA NEUROCHIR, V72, P167, DOI 10.1007/BF01406869; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581; WOLFGOULD C, 1991, J TROP PEDIATRICS, V38, P290; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; ZIMMERMAN JE, 1989, CRIT CARE MED S, V17, pS169	50	88	89	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	1998	44	5					839	845		10.1097/00005373-199805000-00016			7	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	ZN299	WOS:000073632000015	9603086				2022-02-06	
J	Horita, A				Horita, A			An update on the CNS actions of TRH and its analogs	LIFE SCIENCES			English	Article; Proceedings Paper	2nd International Symposium on Membrane Receptors Signal Transduction and Drug Action / 19th Symposium on Biomembrane-Drug Interaction	SEP 24-26, 1997	SAPPORO, JAPAN	Minist Educ Sci Sports & Culture, Japanese Pharmacol Soc, Pharmaceut Soc Japan, Hokkaido Univ, Univ Arizona		thyrotropin releasing hormone; TRH analogs; arousal; amnesia; motor function; spinal cord injury; spinocerebellar injury	THYROTROPIN-RELEASING-HORMONE; VIVO ACETYLCHOLINE-RELEASE; RAT FRONTAL-CORTEX; SPINAL-CORD INJURY; DOSE-RESPONSE; YM-14673; TA-0910; BRAIN; RECEPTOR; MICE	This brief review will discuss the recent literature on several of the central actions of TRH and its analogs. The most prominent of these actions include: (1) the arousal or analeptic effect in drug narcotized animals or in concussion models; (2) the reversal of cognitive deficits produced by various drugs or procedures, and (3) the improvement of several neurological deficits produced in animal models of spinal and/or cerebellar injury. The mediation of these TRH effects by neurotransmitters is discussed. While little has been published on the human neuropsychopharmacology of TRH, and especially of its analogs, the future holds considerable therapeutic promise for these interesting drugs.	Univ Washington, Sch Med, Dept Pharmacol & Psychiat, Seattle, WA 98195 USA		Horita, A (corresponding author), Univ Washington, Sch Med, Dept Pharmacol & Psychiat, Seattle, WA 98195 USA.						BAYLISS DA, 1992, J NEUROPHYSIOL, V68, P1733, DOI 10.1152/jn.1992.68.5.1733; BEHRMANN DL, 1993, EXP NEUROL, V119, P258, DOI 10.1006/exnr.1993.1028; BREESE GR, 1975, J PHARMACOL EXP THER, V193, P11; Callahan AM, 1997, BIOL PSYCHIAT, V41, P264, DOI 10.1016/S0006-3223(97)00372-7; Chizh BA, 1996, EUR J PHARMACOL, V300, P183, DOI 10.1016/0014-2999(95)00869-1; DESHPANDE SB, 1994, EUR J PHARMACOL, V271, P439, DOI 10.1016/0014-2999(94)90804-4; ENGEL WK, 1983, LANCET, V2, P73; FADEN AI, 1981, NEW ENGL J MED, V305, P1063, DOI 10.1056/NEJM198110293051806; FADEN AI, 1984, NEUROLOGY, V34, P1280, DOI 10.1212/WNL.34.10.1280; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; Gershengorn MC, 1996, PHYSIOL REV, V76, P175, DOI 10.1152/physrev.1996.76.1.175; GIOVANNINI MG, 1991, BRIT J PHARMACOL, V102, P363, DOI 10.1111/j.1476-5381.1991.tb12179.x; HEINFLINK M, 1995, MOL ENDOCRINOL, V9, P1455, DOI 10.1210/me.9.11.1455; HORITA A, 1986, FASEB J, V45, P795; HORITA A, 1991, LIFE SCI, V49, P595, DOI 10.1016/0024-3205(91)90258-D; HORITA A, 1989, PEPTIDES, V10, P121, DOI 10.1016/0196-9781(89)90087-9; HORITA A, 1975, PHARM BIOCH BEHAV, V5, P111; HUTSON PH, 1990, NEUROSCI LETT, V116, P149, DOI 10.1016/0304-3940(90)90401-T; ITOH Y, 1994, J PHARMACOL EXP THER, V268, P255; ITOH Y, 1994, J PHARMACOL EXP THER, V271, P884; KALIVAS PW, 1980, J PHARMACOL EXP THER, V212, P203; Kinoshita K, 1997, BIOL PHARM BULL, V20, P36; KINOSHITA K, 1994, NEUROPHARMACOLOGY, V33, P1183, DOI 10.1016/S0028-3908(05)80008-5; Kinoshita K, 1996, JPN J PHARMACOL, V71, P139, DOI 10.1254/jjp.71.139; Kinoshita K, 1995, BRIT J PHARMACOL, V116, P3274, DOI 10.1111/j.1476-5381.1995.tb15135.x; KINOSHITA K, 1995, J PHARM, V24, P65; Koenig ML, 1996, BRAIN RES, V730, P143; KRAEMER GW, 1976, PHARMACOL BIOCHEM BE, V4, P709, DOI 10.1016/0091-3057(76)90224-0; Larsson JE, 1996, PEPTIDES, V17, P293, DOI 10.1016/0196-9781(95)02127-2; Mason George A., 1995, P493; MATSUI K, 1994, EUR J PHARMACOL, V254, P295, DOI 10.1016/0014-2999(94)90469-3; MELLOW AM, 1993, BIOL PSYCHIAT, V34, P271, DOI 10.1016/0006-3223(93)90083-P; MIYAMOTO M, 1982, PHARMACOL BIOCHEM BE, V17, P797, DOI 10.1016/0091-3057(82)90363-X; MIYAMOTO M, 1994, EUR J PHARMACOL, V271, P357; MIYAMOTO M, 1993, EUR J PHARMACOL, V238, P181; MOLCHAN SE, 1990, PSYCHOPHARMACOLOGY, V100, P84, DOI 10.1007/BF02245795; Mushiroi Takeshi, 1996, Folia Pharmacologica Japonica, V107, P237, DOI 10.1254/fpj.107.237; Nakayama T, 1996, EUR J PHARMACOL, V316, P157, DOI 10.1016/S0014-2999(96)00614-0; NICOLL RA, 1977, NATURE, V265, P242, DOI 10.1038/265242a0; Ogasawara T, 1996, PHARMACOL BIOCHEM BE, V53, P391, DOI 10.1016/0091-3057(95)02039-X; OGASAWARA T, 1996, PHARM BIOCH BEHAV, V50, P499; OKADA M, 1991, J NEUROCHEM, V56, P1544, DOI 10.1111/j.1471-4159.1991.tb02049.x; PITTS LH, 1995, J NEUROTRAUM, V12, P235, DOI 10.1089/neu.1995.12.235; POPOLI P, 1995, EUR J PHARMACOL, V272, P119, DOI 10.1016/0014-2999(94)00701-8; SANTORI EM, 1981, PSYCHOPHARMACOLOGY, V74, P13, DOI 10.1007/BF00431749; SOBUE I, 1983, J NEUROL SCI, V61, P235, DOI 10.1016/0022-510X(83)90008-4; Stocca G, 1996, PEPTIDES, V17, P1197, DOI 10.1016/S0196-9781(96)00128-3; TOIDE K, 1993, EUR J PHARMACOL, V233, P21, DOI 10.1016/0014-2999(93)90344-H; Ukai Yojiro, 1996, Folia Pharmacologica Japonica, V107, P273, DOI 10.1254/fpj.107.273; YAMAMOTO M, 1989, EUR J PHARMACOL, V166, P545, DOI 10.1016/0014-2999(89)90373-7; YAMAMURA M, 1991, JPN J PHARMACOL, V55, P69, DOI 10.1254/jjp.55.69	51	88	88	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205			LIFE SCI	Life Sci.	MAR 27	1998	62	17-18					1443	1448		10.1016/S0024-3205(98)00087-3			6	Medicine, Research & Experimental; Pharmacology & Pharmacy	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Pharmacology & Pharmacy	ZE980	WOS:000072850800002	9585116				2022-02-06	
J	Suhr, J; Tranel, D; Wefel, J; Barrash, J				Suhr, J; Tranel, D; Wefel, J; Barrash, J			Memory performance after head injury: Contributions of malingering, litigation status, psychological factors, and medication use	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN INJURY; WAIS-R; DEFICITS; VALIDITY; FAKING; IMPAIRMENT; CONCUSSION; PROSPECTS; SYMPTOMS; TESTS	Impaired memory test performance can reflect a host of factors, such as head injury/postconcussive syndrome, involvement in litigation, malingering behavior, psychological distress, and medication use. Such factors are important in interpreting memory test performances in patients referred in the context of litigation. We examined memory test performance in mild head-injured patients in litigation, mild to moderate head-injured patients not in litigation, severely head-injured patients not in litigation, depressed patients, and patients with somatization disorders. Findings showed that several memory tests were useful in distinguishing probable malingerers from the other groups. There was a complex interaction among malingering status, psychological status, and medication use in the prediction of memory test results. Although nonneurological factors were related to memory impairment, litigation status alone was not predictive of memory performance. The results emphasize the need to consider nonneurological factors in the interpretation of poor memory performance in patients seen for forensic evaluation.	UNIV IOWA,DEPT PSYCHOL,IOWA CITY,IA 52242		Suhr, J (corresponding author), UNIV IOWA,COLL MED,DEPT NEUROL,IOWA CITY,IA 52242, USA.			Barrash, Joseph/0000-0001-9827-0110; Tranel, Daniel/0000-0002-1338-1389	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS19632] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS019632] Funding Source: NIH RePORTER		American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Beck AT, 1987, BECK DEPRESSION INVE; BENTON AL, 1961, ARCH GEN PSYCHIAT, V4, P79; Bernard L C, 1991, Arch Clin Neuropsychol, V6, P81, DOI 10.1016/0887-6177(91)90024-4; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; BERNARD LC, 1993, J CLIN PSYCHOL, V49, P45, DOI 10.1002/1097-4679(199301)49:1<45::AID-JCLP2270490107>3.0.CO;2-7; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BINDER LM, 1993, ARCH CLIN NEUROPSYCH, V8, P137, DOI 10.1016/0887-6177(93)90031-U; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; BOONE KB, 1995, J CLIN PSYCHOL, V51, P457, DOI 10.1002/1097-4679(199505)51:3<457::AID-JCLP2270510322>3.0.CO;2-7; Butcher J.N., 1989, MANUAL RESTANDARDIZE; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Cullum C, 1991, FORENSIC NEUROPSYCHO, P141; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GOEBEL RA, 1983, J CLIN PSYCHOL, V39, P731, DOI 10.1002/1097-4679(198309)39:5<731::AID-JCLP2270390515>3.0.CO;2-T; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GUILMETTE TJ, 1994, PERCEPT MOTOR SKILL, V78, P1179, DOI 10.2466/pms.1994.78.3c.1179; HAYWARD L, 1987, AUST NZ J PSYCHIAT, V21, P87, DOI 10.3109/00048678709160904; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; IVERSON GL, 1996, J CLIN EXPT NEUROPSY, V11, P967; Jones R. D., 1996, P395; KELLY R, 1975, Forensic Science, V6, P17, DOI 10.1016/0300-9432(75)90219-8; Larrabee GJ, 1990, NEUROPSYCHOLOGY, V4, P239, DOI 10.1037/0894-4105.4.4.239; LEESHALEY PR, 1990, PERCEPT MOTOR SKILL, V70, P1379, DOI 10.2466/PMS.70.4.1379-1382; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; Osterrieth P., 1944, ARCH PSYCHOLOGIE, V30, P206; Rawling P, 1990, NEUROPSYCHOLOGY, V4, P223, DOI 10.1037/0894-4105.4.4.223; Rey A., 1941, ARCH PSYCHOL, V37, P126; Rey A., 1964, EXAMEN CLIN PSYCHOL; Rizzo Matthew, 1996, P1; ROGERS R, 1993, CLIN PSYCHOL REV, V13, P255, DOI 10.1016/0272-7358(93)90023-F; RUFF RM, 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199309000-00008; SCHEINBERG P, 1994, ARCH NEUROL-CHICAGO, V51, P650, DOI 10.1001/archneur.1994.00540190024011; Sivan AB., 1992, BENTON VISUAL RETENT; TEASDALE G, 1974, LANCET, V2, P81; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Walsh K. W., 1985, UNDERSTANDING BRAIN; Wechsler, 1997, WECHSLER ADULT INTEL; WIGGINS EC, 1988, LAW HUMAN BEHAV, V12, P57, DOI 10.1007/BF01064274; [No title captured]; [No title captured]	55	88	88	0	10	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	AUG	1997	19	4					500	514		10.1080/01688639708403740			15	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	YA413	WOS:A1997YA41300004	9342686				2022-02-06	
J	Matta, B; Menon, D				Matta, B; Menon, D			Severe head injury in the United Kingdom and Ireland: A survey of practice and implications for management	CRITICAL CARE MEDICINE			English	Article						brain; head injury; traumatic brain injury; head trauma; neurologic emergencies; coma; monitoring, transcranial Doppler ultrasonography; near-infrared spectroscopy; intracranial pressure; hyperventilation; sedation	CEREBRAL BLOOD-FLOW; PROLONGED NEUROMUSCULAR BLOCKADE; INCREASED INTRACRANIAL-PRESSURE; BRAIN INJURY; AGGRESSIVE TREATMENT; CLINICAL-TRIAL; HYPERVENTILATION; HYPERTENSION; ANESTHESIA; SUCCINYLCHOLINE	Objective: To study the current intensive care management of patients with severe head injury (defined as a Glasgow Coma Scale score of less than or equal to 8) in neurosurgical referral centers in the United Kingdom (UK) and Ireland. Data Collection: A questionnaire was sent to the directors of the 44 neurosurgical referral units identified from the UK Medical Directory. After 4 wks, a copy of the questionnaire was sent to all nonresponders, with a cover letter urging them to respond. The aim was to collect data regarding the characteristics of the intensive care units (ICU), sedation, monitoring modalities used, the treatment of intracranial hypertension, and general care of severely head-injured patients. Data Extraction: Forty completed questionnaires were returned. Only 35 (88%) centers provided care for the severely head-injured as defined in the questionnaire. Patients were managed in specialized neurosurgical ICUs in 66% of centers and in general ICUs in the remainder of the centers. The ICUs were coordinated by an anesthesiologist in 66% of instances and by a neurosurgeon in 23%. The mean number of beds per units was 7.9 (range 4 to 16), with 1:1 nurse/bed ratio and 5.5 nurses per bed (total number of nursing staff per bed) (range 2.75 to 8). Annual caseload varied between units with the majority of units (49%) receiving between 25 and 50 patients with severe head injury, 23% receiving between 50 and 100 patients with severe head injury, and 29% receiving >100 patients with severe head injury. There was considerable variability in both the nature of monitoring and therapy between centers. Although blood and central venous pressures were invasively monitored in >50% of the patients in 94% and 77% of the centers, respectively, intracranial pressure was only monitored routinely in 57% of the centers. Jugular venous bulb oximetry, transcranial Doppler ultrasonography, electroencephalography, and near-infrared spectroscopy were rarely used. Nearly all centers used propofol and midazolam for sedation, with morphine, fentanyl, and alfentanil as the main analgesics. Muscle relaxation was commonly used, with 40% of the centers employing it in 100% of their patients. Atracurium and vecuronium were the most commonly used agents. Only 68% of the centers had a protocol for the treatment of intracranial hypertension. Although hyperventilation to a PaCO2 of 26 to 30 torr (3.5 to 4.0 kPa) was the norm in the majority of centers (56%), two centers aimed for PaCO2 values (26 torr ((3.5 kPa). A quarter of the units did not aim for a cerebral perfusion pressure of >60 mm Hg. Mild hypothermia was rarely used and 14% of the centers continued to use corticosteroids for the treatment of intracranial hypertension as a result of head trauma. Conclusion: We conclude that there are wide variations in the management of the severely head injured patient in the UK and Ireland. Some of the therapies employed are not supported by available research findings. Rationalization (using rational management, i.e., based on good evidence) of the intensive care management of severe head injury with the development of widely accepted guidelines may result in an improvement in the quality of care of the head-injured patient.			Matta, B (corresponding author), ADDENBROOKES HOSP, DEPT ANAESTHESIA & NEUROSURG CRIT CARE, CAMBRIDGE, ENGLAND.						ALBANESE J, 1993, ANESTHESIOLOGY, V79, P493, DOI 10.1097/00000542-199309000-00012; ANDREWS PJD, 1995, ACTA ANAESTH SCAND, V39, P112, DOI 10.1111/j.1399-6576.1995.tb04287.x; ARTRU AA, 1992, J NEUROSURG ANESTH, V4, P99, DOI 10.1097/00008506-199204000-00005; BEDFORD RF, 1986, ANESTHESIA, P2253; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BRAAKMAN R, 1983, J NEUROSURG, V58, P326, DOI 10.3171/jns.1983.58.3.0326; Cold G E, 1990, Acta Neurochir Suppl (Wien), V49, P1; COLD GE, 1989, ACTA NEUROCHIR, V96, P100, DOI 10.1007/BF01456166; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; FABIAN TC, 1993, ARCH SURG-CHICAGO, V128, P185; FAHY BG, 1994, J NEUROSURG ANESTH, V6, P136; GEDEIT RG, 1993, CRIT CARE MED, V21, P1850, DOI 10.1097/00003246-199312000-00011; GHAR J, 1995, CRIT CARE MED, V23, P560; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; GRIFFIN D, 1992, CHEST, V102, P510, DOI 10.1378/chest.102.2.510; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; LANIER WL, 1986, ANESTHESIOLOGY, V64, P551, DOI 10.1097/00000542-198605000-00003; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; Marx W, 1989, J Neurosurg Anesthesiol, V1, P3, DOI 10.1097/00008506-198903000-00002; MATTA BF, 1995, BRIT J ANAESTH, V74, P159, DOI 10.1093/bja/74.2.159; MATTA BF, 1994, ANESTH ANALG, V79, P745; MATTA BF, IN PRESS ANAESTHESIA; MAYBERG TS, 1993, ANESTHESIOLOGY, V78, P288, DOI 10.1097/00000542-199302000-00012; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; MINTON MD, 1986, ANESTHESIOLOGY, V65, P165, DOI 10.1097/00000542-198608000-00006; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; OSULLIVAN MG, 1994, J NEUROSURG, V80, P46, DOI 10.3171/jns.1994.80.1.0046; PARTRIDGE BL, 1990, CRIT CARE MED, V18, P1177, DOI 10.1097/00003246-199010000-00025; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SHAPIRA Y, 1992, ANESTH ANALG, V74, pS282; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SPERRY RJ, 1992, ANESTHESIOLOGY, V77, P416, DOI 10.1097/00000542-199209000-00002; SPETZLER R F, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P212; STREBEL S, 1994, ANESTH ANALG, V78, P884; SUTTON LN, 1990, J NEUROSURG, V73, P927, DOI 10.3171/jns.1990.73.6.0927; TODD MM, 1993, ANESTHESIOLOGY, V79, P139, DOI 10.1097/00000542-199307000-00020; TRINDLE MR, 1993, ANESTHESIOLOGY, V78, P454, DOI 10.1097/00000542-199303000-00008; WILSON JA, 1994, J NEUROSURG ANESTH, V6, P139; XUE D, 1992, BRAIN RES, V587, P66, DOI 10.1016/0006-8993(92)91428-H	45	88	92	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	OCT	1996	24	10					1743	1748		10.1097/00003246-199610000-00023			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM725	WOS:A1996VM72500024	8874315				2022-02-06	
J	LEWEN, A; LI, GL; NILSSON, P; OLSSON, Y; HILLERED, L				LEWEN, A; LI, GL; NILSSON, P; OLSSON, Y; HILLERED, L			TRAUMATIC BRAIN INJURY IN RAT PRODUCES CHANGES OF BETA-AMYLOID PRECURSOR PROTEIN IMMUNOREACTIVITY	NEUROREPORT			English	Article						APP; BETA-AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN INJURY; AXONAL DAMAGE; GLUTAMATE; RAT	AMINO-ACIDS; HEAD-INJURY; DEPOSITION; DISEASE	beta-AMYLOID precursor protein immunoreactivity (APP) was studied after a mild compression contusion trauma to rat parietal cortex. Neurones in the periphery of the cortical lesion, i.e. tissue subjected to shear stress, showed markedly reduced immunoreactivity 1 and 3 days after injury. Numerous axons in the ipsilateral subcortical white matter and thalamus became immunoreactive. At 21 days, small rounded profiles appeared in the neuropil of the damaged cortex and in the thalamus. Thus, traumatic brain injury appears to induce several types of APP changes. The accumulation in neuronal processes is probably caused by disturbed axonal transport induced by trauma. Since APP is assumed to be excitoprotective, modulating intracellular Ca2+ responses, the decreased immunoreactivity noticed in the periphery of the lesion may render the neurones in this region more vulnerable to secondary injury mechanisms.	UNIV UPPSALA HOSP,DEPT CLIN CHEM,S-75185 UPPSALA,SWEDEN; UNIV UPPSALA HOSP,DEPT NEUROPATHOL,S-75185 UPPSALA,SWEDEN		LEWEN, A (corresponding author), UNIV UPPSALA HOSP,DEPT NEUROSURG,S-75185 UPPSALA,SWEDEN.		Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348			ABE K, 1991, NEUROSCI LETT, V125, P172, DOI 10.1016/0304-3940(91)90020-T; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAULL RLM, 1985, RAT NERVOUS SYSTEM, P144; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1993, PROGR BRAIN RES, P237; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; ITOH K, 1979, BRAIN RES, V175, P341, DOI 10.1016/0006-8993(79)91013-8; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; NAKAMURA Y, 1992, NEUROSCI LETT, V136, P95, DOI 10.1016/0304-3940(92)90656-R; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; REGAN RF, 1994, NEUROBIOLOGY CENTRAL, P173; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SMITH C, 1994, NEUROPATH APPL NEURO, V20, P322, DOI 10.1111/j.1365-2990.1994.tb00977.x	25	88	88	0	2	RAPID SCIENCE PUBLISHERS	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH	0959-4965			NEUROREPORT	Neuroreport	JAN 26	1995	6	2					357	360		10.1097/00001756-199501000-00032			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QG375	WOS:A1995QG37500033	7756628				2022-02-06	
J	CHERIAN, L; ROBERTSON, CS; CONTANT, CF; BRYAN, RM				CHERIAN, L; ROBERTSON, CS; CONTANT, CF; BRYAN, RM			LATERAL CORTICAL IMPACT INJURY IN RATS - CEREBROVASCULAR EFFECTS OF VARYING DEPTH OF CORTICAL DEFORMATION AND IMPACT VELOCITY	JOURNAL OF NEUROTRAUMA			English	Article							TRAUMATIC BRAIN INJURY; FLUID-PERCUSSION MODEL; CEREBRAL BLOOD-FLOW; HEAD-INJURY; ISOFLURANE; RESPONSES	Intracranial pressure (ICP), blood pressure (BP), cerebral perfusion pressure (CPP), and cortical perfusion (LDF) of the contralateral parietal cortex were measured after cortical impact injury in 36 rats. Changes in these physiologic parameters were compared using analysis of variance to a group of 11 rats who received a sham impact. In one series of experiments, the velocity and duration of the impact injury were kept constant, and the severity of the injury was determined by varying the depth of cortical deformation from 2 to 3 mm. The peak pressure inside the skull was directly related to the depth of cortical deformation, and was 93 +/- 16, 182 +/- 18, and 268 +/- 57 mm Hg with the 2, 2.5, and 3 mm deformation, respectively, when the impact velocity was 5 m/sec. With the 2 mm depth injury, there was a transient decrease in BP (p < 0.05) and a 12% decrease in LDF after the impact. With the 2.5 mm depth injury, a small transient increase in ICP and decrease in BP and a 30% decrease in LDF occurred (p < 0.05). ICP then gradually increased throughout the 8 h experiment, becoming significantly greater than the sham-injured animals by 5 h after the impact. LDF gradually returned toward normal throughout the experiment. With the 3 mm depth injury, a marked transient increase in ICP (p < 0.05) and BP (p < 0.05) occurred immediately after the impact. The increase in BP lasted <5 min, and subsequently the BP decreased to approximately 50 mm Hg for the rest of the experiment. The initial marked increase in ICP lasted 15 min and then remained 5-10 mm Hg higher (p < 0.05) than in the sham-injured animals for the rest of the experiment. LDF decreased by an average of 50% (p < 0.05) immediately after the impact and remained lower than that of the sham-injured animals for the rest of the experiment. In another series of experiments, the depth of cortical deformation was kept constant at 2.5 mm, and the severity of the injury was determined by varying the velocity from 1 to 5 m/sec. The peak ICP was significantly related to the impact velocity, averaging 45 +/- 12, 66 +/- 9, and 182 +/- 18 mm Hg with the 1, 3, and 5 m/sec impact injuries, respectively. The 1 m/sec impact had no effect on ICP and only a transient decrease in BP. LDF was initially slightly decreased but, beginning at 4 h after the impact, increased to levels greater than for the sham-injured animals (p < 0.05). The 3 m/sec impact had no effect on ICP. BP and CPP were 10-15 mm Hg less than in the sham-injured animals throughout the experiment (p < 0.05). With the 5 m/sec impact, ICP was transiently increased for <15 min immediately after the impact. The ICP returned to preinjury levels by 30 min after the impact but then gradually increased throughout the rest of the experiment, becoming significantly greater than in the sham-injured animals by 5.5 h. BP and CPP were 10-15 mm Hg less than in the sham-injured animals throughout the experiment (p < 0.05). LDF immediately decreased by 30% (p < 0.05) and then gradually increased toward control values throughout the 8 h experiment. The cortical impact model of TBI reproduces many of the hemodynamic features of human head injury. Distinct cerebral hemodynamic patterns are related to both the depth of deformation and the velocity of the impact. This model may be useful for studying these manifestations of TBI.	BAYLOR COLL MED,DEPT ANESTHESIOL,HOUSTON,TX 77030		CHERIAN, L (corresponding author), BAYLOR COLL MED,DEPT NEUROSURG,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL041960] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01-HLB41960] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline		BRYAN RM, 1993, 1993 NEUR SOC M; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1992, J NEUROTRAUM, V9, P383; CUCCHIARA RF, 1974, ANESTHESIOLOGY, V40, P571, DOI 10.1097/00000542-197406000-00011; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; GELSEMA AJ, 1989, BRAIN RES, V482, P67, DOI 10.1016/0006-8993(89)90543-X; GOLDMAN H, 1991, J NEUROTRAUM, V8, P128; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; KOHI YM, 1984, INJURY, V16, P25, DOI 10.1016/0020-1383(84)90110-4; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Marmarou A, 1990, Adv Neurol, V52, P233; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; SCHELLER MS, 1987, ANESTHESIOLOGY, V67, P507, DOI 10.1097/00000542-198710000-00011; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YUAN X-Q, 1990, Journal of Neurotrauma, V7, P141, DOI 10.1089/neu.1990.7.141; Yuan XQ, 1991, J NEUROTRAUM, V8, P219, DOI 10.1089/neu.1991.8.219; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	24	88	89	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1994	11	5					573	585		10.1089/neu.1994.11.573			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	PR237	WOS:A1994PR23700010	7861449				2022-02-06	
J	GRATTAN, LM; BLOOMER, RH; ARCHAMBAULT, FX; ESLINGER, PJ				GRATTAN, LM; BLOOMER, RH; ARCHAMBAULT, FX; ESLINGER, PJ			COGNITIVE FLEXIBILITY AND EMPATHY AFTER FRONTAL-LOBE LESION	NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY			English	Article						COGNITIVE FLEXIBILITY; EMPATHY; NEUROANATOMICAL VARIABLES	CLOSED-HEAD-INJURY; CARD SORTING TEST; DAMAGE; CONSEQUENCES; CHILDREN; BEHAVIOR	Although impairments in interpersonal behavior and cognitive flexibility are frequently associated with frontal lobe injury, the relationship between these deficits remains unknown. Social theories have emphasized the importance of flexible thinking for high-level social functioning, including perspective-taking capacities and empathy. We hypothesized that a positive correlation between measures of cognitive flexibility and empathy would be apparent after frontal lobe lesions in the dorsolateral, mesial or orbital sectors and possibly in a diverse group with frontal lobe damage. To test this hypothesis, 40 subjects with frontal or nonfrontal lobe lesions were compared on standardized measures of cognitive flexibility and empathy. Both groups showed similar quantitative alterations on the empathy measure, but responses of the frontal lesion group related these to greater discomfort in changing, novel, or ambiguous situations, while responses of the nonfrontal lesion group indicated reduced social self-confidence. Cognitive flexibility and empathy levels showed a similar pattern of variation in the nonfrontal lesion group, but not in the frontal lesion group because of marked differences among frontal lesion subgroups. Left and right dorsolateral lesions affected both cognitive flexibility and empathy (with a positive correlation after left dorsolateral lesions), while orbital lesions profoundly affected empathy only, and mesial lesions affected cognitive flexibility only. The findings support a model of functional-anatomic distinctions within the frontal lobe that encompasses cognitive and noncognitive mechanisms within a network of cerebral structures subserving complex social processes.	UNIV CONNECTICUT,DEPT EDUC PSYCHOL,STORRS,CT 06268; PENN STATE UNIV,COLL MED,DEPT MED,DIV NEUROL,UNIVERSITY PK,PA 16802; PENN STATE UNIV,COLL MED,DEPT BEHAV SCI,UNIVERSITY PK,PA 16802; PENN STATE UNIV,MILTON S HERSHEY MED CTR,HERSHEY,PA 17033		GRATTAN, LM (corresponding author), UNIV MARYLAND,MED CTR,SCH MED,DEPT NEUROL,NEUROBEHAV DIAGNOST & RES LAB,22 S GREENE ST,BALTIMORE,MD 21201, USA.						ACKERLY SS, 1974, RES PUB ASS RES NERV, V27, P479; ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P926; [Anonymous], 1954, PSYCHOMETRIKA; Benson D.F., 1986, FRONTAL LOBES; BENTON A, 1991, DEV NEUROPSYCHOL, V7, P275, DOI 10.1080/87565649109540495; BRICKNER RM, 1952, AMA ARCH NEUROL PSY, V68, P293, DOI 10.1001/archneurpsyc.1952.02320210003001; BROTHERS L, 1989, AM J PSYCHIAT, V146, P10; CHLOPAN BE, 1985, J PERS SOC PSYCHOL, V48, P635, DOI 10.1037/0022-3514.48.3.635; Cummings J, 1985, CLIN NEUROPSYCHIATRY; DAMASIO A, 1989, LESION ANAL NEUROPSY; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; DREWE E A, 1974, Cortex, V10, P159; Dymond R., 1950, J CONSULT PSYCHOL, V14, P43; EGAN G, 1976, INTERPERSONAL LIVING; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; ESLINGER PJ, 1993, NEUROPSYCHOLOGIA, V31, P17, DOI 10.1016/0028-3932(93)90077-D; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; ESLINGER PJ, 1985, NEUROLOGY, V25, P1731; Fidell L.S., 1983, USING MULTIVARIATE S; GRAFMAN J, 1990, PERCEPT MOTOR SKILL, V71, P1120, DOI 10.2466/PMS.71.7.1120-1122; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; GRATTAN LM, 1991, DEV NEUROPSYCHOL, V7, P283, DOI 10.1080/87565649109540496; GRATTAN LM, 1989, AM J PSYCHIAT, V146, P1521; GRATTAN LM, 1992, BRAIN COGNITION, V20, P185, DOI 10.1016/0278-2626(92)90068-W; GRATTAN LM, 1994, NEUROLOGY, V44, pA292; Grattan LM, 1989, NEUROPSYCHOLOGY, V3, P175, DOI 10.1037//0894-4105.3.3.175; GREENSON RR, 1960, INT J PSYCHOANAL, V41, P418; GRIEF EB, 1973, J COUNS PSYCHOL, V20, P280; Guilford J. P., 1978, ALTERNATE USES MANUA; Hamsher K., 1989, MULTILINGUAL APHASIA; Harlow J.M., 1993, PUBLICATIONS MASSACH, V4, P274, DOI [DOI 10.1177/0957154X9300401407, https://doi.org/10.1177/0957154X9300401407]; Heaton R.K., 1981, WISCONSIN CARD SORTI; Hebb DO, 1940, ARCH NEURO PSYCHIATR, V44, P421, DOI 10.1001/archneurpsyc.1940.02280080181011; HERTEL PT, 1980, J EDUC PSYCHOL, V72, P133, DOI 10.1037/0022-0663.72.2.133; HOGAN R, 1969, J CONSULT CLIN PSYCH, V33, P307, DOI 10.1037/h0027580; JOHNSON JA, 1983, J PERS SOC PSYCHOL, V45, P1299, DOI 10.1037/0022-3514.45.6.1299; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; LEZAK MD, 1987, J HEAD TRAUMA REHABI, V29, P57; Mead GeorgeHerbert., 1934, MIND SELF SOC; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; Milner B., 1964, FRONTAL GRANULAR COR; Mitchell J. V., 1985, 9 MENTAL MEASUREMENT, V1, P73; ODDY M, 1985, J NEUROL NEUROSUR PS, V133, P507; Pandya DN, 1987, FRONTAL LOBES REVISI, P41; Piaget J., 1959, JUDGMENT REASONING C; PIERCE RM, 1972, J CLIN PSYCHOL, V28, P230, DOI 10.1002/1097-4679(197204)28:2<230::AID-JCLP2270280234>3.0.CO;2-9; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; WINNE JF, 1961, J CLIN PSYCHOL MON S, P38; WVIDLAR DC, 1975, J PSYCHOL, V90, P237; [No title captured]; [No title captured]	53	88	89	0	17	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0894-878X			NEUROPSY NEUROPSY BE	Neuropsychiatr. Neuropsychol. Behav. Neurol.	OCT	1994	7	4					251	259					9	Clinical Neurology; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	PY002	WOS:A1994PY00200002					2022-02-06	
J	WILLER, BS; ALLEN, KM; LISS, M; ZICHT, MS				WILLER, BS; ALLEN, KM; LISS, M; ZICHT, MS			PROBLEMS AND COPING STRATEGIES OF INDIVIDUALS WITH TRAUMATIC BRAIN INJURY AND THEIR SPOUSES	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						FAMILY; HEAD INJURIES; MARRIAGE	SEVERE HEAD-INJURY; RECOVERY	A pilot investigation is reported on the problems and coping strategies of 20 married men and 11 married women with traumatic brain injury (TBI) and their able-bodied spouses. All injured subjects experienced severe head injury at least one and a half years earlier. A structured, small-group discussion process was used to elicit a prioritized list of problems and a similar list of coping strategies. Individuals with TBI and their spouses identified problems in living as most important; loss of employment and restrictions on autonomy were reported as the most problematic. Men with TBI placed priority on controlling their anger, whereas, women with TBI were concerned with their mood disorders, particularly depression. Women with TBI and able-bodied wives of men with TBI placed high priority on the use of support groups as a coping strategy. Men placed higher priority on individualistic approaches to adjustment, such as suppression of feelings. A number of testable hypotheses resulted from the pilot study.			WILLER, BS (corresponding author), SUNY BUFFALO,RES & TRAINING CTR TBI,197 FARBER HALL,3435 MAIN ST,BUFFALO,NY 14214, USA.						[Anonymous], 1980, INT CLASSIFICATION I; BENYISHAY Y, 1981, INT J REHABIL RES, V4, P208, DOI 10.1097/00004356-198106000-00012; BOND MR, 1980, J NEUROL NEUROSUR PS, V43, P798; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CRIPE LI, 1989, REHABIL PSYCHOL, V34, P93; DEJONG G, 1982, ARCH PHYS MED REHAB, V63, P68; Delbecq A.L., 1975, GROUP TECHNIQUES PRO; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Thomsen I V, 1989, Brain Inj, V3, P157, DOI 10.3109/02699058909004547; Wood R. L., 1987, BRAIN INJURY REHABIL; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583	14	88	88	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1991	72	7					460	464					5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	FP702	WOS:A1991FP70200003	2059116				2022-02-06	
J	KLONOFF, PS; SNOW, WG; COSTA, LD				KLONOFF, PS; SNOW, WG; COSTA, LD			QUALITY-OF-LIFE IN PATIENTS 2 TO 4 YEARS AFTER CLOSED HEAD-INJURY	NEUROSURGERY			English	Article									ST JOSEPHS HOSP & MED CTR, BARROW NEUROL INST, NEUROPSYCHOL SECT, PHOENIX, AZ 85013 USA; SUNNYBROOK MED CTR, DEPT PSYCHOL, TORONTO M4N 3M5, ONTARIO, CANADA; UNIV VICTORIA, DEPT PSYCHOL, VICTORIA V8W 2Y2, BC, CANADA								BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BERGNER M, 1980, RELEVANCE SOCIAL SCI, P135; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; DENNYBROWN D, 1945, ASS NERV MENT DIS, V24, P467; FLANAGAN JC, 1982, ARCH PHYS MED REHAB, V63, P56; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GRONWALL D, 1974, LANCET, V2, P605; HERTZOG AR, 1981, J GERONTOL, V36, P472; HOGARTY GE, 1971, ARCH GEN PSYCHIAT, V25, P470; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; JENNETT B, 1979, NURS MIRROR, V1, P30; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KESHAVAN MS, 1981, BRIT J PSYCHIAT, V138, P157, DOI 10.1192/bjp.138.2.157; KOTTKE FJ, 1982, ARCH PHYS MED REHAB, V63, P60; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1982, BEHAVIORAL SEQUELAE; LEZAK MD, 1980, FEB M INT NEUR SOC S; LISHMAN WA, ORGANIC PSYCHIATRY P; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; MCSWEENY AJ, 1982, ARCH INTERN MED, V142, P473, DOI 10.1001/archinte.142.3.473; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; NAJENSON T, 1975, SCAND J REHABIL MED, V7, P101; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Rimel R W, 1981, J Neurosurg Nurs, V13, P132; Roueche JR, 1983, COGNITIVE REHABILITA, V1, P4; SISLER GC, 1978, PSYCHIATR CLIN N AM, V1, P137; SPITZER WO, 1981, J CHRON DIS, V34, P585, DOI 10.1016/0021-9681(81)90058-8; THOMSEN I V, 1981, Journal of Clinical Neuropsychology, V3, P43, DOI 10.1080/01688638108403112; TIMMING R, 1982, ARCH PHYS MED REHAB, V63, P154; Van Zomeren A. H., 1981, REACTION TIME ATTENT	34	88	89	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	NOV	1986	19	5					735	743		10.1227/00006123-198611000-00004			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	E7475	WOS:A1986E747500004	3785620				2022-02-06	
J	Coughlin, JM; Wang, YH; Minn, I; Bienko, N; Ambinder, EB; Xu, X; Peters, ME; Dougherty, JW; Vranesic, M; Koo, SM; Ahn, HH; Lee, M; Cottrell, C; Sair, HI; Sawa, A; Munro, CA; Nowinski, CJ; Dannals, RF; Lyketsos, CG; Kassiou, M; Smith, G; Caffo, B; Mori, S; Guilarte, TR; Pomper, MG				Coughlin, Jennifer M.; Wang, Yuchuan; Minn, Il; Bienko, Nicholas; Ambinder, Emily B.; Xu, Xin; Peters, Matthew E.; Dougherty, John W.; Vranesic, Melin; Koo, Soo Min; Ahn, Hye-Hyun; Lee, Merton; Cottrell, Chris; Sair, Haris I.; Sawa, Akira; Munro, Cynthia A.; Nowinski, Christopher J.; Dannals, Robert F.; Lyketsos, Constantine G.; Kassiou, Michael; Smith, Gwenn; Caffo, Brian; Mori, Susumu; Guilarte, Tomas R.; Pomper, Martin G.			Imaging of Glial Cell Activation and White Matter Integrity in Brains of Active and Recently Retired National Football League Players	JAMA NEUROLOGY			English	Article							18 KDA TSPO; CHRONIC TRAUMATIC ENCEPHALOPATHY; SPORTS-RELATED CONCUSSION; TRANSLOCATOR PROTEIN; MICROGLIAL ACTIVATION; MICROGLIA/MACROPHAGE POLARIZATION; THERAPEUTIC TARGET; INJURY; DISEASE; BINDING	IMPORTANCE Microglia, the resident immune cells of the central nervous system, play an important role in the brain's response to injury and neurodegenerative processes. It has been proposed that prolonged microglial activation occurs after single and repeated traumatic brain injury, possibly through sports-related concussive and subconcussive injuries. Limited in vivo brain imaging studies months to years after individuals experience a single moderate to severe traumatic brain injury suggest widespread persistent microglial activation, but there has been little study of persistent glial cell activity in brains of athletes with sports-related traumatic brain injury. OBJECTIVE To measure translocator protein 18 kDa (TSPO), a marker of activated glial cell response, in a cohort of National Football League (NFL) players and control participants, and to report measures of white matter integrity. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional, case-control study included young active (n = 4) or former (n = 10) NFL players recruited from across the United States, and 16 age-, sex-, highest educational level-, and body mass index-matched control participants. This study was conducted at an academic research institution in Baltimore, Maryland, from January 29, 2015, to February 18, 2016. MAIN OUTCOMES AND MEASURES Positron emission tomography-based regional measures of TSPO using [C-11] DPA-713, diffusion tensor imaging measures of regional white matter integrity, regional volumes on structural magnetic resonance imaging, and neuropsychological performance. RESULTS The mean (SD) ages of the 14 NFL participants and 16 control participants were 31.3 (6.1) years and 27.6 (4.9) years, respectively. Players reported a mean (SD) of 7.0 (6.4) years (range, 1-21 years) since the last self-reported concussion. Using [11C] DPA-713 positron emission tomographic data from 12 active or former NFL players and 11 matched control participants, the NFL players showed higher total distribution volume in 8 of the 12 brain regions examined (P < .004). We also observed limited change in white matter fractional anisotropy and mean diffusivity in 13 players compared with 15 control participants. In contrast, these young players did not differ from control participants in regional brain volumes or in neuropsychological performance. CONCLUSIONS AND RELEVANCE The results suggest that localized brain injury and repair, indicated by higher TSPO signal and white matter changes, may be associated with NFL play. Further study is needed to confirm these findings and to determine whether TSPO signal and white matter changes in young NFL athletes are related to later onset of neuropsychiatric symptoms.	[Coughlin, Jennifer M.; Bienko, Nicholas; Peters, Matthew E.; Dougherty, John W.; Cottrell, Chris; Sawa, Akira; Munro, Cynthia A.; Lyketsos, Constantine G.; Smith, Gwenn; Pomper, Martin G.] Johns Hopkins Med Inst, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; [Coughlin, Jennifer M.; Wang, Yuchuan; Minn, Il; Ambinder, Emily B.; Xu, Xin; Vranesic, Melin; Koo, Soo Min; Ahn, Hye-Hyun; Lee, Merton; Sair, Haris I.; Dannals, Robert F.; Mori, Susumu; Pomper, Martin G.] Johns Hopkins Med Inst, Russell H Morgan Dept Radiol & Radiol Sci, 600 N Wolfe St, Baltimore, MD 21205 USA; [Munro, Cynthia A.] Johns Hopkins Med Inst, Dept Neurol, Baltimore, MD 21205 USA; [Nowinski, Christopher J.] Concuss Legacy Fdn, Waltham, MA USA; [Nowinski, Christopher J.] Boston Univ, Sch Med, Alzheimers Dis & CTE Ctr, Boston, MA 02118 USA; [Kassiou, Michael] Univ Sydney, Sch Chem, Sydney, NSW 2006, Australia; [Kassiou, Michael] Univ Sydney, Discipline Med Radiat Sci, Sydney, NSW, Australia; [Caffo, Brian] Johns Hopkins Med Inst, Dept Biostat, Baltimore, MD 21205 USA; [Guilarte, Tomas R.] Florida Int Univ, Dept Environm & Occupat Hlth, Miami, FL 33199 USA; [Guilarte, Tomas R.] Florida Int Univ, Program Cognit Neurosci & Imaging, Miami, FL 33199 USA		Pomper, MG (corresponding author), Johns Hopkins Med Inst, Dept Radiol & Radiol Sci, 1550 Orleans St,CRB 2,Room 492, Baltimore, MD 21231 USA.	mpomper@jhmi.edu	MINN, IL/L-1812-2018; Coughlin, Jennifer M/O-8179-2018	MINN, IL/0000-0002-7822-662X; Coughlin, Jennifer M/0000-0002-2514-9640; Kassiou, Michael/0000-0002-6655-0529	National Association for Research on Schizophrenia and Depression; Alexander Wilson Schweizer Fellowship; NIEHS from the National Institute of Environmental Health Sciences [ES007062]; GE/NFL Head Health Challenge I; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES007062, T32ES007062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG027668, P50AG005146] Funding Source: NIH RePORTER	This study was supported by the National Association for Research on Schizophrenia and Depression (Dr Coughlin), the Alexander Wilson Schweizer Fellowship (Dr Coughlin), grant NIEHS ES007062 from the National Institute of Environmental Health Sciences (Dr Guilarte), and GE/NFL Head Health Challenge I.	Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901; Andersson JLR, 2002, NEUROIMAGE, V16, P177, DOI 10.1006/nimg.2001.1039; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bird JLE, 2010, ATHEROSCLEROSIS, V210, P388, DOI 10.1016/j.atherosclerosis.2009.11.047; Chang LC, 2005, MAGN RESON MED, V53, P1088, DOI 10.1002/mrm.20426; Chauveau F, 2008, EUR J NUCL MED MOL I, V35, P2304, DOI 10.1007/s00259-008-0908-9; Chen MK, 2008, PHARMACOL THERAPEUT, V118, P1, DOI 10.1016/j.pharmthera.2007.12.004; Ching ASC, 2012, INSIGHTS IMAGING, V3, P111, DOI 10.1007/s13244-011-0128-x; Coughlin JM, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.40; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Coughlin JM, 2014, J NEUROVIROL, V20, P219, DOI 10.1007/s13365-014-0239-5; Faria AV, 2010, NEUROIMAGE, V52, P415, DOI 10.1016/j.neuroimage.2010.04.238; Folkersma H, 2011, J NUCL MED, V52, P1235, DOI 10.2967/jnumed.110.084061; Gajawelli N, 2013, WORLD NEUROSURG, V80, P824, DOI 10.1016/j.wneu.2013.10.020; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Green P, 1995, MANUAL ORAL WORD MEM; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Innis RB, 2007, J CEREBR BLOOD F MET, V27, P1533, DOI 10.1038/sj.jcbfm.9600493; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Kettenmann H, 2013, NEURON, V77, P10, DOI 10.1016/j.neuron.2012.12.023; LAMPERT PW, 1984, JAMA-J AM MED ASSOC, V251, P2676, DOI 10.1001/jama.251.20.2676; LOGAN J, 1990, J CEREBR BLOOD F MET, V10, P740, DOI 10.1038/jcbfm.1990.127; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Muccigrosso MM, 2016, BRAIN BEHAV IMMUN, V54, P95, DOI 10.1016/j.bbi.2016.01.009; Oishi K, 2009, NEUROIMAGE, V46, P486, DOI 10.1016/j.neuroimage.2009.01.002; Olmos-Alonso A, 2016, BRAIN, V139, P891, DOI 10.1093/brain/awv379; Owen DR, 2012, J CEREBR BLOOD F MET, V32, P1, DOI 10.1038/jcbfm.2011.147; Owen DRJ, 2011, INT REV NEUROBIOL, V101, P19, DOI 10.1016/B978-0-12-387718-5.00002-X; Papadopoulos V, 2009, EXP NEUROL, V219, P53, DOI 10.1016/j.expneurol.2009.04.016; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295; Salter MW, 2014, CELL, V158, P15, DOI 10.1016/j.cell.2014.06.008; Scarf AM, 2011, J NUCL MED, V52, P667, DOI 10.2967/jnumed.110.086629; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Subcommittee QS, 1997, NEUROLOGY, V48, P581; Tai YF, 2007, BRAIN, V130, P1759, DOI 10.1093/brain/awm044; Team RDC, 2014, R LANG ENV STAT COMP; Venneti S, 2013, GLIA, V61, P10, DOI 10.1002/glia.22357; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wright AD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150215; Zhang YJ, 2010, NEUROIMAGE, V52, P1289, DOI 10.1016/j.neuroimage.2010.05.049; Ziebell JM, 2017, BRAIN BEHAV IMMUN, V59, P1, DOI 10.1016/j.bbi.2016.03.008	48	87	88	0	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	JAN 1	2017	74	1					67	74		10.1001/jamaneurol.2016.3764			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EK1IK	WOS:000393678800014	27893897	Bronze, Green Accepted, Green Submitted			2022-02-06	
J	Henninger, N; Bouley, J; Sikoglu, EM; An, JY; Moore, CM; King, JA; Bowser, R; Freeman, MR; Brown, RH				Henninger, Nils; Bouley, James; Sikoglu, Elif M.; An, Jiyan; Moore, Constance M.; King, Jean A.; Bowser, Robert; Freeman, Marc R.; Brown, Robert H., Jr.			Attenuated traumatic axonal injury and improved functional outcome after traumatic brain injury in mice lacking Sarm1	BRAIN			English	Article						axon; knockout; traumatic axonal injury; traumatic brain injury; Wallerian degeneration	WALLERIAN DEGENERATION; CEREBROVASCULAR PATHOPHYSIOLOGY; NEUROCHEMICAL PROFILE; SECONDARY AXOTOMY; ACTIVATION; MECHANISMS; MODEL; SPECTROSCOPY; REGENERATION; CYTOSKELETON	Axon degeneration is seen consistently after traumatic brain injury (TBI). Henninger et al. show that mice lacking the kinase scaffold Sarm1, a mediator of Wallerian degeneration, display substantially attenuated axon degeneration and reduced functional deficits in a closed-head TBI model. Anti-Sarm1 therapeutics may preserve neurological function after TBI.Axon degeneration is seen consistently after traumatic brain injury (TBI). Henninger et al. show that mice lacking the kinase scaffold Sarm1, a mediator of Wallerian degeneration, display substantially attenuated axon degeneration and reduced functional deficits in a closed-head TBI model. Anti-Sarm1 therapeutics may preserve neurological function after TBI.Axonal degeneration is a critical, early event in many acute and chronic neurological disorders. It has been consistently observed after traumatic brain injury, but whether axon degeneration is a driver of traumatic brain injury remains unclear. Molecular pathways underlying the pathology of traumatic brain injury have not been defined, and there is no efficacious treatment for traumatic brain injury. Here we show that mice lacking the mouse Toll receptor adaptor Sarm1 (sterile alpha/Armadillo/Toll-Interleukin receptor homology domain protein) gene, a key mediator of Wallerian degeneration, demonstrate multiple improved traumatic brain injury-associated phenotypes after injury in a closed-head mild traumatic brain injury model. Sarm1(-/-) mice developed fewer beta-amyloid precursor protein aggregates in axons of the corpus callosum after traumatic brain injury as compared to Sarm1(+/+) mice. Furthermore, mice lacking Sarm1 had reduced plasma concentrations of the phophorylated axonal neurofilament subunit H, indicating that axonal integrity is maintained after traumatic brain injury. Strikingly, whereas wild-type mice exibited a number of behavioural deficits after traumatic brain injury, we observed a strong, early preservation of neurological function in Sarm1(-/-) animals. Finally, using in vivo proton magnetic resonance spectroscopy we found tissue signatures consistent with substantially preserved neuronal energy metabolism in Sarm1(-/-) mice compared to controls immediately following traumatic brain injury. Our results indicate that the SARM1-mediated prodegenerative pathway promotes pathogenesis in traumatic brain injury and suggest that anti-SARM1 therapeutics are a viable approach for preserving neurological function after traumatic brain injury.	[Henninger, Nils; Bouley, James; King, Jean A.; Brown, Robert H., Jr.] Univ Massachusetts, Sch Med, Dept Neurol, 55 Lake Ave North, Worcester, MA 01655 USA; [Henninger, Nils; Sikoglu, Elif M.; Moore, Constance M.; King, Jean A.] Univ Massachusetts, Sch Med, Dept Psychiat, 55 Lake Ave North, Worcester, MA 01655 USA; [An, Jiyan; Bowser, Robert] Barrow Neurol Inst, Div Neurol, Phoenix, AZ 85013 USA; [An, Jiyan; Bowser, Robert] Barrow Neurol Inst, Div Neurobiol, Phoenix, AZ 85013 USA; [Moore, Constance M.; King, Jean A.] Univ Massachusetts, Sch Med, Dept Radiol, Worcester, MA 01655 USA; [Freeman, Marc R.] Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA 01655 USA		Henninger, N (corresponding author), Univ Massachusetts, Sch Med, Dept Neurol, 55 Lake Ave North, Worcester, MA 01655 USA.; Henninger, N (corresponding author), Univ Massachusetts, Sch Med, Dept Psychiat, 55 Lake Ave North, Worcester, MA 01655 USA.	nils.henninger@umassmed.edu		Freeman, Marc/0000-0003-3481-3715; Henninger, Nils/0000-0002-3883-5623	Center for Comparative NeuroImaging at the University of Massachusetts Medical School; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MH073998, OD018132-01, AG046266, DA025690-05, DA026502-04, MH098003-02, AT006963-01A1, NS068179, NS055591, NS088689-02, NS079836-04, FD004127-02, HD060848-08]; ALS Therapy Alliance; Angel Fund; ALS Association; ALSFindingaCure; Cellucci Fund for ALS Research; Project ALS; Pierre deBourghknect ALS Fund; FOOD AND DRUG ADMINISTRATIONUnited States Department of Health & Human Services [R01FD004127] Funding Source: NIH RePORTER; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R34AT006963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH073998, R01MH098003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS055591, RC1NS068179, R01NS088689, R01NS079836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG046266] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [K01DA026502, R01DA025690] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10OD018132] Funding Source: NIH RePORTER	The Magnetic Resonance Spectrocopy examinations were supported by the Center for Comparative NeuroImaging at the University of Massachusetts Medical School. This study was supported by institutional grants, National Institutes of Health grant MH073998 to C.M.M., OD018132-01, AG046266, DA025690-05, DA026502-04, MH098003-02, AT006963-01A1 to J.A.K., NS068179 to R.B., NS055591 to M.R.F., and NS088689-02, NS079836-04, FD004127-02, HD060848-08 to R.H.B. R.B. is the founder of Iron Horse Diagnostics, Inc., a company focused on developing diagnostic and prognostic tests for neurologic disease and brain injury. M.R.F. received support from the ALS Therapy Alliance, and is an Investigator of the Howard Hughes Medical Institute and has been named as an inventor on patents on the Therapeutic applications targeting Sarm1 (#20140079712 and #20120328629). R.H.B. also receives support from the Angel Fund, the ALS Association, ALSFindingaCure, the Cellucci Fund for ALS Research, Project ALS and the Pierre deBourghknect ALS Fund. R.H.B. is a co-founder of AviTx.	Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; BROWN MC, 1994, EUR J NEUROSCI, V6, P420, DOI 10.1111/j.1460-9568.1994.tb00285.x; Chuang CF, 2005, GENE DEV, V19, P270, DOI 10.1101/gad.1276505; Coleman MP, 2010, ANNU REV NEUROSCI, V33, P245, DOI 10.1146/annurev-neuro-060909-153248; Conforti L, 2014, NAT REV NEUROSCI, V15, P394, DOI 10.1038/nrn3680; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Duarte JMN, 2012, NEUROIMAGE, V61, P342, DOI 10.1016/j.neuroimage.2011.12.038; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Faul M, 2010, TRAUMATIC BRAIN INJU; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Freeman MR, 2014, CURR OPIN NEUROBIOL, V27, P224, DOI 10.1016/j.conb.2014.05.001; Gardner A, 2014, J NEUROTRAUM, V31, P1, DOI 10.1089/neu.2013.3079; Gatson JW, 2014, J NEUROSURG, V121, P1232, DOI 10.3171/2014.7.JNS132474; Gerdts J, 2015, SCIENCE, V348, P453, DOI 10.1126/science.1258366; Gerdts J, 2013, J NEUROSCI, V33, P13569, DOI 10.1523/JNEUROSCI.1197-13.2013; Gilley J, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000300; Godzik K, 2015, J MOL NEUROSCI, V55, P865, DOI 10.1007/s12031-014-0440-2; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Harris JL, 2012, J CEREBR BLOOD F MET, V32, P2122, DOI 10.1038/jcbfm.2012.114; Henninger N, 2005, EXP NEUROL, V195, P447, DOI 10.1016/j.expneurol.2005.06.013; Henninger N, 2009, EXP NEUROL, V215, P290, DOI 10.1016/j.expneurol.2008.10.013; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kilinc D, 2009, EXP NEUROL, V219, P553, DOI 10.1016/j.expneurol.2009.07.014; Kim YH, 2007, J EXP MED, V204, P2063, DOI 10.1084/jem.20070868; Kirov II, 2013, J NEUROTRAUM, V30, P1200, DOI 10.1089/neu.2012.2696; Knoferle J, 2010, P NATL ACAD SCI USA, V107, P6064, DOI 10.1073/pnas.0909794107; Lamprecht MR, 2007, BIOTECHNIQUES, V42, P71, DOI 10.2144/000112257; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Lin CW, 2014, INNATE IMMUN-LONDON, V20, P161, DOI 10.1177/1753425913485877; Longhi L, 2011, J CEREBR BLOOD F MET, V31, P1919, DOI 10.1038/jcbfm.2011.42; Ma M, 2013, NEUROBIOL DIS, V56, P34, DOI 10.1016/j.nbd.2013.03.009; Martin SM, 2010, DEVELOPMENT, V137, P3985, DOI 10.1242/dev.053611; Maxwell WL, 2015, J NEUROTRAUM, V32, P780, DOI 10.1089/neu.2014.3369; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; Osterloh JM, 2012, SCIENCE, V337, P481, DOI 10.1126/science.1223899; Penkowa M, 2003, GLIA, V42, P287, DOI 10.1002/glia.10208; Philip S, 2009, J TRAUMA, V67, pS128, DOI 10.1097/TA.0b013e3181ad32c7; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Samoriski GM, 1997, J NEUROSCI, V17, P5581; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Staal JA, 2010, J NEUROCHEM, V112, P1147, DOI 10.1111/j.1471-4159.2009.06531.x; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Walker PA, 2010, STEM CELLS DEV, V19, P867, DOI 10.1089/scd.2009.0188; Waller, 1850, PHILOS T R SOC LOND, VI, P423, DOI [10.1098/rspl.1843.0224, DOI 10.1098/RSTL.1850.0021]; Wang JT, 2012, J CELL BIOL, V196, P7, DOI 10.1083/jcb.201108111; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yang J, 2013, NEURON, V80, P1175, DOI 10.1016/j.neuron.2013.08.034; Yin TC, 2014, CELL REP, V8, P1731, DOI 10.1016/j.celrep.2014.08.030	58	87	87	2	12	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	APR	2016	139		4				1094	1105		10.1093/brain/aww001			12	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DJ5GN	WOS:000374234900020	26912636	Green Published, Bronze			2022-02-06	
J	Siegmund, GP; Guskiewicz, KM; Marshall, SW; DeMarco, AL; Bonin, SJ				Siegmund, Gunter P.; Guskiewicz, Kevin M.; Marshall, Stephen W.; DeMarco, Alyssa L.; Bonin, Stephanie J.			Laboratory Validation of Two Wearable Sensor Systems for Measuring Head Impact Severity in Football Players	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Head impact; Wearable sensors; Validity; Acceleration; Concussion; Football	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL; HYBRID III; HELMET; ACCELERATION; CONCUSSION; KINEMATICS; MODEL; RISK; BIOMECHANICS	Wearable sensors can measure head impact frequency and magnitude in football players. Our goal was to quantify the impact detection rate and validity of the direction and peak kinematics of two wearable sensors: a helmet system (HITS) and a mouthguard system (X2). Using a linear impactor, modified Hybrid-III headform and one helmet model, we conducted 16 impacts for each system at 12 helmet sites and 5 speeds (3.6-11.2 m/s) (N = 896 tests). Peak linear and angular accelerations (PLA, PAA), head injury criteria (HIC) and impact directions from each device were compared to reference sensors in the headform. Both sensors detected similar to 96% of impacts. Median angular errors for impact directions were 34A degrees for HITS and 16A degrees for X2. PLA, PAA and HIC were simultaneously valid at 2 sites for HITS (side, oblique) and one site for X2 (side). At least one kinematic parameter was valid at 2 and 7 other sites for HITS and X2 respectively. Median relative errors for PLA were 7% for HITS and -7% for X2. Although sensor validity may differ for other helmets and headforms, our analyses show that data generated by these two sensors need careful interpretation.	[Siegmund, Gunter P.; DeMarco, Alyssa L.] MEA Forens Engn & Scientists, 11-11151 Horseshoe Way, Richmond, BC V7A 4S5, Canada; [Siegmund, Gunter P.] Univ British Columbia, Sch Kinesiol, Vancouver, BC V5Z 1M9, Canada; [Guskiewicz, Kevin M.; Marshall, Stephen W.] Univ N Carolina, Dept Exercise & Sport Sci, Matthew A Gfeller Sport Related Traumat Brain Inj, Chapel Hill, NC USA; [Guskiewicz, Kevin M.; Marshall, Stephen W.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA; [Bonin, Stephanie J.] MEA Forens Engineers & Scientists, Laguna Hills, CA USA		Siegmund, GP (corresponding author), MEA Forens Engn & Scientists, 11-11151 Horseshoe Way, Richmond, BC V7A 4S5, Canada.	gunter.siegmund@meaforensic.com	Siegmund, Gunter P/B-7003-2013	Siegmund, Gunter/0000-0003-2387-941X; DeMarco, Alyssa/0000-0002-3106-386X	National Football League (NFL); Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49-CE002479]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE002479] Funding Source: NIH RePORTER	This study was funded by the National Football League (NFL). The authors thank Chris Withnall, Michael Wonnacott, Dave Halstead and Elizabeth McCalley for helping refine the protocol and acquire the data; and Christoph Mack, Jason Thibado, Jonathan Beckwith, Richard Greenwald, and Thad Ide for answering questions about their products. Our conclusions do not reflect the views of the NFL. SWM is partly funded by the Centers for Disease Control and Prevention (R49-CE002479). The NFL paid MEA Forensic for time and disbursements related to work performed by GPS, ALD, SJB and other MEA employees for this study. GPS and his spouse own shares in MEA Forensic, and GPS, ALD and SJB are salaried employees of MEA Forensic. KMG is a member of the NFL's Head, Neck and Spine Committee and Chair of the Subcommittee on Equipment and Playing Rules. SWM is associated with the Datalys Center for Sports Injury Research and Prevention. None of the authors have a financial interest in either device. Biokinetics & Associates produce the MLSH and linear impactor, but had no hand in post-processing the data reported here. The NFL also paid Biokinetics & Associates and Southern Impact Research Center for their staff time, disbursements and lab usage. Drs. Barry Myers and David Meaney worked as paid consultants to the NFL and contributed to developing the protocol.	Adams J, 1987, P 31 STAPP CAR CRASH, V96, P1355, DOI DOI 10.4271/872197; Allison MA, 2014, MED SCI SPORT EXER, V46, P115, DOI 10.1249/MSS.0b013e3182a32d0d; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Cobb BR, 2015, P I MECH ENG P-J SPO, V229, P39, DOI 10.1177/1754337114548245; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Higgins M, 2007, J ATHL TRAINING, V42, P5; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Ji SB, 2014, ANN BIOMED ENG, V42, P11, DOI 10.1007/s10439-013-0907-2; KENT JT, 1982, J ROY STAT SOC B MET, V44, P71; Knox T, 2009, SAE INT J PASSENG CA, V1, P652; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Leong P, 1998, J NEUROSCI METH, V80, P191, DOI 10.1016/S0165-0270(97)00201-X; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McCulloch C.E., 2008, GEN LINEAR MIXED MOD, P424; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; Olvey SE, 2004, NEUROSURGERY, V54, P672, DOI 10.1227/01.NEU.0000108782.68099.29; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S, 2014, J NEUROSURG, V120, P919, DOI 10.3171/2014.1.JNS13916; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Siegmund GP, 2014, ANN BIOMED ENG, V42, P1834, DOI 10.1007/s10439-014-1052-2; Stroup WW, 2012, GEN LINEAR MIXED MOD, P555; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2012, ANN BIOMED ENG, V40, P47, DOI 10.1007/s10439-011-0399-x; Weaver AA, 2012, ANN BIOMED ENG, V40, P2005, DOI 10.1007/s10439-012-0553-0; Withnall C., 2010, DEV ARTICULATING MAN; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	45	87	86	0	31	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	APR	2016	44	4					1257	1274		10.1007/s10439-015-1420-6			18	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	DI8HJ	WOS:000373741800036	26268586				2022-02-06	
J	Webster, KM; Wright, DK; Sun, MJ; Semple, BD; Ozturk, E; Stein, DG; O'Brien, TJ; Shultz, SR				Webster, Kyria M.; Wright, David K.; Sun, Mujun; Semple, Bridgette D.; Ozturk, Ezgi; Stein, Donald G.; O'Brien, Terence J.; Shultz, Sandy R.			Progesterone treatment reduces neuroinflammation, oxidative stress and brain damage and improves long-term outcomes in a rat model of repeated mild traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Concussion; Chronic traumatic encephalopathy; Animal model; DTI; MRI; Treatment; Microglia; Macrophages; Astrogliosis; Lipid peroxidation	HIGH-DOSE PROGESTERONE; RECURRENT CONCUSSION; ANIMAL-MODEL; IN-VIVO; INFLAMMATORY RESPONSE; COGNITIVE IMPAIRMENT; SYNAPTIC PLASTICITY; LIPID-PEROXIDATION; CLINICAL-TRIAL; MOUSE MODEL	Background: Repeated mild traumatic brain injuries, such as concussions, may result in cumulative brain damage, neurodegeneration and other chronic neurological impairments. There are currently no clinically available treatment options known to prevent these consequences. However, growing evidence implicates neuroinflammation and oxidative stress in the pathogenesis of repetitive mild brain injuries; thus, these may represent potential therapeutic targets. Progesterone has been demonstrated to have potent anti-inflammatory and anti-oxidant properties after brain insult; therefore, here, we examined progesterone treatment in rats given repetitive mild brain injuries via the repeated mild fluid percussion injury model. Methods: Male Long-Evans rats were assigned into four groups: sham injury + vehicle treatment, sham injury + progesterone treatment (8 mg/kg/day), repeated mild fluid percussion injuries + vehicle treatment, and repeated mild fluid percussion injuries + progesterone treatment. Rats were administered a total of three injuries, with each injury separated by 5 days. Treatment was initiated 1 h after the first injury, then administered daily for a total of 15 days. Rats underwent behavioural testing at 12-weeks post-treatment to assess cognition, motor function, anxiety and depression. Brains were then dissected for analysis of markers for neuroinflammation and oxidative stress. Ex vivo MRI was conducted in order to examine structural brain damage and white matter integrity. Results: Repeated mild fluid percussion injuries + progesterone treatment rats showed significantly reduced cognitive and sensorimotor deficits compared to their vehicle-treated counterparts at 12-weeks post-treatment. Progesterone treatment significantly attenuated markers of neuroinflammation and oxidative stress in rats given repeated mild fluid percussion injuries, with concomitant reductions in grey and white matter damage as indicated by MRI. Conclusions: These findings implicate neuroinflammation and oxidative stress in the pathophysiological aftermath of mild brain injuries and suggest that progesterone may be a viable treatment option to mitigate these effects and their detrimental consequences.	[Webster, Kyria M.; Sun, Mujun; Semple, Bridgette D.; Ozturk, Ezgi; O'Brien, Terence J.; Shultz, Sandy R.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3050, Australia; [Wright, David K.] Univ Melbourne, Anat & Neurosci, Parkville, Vic 3010, Australia; [Wright, David K.] Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3052, Australia; [Stein, Donald G.] Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA		Shultz, SR (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3050, Australia.	sshultz@unimelb.edu.au	O'Brien, Terence/L-8102-2013; Stein, Donald/AAJ-5139-2020; O'Brien, Terence/AAU-5525-2021	Sun, Mujun/0000-0002-9923-9913; O'Brien, Terence/0000-0002-7198-8621; Wright, David/0000-0002-7535-8651	National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia [1062653]; Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR); NHMRCNational Health and Medical Research Council of Australia	We would like to thank Dr. Iqbal Sayeed (Emory University) for his contributions towards this project. This study was funded by a grant to SRS from the National Health and Medical Research Council (NHMRC # 1062653) and fellowships to SRS from the Canadian Institute of Health Research and NHMRC.	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Aebi S, 1999, CANCER CHEMOTH PHARM, V44, P259, DOI 10.1007/s002800050976; Allolio B, 1995, EUR J ENDOCRINOL, V133, P696, DOI 10.1530/eje.0.1330696; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Barha CK, 2011, EXP NEUROL, V231, P72, DOI 10.1016/j.expneurol.2011.05.016; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Cai J, 2015, NEUROSCI LETT, V600, P238, DOI 10.1016/j.neulet.2015.06.023; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Coughlan T, 2005, J NEUROCHEM, V93, P932, DOI 10.1111/j.1471-4159.2005.03068.x; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; Ferrer-Martin RM, 2014, EXP EYE RES, V121, P42, DOI 10.1016/j.exer.2014.02.015; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Howard R.B., 2015, J NEUROTRAUMA; Hylin MJ, 2013, J NEUROTRAUM, V30, P702, DOI 10.1089/neu.2012.2630; Ishihara Y, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/343706; Johnstone VPA, 2015, J NEUROTRAUM, V32, P1333, DOI 10.1089/neu.2014.3785; Johnstone VPA, 2014, J NEUROTRAUM, V31, P1881, DOI 10.1089/neu.2014.3343; Kadhim HJ, 2009, J INTENSIVE CARE MED, V23, P236; KOLB B, 1985, BEHAV BRAIN RES, V17, P25, DOI 10.1016/0166-4328(85)90005-1; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; RABINOWITZ SS, 1991, J EXP MED, V174, P827, DOI 10.1084/jem.174.4.827; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Robertson CL, 2015, PEDIATR CRIT CARE ME, V16, P236, DOI 10.1097/PCC.0000000000000323; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Sheng WS, 2013, NEUROCHEM RES, V38, P2148, DOI 10.1007/s11064-013-1123-z; Shi SR, 2001, J HISTOCHEM CYTOCHEM, V49, P931, DOI 10.1177/002215540104900801; Shultz SR, 2015, BRAIN, V138, P1297, DOI 10.1093/brain/awv053; Shultz SR, 2015, BEHAV BRAIN RES, V278, P542, DOI 10.1016/j.bbr.2014.10.050; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; Shultz SR, 2012, BEHAV BRAIN RES, V229, P145, DOI 10.1016/j.bbr.2011.12.015; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Signoretti S, 2011, PM&R, V3, pS359, DOI 10.1016/j.pmrj.2011.07.018; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Stein D, 2015, FUTURE NEUROL; Stein DG, 2015, BRAIN INJURY, V29, P1259, DOI 10.3109/02699052.2015.1065344; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Wang JP, 2011, MOL MED REP, V4, P319, DOI 10.3892/mmr.2011.418; Whishaw IQ, 1995, HIPPOCAMPUS, V5, P595, DOI 10.1002/hipo.450050610; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Zotova E, 2013, BRAIN, V136, P2677, DOI 10.1093/brain/awt210	74	87	88	0	24	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	DEC 18	2015	12								238	10.1186/s12974-015-0457-7			13	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	CZ6SM	WOS:000367231000001	26683475	gold, Green Published			2022-02-06	
J	Bryan, CJ; Griffith, JE; Pace, BT; Hinkson, K; Bryan, AO; Clemans, TA; Imel, ZE				Bryan, Craig J.; Griffith, James E.; Pace, Brian T.; Hinkson, Kent; Bryan, AnnaBelle O.; Clemans, Tracy A.; Imel, Zac E.			Combat Exposure and Risk for Suicidal Thoughts and Behaviors Among Military Personnel and Veterans: A Systematic Review and Meta-Analysis	SUICIDE AND LIFE-THREATENING BEHAVIOR			English	Article							POSTTRAUMATIC-STRESS-DISORDER; SERVICEMEMBERS ARMY STARRS; TRAUMATIC BRAIN-INJURY; ACQUIRED CAPABILITY; NATIONAL-GUARD; IDEATION; SOLDIERS; HEALTH; RESILIENCE; SYMPTOMS	Due to seemingly mixed empirical results, questions persist about the possible role of deployments and combat exposure. We conducted a narrative review and meta-analysis of 22 published studies to integrate findings regarding the relationship of deployment-related predictors (i.e., deployment, deployment to a combat zone, combat experience, and exposure to specific combat events) with suicide-related outcomes (i.e., suicide ideation, attempt, and death). Across all predictors and outcomes, the combined effect was small and positive, r=.08 [0.04, 0.13], and marked by significant heterogeneity, I-2=99.9%, Q(21)=4880.16, p<.0001, corresponding to a 25% increased risk for suicide-related outcomes among those who have deployed. Studies examining the relationship between exposure to killing and atrocities (k=5) showed the largest combined effect, r=.12 [0.08, 0.17], and less heterogeneity, I-2=84.4%, Q(4)=34.96, p<.0001, corresponding to a 43% increased risk for suicide-related outcomes among those exposed to killing or atrocity. Implications for theory, research, and clinical practice are discussed.	[Bryan, Craig J.; Pace, Brian T.; Imel, Zac E.] Univ Utah, Salt Lake City, UT 84112 USA; [Bryan, Craig J.; Griffith, James E.; Bryan, AnnaBelle O.; Clemans, Tracy A.] Natl Ctr Vet Studies, Salt Lake City, UT USA; [Hinkson, Kent] Utah Valley Univ, Provo, UT USA		Bryan, CJ (corresponding author), Univ Utah, Natl Ctr Vet Studies, 260 S Cent Campus Dr,Room 205, Salt Lake City, UT 84112 USA.	craig.bryan@utah.edu	Imel, Zac E./AAH-9491-2019	Imel, Zac E./0000-0001-9645-7184; Bryan, Craig/0000-0002-9714-0733; Clemans, Tracy/0000-0001-5994-1508			American Psychiatric Association, 2003, PRACT GUID ASS TREAT; Anestis M., 2009, J MENTAL HLTH COUNSE, V31, P60, DOI DOI 10.17744/MEHC.31.1.U394H1470; Bachynski KE, 2012, INJURY PREV, V18, P405, DOI 10.1136/injuryprev-2011-040112; Brown GK, 2000, J CONSULT CLIN PSYCH, V68, P371, DOI 10.1037/0022-006X.68.3.371; Bryan A. O., 2015, TRAUMATOLOGY, V21, P40, DOI DOI 10.1037/TRM0000017; Bryan A.O., 2014, TRAUMATOLOGY, V20, P154, DOI [10.1037/h0099852, DOI 10.1037/H0099852]; Bryan C. J., INT J COGNI IN PRESS; Bryan CJ, 2006, J CLIN PSYCHOL, V62, P185, DOI 10.1002/jclp.20222; Bryan C, 2011, J CLIN PSYCHOL, V67, P856, DOI 10.1002/jclp.20808; Bryan CJ, 2015, J NERV MENT DIS, V203, P48, DOI 10.1097/NMD.0000000000000236; Bryan CJ, 2013, JAMA-J AM MED ASSOC, V310, P2564, DOI 10.1001/jama.2013.282698; Bryan CJ, 2013, COGNITIVE THER RES, V37, P996, DOI 10.1007/s10608-013-9536-1; Bryan CJ, 2013, J AFFECT DISORDERS, V150, P1226, DOI 10.1016/j.jad.2013.05.087; Bryan CJ, 2013, J AFFECT DISORDERS, V148, P37, DOI 10.1016/j.jad.2012.11.044; Bryan CJ, 2013, DEPRESS ANXIETY, V30, P55, DOI 10.1002/da.22002; Bryan CJ, 2013, J CLIN PSYCHOL, V69, P64, DOI 10.1002/jclp.21932; Bryan CJ, 2012, J PSYCHIATR RES, V46, P843, DOI 10.1016/j.jpsychires.2012.03.012; Bryan CJ, 2011, SUICIDE LIFE-THREAT, V41, P126, DOI 10.1111/j.1943-278X.2011.00023.x; Bryan CJ, 2010, J CLIN PSYCHOL, V66, P1044, DOI 10.1002/jclp.20703; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Crosby AE, 2011, SELF DIRECTED VIOLEN; Del Re AC., 2010, R PACKAGE VERSION, V1, P1; Department of Defense, 2013, DODSER DEP DEF SUIC; Department of the Army, 2011, ARM HLTH PROM RISK R; Fanning JR, 2013, J PSYCHIATR RES, V47, P1766, DOI 10.1016/j.jpsychires.2013.07.015; FONTANA A, 1992, J NERV MENT DIS, V180, P748, DOI 10.1097/00005053-199212000-00002; Gibbons RD, 2012, AM J PUBLIC HEALTH, V102, pS17, DOI 10.2105/AJPH.2011.300491; Griffith J, 2013, ARMED FORCES SOC, V39, P628, DOI 10.1177/0095327X12471333; Griffith J, 2012, SUICIDE LIFE-THREAT, V42, P453, DOI 10.1111/j.1943-278X.2012.00104.x; Griffith J, 2012, SUICIDE LIFE-THREAT, V42, P104, DOI 10.1111/j.1943-278X.2011.00075.x; Guerra VS, 2011, J ANXIETY DISORD, V25, P12, DOI 10.1016/j.janxdis.2010.06.025; HENDIN H, 1991, AM J PSYCHIAT, V148, P586; Hoge CW, 2013, JAMA-J AM MED ASSOC, V310, P2565, DOI 10.1001/jama.2013.282701; Hoge CW, 2012, JAMA-J AM MED ASSOC, V308, P671, DOI 10.1001/jama.2012.9955; Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193; Hunter J.E., 2004, METHODS META ANAL CO, V2nd ed.; Joiner T.E., 2005, WHY PEOPLE DIE SUICI; Larson MJ, 2013, JAMA-J AM MED ASSOC, V310, P2565, DOI 10.1001/jama.2013.282695; LeardMann CA, 2013, JAMA-J AM MED ASSOC, V310, P496, DOI 10.1001/jama.2013.65164; Maguen S, 2012, DEPRESS ANXIETY, V29, P918, DOI 10.1002/da.21954; Nevin RL, 2013, JAMA-J AM MED ASSOC, V310, P2563, DOI 10.1001/jama.2013.282692; Nock MK, 2014, JAMA PSYCHIAT, V71, P514, DOI 10.1001/jamapsychiatry.2014.30; Nye EC, 2007, MIL MED, V172, P1144; Pernin C.G., 2011, WAR PREVENTING SUICI; Peterson AL, 2010, J TRAUMA STRESS, V23, P674, DOI 10.1002/jts.20585; Pietrzak RH, 2010, J AFFECT DISORDERS, V123, P102, DOI 10.1016/j.jad.2009.08.001; R Core Development Team, 2011, R LANG ENV STAT COMP; Rudd M. D., AM J PSYCHI IN PRESS; Rudd MD, 2012, MIL PSYCHOL, V24, P592, DOI 10.1080/08995605.2012.736325; Rudd MD, 2006, COGNITION SUICIDE TH, P355, DOI [10.1037/11377-016, DOI 10.1037/11377-016]; Sareen J, 2007, ARCH GEN PSYCHIAT, V64, P843, DOI 10.1001/archpsyc.64.7.843; Schoenbaum M, 2014, JAMA PSYCHIAT, V71, P493, DOI 10.1001/jamapsychiatry.2013.4417; Selby EA, 2010, CLIN PSYCHOL REV, V30, P298, DOI 10.1016/j.cpr.2009.12.004; Thoresen S, 2008, J NERV MENT DIS, V196, P814, DOI 10.1097/NMD.0b013e31818b6a92; Viechtbauer W., 2014, METAFOR METAANALYSIS; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Wampold BE, 1997, PSYCHOL BULL, V122, P203, DOI 10.1037/0033-2909.122.3.203; Wisco BE, 2014, J TRAUMA STRESS, V27, P244, DOI 10.1002/jts.21900	58	87	88	0	21	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0363-0234	1943-278X		SUICIDE LIFE-THREAT	Suicide Life-Threat. Behav.	OCT	2015	45	5					633	649		10.1111/sltb.12163			17	Psychiatry; Psychology, Multidisciplinary	Social Science Citation Index (SSCI)	Psychiatry; Psychology	CT3FR	WOS:000362693100010	29889337				2022-02-06	
J	Koerte, IK; Lin, AP; Muehlmann, M; Merugumala, S; Liao, HJ; Starr, T; Kaufmann, D; Mayinger, M; Steffinger, D; Fisch, B; Karch, S; Heinen, F; Ertl-Wagner, B; Reiser, M; Stern, RA; Zafonte, R; Shenton, ME				Koerte, Inga K.; Lin, Alexander P.; Muehlmann, Marc; Merugumala, Sai; Liao, Huijun; Starr, Tyler; Kaufmann, David; Mayinger, Michael; Steffinger, Denise; Fisch, Barbara; Karch, Susanne; Heinen, Florian; Ertl-Wagner, Birgit; Reiser, Maximilian; Stern, Robert A.; Zafonte, Ross; Shenton, Martha E.			Altered Neurochemistry in Former Professional Soccer Players without a History of Concussion	JOURNAL OF NEUROTRAUMA			English	Article						brain metabolism; repetitive subconcussive brain trauma; MR spectroscopy; soccer	TRAUMATIC BRAIN-INJURY; SPECTROSCOPY; MYOINOSITOL; IMPAIRMENT; DEFICITS; TRAIL; RISK	Soccer is played by more than 250 million people worldwide. Repeatedly heading the ball may place soccer players at high risk for repetitive subconcussive head impacts (RSHI). This study evaluates the long-term effects of RSHI on neurochemistry in athletes without a history of clinically diagnosed concussion, but with a high exposure to RSHI. Eleven former professional soccer players (mean age 52.0 +/- 6.8 years) and a comparison cohort of 14 age- and gender-matched, former non-contact sport athletes (mean age 46.9 +/- 7.9 years) underwent 3T magnetic resonance spectroscopy (MRS) and neurocognitive evaluation. In the soccer players a significant increase was observed in both choline (Cho), a membrane marker, and myo-inositol (ml), a marker of glial activation, compared with control athletes. Additionally, ml and glutathione (GSH) were significantly correlated with lifetime estimate of RSHI within the soccer group. There was no significant difference in neurocognitive tests between groups. Results of this study suggest an association between RSHI in soccer players and MRS markers of neuroinflammation, suggesting that even subconcussive head impacts affect the neurochemistry of the brain and may precede neurocognitive changes. Future studies will need to determine the role of neuroinflammation in RSHI and the effect on neurocognitive function.	[Koerte, Inga K.; Lin, Alexander P.; Muehlmann, Marc; Mayinger, Michael; Shenton, Martha E.] Brigham & Womens Hosp, Psychiat Neuroimaging Lab, Boston, MA 02215 USA; [Lin, Alexander P.; Merugumala, Sai; Liao, Huijun; Starr, Tyler; Shenton, Martha E.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02215 USA; [Shenton, Martha E.] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02215 USA; [Shenton, Martha E.] Harvard Univ, Sch Med, Boston, MA USA; [Koerte, Inga K.; Muehlmann, Marc; Kaufmann, David; Mayinger, Michael; Steffinger, Denise; Fisch, Barbara; Ertl-Wagner, Birgit; Reiser, Maximilian] Univ Munich, Dr von Hauner Childrens Hospital, Inst Clin Radiol, Munich, Germany; [Koerte, Inga K.; Muehlmann, Marc] Univ Munich, Dr von Hauner Childrens Hospital, Dept Child & Adolescent Psychiat Psychosomat & Ps, Munich, Germany; [Karch, Susanne] Univ Munich, Dept Psychiat, Dr von Hauner Childrens Hospital, D-80539 Munich, Germany; [Heinen, Florian] Univ Munich, Dr von Hauner Childrens Hospital, Dept Pediat Neurol, Munich, Germany; [Kaufmann, David] Charite, Dept Radiol, Berlin, Germany; [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurol, Boston Univ Alzheimers Dis Ctr, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Boston Univ Alzheimers Dis Ctr, Dept Neurosurg, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston Univ Alzheimers Dis Ctr, Boston, MA 02118 USA; [Zafonte, Ross] Harvard Univ, Brigham & Womens Hosp, Massachusetts Gen Hosp, Spaulding Rehabil Hosp,Dept Phys Med & Rehabil,Sc, Boston, MA 02115 USA; [Shenton, Martha E.] VA Boston Healthcare Syst, Boston, MA USA		Koerte, IK (corresponding author), Brigham & Womens Hosp, Psychiat Neuroimaging Lab, 1249 Boylston St, Boston, MA 02215 USA.	ikoerte@bwh.harvard.edu	Shenton, Martha/V-8780-2019; Ertl-Wagner, Birgit/AAD-5708-2020; Koerte, Inga Katharina/AAW-3031-2021; Heinen, Florian/B-6594-2015; , Bob/ABA-8507-2020	Heinen, Florian/0000-0002-3872-6136; Ertl-Wagner, Birgit/0000-0002-7896-7049; Stern, Robert/0000-0002-5008-077X	Else Kroner-Fresenius-Stiftung, Germany; Department of DefenseUnited States Department of Defense [W81XWH-10-1-0835, W81XWH-07-CC-CSDoD]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS078337]; VA Merit AwardUS Department of Veterans Affairs; Petraeic Legate Foundation, Germany; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER	This study was supported by the Else Kroner-Fresenius-Stiftung, Germany (I.K.). This work was also partially funded by grants from the Department of Defense (W81XWH-10-1-0835: A.P.L.; W81XWH-07-CC-CSDoD: R.Z., M.E.S.), the National Institutes of Health (R01-NS078337: A.P.L., M.E.S., R.A.S.) and a VA Merit Award (M.E.S.). Michael Mayinger was supported by the Petraeic Legate Foundation, Germany.	Ashendorf L, 2008, ARCH CLIN NEUROPSYCH, V23, P129, DOI 10.1016/j.acn.2007.11.005; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Bjorneboe J, 2014, BRIT J SPORT MED, V48, P774, DOI 10.1136/bjsports-2012-091856; Blanksby B A, 1988, Br J Sports Med, V22, P57; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Bowie CR, 2006, NAT PROTOC, V1, P2277, DOI 10.1038/nprot.2006.390; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Chamard E, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12305; Chio A, 2009, AMYOTROPH LATERAL SC, V10, P205, DOI 10.1080/17482960902721634; DANIELS J, 1992, MED SCI SPORT EXER, V24, P483; Duffy SL, 2014, ALZHEIMERS DEMENT, V10, P67, DOI 10.1016/j.jalz.2013.01.005; EKBLOM B, 1986, SPORTS MED, V3, P50, DOI 10.2165/00007256-198603010-00005; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Johnson B, 2012, J NEUROTRAUM, V29, P2297, DOI 10.1089/neu.2011.2294; Kierans AS, 2014, NEUROLOGY, V82, P521, DOI 10.1212/WNL.0000000000000105; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kreisl WC, 2013, BRAIN, V136, P2228, DOI 10.1093/brain/awt145; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Lin Alexander, 2005, NeuroRx, V2, P197, DOI 10.1602/neurorx.2.2.197; Lin A, 2012, SEMIN NEUROL, V32, P432, DOI 10.1055/s-0032-1331814; Lin AP, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0094-5; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Maher ME, 2014, BRAIN INJURY, V28, P271, DOI 10.3109/02699052.2013.865269; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; O'Kane JW, 2014, JAMA PEDIATR, V168, P258, DOI 10.1001/jamapediatrics.2013.4518; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rutherford A, 2009, J CLIN EXP NEUROPSYC, V31, P664, DOI 10.1080/13803390802484755; Shin MS, 2006, NAT PROTOC, V1, P892, DOI 10.1038/nprot.2006.115; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI70, DOI 10.1136/bjsm.2005.019646; Suchomel A., 2010, INT J TABLE TENNIS S, V6, P79; Tonnessen E, 2013, INT J SPORT PHYSIOL, V8, P323, DOI 10.1123/ijspp.8.3.323; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200	42	87	87	2	40	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 1	2015	32	17					1287	1293		10.1089/neu.2014.3715			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CP0KP	WOS:000359564500001	25843317	Green Published			2022-02-06	
J	Wang, WX; Visavadiya, NP; Pandya, JD; Nelson, PT; Sullivan, PG; Springer, JE				Wang, Wang-Xia; Visavadiya, Nishant P.; Pandya, Jignesh D.; Nelson, Peter T.; Sullivan, Patrick G.; Springer, Joe E.			Mitochondria-associated microRNAs in rat hippocampus following traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						MicroRNA; Mitochondria; Traumatic brain injury; Controlled cortical impact; Hippocampus; Inflammation; MiR-142-3p; MiR-142-5p; MiR-146a; MiR-155; MiR-223; MiR-150	NORMAL IMMUNE FUNCTION; SPINAL-CORD-INJURY; CELL-DEATH; TRANSCRIPTION FACTORS; RNA INTERFERENCE; OXIDATIVE STRESS; P-BODIES; EXPRESSION; DYSFUNCTION; REGULATOR	Traumatic brain injury (TBI) is a major cause of death and disability. However, the molecular events contributing to the pathogenesis are not well understood. Mitochondria serve as the powerhouse of cells, respond to cellular demands and stressors, and play an essential role in cell signaling, differentiation, and survival. There is clear evidence of compromised mitochondrial function following TBI; however, the underlying mechanisms and consequences are not clear. MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression post-transcriptionally, and function as important mediators of neuronal development, synaptic plasticity, and neurodegeneration. Several miRNAs show altered expression following TBI; however, the relevance of mitochondria in these pathways is unknown. Here, we present evidence supporting the association of miRNA with hippocampal mitochondria, as well as changes in mitochondria-associated miRNA expression following a controlled cortical impact (CCI) injury in rats. Specifically, we found that the miRNA processing proteins Argonaute (AGO) and Dicer are present in mitochondria fractions from uninjured rat hippocampus, and immunoprecipitation of AGO associated miRNA from mitochondria suggests the presence of functional RNA-induced silencing complexes. Interestingly, RT-qPCR miRNA array studies revealed that a subset of miRNA is enriched in mitochondria relative to cytoplasm. At 12 h following CCI, several miRNAs are significantly altered in hippocampal mitochondria and cytoplasm. In addition, levels of miR-155 and miR-223, both of which play a role in inflammatory processes, are significantly elevated in both cytoplasm and mitochondria. We propose that mitochondria-associated miRNAs may play an important role in regulating the response to TBI. (C) 2015 Elsevier Inc. All rights reserved.	[Wang, Wang-Xia; Nelson, Peter T.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Visavadiya, Nishant P.; Springer, Joe E.] Univ Kentucky, Phys Med & Rehabil, Lexington, KY 40536 USA; [Visavadiya, Nishant P.; Pandya, Jignesh D.; Sullivan, Patrick G.; Springer, Joe E.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Pandya, Jignesh D.; Sullivan, Patrick G.; Springer, Joe E.] Univ Kentucky, Anat & Neurobiol, Lexington, KY 40536 USA; [Wang, Wang-Xia; Nelson, Peter T.] Univ Kentucky, Dept Pathol, Lexington, KY 40536 USA		Wang, WX (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA.	wwangc@email.uky.edu; jspring@uky.edu	Wang, Wang-Xia/AAD-6900-2019	Wang, Wang-Xia/0000-0002-8104-3779	Morton Cure Paralysis Fund; National Center for Advancing Translational SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UT1TR000117]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1TR000117]; PHSUnited States Department of Health & Human ServicesUnited States Public Health Service [NS085830, AG042419]; KSCHIRT endowed chair funds; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS085830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG042419, P30AG028383] Funding Source: NIH RePORTER	The described work was supported by the Morton Cure Paralysis Fund and an endowment from Cardinal Hill Rehabilitation Hospital (JES), an ADC-Pilot grant by the National Center for Advancing Translational Sciences (UT1TR000117), National Institutes of Health through grant number UL1TR000117 (WXW), PHS grants NS085830 and AG042419 (PTN) and a KSCHIRT endowed chair funds (PGS).	Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Atorino L, 2003, J CELL BIOL, V163, P777, DOI 10.1083/jcb.200304112; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bandiera S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020746; Barrey E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020220; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bian Z, 2010, CELL RES, V20, P1076, DOI 10.1038/cr.2010.119; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen K, 2007, NAT REV GENET, V8, P93, DOI 10.1038/nrg1990; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Das S, 2012, CIRC RES, V110, P1596, DOI 10.1161/CIRCRESAHA.112.267732; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Ernoult-Lange M, 2012, BIOCHIMIE, V94, P1572, DOI 10.1016/j.biochi.2012.03.008; Faul M, 2010, TRAUMATIC BRAIN INJU; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Finkelstein E., 2006, INCIDENCE EC BURDEN; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Hata A, 2013, ANNU REV PHYSIOL, V75, P69, DOI 10.1146/annurev-physiol-030212-183737; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Higgs Gadareth, 2013, J Clin Bioinforma, V3, P17, DOI 10.1186/2043-9113-3-17; Hoshino K, 1999, J IMMUNOL, V162, P3749; Hu JZ, 2013, J NEUROTRAUM, V30, P1349, DOI 10.1089/neu.2012.2748; Hu ZH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039357; Huang L, 2011, J BIOL CHEM, V286, P24219, DOI 10.1074/jbc.M111.240259; Huntzinger E, 2011, NAT REV GENET, V12, P99, DOI 10.1038/nrg2936; Johnnidis JB, 2008, NATURE, V451, P1125, DOI 10.1038/nature06607; Kren BT, 2009, RNA BIOL, V6, P65, DOI 10.4161/rna.6.1.7534; Kurowska-Stolarska M, 2011, P NATL ACAD SCI USA, V108, P11193, DOI 10.1073/pnas.1019536108; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Latronico MVG, 2012, CIRC RES, V110, P1540, DOI 10.1161/CIRCRESAHA.112.271312; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103948; Liu NK, 2009, EXP NEUROL, V219, P424, DOI 10.1016/j.expneurol.2009.06.015; Liu X, 2008, BRAIN PATHOL, V18, P113, DOI 10.1111/j.1750-3639.2007.00121.x; Lung B, 2006, NUCLEIC ACIDS RES, V34, P3842, DOI 10.1093/nar/gkl448; Maniataki E, 2005, RNA, V11, P849, DOI 10.1261/rna.2210805; McBride HM, 2006, CURR BIOL, V16, pR551, DOI 10.1016/j.cub.2006.06.054; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mercer TR, 2011, CELL, V146, P645, DOI 10.1016/j.cell.2011.06.051; Mestdagh P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-r64; Moore CS, 2013, ANN NEUROL, V74, P709, DOI 10.1002/ana.23967; Nelson PT, 2008, BRAIN PATHOL, V18, P130, DOI 10.1111/j.1750-3639.2007.00120.x; Nelson PT, 2007, RNA, V13, P1787, DOI 10.1261/rna.646007; Nelson PT, 2008, BBA-GENE REGUL MECH, V1779, P758, DOI 10.1016/j.bbagrm.2008.03.012; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; Patel SP, 2009, J NEUROSCI RES, V87, P130, DOI 10.1002/jnr.21814; Quinn SR, 2011, INT IMMUNOL, V23, P421, DOI 10.1093/intimm/dxr034; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; RINK A, 1995, AM J PATHOL, V147, P1575; Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Seddiki N, 2014, IMMUNOLOGY, V142, P32, DOI 10.1111/imm.12227; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Sonkoly E, 2008, SEMIN CANCER BIOL, V18, P131, DOI 10.1016/j.semcancer.2008.01.005; Sripada L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044873; Strickland ER, 2011, NEUROSCIENCE, V186, P146, DOI 10.1016/j.neuroscience.2011.03.063; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Sun TY, 2014, J HUAZHONG U SCI-MED, V34, P548, DOI 10.1007/s11596-014-1313-1; Sun W, 2010, CELL RES, V20, P1158, DOI 10.1038/cr.2010.134; Taibi F, 2014, BBA-MOL BASIS DIS, V1842, P1001, DOI 10.1016/j.bbadis.2014.03.005; Truettner JS, 2013, BRAIN RES, V1533, P122, DOI 10.1016/j.brainres.2013.08.011; Truettner JS, 2011, J CEREBR BLOOD F MET, V31, P1897, DOI 10.1038/jcbfm.2011.33; Vasilatou D, 2010, EUR J HAEMATOL, V84, P1, DOI 10.1111/j.1600-0609.2009.01348.x; Vigorito E, 2007, IMMUNITY, V27, P847, DOI 10.1016/j.immuni.2007.10.009; Vigorito E, 2013, IMMUNOL REV, V253, P146, DOI 10.1111/imr.12057; Wang WX, 2008, J NEUROSCI, V28, P1213, DOI 10.1523/JNEUROSCI.5065-07.2008; Wang Wang-Xia, 2014, Genomics Proteomics & Bioinformatics, V12, P19, DOI 10.1016/j.gpb.2013.10.003; Wang WX, 2010, RNA, V16, P394, DOI 10.1261/rna.1905910; Wang WX, 2008, BBA-GENE REGUL MECH, V1779, P749, DOI 10.1016/j.bbagrm.2008.01.005; Xiao CC, 2007, CELL, V131, P146, DOI 10.1016/j.cell.2007.07.021; Yu D, 2014, J MOL NEUROSCI, V53, P242, DOI 10.1007/s12031-014-0293-8; Yunta M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034534; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	84	87	90	0	23	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2015	265						84	93		10.1016/j.expneurol.2014.12.018			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CD3ZH	WOS:000351021900009	25562527	Green Accepted, Green Published			2022-02-06	
J	Zhu, DC; Covassin, T; Nogle, S; Doyle, S; Russell, D; Pearson, RL; Monroe, J; Liszewski, CM; DeMarco, JK; Kaufman, DI				Zhu, David C.; Covassin, Tracey; Nogle, Sally; Doyle, Scarlett; Russell, Doozie; Pearson, Randolph L.; Monroe, Jeffrey; Liszewski, Christine M.; DeMarco, J. Kevin; Kaufman, David I.			A Potential Biomarker in Sports-Related Concussion: Brain Functional Connectivity Alteration of the Default-Mode Network Measured with Longitudinal Resting-State fMRI over Thirty Days	JOURNAL OF NEUROTRAUMA			English	Article						mild traumatic brain injury; sports-related concussion; resting-state fMRI; diffusion-tensor imaging; default-mode network	SCHOOL FOOTBALL PLAYERS; PHYSICAL STRESS TEST; ALZHEIMERS-DISEASE; INJURY; IMPACT; COLLEGIATE; RECOVERY; EPIDEMIOLOGY; ORGANIZATION; TRACTOGRAPHY	Current diagnosis and monitoring of sports-related concussion rely on clinical signs and symptoms, and balance, vestibular, and neuropsychological examinations. Conventional brain imaging often does not reveal abnormalities. We sought to assess if the longitudinal change of functional and structural connectivity of the default-mode network (DMN) can serve as a potential biomarker. Eight concussed Division I collegiate football student-athletes in season (one participated twice) and 11 control subjects participated in this study. ImPACT (Immediate Post-Concussion Assessment and Cognitive Testing) was administered over the course of recovery. High-resolution three dimensional T-1-weighted, T-2*-weighted diffusion-tensor images and resting-state functional magnetic resonance imaging (rs-fMRI) scans were collected from each subject within 24 h, 7 +/- 1 d and 30 +/- 1 d after concussion. Both network based and whole-brain based functional correlation analyses on DMN were performed. ImPACT findings demonstrated significant cognitive impairment across multiple categories and a significant increase of symptom severity on Day 1 following a concussion but full recovery by 6.0 +/- 2.4 d. While the structural connectivity within DMN and gross anatomy appeared unchanged, a significantly reduced functional connectivity within DMN from Day 1 to Day 7 was found in the concussed group in this small pilot study. This reduction was seen in eight of our nine concussion cases. Compared with the control group, there appears a general trend of increased DMN functional connectivity on Day 1, a significant drop on Day 7, and partial recovery on Day 30. The results of this pilot study suggest that the functional connectivity of DMN measured with longitudinal rs-fMRI can serve as a potential biomarker to monitor the dynamically changing brain function after sports-related concussion, even in patients who have shown clinical improvement.	[Zhu, David C.; Doyle, Scarlett; DeMarco, J. Kevin] Michigan State Univ, Dept Radiol, E Lansing, MI 48824 USA; [Covassin, Tracey; Nogle, Sally; Monroe, Jeffrey] Michigan State Univ, Dept Intercollegiate Athlet, E Lansing, MI 48824 USA; [Russell, Doozie; Kaufman, David I.] Michigan State Univ, Dept Neurol & Ophthalmol, E Lansing, MI 48824 USA; [Pearson, Randolph L.] Michigan State Univ, Dept Family Med, E Lansing, MI 48824 USA; [Liszewski, Christine M.] Michigan State Univ, Dept Psychiat, E Lansing, MI 48824 USA; [Zhu, David C.] Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA; [Covassin, Tracey; Nogle, Sally] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; [Zhu, David C.; Doyle, Scarlett] Michigan State Univ, Cognit Imaging Res Ctr, E Lansing, MI 48824 USA		Zhu, DC (corresponding author), Michigan State Univ, Radiol Bldg,846 Serv Rd, E Lansing, MI 48824 USA.	zhuda@msu.edu			Michigan State University Radiology Pilot Scan Program	The authors thank suggestions from Drs. Erik Shapiro and Eric Eggenberger, concussed subject assessment assistance from Drs. Albert Aniskiewicz, Michael Shingles, Douglas Dietzel and Michael Andary, and support from Head Football Coach Mr. Mark Dantonio at Michigan State University. This work was supported by the Michigan State University Radiology Pilot Scan Program.	Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bey T, 2009, WEST J EMERG MED, V10, P6; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Harris JL, 2012, J CEREBR BLOOD F MET, V32, P2122, DOI 10.1038/jcbfm.2012.114; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Messe A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065470; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Murphy K, 2009, NEUROIMAGE, V44, P893, DOI 10.1016/j.neuroimage.2008.09.036; Raichle ME, 2006, ANNU REV NEUROSCI, V29, P449, DOI 10.1146/annurev.neuro.29.051605.112819; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Supekar K, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000100; Ward B., 2000, DECONVOLUTION ANAL F; Ward B. D., 2000, SIMULTANEOUS INFEREN; WOOLSEY TA, 2003, BRAIN ATLAS VISUAL G; Yeo BTT, 2011, J NEUROPHYSIOL, V106, P1125, DOI 10.1152/jn.00338.2011; Zhang HY, 2010, RADIOLOGY, V256, P598, DOI 10.1148/radiol.10091701; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748; Zhu DC, 2014, J NEUROIMAGING, V24, P176, DOI 10.1111/j.1552-6569.2012.00768.x; Zhu DC, 2013, J ALZHEIMERS DIS, V34, P969, DOI 10.3233/JAD-121879	53	87	87	1	32	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2015	32	5					327	341		10.1089/neu.2014.3413			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CC0SD	WOS:000350045700005	25116397				2022-02-06	
J	Diamond, ML; Ritter, AC; Failla, MD; Boles, JA; Conley, YP; Kochanek, PM; Wagner, AK				Diamond, Matthew L.; Ritter, Anne C.; Failla, Michelle D.; Boles, Jennifer A.; Conley, Yvette P.; Kochanek, Patrick M.; Wagner, Amy K.			IL-1 beta associations with posttraumatic epilepsy development: A genetics and biomarker cohort study	EPILEPSIA			English	Article						Posttraumatic epilepsy; Inflammation; Traumatic brain injury; Genetic variation; IL-1 beta	TRAUMATIC BRAIN-INJURY; BINDING CASSETTE TRANSPORTER; RECEPTOR ANTAGONIST; INTERLEUKIN-1-BETA GENE; RISK-FACTORS; RAT MODEL; SEIZURES; SECRETION; INFLAMMATION; POLYMORPHISMS	Objective: Posttraumatic epilepsy (PTE) is a significant complication following traumatic brain injury (TBI), yet the role of genetic variation in modulating PTE onset is unclear. We hypothesized that TBI-induced inflammation likely contributes to seizure development. We assessed whether genetic variation in the interleukin-1beta (IL-1 beta) gene, IL-1 beta levels in cerebrospinal fluid (CSF) and serum, and CSF/serum IL-1 beta ratios would predict PTE development post-TBI. Methods: We investigated PTE development in 256 Caucasian adults with moderate-to-severe TBI. IL-1 beta tagging and functional single nucleotide polymorphisms (SNPs) were genotyped. Genetic variance and PTE development were assessed. Serum and CSF IL-1 beta levels were collected from a subset of subjects (n = 59) during the first week postinjury and evaluated for their associations with IL-1 beta gene variants, and also PTE. Temporally matched CSF/serum IL-1 beta ratios were also generated to reflect the relative contribution of serum IL-1 beta to CSF IL-1 beta. Results: Multivariate analysis showed that higher CSF/serum IL-1 beta ratios were associated with increased risk for PTE over time (p = 0.008). Multivariate analysis for rs1143634 revealed an association between the CT genotype and increased PTE risk over time (p = 0.005). The CT genotype group also had lower serum IL-1 beta levels (p = 0.014) and higher IL-1 beta CSF/serum ratios (p = 0.093). Significance: This is the first report implicating IL-1 beta gene variability in PTE risk and linking (1) IL-1 beta gene variation with serum IL-1 beta levels observed after TBI and (2) IL-1 beta ratios with PTE risk. Given these findings, we propose that genetic and IL-1 beta ratio associations with PTE may be attributable to biologic variability with blood-brain barrier integrity during TBI recovery. These results provide a rationale for further studies (1) validating the impact of genetic variability on IL-1 beta production after TBI, (2) assessing genetically mediated signaling mechanisms that contribute to IL-1 beta CSF/serum associations with PTE, and (3) evaluating targeted IL-1 beta therapies that reduce PTE.	[Diamond, Matthew L.; Ritter, Anne C.; Failla, Michelle D.; Boles, Jennifer A.; Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Failla, Michelle D.; Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Conley, Yvette P.] Univ Pittsburgh, Dept Hlth Promot & Dev, Pittsburgh, PA 15213 USA; [Kochanek, Patrick M.; Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Kochanek, Patrick M/D-2371-2015; Failla, Michelle/AAI-3788-2021	Kochanek, Patrick M/0000-0002-2627-913X; Failla, Michelle/0000-0001-9734-3373; Conley, Yvette/0000-0002-1784-6067	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD048162-02, R01NR008424, 5P01NS030318];  [DODW81XWH-071-0701]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR008424] Funding Source: NIH RePORTER	This work was supported by DODW81XWH-071-0701, NIH R01 HD048162-02, NIH R01NR008424, and NIH 5P01NS030318. Thanks to Sandra Deslouche for support with genotyping, and the subjects and their families for their generous participation. Thanks to the UPMC Trauma Registry for providing some elements of data collection. Thanks to the University of Pittsburgh Cancer Institute for Luminex services.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Boles J, 2013, 2013 ANN S NAT NEUR; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; BROWN R, 1991, CELL IMMUNOL, V132, P84, DOI 10.1016/0008-8749(91)90008-Y; Camargo MC, 2006, CANCER EPIDEM BIOMAR, V15, P1674, DOI 10.1158/1055-9965.EPI-06-0189; Chen HM, 2006, HUM MOL GENET, V15, P519, DOI 10.1093/hmg/ddi469; Chen XP, 2009, J BIOL CHEM, V284, P27857, DOI 10.1074/jbc.M109.000950; Darrah SD, 2013, EPILEPSY RES, V103, P180, DOI 10.1016/j.eplepsyres.2012.07.006; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dominici R, 2002, EXP MOL PATHOL, V73, P139, DOI 10.1006/exmp.2002.2435; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Englander J, 2009, J NEUROTRAUM, V26, P1471, DOI 10.1089/neu.2008.0729; Ferrari D, 1996, J IMMUNOL, V156, P1531; Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x; Formisano R, 2007, BRAIN INJURY, V21, P499, DOI 10.1080/02699050701310994; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Gennarelli TA, 2006, INJURY, V37, P1083, DOI 10.1016/j.injury.2006.07.009; Hall SK, 2004, ARTHRITIS RHEUM-US, V50, P1976, DOI 10.1002/art.20310; Hamon Y, 1997, BLOOD, V90, P2911, DOI 10.1182/blood.V90.8.2911; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Holtman L, 2013, EPILEPSIA, V54, P589, DOI 10.1111/epi.12112; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kauffman MA, 2008, GENET MED, V10, P83, DOI 10.1097/GIM.0b013e318161317c; Kolakowsky-Hayner SA, 2013, BRAIN INJURY, V27, P578, DOI 10.3109/02699052.2013.765595; LEE SC, 1993, J IMMUNOL, V150, P2659; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Mellergard P, 2011, NEUROSURGERY, V68, P12, DOI 10.1227/NEU.0b013e3181ef2a40; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; National Institute of Neurological Disorders and Stroke, 2013, EP RES BENCHM PROGR; Omran A, 2012, EPILEPSIA, V53, P1215, DOI 10.1111/j.1528-1167.2012.03540.x; POCIOT F, 1992, EUR J CLIN INVEST, V22, P396, DOI 10.1111/j.1365-2362.1992.tb01480.x; Ravizza T, 2006, EPILEPSIA, V47, P1160, DOI 10.1111/j.1528-1167.2006.00590.x; Rijkers K, 2009, EXP NEUROL, V216, P258, DOI 10.1016/j.expneurol.2008.12.014; Santarsieri M, 2014, J NEUROTRAUM, V31, P699, DOI 10.1089/neu.2013.3177; Schmitz G, 1999, PATHOBIOLOGY, V67, P236, DOI 10.1159/000028100; Skinner RA, 2009, BRIT J PHARMACOL, V156, P1115, DOI 10.1111/j.1476-5381.2008.00129.x; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; VANDERZEE CEE, 1995, J NEUROSCI, V15, P5316; Vezzani A, 2000, P NATL ACAD SCI USA, V97, P11534, DOI 10.1073/pnas.190206797; Vezzani A, 2008, EPILEPSIA, V49, P24, DOI 10.1111/j.1528-1167.2008.01490.x; von Wedel-Parlow M, 2009, J NEUROCHEM, V111, P111, DOI 10.1111/j.1471-4159.2009.06305.x; Wagner AK, 2010, EPILEPSY RES, V90, P259, DOI 10.1016/j.eplepsyres.2010.06.001; Zhu G, 2006, EPILEPSY RES, V71, P107, DOI 10.1016/j.eplepsyres.2006.05.017; Zou HC, 2013, NEUROREHAB NEURAL RE, V27, P878, DOI 10.1177/1545968313491007	55	87	88	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	JUL	2014	55	7					1109	1119		10.1111/epi.12628			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AN4YI	WOS:000340595500025	24754437	Bronze, Green Accepted			2022-02-06	
J	Ahmadzadeh, H; Smith, DH; Shenoy, VB				Ahmadzadeh, Hossein; Smith, Douglas H.; Shenoy, Vivek B.			Viscoelasticity of Tau Proteins Leads to Strain Rate-Dependent Breaking of Microtubules during Axonal Stretch Injury: Predictions from a Mathematical Model	BIOPHYSICAL JOURNAL			English	Article							TRAUMATIC BRAIN-INJURY; IN-VIVO; SODIUM-CHANNELS; TENSION; BINDING; CELLS; TETRODOTOXIN; DEGENERATION; ELASTICITY; MECHANICS	The unique viscoelastic nature of axons is thought to underlie selective vulnerability to damage during traumatic brain injury. In particular, dynamic loading of axons has been shown to mechanically break microtubules at the time of injury. However, the mechanism of this rate-dependent response has remained elusive. Here, we present a microstructural model of the axonal cytoskeleton to quantitatively elucidate the interaction between microtubules and tau proteins under mechanical loading. Mirroring the axon ultrastructure, the nnicrotubules were arranged in staggered arrays, cross-linked by tau proteins. We found that the viscoelastic behavior specifically of tau proteins leads to mechanical breaking of microtubules at high strain rates, whereas extension of tau allows for reversible sliding of microtubules without any damage at small strain rates. Based on the stiffness and viscosity of tau proteins inferred from single-molecule force spectroscopy studies, we predict the critical strain rate for microtubule breaking to be in the range 22-44 s(-1), in excellent agreement with recent experiments on dynamic loading of micropatterned neuronal cultures. We also identified a characteristic length scale for load transfer that depends on microstructural properties and have derived a phase diagram in the parameter space spanned by loading rate and microtubule length that demarcates those regions where axons can be loaded and unloaded reversibly and those where axons are injured due to breaking of the microtubules.	[Ahmadzadeh, Hossein; Shenoy, Vivek B.] Univ Penn, Dept Mat Sci & Engn, Philadelphia, PA 19104 USA; [Smith, Douglas H.] Univ Penn, Penn Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Smith, Douglas H.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA		Shenoy, VB (corresponding author), Univ Penn, Dept Mat Sci & Engn, 3231 Walnut St, Philadelphia, PA 19104 USA.	vshenoy@seas.upenn.edu	Shenoy, Vivek/ABD-5075-2021		National Science FoundationNational Science Foundation (NSF) [NSF-CMMI-1312392]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS R01-038104, NS P01-056202]; Department of DefenseUnited States Department of Defense [PT110785]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038104, P01NS056202] Funding Source: NIH RePORTER	This study was supported by National Science Foundation grant No. NSF-CMMI-1312392 (to V.B.S.), by National Institutes of Health grant Nos. NS R01-038104 and NS P01-056202, and by Department of Defense grant No. PT110785 (to D.H.S.).	Ahmadzadeh H, 2013, J BIOMECH, V46, P2497, DOI 10.1016/j.jbiomech.2013.07.008; Baas PW, 2013, BRAIN, V136, P2937, DOI 10.1093/brain/awt153; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; Burgoyne R. D, 1991, NEURONAL CYTOSKELETO; Cloots RJH, 2013, BIOMECH MODEL MECHAN, V12, P137, DOI 10.1007/s10237-012-0387-6; Conde C, 2009, NAT REV NEUROSCI, V10, P319, DOI 10.1038/nrn2631; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; Fletcher DA, 2010, NATURE, V463, P485, DOI 10.1038/nature08908; Guo HL, 2006, BIOPHYS J, V90, P2093, DOI 10.1529/biophysj.105.071209; Hinrichs MH, 2012, J BIOL CHEM, V287, P38559, DOI 10.1074/jbc.M112.369785; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; Hui O., 2010, MICR UGIM 2010 18 BI, P1; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kawakami M, 2006, BIOPHYS J, V91, pL16, DOI 10.1529/biophysj.106.085019; Knoferle J, 2010, P NATL ACAD SCI USA, V107, P6064, DOI 10.1073/pnas.0909794107; Makrides V, 2004, P NATL ACAD SCI USA, V101, P6746, DOI 10.1073/pnas.0400992101; Peter SJ, 2012, BIOPHYS J, V102, P749, DOI 10.1016/j.bpj.2011.11.4024; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; Price, 2005, BASIC NEUROCHEMISTRY; Rajagopalan J, 2010, BIOPHYS J, V99, P3208, DOI 10.1016/j.bpj.2010.09.029; Rosenberg KJ, 2008, P NATL ACAD SCI USA, V105, P7445, DOI 10.1073/pnas.0802036105; Saif T., 2010, MRS P; Schaap IAT, 2007, J STRUCT BIOL, V158, P282, DOI 10.1016/j.jsb.2006.11.010; Singh A, 2009, J NEUROTRAUM, V26, P627, DOI 10.1089/neu.2008.0621; Skotak M, 2012, J NEUROSCI METH, V205, P159, DOI 10.1016/j.jneumeth.2012.01.001; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; Suresh S, 2007, ACTA BIOMATER, V3, P413, DOI 10.1016/j.actbio.2007.04.002; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Wang Y, 2011, EPL-EUROPHYS LETT, V96, DOI 10.1209/0295-5075/96/18003; Wegmann S, 2011, J BIOL CHEM, V286, P20512, DOI 10.1074/jbc.M111.237875; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; YU WQ, 1994, J NEUROSCI, V14, P2818	38	87	88	0	26	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0006-3495	1542-0086		BIOPHYS J	Biophys. J.	MAR 4	2014	106	5					1123	1133		10.1016/j.bpj.2014.01.024			11	Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics	AC4OT	WOS:000332501300015	24606936	Green Published, Bronze			2022-02-06	
J	Zheng, WM; Zhuge, QC; Zhong, M; Chen, GR; Shao, B; Wang, H; Mao, XO; Xie, L; Jin, KL				Zheng, WeiMing; ZhuGe, Qichuan; Zhong, Ming; Chen, Gourong; Shao, Bei; Wang, Hong; Mao, XiaoOu; Xie, Lin; Jin, Kunlin			Neurogenesis in Adult Human Brain after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						brain trauma; human; injury; neurogenesis; stem cells	NEURAL STEM-CELLS; ENDOTHELIAL GROWTH-FACTOR; HIPPOCAMPAL CA3 REGION; ENHANCED NEUROGENESIS; SUBVENTRICULAR ZONE; DENTATE GYRUS; NEURONAL DIFFERENTIATION; DIRECTED MIGRATION; PROLIFERATION; DOUBLECORTIN	While much work has been conducted regarding the neurogenesis response to traumatic brain injury (TBI) in rodents, it remains largely unknown whether neurogenesis in adult human brain also responds to TBI in a similar manner. Here, we performed immunocytochemistry on 11 brain specimens from patients with traumatic brain injury, who underwent surgical intervention. We found that expression of neural stem/progenitor cell (NSC) protein markers, including DCX, TUC4, PSA-NCAM, SOX2 and NeuroD, was increased in the perilesional cortex of human brain after TBI compared to that of normal brain. Confocal images showed that these NSC proteins were expressed in one single cell. We also found that proliferative markers were expressed in NSC protein-positive cells after TBI, and the number of proliferative NSCs was significantly increased after TBI. Our data suggest that TBI may also induce neurogenesis in human brain.	[Zheng, WeiMing; ZhuGe, Qichuan; Zhong, Ming; Jin, Kunlin] First Affiliated Hosp, Wenzhou Med Coll, Dept Neurosurg, Wenzhou, Peoples R China; [Chen, Gourong] First Affiliated Hosp, Wenzhou Med Coll, Dept Pathol, Wenzhou, Peoples R China; [Shao, Bei; Wang, Hong] First Affiliated Hosp, Wenzhou Med Coll, Dept Neurol, Wenzhou, Peoples R China; [Mao, XiaoOu; Xie, Lin; Jin, Kunlin] Buck Inst Age Res, Novato, CA 94945 USA		Jin, KL (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	kjin@buckinstitute.org			Wenzhou Medical College; National Institute of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG21980, NS62414]; Foundation of Zhejiang Provincial Top Key Discipline of Surgery; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RL1NS062414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021980] Funding Source: NIH RePORTER	This work was partially supported by a Wenzhou Medical College 5010 grant, a National Institute of Health (NIH) grant (AG21980 and NS62414, to K. J.), and funds from the Foundation of Zhejiang Provincial Top Key Discipline of Surgery. Some of the human tissue were obtained from the NICHD Brain and Tissue Bank for Developmental Disorders at the University of Maryland (Baltimore, MD). The role of the NICHD Brain and Tissue Bank is to distribute tissue, and, therefore, it does not endorse the studies performed or the interpretation of results.	Anderson VA, 2000, BRAIN INJURY, V14, P679; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chiaretti A, 2008, J TRAUMA, V65, P80, DOI 10.1097/TA.0b013e31805f7036; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Crespel A, 2005, NEUROBIOL DIS, V19, P436, DOI 10.1016/j.nbd.2005.01.020; Curtis MA, 2003, P NATL ACAD SCI USA, V100, P9023, DOI 10.1073/pnas.1532244100; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Doetsch F, 1997, J NEUROSCI, V17, P5046; Emery DL, 2005, J NEUROTRAUM, V22, P978, DOI 10.1089/neu.2005.22.978; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Ewing-Cobbs L, 2003, DEV NEUROPSYCHOL, V24, P669, DOI 10.1207/S15326942DN242&3_08; Fanarraga ML, 1999, EUR J NEUROSCI, V11, P517; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; GERDES J, 1984, J IMMUNOL, V133, P1710; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Itoh T, 2009, NEUROL RES, V31, P90, DOI 10.1179/174313208X332995; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Jin KL, 2004, P NATL ACAD SCI USA, V101, P13363, DOI 10.1073/pnas.0403678101; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Jin KL, 2004, P NATL ACAD SCI USA, V101, P343, DOI 10.1073/pnas.2634794100; Jin KL, 2010, P NATL ACAD SCI USA, V107, P7993, DOI 10.1073/pnas.1000154107; Jin KL, 2006, P NATL ACAD SCI USA, V103, P13198, DOI 10.1073/pnas.0603512103; Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435; Komitova M, 2004, NEUROSCI LETT, V369, P24, DOI 10.1016/j.neulet.2004.07.035; Lee C, 2010, J NEUROTRAUM, V27, P541, DOI 10.1089/neu.2009.0905; Lee JE, 1997, DEV NEUROSCI-BASEL, V19, P27, DOI 10.1159/000111182; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Masuda T, 2007, NEUROSCI LETT, V425, P114, DOI 10.1016/j.neulet.2007.08.039; MCDERMOTT KW, 1991, J ANAT, V178, P45; MINTURN JE, 1995, J NEUROSCI, V15, P6757; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; Sgubin D, 2007, J NEUROSCI RES, V85, P1647, DOI 10.1002/jnr.21303; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun D, 2010, J NEUROTRAUM, V27, P923, DOI 10.1089/neu.2009.1209; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; Tatsumi K, 2005, NEUROCHEM INT, V46, P381, DOI 10.1016/j.neuint.2004.12.007; Teramoto T, 2003, J CLIN INVEST, V111, P1125, DOI 10.1172/JCI200317170; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; Zhang CL, 2008, NATURE, V451, P1004, DOI 10.1038/nature06562	54	87	93	1	22	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2013	30	22					1872	1880		10.1089/neu.2010.1579			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	243PH	WOS:000326328400005	21275797	Green Published			2022-02-06	
J	Shultz, SR; Cardamone, L; Liu, YR; Hogan, RE; Maccotta, L; Wright, DK; Zheng, P; Koe, A; Gregoire, MC; Williams, JP; Hicks, RJ; Jones, NC; Myers, DE; O'Brien, TJ; Bouilleret, V				Shultz, Sandy R.; Cardamone, Lisa; Liu, Ying R.; Hogan, R. Edward; Maccotta, Luigi; Wright, David K.; Zheng, Ping; Koe, Amelia; Gregoire, Marie-Claude; Williams, John P.; Hicks, Rodney J.; Jones, Nigel C.; Myers, Damian E.; O'Brien, Terence J.; Bouilleret, Viviane			Can structural or functional changes following traumatic brain injury in the rat predict epileptic outcome?	EPILEPSIA			English	Article						Posttraumatic epilepsy; Lateral fluid percussion injury; MRI; PET; Epileptogenesis	LATE POSTTRAUMATIC SEIZURES; MODEL; MRI; ANXIETY; HIPPOCAMPUS; BEHAVIOR; RISK	Purpose: Posttraumatic epilepsy (PTE) occurs in a proportion of traumatic brain injury (TBI) cases, significantly compounding the disability, and risk of injury and death for sufferers. To date, predictive biomarkers for PTE have not been identified. This study used the lateral fluid percussion injury (LFPI) rat model of TBI to investigate whether structural, functional, and behavioral changes post-TBI relate to the later development of PTE. Methods: Adult male Wistar rats underwent LFPI or sham injury. Serial magnetic resonance (MR) and positron emission tomography (PET) imaging, and behavioral analyses were performed over 6 months postinjury. Rats were then implanted with recording electrodes and monitored for two consecutive weeks using video-electroencephalography (EEG) to assess for PTE. Of the LFPI rats, 52% (n = 12) displayed spontaneous recurring seizures and/or epileptic discharges on the video-EEG recordings. Key Findings: MRI volumetric and signal analysis of changes in cortex, hippocampus, thalamus, and amygdala, F-18-fluorodeoxyglucose (FDG)-PET analysis of metabolic function, and behavioral analysis of cognitive and emotional changes, at 1 week, and 1, 3, and 6 months post-LFPI, all failed to identify significant differences on univariate analysis between the epileptic and nonepileptic groups. However, hippocampal surface shape analysis using large-deformation high-dimensional mapping identified significant changes in the ipsilateral hippocampus at 1 week postinjury relative to baseline that differed between rats that would go onto become epileptic versus those who did not. Furthermore, a multivariate logistic regression model that incorporated the 1 week, and 1 and 3 month F-18-FDG PET parameters from the ipsilateral hippocampus was able to correctly predict the epileptic outcome in all of the LFPI cases. As such, these subtle changes in the ipsilateral hippocampus at acute phases after LFPI may be related to PTE and require further examination. Significance: These findings suggest that PTE may be independent of major structural, functional, and behavioral changes induced by TBI, and suggest that more subtle abnormalities are likely involved. However, there are limitations associated with studying acquired epilepsies in animal models that must be considered when interpreting these results, in particular the failure to detect differences between the groups may be related to the limitations of properly identifying/separating the epileptic and nonepileptic animals into the correct group.	[Shultz, Sandy R.; Cardamone, Lisa; Liu, Ying R.; Zheng, Ping; Koe, Amelia; Jones, Nigel C.; Myers, Damian E.; O'Brien, Terence J.; Bouilleret, Viviane] Univ Melbourne, Dept Med RMH, Parkville, Vic 3050, Australia; [Hogan, R. Edward; Maccotta, Luigi] Washington Univ, Dept Neurol, St Louis, MO USA; [Wright, David K.; Williams, John P.] Florey Inst Neurosci & Mental Hlth, Small Anim MRI Facil, Parkville, Vic, Australia; [Gregoire, Marie-Claude] Australian Nucl Sci & Technol Org, Kirrawee, NSW, Australia; [Hicks, Rodney J.] Peter MacCallum Canc Ctr, Ctr Mol Imaging, Melbourne, Vic, Australia; [Bouilleret, Viviane] CHU Bicetre, APHP, Dept Neurophysiol & Epilepsy, Paris, France		Shultz, SR (corresponding author), Univ Melbourne, Dept Med RMH, 4th Floor Clin Sci Bldg, Parkville, Vic 3050, Australia.	sshultz@unimelb.edu.au	Bouilleret, viviane/AAQ-5878-2021; O'Brien, Terence/AAU-5525-2021; Myers, Damian E/L-5302-2013; O'Brien, Terence/L-8102-2013	Maccotta, Luigi/0000-0003-3702-0331; Myers, Damian/0000-0002-7569-9907; Hogan, Robert/0000-0003-2272-5005; Jones, Nigel/0000-0002-1080-8439; O'Brien, Terence/0000-0002-7198-8621; Shultz, Sandy/0000-0002-2525-8775; Wright, David/0000-0002-7535-8651; Hicks, Rodney/0000-0002-0758-0824	Victorian Government Transport Accident Commission [DP0023]; NHMRC of AustraliaNational Health and Medical Research Council of Australia; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000448, KL2TR000450] Funding Source: NIH RePORTER	We wish to acknowledge the staff of the Howard Florey Institute Small Animal MRI Facility, and the Peter MacCallum Cancer Centre. Funding for this project was provided by the Victorian Government Transport Accident Commission (DP0023). N.J. and T.O. acknowledge the financial support of the NHMRC of Australia.	Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Beghi E, 2003, EPILEPSIA, V44, P21, DOI 10.1046/j.1528-1157.44.s10.1.x; Beyenburg S, 2005, EPILEPSY BEHAV, V7, P161, DOI 10.1016/j.yebeh.2005.05.014; Bouilleret V, 2011, J MAGN RESON IMAGING, V34, P774, DOI 10.1002/jmri.22669; Bouilleret V, 2009, NEUROIMAGE, V45, P267, DOI 10.1016/j.neuroimage.2008.12.019; Carobrez AP, 2005, NEUROSCI BIOBEHAV R, V29, P1193, DOI 10.1016/j.neubiorev.2005.04.017; Casteels C, 2006, J NUCL MED, V47, P1858; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Csernansky JG, 1998, P NATL ACAD SCI USA, V95, P11406, DOI 10.1073/pnas.95.19.11406; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 2010, EPILEPSY CURR, V10, P61, DOI 10.1111/j.1535-7511.2010.01358.x; D'Ambrosio RD, 2005, BRAIN, V132, P2805; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Dichter MA, 2009, EPILEPSIA, V50, P41, DOI 10.1111/j.1528-1167.2008.02009.x; Dudek FE, 2010, EPILEPSY CURR, V10, P91, DOI 10.1111/j.1535-7511.2010.01368.x; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Gardner R, 2005, CLIN ANAT, V18, P481, DOI 10.1002/ca.20183; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Hogan RE, 2008, J NEUROL NEUROSUR PS, V79, P636, DOI 10.1136/jnnp.2007.123406; Hogan RE, 2009, J MAGN RESON IMAGING, V29, P1027, DOI 10.1002/jmri.21766; Hogan RE, 2004, BRAIN, V127, P1731, DOI 10.1093/brain/awh197; Jones NC, 2008, EXP NEUROL, V209, P254, DOI 10.1016/j.expneurol.2007.09.026; Jones NC, 2009, BEHAV BRAIN RES, V203, P81, DOI 10.1016/j.bbr.2009.04.023; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Jupp B, 2012, EPILEPSIA, V53, P1233, DOI 10.1111/j.1528-1167.2012.03525.x; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kharatishvili I, 2010, CURR OPIN NEUROL, V23, P183, DOI 10.1097/WCO.0b013e32833749e4; Li HF, 2011, NEUROSCI LETT, V497, P172, DOI 10.1016/j.neulet.2011.02.042; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mishra AM, 2011, NEUROSCI LETT, V497, P194, DOI 10.1016/j.neulet.2011.01.076; Onyszchuk G, 2009, NEUROSCI LETT, V452, P204, DOI 10.1016/j.neulet.2009.01.049; Pitkanen A, 2011, NEUROSCI LETT, V497, P163, DOI 10.1016/j.neulet.2011.02.033; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; Posener JA, 2003, AM J PSYCHIAT, V160, P83, DOI 10.1176/appi.ajp.160.1.83; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Saucier DM, 2008, ANIM COGN, V11, P129, DOI 10.1007/s10071-007-0096-1; Shultz SR, 2009, BEHAV BRAIN RES, V200, P33, DOI 10.1016/j.bbr.2008.12.023; Snyder A. Z., 1996, QUANTIFICATION BRAIN, P131, DOI DOI 10.1016/B978-012389760-2/50028-1; Stroud LM, 2005, BRAIN RES, V1033, P151, DOI 10.1016/j.brainres.2004.11.022; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; van Raay L, 2009, J NEUROSCI METH, V179, P184, DOI 10.1016/j.jneumeth.2009.01.024; WILLNER P, 1987, PSYCHOPHARMACOLOGY, V93, P358	53	87	89	0	27	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	JUL	2013	54	7					1240	1250		10.1111/epi.12223			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	173VP	WOS:000321110100013	23718645	Bronze, Green Accepted			2022-02-06	
J	Bowers, CA; Riva-Cambrin, J; Hertzler, DA; Walker, ML				Bowers, Christian A.; Riva-Cambrin, Jay; Hertzler, Dean A., II; Walker, Marion L.			Risk factors and rates of bone flap resorption in pediatric patients after decompressive craniectomy for traumatic brain injury Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						decompressive craniectomy; traumatic brain injury; autologous cranioplasty; bone flap resorption	DURA-MATER; CHILDREN; CRANIOPLASTY; OUTCOMES	Object. Decompressive craniectomy with subsequent autologous cranioplasty, or the replacement of the native bone flap, is often used for pediatric patients with traumatic brain injury (TBI) who have a mass lesion and intractable intracranial hypertension. Bone flap resorption is common after bone flap replacement, necessitating additional surgery. The authors reviewed their large database of pediatric patients with TBI who underwent decompressive craniectomy followed by bone flap replacement to determine the rate of bone flap resorption and identify associated risk factors. Methods. A retrospective cohort chart review was performed to identify long-term survivors who underwent decompressive craniectomy for severe TBI with bone flap replacement from January 1, 1996, to December 31, 2011. The risk factors investigated in a univariate statistical analysis were age, sex, underlying parenchymal contusion, Glasgow Coma Scale score on arrival, comminuted skull fracture, posttraumatic hydrocephalus, bone flap wound infection, and freezer time (the amount of time the bone flap was stored in the freezer before replacement). A multivariate logistic regression model was then used to determine which of these were independent risk factors for bone flap resorption. Results. Bone flap replacement was performed at an average of 2.1 months after decompressive craniectomy. Of the 54 patients identified (35 boys, 19 girls; mean age 6.2 years), 27 (50.0%) experienced bone flap resorption after an average of 4.8 months. Underlying parenchymal contusion, comminuted skull fracture, age <= 2.5 years, and posttraumatic hydrocephalus were significant, or nearly significant, on univariate analysis. Multivariate analysis identified underlying contusion (p = 0.004, OR 34.4, 95% CI 3.0-392.7), comminuted skull fractures (p = 0.046, OR 8.5, 95% CI 1.0-69.6), posttraumatic hydrocephalus (p = 0.005, OR 35.9, 95% CI 2.9-436.6), and age <= 2.5 years old (p = 0.01, OR 23.1, 95% CI 2.1-257.7) as independent risk factors for bone flap resorption. Conclusions. After decompressive craniectomy for pediatric TBI, half of the patients (50%) who underwent bone flap replacement experienced resorption. Multivariate analysis indicated young age (<= 2.5 years), hydrocephalus, underlying contusion as opposed to a hemispheric acute subdural hematoma, and a comminuted skull fracture were all independent risk factors for bone flap resorption. Freezer time was not found to be associated with bone flap resorption. (http://thejns.org/doi/abs/10.3171/2013.1.PEDS12483)	[Bowers, Christian A.; Riva-Cambrin, Jay; Hertzler, Dean A., II; Walker, Marion L.] Univ Utah, Primary Childrens Med Ctr, Dept Neurosurg, Salt Lake City, UT 84113 USA		Walker, ML (corresponding author), Univ Utah, Div Pediat Neurosurg, Dept Neurosurg, Primary Childrens Med Ctr, 100 North Med Dr, Salt Lake City, UT 84113 USA.	marion.walker@hsc.utah.edu					Bennett TD, 2012, ARCH PEDIAT ADOL MED, V166, P641, DOI 10.1001/archpediatrics.2012.322; Bhaskar IP, 2011, ANZ J SURG, V81, P137, DOI 10.1111/j.1445-2197.2010.05584.x; Fong KD, 2003, PLAST RECONSTR SURG, V112, P1312, DOI 10.1097/01.PRS.0000079860.14734.D6; Gagan Jeffrey R., 2007, Birth Defects Research, V81, P297, DOI 10.1002/bdrc.20104; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; GRUBER R, 1988, Z KINDERCHIR, V43, P375; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Suarez EP, 2011, J TRAUMA, V71, P133, DOI 10.1097/TA.0b013e318211071f; Piedra MP, 2012, J NEUROSURG-PEDIATR, V10, P268, DOI 10.3171/2012.6.PEDS1268; POCHON JP, 1991, EUR J PEDIATR SURG, V1, P199, DOI 10.1055/s-2008-1042487; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965	13	87	94	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707			J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	MAY	2013	11	5					526	532		10.3171/2013.1.PEDS12483			7	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	131LR	WOS:000317995700012	23473303				2022-02-06	
J	Galanaud, D; Perlbarg, V; Gupta, R; Stevens, RD; Sanchez, P; Tollard, E; de Champfleur, NM; Dinkel, J; Faivre, S; Soto-Ares, G; Veber, B; Cottenceau, V; Masson, F; Tourdias, T; Andre, E; Audibert, G; Schmitt, E; Ibarrola, D; Dailler, F; Vanhaudenhuyse, A; Tshibanda, L; Payen, JF; Le Bas, JF; Krainik, A; Bruder, N; Girard, N; Laureys, S; Benali, H; Puybasset, L				Galanaud, Damien; Perlbarg, Vincent; Gupta, Rajiv; Stevens, Robert D.; Sanchez, Paola; Tollard, Eleonore; de Champfleur, Nicolas Menjot; Dinkel, Julien; Faivre, Sebastien; Soto-Ares, Gustavo; Veber, Benoit; Cottenceau, Vincent; Masson, Francoise; Tourdias, Thomas; Andre, Edith; Audibert, Gerard; Schmitt, Emmanuelle; Ibarrola, Danielle; Dailler, Frederic; Vanhaudenhuyse, Audrey; Tshibanda, Luaba; Payen, Jean-Francois; Le Bas, Jean-Francois; Krainik, Alexandre; Bruder, Nicolas; Girard, Nadine; Laureys, Steven; Benali, Habib; Puybasset, Louis		Neuro Imaging Coma Emergence Recov	Assessment of White Matter Injury and Outcome in Severe Brain Trauma A Prospective Multicenter Cohort	ANESTHESIOLOGY			English	Article							DIFFUSE AXONAL INJURY; COMPUTERIZED-TOMOGRAPHY; PROGNOSTIC VALUE; HEAD-INJURY; MRI; CLASSIFICATION; PREDICTION; IMPACT; IMAGE; STATE	Background: Existing methods to predict recovery after severe traumatic brain injury lack accuracy. The aim of this study is to determine the prognostic value of quantitative diffusion tensor imaging (DTI). Methods: In a multicenter study, the authors prospectively enrolled 105 patients who remained comatose at least 7 days after traumatic brain injury. Patients underwent brain magnetic resonance imaging, including DTI in 20 preselected white matter tracts. Patients were evaluated at 1 yr with a modified Glasgow Outcome Scale. A composite DTI score was constructed for outcome prognostication on this training database and then validated on an independent database (n = 38). DTI score was compared with the International Mission for Prognosis and Analysis of Clinical Trials Score. Results: Using the DTI score for prediction of unfavorable outcome on the training database, the area under the receiver operating characteristic curve was 0.84 (95% CI: 0.75-0.91). The DTI score had a sensitivity of 64% and a specificity of 95% for the prediction of unfavorable outcome. On the validation-independent database, the area under the receiver operating characteristic curve was 0.80 (95% CI: 0.54-0.94). On the training database, reclassification methods showed significant improvement of classification accuracy (P < 0.05) compared with the International Mission for Prognosis and Analysis of Clinical Trials score. Similar results were observed on the validation database. Conclusions: White matter assessment with quantitative DTI increases the accuracy of long-term outcome prediction compared with the available clinical/radiographic prognostic score.	[Galanaud, Damien] Hop La Pitie Salpetriere, Dept Neurol, F-75013 Paris, France; [Perlbarg, Vincent; Dinkel, Julien] Univ Paris 06, UMRS, INSERM, Paris, France; [Gupta, Rajiv; Benali, Habib] Massachusetts Gen Hosp, Dept Neuroradiol, Boston, MA 02114 USA; [Stevens, Robert D.] Johns Hopkins Univ, Sch Med, Div Neurosci Crit Care, Baltimore, MD USA; [Sanchez, Paola] Hop La Pitie Salpetriere, AP HP, Neurosurg Intens Care Unit, Paris, France; [Tollard, Eleonore] CHU, Dept Neuroradiol, Rouen, France; [de Champfleur, Nicolas Menjot] Guy Chauliac Hospi, Dept Neuroradiol, Montpellier, France; [Faivre, Sebastien] Roger Salengro Hosp, Dept Anesthesia, Lille, France; [Faivre, Sebastien] Roger Salengro Hosp, Surg Intens Care Unit, Lille, France; [Soto-Ares, Gustavo] Roger Salengro Hosp, Dept Neuroradiol, Lille, France; [Veber, Benoit] CHU, Surg Intens Care Unit, Rouen, France; [Tourdias, Thomas] CHU, Dept Neuroradiol, Bordeaux, France; [Masson, Francoise] CHU, Dept Anesthesia, Bordeaux, France; [Masson, Francoise] CHU, Surg Intens Care Unit, Bordeaux, France; [Andre, Edith] Guy Chauliac Hosp, Dept Anesthesia, Montpellier, France; [Andre, Edith] Guy Chauliac Hosp, Intens Care Unit, Montpellier, France; [Audibert, Gerard] CHU, Dept Anesthesia, Nancy, France; [Audibert, Gerard] CHU, Surg Intens Care Unit, Nancy, France; [Schmitt, Emmanuelle] CHU, Dept Neuroradiol, Nancy, France; [Ibarrola, Danielle] Pierre Wertheimer Neurol & Neurosurg Hosp, CERMEP, Bron, France; [Dailler, Frederic] Pierre Wertheimer Neurol & Neurosurg Hosp, Surg Intens Care Unit, Lyon, France; [Vanhaudenhuyse, Audrey] Univ Liege, Cyclotron Res Ctr, Liege, Belgium; [Tshibanda, Luaba] Univ Liege, Dept Neuroradiol, Liege, Belgium; [Payen, Jean-Francois] Michallon Hosp, Dept Anesthesia, La Tronche, France; [Payen, Jean-Francois] Michallon Hosp, Surg Intens Care Unit, La Tronche, France; [Krainik, Alexandre] Michallon Hosp, Dept Neuroradiol, La Tronche, France; [Bruder, Nicolas] La Timone Hosp, Dept Anesthesia, Marseille, France; [Bruder, Nicolas] La Timone Hosp, Intens Care Unit, Marseille, France; [Girard, Nadine] La Timone Hosp, Dept Neuroradiol, Marseille, France; [Puybasset, Louis] Hop La Pitie Salpetriere, AP HP, Neurosurg Intens Care Unit, Paris, France		Galanaud, D (corresponding author), Hop La Pitie Salpetriere, Dept Neurol, 47 Blvd Hop, F-75013 Paris, France.	galanaud@gmail.com	Sappey-Marinier, Dominique/L-2925-2014; Vanhaudenhuyse, Audrey/AAP-2455-2020; Girard, Nadine/B-7109-2017; krainik, alexandre/I-2431-2015; Laureys, Steven/AAN-2097-2021; Payen, Jean-Francois/L-6667-2014; KRAINIK, Alexandre/L-5874-2014; Laureys, Steven/A-3349-2011; , Girard/E-8537-2013; Tourdias, Thomas/K-1209-2019	Sappey-Marinier, Dominique/0000-0003-4104-1514; Laureys, Steven/0000-0002-3096-3807; , Girard/0000-0001-8639-9275; Tourdias, Thomas/0000-0002-7151-6325; DOUSSET, VINCENT/0000-0003-0427-3236	French ministry of health, Paris, France [P051061]; "Agence Nationale de la Recherche," Paris FranceFrench National Research Agency (ANR) [ANR-10-IAIHU-06]	This work was funded by a grant from the French ministry of health (ProjetHospitalier de Recherche Clinique registration #P051061 (2005)), Paris, France, and from the "Agence Nationale de la Recherche," Paris France, for the program " investissements d'avenir" under agreement noANR-10-IAIHU-06 for the Paris Institute of Translational Neurosciences-IHU-A-ICM. Other support was provided from institutional and/or departmental sources.	Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Grubb A, 1996, LANCET, V348, P35, DOI 10.1016/S0140-6736(96)02030-2; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; Hou DJ, 2007, J NEUROTRAUM, V24, P1558, DOI 10.1089/neu.2007.0339; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Ichord RN, 2007, J NEUROTRAUM, V24, P106, DOI 10.1089/neu.2006.0087; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mori S, 2005, MRI ATLAS HUMAN WHIT; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Pagani E, 2010, J MAGN RESON IMAGING, V31, P1458, DOI 10.1002/jmri.22186; Park JH, 2009, J KOREAN NEUROSURG S, V46, P365, DOI 10.3340/jkns.2009.46.4.365; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Skandsen T, 2011, J NEUROTRAUM, V28, P691, DOI 10.1089/neu.2010.1590; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; Yanagawa Y, 2009, J TRAUMA, V66, P162, DOI 10.1097/TA.0b013e3181469857	32	87	88	1	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	DEC	2012	117	6					1300	1310		10.1097/ALN.0b013e3182755558			11	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	041PY	WOS:000311414900020	23135261	Bronze			2022-02-06	
J	Ziebell, JM; Taylor, SE; Cao, TX; Harrison, JL; Lifshitz, J				Ziebell, Jenna M.; Taylor, Samuel E.; Cao, Tuoxin; Harrison, Jordan L.; Lifshitz, Jonathan			Rod microglia: elongation, alignment, and coupling to form trains across the somatosensory cortex after experimental diffuse brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Brain injury; Microglial rod cells; Rod microglia; Inflammation	RADIAL GLIAL-CELLS; INFLAMMATORY RESPONSE; IFN-GAMMA; ACTIVATION; EXPRESSION; MOUSE; NEUROPROTECTION; MORPHOLOGY; DYNAMICS; REVEALS	Background: Since their discovery, the morphology of microglia has been interpreted to mirror their function, with ramified microglia constantly surveying the micro-environment and rapidly activating when changes occur. In 1899, Franz Nissl discovered what we now recognize as a distinct microglial activation state, microglial rod cells (Stabchenzellen), which he observed adjacent to neurons. These rod-shaped microglia are typically found in human autopsy cases of paralysis of the insane, a disease of the pre-penicillin era, and best known today from HIV-1-infected brains. Microglial rod cells have been implicated in cortical 'synaptic stripping' but their exact role has remained unclear. This is due at least in part to a scarcity of experimental models. Now we have noted these rod microglia after experimental diffuse brain injury in brain regions that have an associated sensory sensitivity. Here, we describe the time course, location, and surrounding architecture associated with rod microglia following experimental diffuse traumatic brain injury (TBI). Methods: Rats were subjected to a moderate midline fluid percussion injury (mFPI), which resulted in transient suppression of their righting reflex (6 to 10 min). Multiple immunohistochemistry protocols targeting microglia with Iba1 and other known microglia markers were undertaken to identify the morphological activation of microglia. Additionally, labeling with Iba1 and cell markers for neurons and astrocytes identified the architecture that surrounds these rod cells. Results: We identified an abundance of Iba1-positive microglia with rod morphology in the primary sensory barrel fields (S1BF). Although present for at least 4 weeks post mFPI, they developed over the first week, peaking at 7 days post-injury. In the absence of contusion, Iba1-positive microglia appear to elongate with their processes extending from the apical and basal ends. These cells then abut one another and lay adjacent to cytoarchitecture of dendrites and axons, with no alignment with astrocytes and oligodendrocytes. Iba1-positive rod microglial cells differentially express other known markers for reactive microglia including OX-6 and CD68. Conclusion: Diffuse traumatic brain injury induces a distinct rod microglia morphology, unique phenotype, and novel association between cells; these observations entice further investigation for impact on neurological outcome.	[Ziebell, Jenna M.; Taylor, Samuel E.; Harrison, Jordan L.; Lifshitz, Jonathan] Univ Arizona, Coll Med Phoenix, Dept Child Hlth, Phoenix, AZ USA; [Ziebell, Jenna M.; Taylor, Samuel E.; Harrison, Jordan L.; Lifshitz, Jonathan] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ USA; [Ziebell, Jenna M.; Cao, Tuoxin; Harrison, Jordan L.; Lifshitz, Jonathan] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Dept Phys Med & Rehabil,Dept Anat & Neurobiol, Lexington, KY USA; [Harrison, Jordan L.] Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; [Harrison, Jordan L.; Lifshitz, Jonathan] Arizona State Univ, Neurosci Program, Tempe, AZ USA; [Lifshitz, Jonathan] Phoenix VA Healthcare Syst, Phoenix, AZ USA		Lifshitz, J (corresponding author), Univ Arizona, Coll Med Phoenix, Dept Child Hlth, Phoenix, AZ USA.	jlifshitz@email.arizona.edu	Ziebell, Jenna/Y-4496-2019	Ziebell, Jenna/0000-0003-2497-4347	NIH NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS065052]; Mission Support Fund at Phoenix Children's Hospital; University of Arizona; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065052] Funding Source: NIH RePORTER	The authors wish to thank to Amanda M. Lisembee for preparing the diffuse brain-injured rats. Supported by NIH NINDS R01 NS065052 and the Mission Support Fund at Phoenix Children's Hospital and University of Arizona.	ALVAREZBUYLLA A, 1987, J COMP NEUROL, V264, P159, DOI 10.1002/cne.902640203; Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006; Butovsky O, 2005, MOL CELL NEUROSCI, V29, P381, DOI 10.1016/j.mcn.2005.03.005; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Das M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-148; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Gotz M, 2005, NEURON, V46, P369, DOI 10.1016/j.neuron.2005.04.012; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; GRAEBER MB, 1994, NEUROPATH APPL NEURO, V20, P178; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Gregg C, 2003, J NEUROSCI, V23, P11587; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Hartfuss E, 2003, DEVELOPMENT, V130, P4597, DOI 10.1242/dev.00654; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; Jones EG, 1991, HIST NEUROSCIENCE; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lambertsen KL, 2011, J NEUROPATH EXP NEUR, V70, P481, DOI 10.1097/NEN.0b013e31821db3aa; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lifshitz J, 2008, ANIMAL MODELS ACUTE; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lifshitz J, 2012, BRAIN STRUCT FUNCT, V217, P49, DOI 10.1007/s00429-011-0323-z; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Malatesta P, 2000, DEVELOPMENT, V127, P5253; McNamara KCS, 2010, J NEUROTRAUM, V27, P695, DOI 10.1089/neu.2009.1237; Navascues Julio, 2002, P15; Nissl F., 1899, ARCH PSYCHIAT, V32, P656; OHNO M, 1992, DEV BRAIN RES, V67, P37, DOI 10.1016/0165-3806(92)90023-P; Perry VH, 2010, ASN NEURO, V2, P281, DOI 10.1042/AN20100024; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Reneer DV, 2012, BLAST INDUCED BRAIN; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.3.CO;2-A; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Taylor SE, 2012, CURRENT PRO IN PRESS; Trapp BD, 2007, GLIA, V55, P360, DOI 10.1002/glia.20462; Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009; Wierzba-Bobrowicz T, 2002, FOLIA NEUROPATHOL, V40, P125; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; Wolf SA, 2002, J NEUROIMMUNOL, V133, P72, DOI 10.1016/S0165-5728(02)00367-3; Ziebell JM, 2011, BRAIN RES, V1414, P94, DOI 10.1016/j.brainres.2011.07.056; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	46	87	88	0	18	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	OCT 30	2012	9								247	10.1186/1742-2094-9-247			11	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	060NU	WOS:000312785900001	23111107	Green Published, gold			2022-02-06	
J	Balakathiresan, N; Bhomia, M; Chandran, R; Chavko, M; McCarron, RM; Maheshwari, RK				Balakathiresan, Nagaraja; Bhomia, Manish; Chandran, Raghavendar; Chavko, Mikulas; McCarron, Richard M.; Maheshwari, Radha K.			MicroRNA Let-7i Is a Promising Serum Biomarker for Blast-Induced Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarker; blast overpressure injury; microRNA; serum; traumatic brain injury	NEUROTRAUMA; MECHANISMS; EXPRESSION; STRESS; MODEL	Blast-induced traumatic brain injury (TBI) is of significant concern in soldiers returning from the current conflicts in Iraq and Afghanistan. Incidents of TBI have increased significantly in the current conflicts compared to previous wars, and a majority of these injuries are caused by improvised explosive devices. Currently, no specific technique or biomarker is available for diagnosing TBI when no obvious clinical symptoms are present. MicroRNAs are small RNA (similar to 22nts) molecules that are expressed endogenously and play an important role in regulating gene expression. MicroRNAs have emerged as novel serum diagnostic biomarkers for various diseases. In this study, we studied the effect of blast overpressure injury on the microRNA signatures in the serum of rats. Rats were exposed to three serial 120-kPa blast overpressure exposures through a shockwave tube. Blood and cerebrospinal fluid were collected at various time points after injury, and microRNA modulation was analyzed using real-time PCR. Five microRNAs were significantly modulated in the serum samples of these animals at three time points post-injury. Further, we also found that the levels of microRNA let-7i are also elevated in cerebrospinal fluid post-blast wave exposure. The presence of microRNA in both serum and cerebrospinal fluid immediately after injury makes microRNA let-7i an ideal candidate for further studies of biomarkers in TBI.	[Balakathiresan, Nagaraja; Bhomia, Manish; Chandran, Raghavendar; Maheshwari, Radha K.] Uniformed Serv Univ Hlth Sci, Dept Pathol, Bethesda, MD 20814 USA; [Bhomia, Manish; Chandran, Raghavendar] Birla Inst Technol & Sci, Biol Sci Grp, Pilani, Rajasthan, India; [Chavko, Mikulas; McCarron, Richard M.] USN, Med Res Ctr, Silver Spring, MD USA		Maheshwari, RK (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pathol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	radha.maheshwari@usuhs.edu	Balakathiresan, Nagaraja Sethuraman/O-3213-2019; Bhomia, Manish/C-7683-2015; Chandran, Raghavendar/AAB-9402-2019	Balakathiresan, Nagaraja Sethuraman/0000-0001-5756-6070; Bhomia, Manish/0000-0003-2808-9927; Chandran, Raghavendar/0000-0002-7915-2810	Defense Medical Research and Development Program	This work was supported by a grant from the Defense Medical Research and Development Program. The authors are also thankful to Dr. Anuj Sharma for critically reviewing the manuscript, and Dr. Deepti Parashar for her help in real-time PCR assays.	Bak M, 2008, RNA, V14, P432, DOI 10.1261/rna.783108; Barbato C, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/871313; Belanger HG, 2005, J REHABIL RES DEV, V42, P403, DOI 10.1682/JRRD.2004.08.0095; Brown BD, 2009, NAT REV GENET, V10, P578, DOI 10.1038/nrg2628; Bruns JJ, 2009, MT SINAI J MED, V76, P129, DOI 10.1002/msj.20101; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Cullen DK, 2011, J NEUROTRAUM, V28, P2307, DOI [10.1089/neu.2010.1718, 10.1089/neu.2011.1718]; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Geyer C, 2009, J NEUROS-PEDIATR, V4, P339, DOI 10.3171/2009.5.PEDS08481; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Laterza OF, 2009, CLIN CHEM, V55, P1977, DOI 10.1373/clinchem.2009.131797; Leung Lai Yee, 2008, Molecular & Cellular Biomechanics, V5, P155; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lukiw WJ, 2008, J BIOL CHEM, V283, P31315, DOI 10.1074/jbc.M805371200; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Papadopoulos GL, 2009, BIOINFORMATICS, V25, P1991, DOI 10.1093/bioinformatics/btp299; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Polakis P, 2008, J CELL BIOL, V183, P371, DOI 10.1083/jcb.200810040; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Scholer N, 2010, EXP HEMATOL, V38, P1126, DOI 10.1016/j.exphem.2010.10.004; Stuhmiller J.H., 1991, CONVENTIONAL WARFARE, P241; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Young GB, 2010, CRIT CARE MED, V38, P325, DOI 10.1097/CCM.0b013e3181bfeb89; Zhang BH, 2009, ENVIRON HEALTH PERSP, V117, P231, DOI 10.1289/ehp.11841	35	87	94	1	20	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2012	29	7					1379	1387		10.1089/neu.2011.2146			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	933TC	WOS:000303384600012	22352906	Green Published			2022-02-06	
J	McLeod, TCV; Bay, RC; Lam, KC; Chhabra, A				McLeod, Tamara C. Valovich; Bay, R. Curtis; Lam, Kenneth C.; Chhabra, Anikar			Representative Baseline Values on the Sport Concussion Assessment Tool 2 (SCAT2) in Adolescent Athletes Vary by Gender, Grade, and Concussion History	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	37th Annual Meeting of the American-Orthopaedic-Society-for-Sports-Medicine (AOSSM)	JUL, 2011	San Diego, CA	Amer Orthopaed Soc Sports Med (AOSSM)		mild traumatic brain injury; balance; cognition; symptoms	POSTURAL STABILITY; HEAD-INJURY; HIGH-SCHOOL; SYMPTOMS; YOUTH; IDENTIFICATION; SENSITIVITY; RECOVERY; PLAYERS; SCALE	Background: To improve and standardize the sideline evaluation of sports-related concussion, the Sport Concussion Assessment Tool 2 (SCAT2) was developed. This tool assesses concussion-related signs and symptoms, cognition, balance, and coordination. This newly published assessment tool has not established representative baseline data on adolescent athletes. Hypothesis: Representative baseline SCAT2 scores in adolescent athletes will differ by gender, grade in school, and self-reported concussion history. Study Design: Descriptive epidemiology study. Methods: Interscholastic athletes were administered the SCAT2 during a preseason concussion baseline testing session. The SCAT2 total score ranges from 0 to 100 points, with lower scores indicating poorer performance. Overall, representative values were calculated using descriptive statistics. Separate independent-samples t tests, with gender and concussion history as the independent variables, and a 1-way analysis of variance, with grade as the independent variable, were conducted to assess differences in SCAT2 total score (P<.05). Results: There were 1134 high school athletes (872 male and 262 female) who participated. The SCAT2 total score across all participants was 88.3 +/- 6.8 (range, 58-100); skewness was -0.86 +/- 0.07, and kurtosis was 0.73 +/- 0.14. Male athletes scored significantly lower on the SCAT2 total score (P=.03; 87.7 +/- 6.8 vs 88.7 +/- 6.8), and 9th graders (86.9 +/- 6.8) scored significantly lower than 11th (88.7 +/- 7.0) and 12th (89.0 +/- 6.6) graders (P<.001). Athletes with a self-reported concussion history scored significantly lower on the SCAT2 total score than those with no concussion history (P<.001; 87.0 +/- 6.8 vs 88.7 +/- 6.5). Conclusion: These data provide representative scores on the SCAT2 in adolescent athletes and show that male athletes, 9th graders, and those with a self-reported concussion history scored significantly lower than their female, upperclassmen, or non-concussed peers. Clinical Relevance: These results suggest that healthy adolescent athletes display variability on the SCAT2 at baseline. Therefore, clinicians should administer baseline assessments of the SCAT2 because assuming a perfect baseline score of 100 points is not appropriate in an adolescent athlete population.	[McLeod, Tamara C. Valovich] AT Still Univ, Arizona Sch Hlth Sci, Athlet Training Program, Mesa, AZ 85206 USA		McLeod, TCV (corresponding author), AT Still Univ, Arizona Sch Hlth Sci, Athlet Training Program, 5850 E Still Circle, Mesa, AZ 85206 USA.	tmcleod@atsu.edu	Lam, Kenny/ABB-9733-2020; Valovich McLeod, Tamara/AAU-9435-2020	Valovich McLeod, Tamara/0000-0001-9082-8722; Bay, Ralph/0000-0003-3525-9269; Lam, Kenneth/0000-0002-2185-0990			Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Eckner JT, 2010, CURR SPORT MED REP, V9, P8, DOI 10.1249/JSR.0b013e3181caa778; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hunt TN, 2009, J ATHL TRAINING, V44, P405, DOI 10.4085/1062-6050-44.4.405; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; LaBotz M, 2005, CLIN J SPORT MED, V15, P73, DOI 10.1097/01.jsm.0000157649.99867.fc; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Mailer BJ, 2008, J SPORT REHABIL, V17, P11, DOI 10.1123/jsr.17.1.11; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M., 2000, STANDARDIZED ASSESSM; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; Rhee Hyekyun, 2005, Pediatr Nurs, V31, P314; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; McLeod TCV, 2008, CLIN J SPORT MED, V18, P235, DOI 10.1097/JSM.0b013e3181705756; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	29	87	87	0	24	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	APR	2012	40	4					927	933		10.1177/0363546511431573			7	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Orthopedics; Sport Sciences	918XO	WOS:000302285100027	22238056				2022-02-06	
J	Loov, C; Hillered, L; Ebendal, T; Erlandsson, A				Loov, Camilla; Hillered, Lars; Ebendal, Ted; Erlandsson, Anna			Engulfing Astrocytes Protect Neurons from Contact-Induced Apoptosis following Injury	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; CAENORHABDITIS-ELEGANS; NERVOUS-SYSTEM; DENTATE GYRUS; WHITE-MATTER; GLIAL-CELLS; ADULT RAT; C-ELEGANS; OLIGODENDROCYTES; ENGULFMENT	Clearing of dead cells is a fundamental process to limit tissue damage following brain injury. Engulfment has classically been believed to be performed by professional phagocytes, but recent data show that non-professional phagocytes are highly involved in the removal of cell corpses in various situations. The role of astrocytes in cell clearance following trauma has however not been studied in detail. We have found that astrocytes actively collect and engulf whole dead cells in an in vitro model of brain injury and thereby protect healthy neurons from bystander cell death. Time-lapse experiments showed that migrating neurons that come in contact with free-floating cell corpses induced apoptosis, while neurons that migrate through groups of dead cells, garnered by astrocytes, remain unaffected. Furthermore, apoptotic cells are present within astrocytes in the mouse brain following traumatic brain injury (TBI), indicating a possible role for astrocytes in engulfment of apoptotic cells in vivo. qRT-PCR analysis showed that members of both ced pathways and Megf8 are expressed in the cell culture, indicating their possible involvement in astrocytic engulfment. Moreover, addition of dead cells had a positive effect on the protein expression of MEGF10, an ortholog to CED1, known to initiate phagocytosis by binding to phosphatidylserine. Although cultured astrocytes have an immense capacity for engulfment, seemingly without adverse effects, the ingested material is stored rather than degraded. This finding might explain the multinuclear astrocytes that are found at the lesion site in patients with various brain disorders.	[Loov, Camilla; Hillered, Lars; Ebendal, Ted; Erlandsson, Anna] Uppsala Univ, Dept Neurosci, Uppsala, Sweden		Loov, C (corresponding author), Uppsala Univ, Dept Neurosci, Uppsala, Sweden.	anna.erlandsson@neuro.uu.se		Hillered, Lars/0000-0002-2808-9292	Swedish Research CouncilSwedish Research CouncilEuropean Commission; Uppsala University Hospital; Tore Nilssons Foundation; Jeanssons Foundation; Magnus Bergvall Foundation; Swedish Society of Medicine	This study was supported by grants from the Swedish Research Council, the Uppsala University Hospital, Tore Nilssons Foundation, Jeanssons Foundation, Magnus Bergvall Foundation and The Swedish Society of Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acarin L, 2007, GLIA, V55, P954, DOI 10.1002/glia.20518; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Chang GHF, 2000, NEURO-ONCOLOGY, V2, P174, DOI 10.1093/neuonc/2.3.174; Colodner KJ, 2005, J NEUROPATH EXP NEUR, V64, P163, DOI 10.1093/jnen/64.2.163; Cusato K, 2003, J NEUROSCI, V23, P6413; Erwig LP, 2008, CELL DEATH DIFFER, V15, P243, DOI 10.1038/sj.cdd.4402184; Fullard JF, 2009, APOPTOSIS, V14, P1029, DOI 10.1007/s10495-009-0335-9; GALL C, 1979, J COMP NEUROL, V183, P539, DOI 10.1002/cne.901830306; GHATAK NR, 1992, J NEUROPATH EXP NEUR, V51, P40, DOI 10.1097/00005072-199201000-00006; Haase G, 2008, CURR OPIN NEUROBIOL, V18, P284, DOI 10.1016/j.conb.2008.07.013; Hanayama R, 2005, P NATL ACAD SCI USA, V102, P16886, DOI 10.1073/pnas.0508599102; Henson PM, 2001, CURR BIOL, V11, pR795, DOI 10.1016/S0960-9822(01)00474-2; Hirt UA, 2003, CELL DEATH DIFFER, V10, P1156, DOI 10.1038/sj.cdd.4401286; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Kinchen JM, 2005, NATURE, V434, P93, DOI 10.1038/nature03263; Kranich J, 2010, J EXP MED, V207, P2271, DOI 10.1084/jem.20092401; Kurant E, 2008, CELL, V133, P498, DOI 10.1016/j.cell.2008.02.052; LEE KS, 1977, EXP BRAIN RES, V29, P475; LEMKEYJOHNSTON N, 1976, J COMP NEUROL, V167, P481, DOI 10.1002/cne.901670406; Lettre G, 2006, NAT REV MOL CELL BIO, V7, P97, DOI 10.1038/nrm1836; Magnus T, 2002, J NEUROPATH EXP NEUR, V61, P760, DOI 10.1093/jnen/61.9.760; Mangahas PM, 2005, SEMIN CELL DEV BIOL, V16, P295, DOI 10.1016/j.semcdb.2004.12.005; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; MATTHEWS DA, 1976, BRAIN RES, V115, P23, DOI 10.1016/0006-8993(76)90820-9; Miksa M, 2009, J IMMUNOL METHODS, V342, P71, DOI 10.1016/j.jim.2008.11.019; Monks J, 2008, BIOL REPROD, V78, P586, DOI 10.1095/biolreprod.107.065045; Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958; Nakanishi Y, 2004, BIOL PHARM BULL, V27, P13, DOI 10.1248/bpb.27.13; Nishie M, 2006, NEUROPATHOLOGY, V26, P62, DOI 10.1111/j.1440-1789.2006.00633.x; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Poon IKH, 2010, CELL DEATH DIFFER, V17, P381, DOI 10.1038/cdd.2009.195; RAINE CS, 1976, J NEUROL SCI, V30, P13, DOI 10.1016/0022-510X(76)90251-3; RONNEVI LO, 1978, CELL TISSUE RES, V189, P203; Shintaku M, 2004, ACTA NEUROPATHOL, V108, P201, DOI 10.1007/s00401-004-0880-9; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Song JH, 2006, J NEUROSCI, V26, P3299, DOI 10.1523/JNEUROSCI.5572-05.2006; Suzuki E, 2007, EXP CELL RES, V313, P3729, DOI 10.1016/j.yexcr.2007.06.015; TRAPP BD, 1975, NEUROBIOLOGY, V5, P235; Venegas V, 2007, MOL BIOL CELL, V18, P3180, DOI 10.1091/mbc.E07-02-0138; WU E, 1992, LAB INVEST, V67, P88; Wu HH, 2009, NAT NEUROSCI, V12, P1534, DOI 10.1038/nn.2446; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Zhang Y, 2010, CURR OPIN NEUROBIOL, V20, P588, DOI 10.1016/j.conb.2010.06.005	45	87	88	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2012	7	3							e33090	10.1371/journal.pone.0033090			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	943KB	WOS:000304118900009	22461890	Green Published, gold, Green Submitted			2022-02-06	
J	Sullivan, SJ; Schneiders, AG; Cheang, CW; Kitto, E; Lee, H; Redhead, J; Ward, S; Ahmed, OH; McCrory, PR				Sullivan, S. John; Schneiders, Anthony G.; Cheang, Choon-Wi; Kitto, Emma; Lee, Hopin; Redhead, Jason; Ward, Sarah; Ahmed, Osman H.; McCrory, Paul R.			'What's happening?' A content analysis of concussion-related traffic on Twitter	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; SOCIAL NETWORKS; HEALTH INFORMATION; SUPPORT GROUPS; KNOWLEDGE; FOOTBALL; PLAY; MISCONCEPTIONS; MANAGEMENT	Background Twitter is a rapidly growing social networking site (SNS) with approximately 124 million users worldwide. Twitter allows users to post brief messages ('tweets') online, on a range of everyday topics including those dealing with health and wellbeing. Currently, little is known about how tweets are used to convey information relating to specific injuries, such as concussion, that commonly occur in youth sports. Objective The purpose of this study was to analyse the online content of concussion-related tweets on the SNS Twitter, to determine the concept and context of mild traumatic brain injury as it relates to an online population. Study design A prospective observational study using content analysis. Methods Twitter traffic was investigated over a 7-day period in July 2010, using eight concussion-related search terms. From the 3488 tweets identified, 1000 were randomly selected and independently analysed using a customised coding scheme to determine major content themes. Results The most frequent theme was 'news' (33%) followed by 'sharing personal information/situation' (27%) and 'inferred management' (13%). Demographic data were available for 60% of the sample, with the majority of tweets (82%) originating from the USA, followed by Asia (5%) and the UK (4.5%). Conclusion This study highlights the capacity of Twitter to serve as a powerful broadcast medium for sports concussion information and education.	[Sullivan, S. John] Univ Otago, Sch Physiotherapy, Ctr Physiotherapy Res, Dunedin 9054, New Zealand; [McCrory, Paul R.] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia		Sullivan, SJ (corresponding author), Univ Otago, Sch Physiotherapy, Ctr Physiotherapy Res, POB 56, Dunedin 9054, New Zealand.	sjohn.sullivan@otago.ac.nz	McCrory, Paul/Q-8688-2019; Schneiders, Anthony/F-4212-2015	Schneiders, Anthony/0000-0002-1583-3879; McCrory, Paul/0000-0003-4850-0568; Lee, Hopin/0000-0001-5692-0314	International Rugby Board	The authors express their thanks to Andrew Long from the University of Otago Department of Information Science for his guidance on the exploration of Twitter and acknowledge funding support from the International Rugby Board.	Accident Compenstaion Corporation, 2006, ACC1419 SID CONC CHE; Ahmed OH, 2010, DISABIL REHABIL, V32, P1877, DOI 10.3109/09638281003734409; [Anonymous], 2010, MOMSTEAM; [Anonymous], 2010, NY TIMES; [Anonymous], 2010, BOSTON GLOBE; [Anonymous], TWITTER; Baker JR, 2008, CYBERPSYCHOL BEHAV, V11, P747, DOI 10.1089/cpb.2008.0053; Bloom GA, 2008, EUR J SPORT SCI, V8, P295, DOI 10.1080/17461390802251836; Brain Injury New Zealand, CONC; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control and Prevention, 2009, HEADS CONC YOUTH SPO; Chapman RCG, 2010, BRAIN INJURY, V24, P797, DOI 10.3109/02699051003709607; CrunchBase, 2010, TWITT; Deshpande A, 2006, J MENS HLTH GENDER, V3, P332, DOI DOI 10.1016/J.JMHG.2006.09.004; Economist Intelligence Unit, 2010, ECONOMIST; Eysenbach G, 2004, BMJ-BRIT MED J, V328, P1166, DOI 10.1136/bmj.328.7449.1166; Eysenbach G, 2008, J MED INTERNET RES, V10, DOI 10.2196/jmir.1030; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; HERMIDA A, 2010, M C J, V13, P2; Hux K, 2006, BRAIN INJURY, V20, P547, DOI 10.1080/02699050600676784; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; JAVA A, 2007, P JOINT 9 WEBKDD 1 S; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kostkova P, 2010, INT J INFECT DIS, V14, pE384, DOI 10.1016/j.ijid.2010.02.475; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mackenzie JA, 2005, BRIT J CLIN PSYCHOL, V44, P417, DOI 10.1348/014466505X35696; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI58, DOI 10.1136/bjsm.2005.020776; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; Miller C., 2009, NY TIMES; Nardi BA, 2004, COMMUN ACM, V47, P41, DOI 10.1145/1035134.1035163; Nonnecke B., 2000, CHI 2000 Conference Proceedings. Conference on Human Factors in Computing Systems. CHI 2000. The Future is Here, P73; Papacharissi Z, 2009, NEW MEDIA SOC, V11, P199, DOI 10.1177/1461444808099577; Pew Internet & American Life Project, 2010, UND PART NEWS CONS; Pew Internet & American Life Project, 2009, SOC LIF HLTH INF; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Pulman A, 2009, J NURS HEALTHC CHRON, V1, P245; Putukian M, 2009, BRIT J SPORT MED, V43, pI28, DOI 10.1136/bjsm.2009.058230; Scanfeld D, 2010, AM J INFECT CONTROL, V38, P182, DOI 10.1016/j.ajic.2009.11.004; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Thomas D. R., 2003, GEN INDUCTIVE APPROA; Van De Belt TH, 2010, J MED INTERNET RES, V12, DOI 10.2196/jmir.1350; van Uden-Kraan CF, 2008, J MED INTERNET RES, V10, DOI 10.2196/jmir.992; Viralblog, 2010, TWITT FACTS FIG; Wilson P, 2002, BMJ-BRIT MED J, V324, P598, DOI 10.1136/bmj.324.7337.598; Wrightson P, 1999, APPENDIX 2 MILD HEAD, P182; Wyatt JC, 2005, BRIT MED J, V331, P1391, DOI 10.1136/bmj.331.7529.1391	53	87	87	1	50	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAR	2012	46	4					258	263		10.1136/bjsm.2010.080341			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	899PO	WOS:000300828500011	21406451				2022-02-06	
J	Zanier, ER; Montinaro, M; Vigano, M; Villa, P; Fumagalli, S; Pischiutta, F; Longhi, L; Leoni, ML; Rebulla, P; Stocchetti, N; Lazzari, L; De Simoni, MG				Zanier, Elisa R.; Montinaro, Mery; Vigano, Mariele; Villa, Pia; Fumagalli, Stefano; Pischiutta, Francesca; Longhi, Luca; Leoni, Matteo L.; Rebulla, Paolo; Stocchetti, Nino; Lazzari, Lorenza; De Simoni, Maria-Grazia			Human umbilical cord blood mesenchymal stem cells protect mice brain after trauma	CRITICAL CARE MEDICINE			English	Article						human cord blood mesenchymal stem cells; traumatic brain injury; microglia; transplantation; functional recovery; brain protection	MARROW STROMAL CELLS; BONE-MARROW; GENE-EXPRESSION; IN-VITRO; INJURY; TRANSPLANTATION; NEUROPROTECTION; GROWTH; INHIBITION; CHALLENGES	Objective: To investigate whether human umbilical cord blood mesenchymal stem cells, a novel source of progenitors with multilineage potential: 1) decrease traumatic brain injury sequelae and restore brain function; 2) are able to survive and home to the lesioned region; and 3) induce relevant changes in the environment in which they are infused. Design: Prospective experimental study. Setting: Research laboratory. Subjects: Male C57BI/6 mice. Interventions: Mice were subjected to controlled cortical impact/sham brain injury. At 24 hrs postinjury, human umbilical cord blood mesenchymal stem cells (150,000/5 mu L) or phosphate-buffered saline (control group) were infused intracerebroventricularly contralateral to the injured side. Immunosuppression was achieved by cyclosporine A (10 mg/kg intraperitoneally). Measurements and Main Results: After controlled cortical impact, human umbilical cord blood mesenchymal stem cell transplantation induced an early and long-lasting improvement in sensorimotor functions assessed by neuroscore and beam walk tests. One month postinjury, human umbilical cord blood mesenchymal stem cell mice showed attenuated learning dysfunction at the Morris water maze and reduced contusion volume compared with controls. Hoechst positive human umbilical cord blood mesenchymal stem cells homed to lesioned tissue as early as 1 wk after injury in 67% of mice and survived in the injured brain up to 5 wks. By 3 days postinjury, cell infusion significantly increased brain-derived neurotrophic factor concentration into the lesioned tissue, restoring its expression close to the levels observed in sham operated mice. By 7 days postinjury, controlled cortical impact human umbilical cord blood mesenchymal stem cell mice showed a nonphagocytic activation of microglia/macrophages as shown by a selective rise (260%) in CD11b staining (a marker of microglia/macrophage activation/recruitment) associated with a decrease (58%) in CD68 (a marker of active phagocytosis). Thirty-five days postinjury, controlled cortical impact human umbilical cord blood mesenchymal stem cell mice showed a decrease of glial fibrillary acidic protein positivity in the scar region compared with control mice. Conclusions: These findings indicate that human umbilical cord blood mesenchymal stem cells stimulate the injured brain and evoke trophic events, microglia/macrophage phenotypical switch, and glial scar inhibitory effects that remodel the brain and lead to significant improvement of neurologic outcome. (Crit Care Med 2011; 39: 2501-2510)	[Zanier, Elisa R.; Montinaro, Mery; Villa, Pia; Pischiutta, Francesca; Longhi, Luca; De Simoni, Maria-Grazia] Mario Negri Inst Pharmacol Res, Dept Neurosci, Milan, Italy; [Vigano, Mariele; Rebulla, Paolo; Lazzari, Lorenza] Ctr Transfus Med Cellular Therapy & Cryobiol, Dept Regenerat Med, Milan, Italy; [Villa, Pia] CNR, Inst Neurosci, I-20133 Milan, Italy; [Longhi, Luca; Leoni, Matteo L.; Stocchetti, Nino] Univ Milan, Dept Anesthesia & Crit Care Med, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy		De Simoni, MG (corresponding author), Mario Negri Inst Pharmacol Res, Dept Neurosci, Via Eritrea 62, Milan, Italy.	desimoni@marionegri.it	Lazzari, Lorenza/J-4279-2015; Zanier, Elisa/AAA-8095-2020; Longhi, Luca/AAF-9903-2021; Leoni, Matteo L.G./AAT-4422-2020; Pischiutta, Francesca/AAA-7927-2020; De Simoni, Maria Grazia/I-6021-2012; Stocchetti, Nino/O-7444-2017; Fumagalli, Stefano/I-3097-2019; Rebulla, Paolo/I-7684-2015	Lazzari, Lorenza/0000-0002-9434-4538; Zanier, Elisa/0000-0002-3011-8718; Longhi, Luca/0000-0001-9894-8788; Pischiutta, Francesca/0000-0002-7151-0812; De Simoni, Maria Grazia/0000-0001-6695-5297; Stocchetti, Nino/0000-0003-3250-6834; Rebulla, Paolo/0000-0002-3875-5754; Fumagalli, Stefano/0000-0003-3598-6263; Leoni, Matteo Luigi Giuseppe/0000-0001-5228-3733	fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Italy; Fondazione Monzino	Partially supported by fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Italy. Mr. Fumagalli is recipient of a fellowship from Fondazione Monzino.	Bacigaluppi M, 2009, BRAIN, V132, P2239, DOI 10.1093/brain/awp174; Belmadani A, 2006, J NEUROSCI, V26, P3182, DOI 10.1523/JNEUROSCI.0156-06.2006; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; *BRAIN TRAUM FDN, 2007, J NEUROTRAUMA S1, V24, pS45; Brock JH, 2010, J NEUROSCI, V30, P9728, DOI 10.1523/JNEUROSCI.1924-10.2010; Broxmeyer HE, 2005, CYTOTHERAPY, V7, P209, DOI 10.1080/14653240510027190; Capone C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000373; Chen JL, 2000, NEUROPHARMACOLOGY, V39, P711, DOI 10.1016/S0028-3908(00)00006-X; CHENG H, 2010, MOL BIOL REP    1229; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; Faden AI, 2007, ARCH NEUROL-CHICAGO, V64, P794, DOI 10.1001/archneur.64.6.794; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gesuete R, 2009, ANN NEUROL, V66, P332, DOI 10.1002/ana.21740; Griesbach GS, 2009, J NEUROSCI RES, V87, P795, DOI 10.1002/jnr.21893; Gu WD, 2010, NEUROPATHOLOGY, V30, P205, DOI 10.1111/j.1440-1789.2009.01063.x; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Heile AMB, 2009, NEUROSCI LETT, V463, P176, DOI 10.1016/j.neulet.2009.07.071; Jager M, 2009, STEM CELL REV REP, V5, P266, DOI 10.1007/s12015-009-9083-z; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Koh SH, 2008, BRAIN RES, V1229, P233, DOI 10.1016/j.brainres.2008.06.087; Ksiazek K, 2009, REJUV RES, V12, P105, DOI 10.1089/rej.2009.0830; Lambertsen KL, 2009, J NEUROSCI, V29, P1319, DOI 10.1523/JNEUROSCI.5505-08.2009; Liao WB, 2009, CELL PHYSIOL BIOCHEM, V24, P307, DOI 10.1159/000233255; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; LONGHI L, 2011, J CEREB BLOOD F 0406; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A., 2003, NEUROSURGERY, V53, P702; Makri G, 2010, STEM CELLS, V28, P127, DOI 10.1002/stem.258; Morigi M, 2010, STEM CELLS, V28, P513, DOI 10.1002/stem.293; Munoz-Elias G, 2003, STEM CELLS, V21, P437, DOI 10.1634/stemcells.21-4-437; Ortolano F, 2009, J NEUROPATH EXP NEUR, V68, P964, DOI 10.1097/NEN.0b013e3181b20670; Panepucci RA, 2004, STEM CELLS, V22, P1263, DOI 10.1634/stemcells.2004-0024; Paxinos G., 2008, MOUSE BRAIN STEREOTA; Reimann, 2009, DTSCH ARZTEBL INT, V106, P831, DOI 10.3238/arztebl.2009.0831; Salem HK, 2010, STEM CELLS, V28, P585, DOI 10.1002/stem.269; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Son BR, 2006, STEM CELLS, V24, P1254, DOI 10.1634/stemcells.2005-0271; Stocchetti N, 2008, MINERVA ANESTESIOL, V74, P199; Storini C, 2006, J PHARMACOL EXP THER, V318, P849, DOI 10.1124/jpet.106.105064; Valle-Prieto A, 2010, STEM CELLS DEV, V19, P1885, DOI 10.1089/scd.2010.0093; Vigneron A, 2010, AGING-US, V2, P471, DOI 10.18632/aging.100189; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; Wanner IB, 2008, GLIA, V56, P1691, DOI 10.1002/glia.20721; Xiong Y, 2010, DISCOV MED, V10, P434; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Yamaguchi S, 2006, BRAIN RES, V1087, P15, DOI 10.1016/j.brainres.2006.02.127; Yano S, 2005, BRAIN RES, V1065, P60, DOI 10.1016/j.brainres.2005.10.031	55	87	98	0	29	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	2011	39	11					2501	2510		10.1097/CCM.0b013e31822629ba			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	841JV	WOS:000296509500017	21725237				2022-02-06	
J	Ganesalingam, K; Yeates, KO; Taylor, HG; Walz, NC; Stancin, T; Wade, S				Ganesalingam, Kalaichelvi; Yeates, Keith Owen; Taylor, H. Gerry; Walz, Nicolay Chertkoff; Stancin, Terry; Wade, Shari			Executive Functions and Social Competence in Young Children 6 Months Following Traumatic Brain Injury	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; young children; executive functions; social competence	CLOSED-HEAD-INJURY; BEHAVIOR RATING INVENTORY; PRESCHOOL-CHILDREN; EARLY-CHILDHOOD; EXTERNALIZING PROBLEMS; ECOLOGICAL VALIDITY; CONSTRUCT-VALIDITY; SELF-REGULATION; SHAPE SCHOOL; SKILLS	Objective: This study examined the impact of traumatic brain injury (TBI) in young children on executive functions and social competence, and particularly on the role of executive functions as a predictor of social competence. Method: Data were drawn from a prospective, longitudinal study. Participants were children between the ages of 3 years 0 months and 6 years 11 months at time of injury. The initial sample included 23 with severe TBI, 64 with moderate TBI, and 119 with orthopedic injuries (OI). All participants were assessed at 3 and 6 months postinjury. Executive functions were assessed using neuropsychological tests (Delayed Alternation task and Shape School) and parent ratings on the Behavior Rating Inventory of Executive Function and Child Behavior Questionnaire. Parents rated children's social competence on the Adaptive Behavior Assessment System, Preschool and Kindergarten Behavior Scales, and Home and Community Social Behavior Scales. Results: Children with severe TBI displayed more negative outcomes than children with OI on neuropsychological tests, ratings of executive functions, and ratings of social competence (eta(2) ranged from .03 to .11). Neuropsychological tests of executive functions had significant but weak relationships with behavioral ratings of executive functions (Delta R-2 ranged from .06 to .08). Behavioral ratings of executive functions were strongly related to social competence (Delta R-2 ranged from .32 to .42), although shared rater and method variance likely contributed to these associations. Conclusions: Severe TBI in young children negatively impacts executive functions and social competence. Executive functions may be an important determinant of social competence following TBI.	[Ganesalingam, Kalaichelvi; Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Columbus, OH 43205 USA; [Ganesalingam, Kalaichelvi; Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Case Med Ctr, Rainbow Babies & Childrens Hosp, Cleveland, OH USA; [Walz, Nicolay Chertkoff; Wade, Shari] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH USA; [Walz, Nicolay Chertkoff; Wade, Shari] Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; [Stancin, Terry] MetroHlth Med Ctr, Dept Psychiat, Cleveland, OH USA		Yeates, KO (corresponding author), Nationwide Childrens Hosp, Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	Keith.Yeates@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD042729-01, R01 HD042729] Funding Source: Medline		Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Barkley R.A., 1997, ADHD NATURE SELF CON; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; BEAUCHAMP MH, 2009, J NEUROTRAUM, V10, P9; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Canivez GL, 2002, PSYCHOL SCHOOLS, V39, P621, DOI 10.1002/pits.10063; CASPI A, 1995, DEV PSYCHOPATHOL, V0002, P00472; CICCHETTI D, 1994, DEV PSYCHOPATHOL, V6, P533, DOI 10.1017/S0954579400004673; Coie J.D., 1998, HDB CHILD PSYCHOL, VVol. 3, P779, DOI DOI 10.1002/9780470147658; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Eisenberg N, 2000, CHILD DEV, V71, P1367, DOI 10.1111/1467-8624.00233; Eisenberg N, 1997, CHILD DEV, V68, P642, DOI 10.2307/1132116; Espy KA, 1997, DEV NEUROPSYCHOL, V13, P495, DOI 10.1080/87565649709540690; Espy KA, 1999, BRAIN COGNITION, V41, P178, DOI 10.1006/brcg.1999.1117; Espy KA, 2001, CLIN NEUROPSYCHOL, V15, P46, DOI 10.1076/clin.15.1.46.1908; Espy KA, 2006, PSYCHOL ASSESSMENT, V18, P373, DOI 10.1037/1040-3590.18.4.373; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; Gerrard-Morris A, 2010, J INT NEUROPSYCH SOC, V16, P157, DOI 10.1017/S1355617709991135; GERSTADT CL, 1994, COGNITION, V53, P129, DOI 10.1016/0010-0277(94)90068-X; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Goldberg E, 2000, J CLIN EXP NEUROPSYC, V22, P56, DOI 10.1076/1380-3395(200002)22:1;1-8;FT056; Harrison P. L., 2003, ADAPTIVE BEHAV ASSES, V2nd; Hughes C, 1998, BRIT J DEV PSYCHOL, V16, P233, DOI 10.1111/j.2044-835X.1998.tb00921.x; Hughes C, 2000, J CHILD PSYCHOL PSYC, V41, P169, DOI 10.1111/1469-7610.00558; Isquith PK, 2005, MENT RETARD DEV D R, V11, P209, DOI 10.1002/mrdd.20075; Jacobs R, 2007, CORTEX, V43, P792, DOI 10.1016/S0010-9452(08)70507-0; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Mahone EM, 2002, ARCH CLIN NEUROPSYCH, V17, P643, DOI 10.1016/S0887-6177(01)00168-8; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Martin, 1994, DEV STRUCTURE TEMPER, P189; McAuley T, 2010, J INT NEUROPSYCH SOC, V16, P495, DOI 10.1017/S1355617710000093; MCEVOY RE, 1993, J CHILD PSYCHOL PSYC, V34, P563, DOI 10.1111/j.1469-7610.1993.tb01036.x; MERRELL KW, 1995, J PSYCHOEDUC ASSESS, V13, P230, DOI 10.1177/073428299501300302; Merrell KW, 2000, HOME COMMUNITY SOCIA; Moffitt TE, 2003, CAUSES OF CONDUCT DISORDER AND JUVENILE DELINQUENCY, P49; Morse S, 1999, Pediatr Rehabil, V3, P139; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Nigg JT, 2000, PSYCHOL BULL, V126, P220, DOI 10.1037/0033-2909.126.2.220; Olson SL, 1999, J ABNORM CHILD PSYCH, V27, P151, DOI 10.1023/A:1021915615677; Olson SL, 2005, DEV PSYCHOPATHOL, V17, P25, DOI 10.1017/S0954579405050029; Posner MI, 2000, DEV PSYCHOPATHOL, V12, P427, DOI 10.1017/S0954579400003096; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; RICCIO CA, 1994, DEV NEUROPSYCHOL, V10, P215, DOI 10.1080/87565649409540580; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Rothbart M.K., 2006, HDB CHILD PSYCHOL, V6th ed., P99, DOI DOI 10.1002/9780470147658.CHPSY0303; ROTHBART MK, 1989, TEMPERAMENT CHILDHOO, P59; Rubin K.H., 1992, HDB SOCIAL DEV, P283, DOI [10.1007/978-1-4899-0694-6_12, DOI 10.1007/978-1-4899-0694-6]; RUBIN KH, 1986, MINN SYM CHILD PSYCH, V18, P1; Senn TE, 2004, DEV NEUROPSYCHOL, V26, P445, DOI 10.1207/s15326942dn2601_5; Shields A, 1998, J CLIN CHILD PSYCHOL, V27, P381, DOI 10.1207/s15374424jccp2704_2; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Smidts DP, 2004, DEV NEUROPSYCHOL, V26, P385, DOI 10.1207/s15326942dn2601_2; Speltz ML, 1999, J ABNORM PSYCHOL, V108, P315, DOI 10.1037/0021-843X.108.2.315; Taylor HG, 2008, J INT NEUROPSYCH SOC, V14, P734, DOI 10.1017/S1355617708081150; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 1997, J INT NEUROPSYCH SOC, V3, P1; TEASDALE G, 1974, LANCET, V2, P81; Verger K, 2000, BRAIN INJURY, V14, P495; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Vriezen ER, 2001, BRAIN COGNITION, V47, P222; Warschausky S, 2003, REHABIL PSYCHOL, V48, P250, DOI 10.1037/0090-5550.48.4.250; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; WETHERINGTON CE, 2006, EXCEPTIONALITY, V12, P155; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Willmott C, 2000, DEV NEUROPSYCHOL, V17, P361, DOI 10.1207/S15326942DN1703_5; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; ZAHNWAXLER C, 2002, HDB PARENTING, V0004, P00295, DOI DOI 10.4324/9780429398995-17; Zelazo PD, 1996, COGNITIVE DEV, V11, P37, DOI 10.1016/S0885-2014(96)90027-1; [No title captured]	83	87	87	0	42	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JUL	2011	25	4					466	476		10.1037/a0022768			11	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	787WQ	WOS:000292407800005	21463038	Green Accepted			2022-02-06	
J	Kaiser, PR; Valko, PO; Werth, E; Thomann, J; Meier, J; Stocker, R; Bassetti, CL; Baumann, CR				Kaiser, P. R.; Valko, P. O.; Werth, E.; Thomann, J.; Meier, J.; Stocker, R.; Bassetti, C. L.; Baumann, C. R.			Modafinil ameliorates excessive daytime sleepiness after traumatic brain injury	NEUROLOGY			English	Article							FATIGUE; PREVALENCE; VALIDATION; DISABILITY; DISEASE; TRIAL; SCALE	Background: Excessive daytime sleepiness (EDS) and fatigue are common symptoms after traumatic brain injury (TBI), but there is no specific treatment for affected patients. With this pilot study, we aimed at studying the effect of daily modafinil on posttraumatic EDS and fatigue. Methods: We conducted a prospective, double-blind, randomized, placebo-controlled pilot study in 20 patients with TBI who had fatigue or EDS or both. After baseline examinations (questionnaires including the Epworth Sleepiness Scale to assess EDS and the Fatigue Severity Scale to assess fatigue, actigraphy, polysomnography, maintenance of wakefulness test, and psychomotor vigilance test), 10 patients received 100 to 200 mg modafinil every morning, and 10 patients were treated with placebo. After a 6-week treatment period, all examinations were repeated. Results: EDS improved significantly in patients with TBI who were treated with modafinil, compared with the placebo group. Similarly, the ability to stay awake on the maintenance of wakefulness test improved only in the modafinil group. Modafinil, however, had no impact on posttraumatic fatigue. Clinically relevant side effects were not observed. Conclusion: This study indicates that modafinil is effective and well tolerated in the treatment of posttraumatic EDS but not of fatigue. Classification of evidence: This study provides Class I evidence that modafinil (100-200 mg daily) improves posttraumatic EDS compared with placebo. This study provides Class I evidence that modafinil (100-200 mg daily) does not improve posttraumatic fatigue compared with placebo. Neurology (R) 2010;75:1780-1785	[Kaiser, P. R.; Valko, P. O.; Werth, E.; Thomann, J.; Meier, J.; Bassetti, C. L.; Baumann, C. R.] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland; [Stocker, R.] Univ Zurich Hosp, Dept Surg Intens Care, CH-8091 Zurich, Switzerland; [Bassetti, C. L.] Osped Civ, Neuroctr So Switzerland, Dept Neurol, Lugano, Switzerland		Baumann, CR (corresponding author), Univ Zurich Hosp, Dept Neurol, Frauenklin Str 26, CH-8091 Zurich, Switzerland.	christian.baumann@usz.ch	Werth, E/AAN-7955-2021	Werth, Esther/0000-0002-5099-3122; Baumann, Christian/0000-0003-3417-1978	Schweizerischer Versicherungsverband (SVV), Zurich, Switzerland; Cephalon GmbH, Martinsried, Germany; Fresenius Medical Care; Bio-Synthesis Inc.; Swiss National FoundationSwiss National Science Foundation (SNSF); SUVA Foundation; Swiss Academy for Medical Sciences; Swisstransplant; Lundbeck Inc.Lundbeck Corporation; Respironics, Inc.; ResMed Inc.; Vifor Pharma; UCBUCB Pharma SA; Zurich Center for Integrative Human Physiology; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission; Cephalon; NovartisNovartis	Supported by Schweizerischer Versicherungsverband (SVV), Zurich, Switzerland, and Cephalon GmbH, Martinsried, Germany.; Dr. Kaiser, Dr. Valko, Dr. Werth, Ms. Thomann, and Ms. Meier report no disclosures. Prof. Stocker has served on scientific advisory boards for KCI Europe Holding BV and Baxter International Inc.; has received funding for travel or speaker honoraria from Fresenius Medical Care and Bio-Synthesis Inc.; and receives research support from the Swiss National Foundation, SUVA Foundation, the Swiss Academy for Medical Sciences, and Swisstransplant. Prof. Bassetti serves as Chief Editor of the Swiss Archives of Neurology and Psychiatry and on the editorial boards of the Journal of Sleep Research, Sleep Medicine, Somnology, and the Belgian Neurological Journal; has served on scientific advisory boards for and received speaker honoraria from Boehringer Ingelheim, Lundbeck Inc., Novartis, Pfizer Inc, ResMed Inc., and UCB; receives research support from Lundbeck Inc., Respironics, Inc., ResMed Inc., Vifor Pharma, and UCB; and receives institutional research support from the Zurich Center for Integrative Human Physiology and the Swiss National Science Foundation. Dr. Baumann has served on scientific advisory boards for and received speaker honoraria from Boehringer Ingelheim, UCB, and GlaxoSmithKline; receives research support from UCB, Cephalon, and Novartis; and receives institutional research support from the Swiss National Foundation.	Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Black JE, 2005, SLEEP, V28, P464, DOI 10.1093/sleep/28.4.464; Bloch KE, 1999, RESPIRATION, V66, P440, DOI 10.1159/000029408; Brioschi A, 2009, EUR NEUROL, V62, P243, DOI 10.1159/000232927; Broughton RJ, 1997, NEUROLOGY, V49, P444, DOI 10.1212/WNL.49.2.444; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Chaumet G, 2008, NEUROLOGY, V71, P1609, DOI 10.1212/01.wnl.0000334753.49193.48; Czeisler CA, 2005, NEW ENGL J MED, V353, P476, DOI 10.1056/NEJMoa041292; Dorrian J, 2003, SLEEP, V26, pA182; Homaifar BY, 2009, ARCH PHYS MED REHAB, V90, P652, DOI 10.1016/j.apmr.2008.10.028; Jha A, 2008, J HEAD TRAUMA REHAB, V23, P52, DOI 10.1097/01.HTR.0000308721.77911.ea; King MA, 2005, SLEEP MED, V6, P507, DOI 10.1016/j.sleep.2004.12.010; Littner MR, 2005, SLEEP, V28, P113, DOI 10.1093/sleep/28.1.113; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; *NAT CTR INJ PREV, 2006, TRAUM BRAIN INJ US E; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Rechtschaffen A., 1968, MANUAL STANDARDIZED; Teitelman E, 2001, AM J PSYCHIAT, V158, P1341, DOI 10.1176/ajp.158.8.1341; Tyne HL, 2010, J NEUROL, V257, P452, DOI 10.1007/s00415-009-5351-8; Valko PO, 2008, SLEEP, V31, P1601, DOI 10.1093/sleep/31.11.1601; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	23	87	87	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	NOV 16	2010	75	20					1780	1785		10.1212/WNL.0b013e3181fd62a2			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	680EO	WOS:000284215400007	21079179	Green Accepted			2022-02-06	
J	Nelson, DW; Nystrom, H; MacCallum, RM; Thornquist, B; Lilja, A; Bellander, BM; Rudehill, A; Wanecek, M; Weitzberg, E				Nelson, David W.; Nystrom, Harriet; MacCallum, Robert M.; Thornquist, Bjorn; Lilja, Anders; Bellander, Bo-Michael; Rudehill, Anders; Wanecek, Michael; Weitzberg, Eddie			Extended Analysis of Early Computed Tomography Scans of Traumatic Brain Injured Patients and Relations to Outcome	JOURNAL OF NEUROTRAUMA			English	Article						computed tomography; Glasgow Coma Scale; Glasgow Outcome Scale; outcome; traumatic brain injury	SEVERE HEAD-INJURY; SUBARACHNOID HEMORRHAGE; LOGISTIC-REGRESSION; PROGNOSTIC MODELS; ADMISSION CHARACTERISTICS; CLASSIFICATION; IMPACT; SCALE; VALIDATION; MACHINE	Traumatic brain injury (TBI) is responsible for up to 45% of in-hospital trauma mortality. Computed tomography (CT) is central to acute TBI diagnostics, and millions of brain CT scans are conducted yearly worldwide. Though many studies have addressed individual predictors of outcome from findings on CT scans, few have done so from a multivariate perspective. As these parameters are interrelated in a complex manner, there is a need for a better understanding of them in this context. CT scans from 861 TBI patients were reviewed according to an extensive protocol. An extended analysis of CT parameters with respect to outcome was performed using linear and non-linear methods. We identified complex interactions and mutual information in many of the parameters. Variables predicting death differ from those predicting unfavorable versus favorable outcomes (Glasgow Outcome Scale scores of 1-3 versus 4-5 [GOS]). The most important parameter for prediction of unfavorable outcome is the magnitude of midline shift. In fact, this parameter, as a continuous variable, is by itself a better predictor and is better calibrated than the Marshall CT score, even for predicting death. In addition, hematoma volumes are nearly co-linear with midline shift and can be substituted for it. A score of traumatic subarachnoid/intraventricular blood components adds substantially to model calibration. A CT scoring system geared toward dichotomous GOS scores is suggested. CT parameters were found to add 6-10% additional estimated explained variance in the presence of the important clinical variables of age, Glasgow Coma Scale score, and pupillary response. Finally we present a practical clinical "rule of thumb" to help predict the probability of unfavorable outcome using clinical and CT variables.	[Nelson, David W.; Thornquist, Bjorn; Rudehill, Anders; Wanecek, Michael; Weitzberg, Eddie] Karolinska Inst, Dept Physiol & Pharmacol, Sect Anesthesiol & Intens Care, S-17177 Stockholm, Sweden; [Bellander, Bo-Michael] Karolinska Inst, Neurosurg Sect, S-17177 Stockholm, Sweden; [Nystrom, Harriet; Lilja, Anders] Karolinska Inst, Neuroradiol Sect, Dept Clin Neurosci, S-17177 Stockholm, Sweden; [MacCallum, Robert M.] Univ London Imperial Coll Sci Technol & Med, Immunogenom Grp, Div Cell & Mol Biol, London, England		Nelson, DW (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, Sect Anesthesiol & Intens Care, S-17177 Stockholm, Sweden.	david.nelson@karolinska.se	Wanecek, Michael/AAE-7998-2021	Nelson, David/0000-0003-2530-8207	Karolinska Institutet, The Swedish Research CouncilSwedish Research Council; Swedish Cancer and Traffic Injury Fund (CTRF)	Funding for this study was provided in part by the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and the Karolinska Institutet, funds from the Karolinska Institutet, The Swedish Research Council, The Swedish Cancer and Traffic Injury Fund (CTRF)	Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Armin SS, 2006, NEUROL RES, V28, P445, DOI 10.1179/016164106X115053; Ben-Hur A, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000173; Bertolini G, 2000, J Epidemiol Biostat, V5, P251; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P597; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Farin A, 2004, ACT NEUR S, V89, P101; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Gallagher CN, 2007, CURR OPIN NEUROL, V20, P403, DOI 10.1097/WCO.0b013e32821b987b; Gebel JM, 1998, STROKE, V29, P1799, DOI 10.1161/01.STR.29.9.1799; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; Hosmer DW, 2002, STAT MED, V21, P2723, DOI 10.1002/sim.1200; Hosmer DW, 1997, STAT MED, V16, P965; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; JENNETT B, 1975, LANCET, V1, P480; Kramer AA, 2007, CRIT CARE MED, V35, P2052, DOI 10.1097/01.CCM.0000275267.64078.B0; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; Meier L, 2008, J R STAT SOC B, V70, P53, DOI 10.1111/j.1467-9868.2007.00627.x; Miller KJ, 2005, J NEUROSURG, V103, P239, DOI 10.3171/jns.2005.103.2.0239; Mjolsness E, 2001, SCIENCE, V293, P2051, DOI 10.1126/science.293.5537.2051; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Noble WS, 2006, NAT BIOTECHNOL, V24, P1565, DOI 10.1038/nbt1206-1565; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Platt J. C., 1999, ADV LARGE MARGIN CLA; R Development Core Team, 2008, R LANG ENV STAT COMP; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188	36	87	88	0	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2010	27	1					51	64		10.1089/neu.2009.0986			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	548RF	WOS:000273983200004	19698072				2022-02-06	
J	Tamber, AL; Wilhelmsen, KT; Strand, LI				Tamber, Anne-Lise; Wilhelmsen, Kjersti T.; Strand, Liv Inger			Measurement properties of the Dizziness Handicap Inventory by cross-sectional and longitudinal designs	HEALTH AND QUALITY OF LIFE OUTCOMES			English	Article							QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; TRAUMATIC BRAIN-INJURY; VESTIBULAR REHABILITATION; HEALTH-STATUS; COOP/WONCA CHARTS; MULTIPLE-SCLEROSIS; CONSTRUCT-VALIDITY; DUTCH VERSION; RELIABILITY	Background: The impact of dizziness on quality of life is often assessed by the Dizziness Handicap Inventory (DHI), which is used as a discriminate and evaluative measure. The aim of the present study was to examine reliability and validity of a translated Norwegian version (DHI-N), also examining responsiveness to important change in the construct being measured. Methods: Two samples (n = 92 and n = 27) included participants with dizziness of mainly vestibular origin. A cross-sectional design was used to examine the factor structure (exploratory factor analysis), internal consistency (Cronbach's alpha), concurrent validity (Pearson's product moment correlation r), and discriminate ability (ROC curve analysis). Longitudinal designs were used to examine test-retest reliability (intraclass correlation coefficient (ICC) statistics, smallest detectable difference (SDD)), and responsiveness (Pearson's product moment correlation, ROC curve analysis; area under the ROC curve (AUC), and minimally important change (MIC)). The DHI scores range from 0 to 100. Results: Factor analysis revealed a different factor structure than the original DHI, resulting in dismissal of subscale scores in the DHI-N. Acceptable internal consistency was found for the total scale (alpha = 0.95). Concurrent correlations between the DHI-N and other related measures were moderate to high, highest with Vertigo Symptom Scale-short form-Norwegian version (r = 0.69), and lowest with preferred gait (r = -0.36). The DHI-N demonstrated excellent ability to discriminate between participants with and without 'disability', AUC being 0.89 and best cut-off point = 29 points. Satisfactory test-retest reliability was demonstrated, and the change for an individual should be >= 20 DHI-N points to exceed measurement error (SDD). Correlations between change scores of DHI-N and other self-report measures of functional health and symptoms were high (r = 0.50-0.57). Responsiveness of the DHI-N was excellent, AUC = 0.83, discriminating between self-perceived 'improved' versus 'unchanged' participants. The MIC was identified as 11 DHI-N points. Conclusions: The DHI-N total scale demonstrated satisfactory measurement properties. This is the first study that has addressed and demonstrated responsiveness to important change of the DHI, and provided values of SDD and MIC to help interpret change scores.	[Tamber, Anne-Lise] Oslo Univ Coll, Fac Hlth Sci, Oslo, Norway; [Tamber, Anne-Lise] Univ Oslo, Fac Med, Inst Gen Practice & Community Med, N-0316 Oslo, Norway; [Wilhelmsen, Kjersti T.] Bergen Univ Coll, Dept Physiotherapy, Bergen, Norway; [Wilhelmsen, Kjersti T.] Haukeland Hosp, Natl Ctr Vestibular Disorders, Dept Otorhinolaryngol Head & Neck Surg, N-5021 Bergen, Norway; [Wilhelmsen, Kjersti T.; Strand, Liv Inger] Univ Bergen, Sect Physiotherapy Sci, Dept Publ Hlth & Primary Hlth Care, N-5020 Bergen, Norway		Tamber, AL (corresponding author), Oslo Univ Coll, Fac Hlth Sci, Oslo, Norway.	AnneLise.Tamber@hf.hio.no; Kjersti.Wilhelmsen@hib.no; Liv.Strand@isf.uib.no					Ardic FN, 2006, OTOL NEUROTOL, V27, P676; ASMUNDSON GJG, 1999, J VESTIBUL RES-EQUIL, P63; Beaton DE, 2000, SPINE, V25, P3192, DOI 10.1097/00007632-200012150-00015; Bentsen BG, 1999, FAM PRACT, V16, P190, DOI 10.1093/fampra/16.2.190; Bland JM, 1996, BRIT MED J, V312, P1654, DOI 10.1136/bmj.312.7047.1654; BRUUSGAARD D, 1993, FAM PRACT, V10, P212, DOI 10.1093/fampra/10.2.212; Cattaneo D, 2007, CLIN REHABIL, V21, P771, DOI 10.1177/0269215507077602; Cattaneo D, 2006, DISABIL REHABIL, V28, P789, DOI 10.1080/09638280500404289; CHRISTOPHERSEN KA, 2003, DATABEHANDLING STATI, P247; Cohen HS, 2003, OTOLARYNG HEAD NECK, V128, P60, DOI 10.1067/mhn.2003.23; Cohen J., 2013, STAT POWER ANAL BEHA; Crosby RD, 2003, J CLIN EPIDEMIOL, V56, P395, DOI 10.1016/S0895-4356(03)00044-1; de Vet HCW, 2007, QUAL LIFE RES, V16, P131, DOI 10.1007/s11136-006-9109-9; Domholdt E., 2000, PHYS THERAPY RES PRI, V2; Duracinsky M, 2007, VALUE HEALTH, V10, P273, DOI 10.1111/j.1524-4733.2007.00182.x; ENLOE LJ, 1997, PHYS THER, V77; Fielder H, 1996, CLIN OTOLARYNGOL, V21, P124, DOI 10.1111/j.1365-2273.1996.tb01314.x; Finch E, 2002, PHYS REHABILITATION; Hall Courtney D, 2006, J Neurol Phys Ther, V30, P74; Hansson EE, 2006, J REHABIL MED, V38, P387, DOI 10.1080/16501970600768992; Holm I, 2005, EUR J PHYSIOTHER, V7, P40, DOI 10.1080/14038190510009423; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Jacobson GP, 2008, BALANCE FUNCTION ASS, P99; JACOBSON GP, 1991, J AM ACAD AUDIOL, P253; Jarlsater S., 2003, ADV PHYSIOTHER, V5, P137, DOI [10.1080/14038190310004385, DOI 10.1080/14038190310004385]; Jerosch-Herold C, 2005, BRISTISH J OCCUPATIO, V68, P347, DOI DOI 10.1177/030802260506800803; Johansson M, 2001, OTOLARYNG HEAD NECK, V125, P151, DOI 10.1067/mhn.2001.118127; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; KINNERSLEY P, 1994, BRIT J GEN PRACT, V44, P545; KREBS DE, 1993, OTOLARYNG HEAD NECK, V109, P735, DOI 10.1177/019459989310900417; Lemeshow S, 2000, APPL LOGISTIC REGRES; LIANG MH, 1995, J RHEUMATOL, V22, P1191; Liang MH, 2000, MED CARE, V38, P84, DOI 10.1097/00005650-200009002-00013; Linaker OM, 2005, NORD J PSYCHIAT, V59, P121, DOI 10.1080/08039480510022918; Lindegaard PM, 1999, SCAND J PRIM HEALTH, V17, P145; Maneesriwongul W, 2004, J ADV NURS, V48, P175, DOI 10.1111/j.1365-2648.2004.03185.x; MRUZEK M, 1995, LARYNGOSCOPE, V105, P686, DOI 10.1288/00005537-199507000-00004; Murray K, 2001, Physiother Res Int, V6, P251, DOI 10.1002/pri.232; Norman, 2003, HLTH MEASUREMENT SCA; Perez N, 2001, ACTA OTO-LARYNGOL, P145; Poon DMY, 2004, ANN OTO RHINOL LARYN, V113, P1006, DOI 10.1177/000348940411301212; Preacher K. J., 2003, UNDERSTANDING STAT, V2, P13, DOI DOI 10.1207/S15328031US0201_02; Sartorius N., 1994, QUALITY LIFE ASSESSM, P3, DOI [DOI 10.1007/978-3-642-79123-9_1, 10.1007/978-3-642-79123-9_1.]; Shepard NT, 1996, PRACTICAL MANAGEMENT; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Skoien AK, 2008, BRIT J GEN PRACT, V58, P619, DOI 10.3399/bjgp08X330744; Stratford PW, 1996, PHYS THER, V76, P1109, DOI 10.1093/ptj/76.10.1109; STREINER DL, 2003, HLTH MEASUREMENT SCA, P23; Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012; Terwee CB, 2003, QUAL LIFE RES, V12, P349, DOI 10.1023/A:1023499322593; Treleaven J, 2005, J REHABIL MED, V37, P224, DOI 10.1080/16501970510027989; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; Vereeck L, 2007, ACTA OTO-LARYNGOL, V127, P788, DOI 10.1080/00016480601075464; Vereeck L, 2006, B-ENT, V2, P75; Whitney SL, 2004, OTOL NEUROTOL, V25, P139, DOI 10.1097/00129492-200403000-00010; WHITNEY SL, 1994, PHYS THER, pS36; WHITNEY SL, 2000, VESTIBULAR REHABILIT, P371; Wilhelmsen K, 2008, BMC EAR NOSE THROAT, V8, DOI 10.1186/1472-6815-8-2; World Health Organization, 2007, INT CLASS FUNCT DIS; Yardley L, 1998, CLIN OTOLARYNGOL, V23, P442, DOI 10.1046/j.1365-2273.1998.00179.x; Yardley L, 2004, ANN INTERN MED, V141, P598, DOI 10.7326/0003-4819-141-8-200410190-00007; YARDLEY L, 2004, CLIN DISORDERS BALAN, P382; Yardley L, 2006, PSYCHOSOM MED, V68, P762, DOI 10.1097/01.psy.0000232269.17906.92; ZIMBELMAN JE, 1999, PHYS THERAPY CASE RE, V2, P232; [No title captured]; MEASURING FUNCTIONAL	66	87	90	1	4	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1477-7525			HEALTH QUAL LIFE OUT	Health Qual. Life Outcomes	DEC 21	2009	7								101	10.1186/1477-7525-7-101			16	Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Health Care Sciences & Services	544MW	WOS:000273662500001	20025754	Green Published, gold			2022-02-06	
J	Anderson, V; Catroppa, C; Morse, S; Haritou, F; Rosenfeld, JV				Anderson, Vicki; Catroppa, Cathy; Morse, Sue; Haritou, Flora; Rosenfeld, Jeffrey V.			Intellectual Outcome from Preschool Traumatic Brain Injury: A 5-Year Prospective, Longitudinal Study	PEDIATRICS			English	Article						traumatic brain injury; children; recovery of function; intelligence	CLOSED HEAD-INJURY; NEUROBEHAVIORAL RECOVERY; CHILDREN; ADOLESCENTS; SEQUELAE; AGE; PLASTICITY; SEVERITY; COHORT	INTRODUCTION: Traumatic brain injury (TBI) is a common, acquired disability that may be used as a model to understand the impact of early brain injury on brain structure and function. To date, few studies have followed very young children over time after insult. OBJECTIVE: To plot recovery and outcome of intellectual ability after early TBI over the 5 years after injury, and to identify predictors of outcome including injury, sociodemographic and preinjury characteristics, and acute functional recovery. DESIGN: Children aged between 2 and 7 years who were diagnosed with TBI (N = 54) were consecutively recruited on admission to the Royal Children's Hospital, Victoria, Australia, to participate in a prospective, longitudinal study. Our study had a between-factor design that used injury severity as the independent variable. The participants were categorized into groups according to injury severity (mild, moderate, or severe), and were compared with healthy control participants (n = 16) at the acute time point, and at 12 months, 30 months, and 5 years after injury. Intellectual measures, including verbal and nonverbal skills, attention, and processing speed, were administered. RESULTS: Children with severe injuries demonstrated slower recovery and poorer cognitive outcomes up to 5 years after injury than did those who were observed for less severe injuries. Recovery trajectories were associated with injury severity over the first 30 months after injury, with the greatest deterioration in function observed for more severe injuries. From 30 months to 5 years after injury, progress was stable. Only injury severity (as determined by the Glasgow Coma Scale score) and acute cognitive performance were strong predictors of 5-year outcomes. CONCLUSIONS: This study has confirmed the high risk of persisting and global deficits associated with severe brain insult in early childhood. Contrary to previous speculation about "growing into deficits," children with severe brain insults have more protracted recovery periods but do not continue to lose ground compared with their peers. By 30 months after insult, recovery seems to stabilize and children begin to make appropriate developmental gains. Pediatrics 2009; 124: e1064-e1071	[Anderson, Vicki; Catroppa, Cathy] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Anderson, Vicki; Catroppa, Cathy; Morse, Sue; Haritou, Flora] Royal Childrens Hosp, Dept Psychol, Melbourne, Vic, Australia; [Anderson, Vicki] Royal Childrens Hosp, Dept Speech Pathol, Melbourne, Vic, Australia; [Catroppa, Cathy] Univ Melbourne, Dept Psychol, Melbourne, Vic 3010, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia; [Rosenfeld, Jeffrey V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia		Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au	Catroppa, Cathy/AAX-9458-2021; Rosenfeld, Jeffrey V/B-7249-2011	Catroppa, Cathy/0000-0002-9750-0436; 	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia; Royal Children's Hospital Research Foundation	This study was supported by grants from the National Health and Medical Research Council of Australia and the Royal Children's Hospital Research Foundation.	ANDERSON V, 1994, ARCH DIS CHILD, V70, P476, DOI 10.1136/adc.70.6.476; Anderson V, 1997, J Int Neuropsychol Soc, V3, P147; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Bayley N., 1969, BAYLEY SCALES INFANT; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; Catroppa C, 2007, CHILD NEUROPSYCHOL, V13, P240, DOI 10.1080/09297040600837362; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Ciccetti D., 1984, VINELAND ADAPTIVE BE; COUSENS P, 1991, J PEDIATR PSYCHOL, V16, P475, DOI 10.1093/jpepsy/16.4.475; Daniel A., 1983, POWER PRIVILEGE PRES; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P89; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kraus JF., 1995, TRAUMATIC HEAD INJUR, P117; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; Lachar D., 1992, PERSONALITY INVENT S; LANGECOSACK H, 1979, NEUROPADIATRIE, V10, P105, DOI 10.1055/s-0028-1085318; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; RUTTER M, 1983, DEV NEUROPSYCHIATRY, P83; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; TAYLOR HG, 2002, NEUROPSYCHOLOGY, V16, P5; TEASDALE G, 1974, LANCET, V2, P81; TOMPKINS CA, 1990, BRAIN COGNITION, V13, P86, DOI 10.1016/0278-2626(90)90042-M; VANZOMERON E, 1994, CLIN NEUROPSYCHOLOGY; Walsh K. W., 1985, UNDERSTANDING BRAIN; Wechsler D., 1989, MANUAL PRESCHOOL PRI; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; [No title captured]	43	87	88	0	18	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	DEC	2009	124	6					E1064	E1071		10.1542/peds.2009-0365			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	524SE	WOS:000272162400031	19948612				2022-02-06	
J	Sayeed, I; Parvez, S; Wali, B; Siemen, D; Stein, DG				Sayeed, Iqbal; Parvez, Suhel; Wali, Bushra; Siemen, Detlef; Stein, Donald G.			Direct inhibition of the mitochondrial permeability transition pore: A possible mechanism for better neuroprotective effects of allopregnanolone over progesterone	BRAIN RESEARCH			English	Article						Progesterone; Allopregnanolone; Traumatic brain injury; Stroke; Patch clamp; Single channel; Cytochrome c release	TRAUMATIC BRAIN-INJURY; CEREBRAL-ARTERY OCCLUSION; CENTRAL-NERVOUS-SYSTEM; METHYL-D-ASPARTATE; CYTOCHROME-C; CYCLOSPORINE-A; CELL-DEATH; APOPTOTIC PATHWAYS; REPERFUSION INJURY; DOSE-RESPONSE	We previously demonstrated that the progesterone (PROG) metabolite allopregnanolone (AP) is more potent than FROG in the treatment of traumatic brain injury (TBI) and stroke, but the mechanisms for this differential effect are little understood. The mitochondrial permeability transition pore (mtPTP) appears to be a key player in the intrinsic pathway of apoptosis-induced loss of neurons. Its activation is accompanied by the release of cytochrome c (cyt c) from the intermembrane gap and subsequent cell death. We investigated whether mtPTP is implicated in the mechanisms of PROG and AP neuroprotection following traumatic and ischemic brain injury. To assess the neurosteroids' direct effects on mtPTP activity at the single-channel level, recordings from the inner mitochondrial membrane were obtained by a patch-clamp approach in rat liver mitoplasts. AP but not PROG strongly inhibited mtPTP currents. Interaction of AP with the PTP was further supported by a swelling assay demonstrating that AP inhibited Ca2+-triggered swelling in functionally intact rat liver and brain mitochondria. If AP inhibits the mtPTP, it should prevent the mitochondrial cyt c release seen in stroke and TBI. To test this idea, we subjected one group of rats to cortical contusion injury (CCI) and another to transient middle cerebral artery occlusion (MCAO). AP-treated animals showed substantially decreased cyt c release and AP was more potent than PROG in inhibiting mitochondrial cyt c release at 24 h post-CCI and -MCAO. Our results demonstrate that AP inhibits the mtPTP current. This may help to explain its more potent anti-apoptotic and neuroprotective effects compared to FROG. (C) 2009 Elsevier B.V. All rights reserved.	[Sayeed, Iqbal; Wali, Bushra; Stein, Donald G.] Emory Univ, Sch Med, Dept Emergency Med, Brain Res Lab, Atlanta, GA 30322 USA; [Parvez, Suhel; Siemen, Detlef] Otto VonGuericke Univ Magdegurg, Dept Neurol, D-39120 Magdeburg, Germany; [Parvez, Suhel] Leibniz Inst Neurobiol, Dept Neurophysiol, D-39118 Magdeburg, Germany		Sayeed, I (corresponding author), Emory Univ, Sch Med, Dept Emergency Med, Brain Res Lab, 1365 B Clifton Rd,Suite 5100, Atlanta, GA 30322 USA.	isayeed@emory.edu	Parvez, Suhel/E-6778-2010; Stein, Donald/AAJ-5139-2020	Parvez, Suhel/0000-0002-6318-6506; 	National institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS04851]; Alexander von Humboldt FoundationAlexander von Humboldt Foundation	We acknowledge Leslie McCann for her help in manuscript preparation. This work was supported by National institutes of Health Grant R01 NS04851. S.P. was supported by a senior fellowship from Alexander von Humboldt Foundation.	Andersson S, 1997, STEROIDS, V62, P143, DOI 10.1016/S0039-128X(96)00173-0; Andrabi SA, 2004, FASEB J, V18, P869, DOI 10.1096/fj.03-1031fje; Andrabi SA, 2004, BRAIN RES, V1017, P98, DOI 10.1016/j.brainres.2004.05.038; Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; COMPAGNONE NA, 1995, ENDOCRINOLOGY, V136, P2689, DOI 10.1210/en.136.6.2689; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; DENICOLA AF, 1993, ADV NEUROL, V59, P199; Di Lisa F, 2003, BASIC RES CARDIOL, V98, P235, DOI 10.1007/s00395-003-0415-x; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; DJEBAILI MJ, 2002, J NEUROTRAUM, V19, P1287; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; Ferrand-Drake M, 2003, J NEUROCHEM, V85, P1431, DOI 10.1046/j.1471-4159.2003.01794.x; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Garcia-Segura LM, 1999, J NEUROBIOL, V40, P574, DOI 10.1002/(SICI)1097-4695(19990915)40:4<574::AID-NEU12>3.0.CO;2-8; GIESELER A, 2008, BIOCH PHARM; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Johansson IM, 2002, BRAIN RES, V934, P125, DOI 10.1016/S0006-8993(02)02414-9; KINNALLY KW, 1992, J BIOENERG BIOMEMBR, V24, P99, DOI 10.1007/BF00769536; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kristian T, 2002, J NEUROCHEM, V83, P1297, DOI 10.1046/j.1471-4159.2002.01238.x; Kristian T, 2001, J NEUROTRAUM, V18, P1059, DOI 10.1089/08977150152693755; Liu W, 2001, BRAIN RES, V916, P239, DOI 10.1016/S0006-8993(01)03006-2; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Loupatatzis C, 2002, CELL PHYSIOL BIOCHEM, V12, P269, DOI 10.1159/000067897; Mahesh VB, 1996, J STEROID BIOCHEM, V56, P209, DOI 10.1016/0960-0760(95)00238-3; McCullough LD, 2003, TRENDS ENDOCRIN MET, V14, P228, DOI 10.1016/S1043-2760(03)00076-6; Mcewen BS, 1999, ENDOCR REV, V20, P279, DOI 10.1210/er.20.3.279; MCEWEN BS, 1994, EXP GERONTOL, V29, P431, DOI 10.1016/0531-5565(94)90022-1; Merenda A, 2006, CURR OPIN CRIT CARE, V12, P90, DOI 10.1097/01.ccx.0000216573.26686.27; MONNET FP, 1995, P NATL ACAD SCI USA, V92, P3774, DOI 10.1073/pnas.92.9.3774; Morali G, 2005, NEUROSCI LETT, V382, P286, DOI 10.1016/j.neulet.2005.03.066; PURDY RH, 1990, J MED CHEM, V33, P1572, DOI 10.1021/jm00168a008; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; Sayeed I, 2006, FASEB J, V20, P556, DOI 10.1096/fj.05-4748fje; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Schulz JB, 1999, ANN NEUROL, V45, P421, DOI 10.1002/1531-8249(199904)45:4<421::AID-ANA2>3.0.CO;2-Q; Schumacher M, 2004, GROWTH HORM IGF RES, V14, pS18, DOI 10.1016/j.ghir.2004.03.007; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; SMITH SS, 1994, PROG NEUROBIOL, V44, P55, DOI 10.1016/0301-0082(94)90057-4; Springer JE, 2001, CLIN CHEM LAB MED, V39, P299, DOI 10.1515/CCLM.2001.046; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; Tatton WG, 1998, ANN NEUROL, V44, pS134, DOI 10.1002/ana.410440720; Timby E, 2006, PSYCHOPHARMACOLOGY, V186, P414, DOI 10.1007/s00213-005-0148-7; Walf AA, 2006, NEUROBIOL LEARN MEM, V86, P35, DOI 10.1016/j.nlm.2006.01.004; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Wang XD, 2001, GENE DEV, V15, P2922; Xilouri M, 2006, EUR J NEUROSCI, V23, P43, DOI 10.1111/j.1460-9568.2005.04548.x; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Youdim MBH, 2005, J NEUROSCI RES, V79, P172, DOI 10.1002/jnr.20350; Zhu D, 2004, BRIT J ANAESTH, V93, P560, DOI 10.1093/bja/aeh233	75	87	98	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 31	2009	1263						165	173		10.1016/j.brainres.2009.01.045			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	431CV	WOS:000265039800018	19368823				2022-02-06	
J	Lo, C; Shifteh, K; Gold, T; Bello, JA; Lipton, ML				Lo, Calvin; Shifteh, Keivan; Gold, Tamar; Bello, Jacqueline A.; Lipton, Michael L.			Diffusion Tensor Imaging Abnormalities in Patients With Mild Traumatic Brain Injury and Neurocognitive Impairment	JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY			English	Article						traumatic brain injury; diffusion tensor imaging; cognitive impairment	POST-CONCUSSION SYNDROME; WHITE-MATTER INJURY; AXONAL INJURY; HEAD-INJURY; REHABILITATION; PREVALENCE; SYMPTOMS	Objective: To determine if diffusion tensor imaging can differentiate patients with chronic cognitive impairment after mild traumatic brain injury (TBI) from normal controls. Methods: Ten patients with persistent cognitive impairment after mild TBI were evaluated at least 2 years after injury. Fractional anisotropy (FA) and apparent diffusion coefficient (ADC) were measured at white matter regions susceptible to axonal injury after TBI. Comparison was made to 10 normal controls. Results: Fractional anisotropy was significantly lower (4.5%; P = 0.01) and ADC higher (7.1%; P = 0.04) in patients at the left side of the genu of the corpus callosum. The mild TBI group also demonstrated a significant increase in FA within the posterior limb of the internal capsule bilaterally (left, 5.1%; P = 0.03; right, 1.9%; P = 0.04). Conclusions: These results demonstrate low FA and high ADC in the germ of the corpus callosum of mild TBI patients with persistent cognitive impairment, suggesting that permanent white matter ultrastructural damage occurs in mild TBI, and that such damage may be associated with persistent cognitive disability. Further longitudinal studies are warranted to elucidate the full importance of the findings.	[Lo, Calvin; Shifteh, Keivan; Gold, Tamar; Bello, Jacqueline A.; Lipton, Michael L.] Montefiore Med Ctr, Dept Radiol, Bronx, NY 10467 USA; [Lipton, Michael L.] Montefiore Med Ctr, Dept Psychiat & Behav Sci, Bronx, NY 10467 USA; Albert Einstein Coll Med, Bronx, NY 10467 USA; [Lipton, Michael L.] Nathan S Kline Inst Psychiat Res, Ctr Adv Brain Imaging, Orangeburg, NY 10962 USA		Lipton, ML (corresponding author), Montefiore Med Ctr, Dept Radiol, 111 E 210th St, Bronx, NY 10467 USA.	mlipton@aecom.yu.edu					Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Barth JT, 1996, CLIN ELECTROENCEPHAL, V27, P183; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BOHNEN N, 1993, NEUROPSY NEUROPSY BE, V6, P193; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Houenou J, 2007, MOL PSYCHIATR, V12, P1001, DOI 10.1038/sj.mp.4002010; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Palmese CA, 2000, BRAIN INJURY, V14, P535; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Yu CS, 2007, NEUROIMAGE, V36, P411, DOI 10.1016/j.neuroimage.2007.03.003; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	29	87	90	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0363-8715	1532-3145		J COMPUT ASSIST TOMO	J. Comput. Assist. Tomogr.	MAR-APR	2009	33	2					293	297		10.1097/RCT.0b013e31817579d1			5	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	427KB	WOS:000264777100025	19346863				2022-02-06	
J	Hartl, R; Gerber, LM; Ni, QH; Ghajar, J				Haertl, Roger; Gerber, Linda M.; Ni, Quanhong; Ghajar, Jamshid			Effect of early nutrition on deaths due to severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						metabolism; nutrition; outcome; traumatic brain injury	SEVERE HEAD-INJURY; ENTERAL NUTRITION; METABOLIC RESPONSE; CONTROLLED-TRIAL; CARE; MANAGEMENT; MORTALITY; STATE	Object. Traumatic brain injury (TBI) remains a serious public health crisis requiring continuous improvement in pre-hospital and inhospital care. This condition results in a hypermetabolic state that increases systemic and cerebral energy requirements, but achieving adequate nutrition to meet this demand has not been a priority in reducing death due to TBI. The effect of timing and quantity of nutrition on death within the first 2 weeks of injury was analyzed in a large prospective database of adult patients with severe TBI in New York State. Methods. The study is based on 797 patients with severe TBI (Glasgow Coma Scale [GCS] score < 9) treated at 22 trauma centers enrolled in a New York State quality improvement program between 2000 and 2006. The inhospital section of the prospectively collected database includes information on age, initial GCS score, weight and height, results of CT scanning, and daily parameters such as pupillary status, arterial hypotension, GCS score, and number of calories fed per day. Results. Patients who were not fed within 5 and 7 days after TBI had a 2- and 4-fold increased likelihood of death, respectively. The amount of nutrition in the first 5 days was related to death; every 10-kcal/kg decrease in caloric intake was associated with a 30-40% increase in mortality rates. This held up even after controlling for factors known to affect mortality, including arterial hypotension, age, pupillary status, initial GCS score, and CT scan findings. Conclusions. Nutrition is a significant predictor of death due to TBI. Together with prevention of arterial hypotension, hypoxia, and intracranial hypertension it is one of the few therapeutic interventions that can directly affect TBI outcome.	[Haertl, Roger; Ghajar, Jamshid] Weill Cornell Med Coll, Dept Neurol Surg, New York, NY USA; [Gerber, Linda M.; Ni, Quanhong] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY USA; [Ghajar, Jamshid] Brain Trauma Fdn, New York, NY USA		Hartl, R (corresponding author), Weill Cornell Med Coll, Dept Neurol Surg, Starr Bldg,Room 651,525 E 68th St,Box 99, New York, NY USA.	roger@hartlmd.net					Bastian L, 1998, UNFALLCHIRURG, V101, P105, DOI 10.1007/s001130050242; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock RM, 2000, J NEUROTRAUM, V17, P449; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CLIFTON GL, 1986, J NEUROSURG, V64, P895, DOI 10.3171/jns.1986.64.6.0895; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; DEUTSCHMAN CS, 1986, J NEUROSURG, V64, P89, DOI 10.3171/jns.1986.64.1.0089; EYER SD, 1993, J TRAUMA, V34, P639, DOI 10.1097/00005373-199305000-00005; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Jolliet P, 1999, CLIN NUTR, V18, P47, DOI 10.1016/S0261-5614(99)80049-1; Marik PE, 2001, CRIT CARE MED, V29, P2264, DOI 10.1097/00003246-200112000-00005; Merenda A, 2006, CURR OPIN CRIT CARE, V12, P90, DOI 10.1097/01.ccx.0000216573.26686.27; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; PEREL P, 2006, COCHRANE DB SYST REV, V3; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; ROBERTSON CS, 1991, J NEUROSURG, V74, P43, DOI 10.3171/jns.1991.74.1.0043; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Sampalis JS, 1999, J TRAUMA, V46, P565, DOI 10.1097/00005373-199904000-00004; SMITH JS, 1990, J TRAUMA, V30, P1533, DOI 10.1097/00005373-199012000-00017; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Taylor SJ, 1999, CRIT CARE MED, V27, P2525, DOI 10.1097/00003246-199911000-00033; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Weekes Elizabeth, 1996, Journal of Parenteral and Enteral Nutrition, V20, P31, DOI 10.1177/014860719602000131; YOUNG B, 1987, J NEUROSURG, V67, P668, DOI 10.3171/jns.1987.67.5.0668	28	87	98	0	15	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JUL	2008	109	1					50	56		10.3171/JNS/2008/109/7/0050			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	319YS	WOS:000257201500010	18590432				2022-02-06	
J	Parcell, DL; Ponsford, JL; Redman, JR; Rajarathnam, SM				Parcell, Diane L.; Ponsford, Jeitnie L.; Redman, Jenitifet R.; Rajarathnam, Shantha M.			Poor sleep quality and changes in objectively recorded sleep after traumatic brain injury: A preliminary study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						anxiety; brain injuries; depression; recovery of function; rehabilitation; sleep	DAYTIME SLEEPINESS; HOSPITAL ANXIETY; EEG; DEPRESSION; INSOMNIA; DISTURBANCES; MECHANISMS; COMPLAINTS; DISORDERS; PATTERNS	Objectives: To evaluate changes in sleep quality and objectively assessed sleep parameters after traumatic brain injury (TBI) and to investigate the relationship between such changes and mood State and injury characteristics. Design: Survey and laboratory-based nocturnal polysommography. Setting: Sleep laboratory. Participants: Ten community-based subjects with moderate to very severe TBI and 10 age- and sex-matched controls from the general community. Interventions: Not applicable. Main Outcome Measures: Pittsburgh Sleep Quality Index for self-report sleep quality, nocturnal polysommography for objective sleep recording, and Hospital Anxiety and Depression Scales. Results: Compared with controls, TBI patients reported significantly poorer sleep quality and higher levels of anxiety and depression. Objective sleep recording showed that TBI patients showed an increase in deep (slow wave) sleep, a reduction in rapid eye movement sleep, and more frequent nighttime awakenings. No significant relationship was observed between these changes in sleep and injury severity of time. since injury. Anxiety and depression covaried with the observed changes in sleep. Conclusions: The findings contribute to the growing body of evidence that sleep is involved in the physiologic processes Underlying neural recovery. The association between anxiety and depression and the observed changes in sleep in TBI patients warrants further examination to determine whether a causative relationship exists.	[Parcell, Diane L.; Ponsford, Jeitnie L.; Redman, Jenitifet R.; Rajarathnam, Shantha M.] Monash Univ, Sch Psychol Psychiat & Psychol Med, Melbourne, Vic 3800, Australia; [Ponsford, Jeitnie L.] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia		Rajarathnam, SM (corresponding author), Monash Univ, Sch Psychol Psychiat & Psychol Med, Bldg 17, Melbourne, Vic 3800, Australia.	shantha.rajarathnam@med.monash.edu.au	Rajaratnam, Shantha/D-8144-2012; Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604; Rajaratnam, Shantha/0000-0001-7527-8558	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [334002]	Supported in part by the National Health and Medical Research Council (project no. 334002).	Achermann P, 2001, BRAIN RES, V913, P220, DOI 10.1016/S0006-8993(01)02796-2; [Anonymous], 1992, SLEEP, V15, P173; Armitage R, 2001, SLEEP MED REV, V5, P237, DOI 10.1053/smrv.2000.0144; Barbe F, 1998, AM J RESP CRIT CARE, V158, P18, DOI 10.1164/ajrccm.158.1.9709135; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Benca R. M., 2000, PRINCIPLES PRACTICE, P1140; Benington JH, 2003, PROG NEUROBIOL, V69, P71, DOI 10.1016/S0301-0082(03)00018-2; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; BLIWISE BL, 2000, PRINCIPLES PRACTICE, P26; BOURDET C, 1994, J PSYCHOSOM RES, V38, P93, DOI 10.1016/0022-3999(94)90140-6; BROUGHTON RJ, 2000, PRINCIPLES PRACTICE, P693; Busek P, 2000, Sb Lek, V101, P233; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cajochen C, 1999, Sleep Res Online, V2, P65; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Coenen AML, 1998, CONSCIOUS COGN, V7, P42, DOI 10.1006/ccog.1997.0324; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; Evans BM, 2002, J ROY SOC MED, V95, P591, DOI 10.1258/jrsm.95.12.591; FEINBERG I, 1974, J PSYCHIATR RES, V10, P283, DOI 10.1016/0022-3956(74)90011-9; Ferrara M, 1999, Sleep Res Online, V2, P15; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Frieboes RM, 1999, J NEUROPSYCH CLIN N, V11, P354, DOI 10.1176/jnp.11.3.354; GRAHAM DI, 1999, REHABILITATION ADULT, P19; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; Harner P, 1974, REV INT 10 20 SYSTEM; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Huber R, 2004, NATURE, V430, P78, DOI 10.1038/nature02663; Huber R, 2000, J NEUROPHYSIOL, V84, P1888, DOI 10.1152/jn.2000.84.4.1888; Institute of Medicine; Committee on Sleep Medicine and Research, 2006, SLEEP DIS SLEEP DEPR; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kajimura N, 1998, PSYCHIAT CLIN NEUROS, V52, P317, DOI 10.1046/j.1440-1819.1998.00401.x; Kecklund G, 2004, BIOL PSYCHOL, V66, P169, DOI 10.1016/j.biopsycho.2003.10.004; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Kolb B, 2004, SCI PRACT NEUROPSYCH, P30; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LAUER CJ, 1991, BIOL PSYCHIAT, V29, P979, DOI 10.1016/0006-3223(91)90355-P; Legros B, 2003, SLEEP MED, V4, P51, DOI 10.1016/S1389-9457(02)00217-4; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Pace-Schott EF, 2002, NAT REV NEUROSCI, V3, P591, DOI 10.1038/nrn895; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Porkka-Heiskanen T, 1997, SCIENCE, V276, P1265, DOI 10.1126/science.276.5316.1265; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; Rechtschaffen A., 1968, MANUAL STANDARDIZED; Riemann D, 2001, BIOL PSYCHOL, V57, P67, DOI 10.1016/S0301-0511(01)00090-4; Roehrs T, 2001, SLEEP MED REV, V5, P287, DOI 10.1053/smrv.2001.0162; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; Schabus M, 2004, SLEEP, V27, P1479, DOI 10.1093/sleep/27.7.1479; Steele DL, 2005, CHRONOBIOL INT, V22, P89, DOI 10.1081/CBI-200042428; Tononi G, 2003, BRAIN RES BULL, V62, P143, DOI 10.1016/j.brainresbull.2003.09.004; UHDE TW, 2000, PRINCIPLES PRACTICE, P1123; Van Cauter E, 2000, JAMA-J AM MED ASSOC, V284, P861, DOI 10.1001/jama.284.7.861; Voderholzer U, 2003, DEPRESS ANXIETY, V17, P162, DOI 10.1002/da.10101; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	61	87	89	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2008	89	5					843	850		10.1016/j.apmr.2007.09.057			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	341ST	WOS:000258735900007	18452730				2022-02-06	
J	Delaney, JS; Al-Kashmiri, A; Drummond, R; Correa, JA				Delaney, J. S.; Al-Kashmiri, A.; Drummond, R.; Correa, J. A.			The effect of protective headgear on head injuries and concussions in adolescent football (soccer) players	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; UNIVERSITY FOOTBALL; ICE HOCKEY; PREVALENCE; MECHANISMS; COLLEGIATE; STATES; SPORT; RISK	Objective: To examine the effects of protective headgear in adolescent football (soccer) players. Design: Cross-sectional study. Setting: Oakville Soccer Club, Oakville, Canada. Participants: Football players aged 12-17 years. Intervention: A questionnaire examining the 2006 football season using self-reported symptoms. Main outcome measures: The number of concussions experienced during the current football season, the duration of symptoms, injuries to the head and face and any associated risk factors for these injuries. Results: In the population studied, 47.8% had experienced symptoms of a concussion during the current football year. 26.9% of athletes who wore headgear (HG) and 52.8% of those who did not wear headgear (No-HG) had concussions. Approximately 4 out of 5 athletes in each group did not realize they had suffered a concussion. More than one concussion was experienced by 50.0% of the concussed HG athletes and 69.3% of the concussed No-HG group. 23.9% of all concussed players experienced symptoms for at least 1 day or longer. Variables that increased the risk of suffering a concussion during the 2006 football year included being female and not wearing headgear. Being female and not wearing football headgear increased the risk of suffering an abrasion, laceration or contusion on areas of the head covered by football headgear. Conclusion: Adolescent football players experience a significant number of concussions. Being female may increase the risk of suffering a concussion and injuries on the head and face, while the use of football headgear may decrease the risk of sustaining these injuries.	[Delaney, J. S.] McGill Sport Med Clin, Montreal, PQ H2W 1S4, Canada; [Delaney, J. S.; Drummond, R.] McGill Univ, Ctr Hlth, Dept Emergency Med, Montreal, PQ, Canada; [Correa, J. A.] McGill Univ, Dept Math & Stat, Montreal, PQ, Canada		Delaney, JS (corresponding author), McGill Sport Med Clin, 475 Pine Ave W, Montreal, PQ H2W 1S4, Canada.	j.delaney@mcgill.ca	Al-Kashmiri, Ammar/AAG-4008-2020				Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Barth J T, 2000, Dent Clin North Am, V44, P67; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Delaney J Scott, 2005, Clin J Sport Med, V15, P216, DOI 10.1097/01.jsm.0000168077.74497.a4; Delaney JS, 1999, CLIN J SPORT MED, V9, P121; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Delaney JS, 2005, J EMERG MED, V29, P189, DOI 10.1016/j.jemermed.2005.01.020; Delaney JS, 2004, CLIN J SPORT MED, V14, P80, DOI 10.1097/00042752-200403000-00005; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HICKEY JC, 1967, J AM DENT ASSOC, V74, P735, DOI 10.14219/jada.archive.1967.0145; Hinton-Bayre AD, 2004, J SCI MED SPORT, V7, P400, DOI 10.1016/S1440-2440(04)80035-5; JANDA DH, 1995, AM J SPORT MED, V23, P340, DOI 10.1177/036354659502300316; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; *PED AAO, 2000, PEDIATRICS, V105, P659; *PED TAAO, 1988, PHYSICIAN SPORTSMED, V16, P165; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Sallis RE, 2000, MED SCI SPORT EXER, V32, P1820, DOI 10.1097/00005768-200011000-00002; SCHMIDTOLSEN S, 1991, AM J SPORT MED, V19, P273, DOI 10.1177/036354659101900311; Smodlaka VN, 1984, PHYSICIAN SPORTSMED, V12, P127, DOI DOI 10.1080/00913847.1984.11701777; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Spiegelman D, 2005, AM J EPIDEMIOL, V162, P199, DOI 10.1093/aje/kwi188; STENGER J M, 1987, Basal Facts, V9, P133; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Withnall C, 2005, BRIT J SPORT MED, V39, pI40, DOI 10.1136/bjsm.2005.019174; WITHNALL C, 2005, BR J SPORTS MED S1, V39, P48; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	44	87	87	0	32	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	FEB	2008	42	2					110	115		10.1136/bjsm.2007.037689			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	259RU	WOS:000252957200006	17615173				2022-02-06	
J	Meyer-Heim, A; Borggraefe, I; Ammann-Reiffer, C; Berweck, S; Sennhauser, FH; Colombo, G; Knecht, B; Heinen, F				Meyer-Heim, A.; Borggraefe, I.; Ammann-Reiffer, C.; Berweck, St; Sennhauser, F. H.; Colombo, G.; Knecht, B.; Heinen, F.			Feasibility of robotic-assisted locomotor training in children with central gait impairment	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							WEIGHT-SUPPORTED TREADMILL; RANDOMIZED CLINICAL-TRIAL; TRAUMATIC BRAIN-INJURY; SPASTIC CEREBRAL-PALSY; GROSS MOTOR FUNCTION; OUTCOME ASSESSMENTS; REHABILITATION; STROKE; PEOPLE	Intensive, task-specific training enabled by a driven gait orthosis (DGO) may be a cost-effective means of improving walking performance in children. A paediatric DGO has recently been developed. This study was the first paediatric trial aimed to determine the feasibility of robotic-assisted treadmill training in children with central gait impairment (n=26; 11 females, 15 males; mean age 10y 1mo [SD 4y]; range 5y 2mo-19y 5mo). Diagnoses of the study group included cerebral palsy (n=19; Gross Motor Function Classification System Levels I-IV), traumatic brain injury (n=1), Guillain-Barre syndrome (n=2), incomplete paraplegia (n=2), and haemorrhagic shock (n=1), and encephalopathy (n=1). Sixteen children were in-patients and 10 were outpatients. Twenty-four of the 26 patients completed the training which consisted of a mean of 19 sessions (SD 2.2; range 13-21) in the in-patient group and 12 sessions (SD 1.0; range 10-13) in the outpatient group. Gait speed and 6-Minute Walking Test increased significantly (p < 0.01). Functional Ambulation Categories and Standing dimension (in-patient group p < 0.01; outpatient group p < 0.05) of the Gross Motor Function Measure improved significantly. DGO training was successfully integrated into the rehabilitation programme and findings suggest an improvement of locomotor performance.	Univ Childrens Hosp Zurich, CH-8910 Affoltern Am Albis, Switzerland; Univ Childrens Hosp Zurich, Rehabil Ctr, Zurich, Switzerland; Univ Munich, Dr von Haunersches Childrens Hosp, Dept Paediat Neurol & Dev Med, Munich, Germany; AG Hocoma, Volketswil, Switzerland		Meyer-Heim, A (corresponding author), Univ Childrens Hosp Zurich, Muhlebergstr 104, CH-8910 Affoltern Am Albis, Switzerland.	Andreas.Meyer-Heim@kispi.unizh.ch	Berweck, Steffen/N-1422-2013; Borggraefe, Ingo/AAC-4966-2020; Heinen, Florian/B-6594-2015	Heinen, Florian/0000-0002-3872-6136; Ammann-Reiffer, Corinne/0000-0003-1766-7023			Bagley AM, 2007, DEV MED CHILD NEUROL, V49, P181, DOI 10.1111/j.1469-8749.2007.00181.x; Barbeau H, 2003, ARCH PHYS MED REHAB, V84, P1458, DOI 10.1016/S0003-9993(03)00361-7; Behmran AL, 2000, PHYS THER, V80, P688, DOI 10.1093/ptj/80.7.688; Blundell SW, 2003, CLIN REHABIL, V17, P48, DOI 10.1191/0269215503cr584oa; Brown TH, 2005, J HEAD TRAUMA REHAB, V20, P402, DOI 10.1097/00001199-200509000-00002; Cherng RJ, 2007, AM J PHYS MED REHAB, V86, P548, DOI 10.1097/PHM.0b013e31806dc302; Colombo G, 2000, J REHABIL RES DEV, V37, P693; Damiano DL, 1998, ARCH PHYS MED REHAB, V79, P119, DOI 10.1016/S0003-9993(98)90287-8; Day Jane A, 2004, Pediatr Phys Ther, V16, P106, DOI 10.1097/01.PEP.0000127569.83372.C8; Dietz V, 2004, J APPL PHYSIOL, V96, P1954, DOI 10.1152/japplphysiol.00942.2003; Dobkin B, 2006, NEUROLOGY, V66, P484, DOI 10.1212/01.wnl.0000202600.72018.39; Dobkin BH, 2005, NEW ENGL J MED, V352, P1677, DOI 10.1056/NEJMcp043511; Dodd KJ, 2003, DEV MED CHILD NEUROL, V45, P652, DOI 10.1017/S0012162203001221; Duncan P, 2003, STROKE, V34, P2173, DOI 10.1161/01.STR.0000083699.95351.F2; Edgerton V R, 1997, Adv Neurol, V72, P233; Hesse S, 2001, NEUROREHABILITATION, V16, P133; Hesse S, 2003, CURR OPIN NEUROL, V16, P705, DOI 10.1097/00019052-200312000-00010; Johansson BB, 2000, STROKE, V31, P223, DOI 10.1161/01.STR.31.1.223; McNevin NH, 2000, ARCH PHYS MED REHAB, V81, P525, DOI 10.1053/mr.2000.4429; Oeffinger D, 2007, DEV MED CHILD NEUROL, V49, P172, DOI 10.1111/j.1469-8749.2007.00172.x; Riener R, 2005, IEEE T NEUR SYS REH, V13, P380, DOI 10.1109/TNSRE.2005.848628; Russell DJ, 2000, PHYS THER, V80, P873, DOI 10.1093/ptj/80.9.873; Schindl MR, 2000, ARCH PHYS MED REHAB, V81, P301, DOI 10.1053/apmr.2000.0810301; Song WH, 2003, ARCH PHYS MED REHAB, V84, pE2; Wade D, 1992, MEASUREMENT NEUROLOG; Wilson DJ, 2006, AM J PHYS MED REHAB, V85, P68, DOI 10.1097/01.phm.0000193507.28759.37; Winchester Patricia, 2006, Phys Med Rehabil Clin N Am, V17, P159, DOI 10.1016/j.pmr.2005.10.008; Wirz M, 2005, ARCH PHYS MED REHAB, V86, P672, DOI 10.1016/j.apmr.2004.08.004	28	87	89	1	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0012-1622	1469-8749		DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	DEC	2007	49	12					900	906		10.1111/j.1469-8749.2007.00900.x			7	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	234TR	WOS:000251187400007	18039236				2022-02-06	
J	VanLandingham, JW; Cekic, M; Cutler, S; Hoffman, SW; Stein, DG				VanLandingham, Jacob W.; Cekic, Milos; Cutler, Sarah; Hoffman, Stuart W.; Stein, Donald G.			Neurosteroids reduce inflammation after TBI through CD55 induction	NEUROSCIENCE LETTERS			English	Article						traumatic brain injury; progesterone; allopregnanolone CD55; inflammation	TRAUMATIC BRAIN-INJURY; PROGESTERONE TREATMENT; CORTICAL CONTUSION; RECEPTOR PXR; CELL-DEATH; COMPLEMENT; EXPRESSION; ALLOPREGNANOLONE; EDEMA; C3	The inflammatory cascade that follows traumatic brain injury may lead to secondary cell death and can impede recovery of function. Complement factors and their convertases are increased in glia after brain injury and lead to the production of inflammatory products that kill vulnerable neurons. Progesterone and its metabolite allopregnanolone (5 alpha-pregnan-3 beta-ol-20-one) have been shown to reduce the expression of inflammatory cytokines in the acute stages of brain injury, although how they do this is not completely understood. In this study we show that both progesterone and allopregnanolone treatments enhance the production of CD55 following contusion injuries of the cerebral cortex in rats. CD55, a single-chain type 1 cell surface protein, is a potent inhibitor of the complement convertases which are activators of the inflammatory cascade. The increased expression of CD55 could be an important mechanism by which steroids help to reduce the cerebral damage caused by inflammation. (c) 2007 Elsevier Ireland Ltd. All rights reserved.	Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA		Stein, DG (corresponding author), Emory Univ, Brain Res Lab, Suite 5100,1365-B Clifton Rd NE, Atlanta, GA 30322 USA.	dstei04@emory.edu	Cekic, Milos/AAR-8250-2020; Stein, Donald/AAJ-5139-2020		NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM008169] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS048451-02, R01 NS048451, R01 NS048451-01A2, R01 NS048451-03, R01 NS048451-03S1] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R01N538664, R01N540825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048451] Funding Source: NIH RePORTER		Baufreton C, 2005, ANN THORAC SURG, V79, P1597, DOI 10.1016/j.athoracsur.2004.08.061; Birzniece V, 2006, BRAIN RES REV, V51, P212, DOI 10.1016/j.brainresrev.2005.11.001; Blatteis CM, 2004, FRONT BIOSCI-LANDMRK, V9, P915, DOI 10.2741/1297; Boos L, 2004, J IMMUNOL, V173, P4708, DOI 10.4049/jimmunol.173.7.4708; Ciriza I, 2006, J NEUROBIOL, V66, P916, DOI 10.1002/neu.20293; Conti AC, 1998, J NEUROSCI, V18, P5663; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Emmerling MR, 1997, IMMUNOPHARMACOLOGY, V38, P101, DOI 10.1016/S0162-3109(97)00067-2; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Hosie AM, 2006, NATURE, V444, P486, DOI 10.1038/nature05324; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Katayama Y, 2003, ACTA NEUROCHIR SUPPL, V86, P323; KAUL A, 1995, AM J REPROD IMMUNOL, V34, P236, DOI 10.1111/j.1600-0897.1995.tb00947.x; Kim DD, 2006, J IMMUNOL, V177, P5558, DOI 10.4049/jimmunol.177.8.5558; Kliewer SA, 1999, RECENT PROG HORM RES, V54, P345; KUTTNERKONDO L, 2007, J BIOL CHEM; Lang E W, 1995, New Horiz, V3, P400; Langmade SJ, 2006, P NATL ACAD SCI USA, V103, P13807, DOI 10.1073/pnas.0606218103; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Mocco J, 2006, CIRC RES, V99, P209, DOI 10.1161/01.RES.0000232544.90675.42; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; Ogden CA, 2006, CURR DIRECT AUTOIMMU, V9, P120; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Ren K, 2000, BRAIN RES, V865, P272, DOI 10.1016/S0006-8993(00)02267-8; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Singh M, 2006, ENDOCRINE, V29, P271, DOI 10.1385/ENDO:29:2:271; Song WC, 2004, CURR DIRECT AUTOIMMU, V7, P181; Stiefel MF, 2005, J NEUROSURG, V103, P707, DOI 10.3171/jns.2005.103.4.0707; VanLandingham JW, 2006, NEUROPHARMACOLOGY, V51, P1078, DOI 10.1016/j.neuropharm.2006.07.015; Weetman AP, 1999, THYROID, V9, P643, DOI 10.1089/thy.1999.9.643; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; YOU Z, 2007, J CEREB BLOOD FLOW M; Zucchini N, 2005, BBA-MOL CELL RES, V1745, P48, DOI 10.1016/j.bbamcr.2005.02.005	44	87	89	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	SEP 25	2007	425	2					94	98		10.1016/j.neulet.2007.08.045			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	222IZ	WOS:000250291000006	17826908	Green Accepted			2022-02-06	
J	Leinhase, I; Rozanski, M; Harhausen, D; Thurman, JM; Schmidt, OI; Hossini, AM; Taha, ME; Rittirsch, D; Ward, PA; Holers, VM; Ertel, W; Stahel, PF				Leinhase, Iris; Rozanski, Michal; Harhausen, Denise; Thurman, Joshua M.; Schmidt, Oliver I.; Hossini, Amir M.; Taha, Mohy E.; Rittirsch, Daniel; Ward, Peter A.; Holers, V. Michael; Ertel, Wolfgang; Stahel, Philip F.			Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice	JOURNAL OF NEUROINFLAMMATION			English	Article; Proceedings Paper	21st International Complement Workshop	OCT 20-27, 2006	Beijing, PEOPLES R CHINA				CLOSED-HEAD INJURY; CENTRAL-NERVOUS-SYSTEM; NEURONAL CELL-DEATH; CLINICAL-TRIALS; FUNCTIONAL RECOVERY; NEUROPROTECTION; INFLAMMATION; DISEASE; MODEL; PROTEIN	Background: The posttraumatic response to traumatic brain injury (TBI) is characterized, in part, by activation of the innate immune response, including the complement system. We have recently shown that mice devoid of a functional alternative pathway of complement activation ( factor B-/-mice) are protected from complement-mediated neuroinflammation and neuropathology after TBI. In the present study, we extrapolated this knowledge from studies in genetically engineered mice to a pharmacological approach using a monoclonal anti-factor B antibody. This neutralizing antibody represents a specific and potent inhibitor of the alternative complement pathway in mice. Methods: A focal trauma was applied to the left hemisphere of C57BL/ 6 mice (n = 89) using a standardized electric weight-drop model. Animals were randomly assigned to two treatment groups: ( 1) Systemic injection of 1 mg monoclonal anti-factor B antibody (mAb 1379) in 400 mu l phosphate-buffered saline (PBS) at 1 hour and 24 hours after trauma; ( 2) Systemic injection of vehicle only (400 mu l PBS), as placebo control, at identical time-points after trauma. Sham-operated and untreated mice served as additional negative controls. Evaluation of neurological scores and analysis of brain tissue specimens and serum samples was performed at defined time-points for up to 1 week. Complement activation in serum was assessed by zymosan assay and by murine C5a ELISA. Brain samples were analyzed by immunohistochemistry, terminal deoxynucleotidyl transferase dUTP nick-end labeling ( TUNEL) histochemistry, and real-time RT-PCR. Results: The mAb 1379 leads to a significant inhibition of alternative pathway complement activity and to significantly attenuated C5a levels in serum, as compared to head-injured placebo-treated control mice. TBI induced histomorphological signs of neuroinflammation and neuronal apoptosis in the injured brain hemisphere of placebo-treated control mice for up to 7 days. In contrast, the systemic administration of an inhibitory anti-factor B antibody led to a substantial attenuation of cerebral tissue damage and neuronal cell death. In addition, the posttraumatic administration of the mAb 1379 induced a neuroprotective pattern of intracerebral gene expression. Conclusion: Inhibition of the alternative complement pathway by posttraumatic administration of a neutralizing anti-factor B antibody appears to represent a new promising avenue for pharmacological attenuation of the complement-mediated neuroinflammatory response after head injury.	Charite Univ Med Berlin, Sch Med, Dept Trauma & Reconstruct Surg, D-12200 Berlin, Germany; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Colorado, Sch Med, Dept Orthoped Surg, Denver, CO 80204 USA		Stahel, PF (corresponding author), Charite Univ Med Berlin, Sch Med, Dept Trauma & Reconstruct Surg, Campus Benjamin Franklin, D-12200 Berlin, Germany.	iris.leinhase@charite.de; michalr@gazeta.pl; denise.harhausen@charite.de; joshua.thurman@uchsc.edu; olischmidt@web.de; amir.hossini@charite.de; mohy_kom@yahoo.com; drittirs@med.umich.edu; pward@umich.edu; michael.holers@uchsc.edu; wolfgang.ertel@charite.de; philip.stahel@dhha.org		Rittirsch, Daniel/0000-0002-1185-2431	NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01 AI31105, R01 AI031105] Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K08 DK064790] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R37 GM029507, GM 61656, R01 GM029507, GM 029507, R01 GM061656] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI031105] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R37GM029507, R01GM061656, R01GM029507] Funding Source: NIH RePORTER		Atkinson C, 2005, J CLIN INVEST, V115, P2444, DOI 10.1172/JCI25208; Banda NK, 2006, J IMMUNOL, V177, P1904, DOI 10.4049/jimmunol.177.3.1904; Barnum SR, 1999, MOL MED, V5, P569, DOI 10.1007/BF03402070; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Elward K, 2003, MOL IMMUNOL, V40, P85, DOI 10.1016/S0161-5890(03)00109-3; Felderhoff-Mueser U, 2005, TRENDS NEUROSCI, V28, P487, DOI 10.1016/j.tins.2005.06.008; FRANCIS K, 2003, EXPERT REV MOL MED, P1; Harris CL, 2002, BIOCHEM SOC T, V30, P1019, DOI 10.1042/bst0301019; Hicks RR, 2002, J NEUROTRAUM, V19, P705, DOI 10.1089/08977150260139093; Holers VM, 2004, MOL IMMUNOL, V41, P147, DOI 10.1016/j.molimm.2004.03.012; Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kirschfink M, 1997, IMMUNOPHARMACOLOGY, V38, P51, DOI 10.1016/S0162-3109(97)00057-X; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Kulkarni AP, 2005, ANN NY ACAD SCI, V1056, P413, DOI 10.1196/annals.1352.020; Kulkarni AP, 2004, ANN NY ACAD SCI, V1035, P147, DOI 10.1196/annals.1332.010; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Morgan BP, 1997, IMMUNOPHARMACOLOGY, V38, P43; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nataf S, 1999, TRENDS NEUROSCI, V22, P397, DOI 10.1016/S0166-2236(98)01390-3; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pillay NS, 2005, ANN NY ACAD SCI, V1056, P450, DOI 10.1196/annals.1352.021; Qiao F, 2006, AM J PATHOL, V169, P1039, DOI 10.2353/ajpath.2006.060248; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Reinert MM, 1999, NEUROL RES, V21, P330, DOI 10.1080/01616412.1999.11740940; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Sauerland S, 2004, LANCET, V364, P1291, DOI 10.1016/S0140-6736(04)17202-4; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stahel Philip F, 2006, Expert Rev Clin Immunol, V2, P445, DOI 10.1586/1744666X.2.3.445; Taube C, 2006, P NATL ACAD SCI USA, V103, P8084, DOI 10.1073/pnas.0602357103; Thurman JM, 2006, J IMMUNOL, V176, P1305, DOI 10.4049/jimmunol.176.3.1305; Thurman JM, 2005, MOL IMMUNOL, V42, P87, DOI 10.1016/j.molimm.2004.07.043; Thurman JM, 2006, J AM SOC NEPHROL, V17, P707, DOI 10.1681/ASN.2005070698; Van Beek J, 2003, ANN NY ACAD SCI, V992, P56; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Wong A K, 1999, IDrugs, V2, P686; Woodruff TM, 2006, FASEB J, V20, P1407, DOI 10.1096/fj.05-5814com; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008	49	87	87	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	MAY 2	2007	4								13	10.1186/1742-2094-4-13			12	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Immunology; Neurosciences & Neurology	213RX	WOS:000249685900002	17474994	gold, Green Published			2022-02-06	
J	Broglio, SP; Ferrara, MS; Piland, SG; Anderson, RB				Broglio, S. P.; Ferrara, M. S.; Piland, S. G.; Anderson, R. B.			Concussion history is not a predictor of computerised neurocognitive performance	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							NEUROPSYCHOLOGICAL TEST PROTOCOL; SPORT-RELATED CONCUSSION; FOOTBALL PLAYERS; STABILITY; RECOVERY	Background: The long term effects of self reported concussion on neurocognitive functioning have been found to be variable. Objectives: To evaluate cognitive performance on the Headminder concussion resolution index (CRI) and ImPACT assessment tests of subjects with and without a history of self reported concussion. Methods: A retrospective analysis was completed on 235 Headminder CRI baseline assessments and 264 ImPACT baseline assessments. Participants were divided into four groups on the basis of reported number of concussions (zero, one, two, or three). Multivariate analysis of variance was used to evaluate differences between the concussion history groups on the two computer based concussion assessment programs. Results: Multivariate analysis of variance indicated no significant difference between those with and without a history of concussion on the CRI (Lambda = 0.963, F-(15,F- 627.05) = 0.57, p = 0.898). It also revealed no significant differences between groups on the ImPACT test (Lambda = 0.951, F-(12,F- (672.31)) = 1.07, p = 0.381). Conclusions: The results suggest that either long term cognitive decrements may not be associated with a history of concussion or the decrements may be subtle and undetectable by these computer programs.	Univ Georgia, Dept Kinesiol, St Marys Res Lab, Athens, GA 30602 USA; Univ Illinois, Dept Kinesiol & Community Hlth, Champaign, IL 61820 USA; Univ So Mississippi, Sch Human Performance & Recreat, Hattiesburg, MS 39406 USA; Florida Atlantic Univ, Boca Raton, FL 33431 USA		Ferrara, MS (corresponding author), Univ Georgia, Dept Kinesiol, St Marys Res Lab, 330 River Rd, Athens, GA 30602 USA.	mferrara@uga.edu	, scott/ABB-2057-2021	Collie, Alex/0000-0003-2617-9339			Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Keselman HJ, 1998, PSYCHOPHYSIOLOGY, V35, P470, DOI 10.1017/S0048577298000237; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044	23	87	87	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	SEP	2006	40	9					802	805		10.1136/bjsm.2006.028019			4	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	076ZS	WOS:000239998100013	16929049	Green Published			2022-02-06	
J	Cummings, JL; Arciniegas, DB; Brooks, BR; Herndon, RM; Lauterbach, EC; Pioro, EP; Robinson, RG; Scharre, DW; Schiffer, RB; Weintraub, D				Cummings, Jeffrey L.; Arciniegas, David B.; Brooks, Benjamin R.; Herndon, Robert M.; Lauterbach, Edward C.; Pioro, Erik P.; Robinson, Robert G.; Scharre, Douglas W.; Schiffer, Randolph B.; Weintraub, Daniel			DEFINING AND DIAGNOSING INVOLUNTARY EMOTIONAL EXPRESSION DISORDER	CNS SPECTRUMS			English	Article								Uncontrollable episodes of emotional expression occur in a variety of neurological conditions. This emotional disinhibition syndrome is characterized by episodes of crying or laughing that are. unrelated to or out of proportion to the eliciting stimulus. This syndrome is common among patients with amyotrophic lateral sclerosis, multiple sclerosis, stroke, and traumatic brain injury and a variety of terms and definitions have been used to describe it. The confusing nomenclature has been a barrier to understanding, diagnosis, and treatment of this disorder. The authors propose a unifying term, involuntary emotional expression disorder (IEED), and provide diagnostic criteria for this disorder.	[Cummings, Jeffrey L.] Univ Calif Los Angeles, Rush Alzheimers Dis Ctr, Los Angeles, CA 90095 USA; [Cummings, Jeffrey L.] Univ Calif Los Angeles, Deanne F Johnson Ctr Neurotherapeut, Los Angeles, CA USA; [Cummings, Jeffrey L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Cummings, Jeffrey L.] Eli Lilly & Co, Indianapolis, IN USA; [Scharre, Douglas W.] Pfizer, New York, NY USA; [Arciniegas, David B.] Univ Colorado, Sch Med, Neurobehav Disorders Program, Boulder, CO 80309 USA; [Arciniegas, David B.] HealthONE Spalding Rehabil Hosp, Brain Injury Rehabil Unit, Denver, CO USA; [Brooks, Benjamin R.] Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA; [Herndon, Robert M.] Univ Mississippi, Dept Neurol, Jackson, MS USA; [Lauterbach, Edward C.] Mercer Univ, Div Adult & Geriatr Psychiat, Macon, GA 31207 USA; [Pioro, Erik P.] Cleveland Clin, Ctr ALS & Related Disorders, Cleveland, OH 44106 USA; [Pioro, Erik P.] Cleveland Clin, Dept Neurol, Cleveland, OH 44106 USA; [Robinson, Robert G.] Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA; [Scharre, Douglas W.] Ohio State Univ, Dept Neurol, Columbus, OH 43210 USA; [Scharre, Douglas W.] Ohio State Univ, Div Cognit Neurol, Columbus, OH 43210 USA; [Scharre, Douglas W.] Abbott, Abbott Pk, IL USA; [Schiffer, Randolph B.] Texas Tech Univ, Dept Psychiat & Behav Sci, Lubbock, TX 79409 USA; [Weintraub, Daniel] Univ Penn, Sch Med, Sect Geriatr Psychiat, Philadelphia, PA 19104 USA; [Weintraub, Daniel] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany		Cummings, JL (corresponding author), Univ Calif Los Angeles, Rush Alzheimers Dis Ctr, Los Angeles, CA 90095 USA.		Weintraub, Daniel/AAD-8309-2020; Pioro, Erik P/AAZ-5318-2020; Weintraub, Daniel/AAC-5232-2020	Pioro, Erik P/0000-0002-0737-6065; Weintraub, Daniel/0000-0003-0633-7168			ACHARI A N, 1976, Journal of the American Medical Association, V235, P1469, DOI 10.1001/jama.235.14.1469; *AM MED ASS, 2005, INT CLASS DIS, P162; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ANDERSEN G, 1994, STROKE, V25, P1050, DOI 10.1161/01.STR.25.5.1050; ANGST J, 1986, PSYCHOPATHOLOGY, V19, P47, DOI 10.1159/000285131; Arciniegas D B, 2000, Semin Clin Neuropsychiatry, V5, P290, DOI 10.1053/scnp.2000.9554; Arciniegas DB, 2005, CNS SPECTRUMS, V10, P1, DOI 10.1017/S1092852900026602; ARROYO S, 1993, BRAIN, V116, P757, DOI 10.1093/brain/116.4.757; ASFORA WT, 1989, J NEUROL NEUROSUR PS, V52, P523, DOI 10.1136/jnnp.52.4.523; BLACK DW, 1982, J NERV MENT DIS, V170, P67, DOI 10.1097/00005053-198202000-00001; Brooks BR, 2004, NEUROLOGY, V63, P1364; CAROSCIO JT, 1987, NEUROL CLIN, V5, P1; CASCINO GD, 1993, NEUROLOGY, V43, P747, DOI 10.1212/WNL.43.4.747; Dark FL, 1996, AUST NZ J PSYCHIAT, V30, P472, DOI 10.3109/00048679609065020; Feinstein A, 1997, ARCH NEUROL-CHICAGO, V54, P1116, DOI 10.1001/archneur.1997.00550210050012; Feinstein A, 1999, MULT SCLER, V5, P69, DOI 10.1177/135245859900500201; GALLAGHER JP, 1989, ACTA NEUROL SCAND, V80, P114, DOI 10.1111/j.1600-0404.1989.tb03851.x; GhikaSchmid F, 1997, EUR NEUROL, V38, P75, DOI 10.1159/000113164; Green, 1998, Semin Clin Neuropsychiatry, V3, P195; HARVEY PD, 1989, J CLIN PSYCHOL, V45, P786, DOI 10.1002/1097-4679(198909)45:5<786::AID-JCLP2270450515>3.0.CO;2-P; HOUSE A, 1989, BMJ-BRIT MED J, V298, P991, DOI 10.1136/bmj.298.6679.991; IRONSIDE R, 1956, BRAIN, V79, P589, DOI 10.1093/brain/79.4.589; Kaschka WP, 2001, PHARMACOPSYCHIATRY, V34, P254, DOI 10.1055/s-2001-18031; Keller R, 1999, ITAL J NEUROL SCI, V20, P49, DOI 10.1007/s100720050010; Kim JS, 2000, NEUROLOGY, V54, P1805, DOI 10.1212/WNL.54.9.1805; Kim JS, 2002, J NEUROL, V249, P805, DOI 10.1007/s00415-002-0714-4; Kim JS, 1997, STROKE, V28, P2321; LAKE CR, 1982, AM J PSYCHIAT, V139, P1315; Langworthy OR, 1940, ARCH INTERN MED, V65, P106, DOI 10.1001/archinte.1940.00190070116008; Langworthy OR, 1941, AM J PSYCHIAT, V98, P243, DOI 10.1176/ajp.98.2.243; LAUTERBACH EC, 1994, NEUROLOGY, V44, P983, DOI 10.1212/WNL.44.5.983; LAUTERBACH EC, 1991, J CLIN PSYCHOPHARM, V11, P392, DOI 10.1097/00004714-199112000-00021; LAUTERBACH EC, 1994, BIOL PSYCHIAT, V35, P488, DOI 10.1016/0006-3223(94)90048-5; Lopez OL, 1996, NEUROPSY NEUROPSY BE, V9, P154; LUCIANO D, 1993, NEUROLOGY, V43, P2113, DOI 10.1212/WNL.43.10.2113; McGrath J, 2000, BEHAV NEUROL, V12, P201, DOI 10.1155/2000/612185; Moore SR, 1997, J NEUROL NEUROSUR PS, V63, P89, DOI 10.1136/jnnp.63.1.89; MORRIS PLP, 1993, AUST NZ J PSYCHIAT, V27, P601, DOI 10.3109/00048679309075822; Newsom-Davis IC, 1999, J NEUROL SCI, V169, P22, DOI 10.1016/S0022-510X(99)00211-7; Okuda DT, 2005, MOVEMENT DISORD, V20, P1389, DOI 10.1002/mds.20607; Okun MS, 2001, ARCH NEUROL-CHICAGO, V58, P1682, DOI 10.1001/archneur.58.10.1682; Parvizi J, 2001, BRAIN, V124, P1708, DOI 10.1093/brain/124.9.1708; Poeck K., 1969, HDB CLIN NEUROLOGY, P343; Robert D, 1999, ACTA OTO-LARYNGOL, V119, P724; ROBINSON RG, 1993, AM J PSYCHIAT, V150, P286; Schiffer R, 2005, J NEUROPSYCH CLIN N, V17, P447, DOI 10.1176/appi.neuropsych.17.4.447; SCHUCKIT MA, 1982, AM J PSYCHIAT, V139, P1431; Smi CK, 2006, STROKE, V37, P156, DOI 10.1161/01.STR.0000190892.93663.e2; Smith RA, 2004, MULT SCLER, V10, P1; STARKSTEIN SE, 1995, J NEUROL NEUROSUR PS, V59, P55, DOI 10.1136/jnnp.59.1.55; SURRIDGE D, 1969, BRIT J PSYCHIAT, V115, P749, DOI 10.1192/bjp.115.524.749; Tateno A, 2004, J NEUROPSYCH CLIN N, V16, P426, DOI 10.1176/appi.neuropsych.16.4.426; Wilson SAK, 1924, J NEUROL PSYCHOPATHO, V4, P299; Zeilig G, 1996, BRAIN INJURY, V10, P591, DOI 10.1080/026990596124160; 2005, 57 ANN M AM AC NEUR	55	87	90	0	3	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1092-8529	2165-6509		CNS SPECTRUMS	CNS Spectr.	JUN	2006	11	6		6			1	7					7	Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	V04RU	WOS:000207076300001	16816786				2022-02-06	
J	Lepore, AC; Bakshi, A; Swanger, SA; Rao, MS; Fischer, I				Lepore, AC; Bakshi, A; Swanger, SA; Rao, MS; Fischer, I			Neural precursor cells can be delivered into the injured cervical spinal cord by intrathecal injection at the lumbar cord	BRAIN RESEARCH			English	Article						neural stem cell; spinal cord injury; neuron; glial cell; transplantation; neural progenitor	NEUROEPITHELIAL STEM-CELLS; PROGENITOR CELLS; CEREBROSPINAL-FLUID; ADULT BRAIN; RESTRICTED PRECURSORS; CHEMOKINE RECEPTORS; FUNCTIONAL RECOVERY; WHITE-MATTER; RAT MODEL; TRANSPLANTATION	Neural precursor cells (NPCs) are promising grafts for treatment of traumatic CNS injury and neurodegenerative disorders because of their potential to differentiate into neurons and glial cells. When designing clinical protocols for NPC transplantation, it is important to develop alternatives to direct parenchymal injection, particularly at the injury site. We reasoned that since it is minimally invasive, intrathecal delivery of NPCs at lumbar spinal cord (lumbar puncture) represents an important and clinically applicable strategy. We tested this proposition by examining whether NPCs can be delivered to the injured cervical spinal cord via lumbar puncture using a mixed population of neuronal-restricted precursors (NRPs) and glial-restricted precursors (GRPs). For reliable tracking, the NPCs were derived from the embryonic spinal cord of transgenic donor rats that express the marker gene, human placental alkaline phosphatase, under the control of the ubiquitous Rosa 26 promoter. We found that mixed NRP/GRP grafts can be efficiently delivered to a cervical hemisection injury site by intrathecal delivery at the lumbar cord. Similar to direct parenchymal injections, transplanted NRP/GRP cells survive at the injury cavity for at least 5 weeks post-engraftment, migrate into intact spinal cord along white matter tracts and differentiate into all three mature CNS cell types, neurons, astrocytes, and oligodendrocytes. Furthermore, very few graft-derived cells localize to areas outside the injury site, including intact spinal cord and brain. These results demonstrate the potential of delivering lineage-restricted NPCs using the minimally invasive lumbar puncture method for the treatment of spinal cord injury. (C) 2005 Elsevier B.V. All rights reserved.	Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19129 USA; NIA, Neurosci Lab, Baltimore, MD 21224 USA		Fischer, I (corresponding author), Drexel Univ, Coll Med, Dept Neurobiol & Anat, 2900 Queen Lane, Philadelphia, PA 19129 USA.	Itzhak.fischer@drexel.edu	Swanger, Sharon A/ABA-4018-2021; Fischer, Itzhak/D-1080-2012	Fischer, Itzhak/0000-0003-3187-8740; Swanger, Sharon/0000-0003-0615-6244	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS024707, P01NS024707, R01NS037515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [Z01AG000324, ZIAAG000324] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS24707, NS 37515] Funding Source: Medline		Aarum J, 2003, P NATL ACAD SCI USA, V100, P15983, DOI 10.1073/pnas.2237050100; Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; ARMSTRONG RC, 1990, J NEUROSCI RES, V27, P400, DOI 10.1002/jnr.490270319; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bai HL, 2003, J NEUROSCI METH, V124, P181, DOI 10.1016/S0165-0270(03)00007-4; Bakshi A, 2004, J NEUROSURG-SPINE, V1, P330, DOI 10.3171/spi.2004.1.3.0330; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Ben-Hur T, 2003, MOL CELL NEUROSCI, V24, P623, DOI 10.1016/S1044-7431(03)00218-5; Ben-Hur T, 2003, GLIA, V41, P73, DOI 10.1002/glia.10159; Cao QL, 2002, EXP NEUROL, V177, P349, DOI 10.1006/exnr.2002.7981; De la Calle JL, 2002, BRAIN RES BULL, V59, P245, DOI 10.1016/S0361-9230(02)00866-3; De la Calle JL, 2002, BRAIN RES BULL, V59, P205, DOI 10.1016/S0361-9230(02)00867-5; Ehtesham M, 2004, NEOPLASIA, V6, P287, DOI 10.1593/neo.03427; Einstein O, 2003, MOL CELL NEUROSCI, V24, P1074, DOI 10.1016/j.mcn.2003.08.009; Fischer I, 2000, PROG BRAIN RES, V128, P253; Forsberg-Nilsson K, 1998, J NEUROSCI RES, V53, P521, DOI 10.1002/(SICI)1097-4547(19980901)53:5<521::AID-JNR2>3.0.CO;2-B; Han SSW, 2004, GLIA, V45, P1, DOI 10.1002/glia.10282; Han SSW, 2002, EXP NEUROL, V177, P360, DOI 10.1006/exnr.2002.7995; Herrera J, 2001, EXP NEUROL, V171, P11, DOI 10.1006/exnr.2001.7729; Ishii K, 2001, J NEUROSCI RES, V65, P500, DOI 10.1002/jnr.1180; Ji JF, 2004, NEUROSCI LETT, V355, P236, DOI 10.1016/j.neulet.2003.11.024; Kisseberth WC, 1999, DEV BIOL, V214, P128, DOI 10.1006/dbio.1999.9417; Lepore AC, 2004, NEURON GLIA BIOL, V1, P113, DOI 10.1017/S1740925X04000213; MayerProschel M, 1997, NEURON, V19, P773, DOI 10.1016/S0896-6273(00)80960-5; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Mujtaba T, 2002, EXP NEUROL, V174, P48, DOI 10.1006/exnr.2001.7847; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341; Ohta M, 2004, NEUROREPORT, V15, P1249, DOI 10.1097/01.wnr.0000129998.72184.e1; Ohta M, 2004, EXP NEUROL, V187, P266, DOI 10.1016/j.expneurol.2004.01.021; Parent JM, 2002, PROG BRAIN RES, V135, P121; Parent JM, 1997, J NEUROSCI, V17, P3727; Peng H, 2004, J NEUROSCI RES, V76, P35, DOI 10.1002/jnr.20045; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Rao MS, 2000, PROG BRAIN RES, V128, P273; Rao MS, 1997, DEV BIOL, V188, P48, DOI 10.1006/dbio.1997.8597; Snyder EY, 1997, P NATL ACAD SCI USA, V94, P11663, DOI 10.1073/pnas.94.21.11663; Svendsen CN, 1997, EXP NEUROL, V148, P135, DOI 10.1006/exnr.1997.6634; Tran PB, 2004, J NEUROSCI RES, V76, P20, DOI 10.1002/jnr.20001; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; Wu SF, 2002, J NEUROSCI RES, V69, P940, DOI 10.1002/jnr.10346; Yamamoto S, 2001, EXP NEUROL, V172, P115, DOI 10.1006/exnr.2001.7798; Yang H, 2000, P NATL ACAD SCI USA, V97, P13366, DOI 10.1073/pnas.97.24.13366	43	87	97	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAY 31	2005	1045	1-2					206	216		10.1016/j.brainres.2005.03.050			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	932BX	WOS:000229530300024	15910779				2022-02-06	
J	Gabbita, SP; Scheff, SW; Menard, RM; Roberts, K; Fugaccia, I; Zemlan, FP				Gabbita, SP; Scheff, SW; Menard, RM; Roberts, K; Fugaccia, I; Zemlan, FP			Cleaved-tau: A biomarker of neuronal damage after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						axon; controlled cortical impact (CCI); cleaved-tau (C-tau); cyclosporin A; microtubule associated protein-tau (MAP-tau); neuron; traumatic brain injury (TBI)	CONTROLLED CORTICAL IMPACT; CENTRAL-NERVOUS-SYSTEM; CYCLOSPORINE-A; PROTEIN-TAU; S-100B PROTEIN; AXONAL DAMAGE; SERUM-LEVELS; HEAD-INJURY; C-TAU; RAT	Previous studies from our laboratory indicate that traumatic brain injury TBI) in humans results in proteolysis of neuronally-localized, intracellular microtubule associated protein (MAP)-tau to produce cleaved tau (C-tau). The present study evaluated the utility of C-tau to function as a biomarker of neuronal injury and as a biomarker for evaluating neuroprotectant drug efficacy in a controlled cortical impact model of rat TBI. Brain C-tau was determined in rats subjected to controlled cortical impact-induced mild, moderate or severe levels of TBI. A significant severity-dependent increase in C-tau levels was observed in the cortex and hippocampus (1.5-8-fold) of TBI rats compared to shams 72 h after impact. C-tau rat brain and serum time course was determined by measuring levels at 0.25, 6, 24, 48, 72 and 168 h after TBI. A significant time-dependent increase in C-tau levels was observed in ipsilateral cortex (5-16-fold) and hippocampus (2-40-fold) compared to sham animals. C-tau levels increased as early as 6 h after TBI with peak C-tau levels observed 168 h after injury. Elevated brain C-tau levels were associated with TBI-induced tissue loss, which was histologically determined. The effect of cyclosporin-A (CsA), previously demonstrated to be neuroprotective in rat TBI, on brain C-tau levels was examined. CsA (20 mg/kg i.p., 15 min and 24 h after TBI) significantly attenuated the TBI-induced increase in hippocampal C-tau levels observed in vehicle-treated animals confirming CsA's neuroprotectant effect. CsA treatment also lowered ipsilateral cortical C-tau levels, although it did not reach statistical significance. CsA's neuroprotectant effect was confirmed utilizing histologic measures of TBI-induced tissue loss. In addition, serum C-tau levels were significantly increased 6 h after TBI but not at later time points. These results suggest that C-tau is a reliable, quantitative biomarker for evaluating TBI-induced neuronal injury and a potential biomarker of neuroprotectant drug efficacy in the rat TBI model. Serum data suggests that C-tau levels are dependent both on a compromised blood-brain barrier as well as release of TBI biomarkers from the brain, which has implications for the study of human serum TBI biomarkers.	Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45267 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA		Gabbita, SP (corresponding author), Univ Cincinnati, Coll Med, Dept Psychiat, 231 Bethesda Ave, Cincinnati, OH 45267 USA.	prasad.gabbita@psychiatry.uc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39828, NS43837] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R43NS043837, R01NS039828] Funding Source: NIH RePORTER		ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Fasulo L, 2000, J NEUROCHEM, V75, P624, DOI 10.1046/j.1471-4159.2000.0750624.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; Irazuzta JE, 2001, BRAIN RES, V913, P95, DOI 10.1016/S0006-8993(01)02764-0; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; KOSIK KS, 1987, J NEUROSCI, V7, P3142; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; LITMAN P, 1993, NEURON, V10, P627, DOI 10.1016/0896-6273(93)90165-N; Marsan MA, 2000, J SYST ARCHITECT, V46, P105, DOI 10.1016/S1383-7621(98)00064-2; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MCMAHAN BT, 1986, BUS HEALTH, V3, P47; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Rothoerl RD, 2000, ACTA NEUROCHIR, V142, P199, DOI 10.1007/s007010050024; Scallet AC, 1995, ANN NY ACAD SCI, V765, P47, DOI 10.1111/j.1749-6632.1995.tb16559.x; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Towbin H, 1992, Biotechnology, V24, P145; Wallace TL, 2003, NEUROSCIENCE, V116, P1063, DOI 10.1016/S0306-4522(02)00795-9; Woertgen C, 2002, ACT NEUR S, V81, P205; Woertgen C, 2001, J NEUROTRAUM, V18, P569, DOI 10.1089/089771501300227378; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zemlan FP, 2003, NEUROSCIENCE, V121, P399, DOI 10.1016/S0306-4522(03)00459-7; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505	42	87	92	0	18	MARY ANN LIEBERT INC	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2005	22	1					83	94		10.1089/neu.2005.22.83			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	889OF	WOS:000226451600005	15665604				2022-02-06	
J	Tate, DG; Forchheimer, MB; Krause, JS; Meade, MA; Bombardier, CH				Tate, DG; Forchheimer, MB; Krause, JS; Meade, MA; Bombardier, CH			Patterns of alcohol and substance use and abuse in persons with spinal cord injury: Risk factors and correlates	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						alcohol abuse; alcohol consumption; rehabilitation; spinal cord injuries; substance abuse	CAGE QUESTIONNAIRE; BRAIN-INJURY; HISTORY; SATISFACTION	Objective: To investigate patterns of alcohol consumption and abuse and substance use among persons with spinal cord injury (SCI), relating these patterns to demographic and injury-related characteristics, as well as to key medical and psychosocial outcomes. Design: Retrospective cross-sectional. Participants: Subjects with traumatic SCI (N=3041) with dates of injury between June 6, 1975, and June 23, 2002, who were interviewed between November 2000 and March 2003. Setting: Sixteen Model Spinal Cord Injury Systems participating in this collaborative study during the 2000-2005 grant cycle. Interventions: Not applicable. Main Outcome Measures: Alcohol consumption, substance use, CAGE questionnaire, Satisfaction With Life Scale, Craig Handicap Assessment Reporting Technique, and pain. Data were analyzed using chi-square tests, analysis of variance, analysis of covariance, and logistic regression models. Results: Fourteen percent of the subjects were classified as likely to have an alcohol abuse issue, based on the CAGE, and 11% reported using illegal drugs or prescription medications for nonmedical reasons. Demographic and injury characteristics were associated with alcohol consumption patterns, abuse, and substance use. At-risk drinkers and substance users tended to be younger, single, male, and less educated. Those who were CAGE positive and substance users reported more pain and lower satisfaction with life. Persons who drank without indication of problem drinking had superior occupation outcomes. Pressure ulcers were associated with substance use. Conclusions: Alcohol abuse and substance use were related to a number of adverse outcomes. The specific role of drinking with increased work activity deserves further exploration.	Univ Michigan, Model Spinal Cord Injury Care Syst, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; Med Univ S Carolina, Coll Hlth Prof, S Carolina Spinal Cord Injury Ctr, Charleston, SC 29425 USA; Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Reg Spinal Cord Injury Model Syst, Richmond, VA USA; Univ Washington, Dept Rehabil Med, NW Reg Spinal Cord Injury Syst, Seattle, WA USA		Tate, DG (corresponding author), Univ Michigan, Model Spinal Cord Injury Care Syst, Dept Phys Med & Rehabil, 300 N Ingalls,Rm N12A09, Ann Arbor, MI 48109 USA.	dgtate@umich.edu	Bombardier, Charles H./AAZ-3260-2021; Forchheimer, Martin/B-6148-2009	Bombardier, Charles H./0000-0003-4758-6283; Forchheimer, Martin/0000-0002-7709-9622			*AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P175; American Spinal Injury Association, 2000, INT STAND NEUR CLASS, P1; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bombardier CH, 1998, ARCH PHYS MED REHAB, V79, P1110, DOI 10.1016/S0003-9993(98)90180-0; CHARLIFUE SW, 1991, ARCH PHYS MED REHAB, V72, P488; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; Elliott TR, 1996, ARCH PHYS MED REHAB, V77, P816, DOI 10.1016/S0003-9993(96)90263-4; Elliott TR, 2002, REHABIL PSYCHOL, V47, P278, DOI 10.1037//0090-5550.47.3.278; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FULLERTON DT, 1981, ARCH GEN PSYCHIAT, V38, P1369; Hawkins DA, 1998, REHABIL PSYCHOL, V43, P219, DOI 10.1037/0090-5550.43.3.219; Hearne R, 2002, J ROY SOC MED, V95, P84, DOI 10.1258/jrsm.95.2.84; HEINEMANN AW, 1995, REHABIL PSYCHOL, V40, P125; HEINEMANN AW, 1990, REHABIL PSYCHOL, V35, P217, DOI 10.1037/h0079065; HEINEMANN AW, 1988, ARCH PHYS MED REHAB, V69, P619; HEINEMANN AW, 1991, ARCH PHYS MED REHAB, V72, P482; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; Krause JS, 1999, ARCH PHYS MED REHAB, V80, P1435; Marmarou A., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI [10.1097/00001199-199009000-00006, DOI 10.1097/00001199-199009000-00006]; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; McKinley WO, 1999, AM J PHYS MED REHAB, V78, P306, DOI 10.1097/00002060-199907000-00002; *NAT I ALC AB ALC, 2000, NAT I ALC AB ALC PUB; O'Donnell JJ, 1981, ALCOHOL HEALTH RES W, V82, P27; Richards JS, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P11, DOI 10.1037/10361-001; Richards JS, 1999, ARCH PHYS MED REHAB, V80, P1501; Stover SL, 1999, ARCH PHYS MED REHAB, V80, P1365, DOI 10.1016/S0003-9993(99)90246-0; TATE DG, 1994, J REHABIL, V60, P31; TATE DG, 1993, AM J PHYS MED REHAB, V72, P192, DOI 10.1097/00002060-199308000-00004; WARE JE, 1993, SF 36 HLTH SURV MAN; Whiteneck G, 1999, ARCH PHYS MED REHAB, V80, P1485, DOI 10.1016/S0003-9993(99)90262-9; YOUNG ME, 1995, ARCH PHYS MED REHAB, V76, P525, DOI 10.1016/S0003-9993(95)80506-0	33	87	90	1	9	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2004	85	11					1837	1847		10.1016/j.apmr.2004.02.022			11	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	870WO	WOS:000225089700013	15520979				2022-02-06	
J	Moore, BA; Donders, J				Moore, BA; Donders, J			Predictors of invalid neuropsychological test performance after traumatic brain injury	BRAIN INJURY			English	Article							MEMORY MALINGERING TOMM; VERBAL-LEARNING TEST; MILD HEAD-INJURY; VALIDITY; COMPENSATION; INDICATOR; RECOVERY; SCORES	Objective: To investigate the usefulness of the Test of Memory Malingering (TOMM) and the California Verbal Learning Test-Second Edition (CVLT-II) in assessing invalid test performance after traumatic brain injury (TBI). Design: Consecutive 3-year series of rehabilitation referrals (n = 132). Methods and procedures: Percentage of participants who failed validity criteria was determined. Hierarchical logistic regression analysis and odds ratios were used to identify predictors of invalid test performance. Results: Twenty patients (15%) performed in the invalid range when held to a priori specified criteria for invalid test performance (i.e. TOMM <45/50 on Trial 2 or CVLT-II <15/16 on Forced-Choice recognition trial). Both psychiatric history and financial compensation seeking were associated with an almost 4-fold increase in likelihood of invalid responding. Conclusions: The TOMM and CVLT-II are sensitive to the potential impact of current financial compensation seeking and prior psychiatric history on neuropsychological test performance after TBI.	Mary Free Bed Hosp, Psychol Serv, Grand Rapids, MI 49503 USA		Donders, J (corresponding author), Mary Free Bed Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jdonders@mfbrc.com					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ALLEN LM, 1997, MANUAL COMPUTERISED; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC, 1987, CALIFORNIA VERBAL LE; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Evans R. W., 1994, AM J FORENSIC PSYCH, V4, P19; Frederick RI, 2000, ARCH CLIN NEUROPSYCH, V15, P281, DOI 10.1016/S0887-6177(99)00002-5; Frederick RI, 1994, NEUROPSYCHOLOGY, V8, P118, DOI 10.1037/0894-4105.8.1.118; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GERVAIS RO, IN PRESS ARCH CLIN N; Green P, 2001, CLIN NEUROPSYCHOL, V15, P492, DOI 10.1076/clin.15.4.492.1887; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Green P., 1996, MANUAL COMPUTERISED; Greiffenstein M. F., 2000, BRAIN INJ SOURCE, V4, P26; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Hoffman R. G., 1999, J FORENSIC NEUROPSYC, V1, P3, DOI DOI 10.1300/J151V01N02_02; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Larrabee GJ, 2000, CLIN GUIDE NEUROPSYC, P301; LEMMON J, 1995, J COGNITIVE REHABILT, V13, P4; Martelli MF, 1998, NEUROREHABILITATION, V11, P51, DOI 10.1016/S1053-8135(98)00009-2; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR., 2001, J FORENSIC NEUROPSYC, V2, P1, DOI [10.1300/J151v02n01_01, DOI 10.1300/J151V02N01_]; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Paniak C, 2000, BRAIN INJURY, V14, P219; PUTMAN SH, 1994, ADV MED PSYCHOTHERAP, V7, P1; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; RUFF RM, 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199309000-00008; Sherman EMS, 2000, BRAIN INJURY, V14, P621; Slick D.J., 1997, VICTORIA SYMPTOM VAL; Strauss E, 2002, ARCH CLIN NEUROPSYCH, V17, P423, DOI 10.1016/S0887-6177(01)00126-3; Sweet JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P105, DOI 10.1016/S0887-6177(98)00153-X; SWEET JJ, 1999, J FORENSIC NEUROPSYC, V1, P73; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; TEASDALE G, 1974, LANCET, V2, P81; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; vanGorp WG, 1997, CLIN NEUROPSYCHOL, V11, P180, DOI 10.1080/13854049708407048; Youngjohn, 1995, ASSESSMENT, V2, DOI [https://doi.org/10.1177/1073191195002003007, DOI 10.1177/1073191195002003007]; YOUNGQUIST RC, 1984, OPT LETT, V9, P177, DOI 10.1364/OL.9.000177	49	87	88	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2004	18	10					975	984		10.1080/02699050410001672350			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	845LQ	WOS:000223244600002	15370897				2022-02-06	
J	Bigler, ED				Bigler, ED			Neuropsychological results and neuropathological findings at autopsy in a case of mild traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						mild traumatic brain injury; neuropathology; neuroimaging	DIFFUSE AXONAL INJURY; HEAD-INJURY; ALZHEIMERS-DISEASE; WHITE-MATTER; EARLY ADULTHOOD; TIME-COURSE; RISK; DAMAGE; DEGENERATION; RAT	Autopsy studies were undertaken in a 47-year-old college-educated male patient who, 7 months prior to an unexpected death, had sustained a mild traumatic brain injury (TBI) as manifested by brief loss of consciousness and an initial Glasgow Coma Scale score of 14. The patient died from cardiac arrest secondary to an undiagnosed and unknown arteriosclerotic cardiovascular disease as assessed by the coroner's office at the time of autopsy. Gross inspection of the brain at autopsy was normal; however, microscopic analysis demonstrated what were considered trauma findings of hemosiderin-laden macrophages in the perivascular space and macrophages in the white matter, particularly the section taken from the frontal lobe. The patient had partially returned to work at the time of death, but had encountered problems with diminished cognitive performance in his work as an appraiser. Neuropsychological studies were generally within normal limits although several tests of either speed of processing or short-term memory showed lower than expected performance. This case demonstrates the presence of subtle neuropathological changes in the brain of a patient who sustained a mild TBI and was still symptomatic for the residual effects of the injury 7 months post injury when he unexpectedly died.	Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Brigham Young Univ, Dept Neurosci, Provo, UT USA; LDS Hosp, Salt Lake City, UT USA; Univ Utah, Dept Psychiat & Radiol, Salt Lake City, UT USA		Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1001 SWKT, Provo, UT 84602 USA.	erin_bigler@byu.edu					Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Albert CM, 2000, NEW ENGL J MED, V343, P1355, DOI 10.1056/NEJM200011093431902; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Beck, 1978, BECK DEPRESSION INVE; Beck AT, 1990, BECK ANXIETY INVENTO; Benton, 1992, BENTON VISUAL RETENT; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Brandes D, 2002, PSYCHIAT RES, V110, P231, DOI 10.1016/S0165-1781(02)00125-7; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; DAVIS RL, 1985, TXB NEUROPATHOLOGY; DEROGATIS LR, 1996, SYMPTOM CHECKLIST 90; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FASCHINGBAUER TR, 1974, J CONSULT CLIN PSYCH, V42, P645, DOI 10.1037/h0037049; Fazekas F, 1999, AM J NEURORADIOL, V20, P637; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; GOODGLASS H, 1987, ASSESSMENT APHASIA R; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; GREENBERG GD, 1994, ADULT NEUROPSYCHOLOG; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hooper H., 1958, HOOPER VISUAL ORG TE; Imaizumi T, 2004, J NEUROIMAGING, V14, P251, DOI 10.1177/1051228404265714; Jastak S, 1993, WIDE RANGE ACHIEVEME, Vthird; Johnston KC, 2003, NEUROLOGY, V60, P518, DOI 10.1212/01.WNL.0000050462.52753.B2; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kumar R, 2003, AM J NEURORADIOL, V24, P218; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Malamud N., 1973, ATLAS NEUROPATHOLOGY; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Oehmichen M, 2003, J NEUROTRAUM, V20, P87, DOI 10.1089/08977150360517218; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Preul C, 2003, EUR J RADIOL, V48, P244, DOI 10.1016/S0720-048X(03)00050-0; PRITCHARD DA, 1998, TESTS NEUROPSYCHOLOG; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; RAVEN JA, 1947, COLORED PROGRESSIVE; Rey A., 1964, EXAMEN CLIN PSYCHOL; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Schwab JM, 2001, J NEUROTRAUM, V18, P881, DOI 10.1089/089771501750451802; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Soares HD, 1995, J NEUROSCI, V15, P8223; STOLL G, 1989, J NEUROSCI, V9, P2327; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; Tartaglia MC, 2004, ARCH NEUROL-CHICAGO, V61, P201, DOI 10.1001/archneur.61.2.201; TEASDALE G, 1974, LANCET, V2, P81; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Varney NR, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P115; Vela JM, 2002, J NEUROTRAUM, V19, P1503, DOI 10.1089/089771502320914723; Wardlaw JM, 2000, NEURORADIOLOGY, V42, P81, DOI 10.1007/s002340050019; Warrington EK., 1984, WARRINGTON RECOGNITI; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; Wong KS, 2003, NEUROLOGY, V60, P511, DOI 10.1212/01.WNL.0000046583.40125.20; Yokota H, 2002, J NEUROTRAUM, V19, P1007, DOI 10.1089/089771502760341929; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52; [No title captured]	82	87	87	0	6	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2004	10	5					794	806		10.1017/S1355617704105146			13	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	848XZ	WOS:000223502700014	15327725				2022-02-06	
J	Suh, SW; Garnier, P; Aoyama, K; Chen, YM; Swanson, RA				Suh, SW; Garnier, P; Aoyama, K; Chen, YM; Swanson, RA			Zinc release contributes to hypoglycemia-induced neuronal death	NEUROBIOLOGY OF DISEASE			English	Article						zinc; N-(6-methoxy-8-quinolyl)-paro-toluenesulfonamide; TSQ; hypoglycemia; glucose; hippocampus; neuron; insulin; poly (ADP-ribose) polymerase	POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; HISTOCHEMICALLY REACTIVE ZINC; HIPPOCAMPAL MOSSY FIBERS; TRAUMATIC BRAIN-INJURY; CELL-DEATH; CEREBRAL-ISCHEMIA; CORTICAL-NEURONS; GLYCEMIC CONTROL; FOCAL ISCHEMIA; CYCLOSPORINE-A	Neurons exposed to zinc exhibit activation of poly(ADP-ribose) polymerase-1 (PARP-1), an enzyme that normally participates in DNA repair but promotes cell death when extensively activated. Endogenous, vesicular zinc in brain is released to the extracellular space under conditions causing neuronal depolarization. Here, we used a rat model of insulin-induced hypoglycemia to assess the role of zinc release in PARP-I activation and neuronal death after severe hypoglycemia. Zinc staining with N-(6-methoxy-8-quinolyl)-para-toluenesulfonamide (TSQ) showed depletion of presynaptic vesicular zinc from hippocampal mossy fiber terminals and accumulation of weakly bound zinc in hippocampal CA1 cell bodies after severe hypoglycemia. Intracerebroventricular injection of the zinc chelator calcium ethylene-diamine tetraacetic acid (CaEDTA) blocked the zinc accumulation and significantly reduced hypoglycemia-induced neuronal death. CaEDTA also attenuated the accumulation of poly (ADP-ribose), the enzymatic product of PARP-1, in hippocampal neurons. These results suggest that zinc translocation is an intermediary step linking hypoglycemia to PARP-1 activation and neuronal death. (C) 2004 Elsevier Inc. All rights reserved.	Univ Calif San Francisco, Dept Neurol 127, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA		Swanson, RA (corresponding author), Univ Calif San Francisco, Dept Neurol 127, 4150 Clement St, San Francisco, CA 94121 USA.	ray@itsa.ucsf.edu		Garnier, Philippe/0000-0002-7877-3113; Swanson, Raymond/0000-0002-3664-5359	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041421] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS41421] Funding Source: Medline		ANIKSZTEJN L, 1987, BRAIN RES, V404, P58, DOI 10.1016/0006-8993(87)91355-2; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; AUER RN, 1989, CLIN NEUROPATHOL, V8, P63; AUER RN, 1984, ACTA NEUROPATHOL, V64, P177, DOI 10.1007/BF00688108; AUER RN, 1993, BAILLIERE CLIN ENDOC, V7, P611, DOI 10.1016/S0950-351X(05)80210-1; AUER RN, 1984, DIABETES, V33, P1090, DOI 10.2337/diabetes.33.11.1090; BEAULIEU C, 1992, NEUROREPORT, V3, P861, DOI 10.1097/00001756-199210000-00010; Carriedo SG, 1998, J NEUROSCI, V18, P7727; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; DANSCHER G, 1985, HISTOCHEMISTRY, V83, P419, DOI 10.1007/BF00509203; Davis EA, 1998, ARCH DIS CHILD, V78, P111, DOI 10.1136/adc.78.2.111; Dineley KE, 2003, J NEUROCHEM, V85, P563, DOI 10.1046/j.1471-4159.2003.01678.x; Ducrocq S, 2000, J NEUROCHEM, V74, P2504, DOI 10.1046/j.1471-4159.2000.0742504.x; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Ferrand-Drake M, 2003, J NEUROCHEM, V85, P1431, DOI 10.1046/j.1471-4159.2003.01794.x; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; FREDERICKSON CJ, 1987, J NEUROSCI METH, V20, P91, DOI 10.1016/0165-0270(87)90042-2; Frederickson CJ, 2002, J HISTOCHEM CYTOCHEM, V50, P1659, DOI 10.1177/002215540205001210; FREDERICKSON CJ, 1992, J CHEM NEUROANAT, V5, P521, DOI 10.1016/0891-0618(92)90007-D; FREDERICKSON CJ, 1988, BRAIN RES, V446, P383, DOI 10.1016/0006-8993(88)90899-2; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; Kerchner GA, 2000, J PHYSIOL-LONDON, V528, P39, DOI 10.1111/j.1469-7793.2000.00039.x; Kim YH, 2002, EXP NEUROL, V177, P407, DOI 10.1006/exnr.2002.7990; Kim YH, 1999, NEUROSCIENCE, V89, P175, DOI 10.1016/S0306-4522(98)00313-3; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lee JM, 2002, NEUROSCIENCE, V115, P871, DOI 10.1016/S0306-4522(02)00513-4; Lee JY, 2003, EXP NEUROL, V184, P337, DOI 10.1016/S0014-4886(03)00382-0; Lincoln NB, 1996, DIABETES CARE, V19, P656, DOI 10.2337/diacare.19.6.656; Love S, 1999, NEUROPATH APPL NEURO, V25, P98; PEREZCLAUSELL J, 1985, BRAIN RES, V337, P91, DOI 10.1016/0006-8993(85)91612-9; PERRIN DD, 1979, IUPAC CHEM DATA SERI, V22, P399; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; Sensi SL, 1997, J NEUROSCI, V17, P9554; Sensi SL, 1999, P NATL ACAD SCI USA, V96, P2414, DOI 10.1073/pnas.96.5.2414; Sheline CT, 2003, EUR J NEUROSCI, V18, P1402, DOI 10.1046/j.1460-9568.2003.02865.x; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; Suh SW, 2003, J NEUROSCI, V23, P10681; Suh SW, 2001, NEUROREPORT, V12, P1523, DOI 10.1097/00001756-200105250-00044; Suh SW, 1999, J HISTOCHEM CYTOCHEM, V47, P969, DOI 10.1177/002215549904700715; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; TAKATA TOY, 2002, SOC NEUR ABSTR, V28, P197; Tokime T, 1998, J CEREBR BLOOD F MET, V18, P991, DOI 10.1097/00004647-199809000-00008; Virag L, 1999, BRIT J PHARMACOL, V126, P769, DOI 10.1038/sj.bjp.0702332; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Weiss JH, 2000, TRENDS PHARMACOL SCI, V21, P395, DOI 10.1016/S0165-6147(00)01541-8; WEISS JH, 1993, NEURON, V10, P43, DOI 10.1016/0896-6273(93)90240-R; WIELOCH T, 1985, SCIENCE, V230, P681, DOI 10.1126/science.2996146; WIELOCH T, 1984, J NEUROCHEM, V43, P160, DOI 10.1111/j.1471-4159.1984.tb06692.x; Yin HZ, 2002, J NEUROSCI, V22, P1273, DOI 10.1523/JNEUROSCI.22-04-01273.2002; YING W, 2003, BIOCHEM BIOPH RES CO, V308, P89; Ying WH, 2001, P NATL ACAD SCI USA, V98, P12227, DOI 10.1073/pnas.211202598; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221	58	87	93	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	AUG	2004	16	3					538	545		10.1016/j.nbd.2004.04.017			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	841SF	WOS:000222951000007	15262265				2022-02-06	
J	Hawley, CA; Ward, AB; Magnay, AR; Long, J				Hawley, CA; Ward, AB; Magnay, AR; Long, J			Outcomes following childhood head injury: a population study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; CHILDREN; ADOLESCENTS; REHABILITATION; PERFORMANCE; SEQUELAE; INFANTS	Objectives: To identify outcomes following head injury (HI) among a population of children admitted to one hospital centre and to compare outcomes between different severity groups. Methods: A postal follow up of children admitted with HI to one National Health Service Trust, between 1992 and 1998, was carried out. Children were aged 5-15 years at injury (mean 9.8), followed up at a mean of 2.2 years post-injury. Parents of 526 injured children (419 mild, 58 moderate, 49 severe) and 45 controls completed questionnaires. Outcomes were assessed using the King's Outcome Scale for Childhood Head Injury (KOSCHI). Results: Frequent behavioural, emotional, memory, and attention problems were reported by one third of the severe group, one quarter of the moderate, and 10-18% of the mild. Personality change since HI was reported for 148 children (28%; 21% mild HI, 46% moderate, 69% severe). There was a significant relationship between injury severity and KOSCHI outcomes. Following the HI, 252 (48%) had moderate disability (43% mild HI, 64% moderate, 69% severe), while 270 (51%) made a good recovery (57% mild HI, 36% moderate, 22% severe). There was a significant association between social deprivation and poor outcome (p = 0.002). Only 30% (158) of children received hospital follow up after the HI. All children with severe disability received appropriate follow up, but 64% of children with moderate disability received none. No evidence was found to suggest a threshold of injury severity below which the risk of late sequelae could be safely discounted. Conclusions: Children admitted with mild HI may be at risk of poor outcomes, but often do not receive routine hospital follow up. A postal questionnaire combined with the KOSCHI to assess outcomes after HI may be used to identify children who would benefit from clinical assessment. Further research is needed to identify factors that place children with mild HI at risk of late morbidity.	Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England; N Staffordshire Rehabil Ctr, Stoke On Trent ST6 7AG, Staffs, England; City Gen Hosp, Paediat Intens Care Unit, Stoke On Trent ST4 6QG, Staffs, England		Hawley, CA (corresponding author), Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England.	c.a.hawley@warwick.ac.uk	Hawley, Carol/AAG-3830-2019				Audit Commission, 2002, STAT ASS STAT SEN NE; *BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, J CHILD PSYCHOL PSYC, V22, P117, DOI 10.1111/j.1469-7610.1981.tb00538.x; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; Donders J, 1996, J HEAD TRAUMA REHAB, V11, P67, DOI 10.1097/00001199-199606000-00010; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1994, NEUROSURGERY, V35, P225, DOI 10.1227/00006123-199408000-00007; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GUYER B, 1990, AM J DIS CHILD, V144, P649, DOI 10.1001/archpedi.1990.02150300047016; *HC SEL COMM HLTH, 2001, 3 REP HEAD INJ REH; Homer CJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e78; JENNETT B, 1975, LANCET, V1, P480; JOHNSON DA, 1998, ED NEEDS HEAD INJURY; JONES A, 1994, BR J SPEC ED, V21, P113; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; Klonoff H, 1995, TRAUMATIC HEAD INJUR, P219; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Middleton JA, 2001, J CHILD PSYCHOL PSYC, V42, P165, DOI 10.1111/1469-7610.00708; Nash J, 1998, OX MED PUBL, P43; Parmelee D X, 1989, Psychiatr Med, V7, P11; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; RIVARA JB, 1993, ARCH PHYSICAL MED RE, V74, P1947; ROBERTS MA, 1995, BRAIN INJURY, V9, P427, DOI 10.3109/02699059509008202; SCOTTJUPP R, 1992, ARCH DIS CHILD, V67, P222, DOI 10.1136/adc.67.2.222; Sharples PM, 1998, INJURY YOUNG, P151; SNOW JH, 1994, PEDIAT TRAUMATIC BRA; TEASDALE G, 1974, LANCET, V2, P81; Tellier A, 1999, BRAIN INJURY, V13, P463; Townsend P, 1986, INEQUALITIES HLTH NO	35	87	89	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2004	75	5					737	742		10.1136/jnnp.2003.020651			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	813DB	WOS:000220886700017	15090570	Green Published, Green Submitted, Bronze			2022-02-06	
J	Pouthas, V; Perbal, S				Pouthas, V; Perbal, S			Time perception depends on accurate clock mechanisms as well as unimpaired attention and memory processes	ACTA NEUROBIOLOGIAE EXPERIMENTALIS			English	Article; Proceedings Paper	Symposium on Time, Cognition Thinking	JUL 19-23, 2003	Strezekecino, POLAND			aged people; brain damaged patients; clock speed; attention; memory; duration reproduction; duration production	TEMPORAL-ORDER; DURATION JUDGMENTS; DIVIDED ATTENTION; HEAD; SPEED; AGE; DEFICITS; AMNESIA; LESIONS	We report a series of studies aimed at characterizing the relationships between duration judgments and slowing down of the internal clock, attention and memory deficits'. Different groups of participants (elderly people, patients with Parkinson's disease, patients with severe traumatic brain injury, and patients with temporal lobe lesions) performed a duration reproduction task and a duration production task in two conditions: a control counting condition and a concurrent reading condition. Participants were also administered reaction time tasks, tapping tasks, and a battery of attention and memory tests. The results allow us to characterize the relationships between cognitive deficits and impaired duration reproductions and productions in each group. Moreover, results as a whole clarify the respective weight of processing speed, attention and memory in both tasks, and allow better insight into the theoretical models of psychological time.	Hop La Pitie Salpetriere, CNRS, UPR 640, LENA,Unit Cognit Neurosci & Cerebral Imagery, F-75651 Paris 13, France		Pouthas, V (corresponding author), Hop La Pitie Salpetriere, CNRS, UPR 640, LENA,Unit Cognit Neurosci & Cerebral Imagery, 47 Blvd Hop, F-75651 Paris 13, France.	viviane.pouthas@chups.jussieu.fr					ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Baddeley A, 1996, Q J EXP PSYCHOL-A, V49, P5, DOI 10.1080/713755608; Basso G, 1996, NEUROREPORT, V7, P2111, DOI 10.1097/00001756-199609020-00009; Block RA, 1998, PSYCHOL AGING, V13, P584, DOI 10.1037/0882-7974.13.4.584; BOLTZ MG, 1994, J EXP PSYCHOL LEARN, V20, P1154, DOI 10.1037/0278-7393.20.5.1154; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Brown SW, 1997, PERCEPT PSYCHOPHYS, V59, P1118, DOI 10.3758/BF03205526; Casini L, 1999, BEHAV PROCESS, V45, P73, DOI 10.1016/S0376-6357(99)00010-8; Casini L, 1999, NEUROPSYCHOLOGY, V13, P10, DOI 10.1037/0894-4105.13.1.10; CERELLA J, 1990, HDB PSYCHOL AGING, P00201, DOI DOI 10.1016/B978-0-12-101280-9.50018-8; CHURCH RM, 1984, ANN NY ACAD SCI, V423, P566, DOI 10.1111/j.1749-6632.1984.tb23459.x; COOKE DL, 1995, J CLIN EXP NEUROPSYC, V17, P90, DOI 10.1080/13803399508406585; CORKIN S, 1965, NEUROPSYCHOLOGIA, V3, P339, DOI 10.1016/0028-3932(65)90006-0; Craik FIM, 1999, PERCEPT PSYCHOPHYS, V61, P549, DOI 10.3758/BF03211972; DENNER B, 1964, PERCEPT MOTOR SKILL, V19, P723, DOI 10.2466/pms.1964.19.3.723; Deweer B, 2001, BEHAV BRAIN RES, V127, P209, DOI 10.1016/S0166-4328(01)00366-7; Fahn S., 1987, RECENT DEV PARKINSON, P153; Fraisse P., 1957, PSYCHOL TIME; GIBSON JJ, 1975, STUDY TIME, V2, P295; GROBER E, 1987, DEV NEUROPSYCHOL, V3, P13, DOI 10.1080/87565648709540361; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; Harrington DL, 1998, J NEUROSCI, V18, P1085; Harrington DL, 1999, REV NEUROSCIENCE, V10, P91, DOI 10.1515/REVNEURO.1999.10.2.91; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; JonesGotman M, 1997, NEUROPSYCHOLOGIA, V35, P963, DOI 10.1016/S0028-3932(97)00024-9; Kinsbourne M., 1990, NEUROPSYCHOLOGICAL I, P319, DOI DOI 10.1017/CBO9780511665547.017; Lange KW, 1995, J NEURAL TRANSM-SUPP, P423; Lange KW, 1995, J NEURAL TRANSM-SUPP, P433; Lustig C, 2001, PSYCHOL SCI, V12, P478, DOI 10.1111/1467-9280.00389; Malapani C, 1998, J COGNITIVE NEUROSCI, V10, P316, DOI 10.1162/089892998562762; Malapani C, 2002, J COGNITIVE NEUROSCI, V14, P1; Mattis S, 1988, DEMENTIA RATING SCAL; MICHON JA, 1990, COGNITIVE MODELS PSY, P37; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; Mimura M, 2000, J INT NEUROPSYCH SOC, V6, P517, DOI 10.1017/S1355617700655017; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Nichelli P, 1995, ANN NY ACAD SCI, V769, P183, DOI 10.1111/j.1749-6632.1995.tb38139.x; Norman DA., 1986, CONSCIOUSNESS SELF R, P1, DOI [10.1007/978-1-4757-0629-1_1, DOI 10.1007/978-1-4757-0629-1_1]; PASTOR MA, 1992, BRAIN, V115, P211, DOI 10.1093/brain/115.1.211; Perbal S, 2003, NEUROPSYCHOLOGIA, V41, P1599, DOI 10.1016/S0028-3932(03)00110-6; Perbal S, 2002, AGING NEUROPSYCHOL C, V9, P201, DOI 10.1076/anec.9.3.201.9609; Perbal S, 2001, NEUROREPORT, V12, P939, DOI 10.1097/00001756-200104170-00015; Perbal S, 2000, NEUROCASE, V6, P347, DOI 10.1093/neucas/6.4.347; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RICHARDS W, 1973, ACTA PSYCHOL, V37, P279, DOI 10.1016/0001-6918(73)90020-6; Rubia K, 1997, NEUROREPORT, V8, P1273, DOI 10.1097/00001756-199703240-00043; SALTHOUSE TA, 1994, DEV REV, V14, P413, DOI 10.1006/drev.1994.1016; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; Schroots J.J.F., 1990, HDB PSYCHOL AGING, V3, P45; SHAW C, 1994, NEUROPSYCHOLOGIA, V32, P857, DOI 10.1016/0028-3932(94)90023-X; Shimamura AP, 2000, PSYCHOBIOLOGY, V28, P207; SMITH ML, 1981, NEUROPSYCHOLOGIA, V19, P781, DOI 10.1016/0028-3932(81)90090-7; Squire Larry R., 1995, P825; SURWILLO WW, 1968, RECENT ADV RES THEOR, P1; Vakil E, 1998, NEUROPSY NEUROPSY BE, V11, P212; VAKIL E, 1994, NEUROPSY NEUROPSY BE, V7, P281; VAKIL E, 1991, J CLIN EXP NEUROPSYC, V13, P291, DOI 10.1080/01688639108401044; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VanderLinden M, 1996, COGN NEUROPSYCHOL, V13, P391; VANDERLINDEN M, 1995, BROKEN MEMORIES NEUR, P54; Vanneste S, 1999, EXP AGING RES, V25, P49, DOI 10.1080/036107399244138; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Vidalaki VN, 1999, NEUROPSYCHOLOGIA, V37, P1061, DOI 10.1016/S0028-3932(98)00155-9; VILKKI J, 1992, NEUROPSYCHOLOGIA, V30, P807, DOI 10.1016/0028-3932(92)90084-Y; Wearden JH, 1997, J EXP PSYCHOL HUMAN, V23, P962; Wearden JH, 2004, ACTA NEUROBIOL EXP, V64, P303; Wechsler D, 1981, WECHSLER ADULT INTEL; WILLIAMS JM, 1989, J CLIN EXP NEUROPSYC, V11, P713, DOI 10.1080/01688638908400927; Zakay D, 2004, ACTA NEUROBIOL EXP, V64, P319; ZAKAY D, 1993, PERCEPTION, V22, P91, DOI 10.1068/p220091; Zakay D., 1990, COGNITIVE MODELS PSY, P59; ZAKAY D, 1989, TIME HUMAN COGNITION, P365, DOI DOI 10.1016/S0166-4115(08)61047-X	74	87	92	0	7	NENCKI INST EXPERIMENTAL BIOLOGY	WARSAW	UL PASTEURA 3, 02-093 WARSAW, POLAND	0065-1400	1689-0035		ACTA NEUROBIOL EXP	Acta Neurobiol. Exp.		2004	64	3					367	385					19	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	837OQ	WOS:000222645400008	15283479				2022-02-06	
J	Suo, ZM; Wu, M; Citron, BA; Gao, CH; Festoff, BW				Suo, ZM; Wu, M; Citron, BA; Gao, CH; Festoff, BW			Persistent protease-activated receptor 4 signaling mediates thrombin-induced microglial activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; BRAIN; THROMBOMODULIN; INFLAMMATION; MECHANISMS; INJURY	We have previously reported that thrombin, the ultimate serine protease in the coagulation cascades, is a proinflammatory agent that causes proliferation and activation of brain microglial cells. However, participation of its principal receptor, the protease-activated receptor 1 (PAR1) appears to be limited to promoting microglial proliferation and not induction of inflammatory mediators. In the present study, we now report that thrombin action in promoting inflammatory mediators from brain microglia is mediated through another thrombin receptor, PAR4. Here we show that the PAR4 agonist peptide (PAR4AP, GYPGKF), but not the PAR1AP (TRAP, SFLLRN), induced tumor necrosis factor-alpha (TNF-alpha) production not only in cultured murine microglial cells in vitro but also in rat cortex in vivo. Down-regulation of PAR4 expression in microglial cultures by a specific antisense, but not a sense, oligonucleotide reduced PAR4AP- induced TNF-alpha. Mechanistic studies indicated that, in comparison with PAR1 signaling, prolonged increase of [Ca2+](i) and phosphorylation of p44/42 mitogen-activated protein kinases, as well as NFkappaB activation may be responsible for PAR4AP-induced TNF-alpha production in microglia. Taken together, these results demonstrate that PAR4 activation mediates the potentially detrimental effects of thrombin on microglia, implying that perspectives of exploiting PAR1 as a potential anti-inflammatory target should be shifted toward PAR4 as a much more specific therapeutic target in brain inflammatory conditions associated with neurotrauma and neurodegenerations.	Vet Affairs Med Ctr, Lab Alzheimers Dis & Aging Res, Kansas City, MO 64128 USA; Vet Affairs Med Ctr, Mol Biol Res Lab, Kansas City, MO 64128 USA; Vet Affairs Med Ctr, Neurobiol Res Lab, Kansas City, MO 64128 USA; Univ Kansas, Dept Neurol, Sch Med, Kansas City, KS 66170 USA; Univ Kansas, Dept Pharmacol, Sch Med, Kansas City, KS 66170 USA; Univ Kansas, Dept Toxicol, Sch Med, Kansas City, KS 66170 USA; Univ Kansas, Dept Therapeut, Sch Med, Kansas City, KS 66170 USA		Suo, ZM (corresponding author), Vet Affairs Med Ctr, Lab Alzheimers Dis & Aging Res, 4801 Linwood Blvd, Kansas City, MO 64128 USA.	zsuo@kumc.edu					AKIYAMA H, 1992, NEUROSCI LETT, V146, P152, DOI 10.1016/0304-3940(92)90065-F; Benveniste EN, 1997, J MOL MED-JMM, V75, P165, DOI 10.1007/s001090050101; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; CUNNINGHAM DD, 1993, THROMB HAEMOSTASIS, V70, P168; DESCHEPPER CF, 1991, MOL BRAIN RES, V11, P355, DOI 10.1016/0169-328X(91)90045-Y; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; Faruqi TR, 2000, J BIOL CHEM, V275, P19728, DOI 10.1074/jbc.M909960199; FENTON JW, 1986, ANN NY ACAD SCI, V485, P5, DOI 10.1111/j.1749-6632.1986.tb34563.x; FESTOFF BW, 1997, NEUROPROTECTIVE SIGN, P221; FESTOFF BW, 1992, HDB AMYOTROPHIC LATE, V12, P661; HAGLUND RE, 1987, MOL CELL BIOCHEM, V73, P11; HO GJ, 1994, BIOMED PHARMACOTHER, V48, P296, DOI 10.1016/0753-3322(94)90175-9; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Lee KR, 1997, J NEUROSURG, V86, P272, DOI 10.3171/jns.1997.86.2.0272; McGeer EG, 1998, EXP GERONTOL, V33, P371, DOI 10.1016/S0531-5565(98)00013-8; Moller T, 2000, J NEUROCHEM, V75, P1539, DOI 10.1046/j.1471-4159.2000.0751539.x; Mollison J, 2002, J FAM PLAN REPROD H, V28, P101, DOI 10.1783/147118902101196072; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; NISHINO A, 1993, J NEUROTRAUM, V10, P167, DOI 10.1089/neu.1993.10.167; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; Pindon A, 1997, GLIA, V19, P259, DOI 10.1002/(SICI)1098-1136(199703)19:3<259::AID-GLIA8>3.3.CO;2-L; Popovich PG, 2000, PROG BRAIN RES, V128, P43; Ruscher K, 2000, J BIOTECHNOL, V78, P163, DOI 10.1016/S0168-1656(00)00207-8; Ryu J, 2000, J BIOL CHEM, V275, P29955, DOI 10.1074/jbc.M001220200; Sambrano GR, 2001, NATURE, V413, P74, DOI 10.1038/35092573; Sarker KP, 1999, THROMB HAEMOSTASIS, V82, P1071, DOI 10.1055/s-0037-1614331; Shapiro MJ, 2000, J BIOL CHEM, V275, P25216, DOI 10.1074/jbc.M004589200; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Strukova SM, 2001, BIOCHEMISTRY-MOSCOW+, V66, P8, DOI 10.1023/A:1002869310180; Suo ZM, 1997, BRAIN RES, V762, P144, DOI 10.1016/S0006-8993(97)00383-1; Suo ZM, 2002, J NEUROCHEM, V80, P655, DOI 10.1046/j.0022-3042.2001.00745.x; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	36	87	99	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31177	31183		10.1074/jbc.M302137200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	WOS:000184658800095	12775717	hybrid			2022-02-06	
J	Murphy, SJ; Littleton-Kearney, MT; Hurn, PD				Murphy, SJ; Littleton-Kearney, MT; Hurn, PD			Progesterone administration during reperfusion, but not preischemia alone, reduces injury in ovariectomized rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						experimental stroke; progesterone; hormone replacement therapy	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; GABA-A RECEPTOR; STROKE INJURY; BLOOD-FLOW; FEMALE; ESTROGEN; RECOVERY; DAMAGE; EDEMA	Although progesterone is neuroprotective in traumatic brain injury, its efficacy in stroke is unclear. The authors determined whether there are infarction differences after middle cerebral artery occlusion (MCAO) in ovariectomized rats treated acutely with progesterone before MCAO or both pre- and postischemia. Rats received vehicle, 5 (P5), 10 (P10), or 20 (P20) mg/kg progesterone intraperitoneally 30 minutes before MCAO. In another cohort, animals received vehicle or 5 (P5R) mg/kg progesterone intraperitoneally 30 minutes before MCAO, at reperfusion initiation, and at 6-hour reperfusion. Animals underwent 2-hour MCAO by the intraluminal filament technique, followed by 22-hour reperfusion. Cortical (CTX) and caudate-putamen (CP) infarctions were determined by 2,3,5-triphenyltetrazolium chloride staining and digital image analysis. End-ischemic and early reperfusion regional cerebral blood flow (CBF) was measured by [C-14]-iodoantipyrine quantitative autoradiography in vehicle- or progesterone (5 mg/kg)treated rats. Cortical infarction (% contralateral CTX) was 31 30% (vehicle), 39 +/- 23% (P5), 41 +/- 14% (P10), and 28 +/- 20% (P20). Caudate-putamen infarction (% contralateral CP) was 45 +/- 37% (vehicle), 62 +/- 34% (P5), 75 +/- 17% (P10), and 52 30% (P20). In vehicle and P5R groups, CTX infarction was 37 +/- 20% and *20 +/- 17%, respectively (*P < 0.05 from vehicle). In vehicle and P5R groups, CP infarction was 63 +/- 26% and 43 +/- 29%, respectively. End-ischemic regional CBF and CBF recovery during initial reperfusion was unaffected by progesterone treatment. These data suggest that progesterone administration both before MCAO and during reperfusion decreases ischemic brain injury.	Johns Hopkins Med Inst, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA		Murphy, SJ (corresponding author), Johns Hopkins Med Inst, Dept Anesthesiol & Crit Care Med, 600 N Wolfe St,Blalock 1408, Baltimore, MD 21287 USA.	sjmurphy@jhmi.edu			NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P51RR000163] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR00163] Funding Source: Medline		Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; BETZ AL, 1990, ACT NEUR S, V51, P256; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; BUTCHER RL, 1974, ENDOCRINOLOGY, V94, P1704, DOI 10.1210/endo-94-6-1704; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Gillum LA, 2000, JAMA-J AM MED ASSOC, V284, P72, DOI 10.1001/jama.284.1.72; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; Grattan DR, 1996, BRAIN RES, V733, P46, DOI 10.1016/S0006-8993(96)00532-X; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 2000, ANN INTERN MED, V133, P933, DOI 10.7326/0003-4819-133-12-200012190-00008; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; HURN PD, 1995, J CEREBR BLOOD F MET, V15, P666, DOI 10.1038/jcbfm.1995.82; HURN PD, 1998, PHARM CEREBRAL ISCHE, P379; JIANG CW, 1992, EUR J PHARMACOL, V211, P163, DOI 10.1016/0014-2999(92)90524-8; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; JUPTNER M, 1991, J STEROID BIOCHEM, V38, P141, DOI 10.1016/0960-0760(91)90119-P; JUSSOFIE A, 1995, EXP CLIN ENDOCR DIAB, V103, P196, DOI 10.1055/s-0029-1211350; KAGSTROM E, 1983, J CEREBR BLOOD F MET, V3, P170, DOI 10.1038/jcbfm.1983.24; Karas RH, 2001, J CLIN INVEST, V108, P611; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Lee WS, 1997, NAT MED, V3, P1005, DOI 10.1038/nm0997-1005; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Lu GP, 1996, MICROVASC RES, V51, P393, DOI 10.1006/mvre.1996.0035; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; MCCARTHY MM, 1995, HORM BEHAV, V29, P131, DOI 10.1006/hbeh.1995.1010; Moffat CA, 1998, J NEUROSCI, V18, P9556; Moran MH, 1998, BRAIN RES, V807, P84, DOI 10.1016/S0006-8993(98)00782-3; Murphy SJ, 2000, STROKE, V31, P1173, DOI 10.1161/01.STR.31.5.1173; NEQUIN LG, 1979, BIOL REPROD, V20, P659, DOI 10.1095/biolreprod20.3.659; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Rusa R, 1999, STROKE, V30, P1665, DOI 10.1161/01.STR.30.8.1665; Simpkins JW, 1997, J NEUROSURG, V87, P724, DOI 10.3171/jns.1997.87.5.0724; Smith SS, 1998, NATURE, V392, P926, DOI 10.1038/31948; SMITH SS, 1994, PROG NEUROBIOL, V44, P55, DOI 10.1016/0301-0082(94)90057-4; SMITH SS, 1987, BRAIN RES, V400, P353, DOI 10.1016/0006-8993(87)90634-2; SMITH SS, 1991, NEUROSCIENCE, V42, P309, DOI 10.1016/0306-4522(91)90377-Z; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; STEIN DG, 1999, COGNITIVE NEUROREHAB, P73; SUTTERDUB MT, 1974, HORM METAB RES, V6, P297, DOI 10.1055/s-0028-1093852; TISCHKAU SA, 1993, P NATL ACAD SCI USA, V90, P1285, DOI 10.1073/pnas.90.4.1285; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; Vink R, 2001, CLIN EXP PHARMACOL P, V28, P919, DOI 10.1046/j.1440-1681.2001.03548.x; WEILAND NG, 1992, ENDOCRINOLOGY, V131, P2697, DOI 10.1210/en.131.6.2697; WEILAND NG, 1995, MOL BRAIN RES, V32, P271, DOI 10.1016/0169-328X(95)00087-9; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; WIEST WG, 1970, ENDOCRINOLOGY, V87, P43, DOI 10.1210/endo-87-1-43; World Hlth Org, 1998, CONTRACEPTION, V57, P315; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820	57	87	90	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2002	22	10					1181	1188		10.1097/01.WCB.0000037990.07114.07			8	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	600PF	WOS:000178399200005	12368656	Bronze			2022-02-06	
J	Iverson, GL; Lange, RT; Green, P; Franzen, MD				Iverson, GL; Lange, RT; Green, P; Franzen, MD			Detecting exaggeration and malingering with the Trail Making Test	CLINICAL NEUROPSYCHOLOGIST			English	Article							RECOGNITION MEMORY TEST; VERBAL-LEARNING TEST; MILD HEAD-INJURY; ADULT INTELLIGENCE SCALE; NEUROPSYCHOLOGICAL EVALUATION; INCOMPLETE EFFORT; CROSS-VALIDATION; PERFORMANCE; IMPAIRMENT; DEMENTIA	The purpose of this study was to examine whether unusual performance on the Trail Making Test could be indicative of deliberate exaggeration. Participants were 571 patients seen as part of a hospital trauma service who had acute traumatic brain injuries, and 228 patients involved in head injury litigation. As expected, the hospital patients with more severe traumatic brain injuries performed more poorly than the patients with less severe brain injuries on Trails A and Trails B. Cutoff score tables were developed for the patients with acute traumatic brain injuries for the total sample and by injury severity groups. Scores falling at or below the 5th percentile were considered suspicious for possible exaggeration. The performances of the head injury litigants who exaggerated on at least one well-validated symptom validity test were compared to these cutoffs. Very high positive predictive values for individuals with very mild head injuries on Trails A and B were identified (i.e., both 100%); lower positive predictive values were obtained for individuals with more severe head injuries (55.6-60%). The negative predictive values were only moderate (range = 66.4-78.2%), and the sensitivity was very low (range = 7.1-18.5%) for all groups. Scores that fall in the range of possible biased responding should be considered "red flags" for the clinician because they likely do not make biological or psychometric sense. However, the sensitivity of the test for deliberate exaggeration is very low, so clinicians who rely on this test in isolation to identify deliberately poor performance will fail to identify the vast majority of cases.	Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada; Riverview Hosp, Vancouver, BC, Canada; Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; Allegheny Gen Hosp, Dept Psychiat, Pittsburgh, PA 15212 USA		Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	giverson@interchange.ubc.ca		Iverson, Grant/0000-0001-7348-9570			Allen L., 1997, CARB 97 MANUAL COMPU; Amieva H, 1998, J CLIN EXP NEUROPSYC, V20, P280, DOI 10.1076/jcen.20.2.280.1161; Axelrod B N, 2000, Appl Neuropsychol, V7, P186; Camara WJ, 2000, PROF PSYCHOL-RES PR, V31, P141, DOI 10.1037/0735-7028.31.2.141; Coleman RD, 1998, J CLIN EXP NEUROPSYC, V20, P201, DOI 10.1076/jcen.20.2.201.1164; CONDER R, 1992, COMPUTERIZED ASSESSM; CORRIGAN JD, 1987, J CLIN PSYCHOL, V43, P402, DOI 10.1002/1097-4679(198707)43:4<402::AID-JCLP2270430411>3.0.CO;2-E; Gfeller JD, 1998, J CLIN PSYCHOL, V54, P431, DOI 10.1002/(SICI)1097-4679(199806)54:4<431::AID-JCLP5>3.0.CO;2-Q; GOEBEL RA, 1983, J CLIN PSYCHOL, V39, P731, DOI 10.1002/1097-4679(198309)39:5<731::AID-JCLP2270390515>3.0.CO;2-T; Golden C.J., 1981, INTERPRETATION HALST; Green P, 2001, CLIN NEUROPSYCHOL, V15, P492, DOI 10.1076/clin.15.4.492.1887; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Green P., 1996, WORD MEMORY TEST USE; GREEN P, 1997, NAT AC NEUR LAS VEG; Iverson GL, 1998, BRAIN INJURY, V12, P275, DOI 10.1080/026990598122575; Iverson GL, 2000, J CLIN EXP NEUROPSYC, V22, P191, DOI 10.1076/1380-3395(200004)22:2;1-1;FT191; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; IVERSON GL, 1999, J COGNITIVE REHABILI, V17, P48; LAMBERTY GJ, 1994, NEUROPSY NEUROPSY BE, V7, P230; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; MILLIS SR, 1994, J CLIN PSYCHOL, V50, P601, DOI 10.1002/1097-4679(199407)50:4<601::AID-JCLP2270500417>3.0.CO;2-9; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 1998, J CLIN EXP NEUROPSYC, V20, P167, DOI 10.1076/jcen.20.2.167.1171; MILLIS SR, 1994, PERCEPT MOTOR SKILL, V79, P384, DOI 10.2466/pms.1994.79.1.384; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Nilson L, 1999, CLIN NEUROPSYCHOL, V13, P314, DOI 10.1076/clin.13.3.314.1737; Rasmusson DX, 1998, CLIN NEUROPSYCHOL, V12, P169, DOI 10.1076/clin.12.2.169.2005; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; REITAN RM, 1992, TRAIT MAKING TEST MA; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; Slick DJ, 2000, J CLIN EXP NEUROPSYC, V22, P569, DOI 10.1076/1380-3395(200010)22:5;1-9;FT569; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Tenhula WN, 1996, CLIN NEUROPSYCHOL, V10, P104, DOI 10.1080/13854049608406669; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; [No title captured]	38	87	87	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	AUG	2002	16	3					398	406		10.1076/clin.16.3.398.13861			9	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	664UZ	WOS:000182081500017	12607151				2022-02-06	
J	Tong, W; Igarashi, T; Ferriero, DM; Noble, LJ				Tong, W; Igarashi, T; Ferriero, DM; Noble, LJ			Traumatic brain injury in the immature mouse brain: Characterization of regional vulnerability	EXPERIMENTAL NEUROLOGY			English	Article						traumatic brain injury; controlled cortical impact; immature brain; delayed neuronal damage; Fluoro-Jade; axonal degeneration	CLOSED HEAD-INJURY; PERINATAL HYPOXIA-ISCHEMIA; DISMUTASE TRANSGENIC MICE; NEURONAL DEGENERATION; NEONATAL RAT; FLUORO-JADE; CHILDREN; ADOLESCENTS; DAMAGE; NEURODEGENERATION	We characterized the regional and temporal patterns of neuronal injury and axonal degeneration after controlled cortical impact of moderate severity in mice at postnatal day 21. Animals were euthanized at 1, 3, or 7 days after injury or sham operation. The brains were removed and prepared for immunolocalization of neurons and microglia/macrophages or subjected to Fluoro-Jade and silver stains, indicators of irreversible neuronal cell injury and axonal degeneration. There was significant neuronal loss in both the ipsi- and the contralateral cortices, ipsilateral hippocampus, and ipsilateral thalamus by 7 days post injury compared to sham-operated animals. Activated microglia/macrophages were most prominent in regions of neuronal loss including the ipsilateral cortex, hippocampus, and thalamus. Neuronal injury, as evidenced by Fluoro-Jade labeling, was not apparent in sham-operated animals. In injured animals, labeling was identified in the ipsilateral cortex and hippocampus at 1 and 3 days post injury. Silver- and Fluoro-Jade-labeled degenerating axons were observed in the ipsilateral subcortical white matter by 1 day post injury, in the ipsilateral external capsule, caudate putamen, and contralateral subcortical white matter by 3 days post injury, and in the internal capsule, pyramidal tracts, and cerebellar peduncles by 7 days post injury. Our findings demonstrate that controlled cortical impact in the developing brain generates neuronal loss in both the ipsilateral and the contralateral cortex, a temporally distinct pattern of subcortical. neuronal injury/death, and widespread white matter damage. These observations serve as an important baseline for studying human brain injury and optimizing therapies for the brain-injured child. (C) 2002 Elsevier Science (USA).	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA		Noble, LJ (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS014543, P50NS014543] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS14543] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adelson PD, 1998, ACT NEUR S, V71, P104; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; BIROS MH, 1991, RESUSCITATION, V22, P283, DOI 10.1016/0300-9572(91)90036-X; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; CALDER IM, 1984, J CLIN PATHOL, V37, P1095, DOI 10.1136/jcp.37.10.1095; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Chan PH, 1998, J NEUROSCI, V18, P8292, DOI 10.1523/jneurosci.18-20-08292.1998; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DAVISON AN, 1966, BRIT MED BULL, V22, P40, DOI 10.1093/oxfordjournals.bmb.a070434; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Ditelberg JS, 1996, PEDIATR RES, V39, P204, DOI 10.1203/00006450-199602000-00003; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FIFE D, 1984, J NEUROSURG, V60, P697, DOI 10.3171/jns.1984.60.4.0697; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; Fullerton HJ, 1998, ANN NEUROL, V44, P357, DOI 10.1002/ana.410440311; Greenwald B M, 1995, Adv Pediatr, V42, P47; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HUMPHREYS R, 1984, CONCEPTS PEDIAT NEUR, V4, P230; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Joashi UC, 1999, EUR J NEUROSCI, V11, P91, DOI 10.1046/j.1460-9568.1999.00409.x; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; KOLB B, 1986, BRAIN RES, V397, P315, DOI 10.1016/0006-8993(86)90633-5; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1979, CHILD BRAIN, V5, P281; Li L, 1998, MOL CELL NEUROSCI, V12, P157, DOI 10.1006/mcne.1998.0709; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Northington FJ, 2001, NEUROBIOL DIS, V8, P207, DOI 10.1006/nbdi.2000.0371; Northington FJ, 2001, J NEUROSCI, V21, P1931, DOI 10.1523/JNEUROSCI.21-06-01931.2001; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.1289/ehp.00108s3511; RUIJS MBM, 1990, CLIN NEUROL NEUROSUR, V92, P323, DOI 10.1016/0303-8467(90)90058-D; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Soares HD, 1995, J NEUROSCI, V15, P8223; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1; Zuckerman GB, 1997, PEDIATR ANN, V26, P621, DOI 10.3928/0090-4481-19971001-09	56	87	88	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JUL	2002	176	1					105	116		10.1006/exnr.2002.7941			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	574VV	WOS:000176911000010	12093087				2022-02-06	
J	Labombarda, F; Gonzalez, SL; Deniselle, MCG; Guennoun, R; Schumacher, M; de Nicola, AF				Labombarda, F; Gonzalez, SL; Deniselle, MCG; Guennoun, R; Schumacher, M; de Nicola, AF			Cellular basis for progesterone neuroprotection in the injured spinal cord	JOURNAL OF NEUROTRAUMA			English	Article						choline acetyltransferase; GAP-43; Na,K-ATPase; neuroprotection; progesterone; spinal cord injury	CENTRAL-NERVOUS-SYSTEM; GAP-43 MESSENGER-RNA; TRAUMATIC BRAIN INJURY; GROWTH-FACTOR RECEPTOR; ADULT-RAT; GLUCOCORTICOID RECEPTORS; CHOLINE-ACETYLTRANSFERASE; AXONAL REGENERATION; NEUROTROPHIC FACTOR; DOWN-REGULATION	Progesterone (PROG) exerts beneficial and neuroprotective effects in the injured central and peripheral nervous system. In the present! work, we examine PROG effects on three measures of neuronal function under negative regulation (choline acetyltransferase [ChAT] and Na,K-ATPase) or stimulated (growth-associated protein [GAP-43]) after acute spinal cord transection injury in rats. As expected, spinal cord injury reduced ChAT immunostaining intensity of ventral horn neurons. A 3-day course of intensive PROG treatment of transected rats restored ChAT immunoreactivity, as assessed by frequency histograms that recorded shifts from predominantly light neuronal staining to medium, dark or intense staining typical of control rats. Transection also reduced the expression of the mRNA for the alpha3 catalytic and beta1 regulatory subunits of neuronal Na,K-ATPase, whereas PROG treatment restored both subunit mRNA to normal levels. Additionally, the upregulation observed for GAP-43 mRNA in ventral horn neurons in spinal cord-transected rats, was further enhanced by PROG administration. In no case did PROG modify ChAT immunoreactivity, Na,K-ATPase subunit mRNA or GAP-43 mRNA in control, sham-operated rats. Further, the PROG-mediated effects on these three markers were observed in large, presumably Lamina IX motoneurons, as well as in smaller neurons measuring approximately <500 mu(2). Overall, the stimulatory effects of PROG on ChAT appears to replenish acetylcholine, with its stimulatory effects on Na,K-ATPase seems capable of restoring membrane potential, ion transport and nutrient uptake. PROG effects on GAP-43 also appear to accelerate reparative responses to injury. As the cellular basis for PROG neuroprotection becomes better understood it may prove of therapeutic benefit to spinal cord injury patients.	Univ Buenos Aires, Fac Med, Inst Biol & Med Expt, Lab Neuroendocrine Biochem, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Med, Dept Human Biochem, RA-1428 Buenos Aires, DF, Argentina; INSERM U488 Steroids & Syst Nerveux, Le Kremlin Bicetre, France; Univ Buenos Aires, Inst Ciencias Salud, Fdn Barcelo, Buenos Aires, DF, Argentina		de Nicola, AF (corresponding author), Univ Buenos Aires, Fac Med, Inst Biol & Med Expt, Lab Neuroendocrine Biochem, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.		Guennoun, Rachida/F-2420-2011; Schumacher, Michael/G-3581-2013	Guennoun, Rachida/0000-0002-9219-7300; Schumacher, Michael/0000-0001-6117-5371			BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Burke R.E., 1977, HDB PHYSL          1, P877; CHAO HM, 1992, MOL CELL NEUROSCI, V3, P529, DOI 10.1016/1044-7431(92)90065-A; Chen AQ, 1996, EXP NEUROL, V138, P261, DOI 10.1006/exnr.1996.0065; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; CURTIS R, 1993, J NEUROCYTOL, V22, P51, DOI 10.1007/BF01183975; CURTIS R, 1993, J NEUROCYTOL, V22, P39, DOI 10.1007/BF01183974; DENICOLA AF, 1993, ADV NEUROL, V59, P199; Deniselle MCG, 1999, BRAIN RES, V841, P78, DOI 10.1016/S0006-8993(99)01783-7; Derfoul A, 1998, J BIOL CHEM, V273, P20702, DOI 10.1074/jbc.273.33.20702; Desarnaud F, 1998, J NEUROCHEM, V71, P1765; di Michele F, 2000, NEUROSCI LETT, V284, P65, DOI 10.1016/S0304-3940(00)00965-4; DUNCAN GE, 1984, BRAIN RES, V307, P321, DOI 10.1016/0006-8993(84)90486-4; EIDELBERG E, 1989, BRAIN RES BULL, V22, P39, DOI 10.1016/0361-9230(89)90125-1; Elizalde PV, 1998, J STEROID BIOCHEM, V67, P305, DOI 10.1016/S0960-0760(98)00123-X; Elliott EJ, 1997, BRAIN RES, V755, P221, DOI 10.1016/S0006-8993(97)00100-5; FARMAN N, 1994, AM J PHYSIOL, V266, pC423, DOI 10.1152/ajpcell.1994.266.2.C423; FERRINI M, 1995, LIFE SCI, V57, P2403, DOI 10.1016/0024-3205(95)02236-3; FERRINI M, 1993, CELL MOL NEUROBIOL, V13, P387, DOI 10.1007/BF00711579; Forger NG, 1998, J NEUROSCI, V18, P8720; Gonzalez S, 1996, NEUROREPORT, V7, P1041, DOI 10.1097/00001756-199604100-00017; Gonzalez SL, 1999, CELL MOL NEUROBIOL, V19, P597, DOI 10.1023/A:1006980301382; Grillo C, 1997, BRAIN RES, V767, P120, DOI 10.1016/S0006-8993(97)00541-6; GUTH L, 1994, P NATL ACAD SCI USA, V91, P12308, DOI 10.1073/pnas.91.25.12308; HALL ED, 1993, CELL MOL NEUROBIOL, V13, P415, DOI 10.1007/BF00711581; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; JOHNSON H, 1995, J COMP NEUROL, V359, P69, DOI 10.1002/cne.903590106; JONES KJ, 1993, BRAIN RES BULL, V30, P491, DOI 10.1016/0361-9230(93)90283-H; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; KOU SY, 1995, J NEUROBIOL, V27, P561, DOI 10.1002/neu.480270410; Labombarda F, 2000, NEUROSCI LETT, V288, P29, DOI 10.1016/S0304-3940(00)01191-5; Labombarda F, 2000, J STEROID BIOCHEM, V73, P159, DOI 10.1016/S0960-0760(00)00064-9; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; LEES GJ, 1991, BRAIN RES REV, V16, P283, DOI 10.1016/0165-0173(91)90011-V; MCKINNEY M, 1994, MOL BRAIN RES, V23, P213, DOI 10.1016/0169-328X(94)90228-3; MEIRI H, 1986, BRAIN RES, V385, P193, DOI 10.1016/0006-8993(86)91566-0; Nacimiento W, 1996, BRAIN RES, V714, P177, DOI 10.1016/0006-8993(95)01534-5; Oestreicher AB, 1997, PROG NEUROBIOL, V53, P627, DOI 10.1016/S0301-0082(97)00043-9; OGATA T, 1993, NEUROSCIENCE, V55, P445, DOI 10.1016/0306-4522(93)90513-F; ORTH DN, 1998, WILLIAMS TXB ENDOCRI, P605; Oudega M, 1999, EUR J NEUROSCI, V11, P2453, DOI 10.1046/j.1460-9568.1999.00666.x; Peluso JJ, 1999, BIOL REPROD, V60, P290, DOI 10.1095/biolreprod60.2.290; PERRONEBIZZOZERO NI, 1993, J CELL BIOL, V120, P1263, DOI 10.1083/jcb.120.5.1263; RENDE M, 1995, J COMP NEUROL, V363, P249, DOI 10.1002/cne.903630207; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; SANNE JL, 1995, J NEUROCHEM, V65, P528; Schmitt AB, 1999, NEUROBIOL DIS, V6, P122, DOI 10.1006/nbdi.1998.0231; Siegel S., 1989, NONPARAMETRIC STAT B, V2nd; STAHL WL, 1986, NEUROCHEM INT, V8, P449, DOI 10.1016/0197-0186(86)90179-8; Stein DG, 1998, NEUROSCIENTIST, V4, P435, DOI 10.1177/107385849800400615; STEINER T J, 1972, Journal of Physiology (Cambridge), V222, P123; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; VEDECKIS WV, 1992, P SOC EXP BIOL MED, V199, P1; WATTS AG, 1991, P NATL ACAD SCI USA, V88, P7425, DOI 10.1073/pnas.88.16.7425; WOOLE NJ, 1989, NEUROSCIENCE, V30, P143, DOI 10.1016/0306-4522(89)90360-6; YAN Q, 1994, J NEUROSCI, V14, P5281; YU WH, 1989, BRAIN RES, V49, P379; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	61	87	94	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2002	19	3					343	355		10.1089/089771502753594918			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	534BC	WOS:000174563900006	11939502				2022-02-06	
J	Bullinger, M				Bullinger, M		TBI Consensus Grp	Quality of life in patients with traumatic brain injury - basic issues, assessment and recommendations - Results of a consensus meeting	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article; Proceedings Paper	Consensus Conference on Quality of Life after Multiple Trauma	SEP 29-OCT 02, 1999	WERMELSKIRCHEN, GERMANY	German Minist Educ & Res		traumatic brain injury; quality of life; consensus conference	GLASGOW OUTCOME SCALE; SEVERE HEAD-INJURY; OF-LIFE; COMMUNITY; INTEGRATION; PERSPECTIVE; EMPLOYMENT; DISABILITY	Introduction: Traumatic brain injuries (TBI) are one of the most common consequences of traffic accidents. Patients with mild, moderate or severe brain injuries suffer from physical, cognitive, behavioral, emotional and social problems. Most of these problems have been a long standing focus amongst practitioners and researchers. Only recently a development has started that took interest in the quality of life outcome of TBI patients. The international members of this consensus meeting reviewed the literature on Quality of Life assessment after TBI and discussed the applicability of different measurements to this specific patient group. Time Points: During the acute phase (T1; < 3 month after trauma) QoL it is difficult to assess due to the reduced conciousness of TBI patients. In the phase of rehabilitation (T2; < one year after trauma) and in the post-rehabilitation phase (T3) repeated assessment of QoL is recommended. Instruments: Several generic and disease-specific instruments possibly relevant to TBI patients or specifically developed for this group were assessed according to the existing evidence in the literature. Criteria for the evaluation of these intruments were: feasibility, specificity, validity, comprehensiveness, international availability, existence of norms, and psychometric quality. The cognitive impairment and the existential dimension were not sufficiently considered in most of the reviewed instruments. Group Consensus: The familiy's and relatives' view of the patient's QoL should not be used as a proxy but provides an additional source of information in the acute phase. At T2 and T3, assessment of the patient's quality of life should include a generic as well as a disease specific instrument. Among the generic instruments the SF-36, the EuroQol and the WHO-QoL should be considered. The literature about specific instruments for patients with TBI like the EBIC is scarce. Therefore, the group could hardly give an empiracally based recommendation. The need for further investigation on QoL instruments in TBI patients is strongly emphasized.	Univ Hamburg, Dept Med Psychol, D-20246 Hamburg, Germany		Bullinger, M (corresponding author), Univ Hamburg, Dept Med Psychol, Martinistr 52, D-20246 Hamburg, Germany.						Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Bergner M, 1991, MED CARE, V19, P780; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; CHRISTENSEN AL, 1992, ACTA NEUROL SCAND, V85, P32; DELOCHE G, 1994, INT HDB NEUROPSYCHOL, P81; Dijkers M, 1999, AM J PHYS MED REHAB, V78, P286, DOI 10.1097/00002060-199905000-00022; DIKMEN S, 1993, BRAIN INJURY, V7; DIKMEN S, 1995, NEUROPSYCHOLOGY, V4, P80; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; GREENWOOD RJ, 1994, BRIT MED J, V308, P1199, DOI 10.1136/bmj.308.6938.1199; HUNT SM, 1981, SOC SCI MED-MED SOC, V15, P221, DOI 10.1016/0271-7123(81)90005-5; HUTTER BO, 1998, ZENTRALBL NEUROCHIR, V59, P63; HUTTER BO, 1997, QUAL LIFE RES, V6, P662; HUTTER BO, 1999, Z NEUROPSYCHOL, V10, P38; JACKSON H F, 1992, Brain Injury, V6, P109, DOI 10.3109/02699059209029650; Jennett B, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199708000-00003; JENNETT B, 1994, REAN URG, V3, P153; Jennett B., 1997, HEAD INJURY, P439; Kaplan RM, 1996, QUALITY LIFE PHARMEA, P309; Kind P, 1996, QUALITY LIFE PHARMAC, V2, P191; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Lai Y. C., 1998, Annals Academy of Medicine Singapore, V27, P326; Lang DA, 1999, J NEUROSURG, V91, P359, DOI 10.3171/jns.1999.91.3.0359; MOORE A D, 1990, Brain Injury, V4, P379, DOI 10.3109/02699059009026191; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Spilker B., 1996, QUALITY LIFE PHARMAC, P337; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; *WHO QOL GROUP, 1993, QUAL LIF ASS INT PER; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	37	87	90	0	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2002	20	3-4					111	124					14	Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	633MR	WOS:000180287500006	12454360				2022-02-06	
J	Rosenberger, J; Petrovics, G; Buzas, B				Rosenberger, J; Petrovics, G; Buzas, B			Oxidative stress induces proorphanin FQ and proenkephalin gene expression in astrocytes through p38-and ERK-MAP kinases and NF-kappa B	JOURNAL OF NEUROCHEMISTRY			English	Article						astrocyte; mitogen-activated protein kinase; nociceptin; nuclear factor-kappa B; orphanin FQ; oxidative stress	ACTIVATED PROTEIN-KINASE; PREPROENKEPHALIN MESSENGER-RNA; SIGNAL-REGULATED KINASE; BRAIN INJURY; ORPHANIN-FQ; NOCICEPTIN/ORPHANIN FQ; TRANSCRIPTION FACTOR; CULTURED ASTROCYTES; NEUROPEPTIDE GENE; CYCLIC-AMP	Oxidative stress has been implicated in the pathogenesis of stroke, traumatic brain injuries, and neurodegenerative diseases affecting both neuronal and glial cells in the CNS. In this study we have demonstrated that reactive oxygen species (ROS) dramatically induce the expression of two neuropeptide genes, the opioid proenkephalin (pENK) and the opioid-related proorphanin FQ (pOFQ; also known as pronociceptin) in primary astrocytes. Hydrogen peroxide (H2O2) treatment dose-dependently increased pENK and pOFQ mRNA levels with a maximal effect (similar to 15-fold increase) being detected at 50 muM concentration. Exposing the astrocyte cultures to hypoxia and subsequent re-oxygenation also led to a profound elevation of pOFQ and pENK mRNA levels. Western blot analysis and immunocytochemistry revealed that H2O2 treatment elicited the phosphorylation and nuclear translocation of ERK 1/2 and p38 MAP kinases. Blockade of the p38 or the ERK MAP kinase pathways (by SB202190 and PD98059, respectively) prevented the H2O2-induced increase in pENK and pOFQ mRNA levels indicating a central role for these cascades in the regulation of pOFQ and pENK genes In response to oxidative stress. Regulation of pOFQ and pENK gene expression by ERK and p38 activation may be mediated through the transcription factor cAMP-response element binding protein (CREB). We observed CREB phosphorylation in response to H2O2, which was also prevented by SB202190 and PD98059. The nuclear factor-kappaB (NF-kappaB) pathway appears to be involved exclusively in the induction of pOFQ transcription by H2O2, as NF-kappaB inhibitors antagonized the effect of oxidative stress on pOFQ, but not on pENK expression. The profound induction of these genes by oxidative stress and these other factors may suggest a role for orphanin FQ and enkephalin in injury and stress responses of the CNS and neuropathophysiological conditions involving reactive oxygen species.	Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA		Buzas, B (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pharmacol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.			Petrovics, Gyorgy/0000-0003-3732-284X			Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Andoh T, 1997, NEUROREPORT, V8, P2793, DOI 10.1097/00001756-199708180-00028; Armstead WM, 2000, J NEUROTRAUM, V17, P751, DOI 10.1089/neu.2000.17.751; Armstead WM, 2000, BRAIN RES, V868, P48, DOI 10.1016/S0006-8993(00)02262-9; BORSOOK D, 1994, MOL ENDOCRINOL, V8, P116, DOI 10.1210/me.8.1.116; Buzas B, 1998, J NEUROCHEM, V71, P556; Buzas B, 1999, J NEUROCHEM, V72, P1882, DOI 10.1046/j.1471-4159.1999.0721882.x; BUZAS B, 1998, P38 MAP KINASE NFKB; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Christman JW, 2000, BRAIN PATHOL, V10, P153; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; FAN LS, 1999, MOL PHARMACOL, V55, P658; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; Helyes Z, 1997, BRIT J PHARMACOL, V121, P613, DOI 10.1038/sj.bjp.0701209; Juurlink BHJ, 1997, NEUROSCI BIOBEHAV R, V21, P121, DOI 10.1016/S0149-7634(96)00001-2; Kulkarni M, 2000, STROKE, V31, P1990, DOI 10.1161/01.STR.31.8.1990; Laudenbach V, 2001, J CLIN INVEST, V107, P457, DOI 10.1172/JCI9716; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Love S, 1999, BRAIN PATHOL, V9, P119; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Maher P, 2000, CELL MOL LIFE SCI, V57, P1287, DOI 10.1007/PL00000766; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; Nose K, 2000, BIOL PHARM BULL, V23, P897; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Saito Y, 1996, J BIOL CHEM, V271, P15615, DOI 10.1074/jbc.271.26.15615; SAITO Y, 1997, J NEUROSCI RES, V48, P37; Schoonbroodt S, 2000, BIOCHEM PHARMACOL, V60, P1075, DOI 10.1016/S0006-2952(00)00371-3; Serhan CN, 2001, J IMMUNOL, V166, P3650, DOI 10.4049/jimmunol.166.6.3650; SHINODA H, 1992, DEV BRAIN RES, V67, P205, DOI 10.1016/0165-3806(92)90220-Q; SHINODA H, 1989, SCIENCE, V245, P415, DOI 10.1126/science.2569236; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Tsubuki S, 1996, J BIOCHEM-TOKYO, V119, P572, DOI 10.1093/oxfordjournals.jbchem.a021280; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VILIJN MH, 1988, P NATL ACAD SCI USA, V85, P6551, DOI 10.1073/pnas.85.17.6551; Won JS, 2000, MOL BRAIN RES, V76, P396, DOI 10.1016/S0169-328X(00)00032-2; Xie GX, 1999, GENE, V238, P427, DOI 10.1016/S0378-1119(99)00350-9; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; ZURAWSKI G, 1986, SCIENCE, V232, P772, DOI 10.1126/science.2938259	46	87	91	0	4	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	OCT	2001	79	1					35	44		10.1046/j.1471-4159.2001.00520.x			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	480YB	WOS:000171489800005	11595755	Bronze			2022-02-06	
J	Macciocchi, SN; Barth, JT; Littlefield, L; Cantu, RC				Macciocchi, SN; Barth, JT; Littlefield, L; Cantu, RC			Multiple concussions and neuropsychological functioning in collegiate football players	JOURNAL OF ATHLETIC TRAINING			English	Article						sports injuries; neuropsychological tests; symptoms	RECOVERY; SPORTS	Objective: To document neurocognitive and neurobehavioral consequences of 1 versus 2 concussions. Design and Setting: Nonequivalent, pretest-posttest cohort design with multiple dependent measures. Participants were selected from a large sample of athletes who participated in a comprehensive, multiuniversity study of football-related concussion. Subjects: College football players who sustained 1 and 2 grade 1 concussive injuries were matched for age, education, and duration of competitive football. Measurements: Neuropsychological tests and symptoms checklists. Results: Multivariate analysis of variance did not show a statistically significant difference in test performance between players with 1 or 2 concussions. Chi square analyses revealed that concussions significantly increased the number of symptom complaints, but symptoms returned to baseline by 10 days post-injury. The effects of 2 injuries did not appear to be significantly greater than that of a single injury. Differences in response to concussion were observed. Conclusions: Neurocognitive and neurobehavioral consequences of 2 concussions did not appear to be significantly different from those of 1 concussion, but methodologic issues place limitations on data interpretation. Additional studies are needed to clarify the neuropsychological consequences of multiple concussions.	Shepherd Ctr, Atlanta, GA 30309 USA; Emory Univ, Atlanta, GA 30322 USA; Univ Virginia, Sch Med, Charlottesville, VA 22908 USA; Washington Coll, Chestertown, MD USA; Emerson Hosp, Concord, MA USA		Macciocchi, SN (corresponding author), Shepherd Ctr, 2020 Peachtree Rd NW, Atlanta, GA 30309 USA.						Barth JT, 1989, MILD HEAD INJURY; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MACCIOCCHI SN, 1990, J CLIN PSYCHOL, V46, P628, DOI 10.1002/1097-4679(199009)46:5<628::AID-JCLP2270460514>3.0.CO;2-V; MACCIOCCHI SN, 2000, NEUROLOGIC ATHLETIC, P101; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Wechsler D., 2008, WECHSLER ADULT INTEL, V4th Edn	11	87	89	0	10	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2001	36	3					303	306					4	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	557NC	WOS:000175913800014	12937500				2022-02-06	
J	Platz, T; Winter, T; Muller, N; Pinkowski, C; Eickhof, C; Mauritz, KH				Platz, T; Winter, T; Muller, N; Pinkowski, C; Eickhof, C; Mauritz, KH			Arm ability training for stroke and traumatic brain injury patients with mild arm paresis: A single-blind, randomized, controlled trial	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	2nd World Congress in Neurological Rehabilitation	APR 14, 1999	TORONTO, CANADA			activities of daily living; arm; brain injuries; cerebrovascular accident; paresis; rehabilitation	INDUCED MOVEMENT THERAPY; MOTOR; REHABILITATION; PERFORMANCE; RECOVERY; VALIDITY; DEFICITS; HAND	Objective: To test the efficacy of the arm ability training (AAT) on a sample of patients with central arm paresis after traumatic brain injury (TBI) or stroke. Design: Single-blind, randomized, controlled trial. Setting: Inpatient rehabilitation center. Patients: Consecutive sample of 74 patients of whom 60 (45 with stroke, 15 with TBI) completed the study; 37 patients received a 1-year follow-up. Intervention: Daily AAT with (n = 20) or without (n = 20) knowledge of results, or no AAT (n = 20) during a 3-week intervention period. Main Outcome Measures: Summary time scores of the Test Evaluant les Membres superieurs des Personnes Agees (TEMPA)-a test of upper extremity function with daily function-like activities (focal disability)-and kinematic analysis of aimed movements, Results: Patients with AAT realized superior improvement as compared with controls. Mean improvement in the time needed to perform (1) all TEMPA tasks was 41.4 versus 12.8 seconds (p =.0012); (2) unilateral TEMPA tasks, 16.5 versus 4.2 seconds (p=.0036); and (3) the ballistic component of aimed movements, 96 versus 20ms (p =.0115). Knowledge of result did not substantially modify these effects. A functional benefit existed at 1-year follow-up. Conclusion: The AAT reduces focal disability among stroke and TBI patients with mild central arm paresis.	Free Univ Berlin, Abt Neurol Rehabil, Klin Berlin, Klinikum Benjamin Franklin, D-12200 Berlin, Germany		Platz, T (corresponding author), Klin Berlin, Kladower Damm 223, D-14089 Berlin, Germany.			Platz, Thomas/0000-0003-2629-9744; Eickhof, Christel/0000-0002-1312-5297			ASANUMA H, 1991, NEUROREPORT, V2, P217, DOI 10.1097/00001756-199105000-00001; Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; BASMAJIAN JV, 1987, ARCH PHYS MED REHAB, V68, P267; BRAUS DF, 1994, ANN NEUROL, V36, P728, DOI 10.1002/ana.410360507; BUTEFISCH C, 1995, J NEUROL SCI, V130, P59, DOI 10.1016/0022-510X(95)00003-K; CARR J, 1998, NEUROLOGICAL REHABIL, P264; DEMEURISSE G, 1980, EUR NEUROL, V19, P382, DOI 10.1159/000115178; DESROSIERS J, 1994, OCCUP THER J RES, V14, P267, DOI 10.1177/153944929401400405; Desrosiers J, 1993, CAN J OCCUP THER, V60, P9, DOI DOI 10.1177/000841749306000104; DICKSTEIN R, 1986, PHYS THER, V66, P1233, DOI 10.1093/ptj/66.8.1233; Feys HM, 1998, STROKE, V29, P785, DOI 10.1161/01.STR.29.4.785; Fleishman E. A., 1964, STRUCTURE MEASUREMEN; Fleishman EA, 1967, LEARN INDIVID DIFFER, P165; FLEISHMAN EA, 1965, TRAINING RES ED, P37; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, pSC2; KARNI A, 1995, NATURE, V377, P155; Kleinbaum DG., 1988, APPL REGRESSION ANAL; KRAFT GH, 1992, ARCH PHYS MED REHAB, V73, P220; Kramer MS, 1988, CLIN EPIDEMIOLOGY BI; Kunkel A, 1999, ARCH PHYS MED REHAB, V80, P624, DOI 10.1016/S0003-9993(99)90163-6; LOGIGIAN MK, 1983, ARCH PHYS MED REHAB, V64, P364; LORD JP, 1986, ARCH PHYS MED REHAB, V67, P88, DOI 10.1016/0003-9993(86)90108-5; Miltner WHR, 1999, STROKE, V30, P586, DOI 10.1161/01.STR.30.3.586; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PINKOWSKI C, 2000, 9 REH K VDR 2000 MAR, P188; PLATZ T, 1994, NEUROPSYCHOLOGIA, V32, P1209, DOI 10.1016/0028-3932(94)90103-1; Platz T, 1997, BEHAV NEUROL, V10, P15, DOI 10.3233/BEN-1997-10103; Platz T, 1999, ARCH PHYS MED REHAB, V80, P270, DOI 10.1016/S0003-9993(99)90137-5; PLATZ T, 1999, KRANKENGYMNASTIK Z P, V51, P251; ROY CW, 1994, CLIN REHABIL, V8, P334, DOI DOI 10.1177/026921559400800410; SALMONI AW, 1984, PSYCHOL BULL, V95, P355, DOI 10.1037/0033-2909.95.3.355; Schmidt R. A., 1988, MOTOR CONTROL LEARNI; STEM PH, 1970, ARCH PHYS MED REHAB, V51, P526; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; Wade D, 1992, MEASUREMENT NEUROLOG; WILSON R S, 1979, Journal of Clinical Neuropsychology, V1, P49, DOI 10.1080/01688637908401097	36	87	88	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	2001	82	7					961	968		10.1053/apmr.2001.23982			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	450KV	WOS:000169742800017	11441386				2022-02-06	
J	Kersel, DA; Marsh, NV; Havill, JH; Sleigh, JW				Kersel, DA; Marsh, NV; Havill, JH; Sleigh, JW			Neuropsychological functioning during the year following severe traumatic brain injury	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; RECOVERY; COMA	The neuropsychological functioning of a group of 65 adults with severe traumatic brain injury was assessed at 6 months and 1 year post-injury. The cognitive domains assessed were pre-morbid intellectual level, current level of general intellectual functioning, simple and complex attention, verbal memory, executive functioning, and perceptual functioning. At least 40%, and up to 74%, of the TBI patients displayed some degree of impairment on tests administered at 6 months. Improvement was found to occur in all areas of cognitive functioning over the first year following injury. Despite this improvement at least 31%, and up to 63%, of TBI patients displayed some degree of impairment on tests administered at 1 year post-injury. The various types of neuropsychological functioning were affected to different degrees, indicating that different aspects of cognition are more susceptible to injury, and that recovery takes place at a differential rate across functions. The implications of these findings for the appropriate planning and allocation of treatment and rehabilitation resources, and the development of effective rehabilitation interventions are outlined.	Univ Waikato, Dept Psychol, Hamilton, New Zealand; Waikato Hosp, Intens Care Unit, Hamilton, New Zealand		Marsh, NV (corresponding author), Univ Waikato, Dept Psychol, Private Bag 3105, Hamilton, New Zealand.	mvmarsh@waikato.ac.nz	Marsh, Nigel/ABA-3609-2021; Marsh, Nigel V./F-5433-2019	Marsh, Nigel/0000-0002-4060-6432; Marsh, Nigel V./0000-0002-4060-6432			Bond M R, 1975, Ciba Found Symp, P141; Brooks D N, 1979, Int Rehabil Med, V1, P166; Brooks D N, 1979, Int Rehabil Med, V1, P160; Brooks D. N, 1990, REHABILITATION ADULT, P163; CARADOCDAVIES TH, 1995, NEUROEPIDEMIOLOGY, V14, P199, DOI 10.1159/000109797; Conkey RC, 1938, ARCH PSYCHOL, P5; CONZEN M, 1992, Brain Injury, V6, P45, DOI 10.3109/02699059209008121; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DRUDGE OW, 1984, J CLIN PSYCHOL, V40, P259, DOI 10.1002/1097-4679(198401)40:1<259::AID-JCLP2270400149>3.0.CO;2-C; DYE OA, 1979, ACTA NEUROL SCAND, V59, P10; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Havill JH, 1998, NEW ZEAL MED J, V111, P161; JENNETT B, 1975, LANCET, V1, P480; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Reynell WR, 1944, J MENT SCI, V90, P710; Ruesch J, 1943, ARCH NEURO PSYCHIATR, V50, P165, DOI 10.1001/archneurpsyc.1943.02290200065005; Ruesch J, 1944, AM J PSYCHIAT, V100, P480, DOI 10.1176/ajp.100.4.480; Ruff R M, 1986, Arch Clin Neuropsychol, V1, P87, DOI 10.1016/0887-6177(86)90009-0; Shum DHK, 1990, CLIN NEUROPSYCHOL, V4, P151, DOI DOI 10.1080/13854049008401508; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); *SPSS INC, 1998, SPSS BASE 8 0 US GUI; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; TOOTH G, 1947, J NEUROL NEUROSUR PS, V10, P1, DOI 10.1136/jnnp.10.1.1; Vogenthaler D R, 1987, Brain Inj, V1, P113	34	87	90	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2001	15	4					283	296		10.1080/02699050010005887			14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	420ZK	WOS:000168035000001	11299130				2022-02-06	
J	Kamencic, H; Griebel, RW; Lyon, AW; Paterson, PG; Juurlink, BHJ				Kamencic, H; Griebel, RW; Lyon, AW; Paterson, PG; Juurlink, BHJ			Promoting glutathione synthesis after spinal cord trauma decreases secondary damage and promotes retention of function	FASEB JOURNAL			English	Article						central nervous system; functional recovery; neurotrauma; oxidative stress; paraplegia	RANDOMIZED CONTROLLED TRIAL; LIPID-PEROXIDATION PRODUCT; TIRILAZAD MESYLATE; OXIDATIVE STRESS; ISOLATED HEPATOCYTES; N-ACETYLCYSTEINE; INJURY; RAT; METHYLPREDNISOLONE; REDUCTASE	The study aimed to 1) quantify oxidative stress in spinal cord after crush injury at T6, 2) determine whether the administration of the procysteine compound L-2-oxothiazolidine-4-carboxylate (OTC) would up-regulate glutathione (GSH) synthesis and decrease oxidative stress, and 3) determine whether decreased oxidative stress results in better tissue and function retention. We demonstrate that spinal cord compression (5 s with a 50 g aneurysm clip) at T6 in rats results in oxidative stress that is extensive (significant increases in oxidative stress seen at C3 and L4) and rapid in onset. Indices of oxidative stress used were GSH content, protein carbonyl content, and inactivation of glutathione reductase. Administration of OTC resulted in a marked decrease in oxidative stress associated with a sparing of white matter at T6 (16 +/-1.9% retained in OTC-treated animals vs, less than 1% in saline-treated). Behavioral indices in control, saline-treated, and OTC-treated animals after 6 wk were respectively: angle board scores (59 degrees, 32 degrees, and 42 degrees), modified Tarlov score (7, 2.4, and 4.1), and Basso-Beattie-Bresnahan score (21, 5.3, and 12.9). We conclude that administration of OTC after spinal cord trauma greatly decreases oxidative stress and allows tissue preservation, thereby enabling otherwise paraplegic animals to locomote.	Univ Saskatchewan, Dept Anat & Cell Biol, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Dept Surg Neurosurg, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Dept Pathol, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon, SK S7N 5E5, Canada		Juurlink, BHJ (corresponding author), Univ Saskatchewan, Dept Anat & Cell Biol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.						ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; ANDERSON ME, 1989, FASEB J, V3, P1632, DOI 10.1096/fasebj.3.5.2920877; Barker JE, 1996, BRAIN RES, V716, P118, DOI 10.1016/0006-8993(96)00003-0; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BELLOMO G, 1987, BIOCHEM PHARMACOL, V36, P1313, DOI 10.1016/0006-2952(87)90087-6; Bernard GR, 1997, CHEST, V112, P164, DOI 10.1378/chest.112.1.164; Bethea JR, 1998, J NEUROSCI, V18, P3251; Blakeman DP, 1998, J BIOCHEM MOL TOXIC, V12, P185, DOI 10.1002/(SICI)1099-0461(1998)12:3<185::AID-JBT7>3.0.CO;2-H; BLAKYTNY R, 1992, BIOCHEM J, V288, P303, DOI 10.1042/bj2880303; Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; BROWN SA, 1992, J AM VET MED ASSOC, V200, P1849; Burcham PC, 1996, BIOCHEM BIOPH RES CO, V220, P996, DOI 10.1006/bbrc.1996.0521; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Christman JW, 2000, BRAIN PATHOL, V10, P153; EKLOW L, 1984, EUR J BIOCHEM, V138, P459, DOI 10.1111/j.1432-1033.1984.tb07938.x; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; GALANDIUK S, 1993, ANN SURG, V218, P419, DOI 10.1097/00000658-199310000-00003; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; Huang DW, 1999, NEURON, V24, P639, DOI 10.1016/S0896-6273(00)81118-6; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Juurlink BHJ, 1999, NEUROTOX RES, V1, P119, DOI 10.1007/BF03033276; Juurlink BHJ, 1998, GLIA, V22, P371, DOI 10.1002/(SICI)1098-1136(199804)22:4<371::AID-GLIA6>3.0.CO;2-6; KALAYJIAN RC, 1994, J ACQ IMMUN DEF SYND, V7, P369; KHAN M, 1983, CAN J NEUROL SCI, V10, P161, DOI 10.1017/S031716710004484X; Koc RK, 1999, SPINAL CORD, V37, P29, DOI 10.1038/sj.sc.3100732; KOMURO C, 1985, J CHROMATOGR, V338, P209, DOI 10.1016/0378-4347(85)80087-6; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; Lucas JH, 1998, J NEUROPATH EXP NEUR, V57, P937, DOI 10.1097/00005072-199810000-00006; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; MCLELLAN LI, 1995, CARCINOGENESIS, V16, P2099, DOI 10.1093/carcin/16.9.2099; MEISTER A, 1989, GLUTATHIONE CHEM BIO, VA, P367; MESINA JE, 1989, BRAIN RES, V478, P181, DOI 10.1016/0006-8993(89)91494-7; Miyata T, 1998, FEBS LETT, V437, P24, DOI 10.1016/S0014-5793(98)01079-5; Nesathurai S, 1998, J TRAUMA, V45, P1088, DOI 10.1097/00005373-199812000-00021; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; RIVLIN AS, 1979, SURG NEUROL, V9, P39; SCHUPPE I, 1992, BIOCHEM PHARMACOL, V44, P1757, DOI 10.1016/0006-2952(92)90069-U; SHIVAKUMAR BR, 1995, J PHARMACOL EXP THER, V274, P1167; Springer JE, 1997, J NEUROCHEM, V68, P2469; TABATABAIE T, 1994, ARCH BIOCHEM BIOPHYS, V314, P112, DOI 10.1006/abbi.1994.1418; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; Tariq M, 1998, J NEUROTRAUM, V15, P239, DOI 10.1089/neu.1998.15.239; Vita JA, 1998, J CLIN INVEST, V101, P1408, DOI 10.1172/JCI1155	46	87	89	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					243	250		10.1096/fj.00-0228com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	WOS:000166312400033	11149912				2022-02-06	
J	Sanders, MJ; Sick, TJ; Perez-Pinzon, MA; Dietrich, WD; Green, EJ				Sanders, MJ; Sick, TJ; Perez-Pinzon, MA; Dietrich, WD; Green, EJ			Chronic failure in the maintenance of long-term potentiation following fluid percussion injury in the rat	BRAIN RESEARCH			English	Article						brain injury; fluid percussion; hippocampus; LTP; rat	TRAUMATIC BRAIN INJURY; PROTEIN-KINASE-C; HIPPOCAMPAL SLICES; DENTATE GYRUS; CA1 REGION; GLUTAMATE; DEFICITS; IMPAIRMENT; RECEPTORS; INDUCTION	Traumatic brain injury (TBI) can produce chronic cognitive learning/memory deficits that are thought to be mediated, in part, by impaired hippocampal function. Experimentally induced TBI is associated with deficits in hippocampal synaptic plasticity (long-term potentiation, or LTP) at acute post-injury intervals but plasticity has not been examined at long-term survival periods. The present study was conducted to assess the temporal profile of LTP after injury and to evaluate the effects of injury severity on plasticity. Separate groups of rats were subjected to mild (1.1-1.4 atm), moderate (1.8-2.1 arm), or severe (2.2-2.7 atm) fluid percussion (FP) injury (or sham surgery) and processed for hippocampal electrophysiology in the first or eighth week after injury. LTP was defined as a lasting increase in field excitatory post-synaptic potential (fEPSP) slope in area CAI following tetanic stimulation of the Schaffer collaterals. The fEPSP slope was measured for 60 min after tetanus. Assessment of LTP at the acute interval (6 days) revealed modest peak slope potentiation Values (129-139%), which declined in each group (including sham) over the hour-long recording session and did not differ between groups. Eight weeks following injury, slices from all groups exhibited robust maximal potentiation (134-147%). Levels of potentiation among groups were similar at the 5-min test interval but differed significantly at the 30- and 60-min test intervals. Whereas sham slices showed stable potentiation for the entire 60-min assessment period, slices in all of the injury groups exhibited a significant decline in potentiation over this period. These experiments reveal a previously unknown effect of TBI whereby experimentally induced injury results in a chronic inability of the CA1 hippocampus to,maintain synaptic plasticity. They also provide evidence that sham surgical procedures can significantly influence hippocampal physiology at the acute post-TBI intervals. The results have implications for the mechanisms underlying the impaired synaptic plasticity following TBI. (C) 2000 Published by Elsevier Science B.V. All rights reserved.	Univ Miami, Dept Psychol, Coral Gables, FL 33124 USA; Univ Miami, Dept Neurol Surg, Coral Gables, FL 33124 USA; Univ Miami, Dept Neurol, Coral Gables, FL USA; Univ Miami, Program Neurosci, Coral Gables, FL USA		Sanders, MJ (corresponding author), Univ Calif Los Angeles, Dept Psychol, 1285 Franz Hall,Box 951563, Los Angeles, CA 90095 USA.				NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL36588] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 3029] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P01HL036588] Funding Source: NIH RePORTER		Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BEHNISCH T, 1993, NEUROSCIENCE, V54, P37, DOI 10.1016/0306-4522(93)90381-O; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HIROTSU I, 1989, BRAIN RES, V482, P194, DOI 10.1016/0006-8993(89)90561-1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Katsuki H, 1997, NEUROSCIENCE, V76, P1113, DOI 10.1016/S0306-4522(97)80003-6; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Matthies H, 1997, NEUROREPORT, V8, P3533, DOI 10.1097/00001756-199711100-00023; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Sanders MJ, 1999, J NEUROTRAUM, V16, P915, DOI 10.1089/neu.1999.16.915; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; STANTON PK, 1985, J NEUROSCI, V5, P2169; STELZER A, 1994, P NATL ACAD SCI USA, V91, P3058, DOI 10.1073/pnas.91.8.3058; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; WAGNER JJ, 1993, NATURE, V363, P451, DOI 10.1038/363451a0; WANG JH, 1992, P NATL ACAD SCI USA, V89, P2576, DOI 10.1073/pnas.89.7.2576; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287	33	87	92	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	APR 7	2000	861	1					69	76		10.1016/S0006-8993(00)01986-7			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	302DJ	WOS:000086349900008	10751566				2022-02-06	
J	Buchanan, KM; Elias, LJ; Goplen, GB				Buchanan, KM; Elias, LJ; Goplen, GB			Differing perspectives on outcome after subarachnoid hemorrhage: The patient, the relative, the neurosurgeon	NEUROSURGERY			English	Article						family burden; neurobehavioral changes; psychological distress; subarachnoid hemorrhage outcome; surgical outcome	TRAUMATIC BRAIN INJURY; BLUNT HEAD-INJURY; ARTERIOVENOUS-MALFORMATIONS; NEUROPSYCHOLOGICAL DEFICITS; COGNITIVE PERFORMANCE; INTRACRANIAL ANEURYSM; CAREGIVER BURDEN; FAMILY; RECOVERY; REHABILITATION	OBJECTIVE: To better understand patients' and relatives' views of outcome after surgery for subarachnoid hemorrhage (SAH), we evaluated neurobehavioral changes, psychological distress, and family burden of patients who had been considered by their neurosurgeon as having a "good recovery" or a "moderate disability," as rated on the Glasgow Outcome Scale. METHODS: A heterogeneous sample of 28 patients treated surgically for SAH from an aneurysm or an arteriovenous malformation and their relatives separately underwent a semistructured interview. They also completed a revised version of the Adjective Checklist to assess their perceptions of the patient's neurobehavioral changes and the Brief Symptom Inventory as a measure of their own psychological distress. Levels of family burden on the relatives were evaluated with a Likert strain scale and the Zarit Burden Interview. RESULTS: Approximately 19 months after surgery for SAH, the majority of the patients reported significant negative neurobehavioral changes and negative changes in employment, energy levels, tolerance to mild stressors, leisure activities, and social and sexual relationships. Patients and relatives both reported elevated levels of psychological distress, and the relatives reported elevated levels of family burden. Patients' acid relatives' perceptions differed, with the relatives reporting more problems; both viewed the patient's outcome more negatively than did the operating neurosurgeon. CONCLUSION: Despite the neurosurgeon's classification of patients as having a "good recovery" or "moderate disability," the majority of patients surgically treated for SAH reported psychosocial and neurobehavioral changes that were disabling for them and burdensome to their family. Patients and relatives who are interviewed separately by an experienced clinician may provide differing perspectives on SAH outcome that are not necessarily good.	Univ Saskatchewan, Royal Univ Hosp, Div Neurosurg, Saskatoon, SK S7N 0W8, Canada; Univ Saskatchewan, Dept Psychol, Saskatoon, SK S7N 0W8, Canada		Buchanan, KM (corresponding author), Univ Saskatchewan, Royal Univ Hosp, Div Neurosurg, 103 Hosp Dr, Saskatoon, SK S7N 0W8, Canada.						BORNSTEIN RA, 1987, NEUROSURGERY, V21, P651, DOI 10.1227/00006123-198711000-00008; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; CLINCHOT DM, 1994, ARCH PHYS MED REHAB, V75, P1342; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Derogatis LR, 1982, BRIEF SYMPTOM INVENT; DERUTY R, 1988, Neurological Research, V10, P217; Dombovy ML, 1998, BRAIN INJURY, V12, P887; Dywan J, 1996, J HEAD TRAUMA REHAB, V11, P79, DOI 10.1097/00001199-199604000-00008; FRISS LR, 1991, AM J ALZHEIMERS  SEP; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; GOLD DP, 1995, J AM GERIATR SOC, V43, P10, DOI 10.1111/j.1532-5415.1995.tb06235.x; HADJISTAVROPOULOS T, 1994, J AM GERIATR SOC, V42, P308, DOI 10.1111/j.1532-5415.1994.tb01757.x; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; HUTTER BO, 1995, BRIT J NEUROSURG, V9, P465, DOI 10.1080/02688699550041106; HUTTER BO, 1993, NEUROSURGERY, V33, P999; JENNETT B, 1975, LANCET, V1, P480; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LINDBERG M, 1992, BRIT J NEUROSURG, V6, P297, DOI 10.3109/02688699209023787; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; MAHALICK DM, 1991, NEUROSURGERY, V29, P351, DOI 10.1227/00006123-199109000-00003; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; MAURICEWILLIAMS RS, 1991, J NEUROL NEUROSUR PS, V54, P335, DOI 10.1136/jnnp.54.4.335; MCKENNA P, 1989, NEUROSURGERY, V24, P361, DOI 10.1227/00006123-198903000-00009; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MONTGOMERY GK, 1995, BRAIN INJURY, V9, P453, DOI 10.3109/02699059509008205; Ogden J. A., 1990, NEUROPSY NEUROPSY BE, V3, P260; OGDEN JA, 1993, NEUROSURGERY, V33, P572, DOI 10.1227/00006123-199310000-00004; Ogden JA, 1997, NEUROSURGERY, V41, P25, DOI 10.1097/00006123-199707000-00008; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; RICHARDSON JTE, 1991, ACTA NEUROL SCAND, V83, P110, DOI 10.1111/j.1600-0404.1991.tb04659.x; SAVELAND H, 1992, J NEUROSURG, V76, P729, DOI 10.3171/jns.1992.76.5.0729; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; STOREY PB, 1967, BRIT MED J, V3, P261, DOI 10.1136/bmj.3.5560.261; TIDSWELL P, 1995, NEUROLOGY, V45, P875; VILKKI J, 1990, NEUROSURGERY, V26, P579, DOI 10.1227/00006123-199004000-00004; WHITLATCH CJ, 1991, GERONTOLOGIST, V31, P9, DOI 10.1093/geront/31.1.9; ZARIT RH, 1985, HIDDEN VICTIMS ALZHE	42	87	92	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	APR	2000	46	4					831	838		10.1097/00006123-200004000-00012			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Surgery	302HR	WOS:000086360100029	10764256				2022-02-06	
J	Hicks, RR; Martin, VB; Zhang, L; Seroogy, KB				Hicks, RR; Martin, VB; Zhang, L; Seroogy, KB			Mild experimental brain injury differentially alters the expression of neurotrophin and neurotrophin receptor mRNAs in the hippocampus	EXPERIMENTAL NEUROLOGY			English	Article						BDNF; NT-3; trkB; trkC; hippocampus; traumatic brain injury	NERVE GROWTH-FACTOR; LONG-TERM POTENTIATION; TRKB MESSENGER-RNA; FOCAL CEREBRAL-ISCHEMIA; MOTOR-VEHICLE ACCIDENT; HEAD-INJURY; RAT FOREBRAIN; ADULT-RAT; SPREADING DEPRESSION; DOPAMINERGIC-NEURONS	The molecular events responsible for impairments in cognition following mild traumatic brain injury are poorly understood. Neurotrophins, such as brain-derived neurotrophic factor (BDNF), have been identified as having a role in learning and memory. We have previously demonstrated that following experimental brain trauma of moderate severity (2.0-2.1 atm), mRNA levels of BDNF and its high-affinity receptor, trkB, are increased bilaterally in the hippocampus for several hours, whereas NT-3 mRNA expression is decreased. In the present study, we used in situ hybridization to compare BDNF, trkB, NT-3, and trkC mRNA expression in rat hippocampus at 3 or 6 h after a lateral fluid percussion brain injury (FPI) of mild severity (1.0 atm) to sham-injured controls at equivalent time points. Mild FPI induced significant increases in hybridization levels for BDNF and trkB mRNAs, and a decrease in NT-3 mRNA in the hippocampus. However, in contrast to the bilateral effects of moderate experimental brain injury, the present changes with mild injury were restricted to the injured side. These findings demonstrate that even a mild traumatic brain injury differentially alters neurotrophin and neurotrophin receptor levels in the hippocampus. Such alterations may have important implications for neural plasticity and recovery of function in people who sustain a mild head injury. (C) 1999 Academic Press.	Univ Kentucky, Div Phys Therapy, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA		Hicks, RR (corresponding author), Univ Kentucky, Div Phys Therapy, Lexington, KY 40536 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35164] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035164] Funding Source: NIH RePORTER		AKENYA Y, 1997, J NEUROSCI, V17, P6707; Albers KM, 1996, J CELL BIOL, V134, P487, DOI 10.1083/jcb.134.2.487; ALTAR CA, 1994, EUR J NEUROSCI, V6, P1389, DOI 10.1111/j.1460-9568.1994.tb01001.x; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BECK T, 1994, J CEREBR BLOOD F MET, V14, P689, DOI 10.1038/jcbfm.1994.86; Behrens MM, 1999, MICROSC RES TECHNIQ, V45, P276, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<276::AID-JEMT11>3.0.CO;2-4; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Blostein PA, 1997, J NEUROTRAUM, V14, P171, DOI 10.1089/neu.1997.14.171; Borczuk Pierre, 1997, Emergency Medicine Clinics of North America, V15, P563, DOI 10.1016/S0733-8627(05)70318-7; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEKKER AJ, 1994, BRAIN RES, V639, P149, DOI 10.1016/0006-8993(94)91775-2; DIXON JE, 1994, DEV BRAIN RES, V77, P177, DOI 10.1016/0165-3806(94)90194-5; Dragunow M, 1997, MOL BRAIN RES, V46, P274, DOI 10.1016/S0169-328X(97)00021-1; Elmer E, 1997, EXP NEUROL, V145, P93, DOI 10.1006/exnr.1997.6478; EMFORS P, 1990, NEURON, V5, P511; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; Fiumelli H, 1999, EUR J NEUROSCI, V11, P1639, DOI 10.1046/j.1460-9568.1999.00580.x; Fryer RH, 1996, J COMP NEUROL, V374, P21, DOI 10.1002/(SICI)1096-9861(19961007)374:1<21::AID-CNE2>3.0.CO;2-P; GALL CM, 1992, TRENDS PHARMACOL SCI, V13, P401, DOI 10.1016/0165-6147(92)90123-N; Goodness TP, 1997, EUR J NEUROSCI, V9, P1574, DOI 10.1111/j.1460-9568.1997.tb01515.x; Hagg T, 1998, EXP NEUROL, V149, P183, DOI 10.1006/exnr.1997.6684; Hallbook F, 1998, J NEUROSCI, V18, P8700; HAYES RL, 1995, NEUROSCI LETT, V191, P121, DOI 10.1016/0304-3940(95)11561-X; HEFTI F, 1986, J NEUROSCI, V6, P2155; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; Horger BA, 1999, J NEUROSCI, V19, P4110; Huber KM, 1998, NEUROPHARMACOLOGY, V37, P571, DOI 10.1016/S0028-3908(98)00050-1; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; KANG HJ, 1995, J PHYSIOLOGY-PARIS, V89, P11, DOI 10.1016/0928-4257(96)80547-X; Kariko K, 1998, J CEREBR BLOOD F MET, V18, P1308, DOI 10.1097/00004647-199812000-00005; KINDY MS, 1993, J CEREBR BLOOD F MET, V13, P372, DOI 10.1038/jcbfm.1993.50; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; Kokaia M, 1998, J NEUROSCI, V18, P8730; KOKAIA Z, 1993, MOL BRAIN RES, V19, P277, DOI 10.1016/0169-328X(93)90126-A; Korte M, 1996, J PHYSIOLOGY-PARIS, V90, P157, DOI 10.1016/S0928-4257(97)81415-5; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; KUBO T, 1995, DEV BRAIN RES, V85, P249, DOI 10.1016/0165-3806(94)00220-T; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; LAUTERBORN JC, 1994, MOL CELL NEUROSCI, V5, P46, DOI 10.1006/mcne.1994.1005; Lindsay RM, 1996, PHILOS T ROY SOC B, V351, P365, DOI 10.1098/rstb.1996.0030; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; McAllister AK, 1997, NEURON, V18, P767, DOI 10.1016/S0896-6273(00)80316-5; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; NAKAO N, 1995, EXP NEUROL, V131, P1, DOI 10.1016/0014-4886(95)90002-0; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Numan S, 1999, J COMP NEUROL, V403, P295, DOI 10.1002/(SICI)1096-9861(19990118)403:3<295::AID-CNE2>3.0.CO;2-L; Numan S, 1997, EUR J NEUROSCI, V9, P489, DOI 10.1111/j.1460-9568.1997.tb01626.x; Parker RS, 1996, BRAIN INJURY, V10, P287, DOI 10.1080/026990596124467; Parker RS, 1996, J CLIN PSYCHOL, V52, P32, DOI 10.1002/(SICI)1097-4679(199601)52:1<32::AID-JCLP5>3.3.CO;2-1; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; ROCOMORA NE, 1996, J NEUROSCI, V16, P4411; Rudge JS, 1998, EXP NEUROL, V149, P398, DOI 10.1006/exnr.1997.6737; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Seroogy K., 1997, NEUROCHEMISTRY PRACT, P121; SEROOGY KB, 1994, J COMP NEUROL, V342, P321, DOI 10.1002/cne.903420302; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; SINSON G, 1995, J NEUROCHEM, V65, P2209; SKAPER SD, 1993, J NEUROSCI RES, V34, P478, DOI 10.1002/jnr.490340413; Skaper SD, 1998, MOL CELL NEUROSCI, V12, P179, DOI 10.1006/mcne.1998.0714; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; Tokuyama W, 1998, MOL BRAIN RES, V62, P206, DOI 10.1016/S0169-328X(98)00261-7; TUSZYNSKI MH, 1990, J NEUROSCI, V10, P3604; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; von Meyenburg J, 1998, EXP NEUROL, V154, P583, DOI 10.1006/exnr.1998.6912; Warner DS, 1996, ANESTHESIOLOGY, V84, P1475, DOI 10.1097/00000542-199606000-00024; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C	86	87	89	0	2	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	DEC	1999	160	2					469	478		10.1006/exnr.1999.7216			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	264WE	WOS:000084205300016	10619564				2022-02-06	
J	Carbonnel, WS; Grady, MS				Carbonnel, WS; Grady, MS			Regional and temporal characterization of neuronal, glial, and axonal response after traumatic brain injury in the mouse	ACTA NEUROPATHOLOGICA			English	Article						axonal degeneration; gliosis; mice; neuronal death; traumatic brain injury	AMYLOID PRECURSOR PROTEIN; FLUID-PERCUSSION INJURY; CORTICAL IMPACT INJURY; MEMORY DEFICITS; SPATIAL MEMORY; HEAD-INJURY; CELL-DEATH; DAMAGE; MODEL; RATS	Fluid percussion injury (FPI) is a commonly used and clinically relevant model of traumatic brain injury (TBI) in the rat. Recently, our lab successfully adapted FPI to mice. To account for differences in response to injury between mice and rats and provide a foundation for further use of FPI in gene-targeting studies, we sought to characterize the temporal and regional response to FPI in male C57BL/6 mice. Animals were killed at 10 min, 24 h, and 4, 7, 14, and 35 days (n = 3 for each group) after a very severe parasagittal FPI (> 4.0 atm) or sham injury (n = 3). Extensive numbers of damaged neurons were consistently found in the ipsilateral cortex, thalamus, and hippocampus by 10 min. This damage was nearly identical at 24 h, but quickly declined at subsequent time points. Activated microglia were found only in regions of neuronal injury at the earliest time points. Glial fibrillary acidic protein immunoreactivity reached significantly higher levels compared with controls at 7 days (P < 0.05) in the cortex, thalamus, and hippocampus and remained elevated for 35 days. White matter degeneration was present in all regions examined. This damage did not appear until at least day 4, but progressed up to day 35. The spatial pattern of damage we observed in mice after FPI is similar to that seen in rats. However, the temporal progression of neuronal injury in mice is comparatively abbreviated in the hippocampus and thalamus. In conclusion, these results suggest that FPI in mice may be a particularly useful tool for studying mechanisms of TBI in gene-targeting studies.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19096 USA		Grady, MS (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 5th Floor Silverstein Bldg,3400 Spruce St, Philadelphia, PA 19096 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30305, NS33107] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030305, R01NS033107] Funding Source: NIH RePORTER		ADAMS JH, 1988, INTRO NEUROPATHOLOGY; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; FADEN AI, 1989, SCIENCE, V244, P789; FLOYD CL, 1997, NAT NEUR SOC ABS, V15, P34; Franklin K.B., 1997, MOUSE BRAIN STEREOTA; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; Gerlai R, 1996, TRENDS NEUROSCI, V19, P177, DOI 10.1016/S0166-2236(96)20020-7; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Lathe R, 1996, TRENDS NEUROSCI, V19, P183, DOI 10.1016/S0166-2236(96)20022-0; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MCINTOSH TK, 1990, ACT NEUR S, V51, P263; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McNamara RK, 1996, MOL BRAIN RES, V40, P177, DOI 10.1016/0169-328X(96)00048-4; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; NADLER JV, 1983, METHOD ENZYMOL, V103, P393; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soares HD, 1995, J NEUROSCI, V15, P8223; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	36	87	91	0	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	OCT	1999	98	4					396	406		10.1007/s004010051100			11	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	236NQ	WOS:000082605800013	10502046				2022-02-06	
J	Vagnozzi, R; Marmarou, A; Tavazzi, B; Signoretti, S; Di Pierro, D; Del Bolgia, F; Amorini, AM; Fazzina, G; Sherkat, S; Lazzarino, G				Vagnozzi, R; Marmarou, A; Tavazzi, B; Signoretti, S; Di Pierro, D; Del Bolgia, F; Amorini, AM; Fazzina, G; Sherkat, S; Lazzarino, G			Changes of cerebral energy metabolism and lipid peroxidation in rats leading to mitochondrial dysfunction after diffuse brain injury	JOURNAL OF NEUROTRAUMA			English	Article						diffuse brain injury; energy metabolism; lipid peroxidation; MDA; reactive oxygen species; secondary insult	FLUID-PERCUSSION MODEL; OXIDATIVE STRESS; HEAD-INJURY; ISCHEMIA; DISRUPTION; RECOVERY; RADICALS	The effect of mild closed head trauma, induced by the weight-drop method (450 g from a l-m height), on lipid peroxidation and energy metabolism of brain tissue was determined at various times after cerebral injury in spontaneously breathing rats (1, 10, 30 minutes and 2, 6, 15, 24, 48, and 120 hours). Animals were continuously monitored for the evaluation of blood pressure, blood gases, heart rate, and intracranial pressure. Analysis of malondialdehyde (MDA) as an index of lipid peroxidation, ascorbic acid, high-energy phosphates, nicotinic coenzymes, oxypurines, and nucleosides was performed by high-performance liquid chromatography (HPLC) on neutralized perchloric acid extract of the whole brain. Data showed that MDA, undetectable in control, sham-operated rats, was already present within 1 minute of trauma (1.77 nmol/g wet weight; SD = 0.29) and reached maximal values by 2 hours (72.26 nmol/l w.w.; SD = 11.26), showing a progressive slow decrease thereafter. In contrast, ATP, GTP, and nicotinic coenzyme (NAD and NADP) concentrations showed significant reduction only by the second hour postinjury. Maximal decrease of the ATP and GTP concentrations were sceen at 6 hours postinjury, whereas NAD and NADP concentrations showed maximum decline by 15 hours. Values recorded in mechanically ventilated rats did not differ significantly from those obtained in spontaneously breathing animals. These findings, supported by the absence of blood gas and blood pressure changes in the spontaneously breathing rats, strongly support the premise that biochemical changes (primarily lipid peroxidation) are not caused by secondary ischemic-hypoxic phenomena but rather are triggered by these forces acting on the brain at the time of impact. In addition, these results suggest that depression of energy metabolism might be caused by peroxidation of the mitochondrial membrane with a consequent alteration of the main mitochondrial function-that is, the energy supply.	Univ Roma Tor Vergata, Dept Neurosci, I-00133 Rome, Italy; Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Rome, Italy; Univ Catania, Dept Chem Sci, Div Biochem Mol Biol & Pharmacol, Catania, Italy		Vagnozzi, R (corresponding author), Univ Roma Tor Vergata, Dept Neurosci, Via Tor Vergata 135, I-00133 Rome, Italy.		Signoretti, stefano/AAL-5631-2020; TAVAZZI, BARBARA/AAB-9830-2019; lazzarino, giuseppe/K-2277-2015	Signoretti, stefano/0000-0002-8086-1622; TAVAZZI, BARBARA/0000-0001-8743-0895; AMORINI, Angela Maria/0000-0003-3525-9955; lazzarino, giuseppe/0000-0002-5917-7279	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R0I NS 19235] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019235] Funding Source: NIH RePORTER		ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Brown JIM, 1998, NEUROSURGERY, V42, P1057, DOI 10.1097/00006123-199805000-00060; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Hsiang JNK, 1997, ACTA NEUROCHIR, V139, P464, DOI 10.1007/BF01808884; HUMPHREY SM, 1987, BASIC RES CARDIOL, V82, P304, DOI 10.1007/BF01906863; IKEDA Y, 1990, NEUROSURGERY, V27, P1; JANERO DR, 1993, AM J PHYSIOL, V264, pC1401; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; LAZZARINO G, 1991, ANAL BIOCHEM, V197, P191, DOI 10.1016/0003-2697(91)90378-7; LAZZARINO G, 1992, FREE RADICAL BIO MED, V13, P489, DOI 10.1016/0891-5849(92)90143-5; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MONTASSER A, 1994, J NEUROSURG, V80, P301; MORGAN WA, 1995, BIOCHEM PHARMACOL, V49, P1179, DOI 10.1016/0006-2952(95)00034-W; OBRENOVITCH TP, 1988, J CEREBR BLOOD F MET, V8, P866, DOI 10.1038/jcbfm.1988.144; PALOZZA P, 1992, FREE RADICAL BIO MED, V13, P127, DOI 10.1016/0891-5849(92)90074-Q; Siragusa P, 1997, J Neurosurg Sci, V41, P249; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Tavazzi B, 1998, FREE RADICAL RES, V28, P25, DOI 10.3109/10715769809097873; THIES RL, 1991, ARCH BIOCHEM BIOPHYS, V286, P353, DOI 10.1016/0003-9861(91)90051-J; Vagnozzi R, 1997, EXP BRAIN RES, V117, P411, DOI 10.1007/s002210050235	27	87	92	0	5	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1999	16	10					903	913		10.1089/neu.1999.16.903			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	246JD	WOS:000083159900005	10547099				2022-02-06	
J	Gillardon, F; Kiprianova, I; Sandkuhler, J; Hossmann, KA; Spranger, M				Gillardon, F; Kiprianova, I; Sandkuhler, J; Hossmann, KA; Spranger, M			Inhibition of caspases prevents cell death of hippocampal CA1 neurons, but not impairment of hippocampal long-term potentiation following global ischemia	NEUROSCIENCE			English	Article						apoptosis; cerebral ischemia; Z-DEVD-FMK; LTP	CEREBELLAR GRANULE NEURONS; ACTIVATION; APOPTOSIS; PROTEASE; EXPRESSION; NECROSIS; CPP32; BRAIN; IAP; RAT	An essential role for caspases in programmed neuronal cell death has been demonstrated in various in vitro studies, and synthetic caspase inhibitors have recently been shown to prevent neuronal cell loss in animal models of focal cerebral ischemia and traumatic brain injury, respectively. The therapeutic utility of caspase inhibitors, however, will depend on preservation of both structural and functional integrity of neurons under stressful conditions. The present study demonstrates that expression and proteolytic activity of caspase-3 is up-regulated in the rat hippocampus after transient forebrain ischemia. Continuous i.c.v. infusion of the caspase inhibitor N-benzyloxycarbonyl-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-fluoromethyl ketone significantly attenuated caspase-3-like enzymatic activity, and blocked delayed cell loss of hippocampal CA1 neurons after ischemia. Administration of N-benzyloxycarbonyl-Asp(OMe)-Glu(OMe)-Val- Asp(OMe)-fluoromethyl ketone, however, did not prevent impairment of induction of long-term potentiation in postischemic CA1 cells, suggesting that caspase inhibition alone does not preserve neuronal functional plasticity. (C) 1999 IBRO. Published by Elsevier Science Ltd.	Max Planck Inst Neurol Forsch, D-50931 Cologne, Germany; Univ Heidelberg, Neurol Klin, Heidelberg, Germany; Univ Heidelberg, Inst Physiol 2, Heidelberg, Germany		Gillardon, F (corresponding author), Boehringer Ingelheim Pharma KG, ZNS Forsch Mol Biol, Binger Str 173, D-55216 Ingelheim, Germany.		Sandkuhler, Jurgen/B-6648-2012	Sandkuhler, Jurgen/0000-0002-5209-485X			Armstrong RC, 1997, J NEUROSCI, V17, P553; Clem RJ, 1997, TRENDS CELL BIOL, V7, P337, DOI 10.1016/S0962-8924(97)01088-X; Deshmukh M, 1997, MOL PHARMACOL, V51, P897, DOI 10.1124/mol.51.6.897; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; FRANK L, 1993, EXP BRAIN RES, V95, P70; Gillardon F, 1997, MOL BRAIN RES, V50, P16, DOI 10.1016/S0169-328X(97)00162-9; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; HORI N, 1994, EXP NEUROL, V129, P279, DOI 10.1006/exnr.1994.1170; KIPRIANOVA I, 1999, IN PRESS EXPL NEUROL; Krajewska M, 1997, CANCER RES, V57, P1605; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; MIYAZAKI S, 1993, NEUROL RES, V15, P249; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Schwartz LM, 1996, TRENDS NEUROSCI, V19, P555, DOI 10.1016/S0166-2236(96)10067-9; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	17	87	93	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		1999	93	4					1219	1222		10.1016/S0306-4522(99)00292-4			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	233PV	WOS:000082436000001	10501444				2022-02-06	
J	Hurt, CP; Rice, RR; McIntosh, GC; Thaut, MH				Hurt, CP; Rice, RR; McIntosh, GC; Thaut, MH			Rhythmic auditory stimulation in gait training for patients with traumatic brain injury	JOURNAL OF MUSIC THERAPY			English	Article								Rhythmic auditory stimulation (RAS) was studied in a frequency entrainment design and as a therapeutic stimulus to facilitate gait patterns in 8 traumatically brain injured individuals (5 male/3 female; mean age 30 +/- 5 years) with persisting gait disorder, 4-24 months postinjury. During entrainment, with RAS frequency matched to baseline cadence, velocity and stride symmetry both increased by an average of 18%. Increases contributing to the velocity improvement were seen in both stride length (7%) and cadence (8%). With RAS accelerated 5% over the fast walking step rate of the patients, 5 patients could entrain to a higher step frequency. The 2 patients with the slowest baseline gait velocity could not entrain to faster RAS frequencies. After 5 weeks of daily RAS training, 5 patients' mean velocity increased significantly (p <.05) by 51% (38.8 m/min to 57.6 m/min; p <.43). cadence (+16%) and stride length (+29%) also showed statistically significant improvement. Stride symmetry improved nonsignificantly by 12%.	Colorado State Univ, Ctr Biomed Res Music, Ft Collins, CO 80523 USA		Hurt, CP (corresponding author), Colorado State Univ, Ctr Biomed Res Music, Ft Collins, CO 80523 USA.						Ashley MJ, 1995, TRAUMATIC BRAIN INJU; OEBERG T, 1993, J REHABIL RES DEV, V30, P210; PALTSEV YI, 1967, BIOPHYS-USSR, V12, P1219; Perry J, 1992, GAIT ANAL NORMAL PAT; Prassas S, 1997, GAIT POSTURE, V6, P218, DOI 10.1016/S0966-6362(97)00010-6; ROSSIGNOL S, 1976, ELECTROEN CLIN NEURO, V41, P83, DOI 10.1016/0013-4694(76)90217-0; STAUM MJ, 1983, J MUSIC THER, V20, P69, DOI 10.1093/jmt/20.2.69; Thaut M. H., 1992, J NEUROL REHABIL, V6, P185; THAUT MH, 1996, MOVEMENT DISORD, V11, P1; THAUT MH, 1998, BIOL CYBERNETICS; Thaut MH, 1997, J NEUROL SCI, V151, P7	11	87	87	0	17	NATL ASSOC MUSIC THERAPY INC	SILVER SPRING	8455 COLESVILLE RD, STE 1000, SILVER SPRING, MD 20910 USA	0022-2917			J MUSIC THER	J. Music Ther.	WIN	1998	35	4					228	241		10.1093/jmt/35.4.228			14	Music; Rehabilitation	Social Science Citation Index (SSCI)	Music; Rehabilitation	158MR	WOS:000078119700001	10519837				2022-02-06	
J	Henker, RA; Brown, SD; Marion, DW				Henker, RA; Brown, SD; Marion, DW			Comparison of brain temperature with bladder and rectal temperatures in adults with severe head injury	NEUROSURGERY			English	Article						brain injury; hyperthermia; hypothermia	NEUROSURGICAL PATIENTS	OBJECTIVE: The purpose of this study was to compare brain temperature (Tbr) with conventional indicators of core body temperature (i.e., rectal temperature [Tre] and bladder temperature [Tbl]), in adults with severe head injury. METHODS: The relationships between Tbr and Tbl and between Tbr and Tre are described in terms of differences in temperature in eight patients with severe head injury. INSTRUMENTATION: Brain tissue temperature was measured every minute, with a thermocouple embedded 2 cm from the tip of a ventriculostomy catheter used to measure intracranial pressure. Tbl was measured with a thermistor embedded in a bladder catheter, and Tre was measured with a thermistor in a rectal probe. RESULTS: Tbr was usually greater than Tbl and Tre. The average difference between Tbr and Tbl for each patient ranged from 0.32 to 1.9 degrees C, with standard deviations of the difference ranging from 0.30 to 0.80 degrees C. The average difference between Tbr and Tre for each patient ranged from 0.1 to 2.0 degrees C, with, standard deviations of the difference ranging from 0.32 to 1.08 degrees C. In the majority of patients, the differences (Tbr - Tbl and Tbr - Tre) were greater at temperatures outside of the normal temperature range (Tbr less than or equal to 36 degrees C and >38 degrees C). CONCLUSION: Tbl and Tre often underrepresent Tbr after traumatic brain injury, particularly when the patient is hypo- or hyperthermic.	Univ Pittsburgh, Sch Nursing, Dept Acute Tertiary Care, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA		Henker, RA (corresponding author), Univ Pittsburgh, Sch Nursing, Dept Acute Tertiary Care, Pittsburgh, PA 15261 USA.		Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [3 P50 NS30318-05S1] Funding Source: Medline		Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Brengelmann G.L., 1987, MAN STRESSFUL ENV TH, P5; BRENGELMANN GL, 1989, TXB PHYSL, P1584; Crowder CM, 1996, J NEUROSURG, V85, P98, DOI 10.3171/jns.1996.85.1.0098; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; HAYWARD JN, 1968, AM J PHYSIOL, V215, P389, DOI 10.1152/ajplegacy.1968.215.2.389; HAYWARD JN, 1969, BRAIN RES, V16, P417, DOI 10.1016/0006-8993(69)90236-4; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MELLERGARD P, 1991, NEUROSURGERY, V28, P709, DOI 10.1227/00006123-199105000-00012; SHIRAKI K, 1988, J APPL PHYSIOL, V65, P482, DOI 10.1152/jappl.1988.65.1.482; WHITBY JD, 1971, BRIT J ANAESTH, V43, P673, DOI 10.1093/bja/43.7.673	13	87	93	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0148-396X			NEUROSURGERY	Neurosurgery	MAY	1998	42	5					1071	1075		10.1097/00006123-199805000-00071			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	ZK454	WOS:000073322500062	9588552				2022-02-06	
J	Hu, LY; Guo, JQ; Magar, SS; Fischer, JB; Burke-Howie, KJ; Durant, GJ				Hu, LY; Guo, JQ; Magar, SS; Fischer, JB; Burke-Howie, KJ; Durant, GJ			Synthesis and pharmacological evaluation of N-(2,5-disubstituted phenyl)-N '-(3-substituted phenyl)-N '-methylguanidines as N-methyl-D-aspartate receptor ion-channel blockers	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							PHENCYCLIDINE BINDING-SITE; SIGMA; ANTAGONISTS; DERIVATIVES; AFFINITY; COMPLEX; PCP; KETAMINE; LIGANDS; AGENTS	In the mammalian central nervous system, the N-methyl-D-aspartate (NMDA) subclass of glutamate receptors may play an important role in brain diseases such as stroke, brain or spinal cord trauma, epilepsy, and certain neurodegenerative diseases. Compounds which specifically antagonize the actions of the neurotransmitter glutamate at the NMDA receptor ion-channel site offer a novel approach to treating these disorders. CERESTAT (4, aptiganel CNS 1102) is currently undergoing clinical trial for the treatment of traumatic brain injury and stroke. Previously, we reported that analogues of N-1-naphthyl-N'-(3-ethylphenyl)-N'-methylguanidine (4) bound to the NMDA receptor ion-channel site with high potency and selectivity. Recently, molecules active at both a receptors and NMDA receptor sites were investigated. A series of substituted diphenylguanidines 6 which are structurally related to N-1-naphthyl-N'-(3-ethylphenyl)-N'-methylguanidine was prepared. Compounds containing appropriate substitution pattern in one of the phenyl rings of diphenylguanidines displayed high affinity. For example, N-(2,5-dibromophenyl)-N'-(3-ethylphenyl)-N'-methylguanidine (27b, R-2 = R-5 = Br, R-3 = C2H5) exhibited potency at both a receptors and NMDA receptor sites; 27b also showed high efficacy in vivo in a neonatal rat excitotoxicity model. Further studies indicated that substituent effects were important in this compound series, and 2,5-disubstituted phenyl was the preferred substitution pattern for high-affinity binding at NMDA receptor sites. Bromo and methylthio were the optimal substituents for the R-2 and R-5 positions of the 2,5-disubstituted phenyl group, respectively. N-(2-Bromo-5-(methylthio)phenyl)-N'-(3-ethylphenyl)- N'-methylguanidine (34b, R-2 = Br, R-5 = SMe, R-3 = C2H5) was highly active at NMDA receptor sites. We found that the binding affinity of guanidines of type 6 could be further enhanced with the appropriate substitution at R-3. Optimal activity in this series are afforded by 43b and 44b (R-2 = Cl or Br, R-5 = R-3 = SCH3). Both 43b and 44b bound to NMDA receptor sites with high potency and selectivity (K-i vs [H-3]MK-801: 1.87 and 1.65 nM, respectively); these compounds are active in vivo in various animal models of neuroprotection. The structure-activity relationships for-these compounds at the NMDA receptor ion-channel site are discussed.	Cambridge Neurosci Inc, Cambridge, MA 02139 USA		Hu, LY (corresponding author), Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.						BENAVIDES J, 1988, EUR J PHARMACOL, V149, P62; BIGGE CF, 1993, J MED CHEM, V36, P1977, DOI 10.1021/jm00066a007; BIGGE CF, 1992, MULTIPLE SIGMA PCP R, P1; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; GEE KR, 1993, J MED CHEM, V36, P1938, DOI 10.1021/jm00066a002; GREENAMYRE JT, 1986, ARCH NEUROL-CHICAGO, V43, P1058, DOI 10.1001/archneur.1986.00520100062016; HAYS SJ, 1993, J MED CHEM, V36, P654, DOI 10.1021/jm00058a002; HONEY CR, 1985, NEUROSCI LETT, V61, P135, DOI 10.1016/0304-3940(85)90414-8; HU LY, 1994, MED CHEM RES, V4, P146; INAMI Y, 1991, CHEM PHARM BULL, V39, P1426; ITZHAK Y, 1988, LIFE SCI, V42, P745, DOI 10.1016/0024-3205(88)90646-7; IVERSEN LL, 1994, NEUROTRANSMISSION, V10; KEANA, 1988, LIFE SCI, V3, P965; KEANA JFW, 1989, P NATL ACAD SCI USA, V86, P5631, DOI 10.1073/pnas.86.14.5631; KOZIKOWSKI AP, 1990, MOL PHARMACOL, V37, P352; KROGSGAARD P, 1991, TXB DRUG DESIGN DEV, P80; KUENZLE F, 1969, HELV CHIM ACTA, V52, P622; KUMAR V, 1995, J MED CHEM, V38, P1826, DOI 10.1021/jm00010a028; MERCHANT JR, 1978, INDIAN J CHEM B, V16, P385; PONTECORVO MJ, 1991, BRAIN RES BULL, V26, P461, DOI 10.1016/0361-9230(91)90025-F; RAO TS, 1990, NEUROPHARMACOLOGY, V29, P1199, DOI 10.1016/0028-3908(90)90045-S; REDDY NL, 1994, J MED CHEM, V37, P260, DOI 10.1021/jm00028a009; SCHERZ MW, 1990, J MED CHEM, V33, P2421, DOI 10.1021/jm00171a016; SHARP FR, 1992, J NEUROSCI RES, V33, P605, DOI 10.1002/jnr.490330413; THOMPSON WJ, 1990, J MED CHEM, V33, P789, DOI 10.1021/jm00164a052; TRUEDSSON LA, 1982, J CHROMATOGR, V234, P36; WATKINS JC, 1989, NMDA RECEPTOR, P227; WEBER E, 1986, P NATL ACAD SCI USA, V83, P8784, DOI 10.1073/pnas.83.22.8784; WIELOCH T, 1985, SCIENCE, V230, P681, DOI 10.1126/science.2996146; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; ZUKIN SR, 1979, P NATL ACAD SCI USA, V76, P5372, DOI 10.1073/pnas.76.10.5372	31	87	88	0	6	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623			J MED CHEM	J. Med. Chem.	DEC 19	1997	40	26					4281	4289		10.1021/jm970459c			9	Chemistry, Medicinal	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	YQ059	WOS:000071343300009	9435897				2022-02-06	
J	Bond, F; Godfrey, HPD				Bond, F; Godfrey, HPD			Conversation with traumatically brain-injured individuals: A controlled study of behavioural changes and their impact	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; PRAGMATIC LANGUAGE-SKILLS; SOCIAL-INTERACTION; ABILITY; SCHIZOPHRENIA; VALIDATION	The conversations of 62 traumatically brain-injured (TBI) patients, assessed between 6 months and 3 years post-injury, were compared with those of an orthopaedic control (OC) group (n = 25). Conversations involving TBI subjects were rated as significantly less interesting, less appropriate, less rewarding and more effortful than interactions involving OC subjects, and were characterized by differences in the frequency of prompt usage and turn duration. Furthermore, measures of turn duration and prompt frequency were significantly associated with the perceived quality of conversation. These findings provide a microbehavioural description of the social process through which TBI individuals fail to adequately reinforce others.	UNIV OTAGO,CLIN PSYCHOL RES & TRAINING CTR,DUNEDIN,NEW ZEALAND								BARCH D, 1994, J ABNORM PSYCHOL, V103, P371; BELLACK AS, 1994, J ABNORM PSYCHOL, V103, P371, DOI 10.1037/0021-843X.103.2.371; DERLEGA VJ, 1986, FRIENDSHIP SOCIAL IN; DOW MG, 1985, BEHAV THER, V16, P76, DOI 10.1016/S0005-7894(85)80057-5; Duffy, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; GODFREY H P D, 1991, Brain Injury, V5, P207, DOI 10.3109/02699059109008091; GODFREY HPD, 1993, NEW ZEAL MED J, V106, P301; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GODFREY HPD, 1989, PSYCHOL MED, V19, P175, DOI 10.1017/S0033291700011120; Jennett B, 1981, MANAGEMENT HEAD INJU; Linscott RJ, 1996, BRAIN INJURY, V10, P397, DOI 10.1080/026990596124269; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; MCFALL RM, 1982, BEHAV ASSESS, V4, P1; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; Nelson H. E, 1982, NATIONAL ADULT READI; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; PENN DL, 1993, J NERV MENT DIS, V181, P13, DOI 10.1097/00005053-199301000-00003; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; ROMANO JM, 1980, J CONSULT CLIN PSYCH, V48, P478, DOI 10.1037/0022-006X.48.4.478; SMITH LM, 1985, FAMILY SUPPORT PROGR, P175; SPENCE SE, 1993, BRIT J CLIN PSYCHOL, V32, P302; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; TROWER P, 1978, SOCIAL SKILLS MENTAL; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY	28	87	87	0	15	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAY	1997	11	5					319	329		10.1080/026990597123476			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	WW455	WOS:A1997WW45500002	9146837				2022-02-06	
J	Unterberg, AW; Kiening, KL; Hartl, R; Bardt, T; Sarrafzadeh, AS; Lanksch, WR				Unterberg, AW; Kiening, KL; Hartl, R; Bardt, T; Sarrafzadeh, AS; Lanksch, WR			Multimodal monitoring in patients with head injury: Evaluation of the effects of treatment on cerebral oxygenation	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	14th Bodensee Symposium on Microcirculation: Small Volume Resuscitation in Head Injury	JUN 14-16, 1996	BODENSEE, GERMANY			cerebral oxygenation; intracranial pressure; cerebral perfusion pressure; traumatic brain injury; multimodal monitoring	ISCHEMIC BRAIN-DAMAGE; PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; SATURATION; MANNITOL	Background: Recently, invasive intensive care unit monitoring of cerebral oxygenation has become feasible. The purpose of this study was to investigate the effects of standard therapeutic interventions used in the treatment of intracranial hypertension on cerebral oxygenation and other physiologic parameters in comatose patients. Methods: In the neurosurgical intensive care unit, Ptio(2), and jugular bulb oxygen saturation (Sjvo(2)), arterial blood pressure, intracranial pressure (ICP), and cerebral perfusion pressure (CPP) were prospectively studied (0.1 Hz acquisition rate) with a multimodal monitoring system in 21 patients with severe traumatic brain injury during various treatment modalities: dopamine and mannitol infusion, head positioning, and induced arterial hypocapnia. Results: For baseline CPP values below 40 mm Hg, dopamine infusion was more effective in decreasing ICP and improving Ptio(2) and Sjvo(2) than for initial CPP values above 60 mm Hg. Treatment with mannitol, although improving CPP and lowering ICP, did not affect Ptio(2) and Sjvo(2). CPP in this group, however, was always above 60 mm Hg. Forced hyperventilation to an end-tidal Pco(2) of 21 mm Hg normalized ICP and CPP, but significantly reduced cerebral oxygenation. Conclusion: 4 CPP > 60 mm Hg emerges as the crucial factor guaranteeing sufficient brain oxygenation. Any intervention used to further elevate CPP does not improve cerebral oxygenation, to the contrary, forced hyperventilation even bears the risk of inducing brain ischemia.			Unterberg, AW (corresponding author), HUMBOLDT UNIV BERLIN, VIRCHOW KLINIKUM, DEPT NEUROSURG, VIRCHOW MED CTR, AUGUSTENBURGER PL 1, D-13353 BERLIN, GERMANY.						CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CLARK LC, 1956, T AM SOC ART INT ORG, V2, P41; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GAAB MR, 1990, ACT NEUR S, V51, P320; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HARTL R, 1996, IN PRESS CARDIOVASC; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; ROBERTSON C, 1993, ACTA NEUROCHIR, P98; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; ROSNER MJ, 1987, NEUROSURGERY, V21, P147, DOI 10.1227/00006123-198708000-00003; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SCHNEIDER GH, 1993, ACTA NEUROCHIR, P107; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; TAKAGI H, 1983, INTRACRANIAL PRESSUR, V5, P729; THEODORSSONNORHEIM E, 1987, COMPUT BIOL MED, V17, P85, DOI 10.1016/0010-4825(87)90003-5; Unterberg A. W., 1995, Journal of Neurotrauma, V12, P405	23	87	89	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	1997	42	5		S			S32	S37		10.1097/00005373-199705001-00006			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	XE879	WOS:A1997XE87900007	9191693				2022-02-06	
J	Yang, K; PerezPolo, JR; Mu, XS; Yan, HQ; Xue, JJ; Iwamoto, Y; Liu, SJ; Dixon, CE; Hayes, RL				Yang, K; PerezPolo, JR; Mu, XS; Yan, HQ; Xue, JJ; Iwamoto, Y; Liu, SJ; Dixon, CE; Hayes, RL			Increased expression of brain-derived neurotrophic factor but not neurotrophin-3 mRNA in rat brain after cortical impact injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						gene expression; neurotrophin; BDNF; NT3; traumatic brain injury	NERVE GROWTH-FACTOR; BDNF MESSENGER-RNA; CULTURED HIPPOCAMPAL-NEURONS; TRANSIENT FOREBRAIN ISCHEMIA; LIMBIC SEIZURES; DIFFERENTIAL REGULATION; INSITU HYBRIDIZATION; CEREBRAL-ISCHEMIA; SENSORY NEURONS; RAPID INCREASE	Levels of brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT3) mRNA expression were measured in a rodent model of traumatic brain injury (TBI) following unilateral injury to the cerebral cortex, To obtain reliable data on the co-expression of neurotrophin genes, adjacent coronal sections from the same rat brains were hybridized in situ with BDNF and NT3 cRNA probes, BDNF mRNA increased at 1, 3, and 5 hr after unilateral cortical injury in the cortex ipsilateral to the injury site and bilaterally in the dorsal hippocampus, NT3 mRNA did not change significantly following injury. Our results suggest that TBI produces rapid increases in BDNF mRNA expression in rat brain without changes in NT3 mRNA expression, a finding which differs from studies of ischemia and seizures, It is possible that increased levels of BDNF mRNA rather than NT3 are important components of pathophysiological responses to TBI. (C) 1996 Wiley-Liss, Inc.	UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,HOUSTON,TX 77030; UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOCHEM & GENET,GALVESTON,TX 77550				Perez-Polo, Jose R./B-6250-2009		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458, P01NS031998] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS 31998, R01 NS 21458] Funding Source: Medline		ANDERSON RF, 1990, NEURON, V5, P297; BALLARIN M, 1991, EXP NEUROL, V114, P35, DOI 10.1016/0014-4886(91)90082-N; BARDE YA, 1980, P NATL ACAD SCI-BIOL, V77, P1199, DOI 10.1073/pnas.77.2.1199; BESSHO Y, 1993, MOL BRAIN RES, V18, P201, DOI 10.1016/0169-328X(93)90190-Z; COLLAZO D, 1992, NEURON, V9, P643, DOI 10.1016/0896-6273(92)90028-C; DAVIES AM, 1986, J NEUROSCI, V6, P1897; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ERNFORS P, 1991, NEURON, V7, P165, DOI 10.1016/0896-6273(91)90084-D; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FRIEDMAN WJ, 1991, J NEUROSCI, V11, P1577; GALL C, 1991, MOL BRAIN RES, V9, P113, DOI 10.1016/0169-328X(91)90136-L; GALL C, 1992, EPILEPSY RES S, V7, P171; GALL C, 1991, EPILEPSY RES S, V4, P225; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; IP NY, 1993, J NEUROSCI, V13, P3394; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KINDSAY RM, 1985, DEV BIOL, V112, P319; KNUSEL B, 1992, J NEUROCHEM, V59, P715, DOI 10.1111/j.1471-4159.1992.tb09427.x; KNUSEL B, 1991, P NATL ACAD SCI USA, V88, P961, DOI 10.1073/pnas.88.3.961; KOKAIA Z, 1993, MOL BRAIN RES, V19, P277, DOI 10.1016/0169-328X(93)90126-A; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LU B, 1991, P NATL ACAD SCI USA, V88, P6289, DOI 10.1073/pnas.88.14.6289; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAISONPIERRE PC, 1990, SCIENCE, V247, P446; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; PRASAD MR, 1994, J NEUROCHEM, V63, P773; ROCAMORA N, 1992, MOL BRAIN RES, V13, P27, DOI 10.1016/0169-328X(92)90041-9; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; SMITH MA, 1995, J NEUROSCI, V15, P1768, DOI 10.1523/JNEUROSCI.15-03-01768.1995; SPRINGER JE, 1994, MOL BRAIN RES, V23, P135, DOI 10.1016/0169-328X(94)90219-4; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TAKEDA A, 1992, BRAIN RES, V569, P177, DOI 10.1016/0006-8993(92)90388-P; TAKEDA A, 1993, NEUROSCIENCE, V55, P23, DOI 10.1016/0306-4522(93)90451-K; WETMORE C, 1990, EXP NEUROL, V109, P141, DOI 10.1016/0014-4886(90)90068-4; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; ZAAL K, 1993, MOL BRAIN RES, V19, P277; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	55	87	90	0	0	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	APR 15	1996	44	2					157	164		10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UG271	WOS:A1996UG27100008	8723224				2022-02-06	
J	Roberts, WO; Brust, JD; Leonard, B; Hebert, BJ				Roberts, WO; Brust, JD; Leonard, B; Hebert, BJ			Fair-play rules and injury reduction in ice hockey	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article								Objective: To determine the rate, type, and severity of injuries incurred and penalties assessed during the qualifying fair-play (points for playing without excessive penalties) and championship ''regular'' rules (winner advances) portions of a 1994 Junior Gold ice hockey tournament. Design: A prospective evaluation of injuries by certified athletic trainers at the tournament site. Setting: A community-organized, 3-day, 31-game tournament in Minnesota. Participants: Two hundred seventy-three male players, younger than 20 years and in high school. Measurements/Main Results: Injuries were recorded by an on-site certified athletic trainer, and the penalties were tallied from the score sheets. The injury rates for the total number of injuries were 26.4 injuries per 1000 athlete exposures and 273.8 injuries per 1000 player hours. When only notable injuries (concussion, facial laceration, or moderate level of severity and above) were considered, the injury rates were 10 per 1000 athlete exposures and 103.9 per 1000 player hours. The ratio of notable fair-play to notable regular-rules injuries was 1:4.8. The number of penalties assessed per game averaged 7.1 penalties during fair-play rules and 13 penalties during the regular-rules competition. Penalties related to rough play and injury occurred four times more frequently during games with regular rules than those with fair-play rules. Conclusions: The fair-play concept can reduce injury rates, penalty rates, and severity of penalties and should be considered for ice hockey at all levels of play. The fair-play concept could be applied to other contact sports to reduce injury rates and rules infractions.	UNIV MINNESOTA,SCH MED,DEPT FAMILY PRACTICE & COMMUNITY HLTH,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH NURSING,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH PUBL HLTH,MINNEAPOLIS,MN 55455; ALLINA HLTH SYST,PUBL AFFAIRS DEPT,MINNEAPOLIS,MN		Roberts, WO (corresponding author), MINNHLTH SPORTSCARE CONSULTANTS,4786 BANNING AVE,WHITE BEAR LAKE,MN 55110, USA.			Roberts, William O/0000-0003-4517-4330			BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; MARCHAND S, 1993, APS J, V2, P103; PELLETIER RL, 1993, AM J SPORT MED, V21, P78, DOI 10.1177/036354659302100114; ROBERTS WO, 1992, PHYSICIAN SPORTSMED, V20, P66, DOI 10.1080/00913847.1992.11710295; STUART MJ, 1995, MAYO CLIN PROC, V70, P350, DOI 10.4065/70.4.350; STUART MJ, 1995, AM J SPORT MED, V23, P458, DOI 10.1177/036354659502300415; Sutherland G W, 1976, Am J Sports Med, V4, P264, DOI 10.1177/036354657600400605; Vaz EW., 1982, PROFESSIONALIZATION; 1994, NCAA9824394 SPORTS S	10	87	88	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	FEB	1996	150	2					140	145		10.1001/archpedi.1996.02170270022003			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	TT878	WOS:A1996TT87800003	8556117				2022-02-06	
J	WILLINGER, R; TALEB, L; KOPP, CM				WILLINGER, R; TALEB, L; KOPP, CM			MODAL AND TEMPORAL ANALYSIS OF HEAD MATHEMATICAL-MODELS	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	Head Injury 1994 - International Symposium on Head Injury Research	OCT 12-14, 1994	WASHINGTON, DC	Natl Highway Traff Safety Adm, Head Injury Res Program, George Washington Univ		HEAD BIOMECHANICS; MODAL ANALYSIS; TEMPORAL ANALYSIS; LUMPED MODEL; FINITE ELEMENT MODELS; INJURY MECHANISMS		The basic hypotheses used during these investigations were based on the vibration analysis of the head, which demonstrated that the head is not a solid nondeformable body, but a complex structure including deformable elements. Laboratoire des Systemes Biomecanique (LSBM) has recently proposed three mathematical models: a lumped model, a finite element model of the head in its sagittal plane, and a three-dimensional finite element model. These models were validated by their modal behavior and enabled the lesion mechanisms to be distinguished as a function of the spectral characteristics of the shock. The objective of this study is to complete these modal results by temporal analysis of the models by calculating the evolution of the intracranian mechanical parameters under shock conditions. To describe the head's dynamic behavior in the temporal domain, constant energy shocks of variable duration were simulated to evaluate their influence on different quantities as the intracerebral stresses in terms of compression, tensile, and shearing stresses, the relative brain-skull displacement, and the skull deformation. The importance of modal behavior of the head is illustrated by analyzing its temporal response to variable duration impacts, thus exciting very different frequencies. For a triangular shock, the critical duration times are between 10 and 15 x 10(-3) s, which correspond to impacts that excite the first resonance frequency of the head. Taking modal behavior into consideration in developing the finite element model leads to a harmonization of the calculated intracerebral stresses, even for short duration shocks. So, when the head is considered as a complex structure made up of several deformable elements, risk limitation is conditioned by an impact energy reduction for frequencies close to the natural frequencies of the structure. In the time field, the objective will be to avoid a number of impact shapes and durations. Therefore, the aim will not be to dampen the impact at any cost, but to damper it in an ''intelligent'' manner. In the future, this will allow the reduction of an injury mechanism-related risk, without increasing the risk of an injury generated by another mechanism.			WILLINGER, R (corresponding author), UNIV STRASBOURG, LSBM, IMF, CNRS 854, 2 RUE BOUSSINGAULT, STRASBOURG, FRANCE.						ALEM NM, 1974, 18TH STAPP CAR CRASH, P579; BRINN J, 1970, 14TH STAPP CAR CRASH; DIMASI F, 1991, P INT TECHNICAL C EX; GADD CW, 1966, SAE660793; GADD CW, 1968, SAE680053; HARRIS CM, 1988, SHOCK VIBRATION HDB; HODGSON VR, 1968, STAPP C, V12, P280; HODGSON VR, 1967, 11TH STRAPP CAR CRAS, P79; KALLIERIS D, 1980, BRAIN INJURIES HIGH, P229; McElhaney JH, 1976, HDB HUMAN TOLERANCE; PLUCHE R, 1985, ADV ANTHROPOMORPHIC; SHUGER TA, 1977, DOTHS2893550TA REP, V1; SIMPSON DA, 1991, P INT IRCOBI C BIOME, P89; SLATTENSCHEK A, 1968, 1970 INT AUT SAF C; STALNAKER RL, 1971, J BIOMECH, V4, P127, DOI 10.1016/0021-9290(71)90023-6; STALNAKER RL, 1985, C P INT RES COUNC BI, P191; STALNAKER RL, 1991, P INT COUNCIL BIOKIN, P69; THIBAULT LE, 1990, C P INT RES COUNCIL, P191; VIANO DC, 1989, J BIOMECH, V22, P403, DOI 10.1016/0021-9290(89)90201-7; WARD CC, 1975, 19TH P STAPP CAR CRA; WILLINGER R, 1994, ACCIDENT ANAL PREV, V26, P767, DOI 10.1016/0001-4575(94)90053-1; WILLINGER R, 1991, P INT TECHNICAL C EX; Willinger R., 1990, C P INT RES COUNCIL, P203; WILLINGER R, 1995, 1995 IRCOBI C; WILLINGER R, 1993, SEP P INT IRCOBI C B, P229; WILLINGER R, 1992, SEP P INT RES COUNC, P283; WILLINGER R, 1992, MECANIQUE ELECTRICIT, V443, P36; WILLINGER R, 1990, MECANIQUE ELECTRICIT, V434, P45; WILLINGER RW, 1991, 35TH P ANN C DES PLA, P387; ZIENKIEWICZ OC, 1973, METHODE ELEMENTS FIN	30	87	97	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1995	12	4					743	754		10.1089/neu.1995.12.743			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	RY920	WOS:A1995RY92000026	8683626				2022-02-06	
J	PITTS, LH; ROSS, A; CHASE, GA; FADEN, AI				PITTS, LH; ROSS, A; CHASE, GA; FADEN, AI			TREATMENT WITH THYROTROPIN-RELEASING-HORMONE (TRH) IN PATIENTS WITH TRAUMATIC SPINAL-CORD INJURIES	JOURNAL OF NEUROTRAUMA			English	Article						SPINAL CORD INJURY; TRH; HUMAN; BEHAVIORAL OUTCOME	AMYOTROPHIC LATERAL SCLEROSIS; PLATELET-ACTIVATING-FACTOR; EXPERIMENTAL BRAIN TRAUMA; DOSE-RESPONSE; BLOOD-FLOW; BEHAVIORAL DEFICITS; WATER-CONTENT; NALOXONE; RATS; DEXAMETHASONE	Numerous preclinical studies have demonstrated that posttraumatic treatment of spinal cord injury (SCI) with thyrotropin-releasing hormone (TRH) or TRH analogs improves long-term behavioral recovery. The purpose of the present study is to provide preliminary data regarding the safety and potential efficacy of TRH in patients with acute SCI. A total of 20 patients with SCI were classified by clinical examination into complete and incomplete injury groups within 12 h of trauma and randomly assigned in double-blinded fashion to treatment with either TRH (0.2 mg/kg intravenous bolus followed by 0.2 mg/kg/h infusion over 6 h) or vehicle (equal volume physiological saline) placebo. A variety of physiological variables were followed during treatment. Clinical examination included motor and sensory testing, as well as assigning a Sunnybrook score based upon level of function. Patients were examined at 24 h, 72 h, 1 week, 1 month, 4 months, and 12 months after injury. TRH infusions were well tolerated. There appeared to be no discernible treatment effect in patients with complete injuries although data were available from only six such patients at 4 months. For the incomplete injury group, a total of 6 treated and 5 placebo patients had 4-month evaluations. TRH treatment was associated with significantly higher motor, sensory, and Sunnybrook scores than placebo treatment. Because of patients lost to subsequent follow-up, 12-month data were not highly informative. These observations must be interpreted with considerable caution because of the small patient numbers, but together with extensive animal studies they support the need for a larger multicenter clinical trial of TRH.	GEORGETOWN UNIV,MED CTR,DEPT NEUROL & PHARMACOL,WASHINGTON,DC 20007; SAN FRANCISCO GEN HOSP,DEPT NEUROSURG,SAN FRANCISCO,CA 94110				Ross, Amy Miner/W-7789-2019				AKDEMIR H, 1993, RES EXP MED, V193, P297, DOI 10.1007/BF02576237; AKDEMIR H, 1992, RES EXP MED, V192, P177, DOI 10.1007/BF02576273; Allen AR., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; ARIAS MJ, 1987, SURG NEUROL, V28, P335, DOI 10.1016/0090-3019(87)90054-1; BEHRMANN DL, 1993, EXP NEUROL, V119, P258, DOI 10.1006/exnr.1993.1028; BEHRMANN DL, 1994, EXP NEUROL, V126, P61, DOI 10.1006/exnr.1994.1042; BRACKEN MB, 1993, J NEUROSURG, V79, P500, DOI 10.3171/jns.1993.79.4.0500; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRAUGHLER JM, 1988, J NEUROSURG, V64, P985; BROOKS BR, 1987, NEUROL CLIN, V5, P143, DOI 10.1016/S0733-8619(18)30939-3; CEYLAN S, 1992, RES EXP MED, V192, P23, DOI 10.1007/BF02576254; CEYLAN S, 1990, RES EXP MED, V190, P111, DOI 10.1007/PL00020013; DEMEDIUK P, 1985, PROG BRAIN RES, V63, P1; DOYLE WK, 1991, CLIN NEUROLOGY, pCH47; ENGEL WK, 1983, LANCET, V2, P73; FADEN AI, 1981, NEW ENGL J MED, V305, P1063, DOI 10.1056/NEJM198110293051806; FADEN AI, 1983, NEUROLOGY, V33, P673, DOI 10.1212/WNL.33.6.673; FADEN AI, 1983, PEPTIDES, V4, P631, DOI 10.1016/0196-9781(83)90009-8; FADEN AI, 1992, J PHARMACOL EXP THER, V261, P1064; FADEN AI, 1990, J PHARMACOL EXP THER, V255, P608; FADEN AI, 1987, J NEUROCHEM, V48, P1809, DOI 10.1111/j.1471-4159.1987.tb05740.x; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; FADEN AI, 1993, J NEUROTRAUM, V10, P101, DOI 10.1089/neu.1993.10.101; FADEN AI, 1984, NEUROLOGY, V34, P1280, DOI 10.1212/WNL.34.10.1280; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; FADEN AI, 1987, BRAIN RES, V448, P287; FADEN AI, 1993, HDB EXPT PHARM, P325; FEUERSTEIN G, 1984, CIRC SHOCK, V13, P255; FUKUDA N, 1979, FOLIA PHARMACOL JPN, V75, P321, DOI 10.1254/fpj.75.321; Hall E D, 1986, Cent Nerv Syst Trauma, V3, P281; HASHIMOTO T, 1989, Japanese Journal of Pharmacology, V49, p312P; HASHIMOTO T, 1991, EUR J PHARMACOL, V203, P25, DOI 10.1016/0014-2999(91)90786-P; HOERLIEIN BF, 1985, J AM ANIM HOSP ASSOC, V2, P67; HOLADAY JW, 1978, LIFE SCI, V22, P1537, DOI 10.1016/0024-3205(78)90009-7; HOLTZ A, 1989, ACTA NEUROL SCAND, V80, P215, DOI 10.1111/j.1600-0404.1989.tb03865.x; HSU CY, 1985, NEUROLOGY, V35, P1003, DOI 10.1212/WNL.35.7.1003; KOSKINEN LOD, 1989, ANN NY ACAD SCI, V553, P353; LEMKE M, 1987, BIOCHEM BIOPH RES CO, V147, P1170, DOI 10.1016/S0006-291X(87)80192-4; LUX WE, 1983, NATURE, V302, P822, DOI 10.1038/302822a0; MANAKA S, 1978, NEUROSCI LETT, V8, P255, DOI 10.1016/0304-3940(78)90131-3; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P373, DOI 10.1089/neu.1993.10.373; MCINTOSH TK, 1988, AM J PHYSIOL, V254, pR785, DOI 10.1152/ajpregu.1988.254.5.R785; MILLER SC, 1989, ARCH NEUROL-CHICAGO, V46, P330, DOI 10.1001/archneur.1989.00520390096025; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PRANGE A J JR, 1979, P75; Puniak MA, 1991, J NEUROTRAUM, V8, P193, DOI 10.1089/neu.1991.8.193; RENAUD LP, 1979, SCIENCE, V205, P1275, DOI 10.1126/science.224461; Salzman SK, 1991, J NEUROTRAUM, V8, P45, DOI 10.1089/neu.1991.8.45; TAKAMI K, 1991, JPN J PHARMACOL, V57, P405, DOI 10.1254/jjp.57.405; Tator CH., 1982, EARLY MANAGEMENT ACU, P7; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; WANG GL, 1991, CHINESE MED J-PEKING, V104, P939; Young W, 1985, Cent Nerv Syst Trauma, V2, P109	53	87	89	0	8	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	1995	12	3					235	243		10.1089/neu.1995.12.235			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	RM331	WOS:A1995RM33100001	7473798				2022-02-06	
J	SCALEA, TM; MALTZ, S; YELON, J; TROOSKIN, SZ; DUNCAN, AO; SCLAFANI, SJA				SCALEA, TM; MALTZ, S; YELON, J; TROOSKIN, SZ; DUNCAN, AO; SCLAFANI, SJA			RESUSCITATION OF MULTIPLE TRAUMA AND HEAD-INJURY - ROLE OF CRYSTALLOID FLUIDS AND INOTROPES	CRITICAL CARE MEDICINE			English	Article						HEAD INJURY; BLUNT TRAUMA; LACTATE; INTRACRANIAL PRESSURE; HEMODYNAMICS; RESUSCITATION; OXYGENATION; CRYSTALLOIDS; HYPERTENSION, INTRACRANIAL; NEUROLOGIC EMERGENCIES	CEREBRAL BLOOD-FLOW; HEMORRHAGIC-SHOCK; BRAIN INJURY; PRESSURE; VOLUME; SURVIVAL; PATTERNS; EDEMA; MODEL; DEATH	Objectives: To determine the hemodynamic responses to blunt trauma with a closed-head injury and to investigate the effect that volume resuscitation has on intracranial pressure. Design: Prospective study with retrospective analysis of patient data and hemodynamic responses. Setting: Surgical intensive care unit at an inner-city, Level I trauma center. Patients: Consecutive patients (n = 30) who sustained multiple system injury, including a closed-head injury that was severe enough to require intracranial pressure monitoring but not a craniotomy. Interventions: All patients underwent invasive hemodynamic monitoring with percutaneous arterial and pulmonary arterial catheters. Serum lactate concentrations and hemodynamic and oxygen transport variables were measured every 4 hrs. Intracranial pressures and vital signs were recorded each hour. Attempts were made to achieve a state of nonflow-dependent oxygen consumption and a normal serum lactate concentration. Measurements and Main Results: Despite being normotensive and neither tachycardiac nor oliguric, 80% of patients had evidence of inadequate tissue perfusion. Only 50% of the remaining patients had an adequate response to volume. The other 50% received vasodilating inotropic agents. Despite volume loading and the administration of inotropic agents, intracranial pressure did not increase. This observation was found in patients who showed clinically important intracranial pathology on computed tomography scan, as well as in all other patients. Intracranial pressure did not correlate with the amount of fluid or blood infused or with hemodynamic performance, but intracranial pressures did correlate with serum lactate concentrations. Conclusions: Many patients with diffuse blunt trauma closed-head injuries, even when they are normotensive, have evidence of impaired peripheral perfusion. Volume infusion and vasodilating inotropic support improve oxygen transport without increasing intracranial pressure. The observed relationship between intracranial pressure and the serum lactate concentration requires further study.	SUNY HLTH SCI CTR,DEPT EMERGENCY MED,BROOKLYN,NY 11203		SCALEA, TM (corresponding author), SUNY HLTH SCI CTR,DEPT SURG,BOX 40,450 CLARKSON AVE,BROOKLYN,NY 11203, USA.						ABOUKHALIL B, 1994, CRIT CARE MED, V22, P633, DOI 10.1097/00003246-199404000-00020; ABRAMSON D, 1993, J TRAUMA, V35, P584, DOI 10.1097/00005373-199310000-00014; ADAMS S L, 1986, Journal of Emergency Medicine, V4, P383, DOI 10.1016/0736-4679(86)90216-7; BROWN RS, 1973, ANN SURG, V177, P187, DOI 10.1097/00000658-197302000-00011; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; DAVIS DH, 1980, J NEUROSURG, V52, P745, DOI 10.3171/jns.1980.52.6.0745; HAUSDORFER J, 1975, RESUSCITATION, V2, P261; KAISER R, 1989, ANESTHESIOLOGY, V71, P554; MORSE ML, 1985, CRIT CARE MED, V13, P563, DOI 10.1097/00003246-198507000-00011; ORESKOVICH MR, 1984, J TRAUMA, V24, P565, DOI 10.1097/00005373-198407000-00003; PETROPALI JA, 1992, J TRAUMA, V33, P403; POOLE GV, 1987, J TRAUMA, V27, P18, DOI 10.1097/00005373-198701000-00004; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SCALEA TM, 1990, J TRAUMA, V30, P129, DOI 10.1097/00005373-199002000-00001; SCALEA TM, 1988, J TRAUMA, V28, P725, DOI 10.1097/00005373-198806000-00001; SHACKFORD SR, 1990, J TRAUMA, V30, P768, DOI 10.1097/00005373-199007000-00002; SHOEMAKER WC, 1973, ARCH SURG-CHICAGO, V106, P630; SHOEMAKER WC, 1967, ARCH SURG-CHICAGO, V95, P492; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; SMITH SD, 1982, J TRAUMA, V22, P588, DOI 10.1097/00005373-198207000-00011; TOMMASINO C, 1988, CRIT CARE MED, V16, P862, DOI 10.1097/00003246-198809000-00009; WISNER D, 1989, J SURG RES, V46, P49, DOI 10.1016/0022-4804(89)90181-9; ZORNOW MH, 1987, ANESTHESIOLOGY, V67, P936, DOI 10.1097/00000542-198712000-00010; 1988, ADV TRAUMA LIFE SUPP	25	87	94	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0090-3493			CRIT CARE MED	Crit. Care Med.	OCT	1994	22	10					1610	1615					6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK865	WOS:A1994PK86500017	7924373				2022-02-06	
J	TRUEBLOOD, W				TRUEBLOOD, W			QUALITATIVE AND QUANTITATIVE CHARACTERISTICS OF MALINGERED AND OTHER INVALID WAIS-R AND CLINICAL MEMORY DATA	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	Meeting of the National-Academy-of-Neuropsychology	NOV, 1992	PITTSBURGH, PA	NATL ACAD NEUROPSYCHOL			FORCED-CHOICE METHOD; CLOSED-HEAD-INJURY; PERFORMANCE; IMPAIRMENT; DEFICITS; TRAUMA; TESTS	To further the understanding of malingering and other compromises to data validity on standard neuropsychological tasks, the present study evaluated WAIS-R and clinical memory data produced by two groups from a mildly head-injured sample: Malingerers (MPs; n = 12) were identified via below chance forced-choice testing; ''QVs'' (n = 10) provided implausible neuropsychological performances but were not clearly malingering. A low level of performance characterized the data of the MPs and QVs: Full Scale IQ and Performance IQ were significantly lower for MPs and QVs than for matched controls, and obtained IQ for MPs and QVs averaged 18 points below estimated IQ. On the California Verbal Learning Test, total words recalled and recognition memory were significantly lower for MPs and QVs than for controls. In contrast, qualitative analyses, such as approximate answers, bizarre responses, ''scatter'' on the WAIS-R, inconsistency in performance across similar tasks, clustering, and intrusions on memory measures, generally yielded negative findings.									ANDERSON EW, 1956, P ROY SOC MED, V49, P513; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BASH IY, 1980, ANN NY ACAD SCI, V347, P86, DOI 10.1111/j.1749-6632.1980.tb21257.x; Bernard L C, 1991, Arch Clin Neuropsychol, V6, P81, DOI 10.1016/0887-6177(91)90024-4; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; BIGLER ED, 1989, J CLIN PSYCHOL, V45, P277, DOI 10.1002/1097-4679(198903)45:2<277::AID-JCLP2270450216>3.0.CO;2-M; Binder L. M., 1992, HDB NEUROPSYCHOLOGIC, P353; BINDER LM, 1993, ARCH CLIN NEUROPSYCH, V8, P137, DOI 10.1016/0887-6177(93)90031-U; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; Bradley J. V., 1968, DISTRIBUTION FREE ST; BRANDT J, 1988, CLIN ASSESSMENT MALI, P65; BROWN LM, 1990, EFFECTS SEVERITY CLO; CROSSON B, 1989, CLIN NEUROPSYCHOL, V3, P29, DOI DOI 10.1080/13854048908404074; DELIS D, 1987, CALIFORNIA VERBAL LE; DELIS DC, 1991, HDB NEUROPSYCHOLOGY, V3, P3; FRANZEN M D, 1990, Neuropsychology Review, V1, P247, DOI 10.1007/BF01112573; Franzen M. D., 1989, RELIABILITY VALIDITY; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; Hathaway S.R., 1989, MINNESOTA MULTIPHASI; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Hunt W., 1943, NAVAL MED B, V41, P1318; Larrabee GJ, 1990, NEUROPSYCHOLOGY, V4, P239, DOI 10.1037/0894-4105.4.4.239; Levin H. S., 1989, J CLIN EXP NEUROPSYC, V12, P129; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; Macartney-Filgate M S, 1988, Arch Clin Neuropsychol, V3, P121, DOI 10.1016/0887-6177(88)90057-1; Martin R.C., 1991, NEUROPSYCHOLOGY, V5, P3, DOI [10.1037/0894-4105.5.1.3, DOI 10.1037/0894-4105.5.1.3]; MARTZKE JS, 1991, NEUROPSYCHOLOGY, V0005, P00213, DOI DOI 10.1037/0894-4105.5.3.213; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; NORUSIS MJ, 1990, SPSS PC; PANKRATZ L, 1975, J CONSULT CLIN PSYCH, V43, P421, DOI 10.1037/h0076722; PRIGATANO GP, 1993, J CLIN EXP NEUROPSYC, V15, P537, DOI 10.1080/01688639308402577; Rawling P, 1990, NEUROPSYCHOLOGY, V4, P223, DOI 10.1037/0894-4105.4.4.223; Reitan R, 1985, HALSTEAD REITAN NEUR; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Schear JM, 1989, CLIN NEUROPSYCHOL, V3, P162; SCHRETLEN DJ, 1988, CLIN PSYCHOL REV, V8, P451, DOI 10.1016/0272-7358(88)90074-8; SQUIRE LR, 1986, NEUROPSYCHOLOGICAL A, P268; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Wachspress M, 1953, PSYCHIAT QUART, V27, P463, DOI 10.1007/BF01562502; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WIGGINS EC, 1988, LAW HUMAN BEHAV, V12, P57, DOI 10.1007/BF01064274; Wilkinson, 1984, WIDE RANGE ACHIEVEME; WIRSEN A, 1991, NEUROPSYCHOLOGY, V5, P151; ZAPPALA G, 1992, ARCH CLIN NEUROPSYCH, V7, P145, DOI 10.1016/0887-6177(92)90008-B; [No title captured], DOI DOI 10.1037/0894-4105.5.4.253; [No title captured]	48	87	88	0	1	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	AUG	1994	16	4					597	607		10.1080/01688639408402671			11	Psychology, Clinical; Clinical Neurology; Psychology	Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Psychology; Neurosciences & Neurology	NW682	WOS:A1994NW68200012	7962361				2022-02-06	
J	LEECH, PJ; PATERSON, A				LEECH, PJ; PATERSON, A			CONSERVATIVE AND OPERATIVE MANAGEMENT FOR CEREBROSPINAL-FLUID LEAKAGE AFTER CLOSED HEAD-INJURY	LANCET			English	Article									SO GEN HOSP,INST NEUROL SCI,DIV NEUROSURG,GLASGOW G51 4TF,SCOTLAND								ADSON AW, 1948, ARCHS SURG CHICAGO, V58, P623; APPELBAUM A, 1960, J AM MED ASS, V173, P1818; BRAWLEY BW, 1967, J NEUROSURG, V26, P57, DOI 10.3171/jns.1967.26.1part1.0057; CALVERT CA, 1942, P ROY SOC MED, V35, P865; Chiari H, 1884, Z HEILK, V5, P383; CHOROBSKI J, 1950, J NEUROL NEUROSUR PS, V13, P280, DOI 10.1136/jnnp.13.4.280; Dandy WE, 1926, ARCH SURG-CHICAGO, V12, P949, DOI 10.1001/archsurg.1926.01130050003001; Dandy WE, 1944, ARCH SURG-CHICAGO, V49, P75, DOI 10.1001/archsurg.1944.01230020080001; Gissane W, 1940, BRIT J SURG, V27, P717, DOI 10.1002/bjs.18002710811; JEFFERSON A, 1972, BRIT J SURG, V59, P585, DOI 10.1002/bjs.1800590802; JENNETT WB, 1970, INTRO NEUROSURGERY; Lewin W, 1964, Clin Neurosurg, V12, P237; LEWIN W, 1954, BRIT J SURG, V42, P1, DOI 10.1002/bjs.18004217102; LEWIN W, 1951, BRIT MED J, V1, P1, DOI 10.1136/bmj.1.4696.1; LIST C, 1944, J NEUROSURG, V1, P348; MACGEE EE, 1970, J NEUROSURG, V33, P312, DOI 10.3171/jns.1970.33.3.0312; MCKENZIE P, 1967, POSTGRAD MED J, VS 43, P142; MINCY JE, 1966, J TRAUM, V6, P618, DOI 10.1097/00005373-196609000-00007; MORLEY TP, 1957, SURG GYNECOL OBSTET, V104, P88; NORTH JB, 1971, BRIT J SURG, V58, P826, DOI 10.1002/bjs.1800581106; NORTH JB, 1972, LANCET, V1, P598; POTTER JM, 1964, PRACTICAL MANAGEMENT; RASKIND R, 1965, J Int Coll Surg, V43, P141; Raskind R, 1966, Int Surg, V46, P223; TAYLOR J, 1934, T OPHTHAL SOC UK, V54, P312; 1972, LANCET, V1, P134	26	87	90	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet		1973	1	7811					1013	1015					3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P6495	WOS:A1973P649500001	4122107				2022-02-06	
J	Patel, NA; Moss, LD; Lee, JY; Tajiri, N; Acosta, S; Hudson, C; Parag, S; Cooper, DR; Borlongan, CV; Bickford, PC				Patel, Niketa A.; Moss, Lauren Daly; Lee, Jea-Young; Tajiri, Naoki; Acosta, Sandra; Hudson, Charles; Parag, Sajan; Cooper, Denise R.; Borlongan, Cesario V.; Bickford, Paula C.			Long noncoding RNA MALAT1 in exosomes drives regenerative function and modulates inflammation-linked networks following traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article							CELL-PROLIFERATION; STROMAL CELLS; NEUROVASCULAR PLASTICITY; COGNITIVE IMPAIRMENTS; SPLENIC MACROPHAGES; 17-BETA-ESTRADIOL; SNORNA; EXPRESSION; MIGRATION; BARRIER	Background: Neuroinflammation is a common therapeutic target for traumatic brain injury (TBI) due to its contribution to delayed secondary cell death and has the potential to occur for years after the initial insult. Exosomes from adipose-derived stem cells (hASCs) containing the long noncoding RNA MALAT1 are a novel, cellfree regenerative approach to long-term recovery after traumatic brain injury (TBI) that have the potential to modulate inflammation at the genomic level. The long noncoding RNA MALAT1 has been shown to be an important component of the secretome of hASCs. Methods: We isolated exosomes from hASC containing or depleted of MALAT1. The hASC-derived exosomes were then administered intravenously to rats following a mild controlled cortical impact (CCI). We followed the rats with behavior, in vivo imaging, histology, and RNA sequencing (RNA Seq). Results: Using in vivo imaging, we show that exosomes migrate into the spleen within 1 h following administration and enter the brain several hours later following TBI. Significant recovery of function on motor behavior as well as a reduction in cortical brain injury was observed after TBI in rats treated with exosomes. Treatment with either exosomes depleted of MALAT1 or conditioned media depleted of exosomes showed limited regenerative effects, demonstrating the importance of MALAT1 in exosome-mediated recovery. Analysis of the brain and spleen transcriptome using RNA Seq showed MALAT1-dependent modulation of inflammation-related pathways, cell cycle, cell death, and regenerative molecular pathways. Importantly, our data demonstrates that MALAT1 regulates expression of other noncoding RNAs including snoRNAs. Conclusion: We demonstrate that MALAT1 in hASC-derived exosomes modulates multiple therapeutic targets, including inflammation, and has tremendous therapeutic potential for treatment of TBI.	[Patel, Niketa A.; Hudson, Charles; Cooper, Denise R.; Bickford, Paula C.] James A Haley Vet Hosp, Res Serv, Tampa, FL 33612 USA; [Patel, Niketa A.; Parag, Sajan; Cooper, Denise R.] Univ S Florida, Morsani Coll Med, Dept Mol Med, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA; [Moss, Lauren Daly; Lee, Jea-Young; Tajiri, Naoki; Acosta, Sandra; Borlongan, Cesario V.; Bickford, Paula C.] Univ S Florida, Morsani Coll Med, Dept Neurosurg & Brain Repair, Tampa, FL 33612 USA; [Tajiri, Naoki] Nagoya City Univ, Dept Neurophysiol & Brain Sci, Grad Sch Med Sci, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan; [Tajiri, Naoki] Nagoya City Univ, Sch Med, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan; [Borlongan, Cesario V.; Bickford, Paula C.] USF Hlth Ctr Excellence Aging & Brain Repair MDC, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA		Patel, NA; Bickford, PC (corresponding author), James A Haley Vet Hosp, Res Serv, Tampa, FL 33612 USA.; Borlongan, CV; Bickford, PC (corresponding author), Univ S Florida, Morsani Coll Med, Dept Neurosurg & Brain Repair, Tampa, FL 33612 USA.	Niketa.Patel@va.gov; pbickfor@health.usf.edu	Tajiri, Naoki/K-1230-2012; Bickford, Paula/J-5970-2012	Tajiri, Naoki/0000-0003-2189-662X; Patel, Niketa A./0000-0003-4811-8596; Bickford, Paula/0000-0001-9657-7725	USF; VAMR grant [I01BX003421, 821-MR-EN-20606]; Veterans AffairsUS Department of Veterans Affairs [I01BX003836, I01BX003421] Funding Source: NIH RePORTER	This work was supported by a grant from USF to PCB and CB and VAMR grant I01BX003421 to PCB and VAMR grant 821-MR-EN-20606 to NAP.	ACOSTA SA, 2013, PLOS ONE, V8; Aiello A, 2016, SCI REP-UK, V6, DOI 10.1038/srep38414; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bazeley PS, 2008, GENE, V408, P172, DOI 10.1016/j.gene.2007.10.037; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; BORLONGAN CV, 1995, J NEUROSCI, V15, P5372; Borlongan CV, 1998, NEUROREPORT, V9, P3615, DOI 10.1097/00001756-199811160-00012; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Chaudhry MA, 2014, CANCER BIOTHER RADIO, V29, P135, DOI 10.1089/cbr.2013.1574; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2001, DOI 10.1089/neu.2013.3047; de Turris V, 2004, J MOL BIOL, V344, P383, DOI 10.1016/j.jmb.2004.09.049; Du ZW, 2013, DEVELOPMENT, V140, P2611, DOI 10.1242/dev.092809; El Bassit G, 2017, ENDOCRINOLOGY, V158, P183, DOI 10.1210/en.2016-1819; Fang DF, 2015, BIOCHEM BIOPH RES CO, V457, P500, DOI 10.1016/j.bbrc.2014.12.114; Fendler A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080807; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Guo Y, 2012, ONCOL LETT, V4, P561, DOI 10.3892/ol.2012.775; Gupta A, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-68; Hildebrand F, 2006, J LEUKOCYTE BIOL, V79, P1173, DOI 10.1189/jlb.0106029; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kawasaki T, 2008, MOL IMMUNOL, V45, P376, DOI 10.1016/j.molimm.2007.06.148; Kim DK, 2016, P NATL ACAD SCI USA, V113, P170, DOI 10.1073/pnas.1522297113; Kishore S, 2006, SCIENCE, V311, P230, DOI 10.1126/science.1118265; Kishore S, 2006, COLD SPRING HARB SYM, V71, P329, DOI 10.1101/sqb.2006.71.024; Kishore S, 2010, HUM MOL GENET, V19, P1153, DOI 10.1093/hmg/ddp585; Konda N, 2017, HISTOCHEM CELL BIOL, V147, P317, DOI 10.1007/s00418-016-1494-8; Leo P, 2016, TRANSLATIONAL RES TR; Levin H, 2013, LANCET NEUROL, V12, P15, DOI 10.1016/S1474-4422(12)70300-9; Lewis A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173664; Li HP, 2013, CARCINOGENESIS, V34, P2443, DOI 10.1093/carcin/bgt206; Lund AH, 2010, CELL DEATH DIFFER, V17, P209, DOI 10.1038/cdd.2009.58; Magenta A, 2017, CIRC RES, V120, P1399, DOI 10.1161/CIRCRESAHA.116.310274; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Majer A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169081; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Patel Rekha S, 2016, Stem Cell Investig, V3, P2, DOI 10.3978/j.issn.2306-9759.2016.01.02; Qin XY, 2014, INT J CLIN EXP PATHO, V7, P3065; Saiwai H, 2013, J NEUROCHEM, V125, P74, DOI 10.1111/jnc.12135; Schmidt LH, 2014, J THORAC ONCOL, V9, P1294, DOI 10.1097/JTO.0000000000000243; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Stewart IB, 2002, SPORTS MED, V32, P361, DOI 10.2165/00007256-200232060-00002; Suzuki T, 2007, AM J PHYSIOL-CELL PH, V293, pC978, DOI 10.1152/ajpcell.00092.2007; Swirski FK, 2009, SCIENCE, V325, P612, DOI 10.1126/science.1175202; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Tian Y, 2012, INT J ONCOL, V40, P1105, DOI 10.3892/ijo.2011.1306; Ting MJ, 2010, EXP HEMATOL, V38, P1087, DOI 10.1016/j.exphem.2010.07.007; Vendrame M, 2005, STEM CELLS DEV, V14, P595, DOI 10.1089/scd.2005.14.595; Vlassov AV, 2012, BBA-GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017; Walker PA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-228; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Xin HQ, 2013, J CEREBR BLOOD F MET, V33, P1711, DOI 10.1038/jcbfm.2013.152; Xu XM, 2012, ONCOL LETT, V4, P339, DOI 10.3892/ol.2012.714; Zeng Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep12098; Zhang XJ, 2017, J NEUROSCI, V37, P1797, DOI 10.1523/JNEUROSCI.3389-16.2017; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhao Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109782; Zhao ZY, 2014, BIOCHEM BIOPH RES CO, V445, P388, DOI 10.1016/j.bbrc.2014.02.006; Zhu MJ, 2014, FEBS J, V281, P3766, DOI 10.1111/febs.12902; Zhu W, 2012, CANCER CHEMOTH PHARM, V69, P723, DOI 10.1007/s00280-011-1752-3	64	86	92	1	12	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	JUL 12	2018	15								204	10.1186/s12974-018-1240-3			23	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	GM9BC	WOS:000438535100001	30001722	Green Published, gold			2022-02-06	
J	Otero-Ortega, L; de Frutos, MCG; Laso-Garcia, F; Rodriguez-Frutos, B; Medina-Gutierrez, E; Lopez, JA; Vazquez, J; Diez-Tejedor, E; Gutierrez-Fernandez, M				Otero-Ortega, Laura; Gomez de Frutos, Mari Carmen; Laso-Garcia, Fernando; Rodriguez-Frutos, Berta; Medina-Gutierrez, Esperanza; Antonio Lopez, Juan; Vazquez, Jesus; Diez-Tejedor, Exuperio; Gutierrez-Fernandez, Maria			Exosomes promote restoration after an experimental animal model of intracerebral hemorrhage	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Brain repair; exosome; intracerebral hemorrhage; subcortical stroke; white matter injury	MESENCHYMAL STROMAL CELLS; SUBCORTICAL ISCHEMIC-STROKE; TRAUMATIC BRAIN-INJURY; WHITE-MATTER; NEUROVASCULAR PLASTICITY; FUNCTIONAL RECOVERY; THERAPY; DAMAGE; RATS	Exosomes are gaining importance because they show great promise in therapeutic applications for several diseases. Particularly in stroke, exosomes derived from mesenchymal stem cell (MSC) therapy work as paracrine effectors responsible for promoting neurovascular remodeling and functional recovery. Adult male rats were subjected to intracerebral hemorrhage (ICH) by intrastriatal injection of collagenase type IV; 24 h after surgery, MSC-derived exosomes were administered through the tail vein. The rats were euthanized at 7 or 28 days after treatment. Functional evaluation, lesion size, fiber tract integrity, axonal sprouting and white matter repair markers, biodistribution of exosomes and secretome proteomics were analyzed. DiI-labeled exosomes were found in the brains of the ICH-treated group and in the liver, lung and spleen. Animals receiving treatment with exosomes showed significantly better results in terms of functional recovery, lesion size, fiber tract integrity, axonal sprouting and white matter repair markers compared with the control group 28 days after stroke. Proteomics analysis of the exosomes identified more than 2000 proteins that could be implicated in brain repair function. In conclusion, white matter integrity was partly restored by exosome administration mediated by molecular repair factors. Exosomes as a treatment could be a heterogeneous process by nature and presents many factors that can influence brain plasticity in an adaptable and versatile manner.	[Otero-Ortega, Laura; Gomez de Frutos, Mari Carmen; Laso-Garcia, Fernando; Rodriguez-Frutos, Berta; Medina-Gutierrez, Esperanza; Diez-Tejedor, Exuperio; Gutierrez-Fernandez, Maria] Autonomous Univ Madrid, La Paz Univ Hosp, IdiPAZ Hlth Res Inst, Dept Neurol,Neurosci Area, Madrid, Spain; [Otero-Ortega, Laura; Gomez de Frutos, Mari Carmen; Laso-Garcia, Fernando; Rodriguez-Frutos, Berta; Medina-Gutierrez, Esperanza; Diez-Tejedor, Exuperio; Gutierrez-Fernandez, Maria] Autonomous Univ Madrid, La Paz Univ Hosp, IdiPAZ Hlth Res Inst, Neurosci & Cerebrovasc Res Lab,Stroke Ctr,Neurosc, Madrid, Spain; [Antonio Lopez, Juan; Vazquez, Jesus] CNIC, Natl Ctr Cardiovasc Res, Cardiovasc Prote Lab, Madrid, Spain; [Antonio Lopez, Juan; Vazquez, Jesus] CNIC, Natl Ctr Cardiovasc Res, Prote Unit, Madrid, Spain		Diez-Tejedor, E; Gutierrez-Fernandez, M (corresponding author), Univ Autonoma Madrid, Dept Neurol & Stroke, Neurosci & Cerebrovasc Res Lab, La Paz Univ Hosp,IdiPAZ Hlth Res Inst, Paseo Castellana 261, Madrid 28046, Spain.	exuperio.diez@salud.madrid.org; mgutierrezfernandez@salud.madrid.org	Vazquez, Jesus/B-7697-2015; Lopez, Juan Antonio/G-7750-2015; Laso Garcia, Fernando/F-2259-2018	Vazquez, Jesus/0000-0003-1461-5092; Lopez, Juan Antonio/0000-0002-9097-6060; Laso Garcia, Fernando/0000-0002-5481-0514; Otero Ortega, Laura/0000-0001-8765-6341	Spanish Neurovascular Network [PS15/01318, INVICTUS (RD12/0014)]; Research Institute Carlos III [CD12/00706]; Spanish Ministry of Science and InnovationSpanish Government; European Regional Development FundEuropean Commission; Roche Farma project	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study has been partially supported by grants from PS15/01318 and INVICTUS (RD12/0014) (Spanish Neurovascular Network), Miguel Servet (CP15/00069 to Maria Gutierrez-Fernandez) and a Sara Borrell postdoctoral fellowship (CD12/00706, to Laura Otero-Ortega) from the Research Institute Carlos III, the Spanish Ministry of Science and Innovation and the European Regional Development Fund. This study was also co-funded within the Roche Farma project. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Back SA, 2007, STROKE, V38, P724, DOI 10.1161/01.STR.0000254729.27386.05; Baracskay KL, 2007, GLIA, V55, P1001, DOI 10.1002/glia.20519; Barratt HE, 2014, J CEREBR BLOOD F MET, V34, P1463, DOI 10.1038/jcbfm.2014.107; Doeppner TR, 2015, STEM CELL TRANSL MED, V4, P1131, DOI 10.5966/sctm.2015-0078; Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Gatti S, 2011, NEPHROL DIAL TRANSPL, V26, P1474, DOI 10.1093/ndt/gfr015; Gutierrez-Fernandez M, 2011, NEUROSCIENCE, V175, P394, DOI 10.1016/j.neuroscience.2010.11.054; Kanazawa H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019195; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI [10.1111/j.1476-5381.2010.00872.x, 10.1113/jphysiol.2010.192278]; Kumar D, 2015, ONCOTARGET, V6, P3280, DOI 10.18632/oncotarget.2462; Lai RC, 2010, STEM CELL RES, V4, P214, DOI 10.1016/j.scr.2009.12.003; Lee C, 2012, CIRCULATION, V126, P2601, DOI 10.1161/CIRCULATIONAHA.112.114173; Manaenko A, 2011, ACTA NEUROCHIR SUPPL, V111, P9, DOI 10.1007/978-3-7091-0693-8_2; Matute C, 2013, STROKE, V44, P1204, DOI 10.1161/STROKEAHA.112.658328; Navarro P, 2014, J PROTEOME RES, V13, P1234, DOI 10.1021/pr4006958; Otero L, 2010, HISTOL HISTOPATHOL, V25, P453, DOI 10.14670/HH-25.453; Otero L, 2012, CYTOTHERAPY, V14, P34, DOI 10.3109/14653249.2011.608349; Otero L, 2011, CYTOTHERAPY, V13, P562, DOI 10.3109/14653249.2010.544720; Otero-Ortega L, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0111-4; Paschon V, 2016, MOL NEUROBIOL, V53, P2016, DOI 10.1007/s12035-015-9142-1; Ramos-Cejudo J, 2015, STROKE, V46, P221, DOI 10.1161/STROKEAHA.114.006692; Rodriguez-Frutos B, 2016, BIOMATERIALS, V100, P41, DOI 10.1016/j.biomaterials.2016.05.028; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; Sozmen EG, 2009, J NEUROSCI METH, V180, P261, DOI 10.1016/j.jneumeth.2009.03.017; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]; Xin HQ, 2013, STEM CELLS, V31, P2737, DOI 10.1002/stem.1409; Xin HQ, 2013, J CEREBR BLOOD F MET, V33, P1711, DOI 10.1038/jcbfm.2013.152; Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129; Zhang RL, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00201; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhang ZG, 2016, J CLIN INVEST, V126, P1190, DOI 10.1172/JCI81133	35	86	90	2	61	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2018	38	5					767	779		10.1177/0271678X17708917			13	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	GF6ND	WOS:000432083300003	28524762	Green Published, Green Submitted			2022-02-06	
J	Barkhoudarian, G; Hovda, DA; Giza, CC				Barkhoudarian, Garni; Hovda, David A.; Giza, Christopher C.			The Molecular Pathophysiology of Concussive Brain Injury - an Update	PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA			English	Article						Concussion; Traumatic brain injury; Pathophysiology; Molecular mechanisms	CHRONIC TRAUMATIC ENCEPHALOPATHY; FLUID PERCUSSION INJURY; LONG-TERM POTENTIATION; CORTICAL IMPACT INJURY; REPETITIVE HEAD-INJURY; TEMPORAL WINDOW; MITOCHONDRIAL DYSFUNCTION; RECURRENT CONCUSSION; COGNITIVE IMPAIRMENT; GLUCOSE-UTILIZATION	Concussion, or mild traumatic brain injury (TBI), affects millions of patients worldwide. Understanding the pathophysiology of TBI can help manage its repercussions. The brain is significantly altered immediately following mild TBI because of metabolic, hemodynamic, structural, and electrophysiologic changes. This process affects cognition and behavior and can leave the brain vulnerable for worse injury in the setting of repeat insult. This article is an update of our previously published review, reporting relevant and current studies from the bench to the bedside of mild TBI. Understanding the pathobiology can help prevent and treat mild TBI.	[Barkhoudarian, Garni] Providence St Johns Hlth Ctr, John Wayne Canc Inst, Pacific Pituitary Disorders Ctr, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA; [Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Injury Res Ctr, Dept Neurosurg,Interdept Program Neurosci,Semel I, Room 18-228A,10833 Le Conte Blvd, Los Angeles, CA 90095 USA; [Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Injury Res Ctr,Semel Inst, Interdept Program Neurosci,Dept Med & Mol Pharmac, Room 18-228A,10833 Le Conte Blvd, Los Angeles, CA 90095 USA; [Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Injury Res Ctr,Semel Inst,Mattel Child, Interdept Programs Neurosci & Biomed Engn,Dept Ne, Room 18-218B,10833 Le Conte Blvd, Los Angeles, CA 90095 USA; [Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med,Dept Pediat, UCLA Brain Injury Res Ctr,Semel Inst,Mattel Child, Interdept Programs Neurosci & Biomed Engn,Div Ped, Room 18-218B,10833 Le Conte Blvd, Los Angeles, CA 90095 USA		Barkhoudarian, G (corresponding author), Providence St Johns Hlth Ctr, John Wayne Canc Inst, Pacific Pituitary Disorders Ctr, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.	barkhoudariang@jwci.org					Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Arun P, 2010, J NEUROTRAUM, V27, P293, DOI 10.1089/neu.2009.0994; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bouzat P, 2014, INTENS CARE MED, V40, P412, DOI 10.1007/s00134-013-3203-6; Byrnes Kimberly R, 2014, Front Neuroenergetics, V5, P13, DOI 10.3389/fnene.2013.00013; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2010, J NEUROTRAUM, V27, P1557, DOI 10.1089/neu.2010.1334; Ceballos R, 1966, Ala J Med Sci, V3, P185; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Dennis EL, 2015, J NEUROSCI, V35, P10202, DOI 10.1523/JNEUROSCI.1595-15.2015; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; DiFiori JP, 2010, CURR SPORT MED REP, V9, P35, DOI 10.1249/JSR.0b013e3181caba67; Ellis M. U., 2015, J NEUROTRAUMA; Fabricius M, 2008, CLIN NEUROPHYSIOL, V119, P1973, DOI 10.1016/j.clinph.2008.05.025; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Gardner A, 2014, J NEUROTRAUM, V31, P1, DOI 10.1089/neu.2013.3079; Genis L, 2000, J NEUROSCI RES, V60, P559, DOI 10.1002/(SICI)1097-4547(20000515)60:4<559::AID-JNR15>3.0.CO;2-K; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Greco T, 2013, J NEUROTRAUM, V30, P1983, DOI 10.1089/neu.2013.2990; Gurkoff GG, 2009, NEUROSCIENCE, V164, P862, DOI 10.1016/j.neuroscience.2009.08.021; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hartings JA, 2009, J NEUROTRAUM, V26, P1857, DOI [10.1089/neu.2009.0961, 10.1089/neu.2009-0961]; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Henninger N, 2007, CRIT CARE MED, V35, P2607, DOI 10.1097/01.CCM.0000286395.79654.8D; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hoshino S, 1998, NEUROREPORT, V9, P1879, DOI 10.1097/00001756-199806010-00039; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Immonen R, 2010, J CEREBR BLOOD F MET, V30, P1318, DOI 10.1038/jcbfm.2010.15; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; JOHNSON GVW, 1991, NEUROCHEM RES, V16, P869, DOI 10.1007/BF00965535; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kalimo H, 1981, Acta Neuropathol Suppl, V7, P20; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kelly DF, 2014, J NEUROTRAUM, V31, P1161, DOI 10.1089/neu.2013.3212; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; Kissick J, 2005, CLIN J SPORT MED, V15, P426, DOI 10.1097/01.jsm.0000186683.59158.8b; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; KUBOTA M, 1989, Neurosurgical Review, V12, P393, DOI 10.1007/BF01790681; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; LEAO AAP, 1947, J NEUROPHYSIOL, V10, P409, DOI 10.1152/jn.1947.10.6.409; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Liu LD, 2004, SCIENCE, V304, P1021, DOI 10.1126/science.1096615; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 2007, NEUROSURGERY, V61, P359; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Magistretti PJ, 1999, PHILOS T R SOC B, V354, P1155, DOI 10.1098/rstb.1999.0471; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MATA M, 1986, J NEUROBIOL, V17, P449, DOI 10.1002/neu.480170508; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mori T, 2006, ACTA NEUROCHIR SUPPL, V96, P40; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; NAKAMURA Y, 1990, BIOCHEM BIOPH RES CO, V169, P744, DOI 10.1016/0006-291X(90)90394-3; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; NIXON RA, 1993, BRAIN PATHOL, V3, P29, DOI 10.1111/j.1750-3639.1993.tb00723.x; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Pardini JE, 2010, NEUROSURGERY, V67, P1020, DOI 10.1227/NEU.0b013e3181ee33e2; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Povlishock JT, 1996, ACT NEUR S, V66, P81; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Prins ML, 2009, J NEUROTRAUM, V26, P1083, DOI 10.1089/neu.2008-0769; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Provenzano FA, 2010, NUCL MED COMMUN, V31, P952, DOI 10.1097/MNM.0b013e32833e37c4; Putukian Margot, 2006, Curr Sports Med Rep, V5, P15; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Schrader Harald, 2009, BMC Med Imaging, V9, P11, DOI 10.1186/1471-2342-9-11; Schurr A, 2007, NEUROSCIENCE, V147, P613, DOI 10.1016/j.neuroscience.2007.05.002; Schurr A, 2012, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00096; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Signoretti S, 2010, MOL CELL BIOCHEM, V333, P269, DOI 10.1007/s11010-009-0228-9; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; SOMJEN GG, 1985, J NEUROPHYSIOL, V53, P1098, DOI 10.1152/jn.1985.53.4.1098; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; STERNBERGER NH, 1983, ANN NY ACAD SCI, V420, P90, DOI 10.1111/j.1749-6632.1983.tb22192.x; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; Tang YP, 2001, NEUROPHARMACOLOGY, V41, P779, DOI 10.1016/S0028-3908(01)00122-8; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Tremblay S, 2014, CLIN NEUROPHYSIOL, V125, P1371, DOI 10.1016/j.clinph.2013.11.040; Tsacopoulos M, 1996, J NEUROSCI, V16, P877; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; VAGNOZZI R, 2007, NEUROSURGERY, V61, P388, DOI DOI 10.1227/01.NEU.0000280002.41696; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Ware J., 2001, SF 36 PHYS MENTAL HL; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhang L, 2006, AM J NEURORADIOL, V27, P2000	158	86	87	1	50	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1047-9651	1558-1381		PHYS MED REH CLIN N	Phys. Med. Rehabil. Clin. N. Am.	MAY	2016	27	2					373	+		10.1016/j.pmr.2016.01.003			22	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation	DN4RU	WOS:000377055700003	27154851				2022-02-06	
J	Di Battista, AP; Rhind, SG; Hutchison, MG; Hassan, S; Shiu, MY; Inaba, K; Topolovec-Vranic, J; Neto, AC; Rizoli, SB; Baker, AJ				Di Battista, Alex P.; Rhind, Shawn G.; Hutchison, Michael G.; Hassan, Syed; Shiu, Maria Y.; Inaba, Kenji; Topolovec-Vranic, Jane; Neto, Antonio Capone; Rizoli, Sandro B.; Baker, Andrew J.			Inflammatory cytokine and chemokine profiles are associated with patient outcome and the hyperadrenergic state following acute brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Catecholamines; Traumatic brain injury; Systemic inflammation; Sympathetic nervous system activation; Epinephrine; Norepinephrine; IL-10; IL-1 beta	SYSTEMIC INTERLEUKIN-10 RELEASE; SYMPATHETIC-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; ACUTE-PHASE RESPONSE; SEVERE HEAD-INJURY; LEUKOCYTE MOBILIZATION; CEREBROSPINAL-FLUID; SERUM; CATECHOLAMINES; ACTIVATION	Background: Traumatic brain injury (TBI) elicits intense sympathetic nervous system (SNS) activation with profuse catecholamine secretion. The resultant hyperadrenergic state is linked to immunomodulation both within the brain and systemically. Dysregulated inflammation post-TBI exacerbates secondary brain injury and contributes to unfavorable patient outcomes including death. The aim of this study was to characterize the early dynamic profile of circulating inflammatory cytokines/chemokines in patients admitted for moderate-to-severe TBI, to examine interrelationships between these mediators and catecholamines, as well as clinical indices of injury severity and neurological outcome. Methods: Blood was sampled from 166 isolated TBI patients (aged 45 +/- 20.3 years; 74.7 % male) on admission, 6-, 12-, and 24-h post-injury and from healthy controls (N = 21). Plasma cytokine [interleukin (IL)-1 beta, -2, -4, -5, -10, -12p70, -13, tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma] and chemokine [IL-8, eotaxin, eotaxin-3, IFN-gamma-induced protein (IP)-10, monocyte chemoattractant protein (MCP)-1, -4, macrophage-derived chemokine (MDC), macrophage inflammatory protein (MIP)-1 beta, thymus activation regulated chemokine (TARC)] concentrations were analyzed using high-sensitivity electrochemiluminescence multiplex immunoassays. Plasma catecholamines [epinephrine (Epi), norepinephrine (NE)] were measured by immunoassay. Neurological outcome at 6 months was assessed using the extended Glasgow outcome scale (GOSE) dichotomized as good (>4) or poor (<= 4) outcomes. Results: Patients showed altered levels of IL-10 and all chemokines assayed relative to controls. Significant differences in a number of markers were evident between moderate and severe TBI cohorts. Elevated IL-8, IL-10, and TNF-alpha, as well as alterations in 8 of 9 chemokines, were associated with poor outcome at 6 months. Notably, a positive association was found between Epi and IL-1 beta, IL-10, Eotaxin, IL-8, and MCP-1. NE was positively associated with IL-1 beta, IL-10, TNF-alpha, eotaxin, IL-8, IP-10, and MCP-1. Conclusions: Our results provide further evidence that exaggerated SNS activation acutely after isolated TBI in humans may contribute to harmful peripheral inflammatory cytokine/chemokine dysregulation. These findings are consistent with a potentially beneficial role for therapies aimed at modulating the inflammatory response and hyperadrenergic state acutely post-injury.	[Di Battista, Alex P.; Rhind, Shawn G.; Hassan, Syed; Shiu, Maria Y.] Def Res & Dev Canada, Toronto Res Ctr, Toronto, ON, Canada; [Di Battista, Alex P.; Hassan, Syed; Baker, Andrew J.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Rhind, Shawn G.; Hutchison, Michael G.; Shiu, Maria Y.] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Hutchison, Michael G.; Topolovec-Vranic, Jane; Rizoli, Sandro B.; Baker, Andrew J.] St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, 30 Bond St, Toronto, ON M5B 1W8, Canada; [Inaba, Kenji] Univ So Calif, Div Trauma & Crit Care, Los Angeles, CA USA; [Inaba, Kenji] LA Cty USC Med Ctr, Los Angeles, CA USA; [Rizoli, Sandro B.; Baker, Andrew J.] Univ Toronto, St Michaels Hosp, Dept Crit Care, Toronto, ON, Canada; [Rizoli, Sandro B.; Baker, Andrew J.] Univ Toronto, St Michaels Hosp, Dept Anesthesia, Toronto, ON, Canada; [Rizoli, Sandro B.; Baker, Andrew J.] Univ Toronto, St Michaels Hosp, Dept Surg, Toronto, ON, Canada; [Neto, Antonio Capone] IHI, Cambridge, MA USA		Di Battista, AP (corresponding author), Def Res & Dev Canada, Toronto Res Ctr, Toronto, ON, Canada.; Di Battista, AP (corresponding author), Univ Toronto, Inst Med Sci, Toronto, ON, Canada.	dibattista.alex@gmail.com	INABA, KENJI/AAC-8532-2020; Topolovec-Vranic, Jane/A-5293-2013	Topolovec-Vranic, Jane/0000-0001-7695-4212; Rhind, Shawn/0000-0003-2300-0620; Di Battista, Alex/0000-0002-3325-6833	Physicians' Services Incorporated Foundation; Defence Research and Development Canada Technology Investment Fund Programme; Canadian Armed Forces (CAF) Surgeon General's Health Research Program	The authors gratefully acknowledge the assistance of Sandy Trpcic, Yangmei Li, Marlene Santos, Ingrid Smith, and Martin Chapman. This research was funded by the Physicians' Services Incorporated Foundation and Defence Research and Development Canada Technology Investment Fund Programme. This study was approved by the Canadian Armed Forces (CAF) Surgeon General's Health Research Program. In accordance with the Department of National Defence (DND) policy, the paper was reviewed and approved for submission without modification by the DRDC Publications Office.	Anthony DC, 2014, EXP NEUROL, V258, P105, DOI 10.1016/j.expneurol.2014.03.013; Bergold PJ, 2016, EXP NEUROL, V275, P367, DOI 10.1016/j.expneurol.2015.05.024; Bierhaus A, 2003, P NATL ACAD SCI USA, V100, P1920, DOI 10.1073/pnas.0438019100; Ferreira LCB, 2014, BRAIN INJURY, V28, P1311, DOI 10.3109/02699052.2014.916818; Buonora JE, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00068; Campbell SJ, 2007, J NEUROCHEM, V103, P2245, DOI 10.1111/j.1471-4159.2007.04928.x; Campbell SJ, 2003, FASEB J, V17, P1168, DOI 10.1096/fj.02-0757fje; Campbell SJ, 2005, AM J PATHOL, V166, P1487, DOI 10.1016/S0002-9440(10)62365-6; Campbell SJ, 2002, J NEUROCHEM, V83, P432, DOI 10.1046/j.1471-4159.2002.01166.x; Catania A, 2009, BRAIN BEHAV IMMUN, V23, P877, DOI 10.1016/j.bbi.2009.04.006; Chen TJ, 2016, CLIN CHIM ACTA, V454, P6, DOI 10.1016/j.cca.2015.12.033; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Chu WH, 2013, J TRAUMA ACUTE CARE, V74, P1446, DOI 10.1097/TA.0b013e31829246ad; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; Da Luz LT, 2015, CAN J SURG, V18, pS7; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; Di Battista AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00110; Dziurdzik P, 2004, INFLAMM RES, V53, P338, DOI 10.1007/s00011-004-1265-1; Gentile LF, 2012, J TRAUMA ACUTE CARE, V72, P1491, DOI 10.1097/TA.0b013e318256e000; Giles JA, 2015, EUR J IMMUNOL, V45, P525, DOI 10.1002/eji.201444748; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Gopcevic A, 2007, TOHOKU J EXP MED, V211, P387, DOI 10.1620/tjem.211.387; Grund B, 2010, CURR OPIN HIV AIDS, V5, P473, DOI 10.1097/COH.0b013e32833ed742; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Hensler T, 2000, INFLAMM RES, V49, P524, DOI 10.1007/s000110050626; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; Jaerve A, 2012, CELL TISSUE RES, V349, P229, DOI 10.1007/s00441-012-1427-3; Kavelaars A, 1997, J NEUROIMMUNOL, V77, P211, DOI 10.1016/S0165-5728(97)00076-3; Kenney MJ, 2002, AM J PHYSIOL-HEART C, V283, pH501, DOI 10.1152/ajpheart.00181.2002; Kumar RG, 2015, J HEAD TRAUMA REHAB, V30, P369, DOI 10.1097/HTR.0000000000000067; Kushi H, 2003, ACTA NEUROCHIR SUPPL, V86, P347; Ley EJ, 2012, J TRAUMA ACUTE CARE, V73, P33, DOI 10.1097/TA.0b013e31825a769b; Li M, 2011, J TRAUMA, V71, P141, DOI [10.1097/TA.0b013e3181f30fc9, 10.1088/1742-5468/2011/12/P12001]; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Osuchowski MF, 2006, J IMMUNOL, V177, P1967, DOI 10.4049/jimmunol.177.3.1967; QUATTROCCHI K B, 1990, Journal of Neurotrauma, V7, P77, DOI 10.1089/neu.1990.7.77; Rhodes J, 2009, J TRAUMA, V66, P1591, DOI 10.1097/TA.0b013e31819a0344; Rizoli SB, 2006, ANN SURG, V243, P47, DOI 10.1097/01.sla.0000193608.93127.b1; Rough J, 2009, SURGERY, V145, P235, DOI 10.1016/j.surg.2008.09.013; Saindon CS, 2001, AUTON NEUROSCI-BASIC, V87, P243, DOI 10.1016/S1566-0702(00)00280-0; Santarsieri M, 2015, BRAIN BEHAV IMMUN, V45, P15, DOI 10.1016/j.bbi.2014.09.003; Soares FMS, 2012, NEUROIMMUNOMODULAT, V19, P377, DOI 10.1159/000342141; Schroeppel TJ, 2014, J TRAUMA ACUTE CARE, V76, P504, DOI 10.1097/TA.0000000000000104; Schroeppel TJ, 2010, J TRAUMA, V69, P776, DOI 10.1097/TA.0b013e3181e981b8; Shimonkevitz R, 1999, SHOCK, V12, P10, DOI 10.1097/00024382-199907000-00002; Sohrevardi SM, 2013, TURK NEUROSURG, V23, P151, DOI 10.5137/1019-5149.JTN.5858-12.2; Stein DM, 2011, J TRAUMA, V70, P1096, DOI 10.1097/TA.0b013e318216930d; Takahashi H, 2004, BURNS, V30, P317, DOI 10.1016/j.burns.2003.12.005; Tasci A, 2003, NEUROL RES, V25, P871, DOI 10.1179/016164103771953998; vanderPoll T, 1997, INFECT IMMUN, V65, P2378, DOI 10.1128/IAI.65.6.2378-2381.1997; vanderPoll T, 1996, J CLIN INVEST, V97, P713, DOI 10.1172/JCI118469; Venetsanou K, 2007, EUR CYTOKINE NETW, V18, P206, DOI 10.1684/ecn.2007.0112; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Woiciechowsky C, 1999, NEUROBIOL DIS, V6, P200, DOI 10.1006/nbdi.1999.0242; Woiciechowsky C, 2005, ACTA NEUROCHIR S, V95, P373; Wolach B, 2001, J NEUROSURG, V94, P706, DOI 10.3171/jns.2001.94.5.0706; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; WOOLF PD, 1988, AM J PHYSIOL, V254, pE287, DOI 10.1152/ajpendo.1988.254.3.E287; Xu L, 2015, MED SCI MONITOR, V21, P468, DOI 10.12659/MSM.893544	67	86	87	1	12	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	FEB 16	2016	13								40	10.1186/s12974-016-0500-3			14	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	DD9JU	WOS:000370242300001	26883121	gold, Green Published			2022-02-06	
J	Meier, TB; Brummel, BJ; Singh, R; Nerio, CJ; Polanski, DW; Bellgowan, PSF				Meier, Timothy B.; Brummel, Bradley J.; Singh, Rashmi; Nerio, Christopher J.; Polanski, David W.; Bellgowan, Patrick S. F.			The underreporting of self-reported symptoms following sports-related concussion	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Mild traumatic brain injury; Post-concussion symptoms; Neuropsychological testing	STRUCTURED INTERVIEW GUIDE; TRAUMATIC BRAIN-INJURY; RATING-SCALE; DEPRESSION; RELIABILITY; PERFORMANCE; VALIDITY; RATES	Objectives: This cohort study was conducted to examine patterns of symptom reporting in concussed athletes in two different testing environments. Design: A prospective cohort study was conducted with repeated measures. Methods: Self-reported symptoms collected by team athletic trainers using the ImPACT Post-Concussion Scale (PCS) were compared to symptoms collected in a confidential setting using structured interviews for depression and anxiety. Ratings were scaled-to match scoring of the PCS and categorized into symptom-domains. Scores collected 2 days post-concussion were compared across different rating scales. Confidential self-report scores approximately 9 days,post-concussion in cleared athletes were compared to PCS scores collected during return-to-play decisions. Finally, confidential self-report scores collected 9 days post-concussion were compared between cleared and not cleared athletes. Results: Athletes self-reported significantly fewer symptoms to team athletic trainers using the ImPACT test compared to self-reported symptoms collected in a confidential setting during the acute phase of concussion using standard psychiatric interviews'. Athletes cleared to play continued to underreport symptoms 9 days post-concussion, particularly psychiatric symptoms. Finally, cleared athletes self-reported similar magnitude of symptoms than non-cleared athletes 9 days post-concussion in confidential research setting. Conclusions: The systematic underreporting of post-concussion symptoms may represent motivated behavior or differences in self-reporting data acquisition. By underreporting symptoms, many cleared athletes are still symptomatic over 1-week post-concussion. This study highlights the need for objective measures for somatic and psychiatric symptoms. (C) 2014 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Meier, Timothy B.; Singh, Rashmi; Bellgowan, Patrick S. F.] Laureate Inst Brain Res, Tulsa, OK 74136 USA; [Brummel, Bradley J.] Univ Tulsa, Dept Psychol, Tulsa, OK 74104 USA; [Nerio, Christopher J.; Polanski, David W.] Univ Tulsa, Dept Athlet, Tulsa, OK 74104 USA; [Bellgowan, Patrick S. F.] Univ Tulsa, Fac Community Med, Tulsa, OK 74104 USA		Meier, TB (corresponding author), Laureate Inst Brain Res, Tulsa, OK 74136 USA.	tmeier@laureateinstitute.org			Laureate Institute for Brain Research by William K. Warren Foundation	The authors would like to thank the Laureate Institute for Brain Research psychiatric assessment team for conducting the structured interviews and Dr. Sheldon Preskorn, M.D. for his insight on this project. This research was conducted using internal funds from the Laureate Institute for Brain Research, which is supported by The William K. Warren Foundation.	Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 2013, J PEDIATR-US, V163, P1192, DOI 10.1016/j.jpeds.2013.05.061; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory Paul, 2009, Scand J Med Sci Sports, V19, P452, DOI 10.1111/j.1600-0838.2009.00978.x; Ramanathan DM, 2012, J INT NEUROPSYCH SOC, V18, P101, DOI 10.1017/S1355617711001457; Register F., 1979, PROT HUM SUBJ BELM R, V44, P23192; Shear MK, 2001, DEPRESS ANXIETY, V13, P166, DOI 10.1002/da.1033.abs; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Williams J., 2003, STRUCTURED INTERVIEW; WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	26	86	87	1	27	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	SEP	2015	18	5					507	511		10.1016/j.jsams.2014.07.008			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	CP9AM	WOS:000360186100003	25150463				2022-02-06	
J	Howell, DR; Osternig, LR; Chou, LS				Howell, David R.; Osternig, Louis R.; Chou, Li-Shan			Return to Activity after Concussion Affects Dual-Task Gait Balance Control Recovery	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						SPORT CONCUSSION; GAIT STABILITY; RECOVERY; PHYSICAL ACTIVITY	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; EXECUTIVE FUNCTION; PERFORMANCE; STATEMENT; ATTENTION; PARADIGM; MOTION; LEVEL	Background Recent work has identified deficits in dual-task gait balance control for up to 2 months after adolescent concussion; however, how resumption of preinjury physical activities affects recovery is unknown. Purpose The objective of this study is to examine how return to activity (RTA) affects recovery from concussion on measures of symptom severity, cognition, and balance control during single-task and dual-task walking. Methods Nineteen adolescents with concussion who returned to preinjury activity within 2 months after injury and 19 uninjured, matched controls completed symptom inventories, computerized cognitive testing, and single-task and dual-task gait analyses. Concussion participants were assessed at five time points: within 72 h, 1 wk, 2 wk, 1 month, and 2 months postinjury. Control participants were assessed at the same time points as their matched concussion counterparts. RTA day was documented as the postinjury day in which physical activity participation was allowed. The effect of returning to physical activity was assessed by examining the percent change on each dependent variable across time before and directly after the RTA. Data were analyzed by two-way mixed effects ANOVAs. Results After the RTA day, concussion participants significantly increased their total center-of-mass medial/lateral displacement (P = 0.009, (2)(p) = .175) and peak velocity (P = 0.048, (2)(p) = 0.104) during dual-task walking when compared with pre-RTA data, whereas no changes for the concussion group or between groups were detected on measures of single-task walking, forward movement, or cognition. Conclusions Adolescents with concussion displayed increased center-of-mass medial/lateral displacement and velocity during dual-task walking after RTA, suggesting a regression of recovery in gait balance control. This study reinforces the need for a multifaceted approach to concussion management and continued monitoring beyond the point of clinical recovery.	[Howell, David R.; Osternig, Louis R.; Chou, Li-Shan] Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA		Chou, LS (corresponding author), 1240 Univ Oregon, Dept Human Physiol, 122 Esslinger Hall, Eugene, OR 97403 USA.	chou@uoregon.edu	Meijer, Anna/K-5118-2016	Howell, David/0000-0002-2955-0191	Veterans AdministrationUS Department of Veterans Affairs [A4842C8, A4843C]; Translational Research Award from University of Oregon; Peace Health Oregon Region; Department of Defense-TATRC Award [W81XWH-11-1-0717]	This work was supported by Veterans Administration subcontract awards (A4842C8 and A4843C), Translational Research Award from the University of Oregon and Peace Health Oregon Region, and the Department of Defense-TATRC Award (W81XWH-11-1-0717).	Barr WB, 2012, BRAIN INJURY, V26, P58, DOI 10.3109/02699052.2011.608216; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Dettwiler A, 2014, J NEUROTRAUM, V31, P180, DOI 10.1089/neu.2013.2983; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hahn ME, 2004, J BIOMECH, V37, P837, DOI 10.1016/j.jbiomech.2003.11.010; Hahn ME, 2003, CLIN BIOMECH, V18, P737, DOI 10.1016/S0268-0033(03)00139-6; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Huang L, 2013, BRAIN RES, V1499, P109, DOI 10.1016/j.brainres.2012.12.038; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayr U, 2006, PSYCHON B REV, V13, P794, DOI 10.3758/BF03193999; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Powers KC, 2014, GAIT POSTURE, V39, P611, DOI 10.1016/j.gaitpost.2013.05.026; Prichep LS, 2013, J HEAD TRAUMA REHAB, V28, P266, DOI 10.1097/HTR.0b013e318247b54e; Resch JE, 2011, J ATHL TRAINING, V46, P170, DOI 10.4085/1062-6050-46.2.170; ROGERS RD, 1995, J EXP PSYCHOL GEN, V124, P207, DOI 10.1037/0096-3445.124.2.207; Ross LM, 2011, J SPORT REHABIL, V20, P296, DOI 10.1123/jsr.20.3.296; Scherer MR, 2013, PHYS THER, V93, P1254, DOI 10.2522/ptj.20120143; Teel EF, 2014, CLIN NEUROPHYSIOL, V125, P703, DOI 10.1016/j.clinph.2013.08.027; Tomei KL, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12280; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7; Yogev-Seligmann G, 2008, MOVEMENT DISORD, V23, P329, DOI 10.1002/mds.21720; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161	35	86	87	1	27	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	APR	2015	47	4					673	680		10.1249/MSS.0000000000000462			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	CE1QU	WOS:000351587800001	25100340				2022-02-06	
J	Ledig, C; Heckemann, RA; Hammers, A; Lopez, JC; Newcombe, VFJ; Makropoulos, A; Lotjonen, J; Menon, DK; Rueckert, D				Ledig, Christian; Heckemann, Rolf A.; Hammers, Alexander; Lopez, Juan Carlos; Newcombe, Virginia F. J.; Makropoulos, Antonios; Loetjoenen, Jyrki; Menon, David K.; Rueckert, Daniel			Robust whole-brain segmentation: Application to traumatic brain injury	MEDICAL IMAGE ANALYSIS			English	Article						Traumatic brain injury; Magnetic resonance imaging; Multi-atlas segmentation; Brain image segmentation; Expectation-maximisation	MULTI-ATLAS SEGMENTATION; COST FUNCTION MASKING; MR-IMAGES; AXONAL INJURY; VENTRICLE SEGMENTATION; NONRIGID REGISTRATION; DIFFUSION-TENSOR; LABEL FUSION; CLASSIFICATION; HIPPOCAMPUS	We propose a framework for the robust and fully-automatic segmentation of magnetic resonance (MR) brain images called "Multi-Atlas-Label Propagation with Expectation-Maximisation based refinement" (MALP-EM). The presented approach is based on a robust registration approach (MAPER), highly performant label fusion (joint label fusion) and intensity-based label refinement using EM. We further adapt this framework to be applicable for the segmentation of brain images with gross changes in anatomy. We propose to account for consistent registration errors by relaxing anatomical priors obtained by multi-atlas propagation and a weighting scheme to locally combine anatomical atlas priors and intensity-refined posterior probabilities. The method is evaluated on a benchmark dataset used in a recent MICCAI segmentation challenge. In this context we show that MALP-EM is competitive for the segmentation of MR brain scans of healthy adults when compared to state-of-the-art automatic labelling techniques. To demonstrate the versatility of the proposed approach, we employed MALP-EM to segment 125 MR brain images into 134 regions from subjects who had sustained traumatic brain injury (TBI). We employ a protocol to assess segmentation quality if no manual reference labels are available. Based on this protocol, three independent, blinded raters confirmed on 13 MR brain scans with pathology that MALP-EM is superior to established label fusion techniques. We visually confirm the robustness of our segmentation approach on the full cohort and investigate the potential of derived symmetry-based imaging biomarkers that correlate with and predict clinically relevant variables in TBI such as the Marshall Classification (MC) or Glasgow Outcome Score (GOS). Specifically, we show that we are able to stratify TBI patients with favourable outcomes from non-favourable outcomes with 64.7% accuracy using acute-phase MR images and 66.8% accuracy using follow-up MR images. Furthermore, we are able to differentiate subjects with the presence of a mass lesion or midline shift from those with diffuse brain injury with 76.0% accuracy. The thalamus, putamen, pallidum and hippocampus are particularly affected. Their involvement predicts TBI disease progression. (C) 2014 The Authors. Published by Elsevier B.V.	[Ledig, Christian; Makropoulos, Antonios; Rueckert, Daniel] Univ London Imperial Coll Sci Technol & Med, Dept Comp, Biomed Image Anal Grp, London SW7 2AZ, England; [Heckemann, Rolf A.; Hammers, Alexander] CERMEP, Neurodis Fdn, Lyon, France; [Heckemann, Rolf A.; Hammers, Alexander] Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Brain Sci, London, England; [Hammers, Alexander] St Thomas Hosp, Kings Coll London, Div Imaging Sci & Biomed Engn, PET Ctr, London, England; [Heckemann, Rolf A.; Lopez, Juan Carlos] Univ Gothenburg, MedTech West, Inst Neurosci & Physiol, Gothenburg, Sweden; [Loetjoenen, Jyrki] VTT Tech Res Ctr Finland, Knowledge Intens Serv, Tampere, Finland; [Newcombe, Virginia F. J.; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Univ Div Anaesthesia, Cambridge CB2 2QQ, England		Ledig, C (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Comp, 180 Queens Gate, London SW7 2AZ, England.	christian.ledig@imperial.ac.uk	Heckemann, Rolf Andreas/H-9022-2019; Hammers, Alexander/D-9982-2015	Heckemann, Rolf Andreas/0000-0003-3582-3683; Hammers, Alexander/0000-0001-9530-4848; Newcombe, Virginia/0000-0001-6044-9035; Ledig, Christian/0000-0003-4862-3138	7th Framework Programme by the European Commission; National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) based at Imperial College Healthcare NHS Trust; Imperial College LondonGeneral Electric; Department of Health via the NIHR comprehensive BRC award; King's College LondonGeneral Electric; Kings College Hospital NHS Foundation Trust; Medical Research Council (UK) Program GrantUK Research & Innovation (UKRI)Medical Research Council UK (MRC); UK National Institute of Health Research Biomedical Research Centre at CambridgeNational Institute for Health Research (NIHR); Technology Platform - UK Department of Health; EPSRC PathwaysUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC); Health Foundation/Academy of Medical Sciences Clinician Scientist Fellowship; NIHR Senior Investigator Award;  [G9439390 ID 658831]; EPSRCUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/I000445/1] Funding Source: UKRI; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390] Funding Source: UKRI; Academy of Medical Sciences (AMS)Academy of Medical Sciences (AMS) [AMS-CSF4-Newcombe] Funding Source: researchfish; Engineering and Physical Sciences Research CouncilUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/I000445/1, EP/K503733/1] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1000183B, G9439390, G0001354B, G0001354] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish	This work was partially funded under the 7th Framework Programme by the European Commission (http://cordis.europa.eu/ist/, TBIcare: http://www.tbicare.eu/, last accessed: 8 December 2014). The research was further supported by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) based at Imperial College Healthcare NHS Trust and Imperial College London. AH is supported by the Department of Health via the NIHR comprehensive BRC award to Guy's 82 St Thomas' NHS Foundation Trust in partnership with King's College London and Kings College Hospital NHS Foundation Trust. This work was further supported by a Medical Research Council (UK) Program Grant (Acute brain injury: heterogeneity of mechanisms, therapeutic targets and outcome effects [G9439390 ID 658831), the UK National Institute of Health Research Biomedical Research Centre at Cambridge, the Technology Platform funding provided by the UK Department of Health and an EPSRC Pathways to Impact award. VFJN is supported by a Health Foundation/Academy of Medical Sciences Clinician Scientist Fellowship. DKM is supported by an NIHR Senior Investigator Award. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The funders had no role in study design, data collection and analyses, decision to publish, or preparation of the manuscript.	Aljabar P, 2009, NEUROIMAGE, V46, P726, DOI 10.1016/j.neuroimage.2009.02.018; Andersen SM, 2010, NEUROIMAGE, V53, P78, DOI 10.1016/j.neuroimage.2010.06.003; Artaechevarria X, 2009, IEEE T MED IMAGING, V28, P1266, DOI 10.1109/TMI.2009.2014372; Asman AJ, 2013, MED PHYS, V40, DOI 10.1118/1.4794478; Asman AJ, 2013, MED IMAGE ANAL, V17, P194, DOI 10.1016/j.media.2012.10.002; Asman AJ, 2011, IEEE T MED IMAGING, V30, P1779, DOI 10.1109/TMI.2011.2147795; Avants BB, 2008, MED IMAGE ANAL, V12, P26, DOI 10.1016/j.media.2007.06.004; Bauer S, 2013, PHYS MED BIOL, V58, pR97, DOI 10.1088/0031-9155/58/13/R97; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bonilha L, 2014, FRONT PSYCHIATRY, V4, DOI 10.3389/fpsyt.2013.00186; Brett M, 2001, NEUROIMAGE, V14, P486, DOI 10.1006/nimg.2001.0845; Brodersen Kay H, 2010, Proceedings of the 2010 20th International Conference on Pattern Recognition (ICPR 2010), P3121, DOI 10.1109/ICPR.2010.764; Cabezas M, 2011, COMPUT METH PROG BIO, V104, pE158, DOI 10.1016/j.cmpb.2011.07.015; Cardoso M.J., 2013, P MICCAI CHALL WORKS, P23; Cardoso MJ, 2013, MED IMAGE ANAL, V17, P671, DOI 10.1016/j.media.2013.02.006; Cardoso MJ, 2013, NEUROIMAGE, V65, P97, DOI 10.1016/j.neuroimage.2012.08.009; Cardoso MJ, 2011, NEUROIMAGE, V56, P1386, DOI 10.1016/j.neuroimage.2011.02.013; Chitphakdithai N, 2010, LECT NOTES COMPUT SC, V6361, P367; Coupe P, 2011, NEUROIMAGE, V54, P940, DOI 10.1016/j.neuroimage.2010.09.018; DICE LR, 1945, ECOLOGY, V26, P297, DOI 10.2307/1932409; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; GALABURDA AM, 1987, NEUROPSYCHOLOGIA, V25, P853, DOI 10.1016/0028-3932(87)90091-1; Hammers A, 2003, HUM BRAIN MAPP, V19, P224, DOI 10.1002/hbm.10123; Heckemann RA, 2006, NEUROIMAGE, V33, P115, DOI 10.1016/j.neuroimage.2006.05.061; Heckemann RA, 2011, NEUROIMAGE, V56, P2024, DOI 10.1016/j.neuroimage.2011.03.014; Heckemann RA, 2010, NEUROIMAGE, V51, P221, DOI 10.1016/j.neuroimage.2010.01.072; Irimia A, 2012, NEUROIMAGE-CLIN, V1, P1, DOI 10.1016/j.nicl.2012.08.002; Irimia A, 2011, J NEUROTRAUM, V28, P2287, DOI 10.1089/neu.2011.1920; JENNETT B, 1975, LANCET, V1, P480; Kempton MJ, 2011, NEUROIMAGE, V58, P1051, DOI 10.1016/j.neuroimage.2011.06.080; Landman BA, 2012, MICCAI 2012 WORKSH M; Landman BA, 2012, IEEE T MED IMAGING, V31, P512, DOI 10.1109/TMI.2011.2172215; Ledig C, 2014, PROC CVPR IEEE, P3065, DOI 10.1109/CVPR.2014.392; Ledig C, 2012, 2012 9TH IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING (ISBI), P896, DOI 10.1109/ISBI.2012.6235693; Liu XX, 2014, LECT NOTES COMPUT SC, V8675, P97, DOI 10.1007/978-3-319-10443-0_13; Lotjonen JMP, 2010, NEUROIMAGE, V49, P2352, DOI 10.1016/j.neuroimage.2009.10.026; Marcus DS, 2007, J COGNITIVE NEUROSCI, V19, P1498, DOI 10.1162/jocn.2007.19.9.1498; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Modat M, 2010, COMPUT METH PROG BIO, V98, P278, DOI 10.1016/j.cmpb.2009.09.002; Niethammer M, 2011, LECT NOTES COMPUT SC, V6892, P639, DOI 10.1007/978-3-642-23629-7_78; Nugent AC, 2013, HUM BRAIN MAPP, V34, P2313, DOI 10.1002/hbm.22068; Periaswamy S, 2006, MED IMAGE ANAL, V10, P452, DOI 10.1016/j.media.2005.03.006; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rao A, 2014, I S BIOMED IMAGING, P333, DOI 10.1109/ISBI.2014.6867876; Ribbens A, 2014, IEEE T MED IMAGING, V33, P201, DOI 10.1109/TMI.2013.2270114; Rohlfing T, 2004, IEEE T MED IMAGING, V23, P983, DOI 10.1109/TMI.2004.830803; Rohlfing T, 2004, NEUROIMAGE, V21, P1428, DOI 10.1016/j.neuroimage.2003.11.010; Rousseau F, 2011, IEEE T MED IMAGING, V30, P1852, DOI 10.1109/TMI.2011.2156806; Rueckert D, 1999, IEEE T MED IMAGING, V18, P712, DOI 10.1109/42.796284; Sabuncu MR, 2010, IEEE T MED IMAGING, V29, P1714, DOI 10.1109/TMI.2010.2050897; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Stefanescu R, 2004, LECT NOTES COMPUT SC, V3216, P704; Strangman GE, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00182; TEASDALE G, 1974, LANCET, V2, P81; Tong T, 2013, NEUROIMAGE, V76, P11, DOI 10.1016/j.neuroimage.2013.02.069; Tustison NJ, 2010, IEEE T MED IMAGING, V29, P1310, DOI 10.1109/TMI.2010.2046908; van der Lijn F, 2008, NEUROIMAGE, V43, P708, DOI 10.1016/j.neuroimage.2008.07.058; Van Leemput K, 1999, IEEE T MED IMAGING, V18, P897, DOI 10.1109/42.811270; Wang HZ, 2013, IEEE T PATTERN ANAL, V35, P611, DOI 10.1109/TPAMI.2012.143; Wang HZ, 2011, NEUROIMAGE, V55, P968, DOI 10.1016/j.neuroimage.2011.01.006; Wang L, 2014, NEUROIMAGE, V84, P141, DOI 10.1016/j.neuroimage.2013.08.008; Warfield SK, 2004, IEEE T MED IMAGING, V23, P903, DOI 10.1109/TMI.2004.828354; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Wells WM, 1996, IEEE T MED IMAGING, V15, P429, DOI 10.1109/42.511747; Wolz R, 2010, NEUROIMAGE, V52, P109, DOI 10.1016/j.neuroimage.2010.04.006; Wolz R, 2010, NEUROIMAGE, V49, P1316, DOI 10.1016/j.neuroimage.2009.09.069; Zacharaki EI, 2009, NEUROIMAGE, V46, P762, DOI 10.1016/j.neuroimage.2009.01.051; ZHANG J, 1992, IEEE T SIGNAL PROCES, V40, P2570, DOI 10.1109/78.157297; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	74	86	86	1	18	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1361-8415	1361-8423		MED IMAGE ANAL	Med. Image Anal.	APR	2015	21	1					40	58		10.1016/j.media.2014.12.003			19	Computer Science, Artificial Intelligence; Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Computer Science; Engineering; Radiology, Nuclear Medicine & Medical Imaging	CD0PU	WOS:000350777200004	25596765	Green Published, hybrid			2022-02-06	
J	Wunderle, K; Hoeger, KM; Wasserman, E; Bazarian, JJ				Wunderle, Kathryn; Hoeger, Kathleen M.; Wasserman, Erin; Bazarian, Jeffrey J.			Menstrual Phase as Predictor of Outcome After Mild Traumatic Brain Injury in Women	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain concussion; brain injuries; follicular phase; luteal phase; menstrual cycle; postconcussion syndrome; progesterone; quality of life	CONCUSSION SYMPTOMS QUESTIONNAIRE; GENDER-DIFFERENCE; SEX-DIFFERENCES; HEAD-INJURY; CYCLE; PROGESTERONE; FEMALES; HORMONE; IMPACT; TRIAL	Objective: To determine whether menstrual cycle phase in women at the time of mild traumatic brain injury (mTBI) predicts 1-month outcomes. Setting: Six emergency departments; 5 in Upstate New York, and 1 in Pennsylvania. Participants: One hundred forty-four female participants (age, 16-60) who presented to participating emergency departments within 4 hours of mTBI. Design: Nested cohort study with neurologic and quality-of-life outcome assessment, 1 month after enrollment. Female subjects aged 16 to 60 enrolled in the parent cohort study, with 1-month neurological determination data available, were classified into menstrual cycle groups by serum progesterone concentration and self-reported contraceptive use. Main Measures: Rivermead Post Concussion Questionnaire and EuroQoL/EQ5D. Results: Women injured during the luteal phase of their menstrual cycle, when progesterone concentration is high, had significantly lower EuroQoL General Health Ratings and Index Scores than women injured during the follicular phase of their cycle or women taking oral contraceptives. Multivariate analysis confirmed a significant independent effect of menstrual cycle phase on EuroQoL Index Score and the Rivermead Post Concussion Questionnaire Somatic Subscore. Conclusion: Menstrual cycle phase and progesterone concentration at the time of mTBI affect 1-month quality-of-life and neurologic outcomes. This association has important implications for treatment and prognosis after mTBI.	[Wunderle, Kathryn] Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA; [Hoeger, Kathleen M.] Univ Rochester, Sch Med & Dent, Dept Obstet & Gynecol, Rochester, NY 14642 USA; [Wasserman, Erin] Univ Rochester, Sch Med & Dent, Div Epidemiol, Dept Publ Hlth Sci, Rochester, NY 14642 USA; [Bazarian, Jeffrey J.] Univ Rochester, Sch Med & Dent, Dept Emergency Med, Rochester, NY 14642 USA		Bazarian, JJ (corresponding author), Univ Rochester, Sch Med & Dent, Dept Emergency Med, 601 Elmwood Ave,Box 655, Rochester, NY 14642 USA.	Jeff_bazarian@urmc.rochester.edu		Wasserman, Erin/0000-0001-5957-5878	Banyan Biomarkers; Roche Diagnostics; New York State Department of Health; Academic Health Center Consortium; Emergency Research Network of the Empire State (ERNIES); Pilot Research Collaborative Program of the Foundation for Healthy Living; University of Rochester's Clinical and Translational Science Award; Upstate New York Translational Research Network (UNYTRN); Upstate New York Consortium for Healthcare Research and Quality (UNYCHRQ); NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024160, KL2RR024136] Funding Source: NIH RePORTER	Jeffrey J. Bazarian has received consulting fees from Banyan Biomarkers and Roche Diagnostics. Jeffrey J. Bazarian was supported by funds from the New York State Department of Health, the Academic Health Center Consortium, and the Emergency Research Network of the Empire State (ERNIES). ERNIES is supported by the Pilot Research Collaborative Program of the Foundation for Healthy Living, the University of Rochester's Clinical and Translational Science Award, the Upstate New York Translational Research Network (UNYTRN) and the Upstate New York Consortium for Healthcare Research and Quality (UNYCHRQ).	Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Belanger Lesley, 2013, J Can Chiropr Assoc, V57, P76; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; CDC, 2003, NATL CENT INJ PREV C; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Echlin PS, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12286; Echlin PS, 2012, NEUROSURG FOCUS, V33, P1, DOI DOI 10.3171/2012.10.F0CUS12286; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Mihalik JP, 2009, J SCI MED SPORT, V12, P383, DOI 10.1016/j.jsams.2008.05.003; MOLLERNIELSEN J, 1989, MED SCI SPORT EXER, V21, P126; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Ripley DL, 2008, ARCH PHYS MED REHAB, V89, P1090, DOI 10.1016/j.apmr.2007.10.038; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Ross C, 2003, J PSYCHOSOM OBST GYN, V24, P15, DOI 10.3109/01674820309042797; Shaw JW, 2005, MED CARE, V43, P203, DOI 10.1097/00005650-200503000-00003; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wunder DM, 2008, FERTIL STERIL, V89, P927, DOI 10.1016/j.fertnstert.2007.04.054; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	28	86	85	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2014	29	5					E1	E8		10.1097/HTR.0000000000000006			8	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AP2GW	WOS:000341891700001	24220566	Green Accepted			2022-02-06	
J	Valle, EJ; Allen, CJ; Van Haren, RM; Jouria, JM; Li, H; Livingstone, AS; Namias, N; Schulman, CI; Proctor, KG				Valle, Evan J.; Allen, Casey J.; Van Haren, Robert M.; Jouria, Jassin M.; Li, Hua; Livingstone, Alan S.; Namias, Nicholas; Schulman, Carl I.; Proctor, Kenneth G.			Do all trauma patients benefit from tranexamic acid?	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	72nd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma / Clinical Congress of Acute Care Surgery	SEP 18-23, 2013	San Francisco, CA	Amer Assoc Surg Trauma		Hemostasis; resuscitation; transfusion	ACUTE COAGULOPATHY; FIBRINOLYSIS	BACKGROUND: This study tested the hypothesis that early routine use of tranexamic acid (TXA) reduces mortality in a subset of the most critically injured trauma intensive care unit patients. METHODS: Consecutive trauma patients (n = 1,217) who required emergency surgery (OR) and/or transfusions from August 2009 to January 2013 were reviewed. At surgeon discretion, TXA was administered at a median of 97 minutes (1-g bolus then 1-g over 8 hours) to 150 patients deemed high risk for hemorrhagic death. With the use of propensity scores based on age, sex, traumatic brain injury (TBI), mechanism of injury, systolic blood pressure, transfusion requirements, and Injury Severity Score (ISS), these patients were matched to 150 non-TXA patients. RESULTS: The study population was 43 years old, 86% male, 54% penetrating mechanism of injury, 25% TBI, 28 ISS, with 22% mortality. OR was required in 78% at 86 minutes, transfusion was required in 97% at 36 minutes, and 75% received both. For TXA versus no TXA, more packed red blood cells and total fluid were required, and mortality was 27% versus 17% (all p < 0.05). The effects of TXA were similar in those with or without TBI, although ISS, fluid, and mortality were all higher in the TBI group. Mortality associated with TXA was influenced by the timing of administration (p G 0.05), but any benefit was eliminated in those who required more than 2,000-mL packed red blood cells, who presented with systolic blood pressure of less than 120 mm Hg or who required OR (all p G 0.05). CONCLUSION: For the highest injury acuity patients, TXA was associated with increased, rather than reduced, mortality, no matter what time it was administered. This lack of benefit can probably be attributed to the rapid availability of fluids and emergency OR at this trauma center. Prospective studies are needed to further identify conditions that may override the benefits from TXA. (J Trauma Acute Care Surg. 2014; 76: 1373-1378. Copyright (C) 2014 by Lippincott Williams & Wilkins)	Univ Miami, Miller Sch Med, Dewitt Daughtry Family Dept Surg, Div Trauma, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Dewitt Daughtry Family Dept Surg, Div Surg Crit Care, Miami, FL 33136 USA		Proctor, KG (corresponding author), Univ Miami, Sch Med, Ryder Trauma Ctr, Div Trauma,Dewitt Daughtry Family Dept Surg, 1800 NW 10th Ave, Miami, FL 33136 USA.	kproctor@miami.edu	Van Haren, Robert/T-8218-2019; Livingstone, Alan/AAA-4026-2019; Proctor, Kenneth/AAA-2199-2022; Schulman, Carl/AAE-7448-2021	Proctor, Kenneth/0000-0003-1326-6628; Allen, Casey/0000-0001-9890-7417; Namias, Nicholas/0000-0001-7021-2250; Schulman, Carl/0000-0001-8899-4350			Chapman MP, 2013, J TRAUMA ACUTE CARE, V75, P961, DOI 10.1097/TA.0b013e3182aa9c9f; Faraoni D, 2013, MINERVA ANESTESIOL; Hess JR, 2008, J TRAUMA, V65, P748, DOI 10.1097/TA.0b013e3181877a9c; Kashuk JL, 2010, ANN SURG, V252, P434, DOI 10.1097/SLA.0b013e3181f09191; Morrison JJ, 2013, J TRAUMA ACUTE CARE, V75, P743, DOI 10.1097/TA.0b013e3182a53873; Morrison JJ, 2012, ARCH SURG-CHICAGO, V147, P113, DOI 10.1001/archsurg.2011.287; Napolitano LM, 2013, J TRAUMA ACUTE CARE, V74, P1575, DOI 10.1097/TA.0b013e318292cc54; Pusateri AE, 2013, SHOCK, V39, P121, DOI 10.1097/SHK.0b013e318280409a; Roberts I, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5839; Roberts I, 2011, LANCET, V377, P1096, DOI 10.1016/S0140-6736(11)60278-X; Schlimp CJ, 2014, HAMOSTASEOLOGIE, V34, P29, DOI 10.5482/HAMO-13-07-0038; Schochl H, 2013, J TRAUMA ACUTE CARE, V74, P1587, DOI 10.1097/TA.0b013e31828c3171; Schochl H, 2013, CURR OPIN ANESTHESIO, V26, P221, DOI 10.1097/ACO.0b013e32835cca92; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Stuart EA, 2010, STAT SCI, V25, P1, DOI 10.1214/09-STS313; Tranexamic Acid Injection 100 mg/ml NDC 67457-197-10 10 mL single dose vial packages of 10, TRAN AC INJ 100 MG M; Vu Erik Nelson, 2013, Air Med J, V32, P289, DOI 10.1016/j.amj.2013.05.001; Wafaisade A, 2010, EMERG MED J, V27, P934, DOI 10.1136/emj.2009.088484	18	86	86	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUN	2014	76	6					1373	1378		10.1097/TA.0000000000000242			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	AI8FR	WOS:000337145500006	24854303				2022-02-06	
J	Cho, HJ; Sajja, VSSS; Vandevord, PJ; Lee, YW				Cho, H. J.; Sajja, V. S. S. S.; Vandevord, P. J.; Lee, Y. W.			BLAST INDUCES OXIDATIVE STRESS, INFLAMMATION, NEURONAL LOSS AND SUBSEQUENT SHORT-TERM MEMORY IMPAIRMENT IN RATS	NEUROSCIENCE			English	Article						blast-induced neurotrauma; oxidative stress; inflammation; neuronal loss; novel object recognition; short-term memory impairment	TRAUMATIC BRAIN-INJURY; MICROGLIAL-ACTIVATION; INDUCED NEUROTRAUMA; ALZHEIMERS-DISEASE; SHOCK-WAVE; NEURODEGENERATIVE DISEASES; CHRONIC NEUROINFLAMMATION; INTRACRANIAL-PRESSURE; MULTIPLE-SCLEROSIS; COGNITIVE DEFICITS	Molecular and cellular mechanisms of brain injury after exposure to blast overpressure (BOP) are not clearly known. The present study hypothesizes that pro-oxidative and pro-inflammatory pathways in the brain may be responsible for neuronal loss and behavioral deficits following BOP exposure. Male Sprague-Dawley rats were anesthetized and exposed to calibrated BOP of 129.23 +/- 3.01 kPa while controls received only anesthesia. In situ dihydroethidium fluorescence staining revealed that BOP significantly increased the production of reactive oxygen species in the brain. In addition, real-time reverse transcriptase-polymerase chain reaction, immunofluorescence staining and enzyme-linked immunosorbent assay demonstrated a significant up-regulation of mRNA and protein expressions of pro-inflammatory mediators, such as interferon-gamma and monocyte chemoattractant protein-1, in brains collected from BOP-exposed animals compared with the controls. Furthermore, immunoreactivity of neuronal nuclei in brains indicated that fewer neurons were present following BOP exposure. Moreover, novel object recognition paradigm showed a significant impairment in the short-term memory at 2 weeks following BOP exposure. These results suggest that pro-oxidative and pro-inflammatory environments in the brain could play a potential role in BOP-induced neuronal loss and behavioral deficits. It may provide a foundation for defining a molecular and cellular basis of the pathophysiology of blast-induced neurotrauma (BINT). It will also contribute to the development of new therapeutic approaches selectively targeting these pathways, which have great potential in the diagnosis and therapy of BINT. (C) 2013 IBRO. Published by Elsevier Ltd. All rights reserved.	[Cho, H. J.; Sajja, V. S. S. S.; Vandevord, P. J.; Lee, Y. W.] Virginia Polytech Inst & State Univ, Sch Biomed Engn & Sci, Blacksburg, VA 24061 USA; [Lee, Y. W.] Virginia Polytech Inst & State Univ, Dept Biomed Sci & Pathobiol, Blacksburg, VA 24061 USA; [Vandevord, P. J.] Vet Affairs Med Ctr, Salem, VA 24153 USA		Lee, YW (corresponding author), Virginia Polytech Inst & State Univ, Sch Biomed Engn & Sci, Blacksburg, VA 24061 USA.	hjcho79@vt.edu; sujits@vt.edu; pvord@vt.edu; ywlee@vt.edu	Sajja, Sujith/I-5289-2019	Sajja, Sujith/0000-0002-1992-9501; Cho, Hyung Joon/0000-0002-7481-6841			Aarabi B, 2009, CURR OPIN CRIT CARE, V15, P548, DOI 10.1097/MCC.0b013e32833190da; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Agoston DV, 2009, J NEUROTRAUM, V26, P901, DOI 10.1089/neu.2008.0724; Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Amor S, 2010, IMMUNOLOGY, V129, P154, DOI 10.1111/j.1365-2567.2009.03225.x; Armed Forces Health Surveillance Center (AFHSC), 2013, MSMR, V20, P9; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belujon P, 2011, ANN NY ACAD SCI, V1216, P114, DOI 10.1111/j.1749-6632.2010.05896.x; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Block ML, 2007, BIOCHEM SOC T, V35, P1127, DOI 10.1042/BST0351127; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Browne TC, 2013, J IMMUNOL, V190, P2241, DOI 10.4049/jimmunol.1200947; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; Cechetti F, 2012, BRAIN RES BULL, V87, P109, DOI 10.1016/j.brainresbull.2011.10.006; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Choi K, 2009, CURR NEUROVASC RES, V6, P213, DOI 10.2174/156720209789630375; Diaz A, 2012, J ALZHEIMERS DIS, V30, P505, DOI 10.3233/JAD-2012-111979; Dinel AL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024325; do Nascimento AL, 2012, BRAIN RES, V1470, P98, DOI 10.1016/j.brainres.2012.06.008; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Gao HM, 2011, J NEUROSCI, V31, P1081, DOI 10.1523/JNEUROSCI.3732-10.2011; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hauss-Wegrzyniak B, 1998, BRAIN RES, V780, P294, DOI 10.1016/S0006-8993(97)01215-8; Hicks RR, 2010, J TRAUMA, V68, P1257, DOI 10.1097/TA.0b013e3181d8956d; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Ho L, 2012, J ALZHEIMERS DIS, V31, P301, DOI 10.3233/JAD-2012-120598; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kamnaksh A, 2012, ELECTROPHORESIS, V33, P3680, DOI 10.1002/elps.201200319; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Lee WH, 2010, INT J RADIAT BIOL, V86, P132, DOI 10.3109/09553000903419346; Lee YW, 2003, AM J PHYSIOL-HEART C, V284, pH185, DOI 10.1152/ajpheart.00524.2002; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Li GM, 2013, NEUROL SCI, V34, P963, DOI 10.1007/s10072-012-1173-z; Little AR, 2002, NEUROSCIENCE, V115, P307, DOI 10.1016/S0306-4522(02)00359-7; Liu Y, 2006, J NEUROSCI, V26, P12904, DOI 10.1523/JNEUROSCI.2531-06.2006; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Lucca JJD, 2012, J NEUROL SCI, V318, P146, DOI 10.1016/j.jns.2012.02.002; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014; Martino G, 2002, LANCET NEUROL, V1, P499, DOI 10.1016/S1474-4422(02)00223-5; Morley MG, 2010, DISASTER MED PUBLIC, V4, P154, DOI 10.1001/dmp.v4n2.hra10003; Nagamoto-Combs K, 2010, J NEUROTRAUM, V27, P565, DOI 10.1089/neu.2009.0966; Najjar S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-43; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Park E, 2013, NEUROBIOL DIS, V52, P150, DOI 10.1016/j.nbd.2012.12.002; Rauh MJ, 2013, J REHABIL RES DEV, V50, P161, DOI 10.1682/JRRD.2011.11.0212; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Sajja VSSS, 2013, J NEUROSCI RES, V91, P593, DOI 10.1002/jnr.23179; Sajja VSSS, 2012, NMR BIOMED, V25, P1331, DOI 10.1002/nbm.2805; Salim S, 2012, ADV PROTEIN CHEM STR, V88, P1, DOI 10.1016/B978-0-12-398314-5.00001-5; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Schofield E, 2003, BRAIN, V126, P827, DOI 10.1093/brain/awg085; Shapiro LA, 2005, NEUROSCIENCE, V136, P823, DOI 10.1016/j.neuroscience.2005.03.059; Smith JE, 2011, PHILOS T R SOC B, V366, P291, DOI 10.1098/rstb.2010.0251; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Stetler RA, 2010, PROG NEUROBIOL, V92, P184, DOI 10.1016/j.pneurobio.2010.05.002; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Takeuchi H, 2006, NEUROBIOL DIS, V22, P33, DOI 10.1016/j.nbd.2005.09.014; Tansey MG, 2010, NEUROBIOL DIS, V37, P510, DOI 10.1016/j.nbd.2009.11.004; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823; Valiyaveettil M, 2013, CHEM-BIOL INTERACT, V203, P371, DOI 10.1016/j.cbi.2012.10.022; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Wang KC, 2013, NEUROSCIENCE, V234, P146, DOI 10.1016/j.neuroscience.2012.12.049; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Wani Imtiaz, 2009, World J Emerg Surg, V4, P46, DOI 10.1186/1749-7922-4-46; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Yang GA, 2011, BRAIN PATHOL, V21, P279, DOI 10.1111/j.1750-3639.2010.00445.x; Zhang DM, 2012, NEUROCHEM INT, V61, P1021, DOI 10.1016/j.neuint.2012.07.019; Zhang J, 2013, BEHAV BRAIN RES, V244, P70, DOI 10.1016/j.bbr.2013.01.037	94	86	89	0	26	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	DEC 3	2013	253						9	20		10.1016/j.neuroscience.2013.08.037			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	252HZ	WOS:000326997100002	23999126				2022-02-06	
J	Arndt, DH; Lerner, JT; Matsumoto, JH; Madikians, A; Yudovin, S; Valino, H; McArthur, DL; Wu, JY; Leung, M; Buxey, F; Szeliga, C; Van Hirtum-Das, M; Sankar, R; Brooks-Kayal, A; Giza, CC				Arndt, Daniel H.; Lerner, Jason T.; Matsumoto, Joyce H.; Madikians, Andranik; Yudovin, Sue; Valino, Hannah; McArthur, David L.; Wu, Joyce Y.; Leung, Michelle; Buxey, Farzad; Szeliga, Conrad; Van Hirtum-Das, Michele; Sankar, Raman; Brooks-Kayal, Amy; Giza, Christopher C.			Subclinical early posttraumatic seizures detected by continuous EEG monitoring in a consecutive pediatric cohort	EPILEPSIA			English	Article						Clinical neurophysiology; Children; Epilepsy; ICU	TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE-UNIT; CRITICALLY-ILL CHILDREN; HEAD-INJURY; NONCONVULSIVE SEIZURES; EPILEPTIFORM ACTIVITY; VIDEO-EEG; EPILEPSY; PREDICTORS; PREVENTION	PurposeTraumatic brain injury (TBI) is an important cause of morbidity and mortality in children, and early posttraumatic seizures (EPTS) are a contributing factor to ongoing acute damage. Continuous video-EEG monitoring (cEEG) was utilized to assess the burden of clinical and electrographic EPTS. MethodsEighty-seven consecutive, unselected (mild - severe), acute TBI patients requiring pediatric intensive care unit (PICU) admission at two academic centers were monitored prospectively with cEEG per established clinical TBI protocols. Clinical and subclinical seizures and status epilepticus (SE, clinical and subclinical) were assessed for their relation to clinical risk factors and short-term outcome measures. Key FindingsOf all patients, 42.5% (37/87) had seizures. Younger age (p=0.002) and injury mechanism (abusive head trauma - AHT, p<0.001) were significant risk factors. Subclinical seizures occurred in 16.1% (14/87), while 6.9% (6/87) had only subclinical seizures. Risk factors for subclinical seizures included younger age (p<0.001), AHT (p<0.001), and intraaxial bleed (p<0.001). SE occurred in 18.4% (16/87) with risk factors including younger age (p<0.001), AHT (p<0.001), and intraaxial bleed (p=0.002). Subclinical SE was detected in 13.8% (12/87) with significant risk factors including younger age (p<0.001), AHT (p=0.001), and intraaxial bleed (p=0.004). Subclinical seizures were associated with lower discharge King's Outcome Scale for Childhood Head Injury (KOSCHI) score (p=0.002). SE and subclinical SE were associated with increased hospital length of stay (p=0.017 and p=0.041, respectively) and lower hospital discharge KOSCHI (p=0.007 and p=0.040, respectively). SignificancecEEG monitoring significantly improves detection of seizures/SE and is the only way to detect subclinical seizures/SE. cEEG may be indicated after pediatric TBI, particularly in younger children, AHT cases, and those with intraaxial blood on computerized tomography (CT).	[Arndt, Daniel H.] Oakland Univ, Beaumont Childrens Hosp, Dept Pediat & Adult Neurol, Royal Oak, MI USA; [Lerner, Jason T.; Matsumoto, Joyce H.; Yudovin, Sue; Wu, Joyce Y.; Szeliga, Conrad; Sankar, Raman; Giza, Christopher C.] Univ Calif Los Angeles, Dept Pediat, Mattel Childrens Hosp, Div Pediat Neurol, Los Angeles, CA 90024 USA; [Lerner, Jason T.; Matsumoto, Joyce H.; Yudovin, Sue; Valino, Hannah; McArthur, David L.; Wu, Joyce Y.; Leung, Michelle; Buxey, Farzad; Sankar, Raman; Giza, Christopher C.] UCLA Brain Injury Res Ctr, Los Angeles, CA USA; [Madikians, Andranik] Univ Calif Los Angeles, Mattel Childrens Hosp, Div Pediat Crit Care, Los Angeles, CA USA; [Valino, Hannah; McArthur, David L.; Leung, Michelle; Buxey, Farzad; Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Van Hirtum-Das, Michele] Childrens Hosp, Div Pediat Neurol, Los Angeles, CA 90027 USA; [Brooks-Kayal, Amy] Childrens Hosp Colorado, Div Pediat Neurol, Aurora, CO USA; [Brooks-Kayal, Amy] Univ Colorado, Dept Pediat Neurol & Pharmacol Sci, Aurora, CO USA; [Giza, Christopher C.] Univ Calif Los Angeles, Interdept Program Neurosci, Los Angeles, CA USA; [Giza, Christopher C.] Univ Calif Los Angeles, Interdept Program Biomed Engn, Los Angeles, CA USA		Lerner, JT (corresponding author), 10833 Le Conte,22-474 MDCC, Los Angeles, CA 90095 USA.	jlerner@mednet.ucla.edu			Thrasher Research Foundation; National Epifellows Foundation; Child Neurology Foundation/Winokur Family Foundation; Epilepsy Foundation of America; Today's and Tomorrow's Children Fund; UCLA Brain Injury Research Center [NS 058489]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR013642] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL073980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R34MH089299, R21MH079933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058489, K23NS051637, R01NS051710, P20NS080199] Funding Source: NIH RePORTER	We thank the following people for their roles in supporting this project: Susan Koh, MD, Pramote Laoprasert, MD, Kelly Knupp, MD, Kristen Park, MD, Mark Tripputi, PhD, Christine Thompson; and EEG technologists: Andrea Duran, Jimmy Nguyen, Bereket Habibda, Pat Oliver, and Sy Turner. Funding was supported primarily by a grant from the Thrasher Research Foundation. Support for D.H.A. was primarily through the National Epifellows Foundation. Additional support from the Child Neurology Foundation/Winokur Family Foundation, Epilepsy Foundation of America, Today's and Tomorrow's Children Fund, and UCLA Brain Injury Research Center (NS 058489) was also greatly appreciated.	Abend NS, 2011, J CLIN NEUROPHYSIOL, V28, P15, DOI 10.1097/WNP.0b013e3182051123; Anderson, 2010, MODEL SELECTION MULT; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; Barto K., 2012, MUMIN MULTIMODEL INF; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Chiaretti A, 2000, CHILD NERV SYST, V16, P862, DOI 10.1007/s003810000368; Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; DESAI BT, 1983, EPILEPSIA, V24, P289, DOI 10.1111/j.1528-1157.1983.tb04892.x; Faul M, 2010, TRAUMATIC BRAIN INJU; Goldstein JL, 2011, NEUROCRIT CARE, V15, P63, DOI 10.1007/s12028-010-9468-5; Hahn CD, 2011, NEUROLOGY, V76, P1036, DOI 10.1212/WNL.0b013e318211c3dd; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; HENDRICK EB, 1968, J TRAUM, V8, P547; JENNETT B, 1973, DEV MED CHILD NEUROL, V15, P56; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; Kaindl AM, 2006, CELL MOL LIFE SCI, V63, P399, DOI 10.1007/s00018-005-5348-0; Keenan HT, 2007, PEDIATRICS, V119, pE616, DOI 10.1542/peds.2006-2313; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; Maas A, 2011, LANCET NEUROL, V10, P111, DOI 10.1016/S1474-4422(10)70312-4; Mansfield RT, 1997, CRIT CARE CLIN, V13, P611, DOI 10.1016/S0749-0704(05)70331-6; Olney JW, 2004, TRENDS PHARMACOL SCI, V25, P135, DOI 10.1016/j.tips.2004.01.002; Ong LC, 1996, J PAEDIATR CHILD H, V32, P173, DOI 10.1111/j.1440-1754.1996.tb00917.x; PAGNI CA, 1990, ACT NEUR S, V50, P38; Ratan SK, 1999, PEDIATR NEUROSURG, V30, P127, DOI 10.1159/000028779; Ronne-Engstrom E, 2006, ACTA NEUROL SCAND, V114, P47, DOI 10.1111/j.1600-0404.2006.00652.x; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saengpattrachai M, 2006, EPILEPSIA, V47, P1510, DOI 10.1111/j.1528-1167.2006.00624.x; Shahwan A, 2010, EPILEPSIA, V51, P1198, DOI 10.1111/j.1528-1167.2009.02517.x; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1999, J CLIN NEUROPHYSIOL, V16, P1, DOI 10.1097/00004691-199901000-00001; Wilcox R.R., 2012, INTRO ROBUST ESTIMAT; Williams K, 2011, EPILEPSIA, V52, P1130, DOI 10.1111/j.1528-1167.2011.03070.x; WILLMORE LJ, 1978, BRAIN RES, V152, P406, DOI 10.1016/0006-8993(78)90273-1; Young KD, 2004, ANN EMERG MED, V43, P435, DOI 10.1016/j.annemergmed.2003.09.016	45	86	91	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	OCT	2013	54	10					1780	1788		10.1111/epi.12369			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	227UU	WOS:000325141500011	24032982	Green Accepted			2022-02-06	
J	Goyal, A; Failla, MD; Niyonkuru, C; Amin, K; Fabio, A; Berger, RP; Wagner, AK				Goyal, Akash; Failla, Michelle D.; Niyonkuru, Christian; Amin, Krutika; Fabio, Anthony; Berger, Rachel P.; Wagner, Amy K.			S100b as a Prognostic Biomarker in Outcome Prediction for Patients with Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebrospinal fluid; S100b; outcome; serum; traumatic brain injury	FIBRILLARY ACIDIC PROTEIN; NEURON-SPECIFIC ENOLASE; SERUM S-100B PROTEIN; BIOLOGICAL-FLUIDS; HEAD-INJURY; DAMAGE; BLOOD; MARKERS; MODELS; AGE	As an astrocytic protein specific to the central nervous system, S100b is a potentially useful marker in outcome prediction after traumatic brain injury (TBI). Some studies have questioned the validity of S100b, citing the extracerebral origins of the protein as reducing the specificity of the marker. This study evaluated S100b as a prognostic biomarker in adult subjects with severe TBI (sTBI) by comparing outcomes with S100b temporal profiles generated from both cerebrospinal fluid (CSF) (n = 138 subjects) and serum (n = 80 subjects) samples across a 6-day time course. Long-bone fracture, Injury Severity Score (ISS), and isolated head injury status were variables used to assess extracerebral sources of S100b in serum. After TBI, CSF and serum S100b levels were increased over healthy controls across the first 6 days post-TBI (p <= 0.005 and p <= 0.031). Though CSF and serum levels were highly correlated during early time points post-TBI, this association diminished over time. Bivariate analysis showed that subjects who had temporal CSF profiles with higher S100b concentrations had higher acute mortality (p < 0.001) and worse Glasgow Outcome Scale (GOS; p = 0.002) and Disability Rating Scale (DRS) scores (p = 0.039) 6 months post-injury. Possibly as a result of extracerebral sources of S100b in serum, as represented by high ISS scores (p = 0.032), temporal serum profiles were associated with acute mortality (p = 0.015). High CSF S100b levels were observed in women (p = 0.022) and older subjects (p = 0.004). Multivariate logistic regression confirmed CSF S100b profiles in predicting GOS and DRS and showed mean and peak serum S100b as acute mortality predictors after sTBI.	[Goyal, Akash; Failla, Michelle D.; Niyonkuru, Christian; Amin, Krutika; Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Failla, Michelle D.; Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Failla, Michelle D.; Berger, Rachel P.; Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Fabio, Anthony] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA; [Berger, Rachel P.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Failla, Michelle/AAI-3788-2021	Failla, Michelle/0000-0001-9734-3373; Fabio, Anthony/0000-0002-6808-4939	Centers for Disease ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CCR323155]; Department of DefenseUnited States Department of Defense [W81XWH-07-1-0701]	This work was supported by the Centers for Disease Control (grant no.: R49/CCR323155) and the Department of Defense (grant no.: W81XWH-07-1-0701). The authors acknowledge the University of Pittsburgh Medical Center UPMC Trauma Registry team and the Brain Trauma Research Center for their role in data collection.	Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Berger RP, 2010, DEV NEUROSCI-BASEL, V32, P396, DOI 10.1159/000316803; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI 10.1089/neu.2008-0738; Bohmer AE, 2011, NEUROSURGERY, V68, P1624, DOI 10.1227/NEU.0b013e318214a81f; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Crownover J, 2012, CURR TRANSL IN PRESS; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Dimopoulou I, 2003, NEUROLOGY, V60, P947, DOI 10.1212/01.WNL.0000049931.77887.7F; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; Gazzolo D, 2001, CLIN CHEM, V47, P1132; GOLDSTEIN GW, 1986, SCI AM, V255, P74, DOI 10.1038/scientificamerican0986-74; Goncalves CA, 2008, CLIN BIOCHEM, V41, P755, DOI 10.1016/j.clinbiochem.2008.04.003; Hasselblatt M, 2004, NEUROLOGY, V62, P1634, DOI 10.1212/01.WNL.0000123092.97047.B1; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; JENNETT B, 1975, LANCET, V1, P480; Jones BL, 2001, SOCIOL METHOD RES, V29, P374, DOI 10.1177/0049124101029003005; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Kleindienst A, 2010, ACTA NEUROCHIR SUPPL, V106, P247, DOI 10.1007/978-3-211-98811-4_46; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kleindienst Andrea, 2010, Cardiovasc Psychiatry Neurol, V2010, P801295, DOI 10.1155/2010/801295; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Korfias S, 2006, CURR MED CHEM, V13, P3719, DOI 10.2174/092986706779026129; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Michetti F, 2002, CLIN CHEM, V48, P2097; Michetti F, 2012, J NEUROCHEM, V120, P644, DOI 10.1111/j.1471-4159.2011.07612.x; Missler U, 1999, CLIN CHEM, V45, P138; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Niyankuru C., 2013, J NEUROTRAU IN PRESS; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; REEVES RH, 1994, P NATL ACAD SCI USA, V91, P5359, DOI 10.1073/pnas.91.12.5359; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; TEASDALE G, 1974, LANCET, V2, P81; Townend W, 2006, INJURY, V37, P1098, DOI 10.1016/j.injury.2006.07.014; Ucar T, 2004, J TRAUMA, V57, P95, DOI 10.1097/01.TA.0000071352.95491.75; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; van Leeuwen N, 2012, NEUROSURGERY, V70, P811, DOI 10.1227/NEU.0b013e318235d640; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wagner AK, 2011, J CEREBR BLOOD F MET, V31, P1886, DOI 10.1038/jcbfm.2011.31; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Watson P, 2005, AM J PHYSIOL-REG I, V288, pR1689, DOI 10.1152/ajpregu.00676.2004; Zafonte R, 2009, J NEUROTRAUM, V26, P2207, DOI 10.1089/neu.2009.1015	64	86	89	1	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2013	30	11					946	957		10.1089/neu.2012.2579			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	166WD	WOS:000320589300005	23190274	Green Published			2022-02-06	
J	Liu, XQ; Zhou, CL; Li, YJ; Ji, Y; Xu, GP; Wang, XT; Yan, JL				Liu, Xiaoqi; Zhou, Changlong; Li, Yanjing; Ji, Ye; Xu, Gongping; Wang, Xintao; Yan, Jinglong			SDF-1 Promotes Endochondral Bone Repair during Fracture Healing at the Traumatic Brain Injury Condition	PLOS ONE			English	Article							MESENCHYMAL STEM-CELLS; HEAD-INJURY; ENHANCED OSTEOGENESIS; IN-VITRO; MYOCARDIAL-INFARCTION; MARROW; GROWTH; MIGRATION; MODEL; RATS	Purposes: The objective of this study was to investigate the role of stromal cell-derived factor-1 (SDF-1) and its receptor, CXCR4, on bone healing and whether SDF-1 contributes to accelerating bone repair in traumatic brain injury (TBI)/fracture model. Materials and Methods: Real-time polymerase chain reaction and immunohistochemical analysis were used to detect the expression of SDF-1 during the repair of femoral bone in TBI/fracture model. The TBI/fracture model was treated with anti-SDF-1 neutralizing antibody or AMD3100, an antagonist for CXCR4, and evaluated by histomorphometry. In vitro and in vivo migration assays were used to evaluate the functional effect of SDF-1 on primary mesenchymal stem cells. Results: The expression of SDF1 and CXCR4 messenger RNA was increased during the bone healing in TBI/fracture model but was less increased in fracture only model. High expression of SDF-1 protein was observed in the surrounding tissue of the damaged bone. Treated with anti-SDF-1 antibody or AMD3100 could inhibit new bone formation. SDF-1 increased mesenchymal stem cell chemotaxis in vitro in a dose-dependent manner. The in vivo migration study demonstrated that mesenchymal stem cells recruited by SDF-1 participate in endochondral bone repair. Conclusion: The SDF-1/CXCR4 axis plays a crucial role in the accelerating fracture healing under the condition of TBI and contributes to endochondral bone repair.	[Liu, Xiaoqi; Zhou, Changlong; Li, Yanjing; Ji, Ye; Xu, Gongping; Wang, Xintao; Yan, Jinglong] Harbin Med Univ, Affiliated Hosp 1, Dept Orthoped Surg, Harbin, Peoples R China		Yan, JL (corresponding author), Harbin Med Univ, Affiliated Hosp 1, Dept Orthoped Surg, Harbin, Peoples R China.	yanjlhyd@hotmail.com		Liu, Geoffrey/0000-0002-2603-7296	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [100334]	The National Natural Science Foundation of China (100334) (http://www.nsfc.gov.cn/Portal0/default152.htm). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbott JD, 2004, CIRCULATION, V110, P3300, DOI 10.1161/01.CIR.0000147780.30124.CF; Beeton CA, 2004, J BONE JOINT SURG BR, V86B, P912, DOI 10.1302/0301-620x.86b6.14176; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115; Castano-Izquierdo H, 2007, J BIOMED MATER RES A, V82A, P129, DOI 10.1002/jbm.a.31082; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Guo ZK, 2006, STEM CELLS, V24, P992, DOI 10.1634/stemcells.2005-0224; HaraIrie F, 1996, BONE, V18, P29, DOI 10.1016/8756-3282(95)00425-4; Ji JF, 2004, STEM CELLS, V22, P415, DOI 10.1634/stemcells.22-3-415; Jung Y, 2006, BONE, V38, P497, DOI 10.1016/j.bone.2005.10.003; Khare G N, 1995, Indian J Med Sci, V49, P281; Kioi M, 2010, J CLIN INVEST, V120, P694, DOI 10.1172/JCI40283; Kucia M, 2004, BLOOD CELL MOL DIS, V32, P52, DOI 10.1016/j.bcmd.2003.09.025; Liu XQ, 2012, BIOTECHNOL LETT, V34, P387, DOI 10.1007/s10529-011-0757-7; Ma J, 2005, BASIC RES CARDIOL, V100, P217, DOI 10.1007/s00395-005-0521-z; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mori T, 2004, MOL CANCER THER, V3, P29; Otfinowski Janusz, 1993, Patologia Polska, V44, P133; RENFREE KJ, 1994, SPINE, V19, P740, DOI 10.1097/00007632-199404000-00002; Son BR, 2006, STEM CELLS, V24, P1254, DOI 10.1634/stemcells.2005-0271; Sordi V, 2005, BLOOD, V106, P419, DOI 10.1182/blood-2004-09-3507; SPENCER RF, 1990, S AFR J SURG, V28, P51; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525, DOI 10.1302/0301-620X.69B4.3611151; Sun YX, 2005, J BONE MINER RES, V20, P318, DOI 10.1359/JBMR.041109; Thevenot PT, 2010, BIOMATERIALS, V31, P3997, DOI 10.1016/j.biomaterials.2010.01.144; Tiyapatanaputi P, 2004, J ORTHOP RES, V22, P1254, DOI 10.1016/j.orthres.2004.03.017; Togel F, 2005, KIDNEY INT, V67, P1772, DOI 10.1111/j.1523-1755.2005.00275.x; Tsur A, 1996, BRAIN INJURY, V10, P259, DOI 10.1080/026990596124430; Wieczorek G, 2003, CELL TISSUE RES, V311, P227, DOI 10.1007/s00441-002-0671-3; WILDBURGER R, 1995, EUR J CLIN CHEM CLIN, V33, P693; WILDBURGER R, 1994, BONE MINER, V27, P183, DOI 10.1016/S0169-6009(08)80192-4; WILDBURGER R, 1994, RES EXP MED, V194, P247, DOI 10.1007/BF02576386; Wildburger R, 1998, J ENDOCRINOL INVEST, V21, P78, DOI 10.1007/BF03350319; Zhang G, 2007, TISSUE ENG, V13, P2063, DOI 10.1089/ten.2006.0013	35	86	94	1	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2013	8	1							e54077	10.1371/journal.pone.0054077			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	077HS	WOS:000314019100041	24130878	Green Published, gold, Green Submitted			2022-02-06	
J	McIntyre, A; Mehta, S; Aubut, J; Dijkers, M; Teasell, RW				McIntyre, Amanda; Mehta, Swati; Aubut, Joanne; Dijkers, Marcel; Teasell, Robert W.			Mortality among older adults after a traumatic brain injury: A meta-analysis	BRAIN INJURY			English	Article						older adult; mortality; Glasgow Coma Scale; traumatic brain injury	SEVERE HEAD-INJURY; ELDERLY-PATIENTS; PREEXISTING CONDITIONS; GERIATRIC TRAUMA; AGE; RISK; POPULATION; SEVERITY; CARE; PREDICTOR	Primary objective: To examine mortality rates among older adults (>= 60 years) post-traumatic brain injury (TBI). Research design: Systematic review and meta-analysis. Methods and procedures: Using multiple databases, a literature search was conducted for articles on mortality after TBI published up to July 2011. Information on patient characteristics (age, Glasgow Coma Scale (GCS), injury aetiology, etc.), mortality rates, time to death and study design was extracted and pooled. Main outcomes and results: Twenty-four studies had an overall mortality rate of 38.3% (CI 27.1-50.9%). The odds of mortality for those over 75 years compared to those of 65-74 years was 1.734 (CI=1.311-2.292; p<0.0001). Pooled mortality rates for mild (GCS 13-15), moderate (GCS 9-12) and severe (GCS 3-8) head injuries were 12.3% (CI=6.1-23.3%), 34.3% (CI=19.5-53.0%) and 65.3% (CI=53.1-75.9), respectively. Odds ratios comparing severe to mild and moderate to mild head injuries were 12.69 (CI=5.29-30.45; p<0.0001) and 5.31 (CI=3.41-8.29; p<0.0001), respectively. There was no significant difference in the odds of death between severe and moderate injuries (p=0.116). Conclusions: These mortality rates associated with moderate and severe injuries may be attributed to complications, chronic disease prevalence, conservative management techniques or the consequences of biological ageing.	[McIntyre, Amanda; Mehta, Swati; Aubut, Joanne; Teasell, Robert W.] St Josephs Parkwood Hosp, Lawson Hlth Res Inst, London, ON, Canada; [Dijkers, Marcel] Mt Sinai, Dept Rehabil Med, New York, NY USA; [Teasell, Robert W.] Univ Western Ontario, Dept Phys Med & Rehabil, London, ON, Canada		Teasell, RW (corresponding author), Parkwood Hosp, Dept Phys Med & Rehabil, Hobbins Bldg,Suite 404,801 Commissioners Rd E, London, ON N6C 5J1, Canada.	robert.teasell@sjhc.london.on.ca	Heinemann, Allen W/K-6283-2012	Heinemann, Allen W/0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596			Battistella FD, 1998, J TRAUMA, V44, P618, DOI 10.1097/00005373-199804000-00010; Bouras T, 2007, J NEUROTRAUM, V24, P1355, DOI 10.1089/neu.2005.370; Bowen RL, 2004, GERONTOLOGY, V50, P265, DOI 10.1159/000079125; Canadian Institute for Health Information, 2006, HEAD INJ CAN DEC CHA; Colantonio A, 2008, J TRAUMA, V64, P876, DOI 10.1097/TA.0b013e31804d493e; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Dijkers M, 2008, BRAIN INJURY PROFESS, V5, P8; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Ferrell Richard B, 2002, Curr Psychiatry Rep, V4, P354; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Gan BK, 2004, ANN ACAD MED SINGAP, V33, P63; Gomez PA, 2000, ACTA NEUROCHIR, V142, P373, DOI 10.1007/s007010050445; Grossman MD, 2002, J TRAUMA, V52, P242, DOI 10.1097/00005373-200202000-00007; Hartl R, 2008, J NEUROSURG, V109, P50, DOI 10.3171/JNS/2008/109/7/0050; Harris C, 2003, J AM COLL SURGEONS, V197, P711, DOI 10.1016/S1072-7515(03)00729-4; HAYFLICK L, 1994, WHY WE AGE; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Kuhne CA, 2005, WORLD J SURG, V29, P1476, DOI 10.1007/s00268-005-7796-y; Lane P, 2003, ACAD EMERG MED, V10, P244, DOI 10.1197/aemj.10.3.244; Linn S, 2007, ANN EPIDEMIOL, V17, P142, DOI 10.1016/j.annepidem.2006.08.004; Lix LM, 2008, PUBLIC HLTH AGENCY C, V18; MILZMAN DP, 1992, J TRAUMA, V32, P236, DOI 10.1097/00005373-199202000-00021; Mohindra S, 2008, SURG NEUROL, V69, P474, DOI 10.1016/j.surneu.2007.02.031; MORRIS JA, 1990, JAMA-J AM MED ASSOC, V263, P1942, DOI 10.1001/jama.263.14.1942; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Murdoch BE, 2001, TRAUMATIC BRAIN INJU; Patel HC, 2010, ACTA NEUROCHIR, V152, P1353, DOI 10.1007/s00701-010-0666-x; Rapoport MJ, 2000, BRAIN INJURY, V14, P749; Ratcliff G, 2005, DISABIL REHABIL, V27, P305, DOI 10.1080/09638280400018338; Ritchie PD, 2000, J CLIN NEUROSCI, V7, P301, DOI 10.1054/jocn.1999.0198; Salthouse T. A, 1992, HDB AGING COGNITION; Sanchez-Olmedo JI, 2005, TRANSPL P, V37, P1990, DOI 10.1016/j.transproceed.2005.03.048; Sarani B, 2009, J TRAUMA, V67, P954, DOI 10.1097/TA.0b013e3181ae6d39; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Shavelle R, 2000, J Insur Med, V32, P163; Siram SM, 2011, J SURG RES, V167, P14, DOI 10.1016/j.jss.2010.10.007; Skoglund TS, 2005, ACTA ANAESTH SCAND, V49, P337, DOI 10.1111/j.1399-6576.2005.00624.x; Spaniolas K, 2010, J TRAUMA, V69, P821, DOI 10.1097/TA.0b013e3181efc6c6; SPENCE AP, 1995, BIOL HUMAN AGING; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TEASDALE G, 1974, LANCET, V2, P81; Thompson HJ, 2008, CRIT CARE MED, V36, P282, DOI 10.1097/01.CCM.0000297884.86058.8A; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Tokutomi T, 2008, J NEUROTRAUM, V25, P1407, DOI 10.1089/neu.2008.0577; Ushewokunze S, 2004, BRIT J NEUROSURG, V18, P604, DOI 10.1080/02688690400022763; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Wagner AK, 2001, PHYS MED REHABIL STA, V15, P245	50	86	86	2	17	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2013	27	1					31	40		10.3109/02699052.2012.700086			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	059IY	WOS:000312699300004	23163240				2022-02-06	
J	Dzhala, V; Valeeva, G; Glykys, J; Khazipov, R; Staley, K				Dzhala, Volodymyr; Valeeva, Guzel; Glykys, Joseph; Khazipov, Rustem; Staley, Kevin			Traumatic Alterations in GABA Signaling Disrupt Hippocampal Network Activity in the Developing Brain	JOURNAL OF NEUROSCIENCE			English	Article							CATION-CHLORIDE COTRANSPORTERS; GIANT DEPOLARIZING POTENTIALS; GRAMICIDIN-PERFORATED-PATCH; NEONATAL-RAT HIPPOCAMPUS; TEMPORAL-LOBE EPILEPSY; K-CL COTRANSPORTER; IN-VITRO ISCHEMIA; EXCITATORY ACTIONS; INTRACELLULAR CHLORIDE; ELECTROGRAPHIC SEIZURES	Severe head trauma causes widespread neuronal shear injuries and acute seizures. Shearing of neural processes might contribute to seizures by disrupting the transmembrane ion gradients that subserve normal synaptic signaling. To test this possibility, we investigated changes in intracellular chloride concentration ([Cl-](i)) associated with the widespread neural shear injury induced during preparation of acute brain slices. In hippocampal slices and intact hippocampal preparations from immature CLM-1 mice, increases in [Cl-](i) correlated with disruption of neural processes and biomarkers of cell injury. Traumatized neurons with higher [Cl-](i) demonstrated excitatory GABA signaling, remained synaptically active, and facilitated network activity as assayed by the frequency of extracellular action potentials and spontaneous network-driven oscillations. These data support a more inhibitory role for GABA in the unperturbed immature brain, demonstrate the utility of the acute brain slice preparation for the study of the consequences of trauma, and provide potential mechanisms for both GABA-mediated excitatory network events in the slice preparation and early post-traumatic seizures.	[Dzhala, Volodymyr; Glykys, Joseph; Staley, Kevin] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Dzhala, Volodymyr; Glykys, Joseph; Staley, Kevin] Harvard Univ, Sch Med, Boston, MA 02114 USA; [Valeeva, Guzel; Khazipov, Rustem] Natl Inst Hlth & Med Res, INSERM, U901, F-13273 Marseille, France; [Valeeva, Guzel; Khazipov, Rustem] Kazan Fed Univ, Kazan 420008, Russia		Staley, K (corresponding author), MIND, Dept Neurol, MGH 16th St,CNY B-114,Room 2600, Charlestown, MA 02129 USA.	kstaley@partners.org	Valeeva, Guzel/B-2864-2014; Khazipov, Roustem/M-1834-2016	Valeeva, Guzel/0000-0001-6745-059X; Khazipov, Roustem/0000-0002-6763-2841; Glykys, Joseph/0000-0002-1499-9172	U.S. National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 40109-06]; FRMFondation pour la Recherche Medicale; Agence National de la RechercheFrench National Research Agency (ANR); RF Government [11.G34.31.0075]; Russian Foundation for Basic ResearchRussian Foundation for Basic Research (RFBR); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034700, R01NS074772, R01NS040109] Funding Source: NIH RePORTER	This work was supported by the U.S. National Institutes of Health and National Institute of Neurological Disorders and Stroke Grant NS 40109-06 to K. S., by FRM, Agence National de la Recherche, and RF Government 11.G34.31.0075 grants to R. K., and Russian Foundation for Basic Research grant to G. V. We thank our colleagues for discussion of the manuscript.	BAK IJ, 1980, BRAIN RES, V197, P341, DOI 10.1016/0006-8993(80)91120-8; Ben-Ari Y, 1987, Electroencephalogr Clin Neurophysiol Suppl, V39, P209; Ben-Ari Y, 2007, PHYSIOL REV, V87, P1215, DOI 10.1152/physrev.00017.2006; BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; Berglund K, 2008, BRAIN CELL BIOL, V36, P101, DOI 10.1007/s11068-008-9031-x; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Blaesse P, 2009, NEURON, V61, P820, DOI 10.1016/j.neuron.2009.03.003; Bonifazi P, 2009, SCIENCE, V326, P1419, DOI 10.1126/science.1175509; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Brandt C, 2010, J NEUROSCI, V30, P8602, DOI 10.1523/JNEUROSCI.0633-10.2010; Brumback AC, 2008, J NEUROSCI, V28, P1301, DOI 10.1523/JNEUROSCI.3378-07.2008; Cancedda L, 2007, J NEUROSCI, V27, P5224, DOI 10.1523/JNEUROSCI.5169-06.2007; CHERUBINI E, 1991, TRENDS NEUROSCI, V14, P515, DOI 10.1016/0166-2236(91)90003-D; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Cohen I, 2002, SCIENCE, V298, P1418, DOI 10.1126/science.1076510; Cohen I, 2000, J PHYSIOL-LONDON, V524, P485, DOI 10.1111/j.1469-7793.2000.00485.x; Darzynkiewicz Z, 2011, METHODS MOL BIOL, V682, P103, DOI 10.1007/978-1-60327-409-8_9; Davies ML, 2007, J NEUROSCI METH, V166, P203, DOI 10.1016/j.jneumeth.2007.07.012; Delpire E, 2000, NEWS PHYSIOL SCI, V15, P309, DOI 10.1152/physiologyonline.2000.15.6.309; Delpire E, 2009, P NATL ACAD SCI USA, V106, P5383, DOI 10.1073/pnas.0812756106; Duebel J, 2006, NEURON, V49, P81, DOI 10.1016/j.neuron.2005.10.035; Dzhala VI, 2005, NAT MED, V11, P1205, DOI 10.1038/nm1301; Dzhala VI, 2003, J NEUROSCI, V23, P1840; Dzhala VI, 2008, ANN NEUROL, V63, P222, DOI 10.1002/ana.21229; Dzhala VI, 2010, J NEUROSCI, V30, P11745, DOI 10.1523/JNEUROSCI.1769-10.2010; EBIHARA S, 1995, J PHYSIOL-LONDON, V484, P77, DOI 10.1113/jphysiol.1995.sp020649; Galeffi F, 2004, J NEUROSCI, V24, P4478, DOI 10.1523/JNEUROSCI.0755-04.2004; Gamba G, 2005, PHYSIOL REV, V85, P423, DOI 10.1152/physrev.00011.2004; Ge SY, 2006, NATURE, V439, P589, DOI 10.1038/nature04404; Gilles EE, 1998, PEDIATR NEUROL, V19, P119, DOI 10.1016/S0887-8994(98)00038-1; Glickfeld LL, 2009, NAT NEUROSCI, V12, P21, DOI 10.1038/nn.2230; Glykys J, 2006, J NEUROPHYSIOL, V95, P2796, DOI 10.1152/jn.01122.2005; Glykys J, 2009, NEURON, V63, P657, DOI 10.1016/j.neuron.2009.08.022; Grashow R, 2010, J NEUROSCI, V30, P9145, DOI 10.1523/JNEUROSCI.0980-10.2010; Gulledge AT, 2003, NEURON, V37, P299, DOI 10.1016/S0896-6273(02)01146-7; Hannaert P, 2002, N-S ARCH PHARMACOL, V365, P193, DOI 10.1007/s00210-001-0521-y; Hasbani MJ, 1998, EXP NEUROL, V154, P241, DOI 10.1006/exnr.1998.6929; Hasbargen T, 2010, ANN NY ACAD SCI, V1198, P168, DOI 10.1111/j.1749-6632.2010.05462.x; Hoffmann EK, 2009, PHYSIOL REV, V89, P193, DOI 10.1152/physrev.00037.2007; Inglefield JR, 1998, J NEUROCHEM, V70, P2500; Inoue H, 2007, J NEUROSCI, V27, P1445, DOI 10.1523/JNEUROSCI.4694-06.2007; Isenring P, 1998, J BIOL CHEM, V273, P11295, DOI 10.1074/jbc.273.18.11295; Kahle KT, 2008, NAT CLIN PRACT NEURO, V4, P490, DOI 10.1038/ncpneuro0883; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Keenan HT, 2007, PEDIATRICS, V119, pE616, DOI 10.1542/peds.2006-2313; Khalilov I, 2003, NAT NEUROSCI, V6, P1079, DOI 10.1038/nn1125; Khalilov I, 1997, NEURON, V19, P743, DOI 10.1016/S0896-6273(00)80956-3; Khalilov I, 1999, DEV NEUROSCI-BASEL, V21, P310, DOI 10.1159/000017380; Khazipov R, 2004, EUR J NEUROSCI, V19, P590, DOI 10.1111/j.0953-816X.2003.03152.x; Kirov SA, 1999, J NEUROSCI, V19, P2876; KOCH C, 1983, P NATL ACAD SCI-BIOL, V80, P2799, DOI 10.1073/pnas.80.9.2799; Kuner T, 2000, NEURON, V27, P447, DOI 10.1016/S0896-6273(00)00056-8; Lado FA, 2002, EPILEPTIC DISORD, V4, P83; Lee Brian W., 2008, V414, P109; Leinekugel X, 2002, SCIENCE, V296, P2049, DOI 10.1126/science.1071111; Leinekugel X, 1998, J NEUROSCI, V18, P6349; Leinekugel X, 1997, NEURON, V18, P243, DOI 10.1016/S0896-6273(00)80265-2; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; Mazarati A, 2009, EPILEPSIA, V50, P2117, DOI 10.1111/j.1528-1167.2009.02048.x; Monnerie H, 2010, EXP NEUROL, V224, P415, DOI 10.1016/j.expneurol.2010.05.001; Murray DM, 2008, ARCH DIS CHILD-FETAL, V93, pF187, DOI 10.1136/adc.2005.086314; Nabekura J, 2002, J NEUROSCI, V22, P4412, DOI 10.1523/JNEUROSCI.22-11-04412.2002; Nardou R, 2011, BRAIN, V134, P987, DOI 10.1093/brain/awr041; Nardou R, 2009, J NEUROPHYSIOL, V101, P2878, DOI 10.1152/jn.90761.2008; Papp E, 2008, NEUROSCIENCE, V154, P677, DOI 10.1016/j.neuroscience.2008.03.072; Payne JA, 2003, TRENDS NEUROSCI, V26, P199, DOI 10.1016/S0166-2236(03)00068-7; Plotkin MD, 1997, J NEUROBIOL, V33, P781, DOI 10.1002/(SICI)1097-4695(19971120)33:6<781::AID-NEU6>3.0.CO;2-5; Pond BB, 2006, J NEUROSCI, V26, P1396, DOI 10.1523/JNEUROSCI.1421-05.2006; Rheims S, 2008, J NEUROPHYSIOL, V100, P609, DOI 10.1152/jn.90402.2008; Rheims S, 2009, J NEUROCHEM, V110, P1330, DOI 10.1111/j.1471-4159.2009.06230.x; ROTHMAN SM, 1985, J NEUROSCI, V5, P1483; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Scher MS, 2003, PEDIATR NEUROL, V28, P277, DOI 10.1016/S0887-8994(02)00621-5; Sipila ST, 2006, J PHYSIOL-LONDON, V573, P765, DOI 10.1113/jphysiol.2006.107086; Sipila ST, 2009, J NEUROSCI, V29, P6982, DOI 10.1523/JNEUROSCI.0443-09.2009; Sipila ST, 2005, J NEUROSCI, V25, P5280, DOI 10.1523/JNEUROSCI.0378-05.2005; STALEY KJ, 1992, J NEUROPHYSIOL, V68, P197, DOI 10.1152/jn.1992.68.1.197; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P512, DOI 10.1152/jn.1989.61.3.512; Tsourkas A, 2005, ANAL CHEM, V77, P2862, DOI 10.1021/ac0480747; Tyzio R, 2003, J NEUROPHYSIOL, V90, P2964, DOI 10.1152/jn.00172.2003; Tyzio R, 2008, EUR J NEUROSCI, V27, P2515, DOI 10.1111/j.1460-9568.2008.06234.x; Tyzio R, 2007, EPILEPSIA, V48, P96, DOI 10.1111/j.1528-1167.2007.01295.x; Tyzio R, 2011, J NEUROSCI, V31, P34, DOI 10.1523/JNEUROSCI.3314-10.2011; Valeeva G, 2010, FRONT CELL NEUROSCI, V4, DOI 10.3389/fncel.2010.00017; vandenPol AN, 1996, J NEUROSCI, V16, P4283; Wahab A, 2011, EPILEPSIA, V52, P94, DOI 10.1111/j.1528-1167.2010.02722.x; Wang Doris D, 2008, Epilepsy Curr, V8, P137, DOI 10.1111/j.1535-7511.2008.00270.x; Wirrell EC, 2001, PEDIATR RES, V50, P445, DOI 10.1203/00006450-200110000-00005; Wusthoff CJ, 2011, J CHILD NEUROL, V26, P724, DOI 10.1177/0883073810390036	91	86	87	0	14	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 21	2012	32	12					4017	4031		10.1523/JNEUROSCI.5139-11.2012			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	916RB	WOS:000302119800007	22442068	Green Accepted, Green Published, Bronze			2022-02-06	
J	Lau, BC; Collins, MW; Lovell, MR				Lau, Brian C.; Collins, Michael W.; Lovell, Mark R.			Cutoff Scores in Neurocognitive Testing and Symptom Clusters That Predict Protracted Recovery From Concussions in High School Athletes	NEUROSURGERY			English	Article						Concussion; Cutoffs; ImPACT; Prognosis; Receiver-operating characteristic curve; Return to play; Symptoms	SPORTS-RELATED CONCUSSION; FOOTBALL PLAYERS; IMPACT; SPECIFICITY; SENSITIVITY	BACKGROUND: Many studies address diagnosing concussions, but few look at predicting prognosis. A previous discriminant function analysis showed that symptom clusters derived from the Post-Concussion Symptom Scale and Immediate Post-concussion Assessment and Cognitive Testing composite scores used together improved predictions of protracted recovery after a sports-related concussion. OBJECTIVE: To determine cutoff scores in neurocognitive and Post-Concussion Symptom Scale symptom cluster scores when classifying protracted recovery in concussed athletes. METHODS: 108 male high school football athletes completed a computer-based neurocognitive test battery (Immediate Postconcussion Assessment and Cognitive Testing) within a median of 2 days after injury. Patients completed graded exertional protocols requiring athletes to be symptom free at rest and during increasing levels of activity and had recovery of neurocognitive scores before return to play. After return to play, athletes were classified as protracted recovery (>14 days, n = 58) or short-recovery (<= 14 days, n = 50). Receiver-operating characteristic curves analyzed each of the neurocognitive (verbal, visual, processing speed, and reaction time) and symptom cluster (migraine, cognitive, sleep, and neuropsychiatric) scores. RESULTS: Cutoffs for migraine cluster, cognitive cluster, visual memory, and processing speed were statistically significant. Cutoffs at 75%, 80%, and 85% sensitivity to predict protracted recovery for the migraine symptom cluster were 15 or greater, 18, 20; cognitive symptom cluster 18 or greater, 19, 22; visual memory 48 or less, 46, 44.5; and processing speed 24.5 or less, 23.46, 22.5, respectively. Eighty-percent sensitivity indicates that the corresponding cutoff correctly identify 80% of concussed athletes requiring protracted recovery. CONCLUSION: Specific cutoffs may help to set numerical thresholds for clinicians to predict which concussed athletes will have a protracted recovery.	[Lau, Brian C.] Univ Pittsburgh, Sch Med, UPMC Sports Med, Pittsburgh, PA 15203 USA; [Collins, Michael W.; Lovell, Mark R.] Univ Pittsburgh, Med Ctr, Sports Concuss Program, Dept Orthoped Surg, Pittsburgh, PA 15203 USA		Lau, BC (corresponding author), Univ Pittsburgh, Sch Med, UPMC Sports Med, 3200 S Water St, Pittsburgh, PA 15203 USA.	blau10@gmail.com					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gerst EH, 2011, J INT NEUROPSYCHO S1, V17, P134; Gioia GA, 2011, J INT NEUROPSYCHO S1, V17, P135; Gioia GA, 2010, J INT NEUROPSYCH SOC, V16, P178; Gioia Gerard, 2010, COMMITTEE ED LABOR U; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; ImPACT, 2003, IMPACT TEST COMP NEU; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Koch HJ, 2005, PATHOL ONCOL RES, V11, P50, DOI 10.1007/BF03032406; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory P, 2005, CLIN J SPORT MED, V15, P49; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Pardini D., 2004, BR J SPORTS MED, V38, P661; Randolph C, 2005, J ATHL TRAINING, V40, P139; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; ZWEIG MH, 1993, CLIN CHEM, V39, P561	32	86	86	0	26	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	FEB	2012	70	2					371	379		10.1227/NEU.0b013e31823150f0			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	879IK	WOS:000299322700038	21841522				2022-02-06	
J	Yu, FS; Wang, ZF; Tchantchou, F; Chiu, CT; Zhang, YM; Chuang, DM				Yu, Fengshan; Wang, Zhifei; Tchantchou, Flaubert; Chiu, Chi-Tso; Zhang, Yumin; Chuang, De-Maw			Lithium Ameliorates Neurodegeneration, Suppresses Neuroinflammation, and Improves Behavioral Performance in a Mouse Model of Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						GSK-3/beta; lithium; neuroinflammation; neuroprotection; traumatic brain injury	GLYCOGEN-SYNTHASE KINASE-3; FOCAL CEREBRAL-ISCHEMIA; SPINAL-CORD-INJURY; BARRIER BREAKDOWN; NEURONAL SURVIVAL; BIPOLAR DISORDER; RAT MODEL; CYCLOOXYGENASE-2; MICE; INHIBITION	Although traumatic brain injury (TBI) is recognized as one of the leading causes of death from trauma to the central nervous system (CNS), no known treatment effectively mitigates its effects. Lithium, a primary drug for the treatment of bipolar disorder, has been known to have neuroprotective effects in various neurodegenerative conditions such as stroke. Until this study, however, it has not been investigated as a post-insult treatment for TBI. To evaluate whether lithium could have beneficial effects following TBI, lithium at a dose of 1.5 mEq/kg was administered after injury. Assessed at 3 days and 3 weeks post-injury using hematoxylin and eosin staining, lithium treatment was found to reduce lesion volume. Lithium at doses of 2.0 and 3.0 mEq/kg also significantly reduced lesion volume at 3 days after injury, and the therapeutic window was at least 3 h post-injury. TBI-induced neuronal death, microglial activation, and cyclooxygenase-2 induction were all attenuated by lithium at 3 days after injury. In addition, lithium treatment reduced TBI-induced matrix metalloproteinase-9 expression and preserved the integrity of the blood brain barrier. As for behavioral outcomes, lithium treatment reduced anxiety-like behavior in an open-field test, and improved short- and long-term motor coordination in rotarod and beam-walk tests. Lithium robustly increased serine phosphorylation of glycogen synthase kinase-3 beta (GSK-3 beta), suggesting that the underlying mechanisms responsible for lithium's protective effects are triggered by increasing phosphorylation of this kinase and thereby inhibiting its activity. Our results support the notion that lithium has heretofore unrecognized capacity to mitigate the neurodegenerative effects and improve functional outcomes in TBI.	[Yu, Fengshan; Wang, Zhifei; Chiu, Chi-Tso; Chuang, De-Maw] NIMH, Mol Neurobiol Sect, NIH, Bethesda, MD 20892 USA; [Yu, Fengshan; Zhang, Yumin; Chuang, De-Maw] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Yu, Fengshan; Tchantchou, Flaubert; Zhang, Yumin] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA		Chuang, DM (corresponding author), NIMH, Mol Neurobiol Sect, NIH, 10 Ctr Dr,MSC 1363, Bethesda, MD 20892 USA.	yzhang@usuhs.mil; chuang@mail.nih.gov	Wang, Zhifei/I-2787-2013	Yu, Fengshan/0000-0001-8620-3084	Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; Blast Lethality Injury and Research Program; National Institute of Mental Health, National Institutes of Health (NIMH-NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH); NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [ZIAMH002468] Funding Source: NIH RePORTER	Support for this work included funding from the Department of Defense in the Center for Neuroscience and Regenerative Medicine, the Blast Lethality Injury and Research Program, and the Intramural Research Program of the National Institute of Mental Health, National Institutes of Health (NIMH-NIH). The authors wish to gratefully acknowledge the editorial assistance of Dr. Elizabeth Sherman, Ioline Henter, and Peter Leeds of the NIMH. We are also grateful to Dr. Oz Malkesman, Laura Tucker, and Dr. Amanda Fu from the Center for Neuroscience and Regenerative Medicine for help with behavioral tests and CCI surgery.	Adachi M, 2008, BIOL PSYCHIAT, V63, P642, DOI 10.1016/j.biopsych.2007.09.019; Ahmad M, 2008, J NEUROSCI RES, V86, P3605, DOI 10.1002/jnr.21809; Andreasson K, 2010, PROSTAG OTH LIPID M, V91, P104, DOI 10.1016/j.prostaglandins.2009.04.003; Beaulieu JM, 2004, P NATL ACAD SCI USA, V101, P5099, DOI 10.1073/pnas.0307921101; Beurel E, 2010, TRENDS IMMUNOL, V31, P24, DOI 10.1016/j.it.2009.09.007; Bijur GN, 2000, J NEUROCHEM, V75, P2401, DOI 10.1046/j.1471-4159.2000.0752401.x; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Cheng T, 2006, NAT MED, V12, P1278, DOI 10.1038/nm1498; Chiu CT, 2010, PHARMACOL THERAPEUT, V128, P281, DOI 10.1016/j.pharmthera.2010.07.006; Chuang DM, 2007, BIOL PSYCHIAT, V62, P4, DOI 10.1016/j.biopsych.2007.04.008; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Faul M, 2010, TRAUMATIC BRAIN INJU; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Jope RS, 2003, TRENDS PHARMACOL SCI, V24, P441, DOI 10.1016/S0165-6147(03)00206-2; Jope RS, 1999, MOL PSYCHIATR, V4, P117, DOI 10.1038/sj.mp.4000494; Kelso ML, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-108; Kim HJ, 2007, J PHARMACOL EXP THER, V321, P892, DOI 10.1124/jpet.107.120188; Kirshenboim N, 2004, J MOL NEUROSCI, V24, P237, DOI 10.1385/JMN:24:2:237; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Koh SH, 2008, BIOCHEM BIOPH RES CO, V371, P894, DOI 10.1016/j.bbrc.2008.05.006; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; Kunz T, 2006, RESTOR NEUROL NEUROS, V24, P55; Li XH, 2010, NEUROPSYCHOPHARMACOL, V35, P2143, DOI 10.1038/npp.2010.105; Liang MH, 2007, J BIOL CHEM, V282, P3904, DOI 10.1074/jbc.M605178200; Liang MH, 2006, J BIOL CHEM, V281, P30479, DOI 10.1074/jbc.M607468200; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Niwa K, 2000, J NEUROSCI, V20, P763, DOI 10.1523/JNEUROSCI.20-02-00763.2000; Nonaka S, 1998, NEUROREPORT, V9, P2081, DOI 10.1097/00001756-199806220-00031; Omata N, 2011, INT J NEUROPSYCHOPH, V14, P711, DOI 10.1017/S1461145710000726; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Quiroz JA, 2010, NEUROPSYCHOBIOLOGY, V62, P50, DOI 10.1159/000314310; Ren M, 2003, P NATL ACAD SCI USA, V100, P6210, DOI 10.1073/pnas.0937423100; Rosell A, 2008, STROKE, V39, P1121, DOI 10.1161/STROKEAHA.107.500868; Rowe MK, 2007, NEUROSCI BIOBEHAV R, V31, P920, DOI 10.1016/j.neubiorev.2007.03.002; Sassi RB, 2002, NEUROSCI LETT, V329, P243, DOI 10.1016/S0304-3940(02)00615-8; Senatorov VV, 2004, MOL PSYCHIATR, V9, P371, DOI 10.1038/sj.mp.4001463; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Shein NA, 2009, FASEB J, V23, P4266, DOI 10.1096/fj.09-134700; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; Walker CT, 2010, BRAIN RES, V1347, P125, DOI 10.1016/j.brainres.2010.05.075; Wang ZF, 2011, J CEREBR BLOOD F MET, V31, P52, DOI 10.1038/jcbfm.2010.195; Yasuda S, 2009, MOL PSYCHIATR, V14, P51, DOI 10.1038/sj.mp.4002099; Yu F, 2008, J NEUROTRAUM, V25, P184, DOI 10.1089/neu.2007.0438; Yu I, 2010, J NEUROTRAUM, V27, P1463, DOI 10.1089/neu.2009.1196; Yuskaitis CJ, 2009, CELL SIGNAL, V21, P264, DOI 10.1016/j.cellsig.2008.10.014; Zhu ZF, 2010, BRAIN RES BULL, V83, P272, DOI 10.1016/j.brainresbull.2010.07.008	59	86	89	1	11	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					362	374		10.1089/neu.2011.1942			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300015	21895523	Green Published			2022-02-06	
J	Morissette, SB; Woodward, M; Kimbrel, NA; Meyer, EC; Kruse, MI; Dolan, S; Gulliver, SB				Morissette, Sandra B.; Woodward, Matthew; Kimbrel, Nathan A.; Meyer, Eric C.; Kruse, Marc I.; Dolan, Sara; Gulliver, Suzy Bird			Deployment-Related TBI, Persistent Postconcussive Symptoms, PTSD, and Depression in OEF/OIF Veterans	REHABILITATION PSYCHOLOGY			English	Article						PTSD; TBI; postconcussive symptoms; veterans	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; IRAQ WAR VETERANS; UNITED-STATES; PSYCHOMETRIC PROPERTIES; LIFE SATISFACTION; MILD; SOLDIERS; COMBAT	Objective: A substantial proportion of the more than 2 million service members who have served in Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF) have experienced a traumatic brain injury (TBI). Understanding the long-term impact of TBI is complicated by the nonspecific nature of postconcussive symptoms (PCSs) and the high rates of co-occurrence among TBI, posttraumatic stress disorder (PTSD), and depression. The goal of the present research was to examine the relations among TB!, persistent PCSs, and symptoms of PTSD and depression among returning OEF/OIF veterans. Method: 213 OEF/OIF veterans (87% male) completed a semistructured screening interview assessing deployment-related TBI and current, persistent PCSs. Participants also completed self-report measures of combat exposure and current symptoms of PTSD and depression. Results: Nearly half (46%) of sampled veterans screened positive for TBI, the majority of whom (85%) reported at least one persistent PCS after removing PCSs that overlapped with PTSD and depression. Veterans with deployment-related TBI reported higher levels of combat exposure and symptoms of PTSD and depression. Structural equation modeling was used to assess the fit of 3 models of the relationships among TBI, combat exposure, persistent PCSs, PTSD, and depression. Consistent with hypotheses, the best-fitting model was one in which the effects of TBI on both PTSD and depression were fully mediated by nonoverlapping persistent PCSs. Conclusions: These findings highlight the importance of addressing persistent PCSs in order to facilitate the functional recovery of returning war veterans.	[Morissette, Sandra B.; Woodward, Matthew; Kimbrel, Nathan A.; Meyer, Eric C.; Kruse, Marc I.; Gulliver, Suzy Bird] Ctr Excellence Res Returning War Vet, Dept Vet Affairs VISN 17, Waco, TX USA; [Morissette, Sandra B.; Kimbrel, Nathan A.; Meyer, Eric C.; Kruse, Marc I.; Gulliver, Suzy Bird] Texas A&M Hlth Sci Ctr, Coll Med, Bryan, TX USA; [Dolan, Sara] Baylor Univ, Dept Psychol & Neurosci, Waco, TX 76798 USA		Morissette, SB (corresponding author), 4800 Mem Dr,151C, Waco, TX 76711 USA.	sandra.morissette@va.gov	Gulliver, Suzy/X-9776-2019; Kimbrel, Nathan/P-3109-2016; Woodward, Matthew J./L-2971-2019	Kimbrel, Nathan/0000-0001-7218-1005; Dolan, Sara/0000-0002-0156-8226; Gulliver, Suzy Bird/0000-0002-6476-9447	Veterans AffairsUS Department of Veterans Affairs [I01RX000304] Funding Source: NIH RePORTER; RRD VA [I01 RX000304] Funding Source: Medline; VAUS Department of Veterans Affairs [5I01RX000304-02] Funding Source: Federal RePORTER		Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Arbuckle J. L., 2006, AMOS 7 0 USERS GUIDE; Armed Forces Health Surveillance Center, 2011, DOD NUMB TRAUM BRAIN; Bagozzi RP, 1994, STRUCT EQU MODELING, V1, P35, DOI 10.1080/10705519409539961; Barth JT, 2006, PSYCHOLOGICAL KNOWLEDGE IN COURT: PTSD, PAIN, AND TBI, P271, DOI 10.1007/0-387-25610-5_15; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder S, 2003, REPORT C MILD TRAUMA; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bullman TA, 1996, AM J PUBLIC HEALTH, V86, P662, DOI 10.2105/AJPH.86.5.662; BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Defense Manpower Data Center, 2009, OEF OIF DEPL SEPT 11; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Enders C. K., 2010, APPL MISSING DATA AN; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Faul M, 2010, TRAUMATIC BRAIN INJU; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Gordon SN, 2011, CLIN NEUROPSYCHOL, V25, P337, DOI 10.1080/13854046.2010.550634; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; HOLLNAGEL H, 1980, Ugeskrift for Laeger, V142, P3071; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Jaffee CMS, 2009, CLIN NEUROPSYCHOL, V23, P1291, DOI 10.1080/13854040903307250; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kang HK, 2008, JAMA-J AM MED ASSOC, V300, P652, DOI 10.1001/jama.300.6.652; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; Kline R.B., 2005, PRINCIPLES PRACTICE, V2nd; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; Leone L, 2001, EUR J PERSONALITY, V15, P373, DOI 10.1002/per.415; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Pomerantz AS, 2010, FAM SYST HEALTH, V28, P114, DOI 10.1037/a0020261; Porto PR, 2009, J NEUROPSYCH CLIN N, V21, P114, DOI 10.1176/appi.neuropsych.21.2.114; Qureshi SU, 2011, J NEUROPSYCH CLIN N, V23, P16, DOI 10.1176/appi.neuropsych.23.1.16; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Resch JA, 2009, REHABIL PSYCHOL, V54, P51, DOI 10.1037/a0015051; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schwab KA, 2006, NEUROLOGY, V66, pA235; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling J. J., 2008, TBI SCREENING UNPUB; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Veterans Benefits Administration, 2010, VET BEN ADM ANN BEN; Veterans Health Administration Office of Public Health and Environmental Hazards, 2010, AN VA HLTH CAR UT US; Weathers F.W., 1993, ANN CONV INT SOC TRA; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wright KM, 2009, PSYCHOL SERV, V6, P108, DOI 10.1037/a0012620; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	78	86	87	0	19	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2011	56	4					340	350		10.1037/a0025462			11	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	862AQ	WOS:000298062600007	22121940	Green Accepted			2022-02-06	
J	Xu, S; Zhuo, JC; Racz, J; Shi, D; Roys, S; Fiskum, G; Gullapalli, R				Xu, Su; Zhuo, Jiachen; Racz, Jennifer; Shi, Da; Roys, Steven; Fiskum, Gary; Gullapalli, Rao			Early Microstructural and Metabolic Changes following Controlled Cortical Impact Injury in Rat: A Magnetic Resonance Imaging and Spectroscopy Study	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; diffusion tensor imaging; early changes; MR spectroscopy; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SWELLING-ACTIVATED RELEASE; ACUTE PATHOLOGICAL-CHANGES; PROTON MR SPECTROSCOPY; DIFFUSE AXONAL INJURY; ACUTE HEAD-INJURY; N-ACETYLASPARTATE; MITOCHONDRIAL DYSFUNCTION; CHRONIC HYPONATREMIA; OUTCOME PREDICTION	Understanding tissue alterations at an early stage following traumatic brain injury (TBI) is critical for injury management and limiting severe consequences from secondary injury. We investigated the early microstructural and metabolic profiles using in vivo diffusion tensor imaging (DTI) and proton magnetic resonance spectroscopy (H-1 MRS) at 2 and 4 h following a controlled cortical impact injury in the rat brain using a 7.0 Tesla animal MRI system and compared profiles to baseline. Significant decrease in mean diffusivity (MD) and increased fractional anisotropy (FA) was found near the impact site (hippocampus and bilateral thalamus; p < 0.05) immediately following TBI, suggesting cytotoxic edema. Although the DTI parameters largely normalized on the contralateral side by 4 h, a large inter-individual variation was observed with a trend towards recovery of MD and FA in the ipsilateral hippocampus and a sustained elevation of FA in the ipsilateral thalamus (p < 0.05). Significant reduction in metabolite to total creatine ratios of N-acetylaspartate (NAA, p = 0.0002), glutamate (p = 0.0006), myoinositol (Ins, p = 0.04), phosphocholine and glycerophosphocholine (PCh + GPC, p = 0.03), and taurine (Tau, p = 0.009) were observed ipsilateral to the injury as early as 2 h, while glutamine concentration increased marginally (p = 0.07). These metabolic alterations remained sustained over 4 h after TBI. Significant reductions of Ins (p = 0.024) and Tau (p = 0.013) and marginal reduction of NAA (p = 0.06) were also observed on the contralateral side at 4 h after TBI. Overall our findings suggest significant microstructural and metabolic alterations as early as 2 h following injury. The tendency towards normalization at 4 h from the DTI data and no further metabolic changes at 4 h from MRS suggest an optimal temporal window of about 3 h for interventions that might limit secondary damage to the brain. Results indicate that early assessment of TBI patients using DTI and MRS may provide valuable information on the available treatment window to limit secondary brain damage.	[Xu, Su; Zhuo, Jiachen; Shi, Da; Roys, Steven; Gullapalli, Rao] Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, Baltimore, MD 21201 USA; [Racz, Jennifer; Fiskum, Gary] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Racz, Jennifer; Fiskum, Gary] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA		Gullapalli, R (corresponding author), Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, 22 S Greene St, Baltimore, MD 21201 USA.	gullapalli@umm.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1S10RR019935]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR019935] Funding Source: NIH RePORTER	This study was supported in part by grants from the National Institutes of Health (1S10RR019935).	Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Arieff A I, 1987, Adv Intern Med, V32, P325; Arnold DL, 1996, MR SPECTROSCOPY CLIN, P139; Baslow MH, 2003, NEUROCHEM RES, V28, P941, DOI 10.1023/A:1023250721185; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bothwell JH, 2001, J NEUROCHEM, V77, P1632, DOI 10.1046/j.1471-4159.2001.00403.x; BRAND A, 1993, DEV NEUROSCI-BASEL, V15, P289, DOI 10.1159/000111347; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; Cooper CE, 2000, BIOCHEM SOC T, V28, P121, DOI 10.1042/bst0280121; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DUTTON GR, 1991, ANN NY ACAD SCI, V633, P489; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; FRAHM J, 1986, MAGNET RESON MED, V3, P321, DOI 10.1002/mrm.1910030217; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gass A, 2001, J NEUROL SCI, V186, pS15, DOI 10.1016/S0022-510X(01)00487-7; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; GRUETTER R, 1993, MAGNET RESON MED, V29, P804, DOI 10.1002/mrm.1910290613; HAASE A, 1986, J MAGN RESON, V67, P258, DOI 10.1016/0022-2364(86)90433-6; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; HAUSSINGER D, 1994, GASTROENTEROLOGY, V107, P1475; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Holshouser BA, 2000, J MAGN RESON IMAGING, V11, P9, DOI 10.1002/(SICI)1522-2586(200001)11:1<9::AID-JMRI2>3.3.CO;2-Y; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kimelberg HK, 1998, CONTRIB NEPHROL, V123, P240, DOI 10.1159/000059916; Lang F, 1998, CELL PHYSIOL BIOCHEM, V8, P1, DOI 10.1159/000016269; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Law RO, 1996, BBA-MOL CELL RES, V1314, P34, DOI 10.1016/S0167-4889(96)00070-5; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lescot T, 2010, J NEUROTRAUM, V27, P85, DOI 10.1089/neu.2009.0982; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Macmillan CSA, 2002, ACTA NEUROCHIR, V144, P853, DOI 10.1007/s00701-002-0966-x; Mamere AE, 2009, AM J NEURORADIOL, V30, P947, DOI 10.3174/ajnr.A1477; Marino S, 2007, J NEUROL NEUROSUR PS, V78, P501, DOI 10.1136/jnnp.2006.099796; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Meyer MJ, 2010, BRAIN INJURY, V24, P706, DOI 10.3109/02699051003692126; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; OLSON JE, 1995, BRAIN RES, V682, P197, DOI 10.1016/0006-8993(95)00368-Z; Onyszchuk G, 2009, NEUROSCI LETT, V452, P204, DOI 10.1016/j.neulet.2009.01.049; Park HK, 1999, CRIT REV NEUROSURG, V9, P44, DOI 10.1007/s003290050108; Peled S, 2007, IEEE T MED IMAGING, V26, P1448, DOI 10.1109/TMI.2007.906787; Phillis JW, 1998, BRAIN RES, V780, P352, DOI 10.1016/S0006-8993(97)01352-8; Price WS, 1996, J MAGN RESON SER B, V112, P190, DOI 10.1006/jmrb.1996.0129; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Ross B, 2001, ANAT RECORD, V265, P54, DOI 10.1002/ar.1058; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rutgers D.R., 2007, AM J NEURORADIOL, V29, P51451; Sager TN, 1997, J NEUROCHEM, V68, P675; SANCHEZOLEA R, 1993, NEUROSCI LETT, V156, P141, DOI 10.1016/0304-3940(93)90458-W; SanchezOlea R, 1996, AM J PHYSIOL-CELL PH, V270, pC1703, DOI 10.1152/ajpcell.1996.270.6.C1703; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signoretti S, 2002, ACT NEUR S, V81, P373; Signoretti S, 2008, J NEUROSURG, V108, P42, DOI 10.3171/JNS/2008/108/01/0042; Sigurdardottir S, 2010, NEUROPSYCHOLOGY, V24, P504, DOI 10.1037/a0018934; Silver SM, 2006, J NEUROPATH EXP NEUR, V65, P37, DOI 10.1097/01.jnen.0000195938.02292.39; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Stein D.G, 2011, NEUROSCIENCE, V14; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Tkac I, 1999, MAGNET RESON MED, V41, P649, DOI 10.1002/(SICI)1522-2594(199904)41:4<649::AID-MRM2>3.0.CO;2-G; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; VAGNOZZI R, 2007, NEUROSURGERY, V61, P388, DOI DOI 10.1227/01.NEU.0000280002.41696; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; VERBALIS JG, 1991, BRAIN RES, V567, P274, DOI 10.1016/0006-8993(91)90806-7; Viant MR, 2005, NMR BIOMED, V18, P507, DOI 10.1002/nbm.980; VIDEEN JS, 1995, J CLIN INVEST, V95, P788, DOI 10.1172/JCI117728; Wild JM, 1999, MAGN RESON MATER PHY, V8, P109; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; Yoon SJ, 2005, CLIN REHABIL, V19, P209, DOI 10.1191/0269215505cr813oa; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	109	86	88	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2091	2102		10.1089/neu.2010.1739			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500010	21761962	Green Submitted, Green Published			2022-02-06	
J	Barha, CK; Ishrat, T; Epp, JR; Galea, LAM; Stein, DG				Barha, Cindy K.; Ishrat, Tauheed; Epp, Jonathan R.; Galea, Liisa A. M.; Stein, Donald G.			Progesterone treatment normalizes the levels of cell proliferation and cell death in the dentate gyrus of the hippocampus after traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Progesterone; Hippocampal neurogenesis	18 KDA TSPO; ESTRADIOL ENHANCES NEUROGENESIS; FOCAL CEREBRAL-ISCHEMIA; DENDRITIC SPINE DENSITY; BINDING PROTEIN 25-DX; ADULT MALE-MICE; FLUORO-JADE-B; PROGENITOR CELLS; NEURONAL DIFFERENTIATION; FUNCTIONAL DEFICITS	Traumatic brain injury (TB!) increases cell death in the hippocampus and impairs hippocampus-dependent cognition. The hippocampus is also the site of ongoing neurogenesis throughout the lifespan. Progesterone treatment improves behavioral recovery and reduces inflammation, apoptosis, lesion volume, and edema, when given after TBI. The aim of the present study was to determine whether progesterone altered cell proliferation and short-term survival in the dentate gyrus after TBI. Male Sprague-Dawley rats with bilateral contusions of the frontal cortex or sham operations received progesterone or vehicle at 1 and 6 h post-surgery and daily through post-surgery Day 7, and a single injection of bromodeoxyuridine (BrdU) 48 h after injury. Brains were then processed for Ki67 (endogenous marker of cell proliferation), BrdU (short-term cell survival), doublecortin (endogenous marker of immature neurons), and Fluoro-jade B (marker of degenerating neurons). TBI increased cell proliferation compared to shams and progesterone normalized cell proliferation in injured rats. Progesterone alone increased cell proliferation in intact rats. Interestingly, injury and/or progesterone treatment did not influence short-term cell survival of BrdU-ir cells. All treatments increased the percentage of BrdU-ir cells that were co-labeled with doublecortin (an immature neuronal marker in this case labeling new neurons that survived 5 days), indicating that cell fate is influenced independently by TBI and progesterone treatment. The number of immature neurons that survived 5 days was increased following TBI, but progesterone treatment reduced this effect. Furthermore, TBI increased cell death and progesterone treatment reduced cell death to levels seen in intact rats. Together these findings suggest that progesterone treatment after TBI normalizes the levels of cell proliferation and cell death in the dentate gyrus of the hippocampus. (C) 2011 Elsevier Inc. All rights reserved.	[Barha, Cindy K.; Galea, Liisa A. M.] Univ British Columbia, Dept Psychol, Vancouver, BC V6T 1Z4, Canada; [Epp, Jonathan R.; Galea, Liisa A. M.] Univ British Columbia, Grad Program Neurosci, Vancouver, BC V6T 1Z4, Canada; [Galea, Liisa A. M.] Univ British Columbia, Brain Res Ctr, Vancouver, BC V6T 1Z4, Canada; [Ishrat, Tauheed; Stein, Donald G.] Emory Univ, Sch Med, Dept Emergency Med, Brain Res Lab, Atlanta, GA USA		Galea, LAM (corresponding author), Univ British Columbia, Dept Psychol, 2136 W Mall, Vancouver, BC V6T 1Z4, Canada.	lgalea@psych.ubc.ca	Stein, Donald/AAJ-5139-2020	Galea, Liisa/0000-0003-2874-9972; Barha, Cindy/0000-0003-3149-5539	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for Medical Research; BHR Pharma; LLC; Allen Company;  [U01-NSO-62676-02A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS062676] Funding Source: NIH RePORTER	We would like to thank Stephanie Lieblich for assistance with this work. Financial support for this research was provided by the Canadian Institutes of Health Research (LAMG) and U01-NSO-62676-02A2 (DGS). CKB and JRE are funded by Michael Smith Foundation for Medical Research senior trainee awards. LAMG is a Michael Smith Senior Scholar. DGS receives research support from BHR Pharma, LLC and Allen & Company.	Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Barha CK, 2009, HORMONES, BRAIN AND BEHAVIOR, VOLS 1-5, 2ND EDITION, P2165; Barha CK, 2009, J NEUROENDOCRINOL, V21, P155, DOI 10.1111/j.1365-2826.2008.01809.x; Barha CK, 2011, HIPPOCAMPUS, V21, P1216, DOI 10.1002/hipo.20829; BARHA CK, NEUROBIOL AGING; Batarseh A, 2010, MOL CELL ENDOCRINOL, V327, P1, DOI 10.1016/j.mce.2010.06.013; Baulieu EE, 2000, HUM REPROD, V15, P1; Bimonte-Nelson HA, 2004, BEHAV NEUROSCI, V118, P707, DOI 10.1037/0735-7044.118.4.707; Birzniece V, 2006, BRAIN RES REV, V51, P212, DOI 10.1016/j.brainresrev.2005.11.001; Boonyaratanakornkit V, 2008, STEROIDS, V73, P922, DOI 10.1016/j.steroids.2008.01.010; Brandt MD, 2010, EUR J NEUROSCI, V32, P1256, DOI 10.1111/j.1460-9568.2010.07410.x; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Brinton Roberta Diaz, 2006, Current Alzheimer Research, V3, P185; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Brown RC, 2001, INT REV NEUROBIOL, V46, P117; Butz M, 2008, HIPPOCAMPUS, V18, P879, DOI 10.1002/hipo.20445; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Bottino MC, 2011, BREAST CANCER RES TR, V126, P621, DOI 10.1007/s10549-010-0971-3; Chen MK, 2008, PHARMACOL THERAPEUT, V118, P1, DOI 10.1016/j.pharmthera.2007.12.004; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Choi JM, 2003, ENDOCRINOLOGY, V144, P4734, DOI 10.1210/en.2003-0216; Chrousos GP, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3143pe36; Cutler SM, 2006, EXP NEUROL, V200, P378, DOI 10.1016/j.expneurol.2006.02.137; Dalla C, 2009, P NATL ACAD SCI USA, V106, P2927, DOI 10.1073/pnas.0809650106; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Eadie BD, 2005, J COMP NEUROL, V486, P39, DOI 10.1002/cne.20493; Emery DL, 2005, J NEUROTRAUM, V22, P978, DOI 10.1089/neu.2005.22.978; Epp JR, 2011, NEUROSCIENCE, V172, P342, DOI 10.1016/j.neuroscience.2010.10.025; Epp JR, 2010, HIPPOCAMPUS, V20, P866, DOI 10.1002/hipo.20692; Epp JR, 2009, NEUROBIOL LEARN MEM, V91, P437, DOI 10.1016/j.nlm.2009.01.001; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Esposito MS, 2005, J NEUROSCI, V25, P10074, DOI 10.1523/JNEUROSCI.3114-05.2005; Falkenstein E, 2000, PHARMACOL REV, V52, P513; FARR SA, 1995, PHYSIOL BEHAV, V58, P715, DOI 10.1016/0031-9384(95)00124-2; Foy MR, 2010, VITAM HORM, V82, P219, DOI 10.1016/S0083-6729(10)82012-6; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2009, EXP NEUROL, V219, P516, DOI 10.1016/j.expneurol.2009.07.007; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2009, NEUROSCIENTIST, V15, P324, DOI 10.1177/1073858409333069; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; GOULD E, 1990, J NEUROSCI, V10, P1286; Gould E, 2001, P NATL ACAD SCI USA, V98, P10910, DOI 10.1073/pnas.181354698; Gould E, 1997, J NEUROSCI, V17, P2492; Guennoun R, 2008, BRAIN RES REV, V57, P493, DOI 10.1016/j.brainresrev.2007.05.009; Harburger LL, 2008, BEHAV BRAIN RES, V194, P174, DOI 10.1016/j.bbr.2008.07.014; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Huang S, 1998, MECH DEVELOP, V71, P23, DOI 10.1016/S0925-4773(97)00199-8; Ishrat T, 2010, EXP NEUROL, V226, P183, DOI 10.1016/j.expneurol.2010.08.023; Ishrat T, 2009, BRAIN RES, V1257, P94, DOI 10.1016/j.brainres.2008.12.048; Jessberger S, 2007, J NEUROSCI, V27, P5967, DOI 10.1523/JNEUROSCI.0110-07.2007; Johansson IM, 2002, BRAIN RES, V934, P125, DOI 10.1016/S0006-8993(02)02414-9; Kee N, 2002, J NEUROSCI METH, V115, P97, DOI 10.1016/S0165-0270(02)00007-9; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; Kronenberg G, 2003, J COMP NEUROL, V467, P455, DOI 10.1002/cne.10945; Labombarda F, 2010, NEUROIMMUNOMODULAT, V17, P146, DOI 10.1159/000258709; Lacapere JJ, 2003, STEROIDS, V68, P569, DOI 10.1016/S0039-128X(03)00101-6; Lavenex P, 2000, EUR J NEUROSCI, V12, P643, DOI 10.1046/j.1460-9568.2000.00949.x; Leclerc N, 1996, MOL BIOL CELL, V7, P443, DOI 10.1091/mbc.7.3.443; Leuner B, 2009, J COMP NEUROL, V517, P123, DOI 10.1002/cne.22107; Liu LF, 2009, ENDOCRINOLOGY, V150, P3186, DOI 10.1210/en.2008-1447; Losel RM, 2003, PHYSIOL REV, V83, P965, DOI 10.1152/physrev.00003.2003; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; Mani SK, 2006, NEUROSCIENCE, V138, P773, DOI 10.1016/j.neuroscience.2005.07.034; Meffre D, 2007, ENDOCRINOLOGY, V148, P2505, DOI 10.1210/en.2006-1678; Meffre D, 2005, J NEUROCHEM, V93, P1314, DOI 10.1111/j.1471-4159.2005.03127.x; Meffre D, 2007, J STEROID BIOCHEM, V104, P293, DOI 10.1016/j.jsbmb.2007.03.003; MONNET FP, 1995, P NATL ACAD SCI USA, V92, P3774, DOI 10.1073/pnas.92.9.3774; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; OGATA T, 1993, NEUROSCIENCE, V55, P445, DOI 10.1016/0306-4522(93)90513-F; Ormerod BK, 2004, NEUROSCIENCE, V128, P645, DOI 10.1016/j.neuroscience.2004.06.039; Ormerod BK, 2001, NEUROSCIENCE, V102, P369, DOI 10.1016/S0306-4522(00)00474-7; Orr PI, 2009, PHARMACOL BIOCHEM BE, V93, P177, DOI 10.1016/j.pbb.2009.05.012; Packard D S Jr, 1973, Differentiation, V1, P397, DOI 10.1111/j.1432-0436.1973.tb00137.x; Papadopoulos V, 1997, STEROIDS, V62, P21, DOI 10.1016/S0039-128X(96)00154-7; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Ramirez-Rodriguez G, 2009, NEUROPSYCHOPHARMACOL, V34, P2180, DOI 10.1038/npp.2009.46; Reyna-Neyra A, 2002, BRAIN RES BULL, V58, P607, DOI 10.1016/S0361-9230(02)00829-8; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Sliwowska JH, 2010, STRESS, V13, P302, DOI 10.3109/10253890903531582; Smith Sheryl S, 2004, Cleve Clin J Med, V71 Suppl 2, pS4; SMITH SS, 1987, BRAIN RES, V400, P353, DOI 10.1016/0006-8993(87)90634-2; Stein DG, 2007, PROG BRAIN RES, V161, P339, DOI 10.1016/S0079-6123(06)61024-8; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Stein DG, 2010, AM J ROENTGENOL, V194, P20, DOI 10.2214/AJR.09.3407; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2010, J NEUROTRAUM, V27, P923, DOI 10.1089/neu.2009.1209; Suzuki S, 2007, J COMP NEUROL, V500, P1064, DOI 10.1002/cne.21240; Taupin P, 2007, BRAIN RES REV, V53, P198, DOI 10.1016/j.brainresrev.2006.08.002; Tsutsui K, 2004, NEUROSCI RES, V49, P273, DOI 10.1016/j.neures.2004.03.006; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Wang JP, 2009, BRAIN RES BULL, V79, P426, DOI 10.1016/j.brainresbull.2009.05.018; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Wang JM, 2008, BRAIN RES REV, V57, P398, DOI 10.1016/j.brainresrev.2007.08.010; Waters EM, 2008, J COMP NEUROL, V511, P34, DOI 10.1002/cne.21826; WOOLLEY CS, 1993, J COMP NEUROL, V336, P293, DOI 10.1002/cne.903360210; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Zhang Z, 2010, NEUROPHARMACOLOGY, V58, P930, DOI 10.1016/j.neuropharm.2010.01.002; Zhang Z, 2010, HIPPOCAMPUS, V20, P402, DOI 10.1002/hipo.20642; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100	130	86	89	0	24	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	SEP	2011	231	1					72	81		10.1016/j.expneurol.2011.05.016			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	810DX	WOS:000294106700009	21684276	Green Accepted			2022-02-06	
J	Ennen, CS; Huisman, TAGM; Savage, WJ; Northington, FJ; Jennings, JM; Everett, AD; Graham, EM				Ennen, Christopher S.; Huisman, Thierry A. G. M.; Savage, William J.; Northington, Frances J.; Jennings, Jacky M.; Everett, Allen D.; Graham, Ernest M.			Glial fibrillary acidic protein as a biomarker for neonatal hypoxic-ischemic encephalopathy treated with whole-body cooling	AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY			English	Article						fetal acidosis; glial fibrillary acidic protein; hypoxicischemic encephalopathy; neonatal seizures; whole-body cooling	TRAUMATIC BRAIN-INJURY; SYSTEMIC HYPOTHERMIA; RANDOMIZED-TRIAL; CARDIAC-ARREST; TERM INFANTS; SERUM; ASSOCIATION; LESIONS; MRI; AGE	OBJECTIVE: Glial fibrillary acidic protein (GFAP) is specific to astrocytes in the central nervous system. We hypothesized that serum GFAP would be increased in neonates with hypoxic-ischemic encephalopathy (HIE) treated with whole-body cooling. STUDY DESIGN: We measured GFAP at birth and daily for up to 7 days for neonates in the intensive care unit. We compared neonates with HIE treated with whole-body cooling to gestational age-matched controls without neurological injury and neonates with HIE by brain abnormalities on magnetic resonance imaging (MRI). RESULTS: Neonates with HIE had increased GFAP levels compared with controls. Neonates with HIE and abnormal brain imaging had elevated GFAP levels compared with neonates with HIE and normal imaging. CONCLUSION: Serum GFAP levels during the first week of life were increased in neonates with HIE and were predictive of brain injury on MRI. Biomarkers such as GFAP could help triage neonates with HIE to treatment, measure treatment efficacy, and provide prognostic information.	[Ennen, Christopher S.; Graham, Ernest M.] Johns Hopkins Univ, Sch Med, Dept Obstet & Gynecol, Div Maternal Fetal Med, Baltimore, MD 21205 USA; [Huisman, Thierry A. G. M.] Johns Hopkins Univ, Sch Med, Div Pediat Radiol, Dept Radiol & Radiol Sci, Baltimore, MD USA; [Savage, William J.] Johns Hopkins Univ, Sch Med, Dept Pathol Transfus Med, Baltimore, MD USA; [Northington, Frances J.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Neonatol, Baltimore, MD 21205 USA; [Jennings, Jacky M.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Gen Pediat & Adolescent Med, Baltimore, MD 21205 USA; [Everett, Allen D.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Cardiol, Baltimore, MD 21205 USA; [Jennings, Jacky M.] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Sch Med, Baltimore, MD USA		Ennen, CS (corresponding author), Johns Hopkins Univ, Sch Med, Dept Obstet & Gynecol, Div Maternal Fetal Med, Baltimore, MD 21205 USA.			jennings, jacky/0000-0002-3789-5122	National Institute of Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [K01 DA022298-01A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD042854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [K01DA022298] Funding Source: NIH RePORTER	J.M.J. is supported by National Institute of Drug Abuse Grant no. K01 DA022298-01A1. The other authors report no conflict of interest.	American College of Obstetricians and Gynecologists American Academy of Pediatricians, 2003, NEON ENC CER PALS, P73; Barnett A, 2002, NEUROPEDIATRICS, V33, P242, DOI 10.1055/s-2002-36737; Bembea MM, 2010, PEDIATR CRIT CARE ME, V11, P723, DOI 10.1097/PCC.0b013e3181dde659; Blennow M, 2001, ACTA PAEDIATR, V90, P1171, DOI 10.1080/080352501317061594; Cowan F, 2003, LANCET, V361, P736, DOI 10.1016/S0140-6736(03)12658-X; East CE, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004075.pub3; Edwards AD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c363; Fraser DD, 2011, PEDIATR CRIT CARE ME, V12, P319, DOI 10.1097/PCC.0b013e3181e8b32d; Glass Hannah C, 2007, Curr Treat Options Neurol, V9, P414, DOI 10.1007/s11940-007-0043-0; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Graham EM, 2008, AM J OBSTET GYNECOL, V199, P587, DOI 10.1016/j.ajog.2008.06.094; HADLOCK FP, 1991, RADIOLOGY, V181, P129, DOI 10.1148/radiology.181.1.1887021; Hobbs C, 2008, STROKE, V39, P1307, DOI 10.1161/STROKEAHA.107.499822; Inder TE, 2004, J PEDIATR-US, V145, P835, DOI 10.1016/j.jpeds.2004.07.034; Kaneko T, 2009, RESUSCITATION, V80, P790, DOI 10.1016/j.resuscitation.2009.04.003; Kim SS, 2008, J KOREAN MED SCI, V23, P484, DOI 10.3346/jkms.2008.23.3.484; Larma JD, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.06.053; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Oh W, 2008, J PEDIATR-US, V153, P375, DOI 10.1016/j.jpeds.2008.03.041; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Petzold A, 2004, J IMMUNOL METHODS, V287, P169, DOI 10.1016/j.jim.2004.01.015; Pimentel-Coelho PM, 2010, STEM CELLS DEV, V19, P299, DOI 10.1089/scd.2009.0403; Ramaswamy V, 2009, PEDIATR NEUROL, V40, P215, DOI 10.1016/j.pediatrneurol.2008.09.026; Rouse DJ, 2008, NEW ENGL J MED, V359, P895, DOI 10.1056/NEJMoa0801187; Rutherford MA, 2005, PEDIATRICS, V116, P1001, DOI 10.1542/peds.2005-0328; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Shah PS, 2007, ARCH PEDIAT ADOL MED, V161, P951, DOI 10.1001/archpedi.161.10.951; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Silva AM, 2008, J PERINAT MED, V36, P151, DOI 10.1515/JPM.2008.023; Thoresen M, 2000, Semin Neonatol, V5, P61, DOI 10.1053/siny.1999.0118; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC	32	86	89	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9378	1097-6868		AM J OBSTET GYNECOL	Am. J. Obstet. Gynecol.	SEP	2011	205	3							251.e1	10.1016/j.ajog.2011.06.025			7	Obstetrics & Gynecology	Science Citation Index Expanded (SCI-EXPANDED)	Obstetrics & Gynecology	812YF	WOS:000294330000045	21784396	Green Accepted			2022-02-06	
J	Clayton, EH; Garbow, JR; Bayly, PV				Clayton, E. H.; Garbow, J. R.; Bayly, P. V.			Frequency-dependent viscoelastic parameters of mouse brain tissue estimated by MR elastography	PHYSICS IN MEDICINE AND BIOLOGY			English	Article							MAGNETIC-RESONANCE-ELASTOGRAPHY; ACOUSTIC STRAIN WAVES; HEPATIC-FIBROSIS; HUMAN HEART; VISUALIZATION; ELASTICITY; PROSTATE; MODULUS; LIVER; MODEL	Viscoelastic properties of mouse brain tissue were estimated non-invasively, in vivo, using magnetic resonance elastography (MRE) at 4.7 T to measure the dispersive properties of induced shear waves. Key features of this study include (i) the development and application of a novelMR-compatible actuation system which transmits vibratory motion into the brain through an incisor bar, and (ii) the investigation of the mechanical properties of brain tissue over a 1200 Hz bandwidth from 600-1800 Hz. Displacement fields due to propagating shear waves were measured during continuous, harmonic excitation of the skull. This protocol enabled characterization of the true steady-state patterns of shear wave propagation. Analysis of displacement fields obtained at different frequencies indicates that the viscoelastic properties of mouse brain tissue depend strongly on frequency. The average storage modulus (G') increased from approximately 1.6 to 8 kPa over this range; average loss modulus (G '') increased from approximately 1 to 3 kPa. Both moduli were well approximated by a power-law relationship over this frequency range. MRE may be a valuable addition to studies of disease in murine models, and to pre-clinical evaluations of therapies. Quantitative measurements of the viscoelastic parameters of brain tissue at high frequencies are also valuable for modeling and simulation of traumatic brain injury.	[Clayton, E. H.; Bayly, P. V.] Washington Univ, Dept Mech Engn & Mat Sci, St Louis, MO 63130 USA; [Bayly, P. V.] Washington Univ, Dept Biomed Engn, St Louis, MO 63130 USA; [Garbow, J. R.] Washington Univ, Dept Radiol, Biomed Magnet Resonance Lab, St Louis, MO 63110 USA		Clayton, EH (corresponding author), Washington Univ, Dept Mech Engn & Mat Sci, 1 Brookings Dr,Campus Box 1185, St Louis, MO 63130 USA.	clayton@wustl.edu; garbow@wustl.edu; pvb@wustl.edu	Clayton, Erik/A-9263-2012	Bayly, Philip/0000-0003-4303-0704	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS055951]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055951] Funding Source: NIH RePORTER	Financial support was provided by NIH RO1 NS055951 (Bayly). Dr Mark Conradi supported MR Tx/Rx coil development. Special thanks to colleagues in the Biomedical Magnetic Resonance Laboratory at Washington University for additional assistance. Numerical simulations performed in this study were made	Asbach P, 2008, MAGN RESON MED, V60, P373, DOI 10.1002/mrm.21636; Beltzer AI, 1988, ACOUSTICS SOLIDS; Chopra R, 2009, MAGN RESON MED, V62, P665, DOI 10.1002/mrm.22038; CLAYTON EH, 2010, P INT SOC MAGN RES M, P3400; Diguet E., 2009, P 17 ISMRM C, P714; Elgeti T, 2008, INVEST RADIOL, V43, P762, DOI 10.1097/RLI.0b013e3181822085; Flugge W., 1975, VISCOELASTICITY; Garbow JR, 2008, CONCEPT MAGN RESON B, V33B, P252, DOI 10.1002/cmr.b.20124; Hackbusch W., 1985, MULTIGRID METHODS AP; Hamhaber U, 2007, ACTA BIOMATER, V3, P127, DOI 10.1016/j.actbio.2006.08.007; Kemper J, 2004, ROFO-FORTSCHR RONTG, V176, P1094, DOI 10.1055/s-2004-813279; Kolipaka A, 2010, MAGN RESON MED, V64, P862, DOI 10.1002/mrm.22467; Kolsky H., 1963, STRESS WAVES SOLIDS; Kruse SA, 2008, NEUROIMAGE, V39, P231, DOI 10.1016/j.neuroimage.2007.08.030; Litwiller DV, 2010, J MAGN RESON IMAGING, V32, P44, DOI 10.1002/jmri.22217; Lockett F.J., 1972, NONLINEAR VISCOELAST; Madsen EL, 2008, PHYS MED BIOL, V53, P5313, DOI 10.1088/0031-9155/53/19/004; Manduca A, 2001, MED IMAGE ANAL, V5, P237, DOI 10.1016/S1361-8415(00)00039-6; MURPHY MC, 2010, P INT SOC MAGN RES M, P2360; MUTHUPILLAI R, 1995, SCIENCE, V269, P1854, DOI 10.1126/science.7569924; Muthupillai R, 1996, MAGN RESON MED, V36, P266, DOI 10.1002/mrm.1910360214; ODONNELL M, 1981, J ACOUST SOC AM, V69, P696, DOI 10.1121/1.385566; Pattison AJ, 2010, J BIOMECH, V43, P2747, DOI 10.1016/j.jbiomech.2010.06.008; Plewes DB, 2000, PHYS MED BIOL, V45, P1591, DOI 10.1088/0031-9155/45/6/314; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Pritz T, 1999, J SOUND VIB, V228, P1145, DOI 10.1006/jsvi.1999.2495; Robert B, 2009, MAGN RESON MED, V62, P1155, DOI 10.1002/mrm.22124; Romano AJ, 2005, MAGN RESON MED, V54, P893, DOI 10.1002/mrm.20607; Rouviere O, 2006, RADIOLOGY, V240, P440, DOI 10.1148/radiol.2402050606; Sack I, 2009, MAGN RESON MED, V61, P668, DOI 10.1002/mrm.21878; SCHREGEL K, 2010, P INT SOC MAGN RES M, P2134; Sinkus R, 2005, MAGN RESON IMAGING, V23, P159, DOI 10.1016/j.mri.2004.11.060; Sinkus R, 2005, MAGNET RESON MED, V53, P372, DOI 10.1002/mrm.20355; Wuerfel J, 2010, NEUROIMAGE, V49, P2520, DOI 10.1016/j.neuroimage.2009.06.018; Yin M, 2007, CLIN GASTROENTEROL H, V5, P1207, DOI 10.1016/j.cgh.2007.06.012; Yin M, 2007, MAGN RESON MED, V58, P346, DOI 10.1002/mrm.21286	36	86	86	0	14	IOP PUBLISHING LTD	BRISTOL	DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND	0031-9155			PHYS MED BIOL	Phys. Med. Biol.	APR 21	2011	56	8					2391	2406		10.1088/0031-9155/56/8/005			16	Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Radiology, Nuclear Medicine & Medical Imaging	749PL	WOS:000289480700006	21427486	Green Accepted			2022-02-06	
J	Warner, MA; de la Plata, CM; Spence, J; Wang, JY; Harper, C; Moore, C; Devous, M; Diaz-Arrastia, R				Warner, Matthew A.; de la Plata, Carlos Marquez; Spence, Jeffrey; Wang, Jun Yi; Harper, Caryn; Moore, Carol; Devous, Michael; Diaz-Arrastia, Ramon			Assessing Spatial Relationships between Axonal Integrity, Regional Brain Volumes, and Neuropsychological Outcomes after Traumatic Axonal Injury	JOURNAL OF NEUROTRAUMA			English	Article						atrophy; diffuse axonal injury; diffusion tensor imaging; traumatic brain injury; volumetric magnetic resonance imaging	MAGNETIC-RESONANCE IMAGES; SURFACE-BASED ANALYSIS; WHITE-MATTER INJURY; NEURONS IN-VIVO; HEAD-INJURY; CEREBRAL ATROPHY; MILD; AXOTOMY; SEGMENTATION; DISABILITY	Diffuse traumatic axonal injury (TAI) is a type of traumatic brain injury (TBI) characterized predominantly by white matter damage. While TAI is associated with cerebral atrophy, the relationship between gray matter volumes and TAI of afferent or efferent axonal pathways remains unknown. Moreover, it is unclear if deficits in cognition are associated with post-traumatic brain volumes in particular regions. The goal of this study was to determine the relationship between markers of TAI and volumes of cortical and subcortical structures, while also assessing the relationship between cognitive outcomes and regional brain volumes. High-resolution magnetic resonance imaging scans were performed in 24 patients with TAI within 1 week of injury and were repeated 8 months later. Diffusion tensor imaging (DTI) tractography was used to reconstruct prominent white matter tracts and calculate their fractional anisotropy (FA) and mean diffusivity (MD) values. Regional brain volumes were computed using semi-automated morphometric analysis. Pearson's correlation coefficients were used to assess associations between brain volumes, white matter integrity (i.e., FA and MD), and neuropsychological outcomes. Post-traumatic volumes of many gray matter structures were associated with chronic damage to related white matter tracts, and less strongly associated with measures of white matter integrity in the acute scans. For example, left and right hippocampal volumes correlated with FA in the fornix body (r = 0.600, p = 0.001; r = 0.714, p<0.001, respectively). In addition, regional brain volumes were associated with deficits in corresponding neuropsychological domains. Our results suggest that TAI may be a primary mechanism of post-traumatic atrophy, and provide support for regional morphometry as a biomarker for cognitive outcome after injury.	[Warner, Matthew A.; Harper, Caryn; Moore, Carol; Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Spence, Jeffrey] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA; [Devous, Michael] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA; [de la Plata, Carlos Marquez] Univ Texas Dallas, Ctr Brain Hlth, Dallas, TX 75230 USA; [Wang, Jun Yi] Univ Calif Davis, Ctr Mind & Brain, Davis, CA 95616 USA		Diaz-Arrastia, R (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Ramon.Diaz-Arrastia@UTSouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	Doris Duke Charitable FoundationDoris Duke Charitable Foundation (DDCF); National Institutes of Health-National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD48179, U01 HD42652]; United States Department of EducationUS Department of Education [H133 A020526]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER	This work was supported by the Doris Duke Charitable Foundation (Clinical Research Fellowship to M.W.); the National Institutes of Health-National Institute of Child Health and Human Development (R01 HD48179 to R.D.-A and, U01 HD42652 to R.D.-A.); and the United States Department of Education Grant (H133 A020526 to R.D.-A.).	Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 2006, AM J PHYS MED REHAB, V85, P793, DOI 10.1097/01.phm.0000237873.26250.e1; Bonatz H, 2000, J NEUROSCI METH, V100, P105, DOI 10.1016/S0165-0270(00)00238-7; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Delis D.C., 2000, CALIFORNIA VERBAL LE; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; DODRILL CB, 1978, EPILEPSIA, V19, P611, DOI 10.1111/j.1528-1157.1978.tb05041.x; Evans SA, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-8; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Giehl KM, 1996, EUR J NEUROSCI, V8, P1167, DOI 10.1111/j.1460-9568.1996.tb01284.x; Hamster K., 1983, MULTILINGUAL APHASIA; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; McAllister TW, 2002, NEUROREHABILITATION, V17, P263; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Reitan RM, 1992, TRAIL MAKING TEST MA; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schiff ND, 2006, J HEAD TRAUMA REHAB, V21, P388, DOI 10.1097/00001199-200609000-00003; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; WARNER MA, 2010, ARCH NEUROL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	49	86	90	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2010	27	12					2121	2130		10.1089/neu.2010.1429			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	691PN	WOS:000285093400001	20874032	Green Published			2022-02-06	
J	Morganti-Kossmann, MC; Yan, E; Bye, N				Morganti-Kossmann, M. C.; Yan, E.; Bye, N.			Animal models of traumatic brain injury: Is there an optimal model to reproduce human brain injury in the laboratory?	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article; Proceedings Paper	Annual Trauma Research Methods Workshop	NOV 19, 2009	Monash Univ, Melbourne, AUSTRALIA	Australian Natl Trauma Res Inst	Monash Univ	Model of brain injury; Diffuse injury; Focal injury; Rodents; In vitro models	CLOSED-HEAD INJURY; PATHOPHYSIOLOGY; MICE; NEUROPROTECTION; RATS; COMA	Compared to other neurological diseases, the research surrounding traumatic brain injury (TBI) has a more recent history. The establishment and use of animal models of TBI remains vital to understand the pathophysiology of this highly complex disease. Such models share the ultimate goals of reproducing patterns of tissue damage observed in humans (thus rendering them clinically relevant), reproducible and highly standardised to allow for the manipulation of individual variables, and to finally explore novel therapeutics for clinical translation. There is no doubt that the similarity of cellular and molecular events observed in human and rodent TBI has reinforced the use of small animals for research. When confronted with the choice of the experimental model it becomes clear that the ideal animal model does not exist. This limitation derives from the fact that most models mimic either focal or diffuse brain injury, whereas the clinical reality suggests that each patient has an individual form of TBI characterised by various combinations of focal and diffuse patterns of tissue damage. This is additionally complicated by the occurrence of secondary insults such as hypotension, hypoxia, ischaemia, extracranial injuries, modalities of traumatic events, age, gender and heterogeneity of medical treatments and pre-existing conditions. This brief review will describe the variety of TBI models available for laboratory research beginning from the most widely used rodent models of focal brain trauma, to complex large species such as the pig. In addition, the models mimicking diffuse brain damage will be discussed in relation to the early primate studies until the use of most common rodent models to elucidate the intriguing and less understood pathology of axonal dysfunction. The most recent establishment of in vitro paradigms has complemented the in vivo modelling studies offering a further cellular and molecular insight of this pathology. (C) 2010 Elsevier Ltd. All rights reserved.	[Morganti-Kossmann, M. C.; Yan, E.; Bye, N.] Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Morganti-Kossmann, M. C.; Yan, E.; Bye, N.] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia		Morganti-Kossmann, MC (corresponding author), Natl Trauma Res Inst, 89 Commercial Rd, Melbourne, Vic 3004, Australia.	cristina.morganti-kossmann@med.monash.edu.au		Morganti-Kossmann, Cristina/0000-0002-0807-2063			Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Centers for Disease Control and Prevention, 2001, TRAUM BRAIN INJ US R; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Crack P, 2009, J NEURAL TRANSM, V116, P1, DOI 10.1007/s00702-008-0145-1; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Duhaime AC, 2006, DEV NEUROSCI-BASEL, V28, P380, DOI 10.1159/000094164; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Laurer HL., 2000, EUR J TRAUMA, V26, P95, DOI [10.1007/s000680050007, DOI 10.1007/S000680050007]; Longhi L, 2001, J CEREBR BLOOD F MET, V21, P1241, DOI 10.1097/00004647-200111000-00001; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Marmarou A, 2003, ACT NEUR S, V86, P7; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McIntosh TK, 1996, LAB INVEST, V74, P315; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Statler KD, 2006, BRAIN RES, V1076, P216, DOI 10.1016/j.brainres.2005.12.106; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42	30	86	90	2	20	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	JUL	2010	41			1			10	13		10.1016/j.injury.2010.03.032			4	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	617ZV	WOS:000279321600004	20416875				2022-02-06	
J	Cho, Y; Shi, RY; Borgens, RB				Cho, Youngnam; Shi, Riyi; Borgens, Richard B.			Chitosan produces potent neuroprotection and physiological recovery following traumatic spinal cord injury	JOURNAL OF EXPERIMENTAL BIOLOGY			English	Article						chitosan; nanoparticle; nerve tissue engineering; membrane; self assembly	ATOMIC-FORCE MICROSCOPY; POLYETHYLENE-GLYCOL; OXIDATIVE STRESS; SURFACTANT POLOXAMER-188; PHOSPHOLIPID-BILAYER; MOLECULAR REPAIR; BRAIN-INJURY; PC12 CELLS; IN-VITRO; MEMBRANES	Chitosan, a non-toxic biodegradable polycationic polymer with low immunogenicity, has been extensively investigated in various biomedical applications. In this work, chitosan has been demonstrated to seal compromised nerve cell membranes thus serving as a potent neuroprotector following acute spinal cord trauma. Topical application of chitosan after complete transection or compression of the guinea pig spinal cord facilitated sealing of neuronal membranes in ex vivo tests, and restored the conduction of nerve impulses through the length of spinal cords in vivo, using somatosensory evoked potential recordings. Moreover, chitosan preferentially targeted damaged tissues, served as a suppressor of reactive oxygen species ( free radical) generation, and the resultant lipid peroxidation of membranes, as shown in ex vivo spinal cord samples. These findings suggest a novel medical approach to reduce the catastrophic loss of behavior after acute spinal cord and brain injury.	[Cho, Youngnam; Shi, Riyi; Borgens, Richard B.] Purdue Univ, Sch Vet Med, Ctr Paralysis Res, W Lafayette, IN 47907 USA; [Shi, Riyi; Borgens, Richard B.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA		Cho, Y (corresponding author), Purdue Univ, Sch Vet Med, Ctr Paralysis Res, W Lafayette, IN 47907 USA.	cho22@purdue.edu	sadeghi, meisam/K-2389-2018	sadeghi, meisam/0000-0002-8448-0149	General Funds of the Center for Paralysis Research; The State of Indiana	We would like to thank Debra Bohnert for her expert handling of whole animal experiments. We appreciate the excellent illustrations and graphics of Michel Schweinsberg, and financial support from the General Funds of the Center for Paralysis Research, The State of Indiana, and a generous endowment from Mrs Mari Hulman George.	BODMEIER R, 1989, PHARMACEUT RES, V6, P413, DOI 10.1023/A:1015987516796; Borgens R B, 1988, Adv Neurol, V47, P51; Borgens RB, 2000, FASEB J, V14, P27, DOI 10.1096/fasebj.14.1.27; Borgens RB, 2004, J NEUROSCI RES, V76, P141, DOI 10.1002/jnr.20053; Borgens RB, 2002, J EXP BIOL, V205, P1; Borgens RB, 2001, NEUROSURGERY, V49, P370, DOI 10.1097/00006123-200108000-00021; BORGENS RB, 2003, RESTORING FUNCTION I; Brent J, 2001, DRUGS, V61, P979, DOI 10.2165/00003495-200161070-00006; Burcham PC, 2004, MOL PHARMACOL, V65, P655, DOI 10.1124/mol.65.3.655; Burcham PC, 2006, MOL PHARMACOL, V69, P1056, DOI 10.1124/mol.105.018168; Cadichon SB, 2007, J NEUROSURG, V106, P36, DOI 10.3171/ped.2007.106.1.36; Caravati EM, 2005, CLIN TOXICOL, V43, P327, DOI 10.1080/07313820500184971; Cho Y, 2008, SMALL, V4, P1676, DOI 10.1002/smll.200800838; Chung YC, 2004, ACTA PHARMACOL SIN, V25, P932; COLLINS JM, 2006, J SURG RES, V130, P288; Fang N, 2003, BIOMACROMOLECULES, V4, P1596, DOI 10.1021/bm034259w; Fang N, 2001, BIOMACROMOLECULES, V2, P1161, DOI 10.1021/bm015548s; Frim DM, 2004, NEUROREPORT, V15, P171, DOI 10.1097/00001756-200401190-00033; Gan Q, 2007, COLLOID SURFACE B, V59, P24, DOI 10.1016/j.colsurfb.2007.04.009; ILLUM L, 1994, PHARMACEUT RES, V11, P1186, DOI 10.1023/A:1018901302450; Janes KA, 2001, J CONTROL RELEASE, V73, P255, DOI 10.1016/S0168-3659(01)00294-2; Koob AO, 2006, J NEUROSCI RES, V83, P1558, DOI 10.1002/jnr.20837; Koob AO, 2005, J NEUROTRAUM, V22, P1092, DOI 10.1089/neu.2005.22.1092; Kumari S, 2008, NAT CELL BIOL, V10, P30, DOI 10.1038/ncb1666; Laverty PH, 2004, J NEUROTRAUM, V21, P1767, DOI 10.1089/neu.2004.21.1767; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; Liu-Snyder P, 2007, J EXP BIOL, V210, P1455, DOI 10.1242/jeb.02756; Liu-Snyder P, 2006, J NEUROSCI RES, V84, P219, DOI 10.1002/jnr.20862; Luo H, 2004, NEUROCHEM INT, V44, P475, DOI 10.1016/j.neuint.2003.09.006; Luo J, 2005, NEUROCHEM INT, V46, P243, DOI 10.1016/j.neuint.2004.09.001; Luo J, 2005, NEUROCHEM INT, V47, P449, DOI 10.1016/j.neuint.2005.07.002; Luo J, 2004, J NEUROTRAUM, V21, P994, DOI 10.1089/0897715041651097; Luo J, 2002, J NEUROCHEM, V83, P471, DOI 10.1046/j.1471-4159.2002.01160.x; Madihally SV, 1999, BIOMATERIALS, V20, P1133, DOI 10.1016/S0142-9612(99)00011-3; Maskarinec SA, 2002, BIOPHYS J, V82, P1453, DOI 10.1016/S0006-3495(02)75499-4; McNally HA, 2004, J NEUROCYTOL, V33, P251, DOI 10.1023/B:NEUR.0000030700.48612.0b; Merchant FA, 1998, J SURG RES, V74, P131, DOI 10.1006/jsre.1997.5252; Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349; Pavinatto FJ, 2007, BIOMACROMOLECULES, V8, P1633, DOI 10.1021/bm0701550; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Qaqish RB, 1999, CARBOHYD POLYM, V38, P99, DOI 10.1016/S0144-8617(98)00109-X; Roy K, 1999, NAT MED, V5, P387, DOI 10.1038/7385; Serbest G, 2006, FASEB J, V20, P308, DOI 10.1096/fj.05-4024fje; Shi R, 1999, J NEUROPHYSIOL, V81, P2406, DOI 10.1152/jn.1999.81.5.2406; Shi R, 2002, NEUROSCIENCE, V115, P337, DOI 10.1016/S0306-4522(02)00457-8; Ueno H, 1999, BIOMATERIALS, V20, P1407, DOI 10.1016/S0142-9612(99)00046-0; Working PK, 1997, ACS SYM SER, V680, P45; Yuan Y, 2004, BIOMATERIALS, V25, P4273, DOI 10.1016/j.biomaterials.2003.11.029; Zuo YY, 2006, PEDIATR RES, V60, P125, DOI 10.1203/01.pdr.0000227558.14024.57	49	86	93	4	27	COMPANY OF BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND	0022-0949			J EXP BIOL	J. Exp. Biol.	MAY 1	2010	213	9					1513	1520		10.1242/jeb.035162			8	Biology	Science Citation Index Expanded (SCI-EXPANDED)	Life Sciences & Biomedicine - Other Topics	584XJ	WOS:000276787200023	20400636	Bronze			2022-02-06	
J	Fergenbaum, JH; Bruce, S; Lou, W; Hanley, AJG; Greenwood, C; Young, TK				Fergenbaum, Jennifer H.; Bruce, Sharon; Lou, Wendy; Hanley, Anthony J. G.; Greenwood, Carol; Young, T. Kue			Obesity and Lowered Cognitive Performance in a Canadian First Nations Population	OBESITY			English	Article							BODY-MASS INDEX; TRAUMATIC BRAIN-INJURY; RISK-FACTORS; EXECUTIVE DYSFUNCTION; INSULIN-RESISTANCE; INCIDENT DEMENTIA; TRAIL; IMPAIRMENT; ADIPOSITY; DECLINE	The association between obesity, other cardiovascular risk factors, and cognitive function in a Canadian First Nations population was investigated using a cross-sectional design. Eligible individuals were aged >= 18 years, without a history of stroke, nonpregnant, with First Nations status, and who had undergone cognitive function assessment by the Clock Drawing Test (CDT) and Trail Making Test Parts A and B. Parts A and B were combined into an Executive Function Score (TMT-exec). Hypertension, a previous history of cardiovascular disease, dyslipidemia, metabolic syndrome, insulin resistance, and the presence and duration of diabetes were examined in addition to obesity. In the case of TMT-exec only, obese individuals were at an approximately fourfold increased risk for lowered cognitive performance compared to those who were not obese in multivariable models (odds ratio (OR): 3.77, 95% confidence interval (CI): 1.46-9.72) whereas there was no effect for overweight individuals compared to those with a normal weight in unadjusted analysis. Those having an increased waist circumference also had 5 times the risk compared to those without an increased waist circumference (OR: 5.41, 95% CI: 1.83-15.99). Adjusted for age, sex, and insulin resistance, individuals having the metabolic syndrome were at an approximately fourfold increased risk compared to those without the metabolic syndrome (OR: 3.67, 95% CI: 1.34-10.07). No other cardiovascular risk factors were associated. Obesity and metabolic syndrome were associated with lowered cognitive performance. These results highlight the importance of studying the health effects of obesity beyond traditional disease endpoints, even in a relatively youthful population.	[Fergenbaum, Jennifer H.; Lou, Wendy; Hanley, Anthony J. G.; Young, T. Kue] Univ Toronto, Div Epidemiol, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Bruce, Sharon] Univ Manitoba, Dept Community Hlth Sci, Fac Med, Winnipeg, MB R3T 2N2, Canada; [Hanley, Anthony J. G.; Greenwood, Carol] Univ Toronto, Fac Med, Dept Nutr Sci, Toronto, ON, Canada		Fergenbaum, JH (corresponding author), Univ Toronto, Div Epidemiol, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.	jennifer.fergenbaum@utoronto.ca	Duran, Bonnie m/A-3029-2009	Salerno, Jennifer/0000-0001-7282-5579	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [CRT-43825]; Canadian Stroke Network	Funding for the study was provided by Canadian Institutes of Health Research (CIHR) (CRT-43825, PI: T. K. Y.) and the Canadian Stroke Network (PI: S. B.). J. H. F. is the recipient of a CIHR doctoral award.	Abbatecola AM, 2004, J AM GERIATR SOC, V52, P1713, DOI 10.1111/j.1532-5415.2004.52466.x; [Anonymous], 2000, WHO TECHN REP SER; Beydoun MA, 2008, OBES REV, V9, P204, DOI 10.1111/j.1467-789X.2008.00473.x; Bowler JV, 2005, J NEUROL NEUROSUR PS, V76, pV35, DOI 10.1136/jnnp.2005.082313; Bruce SG, 2008, DIABETES CARE, V31, P1837, DOI 10.2337/dc08-0278; Cukierman T, 2005, DIABETOLOGIA, V48, P2460, DOI 10.1007/s00125-005-0023-4; Dufouil C, 2005, NEUROLOGY, V64, P1531, DOI 10.1212/01.WNL.0000160114.42643.31; Elias MF, 2005, NEUROBIOL AGING, V26, pS11, DOI 10.1016/j.neurobiolaging.2005.08.019; Greenwood CE, 2005, NEUROBIOL AGING, V26, pS42, DOI 10.1016/j.neurobiolaging.2005.08.017; Gunstad J, 2007, COMPR PSYCHIAT, V48, P57, DOI 10.1016/j.comppsych.2006.05.001; Gustafson D, 2008, EUR J PHARMACOL, V585, P163, DOI 10.1016/j.ejphar.2008.01.052; Gustafson D, 2006, LANCET NEUROL, V5, P713, DOI 10.1016/S1474-4422(06)70526-9; Hester RL, 2005, CLIN NEUROPSYCHOL, V19, P45, DOI 10.1080/13854040490524137; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; KALMIJN S, 1995, DIABETOLOGIA, V38, P1096, DOI 10.1007/s001250050397; Knecht S, 2008, PROG NEUROBIOL, V84, P85, DOI 10.1016/j.pneurobio.2007.09.003; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Lyon CJ, 2003, ENDOCRINOLOGY, V144, P2195, DOI 10.1210/en.2003-0285; Naismith SL, 2003, J CLIN EXP NEUROPSYC, V25, P866, DOI 10.1076/jcen.25.6.866.16472; National Institutes of Health, 2000, NIH PUBL; Ogden CL, 2007, GASTROENTEROLOGY, V132, P2087, DOI 10.1053/j.gastro.2007.03.052; Peila R, 2004, NEUROLOGY, V63, P228, DOI 10.1212/01.WNL.0000129989.28404.9B; Perianez JA, 2007, ARCH CLIN NEUROPSYCH, V22, P433, DOI 10.1016/j.acn.2007.01.022; Qiu CX, 2005, LANCET NEUROL, V4, P487, DOI 10.1016/S1474-4422(05)70141-1; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rosengren A, 2005, ARCH INTERN MED, V165, P321, DOI 10.1001/archinte.165.3.321; Russell D, 2002, J NEUROL SCI, V203, P211, DOI 10.1016/S0022-510X(02)00293-9; STUNKARD AJ, 1993, NEW ENGL J MED, V329, P1036, DOI 10.1056/NEJM199309303291411; Stuss DT, 2001, PSYCHOL ASSESSMENT, V13, P230, DOI 10.1037//1040-3590.13.2.230; Turgeon JL, 2006, ENDOCR REV, V27, P575, DOI 10.1210/er.2005-0020; van Exel E, 2002, ANN NEUROL, V51, P716, DOI 10.1002/ana.10220; Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487; WATSON YI, 1993, J AM GERIATR SOC, V41, P1235, DOI 10.1111/j.1532-5415.1993.tb07308.x; Whitmer RA, 2008, NEUROLOGY, V71, P1057, DOI 10.1212/01.wnl.0000306313.89165.ef; Whitmer RA, 2005, BMJ-BRIT MED J, V330, P1360, DOI 10.1136/bmj.38446.466238.E0; Whitmer RA, 2007, CURR ALZHEIMER RES, V4, P103, DOI 10.2174/156720507780362047; Wolf PA, 2007, CURR ALZHEIMER RES, V4, P111, DOI 10.2174/156720507780362263; Yaffe K, 2002, ARCH NEUROL-CHICAGO, V59, P378, DOI 10.1001/archneur.59.3.378; Yaffe K, 2007, J AM GERIATR SOC, V55, P758, DOI 10.1111/j.1532-5415.2007.01139.x; Young SE, 2006, DIABETES CARE, V29, P2688, DOI 10.2337/dc06-0915; [No title captured]	42	86	86	0	16	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1930-7381	1930-739X		OBESITY	Obesity	OCT	2009	17	10					1957	1963		10.1038/oby.2009.161			7	Endocrinology & Metabolism; Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Endocrinology & Metabolism; Nutrition & Dietetics	502UD	WOS:000270484800022	19478788				2022-02-06	
J	Piermartiri, TCB; Vandresen, S; Herculano, BD; Martins, WC; Dal'Agnolo, D; Stroeh, E; Carqueja, CL; Boeck, CR; Tasca, CI				Piermartiri, Tetsade C. B.; Vandresen-Filho, Samuel; Herculano, Bruno de Araujo; Martins, Wagner C.; Dal'Agnolo, Denis; Stroeh, Ellen; Carqueja, Cristiane Lima; Boeck, Carina R.; Tasca, Carla I.			Atorvastatin Prevents Hippocampal Cell Death due to Quinolinic Acid-Induced Seizures in Mice by Increasing Akt Phosphorylation and Glutamate Uptake	NEUROTOXICITY RESEARCH			English	Article						Atorvastatin; Quinolinic acid; Seizures; Neuroprotection; Hippocampus	TRAUMATIC BRAIN-INJURY; NMDA PRECONDITIONING PROTECTS; NITRIC-OXIDE SYNTHASE; CEREBROSPINAL-FLUID; SYNAPTIC VESICLES; CEREBRAL-ISCHEMIA; CORTICAL-NEURONS; LIPID RAFTS; YOUNG-RATS; SIMVASTATIN	Statins are cholesterol-lowering agents due to the inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Recent studies have shown statins possess pleiotropic effects, which appear to be independent from its cholesterol-lowering action. In this study, we investigated whether atorvastatin would have protective effects against hippocampal cell death promoted by quinolinic acid (QA)-induced seizures in mice. Mice were pretreated with Atorvastatin (1 or 10 mg/kg) or vehicle (saline, 0.9%), orally, once a day for 7 days before the intracerebroventricular (i.c.v.) QA infusion (36.8 nmol/site). Atorvastatin treatment with 1 mg/kg/day did not significantly prevent QA-induced seizures (13.34%). However, administration of atorvastatin 10 mg/kg/day prevented the clonic and/or tonic seizures induced by QA in 29.41% of the mice. Additionally, administration of atorvastatin 10 mg/kg/day significantly prevented QA-induced cell death in the hippocampus. Atorvastatin treatment promoted an increased Akt phosphorylation, which was sustained after QA infusion in both convulsed and non-convulsed mice. Moreover, atorvastatin pretreatment prevented the reduction in glutamate uptake into hippocampal slices induced by QA i.c.v. infusion. These results show that atorvastatin attenuated QA-induced hippocampal cellular death involving the Akt pathway and glutamate transport modulation. Therefore, atorvastatin treatment might be a useful strategy in the prevention of brain injury caused by the exacerbation of glutamatergic toxicity in neurological diseases such as epilepsy.	[Piermartiri, Tetsade C. B.; Vandresen-Filho, Samuel; Herculano, Bruno de Araujo; Martins, Wagner C.; Dal'Agnolo, Denis; Stroeh, Ellen; Carqueja, Cristiane Lima; Tasca, Carla I.] Univ Fed Santa Catarina, Dept Bioquim, Ctr Ciencias Biol, BR-88040900 Florianopolis, SC, Brazil; [Boeck, Carina R.] Univ Extremo Catarinense, Lab Neurociencias, Programa Posgrad Ciencias Saude, BR-88806000 Criciuma, SC, Brazil		Tasca, CI (corresponding author), Univ Fed Santa Catarina, Dept Bioquim, Ctr Ciencias Biol, BR-88040900 Florianopolis, SC, Brazil.	tasca@ccb.ufsc.br	Herculano, Bruno/N-4587-2019; Tasca, Carla Ines/AAB-8287-2019; Herculano, Bruno/F-8917-2018; Boeck, Carina Rodrigues/E-9472-2011; Vandresen-Filho, Samuel/A-1239-2013	Herculano, Bruno/0000-0003-0095-3381; Tasca, Carla Ines/0000-0002-3414-6150; Herculano, Bruno/0000-0003-0095-3381; Boeck, Carina Rodrigues/0000-0002-6828-5634; Vandresen-Filho, Samuel/0000-0002-4718-2900; Piermartiri, Tetsade/0000-0002-9773-6983	CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); FAPESCFundacao de Amparo a Pesquisa e Inovacoo Estado de Santa Catarina (FAPESC); FINEP-IBN(Net)Financiadora de Inovacao e Pesquisa (Finep) [01.06.0842-00]	This work was supported by grants from CNPq, FAPESC, and FINEP-IBN(Net)#01.06.0842-00 to C. I. Tasca. C. I. T. is recipient of CNPq productivity fellowship.	Boeck CR, 2005, J NEUROCHEM, V94, P48; Boeck CR, 2004, EPILEPSIA, V45, P745, DOI 10.1111/j.0013-9580.2004.65203.x; Bosel J, 2005, J NEUROCHEM, V92, P1386, DOI 10.1111/j.1471-4159.2004.02980.x; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Cheng Y, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-156; CLARKE RM, 1942, NEUROPHARMACOLOGY, V1, P136; Cordle A, 2005, J NEUROSCI, V25, P299, DOI 10.1523/JNEUROSCI.2544-04.2005; de Oliveira DL, 2004, BRAIN RES, V1018, P48, DOI 10.1016/j.brainres.2004.05.033; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Ferrer I, 2001, MOL BRAIN RES, V94, P48, DOI 10.1016/S0169-328X(01)00198-X; FOSTER AC, 1983, NEUROPHARMACOLOGY, V22, P1331, DOI 10.1016/0028-3908(83)90221-6; Ganzella M, 2006, NEUROSCI RES, V55, P397, DOI 10.1016/j.neures.2006.05.003; Greenwood J, 2006, NAT REV IMMUNOL, V6, P358, DOI 10.1038/nri1839; Hayashi T, 2005, BRAIN RES, V1037, P52, DOI 10.1016/j.brainres.2004.12.051; Hering H, 2003, J NEUROSCI, V23, P3262; HEYES MP, 1989, ANN NEUROL, V26, P275; HEYES MP, 1990, EPILEPSIA, V31, P172, DOI 10.1111/j.1528-1167.1990.tb06302.x; Kim D, 2002, J BIOCHEM MOL BIOL, V35, P106; Kretz A, 2006, NEUROBIOL DIS, V21, P421, DOI 10.1016/j.nbd.2005.08.003; LAPIN IP, 1981, EPILEPSIA, V22, P257, DOI 10.1111/j.1528-1157.1981.tb04108.x; Laufs U, 2000, STROKE, V31, P2442, DOI 10.1161/01.STR.31.10.2442; Lee JK, 2008, NEUROSCI LETT, V440, P260, DOI 10.1016/j.neulet.2008.05.112; Lee ST, 2008, J NEUROCHEM, V104, P1190, DOI 10.1111/j.1471-4159.2007.05044.x; Leipnitz G, 2005, INT J DEV NEUROSCI, V23, P695, DOI 10.1016/j.ijdevneu.2005.08.004; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Miida Takashi, 2004, J Atheroscler Thromb, V11, P253; Molz S, 2005, NEUROCHEM RES, V30, P83, DOI 10.1007/s11064-004-9689-0; Molz S, 2008, NEUROCHEM RES, V33, P27, DOI 10.1007/s11064-007-9402-1; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nakao T, 2007, J PHARMACOL SCI, V105, P334, DOI 10.1254/jphs.FP0070682; Nieoullon A, 2006, J NEUROCHEM, V98, P1007, DOI 10.1111/j.1471-4159.2006.03978.x; Patassini S, 2008, NEUROSCI LETT, V448, P166, DOI 10.1016/j.neulet.2008.10.023; PERKINS MN, 1983, J PHARMACOL EXP THER, V226, P551; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Piamsomboon Chumpol, 2002, Journal of the Medical Association of Thailand, V85, P297; Ponce J, 2008, STROKE, V39, P1269, DOI 10.1161/STROKEAHA.107.498923; Rangel P, 2005, ARQ NEURO-PSIQUIAT, V63, P972, DOI 10.1590/S0004-282X2005000600013; Rikitake Y, 2005, CIRC RES, V97, P1232, DOI 10.1161/01.RES.0000196564.18314.23; Schmidt AP, 2000, BRAIN RES, V864, P40, DOI 10.1016/S0006-8993(00)02106-5; Sims KD, 2000, J BIOL CHEM, V275, P5228, DOI 10.1074/jbc.275.7.5228; Stepien K, 2005, PHARMACOL REP, V57, P561; STONE TW, 1993, PHARMACOL REV, V45, P309; Stone TW, 2001, PROG NEUROBIOL, V64, P185, DOI 10.1016/S0301-0082(00)00032-0; Tavares RG, 2008, NEUROCHEM RES, V33, P97, DOI 10.1007/s11064-007-9421-y; Tavares RG, 2000, NEUROREPORT, V11, P249, DOI 10.1097/00001756-200002070-00005; Tavares RG, 2002, NEUROCHEM INT, V40, P621, DOI 10.1016/S0197-0186(01)00133-4; Torres GE, 2007, CURR OPIN NEUROBIOL, V17, P304, DOI 10.1016/j.conb.2007.05.002; Wallis RA, 2005, EPILEPSIA, V46, P128; Waters DD, 2005, AM J CARDIOL, V96, p69F, DOI 10.1016/j.amjcard.2005.06.028; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Yoshida Masayuki, 2003, J Atheroscler Thromb, V10, P140; Yrjanheikki J, 2005, BRAIN RES, V1052, P174, DOI 10.1016/j.brainres.2005.06.004; Zacco A, 2003, J NEUROSCI, V23, P11104; Zhang L, 2007, ARTERIOSCL THROM VAS, V27, P2470, DOI 10.1161/ATVBAHA.107.150748	57	86	86	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1029-8428	1476-3524		NEUROTOX RES	Neurotox. Res.	AUG	2009	16	2					106	115		10.1007/s12640-009-9057-6			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	458AY	WOS:000266984000002	19526287				2022-02-06	
J	Poddar, R; Paul, S				Poddar, Ranjana; Paul, Surojit			Homocysteine-NMDA receptor-mediated activation of extracellular signal-regulated kinase leads to neuronal cell death	JOURNAL OF NEUROCHEMISTRY			English	Article						Ca2+ influx; cAMP response-element binding protein; extracellular signal-regulated mitogen-activated protein kinase; homocysteine; neuronal cell death; NMDA receptors	D-ASPARTATE RECEPTOR; FOCAL CEREBRAL-ISCHEMIA; ELEMENT-BINDING PROTEIN; METABOTROPIC GLUTAMATE RECEPTORS; TRAUMATIC BRAIN-INJURY; MAP KINASE; HIPPOCAMPAL-NEURONS; ALZHEIMERS-DISEASE; PLASMA HOMOCYSTEINE; CORTICAL-NEURONS	Hyperhomocysteinemia is an independent risk factor for stroke and neurological abnormalities. However, the underlying cellular mechanisms by which elevated homocysteine can promote neuronal death is not clear. In the present study we have examined the role of NMDA receptor-mediated activation of the extracellular signal-regulated kinase-mitogen-activated protein (ERK-MAP) kinase pathway in homocysteine-dependent neurotoxicity. The study demonstrates that in neurons l-homocysteine-induced cell death was mediated through activation of NMDA receptors. The study also shows that homocysteine-dependent NMDA receptor stimulation and resultant Ca2+ influx leads to rapid and sustained phosphorylation of ERK-MAP kinase. Inhibition of ERK phosphorylation attenuates homocysteine-mediated neuronal cell death thereby demonstrating that activation of ERK-MAP kinase signaling pathway is an intermediate step that couples homocysteine-mediated NMDA receptor stimulation to neuronal death. The findings also show that cAMP response-element binding protein (CREB), a pro-survival transcription factor and a downstream target of ERK, is only transiently activated following homocysteine exposure. The sustained activation of ERK but a transient activation of CREB together suggest that exposure to homocysteine initiates a feedback loop that shuts off CREB signaling without affecting ERK phosphorylation and thereby facilitates homocysteine-mediated neurotoxicity.	[Poddar, Ranjana; Paul, Surojit] Univ New Mexico, Hlth Sci Ctr, Dept Neurol, Albuquerque, NM 87131 USA		Poddar, R (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Neurol, 1 Univ New Mexico, Albuquerque, NM 87131 USA.	rpoddar@salud.unm.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P20 RR15636]; New Mexico Trust Fund, UNM HSC RAC; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR015636] Funding Source: NIH RePORTER	We would like to thank CW Shuttleworth and JA Connor for their helpful comments. This work was supported by the National Institutes of Health Grants P20 RR15636 (Okada, Y.) and New Mexico Trust Fund, UNM HSC RAC (Poddar, R).	Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Austin RC, 2004, CELL DEATH DIFFER, V11, pS56, DOI 10.1038/sj.cdd.4401451; Banko JL, 2004, J NEUROCHEM, V91, P462, DOI 10.1111/j.1471-4159.2004.02734.x; Bhat NR, 1999, J NEUROCHEM, V72, P112, DOI 10.1046/j.1471-4159.1999.0720112.x; Blum S, 1999, J NEUROSCI, V19, P3535; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BROCH OJ, 1984, J NEUROCHEM, V43, P1755, DOI 10.1111/j.1471-4159.1984.tb06105.x; Cao J, 2005, J CELL BIOL, V168, P117, DOI 10.1083/jcb.200407024; Chandler LJ, 2001, J BIOL CHEM, V276, P2627, DOI 10.1074/jbc.M003390200; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; Colucci-D'Amato L, 2003, BIOESSAYS, V25, P1085, DOI 10.1002/bies.10355; Coogan AN, 1999, J NEUROPHYSIOL, V81, P103, DOI 10.1152/jn.1999.81.1.103; DAXHELET GA, 1989, ANAL BIOCHEM, V179, P401, DOI 10.1016/0003-2697(89)90152-8; den Heijer T, 2003, BRAIN, V126, P170, DOI 10.1093/brain/awg006; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; Duan W, 2002, J NEUROCHEM, V80, P101, DOI 10.1046/j.0022-3042.2001.00676.x; Durkin JP, 1996, J NEUROCHEM, V66, P951; Endres M, 2005, STROKE, V36, P321, DOI 10.1161/01.STR.0000153008.60517.ab; English JD, 1997, J BIOL CHEM, V272, P19103, DOI 10.1074/jbc.272.31.19103; Gottfries CG, 1998, J NEURAL TRANSM, V105, P773, DOI 10.1007/s007020050094; Hankey GJ, 2001, CURR OPIN NEUROL, V14, P95, DOI 10.1097/00019052-200102000-00015; Hara T, 2003, J NEUROCHEM, V86, P805, DOI 10.1046/j.1471-4159.2003.01847.x; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Ho PI, 2002, J NEUROSCI RES, V70, P694, DOI 10.1002/jnr.10416; Irving EA, 2000, MOL BRAIN RES, V77, P65, DOI 10.1016/S0169-328X(00)00043-7; Ivanov A, 2006, J PHYSIOL-LONDON, V572, P789, DOI 10.1113/jphysiol.2006.105510; Jara-Prado A, 2003, NEUROTOX RES, V5, P237, DOI 10.1007/BF03033381; Jiang Q, 2000, BRAIN RES, V887, P285, DOI 10.1016/S0006-8993(00)03003-1; Jiang Q, 2000, BRAIN RES, V857, P71, DOI 10.1016/S0006-8993(99)02364-1; Kamath AF, 2006, BLOOD, V107, P591, DOI 10.1182/blood-2005-06-2506; Kim MJ, 2005, NEURON, V46, P745, DOI 10.1016/j.neuron.2005.04.031; Kornhauser JM, 1997, NEURON, V18, P839, DOI 10.1016/S0896-6273(00)80322-0; Kruman II, 2002, J NEUROSCI, V22, P1752, DOI 10.1523/JNEUROSCI.22-05-01752.2002; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Lazarewicz JW, 2003, NEUROCHEM RES, V28, P259, DOI 10.1023/A:1022329317218; Lee B, 2005, J NEUROSCI, V25, P1137, DOI 10.1523/JNEUROSCI.4288-04.2005; Lenz G, 2005, J BIOL CHEM, V280, P38121, DOI 10.1074/jbc.C500363200; Lesuisse C, 2002, J CEREBR BLOOD F MET, V22, P935, DOI 10.1097/00004647-200208000-00005; LINDGREN A, 1995, STROKE, V26, P795, DOI 10.1161/01.STR.26.5.795; Lipton SA, 1997, P NATL ACAD SCI USA, V94, P5923, DOI 10.1073/pnas.94.11.5923; Luchowska E, 2005, J NEUROSCI RES, V79, P375, DOI 10.1002/jnr.20359; Luo JH, 1997, MOL PHARMACOL, V51, P79, DOI 10.1124/mol.51.1.79; Mabuchi T, 2001, J NEUROSCI, V21, P9204, DOI 10.1523/JNEUROSCI.21-23-09204.2001; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Miller JW, 1999, NUTR REV, V57, P126; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Obeid R, 2006, FEBS LETT, V580, P2994, DOI 10.1016/j.febslet.2006.04.088; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Paul S, 2003, NAT NEUROSCI, V6, P34, DOI 10.1038/nn989; Pende M, 1997, J NEUROSCI, V17, P1291; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; PHILLIS JW, 1994, NEUROCHEM RES, V19, P1125, DOI 10.1007/BF00965145; Poddar R, 2001, CIRCULATION, V103, P2717; Robert K, 2005, NEUROSCIENCE, V133, P925, DOI 10.1016/j.neuroscience.2005.03.034; Runden E, 1998, J NEUROSCI, V18, P7296; Sacco RL, 1998, NEUROEPIDEMIOLOGY, V17, P167, DOI 10.1159/000026169; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; Shi Q, 2003, J PHARMACOL EXP THER, V305, P131, DOI 10.1124/jpet.102.047092; Stanciu M, 2002, J BIOL CHEM, V277, P4010, DOI 10.1074/jbc.M104479200; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; VANDENBERG M, 1995, EUR J CLIN INVEST, V25, P176; Vanhoutte P, 1999, MOL CELL BIOL, V19, P136; Vincent SR, 1998, SYNAPSE, V29, P29, DOI 10.1002/(SICI)1098-2396(199805)29:1<29::AID-SYN3>3.3.CO;2-T; Wang ZQ, 2004, BRAIN RES, V996, P55, DOI 10.1016/j.brainres.2003.09.074; WATKINS D, 1989, AM J MED GENET, V34, P427, DOI 10.1002/ajmg.1320340320; Waxman EA, 2005, J BIOL CHEM, V280, P29322, DOI 10.1074/jbc.M502080200; Waxman EA, 2005, NEUROSCIENTIST, V11, P37, DOI 10.1177/1073858404269012; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yun HY, 1999, DIABETES RES CLIN PR, V45, P113, DOI 10.1016/S0168-8227(99)00039-X; Yuzaki M, 1999, J NEUROPHYSIOL, V82, P2820, DOI 10.1152/jn.1999.82.5.2820; Zhuang SG, 2006, J PHARMACOL EXP THER, V319, P991, DOI 10.1124/jpet.106.107367; Zieminska E, 2003, NEUROCHEM INT, V43, P481, DOI 10.1016/S0197-0186(03)00038-X; Zoccolella Stefano, 2006, Current Vascular Pharmacology, V4, P237, DOI 10.2174/157016106777698414	79	86	89	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	2009	110	3					1095	1106		10.1111/j.1471-4159.2009.06207.x			12	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	470IP	WOS:000267968700030	19508427	Green Accepted, Bronze			2022-02-06	
J	Knox, L; Douglas, J				Knox, Lucy; Douglas, Jacinta			Long-term ability to interpret facial expression after traumatic brain injury and its relation to social integration	BRAIN AND COGNITION			English	Article						Traumatic brain injury; Facial expression; Pragmatics; Social integration	QUALITY-OF-LIFE; NEURAL SYSTEMS; COMMUNICATION; RECOGNITION; EMOTION; PERCEPTION; FACES; COMPETENCE; HANDICAP; BEHAVIOR	There is considerable evidence that individuals with traumatic brain injury (TBI) experience problems interpreting the emotional state of others. However, the functional implications of these changes have not been fully investigated. A study of 13 individuals with severe TBI and an equal number of matched controls found that TBI participants had significantly more difficulty interpreting facial expression and matching emotions to social situations. A significant relationship was also established between social integration and ability to interpret facial expression for TBI participants. These results support the inclusion of therapy targeting this area within rehabilitation programs for individuals with TBI. Crown Copyright (C) 2008 Published by Elsevier Inc. All rights reserved.	[Knox, Lucy; Douglas, Jacinta] La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3086, Australia		Douglas, J (corresponding author), La Trobe Univ, Sch Human Commun Sci, Kingsbury Dr, Bundoora, Vic 3086, Australia.	j.douglas@latrobe.edu.au	Knox, Lucy/E-8642-2013; Douglas, Jacinta M/C-2380-2009	Knox, Lucy/0000-0001-8331-6032; Douglas, Jacinta/0000-0003-0940-6624			Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Adolphs R, 2003, BRAIN COGNITION, V52, P61, DOI 10.1016/S0278-2626(03)00009-5; Adolphs R, 1996, J NEUROSCI, V16, P7678; ALBERT ML, 1973, NEUROLOGY, V23, P658, DOI 10.1212/WNL.23.6.658; BASSILI JN, 1978, J EXP PSYCHOL HUMAN, V4, P373, DOI 10.1037/0096-1523.4.3.373; BAYLES K, 1990, ARIZONA BATTERY COMM; Biehl M, 1997, J NONVERBAL BEHAV, V21, P3, DOI 10.1023/A:1024902500935; Birdwhistell R., 1970, KINESICS CONTEXT ESS; Borgaro SR, 2004, BRAIN INJURY, V18, P33, DOI 10.1080/0269905031000110562; BOROD JC, 1986, NEUROPSYCHOLOGIA, V24, P169; Braun C M, 1989, Brain Inj, V3, P5, DOI 10.3109/02699058909008068; BURLEIGH SA, 1997, AM J OCCUPATIONAL TH, V52, P42; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; DEKOSKY ST, 1980, BRAIN LANG, V9, P206, DOI 10.1016/0093-934X(80)90141-8; Douglas J., 2004, EVIDENCE BASED PRACT, P59; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Ekman P., 2004, JAPANESE CAUCASIAN F; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; HUMPHREYS GW, 1993, NEUROPSYCHOLOGIA, V31, P173, DOI 10.1016/0028-3932(93)90045-2; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; KAROW CM, 2003, SEMINARS SPEECH LANG, V242, P69; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Mandal MK, 1996, INT J NEUROSCI, V84, P87, DOI 10.3109/00207459608987253; Marosszeky NEV, 1997, PTA PROTOCOL GUIDELI; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2000, APHASIOLOGY, V14, P339, DOI 10.1080/026870300401397; McDonald S., 1999, BRAIN DAM B; McDonald S., 2003, BRAIN IMPAIR, V4, P36, DOI [10.1375/brim.4.1.36.27032, DOI 10.1375/BRIM.4.1.36.27032, DOI 10.1375/brim.4.1.36.27032]; McDonald S., 2002, AWARENESS SOCIAL INF; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Morris JS, 1998, NATURE, V393, P467, DOI 10.1038/30976; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Perry RJ, 2001, NEUROCASE, V7, P145, DOI 10.1076/neur.7.2.145.16267; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PRIGATANO GP, 1982, PERCEPT MOTOR SKILL, V54, P859, DOI 10.2466/pms.1982.54.3.859; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Watkins MP., 2015, FDN CLIN RES APPL PR, V3rd; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Zhang L, 2002, J HEAD TRAUMA REHAB, V17, P497, DOI 10.1097/00001199-200212000-00002	48	86	86	0	12	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626	1090-2147		BRAIN COGNITION	Brain Cogn.	MAR	2009	69	2					442	449		10.1016/j.bandc.2008.09.009			8	Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	410MP	WOS:000263581900026	18951674				2022-02-06	
J	Faux, S; Sheedy, J				Faux, S.; Sheedy, J.			A Prospective Controlled Study in the Prevalence of Posttraumatic Headache Following Mild Traumatic Brain Injury	PAIN MEDICINE			English	Article						Mild Truamatic Brain Injury; Posttraumatic Headache; Epidemiology; Pain; Prevalence; Head Injury	POST-CONCUSSION SYNDROME; EPIDEMIOLOGY; SYMPTOMS; COMPLAINTS; SEVERITY; MODERATE; COHORT; SCALE; PAIN	To establish the prevalence of post traumatic headache, persisting at 3 months following minor traumatic brain injury. A prospective controlled study of patients admitted with a diagnosis of mild traumatic brain injury and matched orthopedic controls over 12 months during 2004. A level two inner city Emergency Department in Sydney, Australia. One hundred eligible sequential admissions with mild traumatic brain injury as defined by American Congress of Rehabilitation Medicine, 1993, and 100 matched minor injury controls with nondeceleration injuries. Subjects were part of a study on prediction of postconcussive syndrome and had neuropsychological tests, balance test and pain recordings taken at the time of injury, at 1 month and at 3 months post injury. Main measures were the reporting of headache "worse than prior to the injury" and concordant with the definition of Posttraumatic Headache according to International Headache Society Classification of Headache Disorders 2003. 15.34% of those with minor head injury continued to complain of perisistant posttraumatic headache at 3 months compared to 2.2% of the minor injury controls. To the authors' knowledge this is the first controlled prospective study in the prevalence of posttraumatic headache following mild traumatic brain injury.	[Faux, S.; Sheedy, J.] St Vincents Hosp, Darlinghurst, NSW 2010, Australia; [Faux, S.; Sheedy, J.] St Vincents Hosp, Sacred Heart Rehabil Unit, Sydney, NSW 2010, Australia		Faux, S (corresponding author), St Vincents Hosp, Sydney 170 Darlinghurst Rd, Darlinghurst, NSW 2010, Australia.	sfaux@optusnet.com.au	Faux, Steven/Y-3409-2019	Faux, Steven/0000-0001-8846-216X			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; BARNAT MR, 1986, HEADACHE, V26, P271, DOI 10.1111/j.1526-4610.1986.hed2606271.x; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; COPES WS, 1990, J TRAUMA, V30, P1200, DOI 10.1097/00005373-199010000-00003; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; EVANS RW, 1994, HEADACHE, V34, P268, DOI 10.1111/j.1526-4610.1994.hed3405268.x; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; *INT HEAD SOC, 2003, INT CLASS HEAD DIS, P56; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; JENSEN OK, 1990, CEPHALALGIA, V10, P285, DOI 10.1046/j.1468-2982.1990.1006285.x; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; PACKARD RC, 2005, CURR PAIN HEADACHE R, V9, P58; Packard Russell C, 2002, Curr Pain Headache Rep, V6, P301, DOI 10.1007/s11916-002-0051-4; Pons-Sanz SM, 2005, ANQ-Q J SHORT ART N, V18, P6; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Povlishock JT., 1996, NEUROTRAUMA, P1325; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Todd KH, 2005, EMERG MED CLIN N AM, V23, P285, DOI 10.1016/j.emc.2004.12.002; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Warner JS, 1996, NEUROLOGY, V46, P915, DOI 10.1212/WNL.46.4.915; Wasserberg J, 2002, BMJ-BRIT MED J, V325, P454, DOI 10.1136/bmj.325.7362.454; Williams RA, 1998, ARCH PHYS MED REHAB, V79, P366, DOI 10.1016/S0003-9993(98)90135-6	39	86	86	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	NOV-DEC	2008	9	8					1001	1011		10.1111/j.1526-4637.2007.00404.x			11	Anesthesiology; Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Anesthesiology; General & Internal Medicine	375HZ	WOS:000261106100007	18266807	Bronze			2022-02-06	
J	Lord-Fontaine, S; Yang, F; Diep, Q; Dergham, P; Munzer, S; Tremblay, P; McKerracher, L				Lord-Fontaine, Stephanie; Yang, Fan; Diep, Quy; Dergham, Pauline; Munzer, Scott; Tremblay, Patrick; McKerracher, Lisa			Local Inhibition of Rho Signaling by Cell-Permeable Recombinant Protein BA-210 Prevents Secondary Damage and Promotes Functional Recovery following Acute Spinal Cord Injury	JOURNAL OF NEUROTRAUMA			English	Article						contusion; neuroprotection; regeneration; Rho GTPase; spinal cord injury	TRAUMATIC BRAIN-INJURY; NEURITE OUTGROWTH; CLOSTRIDIUM-BOTULINUM; LESIONAL EXPRESSION; AXON REGENERATION; C3 EXOENZYME; NOGO-A; GROWTH; KINASE; ACTIVATION	Spinal cord injury (SCI) leads to robust Rho activation at the lesion site. Here, we demonstrate that BA-210, a cell-permeable fusion protein derived from C3 transferase, formulated in fibrin sealant and delivered topically onto the dura matter, diffuses into the spinal cord and inactivates Rho in a dose-dependent manner. Treatment with BA-210 in rats with thoracic spinal cord contusion increased tissue sparing around the lesion area and led to significant improvement of locomotor function. In mice, BA-210 improved functional outcome when treatment was either applied at the time of injury or delayed by 24 h. In both rats and mice, treatment with BA-210 was well tolerated. Rats gained body weight normally, and BA-210 treatment had no impact on the development of allodynia. Inactivating Rho with BA-210 holds promise for treating patients with SCI.	[Lord-Fontaine, Stephanie; Yang, Fan; Diep, Quy; Dergham, Pauline; Munzer, Scott; Tremblay, Patrick; McKerracher, Lisa] BioAxone Therapeut Inc, Montreal, PQ, Canada; [Dergham, Pauline; McKerracher, Lisa] Univ Montreal, Dept Pathol & Biol Cellulaire, Montreal, PQ, Canada		Tremblay, P (corresponding author), 1100 Boul Rene Levesque Ouest,25E Etage, Montreal, PQ H3B 5C9, Canada.	tremblay-patrick@videotron.ca			CIHRCanadian Institutes of Health Research (CIHR); NSERCNatural Sciences and Engineering Research Council of Canada (NSERC)	We thank Dr. Louise Laberge-Caouette for her helpful discussions and for her help with spinal cord surgery protocols. We thank Rozica Bolovan, Annie Salesse, Rathna Chaudry, and Charles Essagian for their help with surgery, animal care, histology, and behavioral analysis. We thank Veronique Boulanger for her contributions to the characterization of BA-210. This work was supported by BioAxone Therapeutic and by grants from the CIHR to L. M. Pauline Dergham was the recipient of a NSERC Industrial Fellowship.	Adcock KH, 2004, EUR J NEUROSCI, V20, P1425, DOI 10.1111/j.1460-9568.2004.03573.x; Ahmed Z, 2005, MOL CELL NEUROSCI, V28, P509, DOI 10.1016/j.mcn.2004.11.002; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 2000, PHYS THER, V80, P808, DOI 10.1093/ptj/80.8.808; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bertrand J, 2007, NEUROBIOL DIS, V25, P65, DOI 10.1016/j.nbd.2006.08.008; Bertrand J, 2005, J NEUROSCI, V25, P1113, DOI 10.1523/JNEUROSCI.3931-04.2005; Brabeck C, 2004, J NEUROTRAUM, V21, P697, DOI 10.1089/0897715041269597; Conrad S, 2005, J COMP NEUROL, V487, P166, DOI 10.1002/cne.20561; CONSTANTINI S, 1994, J NEUROSURG, V80; Dergham P, 2002, J NEUROSCI, V22, P6570; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; Figueroa JD, 2006, J NEUROSCI RES, V84, P1438, DOI 10.1002/jnr.21048; Fischer D, 2004, J NEUROSCI, V24, P8726, DOI 10.1523/JNEUROSCI.2774-04.2004; Fournier AE, 2003, J NEUROSCI, V23, P1416, DOI 10.1523/JNEUROSCI.23-04-01416.2003; Genth H, 2003, J BIOL CHEM, V278, P28523, DOI 10.1074/jbc.M301915200; Gingras K, 2004, BIOORG MED CHEM LETT, V14, P4931, DOI 10.1016/j.bmcl.2004.07.025; Guest JD, 1997, J NEUROSCI RES, V50, P888, DOI 10.1002/(SICI)1097-4547(19971201)50:5<888::AID-JNR24>3.0.CO;2-W; Han SI, 2001, J MOL BIOL, V305, P95, DOI 10.1006/jmbi.2000.4292; Hata K, 2006, J CELL BIOL, V173, P47, DOI 10.1083/jcb.200508143; Kassam Amin, 2004, Ear Nose Throat J, V83, P246; Kubo T, 2008, J NEUROCHEM, V105, P113, DOI 10.1111/j.1471-4159.2007.05125.x; Lasko D, 2006, METHOD ENZYMOL, V406, P512, DOI 10.1016/S0076-6879(06)06039-3; Laufs U, 2000, J CLIN INVEST, V106, P15, DOI 10.1172/JCI9639; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Logan A, 2006, BRAIN, V129, P490, DOI 10.1093/brain/awh706; Macias MY, 2006, EXP NEUROL, V201, P335, DOI 10.1016/j.expneurol.2006.04.035; Madura T, 2004, EMBO REP, V5, P412, DOI 10.1038/sj.embor.7400117; McKerracher L, 2006, J NEUROTRAUM, V23, P309, DOI 10.1089/neu.2006.23.309; McKerracher L, 2004, NAT MED, V10, P1052, DOI 10.1038/nm1004-1052; Monnier PP, 2003, MOL CELL NEUROSCI, V22, P319, DOI 10.1016/S1044-7431(02)00035-0; Niederost B, 2002, J NEUROSCI, V22, P10368; Nusser N, 2006, CELL SIGNAL, V18, P704, DOI 10.1016/j.cellsig.2005.06.010; Obata K, 2006, NEUROSCI RES, V55, P1, DOI 10.1016/j.neures.2006.01.005; Ozdinler PH, 2001, J COMP NEUROL, V438, P377; Ramer LM, 2004, J NEUROSCI, V24, P10796, DOI 10.1523/JNEUROSCI.3337-04.2004; Romero MI, 2000, J NEUROSCI, V20, P4435, DOI 10.1523/JNEUROSCI.20-12-04435.2000; Rosenzweig ES, 2004, CURR OPIN NEUROL, V17, P121, DOI 10.1097/00019052-200404000-00007; Schwab JM, 2004, GLIA, V47, P377, DOI 10.1002/glia.20031; Schweigreiter R, 2004, MOL CELL NEUROSCI, V27, P163, DOI 10.1016/j.mcn.2004.06.004; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Sung JK, 2003, BRAIN RES, V959, P29, DOI 10.1016/S0006-8993(02)03717-4; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Winton MJ, 2002, J BIOL CHEM, V277, P32820, DOI 10.1074/jbc.M201195200; Yamagishi S, 2005, J BIOL CHEM, V280, P20384, DOI 10.1074/jbc.M501945200; Yamashita T, 2005, MOL NEUROBIOL, V32, P105, DOI 10.1385/MN:32:2:105; Zhang YP, 2004, J NEUROSURG, V100, P343, DOI 10.3171/spi.2004.100.4.0343	49	86	93	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2008	25	11					1309	1322		10.1089/neu.2008.0613			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	384BP	WOS:000261718900003	19061375				2022-02-06	
J	Lee, JK; Won, JS; Singh, AK; Singh, I				Lee, Jin-Koo; Won, Je-Seong; Singh, Avtar K.; Singh, Inderjit			Statin inhibits kainic acid-induced seizure and associated inflammation and hippocampal cell death	NEUROSCIENCE LETTERS			English	Article						atorvastatin; excitotoxicity; inflammation; hippocampus; kainic acid; lovastatin and seizure	NITRIC-OXIDE SYNTHASE; TRAUMATIC BRAIN-INJURY; INDUCED STATUS-EPILEPTICUS; COA REDUCTASE INHIBITOR; TEMPORAL-LOBE EPILEPSY; SPINAL-CORD-INJURY; MULTIPLE-SCLEROSIS; LEWIS RATS; NEUROLOGIC DISEASES; ALZHEIMERS-DISEASE	Statins are inhibitors of HMG-CoA reductase that have been recently recognized as anti-inflammatory and neuroprotective drugs. Herein, we investigated anti-excitotoxic and anti-seizure effects of statins by using kainic acid (KA)-rat seizure model, an animal model for temporal lobe epilepsy and excitotoxic neurodegeneration. We observed that pre-treatment with Lipitor (atorvastatin) efficiently reduced KA-induced seizure activities, hippocampal neuron death, monocyte infiltration and proinflammatory gene expression. In addition, we also observed that lovastatin treatment attenuated KA- or glutamate-induced excitotoxicity of cultured hippocampal neurons. These observations suggest a potential for use of statin treatment in modulation of seizures and other neurological diseases associated with excitotoxicity. (C) 2008 Elsevier Ireland Ltd. All rights reserved.	[Lee, Jin-Koo; Won, Je-Seong; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; [Won, Je-Seong; Singh, Avtar K.] Med Univ S Carolina, Dept Pathol, Charleston, SC 29425 USA; [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA; [Lee, Jin-Koo] Hallym Univ, Inst Nat Med, Chunchon, South Korea		Singh, I (corresponding author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave,505 Childrens Res Bldg, Charleston, SC 29425 USA.	singhi@musc.edu		Won, Jeseong/0000-0003-2408-0386	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS022576, R01 NS034741, R37 NS022576, NS-22576, R01 NS037766-10, NS-37766, R01 NS040144, NS-40144, R01 NS022576-17, R01 NS037766, R01 NS034741-12, NS-34741] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040144, R01NS037766, R01NS022576, R01NS034741, R37NS022576] Funding Source: NIH RePORTER		Ananth C, 2003, HIPPOCAMPUS, V13, P375, DOI 10.1002/hipo.10090; BEAL MF, 1992, FASEB J, V6, P3338, DOI 10.1096/fasebj.6.15.1464368; Ben-Ari Y, 2000, TRENDS NEUROSCI, V23, P580, DOI 10.1016/S0166-2236(00)01659-3; BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; Bittigau P, 1997, J CHILD NEUROL, V12, P471, DOI 10.1177/088307389701200802; Cordle A, 2005, J NEUROSCI, V25, P299, DOI 10.1523/JNEUROSCI.2544-04.2005; COYLE JT, 1976, NATURE, V263, P244, DOI 10.1038/263244a0; Diaz-Villoslada P, 1998, CURR OPIN NEUROL, V11, P235, DOI 10.1097/00019052-199806000-00008; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Hering H, 2003, J NEUROSCI, V23, P3262; Hong H, 2006, AM J PHYSIOL-HEART C, V291, pH2210, DOI 10.1152/ajpheart.01270.2005; Kirsch C, 2003, PHARMACOPSYCHIATRY, V36, pS113; Kirsch C, 2003, BIOCHEM PHARMACOL, V65, P843, DOI 10.1016/S0006-2952(02)01654-4; Laufs U, 2002, BRAIN RES, V942, P23, DOI 10.1016/S0006-8993(02)02649-5; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lutjohann D, 2004, STEROIDS, V69, P431, DOI 10.1016/j.steroids.2004.03.012; Martinez-Palma L, 2003, NEUROTOX RES, V5, P399, DOI 10.1007/BF03033168; Molinuevo Jose L, 2005, Am J Alzheimers Dis Other Demen, V20, P77, DOI 10.1177/153331750502000206; Nath N, 2004, J IMMUNOL, V172, P1273, DOI 10.4049/jimmunol.172.2.1273; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pai GS, 2000, MOL GENET METAB, V69, P312; Paintlia AS, 2005, FASEB J, V19, P1407, DOI 10.1096/fj.05-3861com; Pannu R, 2007, J NEUROCHEM, V101, P182, DOI 10.1111/j.1471-4159.2006.04354.x; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Prasad R, 2005, J NEUROCHEM, V94, P204, DOI 10.1111/j.1471-4159.2005.03182.x; Rangel P, 2005, ARQ NEURO-PSIQUIAT, V63, P972, DOI 10.1590/S0004-282X2005000600013; Rizzi M, 2003, NEUROBIOL DIS, V14, P494, DOI 10.1016/j.nbd.2003.08.001; Ruocco A, 2007, EUR J NEUROSCI, V26, P3261, DOI 10.1111/j.1460-9568.2007.05935.x; Semenova MM, 2007, NAT NEUROSCI, V10, P436, DOI 10.1038/nn1869; Singh I, 1998, FEBS LETT, V426, P342, DOI 10.1016/S0014-5793(98)00370-6; SPERK G, 1994, PROG NEUROBIOL, V42, P1, DOI 10.1016/0301-0082(94)90019-1; Stanislaus R, 2002, NEUROSCI LETT, V333, P167, DOI 10.1016/S0304-3940(02)00943-6; Stanislaus R, 1999, NEUROSCI LETT, V269, P71, DOI 10.1016/S0304-3940(99)00414-0; Stanislaus R, 2001, J NEUROSCI RES, V66, P155, DOI 10.1002/jnr.1207; van Vliet EA, 2007, BRAIN, V130, P521, DOI 10.1093/brain/awl318; Vaughan CJ, 1999, STROKE, V30, P1969, DOI 10.1161/01.STR.30.9.1969; Vollmer T, 2004, LANCET, V363, P1607, DOI 10.1016/S0140-6736(04)16205-3; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wang JQ, 2004, MOL NEUROBIOL, V29, P1, DOI 10.1385/MN:29:1:01; Won JS, 2003, J NEUROSCI, V23, P7470; WON JS, 2008, J NEUROCHEM; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zacco A, 2003, J NEUROSCI, V23, P11104	44	86	89	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	AUG 8	2008	440	3					260	264		10.1016/j.neulet.2008.05.112			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	331MP	WOS:000258016600014	18583044	Green Accepted			2022-02-06	
J	Terrell, TR; Bostick, RM; Abramson, R; Xie, D; Barfield, W; Cantu, R; Stanek, M; Ewing, T				Terrell, Thomas Roland; Bostick, Roberd M.; Abramson, Ruth; Xie, Dawen; Barfield, William; Cantu, Robert; Stanek, Michele; Ewing, Trina			APOE, APOE promoter, and tau genotypes and risk for concussion in college athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; soccer; football; genetic polymorphism; APOE; APOE G-219T promoter polymophism	TRAUMATIC BRAIN-INJURY; APOLIPOPROTEIN-E EPSILON-4; DEVELOPING ALZHEIMERS-DISEASE; HEAD-INJURY; REGULATORY REGION; FOOTBALL PLAYERS; SOCCER PLAYERS; GENE PROMOTER; POLYMORPHISMS; ASSOCIATION	Objective: To investigate associations of APOE, APOE promoter (G-219T), and tau protein exon 6 polymorphisms ((His)47(Tyr) and (Ser)53(Pro)) and a history of self-reported concussion in college athletes. Design: Multi-center cross-sectional study. Setting: Male football and male and female soccer programs at the University of South Carolina, Jacksonville University, Benedict College, and the College of Charleston. Participants: Active 18- to 30-year-old (n = 195) intercollegiate male football players and male and female soccer players during 2001 and 2002. Assessment of Risk Factors: Written questionnaires and blood or mouthwash samples for DNA for genotyping by RFLP/PCR. Main Outcome Measurement: Self-reported history of concussions over the previous 8 years. Results: A statistically significant, nearly 3-fold increase in risk of a history of concussion for those with the APOE promoter G-219T TT genotype relative to the GG genotype (OR, 2.8; 95% CI, 1.1 to 6.9) adjusted for age, sport, school, and years in their primary sport a finding that was stronger for Cantu grade 2 and 3 concussions. Conclusions: These results suggest that college athletes with an APOE promoter G-219T TT genotype may be at increased risk for having a history of concussions, especially more severe concussions. Although there was some support for the possibility that the tau (Ser)53(Pro) polymorphism may be associated with increased risk of prior concussion (OR, 2.1; 95% CI, 0.3 to 14.5), there was no support for an association with APOE genotypes. The results of this crosssectional study support the need for a prospective study of genetic factors, such as APOE promoter polymorphisms, and the incidence of and sequelae from concussions in college athletes.	[Terrell, Thomas Roland] E Carolina Univ, Brody Sch Med, Dept Family Med, Greenville, NC 27834 USA; [Bostick, Roberd M.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA USA; [Bostick, Roberd M.] Emory Univ, Rollins Sch Publ Hlth, Dept Hematol Oncol, Atlanta, GA USA; [Abramson, Ruth] Univ S Carolina, Sch Med, Dept Neuropsychiat, Columbia, SC USA; [Xie, Dawen] Univ S Carolina, Dept Epidemiol & Biostat, Mol Epidemiol Res Lab, Columbia, SC USA; [Barfield, William] Med Univ S Carolina, Dept Orthoped Surg, Charleston, SC 29425 USA; [Cantu, Robert] Emerson Hosp, Dept Surg, Concord, MA USA; [Stanek, Michele; Ewing, Trina] Univ S Carolina, Sch Med, Dept Family & Prevent Med, Columbia, SC USA		Terrell, TR (corresponding author), E Carolina Univ, Brody Sch Med, Dept Family Med, 600 Moye Blvd,Brody 4N-51, Greenville, NC 27834 USA.	tomterrell@earthlink.net					Artiga MJ, 1998, HUM MOL GENET, V7, P1887, DOI 10.1093/hmg/7.12.1887; Artiga MJ, 1998, FEBS LETT, V421, P105, DOI 10.1016/S0014-5793(97)01543-3; Barnes MP, 1999, BRIT MED BULL, V55, P927, DOI 10.1258/0007142991902727; Berr C, 2001, NEUROBIOL AGING, V22, P227, DOI 10.1016/S0197-4580(00)00227-X; Beyer K, 2002, NEUROREPORT, V13, P1403, DOI 10.1097/00001756-200208070-00011; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Crawford F, 1999, NEUROSCI LETT, V266, P193, DOI 10.1016/S0304-3940(99)00303-1; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; HAYNEY MS, 1995, MAYO CLIN PROC, V70, P951, DOI 10.4065/70.10.951; HECHT S, 2005, CLIN J SPORT MED, V15, P279; HUANG DY, 1995, NEUROSCI LETT, V192, P209, DOI 10.1016/0304-3940(95)11649-H; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kimura M, 2000, J NEURAL TRANSM, V107, P1449, DOI 10.1007/s007020070008; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Kwon JM, 2000, NEUROSCI LETT, V284, P77, DOI 10.1016/S0304-3940(00)00972-1; Lambert JC, 1997, HUM MOL GENET, V6, P2151, DOI 10.1093/hmg/6.12.2151; Lambert JC, 2000, HUM MOL GENET, V9, P57, DOI 10.1093/hmg/9.1.57; Lambert JC, 1998, HUM MOL GENET, V7, P533, DOI 10.1093/hmg/7.3.533; Lambert JC, 1998, HUM MOL GENET, V7, P1511, DOI 10.1093/hmg/7.9.1511; Lambert JC, 2002, NEUROLOGY, V59, P59, DOI 10.1212/WNL.59.1.59; Laws SM, 1999, NEUROREPORT, V10, P879, DOI 10.1097/00001756-199903170-00038; Lendon CL, 2003, NEUROLOGY, V61, P683, DOI 10.1212/01.WNL.0000078033.81925.80; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lilius L, 1999, NEUROSCI LETT, V277, P29, DOI 10.1016/S0304-3940(99)00833-2; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SKENE JHP, 1983, P NATL ACAD SCI-BIOL, V80, P4169, DOI 10.1073/pnas.80.13.4169; STOLL G, 1989, GLIA, V2, P170, DOI 10.1002/glia.440020306; Sun YL, 1998, J NEUROSCI, V18, P3261; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	52	86	86	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2008	18	1					10	17		10.1097/JSM.0b013e31815c1d4c			8	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	249XK	WOS:000252263600004	18185033				2022-02-06	
J	Shichinohe, H; Kuroda, S; Yano, S; Hida, K; Iwasaki, Y				Shichinohe, Hideo; Kuroda, Satoshi; Yano, Shunsuke; Hida, Kazutoshi; Iwasaki, Yoshinobu			Role of SDF-1/CXCR4 system in survival and migration of bone marrow stromal cells after transplantation into mice cerebral infarct	BRAIN RESEARCH			English	Article						bone marrow stromal cell; cerebral infarct; stromal derived factor-1; CXCR4; migration; transplantation	TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; NEURAL STEM-CELLS; SDF-1 CXCL12; IN-VITRO; STROKE; RAT; EXPRESSION; ASTROCYTES; CXCR4	Recent studies have indicated that bone marrow stromal cells (BMSC) have the potential to improve neurological function when transplanted into animal models of cerebral infarction. However, it is still obscure how the transplanted BMSC restore the lost neurological function. in this study, therefore, we aimed to elucidate the role of stromal cell-derived factor-1 (SDF-1) and its specific receptor, CXCR4, in BMSC transplantation into the brain subjected to cerebral infarction. The BMSC were harvested from the wild type (WT) and CXCR4-knockout (CXCR4-KO) mice and were cultured. The mice were subjected to permanent middle cerebral artery occlusion. The WT or CXCR4-KO BMSC was injected into the ipsilateral striatum 7 days after the insult. Motor function of the animals was serially evaluated, using a rotarod treadmill. Using fluorescence immunohistochemistry, we evaluated the distribution and phenotype of the transplanted cells 4 weeks after transplantation. Recovery of motor function in the WT BMSC-transplanted mice was more pronounced than in the CXCR4-KO-transplanted mice and the vehicle-treated ones. SDF-1 was extensively expressed in peri-infarct area. In the WT BMSC-transplanted mice, the transplanted cells were extensively distributed in the ipsilateral hemisphere, and many of them migrated towards the peri-infarct area and expressed the proteins specific for neurons and astrocytes, although these findings were not observed in the CXCR4-KO-transplanted mice. The results suggest that the SDF-1/CXCR4 system may play a critical role in the survival, proliferation and migration of the transplanted BMSC and contribute to recovery of neurological function. (c) 2007 Elsevier B.V. All rights reserved.	[Shichinohe, Hideo; Kuroda, Satoshi; Yano, Shunsuke; Hida, Kazutoshi; Iwasaki, Yoshinobu] Hokkaido Univ, Grad Sch Med, Dept Neurosurg, Kita Ku, Sapporo, Hokkaido 0608638, Japan		Shichinohe, H (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Neurosurg, Kita Ku, N 15 W 7, Sapporo, Hokkaido 0608638, Japan.	hshichi@stanford.edu	Shichinohe, Hideo/G-5367-2012				Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Borlongan CV, 2004, BRAIN RES, V1010, P108, DOI 10.1016/j.brainres.2004.02.072; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Guillemin GJ, 2003, GLIA, V41, P371, DOI 10.1002/glia.10175; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hess DC, 2002, STROKE, V33, P1362, DOI 10.1161/01.STR.0000014925.09415.C3; Hill WD, 2004, J NEUROPATH EXP NEUR, V63, P84, DOI 10.1093/jnen/63.1.84; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Kortesidis A, 2005, BLOOD, V105, P3793, DOI 10.1182/blood-2004-11-4349; Kurozumi K, 2004, MOL THER, V9, P189, DOI 10.1016/j.ymthe.2003.10.012; Lazarini F, 2003, GLIA, V42, P139, DOI 10.1002/glia.10139; Lee JB, 2004, BRAIN RES PROTOC, V14, P37, DOI 10.1016/j.brainresprot.2004.09.004; Lee JB, 2003, NEUROPATHOLOGY, V23, P169, DOI 10.1046/j.1440-1789.2003.00496.x; Liles WC, 2003, BLOOD, V102, P2728, DOI 10.1182/blood-2003-02-0663; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Miller JT, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-63; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Pujol F, 2005, J CELL SCI, V118, P1071, DOI 10.1242/jcs.01694; Shichinohe H, 2004, BRAIN RES PROTOC, V13, P166, DOI 10.1016/j.brainresprot.2004.04.004; Shichinohe H, 2004, BRAIN RES, V1001, P51, DOI 10.1016/j.brainres.2003.11.054; Shichinohe H, 2006, J NUCL MED, V47, P486; Son BR, 2006, STEM CELLS, V24, P1254, DOI 10.1634/stemcells.2005-0271; Stumm RK, 2003, J NEUROSCI, V23, P5123; Wang L, 2002, EXP HEMATOL, V30, P831, DOI 10.1016/S0301-472X(02)00829-9; Wang Lei, 2002, Hematology, V7, P113; Yamaguchi S, 2006, BRAIN RES, V1087, P15, DOI 10.1016/j.brainres.2006.02.127; Yano S, 2005, BRAIN RES, V1065, P60, DOI 10.1016/j.brainres.2005.10.031; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853	35	86	98	0	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 5	2007	1183						138	147		10.1016/j.brainres.2007.08.091			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	244NC	WOS:000251871600014	17976542				2022-02-06	
J	Cherian, L; Goodman, JC; Robertson, C				Cherian, Leela; Clay Goodman, J.; Robertson, Claudia			Neuroprotection with erythropoietin administration following controlled cortical impact injury in rats	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; NITRIC-OXIDE SYNTHASE; ENDOTHELIAL-CELLS; CEREBRAL-ISCHEMIA; SUBARACHNOID HEMORRHAGE; ENHANCES NEUROGENESIS; FUNCTIONAL RECOVERY; NEURONAL APOPTOSIS; BRAIN-INJURY; EXPRESSION	This study was designed to determine the effect of erythropoietin (Epo) on cerebral blood flow (CBF), nitric oxide (NO) concentration, and neurological outcome after traumatic brain injury. In one experiment, the hemodynamic effects of Epo were determined after controlled cortical impact injury (CCII) by measuring mean arterial pressure, intracranial pressure, CBF using laser Doppler flowmetry, and brain tissue NO concentrations using an NO electrode. In total, 41 rats were given either Epo (5000 U/kg) or saline s.c. 3 days before injury. In animals pretreated with saline, L-arginine but not D-arginine administration resulted in a significant increase in tissue NO concentrations and an improvement in CBF at the impact site. Likewise, in animals pretreated with Epo, L-arginine but not D-arginine given postinjury increased brain tissue NO concentrations and increased CBF. In another experiment, 74 rats underwent CCII (3-mm deformation, velocity 5 m/s), and they were given saline or Epo 5000 U/kg s.c. at 5 min, 1 h, 3 h, 6 h, 9 h, or 12 h postinjury. The contusion volume and cell counts of viable neurons in the CA1 and CA3 regions of the hippocampus were assessed at 2 weeks postinjury. The contusion volume was significantly reduced at 5 min, 1 h, 3 h, and 6 h postinjury Epo administration. The neuron density in the CA1 and CA3 region of the hippocampus was increased at 1, 3, and 6 h after injury. These data demonstrate the neuroprotective effects of Epo in traumatic injury, and the effects are optimal when Epo is given within 6 h of injury.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA		Cherian, L (corresponding author), Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.	lcherian@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS38660] Funding Source: Medline		Alafaci C, 2000, EUR J PHARMACOL, V406, P219, DOI 10.1016/S0014-2999(00)00691-9; Banerjee D, 2000, KIDNEY INT, V57, P1895, DOI 10.1046/j.1523-1755.2000.00039.x; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Calapai G, 2000, EUR J PHARMACOL, V401, P349, DOI 10.1016/S0014-2999(00)00466-0; Catania MA, 2002, EUR J PHARMACOL, V437, P147, DOI 10.1016/S0014-2999(02)01292-X; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Cerami A, 2001, SEMIN HEMATOL, V38, P33, DOI 10.1053/shem.2001.27484; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171, DOI 10.1152/jn.2000.83.4.2171; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; Chong ZZ, 2003, BRIT J PHARMACOL, V138, P1107, DOI 10.1038/sj.bjp.0705161; Chong ZZ, 2003, J CEREBR BLOOD F MET, V23, P320, DOI 10.1097/01.WCB.0000050061.57184.AE; DELCASTILLO D, 1995, NEPHROL DIAL TRANSPL, V10, P505, DOI 10.1093/ndt/10.4.505; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; EGRIE J C, 1988, Kidney International, V33, P262; Genc S, 2001, NEUROSCI LETT, V298, P139, DOI 10.1016/S0304-3940(00)01716-X; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Grasso G, 2001, J Neurosurg Sci, V45, P7; Hlatky R, 2003, J NEUROTRAUM, V20, P995, DOI 10.1089/089771503770195849; Iwasaki Y, 2002, NEUROL RES, V24, P643, DOI 10.1179/016164102101200681; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Kang JQ, 2003, MOL PHARMACOL, V64, P557, DOI 10.1124/mol.64.3.557; Kolb B, 2007, J CEREBR BLOOD F MET, V27, P983, DOI 10.1038/sj.jcbfm.9600402; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Noguchi K, 2001, BRIT J PHARMACOL, V133, P395, DOI 10.1038/sj.bjp.0704083; Ongil SL, 1996, EXP NEPHROL, V4, P37; Schena F, 2002, J SPORT MED PHYS FIT, V42, P129; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Springborg JB, 2002, BRIT J PHARMACOL, V135, P823, DOI 10.1038/sj.bjp.0704521; Sun Y, 2005, STROKE, V36, P1672, DOI 10.1161/01.STR.0000173406.04891.8c; Tsukahara H, 1997, SCAND J CLIN LAB INV, V57, P487, DOI 10.3109/00365519709084598; Vaziri ND, 1995, AM J PHYSIOL-RENAL, V269, pF838, DOI 10.1152/ajprenal.1995.269.6.F838; Wada Y, 1999, AM J HYPERTENS, V12, P980, DOI 10.1016/S0895-7061(99)00081-3; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang XQ, 1999, HYPERTENSION, V33, P894, DOI 10.1161/01.HYP.33.3.894; Wen TC, 2002, J NEUROSCI RES, V67, P795, DOI 10.1002/jnr.10166; Wu XC, 1999, CLIN SCI, V97, P413, DOI 10.1042/CS19990055; Yamamoto M, 2000, NEUROSCI LETT, V292, P131, DOI 10.1016/S0304-3940(00)01441-5; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje	40	86	93	0	6	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	AUG	2007	322	2					789	794		10.1124/jpet.107.119628			6	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	192IM	WOS:000248194600041	17470644				2022-02-06	
J	Darwish, RS; Amiridze, N; Aarabi, B				Darwish, Ribal S.; Amiridze, Nana; Aarabi, Bizhan			Nitrotyrosine as an oxidative stress marker: Evidence for involvement in neurologic outcome in human traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 22-26, 2005	Atlanta, GA	Amer Soc Anesthesiologists		nitrotyrosine; activated caspase-3; traumatic brain injury; oxidative stress	NITRIC-OXIDE SYNTHASE; NEUROPROTECTION; DYSFUNCTION; APOPTOSIS; INDUCTION; CASPASE-3; CONTUSION; DAMAGE; RATS	Background. Oxidative stress has been indicated as a mechanism of secondary neuronal injury in traumatic brain injury (TBI). Nitrotyrosine in the cerebrospinal fluid (CSF) may be an in vivo marker of oxidative nitric oxide damage. We tested the hypothesis that increased levels of nitrotyrosine correlate with poor neurologic outcomes in patients with TBI and attempted to identify the source of increased CSF nitrotyrosine. Methods. This institutional-reviewboard-approved study included 10 adults with severe closed TBI (Glasgow Coma Scale score <8) and no documented hypoxic brain injury. These patients underwent routine evaluation and, when indicated, placement of an intraventricular catheter. CSF samples (n = 27) were collected 2 to 72 hours after TBI and were also obtained from four healthy individuals. Nitrotyrosine levels were measured, and immunohistochemistry was performed. Neurologic follow-up extended to 1 month after injury. Results. Nitrotyrosine was not detected in the control samples but was detected in 13 CSF samples from 7 TBI patients (range, 22.4-97.6 nM/mL). Seven patients had poor outcomes, and, in each, ni- trotyrosine was detected. Nitrotyrosine immunoreactivity was detected in neurons and glia and confirmed in brain homogenate. Conclusion. Oxidative stress contributes to secondary brain injury in patients with TBI. Poor neurologic outcome is associated with increased levels of nitrotyrosine in the CSF. Identifying patients or the stage at which oxidative stress is more active using CSF markers of oxidative injury may help in the development of more targeted treatments.	Univ Maryland, Sch Med, Med Ctr, Dept Anesthesiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Diagnost Radiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA		Darwish, RS (corresponding author), Univ Maryland, Sch Med, Med Ctr, Dept Anesthesiol, 22 S Greene St, Baltimore, MD 21201 USA.	rdarwish@anes.umm.edu		Darwish, Ribal/0000-0003-0727-0401			Acarin L, 2005, J NEUROTRAUM, V22, P189, DOI 10.1089/neu.2005.22.189; Bayir H, 2003, J CEREBR BLOOD F MET, V23, P51, DOI 10.1097/01.WCB.0000040399.30600.E3; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Gahm C, 2006, J NEUROTRAUM, V23, P1343, DOI 10.1089/neu.2006.23.1343; Hall ED, 1999, ANN NY ACAD SCI, V890, P462, DOI 10.1111/j.1749-6632.1999.tb08025.x; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Peluffo H, 2004, J NEUROCHEM, V89, P602, DOI 10.1046/j.1471-4159.2004.02363.x; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	14	86	89	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2007	63	2					439	442		10.1097/TA.0b013e318069178a			4	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	200AC	WOS:000248735300037	17693848				2022-02-06	
J	Plesnila, N; von Baumgarten, L; Retiounskaia, M; Engel, D; Ardeshiri, A; Zimmermann, R; Hoffmann, F; Landshamer, S; Wagner, E; Culmsee, C				Plesnila, N.; von Baumgarten, L.; Retiounskaia, M.; Engel, D.; Ardeshiri, A.; Zimmermann, R.; Hoffmann, F.; Landshamer, S.; Wagner, E.; Culmsee, C.			Delayed neuronal death after brain trauma involves p53-dependent inhibition of NF-kappa B transcriptional activity	CELL DEATH AND DIFFERENTIATION			English	Article						programmed cell death; apoptosis; pifithrin; XIAP; Bax; DNA damage	FOCAL CEREBRAL-ISCHEMIA; ANTI-APOPTOTIC ACTIVITY; CELL-DEATH; P53-INDUCED APOPTOSIS; TRANSGENIC MICE; NERVOUS-SYSTEM; RAT-BRAIN; P53; XIAP; PROTECTS	Acute and chronic neurodegeneration, for example, following brain injury or Alzheimer's disease, is characterized by programmed death of neuronal cells. The present study addresses the role and interaction of p53- and NF-kappa B- dependent mechanisms in delayed neurodegeneration following traumatic brain injury ( TBI). After experimental TBI in mice p53 rapidly accumulated in the injured brain tissue and translocated to the nucleus of damaged neurons, whereas NF-kappa B transcriptional activity simultaneously declined. Post- traumatic neurodegeneration correlated with the increase in p53 levels and was significantly reduced by the selective p53 inhibitor pifithrin-alpha ( PFT). Strikingly, this protective effect was observed even when PFT treatment was delayed up to 6 h after trauma. Inhibition of p53 activity resulted in the concomitant increase in NF-kappa B transcriptional activity and upregulation of NF-kappa B- target proteins, for example X- chromosomal- linked inhibitor of apoptosis (XIAP). It is interesting to note that inhibition of XIAP abolished the neuroprotective effects of PFT in cultured neurons exposed to camptothecin, glutamate, or oxygen glucose deprivation. In conclusion, delayed neuronal cell death after brain trauma is mediated by p53- dependent mechanisms that involve inhibition of NF-kappa B transcriptional activity. Hence, p53 inhibition provides a promising approach for the treatment of acute brain injury, since it blocks apoptotic pathways and concomitantly triggers survival signaling with a therapeutic window relevant for clinical applications.	Univ Munich, Ctr Med, Inst Surg Res, Dept Neurosurg, D-81377 Munich, Germany; Univ Munich, Dept Pharm, D-81377 Munich, Germany; Erasmus MC, Dept Neurosci, Rotterdam, Netherlands; Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands		Culmsee, C (corresponding author), Univ Munich, Dept Pharm, Butenandtstr 5-13, D-81377 Munich, Germany.	carsten.culmsee@cup.uni-muenchen.de	von Baumgarten, Louisa/A-4636-2016; Plesnila, Nikolaus/T-7522-2019; Wagner, Ernst/A-7435-2012; Wagner, Ernst/ABB-5976-2020; Culmsee, Carsten/ABC-3120-2021	Wagner, Ernst/0000-0001-8413-0934; Wagner, Ernst/0000-0001-8413-0934; Culmsee, Carsten/0000-0002-5121-5015			Bhakar AL, 2002, J NEUROSCI, V22, P8466; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P994, DOI 10.1038/sj.cdd.4401908; Chopp M, 2006, ADV EXP MED BIOL, V585, P49; Cregan SP, 1999, J NEUROSCI, V19, P7860; CRUMRINE RC, 1994, J CEREBR BLOOD F MET, V14, P887, DOI 10.1038/jcbfm.1994.119; Culmsee C, 2005, J NEUROSCI, V25, P10262, DOI 10.1523/JNEUROSCI.2818-05.2005; Culmsee C, 2005, BIOCHEM BIOPH RES CO, V331, P761, DOI 10.1016/j.bbrc.2005.03.149; Culmsee C, 2003, J NEUROSCI, V23, P8586; Culmsee C, 2002, NEUROSCIENCE, V115, P1089, DOI 10.1016/S0306-4522(02)00539-0; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.00220.x; Deveraux Quinn L., 2001, Cardiology Clinics, V19, P57; Endo H, 2006, J NEUROSCI, V26, P7974, DOI 10.1523/JNEUROSCI.0897-06.2006; Guegan C, 2006, NEUROBIOL DIS, V22, P177, DOI 10.1016/j.nbd.2005.10.014; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Leker RR, 2004, EXP NEUROL, V187, P478, DOI 10.1016/j.expneurol.2004.01.030; Li TF, 2006, EXP NEUROL, V197, P301, DOI 10.1016/j.expneurol.2005.08.021; LI Y, 1994, STROKE, V25, P849, DOI 10.1161/01.STR.25.4.849; Mattson MP, 2005, NEUROCHEM RES, V30, P883, DOI 10.1007/s11064-005-6961-x; Millet I, 2000, J BIOL CHEM, V275, P15114, DOI 10.1074/jbc.275.20.15114; Morrison RS, 2003, NEUROCHEM RES, V28, P15, DOI 10.1023/A:1021687810103; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Polster BM, 2004, J NEUROCHEM, V90, P1281, DOI 10.1111/j.1471-4159.2004.02572.x; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Renwick J, 2006, GENE THER, V13, P339, DOI 10.1038/sj.gt.3302683; SALMINEN A, 1995, BIOCHEM BIOPH RES CO, V212, P939, DOI 10.1006/bbrc.1995.2060; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Siegelin M, 2005, NEUROBIOL DIS, V20, P509, DOI 10.1016/j.nbd.2005.04.006; Silke J, 2002, J CELL BIOL, V157, P115, DOI 10.1083/jcb.200108085; Silke J, 2001, EMBO J, V20, P3114, DOI 10.1093/emboj/20.12.3114; Tomita Y, 2006, J BIOL CHEM, V281, P8600, DOI 10.1074/jbc.M507611200; Trapp T, 2003, MOL CELL NEUROSCI, V23, P302, DOI 10.1016/S1044-7431(03)00013-7; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; Wang XY, 2004, NEUROBIOL DIS, V16, P179, DOI 10.1016/j.nbd.2004.01.014; Webster GA, 1999, MOL CELL BIOL, V19, P3485; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang W, 2005, J CEREBR BLOOD F MET, V25, P30, DOI 10.1038/sj.jcbfm.9600004; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	39	86	89	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1350-9047	1476-5403		CELL DEATH DIFFER	Cell Death Differ.	AUG	2007	14	8					1529	1541		10.1038/sj.cdd.4402159			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	192OI	WOS:000248211000015	17464322	Bronze			2022-02-06	
J	Bodnar, LE; Pralune, MC; Cutting, LE; Denckla, MB; Mahone, EM				Bodnar, L. Elizabeth; Pralune, M. Cristine; Cutting, Laurie E.; Denckla, Martha B.; Mahone, E. Mark			Construct validity of parent ratings of inhibitory control	CHILD NEUROPSYCHOLOGY			English	Article; Proceedings Paper	32nd Annual Meeting of the International-Neuropsychological-Society	FEB 04-07, 2004	Baltimore, MD	Int Neuropsychol Soc		BRIEF; continuous performance test; attention; executive functions; ADHD	CONTINUOUS PERFORMANCE-TEST; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; TRAUMATIC BRAIN-INJURY; EXECUTIVE FUNCTION; RESPONSE-INHIBITION; TOURETTE-SYNDROME; CHILDREN; ADHD; METHYLPHENIDATE	Recent literature has emphasized the need to examine executive functions (EF) in children using multiple sources, including both parent rating and performance-based measures. Computerized Go/No-Go tests, including commercially available continuous performance tests (CPTs), represent one of the most commonly used methods of assessing inhibitory control-a variable central to the executive function construct. We examined the relationship between parent ratings of inhibitory control and CPT performance in two mixed clinical samples. Experiment I examined 109 children ages 6-18 using the Behavior Rating Inventory of Executive Function (BRIEF; Gioia, Isquith, Guy, & Kenworthy, 2000) and the Conners' CPT-II (Conners, 2000). In this sample, ratings on the BRIEF Inhibit scale (mean T-score = 62.3) were significantly higher than the CPT-II commissions score (mean T-score = 50.7, p < .0001); and the BRIEF and CPT-II scores were not highly correlated (r = -.12). Experiment 2 examined a sample of 131 children ages 7-18 using the BRIEF and the Tests of Variables of Attention (TOVA; Greenberg, 1996). In this sample, parent ratings on the BRIEF Inhibit scale (mean T-score = 56.8) were similar to TOVA commissions scores (mean T-score = 58.6; p = .33), although still poorly correlated (r = -.02). Factor analyses exploring covariance between BRIEF scales CPT-II variables (Experiment 1) and between BRIEF and TOVA (Experiment 2) yielded similar findings. In both experiments, all eight BRIEF scales loaded on a single factor, with no overlap with either the CPT-II or the TOVA. In mixed outpatient clinical samples, the BRIEF appears to measure different elements of inhibitory control than those assessed by computerized continuous performance tests.	Kennedy Krieger Inst, Dept Neuropsychol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA; American Univ, Washington, DC 20016 USA		Mahone, EM (corresponding author), Kennedy Krieger Inst, Dept Neuropsychol, 1750 E Fairmt Ave, Baltimore, MD 21231 USA.	mahone@kennedykrieger.org		Mahone, E. Mark/0000-0002-5022-1499	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR00052] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD-24061] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS 35359] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD024061] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS035359] Funding Source: NIH RePORTER		Anderson SW, 1999, NAT NEUROSCI, V2, P1032, DOI 10.1038/14833; Anderson V, 1997, Pediatr Rehabil, V1, P63; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Aron AR, 2005, BIOL PSYCHIAT, V57, P1285, DOI 10.1016/j.biopsych.2004.10.026; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Barkley RA, 2000, J AM ACAD CHILD PSY, V39, P1064, DOI 10.1097/00004583-200008000-00025; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Bedard AC, 2004, J AM ACAD CHILD PSY, V43, P260, DOI 10.1097/00004583-200403000-00006; Beebe DW, 2004, J INT NEUROPSYCH SOC, V10, P962, DOI 10.1017/S135561770410708X; Brewis A, 2002, SOC BIOL, V49, P99; Brocki KC, 2004, DEV NEUROPSYCHOL, V26, P571, DOI 10.1207/s15326942dn2602_3; Burmeister R, 2005, CHILD NEUROPSYCHOL, V11, P265, DOI 10.1080/092970490911324; Castellanos FX, 2002, JAMA-J AM MED ASSOC, V288, P1740, DOI 10.1001/jama.288.14.1740; Christ SE, 2003, NEUROPSYCHOLOGY, V17, P171, DOI 10.1037/0894-4105.17.1.171; Conners CK, 2000, CONNERS CONTINOUS PE; Delis DC., 2001, DELIS KAPLAN EXECUTI; Denckla MB, 1996, DEV NEUROPSYCHOL, V12, P5, DOI 10.1080/87565649609540637; Dodrill CB, 1997, CLIN NEUROPSYCHOL, V11, P1, DOI 10.1080/13854049708407025; Dunn L.M., 1997, PEABODY PICTURE VOCA, V3rd Edition; Epstein JN, 2003, J ABNORM CHILD PSYCH, V31, P543, DOI 10.1023/A:1025405216339; Evans DW, 2004, BRAIN COGNITION, V55, P220, DOI 10.1016/s0278-2626(03)00274-4; Gassio R, 2005, DEV MED CHILD NEUROL, V47, P443, DOI 10.1017/S0012162205000861; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gioia GA IP, 2000, BEHAV RATING INVENTO; Goldberg MC, 2005, J AUTISM DEV DISORD, V35, P279, DOI 10.1007/s10803-005-3291-4; GREEBERG LM, 1996, TEST VARIABLES ATTEN; GREENBERG LM, 1993, J CHILD PSYCHOL PSYC, V34, P1019, DOI 10.1111/j.1469-7610.1993.tb01105.x; Grodzinsky GM, 1999, CLIN NEUROPSYCHOL, V13, P12, DOI 10.1076/clin.13.1.12.1983; Harris E L, 1995, J Int Neuropsychol Soc, V1, P511; HAYS WL, 1988, STATISTICS; Holmes-Bernstein J., 1990, NEUROPSYCHOLOGY, P311, DOI DOI 10.1385/0-89603-133-0:311; Losier BJ, 1996, J CHILD PSYCHOL PSYC, V37, P971, DOI 10.1111/j.1469-7610.1996.tb01494.x; Mahone EM, 2005, DEV NEUROPSYCHOL, V27, P11, DOI 10.1207/s15326942dn2701_2; Mahone EM, 2002, CHILD NEUROPSYCHOL, V8, P258, DOI 10.1076/chin.8.4.258.13510; Mahone EM, 2002, ARCH CLIN NEUROPSYCH, V17, P643, DOI 10.1016/S0887-6177(01)00168-8; Mahone EM, 2001, J INT NEUROPSYCH SOC, V7, P102, DOI 10.1017/S1355617701711101; Mariani MA, 1997, DEV NEUROPSYCHOL, V13, P111, DOI 10.1080/87565649709540671; Martinussen R, 2005, J AM ACAD CHILD PSY, V44, P377, DOI 10.1097/01.chi.0000153228.72591.73; McGee RA, 2000, J ABNORM CHILD PSYCH, V28, P415, DOI 10.1023/A:1005127504982; Mostofsky SH, 2003, PERCEPT MOTOR SKILL, V97, P1315, DOI 10.2466/PMS.97.8.1315-1331; Mostofsky SH, 2002, BIOL PSYCHIAT, V52, P785, DOI 10.1016/S0006-3223(02)01412-9; *NAT I HLTH CONS S, 1998, DIAGN TREAT ATT DEF; Nigg JT, 1996, J CLIN CHILD PSYCHOL, V25, P330, DOI 10.1207/s15374424jccp2503_9; Nyden A, 2000, EUR CHILD ADOLES PSY, V9, P180, DOI 10.1007/s007870070041; OToole K, 1997, J AM ACAD CHILD PSY, V36, P531, DOI 10.1097/00004583-199704000-00016; Ozonoff S, 1999, J AUTISM DEV DISORD, V29, P171, DOI 10.1023/A:1023052913110; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; Pliszka SR, 1997, J DEV BEHAV PEDIATR, V18, P254; Rice J.A., 2000, ADHD REPORT, V8, P1; Riva D, 2005, NEUROL SCI, V26, P263, DOI 10.1007/s10072-005-0469-7; Rubia K, 2001, NEUROIMAGE, V13, P250, DOI 10.1006/nimg.2000.0685; Scheres A, 2003, J ABNORM CHILD PSYCH, V31, P105, DOI 10.1023/A:1021729501230; Seidman LJ, 1997, J AM ACAD CHILD PSY, V36, P366, DOI 10.1097/00004583-199703000-00015; Shucard DW, 1997, NEUROPSYCHOLOGY, V11, P147, DOI 10.1037/0894-4105.11.1.147; Slomine BS, 2005, J INT NEUROPSYCH SOC, V11, P645, DOI 10.1017/S1355617705050769; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wechsler D., 2011, WECHSLER ABBREVIATED; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; WHITE JL, 1994, J ABNORM PSYCHOL, V103, P192, DOI 10.1037/0021-843X.103.2.192; Willcutt EG, 2005, DEV NEUROPSYCHOL, V27, P35, DOI 10.1207/s15326942dn2701_3; WODKA EL, IN PRESS J CLIN EXPT	61	86	86	0	17	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.	JUL	2007	13	4					345	362		10.1080/09297040600899867			18	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	207ZU	WOS:000249290400004	17564851				2022-02-06	
J	Arimoto, T; Choi, DY; Lu, X; Liu, M; Nguyen, XV; Zheng, NY; Stewart, CA; Kim, HC; Bing, GY				Arimoto, Toyoko; Choi, Dong-Young; Lu, Xin; Liu, Mei; Nguyen, Xuan V.; Zheng, Naiying; Stewart, Charles A.; Kim, Hyoung-Chun; Bing, Guoying			Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra	NEUROBIOLOGY OF AGING			English	Article						lipopolysaccharide (LPS); inflammation; neurodegeneration; dopaminergic neuron; apoptosis; microglia; interleukin-10 (IL-10); Parkinson's disease (PD)	NITRIC-OXIDE SYNTHASE; TUMOR-NECROSIS-FACTOR; TRAUMATIC BRAIN-INJURY; PARKINSONS-DISEASE; MICROGLIAL ACTIVATION; FACTOR-ALPHA; CELL-DEATH; ALZHEIMERS-DISEASE; PC12 CELLS; INTRANIGRAL INJECTION	Inflammation has been increasingly recognized to play an important role in the pathogenesis of Parkinson's disease (PD). Using immunocytochemistry and electron microscopy, we found that intranigral injection of lipopolysaccharide (LPS) caused marked microglial activation and a dose-dependent selective loss of dopaminergic neurons, which was mediated by apoptosis as evidenced by prominent TUNEL labeling. RNase protection assays revealed that mRNA for Bax, Fas and the pro-inflammatory cytokines interleukin (IL)-1 alpha, IL-1 beta, IL-6 and tumor necrosis factor (TNF)-alpha were significant increased ipsilaterally in LPS-injected side of SN, while expression of the anti-apoptotic gene Bcl-2 was decreased. Osmotic pump infusion of IL-10, a global inhibitor of cytokine synthesis, protected against LPS-induced cell death of dopaminergic neurons, with a corresponding decrease in the number of activated microglia, suggesting that the reduction in microglia-mediated release of inflammatory mediators may contribute to the anti-inflammatory effect of IL-10. Our results provide evidence that LPS induces apoptotic cell death in SNpc, which is likely through the expression of Fas, Bax, caspase-3, and the pro- inflammatory cytokines. (c) 2006 Elsevier Inc. All rights reserved.	Univ Kentucky, Med Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Natl Inst Environm Studies, Div Environm Hlth Sci, Tsukuba, Ibaraki, Japan; Oklahoma Med Res Fdn, Free Rad Aging Res Program, Oklahoma City, OK 73104 USA; Kangwon Natl Univ, Coll Pharm, Chunchon 200701, South Korea		Bing, GY (corresponding author), Univ Kentucky, Med Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA.	gbing@pop.uky.edu	Nguyen, Xuan V/G-5532-2012	Nguyen, Xuan V/0000-0002-2617-1938; Bing, Guoying/0000-0003-0609-8152	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39345] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039345] Funding Source: NIH RePORTER		Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Arimoto T, 2003, NEUROBIOL DIS, V12, P35, DOI 10.1016/S0969-9961(02)00017-7; Bachis A, 2001, J NEUROSCI, V21, P3104, DOI 10.1523/JNEUROSCI.21-09-03104.2001; Bagasra O, 1995, P NATL ACAD SCI USA, V92, P12041, DOI 10.1073/pnas.92.26.12041; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Becher B, 1996, J NEUROSCI RES, V45, P375; Bing G., 1998, NEUR ABSTR, V24, P44; BOKA G, 1994, NEUROSCI LETT, V172, P151, DOI 10.1016/0304-3940(94)90684-X; Bronstein DM, 1995, BRAIN RES, V704, P112, DOI 10.1016/0006-8993(95)01189-7; BROSNAN CF, 1994, DEV NEUROSCI-BASEL, V16, P152, DOI 10.1159/000112102; Castano A, 1998, J NEUROCHEM, V70, P1584; CHAO CC, 1992, J IMMUNOL, V149, P2736; CHAO CC, 1995, DEV NEUROSCI-BASEL, V17, P97, DOI 10.1159/000111278; Cheeran MCJ, 2003, J VIROL, V77, P4502, DOI 10.1128/JVI.77.8.4502-4515.2003; Chun HS, 2001, J NEUROCHEM, V76, P1010, DOI 10.1046/j.1471-4159.2001.00096.x; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; Dietrich WD, 1999, EXP NEUROL, V158, P444, DOI 10.1006/exnr.1999.7115; Ding MZ, 1997, J BIOL CHEM, V272, P11327; Dodel RC, 1999, MOL BRAIN RES, V64, P141, DOI 10.1016/S0169-328X(98)00318-0; DORHEIM MA, 1994, BIOCHEM BIOPH RES CO, V205, P659, DOI 10.1006/bbrc.1994.2716; Dugas N, 1998, CYTOKINE, V10, P680, DOI 10.1006/cyto.1998.0352; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Espey MG, 1997, NEUROREPORT, V8, P431, DOI 10.1097/00001756-199701200-00011; Ferrante RJ, 1999, BRAIN RES, V823, P177, DOI 10.1016/S0006-8993(99)01166-X; Froen JF, 2002, BRAIN RES, V942, P87, DOI 10.1016/S0006-8993(02)02700-2; Galea E, 1996, J NEUROIMMUNOL, V64, P19, DOI 10.1016/0165-5728(95)00143-3; Glabinski AR, 1999, J NEUROVIROL, V5, P3, DOI 10.3109/13550289909029740; Glabinski AR, 1999, J NEUROVIROL, V5, P623, DOI 10.3109/13550289909021291; Grilli M, 2000, EUR J NEUROSCI, V12, P2265, DOI 10.1046/j.1460-9568.2000.00090.x; Gunnett C.A., 1999, STROKE, V30, P5; Gunnett CA, 1999, STROKE, V30, P2191, DOI 10.1161/01.STR.30.10.2191; HAGG T, 1993, P NATL ACAD SCI USA, V90, P6315, DOI 10.1073/pnas.90.13.6315; HARTLEY A, 1994, J NEUROCHEM, V63, P1987; Hartmann A, 2002, NEUROLOGY, V58, P308, DOI 10.1212/WNL.58.2.308; He Y, 2001, BRAIN RES, V909, P187, DOI 10.1016/S0006-8993(01)02681-6; Herrera AJ, 2000, NEUROBIOL DIS, V7, P429, DOI 10.1006/nbdi.2000.0289; HU SX, 1995, GLIA, V13, P45, DOI 10.1002/glia.440130106; Hu SX, 1999, J LEUKOCYTE BIOL, V65, P815, DOI 10.1002/jlb.65.6.815; Hunot S, 1996, NEUROSCIENCE, V72, P355, DOI 10.1016/0306-4522(95)00578-1; Janabi N, 1998, GLIA, V23, P304; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Kingsbury AE, 1998, MOVEMENT DISORD, V13, P877, DOI 10.1002/mds.870130604; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kremlev SG, 2005, J NEUROIMMUNOL, V162, P71, DOI 10.1016/j.jneuroim.2005.01.010; Kremlev SG, 2004, J NEUROIMMUNOL, V149, P1, DOI 10.1016/j.jneuroim.2003.11.012; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Ledeboer A, 2000, GLIA, V30, P134, DOI 10.1002/(SICI)1098-1136(200004)30:2<134::AID-GLIA3>3.0.CO;2-3; Lee HO, 2003, CYTOKINE GROWTH F R, V14, P325, DOI 10.1016/S1359-6101(03)00028-5; LEE SC, 1993, J IMMUNOL, V150, P2659; LEES GJ, 1993, J NEUROL SCI, V114, P119, DOI 10.1016/0022-510X(93)90285-7; Liu B, 2000, J PHARMACOL EXP THER, V293, P607; Lodge PA, 1996, J LEUKOCYTE BIOL, V60, P502, DOI 10.1002/jlb.60.4.502; Lu X, 2000, NEUROSCIENCE, V97, P285, DOI 10.1016/S0306-4522(00)00033-6; Marques CP, 2004, GLIA, V47, P358, DOI 10.1002/glia.20045; MATSUO M, 1995, BRAIN RES, V685, P201, DOI 10.1016/0006-8993(95)00490-H; MCGEER PL, 1988, ANN NEUROL, V24, P574, DOI 10.1002/ana.410240415; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; Mesples B, 2003, DEV BRAIN RES, V141, P25, DOI 10.1016/S0165-3806(02)00636-3; MINGHETTI L, 1995, J NEUROCHEM, V65, P2690; MOCHIZUKI H, 1994, NEUROSCI LETT, V170, P191, DOI 10.1016/0304-3940(94)90271-2; MOGI M, 1994, NEUROSCI LETT, V180, P147, DOI 10.1016/0304-3940(94)90508-8; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; Mogi M, 1996, NEUROSCI LETT, V220, P195, DOI 10.1016/S0304-3940(96)13257-2; Molina-Holgado F, 2001, GLIA, V33, P97, DOI 10.1002/1098-1136(200102)33:2<97::AID-GLIA1009>3.0.CO;2-N; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; Nagatsu T, 2000, ADV RES NEURODEGENER, V8, P277; Ochu EE, 1998, J NEUROCHEM, V70, P2637; Paxinos G, 1998, PACE, V21, P728, DOI 10.1111/j.1540-8159.1998.tb00130.x; Peterson PK, 1997, J INFECT DIS, V175, P478, DOI 10.1093/infdis/175.2.478; RINK A, 1995, AM J PATHOL, V147, P1575; Sawa A, 1997, MOL BRAIN RES, V48, P53, DOI 10.1016/S0169-328X(97)00078-8; Sawada M, 1999, J NEUROCHEM, V72, P1466, DOI 10.1046/j.1471-4159.1999.721466.x; SELBY G, 1968, J NEUROL SCI, V6, P517, DOI 10.1016/0022-510X(68)90034-8; SHENG WS, 1995, CLIN DIAGN LAB IMMUN, V2, P604, DOI 10.1128/CDLI.2.5.604-608.1995; SHIGEMATSU K, 1992, J NEUROSCI RES, V31, P443, DOI 10.1002/jnr.490310306; SPOOREN WP, 1998, NEUROSCIENCE, V85, P53; Spooren WPJM, 1998, NEUROSCIENCE, V85, P649; Stennicke HR, 2000, BBA-PROTEIN STRUCT M, V1477, P299, DOI 10.1016/S0167-4838(99)00281-2; Takai N, 1998, J NEUROSCI RES, V54, P214, DOI 10.1002/(SICI)1097-4547(19981015)54:2<214::AID-JNR9>3.0.CO;2-H; Tatton NA, 1998, ANN NEUROL, V44, pS142, DOI 10.1002/ana.410440721; Tatton NA, 1997, NEUROSCIENCE, V77, P1037, DOI 10.1016/S0306-4522(96)00545-3; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Williams K, 1996, NEUROCHEM INT, V29, P55, DOI 10.1016/0197-0186(95)00138-7; Youdim MBH, 1997, SCI AM, V276, P52, DOI 10.1038/scientificamerican0197-52; Zhao ML, 2001, J NEUROIMMUNOL, V115, P182, DOI 10.1016/S0165-5728(00)00463-X	85	86	90	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	JUN	2007	28	6					894	906		10.1016/j.neurobiolaging.2006.04.011			13	Geriatrics & Gerontology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Geriatrics & Gerontology; Neurosciences & Neurology	164SB	WOS:000246253300011	21887889				2022-02-06	
J	Agel, J; Dick, R; Nelson, B; Marshall, SW; Dompier, TP				Agel, Julie; Dick, Randall; Nelson, Bradley; Marshall, Stephen W.; Dompier, Thomas P.			Descriptive epidemiology of collegiate women's ice hockey injuries: National Collegiate Athletic Association injury surveillance system, 2000-2001 through 2003-2004	JOURNAL OF ATHLETIC TRAINING			English	Article						athletic injuries; injury prevention; concussions		Objective: To review 4 years of National Collegiate Athletic Association (NCAA) injury surveillance data for women's ice hockey and to identify potential areas for injury prevention initiatives. Background: The NCAA ISS prospectively collects data on injuries sustained during collegiate participation. Women's NCAA ice hockey began participation in the ISS during the 2000-2001 season. On average, over the 4 years, 15.6% of the eligible schools elected to send their injury data. Main Results: Over the 4 years of study, the rate of injury in games was more than 5 times higher than the injury rate in practices (12.6 versus 2.5 injuries per 1000 athlete-exposures, rate ratio = 5.0, 95% confidence interval = 4.2, 6.1, P <.01). Preseason practice injury rates were almost twice as high as in-season practice rates (4.2 versus 2.3 injuries per 1000 athlete-exposures, rate ratio = 1.8, 95% confidence interval = 1.7, 2.0, P <.01). Concussions were the most common injury in both games (21.6%) and practices (13.2%). The rate of concussions in games appeared to be trending upward over the study period. The greatest number of game injuries (approximately 50%) resulted from player contact, whereas practice injuries were from. either contact with another object or non-contact mechanisms. Recommendations: Women's ice hockey is an evolving NCAA sport. Only 4 years of ISS data are available and, therefore, data should be interpreted with caution. Women's ice hockey does not allow for formal body checking; however, approximately 50% of all game injuries were reported to result from contact with another player. Future researchers need to evaluate the effectiveness of the no-checking rule. Additional years of data collection will be required to allow the data to become more stable, and to increase attention to mechanism-of-injury issues. We anticipate that the hypothesized inconsistencies in skill level across and within the various women's teams also will be reduced as more consistently skilled players develop, allowing for more stability in the injury scenario.	Univ Minnesota, Minneapolis, MN 55455 USA; Natl Coll Athlet Assoc, Indianapolis, IN USA; Univ N Carolina, Chapel Hill, NC 27515 USA; Univ No Iowa, Cedar Falls, IA USA		Agel, J (corresponding author), Univ Minnesota, 2450 Riverside Ave, Minneapolis, MN 55455 USA.	agelx001@umn.edu		Marshall, Stephen/0000-0002-2664-9233; Nelson, Bradley J/0000-0002-7931-5085			BUESCHER P, PROBLEMS RATES BASED; Dick R, 2007, J ATHL TRAINING, V42, P173; Dryden DM, 2006, MED SCI SPORT EXER, V38, P799, DOI 10.1249/01.mss.0000210152.83076.f1; Marchie A, 2003, CAN MED ASSOC J, V169, P124; *NAT COLL ATHL ASS, 2006, 1981 82 2004 05 NCAA; Willer B, 2005, MED SCI SPORT EXER, V37, P1658, DOI 10.1249/01.mss.0000181839.86170.06	6	86	86	0	5	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	APR-JUN	2007	42	2					249	254					6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	180RC	WOS:000247382300011	17710173				2022-02-06	
J	Hanks, RA; Rapport, LJ; Vangel, S				Hanks, Robin A.; Rapport, Lisa J.; Vangel, Stephen			Caregiving appraisal after traumatic brain injury: The effects of functional status, coping style, social support and family functioning	NEUROREHABILITATION			English	Article						caregiving; traumatic brain injury; TBI; burden of care; satisfaction with caregiving; mastery of caregiving; family functioning; social support; coping style	ASSESSMENT DEVICE; HEAD-INJURY; DISTRESS; SCALE; PREDICTORS; IMPACT; COMA	Perception of caregiving after traumatic brain injury (TBI) has been shown to be an important part of both survivor and family adjustment. The roles of coping style, family functioning, perceived social support and the TBI survivor's functional status have not been fully examined with respect to appraisal of caregiving. This study examined these factors with respect to both positive and negative appraisals of caregiving in four main areas: perceived burden, caregiving relationship satisfaction, beliefs about caregiving, and mastery with caregiving. Sixty primary caregivers of individuals who sustained a TBI within the last 6 months to 15 years were administered the Caregiver Appraisal Scale, as well as the Coping Inventory for Stressful Situations, a 21-item version of the Family Assessment Device, and the Social Provision Scale. These findings were examined in relation to the TBI survivor's scores on the Disability Rating Scale and the Functional Independence Measure at the same time points post-injury. Results revealed that the majority of caregivers in those with moderate to severe brain injuries experienced dissatisfaction with many aspects of caregiving, especially with respect to feelings of burden and mastery. Additionally, emotionally-focused coping, behavioral control issues with respect to family functioning, and perceived social support appear to be most highly related to perceptions of burden, whereas perceived social support alone was the strongest factor in one's perception of caregiving mastery and satisfaction with the caregiving relationship. Interestingly, caregiving ideology was most closely related to avoidance-oriented coping. These results have direct implications for the development of interventions for caregivers of persons with TBI, especially with respect for the need to assess coping style and the development of social support networks.	Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; Wayne State Univ, Dept Psychol, Detroit, MI USA		Hanks, RA (corresponding author), Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, 261 Mack Blvd, Detroit, MI 48201 USA.	rhanks@dmc.org		Rapport, Lisa/0000-0001-8014-9523			BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Curtiss G, 2000, J HEAD TRAUMA REHAB, V15, P1113, DOI 10.1097/00001199-200010000-00005; Cutrona EC., 1987, ADV PERSONAL RELATIO, V1, P37, DOI DOI 10.1037/0882-7974.1.1.47; ENDLER NS, 1990, J PERS SOC PSYCHOL, V58, P844, DOI 10.1037/0022-3514.58.5.844; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; Jones TG, 2003, CLIN NEUROPSYCHOL, V17, P3, DOI 10.1076/clin.17.1.3.15626; Kabacoff R.I., 1990, J FAM PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; KINNEY JM, 1989, PSYCHOL AGING, V4, P402, DOI 10.1037/0882-7974.4.4.402; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Lawton M. P., 1989, J GERONTOL, V44, P61, DOI 10.1093/geronj/44.3.P61; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; MAITZ EA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199504000-00003; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Ridenour TA, 1999, FAM PROCESS, V38, P497, DOI 10.1111/j.1545-5300.1999.00497.x; Semlyen JK, 1998, J NEUROL REHABIL, V12, P53; Stebbins P, 2001, REHABIL PSYCHOL, V46, P178, DOI 10.1037/0090-5550.46.2.178; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; [No title captured]; [No title captured]; [No title captured]	30	86	90	2	18	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2007	22	1					43	52					10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	150TE	WOS:000245240600005	17379947				2022-02-06	
J	Zhu, XL; Poon, WS; Chan, CCH; Chan, SSH				Zhu, X. L.; Poon, W. S.; Chan, Chetwyn C. H.; Chan, Susanna S. H.			Does intensive rehabilitation improve the functional outcome of patients with traumatic brain injury (TBI)? A randomized controlled trial	BRAIN INJURY			English	Article						traumatic brain injury; rehabilitation; intensity; functional independence measure (FIM); Glasgow outcome scale (GOS); Neurobehavioural Cognitive Status Examination (NCSE)	COGNITIVE STATUS EXAMINATION; HEAD-INJURY; INPATIENT REHABILITATION; MULTICENTER ANALYSIS; ACUTE STROKE; THERAPY; MANAGEMENT; SCALE	Objective: To evaluate the effects of an increase in the intensity of rehabilitation on the functional outcome of patients with traumatic brain injury ( TBI). Design and methods: Sixty- eight patients ( age 12 - 65 years) with moderate- to- severe TBI were included. They were randomized into high ( 4- hour/ day) or control ( 2- hour/ day) intensity rehabilitation programmes at an average of 20 days after the injury. The programmes ended when the patients achieved independence in daily activities or when 6 months had passed. Outcome and results: No significant differences were found in the Functional Independence Measure ( FIM) ( primary outcome) and Neurobehavioural Cognitive Status Examination ( NCSE) total scores between the two groups. There were significantly more patients in the high intensity group than in the control group who achieved a maximum FIM total score at the third month ( 47% vs. 19%, p = 0.015) and a maximum Glasgow Outcome Scale ( GOS) score at the second ( 28% vs. 8%, p = 0.034) and third months ( 34% vs. 14%, p = 0.044). Conclusions: Early intensive rehabilitation may improve the functional outcome of patients with TBI in the early months post- injury and hence increase the chance of their returning to work early. Intensive rehabilitation in this study speeded up recovery rather than changed the final outcome.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Div Neurosurg, Hong Kong, Hong Kong, Peoples R China; Hong Kong Polytech Univ, Dept Rehabil Sci, Appl Cognit Neurosci Lab, Hong Kong, Hong Kong, Peoples R China; Shatin Cheshire Home, Hong Kong, Hong Kong, Peoples R China		Poon, WS (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Div Neurosurg, Hong Kong, Hong Kong, Peoples R China.	wpoon@cuhk.edu.hk	Poon, Wai Sang/F-1558-2011	Chan, Chetwyn C. H./0000-0003-0307-6337			ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; BARNES M, 1998, REHABILITATION TRAUM; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; Chan CCH, 2002, BRAIN INJURY, V16, P873, DOI 10.1080/02699050210131975; Chan CHC, 1999, ARCH CLIN NEUROPSYCH, V14, P71, DOI 10.1093/arclin/14.1.71; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Cifu DX, 2003, ARCH PHYS MED REHAB, V84, P1441, DOI 10.1016/S0003-9993(03)00272-7; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; Doninger NA, 2000, J HEAD TRAUMA REHAB, V15, P683, DOI 10.1097/00001199-200002000-00007; EVANS CD, 1994, NEUROLOGICAL REHABIL; Fong KNK, 2001, BRAIN INJURY, V15, P443, DOI 10.1080/02699050010005940; GARRAWAY WM, 1980, BRIT MED J, V280, P1040, DOI 10.1136/bmj.280.6220.1040; GARRAWAY WM, 1980, BRIT MED J, V281, P827, DOI 10.1136/bmj.281.6244.827; Gurka JA, 1999, J HEAD TRAUMA REHAB, V14, P247, DOI 10.1097/00001199-199906000-00005; HALL KM, 1994, ARCH PHYSICAL MED RE, V75, P10; Hamilton BB, 1987, REHABILITATION OUTCO, P137; Hawley CA, 1999, J NEUROL NEUROSUR PS, V67, P749, DOI 10.1136/jnnp.67.6.749; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; HETHERINGTON H, 1994, INJURY, V25, P527, DOI 10.1016/0020-1383(94)90095-7; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; Kunishio Katsuzo, 1993, Neurologia Medico-Chirurgica, V33, P824, DOI 10.2176/nmc.33.824; Kwakkel G, 1997, STROKE, V28, P1550, DOI 10.1161/01.STR.28.8.1550; Kwakkel G, 2004, STROKE, V35, P2529, DOI 10.1161/01.STR.0000143153.76460.7d; LAU AEC, 1998, HONG KONG J OCCUPATI, V9, P52; LEE CMS, 1998, HONG KONG J OCCUPATI, V9, P52; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MITRUSHINA M, 1994, HOSP COMMUNITY PSYCH, V45, P252; MOONEY GF, 1988, COGNITIVE REHABILITA, V6, P14; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; *NO CAL NEUR GROUP, 1995, MAN COGN NEUR COGN S; Oehlert ME, 1997, J CLIN PSYCHOL, V53, P733, DOI 10.1002/(SICI)1097-4679(199711)53:7<733::AID-JCLP11>3.0.CO;2-M; PRIGATANO GP, 1988, BNI Q, V4, P30; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rice-Oxley M, 1999, CLIN REHABIL, V13, P7, DOI 10.1191/026921599668051623; Shiel A, 2001, CLIN REHABIL, V15, P501, DOI 10.1191/026921501680425225; Slade A, 2002, J REHABIL MED, V34, P260, DOI 10.1080/165019702760390347; SPIVACK G, 1992, Brain Injury, V6, P419, DOI 10.3109/02699059209008138; Turner-Stokes L, 1999, CLIN REHABIL, V13, P277, DOI 10.1191/026921599676896799; Turner-Stokes L, 2005, COCHRANE DB SYST REV, V20; Van Peppen RPS, 2004, CLIN REHABIL, V18, P833, DOI 10.1191/0269215504cr843oa; WILLIAM HB, 1988, BRAIN INJURY, V2, P313; Zhu XL, 2001, BRIT J NEUROSURG, V15, P464, DOI 10.1080/02688690120097688	45	86	87	0	25	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	7					681	690		10.1080/02699050701468941			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	192LX	WOS:000248204400004	17653942				2022-02-06	
J	Iverson, GL				Iverson, Grant L.			Complicated vs uncomplicated mild traumatic brain injury: Acute neuropsychological outcome	BRAIN INJURY			English	Article						mild traumatic brain injury; complicated; outcome; neurocognitive	WORD-ASSOCIATION TEST; HEAD-INJURY; COMPUTED-TOMOGRAPHY; RISK-FACTORS; CONCUSSION; MODERATE; CT; RECOVERY; PERFORMANCE; DEPRESSION	Primary objective: The purpose of this study was to carefully examine the effects of a complicated vs uncomplicated mild traumatic brain injury (MTBI) on acute neuropsychological outcome. Research design: Participants were derived from an archival trauma database. This is a retrospective matched groups design. Methods and procedures: All patients were seen through a Head Injury Trauma Service clinical pathway. To be included, all patients must have undergone a day-of-injury CT scan and completed a small battery of neuropsychological tests within 2 weeks of injury. Patients were sorted into two groups on the basis of having a normal or abnormal CT scan. Patients were then carefully matched on age, education, gender and mode of injury (e.g. car accident, fall or assault). The final sample consisted of 100 patients, with 50 in each group. Main outcomes and results: The patients with complicated MTBIs performed significantly more poorly on some of the neuropsychological tests. However, the effect sizes were small or medium and the two groups could not be differentiated using logistic regression analysis. Conclusions: The reasons why people recover slowly or fail to recover fully from MTBIs remain poorly understood. Visible structural brain damage carries increased risk for slow and incomplete recovery, but certainly does not provide an explanation for good or poor outcome in the majority of patients.	Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada; Riverview Hosp, Vancouver, BC V6T 2A1, Canada		Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	giverson@interchange.ubc.ca		Iverson, Grant/0000-0001-7348-9570			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benton AL, 1994, MULTILINGUAL APHASIA; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; de Rotrou J, 2005, EUR J NEUROL, V12, P879, DOI 10.1111/j.1468-1331.2005.01100.x; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; FRENCH BN, 1977, SURG NEUROL, V7, P171; Giza CC, 2004, STUD NEUROPSYCHOL DE, P45; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Heaton R., 2000, WISCONSIN CARD SORTI; Heaton R. K., 2004, REVISED COMPREHENSIV; Heaton RK, 1991, COMPREHENSIVE NORMS; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson G L, 2000, Appl Neuropsychol, V7, P247, DOI 10.1207/S15324826AN0704_7; Iverson G.L., 2006, BRAIN INJURY MED PRI, P333; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 1999, CLIN NEUROPSYCHOL, V13, P437, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT437; IVERSON GL, 2006, CANADIAN PSYCHOL, V47, P110; IVERSON GL, 1998, J INT NEUROPSYCH SOC, V4, P75; Iverson GL, 2006, BRAIN INJURY MED PRI, P373; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Palmer BW, 1998, ARCH CLIN NEUROPSYCH, V13, P503, DOI 10.1016/S0887-6177(97)00037-1; Paolo AM, 1996, J CLIN EXP NEUROPSYC, V18, P892, DOI 10.1080/01688639608408310; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Reitan RM, 1992, TRAIL MAKING TEST MA; Robinson L J, 1991, Arch Clin Neuropsychol, V6, P27, DOI 10.1016/0887-6177(91)90019-6; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Stern RA, 2003, NEUROPSYCHOLOGICAL A; Tellier A, 1999, BRAIN INJURY, V13, P463; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Wechsler D, 1987, MEMORY SCALE REVISED; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson J. T. L, 1996, RECOVERY TRAUMATIC B, P29	64	86	86	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2006	20	13-14					1335	1344		10.1080/02699050601082156			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	130GF	WOS:000243787100003	17378225				2022-02-06	
J	Tien, HCN; Tremblay, LN; Rizoli, SB; Gelberg, J; Chughtai, T; Tikuisis, P; Shek, P; Brenneman, FD				Tien, Homer C. N.; Tremblay, Lorraine N.; Rizoli, Sandro B.; Gelberg, Jacob; Chughtai, Talat; Tikuisis, Peter; Shek, Pang; Brenneman, Frederick D.			Association between alcohol and mortality in patients with severe traumatic head injury	ARCHIVES OF SURGERY			English	Article; Proceedings Paper	Joint Meeting of the Trauma-Association-of-Canada/Australasian-Trauma-Society	APR 06-09, 2005	Whistler, CANADA	Trauma Assoc Canada, Australasian Trauma Soc			ACUTE ETHANOL INTOXICATION; MOTOR-VEHICLE CRASHES; BRAIN-INJURY; HEMORRHAGIC-SHOCK; HOSPITAL COURSE; LEVEL; MODEL; RATS; HYPOTENSION; INGESTION	Hypothesis: Admission blood alcohol concentration (BAC) is associated with in-hospital death in patients with severe brain injury from blunt head trauma. Design: Retrospective cohort study. Setting: Academic level I trauma center in Toronto, Ontario. Patients: Using trauma registry data, between January 1, 1988, and December 31, 2003, we identified 1158 consecutive patients with severe brain injury from blunt head trauma. Intervention: There was no active intervention. The primary exposure of interest was the BAC at admission, stratified into the following 3 levels: 0, no BAC; 0 to less than 230 mg/dL, low to moderate BAC; and 230 mg/dL or greater, high BAC. Main Outcome Measure: in-hospital death. Results: In patients with severe brain injury, low to moderate BAC was associated with lower mortality than was no BAC (27.9% vs 36.3%; P=.008). High BAC was associated with higher mortality than was no BAC (44.7% vs 36.3%), although this was not statistically significant (P=.10). These associations were all statistically significant after adjusting for demographic data and injury factors using logistic regression analysis. The odds ratio for death was 0.76 (95% confidence interval, 0.52-0.98) for low to moderate BAC compared with no BAC. The odds ratio for death was 1.73 (95% confidence interval, 1.05-2.84) for high BAC compared with no BAC. Conclusions: Low to moderate BAC may be beneficial in patients with severe brain injury from blunt head trauma. In contrast, high BAC seems to have a deleterious effect on in-hospital death in these patients, which may be related to its detrimental hemodynamic and physiologic effects. Alcohol-based fluids may have a role in the management of patients with severe brain injury after they have been well resuscitated.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Trauma Program, Toronto, ON M4N 3M5, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Surg, Toronto, ON, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON, Canada; Dept Natl Def, Canadian Forces Hlth Serv Grp, Ottawa, ON, Canada; Def Res & Dev, Toronto, ON, Canada		Tien, HCN (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Trauma Program, 2075 Bayview Ave,Suite H186, Toronto, ON M4N 3M5, Canada.	homer.tien@sw.ca					Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; American College of Surgeons Committee on Trauma, 1997, ADV TRAUM LIF SUPP D; ANDERSEN JA, 1990, J TRAUMA, V30, P415, DOI 10.1097/00005373-199030040-00007; Association for the Advancement of Automotive Medicine, 1998, ABBR INJ SCAL; Bell CM, 2001, NEW ENGL J MED, V345, P663, DOI 10.1056/NEJMsa003376; Blondell RD, 2002, J STUD ALCOHOL, V63, P380, DOI 10.15288/jsa.2002.63.380; BRICKLEY MR, 1995, INJURY, V26, P311, DOI 10.1016/0020-1383(95)00034-7; BULLOCK MR, BRAIN TRAUMA FDN GUI; Crews FT, 1998, PHARMACOL BIOCHEM BE, V59, P981, DOI 10.1016/S0091-3057(97)00538-8; Dash PK, 2004, J NEUROTRAUM, V21, P1573, DOI 10.1089/0897715042441828; Elder RW, 2004, AM J PREV MED, V27, P57, DOI 10.1016/j.amepre.2004.03.002; Fabbri A, 2002, EMERG MED J, V19, P210, DOI 10.1136/emj.19.3.210; Fabian MJ, 2002, J TRAUMA, V53, P864, DOI 10.1097/00005373-200211000-00010; FLETCHER F, 1996, CLIN EPIDEMIOLOGY ES; GABRIEL EJ, 2000, BRAIN TRAUMA FDN GUI; George RL, 2003, J TRAUMA, V54, P464, DOI 10.1097/01.TA.0000051939.95039.E6; GETTLER DT, 1963, ANN SURG, V158, P151, DOI 10.1097/00000658-196308000-00001; Goodnough LT, 1999, NEW ENGL J MED, V340, P525, DOI 10.1056/NEJM199902183400706; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HUTH JF, 1983, J TRAUMA, V23, P494, DOI 10.1097/00005373-198306000-00009; Iida H, 1999, J TRAUMA, V46, P450, DOI 10.1097/00005373-199903000-00018; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; KNOTT DH, 1963, NEW ENGL J MED, V269, P292, DOI 10.1056/NEJM196308082690604; KNOTT DH, 1967, JAMA-J AM MED ASSOC, V84, P178; Li GH, 1997, J TRAUMA, V42, P562, DOI 10.1097/00005373-199703000-00032; Li GH, 2001, JAMA-J AM MED ASSOC, V285, P893, DOI 10.1001/jama.285.7.893; LOWENFELS AB, 1984, ANN EMERG MED, V13, P1056, DOI 10.1016/S0196-0644(84)80070-0; LUCAS CE, 2000, TRAUMA, P1059; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; MALT SH, 1971, J TRAUM, V11, P76, DOI 10.1097/00005373-197101000-00007; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Martin RCG, 2002, AM SURGEON, V68, P477; MILZMAN DP, 1992, J TRAUMA, V32, P236, DOI 10.1097/00005373-199202000-00021; OSLER T, 1988, AM J SURG, V156, P537, DOI 10.1016/S0002-9610(88)80548-8; Piriyawat P, 2003, STROKE, V34, P1242, DOI 10.1161/01.STR.0000067706.23777.04; Poole GV, 1997, J TRAUMA, V42, P711, DOI 10.1097/00005373-199704000-00022; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Schenker S, 1998, Adv Intern Med, V43, P27; Shih HC, 2003, AM J EMERG MED, V21, P91, DOI 10.1053/ajem.2003.50025; SPAITE DW, 1995, J TRAUMA, V38, P287, DOI 10.1097/00005373-199502000-00028; Stewart RM, 2003, J TRAUMA, V54, P66, DOI 10.1097/00005373-200301000-00009; Strong R, 2000, NEUROPHARMACOLOGY, V39, P515, DOI 10.1016/S0028-3908(99)00156-2; Tate PS, 1999, BRAIN INJURY, V13, P767; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TULLOH BR, 1994, INJURY, V25, P539, DOI 10.1016/0020-1383(94)90097-3; Tureci E, 2004, NEUROL RES, V26, P108, DOI 10.1179/016164104225013699; VANNATTA TL, 2000, TRAUMA; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; Winchell RJ, 1996, ARCH SURG-CHICAGO, V131, P533; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275; Zink BJ, 1996, ALCOHOL CLIN EXP RES, V20, P1518, DOI 10.1111/j.1530-0277.1996.tb01693.x; Zink BJ, 1998, J NEUROSURG, V89, P983, DOI 10.3171/jns.1998.89.6.0983; Zink BJ, 1998, ACAD EMERG MED, V5, P9, DOI 10.1111/j.1553-2712.1998.tb02568.x	59	86	92	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0004-0010			ARCH SURG-CHICAGO	Arch. Surg.	DEC	2006	141	12					1185	1191		10.1001/archsurg.141.12.1185			7	Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Surgery	114ME	WOS:000242669500006	17178960	Bronze			2022-02-06	
J	Tian, DS; Yu, ZY; Xie, MJ; Bu, BT; Witte, OW; Wang, W				Tian, Dai-Shi; Yu, Zhi-Yuan; Xie, Min-Jie; Bu, Bi-Tao; Witte, Otto W.; Wang, Wei			Suppression of astroglial scar formation and enhanced axonal regeneration associated with functional recovery in a spinal cord injury rat model by the cell cycle inhibitor olomoucine	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						cell cycle; olomoucine; spinal cord injury; glial scar; CSPGs; GAP-43	CENTRAL-NERVOUS-SYSTEM; DEPENDENT KINASES; ALZHEIMERS-DISEASE; PROTEIN EXPRESSION; CORTICAL-NEURONS; WHITE-MATTER; GLIAL-CELLS; BRAIN; DEATH; INDUCTION	It is well established that axons of the adult mammalian CNS are capable of regrowing only a limited amount after injury. Astrocytes are believed to play a crucial role in the failure to regenerate, producing multiple inhibitory proteoglycans, such as chondroitin sulphate proteoglycans (CSPGs). After spinal cord injury (SCI), astrocytes become hypertrophic and proliferative and form a dense network of astroglial processes at the site of lesion constituting a physical and biochemical barrier. Downregulations of astroglial proliferation and inhibitory CSPG production might facilitate axonal regeneration. Recent reports indicated that aberrant activation of cell cycle machinery contributed to overproliferation and apoptosis of cells in various insults. In the present study, we sought to determine whether a cell cycle inhibitior, olomoucine, would decrease neuronal cell death, limit astroglial proliferation and production of inhibitory CSPGs, and eventually enhance the functional compensation after SCI in rats. Our results showed that up-regulations of cell cycle components were closely associated with neuronal cell death and astroglial proliferation as well as the production of CSPGs after SCI. Meanwhile, administration of olomoucine, a selective cell cycle kinase (CDK) inhibitor, has remarkably reduced the up-regulated cell cycle proteins and then decreased neuronal cell death, astroglial proliferation, and accumulation of CSPGs. More importantly, the treatment with olomoucine has also increased expression of growth-associated proteins-43, reduced cavity formation, and improved functional deficits. We consider that suppressing astroglial cell cycle in acute SCIs is beneficial to axonal growth. In the future, therapeutic strategies can be.-designed to achieve efficient axonal regeneration and functional compensation after traumatic CNS injury. (c) 2006 Wiley-Liss, Inc.	Huazhong Univ Sci & Technol, Dept Neurol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China; Univ Jena, Dept Neurol, D-6900 Jena, Germany		Wang, W (corresponding author), Huazhong Univ Sci & Technol, Dept Neurol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.	wwang_tjh@yaboo.com.cn	Witte, Otto/P-4127-2018; TIAN, DAISHI/A-8744-2018	Witte, Otto/0000-0003-2101-4105; 			AIGNER L, 1995, CELL, V83, P269, DOI 10.1016/0092-8674(95)90168-X; Amat JA, 1996, GLIA, V16, P368, DOI 10.1002/(SICI)1098-1136(199604)16:4<368::AID-GLIA9>3.0.CO;2-W; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Copani A, 2001, TRENDS NEUROSCI, V24, P25, DOI 10.1016/S0166-2236(00)01663-5; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; Davies JE, 2004, EUR J NEUROSCI, V19, P1226, DOI 10.1111/j.1460-9568.2004.03184.x; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Eclancher F, 1996, BRAIN RES, V737, P201, DOI 10.1016/0006-8993(96)00732-9; Fitch MT, 1997, EXP NEUROL, V148, P587, DOI 10.1006/exnr.1997.6701; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; Gallo V, 2001, SCIENCE, V292, P872, DOI 10.1126/science.1060854; GAO CY, 1995, EXP CELL RES, V219, P612, DOI 10.1006/excr.1995.1271; Hayashi T, 2000, NEUROPATH APPL NEURO, V26, P390, DOI 10.1046/j.1365-2990.2000.00264.x; HERRUP K, 1995, DEVELOPMENT, V121, P2385; Irwin N, 1997, PEDIATR NEUROSURG, V27, P113, DOI 10.1159/000121238; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; Kalderon N, 2005, CURR PHARM DESIGN, V11, P1237, DOI 10.2174/1381612053507477; KERASIDIS H, 1987, J NEUROSCI METH, V20, P167, DOI 10.1016/0165-0270(87)90048-3; Kerr BJ, 2004, EXP NEUROL, V188, P391, DOI 10.1016/j.expneurol.2004.04.012; Krum JM, 2003, EXP NEUROL, V181, P241, DOI 10.1016/S0014-4886(03)00039-6; Liu DX, 2001, CELL TISSUE RES, V305, P217, DOI 10.1007/s004410100396; McShea A, 1999, MED HYPOTHESES, V52, P525, DOI 10.1054/mehy.1997.0680; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Nagy Z, 1998, NEUROSCIENCE, V87, P731; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 1997, J NEUROSCI, V17, P8975; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Rideout HJ, 2003, J NEUROSCI, V23, P1237, DOI 10.1523/JNEUROSCI.23-04-01237.2003; Schutte B, 1997, EXP CELL RES, V236, P4, DOI 10.1006/excr.1997.3700; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Silver IA, 1997, NEUROSCIENCE, V78, P589, DOI 10.1016/S0306-4522(96)00600-8; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Smith DS, 2000, CELL GROWTH DIFFER, V11, P625; Smith MZ, 1999, NEUROSCI LETT, V271, P45, DOI 10.1016/S0304-3940(99)00509-1; Stefanis L, 1999, J NEUROSCI, V19, P6235; Tang XF, 2003, J NEUROSCI RES, V71, P427, DOI 10.1002/jnr.10523; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7; Zai LJ, 2005, GLIA, V50, P247, DOI 10.1002/glia.20176	43	86	91	0	6	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	OCT	2006	84	5					1053	1063		10.1002/jnr.20999			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	092VG	WOS:000241124800015	16862564				2022-02-06	
J	Greve, KW; Bianchini, KJ; Love, JM; Brennan, A; Heinly, MT				Greve, Kevin W.; Bianchini, Kevin J.; Love, Jeffrey M.; Brennan, Adrianne; Heinly, Matthew T.			Sensitivity and specificity of MMPI-2 validity scales and indicators to malingered neurocognitive dysfunction in traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							FAKE-BAD SCALE; ADULT INTELLIGENCE SCALE; CARD SORTING TEST; MILD HEAD-INJURY; SYMPTOM EXAGGERATION; INCOMPLETE EFFORT; RESPONSE BIAS; LITIGANTS; PERFORMANCE; TESTS	The present study used a known-groups design to determine the classification accuracy of 10 MMPI-2 validity scales and indicators in the detection of cognitive malingering in traumatic brain injury. Participants were 259 traumatic brain injury and 133 general clinical patients seen for neuropsychological evaluation. The TBI patients were subdivided into groups based on a comprehensive examination of effort following Slick, Sherman, and Iverson's (1999) criteria. More extreme scores demonstrated excellent specificity; often impressive sensitivity was seen even while maintaining a low false positive error rate. Specificity was good even in stroke, memory disorder, and psychiatric patients without incentive. The results of this study are presented in frequency tables that can be easily referenced in clinical practice.	Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; Jefferson Neurobehav Grp, Metairie, LA USA		Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					Arbisi PA, 1995, PSYCHOL ASSESSMENT, V7, P424, DOI 10.1037/1040-3590.7.4.424; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BINDER LM, 1993, PORTLAND DIGIT RECOG; BUTCHER JN, 1989, MMPI2 MANUAL ADM SCO; Daubert V., 1993, MERRELL DOW PHARM, V113; Friedman A.F., 2001, PSYCHOL ASSESSMENT M, V2nd ed.; Gouvier WD, 1998, CRIT ISS NE, P55; GRAHAM JR, 1990, MMPI2 ASSESSING PERS; Greene R. L., 2000, MMPI2 INTERPRETIVE M; Greiffenstein MF, 2002, J CLIN PSYCHOL, V58, P1591, DOI 10.1002/jclp.10077; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; HENNEKENS CH, 1987, EPIDEMIOLOGY MED; Iverson GL, 2002, PSYCHOL REP, V90, P131, DOI 10.2466/PR0.90.1.131-136; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P54, DOI 10.1076/clin.17.1.54.15627; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEESHALEY PR, 2003, J FORENSIC NEUROPSYC, V3, P167, DOI DOI 10.1300/J151V03N01_01; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; McCusker PJ, 2003, INT J OFFENDER THER, V47, P585, DOI 10.1177/0306624X03254013; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P157, DOI 10.1016/S0887-6177(00)00107-4; Mild Traumatic Brain Injury Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; Millis S. R., 2004, PRINCIPLES PRACTICE, P1077; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Rogers R, 2003, ASSESSMENT, V10, P160, DOI 10.1177/1073191103010002007; Ross SR, 2004, J CLIN EXP NEUROPSYC, V26, P115, DOI 10.1076/jcen.26.1.115.23933; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Tombaugh T.N., 1996, TEST MEMORY MALINGER	37	86	86	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	SEP	2006	20	3					491	512		10.1080/13854040590967144			22	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	071MT	WOS:000239607000010	16895861				2022-02-06	
J	Chambers, IR; Jones, PA; Lo, TYM; Forsyth, RJ; Fulton, B; Andrews, PJD; Mendelow, AD; Minns, RA				Chambers, IR; Jones, PA; Lo, TYM; Forsyth, RJ; Fulton, B; Andrews, PJD; Mendelow, AD; Minns, RA			Critical thresholds of intracranial pressure and cerebral perfusion pressure related to age in paediatric head injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE; SECONDARY INSULTS; YOUNG-CHILDREN; ADULTS; MANAGEMENT; INFANTS; SCALE; COMA	Background: The principal strategy for managing head injury is to reduce the frequency and severity of secondary brain insults from intracranial pressure (ICP) and cerebral perfusion pressure (CPP), and hence improve outcome. Precise critical threshold levels have not been determined in head injured children. Objective: To create a novel pressure-time index (PTI) measuring both duration and amplitude of insult, and then employ it to determine critical insult thresholds of ICP and CPP in children. Methods: Prospective, observational, physiologically based study from Edinburgh and Newcastle, using patient monitored blood pressure, ICP, and CPP time series data. The PTI for ICP and CPP for 81 children, using theoretical values derived from physiological norms, was varied systematically to derive critical insult thresholds which delineate Glasgow outcome scale categories. Results: The PTI for CPP had a very high predictive value for outcome (receiver operating characteristic analyses: area under curve=0.957 and 0.890 for mortality and favourable outcome, respectively) and was more predictive than for ICP. Initial physiological values most accurately predicted favourable outcome. The CPP critical threshold values determined for children aged 2-6, 7-10, and 11-15 years were 48, 54, and 58 mm Hg. respectively. Conclusions: The PTI is the first substantive paediatric index of total ICP and CPP following head injury. The insult thresholds generated are identical to age related physiological values. Management guidelines for paediatric head injuries should take account of these CPP thresholds to titrate appropriate pressor therapy.	Newcastle Gen Hosp, Dept Reg Med Phys, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Newcastle Gen Hosp, Dept Paediat, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Newcastle Gen Hosp, Dept Anaesthet, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Newcastle Gen Hosp, Dept Neurosurg, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Univ Edinburgh, Royal Hosp Sick Children, Edinburgh, Midlothian, Scotland; Western Gen Hosp, Dept Anaesthet, Edinburgh EH4 2XU, Midlothian, Scotland		Chambers, IR (corresponding author), Newcastle Gen Hosp, Dept Reg Med Phys, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	i.r.chambers@ncl.ac.uk	Forsyth, Rob J/I-9226-2012; Forsyth, Rob/H-9193-2019; Mendelow, Alexander/AAW-2878-2021	Forsyth, Rob J/0000-0002-5657-4180; Forsyth, Rob/0000-0002-5657-4180; 			Abbate B, 2000, Minerva Pediatr, V52, P623; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; BROOKES M, 1990, J EPIDEMIOL COMMUN H, V44, P147, DOI 10.1136/jech.44.2.147; *BTF AANS, 2000, MAN PROGN SEV TRAUM; Chambers IR, 2000, BRIT J NEUROSURG, V14, P424; Chambers IR, 2005, CHILD NERV SYST, V21, P195, DOI 10.1007/s00381-004-1060-x; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; EMAUELSON I, 1997, ACTA PAEDIATR, V86, P730; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HOWELLS TP, 1994, EDINBURGH MONITOR BR; JACKSON S, 1999, BRIT J NEUROSURG, V13, P104; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Jones PA, 2003, BRIT J NEUROSURG, V17, P29, DOI 10.1080/0268869031000093708; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MINNS RA, 2005, PAEDIAT FORENSIC MED; *NHLBI, 1987, REP 2 TASK FORC BLOO; REILLY PL, 1988, CHILD NERV SYST, V4, P30; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; *SIGN, 2000, 46 SIGN; TEASDALE G, 1974, LANCET, V2, P81	26	86	91	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	2006	77	2					234	240		10.1136/jnnp.2005.072215			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	011QY	WOS:000235284400025	16103043	Green Published			2022-02-06	
J	Bartnik, BL; Sutton, RL; Fukushima, M; Harris, NG; Hovda, DA; Lee, SM				Bartnik, BL; Sutton, RL; Fukushima, M; Harris, NG; Hovda, DA; Lee, SM			Upregulation of pentose phosphate pathway and preservation of tricarboxylic acid cycle flux after experimental brain injury	JOURNAL OF NEUROTRAUMA			English	Article						C-13 nuclear magnetic resonance spectroscopy; glucose metabolism; pentose phosphate pathway; traumatic brain injury; tricarboxylic acid cycle	NUCLEAR-MAGNETIC-RESONANCE; ALPHA-KETOGLUTARATE DEHYDROGENASE; GLIAL-NEURONAL INTERACTIONS; CORTICAL CONTUSION INJURY; CEREBRAL-ARTERY OCCLUSION; EXPERIMENTAL HEAD-INJURY; EXCITATORY AMINO-ACIDS; IN-VIVO; RAT-BRAIN; C-13 NMR	The metabolic fate of [1,2 C-13]-labeled glucose was determined in male control and unilateral controlled cortical impact (CCI) injured rats at 3.5 and 24 h after surgery. The concentration of 13 C-labeled glucose, lactate, glutamate and glutamine were measured in the injured and contralateral cortex. CCI animals showed a 145% increase in C-13 lactate in the injured cortex at 3.5 h, but not at 24 h after injury, indicating increased glycolysis in neurons and/or astrocytes ipsilateral to CCI. Total levels of C-13 glutamate in cortical tissue extracts did not differ between groups. However, C-13 glutamine increased by 40% in the left and 98% in the right cortex at 3.5 h after injury, most likely resulting from an increase in astrocytic metabolism of glutamate. Levels of C-13 incorporation into the glutamine isotopomers had returned to control levels by 24 h after CCI. The singlet to doublet ratio of the lactate C3 resonances was calculated to estimate the flux of glucose through the pentose phosphate pathway (PPP). CCI resulted in bilateral increases (9-12%) in the oxidation of glucose via the PPP, with the largest increase occurring at 24 h. Since an increase in PPP activity is associated with NADPH generation, the data suggest that there was an increasing need for reducing equivalents after CCI. Furthermore, C-13 was incorporated into glutamate and glutamine isotopomers associated with multiple turns of the tricarboxylic acid (TCA) cycle, indicating that oxidative phosphorylation of glucose was maintained in the injured cortex at 3.5 and 24 h after a moderate to severe CCI injury.	Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Dept Surg, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA USA		Bartnik, BL (corresponding author), Loma Linda Univ, Dept Radiol, 11234 Anderson St,Room B623, Loma Linda, CA 92354 USA.	bbartnik@ahs.llume.edu		Bartnik-Olson, Brenda/0000-0002-1137-9437; Harris, Neil/0000-0002-1965-6750	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36373, NS27544] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544] Funding Source: NIH RePORTER		Auer DP, 2000, BIOL PSYCHIAT, V47, P305, DOI 10.1016/S0006-3223(99)00159-6; Aureli T, 1997, BRAIN RES, V765, P218, DOI 10.1016/S0006-8993(97)00514-3; BACHELARD H, 1993, J NEUROCHEM, V61, P412; BADARGOFFER RS, 1990, BIOCHEM J, V266, P133, DOI 10.1042/bj2660133; BAQUER NZ, 1988, CURR TOP CELL REGUL, V29, P265; Bartnik BL, 2003, J NEUROTRAUM, V20, P1093; BenYoseph O, 1996, J NEUROCHEM, V66, P2329; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Brand A, 1999, J NEUROSCI RES, V58, P576, DOI 10.1002/(SICI)1097-4547(19991115)58:4<576::AID-JNR10>3.3.CO;2-4; Chapa F, 2000, NEUROCHEM INT, V37, P217, DOI 10.1016/S0197-0186(00)00025-5; CHATENEVER D, 2001, J MINIMALLY INVASIVE, V1, P2; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Chen T, 2000, ACT NEUR S, V76, P359; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Cruz F, 1998, J NEUROCHEM, V70, P2613; Cruz F, 1999, NMR BIOMED, V12, P451, DOI 10.1002/(SICI)1099-1492(199911)12:7<451::AID-NBM571>3.3.CO;2-5; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Dhillon HS, 1999, J NEUROTRAUM, V16, P455, DOI 10.1089/neu.1999.16.455; Eloqayli H, 2003, J NEUROCHEM, V85, P1200, DOI 10.1046/j.1471-4159.2003.01781.x; ERECINSKA M, 1990, PROG NEUROBIOL, V35, P245, DOI 10.1016/0301-0082(90)90013-7; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; GAITONDE MK, 1983, J NEUROCHEM, V41, P1253, DOI 10.1111/j.1471-4159.1983.tb00819.x; Garcia-Nogales P, 2003, J BIOL CHEM, V278, P864, DOI 10.1074/jbc.M206835200; Gibson GE, 2000, NEUROCHEM INT, V36, P97, DOI 10.1016/S0197-0186(99)00114-X; Goss JR, 1997, EXP NEUROL, V146, P291, DOI 10.1006/exnr.1997.6515; Gruetter R, 2002, NEUROCHEM INT, V41, P143, DOI 10.1016/S0197-0186(02)00034-7; Haberg A, 2001, J CEREBR BLOOD F MET, V21, P1451, DOI 10.1097/00004647-200112000-00010; Haberg A, 1998, J CEREBR BLOOD F MET, V18, P1223, DOI 10.1097/00004647-199811000-00008; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; HASSEL B, 1995, J NEUROCHEM, V64, P2773; HOFFMAN WE, 1991, ANESTH ANALG, V73, P753; HOTHERSALL JS, 1982, J NEUROCHEM, V39, P1325, DOI 10.1111/j.1471-4159.1982.tb12574.x; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; Kanamori K, 2002, J NEUROCHEM, V83, P682, DOI 10.1046/j.1471-4159.2002.01161.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Kondrat RW, 2002, J NEUROSCI METH, V120, P179, DOI 10.1016/S0165-0270(02)00201-7; LEE JG, 1994, ANESTH ANALG, V79, P58; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Lee WNP, 1998, AM J PHYSIOL-ENDOC M, V274, pE843, DOI 10.1152/ajpendo.1998.274.5.E843; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; McKenna MC, 1996, J NEUROCHEM, V66, P386; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; MURR R, 1993, ANESTH ANALG, V77, P898; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OPII WO, 2004, PROTEOMIC STUDY OXID; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Pascual JM, 1998, STROKE, V29, P1048, DOI 10.1161/01.STR.29.5.1048; Patel AB, 2004, J CEREBR BLOOD F MET, V24, P972, DOI 10.1097/01.WCB.0000126234.16188.71; Preece NE, 1996, J NEUROCHEM, V67, P1718; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Qu H, 2003, NEUROCHEM INT, V42, P101, DOI 10.1016/S0197-0186(02)00051-7; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Ramonet D, 2004, HIPPOCAMPUS, V14, P586, DOI 10.1002/hipo.10188; Rose ME, 2002, BRAIN RES, V935, P40, DOI 10.1016/S0006-8993(02)02445-9; Samii A, 1999, J NEUROTRAUM, V16, P879, DOI 10.1089/neu.1999.16.879; SCHRADER MC, 1993, BIOCHIM BIOPHYS ACTA, V1182, P162, DOI 10.1016/0925-4439(93)90138-Q; Schuhmann MU, 2000, ACTA NEUROCHIR SUPPL, V76, P3; Serres S, 2003, NMR BIOMED, V16, P430, DOI 10.1002/nbm.838; SHANK RP, 1993, J NEUROCHEM, V61, P315, DOI 10.1111/j.1471-4159.1993.tb03570.x; Sibson NR, 1998, DEV NEUROSCI-BASEL, V20, P321, DOI 10.1159/000017327; Sibson NR, 1997, P NATL ACAD SCI USA, V94, P2699, DOI 10.1073/pnas.94.6.2699; Sibson NR, 2001, J NEUROCHEM, V76, P975, DOI 10.1046/j.1471-4159.2001.00074.x; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; STANLEY JA, 1995, MAGNET RESON MED, V34, P17, DOI 10.1002/mrm.1910340105; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; Tretter L, 2000, J NEUROSCI, V20, P8972; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	91	86	87	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2005	22	10					1052	1065		10.1089/neu.2005.22.1052			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	977ZS	WOS:000232842600003	16238483				2022-02-06	
J	Cunningham, AS; Salvador, R; Coles, JP; Chatfield, DA; Bradley, PG; Johnston, AJ; Steiner, LA; Fryer, TD; Aigbirhio, FI; Smielewski, P; Williams, GB; Carpenter, TA; Gillard, JH; Pickard, JD; Menon, DK				Cunningham, AS; Salvador, R; Coles, JP; Chatfield, DA; Bradley, PG; Johnston, AJ; Steiner, LA; Fryer, TD; Aigbirhio, FI; Smielewski, P; Williams, GB; Carpenter, TA; Gillard, JH; Pickard, JD; Menon, DK			Physiological thresholds for irreversible tissue damage in contusional regions following traumatic brain injury	BRAIN			English	Article						traumatic brain injury; CBF; cerebral metabolism; physiological thresholds; prediction	CEREBRAL-BLOOD-FLOW; POSITRON-EMISSION-TOMOGRAPHY; MAGNETIC-RESONANCE-SPECTROSCOPY; HEAD-INJURY; MODERATE HYPERVENTILATION; OXYGEN-CONSUMPTION; PERFUSION-PRESSURE; STROKE PATIENTS; FOCAL ISCHEMIA; METABOLISM	Cerebral ischaemia appears to be an important mechanism of secondary neuronal injury in traumatic brain injury (TBI) and is an important predictor of outcome. To date, the thresholds of cerebral blood flow (CBF) and cerebral oxygen utilization (CMRO2) for irreversible tissue damage used in TBI studies have been adopted from experimental and clinical ischaemic stroke studies. Identification of irreversibly damaged tissue in the acute phase following TBI could have considerable therapeutic and prognostic implications. However, it is questionable whether stroke thresholds are applicable to TBI. Therefore, the aim of this study was to determine physiological thresholds for the development of irreversible tissue damage in contusional and pericontusional regions in TBI, and to determine the ability of such thresholds to accurately differentiate irreversibly damaged tissue. This study involved 14 patients with structural abnormalities on late-stage MRI, all of whom had been studied with O-15 PET within 72 h of TBI. Lesion regions of interest (ROI) and non-lesion ROIs were constructed on late-stage MRIs and applied to co-registered PET maps of CBF, CMRO2 and oxygen extraction fraction (OEF). From the entire population of voxels in non-lesion ROIs, we determined thresholds for the development of irreversible tissue damage as the lower limit of the 95% confidence interval for CBF, CMRO2 and OEF. To test the ability of a physiological variable to differentiate lesion and non-lesion tissue, we constructed probability curves, demonstrating the ability of a physiological variable to predict lesion and non-lesion outcomes. The lower limits of the 95% confidence interval for CBF, CMRO2 and OEF in non-lesion tissue were 15.0 ml/100 ml/min, 36.7 mu mol/100 ml/min and 25.9% respectively. Voxels below these values were significantly more frequent in lesion tissue (all P < 0.005, Mann-Whitney U-test). However, a significant proportion of lesion voxels had values above these thresholds, so that definition of the full extent of irreversible tissue damage would not be possible based upon single physiological thresholds. We conclude that, in TBI, the threshold of CBF below which irreversible tissue damage consistently occurs differs from the classical CBF threshold for stroke (where similar methodology is used to define such thresholds). The CMRO2 threshold is comparable to that reported in the stroke literature. At a voxel-based level, however (and in common with ischaemic stroke), the extent of irreversible tissue damage cannot be accurately predicted by early abnormalities of any single physiological variable.	Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Dept Med, Cambridge CB2 2QQ, England; Univ Cambridge, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; Univ Cambridge, Acad Neurosurg Unit, Dept Clin Neurosci, Cambridge CB2 2QQ, England; Univ Cambridge, Dept Radiol, Cambridge CB2 2QQ, England		Menon, DK (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Dept Med, Box 93, Cambridge CB2 2QQ, England.	dkm13@wbic.cam.ac.uk	Steiner, Luzius/J-1987-2019	Smielewski, Peter/0000-0001-5096-3938; Salvador, Raymond/0000-0001-5557-1562; Coles, Jonathan/0000-0003-4013-679X	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001237] Funding Source: Medline; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0001237, G9439390] Funding Source: UKRI		ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Baron JC, 1999, CEREBROVASC DIS, V9, P193, DOI 10.1159/000015955; BARON JC, 1984, J CEREBR BLOOD F MET, V4, P140, DOI 10.1038/jcbfm.1984.22; BARON JC, 1983, J CEREB BLOOD FLOW M, V1, pS1; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; FRACKOWIAK RSJ, 1980, J COMPUT ASSIST TOMO, V4, P727, DOI 10.1097/00004728-198012000-00001; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Furlan M, 1996, ANN NEUROL, V40, P216, DOI 10.1002/ana.410400213; Furuya Y, 2003, NEUROSURGERY, V52, P340, DOI 10.1227/01.NEU.0000043931.83041.AA; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Heiss WD, 2000, STROKE, V31, P366, DOI 10.1161/01.STR.31.2.366; Heiss WD, 1998, J CEREBR BLOOD F MET, V18, P1298, DOI 10.1097/00004647-199812000-00004; HEISS WD, 1992, J CEREBR BLOOD F MET, V12, P193, DOI 10.1038/jcbfm.1992.29; Heiss WD, 2001, BRAIN, V124, P20, DOI 10.1093/brain/124.1.20; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Imberti R, 2002, J NEUROSURG, V96, P97, DOI 10.3171/jns.2002.96.1.0097; JENNETT B, 1975, LANCET, V1, P480; Jiang Q, 1997, J NEUROL SCI, V145, P15, DOI 10.1016/S0022-510X(96)00286-9; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; LAMMERTSMA AA, 1987, J CEREBR BLOOD F MET, V7, P372, DOI 10.1038/jcbfm.1987.75; Marchal G, 1999, BRAIN, V122, P2387, DOI 10.1093/brain/122.12.2387; Marchal G, 1996, STROKE, V27, P599, DOI 10.1161/01.STR.27.4.599; MARCHAL G, 1992, ARCH NEUROL-CHICAGO, V49, P1013, DOI 10.1001/archneur.1992.00530340029014; MARCOUX FW, 1982, STROKE, V13, P339, DOI 10.1161/01.STR.13.3.339; Marion DW, 2002, CRIT CARE MED, V30, P2619, DOI 10.1097/00003246-200212000-00001; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Menon DK, 2003, ANESTHESIOLOGY, V98, P805, DOI 10.1097/00000542-200304000-00002; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Pantoni L, 1996, STROKE, V27, P1641, DOI 10.1161/01.STR.27.9.1641; PHELPS ME, 1979, J NUCL MED, V20, P328; POWERS WJ, 1985, J CEREBR BLOOD F MET, V5, P600, DOI 10.1038/jcbfm.1985.89; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SETTE G, 1993, STROKE, V24, P2046, DOI 10.1161/01.STR.24.12.2046; Smielewski Peter, 1800, J Clin Monit Comput, V17, P427, DOI 10.1023/A:1026293611455; Steiner LA, 2003, J CEREBR BLOOD F MET, V23, P1371, DOI 10.1097/01.WCB.0000090861.67713.10; TEASDALE G, 1974, LANCET, V2, P81; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Warach S, 2001, STROKE, V32, P2460; Wu O, 2001, STROKE, V32, P933, DOI 10.1161/01.STR.32.4.933	59	86	91	1	7	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	AUG	2005	128		8				1931	1942		10.1093/brain/awh536			12	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	948OB	WOS:000230724500021	15888537	Bronze			2022-02-06	
J	D'Ambrosio, R; Perucca, E				D'Ambrosio, R; Perucca, E			Epilepsy after head injury	CURRENT OPINION IN NEUROLOGY			English	Article						posttraumatic epilepsy; partial seizures; head trauma; epileptogenesis; antiepileptic drugs; microdialysis	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC EPILEPSY; ANTIEPILEPTIC DRUGS; MECHANICAL INJURY; ANIMAL-MODELS; RISK-FACTORS; SEIZURES; PREVENTION; EPILEPTOGENESIS; MODERATE	Purpose of review The purpose of this short review is to provide an update on the epidemiology of posttraumatic epilepsy, associated risk factors, data from prevention studies, and recent breakthroughs in experimental research. Recent findings There is increasing evidence that neuroimaging findings, stratification by neurosurgical procedures performed, and genomic information (e.g. apolipoprotein E and haptoglobin genotypes) may provide useful predictors of the individual risk of developing posttraumatic epilepsy. While antiepileptic drug prophylaxis can be effective in protecting against acute (provoked) seizures occurring within 7 days after injury, no antiepileptic drug treatment has been found to protect against the development of posttraumatic epilepsy and therefore long-term anticonvulsant prophylaxis is not recommended. Glucocorticoid administration early after head injury also has not been found to reduce the risk of posttraurnatic epilepsy. At the basic research level, there have been advances in the understanding of pathophysiological changes in posttraumatic excitatory and inhibitory synapses, and the critical period for epileptogenesis after head injury has been better defined. Finally, the development of a novel animal model, which mimicks more closely human posttraurnatic epilepsy, may facilitate efforts to characterize relevant epileptogenic mechanisms and to identify clinically effective antiepileptogenic treatments. Summary Despite the continuing lack of clinically effective agents for posttraurnatic epilepsy prophylaxis, recent advances in basic and clinical research offer new hope for success in the development of new strategies for prevention and treatment.	Univ Washington, Dept Neurol Surg, Seattle, WA 98104 USA; Univ Washington, Reg Epilepsy Ctr, Seattle, WA 98104 USA; IRCCS, Mondino Fdn, Neurol Inst, Pavia, Italy		D'Ambrosio, R (corresponding author), Univ Washington, Harborview Med Ctr, Dept Neurosurg, 325 9Th Ave,Box 359915, Seattle, WA 98104 USA.	raid@u.washington.edu	Perucca, Emilio/Q-7308-2019		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS040823, R01 NS040823, R01 NS040823-03] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040823] Funding Source: NIH RePORTER		Alves OL, 2003, ANN NY ACAD SCI, V993, P25, DOI 10.1111/j.1749-6632.2003.tb07508.x; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Beghi E, 2003, EPILEPSIA, V44, P21, DOI 10.1046/j.1528-1157.44.s10.1.x; Benardo LS, 2003, EPILEPSIA, V44, P27, DOI 10.1046/j.1528-1157.44.s10.2.x; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 2003, J NEUROTRAUM, V20, P1059; DAMBROSIO R, 2004, IN PRESS J NEUROTRAU; DIAZARRASTIA R, 2003, ARCH NEUROL-CHICAGO, V60, P318; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Goforth PB, 2004, J NEUROTRAUM, V21, P719, DOI 10.1089/0897715041269704; Graber KD, 2004, ANN NEUROL, V55, P860, DOI 10.1002/ana.20124; Graber KD, 1999, ANN NEUROL, V46, P234, DOI 10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; Kao CQ, 2004, J NEUROTRAUM, V21, P259, DOI 10.1089/089771504322972059; Kumar R, 2003, AM J NEURORADIOL, V24, P218; Lendon CL, 2003, NEUROLOGY, V61, P683, DOI 10.1212/01.WNL.0000078033.81925.80; Loscher W, 2002, EPILEPSY RES, V50, P105, DOI 10.1016/S0920-1211(02)00073-6; Loscher W, 2002, EPILEPSY RES, V50, P3, DOI 10.1016/S0920-1211(02)00063-3; Mazzini L, 2003, EPILEPSIA, V44, P569, DOI 10.1046/j.1528-1157.2003.34902.x; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; Nissinen Jari P. T., 2003, Epilepsia, V44, P175; PANTER SS, 1985, J EXP MED, V161, P748, DOI 10.1084/jem.161.4.748; Sadrzadeh SMH, 2004, CLIN CHEM, V50, P1095, DOI 10.1373/clinchem.2003.028001; Schmidt D, 2002, EPILEPSY RES, V50, P71, DOI 10.1016/S0920-1211(02)00070-0; Stables James P., 2002, Epilepsia, V43, P1410, DOI 10.1046/j.1528-1157.2002.06702.x; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Watson NF, 2004, EPILEPSIA, V45, P690, DOI 10.1111/j.0013-9580.2004.59403.x; White HS, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s7.10.x; White HS, 2002, NEUROLOGY, V59, pS7, DOI 10.1212/WNL.59.9_suppl_5.S7; Young KD, 2004, ANN EMERG MED, V43, P435, DOI 10.1016/j.annemergmed.2003.09.016	37	86	89	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2004	17	6					731	735		10.1097/00019052-200412000-00014			5	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	878XY	WOS:000225682000013	15542983	Green Accepted			2022-02-06	
J	Kliegel, M; Eschen, A; Thone-Otto, AIT				Kliegel, M; Eschen, A; Thone-Otto, AIT			Planning and realization of complex intentions in traumatic brain injury and normal aging	BRAIN AND COGNITION			English	Article							PROSPECTIVE MEMORY IMPAIRMENT; EXECUTIVE FUNCTIONS; ELECTRONIC MEMORY; PREFRONTAL CORTEX; EVENT; PERFORMANCE; DEFICITS; AGE; TASK; TIME	I. The realization of delayed intentions (i.e., prospective memory) is a highly complex process composed of four phases: intention formation, retention, re-instantiation, and execution. The aim of this study was to investigate if executive functioning impairments are related to problems in the formation, re-instantiation, and execution of a delayed complex intention. In this context, it was another aim of the study to investigate the executive functioning hypothesis of cognitive aging in prospective memory performance. It, was, therefore, explored if age-related prospective memory decline leads to similar decrements in the process of prospective remembering as executive functioning-related decline in young patients with traumatic brain injury. A group of patients with traumatic brain injury with retrospective memory within normal limits but impaired executive functions, a group of healthy older and a group of healthy younger adults completed a complex prospective memory task that allows for the separate assessment of the four phases of the prospective memory process. All groups showed a similarly high performance in the intention retention phase, whereas the patients with deficits in executive functioning and the older participants performed worse than the healthy young participants in the intention formation, re-instantiation and execution phases. The importance of executive functioning for prospective remembering in traumatic brain injury and normal aging is discussed. (C) 2004 Elsevier Inc. All rights reserved.	Univ Zurich, Dept Gerontopsychol, CH-8006 Zurich, Switzerland; Univ Zurich Hosp, CH-8091 Zurich, Switzerland; Univ Leipzig, Day Care Clin Cognit Neurol, Leipzig, Germany		Kliegel, M (corresponding author), Univ Zurich, Dept Gerontopsychol, CH-8006 Zurich, Switzerland.	m.kliegel@psychologic.unizh.ch		Kliegel, Matthias/0000-0002-2001-2522			Benton AL, 1991, FRONTAL LOBE FUNCTIO; Bisiacchi PS, 1996, PROSPECTIVE MEMORY T, P297; BISIACCHI PS, 2000, 1 INT C PROSP MEM HA; Brunfaut E, 2000, NEUROPSYCHOLOGIA, V38, P975, DOI 10.1016/S0028-3932(00)00016-6; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess P., 1997, METHODOLOGY FRONTAL, P81; Burgess P. W., 1997, COGNITIVE MODELS MEM, P247; Burgess PW, 2001, NEUROPSYCHOLOGIA, V39, P545, DOI 10.1016/S0028-3932(00)00149-4; COCKBURN J, 1995, CORTEX, V31, P87, DOI 10.1016/S0010-9452(13)80107-4; CRAMON GM, 2000, LEHRBUCH KLIN NEUROP, P392; Crawford JR, 2000, AGING NEUROPSYCHOL C, V7, P9, DOI 10.1076/anec.7.1.9.806; DAIGNEAULT S, 1992, DEV NEUROPSYCHOL, V8, P99, DOI 10.1080/87565649209540518; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; DOBBS AR, 1987, CAN J PSYCHOL, V41, P209, DOI 10.1037/h0084152; Einstein, 2002, PSYCHOL BEITR, V44, P303, DOI [10.1037/0012-1649.44.2.612, DOI 10.1037/0012-1649.44.2.612]; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Ellis J, 2000, APPL COGNITIVE PSYCH, V14, pS1, DOI 10.1002/acp.767; FUNKE J, 1993, PLAN DAY; GLISKY EL, 1996, PROSPECTIVE MEMORY T, P249; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Harting C., 2000, DTSCH ADAPTATION REV; HEATON RK, 1993, WISCONSIN SORTING TE; HUPPERT FA, 1993, J CLIN EXP NEUROPSYC, V15, P805, DOI 10.1080/01688639308402597; Huppert FA, 2000, APPL COGNITIVE PSYCH, V14, pS63, DOI 10.1002/acp.771; KEIDEL M, 1998, THERAPIE VERLAUF NEU, P569; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kliegel M, 2000, MEM COGNITION, V28, P1041, DOI 10.3758/BF03209352; Kliegel M, 2001, MEMORY, V9, P1, DOI 10.1080/09658210042000003; Kliegel M, 2003, Z GERONTOL GERIATR, V36, P35, DOI 10.1007/s00391-003-0081-5; Kliegel M, 2003, INT J PSYCHOL, V38, P207, DOI 10.1080/00207590344000132; Kliegel M, 2003, INT J PSYCHOL, V38, P193, DOI 10.1080/00207590344000114; KLIEGEL M, 2003, Z NEUROPSYCHOL, V14, P293; KLIEGEL M, IN PRESS MEMORY; Knight R.G., 1998, MEMORY NEURODEGENERA, P172; Kopp UA, 2003, INT J PSYCHOL, V38, P229, DOI 10.1080/00207590344000150; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, V6, P183; Lehrl S., 1977, MEHRFACHWAHLWORTSCHA; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Mantyla T, 1997, AGING NEUROPSYCHOL C, V4, P81, DOI 10.1080/13825589708256638; Martin M, 2003, INT J PSYCHOL, V38, P195, DOI 10.1080/00207590344000123; Maylor EA, 2002, MEM COGNITION, V30, P871, DOI 10.3758/BF03195773; McCauley SR, 2004, DEV NEUROPSYCHOL, V25, P5, DOI 10.1207/s15326942dn2501&2_2; McDaniel M.A., 1996, PROSPECT MEM THEORY, P115; McDaniel MA, 1999, NEUROPSYCHOLOGY, V13, P103, DOI 10.1037/0894-4105.13.1.103; McDaniel MA., 1996, PROSPECTIVE MEMORY T, P1; Meissner F, 2001, PSYCHIAT PRAX, V28, P180, DOI 10.1055/s-2001-13266; Okuda J, 1998, NEUROSCI LETT, V253, P127, DOI 10.1016/S0304-3940(98)00628-4; OURIACHE S, 2000, 1 INT C PROSP MEM HA; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; Rude SS, 1999, COGNITION EMOTION, V13, P267, DOI 10.1080/026999399379276; Salat DH, 2001, ARCH NEUROL-CHICAGO, V58, P1403, DOI 10.1001/archneur.58.9.1403; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; Sgaramella TM, 2000, BRAIN COGNITION, V43, P388; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shapiro JK, 1998, BRAIN COGNITION, V37, P175; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Thone A.I.T., 2001, Z NEUROPSYCHOL Z NEUROPSYCHOL, V12, P102; Thone-Otto AIT, 2003, INT J PSYCHOL, V38, P236, DOI 10.1080/00207590344000169; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Ward G, 1997, Q J EXP PSYCHOL-A, V50, P49, DOI 10.1080/027249897392224; West R, 2001, NEUROREPORT, V12, P2855, DOI 10.1097/00001756-200109170-00020; West R, 2001, COGNITIVE BRAIN RES, V12, P1, DOI 10.1016/S0926-6410(01)00014-3; West R, 2001, PSYCHOL AGING, V16, P682, DOI 10.1037//0882-7974.16.4.682; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272	67	86	92	1	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626	1090-2147		BRAIN COGNITION	Brain Cogn.	OCT	2004	56	1					43	54		10.1016/j.bandc.2004.05.005			12	Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	860BU	WOS:000224313600007	15380875				2022-02-06	
J	Larrabee, GJ				Larrabee, GJ			Exaggerated MMPI-2 symptom report in personal injury litigants with malingered neurocognitive deficit	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	28th Annual Meeting of the International-Neuropsychological-Society	FEB 09-12, 2000	DENVER, COLORADO	Int Neuropsychol Soc		FBS; MND; MMPI-2	FAKE BAD SCALE; HEAD-INJURY; VALIDITY SCALES; PERFORMANCE; LITIGATION; VALIDATION; CLAIMANTS; SEVERITY; PROFILES; SAMPLES	Traditional MMPI-2 validity scales, the Lees-Haley Fake Bad Scale (FBS), and the Arbisi and Ben Porath Infrequency Psychopathology Scale (F(p)) were evaluated in 33 personal injury litigants who had failed forced-choice symptom validity testing and other measures of effort in patterns consistent with the Slick, Sherman, and Iverson (1999) criteria for definite and probable malingered neurocognitive deficit (MND). The FBS was more sensitive to symptom exaggeration than F, Fb, and F(p). The definite and probable MND litigants also produced mean elevations on MMPI-2 scales 1, 3 and 7 that were significantly higher than those produced by various clinical groups including non-litigating severe closed head injury, multiple sclerosis, spinal cord injury, chronic pain, and depression. These data suggest that MMPI-2 profiles characteristic of malingered injury differ from those associated with malingered psychopathology. (C) 2002 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.			Larrabee, GJ (corresponding author), Suite 202,630 S Orange Ave, Sarasota, FL 34236 USA.						Arbisi P. A., 1995, PSYCHOL ASSESSMENT, V7, P425; Berry DTR, 1995, PSYCHOL ASSESSMENT, V7, P517; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P461, DOI 10.1076/clin.15.4.461.1890; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; Boone KB, 1999, CLIN NEUROPSYCHOL, V13, P414; Butcher J, 1989, MANUAL ADM SCORING M; BUTCHER JN, IN PRESS ARCH CLIN N; Cohen J., 2013, STAT POWER ANAL BEHA; Connor B, 1998, ARCH CLIN NEUROPSYCH, V13, P109; GRAHAM JR, 1991, J PERS ASSESS, V57, P264, DOI 10.1207/s15327752jpa5702_6; GRAHAM JR, 2000, ASSESSING PERSONALIT; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; Guilford J. P., 1973, FUNDAMENTAL STAT PSY; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Keller L S., 1991, ASSESSMENT CHRONIC P; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; Larrabee GJ, 2000, CLIN GUIDE NEUROPSYC, P301; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEESHALEY PR, 1992, J CLIN PSYCHOL, V48, P681, DOI 10.1002/1097-4679(199209)48:5<681::AID-JCLP2270480516>3.0.CO;2-Q; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P157, DOI 10.1016/S0887-6177(00)00107-4; MILLER JS, 1995, CHEM ENG NEWS, V73, P30, DOI 10.1021/cen-v073n040.p030; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Nelson L, 1998, ARCH CLIN NEUROPSYCH, V13, P92; PUTNAM SH, 1998, ANN M AM PSYCH ASS S; RODEVICH MA, 1995, REHABIL PSYCHOL, V40, P181; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Tombaugh T.N., 1996, TOMM TEST MEMORY MAL; Tsushima WT, 2001, ASSESSMENT, V8, P205, DOI 10.1177/107319110100800208; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Youngjohn JR, 1997, PSYCHOL ASSESSMENT, V9, P177, DOI 10.1037/1040-3590.9.3.177; [No title captured]; [No title captured]	41	86	87	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2003	18	6					673	686	PII S0887-6177(02)00157-9	10.1016/S0887-6177(02)00157-9			14	Psychology, Clinical; Psychology	Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	715FU	WOS:000184961000010	14591440				2022-02-06	
J	Pfister, BJ; Weihs, TP; Betenbaugh, M; Bao, G				Pfister, BJ; Weihs, TP; Betenbaugh, M; Bao, G			An in vitro uniaxial stretch model for axonal injury	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						diffuse axonal injury; uniaxial stretch; neural cell death; traumatic brain injury; biomechanics	BRAIN-INJURY; CORTICAL-NEURONS; DEFORMATION; CELLS	We have developed a unique uniaxial stretching device to study axonal injury and neural cell death resulting from brain tissue deformations common in traumatic head injuries. Using displacement control rather than force control, this device is capable of achieving strains >70% and strain rates up to 90 s(-1), well above those currently used for studying axonal injury. We have demonstrated that the deformation of the specimen was uniaxial, uniform and highly reproducible; the prespecified displacement profiles could be realized almost precisely; and adequate cell adhesion could be achieved readily. The entire device can fit into a biological safety cabinet to maintain sterility, and the specimens are convenient for cell culture. This device can be used to investigate a wide range of biomechanical issues involved in diffuse axonal injury. (C) 2003 Biomedical Engineering Society.	Emory Univ, Atlanta, GA 30322 USA; Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30332 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21287 USA; Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21287 USA		Bao, G (corresponding author), Georgia Inst Technol, Dept Biomed Engn, 315 Ferest Dr,Room 2306, Atlanta, GA 30332 USA.	gang.bao@bme.gatech.edu	Weihs, Timothy P/A-3313-2010; Betenbaugh, Michael J./A-3252-2010	Betenbaugh, Michael J./0000-0002-6336-4659			Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Gallant PE, 1997, J NEUROTRAUM, V14, P811, DOI 10.1089/neu.1997.14.811; Gennarelli T, 1996, NEUROSURGERY, V2, P2611; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1997, NEUROSCIENTIST, V3, P73, DOI 10.1177/107385849700300117; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; KLEE WA, 1974, P NATL ACAD SCI USA, V71, P3474, DOI 10.1073/pnas.71.9.3474; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; McIntosh TK, 1996, LAB INVEST, V74, P315; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MEANEY DF, 1993, CRASHWORTHINESS OCCU, V169, P169; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; NIRENBERG M, 1983, SCIENCE, V222, P794, DOI 10.1126/science.6314503; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Sengoku T., 2000, Journal of Neurotrauma, V17, P971; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; STRICH SJ, 1961, LANCET, V2, P443; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632, DOI 10.1152/jn.1997.77.2.632; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; Zhang S. X., 2000, Journal of Neurotrauma, V17, P979	36	86	88	0	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	MAY	2003	31	5					589	598		10.1114/1.1566445			10	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	675NJ	WOS:000182701200009	12757202				2022-02-06	
J	Alderman, N				Alderman, N			Contemporary approaches to the management of irritability and aggression following traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							CLOSED-HEAD-INJURY; NEUROPSYCHIATRIC SEQUELAE; COGNITIVE THERAPY; OVERT AGGRESSION; CLINICAL-USE; OAS-MNR; BEHAVIOR; REHABILITATION; REDUCTION; MILD	In this paper, the principal means of managing irritability and aggression following traumatic brain injury (TBI) will be briefly reviewed. The paper will initially consider the prevalence of irritability, what it is and some of the likely causes that drive the condition. Aggression will then be similarly contemplated. Prior to a discussion regarding those methods most regularly employed in their management, the attention of the reader will be directed to a range of methodological issues that need to be considered in relation to reporting treatment efficacy, including lack of homogeneity and the need to use standardised assessment tools. Three principal management approaches will then be described and appraised, these being pharmacology, psychotherapy, and behaviour therapy. Within the discussion of psychotherapeutic methods, special mention will be made with regard to use of cognitive behaviour therapy, and two detailed case studies will be employed to illustrate issues relating to both cognitive behaviour therapy and behaviour therapy.	St Andrews Hosp, Kemsley Div, Northampton NN1 5DG, England		Alderman, N (corresponding author), St Andrews Hosp, Kemsley Div, Northampton NN1 5DG, England.			Alderman, Nick/0000-0002-8523-4142			ALDERMAN N, 1995, NEUROPSYCHOL REHABIL, V5, P193, DOI 10.1080/09602019508401467; Alderman N, 1996, NEUROPSYCHOL REHABIL, V6, P161, DOI 10.1080/713755505; Alderman N, 2001, BRAIN DAM B, P175; ALDERMAN N, 1991, Brain Injury, V5, P77, DOI 10.3109/02699059108998516; Alderman N, 2002, BRAIN INJURY, V16, P469, DOI 10.1080/02699050110118458; Alderman N, 1999, NEUROPSYCHOL REHABIL, V9, P385, DOI 10.1080/096020199389455; Alderman N, 1997, BRAIN INJURY, V11, P503, DOI 10.1080/713802182; Alderman N, 1999, BRAIN INJURY, V13, P669; Alderman N, 1997, BRAIN INJURY, V11, P79, DOI 10.1080/026990597123683; Alderman N., 2002, EVIDENCE MENTAL HLTH; ALDERMAN N, 1992, PHYSIOTHERAPY, V78, P335; ALDERMAN N, 1991, NEUROPSYCHOL REHABIL, V1, P65, DOI DOI 10.1080/09602019108401380; ALDERMAN N, 2002, NEUROLOGICAL REHABIL; Azouvi P, 1999, BRAIN INJURY, V13, P797, DOI 10.1080/026990599121188; Beck A.T, 1976, COGNITIVE THERAPY EM; Beck AT., 1979, COGNITIVE THERAPY DE; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BURGESS PW, 1990, COGNITIVE REHABILITA; Burgess PW., 1996, BEHAV ASSESSMENT DYS; BURGESS PW, 1990, NEUROBEHAVIOURAL SEQ; BURKE WH, 1988, INT J REHABIL RES, V11, P235, DOI 10.1097/00004356-198809000-00003; CLARK DM, 1986, BEHAV PSYCHOTHER, V14, P283, DOI 10.1017/S0141347300014907; CLARK DM, 1994, BRIT J PSYCHIAT, V164, P759, DOI 10.1192/bjp.164.6.759; CLARK DM, 1989, COGNITIVE BEHAV THER; DAVIS JR, 1994, BRAIN INJURY, V8, P589, DOI 10.3109/02699059409151011; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; Demark J, 2002, BRAIN INJURY, V16, P91, DOI 10.1080/02699050110102059; EAMES P, 1985, J NEUROL NEUROSUR PS, V48, P613, DOI 10.1136/jnnp.48.7.613; Eames P, 1996, BRAIN INJURY, V10, P631, DOI 10.1080/026990596124061; Eames P, 1985, Int Rehabil Med, V7, P130; EAMES P, 1988, J HEAD TRAUMA REHAB, V3, P1; Eames P. G., 1990, NEUROBEHAVIOURAL SEQ; Eames PG, 2001, BRAIN DAM B, P29; FOSTER HG, 1989, PROG NEURO-PSYCHOPH, V13, P865, DOI 10.1016/0278-5846(89)90038-9; GIAKAS WJ, 1990, J CLIN PSYCHIAT, V51, P525; Gibbs JC, 1996, AGGRESS VIOLENT BEH, V1, P283, DOI 10.1016/1359-1789(95)00018-6; GILES GM, 1988, REHABILITATION SEVER; GOLL S, 1988, MODELS BRAIN INJURY; GUALTIERI CT, 1991, NEUROPSYCHIATRY BEHA; HAAGA DA, 1986, HELPING PEOPLE CHANG; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Hawton K., 1989, COGNITIVE BEHAV TREA; Hayes N, 1997, ARCH CLIN NEUROPSYCH, V12, P333; Hegel MT, 2000, BEHAV MODIF, V24, P94, DOI 10.1177/0145445500241005; HIRSCH J, 1993, HEADLINES        MAR, P10; JACKSON WT, 1992, HDB HEAD TRAUMA ACUT; Jahoda A, 2001, BRIT J MED PSYCHOL, V74, P305, DOI 10.1348/000711201161000; JOHNSTON S, 1991, J NEUROL NEUROSUR PS, V54, P272, DOI 10.1136/jnnp.54.3.272; JONES RSP, 1993, PEOPLE SEVERE LEARNI; KANFER F, 1986, HELPING PEOPLE CHANG; Kim SH, 1999, J NERV MENT DIS, V187, P327, DOI 10.1097/00005053-199906000-00001; Kinney A, 2001, J CONTEMP PSYCHOTHER, V31, P89; LEWIN J, 1992, BRIT J PSYCHIAT, V161, P261, DOI 10.1192/bjp.161.2.261; LONG CJ, 1995, NEUROPSYCHOLOGICAL A; Manchester D, 2001, BRAIN DAM B, P157; MATEER CA, 1990, NEUROBEHAVIOURAL SEQ; Mattes J A, 1990, J Neuropsychiatry Clin Neurosci, V2, P159; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MCMILLAN T M, 1990, Brain Injury, V4, P399, DOI 10.3109/02699059009026193; McMillan TM, 2001, NEUROBEHAVIOURAL DIS; MEICHENBAUM D, 1986, HELPING PEOPLE CHANG; MILLER E, 1981, BRIT J CLIN PSYCHOL, V20, P69, DOI 10.1111/j.2044-8260.1981.tb00498.x; MILLER L, 1994, J OFFENDER REHABILIT, V21, P91, DOI DOI 10.1300/J076; MONROE RR, 1989, COMPR PSYCHIAT, V30, P489, DOI 10.1016/0010-440X(89)90078-3; MOONEY GF, 1993, ARCH PHYS MED REHAB, V74, P153; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; PATTERSON CH, 1986, THEORIES COUNSELLING; POWELL GE, 1981, BRAIN FUNCTION THERA; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; PRIGATANO GP, 1987, BNI Q, V3, P2; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Reeder D M, 1991, Arch Psychiatr Nurs, V5, P147, DOI 10.1016/0883-9417(91)90015-W; ROBINSON RG, 1983, COMPR PSYCHIAT, V24, P555, DOI 10.1016/0010-440X(83)90024-X; ROHRBAUGH RM, 1988, J AM GERIATR SOC, V36, P736, DOI 10.1111/j.1532-5415.1988.tb07177.x; SAZBON L, 1991, Brain Injury, V5, P3, DOI 10.3109/02699059108998505; Scott J, 1997, CURR OPIN PSYCHIATR, V10, P256, DOI 10.1097/00001504-199705000-00016; SLAGLE DA, 1990, INT J PSYCHIAT MED, V20, P1, DOI 10.2190/BE6W-DCY1-V71N-N7J7; Starkstein S. E., 1991, FRONTAL LOBE FUNCTIO; STEIN G, 1992, BRIT J PSYCHIAT, V161, P167, DOI 10.1192/bjp.161.2.167; SUKHODOLSKY DG, 2000, J CHILD ADOLESC GROU, V10, P159, DOI DOI 10.1023/A:1009488701736; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Watson C, 2001, BRAIN INJURY, V15, P1003, DOI 10.1080/02699050010022662; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WILLIAMS WH, 1997, COGNITIVE BEHAV THER; Wilson B., 1989, PRACTICE BEHAV MED; Wing J. K., 1974, MEASUREMENT CLASSIFI; WOOD R, 1988, J HEAD TRAUMA REHAB, V3, P53; Wood R. L., 1987, BRAIN INJURY REHABIL; Wood R. L. L., 1981, APPL CONDITIONING TH; Wood R. L1., 1990, NEUROBEHAVIOURAL SEQ; Wood RL, 2001, NEUROBEHAVIOURAL DIS, P1; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	96	86	88	0	11	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	MAR-MAY	2003	13	1-2			SI		211	240		10.1080/09602010244000327			30	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	665EK	WOS:000182106500012	21854335				2022-02-06	
J	Grandmaison, E; Simard, M				Grandmaison, E; Simard, M			A critical review of memory stimulation programs in Alzheimer's disease	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							TRAUMATIC BRAIN INJURY; COGNITIVE REHABILITATION; EARLY DEMENTIA; ENCODING SPECIFICITY; PROCEDURAL MEMORY; IMPAIRED PATIENTS; EVERYDAY MEMORY; SENILE DEMENTIA; MENTAL-IMAGERY; AMNESIA	The authors describe the memory stimulation programs used in the treatment of Alzheimer's disease (AD) and review their efficacy. Visual imagery, errorless learning, dyadic approaches, spaced retrieval techniques, encoding specificity with cognitive support at retrieval, and external memory aids were the memory stimulation programs used alone or in combination in AD. Preliminary evidence suggests that the errorless learning, spaced retrieval, and vanishing cues techniques and the dyadic approach, used alone or in combination are efficacious in stimulating memory in patients with AD.	Univ Moncton, Sch Psychol, Geriatr Neuropsychol Lab, Moncton, NB E1A 3E9, Canada; Ctr Addict & Mental Hlth, Neuropsychiat Program, Toronto, ON, Canada		Grandmaison, E (corresponding author), Univ Moncton, Sch Psychol, Geriatr Neuropsychol Lab, Moncton, NB E1A 3E9, Canada.	eric.grandmaison@gnb.ca	Simard/Q-9675-2019	Simard/0000-0003-1257-8275			Alivisatos B, 1997, NEUROPSYCHOLOGIA, V35, P111, DOI 10.1016/S0028-3932(96)00083-8; Andrewes D, 1999, NEUROPSYCHOL REHABIL, V9, P77, DOI 10.1080/713755591; Arkin S, 2000, AM J ALZHEIMERS DIS, V15, P152; Arkin SM, 1991, AM J ALZHEIMERS CARE, V6, P17; BACKMAN L, 1991, PSYCHOL AGING, V6, P489; BACKMAN L, 1992, ACTA NEUROL SCAND, V85, P84; Backman L, 1998, SCAND J PSYCHOL, V39, P131, DOI 10.1111/1467-9450.393067; BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; BADDELEY AD, 1992, CLIN MANAGEMENT MEMO, P1; Beck C, 1988, J Geriatr Psychiatry, V21, P73; Bjork R., 1988, PRACT ASP MEM, V2; BOWERS D, 1991, BRAIN, V114, P2593, DOI 10.1093/brain/114.6.2593; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BREUIL V, 1994, INT J GERIATR PSYCH, V9, P211, DOI 10.1002/gps.930090306; Buschke H, 1997, NEUROLOGY, V48, P989, DOI 10.1212/WNL.48.4.989; Buschke H, 1995, J Int Neuropsychol Soc, V1, P483; BUSCHKE H, 1994, J CLIN NEUROPSYCH, V6, P433; CALVANIO R, 1993, NEUROL CLIN, V11, P25, DOI 10.1016/S0733-8619(18)30169-5; Camp CJ, 1996, APPL COGNITIVE PSYCH, V10, P193, DOI 10.1002/(SICI)1099-0720(199606)10:3<193::AID-ACP374>3.0.CO;2-4; CAMP CJ, 1992, EVERYDAY MEMORY AGIN, P155; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Clare L, 2001, NEUROPSYCHOL REHABIL, V11, P477, DOI 10.1080/09602010042000213; Clare L, 2000, J CLIN EXP NEUROPSYC, V22, P132, DOI 10.1076/1380-3395(200002)22:1;1-8;FT132; Clare L, 1999, NEUROCASE, V5, P37, DOI 10.1080/13554799908404063; DAMASIO AR, 1990, MOL DEFICITS ALZHEIM; Davis RN, 2001, ALZ DIS ASSOC DIS, V15, P1, DOI 10.1097/00002093-200101000-00001; De Vreese LP, 2001, INT J GERIATR PSYCH, V16, P794, DOI 10.1002/gps.428; DEWEER B, 1995, J NEUROL NEUROSUR PS, V58, P590, DOI 10.1136/jnnp.58.5.590; DIESFELDT HFA, 1984, ARCH GERONTOL GERIAT, V3, P51, DOI 10.1016/0167-4943(84)90014-1; FARAH MJ, 1984, COGNITION, V18, P245, DOI 10.1016/0010-0277(84)90026-X; FARAH MJ, 1988, PSYCHOL REV, V95, P307, DOI 10.1037/0033-295X.95.3.307; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; GLISKY EL, 1987, NEUROPSYCHOLOGIA, V25, P893, DOI 10.1016/0028-3932(87)90094-7; GLISKY EL, 1986, J CLIN EXP NEUROPSYC, V8, P292, DOI 10.1080/01688638608401320; Gray DS, 2000, BRAIN INJURY, V14, P1003, DOI 10.1080/02699050050191940; HAXBY JV, 1990, ARCH NEUROL-CHICAGO, V47, P753, DOI 10.1001/archneur.1990.00530070043010; HERLITZ A, 1991, BRAIN COGNITION, V15, P119, DOI 10.1016/0278-2626(91)90020-9; Hersh N A, 1994, NeuroRehabilitation, V4, P187, DOI 10.3233/NRE-1994-4309; HODGES JR, 1995, NEUROPSYCHOLOGIA, V33, P441, DOI 10.1016/0028-3932(94)00127-B; Iyo M, 1997, LANCET, V349, P1805, DOI 10.1016/S0140-6736(96)09124-6; Jobst K A, 1998, Int Psychogeriatr, V10, P271, DOI 10.1017/S1041610298005389; KARLSSON T, 1989, NEUROPSYCHOLOGIA, V27, P737, DOI 10.1016/0028-3932(89)90119-X; Kasl-Godley J, 2000, CLIN PSYCHOL REV, V20, P755, DOI 10.1016/S0272-7358(99)00062-8; Kesslak JP, 1997, BEHAV NEUROL, V10, P137, DOI 10.3233/BEN-1997-10407; Kime SK, 1996, BRAIN INJURY, V10, P17; Kixmiller JS, 2002, BRAIN COGNITION, V49, P237, DOI 10.1006/brcg.2001.1476; Kuzis G, 1999, NEUROPSY NEUROPSY BE, V12, P265; LEVINE DN, 1985, NEUROLOGY, V35, P1010, DOI 10.1212/WNL.35.7.1010; LINTON M, 1988, PRACTICAL ASPECTS ME, P378; Lipinska B, 1997, BRAIN COGNITION, V34, P274, DOI 10.1006/brcg.1997.0916; LIPINSKA B, 1994, J CLIN EXP NEUROPSYC, V16, P809, DOI 10.1080/01688639408402695; MARTIN A, 1985, BRAIN LANG, V25, P323, DOI 10.1016/0093-934X(85)90088-4; MCKITRICK LA, 1992, J GERONTOL, V47, pP337, DOI 10.1093/geronj/47.5.P337; MOFFAT N, 1992, CLIN MANAGEMENT MEMO, P87; MONTALDI D, 1990, J NEUROL NEUROSUR PS, V53, P33, DOI 10.1136/jnnp.53.1.33; MORRIS RG, 1988, J CLIN EXP NEUROPSYC, V10, P279, DOI 10.1080/01688638808408242; OTTENBACHER KJ, 1993, ARCH NEUROL-CHICAGO, V50, P37, DOI 10.1001/archneur.1993.00540010033014; Postle BR, 1996, LEARN MEMORY, V3, P305, DOI 10.1101/lm.3.4.305; QUAYHAGEN MP, 1995, NURS RES, V44, P153; QUAYHAGEN MP, 1989, GERONTOLOGIST, V29, P150, DOI 10.1093/geront/29.2.150; Quayhagen MP, 2000, INT PSYCHOGERIATR, V12, P249, DOI 10.1017/S1041610200006360; Rapoport MJ, 2000, BRAIN INJURY, V14, P749; ROBERTSON IH, 1993, CURR OPIN NEUROL, V6, P756, DOI 10.1097/00019052-199310000-00013; Sandman Curt A., 1993, Clinical Gerontologist, V13, P19, DOI 10.1300/J018v13n04_03; SCHACTER DL, 1985, J CLIN EXP NEUROPSYC, V7, P79, DOI 10.1080/01688638508401243; Simard M, 1999, DRUG AGING, V14, P197, DOI 10.2165/00002512-199914030-00004; SIMARD M, 2000, CLIN GERIATR MED, V8, P32; Squire LR., 1987, MEMORY BRAIN; Squires EJ, 1997, NEUROPSYCHOLOGIA, V35, P1103, DOI 10.1016/S0028-3932(97)00039-0; Squires EJ, 1996, NEUROPSYCHOL REHABIL, V6, P55, DOI 10.1080/713755494; Sykes, 1978, PRACTICAL ASPECTS ME, P625; TERI L, 1991, GERONTOLOGIST, V31, P413, DOI 10.1093/geront/31.3.413; TULVING E, 1973, PSYCHOL REV, V80, P352, DOI 10.1037/h0020071; Verfaellie M, 2000, NEUROPSYCHOLOGIA, V38, P1581, DOI 10.1016/S0028-3932(00)00073-7; WECHSLER D, 1987, WECHLSER MEMORY SCAL; WILSON B, 1988, BRAIN COGNITION, V8, P31, DOI 10.1016/0278-2626(88)90037-1; Wilson B, 1999, CASE STUDIES NEUROPS; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wilson BA, 1997, J INT NEUROPSYCH SOC, V3, P487, DOI 10.1017/S1355617797004876; WOLFE N, 1995, ARCH NEUROL-CHICAGO, V52, P257, DOI 10.1001/archneur.1995.00540270049018; Wykle M., 1989, MEMORY AGING THEORY, P212; Zanetti O, 2001, NEUROPSYCHOL REHABIL, V11, P263, DOI 10.1080/09602010042000088; ZARIT SH, 1982, GERONTOLOGIST, V22, P373, DOI 10.1093/geront/22.4.373	85	86	91	0	16	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SPR	2003	15	2					130	144		10.1176/appi.neuropsych.15.2.130			15	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	672VQ	WOS:000182544000002	12724453				2022-02-06	
J	Nesic, O; Svrakic, NM; Xu, GY; McAdoo, D; Westlund, KN; Hulsebosch, CE; Ye, ZM; Galante, A; Soteropoulos, P; Tolias, P; Young, W; Hart, RP; Perez-Polo, JR				Nesic, O; Svrakic, NM; Xu, GY; McAdoo, D; Westlund, KN; Hulsebosch, CE; Ye, ZM; Galante, A; Soteropoulos, P; Tolias, P; Young, W; Hart, RP; Perez-Polo, JR			DNA microarray analysis of the contused spinal cord: Effect of NMDA receptor inhibition	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						spinal cord injury; NMDA receptor; MK-801; DNA microarray; Affymetrix; expression profile	MESSENGER-RNA EXPRESSION; KAPPA-B ACTIVATION; FUNCTIONAL RECOVERY; GENE-EXPRESSION; CELLULAR-LOCALIZATION; TRANSCRIPTION FACTORS; IMPACT INJURY; BRAIN-INJURY; C-FOS; RAT	Spinal cord injury (SCI)-induced neurodegeneration leads to irreversible and devastating motor and sensory dysfunction. Post-traumatic outcomes are determined by events occurring during the first 24 hours after SCI. An increase in extracellular glutamate concentration to neurotoxic levels is one of the earliest events after SCI. We used Affymetrix DNA oligonucleotide microarrays (with 1,322 DNA probes) analysis to measure gene expression in order to test the hypothesis that SCI-induced N-methyl-D-aspartate (NMDA) receptor activation triggers significant postinjury transcriptional changes. Here we report that SCI, 1 hour after trauma, induced change in mRNA levels of 165 genes and expression sequence tags (ESTs). SCI affected mRNA levels of those genes that regulate predominantly transcription factors, inflammation, cell survival, and membrane excitability. We also report that NMDA receptor inhibition (with -(+)-5-methyl-10,11 -dihydro-5H-dibenzo[a,d]-cyclohepten-5, 10-imine hydrogen maleate [MK-801]) reversed the effect of SCI on about 50% of the SCI-affected mRNAs. Especially interesting is the finding that NMDA receptor activation participates in the up-regulation of inflammatory factors. Therefore, SCI-induced NMDA receptor activation is one of the dominant, early signals after trauma that leads to changes in mRNA levels of a number of genes relevant to recovery processes. The majority of MK-801 effects on the SCI-induced mRNA changes reported here are novel. Additionally, we found that the MK-801 treatment also changed the mRNA levels of 168 genes and ESTs that had not been affected by SCI alone, and that some of their gene products could have harmful effects on SCI outcome. (C) 2002 Wiley-Liss, Inc.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Inst Marine Biomed, Galveston, TX 77550 USA; Univ Texas, Med Branch, Dept Anat & Neurosci, Galveston, TX 77550 USA; Washington Univ, St Louis, MO USA; Publ Hlth Res Inst, Ctr Appl Genomics, Newark, NJ USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA; UND, New Jersey Med Sch, Newark, NJ USA		Nesic, O (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, 4 Floor,301 Univ Blvd, Galveston, TX 77555 USA.	olnesic@utmb.edu	nesic, olivera/C-6456-2012; Westlund, Karin/R-6960-2019; Perez-Polo, Jose R./B-6250-2009	Westlund High, Karin/0000-0002-7388-4834	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS011255] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS011255] Funding Source: Medline		Allsopp TE, 2000, CELL DEATH DIFFER, V7, P984, DOI 10.1038/sj.cdd.4400733; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Bethea JR, 2000, PROG BRAIN RES, V128, P33; Bethea JR, 1998, J NEUROSCI, V18, P3251; BUNGE RP, 1993, ADV NEUROL, V59, P75; Butte A J, 2001, Pac Symp Biocomput, P6; Cattaneo E, 1999, TRENDS NEUROSCI, V22, P365, DOI 10.1016/S0166-2236(98)01378-2; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Farooque M, 1999, ACTA NEUROPATHOL, V98, P22, DOI 10.1007/s004010051047; GADIENT RA, 1994, NEUROSCI LETT, V182, P243, DOI 10.1016/0304-3940(94)90807-9; Ginsberg SD, 2000, ANN NEUROL, V48, P77, DOI 10.1002/1531-8249(200007)48:1<77::AID-ANA12>3.0.CO;2-A; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Haghighi SS, 2000, SPINAL CORD, V38, P733, DOI 10.1038/sj.sc.3101074; Hamada Y, 1996, NEUROSCI LETT, V203, P97, DOI 10.1016/0304-3940(95)12271-0; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184, DOI 10.1097/00004647-199902000-00010; Hayashi M, 2000, J NEUROTRAUM, V17, P203, DOI 10.1089/neu.2000.17.203; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Hughes PE, 1999, PROG NEUROBIOL, V57, P421, DOI 10.1016/S0301-0082(98)00057-4; HUMPEL C, 1994, EXP BRAIN RES, V98, P229; JACKSON GR, 1996, PARADIGMS NEURAL INJ, P1; Jander S, 2000, J NEUROIMMUNOL, V109, P181, DOI 10.1016/S0165-5728(00)00317-9; Kent TA, 1999, J NEUROSCI RES, V55, P357, DOI 10.1002/(SICI)1097-4547(19990201)55:3<357::AID-JNR11>3.0.CO;2-W; Lai M, 1997, NEUROREPORT, V8, P2691, DOI 10.1097/00001756-199708180-00011; LI S, 1997, SPINAL CORD, V12, P820; Li SX, 2000, NEUROL RES, V22, P171, DOI 10.1080/01616412.2000.11758605; Liu D, 1999, NEUROSCIENCE, V93, P1383, DOI 10.1016/S0306-4522(99)00278-X; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; Liu SL, 1997, BRAIN RES, V756, P160, DOI 10.1016/S0006-8993(97)00137-6; Luque JM, 2001, NEUROSCI LETT, V305, P87, DOI 10.1016/S0304-3940(01)01833-X; McAdoo DJ, 1999, EXP NEUROL, V159, P538, DOI 10.1006/exnr.1999.7166; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; McTigue DM, 2000, PROG BRAIN RES, V128, P3; Mirnics K, 2000, NEURON, V28, P53, DOI 10.1016/S0896-6273(00)00085-4; Nesic O, 2001, J NEUROTRAUM, V18, P947, DOI 10.1089/089771501750451857; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pulford BE, 1999, EXP NEUROL, V159, P114, DOI 10.1006/exnr.1999.7143; Qin ZH, 2000, MOL BRAIN RES, V80, P111, DOI 10.1016/S0169-328X(00)00147-9; Rabchevsky AG, 2000, EXP NEUROL, V164, P280, DOI 10.1006/exnr.2000.7399; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; Ringheim GE, 1995, J NEUROIMMUNOL, V63, P113, DOI 10.1016/0165-5728(95)00134-4; Sallmann S, 2000, J NEUROSCI, V20, P8637; Sapolsky RM, 2001, J NEUROCHEM, V76, P1601, DOI 10.1046/j.1471-4159.2001.00203.x; Sattler R, 2000, J MOL MED, V78, P3, DOI 10.1007/s001090000077; SCHOBITZ B, 1993, EUR J NEUROSCI, V5, P1426, DOI 10.1111/j.1460-9568.1993.tb00210.x; Schulze A, 2001, NAT CELL BIOL, V3, pE190, DOI 10.1038/35087138; Segal JL, 1997, ARCH PHYS MED REHAB, V78, P44, DOI 10.1016/S0003-9993(97)90008-3; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; Taoka Y, 1998, PROG NEUROBIOL, V56, P341, DOI 10.1016/S0301-0082(98)00049-5; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tuna M, 2001, J NEUROSURG, V95, P64, DOI 10.3171/spi.2001.95.1.0064; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; VandeMeent H, 1996, J NEUROTRAUM, V13, P741; Wada S, 1999, J NEUROSURG, V91, P98, DOI 10.3171/spi.1999.91.1.0098; Wong CS, 1998, ANESTH ANALG, V87, P605, DOI 10.1097/00000539-199809000-00021; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; Yan CH, 2000, J CEREBR BLOOD F MET, V20, P620, DOI 10.1097/00004647-200003000-00020; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; Zurita M, 2001, J NEUROSURG, V94, P257, DOI 10.3171/spi.2001.94.2.0257; J NEUROPATHOL EXP NE, V60, P422	67	86	90	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	MAY 15	2002	68	4					406	423		10.1002/jnr.10171			18	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	550AN	WOS:000175481100004	11992467	Bronze			2022-02-06	
J	Wardlaw, JM; Easton, VJ; Statham, P				Wardlaw, JM; Easton, VJ; Statham, P			Which CT features help predict outcome after head injury?	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							COMA DATA-BANK; COMPUTERIZED-TOMOGRAPHY; CLASSIFICATION; VARIABLES; LESION	Background: Information collected at baseline can be useful in predicting patient outcome after head injury. The appearance of the CT brain scan may add useful baseline information. The aim of this study was to evaluate which features on the admission CT scan might add significantly to other baseline clinical information for predicting survival in patients with head injury. Methods: Baseline CT scans were reviewed for patients with all grades of traumatic head injury in a head injury registry, in which baseline demographic and injury status and outcome at 1 year were recorded. Details from the CT scan on haemorrhage, brain swelling, and focal or diffuse damage were noted blind to clinical or outcome information and the scans classified according to the simple seven point grading (normal, mild, moderate, or severe focal injury, mild, moderate, or severe diffuse injury). An existing CT scoring system, the trauma coma databank (TCDB) classification, was also used. Logistic regression modelling was used to test the value of the CT appearance, in addition to the other baseline clinical characteristics, in predicting survival at 1 year. Results: 425 CT scans were read from patients with all severities of injury. Significant independent outcome predictors were age, Glasgow coma score (GCS), pupil reaction, presence of subarachnoid blood, and the simple grading of the overall appearance of the scan (all p<0.001). The TCDB classification was not a significant predictor of outcome. Conclusion: Age, GCS, and pupil reaction were all previously shown to be significant predictors of patient survival after head injury. A further two, easy to identify, CT scan variables are independent prognostic variables, and might help to identify patients at high risk of death at the time of admission.	Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland		Wardlaw, JM (corresponding author), Western Gen Hosp, Dept Clin Neurosci, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.		Wardlaw, Joanna M/Y-3456-2019	Wardlaw, Joanna M/0000-0002-9812-6642			ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; Hosmer D, 1989, APPL LOGISTIC REGRES; KIDO DK, 1992, RADIOLOGY, V182, P777, DOI 10.1148/radiology.182.3.1535893; LIU HM, 1995, J TRAUMA, V38, P330, DOI 10.1097/00005373-199503000-00003; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Poca MA, 1998, ACT NEUR S, V71, P27; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; TEASDALE E, 1996, NEURORADIOLOGY, V38, P192; TEASDALE G, 1992, J NEUROTRAUM, V9, pS249; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L	19	86	91	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	2002	72	2					188	192		10.1136/jnnp.72.2.188			5	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	515AA	WOS:000173472200010	11796768	Green Published, Bronze			2022-02-06	
J	Paniak, C; Reynolds, S; Toller-Lobe, G; Melnyk, A; Nagy, J; Schmidt, D				Paniak, C; Reynolds, S; Toller-Lobe, G; Melnyk, A; Nagy, J; Schmidt, D			A longitudinal study of the relationship between financial compensation and symptoms after treated mild traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; RANDOMIZED TRIAL; LITIGATION; MMPI-2	Demographic, injury-related, and symptom variables at intake, 3 months, and 12 months postinjury were compared between 50 treated adults with mild traumatic brain injury (MTBI) who were not seeking or receiving financial compensation at any time and 18 who were at each time. Compensation seekers/receivers reported symptom incidence and severity as approximately 1 SD higher at each time. The level of difference between the groups did not significantly differ across time. No demographic variables distinguished the groups. No injury-related variable other than more immediate postinjury prescription medication use was predictive of the greater symptom complaints for the patients seeking or receiving compensation. However, this medication effect did not explain away the compensation effect when medication use was co-varied in an analysis. Our study appears to be the first to examine the relationship between financial compensation and symptom report in an MTBI sample specifically treated for their condition. Our results indicate that even highly patient-rated treatment is not adequate to wash out the strong relationship between financial compensation status and symptom report after MTBI.	Glenrose Rehabil Hosp, Edmonton, AB T5G 0B7, Canada; Univ Alberta, Edmonton, AB, Canada		Paniak, C (corresponding author), Glenrose Rehabil Hosp, 10230-111 Ave, Edmonton, AB T5G 0B7, Canada.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; *AM MED ASS, 1995, AMA DRUG EV; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BINDER RL, 1991, AM J PSYCHIAT, V148, P1073; BLISHEN BR, 1987, CAN REV SOC ANTHROP, V24, P465; Cook J B, 1972, Scand J Rehabil Med, V4, P27; Deb S, 1999, AM J PSYCHIAT, V156, P374; DUSH DM, 1994, J PERS ASSESS, V62, P299, DOI 10.1207/s15327752jpa6202_10; GREIFFENSTEIN MF, 2001, J INT NEUROPSYCH SOC, V7, P181; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; LeesHaley PR, 1997, J CLIN PSYCHOL, V53, P745, DOI 10.1002/(SICI)1097-4679(199711)53:7<745::AID-JCLP13>3.3.CO;2-7; MENDELSON G, 1995, J PSYCHOSOM RES, V39, P695, DOI 10.1016/0022-3999(94)00154-W; Mild Traumatic Brain Injury Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Paniak C, 1998, J CLIN EXP NEUROPSYC, V20, P852, DOI 10.1076/jcen.20.6.852.1108; Paniak C, 2000, BRAIN INJURY, V14, P219; PANIAK CE, 1992, ARCH CLIN NEUROPSYCH, V7, P529, DOI 10.1016/0887-6177(92)90143-B; Youngjohn JR, 1997, PSYCHOL ASSESSMENT, V9, P177, DOI 10.1037/1040-3590.9.3.177	21	86	86	0	4	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2002	24	2					187	193		10.1076/jcen.24.2.187.999			7	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	549MN	WOS:000175448100006	11992201				2022-02-06	
J	Degeneffe, CE				Degeneffe, CE			Family caregiving and traumatic brain injury	HEALTH & SOCIAL WORK			English	Article						care giving; families; traumatic brain injury	HEAD-INJURY; SOCIAL SUPPORT; ADULTS; RELATIVES; STRESS; DISABILITIES; INDIVIDUALS; ADAPTATION; DISTRESS; PARENTS	This article discusses the extensive challenges faced by those providing long-term care for family members with traumatic brain injury. Areas reviewed include the nature of care needs, stress and burden experienced, and how families cope with caregiving demands. This article concludes with a discussion of what social workers can do to reduce the demands of family caregiving and subsequently, improve caregivers' quality of life.	Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA		Degeneffe, CE (corresponding author), Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA.						ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/0090-5550.39.1.29; *BRAIN INJ ASS INC, 2000, ISS BRIEF TRAUM BRAI; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Carson P, 1993, J Neurosci Nurs, V25, P165; Chwalisz K, 1996, Appl Neuropsychol, V3, P28, DOI 10.1207/s15324826an0301_5; CHWALISZ K, 1992, REHABIL PSYCHOL, V37, P189, DOI 10.1037/h0079103; Cicirelli V.G., 1982, SIBLING RELATIONSHIP, P267; CORRIGAN JD, 1999, REPORT NIH CONSENSUS, P64; Cunningham JM, 1999, HLTH CARE DISABILITY, P475; DeJong G., 1999, REPORT NIH CONSENSUS, P121; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; *FAM CAR ALL, 1999, LONGT CAR STAT; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Gilson SF, 1998, FAM SOC-J CONTEMP H, V79, P188, DOI 10.1606/1044-3894.1818; Graffi S, 1989, J APPLIED SOCIAL SCI, V13, P293; GREENBERG JS, 1993, GERONTOLOGIST, V33, P542, DOI 10.1093/geront/33.4.542; Greenberg JS, 1997, FAM RELAT, V46, P383, DOI 10.2307/585098; HALLETT JD, 1994, AM J OCCUP THER, V48, P241, DOI 10.5014/ajot.48.3.241; HARDGROVE H, 1991, HEAD INJURY FAMILY M, P25; HEPWORTH D, 1990, DIRECT SOCIAL WORK P; HOSACK KR, 1995, J HEAD TRAUMA REHAB, V10, P57, DOI 10.1097/00001199-199504000-00007; JACOB E, 1993, QUALITATIVE RES HIGH, P47; JACOBS HE, 1989, NEUROPSYCHOLOGICAL T, P297; Johnson B P, 1995, J Neurosci Nurs, V27, P113; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kosciulek JF, 1996, J REHABIL, V62, P49; KOSCIULEK JF, 1994, REHABIL PSYCHOL, V39, P215, DOI 10.1037/h0080325; KOSCIULEK JF, 1993, J REHABIL, V59, P40; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; KREUTZER JS, 1999, REPORT NIH CONSENSUS, P59; Leathem J, 1996, BRAIN INJURY, V10, P27; Lees M., 1988, REHABILITATION SEVER, P166; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVNEH H, 1997, PSYCHOL ADAPTATION C; Lynch R. T., 1986, APPL REHABILITATION, P262; MAITZ EA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199504000-00003; Mathis M, 1984, J Neurosurg Nurs, V16, P36; McKinlay WW, 1988, J HEAD TRAUMA REHAB, p[3, 64]; MINTZ MC, 1995, BRAIN INJURY, V9, P173, DOI 10.3109/02699059509008190; Moore A. D., 1991, J HEAD TRAUMA REHAB, V6, P83; MUIR CR, 1984, BEHAV ASSESSMENT REB; National Institutes of Health, 1999, REP NIH CONS DEV C R; OLSON D, 1990, FAMILY ADAPTABILITY; ORSILLO SM, 1993, J HEAD TRARMA REHABI, V8, P105; PESSAR LF, 1993, BRAIN INJURY, V7, P231, DOI 10.3109/02699059309029675; Quine S, 1993, Health Soc Work, V18, P114; Quinn P., 1995, J TEACH SOC WORK, V12, P55; Rosenthal M., 1989, TRAUMATIC BRAIN INJU, P191; Rosenthal M, 1988, J HEAD TRAUMA REHAB, V3, P42; SACHS PR, 1991, TREATING FAMILIES BR; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; SARGENT MM, 1997, NEUROPSYCHOLOGICAL T, P183; Spivack Marilyn Price, 1994, J HEAD TRAUMA REHAB, V9, P82; STEBBINS P, 1997, AUSTR J REHABILITATI, V9, P30; [No title captured]; [No title captured], DOI DOI 10.1097/00001199-198812000-00004; [No title captured]	60	86	89	0	8	NATL ASSOC SOCIAL WORKERS	WASHINGTON	750 FIRST ST, NE, STE 700, WASHINGTON, DC 20002-4241 USA	0360-7283			HEALTH SOC WORK	Health Soc. Work	NOV	2001	26	4					257	268		10.1093/hsw/26.4.257			12	Social Work	Social Science Citation Index (SSCI)	Social Work	497TT	WOS:000172472100006	11758867				2022-02-06	
J	Turkstra, LS; McDonald, S; DePompei, R				Turkstra, LS; McDonald, S; DePompei, R			Social information processing in adolescents: Data from normally developing adolescents and preliminary data from their peers with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adolescent brain injury; communication; pragmatic competence	CLOSED-HEAD-INJURY; PRAGMATIC LANGUAGE-SKILLS; ABILITY; STUDENTS; BEHAVIOR; MODEL	Objective: To assess aspects of social information processing in naturalistic conversations, using online videotape tasks. Design and Participants: The tasks were administered to 60 normally developing (ND) subjects ages 13 to 21, and 10 adolescents with traumatic brain injury (TBT). Setting: University. Main Outcome Measure: Task accuracy scores and measures of reliability, and validity Results and Conclusions: ND group scores were generally high, without significant differences by race, sex or age, TBI group scores were significantly lower than ND group scores for both emotion recognition and detection of conversation skills, The results are discussed in light of the evaluation of pragmatic competence in adolescents with TBI.	Case Western Reserve Univ, Dept Commun Sci, Cleveland, OH 44106 USA; Univ New S Wales, Sch Psychol, Kensington, NSW 2033, Australia; Univ Akron, Sch Speech Language Pathol & Audiol, Akron, OH 44325 USA		Turkstra, LS (corresponding author), Case Western Reserve Univ, Dept Commun Sci, 11206 Euclid Ave, Cleveland, OH 44106 USA.	lst2@po.cwru.edu	Turkstra, Lyn/ABC-5831-2021; McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094; Turkstra, Lyn/0000-0002-6948-6921	NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC-00163] Funding Source: Medline		Achenbach T, 1980, CHILD BEHAV CHECKLIS; ARGYLE M, 1986, INT J PSYCHOL, V21, P287, DOI 10.1080/00207598608247591; Belenky M.F., 1986, WOMENS WAYS KNOWING; BLOSSER J, 1994, PEDIAT TRAUMATIC BRA; Braun C M, 1989, Brain Inj, V3, P5, DOI 10.3109/02699058909008068; Brice A, 1996, LANG SPEECH HEAR SER, V27, P68, DOI 10.1044/0161-1461.2701.68; BROWN L, 1992, MEETING CROSSROADS; BRYAN TH, 1977, J LEARN DISABIL, V10, P501, DOI 10.1177/002221947701000808; CAVELL TA, 1990, J CLIN CHILD PSYCHOL, V19, P111, DOI 10.1207/s15374424jccp1902_2; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; CHAPMAN SB, 1997, AM J SPEECH-LANG PAT, V6, P50, DOI DOI 10.1044/1058-0360.0602.50; Cohen J, 1977, STAT POWER ANAL BEHA; COHEN S, 1997, ACQUIRED BRAIN INJUR; CONDERMAN G, 1995, LEARN DISABILITY Q, V18, P13, DOI 10.2307/1511362; COOLEY EA, 1997, STUDENTS ACQUIRED BR; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; DAMICO JS, 1993, LANG SPEECH HEAR SER, V24, P29; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; DODGE KA, 1994, CHILD DEV, V65, P1385, DOI 10.2307/1131505; Gioia GA IP, 2000, BEHAV RATING INVENTO; HARTLEY LL, 1995, NEUROGENIC COMMUNICA; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; KIM YY, 1985, INTERETHNIC COMMUNIC; Leffert JS, 1996, AM J MENT RETARD, V100, P441; Matthys W, 1999, J AM ACAD CHILD PSY, V38, P311, DOI 10.1097/00004583-199903000-00019; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; MCDONALD S, 1995, BRAIN INJURY, V9, P255, DOI 10.3109/02699059509008197; MCDONALD S, 1998, UNPUB FIELD TEST DAT; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Raven, 1938, PROGR MATRICES PERCE; Rollins, 1998, AWARENESS SOCIAL INF; SABORNIE EJ, 1994, LEARN DISABILITY Q, V17, P268, DOI 10.2307/1511124; SCHUMAKER JB, 1984, J LEARN DISABIL, V17, P422, DOI 10.1177/002221948401700708; SCHUMAKER JB, 1982, LEARN DISABILITY Q, V5, P409, DOI 10.2307/1510924; Singer BD, 1999, LANG SPEECH HEAR SER, V30, P265, DOI 10.1044/0161-1461.3003.265; Stevens J.P., 1992, APPL MULTIVARIATE ST, V2nd; TRANEL D, 1989, NEUROPSYCHOLOGIA, V27, P381, DOI 10.1016/0028-3932(89)90046-8; TURKSTRA L, IN PRESS J COMMUN DI; Turkstra LS, 1996, BRAIN INJURY, V10, P329, DOI 10.1080/026990596124359; Turkstra LS, 2000, APHASIOLOGY, V14, P349, DOI 10.1080/026870300401405; Urbina S, 1997, PSYCHOL TESTING; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; WIIG EH, 1974, PERCEPT MOTOR SKILL, V38, P239, DOI 10.2466/pms.1974.38.1.239; WINDSOR J, 1995, LANGUAGE INTERVENTIO; YEATES KO, 1989, DEV REV, V9, P64, DOI 10.1016/0273-2297(89)90024-5; Ylvisaker M. E., 1998, TRAUMATIC BRAIN INJU	52	86	86	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	2001	16	5					469	483		10.1097/00001199-200110000-00006			15	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	483JF	WOS:000171631700006	11574042				2022-02-06	
J	Suh, DY; Davis, PC; Hopkins, KL; Fajman, NN; Mapstone, TB				Suh, DY; Davis, PC; Hopkins, KL; Fajman, NN; Mapstone, TB			Nonaccidental pediatric head injury: Diffusion-weighted imaging findings	NEUROSURGERY			English	Article						child abuse; diffusion-weighted imaging; magnetic resonance imaging; traumatic brain injury	TRAUMATIC BRAIN INJURY; FOCAL CEREBRAL-ISCHEMIA; SHAKEN IMPACT SYNDROME; YOUNG-CHILDREN; T2-WEIGHTED MRI; INFANTS; RATS; HISTOPATHOLOGY; SPECTROSCOPY; DAMAGE	OBJECTIVE: Diffusion-weighted imaging (DWI) reveals nonhemorrhagic posttraumatic infarction hours to days before conventional computed tomographic scanning or magnetic resonance imaging (MRI). We evaluated the diagnostic utility of DWI in children with nonaccidental head trauma. METHODS: The medical records and imaging examinations obtained between January 1998 and May 2000 for all children less than 2 years of age with presumed or suspected nonaccidental head injury were reviewed retrospectively. Twenty children who had undergone DWI within 5 days of presentation were included in the study. Computed tomographic scans, conventional MRI sequences, and DWI combined with apparent diffusion coefficient (ADC) maps were evaluated. RESULTS: Eleven girls and nine boys (median age, 5 mo) were studied. Eighteen children had presumed nonaccidental head trauma, and two children had suspected nonaccidental head trauma. Of the 18 children with presumed nonaccidental trauma, 16 (89%) demonstrated abnormalities on DWI/ADC, as compared with neither of the two children with suspected nonaccidental trauma. In 13 (81%) of 16 positive cases, DWI revealed more extensive brain injury than was demonstrated on conventional MRI sequences or showed injuries not observed on conventional MRI. DWI combined with ADC maps allowed better delineation of the extent of white matter injury. DWI/ADC abnormalities in the nonaccidental head-injured children were likely to involve posterior aspects of the cerebral hemispheres, with relative sparing of the frontal and temporal poles. Severity on DWI correlated significantly with poor outcome (P < 0.005). CONCLUSION: DWI has broad applications in the early detection of infarction in children with nonaccidental head injury and enhances the sensitivity of conventional MRI. In the patients in this study, early DWI provided an indicator of severity that was more complete than any other imaging modality. The use of DWI may help to identify children at high risk for poor outcome and to guide management decisions.	Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA 30322 USA; Childrens Hosp Atlanta Egleston, Dept Pediat, Atlanta, GA USA; Childrens Hosp Atlanta Egleston, Dept Neurosurg, Atlanta, GA USA; Childrens Hosp Atlanta Egleston, Dept Radiol, Atlanta, GA USA		Suh, DY (corresponding author), Care Of Sherry A Ballenger, Emory Univ, Dept Neurosurg, 1365-B Clifton Rd,NE,Suite 6400, Atlanta, GA 30322 USA.						Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Barzo P, 1997, ACT NEUR S, V70, P115; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; Bruce DA, 1996, NEUROSURGERY, P2709; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; CHIEN D, 1992, AM J NEURORADIOL, V13, P1097; Dashti SR, 1999, PEDIATR NEUROSURG, V31, P302, DOI 10.1159/000028880; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; Gilles EE, 1998, PEDIATR NEUROL, V19, P119, DOI 10.1016/S0887-8994(98)00038-1; GILLILAND MG, 1996, FORENSIC SCI INT, V68, P117; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P1328, DOI 10.1097/00003246-199309000-00016; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; Kidwell CS, 1999, STROKE, V30, P1174, DOI 10.1161/01.STR.30.6.1174; KLEINMAN PK, 1987, DIAGNOSTIC IMAGING C, P159; KNIGHT RA, 1994, STROKE, V25, P1252, DOI 10.1161/01.STR.25.6.1252; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Li FH, 1999, ANN NEUROL, V46, P333, DOI 10.1002/1531-8249(199909)46:3<333::AID-ANA9>3.0.CO;2-X; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Lutsep HL, 1997, ANN NEUROL, V41, P574, DOI 10.1002/ana.410410505; MINEMATSU K, 1992, STROKE, V23, P1304, DOI 10.1161/01.STR.23.9.1304; MINTOROVITCH J, 1991, MAGNET RESON MED, V18, P39, DOI 10.1002/mrm.1910180106; MOSELEY ME, 1990, RADIOLOGY, V176, P439, DOI 10.1148/radiology.176.2.2367658; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; Neumann-Haefelin T, 2000, STROKE, V31, P1965, DOI 10.1161/01.STR.31.8.1965; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; Ricci PE, 1999, AM J NEURORADIOL, V20, P1535; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; Sane SM, 2000, PEDIATRICS, V105, P1345; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; WELCH KMA, 1995, STROKE, V26, P1983, DOI 10.1161/01.STR.26.11.1983; Zimmerman R A, 1994, Neuroimaging Clin N Am, V4, P349	43	86	90	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	AUG	2001	49	2					309	318		10.1097/00006123-200108000-00011			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	457MQ	WOS:000170141700035	11504106				2022-02-06	
J	Philips, MF; Mattiasson, G; Wieloch, T; Bjorklund, A; Johansson, BB; Tomasevic, G; Martinez-Serrano, A; Lenzlinger, PM; Sinson, G; Grady, MS; McIntosh, TK				Philips, MF; Mattiasson, G; Wieloch, T; Bjorklund, A; Johansson, BB; Tomasevic, G; Martinez-Serrano, A; Lenzlinger, PM; Sinson, G; Grady, MS; McIntosh, TK			Neuroprotective and behavioral efficacy of nerve growth factor-transfected hippocampal progenitor cell transplants after experimental traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						stem cell; growth factor; traumatic brain injury; transplantation; neuroprotection; gene therapy; rat	FETAL MESENCEPHALIC TISSUE; CHOLINERGIC NEURON ATROPHY; FLUID-PERCUSSION INJURY; FACTOR GENE-TRANSFER; RAT BASAL FOREBRAIN; LONG-TERM SURVIVAL; ADULT-RAT; PARKINSONS-DISEASE; ASTROCYTES PROMOTE; NEURITE OUTGROWTH	Object. Immortalized neural progenitor cells derived from embryonic rat hippocampus (HiB5), were transduced ex vivo with the gene for mouse nerve growth factor (NGF) to secrete NGF (NGF-HiB5) at 2 ng/hr/10(5) cells in culture. Methods. Fifty-nine male Wistar rats weighing 300 to 370 g each were anesthetized with 60 mg/kg sodium pentobarbital and subjected to lateral fluid-percussion brain injury of moderate severity (2.3-2.4 atm, 34 rats) or sham injury (25 rats). At 24 hours postinjury, 2 mul (150,000 cells/mul) of [H-3]thymidine-labeled NGF-HiB5 cells were transplanted stereotactically into three individual sites in the cerebral cortex adjacent to the injury site (14 rats). Separate groups of brain-injured rats received nontransfected (naive [n])-HiB5 cells (12 animals) or cell suspension vehicle (eight animals). One week postinjury, animals underwent neurological evaluation for motor function and cognition (Morris water maze) and were killed for histological, autoradiographic, and immunocytochemical analysis. Viable HiB5 cell grafts were identified in all animals, together with reactive microglia and macrophages located throughout the periinjured parenchyma and grafts (OX-42 immunohistochemistry). Brain-injured animals transplanted with either NGF-HiB5 or n-HiB5 cells displayed significantly improved neuromotor function (p < 0.05) and spatial learning behavior (p < 0.005) compared with brain-injured animals receiving microinjections of vehicle alone. A significant reduction in hippocampal CA3 cell death was observed in brain-injured animals receiving transplants of NGF-HiB5 cells compared with those receiving n-HiB5 cells or vehicle (p < 0.025). Conclusions. This study demonstrates that immortalized neural stem cells that have been retrovirally transduced to produce NGF can markedly improve cognitive and neuromotor function and rescue hippocampal CA3 neurons when transplanted into the injured brain during the acute posttraumatic period.	Univ Penn, Dept Neurosurg, Sch Med, Philadelphia, PA 19144 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Univ Lund, Dept Physiol & Neurosci, Lund, Sweden; Univ Lund Hosp, Div Expt Brain Res, S-22185 Lund, Sweden; Autonomous Univ Madrid, Ctr Mol Biol Severo Ochoa, Madrid, Spain		McIntosh, TK (corresponding author), Univ Penn, Dept Neurosurg, Sch Med, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19144 USA.		Bjorklund, Anders/ABA-1326-2020; Lenzlinger, Philipp/A-3822-2008; Bjorklund, Geir/B-7319-2014; Martinez-Serrano, Alberto/J-8146-2014	Bjorklund, Geir/0000-0003-2632-3935; Bjorklund, Anders/0000-0002-5676-6203; Martinez Serrano, Alberto/0000-0003-3927-6699; Wieloch, Tadeusz/0000-0002-7669-2520	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM74690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803] Funding Source: NIH RePORTER		Andsberg G, 1998, EUR J NEUROSCI, V10, P2026, DOI 10.1046/j.1460-9568.1998.00214.x; BORLONGAN CV, 1995, J NEUROSCI, V15, P5372; BRADBURY EJ, 1995, NEUROSCIENCE, V65, P955, DOI 10.1016/0306-4522(94)00540-L; BRUCKNER MK, 1992, NEUROSCI LETT, V141, P251, DOI 10.1016/0304-3940(92)90906-N; CONNER JM, 1992, J COMP NEUROL, V319, P454, DOI 10.1002/cne.903190310; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FRIM DM, 1993, J NEUROSURG, V78, P267, DOI 10.3171/jns.1993.78.2.0267; FRODL EM, 1994, BRAIN RES, V647, P286, DOI 10.1016/0006-8993(94)91328-5; Goss JR, 1997, EXP NEUROL, V146, P291, DOI 10.1006/exnr.1997.6515; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; GRABOWSKI M, 1993, ANN NEUROL, V34, P362, DOI 10.1002/ana.410340310; HADANI M, 1992, J NEUROTRAUM, V9, P107, DOI 10.1089/neu.1992.9.107; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; KESSLAK JP, 1988, BRAIN RES, V454, P347, DOI 10.1016/0006-8993(88)90836-0; KESSLAK JP, 1986, EXP NEUROL, V92, P377, DOI 10.1016/0014-4886(86)90089-0; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; Krobert K, 1997, EXP NEUROL, V145, P511, DOI 10.1006/exnr.1997.6483; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LINDVALL O, 1994, ANN NEUROL, V35, P172, DOI 10.1002/ana.410350208; LINDVALL O, 1997, NEUROREPORT, V8, P3; Lundberg C, 1996, NEUROREPORT, V7, P847, DOI 10.1097/00001756-199603220-00002; Lundberg C, 1997, EXP NEUROL, V145, P342, DOI 10.1006/exnr.1997.6503; Martinez-Serrano A, 1998, P NATL ACAD SCI USA, V95, P1858, DOI 10.1073/pnas.95.4.1858; MartinezSerrano A, 1996, P NATL ACAD SCI USA, V93, P6355, DOI 10.1073/pnas.93.13.6355; MARTINEZSERRANO A, 1995, NEURON, V15, P473, DOI 10.1016/0896-6273(95)90051-9; MartinezSerrano A, 1997, TRENDS NEUROSCI, V20, P530, DOI 10.1016/S0166-2236(97)01119-3; MartinezSerrano A, 1996, J NEUROSCI, V16, P4604; MARTINEZSERRANO A, 1995, J NEUROSCI, V15, P5668; Mattiasson GJ, 2000, J NEUROSCI METH, V95, P75, DOI 10.1016/S0165-0270(99)00162-4; Mattsson B, 1997, STROKE, V28, P1225, DOI 10.1161/01.STR.28.6.1225; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; MCKEON RJ, 1995, EXP NEUROL, V136, P32, DOI 10.1006/exnr.1995.1081; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; OHLSSON AL, 1995, STROKE, V26, P644, DOI 10.1161/01.STR.26.4.644; Olby NJ, 1996, J NEUROCYTOL, V25, P481, DOI 10.1007/BF02284817; Onizuka K, 1996, EXP NEUROL, V137, P324, DOI 10.1006/exnr.1996.0033; Paxinos G, 1997, RAT BRAIN STEREOTAXI; Peschanski M, 1996, NEUROSCIENCE, V71, P899, DOI 10.1016/0306-4522(95)00575-7; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; ROTHWELL NJ, 1995, INT J DEV NEUROSCI, V13, P179, DOI 10.1016/0736-5748(95)00018-C; RUDGE JS, 1990, J NEUROSCI, V10, P3594; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SCHUMACHER JM, 1991, NEUROSCIENCE, V45, P561, DOI 10.1016/0306-4522(91)90271-O; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Sinson G, 1996, Clin Neurosurg, V43, P219; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; SMITH GM, 1990, DEV BIOL, V138, P377, DOI 10.1016/0012-1606(90)90204-V; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; Snyder Evan Y., 1994, Current Opinion in Neurobiology, V4, P742, DOI 10.1016/0959-4388(94)90018-3; Snyder EY, 1998, NEUROSCIENTIST, V4, P408, DOI 10.1177/107385849800400613; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; Soares HD, 1995, J NEUROSCI, V15, P8223; Sorensen JC, 1996, EXP NEUROL, V138, P227, DOI 10.1006/exnr.1996.0061; SPENCER DD, 1992, NEW ENGL J MED, V327, P1541, DOI 10.1056/NEJM199211263272201; Spenger C, 1996, EXP BRAIN RES, V112, P47; Trojanowski JQ, 1997, EXP NEUROL, V144, P92, DOI 10.1006/exnr.1996.6393; VICARIOABEJON C, 1995, J NEUROSCI, V15, P6351; WANG JJ, 1995, NEUROSCIENCE, V65, P973, DOI 10.1016/0306-4522(94)00519-B; Wenning GK, 1997, ANN NEUROL, V42, P95, DOI 10.1002/ana.410420115; WUNDERLICH G, 1994, GLIA, V10, P49, DOI 10.1002/glia.440100107; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415	74	86	108	0	8	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	2001	94	5					765	774		10.3171/jns.2001.94.5.0765			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	429NV	WOS:000168524600011	11354408				2022-02-06	
J	Fasotti, L; Kovacs, F; Eling, PATM; Brouwer, WH				Fasotti, L; Kovacs, F; Eling, PATM; Brouwer, WH			Time pressure management as a compensatory strategy training after closed head injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							ANTICIPATORY BEHAVIOR DEFICITS; PERFORMANCE; ATTENTION; BRAIN	Following severe closed head injury, deficits in speed of information processing are common. As a result, many head-injured patients experience a feeling of "information overload" in daily tasks that once were relatively easy. Many remedial programmes have been designed that treat different aspects of attention (often including mental speed requirements) by repetitive exercises. In the present study, a different approach to slow information processing has been taken, namely Time Pressure Management (TPM). TPM consists of a set of alternative cognitive strategies that allow head-injured patients in real-life tasks to compensate for their mental slowness. In a randomised pre-training vs. post-training vs. follow-up group study, the effectiveness of TPM training was compared with concentration training in which verbal instruction was the key element. The results indicate that specific TPM strategies are learned by the experimental subjects but that both treatments improve task performance significantly for an information intake task. TPM, however, produces greater gains than concentration training and also appears to generalise to other measures of speed and memory function.	St Maartensklin Res, NL-6500 GM Nijmegen, Netherlands; Rijnlands Zeehospitium, Katwijk Aan Zee, Netherlands; Univ Nijmegen, Dept Comparat & Physiol Psychol, Nijmegen, Netherlands; Univ Groningen, Dept Neuropsychol & Gerontol, Groningen, Netherlands				Eling, Paul/D-5786-2012				BLEIBERG J, 1985, INT J CLIN NEUROPSYC, V7, P153; BROUWER WH, 1985, THESIS STATE U GRONI; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [DOI 10.1097/00001199-198909000-00008, 10.1097/00001199-198909000-00008]; FREEDMAN PE, 1987, J NEUROL NEUROSUR PS, V50, P398, DOI 10.1136/jnnp.50.4.398; GRONWALL DMA, 1981, J NEUROL NEUROSUR PS, V44, P880; Meichenbaum, 1977, COGNITIVE BEHAV MODI; Meichenbaum D., 1980, HELPING PEOPLE CHANG; MELAMED S, 1985, SCAND J REHABIL MED, P16; MICHON JA, 1979, SUMM REP WORKSH TRAF; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; Ponsford JL, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; PONSFORD JL, 1990, COGNITIVE REHABILITA, P50; ROBERTSON I, 1990, APHASIOLOGY, V4, P381, DOI 10.1080/02687039008249090; RUSSEL WR, 1971, TRAUMATIC AMNESIAS; SCHMITTEREDGECOMBE ME, 1992, J CLIN EXP NEUROPSYC, V14, P717, DOI 10.1080/01688639208402858; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1992, NEUROPSYCHOL REHABIL, P183; VANZOOMEREN AH, 1981, THESIS STATE U GRONI; Ylvisaker M., 1987, COMMUNITY REENTRY HE, P137	23	86	87	0	20	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JAN	2000	10	1					47	65		10.1080/096020100389291			19	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	290TT	WOS:000085694500004					2022-02-06	
J	Gordon, WA; Haddad, L; Brown, M; Hibbard, MR; Sliwinski, M				Gordon, WA; Haddad, L; Brown, M; Hibbard, MR; Sliwinski, M			The sensitivity and specificity of self-reported symptoms in individuals with traumatic brain injury	BRAIN INJURY			English	Article							MILD HEAD-INJURY; BASE RATES; ETIOLOGY	In this study, self-reported symptoms (cognitive, physical, behavioural/affective) from the TIRR Symptom Checklist are compared across six panels: 135 individuals with mild TBI, 275 with moderate/severe TBI, 287 with no disability, 104 with spinal cord injury:, 197 who are HIV positive and 107 who had undergone liver transplantation. Participants with TBI and SCI were at least 1 year post injury. Individuals with TBI reported significantly more symptoms than other panels. Symptom repot ts in the: TBI panels were independent of demographic variables (gender, education, income, ethnicity, age), as well as time since injury and depression Five of the 67 symptoms were found to be sensitive/specific to TBI in general; 25 symptoms were sensitive/specific to mild TBI (23 were cognitive, one physical and one behavioural/affective). Implications of these results in terms of current debates about the 'reality' of symptom reports in individuals with mild TBI are discussed, as well as implications for using symptom checklists for TBI screening.	CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; Albert Einstein Coll Med, New York, NY USA		Gordon, WA (corresponding author), CUNY Mt Sinai Sch Med, Dept Rehabil Med, Box 1240,1425 Madison Ave, New York, NY 10029 USA.		; Carneiro D'Albuquerque, Luiz Augusto/A-8812-2013	Haddad, Lisa/0000-0002-7631-6760; Carneiro D'Albuquerque, Luiz Augusto/0000-0001-7607-7168			Beck AT, 1987, BECK DEPRESSION INVE; BINDER LM, 1997, J CLIN EXPT NEUROPSY, V5, P361; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; GORDON W A, 1991, Archives of Physical Medicine and Rehabilitation, V72, P798; GORDON WA, 1998, J HEAD TRAUMA REHAB, V13, P17; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Lehmkuhl D, 1988, TIRR SYMPTOM CHECKLI; Marsh NV, 1991, NEUROPSYCHOLOGY, V5, P107, DOI 10.1037/0894-4105.5.2.107; MARSH NV, 1995, BRAIN INJURY, V9, P553, DOI 10.3109/02699059509008214; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; *NEW YORK RES TRAI, 1994, QUAL LIF INT HLTH IN; Reitan RM, 1999, ARCH CLIN NEUROPSYCH, V14, P191, DOI 10.1016/S0887-6177(98)00012-2; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; VONZOMEREN AH, 1984, CLOSED HEAD INJURY P, P74; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; 1997, SPSS WINDOWS VERSION	21	86	86	0	7	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2000	14	1					21	33		10.1080/026990500120907			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	274CY	WOS:000084747200004	10670659				2022-02-06	
J	Quinn, SM; Walters, WM; Vescovi, AL; Whittemore, SR				Quinn, SM; Walters, WM; Vescovi, AL; Whittemore, SR			Lineage restriction of neuroepithelial precursor cells from fetal human spinal cord	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						stem cells; neurons; astrocytes; differentiation; human spinal cord	CENTRAL-NERVOUS-SYSTEM; NEURAL PROGENITOR CELLS; FIBROBLAST GROWTH-FACTOR; ADULT-MOUSE BRAIN; STEM-CELLS; NEURONAL DIFFERENTIATION; TRANSPLANTATION; RAT; SURVIVAL; CULTURE	In the presence of epidermal growth factor (EGF) and/or fibroblast growth factor 2 (FGF2), neuroepithelial precursor cells from dissociated fetal human spinal cord are mitotically active and form free-floating spheres of undifferentiated cells, Proliferating cells were obtained in approximately 40% of preparations with each mitogen, were immunoreactive for the intermediate filament nestin, and did not express neuronal- or glial-specific markers, Early passage neuroepithelial precursor cells were pluripotent and differentiated into neurons expressing MAP2a,b, NF-M, and Tall, and GFAP-positive astrocytes; however, oligodendrocytes were never seen. As the cells were passaged from PO to P4, the percentage of differentiating neurons significantly decreased and the prevalence of astrocytes significantly increased. While the majority of cell populations from individual preparations stopped proliferating between 3 and 6 passages, two expanding cell lines have been successfully expanded in EGF and FGF2 for over 25 passages and have been maintained in culture for over one year. These cells express nestin and not other cell-specific lineage markers. When differentiated, these neuroepithelial cell lines differentiate only into astrocytes, showing no expression of any neuronal marker. These data suggest that continued passage under these conditions preferentially selects for spinal cord neural precursors that are restricted to the astrocytic lineage. Despite the lineage restriction of later passage cell populations, these results provide a rationale for future investigation into the lineage potential of these cells in vivo following transplantation into the adult CNS, potentially as a therapeutic approach. for traumatic injury and neurodegenerative disease. J. Neurosci. Res. 57:590-602, 1999, (C) 1999 Wiley-Liss, Inc.	Univ Louisville, Sch Med, Dept Neurol Surg, Louisville, KY 40202 USA; Univ Miami, Sch Med, Miami Project, Miami, FL USA; Univ Miami, Sch Med, Dept Biol, Miami, FL USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA; Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA; Natl Neurol Inst, Milan, Italy		Whittemore, SR (corresponding author), Univ Louisville, Sch Med, Dept Neurol Surg, 210 E Gray St,Suite 1102, Louisville, KY 40202 USA.	swhittemore@louisville.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R55NS026887, R01NS026887] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26887] Funding Source: Medline		BAYER SA, 1993, NEUROTOXICOLOGY, V14, P83; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BREWER GJ, 1989, BRAIN RES, V494, P65, DOI 10.1016/0006-8993(89)90144-3; Brustle O, 1998, NAT BIOTECHNOL, V16, P1040, DOI 10.1038/3481; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; DELOULME JC, 1991, J NEUROSCI RES, V29, P499, DOI 10.1002/jnr.490290410; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; FRIEDMAN B, 1989, GLIA, V2, P380, DOI 10.1002/glia.440020510; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; Gage FH, 1998, CURR OPIN NEUROBIOL, V8, P671, DOI 10.1016/S0959-4388(98)80098-6; Ghosh MM, 1995, BIOREMED SER, V3, P15; Gritti A, 1996, J NEUROSCI, V16, P1091; Hammang JP, 1997, EXP NEUROL, V147, P84, DOI 10.1006/exnr.1997.6592; HOFFER BJ, 1991, TRENDS NEUROSCI, V14, P384, DOI 10.1016/0166-2236(91)90168-T; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Kalyani A, 1997, DEV BIOL, V186, P202, DOI 10.1006/dbio.1997.8592; KAWAMOTO JC, 1986, BRAIN RES, V384, P84, DOI 10.1016/0006-8993(86)91222-9; KILPATRICK TJ, 1994, NEUROSCI LETT, V181, P129, DOI 10.1016/0304-3940(94)90576-2; KILPATRICK TJ, 1993, NEURON, V10, P255, DOI 10.1016/0896-6273(93)90316-J; Kopyov OV, 1998, EXP NEUROL, V149, P97, DOI 10.1006/exnr.1997.6685; LIU RH, 1999, IN PRESS EXP NEUROL; Lundberg C, 1996, NEUROBIOL DIS, V3, P33, DOI 10.1006/nbdi.1996.0004; MayerProschel M, 1997, NEURON, V19, P773, DOI 10.1016/S0896-6273(00)80960-5; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Moyer MP, 1997, TRANSPLANT P, V29, P2040, DOI 10.1016/S0041-1345(97)00221-2; Onifer SM, 1997, CELL TRANSPLANT, V6, P327, DOI 10.1016/S0963-6897(97)00037-7; Onifer SM, 1997, TRANSPL P, V29, P2221, DOI 10.1016/S0041-1345(97)00308-4; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; RAFF MC, 1978, NATURE, V274, P813, DOI 10.1038/274813a0; Rao MS, 1997, DEV BIOL, V188, P48, DOI 10.1006/dbio.1997.8597; RAY J, 1994, J NEUROSCI, V14, P3548; RAY J, 1994, ABSTS AM SOC NEUR, V20, P670; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; RICHARDS LJ, 1992, P NATL ACAD SCI USA, V89, P8591, DOI 10.1073/pnas.89.18.8591; SABATE O, 1995, NAT GENET, V9, P256, DOI 10.1038/ng0395-256; Shihabuddin LS, 1997, EXP NEUROL, V148, P577, DOI 10.1006/exnr.1997.6697; Shihabuddin LS, 1996, EXP NEUROL, V139, P61, DOI 10.1006/exnr.1996.0081; STREILEIN JW, 1988, INT J DEV NEUROSCI, V6, P497; Studer L, 1998, NAT NEUROSCI, V1, P290, DOI 10.1038/1105; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0; Svendsen CN, 1996, EXP NEUROL, V137, P376, DOI 10.1006/exnr.1996.0039; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998; Weiss S, 1996, J NEUROSCI, V16, P7599; Weiss S, 1996, TRENDS NEUROSCI, V19, P387, DOI 10.1016/S0166-2236(96)10035-7; WHITE LA, 1994, J NEUROSCI, V14, P6744; Whittemore SR, 1996, MOL NEUROBIOL, V12, P13, DOI 10.1007/BF02740745; WHITTEMORE SR, 1993, BRAIN RES, V615, P27, DOI 10.1016/0006-8993(93)91111-5; WHITTEMORE SR, 1993, INT J DEV NEUROSCI, V11, P755, DOI 10.1016/0736-5748(93)90064-K; WIDNER H, 1988, BRAIN RES REV, V13, P287, DOI 10.1016/0165-0173(88)90010-0; WIDNER H, 1992, NEW ENGL J MED, V327, P1556, DOI 10.1056/NEJM199211263272203; WIRTH ED, 1998, ABST AM SOC NEUR, V24, P70	54	86	91	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	SEP 1	1999	57	5					590	602		10.1002/(SICI)1097-4547(19990901)57:5<590::AID-JNR2>3.0.CO;2-X			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	229WF	WOS:000082218200002	10462684				2022-02-06	
J	Feickert, HJ; Drommer, S; Heyer, R				Feickert, HJ; Drommer, S; Heyer, R			Severe head injury in children: Impact of risk factors on outcome	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						head injury; brain damage; trauma; child; seizure; intracranial pressure; brain swelling edema; skull fracture	TRAUMATIC BRAIN INJURY; COMA-DATA-BANK; ACUTE SUBDURAL-HEMATOMA; COMPUTERIZED-TOMOGRAPHY; PEDIATRIC TRAUMA; BLUNT TRAUMA; ADULTS; ADOLESCENTS; LESION; SCALE	Background: Outcome after severe head injury has been shown in some studies to be more favorable in children than in adults. Mortality rates reported range between 20% and 40% for children. Only contradicting data are available regarding the impact of trauma modalities on long-term outcome, or the relative influence of head fractures, intracranial hemorrhages, and brain edema on survival or neurologic sequelae in children. Methods: A retrospective study in a tertiary care facility of long-term outcome of children after severe head injury, and analysis of risk factors for poor outcome. All children up to 16 years of age with severe head injury (Glasgow Coma Scale [GCS] score less than or equal to 8), which have been treated in the pediatric intensive care unit from 1977 until 1994 in a single institution. Results: A total of 150 children with severe head injury (GCS score less than or equal to 8) were treated, 92 of them (61.3%) had traffic-related injuries, The median age was 6.6 years (SD +/- 3.6), There were 96 boys (64%) and 54 girls (36%), Sixty-five children (43.3%) had skull fractures, 87 patients (58.0%) developed an intracranial hemorrhage, and 79 patients (52.7%) developed a diffuse brain swelling/edema visible in computed tomographic scans within 72 hours after trauma. Of 150 children treated, 33 died (22%), In most cases, death was related to the development of secondary brain edema. Fifty-nine children (39.3%) had severe neurologic impairments at the time of discharge, The most significant risk factors for adverse outcome, shown by multivariate analysis, were primary areflexia and secondary brain edema. The risk for development of brain edema and poor prognosis was well predicted by the GCS score. Conclusion: The overall death rate in this study of children with severe head injury was low (22%) compared with other studies, However, the incidence of severe neurologic impairment at discharge remained high. The major risks for death or neurologic impairment were primary areflexia and the development of secondary brain swelling/edema, indicated by a low GCS score.	MHH, Kinderklin, D-30623 Hannover, Germany		Feickert, HJ (corresponding author), MHH, Kinderklin, D-30623 Hannover, Germany.						ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; AOKI N, 1984, J NEUROSURG, V61, P273, DOI 10.3171/jns.1984.61.2.0273; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BULLOCK R, 1993, SCHWEIZ MED WSCHR, V123, P449; COSTER WJ, 1994, AM J OCCUP THER, V48, P211, DOI 10.5014/ajot.48.3.211; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; EICHELBERGER MR, 1988, J TRAUMA, V28, P430, DOI 10.1097/00005373-198804000-00002; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Gjerris F, 1986, Acta Neurochir Suppl (Wien), V36, P155; HALLER JA, 1983, JAMA-J AM MED ASSOC, V249, P47, DOI 10.1001/jama.249.1.47; JACOBI G, 1982, PADIAT FORTBILD PRAX, V55, P76; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JAIMOVICH DG, 1991, J TRAUMA, V31, P196; KALFF R, 1989, CHILD NERV SYST, V5, P156, DOI 10.1007/BF00272118; Kazan S, 1997, ACTA NEUROCHIR, V139, P295, DOI 10.1007/BF01808824; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; KRAUS JF, 1987, PEDIATRICS, V79, P501; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; LEVI L, 1991, BRIT J NEUROSURG, V5, P617, DOI 10.3109/02688699109002885; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1992, NEUROSURGERY, V31, P1117, DOI 10.1227/00006123-199212000-00021; Lieb L, 1991, Anaesthesiol Reanim, V16, P118; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MAZUREK AJ, 1994, J ACCID EMERG MED, V11, P9; MAZZA C, 1982, ACTA NEUROCHIR, V65, P67, DOI 10.1007/BF01405443; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; MICHAUD LJ, 1993, PEDIATR CLIN N AM, V40, P553; MILLER JD, 1994, LANCET, V344, P421; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; Pospiech J, 1993, Aktuelle Traumatol, V23, P1; Quigley MR, 1997, J TRAUMA, V42, P7, DOI 10.1097/00005373-199701000-00003; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; RIVARA FP, 1993, PEDIATRICS, V92, P61; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; RUIJS MBM, 1993, EUR J PEDIATR, V152, P844, DOI 10.1007/BF02073384; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SERVADEI F, 1993, SURG NEUROL, V39, P269, DOI 10.1016/0090-3019(93)90003-J; SNYDER CL, 1990, J TRAUMA, V30, P1239, DOI 10.1097/00005373-199010000-00008; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; TEPAS JJ, 1990, J PEDIATR SURG, V25, P92, DOI 10.1016/S0022-3468(05)80170-8; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; WAGSTYL J, 1987, J PEDIATR SURG, V22, P127, DOI 10.1016/S0022-3468(87)80427-X; WARD JD, 1994, PEDIATR NEUROSURG, V20, P183, DOI 10.1159/000120784; WESSON DE, 1989, J TRAUMA, V29, P589, DOI 10.1097/00005373-198905000-00008; Zukiel R, 1994, Neurol Neurochir Pol, V28, P201	55	86	90	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	1999	47	1					33	38		10.1097/00005373-199907000-00008			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	216ZQ	WOS:000081474700006	10421183				2022-02-06	
J	Lewine, JD; Davis, JT; Sloan, JH; Kodituwakku, PW; Orrison, WW				Lewine, JD; Davis, JT; Sloan, JH; Kodituwakku, PW; Orrison, WW			Neuromagnetic assessment of pathophysiologic brain activity induced by minor head trauma	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							CONCUSSION; MR	BACKGROUND AND PURPOSE: Patients with mild traumatic brain injury (TBI) often show significant neuropsychological dysfunction despite the absence of abnormalities on traditional neuroradiologic examinations or EEG, Our objective was to determine if magnetic source imaging (MSI), using a combination of MR imaging and magnetoencephalography (MEG), is more sensitive than EEG and MR imaging in providing objective evidence of minor brain injury. METHODS: Four subject groups were evaluated with MR, MSI, and EEG, Group A consisted of 20 neurologically normal control subjects without histories of head trauma, Group B consisted of 10 subjects with histories of mild head trauma but complete recovery, Group C consisted of 20 subjects with histories of mild head injury and persistent postconcussive symptoms. The 15 subjects included in group D underwent repeat examinations at an interval of 2 to 4 months. RESULTS: No MR abnormalities were seen in the normal control group or the asymptomatic group, but five (20%) of the patients with persistent postconcussive symptoms had abnormal MR findings. EEG was abnormal for one subject (5%) from the normal control group, one (10%) from the asymptomatic group, and five (20%) from the group with persistent postconcussive symptoms, MSI was abnormal for one subject (5%) from the normal control group, one (10%) from the asymptomatic group, and 13 (65%) from the group with persistent postconcussive symptoms, There was a direct correlation between symptom resolution and MSI findings for the symptomatic head trauma group, CONCLUSION: MSI indicated brain dysfunction in significantly more patients with postconcussive symptoms than either EEG or MR imaging (P <.01). The presence of excessive abnormal low-frequency magnetic activity provides objective evidence of brain injury in patients with postconcussive syndromes and correlates well with the degree of symptomatic recovery.	New Mexico Reg Fed Med Ctr, Albuquerque, NM USA; Univ New Mexico, Sch Med, Dept Radiol, Albuquerque, NM 87131 USA; Univ New Mexico, Sch Med, Dept Psychol, Albuquerque, NM 87131 USA; Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA; Univ New Mexico, Sch Med, Dept Psychiat, Albuquerque, NM 87131 USA; St Josephs Med Ctr, St Josephs Rehabil Ctr, Albuquerque, NM USA		Lewine, JD (corresponding author), Univ Utah, Sch Med, Dept Radiol, Med Ctr 1A71, 50 N Med Dr, Salt Lake City, UT 84132 USA.						BAKER SP, 1989, JAMA-J AM MED ASSOC, V262, P2248; BENZEL EC, 1993, NEUROSURGERY, V33, P252, DOI 10.1227/00006123-199308000-00011; Gallen CC, 1997, EPILEPSIA, V38, P452, DOI 10.1111/j.1528-1157.1997.tb01735.x; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; HARI R, 1986, CRIT REV BIOMED ENG, V14, P93; HESSELINK JR, 1988, AM J ROENTGENOL, V150, P1133; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; HUGHES JR, 1977, J NEUROL, V217, P79, DOI 10.1007/BF00312921; LENINGER B, 1990, J NEUROL NEUROSUR PS, V53, P293; Levin HS., 1982, NEUROBEHAVIORAL CONS; Lewine JD, 1995, STUD APPL ELECTROMAG, V7, P55; LEWINE JD, 1997, J NEUROSURG; Lewine JD, 1990, NONINVASIVE TECHNIQU; LEWINE JD, 1996, NEUROIMAGING EPILEPS, P193; McNemar Q, 1947, PSYCHOMETRIKA, V12, P153, DOI 10.1007/BF02295996; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Ruff R. M., 1989, NEUROPSY NEUROPSY BE, V2, P103; RUTHERFORD WH, 1977, LANCET, V1, P1; Schwartz BJ, 1995, STUD APPL ELECTROMAG, V7, P66; SHOENHUBER R, 1982, NEUROBEHAVIORAL CONS, P142; *US OFF SCI TECHN, 1991, MAX HUM POT DEC BRAI; Vieth J B, 1990, Adv Neurol, V54, P261; WILLIAMSON SI, 1987, HDB ELECTROENCEPHALO, V1; [No title captured]; [No title captured]	25	86	86	0	7	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521 USA	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	MAY	1999	20	5					857	866					10	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	198RY	WOS:000080439000021	10369357				2022-02-06	
J	Raby, CA; Morganti-Kossmann, MC; Kossmann, T; Stahel, PF; Watson, MD; Evans, LM; Mehta, PD; Spiegel, K; Kuo, YM; Roher, AE; Emmerling, MR				Raby, CA; Morganti-Kossmann, MC; Kossmann, T; Stahel, PF; Watson, MD; Evans, LM; Mehta, PD; Spiegel, K; Kuo, YM; Roher, AE; Emmerling, MR			Traumatic brain injury increases beta-amyloid peptide 1-42 in cerebrospinal fluid	JOURNAL OF NEUROCHEMISTRY			English	Article						Alzheimer's disease; beta-amyloid precursor protein; risk factors; brain; CSF; head trauma; injury	GROWTH-FACTOR PRODUCTION; ALZHEIMERS-DISEASE; HEAD-INJURY; PRECURSOR PROTEIN; BLOOD; INTERLEUKIN-6; ACCUMULATION; NEURONS; APP	The p-amyloid peptides, A beta 1-42 and A beta 1-40, were quantified in ventricular CSF taken daily for up to 3 weeks from six individuals with severe traumatic brain injury (TBI). There was considerable interindividual variability in the levels of A beta peptides, but in general A beta 1-42 levels equalled or exceeded those of A beta 1-40. Averaging the daily totals of our trauma cohort revealed that the levels of A beta 1-42 and A beta 1-40 rose after injury, peaking in the first week and then declining toward control levels over the next 2 weeks. A beta 1-42 levels were on average two to three times higher in the trauma cohort than in CSF from nontrauma samples. Compared with nontrauma samples, the A beta 1-40/A beta 1-42 ratio decreased about fivefold in the trauma patients, further indicative of increased A beta 1-42 levels. The ratio remained low at all time points studied. No change was measured in the levels of beta-amyloid precursor protein during the same interval, These results suggest that A beta 1-42 becomes elevated in the CSF after severe brain trauma.	Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Neurosci Therapeut, Ann Arbor, MI 48105 USA; New york Inst Basic Res, Staten Isl, NY USA; Sun Hlth Res Inst, Haldeman Lab Alzheimers Dis Res, Sun City, AZ USA; Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland		Emmerling, MR (corresponding author), Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Neurosci Therapeut, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.		Kuo, Yu-Min/A-9050-2013	Kuo, Yu-Min/0000-0003-4867-2482; Morganti-Kossmann, Cristina/0000-0002-0807-2063			CARROLL RT, 1995, BIOCHEM BIOPH RES CO, V210, P345, DOI 10.1006/bbrc.1995.1667; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; Diamond PT, 1996, BRAIN INJURY, V10, P413, DOI 10.1080/026990596124278; Frautschy SA, 1996, NEUROBIOL AGING, V17, P311, DOI 10.1016/0197-4580(95)02073-X; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GhersiEgea JF, 1996, J NEUROCHEM, V67, P880; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; HILBICH C, 1993, J BIOL CHEM, V268, P26571; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; JENNETT B, 1975, LANCET, V1, P480; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martel CL, 1997, J NEUROCHEM, V69, P1995; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Mehta PD, 1998, NEUROSCI LETT, V241, P13, DOI 10.1016/S0304-3940(97)00966-X; MOTTER R, 1995, ANN NEUROL, V38, P643, DOI 10.1002/ana.410380413; NAKAMURA T, 1994, ANN NEUROL, V36, P903, DOI 10.1002/ana.410360616; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; STOCKER R, 1995, INTEGRATED APPROACH, P197; Tamaoka A, 1997, J NEUROL SCI, V148, P41, DOI 10.1016/S0022-510X(96)00314-0; TEASDALE G, 1974, LANCET, V2, P81; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085	33	86	86	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	DEC	1998	71	6					2505	2509					5	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	139QH	WOS:000077040400030	9832149				2022-02-06	
J	Leathem, JM; Murphy, LJ; Flett, RA				Leathem, JM; Murphy, LJ; Flett, RA			Self- and informant-ratings on the patient competency rating scale in patients with traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							HEAD-INJURY; QUESTIONNAIRE; MEMORY; TESTS	The Patient Competency Rating Scale (PCRS) provides self- and informant-ratings of everyday memory and gives a guide to patients' awareness of their difficulties. Research using the PCRS has focussed on groups with severe TBI and little is known about ratings of functioning in other severity groups or in a non-TBI population. In the current study the TBI group (n = 53) overrated their pre-accident competency compared to controls (n = 131). Patients with severe TBI (n = 25) underestimated their difficulties, while ratings of those with moderate (n = 14) and mild (n = 14) TBI were consistent with their informants, that is, in areas of cognition and emotion. Controls reported difficulty in interpersonal functioning and emotional control that their informants were unaware of.	Massey Univ, Sch Psychol, Palmerston North, New Zealand		Leathem, JM (corresponding author), Massey Univ, Sch Psychol, Palmerston North, New Zealand.	J.M.Leathem@massey.ac.nz		Flett, Ross/0000-0002-3638-710X			*ACC REH COMP INS, 1994, 1994 ACC ACC COMP CO; Acker MB, 1990, NEUROPSYCHOLOGY EVER, P19; ACRIMONVIC ML, 1993, J COGNITIVE REHABILI, V4, P8; ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; BENNETTLEVY J, 1980, BRIT J SOC CLIN PSYC, V19, P177, DOI 10.1111/j.2044-8260.1980.tb00946.x; Benson D.F., 1986, FRONTAL LOBES; BOLLER K, 1991, ARCH NEUROL-CHICAGO, V48, P661; BOND MR, 1986, NEUROPSYCHOLOGICAL A, P347; *DEP STAT NZ, 1994, 1991 CENS POP DWELL; Gilewski M.J., 1986, CLIN MEMORY ASSESSME, P93, DOI [10.1037/10057-008, DOI 10.1037/10057-008]; Goldstein G., 1995, INT J REHABILITATION, V1, DOI [10.1007/BF02214959, DOI 10.1007/BF02214959]; Gronwall Dorothy, 1990, HEAD INJURY FACTS GU; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; HEILBRONNER RL, 1993, J CLIN EXP NEUROPSYC, V15, P67; Lezak M., 1989, ASSESSMENT BEHAV CON; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Morse P, 1992, CLIN SYNDROMES ADULT, P85; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P96; PRIGATANO GP, 1991, BARROW NEUROLOGICAL, V7, P17; RUFF RM, 1987, SAN DIEGO NEUROPSYCH; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; SEIDENBERG M, 1994, J CLIN EXP NEUROPSYC, V16, P93, DOI 10.1080/01688639408402620; SEIDENBERG M, 1994, ARCH CLIN NEUROPSYCH, V9, P353, DOI 10.1016/0887-6177(94)90023-X; Sherer M., 1995, J INT NEUROPSYCH SOC, V1, P163; SHERER M, 1996, ANN C INT NEUR SOC C; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; SWARTZ AF, 1989, CORTEX, V25, P665; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002	31	86	88	0	7	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	1998	20	5					694	705		10.1076/jcen.20.5.694.1122			12	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	170ZB	WOS:000078836300010	10079045				2022-02-06	
J	Max, JE; Arndt, S; Castillo, CS; Bokura, H; Robin, DA; Lindgren, SD; Smith, WL; Sato, Y; Mattheis, PJ				Max, JE; Arndt, S; Castillo, CS; Bokura, H; Robin, DA; Lindgren, SD; Smith, WL; Sato, Y; Mattheis, PJ			Attention-deficit hyperactivity symptomatology after traumatic brain injury: A prospective study	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						traumatic brain injury; attention-deficit hyperactivity disorder	DISORDER; CHILDREN; RELIABILITY; DEPRESSION; SCALE	Objective: To study prospectively the course of attention-deficit hyperactivity (ADH) symptomatology in children and adolescents after traumatic brain injury (TBI). It was hypothesized that ADH symptomatology would be significantly related to severity of injury. Method: Subjects were children (n = 50) aged 6 to 14 years at the time they were hospitalized after TBI.The study used a prospective follow-up design. Assessments of preinjury psychiatric, behavioral, socioeconomic, family functioning, and family psychiatric history status were conducted. Severity of injury was assessed by standard clinical scales, and neuroimaging was analyzed. Results: The main finding of this study was that change in ADH symptomatology in the first 2 years after TBI in children and adolescents was significantly related to severity of injury. Overall ADH symptomatology during the study was significantly related to a measure of family dysfunction when family psychiatric history, socioeconomic status, and severity of injury were controlled. Conclusion: The presence of a positive "dose-response" relationship between severity of injury and change in ADH symptoms, present from the 3-month assessment, was consistent with an effect directly related to brain damage.	Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Dept Speech Pathol & Audiol, Iowa City, IA 52242 USA; Univ Montana, Missoula, MT 59812 USA; Cedar Ctr Psychiat Grp, Cedar Rapids, IA USA		Max, JE (corresponding author), Univ Iowa, Dept Psychiat, 1876 JPP, Iowa City, IA 52242 USA.		Arndt, Stephan/A-6976-2013; Robin, Donald/F-2109-2010	Arndt, Stephan/0000-0003-0783-8204; Sato, Yutaka/0000-0002-5245-232X	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH31593, MH40856, MHCRC43271] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH031593, R37MH031593, P30MH043271, P50MH043271, R01MH040856] Funding Source: NIH RePORTER		ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; BIEDERMAN J, 1995, ARCH GEN PSYCHIAT, V52, P464; BLACK P, 1971, HEAD INJURIES, P131; BOCK RD, 1975, MULTIVARIATE STAT ME, P148; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Cantwell DP, 1996, J AM ACAD CHILD PSY, V35, P978, DOI 10.1097/00004583-199608000-00008; Castellanos FX, 1996, ARCH GEN PSYCHIAT, V53, P607; CHAMBERS WJ, 1985, ARCH GEN PSYCHIAT, V42, P696; Ebaugh FG, 1923, AM J DIS CHILD, V25, P89; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; HYND GW, 1990, ARCH NEUROL-CHICAGO, V47, P919, DOI 10.1001/archneur.1990.00530080107018; KRAUS JF, 1987, PEDIATRICS, V79, P501; Lindgren S.D., 1987, ADV BEHAVIORAL ASSES, V3, P57; LOU HC, 1989, ARCH NEUROL-CHICAGO, V46, P48, DOI 10.1001/archneur.1989.00520370050018; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; Spector, 1991, SAS SYSTEM LINEAR MO; Starkstein SE, 1997, J NERV MENT DIS, V185, P108, DOI 10.1097/00005053-199702000-00007; TEASDALE G, 1974, LANCET, V2, P81; ZAMETKIN AJ, 1990, NEW ENGL J MED, V323, P1361, DOI 10.1056/NEJM199011153232001; ZIMMERMAN M, 1985, ARCH GEN PSYCHIAT, V42, P300; [No title captured]	28	86	89	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	AUG	1998	37	8					841	847		10.1097/00004583-199808000-00014			7	Psychology, Developmental; Pediatrics; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Pediatrics; Psychiatry	103ZY	WOS:000074988800014	9695446				2022-02-06	
J	Murdoch, I; Perry, EK; Court, JA; Graham, DI; Dewar, D				Murdoch, I; Perry, EK; Court, JA; Graham, DI; Dewar, D			Cortical cholinergic dysfunction after human head injury	JOURNAL OF NEUROTRAUMA			English	Article						head-injury; choline acetyltransferase; nicotine; synaptophysin	TRAUMATIC BRAIN INJURY; NUCLEUS BASALIS MAGNOCELLULARIS; TRANSIENT CEREBRAL-ISCHEMIA; ALZHEIMERS-DISEASE; ACETYLTRANSFERASE ACTIVITY; BINDING-SITES; NICOTINE BINDING; H-3 NICOTINE; RAT-BRAIN; NEURONS	Loss of cholinergic neurotransmission is implicated in memory impairment and cognitive dysfunction after head injury. The aim of the present study was to investigate presynaptic markers, particularly in relation to cholinergic neurotransmission in human postmortem brain from patients who died following a head injury and age-matched controls. Choline acetyltransferase activity and high-affinity nicotinic receptor binding sites were assayed in the inferior temporal gyrus, cingulate gyrus, and superior parietal cortex of 16 head-injured patients and 8 controls. Synaptophysin immunoreactivity was determined in the left cingulate gyrus from the same patient groups. In the head-injured group, choline acetyltransferase activity was consistently reduced in each cortical region compared to control subjects. The presence of a subdural haematoma and a prolonged survival period after head injury tended to be associated with lower choline acetyltransferase activity. In contrast to the marked reduction in choline acetyltransferase activity, nicotine receptor binding was unchanged in head-injured compared to control patients. Synaptophysin immunoreactivity in the cingulate gyrus was reduced by approximately 30% (p < 0.05) in the head-injured group compared to controls. Correlation of choline acetyltransferase activity with synaptophysin immunoreactivity indicated there is a deficit of cholinergic presynaptic terminals in postmortem human brain following head injury.	Univ Glasgow, Wellcome Surg Inst, Glasgow G61 1QH, Lanark, Scotland; Univ Glasgow, Hugh Fraser Neurosci Labs, Glasgow G61 1QH, Lanark, Scotland; Univ Glasgow, Dept Neuropathol, Glasgow G61 1QH, Lanark, Scotland; Newcastle Gen Hosp, MRC, Neurochem Pathol Unit, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England		Murdoch, I (corresponding author), Univ Glasgow, Wellcome Surg Inst, Garscube Estate,Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.						ABDULLA FA, 1995, SYNAPSE, V21, P281, DOI 10.1002/syn.890210402; ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; CARLSEN J, 1985, J COMP NEUROL, V234, P155, DOI 10.1002/cne.902340203; CLARKE PBS, 1985, J NEUROSCI, V5, P1307; COURT JA, 1994, CNS DRUGS, V2, P216, DOI 10.2165/00023210-199402030-00006; COURT JA, 1992, NEUROSCI RES COMMUN, V10, P125; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Dewar D., 1996, Society for Neuroscience Abstracts, V22, P1900; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; FLORES CM, 1992, MOL PHARMACOL, V41, P31; FONNUM F, 1975, J NEUROCHEM, V24, P407, DOI 10.1111/j.1471-4159.1975.tb11895.x; FRANCIS A, 1982, BRAIN RES, V243, P271, DOI 10.1016/0006-8993(82)90250-5; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; GOTO S, 1993, ACTA NEUROPATHOL, V85, P515; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Henderson Z, 1996, PROG NEUROBIOL, V48, P219, DOI 10.1016/0301-0082(95)00041-0; ISHIMARU H, 1995, BRAIN RES, V673, P112, DOI 10.1016/0006-8993(94)01409-B; ISHIMARU H, 1995, NEUROREPORT, V6, P557, DOI 10.1097/00001756-199502000-00037; KELLER KJ, 1990, NICOTINE PHARM; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Levin H., 1987, HEAD INJURY, P442; Lindstrom J, 1996, PROG BRAIN RES, V109, P125; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marchi M, 1996, J NEUROCHEM, V67, P1974; MASLIAH E, 1991, AM J PATHOL, V138, P235; Masliah E, 1996, ANN NEUROL, V40, P759, DOI 10.1002/ana.410400512; MASLIAH E, 1989, NEUROSCI LETT, V103, P234, DOI 10.1016/0304-3940(89)90582-X; Masliah E, 1996, AM J PATHOL, V148, P201; MCGEHEE DS, 1995, SCIENCE, V269, P1692, DOI 10.1126/science.7569895; MCKENZIE JE, 1994, NEUROREPORT, V6, P161, DOI 10.1097/00001756-199412300-00041; MESULAM MM, 1983, J COMP NEUROL, V214, P170, DOI 10.1002/cne.902140206; MESULAM MM, 1983, NEUROSCIENCE, V10, P1185, DOI 10.1016/0306-4522(83)90108-2; MIYAI I, 1990, J NEURAL TRANSM-GEN, V82, P79, DOI 10.1007/BF01245165; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; NYBERG P, 1989, STROKE, V20, P495, DOI 10.1161/01.STR.20.4.495; PERRY EK, 1987, J NEUROL NEUROSUR PS, V50, P806, DOI 10.1136/jnnp.50.6.806; PERRY EK, 1990, J NEURAL TRANSM-PARK, V2, P149, DOI 10.1007/BF02257646; PERRY RH, 1982, NEUROSCI LETT, V33, P311, DOI 10.1016/0304-3940(82)90391-3; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; WHITEHOUSE PJ, 1986, BRAIN RES, V371, P146, DOI 10.1016/0006-8993(86)90819-X	47	86	89	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	1998	15	5					295	305		10.1089/neu.1998.15.295			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	ZL515	WOS:000073441300001	9605345				2022-02-06	
J	Jupiter, JB; Ring, D				Jupiter, JB; Ring, D			Operative treatment of post-traumatic proximal radioulnar synostosis	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							BONE	The results of operative resection of a post-traumatic proximal radioulnar synostosis performed by one surgeon in eighteen limbs of seventeen consecutive patients during an eight-year period were reviewed retrospectively, The resection was performed an average of nineteen months after the injury; eight limbs had the resection less than twelve months after the injury, A free fat graft was used in the first eight patients, No adjuvant non-steroidal anti-inflammatory medication or low-dose radiation was used postoperatively as prophylaxis against heterotopic ossification, We classified the proximal radioulnar synostoses into three subgroups: A indicated a synostosis at or distal to the bicipital tuberosity (four limbs), B indicated a synostosis involving the radial head and the proximal radioulnar joint (seven limbs), and C indicated a synostosis that was contiguous with bone extending across the elbow to the distal aspect of the humerus (seven limbs), The patients were followed for an average of thirty-four months (range, twenty-four to sixty months), The synostosis recurred in one patient, the only patient in the series who had sustained a closed head injury at the time of the initial injury, Additional complications included a fracture of the ulna, a broken pin on a hinged elbow distracter, and dislodgment of a free nonvascularized fat graft in one patient each, The seventeen limbs that did not have a recurrence regained an average of 139 degrees of rotation of the forearm, With the number of patients available, we could not detect a significant relationship between subsequent rotation of the forearm and the size of the synostosis, the use of interpositional fat, or the concomitant use of a hinged elbow distracter, The eight limbs that had resection of the synostosis less than twelve months after the injury regained an average of 144 degrees of rotation compared with 134 degrees in the nine limbs that had resection at least twelve months after the injury, This difference could not be shown to be significant. In this series, operative resection of a post-traumatic proximal radioulnar synostosis led to good results despite the lack of adjuvant radiation therapy or antiinflammatory medication.	Massachusetts Gen Hosp, Orthopaed Hand Serv, Dept Orthopaed Surg, Boston, MA 02114 USA		Jupiter, JB (corresponding author), Massachusetts Gen Hosp, Orthopaed Hand Serv, Dept Orthopaed Surg, WAC-527, Boston, MA 02114 USA.						ABRAMS RA, 1993, J HAND SURG-AM, V18A, P703, DOI 10.1016/0363-5023(93)90322-T; AYERS DC, 1986, J BONE JOINT SURG AM, V68A, P1423, DOI 10.2106/00004623-198668090-00016; BENJAMIN A, 1982, WATSONJONES FRACTURE, V2, P650; BOTTING TDJ, 1970, J TRAUM, V10, P16, DOI 10.1097/00005373-197001000-00002; BRADY L P, 1960, South Med J, V53, P507; BRADY LW, 1979, SKELETAL RADIOL, V4, P72, DOI 10.1007/BF00349330; BREIT R, 1983, CLIN ORTHOP RELAT R, P149; CARSTAM N, 1971, Scandinavian Journal of Plastic and Reconstructive Surgery, V5, P57; CORLESS JR, 1977, J BONE JOINT SURG BR, V59, P510; CULLEN JP, 1994, J HAND SURG-AM, V19A, P394, DOI 10.1016/0363-5023(94)90051-5; FAILLA JM, 1989, J BONE JOINT SURG AM, V71A, P1208, DOI 10.2106/00004623-198971080-00014; FIELDING JW, 1964, J BONE JOINT SURG AM, V46, P1277, DOI 10.2106/00004623-196446060-00014; FREITAG P, 1981, Orthopaedic Transactions, V5, P42; GARLAND DE, 1991, CLIN ORTHOP RELAT R, P13; Jupiter JB, 1991, INSTRUCTIONAL COURSE, V40, P41; Kapandji I.A., 1982, PHYSL JOINTS, V2nd ed; KELIKIAN H, 1957, J BONE JOINT SURG AM, V39, P945, DOI 10.2106/00004623-195739040-00017; KIM JH, 1978, RADIOLOGY, V129, P501, DOI 10.1148/129.2.501; KONSKI A, 1990, INT J RADIAT ONCOL, V18, P1139, DOI 10.1016/0360-3016(90)90450-X; MAEMPEL EZ, 1984, CLIN ORTHOPAEDICS, V186, P182; MODABBER R, 1995, J BONE JOINT SURG AM, V77, P1431, DOI 10.2106/00004623-199509000-00021; MORREY BF, 1981, J BONE JOINT SURG AM, V63, P872, DOI 10.2106/00004623-198163060-00002; ORZEL JA, 1985, J NUCL MED, V26, P1125; ROBERTS JB, 1979, J BONE JOINT SURG AM, V61, P760, DOI 10.2106/00004623-197961050-00018; SACHAR K, 1994, HAND CLIN, V10, P399; THURSTON AJ, 1993, AUST NZ J SURG, V63, P976, DOI 10.1111/j.1445-2197.1993.tb01728.x; TOOMS RE, 1986, COMPLICATIONS ORTHOP, V1, P325; VINCE KG, 1987, J BONE JOINT SURG AM, V69A, P640, DOI 10.2106/00004623-198769050-00002; WARREN SB, 1992, J BONE JOINT SURG AM, V74A, P201, DOI 10.2106/00004623-199274020-00006; WATSON FM, 1978, J TRAUMA, V18, P467, DOI 10.1097/00005373-197806000-00013; YONGHING K, 1983, J BONE JOINT SURG BR, V65, P435	31	86	87	0	5	JOURNAL BONE JOINT SURGERY INC	NEEDHAM	20 PICKERING ST, NEEDHAM, MA 02192 USA	0021-9355			J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	FEB	1998	80A	2					248	257		10.2106/00004623-199802000-00012			10	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	YY436	WOS:000072146400012	9486731				2022-02-06	
J	Ellenberg, JH; Levin, HS; Saydjari, C				Ellenberg, JH; Levin, HS; Saydjari, C			Posttraumatic amnesia as a predictor of outcome after severe closed head injury - Prospective assessment	ARCHIVES OF NEUROLOGY			English	Article							COMA DATA-BANK; PRACTICAL SCALE; SEQUELAE	Objectives: To identify the demographic and clinical variables related to the duration of posttraumatic amnesia after severe closed head injury; to evaluate the usefulness of posttraumatic amnesia duration in predicting outcome at the time of hospital discharge and at 6 months after injury. Setting: Four clinical centers located in primary care hospitals. Patients: Three hundred fourteen severely injured subjects aged 16 years or older who did not have trauma as a result of a penetrating injury and came out of coma before hospital discharge. Interventions: Approximately half of the subjects were administered phenytoin sodium for some period after termination of coma; 17% were administered dexamethasone and 41% morphine sulfate. Main Outcome Measures: Galveston Orientation and Amnesia Test scores defined the duration of posttraumatic amnesia. The Glasgow Outcome Scale was used to grade outcome at the time of hospital discharge and at 6 months. Results: Older age, low initial Glasgow Coma Scale score, nonreactive pupil(s), coma duration, and use of phenytoin were associated with a longer duration of posttraumatic amnesia. Poor pupillary response, time in coma, and duration of posttraumatic amnesia and use of phenytoin was predictive of the 6-month outcome. Conclusions:. The results support the prognostic usefulness of prospectively measuring duration of posttraumatic amnesia after termination of coma. Pending replication, our findings suggest that posttraumatic amnesia duration may be a useful surrogate outcome measure for clinical trials involving interventions for acute head injury.	WESTAT CORP,ROCKVILLE,MD; UNIV MARYLAND,DIV NEUROSURG,BALTIMORE,MD						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01-NS-3-2339, N01-NS-3-2341, N01-NS-3-2340] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01NS032340, N01NS032341, N01NS032339] Funding Source: NIH RePORTER		BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; Cox DR., 1970, ANAL BINARY DATA; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Levin H. S., 1992, NEUROPSYCHOLOGY MEMO, P290; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MANTEL N, 1959, J NATL CANCER I, V22, P719; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NATELSON BH, 1979, ARCH NEUROL-CHICAGO, V36, P444, DOI 10.1001/archneur.1979.00500430074014; NEWCOMER JW, 1994, J NEUROSCI, V14, P2047; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUSSELL WR, 1932, TRAUMATIC AMNESIAS; *SAS I INC, 1988, SAS STAT US GUID LIF; *SAS I INC, 1990, SAS STAT US GUID LOG; *SAS I INC, 1991, P217 SAS; SHORES A, 1990, AUST NZ J PSYCHIAT, V24, P133, DOI 10.3109/00048679009062895; TEASDALE G, 1974, LANCET, V2, P81; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V57, P198, DOI 10.1136/jnnp.57.2.198; WOLKOWITZ OM, 1992, AM J PSYCHIAT, V124, P1125	31	86	88	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	AUG	1996	53	8					782	791		10.1001/archneur.1996.00550080104018			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	VB471	WOS:A1996VB47100014	8759985				2022-02-06	
J	Fortune, JB; Feustel, PJ; Graca, L; Hasselbarth, J; Kuehler, DH				Fortune, JB; Feustel, PJ; Graca, L; Hasselbarth, J; Kuehler, DH			Effect of hyperventilation, mannitol, and ventriculostomy drainage on cerebral blood flow after head injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	8th Annual Scientific Session of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 14, 1995	SANIBEL, FL	E Assoc Surg Trauma			ACUTE BRAIN INJURY; INTRACRANIAL HYPERTENSION; COMATOSE PATIENTS; PRESSURE; MANAGEMENT; ICP; OXYGENATION; METABOLISM; VISCOSITY; CHILDREN	Therapies to lower intracranial pressure (ICP) after traumatic brain injury (TBI) include hyperventilation (HV), intravenous mannitol (IM), and cerebrospinal fluid drainage from a ventriculostomy (DV), To determine the effects of these therapies on cerebral blood flow (CBF), fiberoptic oximetry was used to measure jugular venous O-2 saturation (SjvO2) as an index of the CBF to cerebral metabolic rate for O-2 (CMRO(2)) ratio after IM (25 g IV for more than 5 min), DV (3 min), or HV (increase respiratory rate by 4) therapy for elevated ICP, Assuming CMRO(2) is constant, changes in SjvO2 reflect changes in CBF, Continuous measurements of SjvO2, ICP, blood pressure, artery rial O-2 saturation, and end-tidal CO2 were obtained in 22 patients with a Glasgow Coma Scale score of 5.3 +/- 0.4 (mean +/- SD) in the first 5 days after TBI, Therapy was initiated a total of 196 times when ICP was > 15 mm Hg for > 5 minutes, and measurements made at 20 minutes after treatment were compared with those made just before, After DV, ICP fell in 90% of the observations by 8.6 +/- 0.7 mm Hg (mean +/- SEM, n = 119); after IM, ICP fell in 90% of the observations by 7.4 +/- 0.7 mm Hg (n = 43); and after HV, ICP fell in 88% of the observations by 6.3 +/- 1.2 mm Hg (n = 14), In patients where ICP fell, SjvO2 increased by 2.49 +/- 0.7% saturation (from 68.0 +/- 1.3%) with IM, but only by 0.39 +/- 0.4% saturation (from 67.2 +/- 0.9%) with DV, When HV resulted in a decrease in ICP, SjvO2 decreased by 7.7 +/- 1.0% saturation (from 63.4 +/- 2.5%), The magnitude of the effect was assessed by considering the change in SjvO2 resulting from a measured change in ICP (SjvO2/ICP). For each decrease in ICP of 1 mm Hg, SjvO2 increased 0.53 +/- 0.14% saturation with IM, 0.10 +/- 0.10 with DV, and decreased by 1.95 +/- 0.53 with HV, In this study DV, IM, and HV effectively reduced elevated ICP after cerebral injury, For a given change in ICP, however, LM increased the CBF to CMRO(2) ratio nearly five times as much as DV, whereas HV decreased this ratio in all cases, These data suggest that mannitol improves CBF while reducing ICP; HV, although effective at reducing ICP, results in marked lowering of CBF and should be used cautiously.	ALBANY MED COLL, DEPT SURG, SECT TRAUMA SURG, ALBANY, NY USA				Feustel, Paul/AAW-5157-2021	Feustel, Paul/0000-0002-6963-4349	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030303] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-30303] Funding Source: Medline		BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BURKE AM, 1981, J NEUROSURG, V55, P550, DOI 10.3171/jns.1981.55.4.0550; COLD GE, 1989, ACTA NEUROCHIR, V96, P100, DOI 10.1007/BF01456166; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P359, DOI 10.1111/j.1399-6576.1977.tb01232.x; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; CRUZ J, 1991, NEUROSURGERY, V29, P743, DOI 10.1227/00006123-199111000-00017; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; DARBY JM, 1988, NEUROSURGERY, V23, P84, DOI 10.1227/00006123-198807000-00014; DURIVAND QJ, 1983, J NEUROSURG, V59, P803; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; FORTUNE JB, 1992, J TRAUMA, V32, P618, DOI 10.1097/00005373-199205000-00014; GAAB MR, 1990, ACT NEUR S, V51, P320; GOBIET W, 1975, ACTA NEUROCHIR, V32, P13, DOI 10.1007/BF01405899; Kanter M J, 1991, Neurosurg Clin N Am, V2, P257; MARMAROU A, 1987, J NEUROSURG, V66, P883, DOI 10.3171/jns.1987.66.6.0883; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Monro A., 1783, OBSERVATIONS STRUCTU; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NATH F, 1986, J NEUROSURG, V65, P41, DOI 10.3171/jns.1986.65.1.0041; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Procaccio F, 1991, Agressologie, V32, P381; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROSNER MJ, 1987, NEUROSURGERY, V21, P147, DOI 10.1227/00006123-198708000-00003; SHALMON E, 1990, ACT NEUR S, V51, P116; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; STRINGER WA, 1993, AM J NEURORADIOL, V14, P475; Tomei G, 1991, J Neurosurg Sci, V35, P61; WISE BL, 1962, J NEUROSURG, V19, P1038, DOI 10.3171/jns.1962.19.12.1038; YOSHIDA K, 1991, J NEUROSURG, V74, P87, DOI 10.3171/jns.1991.74.1.0087; ZORNOW MH, 1990, ACT NEUR S, V51, P324	37	86	87	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1995	39	6					1091	1099		10.1097/00005373-199512000-00014			9	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	TL905	WOS:A1995TL90500014	7500400				2022-02-06	
J	HANSTOCK, CC; FADEN, AI; BENDALL, R; VINK, R				HANSTOCK, CC; FADEN, AI; BENDALL, R; VINK, R			DIFFUSION-WEIGHTED IMAGING DIFFERENTIATES ISCHEMIC TISSUE FROM TRAUMATIZED TISSUE	STROKE			English	Article						BRAIN EDEMA; BRAIN INJURIES; MAGNETIC RESONANCE IMAGING; RATS	MAGNETIC-RESONANCE SPECTROSCOPY; CEREBRAL BLOOD-FLOW; EXPERIMENTAL BRAIN INJURY; T2-WEIGHTED MRI; FLUID; EDEMA; P-31; RATS; PERFUSION; CLEARANCE	Background and Purpose Diffusion-weighted magnetic resonance imaging (MRI) has been shown to be particularly effective in detecting early (0 to 4 hours) pathophysiological changes in localized brain regions after cerebral ischemia. The present study sought to establish whether diffusion-weighted MRI would be similarly effective in predicting outcome after traumatic brain injury. Methods Diffusion-weighted MRI images and T2-weighted MRI images were obtained over 4 hours after either moderate fluid percussion-induced traumatic brain injury or unilateral carotid ligation in rats. Results Diffusion-weighted MRI images of traumatic brain injury demonstrated focal regions of image hypointensity as early as 1 hour after trauma. The relative diffusion coefficient in these hypointense regions was significantly increased (P<.005) by 4 hours after trauma compared with the noninjured hemisphere, but only in the transverse plane in the x direction. In contrast, induction of diffuse, nonfocal ischemia by unilateral carotid ligation resulted in scattered regions of hyperintensity with a significant (P<.001) decrease in relative diffusion coefficient as early as 1 hour after ligation compared with the noninjured hemisphere. This decrease exhibited no directionality. Conclusions We conclude that traumatic brain injury results in an increased water diffusion distance with the directionality indicative of bulk flow of extracellular fluid toward the lateral ventricles (vasogenic edema). In contrast, the decreased water diffusion distance with no apparent directionality observed in ischemia is most likely indicative of cytotoxic edema. Diffusion-weighted MRI therefore has the potential to differentiate cases of traumatic brain injury with no focal ischemia from those instances of traumatic brain injury in which focal ischemia is a complication.	JAMES COOK UNIV N QUEENSLAND, DEPT MOLEC SCI, TOWNSVILLE, QLD 4811, AUSTRALIA; UNIV ALBERTA, DEPT APPL SCI MED, EDMONTON T6G 2E1, ALBERTA, CANADA; GEORGETOWN UNIV, MED CTR, DEPT NEUROL, WASHINGTON, DC 20007 USA				Vink, Robert/S-5616-2019; Vink, Robert/J-7351-2012	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS27849] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR306634] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027849] Funding Source: NIH RePORTER		BOUMA GJ, 1992, 1991 MA LIEB INC CEN, P333; BRAUGHLER JM, 1992, 1991 MA LIEB INC CEN, P1; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CROCKARD HA, 1987, J CEREBR BLOOD F MET, V7, P394, DOI 10.1038/jcbfm.1987.82; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; FADEN AI, 1989, SCIENCE, V244, P7988; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KUCHARCZYK J, 1991, MAGNET RESON MED, V19, P311, DOI 10.1002/mrm.1910190220; Kulkarni M V, 1988, Radiographics, V8, P1059; KUWASHIMA J, 1978, JPN J PHARMACOL, V28, P277, DOI 10.1254/jjp.28.277; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; LEBIHAN D, 1991, MAGNET RESON MED, V19, P221, DOI 10.1002/mrm.1910190206; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MINTOROVITCH J, 1991, MAGNET RESON MED, V18, P39, DOI 10.1002/mrm.1910180106; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; NARITOMI H, 1988, J CEREBR BLOOD F MET, V8, P16, DOI 10.1038/jcbfm.1988.3; REULEN HJ, 1978, J NEUROSURG, V48, P754, DOI 10.3171/jns.1978.48.5.0754; REULEN HJ, 1977, J NEUROSURG, V46, P24, DOI 10.3171/jns.1977.46.1.0024; SCHUIER FJ, 1980, STROKE, V11, P593, DOI 10.1161/01.STR.11.6.593; SIESJO BK, 1988, CRIT CARE MED, V16, P954, DOI 10.1097/00003246-198810000-00006; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; TAYLOR DG, 1985, PHYS MED BIOL, V30, P341; TORNHEIM PA, 1985, CENTRAL NERVOUS SYST, P431; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; VINK R, 1991, MAGNESIUM EXCITABLE, P695; WEINSTEIN PR, 1990, PROTECTION BRAIN ISC, P111; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOUNG W, 1992, CENTRAL NERVOUS SYST, P9; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	36	86	87	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	APR	1994	25	4					843	848		10.1161/01.STR.25.4.843			6	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	ND342	WOS:A1994ND34200016	8160231	Bronze			2022-02-06	
J	ROSS, DT; MEANEY, DF; SABOL, MK; SMITH, DH; GENNARELLI, TA				ROSS, DT; MEANEY, DF; SABOL, MK; SMITH, DH; GENNARELLI, TA			DISTRIBUTION OF FOREBRAIN DIFFUSE AXONAL INJURY FOLLOWING INERTIAL CLOSED HEAD INJURY IN MINIATURE SWINE	EXPERIMENTAL NEUROLOGY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; ABERRANT NEUROFILAMENT PHOSPHORYLATION; MONOCLONAL-ANTIBODIES DISTINGUISH; ALPHA-B-CRYSTALLIN; NEURONAL PERIKARYA; BALLOONED NEURONS; SCIATIC-NERVE; TRANSECTION; EPITOPES; PRIMATE	Diffuse axonal injury (DAI) is one of the most frequently encountered types of brain damage resulting from closed head injury. This study was designed to verify whether DAI could be produced in miniature swine by rapid acceleration and deceleration of the head in the coronal plane. Hanford miniature swine (16-19 kg) were anesthetized with 3% isoflurane and their heads accelerated rapidly once through a 60-105 degrees arc in the coronal plane, producing only transient post-traumatic unconsciousness without prolonged coma. All animals made a good recovery and were sacrificed between 6 h and 10 days after injury. The response of forebrain projection systems to this injury was studied using neurofilament immunohistochemistry with antisera to nonphosphorylated (SMI-32) and phosphorylated (SMI-31) epitopes common to heavy (200 kDa) and medium (160 kDa) neurofilament proteins. In 9 of 12 animals, lesions characterized by foci of SMI-32 positive axonal retraction balls were present at the white matter/gray matter junction at the crests of gyri in the dorsolateral regions of the frontal, parietal, and temporal cortices and along margins of the lateral ventricles. A high density of pyramidal neuron perikarya in layers III and V within cortical gyri associated with subcortical DAI were intensely positive for SMI-31 immunohistochemistry. These results validate the use of miniature swine in studies of axonal injury and demonstrate that axonal injury analogous to that seen in the mildest form of DAI (grade I) can be produced in these animals without producing prolonged coma. (C) 1994 Academic Press, Inc.	UNIV PENN, DEPT BIOENGN, PHILADELPHIA, PA 19104 USA; UNIV PENN, ANIM RESOURCES LAB, PHILADELPHIA, PA 19104 USA		ROSS, DT (corresponding author), UNIV PENN, CTR HEAD INJURY, DIV NEUROSURG, PHILADELPHIA, PA 19104 USA.		smith, douglas/A-1321-2007	Meaney, David/0000-0002-0954-4122	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-08803-21-22] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803] Funding Source: NIH RePORTER		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65; Adams JH, 1982, RECENT ADV NEUROPATH, P165; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Brasko J., 1993, Society for Neuroscience Abstracts, V19, P1659; DRAGER UC, 1984, NATURE, V309, P624, DOI 10.1038/309624a0; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; Gennarelli T.A., 1985, CENTRAL NERVOUS SYST, P391; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1985, TRAUMA CENTRAL NERVO, P169; GENNARELLI TA, 1987, STAPP CAR CRASH C, P49; GOLD BG, 1991, BRAIN RES, V563, P151, DOI 10.1016/0006-8993(91)91528-9; GOLD BG, 1991, J NEUROPATH EXP NEUR, V50, P615, DOI 10.1097/00005072-199109000-00007; GOLDSTEIN ME, 1987, J NEUROSCI, V7, P1586; GOLDSTEIN ME, 1987, J NEUROIMMUNOL, V14, P149, DOI 10.1016/0165-5728(87)90049-X; GRCEVIC N, 1988, SCAND J REHABIL MED, P25; ITOH T, 1992, ACTA NEUROPATHOL, V83, P240, DOI 10.1007/BF00296785; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; KATO S, 1992, ACTA NEUROPATHOL, V84, P443; KATO S, 1990, ACTA NEUROPATHOL, V80, P334, DOI 10.1007/BF00294653; KLOSEN P, 1990, BRAIN RES, V526, P259, DOI 10.1016/0006-8993(90)91230-E; KOLIATSOS VE, 1989, BRAIN RES, V482, P205, DOI 10.1016/0006-8993(89)91183-9; LEE VMY, 1987, J NEUROSCI, V7, P3474; LOWE J, 1992, NEUROPATH APPL NEURO, V18, P341, DOI 10.1111/j.1365-2990.1992.tb00796.x; MANSOUR H, 1989, J COMP NEUROL, V283, P481, DOI 10.1002/cne.902830404; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; MAXWELL WL, 1992, ACTA NEUROPATHOL, V84, P78, DOI 10.1007/BF00427218; MEANEY DF, 1990, P IRCOBI C, V11, P215; MEANEY DF, 1993, P AM SOC MECH ENG, V169, P169; MIZUSAWA H, 1989, ACTA NEUROPATHOL, V79, P37, DOI 10.1007/BF00308955; MUNOZ DG, 1988, J NEUROPATH EXP NEUR, V47, P9, DOI 10.1097/00005072-198801000-00002; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; PREISEGGER KH, 1992, LAB INVEST, V66, P193; Ramon y Cajal S., 1928, DEGENERATION REGENER, VI; ROSENFELD J, 1987, J NEUROPATH EXP NEUR, V46, P269, DOI 10.1097/00005072-198705000-00004; Ross D. T., 1992, Society for Neuroscience Abstracts, V18, P1088; ROSS D T, 1991, Society for Neuroscience Abstracts, V17, P1081; ROSS DT, 1994, UNPUB DISPARITY EXTE; ROSS DT, 1994, UNPUB INFLUENCE INDE; ROSS DT, 1994, UNPUB OPTIC NERVE ST; ROSS DT, 1994, UNPUB INFLUENCE IMPA; SAHUQUILLO J, 1989, ACTA NEUROCHIR, V101, P149, DOI 10.1007/BF01410531; SHANKAR SK, 1989, ANN NEUROL, V25, P146, DOI 10.1002/ana.410250207; SHAW G, 1986, EUR J CELL BIOL, V42, P1; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; STRICH SJ, 1961, LANCET, V2, P443; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; THIBAULT LE, 1982, ADV BIOENG, V7, P85; WANG LN, 1991, CHINESE MED J-PEKING, V104, P1011; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; [No title captured]	59	86	89	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	APR	1994	126	2					291	299		10.1006/exnr.1994.1067			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NM716	WOS:A1994NM71600015	7925827				2022-02-06	
J	PALMER, AM; MARION, DW; BOTSCHELLER, ML; REDO, EE				PALMER, AM; MARION, DW; BOTSCHELLER, ML; REDO, EE			THERAPEUTIC HYPOTHERMIA IS CYTOPROTECTIVE WITHOUT ATTENUATING THE TRAUMATIC BRAIN INJURY-INDUCED ELEVATIONS IN INTERSTITIAL CONCENTRATIONS OF ASPARTATE AND GLUTAMATE	JOURNAL OF NEUROTRAUMA			English	Article							MILD HYPOTHERMIA; AMINO-ACIDS; ISCHEMIA; RAT; DAMAGE; TEMPERATURE; RECEPTORS; RELEASE	Moderate hypothermia has been shown to have therapeutic utility in the treatment of cerebral ischemia and to attenuate the rise in interstitial concentrations of the excitatory amino acid neurotransmitter L-glutamate. In this study, the influence of hypothermia on traumatic brain injury (TBI) was assessed using a controlled cortical impact model. Rats were cooled to 32.0-33.0 degrees C at least 30 min before injury and maintained at this temperature for 2 h after injury. The influence of hypothermia on the immediate increase in interstitial concentrations of aspartate and glutamate and the volume of the resultant lesion 14 days after TBI was then determined. The volume of the lesion (mean +/- SEM) in hypothermic animals (8.2 +/- 1.3 mm(3), n = 9) was significantly smaller than that of normothermic animals (13.2 +/- 1.7 mm(3), n = 8). By contrast, TBI-induced increases in dialysate concentrations of aspartate and glutamate were similar at the two temperatures. Thus, aspartate content (nmol/10 min) in animals maintained at 37.0-37.5 degrees C (n = 6) and 32.0-33.0 degrees C (n = 6) increased from respective mean preinjury values of 0.05 +/- 0.02 and 0.08 +/- 0.02 to much larger peak values (0.78 +/- 0.13 and 0.71 +/- 0.09, respectively). Similarly, under normothermic conditions glutamate content (nmol/10 min) increased from 0.13 +/- 0.03 to 3.08 +/- 0.52 and from 0.19 +/- 0.06 to a peak value of 3.09 +/- 0.26 under hypothermic conditions. These data clearly demonstrate the cytoprotective action of moderate hypothermia and further suggest that this action is not mediated by attenuation of the rise in interstitial concentrations of aspartate and glutamate.	UNIV PITTSBURGH,SCH MED,DEPT PHARMACOL,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,DEPT NEUROL SURG,PITTSBURGH,PA 15213		PALMER, AM (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT PSYCHIAT,W1642 BIOMED SCI TOWER,3811 OHARA ST,PITTSBURGH,PA 15213, USA.		Palmer, Alan/AAP-8650-2020; Marion, Donald/AAR-5749-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30318] Funding Source: Medline		ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; BENVENISTE H, 1991, CEREBROVAS BRAIN MET, V3, P213; BERNERT H, 1992, SOC NEUR ABSTR, V18, P457; BORISMOLLER F, 1989, NEUROSCI RES COMMUN, V5, P87; BUCHAN A, 1990, J NEUROSCI, V10, P311; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COHADON F, 1991, J NEUROSCI S, V103, pS23; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAY T, 1943, ASS RES NERV MENT DI, V24, P611; Graham D.I., 1992, GREENFIELDS NEUROPAT, P153; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HENDRICK EB, 1959, ARCH SURG-CHICAGO, V79, P362; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LAZORTHES G, 1958, J NEUROSURG, V15, P162, DOI 10.3171/jns.1958.15.2.0162; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; MITANI A, 1991, NEUROSCIENCE, V42, P661, DOI 10.1016/0306-4522(91)90035-M; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; ONESTI ST, 1991, NEUROSURGERY, V29, P369, DOI 10.1227/00006123-199109000-00005; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Paxinos G, 1986, RAT BRAIN STEREOTAXI; SEDZIMIR CB, 1959, J NEUROSURG, V16, P407, DOI 10.3171/jns.1959.16.4.0407; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIMS NR, 1987, J NEUROCHEM, V49, P1367, DOI 10.1111/j.1471-4159.1987.tb01001.x; STRICH SJ, 1970, J CLIN PATHOL S4, V23, P166; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; WELSH FA, 1990, J CEREBR BLOOD F MET, V10, P557, DOI 10.1038/jcbfm.1990.98; Whittingham TS, 1990, CEREBRAL ISCHEMIA RE, P101	40	86	87	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	WIN	1993	10	4					363	372		10.1089/neu.1993.10.363			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	MQ818	WOS:A1993MQ81800001	7908337				2022-02-06	
J	LYETH, BG; JIANG, JY; LIU, S				LYETH, BG; JIANG, JY; LIU, S			BEHAVIORAL PROTECTION BY MODERATE HYPOTHERMIA INITIATED AFTER EXPERIMENTAL TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article							ISCHEMIC NEURONAL INJURY; CEREBRAL-ISCHEMIA; RAT; TEMPERATURE; ACIDS; DEATH	The effects of postinjury hypothermia on behavioral outcome following moderate fluid percussion traumatic brain injury (TBI) were examined. In Experiment 1, three groups of rats were examined. The first group was normothermic (37.5-degrees-C); and hypothermia (30-degrees-C) was initiated 15 min and 30 min postinjury in the second and third groups, respectively. Whole body cooling was achieved by ventral ice pack. Cooling of the brain to 30-degrees-C was achieved in 25 min and maintained for 60 min. Brain temperature was measured indirectly by a probe in the temporalis muscle. Behavioral outcome was assessed by beam-balance performance, beam-walking performance, and body weight loss measured daily for 5 days after TBI. Both the normothermic group and the 30-min postinjury hypothermic group exhibited significant (p < 0.05) beam-balance and beam-walking deficits on days 1 through 5 after TBI. In contrast, the 15-min postinjury hypothermic group exhibited significant (p < 0.05) beam-walking deficits only on day 1 after TBI and significant (p < 0.05) beam-balance deficits on days 1, 3, and 4 after TBI. In Experiment II, subcortical brain temperature was compared to temporalis muscle temperature in normothermic (37.5-degrees-C) and hypothermic (30-degrees-C) rats subjected to TBI. In both groups brain temperature tracked within 0.4-degrees-C of temporalis muscle temperature. These results are similar to post-TBI excitatory receptor antagonist studies and indicate a therapeutic window for moderate hypothermia of less than 30 min after moderate fluid percussion TBI in the rat.	CHANG ZHENG HOSP,DEPT NEUROSURG,SHANGHAI,PEOPLES R CHINA		LYETH, BG (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT SURG,DIV NEUROSURG,BOX 693,MCV STN,RICHMOND,VA 23298, USA.			Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995, P50NS012587, P01NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 29995, NS 12587] Funding Source: Medline		BAKER AJ, 1991, STROKE, V22, P666, DOI 10.1161/01.STR.22.5.666; BAKER AJ, 1991, STROKE, V22, P673; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CHOU C-L, 1991, Society for Neuroscience Abstracts, V17, P722; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HOFFMAN WE, 1991, J NEUROSURG ANESTH, V3, P34, DOI 10.1097/00008506-199103000-00006; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MITANI A, 1991, NEUROSCIENCE, V42, P661, DOI 10.1016/0306-4522(91)90035-M; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V	20	86	87	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	SPR	1993	10	1					57	64		10.1089/neu.1993.10.57			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	LC106	WOS:A1993LC10600006	8320732				2022-02-06	
J	HSIEH, AHH; BISHOP, MJ; KUBILIS, PS; NEWELL, DW; PIERSON, DJ				HSIEH, AHH; BISHOP, MJ; KUBILIS, PS; NEWELL, DW; PIERSON, DJ			PNEUMONIA FOLLOWING CLOSED HEAD-INJURY	AMERICAN REVIEW OF RESPIRATORY DISEASE			English	Article							CONTINUOUS MECHANICAL VENTILATION; QUANTITATIVE CULTURE TECHNIQUES; PROTECTED SPECIMEN BRUSH; GRAM-NEGATIVE BACILLI; NOSOCOMIAL PNEUMONIA; RESPIRATORY-TRACT; CARE; RISK; INFECTION; DIAGNOSIS	Pneumonia is common among patients with artificial airways in place. Most prior studies of such pneumonia involve a heterogeneous group of patients, usually with major medical or surgical illnesses. We studied the incidence of pneumonia in a group of patients with isolated closed head injury (CHI) in an effort to determine the pattern of the problem in the absence of other injuries and to determine whether the pattern of development of pneumonia in these patients was comparable to that in more heterogeneous groups of mechanically ventilated patients. We studied 109 initially comatose patients with isolated CHI who were ventilated 24 h or more. The mean age was 30.3 +/- 20.2 yr, 72% were male, and the admission Glasgow coma score was 4.9T +/- 1.4. Overall, 45 patients (41%) developed pneumonia, with the majority (29/45) occurring during the first 3 days of hospitalization. No patient developed pneumonia after the first week despite the fact that many were still ventilated, others remained intubated, and yet others were extubated but comatose. Patients who developed pneumonia experienced a longer ICU stay (10.5 +/- 5.4 days versus 7.2 +/- 4.3 days, p = 0.001) and hospital stay (34.8 +/- 27.6 versus 22.5 +/- 20.2 days, p = 0.01). We concluded that (1) CHI is associated with a high incidence of pneumonia; (2) pneumonia occurs earlier in CHI than in other patient groups, suggesting that the etiology may be different; (3) pneumonia does not tend to occur after the first week of hospitalization in CHI; (4) extubation of CHI patients did not tend to lead to pneumonia; and (5) pneumonia prolongs ICU and hospital stay in CHI patients.	UNIV WASHINGTON,HARBORVIEW MED CTR,SCH MED,DEPT MED PULM & CRIT CARE,SEATTLE,WA 98104; UNIV WASHINGTON,HARBORVIEW MED CTR,SCH MED,DEPT ANESTHESIOL,SEATTLE,WA 98104; UNIV WASHINGTON,HARBORVIEW MED CTR,SCH MED,DEPT NEUROSURG,SEATTLE,WA 98104				Pierson, David/AAJ-9872-2021		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [30543] Funding Source: Medline		ANDREWS CP, 1981, CHEST, V80, P254, DOI 10.1378/chest.80.3.254; ATHERTON ST, 1978, LANCET, V2, P968; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BELL RC, 1983, ANN INTERN MED, V99, P293, DOI 10.7326/0003-4819-99-3-293; BRAUN SR, 1986, CRIT CARE MED, V14, P198, DOI 10.1097/00003246-198603000-00006; BRYAN CS, 1984, AM REV RESPIR DIS, V129, P668, DOI 10.1164/arrd.1984.129.5.668; CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318; Cox DR, 1984, ANAL SURVIVAL DATA; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; CROSS AS, 1981, AM J MED, V70, P681, DOI 10.1016/0002-9343(81)90596-9; DRICKS MR, 1987, NEW ENGL J MED, V317, P1376; ESPERSEN F, 1981, J INFECT DIS, V144, P19, DOI 10.1093/infdis/144.1.19; FAGON JY, 1988, AM REV RESPIR DIS, V138, P110, DOI 10.1164/ajrccm/138.1.110; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; Fleiss J, 1981, STAT METHODS RATES P, V2nd; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; JIMENEZ P, 1989, CRIT CARE MED, V17, P882, DOI 10.1097/00003246-198909000-00007; JOHANSON WG, 1972, ANN INTERN MED, V77, P701, DOI 10.7326/0003-4819-77-5-701; LAFORCE FM, 1981, AM J MED, V70, P664, DOI 10.1016/0002-9343(81)90593-3; LANGER M, 1989, AM REV RESPIR DIS, V140, P302, DOI 10.1164/ajrccm/140.2.302; LANGER M, 1987, INTENS CARE MED, V13, P342; MANDELLI M, 1986, LANCET, V2, P1094; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; SALATA RA, 1987, AM REV RESPIR DIS, V135, P426; SCHWARTZ SN, 1978, J INFECT DIS, V138, P227, DOI 10.1093/infdis/138.2.227; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523	26	86	87	0	0	AMER LUNG ASSOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019	0003-0805			AM REV RESPIR DIS	Am. Rev. Respir. Dis.	AUG	1992	146	2					290	294		10.1164/ajrccm/146.2.290			5	Respiratory System	Science Citation Index Expanded (SCI-EXPANDED)	Respiratory System	JP348	WOS:A1992JP34800004	1489114				2022-02-06	
J	CANTU, RC				CANTU, RC			CEREBRAL CONCUSSION IN SPORT - MANAGEMENT AND PREVENTION	SPORTS MEDICINE			English	Article								This article explains the various stresses (tensile, compressive, and shearing) that can affect the brain, and how they may produce the different types of brain injury. The biomechanical forces and dynamics that produce coup versus contra coup injury are covered, as are the common intracranial athletic head injuries, i.e. concussion and the various intracranial haematomas (epidural, subdural, subarachnoid and intracerebral). Though less common in occurrence, because their outcome is so catastrophic, space is also devoted to the recognition, the treatment and (especially in the latter case) the prevention of the malignant brain oedema syndrome of the adolescent and the second impact syndrome of the adult. A major emphasis of this paper is the recognition of the 3 grades of cerebral concussion and the delineation of clear guidelines as to when it is safe to return to collision sports after sustaining such injuries, for the first, second or third time during a given season. Clear guidelines are also presented as to when to discontinue collision sport competition for the remainder of the season after multiple concussions. Because of the concern for the second impact syndrome, the requirement to never allow an athlete with postconcussion syndrome symptoms to return to competition is emphasised. Also covered is the prevention of head injuries, which sports are at greatest risk, and the need for additional research on the cumulative effects of concussion.			CANTU, RC (corresponding author), EMERSON HOSP,NEUROSURG SERV,JOHN CUMING BLDG,SUITE 820,CONCORD,MA 01742, USA.							0	86	86	0	20	ADIS INTERNATIONAL LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 10, NEW ZEALAND	0112-1642			SPORTS MED	Sports Med.	JUL	1992	14	1					64	74		10.2165/00007256-199214010-00005			11	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	HZ813	WOS:A1992HZ81300005	1641543				2022-02-06	
J	LEVIN, HS; EISENBERG, HM				LEVIN, HS; EISENBERG, HM			NEUROPSYCHOLOGICAL OUTCOME OF CLOSED HEAD-INJURY IN CHILDREN AND ADOLESCENTS	CHILDS BRAIN			English	Article											LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DEPT SURG,DIV NEUROSURG,GALVESTON,TX 77550, USA.						Benton A. L., 1959, RIGHT LEFT DISCRIMIN; Benton A.L., 1967, CORTEX, V3, P32, DOI [10.1016/s0010-9452(67)80005-4, DOI 10.1016/S0010-9452(67)80005-4]; BENTON AL, 1962, ARCH NEUROL-CHICAGO, V7, P347, DOI 10.1001/archneur.1962.04210040099011; BENTON AL, 1969, STEREOGNOSIS TEST; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BUSCHKE H, 1974, J EXP CHILD PSYCHOL, V18, P488, DOI 10.1016/0022-0965(74)90126-X; CRAFT AW, 1972, HDB CLIN NEUROLOGY, V23, P445; DENCKLA MB, 1973, DEV MED CHILD NEUROL, V15, P635; Flach J, 1972, Scand J Rehabil Med, V4, P9; HECAEN H, 1976, BRAIN LANG, V3, P114, DOI 10.1016/0093-934X(76)90009-2; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1969, BRIT J PSYCHIAT; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; Koppitz E. M, 1964, BENDER GESTALT TEST; LEVIN HS, 1976, CORTEX, V12, P175, DOI 10.1016/S0010-9452(76)80021-4; LEVIN HS, 1977, CORTEX, V13, P119, DOI 10.1016/S0010-9452(77)80003-8; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; LEVIN HS, ARCH NEUROL; LEVIN HS, 1976, J PEDIATR PSYCHOL, V1, P38; SCHAFFER D, 1975, CIBA F S, V34; Spreen O., 1969, CORTEX, V5, P171; Spreen O., 1969, NEUROSENSORY CTR COM; STOVER SL, 1976, ARCH PHYS MED REHAB, V57, P201; TEASDALE G, 1974, LANCET, V2, P81; Van Allen MW, 1968, CORTEX, V93, P38, DOI [10.1016/S0010-9452(68)80018-8, DOI 10.1016/S0010-9452(68)80018, 10.1016/S0010-9452(68)80018]; WARRINGT.EK, 1970, NATURE, V228, P628, DOI 10.1038/228628a0	26	86	86	1	5	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0302-2803			CHILD BRAIN			1979	5	3					281	292					12	Clinical Neurology; Neurosciences; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pediatrics	GS718	WOS:A1979GS71800011	456104				2022-02-06	
J	BAKAY, L; LEE, JC; LEE, GC; PENG, JR				BAKAY, L; LEE, JC; LEE, GC; PENG, JR			EXPERIMENTAL CEREBRAL CONCUSSION .1. ELECTRON-MICROSCOPIC STUDY	JOURNAL OF NEUROSURGERY			English	Article									SUNY BUFFALO,CTR CLIN,DEPT NEUROSURG,BUFFALO,NY 14214; SUNY BUFFALO,DEPT ANAT SCI,BUFFALO,NY 14214; SUNY BUFFALO,DEPT CIVIL ENGN,BUFFALO,NY 14214								BAKAY L, 1968, BRAIN, V91, P697, DOI 10.1093/brain/91.4.697; BAKAY L, 1975, EXP BRAIN RES, V23, P241; BRODERSON P, 1975, BRAIN WORK, P269; CASSEN B, 1960, AM J PHYSIOL, V198, P1296, DOI 10.1152/ajplegacy.1960.198.6.1296; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DENNYBROWN D, 1961, ARCH NEUROL-CHICAGO, V5, P1; GRONWALL D, 1975, LANCET, V2, P995; Gurdjian E S, 1972, Clin Neurosurg, V19, P1; HAMBERGER A, 1966, J NEUROPATH EXP NEUR, V25, P68, DOI 10.1097/00005072-196601000-00004; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; QUADBECK G, 1955, Z NATURFORSCH PT B, V10, P168, DOI 10.1515/znb-1955-0310; RINDER L, 1968, ACTA NEUROPATHOL, V11, P201; RINDER L, 1968, ACTA NEUROPATHOL, V11, P183; ROIZIN L, 1975, J HISTOCHEM CYTOCHEM, V23, P402, DOI 10.1177/23.6.168247; WARD AA, 1966, CLIN NEUROSURG, V12, P95; YU MC, 1972, ACTA NEUROPATHOL, V22, P222, DOI 10.1007/BF00684525	17	86	89	1	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1977	47	4					525	531		10.3171/jns.1977.47.4.0525			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DW525	WOS:A1977DW52500004	903805				2022-02-06	
J	DENNYBROWN, D				DENNYBROWN, D			DISABILITY ARISING FROM CLOSED HEAD INJURY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																	Abbott WD, 1943, J AMER MED ASSOC, V121, P739, DOI 10.1001/jama.1943.02840100025007; Abbott WD, 1943, J AMER MED ASSOC, V121, P664, DOI 10.1001/jama.1943.02840090034010; COLE EM, IN PRESS A RES NERV; Denny-Brown D., 1942, NEW ENGL J MED, V227, P771; DENNYBROWN D, IN PRESS A RES NERV; GREENWOOD J, 1940, SO M J, V33, P1077; Moore BE, 1944, NEW ENGL J MED, V230, P445, DOI 10.1056/NEJM194404132301501; MUNRO D, 1938, CRANIOCEREBRAL INJUR; PILCHER C, 1942, WAR MED, V2, P114; Ruesch J, 1943, ARCH NEURO PSYCHIATR, V50, P165, DOI 10.1001/archneurpsyc.1943.02290200065005; Ruesch J, 1944, AM J PSYCHIAT, V100, P480, DOI 10.1176/ajp.100.4.480; Russell W Ritchie, 1934, Edinb Med J, V41, P129; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Schaller WF, 1939, J AMER MED ASSOC, V113, P1779; Symonds C P, 1937, Proc R Soc Med, V30, P1081; Symonds CP, 1943, LANCET, V1, P7; [No title captured]; [No title captured]	18	86	86	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.		1945	127	8					429	436		10.1001/jama.1945.02860080001001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA929	WOS:A1945YA92900001					2022-02-06	
J	Jiang, JY; Gao, GY; Feng, JF; Mao, Q; Chen, LG; Yang, XF; Liu, JF; Wang, YH; Qiu, BH; Huang, XJ				Jiang, Ji-Yao; Gao, Guo-Yi; Feng, Jun-Feng; Mao, Qing; Chen, Li-Gang; Yang, Xiao-Feng; Liu, Jin-Fang; Wang, Yu-Hai; Qiu, Bing-Hui; Huang, Xian-Jian			Traumatic brain injury in China	LANCET NEUROLOGY			English	Article							MILD HYPOTHERMIA THERAPY; DECOMPRESSIVE CRANIECTOMY; HEAD TRAUMA; TARGETED MANAGEMENT; EASTERN CHINA; EPIDEMIOLOGY; MULTICENTER; PRESSURE; TRIAL; CRANIOPLASTY	China has more patients with traumatic brain injury (TBI) than most other countries in the world, making this condition a major public health concern. Population-based mortality of TBI in China is estimated to be approximately 13 cases per 100 000 people, which is similar to the rates reported in other countries. The implementation of various measures, such as safety legislation for road traffic, establishment of specialised neurosurgical intensive care units, and the development of evidence-based guidelines, have contributed to advancing prevention and care of patients with TBI in China. However, many challenges remain, which are augmented further by regional differences in TBI care. High-level care, such as intracranial pressure monitoring, is not universally available yet. In the past 30 years, the quality of TBI research in China has substantially improved, as evidenced by an increasing number of clinical trials done. The large number of patients with TBI and specialised trauma centres offer unique opportunities for TBI research in China. Furthermore, the formation and development of research collaborations between China and international groups are considered essential to advancing the quality of TBI care and research in China, and to improve quality of life in patients with this condition.	[Jiang, Ji-Yao; Gao, Guo-Yi; Feng, Jun-Feng; Mao, Qing] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Neurosurg, Shanghai 200127, Peoples R China; [Chen, Li-Gang] Southwest Med Univ, Affiliated Hosp, Dept Neurosurg, Luzhou, Peoples R China; [Yang, Xiao-Feng] Zhejiang Univ, Affiliated Hosp 1, Dept Neurosurg, Hangzhou, Zhejiang, Peoples R China; [Liu, Jin-Fang] Southcent Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Hunan, Peoples R China; [Wang, Yu-Hai] Wuxi Taihu Hosp, Dept Neurosurg, Wuxi, Peoples R China; [Qiu, Bing-Hui] Southern Med Univ, Southern Hosp, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China; [Huang, Xian-Jian] Shenzhen Univ, Affiliated Hosp 1, Dept Neurosurg, Shenzhen, Peoples R China		Jiang, JY (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Neurosurg, Shanghai 200127, Peoples R China.	jiyaojiang@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81772058, 81671198, 81771317, 81571883]	The National Natural Science Foundation of China provides financial support to J-YJ (81772058), G-YG (81671198), J-FF (81771317), and QM (81571883) for traumatic brain injury research. J-YJ, G-YG, J-FF, QM, L-GC, X-FY, J-FL, Y-HW, B-HQ, and X-JH declare no competing interests.	Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Cheng PC, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002332; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Chinabgao, CHIN REP HALL; Chinese Congress of Neurological Surgeons, 2015, CHIN J NEUROSURG, V31, P757; Chinese Congress of Neurological Surgeons, 2018, CHIN J NEUROSURG, V34, P649; Chinese Congress of Neurological Surgeons, 2014, CHIN J NEUROSURG, V30, P840; Chinese Congress of Neurological Surgeons, 2016, CHIN J NEUROSURG, V32, P767; Chinese Congress of Neurological Surgeons, 2017, CHIN J NEUROSURG, V33, P652; Chinese Congress of Neurological Surgeons CNEC, 2011, CHIN J NEUROSURG, V27, P1073; Chinese Congress of Neurological Surgeons CNEC, 2008, CHIN J NEUROSURG, V24, P723; Chinese Congress of Neurological Surgeons CNEC, 2013, CHIN J NEUROSURG, V29, P967; Chinese Congress of Neurological Surgeons CNEC, 2009, CHIN J NEUROSURG, V25, P100; Clifton GL, 2011, THER HYPOTHERMIA TEM, V1, P3, DOI 10.1089/ther.2010.1500; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Hu J, 2009, CHIN J NEUROSURG DIS, V8, P47; [惠纪元 Hui Jiyuan], 2014, [中华神经外科杂志, Chinese Journal of Neurosurgery], V30, P56; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Jiang JY, 2007, SURG NEUROL, V68, P2, DOI 10.1016/j.surneu.2007.09.016; Jiang JY, 2013, INJURY, V44, P1453, DOI 10.1016/j.injury.2012.08.045; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Jiang RC, 2018, JAMA NEUROL, V75, P1338, DOI 10.1001/jamaneurol.2018.2030; Khor D, 2018, WORLD J SURG, V42, P1727, DOI 10.1007/s00268-017-4373-0; Kou K, 2014, WORLD J EMERG MED, V5, P245, DOI 10.5847/wjem.j.issn.1920-8642.2014.04.001; Lei J, 2015, J NEUROTRAUM, V32, P1584, DOI 10.1089/neu.2014.3768; Lei J, 2015, CONTEMP CLIN TRIALS, V40, P9, DOI 10.1016/j.cct.2014.11.008; [李谷 LI Gu], 2008, [中华神经外科杂志, Chinese Journal of Neurosurgery], V24, P750; Li JL, 2013, J TRAUMA SURG, V15, P492; Li YM, 2017, J CLIN NEUROSCI, V44, P107, DOI 10.1016/j.jocn.2017.05.026; Li YM, 2017, BRAIN INJURY, V31, P1094, DOI 10.1080/02699052.2017.1298004; Lin SQ, 2016, CHIN MED EQUIP, V13, P121; [刘兵 LIU Bing], 2007, [中华神经外科杂志, Chinese Journal of Neurosurgery], V23, P496; Liu H, 2015, WORLD NEUROSURG, V83, P794, DOI 10.1016/j.wneu.2014.12.040; [刘永 LIU Yong], 2008, [苏州大学学报. 医学版, Suzhou University Journal of Medical Science], V28, P402; Ma JH, 2017, J TRAUMA SURG, V19, P411; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Majdan M, 2016, LANCET PUBLIC HEALTH, V1, pE76, DOI 10.1016/S2468-2667(16)30017-2; National Bureau of Statistics of China, NAT DAT; National Health Commission of China, CONT IMPR TRAUM RESC; [倪燕青 Ni Yanqing], 2018, [中华创伤杂志, Chinese Journal of Trauma], V34, P293; Qiu WS, 2009, CRIT CARE, V13, DOI 10.1186/cc8178; Qiu WS, 2006, J CLIN NEUROSCI, V13, P995, DOI 10.1016/j.jocn.2006.02.027; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Shao JB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051634; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Stocchetti N, 2017, LANCET NEUROL, V16, P452, DOI 10.1016/S1474-4422(17)30118-7; Stocchetti N, 2014, NEW ENGL J MED, V370, P2121, DOI 10.1056/NEJMra1208708; Tian HL, 2008, NEUROSURG REV, V31, P431, DOI 10.1007/s10143-008-0153-5; Vergouwen MDI, 2006, LANCET NEUROL, V5, P1029, DOI 10.1016/S1474-4422(06)70582-8; WANG CC, 1986, ARCH NEUROL-CHICAGO, V43, P570, DOI 10.1001/archneur.1986.00520060034013; Wang HQ, 2013, EPILEPSY RES, V107, P272, DOI 10.1016/j.eplepsyres.2013.10.006; Wang L, 2018, CHIN J DISASTER MED, V6, P485; Wen L, 2007, J CRANIOFAC SURG, V18, P526, DOI 10.1097/scs.0b013e3180534348; Wen L, 2015, BRAIN INJURY, V29, P1654, DOI 10.3109/02699052.2015.1075248; Weng CQ, 2006, FUJIAN MED J, V28, P44; Weng WJ, 2019, J NEUROTRAUM, V36, P1168, DOI 10.1089/neu.2018.5881; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Wu X, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2045-x; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Xu HM, 2016, WORLD NEUROSURG, V88, P289, DOI 10.1016/j.wneu.2015.12.028; Yang SZ, 2006, CHIN J NEUROMED, V5, P274; Yang YC, 1987, CHINESE J NEUROSURGE, V3, P23; Yuan Q, 2016, NEUROSURGERY, V78, P361, DOI 10.1227/NEU.0000000000001050; Yuan Q, 2015, CRIT CARE MED, V43, P1405, DOI 10.1097/CCM.0000000000000965; [袁强 Yuan Qiang], 2013, [中华神经外科杂志, Chinese Journal of Neurosurgery], V29, P120; Yuan Q, 2012, INJURY, V43, P2094, DOI 10.1016/j.injury.2012.03.028; Zhang QS, 2014, CHIN J PRACT NERV DI, V11, P33; Zhang YiHua, 2015, Journal of Third Military Medical University, V37, P480; Zhao QJ, 2011, J CRIT CARE, V26, P311, DOI 10.1016/j.jcrc.2010.08.014; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4; Zhi DS, 1999, SURG NEUROL, V52, P393, DOI 10.1016/S0090-3019(99)00101-9; Zhou L, 2000, CHIN J TRAUMATOL, V16, P147; Zhu GL, 1989, CHIN J NEUROSURG S, V5, P44; 张玉琪, 2011, [中华神经外科杂志, Chinese Journal of Neurosurgery], V27, P217; 刘敬业, 2007, [中华神经外科杂志, Chinese Journal of Neurosurgery], V23, P510; 和崇军, 2007, [中华神经外科杂志, Chinese Journal of Neurosurgery], V23, P236	83	85	116	17	52	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2019	18	3					286	295		10.1016/S1474-4422(18)30469-1			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HL2BV	WOS:000458509100020	30784557		Y	N	2022-02-06	
J	Sun, GY; Simonyi, A; Fritsche, KL; Chuang, DY; Hannink, M; Gu, ZZ; Greenlie, CM; Yao, JK; Lee, JC; Beversdorf, DQ				Sun, Grace Y.; Simonyi, Agnes; Fritsche, Kevin L.; Chuang, Dennis Y.; Hannink, Mark; Gu, Zezong; Greenlie, C. Michael; Yao, Jeffrey K.; Lee, James C.; Beversdorf, David Q.			Docosahexaenoic acid (DHA): An essential nutrient and a nutraceutical for brain health and diseases	PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS			English	Article						Docosahexaenoic acid (DHA); Polyunsaturated fatty acids (PUFA); IPLA(2); Alox 15; Oxylipins Neuroprotectin 1 (NPD1); Resolving; Neuroinflammation; Signaling pathways; Oxidative metabolites; 4-hydoxyhexenal (4-HHE); Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B); Nuclear factor (erythroid-derived 2)-like 2 (Nrf2); Antioxidant response element (ARE); Heme oxygenase-1 (HO-1); Brain-derived neurotropic factor (BDNF); Brain development; Life spectrum	POLYUNSATURATED FATTY-ACIDS; LONG-CHAIN OMEGA-3-FATTY-ACIDS; INDEPENDENT PHOSPHOLIPASE A(2); AUTISM SPECTRUM DISORDERS; PLACEBO-CONTROLLED TRIAL; AMYLOID-BETA PEPTIDE; DIETARY N-3 PUFA; ALZHEIMERS-DISEASE; EICOSAPENTAENOIC ACID; LIPID-PEROXIDATION	Docosahexaenoic acid (DHA), a polyunsaturated fatty acid (PUFA) enriched in phospholipids in the brain and retina, is known to play multi-functional roles in brain health and diseases. While arachidonic acid (AA) is released from membrane phospholipids by cytosolic phospholipase A(2) (cPLA(2)), DHA is linked to action of the Ca2+-independent iPLA2. DHA undergoes enzymatic conversion by 15-lipoxygenase (Alox 15) to form oxylipins including resolvins and neuroprotectins, which are powerful lipid mediators. DHA can also undergo non enzymatic conversion by reacting with oxygen free radicals (ROS), which cause the production of 4-hydoxyhexenal (4-HHE), an aldehyde derivative which can form adducts with DNA, proteins and lipids. In studies with both animal models and humans, there is evidence that inadequate intake of maternal n-3 PUFA may lead to aberrant development and function of the central nervous system (CNS). What is less certain is whether consumption of n-3 PUFA is important in maintaining brain health throughout one's life span. Evidence mostly from non-human studies suggests that DHA intake above normal nutritional requirements might modify the risk/course of a number of diseases of the brain. This concept has fueled much of the present interest in DHA research, in particular, in attempts to delineate mechanisms whereby DHA may serve as a nutraceutical and confer neuroprotective effects. Current studies have revealed ability for the oxylipins to regulation of cell redox homeostasis through the Nuclear factor (erythroid-derived 2)-like 2/Antioxidant response element (Nrf2/ARE) anti-oxidant pathway, and impact signaling pathways associated with neurotransmitters, and modulation of neuronal functions involving brain-derived neurotropic factor (BDNF). This review is aimed at describing recent studies elaborating these mechanisms with special regard to aging and Alzheimer's disease, autism spectrum disorder, schizophrenia, traumatic brain injury, and stroke.	[Sun, Grace Y.; Simonyi, Agnes; Hannink, Mark] Univ Missouri, Dept Biochem, 117 Schweitzer Hall, Columbia, MO 65211 USA; [Fritsche, Kevin L.] Univ Missouri, Dept Nutr & Exercise Physiol, Columbia, MO 65211 USA; [Chuang, Dennis Y.] Univ Hosp Cleveland, Med Ctr, Dept Neurol, Cleveland, OH 44106 USA; [Chuang, Dennis Y.] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Gu, Zezong] Univ Missouri, Sch Med, Dept Pathol & Anat Sci, Columbia, MO 65211 USA; [Greenlie, C. Michael] Univ Missouri, Dept Chem, Columbia, MO 65211 USA; [Yao, Jeffrey K.] Univ Pittsburgh, Sch Med, Med Res Serv, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA; [Yao, Jeffrey K.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA; [Lee, James C.] Univ Illinois, Dept Bioengn, Chicago, IL USA; [Beversdorf, David Q.] Univ Missouri, Sch Med, Dept Radiol Neurol & Psychol Sci, Columbia, MO 65211 USA; [Beversdorf, David Q.] Univ Missouri, Sch Med, Thompson Ctr, Radiol, Columbia, MO 65211 USA		Sun, GY (corresponding author), Univ Missouri, Dept Biochem, 117 Schweitzer Hall, Columbia, MO 65211 USA.			Lee, James/0000-0002-7173-4875	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG044404] Funding Source: NIH RePORTER		Afshordel S, 2015, PROSTAG LEUKOTR ESS, V92, P23, DOI 10.1016/j.plefa.2014.05.008; Ajit D, 2016, NEUROCHEM INT, V97, P49, DOI 10.1016/j.neuint.2016.05.004; Al-Farsi YM, 2013, NUTRITION, V29, P1142, DOI 10.1016/j.nut.2013.03.009; Amminger GP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8934; Amminger GP, 2010, ARCH GEN PSYCHIAT, V67, P146, DOI 10.1001/archgenpsychiatry.2009.192; Anderson R, 2001, J MOL NEUROSCI, V16, P279; Anthonymuthu TS, 2016, BRAIN RES, V1640, P57, DOI 10.1016/j.brainres.2016.02.006; Arsenault D., 2011, PLOS ONE, V6; Bazan NG, 2013, PROSTAG LEUKOTR ESS, V88, P127, DOI 10.1016/j.plefa.2012.08.008; BAZAN N G, 1981, Progress in Lipid Research, V20, P523; Bazan NG, 2005, BRAIN PATHOL, V15, P159; Bazan NG, 2012, EXP NEUROL, V236, P122, DOI 10.1016/j.expneurol.2012.04.007; Begum G, 2013, TRANSL STROKE RES, V4, P635, DOI 10.1007/s12975-013-0282-1; Bentsen H, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.110; Bentsen H, 2011, BIOL PSYCHIAT, V70, P97, DOI 10.1016/j.biopsych.2011.02.011; Berger GE, 2007, J CLIN PSYCHIAT, V68, P1867, DOI 10.4088/JCP.v68n1206; Bu JY, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/6906712; Burckhardt M, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009002.pub3; Calon F, 2004, NEURON, V43, P633, DOI 10.1016/j.neuron.2004.08.013; Carabelli B, 2015, MOL NEUROBIOL, V52, P206, DOI 10.1007/s12035-014-8849-8; Cederholm T, 2017, CURR OPIN CLIN NUTR, V20, P104, DOI 10.1097/MCO.0000000000000350; Chalon S, 2006, PROSTAG LEUKOTR ESS, V75, P259, DOI 10.1016/j.plefa.2006.07.005; Chang CY, 2013, J NUTR BIOCHEM, V24, P2127, DOI 10.1016/j.jnutbio.2013.08.004; Chen CT, 2008, PROSTAG LEUKOTR ESS, V79, P85, DOI 10.1016/j.plefa.2008.09.003; Chen ZH, 2006, FEBS LETT, V580, P479, DOI 10.1016/j.febslet.2005.12.045; Chen ZH, 2005, J BIOL CHEM, V280, P41921, DOI 10.1074/jbc.M508556200; Chew EY, 2015, JAMA-J AM MED ASSOC, V314, P791, DOI 10.1001/jama.2015.9677; Chew WS, 2017, NEUROSCIENCE, V340, P91, DOI 10.1016/j.neuroscience.2016.10.037; Chew WS, 2016, MOL NEUROBIOL, V53, P500, DOI 10.1007/s12035-014-9026-9; Chuang DY, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0419-0; Cipollina C, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/501792; Cipollina C, 2014, BBA-GEN SUBJECTS, V1840, P2299, DOI 10.1016/j.bbagen.2014.02.024; Cipollina C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094836; Condray Ruth, 2011, Front Biosci (Schol Ed), V3, P298, DOI 10.2741/s153; Csala M, 2015, BBA-MOL BASIS DIS, V1852, P826, DOI 10.1016/j.bbadis.2015.01.015; Cunnane SC, 2003, PROG LIPID RES, V42, P544, DOI 10.1016/S0163-7827(03)00038-9; Davis-Bruno K, 2011, BIRTH DEFECTS RES B, V92, P240, DOI 10.1002/bdrb.20311; Fernandes DPD, 2015, NUTR HOSP, V32, P528, DOI 10.3305/nh.2015.32.2.9111; Denis I, 2013, AGEING RES REV, V12, P579, DOI 10.1016/j.arr.2013.01.007; Derosa G, 2012, J CLIN LIPIDOL, V6, P553, DOI 10.1016/j.jacl.2012.02.010; Devassy JG, 2016, ADV NUTR, V7, P905, DOI 10.3945/an.116.012187; du Bois TM, 2005, PROG NEURO-PSYCHOPH, V29, P878, DOI 10.1016/j.pnpbp.2005.04.034; Dyall SC, 2008, NEUROMOL MED, V10, P219, DOI 10.1007/s12017-008-8036-z; Dyall SC, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00052; Eady TN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046151; Eckert GP, 2011, BBA-BIOMEMBRANES, V1808, P236, DOI 10.1016/j.bbamem.2010.10.014; El-Ansary AK, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-63; Emsley R, 2008, PSYCHIAT RES, V161, P284, DOI 10.1016/j.psychres.2007.06.029; Farias J. G., 2016, EXP BIOL MED; Fedorova I, 2009, BEHAV NEUROSCI, V123, P196, DOI 10.1037/a0013801; Fenton WS, 2000, BIOL PSYCHIAT, V47, P8, DOI 10.1016/S0006-3223(99)00092-X; Figueroa JD, 2013, J NEUROTRAUM, V30, P853, DOI 10.1089/neu.2012.2718; Fiol-deRoque MA, 2013, BIOGERONTOLOGY, V14, P763, DOI 10.1007/s10522-013-9461-4; Freeman MP, 2006, J CLIN PSYCHIAT, V67, P1954, DOI 10.4088/JCP.v67n1217; Freund-Levi Y, 2006, ARCH NEUROL-CHICAGO, V63, P1402, DOI 10.1001/archneur.63.10.1402; Gan L, 2014, BBA-MOL BASIS DIS, V1842, P1208, DOI 10.1016/j.bbadis.2013.12.011; Gao B, 2014, CLIN PHARMACOL-ADV A, V6, P19, DOI 10.2147/CPAA.S35078; Gao JQ, 2016, INT J DEV NEUROSCI, V49, P67, DOI 10.1016/j.ijdevneu.2015.11.006; Gatbonton-Schwager TN, 2014, REDOX BIOL, V2, P755, DOI 10.1016/j.redox.2014.04.009; Gharami K, 2015, NEUROCHEM INT, V89, P51, DOI 10.1016/j.neuint.2015.08.014; Green JT, 2008, J LIPID RES, V49, P939, DOI 10.1194/jlr.R700017-JLR200; Green KN, 2007, J NEUROSCI, V27, P4385, DOI 10.1523/JNEUROSCI.0055-07.2007; Grosso G, 2016, J AFFECT DISORDERS, V205, P269, DOI 10.1016/j.jad.2016.08.011; Guesnet P, 2011, BIOCHIMIE, V93, P7, DOI 10.1016/j.biochi.2010.05.005; Guichardant M, 2006, PROSTAG LEUKOTR ESS, V75, P179, DOI 10.1016/j.plefa.2006.05.006; Guixa-Gonzalez R, 2016, SCI REP-UK, V6, DOI 10.1038/srep19839; Harris WS, 2008, ATHEROSCLEROSIS, V197, P12, DOI 10.1016/j.atherosclerosis.2007.11.008; Harris WS, 2007, PHARMACOL RES, V55, P217, DOI 10.1016/j.phrs.2007.01.013; Harvey LD, 2015, ASN NEURO, V7, DOI 10.1177/1759091415618969; Hashimoto M, 2006, CLIN EXP PHARMACOL P, V33, P934, DOI 10.1111/j.1440-1681.2006.04467.x; Hashimoto M, 2015, BBA-MOL CELL BIOL L, V1851, P203, DOI 10.1016/j.bbalip.2014.10.009; He Y, 2011, ASN NEURO, V3, P13, DOI 10.1042/AN20100025; Hedelin M, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-38; Heras-Sandoval D, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0525-7; Hjorth E, 2013, J ALZHEIMERS DIS, V35, P697, DOI 10.3233/JAD-130131; Hoen WP, 2013, PSYCHIAT RES, V207, P1, DOI 10.1016/j.psychres.2012.09.041; Hong S, 2007, J AM SOC MASS SPECTR, V18, P128, DOI 10.1016/j.jasms.2006.09.002; Hooijmans CR, 2009, NEUROBIOL DIS, V33, P482, DOI 10.1016/j.nbd.2008.12.002; Hooijmans CR, 2007, BRAIN RES, V1181, P93, DOI 10.1016/j.brainres.2007.08.063; Horvath A., 2017, J NUTR; Hosono T, 2015, J ALZHEIMERS DIS, V48, P149, DOI 10.3233/JAD-150341; Huang Y, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-40; Ishikado A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069415; Ishikado A, 2010, BIOCHEM BIOPH RES CO, V402, P99, DOI 10.1016/j.bbrc.2010.09.124; Jacobson TA, 2012, J CLIN LIPIDOL, V6, P5, DOI 10.1016/j.jacl.2011.10.018; James S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007992.pub2; Jiang LH, 2009, J NUTR BIOCHEM, V20, P735, DOI 10.1016/j.jnutbio.2008.07.003; Jones KL, 2013, BEHAV BRAIN RES, V238, P193, DOI 10.1016/j.bbr.2012.10.028; Julvez J, 2016, AM J EPIDEMIOL, V183, P169, DOI 10.1093/aje/kwv195; Kariv-Inbal Z, 2012, J ALZHEIMERS DIS, V28, P667, DOI 10.3233/JAD-2011-111265; KESHAVAN MS, 1994, J PSYCHIATR RES, V28, P239, DOI 10.1016/0022-3956(94)90009-4; Kim HY, 2014, PROG LIPID RES, V56, P1, DOI 10.1016/j.plipres.2014.06.002; Kondo K, 2014, METABOLISM, V63, P930, DOI 10.1016/j.metabol.2014.04.005; Kusunoki C, 2013, BIOCHEM BIOPH RES CO, V430, P225, DOI 10.1016/j.bbrc.2012.10.115; Labrousse VF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036861; Lee LHW, 2012, INT J NEUROPSYCHOPH, V15, P1087, DOI 10.1017/S1461145711001234; Leslie CC, 2015, J LIPID RES, V56, P1386, DOI 10.1194/jlr.R057588; Lim GP, 2005, J NEUROSCI, V25, P3032, DOI 10.1523/JNEUROSCI.4225-04.2005; Lim SN, 2013, NEUROBIOL DIS, V51, P104, DOI 10.1016/j.nbd.2012.10.021; Lim SN, 2013, EXP NEUROL, V239, P13, DOI 10.1016/j.expneurol.2012.09.015; Liu JJ, 2015, BRAIN RES, V1597, P220, DOI 10.1016/j.brainres.2014.11.059; Long EK, 2010, FREE RADICAL BIO MED, V49, P1, DOI 10.1016/j.freeradbiomed.2010.03.015; Luchtman DW, 2013, NEUROPHARMACOLOGY, V64, P550, DOI 10.1016/j.neuropharm.2012.07.019; Lyall K, 2013, AM J EPIDEMIOL, V178, P209, DOI 10.1093/aje/kws433; Mankad D, 2015, MOL AUTISM, V6, DOI 10.1186/s13229-015-0010-7; Matsui Y. K., 2015, SOC NEUR ABSTR, P26; Mazzocchi-Jones D, 2015, BRAIN RES BULL, V111, P69, DOI 10.1016/j.brainresbull.2014.12.010; McEvoy J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068717; McNamara R.K., 2013, CARDIOVASC PSYCHIAT, V2013; McNamara RK, 2016, EARLY INTERV PSYCHIA, V10, P203, DOI 10.1111/eip.12282; Mechelli A., 2016, SCHIZOPHR RES; Medema S, 2016, SCHIZOPHRENIA BULL, V42, P358, DOI 10.1093/schbul/sbv133; Messamore E, 2017, PROG LIPID RES, V66, P1, DOI 10.1016/j.plipres.2017.01.001; Messamore J. K., 2016, OILSEEDS FATS CORPS, V23, pD112; Meyza K. Z., 2017, NEUROSCI BIOBEHAV RE; Meyza KZ, 2013, BEHAV BRAIN RES, V251, P25, DOI 10.1016/j.bbr.2012.07.021; Morgese MG, 2016, BRAIN SCI, V6, DOI 10.3390/brainsci6030024; Morris MC, 2005, ARCH NEUROL-CHICAGO, V62, P1849, DOI 10.1001/archneur.62.12.noc50161; Mostafa GA, 2015, BEHAV BRAIN FUNCT, V11, DOI 10.1186/s12993-014-0048-2; Nakagawa F, 2014, BIOCHEM BIOPH RES CO, V443, P991, DOI 10.1016/j.bbrc.2013.12.085; NEURINGER M, 1988, ANNU REV NUTR, V8, P517, DOI 10.1146/annurev.nu.08.070188.002505; Nordmann C, 2014, J NEUROCHEM, V131, P163, DOI 10.1111/jnc.12789; Norris SE, 2015, NEUROBIOL AGING, V36, P1659, DOI 10.1016/j.neurobiolaging.2015.01.002; Ohara K, 2007, PROG NEURO-PSYCHOPH, V31, P469, DOI 10.1016/j.pnpbp.2006.11.013; Oksman M, 2006, NEUROBIOL DIS, V23, P563, DOI 10.1016/j.nbd.2006.04.013; Ooi YP, 2017, PHARMACOPSYCHIATRY, V50, DOI 10.1055/s-0042-109400; Osborne C, 2016, NEUROPHARMACOLOGY, V101, P225, DOI 10.1016/j.neuropharm.2015.09.030; Pan JP, 2011, BRAIN RES, V1412, P18, DOI 10.1016/j.brainres.2011.07.015; Parrott MD, 2015, NEUROBIOL AGING, V36, P90, DOI 10.1016/j.neurobiolaging.2014.08.013; Paterniti I, 2014, J NEUROINFLAMM, V11, DOI [10.1186/1742-2094-11-6, 10.1186/s12974-014-0136-0]; Patrick RP, 2015, FASEB J, V29, P2207, DOI 10.1096/fj.14-268342; Pawelczyk T, 2016, J PSYCHIATR RES, V73, P34, DOI 10.1016/j.jpsychires.2015.11.013; Perez SE, 2010, J NEUROSCI RES, V88, P1026, DOI 10.1002/jnr.22266; Perica MM, 2011, NUTR CLIN PRACT, V26, P409, DOI 10.1177/0884533611411306; Pietropaolo S, 2014, PSYCHONEUROENDOCRINO, V49, P119, DOI 10.1016/j.psyneuen.2014.07.002; Posar A, 2016, J PEDIATR NEUROSCI, V11, P225, DOI 10.4103/1817-1745.193363; PREMKUMAR N, 1993, J NEUROSCI RES, V35, P321, DOI 10.1002/jnr.490350312; Pu HJ, 2013, J CEREBR BLOOD F MET, V33, P1474, DOI 10.1038/jcbfm.2013.108; Pusceddu M. M., 2016, INT J NEUROPSYCHOPHA; Ramanadham S, 2015, J LIPID RES, V56, P1643, DOI 10.1194/jlr.R058701; Rao JS, 2007, MOL PSYCHIATR, V12, P151, DOI 10.1038/sj.mp.4001887; Rao JS, 2007, MOL PSYCHIATR, V12, P36, DOI 10.1038/sj.mp.4001888; Reddy R, 2011, PROSTAG LEUKOTR ESS, V84, P79, DOI 10.1016/j.plefa.2010.12.001; Rey C, 2016, BRAIN BEHAV IMMUN, V55, P249, DOI 10.1016/j.bbi.2015.12.013; Riahi Y, 2010, AM J PHYSIOL-ENDOC M, V299, pE879, DOI 10.1152/ajpendo.00508.2010; Richardson AJ, 2000, EUR NEUROPSYCHOPHARM, V10, P189, DOI 10.1016/S0924-977X(00)00068-7; Sandberg M, 2014, NEUROPHARMACOLOGY, V79, P298, DOI 10.1016/j.neuropharm.2013.11.004; Saponetti MS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115780; Scapagnini G, 2011, MOL NEUROBIOL, V44, P192, DOI 10.1007/s12035-011-8181-5; Schaeffer EL, 2005, PSYCHOPHARMACOLOGY, V181, P392, DOI 10.1007/s00213-005-2256-9; Schaeffer EL, 2009, PSYCHOPHARMACOLOGY, V202, P37, DOI 10.1007/s00213-008-1351-0; Schaur RJ, 2015, BIOMOLECULES, V5, P2247, DOI 10.3390/biom5042247; Schlogelhofer M, 2014, EARLY INTERV PSYCHIA, V8, P199, DOI 10.1111/eip.12151; Segawa K, 2014, SCIENCE, V344, P1164, DOI 10.1126/science.1252809; Serhan CN, 2011, CHEM BIOL, V18, P976, DOI 10.1016/j.chembiol.2011.06.008; Serhan CN, 2004, PROSTAG OTH LIPID M, V73, P155, DOI 10.1016/j.prostaglandins.2004.03.005; Serini S, 2016, CURR ALZHEIMER RES, V13, P123, DOI 10.2174/1567205012666150921101147; Shalini S. M, 2017, MOL NEUROBIOL; Shalini SM, 2016, MOL NEUROBIOL; Shalini SM, 2014, NEUROCHEM INT, V78, P96, DOI 10.1016/j.neuint.2014.08.006; Shelat PB, 2008, J NEUROCHEM, V106, P45, DOI 10.1111/j.1471-4159.2008.05347.x; Sliwinski S, 2006, NEUROENDOCRINOL LETT, V27, P465; Smith T, 2010, AM FAM PHYSICIAN, V82, P338; Solberg DK, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-1006-3; Spector AA, 1999, LIPIDS, V34, pS1, DOI 10.1007/BF02562220; Stillwell W, 2003, CHEM PHYS LIPIDS, V126, P1, DOI 10.1016/S0009-3084(03)00101-4; Strokin M, 2007, J NEUROCHEM, V102, P1771, DOI 10.1111/j.1471-4159.2007.04663.x; Sugasini D, 2015, NUTR NEUROSCI, V18, P87, DOI 10.1179/1476830514Y.0000000111; Sumiyoshi T, 2011, PSYCHIAT RES, V186, P23, DOI 10.1016/j.psychres.2010.07.049; Sun GY, 2016, NEUROMOL MED, V18, P241, DOI 10.1007/s12017-016-8411-0; Sun GY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141509; Sun GY, 2014, MOL NEUROBIOL, V50, P6, DOI 10.1007/s12035-014-8662-4; SUN GY, 1968, LIPIDS, V3, P79, DOI 10.1007/BF02530973; SUN GY, 1970, LIPIDS, V5, P1006, DOI 10.1007/BF02533205; Tang MM, 2016, LIPIDS HEALTH DIS, V15, DOI 10.1186/s12944-016-0236-1; Torres M, 2014, BBA-BIOMEMBRANES, V1838, P1680, DOI 10.1016/j.bbamem.2013.12.016; Tremblay ME, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0580-0; Trepanier MO, 2016, EUR J PHARMACOL, V785, P187, DOI 10.1016/j.ejphar.2015.05.045; van de Rest O, 2016, NEUROLOGY, V86, P2063, DOI 10.1212/WNL.0000000000002719; van der Kemp WJM, 2012, SCHIZOPHR RES, V141, P153, DOI 10.1016/j.schres.2012.08.014; Vancassel S, 2001, PROSTAG LEUKOTR ESS, V65, P1, DOI 10.1054/plef.2001.0281; Vandal M, 2014, J NEUROCHEM, V129, P516, DOI 10.1111/jnc.12640; Weiser MJ, 2016, NUTRIENTS, V8, DOI 10.3390/nu8020099; Weiser MJ, 2016, PROSTAG LEUKOTR ESS, V106, P27, DOI 10.1016/j.plefa.2015.10.005; Wellhauser L, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-60; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu AG, 2015, BBA-MOL BASIS DIS, V1852, P951, DOI 10.1016/j.bbadis.2014.12.005; Yanai Hidekatsu, 2017, J Clin Med Res, V9, P1; Yang XG, 2011, NEUROCHEM INT, V58, P321, DOI 10.1016/j.neuint.2010.12.004; Yao J.K., 2003, ABNORMALITIES FATTY, P193; Yao JK, 2016, SCHIZOPHRENIA BULL, V42, P369, DOI 10.1093/schbul/sbv130; Yao JK, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00090; Yao JK, 2011, ANTIOXID REDOX SIGN, V15, P1999, DOI 10.1089/ars.2010.3646; Yavin E, 2001, J MOL NEUROSCI, V16, P229, DOI 10.1385/JMN:16:2-3:229; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zhang MJ, 2014, J NEUROSCI, V34, P1903, DOI 10.1523/JNEUROSCI.4043-13.2014; Zhang WT, 2016, NEUROBIOL DIS, V91, P37, DOI 10.1016/j.nbd.2016.02.020; Zhang Y, 2016, AM J CLIN NUTR, V103, P330, DOI 10.3945/ajcn.115.124081; Zhu DH, 2006, J NEUROSCI, V26, P11111, DOI 10.1523/JNEUROSCI.3505-06.2006; Zilkha N., 2016, NEUROSCIENCE; Zimmer L, 2000, NEUROSCI LETT, V284, P25, DOI 10.1016/S0304-3940(00)00950-2	201	85	88	3	53	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0952-3278	1532-2823		PROSTAG LEUKOTR ESS	Prostaglandins Leukot. Essent. Fatty Acids	SEP	2018	136				SI		3	13		10.1016/j.plefa.2017.03.006			11	Biochemistry & Molecular Biology; Cell Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Endocrinology & Metabolism	GZ5GK	WOS:000449447000002	28314621				2022-02-06	
J	Di Pietro, V; Ragusa, M; Davies, D; Su, ZJ; Hazeldine, J; Lazzarino, G; Hill, LJ; Crombie, N; Foster, M; Purrello, M; Logan, A; Belli, A				Di Pietro, Valentina; Ragusa, Marco; Davies, David; Su, Zhangjie; Hazeldine, Jon; Lazzarino, Giacomo; Hill, Lisa J.; Crombie, Nicholas; Foster, Mark; Purrello, Michele; Logan, Ann; Belli, Antonio			MicroRNAs as Novel Biomarkers for the Diagnosis and Prognosis of Mild and Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; concussion; diagnosis; microRNAs; prognosis; traumatic brain injury	IN-VITRO MODEL; TEMPORAL WINDOW; MESSENGER-RNAS; VULNERABILITY; EXPRESSION; REGULATORS; CONCUSSIONS; TARGETS; CELLS	Traumatic brain injury (TBI) is the leading cause of death and disability in people younger than 45 in Western countries. Despite many studies, no reliable biomarkers have been found to assess TBI severity and predict recovery. MicroRNA (miRNA) profiling has become widely used to identify biomarkers and therapeutic targets. Through use of the TaqMan Array Human MicroRNA A+B Cards, the expression of 754 miRNAs was analyzed in serum of five mild TBI (mTBI) patients with extra-cranial injury (EC), five severe TBI (sTBI) patients with EC, and five healthy volunteers (HV) at 1 day and 15 days post-injury. The aim was to find candidate biomarkers able to discriminate between mTBI and sTBI. Following this, it was possible to select 10 miRNAs for further study in an enlarged validation cohort of 120 patients by using single TaqMan assays at the following time-points: T0-1 h, T4-12 h, T48-72 h, and 15 days from the injury. Analysis revealed two miRNAs (miR-425-5p and miR-502) that were significantly downregulated (p < 0.05) in mTBI at early time-points and are ideal candidates for diagnosis of mTBI, and two miRNAs (miR-21 and miR-335) that were significantly upregulated (p < 0.01) and are valid biomarkers for the diagnosis of sTBI. In addition, miR-425-5p was a strong predictor of 6-month outcome at T0-1 h and T4-12 h, while miR-21 was predictive of the outcome at T4-12 h. The panel of selected miRNAs shows promise as biomarkers to discriminate mTBI from sTBI. In addition, the selected miRNAs represent new potential therapeutic targets.	[Di Pietro, Valentina; Hazeldine, Jon; Hill, Lisa J.; Logan, Ann; Belli, Antonio] Univ Birmingham, Inst Inflammat & Aging, Neurotrauma & Ophthalmol Res Grp, Birmingham, W Midlands, England; [Di Pietro, Valentina; Davies, David; Su, Zhangjie; Hazeldine, Jon; Hill, Lisa J.; Crombie, Nicholas; Logan, Ann; Belli, Antonio] Queen Elizabeth Hosp, Natl Inst Hlth Res, Surg Reconstruct & Microbiol Res Ctr, Birmingham, W Midlands, England; [Ragusa, Marco; Purrello, Michele] Univ Catania, Dept Biomed Sci & Biotechnol, Catania, Italy; [Lazzarino, Giacomo] Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; [Crombie, Nicholas] West Midlands Air Ambulance Trust, Stourbridge, W Midlands, England; [Foster, Mark] Acad Dept Mil Surg & Trauma, Royal Ctr Def Med, Inst Res & Dev, Birmingham, W Midlands, England		Di Pietro, V (corresponding author), Univ Birmingham, Sch Clin & Expt Med, Neurotrauma & Ophtalmol Res Grp, Birmingham B15 2TT, W Midlands, England.	v.dipietro@bham.ac.uk	Ragusa, Marco/D-7691-2010; Belli, Antonio/I-3799-2015; Foster, Mark Anthony/AAS-9284-2020; Hazeldine, Jon/T-5725-2019; Hill, Lisa J/AAO-1560-2021	Ragusa, Marco/0000-0002-4282-920X; Belli, Antonio/0000-0002-3211-9933; Hill, Lisa J/0000-0001-8431-7029; Logan, Ann/0000-0003-3215-5042; Lazzarino, Giacomo/0000-0003-1639-0966	National Institute for Health Research (NIHR)National Institute for Health Research (NIHR); Midlands Neuroscience Training and Research Fund; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MR/N019016/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [G18986] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/N019016/1] Funding Source: researchfish	This study was funded by the National Institute for Health Research (NIHR) and by the Midlands Neuroscience Training and Research Fund. The views expressed are those of the authors and not necessarily those of the National Heath Service, the NIHR or the Department of Health.	Belli A, 2006, J NEUROCHEM, V96, P861, DOI 10.1111/j.1471-4159.2005.03602.x; Bhomia M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28148; Bi YJ, 2009, J CELL PHYSIOL, V218, P467, DOI 10.1002/jcp.21639; Bracko O, 2014, J CEREBR BLOOD F MET, V34, P1522, DOI 10.1038/jcbfm.2014.112; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Di Pietro V, 2015, NEUROCHEM RES, V40, P991, DOI 10.1007/s11064-015-1554-9; Di Pietro V, 2013, MOL CELL BIOCHEM, V375, P185, DOI 10.1007/s11010-012-1541-2; Di Pietro V, 2010, J NEUROTRAUM, V27, P349, DOI 10.1089/neu.2009.1095; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Gauthier BR, 2006, NAT MED, V12, P36, DOI 10.1038/nm0106-36; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Li MA, 2012, BIOESSAYS, V34, P670, DOI 10.1002/bies.201200019; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Omalu B, 2014, PROG NEUROL SURG, V28, P38, DOI 10.1159/000358761; Pritchard CC, 2012, CANCER PREV RES, V5, P492, DOI 10.1158/1940-6207.CAPR-11-0370; Ragusa M, 2013, MOL VIS, V19, P430; Ragusa M, 2010, MOL CANCER THER, V9, P3396, DOI 10.1158/1535-7163.MCT-10-0137; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Sariaslan A., 2016, PLOS MED, V23, P13; Sharma A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112019; Signoretti S., 2001, PM R S2, V3, pS359; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Szafranskil K, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00087; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Toman E, 2016, J ROY ARMY MED CORPS, V162, P103, DOI 10.1136/jramc-2015-000517; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Yokota M, 1999, J CLIN LAB ANAL, V13, P133, DOI 10.1002/(SICI)1098-2825(1999)13:3<133::AID-JCLA8>3.0.CO;2-0; Zafari S., 2015, GERONTOLOGY, V25	33	85	86	5	28	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2017	34	11					1948	1956		10.1089/neu.2016.4857			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EV4KD	WOS:000401727500005	28279125				2022-02-06	
J	Cross, M; Kemp, S; Smith, A; Trewartha, G; Stokes, K				Cross, Matthew; Kemp, Simon; Smith, Andrew; Trewartha, Grant; Stokes, Keith			Professional Rugby Union players have a 60% greater risk of time loss injury after concussion: a 2-season prospective study of clinical outcomes	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							STABILITY FOLLOWING CONCUSSION; TRAUMATIC BRAIN-INJURY; CONSENSUS STATEMENT; FOOTBALL PLAYERS; RECOVERY; SPORT; EPIDEMIOLOGY; SYMPTOMS; RATES; CUP	Aim To investigate incidence of concussion, clinical outcomes and subsequent injury risk following concussion. Methods In a two-season ( 2012/2013, 2013/2014) prospective cohort study, incidence of diagnosed match concussions ( injuries/1000 h), median time interval to subsequent injury of any type ( survival time) and time spent at each stage of the graduated return to play pathway were determined in 810 professional Rugby Union players ( 1176 player seasons). Results Match concussion incidence was 8.9/1000 h with over 50% occurring in the tackle. Subsequent incidence of any injury for players who returned to play in the same season following a diagnosed concussion ( 122/1000 h, 95% CI 106 to 141) was 60% higher ( IRR 1.6, 95% CI 1.4 to 1.8) than for those who did not sustain a concussion ( 76/1000 h, 95% CI 72 to 80). Median time to next injury following return to play was shorter following concussion ( 53 days, 95% CI 41 to 64) than following non-concussive injuries ( 114 days, 95% CI 85 to 143). 38% of players reported recurrence of symptoms or failed to match their baseline neurocognitive test during the graduated return to play protocol. Summary and conclusions Players who returned to play in the same season after a diagnosed concussion had a 60% greater risk of time-loss injury than players without concussion. A substantial proportion of players reported recurrence of symptoms or failed to match baseline neurocognitive test scores during graduated return to play. These data pave the way for trials of more conservative and comprehensive graduated return to play protocols, with a greater focus on active rehabilitation.	[Cross, Matthew; Trewartha, Grant; Stokes, Keith] Univ Bath, Dept Hlth, Bath BA2 7AY, Avon, England; [Kemp, Simon] Rugby Football Union, Twickenham, England; [Smith, Andrew] Mid Yorkshire Hosp NHS Trust, Wakefield, England; [Smith, Andrew] Premiership Rugby, Twickenham, England		Stokes, K (corresponding author), Univ Bath, Dept Hlth, Bath BA2 7AY, Avon, England.	K.Stokes@bath.ac.uk	; Stokes, Keith/C-2605-2009	Trewartha, Grant/0000-0002-9021-8956; Stokes, Keith/0000-0002-5049-2838; Kemp, Simon/0000-0002-3250-2713	Rugby Football Union; Premiership Rugby	Rugby Football Union and Premiership Rugby.	Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Broglio SP, 2015, CLIN SPORT MED, V34, P213, DOI 10.1016/j.csm.2014.12.005; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Fraas MR, 2014, PHYS THER SPORT, V15, P136, DOI 10.1016/j.ptsp.2013.08.002; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Fuller CW, 2015, BRIT J SPORT MED, V49, P478, DOI 10.1136/bjsports-2013-093381; Fuller CW, 2013, J SPORT SCI, V31, P795, DOI 10.1080/02640414.2012.753156; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; Kutcher JS, 2013, BRIT J SPORT MED, V47, P299, DOI 10.1136/bjsports-2013-092257; Louey AG, 2014, ARCH CLIN NEUROPSYCH, V29, P432, DOI 10.1093/arclin/acu020; Lynall RC, 2015, MED SCI SPORT EXER, V47, P2487, DOI 10.1249/MSS.0000000000000716; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; Mayer AR, 2015, NEUROSCI BIOBEHAV R, V49, P8, DOI 10.1016/j.neubiorev.2014.11.016; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory PR, 2002, PHYSICIAN SPORTSMED, V30, P43, DOI 10.3810/psm.2002.08.403; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Quarrie KL, 2007, J SPORT SCI, V25, P895, DOI 10.1080/02640410600944659; RFU, 2015, PREM RUGB INJ SURV P; Shahim P, 2016, J NEUROTRAUM, V33, P1995, DOI 10.1089/neu.2014.3741; Williams S, 2013, SPORTS MED, V43, P1043, DOI 10.1007/s40279-013-0078-1; World Rugby, 2014, IRB CONC MAN 2014	28	85	85	0	30	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2016	50	15					926	931		10.1136/bjsports-2015-094982			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	DS7AR	WOS:000380935300010	26626266	Green Published, hybrid			2022-02-06	
J	Stern, RA; Tripodis, Y; Baugh, CM; Fritts, NG; Martin, BM; Chaisson, C; Cantu, RC; Joyce, JA; Shah, S; Ikezu, T; Zhang, J; Gercel-Taylor, C; Taylor, DD				Stern, Robert A.; Tripodis, Yorghos; Baugh, Christine M.; Fritts, Nathan G.; Martin, Brett M.; Chaisson, Christine; Cantu, Robert C.; Joyce, James A.; Shah, Sahil; Ikezu, Tsuneya; Zhang, Jing; Gercel-Taylor, Cicek; Taylor, Douglas D.			Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Biomarker; chronic traumatic encephalopathy; diagnosis; exosome; football; neurodegeneration; plasma; tau	REPETITIVE BRAIN TRAUMA; RESEARCH DIAGNOSTIC-CRITERIA; COLLEGIATE FOOTBALL PLAYERS; ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; PATHOGENIC PROTEINS; MILITARY PERSONNEL; 1ST EXPOSURE; INJURY; BLOOD	Background: Chronic traumatic encephalopathy (CTE) is a tauopathy associated with prior exposure to repetitive head impacts, such as those incurred through American football and other collision sports. Diagnosis is made through neuropathological examination. Many of the clinical features of CTE are common in the general population, with and without a history of head impact exposure, making clinical diagnosis difficult. As is now common in the diagnosis of other neurodegenerative disorders, such as Alzheimer's disease, there is a need for methods to diagnose CTE during life through objective biomarkers. Objective: The aim of this study was to examine tau-positive exosomes in plasma as a potential CTE biomarker. Methods: Subjects were 78 former National Football League (NFL) players and 16 controls. Extracellular vesicles were isolated from plasma. Fluorescent nanoparticle tracking analysis was used to determine the number of vesicles staining positive for tau. Results: The NFL group had higher exosomal tau than the control group (p < 0.0001). Exosomal tau discriminated between the groups, with 82% sensitivity, 100% specificity, 100% positive predictive value, and 53% negative predictive value. Within the NFL group, higher exosomal tau was associated with worse performance on tests of memory (p = 0.0126) and psychomotor speed (p = 0.0093). Conclusion: These preliminary findings suggest that exosomal tau in plasma may be an accurate, noninvasive CTE biomarker.	[Stern, Robert A.; Tripodis, Yorghos; Baugh, Christine M.; Fritts, Nathan G.; Martin, Brett M.; Chaisson, Christine; Cantu, Robert C.] Boston Univ, Alzheimers Dis & CTE Ctr, Boston, MA 02118 USA; [Stern, Robert A.; Cantu, Robert C.; Ikezu, Tsuneya] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Stern, Robert A.; Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Tripodis, Yorghos; Chaisson, Christine] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA; [Martin, Brett M.; Chaisson, Christine] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Joyce, James A.] Aethlon Med, San Diego, CA USA; [Shah, Sahil; Gercel-Taylor, Cicek; Taylor, Douglas D.] Exosome Sci, San Diego, CA USA; [Ikezu, Tsuneya] Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA; [Zhang, Jing] Univ Washington, Dept Pathol, Seattle, WA 98195 USA; [Baugh, Christine M.] Harvard Univ, Interfac Initiat Hlth Policy, Cambridge, MA 02138 USA; [Fritts, Nathan G.] OHSU Collaborat Life Sci Bldg, Portland, OR USA; [Gercel-Taylor, Cicek; Taylor, Douglas D.] Theragnostex Inc, Monmouth Jct, NJ USA		Stern, RA (corresponding author), Boston Univ, Sch Med, Alzheimers Dis & CTE Ctr, Dept Neurol, 71 East Concord St, Boston, MA 02118 USA.; Stern, RA (corresponding author), Boston Univ, Sch Med, Alzheimers Dis & CTE Ctr, Dept Neurosurg, 71 East Concord St, Boston, MA 02118 USA.; Stern, RA (corresponding author), Boston Univ, Sch Med, Alzheimers Dis & CTE Ctr, Dept Anat & Neurobiol, 71 East Concord St, Boston, MA 02118 USA.	bobstern@bu.edu	Baugh, Christine/AAG-2324-2020; , Bob/ABA-8507-2020	Baugh, Christine/0000-0002-9340-6338; Tripodis, Yorghos/0000-0003-2190-7608; Ikezu, Tsuneya/0000-0002-3979-8596	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS 078337, R56 NS 078337, P30 AG13846]; National Institutes of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019733]; JetBlue Airlines; National Football League; NFL Players Association; Exosome Sciences, Inc., a subsidiary of Aethlon Medical, Inc.; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS078337, U01NS093334, R01NS078337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG019610, P30AG013846] Funding Source: NIH RePORTER	This study was supported by grants from the National Institutes of Health (R01 NS 078337; R56 NS 078337; P30 AG13846). Christine Baugh is currently supported by the National Institutes of Mental Health under award number T32MH019733. Participant travel was funded by gifts from JetBlue Airlines, the National Football League, and the NFL Players Association. All procedures related to exosome isolation and measurement were conducted at, and fully funded by Exosome Sciences, Inc., a subsidiary of Aethlon Medical, Inc.	Apostolova LG, 2015, NEUROLOGY, V84, P729, DOI 10.1212/WNL.0000000000001231; Aryani A, 2016, MOL NEUROBIOL, V53, P818, DOI 10.1007/s12035-014-9054-5; Asai H, 2015, NAT NEUROSCI, V18, P1584, DOI 10.1038/nn.4132; Baayen RH, 2008, J MEM LANG, V59, P390, DOI 10.1016/j.jml.2007.12.005; BARRATT ES, 1965, PSYCHOL REP, V16, P547, DOI 10.2466/pr0.1965.16.2.547; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BECK AT, 1974, J CONSULT CLIN PSYCH, V42, P861, DOI 10.1037/h0037562; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; BUSS AH, 1957, J CONSULT PSYCHOL, V21, P343, DOI 10.1037/h0046900; Chien DT, 2014, J ALZHEIMERS DIS, V38, P171, DOI 10.3233/JAD-130098; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Dubois B, 2014, LANCET NEUROL, V13, P614, DOI 10.1016/S1474-4422(14)70090-0; Esteves-Villanueva JO, 2015, BIOCHEMISTRY-US, V54, P293, DOI 10.1021/bi501272x; Fiandaca MS, 2015, ALZHEIMERS DEMENT, V11, P600, DOI 10.1016/j.jalz.2014.06.008; Gandy Sam, 2014, F1000Res, V3, P229, DOI 10.12688/f1000research.5372.1; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gardner RC, 2016, J NEUROTRAUM, V33, P157, DOI 10.1089/neu.2014.3805; Goetzl EJ, 2015, NEUROLOGY, V85, P40, DOI 10.1212/WNL.0000000000001702; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Grant D.A., 1981, WISCONSIN CARD SORTI; Gu YJ, 1996, J NEUROCHEM, V67, P1235; Guo JL, 2014, NAT MED, V20, P130, DOI 10.1038/nm.3457; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hampshire A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02972; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Iverson GL, 2015, NEUROSCI BIOBEHAV R, V56, P276, DOI 10.1016/j.neubiorev.2015.05.008; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kang JH, 2015, ALZHEIMERS DEMENT, V11, P772, DOI 10.1016/j.jalz.2015.05.003; Kang JH, 2013, CLIN CHEM, V59, P903, DOI 10.1373/clinchem.2013.202937; Kiernan PT, 2015, SEMIN NEUROL, V35, P20, DOI 10.1055/s-0035-1545080; Klein C, 2002, J NEUROSCI, V22, P698, DOI 10.1523/JNEUROSCI.22-03-00698.2002; Koerte IK, 2016, J NEUROTRAUM, V33, P346, DOI 10.1089/neu.2015.3880; Koerte IK, 2015, BRAIN PATHOL, V25, P318, DOI 10.1111/bpa.12249; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; LaValley MP, 2008, CIRCULATION, V117, P2395, DOI 10.1161/CIRCULATIONAHA.106.682658; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lin AP, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0094-5; LUBKE U, 1994, AM J PATHOL, V145, P175; Molinuevo JL, 2014, ALZHEIMERS DEMENT, V10, P808, DOI 10.1016/j.jalz.2014.03.003; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; Menendez-Gonzalez M, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00065; Montenigro PH, 2015, ANNU REV CLIN PSYCHO, V11, P309, DOI 10.1146/annurev-clinpsy-032814-112814; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Ng TSC, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt239; O'Bryant SE, 2015, ALZHEIMERS DEMENT, V11, P549, DOI 10.1016/j.jalz.2014.08.099; Olazaran J, 2015, J ALZHEIMERS DIS, V45, P1157, DOI 10.3233/JAD-142925; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Peskind ER, 2015, JAMA NEUROL, V72, P1103, DOI 10.1001/jamaneurol.2015.1789; Properzi F, 2013, BIOMARK MED, V7, P769, DOI 10.2217/bmm.13.63; Reitan RM, 1992, TRAIL MAKING TEST MA; Ren Y, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00102; Roth RM, 2005, BRIEF A BEHAV RATING; Schey KL, 2015, METHODS, V87, P75, DOI 10.1016/j.ymeth.2015.03.018; Schneider P, 2009, CNS NEUROSCI THER, V15, P358, DOI 10.1111/j.1755-5949.2009.00104.x; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stern R., 1999, BOSTON QUALITATIVE S; Stern RA, 2003, NEUROPSYCHOLOGICAL A; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Strain JF, 2015, JAMA NEUROL, V72, P773, DOI 10.1001/jamaneurol.2015.0206; Tashiro K, 1997, NEUROREPORT, V8, P2797, DOI 10.1097/00001756-199708180-00029; TAYLOR DD, 1979, ANAL BIOCHEM, V98, P53, DOI 10.1016/0003-2697(79)90704-8; Taylor DD, 2015, METHODS, V87, P1, DOI 10.1016/j.ymeth.2015.08.006; Taylor DD, 2015, METHODS, V87, P3, DOI 10.1016/j.ymeth.2015.02.019; Taylor DD, 2011, SEMIN IMMUNOPATHOL, V33, P441, DOI 10.1007/s00281-010-0234-8; TRAMS EG, 1981, BIOCHIM BIOPHYS ACTA, V645, P63, DOI 10.1016/0005-2736(81)90512-5; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; Turner RC, 2013, FRONT NEUROL, V3, DOI 10.3389/fneur.2012.00186; Villemagne VL, 2015, LANCET NEUROL, V14, P114, DOI 10.1016/S1474-4422(14)70252-2; Villemagne VL, 2014, ALZHEIMERS DEMENT, V10, pS254, DOI 10.1016/j.jalz.2014.04.013; Voyle N, 2015, J ALZHEIMERS DIS, V46, P947, DOI 10.3233/JAD-150020; Wang G, 2014, J PROTEOME RES, V13, P2649, DOI 10.1021/pr5000895; Wechsler, 1997, WECHSLER ADULT INTEL; Weiner Michael W, 2015, Alzheimers Dement, V11, pe1, DOI 10.1016/j.jalz.2014.11.001; Zetterberg H, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt163	85	85	87	6	39	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2016	51	4					1099	1109		10.3233/JAD-151028			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DJ5ID	WOS:000374239300015	26890775	Green Submitted, Green Published, Bronze, Green Accepted			2022-02-06	
J	Pitkanen, A; Lukasiuk, K; Dudek, FE; Staley, KJ				Pitkanen, Asla; Lukasiuk, Katarzyna; Dudek, F. Edward; Staley, Kevin J.			Epileptogenesis	COLD SPRING HARBOR PERSPECTIVES IN MEDICINE			English	Article							TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; DENTATE GRANULE CELLS; SPONTANEOUS RECURRENT SEIZURES; CONTROLLED CORTICAL IMPACT; INDUCED STATUS EPILEPTICUS; FLUID PERCUSSION INJURY; MIDDLE CEREBRAL-ARTERY; SPRAGUE-DAWLEY RATS; TERM VIDEO-EEG	Epileptogenesis is a chronic process that can be triggered by genetic or acquired factors, and that can continue long after epilepsy diagnosis. In 2015, epileptogenesis is not a treatment indication, and there are no therapies available in clinic to treat individuals at risk of epileptogenesis. However, thanks to active research, a large number of animal models have become available for search of molecular mechanisms of epileptogenesis. The first glimpses of treatment targets and biomarkers that could be developed to become useful in clinic are in sight. However, the heterogeneity of the epilepsy condition, and the dynamics of molecular changes over the course of epileptogenesis remain as challenges to overcome.	[Pitkanen, Asla] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, FI-70211 Kuopio, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, FI-70211 Kuopio, Finland; [Lukasiuk, Katarzyna] Polish Acad Sci, M Nencki Inst Expt Biol, PL-02093 Warsaw, Poland; [Dudek, F. Edward] Univ Utah, Dept Neurosurg, Sch Med, Salt Lake City, UT 84108 USA; [Staley, Kevin J.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA		Pitkanen, A (corresponding author), Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, FI-70211 Kuopio, Finland.	asla.pitkanen@uef.fi	Lukasiuk, Katarzyna/F-4636-2010	Lukasiuk, Katarzyna/0000-0002-1582-0920	Academy of FinlandAcademy of FinlandEuropean Commission; UEF Spearhead Project "UEF-Brain"; ERA-NET NEURON II [FA0200006175]; Polish National Research Centre Grant [2011/01/M/NZ3/02139]; Polish Ministry of Science and Education Grant [DNP/N119/ESF-EuroEPINOMICS/2012]; United States National Institutes of Health GrantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS086364]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS086364] Funding Source: NIH RePORTER	This work is supported by the Academy of Finland (A.P.), UEF Spearhead Project "UEF-Brain" (A.P.), ERA-NET NEURON II FA0200006175 (A.P.), Polish National Research Centre Grant 2011/01/M/NZ3/02139 (K.L.), Polish Ministry of Science and Education Grant DNP/N119/ESF-EuroEPINOMICS/2012 (K.L.), and the United States National Institutes of Health Grant R01NS086364 (F.E.D. and K.J.S.).	Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Arntz R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055498; Aronica E, 2007, NEUROBIOL DIS, V26, P497, DOI 10.1016/j.nbd.2007.01.015; Aronica E, 2010, EUR J NEUROSCI, V31, P1100, DOI 10.1111/j.1460-9568.2010.07122.x; BABB TL, 1989, J NEUROSCI, V9, P2562; Baulac M., 2009, EPILEPSIA, V50, P571; Bausch SB, 2000, J NEUROPHYSIOL, V84, P2918, DOI 10.1152/jn.2000.84.6.2918; Beaumont TL, 2012, J NEUROSCI, V32, P14389, DOI 10.1523/JNEUROSCI.3408-12.2012; Becker AJ, 2003, EUR J NEUROSCI, V18, P2792, DOI 10.1111/j.1460-9568.2003.02993.x; Berdichevsky Y, 2013, J NEUROSCI, V33, P9056, DOI 10.1523/JNEUROSCI.3870-12.2013; Berdichevsky Y, 2012, NEUROBIOL DIS, V45, P774, DOI 10.1016/j.nbd.2011.11.001; Berg AT, 2006, NEUROLOGY, V67, P12, DOI 10.1212/01.wnl.0000227190.64928.67; BERTRAM EH, 1993, BRAIN RES, V625, P295, DOI 10.1016/0006-8993(93)91071-Y; BERTRAM EH, 1994, BRAIN RES, V661, P157, DOI 10.1016/0006-8993(94)91192-4; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Bot AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076051; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Buckmaster PS, 2012, JASPERS BASIC MECH E, DOI [10.1093/med/9780199746545.003.0032, DOI 10.1093/MED/9780199746545.003.0032]; Cacheaux LP, 2009, J NEUROSCI, V29, P8927, DOI 10.1523/JNEUROSCI.0430-09.2009; Casals JB, 2011, COMPARATIVE MED, V61, P305; Crawford F, 2009, NEUROSCIENCE, V159, P1349, DOI 10.1016/j.neuroscience.2009.01.033; CRONIN J, 1992, BRAIN RES, V573, P305, DOI 10.1016/0006-8993(92)90777-7; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 2013, ANN NEUROL, V73, P199, DOI 10.1002/ana.23764; D'Ambrosio R, 2010, EPILEPSY CURR, V10, P61, DOI 10.1111/j.1535-7511.2010.01358.x; D'Ambrosio R, 2009, BRAIN, V132, P2805, DOI 10.1093/brain/awp217; Darrah SD, 2013, EPILEPSY RES, V103, P180, DOI 10.1016/j.eplepsyres.2012.07.006; Diamond ML, 2014, EPILEPSIA, V55, P1109, DOI 10.1111/epi.12628; Dudek FE, 2011, NEUROSCI LETT, V497, P240, DOI 10.1016/j.neulet.2011.03.071; Dudek FE, 2010, EPILEPSY CURR, V10, P91, DOI 10.1111/j.1535-7511.2010.01368.x; Dudek FE, 2012, JASPERS BASIC MECH E; Dyhrfjeld-Johnsen J, 2010, J CLIN NEUROPHYSIOL, V27, P418, DOI 10.1097/WNP.0b013e3181fe0709; Elliott RC, 2003, J NEUROSCI, V23, P2218; Engel J, 2005, EPILEPSIA, V46, P1333, DOI 10.1111/j.1528-1167.2005.18505_2.x; Engel J Jr, 1996, Epilepsy Res Suppl, V12, P9; Engel J, 2008, CURR OPIN NEUROL, V21, P150, DOI 10.1097/WCO.0b013e3282f4edc3; Engel J, 2013, EPILEPSIA, V54, P61, DOI 10.1111/epi.12299; Filibian M, 2012, EPILEPSIA, V53, P1907, DOI 10.1111/j.1528-1167.2012.03685.x; Giger RJ, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001867; Goffin K, 2007, EXP NEUROL, V205, P501, DOI 10.1016/j.expneurol.2007.03.008; Gorter JA, 2001, EUR J NEUROSCI, V13, P657, DOI 10.1046/j.1460-9568.2001.01428.x; Gorter JA, 2007, EPILEPSIA, V48, P53, DOI 10.1111/j.1528-1167.2007.01290.x; Gorter JA, 2006, J NEUROSCI, V26, P11083, DOI 10.1523/JNEUROSCI.2766-06.2006; Gorter JA, 2014, NEUROBIOL DIS, V62, P508, DOI 10.1016/j.nbd.2013.10.026; Graham NSN, 2013, STROKE, V44, P605, DOI 10.1161/STROKEAHA.111.000220; Guo DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064078; Heinemann U, 2014, ADV EXP MED BIOL, V813, P25, DOI 10.1007/978-94-017-8914-1_2; Hellier JL, 1998, EPILEPSY RES, V31, P73, DOI 10.1016/S0920-1211(98)00017-5; Hendriksen H, 2001, EUR J NEUROSCI, V14, P1475, DOI 10.1046/j.0953-816x.2001.01778.x; Henshall JM, 2014, GENET SEL EVOL, V46, DOI 10.1186/s12711-014-0051-y; Hesdorffer DC, 1998, ANN NEUROL, V44, P908, DOI 10.1002/ana.410440609; Holtman L, 2013, EPILEPSIA, V54, P589, DOI 10.1111/epi.12112; Hu XL, 2011, CEREB CORTEX, V21, P2158, DOI 10.1093/cercor/bhq284; Hu ZH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039357; Hunt RF, 2010, J NEUROPHYSIOL, V103, P1490, DOI 10.1152/jn.00957.2009; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Ioannidis JPA, 2009, NAT GENET, V41, P149, DOI 10.1038/ng.295; Iyer A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044789; JENNETT B, 1975, EPILEPSIA, V16, P251, DOI 10.1111/j.1528-1157.1975.tb06055.x; Jirsa VK, 2014, BRAIN, V137, P2210, DOI 10.1093/brain/awu133; Jovicic A, 2013, J NEUROSCI, V33, P5127, DOI 10.1523/JNEUROSCI.0600-12.2013; Kadam SD, 2010, J NEUROSCI, V30, P404, DOI 10.1523/JNEUROSCI.4093-09.2010; Kandel ER, 2013, NAT REV NEUROSCI, V14, P659, DOI 10.1038/nrn3578; Kanner AM, 2014, NEUROTHERAPEUTICS, V11, P358, DOI 10.1007/s13311-014-0271-4; Karhunen H, 2007, NEUROSCIENCE, V148, P314, DOI 10.1016/j.neuroscience.2007.05.047; Karhunen H, 2003, EPILEPSY RES, V54, P1, DOI 10.1016/S0920-1211(03)00034-2; Karhunen H, 2006, EPILEPSY RES, V72, P25, DOI 10.1016/j.eplepsyres.2006.07.003; Kelley Melinda S, 2009, Epilepsia, V50, P579, DOI 10.1111/j.1528-1167.2008.01813.x; Kelly KM, 2006, EXP NEUROL, V201, P495, DOI 10.1016/j.expneurol.2006.05.006; Kelly Kevin M, 2004, Epilepsy Curr, V4, P176, DOI 10.1111/j.1535-7597.2004.04503.x; Kelly KM, 2001, EPILEPSY RES, V47, P189, DOI 10.1016/S0920-1211(01)00294-7; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kharlamov EA, 2003, EPILEPSY RES, V56, P185, DOI 10.1016/j.eplepsyres.2003.09.005; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Kobow K, 2014, PROG BRAIN RES, V213, P279, DOI 10.1016/B978-0-444-63326-2.00014-4; Kobow K, 2013, ACTA NEUROPATHOL, V126, P741, DOI 10.1007/s00401-013-1168-8; Kojima N, 2008, J NEUROSCI, V28, P6459, DOI 10.1523/JNEUROSCI.0412-08.2008; Lauren HB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010733; Lew FH, 2011, EPILEPSIA, V52, P2326, DOI 10.1111/j.1528-1167.2011.03315.x; Li AQ, 2010, BRAIN PATHOL, V20, P1077, DOI 10.1111/j.1750-3639.2010.00414.x; Liu DZ, 2010, J CEREBR BLOOD F MET, V30, P92, DOI 10.1038/jcbfm.2009.186; Liu JP, 2002, EPILEPSY RES, V52, P85, DOI 10.1016/S0920-1211(02)00194-8; Lukasiuk K, 2003, EUR J NEUROSCI, V17, P271, DOI 10.1046/j.1460-9568.2003.02461.x; Lukasiuk K, 2006, PROG BRAIN RES, V158, P223, DOI 10.1016/S0079-6123(06)58011-2; Lukasiuk K, 2014, NEUROTHERAPEUTICS, V11, P319, DOI 10.1007/s13311-014-0261-6; MACVICAR BA, 1980, BRAIN RES, V184, P220, DOI 10.1016/0006-8993(80)90602-2; Mateffyova A, 2006, EUR J NEUROSCI, V24, P351, DOI 10.1111/j.1460-9568.2006.04910.x; MCBAIN CJ, 1989, J NEUROSCI METH, V27, P35, DOI 10.1016/0165-0270(89)90051-4; McClelland S, 2014, ELIFE, V3, DOI 10.7554/eLife.01267; MILES R, 1987, J PHYSIOL-LONDON, V388, P611, DOI 10.1113/jphysiol.1987.sp016634; Miller MA, 2010, BRAIN INJURY, V24, P1468, DOI 10.3109/02699052.2010.520299; Ndode-Ekane XE, 2013, MOL NEUROBIOL, V47, P914, DOI 10.1007/s12035-012-8386-2; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; Okamoto OK, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-230; Pearce PS, 2014, EPILEPSY BEHAV, V32, P121, DOI 10.1016/j.yebeh.2014.01.004; Perin R, 2011, P NATL ACAD SCI USA, V108, P5419, DOI 10.1073/pnas.1016051108; Pitkanen A, 2004, EXPERT OPIN PHARMACO, V5, P777, DOI 10.1517/eoph.5.4.777.30162; Pitkanen A, 2002, PROG BRAIN RES, V135, P67; Pitkanen A, 2014, NEUROBIOL DIS, V72, P224, DOI 10.1016/j.nbd.2014.05.037; Pitkanen A, 2014, NEUROTHERAPEUTICS, V11, P286, DOI 10.1007/s13311-014-0260-7; Pitkanen A, 2014, NEUROTHERAPEUTICS, V11, P231, DOI 10.1007/s13311-014-0257-2; Pitkanen A, 2013, EPILEPSIA, V54, P35, DOI 10.1111/epi.12297; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Porter BE, 2008, NEUROSCIENCE, V152, P829, DOI 10.1016/j.neuroscience.2007.10.064; Rakhade SN, 2009, NAT REV NEUROL, V5, P380, DOI 10.1038/nrneurol.2009.80; Risbud RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053464; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schauwecker PE, 2000, EXP NEUROL, V161, P139, DOI 10.1006/exnr.1999.7251; Shao LR, 2005, J NEUROPHYSIOL, V94, P952, DOI 10.1152/jn.01342.2004; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Simonato M, 2012, EPILEPSIA, V53, P1860, DOI 10.1111/j.1528-1167.2012.03541.x; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; Sutula TP, 2007, PROG BRAIN RES, V163, P541, DOI 10.1016/S0079-6123(07)63029-5; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Theilhaber J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074428; Thind KK, 2010, J COMP NEUROL, V518, P647, DOI 10.1002/cne.22235; Wagner AK, 2010, EPILEPSY RES, V90, P259, DOI 10.1016/j.eplepsyres.2010.06.001; White A, 2010, EPILEPSIA, V51, P371, DOI 10.1111/j.1528-1167.2009.02339.x; Williams PA, 2009, J NEUROSCI, V29, P2103, DOI 10.1523/JNEUROSCI.0980-08.2009; Winden KD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020763; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zhang W, 2009, J NEUROSCI, V29, P14247, DOI 10.1523/JNEUROSCI.3842-09.2009; Zhang Y, 2011, J CELL BIOCHEM, V112, P2435, DOI 10.1002/jcb.23168	126	85	86	1	21	COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT	COLD SPRING HARBOR	1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA	2157-1422			CSH PERSPECT MED	Cold Spring Harb. Perspect. Med.	OCT	2015	5	10							a022822	10.1101/cshperspect.a022822			17	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	CZ9WM	WOS:000367448000009	26385090	Bronze, Green Published			2022-02-06	
J	Lu, SM; Kanekura, K; Hara, T; Mahadevan, J; Spears, LD; Oslowski, CM; Martinez, R; Yamazaki-Inoue, M; Toyoda, M; Neilson, A; Blanner, P; Brown, CM; Semenkovich, CF; Marshall, BA; Hershey, T; Umezawa, A; Greer, PA; Urano, F				Lu, Simin; Kanekura, Kohsuke; Hara, Takashi; Mahadevan, Jana; Spears, Larry D.; Oslowski, Christine M.; Martinez, Rita; Yamazaki-Inoue, Mayu; Toyoda, Masashi; Neilson, Amber; Blanner, Patrick; Brown, Cris M.; Semenkovich, Clay F.; Marshall, Bess A.; Hershey, Tamara; Umezawa, Akihiro; Greer, Peter A.; Urano, Fumihiko			A calcium-dependent protease as a potential therapeutic target for Wolfram syndrome	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						Wolfram syndrome; endoplasmic reticulum; diabetes; neurodegeneration; treatment	ENDOPLASMIC-RETICULUM STRESS; UBIQUITOUS CALPAINS PROMOTE; TRAUMATIC BRAIN-INJURY; BETA-CELL DEATH; HYPERINSULINEMIC HYPOGLYCEMIA; METABOLIC DISEASE; DIDMOAD SYNDROME; ER STRESS; APOPTOSIS; MICE	Wolfram syndrome is a genetic disorder characterized by diabetes and neurodegeneration and considered as an endoplasmic reticulum (ER) disease. Despite the underlying importance of ER dysfunction in Wolfram syndrome and the identification of two causative genes, Wolfram syndrome 1 (WFS1) and Wolfram syndrome 2 (WFS2), a molecular mechanism linking the ER to death of neurons and beta cells has not been elucidated. Here we implicate calpain 2 in the mechanism of cell death in Wolfram syndrome. Calpain 2 is negatively regulated by WFS2, and elevated activation of calpain 2 by WFS2-knockdown correlates with cell death. Calpain activation is also induced by high cytosolic calcium mediated by the loss of function of WFS1. Calpain hyperactivation is observed in the WFS1 knockout mouse as well as in neural progenitor cells derived from induced pluripotent stem (iPS) cells of Wolfram syndrome patients. A small-scale small-molecule screen targeting ER calcium homeostasis reveals that dantrolene can prevent cell death in neural progenitor cells derived from Wolfram syndrome iPS cells. Our results demonstrate that calpain and the pathway leading its activation provides potential therapeutic targets for Wolfram syndrome and other ER diseases.	[Lu, Simin; Kanekura, Kohsuke; Hara, Takashi; Mahadevan, Jana; Spears, Larry D.; Brown, Cris M.; Semenkovich, Clay F.; Urano, Fumihiko] Washington Univ, Div Endocrinol Metab & Lipid Res, Sch Med, Dept Med, St Louis, MO 63110 USA; [Lu, Simin] Univ Massachusetts, Sch Med, Grad Sch Biomed Sci, Worcester, MA 01655 USA; [Oslowski, Christine M.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; [Martinez, Rita; Neilson, Amber; Blanner, Patrick] Washington Univ, Sch Med, iPSC Core Facil, Dept Genet, St Louis, MO 63110 USA; [Yamazaki-Inoue, Mayu; Toyoda, Masashi; Umezawa, Akihiro] Natl Ctr Child Hlth & Dev, Dept Reprod Biol, Tokyo 1578535, Japan; [Marshall, Bess A.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Hershey, Tamara] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; [Hershey, Tamara] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Hershey, Tamara] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA; [Greer, Peter A.] Queens Univ, Queens Canc Res Inst, Div Canc Biol & Genet, Dept Pathol & Mol Med, Kingston, ON K7L3N6, Canada; [Urano, Fumihiko] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA		Urano, F (corresponding author), Washington Univ, Div Endocrinol Metab & Lipid Res, Sch Med, Dept Med, St Louis, MO 63110 USA.	urano@dom.wustl.edu	Urano, Fumihiko/AAF-4492-2020	Hershey, Tamara/0000-0001-7549-0698; Semenkovich, Clay/0000-0003-1163-1871; Spears, Larry/0000-0003-2797-684X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DK067493, P60 DK020579, UL1 TR000448]; Juvenile Diabetes Research FoundationJuvenile Diabetes Research Foundation [47-2012-760, 17-2013-512]; American Diabetes AssociationAmerican Diabetes Association [1-12-CT-61]; Team Alejandro; Team Ian; Ellie White Foundation for Rare Genetic Disorders; Scientific Research Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD070855] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P60DK020579, R01DK067493, P30DK020579] Funding Source: NIH RePORTER	We thank all of the participants in the Washington University Wolfram Registry and Clinic and their families for their time and effort (wolframsyndrome.dom.wustl.edu/). We also thank Mai Kanekura, Mariko Hara, and Karen Sargent for technical support and the Washington University Wolfram Study Group Members and the study staff for advice and support in the greater research program. This work was supported by NIH Grants DK067493, P60 DK020579, and UL1 TR000448; Juvenile Diabetes Research Foundation Grants 47-2012-760 and 17-2013-512; American Diabetes Association Grant 1-12-CT-61, the Team Alejandro, The Team Ian, the Ellie White Foundation for Rare Genetic Disorders, and the Jack and J. T. Snow Scientific Research Foundation (F.U.).	Akiyama M, 2009, DIABETOLOGIA, V52, P653, DOI 10.1007/s00125-009-1270-6; Amr S, 2007, AM J HUM GENET, V81, P673, DOI 10.1086/520961; Arya VB, 2014, HORM METAB RES, V46, P157, DOI 10.1055/s-0034-1367063; Bachar-Wikstrom E, 2013, DIABETES, V62, P1227, DOI 10.2337/db12-1474; Barrett TG, 1997, J MED GENET, V34, P838, DOI 10.1136/jmg.34.10.838; BARRETT TG, 1995, LANCET, V346, P1458, DOI 10.1016/S0140-6736(95)92473-6; Bonnycastle LL, 2013, DIABETES, V62, P3943, DOI 10.2337/db13-0571; Chakroborty S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052056; Chang NC, 2010, EMBO J, V29, P606, DOI 10.1038/emboj.2009.369; Chen YF, 2009, GENE DEV, V23, P1183, DOI 10.1101/gad.1779509; Cui W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059921; Dutt P, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-3; DYKES MHM, 1975, JAMA-J AM MED ASSOC, V231, P862, DOI 10.1001/jama.231.8.862; Fonseca SG, 2005, J BIOL CHEM, V280, P39609, DOI 10.1074/jbc.M507426200; Fonseca SG, 2010, J CLIN INVEST, V120, P744, DOI 10.1172/JCI39678; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Hara T, 2014, ENDOCRINOLOGY, V155, P758, DOI 10.1210/en.2013-1519; Hershey T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040604; Hetz C, 2013, NAT REV DRUG DISCOV, V12, P703, DOI 10.1038/nrd3976; Hotamisligil GS, 2010, NAT MED, V16, P396, DOI 10.1038/nm0410-396; Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034; Huang CJ, 2010, J BIOL CHEM, V285, P339, DOI 10.1074/jbc.M109.024190; Inoue H, 1998, NAT GENET, V20, P143, DOI 10.1038/2441; Ishihara H, 2004, HUM MOL GENET, V13, P1159, DOI 10.1093/hmg/ddh125; Krause T, 2004, ANAESTHESIA, V59, P364, DOI 10.1111/j.1365-2044.2004.03658.x; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Luciani DS, 2009, DIABETES, V58, P422, DOI 10.2337/db07-1762; Marshall BA, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-64; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Ozcan L, 2012, ANNU REV MED, V63, P317, DOI 10.1146/annurev-med-043010-144749; Riggs AC, 2005, DIABETOLOGIA, V48, P2313, DOI 10.1007/s00125-005-1947-4; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Sandhu MS, 2007, NAT GENET, V39, P951, DOI 10.1038/ng2067; Shah P, 2014, SEMIN PEDIATR SURG, V23, P76, DOI 10.1053/j.sempedsurg.2014.03.005; Shang LS, 2014, DIABETES, V63, P923, DOI 10.2337/db13-0717; Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takei D, 2006, FEBS LETT, V580, P5635, DOI 10.1016/j.febslet.2006.09.007; Tan YF, 2006, J BIOL CHEM, V281, P16016, DOI 10.1074/jbc.M601299200; Tan Y, 2006, J BIOL CHEM, V281, P17689, DOI 10.1074/jbc.M601978200; Urano F, 2014, NAT REV ENDOCRINOL, V10, P129, DOI 10.1038/nrendo.2013.261; Wang SY, 2012, J CELL BIOL, V197, P857, DOI 10.1083/jcb.201110131; Wei HF, 1996, J NEUROCHEM, V67, P2390; Wiley SE, 2013, EMBO MOL MED, V5, P904, DOI 10.1002/emmm.201201429; Wolfram DJ., 1938, MAYO CLIN PROC, V13, P715; Yusta B, 2006, CELL METAB, V4, P391, DOI 10.1016/j.cmet.2006.10.001; Zatyka M, 2008, HUM MOL GENET, V17, P190, DOI 10.1093/hmg/ddm296	48	85	89	2	10	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	DEC 9	2014	111	49					E5292	E5301		10.1073/pnas.1421055111			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU9NR	WOS:000345921500007	25422446	Green Published, Bronze			2022-02-06	
J	Singh, R; Meier, TB; Kuplicki, R; Savitz, J; Mukai, I; Cavanagh, L; Allen, T; Teague, TK; Nerio, C; Polanski, D; Bellgowan, PSF				Singh, Rashmi; Meier, Timothy B.; Kuplicki, Rayus; Savitz, Jonathan; Mukai, Ikuko; Cavanagh, LaMont; Allen, Thomas; Teague, T. Kent; Nerio, Christopher; Polanski, David; Bellgowan, Patrick S. F.			Relationship of Collegiate Football Experience and Concussion With Hippocampal Volume and Cognitive Outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL FOOTBALL; DEFICITS; PLAYERS; STRESS; IDENTIFICATION; PERFORMANCE; RECOVERY; IMPACT; MODEL	IMPORTANCE Concussion and subconcussive impacts have been associated with short-term disrupted cognitive performance in collegiate athletes, but there are limited data on their long-term neuroanatomic and cognitive consequences. OBJECTIVE To assess the relationships of concussion history and years of football experience with hippocampal volume and cognitive performance in collegiate football athletes. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional study conducted between June 2011 and August 2013 at a US psychiatric research institute specializing in neuroimaging among collegiate football players with a history of clinician-diagnosed concussion (n = 25), collegiate football players without a history of concussion (n = 25), and non-football-playing, age-, sex-, and education-matched healthy controls (n = 25). EXPOSURES History of clinician-diagnosed concussion and years of football experience. MAIN OUTCOMES AND MEASURES High-resolution anatomical magnetic resonance imaging was used to quantify brain volumes. Baseline scores on a computerized concussion-related cognitive battery were used for cognitive assessment in athletes. RESULTS Players with and without a history of concussion had smaller hippocampal volumes relative to healthy control participants (with concussion: t(48) = 7.58; P < .001; mean difference, 1788 mu L; 95% CI, 1317-2258 mu L; without concussion: t(48) = 4.35; P < .001, mean difference, 1027 mu L; 95% CI, 556-1498 mu L). Players with a history of concussion had smaller hippocampal volumes than players without concussion (t(48) = 3.15; P < .001; mean difference, 761 mu L; 95% CI, 280-1242 mu L). In both athlete groups, there was a statistically significant inverse relationship between left hippocampal volume and number of years of football played (t(46) = -3.62; P < .001; coefficient = -43.54; 95% CI, -67.66 to -19.41). Behavioral testing demonstrated no differences between athletes with and without a concussion history on 5 cognitive measures but did show an inverse correlation between years of playing football and reaction time (rho(42) = -0.43; 95% CI, -0.46 to -0.40; P = .005). CONCLUSIONS AND RELEVANCE Among a group of collegiate football athletes, there was a significant inverse relationship of concussion and years of football played with hippocampal volume. Years of football experience also correlated with slower reaction time. Further research is needed to determine the temporal relationships of these findings.	[Singh, Rashmi; Meier, Timothy B.; Kuplicki, Rayus; Savitz, Jonathan; Mukai, Ikuko; Bellgowan, Patrick S. F.] Laureate Inst Brain Res, Tulsa, OK 74136 USA; [Kuplicki, Rayus] Univ Tulsa, Tandy Sch Comp Sci, Tulsa, OK 74104 USA; [Savitz, Jonathan; Bellgowan, Patrick S. F.] Univ Tulsa, Fac Community Med, Tulsa, OK 74104 USA; [Cavanagh, LaMont; Allen, Thomas] Univ Oklahoma, Dept Family Med, Oklahoma Sch Community Med, Tulsa, OK USA; [Teague, T. Kent] Univ Oklahoma, Dept Surg, Oklahoma Sch Community Med, Tulsa, OK USA; [Teague, T. Kent] Univ Oklahoma, Dept Psychiat, Oklahoma Sch Community Med, Tulsa, OK USA; [Teague, T. Kent] Univ Oklahoma, Dept Pharmaceut Sci, Oklahoma Coll Pharm, Tulsa, OK USA; [Teague, T. Kent] Oklahoma State Univ, Ctr Hlth Sci, Dept Biochem & Microbiol, Tulsa, OK USA; [Nerio, Christopher; Polanski, David] Univ Tulsa, Dept Athlet, Tulsa, OK 74104 USA		Bellgowan, PSF (corresponding author), Laureate Inst Brain Res, 6655 S Yale Ave, Tulsa, OK 74136 USA.	pbellgowan@laureateinstitute.org	Savitz, Jonathan/C-3088-2009; Teague, T. Kent/A-2527-2008	Savitz, Jonathan/0000-0001-8143-182X; Teague, T. Kent/0000-0002-4680-5440	Laureate Institute for Brain Research; William K. Warren Foundation	This research was conducted using internal funds from the Laureate Institute for Brain Research, which is supported by the William K. Warren Foundation.	Beauchamp MH, 2011, INT J DEV NEUROSCI, V29, P137, DOI 10.1016/j.ijdevneu.2010.12.003; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2013, AM J SPORT MED, V41, P2885, DOI 10.1177/0363546513499230; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Erk S, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.57; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Franko E, 2014, HUM BRAIN MAPP, V35, P248, DOI 10.1002/hbm.22170; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mastorakos G, 2005, HORM METAB RES, V37, P577, DOI 10.1055/s-2005-870426; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McEwen BS, 2001, ANN NY ACAD SCI, V933, P265, DOI 10.1111/j.1749-6632.2001.tb05830.x; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Nakajima Y, 2010, TOHOKU J EXP MED, V221, P229, DOI 10.1620/tjem.221.229; Nelson LD, 2013, NEUROPSYCHOL REV, V23, P285, DOI 10.1007/s11065-013-9240-7; Sapolsky RM, 2000, BIOL PSYCHIAT, V48, P755, DOI 10.1016/S0006-3223(00)00971-9; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Stein JL, 2012, NAT GENET, V44, P552, DOI 10.1038/ng.2250; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x	30	85	85	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	2014	311	18					1883	1888		10.1001/jama.2014.3313			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AH0GT	WOS:000335798100020	24825643	Bronze			2022-02-06	
J	Lin, CJ; Chen, TH; Yang, LY; Shih, CM				Lin, C-J; Chen, T-H; Yang, L-Y; Shih, C-M			Resveratrol protects astrocytes against traumatic brain injury through inhibiting apoptotic and autophagic cell death	CELL DEATH & DISEASE			English	Article						traumatic brain injury; resveratrol; glycogen synthase kinase-3 beta; mitochondrial permeability transition pore; autophagy; apoptosis	GLYCOGEN-SYNTHASE KINASE-3; OXIDATIVE STRESS; IN-VITRO; GLUTAMATE; PERMEABILITY; DEGRADATION; NEURONS; GLYCOGEN-SYNTHASE-KINASE-3-BETA; INVOLVEMENT; ACTIVATION	Traumatic brain injury (TBI) is often caused by accidents that damage the brain. TBI can induce glutamate excitotoxicity and lead to neuronal and glial cell death. In this study, we investigated the mechanism of cell death during the secondary damage caused by TBI in vivo and in vitro, as well as the protective effect of resveratrol (RV). Here we report that glycogen synthase kinase-3 beta (GSK-3 beta) activation and microtubule-associated protein light chain 3 processing were induced in rat brains exposed to TBI. In the in vitro TBI model, apoptotic and autophagic cell death were induced through glutamate-mediated GSK-3b activation in normal CTX TNA2 astrocytes. The GSK-3 beta inhibitor SB216763 or transfection of GSK-3 beta small-interfering RNA increases cell survival. By contrast, overexpression of GSK-3 beta enhanced glutamate excitotoxicity. Administration of RV reduced cell death in CTX TNA2 astrocytes by suppressing reactive oxygen species (ROS)-mediated GSK-3 beta activation, the mechanism by which RV also exerted protective effects in vivo. Mitochondrial damages, including the opening of mitochondrial permeability transition pore (MPTP) and mitochondrial depolarization, were induced by glutamate through the ROS/GSK-3 beta pathway. Moreover, cyclosporine A, an MPTP inhibitor, suppressed mitochondrial damage and the percentages of cells undergoing autophagy and apoptosis and thereby increased cell survival. Taken together, our results demonstrated that cell death occurring after TBI is induced through the ROS/GSK-3 beta/mitochondria signaling pathway and that administration of RV can increase cell survival by suppressing GSK-3 beta-mediated autophagy and apoptosis. Therefore, the results indicated that resveratrol may serve as a potential therapeutic agent in the treatment of TBI.	[Lin, C-J; Yang, L-Y; Shih, C-M] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei 110, Taiwan; [Lin, C-J; Shih, C-M] Taipei Med Univ, Sch Med, Dept Biochem, Taipei 110, Taiwan; [Chen, T-H] Cathay Gen Hosp, Div Cardiovasc Surg, Dept Surg, Taipei 106, Taiwan; [Yang, L-Y] Taipei Med Univ, Dept Physiol, Coll Med, Taipei 110, Taiwan; [Shih, C-M] Taipei Med Univ Hosp, Tradit Herbal Med Res Ctr, Taipei 110, Taiwan; [Shih, C-M] Taipei Med Univ Hosp, Ctr Reprod Med & Sci, Taipei 110, Taiwan		Shih, CM (corresponding author), Taipei Med Univ, Sch Med, Dept Biochem, 250 Wu Hsing St, Taipei 110, Taiwan.	cmshih@tmu.edu.tw		Lin, Chien-Ju/0000-0001-5224-3539	Cathay General Hospital [101CGH-TMU-05]; National Science CouncilMinistry of Science and Technology, Taiwan [NSC99-2320-B08-008-MY3]	This work was supported by grants from Cathay General Hospital (101CGH-TMU-05) and the National Science Council (NSC99-2320-B08-008-MY3) to CMS.	Alayev A, 2014, CELL CYCLE, V13, P371, DOI 10.4161/cc.27355; Armour SM, 2009, AGING-US, V1, P515, DOI 10.18632/aging.100056; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Bell JD, 2007, BRAIN, V130, P2528, DOI 10.1093/brain/awm164; Bhat RV, 2002, NEUROSIGNALS, V11, P251, DOI 10.1159/000067423; Chen HC, 2012, SPINE, V37, P470, DOI 10.1097/BRS.0b013e318221e859; Chen ML, 2013, AUTOPHAGY, V9, P2033, DOI 10.4161/auto.26336; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Chen ZY, 2010, NEUROSCI LETT, V482, P264, DOI 10.1016/j.neulet.2010.07.052; Cheng HY, 2008, J PHARMACOL SCI, V107, P21, DOI 10.1254/jphs.FP0072394; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; Cucciolla V, 2007, CELL CYCLE, V6, P2495, DOI 10.4161/cc.6.20.4815; Emamian ES, 2004, NAT GENET, V36, P131, DOI 10.1038/ng1296; Forde JE, 2007, CELL MOL LIFE SCI, V64, P1930, DOI 10.1007/s00018-007-7045-7; Gould TD, 2004, J CLIN PSYCHIAT, V65, P10; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hisano K, 2009, J ANESTH, V23, P363, DOI 10.1007/s00540-009-0766-z; Jeong JK, 2012, NEUROSCI RES, V73, P99, DOI 10.1016/j.neures.2012.03.005; Kanzawa T, 2003, J NEUROSURG, V99, P1047, DOI 10.3171/jns.2003.99.6.1047; Karmarkar SW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023493; Kim H, 2009, BIOCHEM BIOPH RES CO, V388, P339, DOI 10.1016/j.bbrc.2009.08.007; Lee KY, 2007, BRAIN RES, V1129, P89, DOI 10.1016/j.brainres.2006.10.055; Leon R, 2009, J NEUROSCI RES, V87, P1185, DOI 10.1002/jnr.21926; Liu CJ, 2011, BRAIN RES, V1374, P100, DOI 10.1016/j.brainres.2010.11.061; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Liu H, 2013, AUTOPHAGY, V9, P730, DOI 10.4161/auto.24039; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Lv XC, 2012, CAN J PHYSIOL PHARM, V90, P655, DOI [10.1139/Y2012-051, 10.1139/y2012-051]; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Matute C, 2006, GLIA, V53, P212, DOI 10.1002/glia.20275; Molz S, 2008, NEUROCHEM RES, V33, P27, DOI 10.1007/s11064-007-9402-1; Nolan S, 2005, CRIT CARE NURS Q, V28, P188, DOI 10.1097/00002727-200504000-00010; Obame FN, 2008, J PHARMACOL EXP THER, V326, P252, DOI 10.1124/jpet.108.138008; Pan CL, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-S1-S18; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Parr C, 2012, MOL CELL BIOL, V32, P4410, DOI 10.1128/MCB.00930-12; Petit-Paitel A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005491; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Pietra G, 2001, CANCER RES, V61, P8218; Pozo-Guisado E, 2004, INT J CANCER, V109, P167, DOI 10.1002/ijc.11720; Ray SK, 2006, NEUROSCIENCE, V139, P577, DOI 10.1016/j.neuroscience.2005.12.057; Rosin C, 2004, J NEUROCHEM, V90, P1173, DOI 10.1111/j.1471-4159.2004.02584.x; Saiko P, 2008, MUTAT RES-REV MUTAT, V658, P68, DOI 10.1016/j.mrrev.2007.08.004; Shin SM, 2009, MOL PHARMACOL, V76, P884, DOI 10.1124/mol.109.058479; Shin SY, 2006, CELL SIGNAL, V18, P601, DOI 10.1016/j.cellsig.2005.06.001; Smith JS, 2000, NEURAL PLAST, V7, P73, DOI 10.1155/NP.2000.73; Thevenod F, 1999, FASEB J, V13, P1751, DOI 10.1096/fasebj.13.13.1751; Varamini B, 2014, INT J FOOD SCI NUTR, V65, P89, DOI 10.3109/09637486.2013.832171; Wang H, 2010, BIOCHEM PHARMACOL, V80, P1386, DOI 10.1016/j.bcp.2010.07.034; Wang Q, 2002, BRAIN RES, V958, P439, DOI 10.1016/S0006-8993(02)03543-6; Wang SH, 2009, TOXICOL SCI, V108, P124, DOI 10.1093/toxsci/kfn266; Wu Y, 2007, APOPTOSIS, V12, P1365, DOI 10.1007/s10495-007-0065-9; Yao LL, 2010, AM J PHYSIOL-HEART C, V298, pH1310, DOI 10.1152/ajpheart.00339.2009; Zamin LL, 2006, NEUROBIOL DIS, V24, P170, DOI 10.1016/j.nbd.2006.06.002; Zhang XJ, 2011, AUTOPHAGY, V7, P412, DOI 10.4161/auto.7.4.14541; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0; Zhao Y, 2012, J CELL PHYSIOL, V227, P639, DOI 10.1002/jcp.22768; Zschocke J, 2011, NEUROPSYCHOPHARMACOL, V36, P1754, DOI 10.1038/npp.2011.57	58	85	90	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	MAR	2014	5								e1147	10.1038/cddis.2014.123			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	AE1TW	WOS:000333754100051	24675465	Green Published, gold			2022-02-06	
J	Chauhan, NB				Chauhan, Neelima B.			Chronic neurodegenerative consequences of traumatic brain injury	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Traumatic brain injury; traumatic axonal injury; chronic traumatic encephalopathy; dementia pugilistica; amyotrophic lateral sclerosis; Parkinson's disease; Alzheimer's disease; dementia	AMYLOID PRECURSOR PROTEIN; POSTTRAUMATIC-STRESS-DISORDER; HUMAN APOLIPOPROTEIN E4; DIFFUSE AXONAL INJURY; MICROTUBULE-ASSOCIATED PROTEINS; ANTERIOR-PITUITARY DYSFUNCTION; LONG-TERM ACCUMULATION; ALZHEIMERS-DISEASE; HEAD-INJURY; INTRACEREBRAL HEMORRHAGE	Traumatic brain injury (TBI) is a serious public health concern and a major cause of death and disability worldwide. Each year, an estimated 1.7 million Americans sustain TBI of which similar to 52,000 people die, similar to 275,000 people are hospitalized and 1,365,000 people are treated as emergency outpatients. Currently there are similar to 5.3 million Americans living with TBI. TBI is more of a disease process than of an event that is associated with immediate and long-term sensomotor, psychological and cognitive impairments. TBI is the best known established epigenetic risk factor for later development of neurodegenerative diseases and dementia. People sustaining TBI are similar to 4 times more likely to develop dementia at a later stage than people without TBI. Single brain injury is linked to later development of symptoms resembling Alzheimer's disease while repetitive brain injuries are linked to later development of chronic traumatic encephalopathy (CTE) and/or Dementia Pugilistica (DP). Furthermore, genetic background of beta-amyloid precursor protein (APP), Apolipoprotein E (ApoE), presenilin (PS) and neprilysin (NEP) genes is associated with exacerbation of neurodegenerative process after TBI. This review encompasses acute effects and chronic neurodegenerative consequences after TBI.	[Chauhan, Neelima B.] Jesse Brown VA Med Ctr, R&D 151,820 South Damen Ave, Chicago, IL 60612 USA; [Chauhan, Neelima B.] Univ Illinois, Dept Pediat, Chicago, IL USA; [Chauhan, Neelima B.] Univ Illinois, Childrens Hosp, Chicago, IL USA		Chauhan, NB (corresponding author), Jesse Brown VA Med Ctr, R&D 151,820 South Damen Ave, Chicago, IL 60612 USA.	nchauhan@uic.edu			Westside Institute for Science and Education; Department of Pediatrics, University of Illinois at Chicago; Children's Hospital of the University of Illinois, Chicago, IL; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG039625, NS079614]; Westside Institute of Science AMP; Education, Chicago, IL; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation RDUS Department of Veterans Affairs [I0880R]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS079614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG039625] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000880] Funding Source: NIH RePORTER	This material is the result of work supported with resources and use of facilities provided by the Jesse Brown VA medical center Chicago, Chicago, IL. Authors acknowledge the support provided by the Westside Institute for Science and Education; Department of Pediatrics, University of Illinois at Chicago; Children's Hospital of the University of Illinois, Chicago, IL. This work has been supported in part by National Institute of Health (AG039625, NS079614 NBC); by Westside Institute of Science & Education, Chicago, IL; and by Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation R&D (I0880R, NBC).	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Acerini CL, 2007, HORM RES, V68, P14, DOI 10.1159/000110465; Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; Adibhatla RM, 2010, ANTIOXID REDOX SIGN, V12, P125, DOI [10.1089/ars.2009.2668, 10.1089/ARS.2009.2668]; Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Aimaretti G, 2005, J ENDOCRINOL INVEST, V28, P984, DOI 10.1007/BF03345336; Al-Bassam J, 2002, J CELL BIOL, V157, P1187, DOI 10.1083/jcb.200201048; Al-Chalabi A, 2012, ACTA NEUROPATHOL, V124, P339, DOI 10.1007/s00401-012-1022-4; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Ali A, 2012, NEUROL RES, V34, P462, DOI 10.1179/1743132812Y.0000000014; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; ASSERY M, 1992, J PROSTHET DENT, V67, P275, DOI 10.1016/0022-3913(92)90467-O; Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Back S, 2007, J NEUROSCI RES, V85, P2580, DOI 10.1002/jnr.21239; Bajwa R, 2012, PEDIATR TRANSPLANT, V16, P872, DOI 10.1111/petr.12002; Bakshi A, 2005, BRAIN RES, V1065, P8, DOI 10.1016/j.brainres.2005.09.059; Balan IS, 2013, J NEUROTRAUM, V30, P367, DOI 10.1089/neu.2012.2339; Bao X, 2008, ACTA NEUROCHIR SUPPL, V105, P23; Bar-Haim Y, 2007, PSYCHOL BULL, V133, P1, DOI 10.1037/0033-2909.133.1.1; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Baxter D., 2013, ANN NEUROL; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Beghi E, 2003, EPILEPSIA, V44, P21, DOI 10.1046/j.1528-1157.44.s10.1.x; Behan LA, 2007, HORM RES, V68, P18, DOI 10.1159/000110466; Benardo LS, 2003, EPILEPSIA, V44, P27, DOI 10.1046/j.1528-1157.44.s10.2.x; Blain JF, 2006, NEUROBIOL DIS, V21, P505, DOI 10.1016/j.nbd.2005.08.010; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Blissitt Patricia A, 2006, Crit Care Nurs Clin North Am, V18, P321, DOI 10.1016/j.ccell.2006.05.006; Bocksch L., 2001, Current Drug Targets - Cardiovascular and Haematological Disorders, V1, P93, DOI 10.2174/1568006013337944; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Braak H, 1999, NEUROSCI LETT, V265, P67, DOI 10.1016/S0304-3940(99)00208-6; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Braak H, 2010, ACTA NEUROPATHOL, V120, P67, DOI 10.1007/s00401-010-0683-0; Brailey K, 2007, J TRAUMA STRESS, V20, P495, DOI 10.1002/jts.20234; Bramlett HM, 2003, EXP NEUROL, V184, P27, DOI 10.1016/S0014-4886(03)00401-1; Brennan FH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-137; Brewin CR, 2007, J ABNORM PSYCHOL, V116, P448, DOI 10.1037/0021-843X.116.3.448; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Brooks J.C., 2013, ARCH PHYS MED REHABI; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Brunholz S, 2012, EXP BRAIN RES, V217, P353, DOI 10.1007/s00221-011-2870-1; Buckley TC, 2000, CLIN PSYCHOL REV, V20, P1041, DOI 10.1016/S0272-7358(99)00030-6; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buxbaum JD, 1998, J NEUROSCI, V18, P9629; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Cantor JB, 2012, J HEAD TRAUMA REHAB, V27, pE1, DOI 10.1097/HTR.0b013e318270f91e; Cap AP, 2011, J TRAUMA, V71, pS78, DOI 10.1097/TA.0b013e3182218cd8; Capehart B, 2012, J REHABIL RES DEV, V49, P789, DOI 10.1682/JRRD.2011.10.0185; Capell A, 2002, J BIOL CHEM, V277, P5637, DOI 10.1074/jbc.M109119200; Carlson KF, 2013, BRAIN INJURY, V27, P640, DOI 10.3109/02699052.2013.771795; Carro E, 2002, NAT MED, V8, P1390, DOI 10.1038/nm793; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Casano-Sancho P, 2013, CLIN ENDOCRINOL OXF; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Christensen J, 2012, EPILEPSIA, V53, P43, DOI 10.1111/j.1528-1167.2012.03612.x; Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; Dai SS, 2013, J EXP MED, V210, P839, DOI 10.1084/jem.20122196; Dal Monte O, 2013, SOC COGN AFFECT NEUR, V8, P632, DOI 10.1093/scan/nss041; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; de Calignon A, 2012, NEURON, V73, P685, DOI 10.1016/j.neuron.2011.11.033; Dehmelt L, 2005, GENOME BIOL, V6; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Dickson DW, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009258; Dickson DW, 2010, INT J CLIN EXP PATHO, V3, P1; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Dolan S, 2012, NEUROPSYCHOL REV, V22, P21, DOI 10.1007/s11065-012-9190-5; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Drewes G, 1998, TRENDS BIOCHEM SCI, V23, P307, DOI 10.1016/S0968-0004(98)01245-6; Dumanis SB, 2009, J NEUROSCI, V29, P15317, DOI 10.1523/JNEUROSCI.4026-09.2009; Einaudi S, 2006, J PEDIATR ENDOCR MET, V19, P691; Ennis N, 2013, NEUROPSYCHOL REHABIL, V23, P1, DOI 10.1080/09602011.2012.712871; Ertekin MV, 2004, BIOL TRACE ELEM RES, V100, P63, DOI 10.1385/BTER:100:1:063; Eskandari R, 2013, J NEUROSURG, V119, P338, DOI 10.3171/2013.4.JNS121541; Evans MC, 2013, MOL CELL NEUROSCI, V53, P34, DOI 10.1016/j.mcn.2012.10.008; Farlow MR, 2004, NEUROLOGY, V63, P1898, DOI 10.1212/01.WNL.0000144279.21502.B7; Ferrer I, 2011, J NEURAL TRANSM, V118, P821, DOI 10.1007/s00702-010-0482-8; Feussner G, 1998, HUM MUTAT, V11, P417, DOI 10.1002/(SICI)1098-1004(1998)11:6<417::AID-HUMU1>3.3.CO;2-X; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; Forslund M.V., 2013, ACTA NEUROL SCAND; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gale CR, 2008, ARCH GEN PSYCHIAT, V65, P1410, DOI 10.1001/archpsyc.65.12.1410; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; Gatson JW, 2013, J NEUROSURG, V118, P1336, DOI 10.3171/2013.2.JNS121771; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Geser F, 2009, J NEUROL, V256, P1205, DOI 10.1007/s00415-009-5069-7; Gilbertson MW, 2001, J TRAUMA STRESS, V14, P413, DOI 10.1023/A:1011181305501; Giunta B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-185; Giza CC, 2001, J ATHL TRAINING, V36, P228; GLASS AM, 1980, APPL OPTICS, V19, P276, DOI 10.1364/AO.19.000276; Godoy DA, 2010, NEUROCRIT CARE, V13, P425, DOI 10.1007/s12028-010-9404-8; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Goodwin Linda, 2006, J Insur Med, V38, P300; Gotow Takahiro, 2000, Medical Electron Microscopy, V33, P173, DOI 10.1007/s007950000019; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Graham DI, 2004, FORENSIC SCI INT, V146, P89, DOI 10.1016/S0379-0738(03)00274-3; Granieri E, 2000, J NEUROVIROL, V6, pS141; Greco T, 2013, J NEUROTRAUMA; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Halpain S, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-6-224; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Hannon MJ, 2011, BEST PRACT RES CL EN, V25, P783, DOI 10.1016/j.beem.2011.06.001; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Hinkebein JH, 2003, BRAIN INJURY, V17, P1035, DOI 10.1080/0269905031000110490; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hohl A, 2009, ARQ BRAS ENDOCRINOL, V53, P908, DOI 10.1590/S0004-27302009000800003; Honeybul S, 2011, J NEUROSURG SCI, V55, P343; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Hsieh H.L., 2013, MOL NEUROBIOL; Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287; Huang JH, 2013, NEUROL RES, V35, P221, DOI 10.1179/1743132813Y.0000000178; Huang YD, 2004, J MOL NEUROSCI, V23, P189, DOI 10.1385/JMN:23:3:189; Huh JW, 2002, EXP NEUROL, V175, P198, DOI 10.1006/exnr.2002.7880; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Itoh T, 2013, BRAIN STRUCT FUNCT, V218, P209, DOI 10.1007/s00429-012-0394-5; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Jang SH, 2011, NEUROREHABILITATION, V29, P339, DOI 10.3233/NRE-2011-0710; Janke C, 2011, NAT REV MOL CELL BIO, V12, P773, DOI 10.1038/nrm3227; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Johnsen GE, 2008, J AFFECT DISORDERS, V111, P74, DOI 10.1016/j.jad.2008.02.007; Johnson GVW, 2004, J CELL SCI, V117, P5721, DOI 10.1242/jcs.01558; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2009, J NEUROTRAUM, V26, P1197, DOI [10.1089/neu.2008.0843, 10.1089/neu.2008-0843]; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kagansky N, 2001, ARCH NEUROL-CHICAGO, V58, P1209, DOI 10.1001/archneur.58.8.1209; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Kamal AK, 2003, AM J NEURORADIOL, V24, P895; Kanayama G, 1997, PSYCHIAT CLIN NEUROS, V51, P157, DOI 10.1111/j.1440-1819.1997.tb02379.x; Kang JH, 2012, J NEUROTRAUM, V29, P90, DOI 10.1089/neu.2011.1936; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Khadr SN, 2010, CLIN ENDOCRINOL, V73, P637, DOI 10.1111/j.1365-2265.2010.03857.x; Kim HJ, 2013, NEUROBIOL AGING; Kinoshita K, 2002, J NEUROTRAUM, V19, P681, DOI 10.1089/08977150260139075; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Kiris E, 2010, METHOD CELL BIOL, V95, P481, DOI 10.1016/S0091-679X(10)95024-3; Kolakowsky-Hayner SA, 2012, BRAIN INJURY, V26, P1328, DOI 10.3109/02699052.2012.706353; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Kouloulas E.J., 2013, INT J REHABIL RES; Krahulik D, 2010, J NEUROSURG, V113, P581, DOI 10.3171/2009.10.JNS09930; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; KURLAND LT, 1994, ANN NEUROL, V36, pS33, DOI 10.1002/ana.410360711; Lafrenaye AD, 2012, J CEREBR BLOOD F MET, V32, P1919, DOI 10.1038/jcbfm.2012.95; Lariviere RC, 2004, J NEUROBIOL, V58, P131, DOI 10.1002/neu.10270; Lasagna-Reeves CA, 2011, CURR ALZHEIMER RES, V8, P659; Lasagna-Reeves CA, 2012, SCI REP-UK, V2, DOI 10.1038/srep00700; Lasagna-Reeves CA, 2012, FASEB J, V26, P1946, DOI 10.1096/fj.11-199851; Lazarov O, 2002, J NEUROSCI, V22, P9785; Lazarov O, 2005, J NEUROSCI, V25, P2386, DOI 10.1523/JNEUROSCI.3089-04.2005; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; Lee D, 2013, PEDIATR DRUGS, V15, P151, DOI 10.1007/s40272-013-0009-5; Li XY, 2010, NEUROSCIENCE, V169, P357, DOI 10.1016/j.neuroscience.2010.04.075; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; Liraz O, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-16; Liu L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031302; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; Liu-DeRyke X, 2009, NEUROCRIT CARE, V11, P151, DOI 10.1007/s12028-009-9228-6; Llompart-Pou JA, 2008, NEUROCRIT CARE, V9, P230, DOI 10.1007/s12028-008-9115-6; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; Ludolph AC, 2012, CURR OPIN NEUROL, V25, P530, DOI 10.1097/WCO.0b013e328356d328; Luth HJ, 2001, BRAIN RES, V913, P57, DOI 10.1016/S0006-8993(01)02758-5; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Macklin ML, 1998, J CONSULT CLIN PSYCH, V66, P323, DOI 10.1037/0022-006X.66.2.323; Maeda S, 2006, NEUROSCI RES, V54, P197, DOI 10.1016/j.neures.2005.11.009; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Marx BP, 2009, J INT NEUROPSYCH SOC, V15, P840, DOI 10.1017/S1355617709990488; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; Masada T, 2000, BRAIN RES, V867, P173, DOI 10.1016/S0006-8993(00)02302-7; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Matenia D, 2009, TRENDS BIOCHEM SCI, V34, P332, DOI 10.1016/j.tibs.2009.03.008; MATUS A, 1990, J PHYSIOL-PARIS, V84, P134; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MCNALLY RJ, 1995, AM J PSYCHIAT, V152, P936; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Miller CCJ, 2002, CELL MOL LIFE SCI, V59, P323, DOI 10.1007/s00018-002-8425-7; Miller RG, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001447.pub3; Moon RJ, 2010, J NEUROTRAUM, V27, P1827, DOI 10.1089/neu.2010.1408; Moretti L, 2012, LANCET NEUROL, V11, P1103, DOI 10.1016/S1474-4422(12)70226-0; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; MULDER DW, 1986, NEUROLOGY, V36, P511, DOI 10.1212/WNL.36.4.511; Munoz A, 2013, CURR OPIN ENDOCRINOL, V20, P354, DOI 10.1097/MED.0b013e32836318ba; Nakajima Y, 2010, TOHOKU J EXP MED, V221, P229, DOI 10.1620/tjem.221.229; Nelson PT, 2009, J NEUROPATH EXP NEUR, V68, P1, DOI 10.1097/NEN.0b013e3181919a48; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Niles SE, 2008, J TRAUMA, V64, P1459, DOI 10.1097/TA.0b013e318174e8bc; Niyonkuru C, 2013, J NEUROTRAUM, V30, P938, DOI 10.1089/neu.2012.2578; Norwood KW, 2010, CLIN PEDIATR, V49, P1044, DOI 10.1177/0009922810376234; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Oliveros-Juste A, 2002, REV NEUROLOGIA, V34, P448, DOI 10.33588/rn.3405.2001439; Orman JA, 2012, J TRAUMA ACUTE CARE, V73, pS496, DOI 10.1097/TA.0b013e318275473c; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Paglini G, 2000, NEUROCHEM RES, V25, P37, DOI 10.1023/A:1007531230651; Parikh S, 2007, INT ANESTHESIOL CLIN, V45, P119, DOI 10.1097/AIA.0b013e318078cfe7; Park E, 2007, EXP NEUROL, V204, P49, DOI 10.1016/j.expneurol.2006.09.012; Park KD, 2010, BRAIN INJURY, V24, P1330, DOI 10.3109/02699052.2010.506863; Patel MB, 2006, J TRAUMA, V61, P46, DOI 10.1097/01.ta.0000219730.71206.3a; Pearson WS, 2012, PREHOSP EMERG CARE, V16, P323, DOI 10.3109/10903127.2012.682701; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; POIRIER J, 1991, MOL BRAIN RES, V11, P97, DOI 10.1016/0169-328X(91)90111-A; Poirier J, 2000, ANN NY ACAD SCI, V924, P81; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; POSER CM, 1994, CLIN NEUROL NEUROSUR, V96, P103, DOI 10.1016/0303-8467(94)90042-6; Posmantur RM, 2000, EXP NEUROL, V161, P15, DOI 10.1006/exnr.1999.7244; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Qing WG, 2009, J NEUROSURG, V110, P462, DOI 10.3171/2008.4.JNS17512; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; Reeves RR, 2012, J PSYCHOSOC NURS MEN, V50, P32, DOI 10.3928/02793695-20120207-02; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Riggio S, 2010, PSYCHIAT CLIN N AM, V33, P807, DOI 10.1016/j.psc.2010.08.004; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rose SR, 2012, PITUITARY, V15, P267, DOI 10.1007/s11102-011-0360-x; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; Ross DE, 2013, J NEUROPSYCH CLIN N, V25, P32, DOI 10.1176/appi.neuropsych.11120377; Rubin DC, 2008, PSYCHOL REV, V115, P985, DOI 10.1037/a0013397; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saulle M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/816069; Schmidt S, 2010, J NEUROL SCI, V291, P22, DOI 10.1016/j.jns.2010.01.011; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; SHEA TB, 1994, MOL BIOL CELL, V5, P863, DOI 10.1091/mbc.5.8.863; Shea TB, 2003, TRENDS NEUROSCI, V26, P397, DOI 10.1016/S0166-2236(03)00199-1; Shea TB, 2009, RESULTS PROBL CELL D, V48, P29, DOI 10.1007/400_2009_8; Sheng JG, 2003, EXP NEUROL, V184, P1053, DOI 10.1016/j.expneurol.2003.08.018; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sherer M., 2013, J HEAD TRAUMA REHABI; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Shively SB, 2012, J HEAD TRAUMA REHAB, V27, P234, DOI 10.1097/HTR.0b013e318250e9dd; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Simpson IA, 2007, J CEREBR BLOOD F MET, V27, P1766, DOI 10.1038/sj.jcbfm.9600521; Singh B, 2013, BRAIN INJURY, V27, P293, DOI 10.3109/02699052.2012.743182; Singh PP, 2002, HUM BIOL, V74, P673, DOI 10.1353/hub.2002.0057; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Small D H, 1999, J Alzheimers Dis, V1, P275; Small DH, 1998, NEUROCHEM RES, V23, P795, DOI 10.1023/A:1022471729291; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Somali M, 2005, HORM METAB RES, V37, P494, DOI 10.1055/s-2005-870308; Srinivas R, 2010, CHILD NERV SYST, V26, P647, DOI 10.1007/s00381-009-1038-9; Starkstein SE, 2005, INT PSYCHOGERIATR, V17, pS93, DOI 10.1017/S1041610205001973; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sugerman DE, 2012, J TRAUMA ACUTE CARE, V73, P1491, DOI 10.1097/TA.0b013e3182782675; Tang BL, 2009, CELL ADHES MIGR, V3, P118, DOI 10.4161/cam.3.1.7254; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tanriverdi F, 2010, PITUITARY, V13, P111, DOI 10.1007/s11102-009-0204-0; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2007, BRAIN INJURY, V21, P433, DOI 10.1080/02699050701311083; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasell R, 2007, BRAIN INJURY, V21, P201, DOI 10.1080/02699050701201854; Teter B, 1999, J NEUROCHEM, V73, P2613, DOI 10.1046/j.1471-4159.1999.0732613.x; Teter B, 2002, J NEUROSCI RES, V68, P331, DOI 10.1002/jnr.10221; Thinakaran G, 2008, J BIOL CHEM, V283, P29615, DOI 10.1074/jbc.R800019200; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Tran HT, 2012, J NEUROPATH EXP NEUR, V71, P116, DOI 10.1097/NEN.0b013e3182456aed; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Tsitsopoulos PP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00079; Turnbull SJ, 2001, BRAIN INJURY, V15, P775, DOI 10.1080/02699050110034334; Turner RC, 2013, FRONT NEUROL, V3, DOI 10.3389/fneur.2012.00186; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Van den Heuvel C, 2000, J NEUROTRAUM, V17, P1041, DOI 10.1089/neu.2000.17.1041; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Vasterling JJ, 2009, J INT NEUROPSYCH SOC, V15, P826, DOI 10.1017/S1355617709990683; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Verghese PB, 2011, LANCET NEUROL, V10, P241, DOI 10.1016/S1474-4422(10)70325-2; Viola-Saltzman M, 2012, NEUROL CLIN, V30, P1299, DOI 10.1016/j.ncl.2012.08.008; Wang JZ, 2008, PROG NEUROBIOL, V85, P148, DOI 10.1016/j.pneurobio.2008.03.002; Wang JZ, 2013, J ALZHEIMERS DIS, V33, pS123, DOI 10.3233/JAD-2012-129031; Weber JT, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00060; Wei W, 2010, NAT NEUROSCI, V13, P190, DOI 10.1038/nn.2476; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xi GH, 1998, J NEUROSURG, V89, P991, DOI 10.3171/jns.1998.89.6.0991; Xi GH, 2002, NEUROSURG CLIN N AM, V13, P371, DOI 10.1016/S1042-3680(02)00007-4; Xi GH, 2001, STROKE, V32, P2932, DOI 10.1161/hs1201.099820; Xie YY, 2003, J NEUROSCI RES, V73, P557, DOI 10.1002/jnr.10667; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xydakis MS, 2012, ANN NEUROL, V72, P673, DOI 10.1002/ana.23757; YAMAZAKI T, 1995, J CELL BIOL, V129, P431, DOI 10.1083/jcb.129.2.431; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zazulia AR, 1999, STROKE, V30, P1167, DOI 10.1161/01.STR.30.6.1167; Zhang HB, 2006, NEUROL RES, V28, P104, DOI 10.1179/016164106X91960; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhang Y, 2000, NEUROBIOL DIS, V7, P240, DOI 10.1006/nbdi.2000.0319; Zhang YW, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-3; Zhang ZR, 2012, BRAIN RES, V1461, P102, DOI 10.1016/j.brainres.2012.04.038; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zink BJ, 2010, PSYCHIAT CLIN N AM, V33, P741, DOI 10.1016/j.psc.2010.08.005	363	85	90	2	44	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2014	32	2					337	365		10.3233/RNN-130354			29	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AC4GD	WOS:000332478200011	24398724				2022-02-06	
J	Luo, J; Nguyen, A; Villeda, S; Zhang, H; Ding, ZQ; Lindsey, D; Bieri, G; Castellano, JM; Beaupre, GS; Wyss-Coray, T				Luo, Jian; Nguyen, Andy; Villeda, Saul; Zhang, Hui; Ding, Zhaoqing; Lindsey, Derek; Bieri, Gregor; Castellano, Joseph M.; Beaupre, Gary S.; Wyss-Coray, Tony			Long-term cognitive impairments and pathological alterations in a mouse model of repetitive mild traumatic brain injury	FRONTIERS IN NEUROLOGY			English	Article						mild traumatic brain injury; long-term; neurobehavior; bioluminescence; astrogliosis		Mild traumatic brain injury (mTBI, also referred to as concussion) accounts for the majority of all traumatic brain injuries. The consequences of repetitive mTBI have become of particular concern for individuals engaged in certain sports or in military operations. Many mTBI patients suffer long-lasting neurobehavioral impairments. In order to expedite pre-clinical research and therapy development, there is a need for animal models that reflect the long-term cognitive and pathological features seen in patients. In the present study, we developed and characterized a mouse model of repetitive mTBI, induced onto the closed head over the left frontal hemisphere with an electromagnetic stereotaxic impact device. Using GFAP-luciferase bioluminescence reporter mice that provide a readout of astrocyte activation, we observed an increase in bioluminescence relative to the force delivered by the impactor after single impact and cumulative effects of repetitive mTBI. Using the injury parameters established in the reporter mice, we induced a repetitive mTBI in wild type C57BL/6J mice and characterized the long-term outcome. Animals received repetitive mTBI showed a significant impairment in spatial learning and memory when tested at 2 and 6 months after injury. A robust astrogliosis and increased p-Tau immunoreactivity were observed upon post-mortem pathological examinations. These findings are consistent with the deficits and pathology associated with mTBI in humans and support the use of this model to evaluate potential therapeutic approaches.	[Luo, Jian; Nguyen, Andy; Villeda, Saul; Zhang, Hui; Ding, Zhaoqing; Bieri, Gregor; Castellano, Joseph M.; Wyss-Coray, Tony] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; [Luo, Jian; Nguyen, Andy; Villeda, Saul; Zhang, Hui; Ding, Zhaoqing; Lindsey, Derek; Bieri, Gregor; Castellano, Joseph M.; Beaupre, Gary S.; Wyss-Coray, Tony] VA Palo Alto Hlth Care Syst, Ctr Tissue Regenerat Repair & Restorat, Palo Alto, CA USA		Luo, J (corresponding author), Stanford Univ, VA Palo Alto Hlth Care Syst, Sch Med, Dept Neurol & Neurol Sci, 3801 Miranda Ave,Bldg 100,Room D3-111, Palo Alto, CA 94304 USA.	jianl@stanford.edu; twc@stanford.edu	Luo, Jian/B-8449-2014; Castellano, Joseph M/ABD-7639-2021; Wyss-Coray, Tony/AAF-3380-2019; Lindsey, Derek/K-2579-2019; Beaupre, Gary/B-9880-2013	Luo, Jian/0000-0002-2064-8467; Wyss-Coray, Tony/0000-0001-5893-0831; Lindsey, Derek/0000-0003-2699-8190; Castellano, Joseph/0000-0002-8026-6292; Beaupre, Gary/0000-0002-6211-7621	Center for Tissue Regeneration, Repair and Restoration, VA Palo Alto Health Care System; Department of Veterans AffairsUS Department of Veterans Affairs [RX001218]; Veterans AffairsUS Department of Veterans Affairs [I01RX001218] Funding Source: NIH RePORTER	This work was supported by the Center for Tissue Regeneration, Repair and Restoration, VA Palo Alto Health Care System, and a grant from the Department of Veterans Affairs (RX001218, to Tony Wyss-Coray).	Atkins CM, 2009, NEUROSCI LETT, V459, P52, DOI 10.1016/j.neulet.2009.04.064; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Britschgi M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-220; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Coutellier L, 2011, BEHAV BRAIN RES, V222, P265, DOI 10.1016/j.bbr.2011.02.043; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Faizi M, 2012, BRAIN BEHAV, V2, P142, DOI 10.1002/brb3.41; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Gerberding JLBS, 2003, REP C MILD TRAUM BRA; Gold EM, 2013, REGEN MED, V8, P483, DOI 10.2217/rme.13.41; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hu BR, 2004, J CEREBR BLOOD F MET, V24, P934, DOI 10.1097/01.WCB.0000125888.56462.A1; Hughes RN, 2004, NEUROSCI BIOBEHAV R, V28, P497, DOI 10.1016/j.neubiorev.2004.06.006; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Khroyan TV, 2012, CLIN EXP PHARMACOL P, V39, P614, DOI 10.1111/j.1440-1681.2012.05719.x; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Konrad KN, 2000, BRAIN INJURY, V14, P859; Lin AH, 2005, J IMMUNOL, V175, P547, DOI 10.4049/jimmunol.175.1.547; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Luo J, 2007, J CLIN INVEST, V117, P3306, DOI 10.1172/JCI31763; Luo J, 2006, P NATL ACAD SCI USA, V103, P18326, DOI 10.1073/pnas.0605077103; Luo J, 2013, J EXP MED, V210, P157, DOI 10.1084/jem.20120412; Luo J, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-6; Mandillo S, 2008, PHYSIOL GENOMICS, V34, P243, DOI 10.1152/physiolgenomics.90207.2008; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Paxinos GFK., 2001, MOUSE BRAIN STEREOTA, V2nd ed.; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Rigg JL, 2011, PM&R, V3, pS380, DOI 10.1016/j.pmrj.2011.08.005; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zhu LY, 2004, NEUROSCI LETT, V367, P210, DOI 10.1016/j.neulet.2004.06.020; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	47	85	85	1	14	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2014	5								12	10.3389/fneur.2014.00012			13	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V42QW	WOS:000209629300012	24550885	Green Published, gold			2022-02-06	
J	Sawmiller, D; Li, S; Shahaduzzaman, M; Smith, AJ; Obregon, D; Giunta, B; Borlongan, CV; Sanberg, PR; Tan, J				Sawmiller, Darrell; Li, Song; Shahaduzzaman, Md; Smith, Adam J.; Obregon, Demian; Giunta, Brian; Borlongan, Cesar V.; Sanberg, Paul R.; Tan, Jun			Luteolin Reduces Alzheimer's Disease Pathologies Induced by Traumatic Brain Injury	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES			English	Article						traumatic brain injury; tauopathy; neuroinflammation; luteolin; amyloidogenesis; GSK; Alzheimer's disease	AMYLOID PRECURSOR PROTEIN; HEAD-INJURY; AXONAL INJURY; BETA-APP; RISK; ACCUMULATION; DIAGNOSIS; PLAQUES; EGCG	Traumatic brain injury (TBI) occurs in response to an acute insult to the head and is recognized as a major risk factor for Alzheimer's disease (AD). Indeed, recent studies have suggested a pathological overlap between TBI and AD, with both conditions exhibiting amyloid-beta (A beta) deposits, tauopathy, and neuroinflammation. Additional studies involving animal models of AD indicate that some AD-related genotypic determinants may be critical factors enhancing temporal and phenotypic symptoms of TBI. Thus in the present study, we examined sub-acute effects of moderate TBI delivered by a gas-driven shock tube device in A beta depositing Tg2576 mice. Three days later, significant increases in b-amyloid deposition, glycogen synthase-3 (GSK-3) activation, phospho-tau, and pro-inflammatory cytokines were observed. Importantly, peripheral treatment with the naturally occurring flavonoid, luteolin, significantly abolished these accelerated pathologies. This study lays the groundwork for a safe and natural compound that could prevent or treat TBI with minimal or no deleterious side effects in combat personnel and others at risk or who have experienced TBI.	[Sawmiller, Darrell; Obregon, Demian; Tan, Jun] James A Haley Vet Adm Hosp, Tampa, FL 33612 USA; [Sawmiller, Darrell; Li, Song; Obregon, Demian; Giunta, Brian; Tan, Jun] Univ S Florida, Dept Psychiat, Morsani Coll Med, Tampa, FL 33613 USA; [Li, Song] Dalian Univ Technol, Sch Phys & Optoelect Technol, Dept Biophys, Dalian 116024, Peoples R China; [Shahaduzzaman, Md; Smith, Adam J.; Borlongan, Cesar V.; Sanberg, Paul R.] Univ S Florida, Dept Neurosurg & Brain Repair, Morsani Coll Med, Ctr Excellence Aging & Brain Repair, Tampa, FL 33613 USA		Sawmiller, D (corresponding author), James A Haley Vet Adm Hosp, Tampa, FL 33612 USA.	dsawmill@health.usf.edu; songli@mail.usf.edu; mshahad@health.usf.edu; asmith1@health.usf.edu; dobregon@health.usf.edu; bgiunta@health.usf.edu; cborlong@health.usf.edu; psanberg@health.usf.edu; jtan@health.usf.edu	Sawmiller, Darrell/AAQ-9722-2021; Borlongan, Cesar/I-5696-2012; Li, Song/C-6701-2014	Borlongan, Cesar/0000-0002-2966-9782; Li, Song/0000-0003-2713-9136; Sawmiller, Darrell/0000-0003-3599-6859	Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Medical Research Service - DoD TATRCUS Department of Veterans Affairs [W81XWH-11-1-0634]; Veterans AffairsUS Department of Veterans Affairs [I01BX001143] Funding Source: NIH RePORTER	This work was supported, in whole or in part, by funds from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Medical Research Service through a Veterans Affairs Merit grant to J.T. C.V.B. and P.R.S. are funded by DoD TATRC W81XWH-11-1-0634. Luteolin (Pureolin (TM)) was a gift from Pharma Science Nutrients, Inc. (Tampa Bay, FL, USA). We would like to thank Doug Shytle for his helpful discussion. Contents of this publication do not represent the views of the Department of Veterans Affairs or the United States Government.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BRAAK H, 1993, EUR NEUROL, V33, P403, DOI 10.1159/000116984; Chauhan NB, 2005, NEUROPHARMACOLOGY, V48, P93, DOI 10.1016/j.neuropharm.2004.09.014; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Geddes JF, 1997, J CLIN PATHOL, V50, P271, DOI 10.1136/jcp.50.4.271; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Giunta B, 2010, NEUROSCI LETT, V471, P134, DOI 10.1016/j.neulet.2010.01.026; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Graham DI, 1996, ACT NEUR S, V66, P96; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jellinger KA, 1998, J NEURAL TRANSM-SUPP, P77; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Lee K. K., 2006, SMJ Singapore Medical Journal, V47, P31; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MOLGAARD CA, 1990, NEUROEPIDEMIOLOGY, V9, P233, DOI 10.1159/000110778; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Reichard RR, 2003, J NEUROTRAUM, V20, P347, DOI 10.1089/089771503765172309; Rezai-Zadeh K, 2009, J CELL MOL MED, V13, P574, DOI 10.1111/j.1582-4934.2008.00344.x; ROBERTS SB, 1994, J BIOL CHEM, V269, P3111; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith A, 2010, INT J PHARMACEUT, V389, P207, DOI 10.1016/j.ijpharm.2010.01.012; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; Tajiri N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078851; Tan J, 1999, SCIENCE, V286, P2352, DOI 10.1126/science.286.5448.2352; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Zhou FT, 2012, BIOL TRACE ELEM RES, V149, P273, DOI 10.1007/s12011-012-9411-z	33	85	85	2	14	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1422-0067			INT J MOL SCI	Int. J. Mol. Sci.	JAN	2014	15	1					895	904		10.3390/ijms15010895			10	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Chemistry	AG9YM	WOS:000335776100052	24413756	Green Submitted, Green Published, gold			2022-02-06	
J	Parsey, CM; Schmitter-Edgecombe, M				Parsey, Carolyn M.; Schmitter-Edgecombe, Maureen			Applications of Technology in Neuropsychological Assessment	CLINICAL NEUROPSYCHOLOGIST			English	Article						Neuropsychological assessment; Technology; Computerized Testing; Virtual Reality	MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; SPATIAL WORKING-MEMORY; VIRTUAL-REALITY; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; ASSESSMENT METRICS; OLDER-ADULTS; TEST BATTERY; DRIVING PERFORMANCE	Most neuropsychological assessments include at least one measure that is administered, scored, or interpreted by computers or other technologies. Despite supportive findings for these technology-based assessments, there is resistance in the field of neuropsychology to adopt additional measures that incorporate technology components. This literature review addresses the research findings of technology-based neuropsychological assessments, including computer- and virtual reality-based measures of cognitive and functional abilities. We evaluate the strengths and limitations of each approach, and examine the utility of technology-based assessments to obtain supplemental cognitive and behavioral information that may be otherwise undetected by traditional paper-and-pencil measures. We argue that the potential of technology use in neuropsychological assessment has not yet been realized, and continued adoption of new technologies could result in more comprehensive assessment of cognitive dysfunction and in turn, better informed diagnosis and treatments. Recommendations for future research are also provided.	[Parsey, Carolyn M.; Schmitter-Edgecombe, Maureen] Washington State Univ, Dept Psychol, Pullman, WA 99164 USA		Parsey, CM (corresponding author), Washington State Univ, Dept Psychol, POB 644820, Pullman, WA 99164 USA.	cparsey@wsu.edu	Parsey, Carolyn/J-2720-2019	Parsey, Carolyn/0000-0002-8555-6512	NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01 EB015853, R01 EB009675] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB009675, R01EB015853] Funding Source: NIH RePORTER		Adams R, 2009, CHILD NEUROPSYCHOL, V15, P120, DOI 10.1080/09297040802169077; Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; Allen BJ, 2011, BRAIN INJURY, V25, P179, DOI 10.3109/02699052.2010.541897; Aprahamian I, 2011, INT J GERIATR PSYCH, V26, P403, DOI 10.1002/gps.2540; Aprahamian I, 2011, INT PSYCHOGERIATR, V23, P96, DOI 10.1017/S104161021000116X; Asimakopulos J, 2012, AUST OCCUP THER J, V59, P402, DOI 10.1111/j.1440-1630.2011.00963.x; Athey RJ, 2006, INT J GERIATR PSYCH, V21, P977, DOI 10.1002/gps.1595; Athey RJ, 2005, AGE AGEING, V34, P268, DOI 10.1093/ageing/afi098; Bauer RM, 2012, CLIN NEUROPSYCHOL, V26, P177, DOI 10.1080/13854046.2012.663001; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Bryan C, 2012, J HEAD TRAUMA REHAB, V27, P45, DOI 10.1097/HTR.0b013e318238f146; Buchman AS, 2011, AM J GERIAT PSYCHIAT, V19, P571, DOI 10.1097/JGP.0b013e3181ef7a2e; Burton EJ, 2004, BRAIN, V127, P791, DOI 10.1093/brain/awh088; Cain AE, 2009, J PSYCHIATR RES, V43, P987, DOI 10.1016/j.jpsychires.2009.01.014; Calhoun VD, 2012, NEUROIMAGE, V59, P25, DOI 10.1016/j.neuroimage.2011.06.037; Chamberlain SR, 2011, BIOL PSYCHIAT, V69, P1192, DOI 10.1016/j.biopsych.2010.08.019; Chen CM, 2000, J AM SOC INFORM SCI, V51, P529, DOI 10.1002/(SICI)1097-4571(2000)51:6<529::AID-ASI5>3.3.CO;2-6; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Conde-Sala JL, 2012, INT PSYCHOGERIATR, V24, P948, DOI 10.1017/S1041610211002158; Cook D.J., 2012, P 8 INT C INT ENV IE, V13, P169; Courtney KL, 2008, METHOD INFORM MED, V47, P76, DOI 10.3414/ME9104; Cumming TB, 2012, J NEUROL SCI, V322, P102, DOI 10.1016/j.jns.2012.07.004; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; Darby D, 2002, NEUROLOGY, V59, P1042, DOI 10.1212/WNL.59.7.1042; Dassel KB, 2008, GERONTOLOGIST, V48, P781, DOI 10.1093/geront/48.6.781; De Jager CA, 2005, NEUROCASE, V11, P72, DOI 10.1080/13554790490896820; de Koning I, 2005, J NEUROL NEUROSUR PS, V76, P263, DOI 10.1136/jnnp.2004.039511; Demiris G, 2008, INT J TECHNOL ASSESS, V24, P120, DOI 10.1017/S0266462307080154; Doniger Glen M, 2006, Am J Alzheimers Dis Other Demen, V21, P28; Doniger GM, 2009, ALZHEIMERS DEMENT, V5, P439, DOI 10.1016/j.jalz.2009.03.003; DOWNES JJ, 1989, NEUROPSYCHOLOGIA, V27, P1329, DOI 10.1016/0028-3932(89)90128-0; Dwolatzky T, 2004, J MOL NEUROSCI, V24, P33, DOI 10.1385/JMN:24:1:033; Dwolatzky T., 2003, BIOMED CENTRAL BMC G, V2, P3; Dwolatzky T, 2010, INT PSYCHOGERIATR, V22, P795, DOI 10.1017/S1041610210000621; Edwards S, 1996, PHARMACOL BIOCHEM BE, V54, P309, DOI 10.1016/0091-3057(95)02116-7; Egerhazi A, 2007, PROG NEURO-PSYCHOPH, V31, P746, DOI 10.1016/j.pnpbp.2007.01.011; Elkind JS, 2001, CYBERPSYCHOL BEHAV, V4, P489, DOI 10.1089/109493101750527042; Falleti MG, 2006, J CLIN EXP NEUROPSYC, V28, P1095, DOI 10.1080/13803390500205718; Feldstein SN, 1999, CLIN NEUROPSYCHOL, V13, P303, DOI 10.1076/clin.13.3.303.1744; Fillit HM, 2008, ALZHEIMERS DEMENT, V4, P14, DOI 10.1016/j.jalz.2007.09.008; Flynn D, 2003, CYBERPSYCHOL BEHAV, V6, P591, DOI 10.1089/109493103322725379; Fowler KS, 2002, J INT NEUROPSYCH SOC, V8, P58, DOI 10.1017/S1355617701020069; Fredrickson J, 2010, NEUROEPIDEMIOLOGY, V34, P65, DOI 10.1159/000264823; Gaggioli A, 2012, STUD HEALTH TECHNOL, V181, P177, DOI 10.3233/978-1-61499-121-2-177; Gaspar J. G., 2013, J AGING RES, V2013; Gau SSF, 2010, J CHILD PSYCHOL PSYC, V51, P838, DOI 10.1111/j.1469-7610.2010.02215.x; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Gualtieri C Thomas, 2005, Am J Alzheimers Dis Other Demen, V20, P359; Gualtieri C Thomas, 2008, Medscape J Med, V10, P90; Guevara MA, 2009, COMPUT METH PROG BIO, V95, P158, DOI 10.1016/j.cmpb.2009.02.007; Hagler S, 2010, IEEE T BIO-MED ENG, V57, P813, DOI 10.1109/TBME.2009.2036732; Hanna-Pladdy B, 2010, INT J NEUROSCI, V120, P538, DOI 10.3109/00207454.2010.496539; Harel BT, 2011, NEUROPSYCHOLOGY, V25, P752, DOI 10.1037/a0024237; Hawkins KA, 2012, PARKINSONISM RELAT D, V18, P864, DOI 10.1016/j.parkreldis.2012.04.021; Hayes TL, 2008, ALZHEIMERS DEMENT, V4, P395, DOI 10.1016/j.jalz.2008.07.004; Heaton, 2010, NEUROPSYCHOLOGY EVER, P5; Heinik J, 2004, ARCH GERONTOL GERIAT, V38, P77, DOI 10.1016/j.archger.2003.08.004; Hobson P, 1999, AGE AGEING, V28, P39, DOI 10.1093/ageing/28.1.39; Iverson GL, 2009, J CLIN EXP NEUROPSYC, V31, P594, DOI 10.1080/13803390802372125; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Jones M, 2011, J HEALTH SERV RES PO, V16, P172, DOI 10.1258/jhsrp.2010.010016; Junkkila J, 2012, DEMENT GERIATR COGN, V34, P83, DOI 10.1159/000342116; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS115, DOI 10.1016/j.acn.2006.10.006; Kang YJ, 2008, CYBERPSYCHOL BEHAV, V11, P329, DOI 10.1089/cpb.2007.0116; Koski L, 2011, HIV MED, V12, P472, DOI 10.1111/j.1468-1293.2010.00910.x; Kush JC, 2012, BEHAV RES METHODS, V44, P125, DOI 10.3758/s13428-011-0136-2; Law AS, 2006, ACTA PSYCHOL, V122, P27, DOI 10.1016/j.actpsy.2005.09.002; Leeds L, 2001, AGE AGEING, V30, P251, DOI 10.1093/ageing/30.3.251; Levinson D, 2005, ARCH CLIN NEUROPSYCH, V20, P403, DOI 10.1016/j.acn.2004.09.001; Levinson DM, 1997, ARCH CLIN NEUROPSYCH, V12, P155, DOI 10.1016/S0887-6177(96)00026-1; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P7; Lowe C, 1998, NEUROPSYCHOLOGIA, V36, P915, DOI 10.1016/S0028-3932(98)00036-0; Lundqvist A, 2000, APPL COGNITIVE PSYCH, V14, P135, DOI 10.1002/(SICI)1099-0720(200003/04)14:2<135::AID-ACP628>3.0.CO;2-S; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; Maruff P, 2004, DEMENT GERIATR COGN, V18, P342, DOI 10.1159/000080229; Maruff P, 2009, ARCH CLIN NEUROPSYCH, V24, P165, DOI 10.1093/arclin/acp010; Mataix-Cols David, 2002, Appl Neuropsychol, V9, P117, DOI 10.1207/S15324826AN0902_8; Matheis RJ, 2007, CLIN NEUROPSYCHOL, V21, P146, DOI 10.1080/13854040601100668; Mayhew DR, 2011, J SAFETY RES, V42, P267, DOI 10.1016/j.jsr.2011.06.004; McGough EL, 2011, PHYS THER, V91, P1198, DOI 10.2522/ptj.20100372; McKinlay A, 2009, APPL NEUROPSYCHOL, V16, P177, DOI 10.1080/09084280903098661; MORRIS RG, 1988, J NEUROL NEUROSUR PS, V51, P757, DOI 10.1136/jnnp.51.6.757; Mullen NW, 2010, AM J OCCUP THER, V64, P288, DOI 10.5014/ajot.64.2.288; Nichols S, 2002, APPL ERGON, V33, P251, DOI 10.1016/S0003-6870(02)00020-0; Noyes JM, 2008, ERGONOMICS, V51, P1352, DOI 10.1080/00140130802170387; Noyes JM, 2003, COMPUT HUM BEHAV, V19, P579, DOI 10.1016/S0747-5632(03)00002-5; Nunes PV, 2008, INT J GERIATR PSYCH, V23, P1127, DOI 10.1002/gps.2038; O'Connell H, 2004, INT J GERIATR PSYCH, V19, P1207, DOI 10.1002/gps.1180; Osher Y, 2011, PSYCHOTHER PSYCHOSOM, V80, P298, DOI 10.1159/000324508; Parsons TD, 2008, CYBERPSYCHOL BEHAV, V11, P17, DOI 10.1089/cpb.2007.9934; Parsons TD, 2007, CHILD NEUROPSYCHOL, V13, P363, DOI 10.1080/13825580600943473; Parsons Thomas D, 2012, Stud Health Technol Inform, V173, P331; Parsons TD, 2011, STUD HEALTH TECHNOL, V163, P433, DOI 10.3233/978-1-60750-706-2-433; Parsons TD, 2008, STUD HEALTH TECHNOL, V132, P351; Patomella AH, 2006, J REHABIL MED, V38, P273, DOI 10.1080/16501970600632594; Pietrzak RH, 2008, ARCH CLIN NEUROPSYCH, V23, P433, DOI 10.1016/j.acn.2008.03.002; PUGNETTI L, 1995, COMPUT BIOL MED, V25, P213, DOI 10.1016/0010-4825(94)00040-W; Rajendran G, 2011, J AUTISM DEV DISORD, V41, P1445, DOI 10.1007/s10803-010-1151-3; Rand D, 2009, NEUROPSYCHOL REHABIL, V19, P583, DOI 10.1080/09602010802469074; Rashidi P, 2011, IEEE T KNOWL DATA EN, V23, P527, DOI 10.1109/TKDE.2010.148; Raspelli S, 2010, STUD HEALTH TECHNOL, V154, P115, DOI 10.3233/978-1-60750-561-7-115; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; Retzlaff P. D., 2000, CLIN GUIDE NEUROPSYC, P277; Riva G, 2003, METHOD INFORM MED, V42, P524; Rizzo AA, 2006, CNS SPECTRUMS, V11, P35, DOI 10.1017/S1092852900024196; Rizzo AA, 1997, ST HEAL T, V44, P123; Rizzo M, 2001, ALZ DIS ASSOC DIS, V15, P10, DOI 10.1097/00002093-200101000-00002; Robbins TW, 1998, J INT NEUROPSYCH SOC, V4, P474, DOI 10.1017/s1355617798455073; ROBBINS TW, 1994, DEMENTIA, V5, P266, DOI 10.1159/000106735; ROSSER A, 1994, J NEUROL NEUROSUR PS, V57, P1389, DOI 10.1136/jnnp.57.11.1389; SAHAKIAN BJ, 1992, J ROY SOC MED, V85, P399; SAHAKIAN BJ, 1988, BRAIN, V111, P695, DOI 10.1093/brain/111.3.695; Sahgal A, 1991, DEMENTIA, V2, P150; Salnaitis CL, 2011, APPL NEUROPSYCHOL, V18, P37, DOI 10.1080/09084282.2010.523381; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2002, J HEAD TRAUMA REHAB, V17, P395, DOI 10.1097/00001199-200210000-00003; Schmitter-Edgecombe M, 2013, POSITIVE NEUROPSYCHO; Schultheis MT, 2007, ASSIST TECHNOL, V19, P1, DOI 10.1080/10400435.2007.10131860; Schultheis Maria T, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P4921; Schultheis MT, 2009, ARCH PHYS MED REHAB, V90, P975, DOI 10.1016/j.apmr.2008.12.017; Schweiger A, 2007, J CLIN EXP NEUROPSYC, V29, P100, DOI 10.1080/13803390500519738; Seelye Adriana M, 1800, IEEE Rev Biomed Eng, V5, P29, DOI 10.1109/RBME.2012.2196691; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shiffman S, 2008, ANNU REV CLIN PSYCHO, V4, P1, DOI 10.1146/annurev.clinpsy.3.022806.091415; Singla G, 2010, J AMB INTEL HUM COMP, V1, P57, DOI 10.1007/s12652-009-0007-1; Smyth J.M., 2003, J HAPPINESS STUD, V4, P35, DOI 10.1023/A:1023657221954; Stanley KG, 2011, ANN FAM MED, V9, P296, DOI 10.1370/afm.1292; Steinmetz JP, 2010, PSYCHOL ASSESSMENT, V22, P199, DOI 10.1037/a0017661; Stone Arthur S., 1994, Annals of Behavioral Medicine, V16, P199; Suchy Y, 2011, J CLIN EXP NEUROPSYC, V33, P92, DOI 10.1080/13803395.2010.493148; Suchy Y, 2010, J GERONTOL B-PSYCHOL, V65, P542, DOI 10.1093/geronb/gbq037; Tien Allen Y., 1996, Kaohsiung Journal of Medical Sciences, V12, P479; Tun PA, 2010, PSYCHOL AGING, V25, P560, DOI 10.1037/a0019543; Vincent AS, 2012, MIL MED, V177, P256, DOI 10.7205/MILMED-D-11-00289; Wald J, 2000, Stud Health Technol Inform, V70, P365; Wang Y, 2010, ERGONOMICS, V53, P404, DOI 10.1080/00140130903464358; Wild K, 2008, ALZHEIMERS DEMENT, V4, P428, DOI 10.1016/j.jalz.2008.07.003; Wild KV, 2012, ALZHEIMERS DEMENT, V8, P544, DOI 10.1016/j.jalz.2011.12.008; Williams DJ, 2007, COMPUT HUM BEHAV, V23, P258, DOI 10.1016/j.chb.2004.10.011; Winkel-Witlox ACMT, 2008, DISABIL REHABIL, V30, P1386, DOI 10.1080/09638280701623000; Zhang L, 2003, ARCH PHYS MED REHAB, V84, P1118, DOI 10.1016/S0003-9993(03)00203-X; Zhang L, 2001, AM J PHYS MED REHAB, V80, P597, DOI 10.1097/00002060-200108000-00010	147	85	86	2	64	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	NOV 1	2013	27	8					1328	1361		10.1080/13854046.2013.834971			34	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	273KW	WOS:000328534700009	24041037	Green Accepted			2022-02-06	
J	Liao, YL; Liu, P; Guo, FY; Zhang, ZY; Zhang, ZR				Liao, Yiliu; Liu, Peng; Guo, Fangyuan; Zhang, Zhi-Yuan; Zhang, Zhiren			Oxidative Burst of Circulating Neutrophils Following Traumatic Brain Injury in Human	PLOS ONE			English	Article							SYSTEMIC INFLAMMATORY RESPONSE; SPINAL-CORD-INJURY; SEVERE HEAD-INJURY; MULTIPLE ORGAN FAILURE; C-REACTIVE PROTEIN; LEUKOCYTE MOBILIZATION; ANTIOXIDANT THERAPIES; BLOOD NEUTROPHILS; BLUNT TRAUMA; RATS	Besides secondary injury at the lesional site, Traumatic brain injury (TBI) can cause a systemic inflammatory response, which may cause damage to initially unaffected organs and potentially further exacerbate the original injury. Here we investigated plasma levels of important inflammatory mediators, oxidative activity of circulating leukocytes, particularly focusing on neutrophils, from TBI subjects and control subjects with general trauma from 6 hours to 2 weeks following injury, comparing with values from uninjured subjects. We observed increased plasma level of inflammatory cytokines/molecules TNF-alpha, IL-6 and CRP, dramatically increased circulating leukocyte counts and elevated expression of TNF-alpha and iNOS in circulating leukocytes from TBI patients, which suggests a systemic inflammatory response following TBI. Our data further showed increased free radical production in leukocyte homogenates and elevated expression of key oxidative enzymes iNOS, COX-2 and NADPH oxidase (gp91(phox)) in circulating leukocytes, indicating an intense induction of oxidative burst following TBI, which is significantly greater than that in control subjects with general trauma. Furthermore, flow cytometry assay proved neutrophils as the largest population in circulation after TBI and showed significantly up-regulated oxidative activity and suppressed phagocytosis rate for circulating neutrophils following brain trauma. It suggests that the highly activated neutrophils might play an important role in the secondary damage, even outside the injured brain. Taken together, the potent systemic inflammatory response induced by TBI, especially the intensively increase oxidative activity of circulating leukocytes, mainly neutrophils, may lead to a systemic damage, dysfunction/damage of bystander tissues/organs and even further exacerbate secondary local damage. Controlling these pathophysiological processes may be a promising therapeutic strategy and will protect unaffected organs and the injured brain from the secondary damage.	[Liao, Yiliu; Liu, Peng; Guo, Fangyuan] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Traumat Surg, Wuhan 430074, Peoples R China; [Zhang, Zhi-Yuan] Univ Tubingen, Dept Neuropathol, Tubingen, Germany; [Zhang, Zhiren] Third Mil Med Univ PLA, Inst Immunol, Chongqing, Peoples R China		Zhang, ZY (corresponding author), Univ Tubingen, Dept Neuropathol, Tubingen, Germany.	zhiyuan.zhang@medizin.uni-tuebingen.de; zhangzhiren@yahoo.com	zhang, zhiren/I-1046-2014; Zhang, Zhiren/O-1012-2019	zhang, zhiren/0000-0002-5238-2835; Zhang, Zhiren/0000-0002-5238-2835	Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC); CQ CSTCNatural Science Foundation Project of CQ CSTC [2010BB5025]; State Science and Technology Major Projects of New Drugs [2012ZX09103301-035]	The present study was partially supported by two project fundings as following: Natural Science Foundation of China (http://www.nsfc.gov.cn/e_nsfc/desktop/zn/0101.htm), Project of CQ CSTC (No. 2010BB5025); and State Science and Technology Major Projects of New Drugs (http://www.nmp.gov.cn/) (No. 2012ZX09103301-035). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Bao F, 2005, J NEUROCHEM, V94, P1361, DOI 10.1111/j.1471-4159.2005.03280.x; Bao F, 2004, J NEUROCHEM, V88, P1335, DOI 10.1046/j.1471-4159.2003.02240.x; Bao F, 2009, EXP NEUROL, V215, P308, DOI 10.1016/j.expneurol.2008.10.022; Baskaran H, 2000, J SURG RES, V93, P88, DOI 10.1006/jsre.2000.5955; Basu S, 2009, FREE RADICAL RES, V43, P85, DOI 10.1080/10715760802610851; Bhatia R, 2006, J TRAUMA, V60, P590, DOI 10.1097/01.ta.0000205614.51885.ff; Bhatia RK, 2005, INJURY, V36, P956, DOI 10.1016/j.injury.2005.03.009; Bone RC, 1996, CRIT CARE MED, V24, P163, DOI 10.1097/00003246-199601000-00026; BOTHA AJ, 1995, J TRAUMA, V39, P411; Campbell SJ, 2003, FASEB J, V17, P1168, DOI 10.1096/fj.02-0757fje; Campbell SJ, 2005, AM J PATHOL, V166, P1487, DOI 10.1016/S0002-9440(10)62365-6; Castelli GP, 2004, CRIT CARE, V8, pR234, DOI 10.1186/cc2877; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Cocks RA, 1998, J TRAUMA, V45, P1, DOI 10.1097/00005373-199807000-00001; D'Aiuto F, 2010, J DENT RES, V89, P1241, DOI 10.1177/0022034510375830; Furlan JC, 2006, SPINE, V31, P2674, DOI 10.1097/01.brs.0000244569.91204.01; Gaforio JJ, 2002, CYTOMETRY, V48, P93, DOI 10.1002/cyto.10107; Gahm C, 2006, J NEUROTRAUM, V23, P1343, DOI 10.1089/neu.2006.23.1343; Gris D, 2008, EXP NEUROL, V211, P259, DOI 10.1016/j.expneurol.2008.01.033; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Kanyilmaz S, 2013, ARCH PHYS MED REHAB, V94, P369, DOI 10.1016/j.apmr.2012.09.015; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; LaPar DJ, 2012, J AM COLL SURGEONS, V214, P478, DOI 10.1016/j.jamcollsurg.2011.12.015; Lenz A, 2007, INJURY, V38, P1336, DOI 10.1016/j.injury.2007.10.003; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Mimoz O, 1998, INTENS CARE MED, V24, P185, DOI 10.1007/s001340050543; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Motoyama T, 2003, CRIT CARE MED, V31, P1048, DOI 10.1097/01.CCM.0000055371.27268.36; Namas R, 2009, LIBYAN J MED, V4, P97, DOI 10.4176/090325; Nowotarski PJ, 2000, J BONE JOINT SURG AM, V82A, P781, DOI 10.2106/00004623-200006000-00004; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Pasquale MD, 1996, CRIT CARE MED, V24, P1238, DOI 10.1097/00003246-199607000-00029; Peluso I, 2013, J IMMUNOL METHODS, V390, P113, DOI 10.1016/j.jim.2013.02.005; Peluso I, 2012, J IMMUNOL METHODS, V379, P61, DOI 10.1016/j.jim.2012.02.015; Pillay J, 2007, INJURY, V38, P1365, DOI 10.1016/j.injury.2007.09.016; Rovlias A, 2001, SURG NEUROL, V55, P190, DOI 10.1016/S0090-3019(01)00414-1; Rovlias A, 2004, J NEUROTRAUM, V21, P886, DOI 10.1089/0897715041526249; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Sunil VR, 2002, RESP RES, V3, DOI 10.1186/rr171; TEASDALE G, 1974, LANCET, V2, P81; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Venetsanou K, 2007, EUR CYTOKINE NETW, V18, P206, DOI 10.1684/ecn.2007.0112; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Xie LK, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-53	49	85	87	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2013	8	7							e68963	10.1371/journal.pone.0068963			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	188BY	WOS:000322167900033	23894384	Green Submitted, gold, Green Published			2022-02-06	
J	Ganpule, S; Alai, A; Plougonven, E; Chandra, N				Ganpule, S.; Alai, A.; Plougonven, E.; Chandra, N.			Mechanics of blast loading on the head models in the study of traumatic brain injury using experimental and computational approaches	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Blast; TBI; Head; Mechanics; Experiments; Numerical models; FSI	BIOMECHANICS; GENERATION; RESPONSES; EXPOSURE; IMPACT; TISSUE; WAVE; RAT	Blast waves generated by improvised explosive devices can cause mild, moderate to severe traumatic brain injury in soldiers and civilians. To understand the interactions of blast waves on the head and brain and to identify the mechanisms of injury, compression-driven air shock tubes are extensively used in laboratory settings to simulate the field conditions. The overall goal of this effort is to understand the mechanics of blast wave-head interactions as the blast wave traverses the head/brain continuum. Toward this goal, surrogate head model is subjected to well-controlled blast wave profile in the shock tube environment, and the results are analyzed using combined experimental and numerical approaches. The validated numerical models are then used to investigate the spatiotemporal distribution of stresses and pressure in the human skull and brain. By detailing the results from a series of careful experiments and numerical simulations, this paper demonstrates that: (1) Geometry of the head governs the flow dynamics around the head which in turn determines the net mechanical load on the head. (2) Biomechanical loading of the brain is governed by direct wave transmission, structural deformations, and wave reflections from tissue-material interfaces. (3) Deformation and stress analysis of the skull and brain show that skull flexure and tissue cavitation are possible mechanisms of blast-induced traumatic brain injury.	[Ganpule, S.; Alai, A.; Plougonven, E.; Chandra, N.] Univ Nebraska, Dept Mech & Mat Engn, Lincoln, NE 68588 USA		Chandra, N (corresponding author), Univ Nebraska, Dept Mech & Mat Engn, Lincoln, NE 68588 USA.	nchandra2@unl.edu	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146	U.S. Army Research Office [W911NF-08-1-0483]	The authors acknowledge the financial support provided by the U.S. Army Research Office for the project on "Army-UNL Center for Trauma Mechanics", Contract No. W911NF-08-1-0483 (Project Manager: Larry Russell, P.I: Namas Chandra). The authors thank Ruqiang Feng, Aaron Holmberg of University of Nebraska-Lincoln (UNL) for many useful discussions.	Anderson JD., 2001, FUNDAMENTALS AERODYN, V3; Baker TJ, 2005, PROG AEROSP SCI, V41, P29, DOI 10.1016/j.paerosci.2005.02.002; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Belingardi G, 2005, 19 INT TECHN C ENH S; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; Bourdin X, 2007, 20 ENH SAF VEH C INN; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; CERNAK I, 2005, RESTORATIVE NEUROLOG, V23, P139; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Chandra N., 2011, U.S. provisional patent application, Patent No. 61542354; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Chen Y, 2010, ACTA MECH, V213, P155, DOI 10.1007/s00707-009-0274-0; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Desmoulin GT, 2009, J TRAUMA, V67, P1113, DOI 10.1097/TA.0b013e3181bb8e84; Dogan A, 1999, J NEUROSURG, V90, P1078, DOI 10.3171/jns.1999.90.6.1078; El Sayed T, 2008, COMPUT METHOD APPL M, V197, P4692, DOI 10.1016/j.cma.2008.06.006; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Ganpule S., 2011, COMPUT METHOD BIOMEC, DOI [10.1080/10255842.2011.597353, DOI 10.1080/10255842.2011.597353]; Grujicic M, 2011, J MATER ENG PERFORM, V20, P877, DOI 10.1007/s11665-010-9724-z; Honma H, 2003, SHOCK WAVES, V13, P179, DOI 10.1007/s00193-003-0206-1; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Jiang Z, 2003, SHOCK WAVES, V13, P103, DOI 10.1007/s00193-003-0197-y; Kalbag A., 1992, FINITE ELEM ANAL DES, V12, P313, DOI DOI 10.1016/0168-874X(92)90040-J; Kashimura H., 2000, J THERM SCI, V9, P30, DOI [10.1007/s11630-000-0042-x, DOI 10.1007/S11630-000-0042-X]; Kennedy EA, 2007, THESIS VIRGINIA POLY; Khalil TB, 1982, P 26 STAPP CAR CRASH; Kleinschmit N.N., 2011, THESIS U NEBRASKA LI; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Krave U, 2005, EUR J NEUROSCI, V21, P2876, DOI 10.1111/j.1460-9568.2005.04115.x; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; LUBOCK P, 1980, J BIOMECH, V13, P1041, DOI 10.1016/0021-9290(80)90048-2; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; McElhaney JH, 1973, PERSPECTIVES BIOMEDI, P215, DOI DOI 10.1007/978-1-349-01604-4_34; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Moore DF, 2008, FUTUR NEUROL, V3, P243, DOI 10.2217/14796708.3.3.243; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Mott DR SD, 2008, 20 INT S MIL ASP BLA; Nahum A., 1977, 21 STAPP CAR CRASH C, DOI DOI 10.4271/770922; Nakagawa A, 2008, ACTA NEUROCHIR SUPPL, V102, P421, DOI 10.1007/978-3-211-85578-2_82; Nicolle S, 2005, BIORHEOLOGY, V42, P209; NUSHOLTZ GS, 1987, AVIAT SPACE ENVIR MD, V58, P1157; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Prevost TP, 2011, ACTA BIOMATER, V7, P83, DOI 10.1016/j.actbio.2010.06.035; Ramos A, 2006, MED ENG PHYS, V28, P916, DOI 10.1016/j.medengphy.2005.12.006; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Schneiders R, 2000, P VKI LECT SERIES CO; Stalnaker RL, 1969, THESIS W VIRGINIA U; Sundaramurthy A, 2012, J NEUROTRAUM, DOI [10.1089/neu.2012.2413, DOI 10.1089/NEU.2012.2413]]; Takhounts Erik G, 2003, Stapp Car Crash J, V47, P107; Takhounts EG, 2008, STAPP CAR C, V52, P1; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; TEASDALE G, 1974, LANCET, V2, P81; Trosseille X, 1992, STAPP CAR CRASH C, DOI [10.4271/922527, DOI 10.4271/922527]; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Ward C, 1980, P 24 STAPP CAR CRASH, P161, DOI [10.2307/44632636, DOI 10.2307/446326]; Wieding J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033776; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; Wismans, 1997, P 41 STAPP CAR CRASH, V41, P315, DOI DOI 10.4271/973338; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zhu F, 2012, BIOMECH MODEL MECHAN, V11, P341, DOI 10.1007/s10237-011-0314-2; Zhu Feng, 2010, Stapp Car Crash J, V54, P211; Zoghi-Moghadam M, 2009, COMPUT METHOD BIOMEC, V12, P1, DOI [10.1080/10255840802020420, 10.1080/10255840903064897]	72	85	88	4	71	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959	1617-7940		BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	JUN	2013	12	3					511	531		10.1007/s10237-012-0421-8			21	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	149AA	WOS:000319289200008	22832705	Green Submitted			2022-02-06	
J	Rockswold, SB; Rockswold, GL; Zaun, DA; Liu, JN				Rockswold, Sarah B.; Rockswold, Gaylan L.; Zaun, David A.; Liu, Jiannong			A prospective, randomized Phase II clinical trial to evaluate the effect of combined hyperbaric and normobaric hyperoxia on cerebral metabolism, intracranial pressure, oxygen toxicity, and clinical outcome in severe traumatic brain injury Clinical article	JOURNAL OF NEUROSURGERY			English	Article						hyperbaric oxygen; normobaric hyperoxia; traumatic brain injury cerebral metabolism; intracranial pressure; oxygen toxicity; clinical outcome	HEAD-INJURY; CEREBROSPINAL-FLUID; BLOOD-FLOW; RAT MODEL; INTRACEREBRAL MICRODIALYSIS; MITOCHONDRIAL-FUNCTION; ISCHEMIC TOLERANCE; THERAPY; MECHANISMS; DAMAGE	Object. Preclinical and clinical investigations indicate that the positive effect of hyperbaric oxygen (HBO2) for severe traumatic brain injury (TBI) occurs after rather than during treatment. The brain appears better able to use baseline O-2 levels following HBO2 treatments. In this study, the authors evaluate the combination of HBO2 and normobaric hyperoxia (NBH) as a single treatment. Methods. Forty-two patients who sustained severe TBI (mean Glasgow Coma Scale [GCS] score 5.7) were prospectively randomized within 24 hours of injury to either: 1) combined HBO2/NBH (60 minutes of HBO2 at 1.5 atmospheres absolute [ATA] followed by NBH, 3 hours of 100% fraction of inspired oxygen [FiO(2)] at 1.0 ATA) or 2) control, standard care. Treatments occurred once every 24 hours for 3 consecutive days. Intracranial pressure, surrogate markers for cerebral metabolism, and O-2 toxicity were monitored. Clinical outcome was assessed at 6 months using the sliding dichotomized Glasgow Outcome Scale (GOS) score. Mixed-effects linear modeling was used to statistically test differences between the treatment and control groups. Functional outcome and mortality rates were compared using chi-square tests. Results. There were no significant differences in demographic characteristics between the 2 groups. In comparison with values in the control group, brain tissue partial pressure of O-2 (PO2) levels were significantly increased during and following combined HBO2/NBH treatments in both the noninjured and pericontusional brain (p < 0.0001). Microdialysate lactate/pyruvate ratios were significantly decreased in the noninjured brain in the combined HBO2/NBH group as compared with controls (p < 0.0078). The combined HBO2/NBH group's intracranial pressure values were significantly lower than those of the control group during treatment, and the improvement continued until the next treatment session (p < 0.0006). The combined HBO2/NBH group's levels of microdialysate glycerol were significantly lower than those of the control group in both noninjured and pericontusional brain (p < 0.001). The combined HBO2/NBH group's level of CSF F2-isoprostane was decreased at 6 hours after treatment as compared with that of controls, but the difference did not quite reach statistical significance (p < 0.0692). There was an absolute 26% reduction in mortality for the combined HBO2/NBH group (p = 0.048) and an absolute 36% improvement in favorable outcome using the sliding dichotomized GOS (p = 0.024) as compared with the control group. Conclusions. In this Phase II clinical trial, in comparison with standard care (control treatment) combined HBO2/NBH treatments significantly improved markers of oxidative metabolism in relatively uninjured brain as well as pericontusional tissue, reduced intracranial hypertension, and demonstrated improvement in markers of cerebral toxicity. There was significant reduction in mortality and improved favorable outcome as measured by GOS. The combination of HBO2 and NBH therapy appears to have potential therapeutic efficacy as compared with the 2 treatments in isolation.	[Rockswold, Sarah B.] Hennepin Cty Med Ctr, Dept Phys Med & Rehabil, Minneapolis, MN 55415 USA; [Rockswold, Sarah B.; Rockswold, Gaylan L.] Hennepin Cty Med Ctr, Dept Surg, Div Neurosurg, Minneapolis, MN 55415 USA; [Rockswold, Sarah B.] Univ Minnesota, Dept Med & Rehabil, Minneapolis, MN USA; [Rockswold, Gaylan L.] Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA; [Zaun, David A.; Liu, Jiannong] Minneapolis Med Res Fdn Inc, Chron Dis Res Grp, Analyt Serv, Minneapolis, MN USA		Rockswold, GL (corresponding author), Hennepin Cty Med Ctr, 701 Pk Ave, Minneapolis, MN 55415 USA.	gaylan.rockswold@hcmed.org			National Institute of Neurological Disorders and Stroke Hyperbaric and Normobaric Oxygen in Severe Brain Injury [R01-NS042126-03S1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042126] Funding Source: NIH RePORTER	This work was supported by the National Institute of Neurological Disorders and Stroke Hyperbaric and Normobaric Oxygen in Severe Brain Injury Grant no. R01-NS042126-03S1 (G.L.R.). Integra Life Sciences provided technical assistance and supplies related to brain tissue O<INF>2</INF> monitoring.	Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; DEATON PR, 1994, AM J PHYSIOL, V267, pL187, DOI 10.1152/ajplung.1994.267.2.L187; DEFORGE LE, 1993, J BIOL CHEM, V268, P25568; DEMOPOULOS HB, 1982, CAN J PHYSIOL PHARM, V60, P1415, DOI 10.1139/y82-210; DEMOPOULOS HB, 1982, PATHOLOGY OXYGEN, P127; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; Desmarquest P, 1998, RESP MED, V92, P951, DOI 10.1016/S0954-6111(98)90195-0; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; Fam SS, 2003, CURR MED CHEM, V10, P1723, DOI 10.2174/0929867033457115; Finkelstein E., 2006, INCIDENCE EC BURDEN; Frykholm P, 2001, J NEUROL NEUROSUR PS, V71, P455, DOI 10.1136/jnnp.71.4.455; Furuya Y, 2003, NEUROSURGERY, V52, P340, DOI 10.1227/01.NEU.0000043931.83041.AA; Gossett WA, 2010, UNDERSEA HYPERBAR M, V37, P35; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kinoshita K, 2002, J NEUROTRAUM, V19, P681, DOI 10.1089/08977150260139075; KLEIN J, 1990, ANESTH ANALG, V70, P195; Krebs E G, 1972, Curr Top Cell Regul, V5, P99; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Merenda A, 2008, J NEUROTRAUM, V25, P527, DOI 10.1089/neu.2007.0359; METZEL E, 1971, ACTA NEUROCHIR, V25, P177, DOI 10.1007/BF01809099; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Morrow JD, 2000, DRUG METAB REV, V32, P377, DOI 10.1081/DMR-100102340; Muehstedt SG, 2001, SURGERY, V130, P602, DOI 10.1067/msy.2001.117105; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Palzur E, 2008, BRAIN RES, V1221, P126, DOI 10.1016/j.brainres.2008.04.078; REA GL, 1983, NEUROSURGERY, V12, P401, DOI 10.1227/00006123-198304000-00005; ROCKSWOLD G L, 1985, HYPERBARIC OXYGEN RE, V6, P161; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; Rogatsky GG, 2005, BRAIN RES, V1047, P131, DOI 10.1016/j.brainres.2005.02.049; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Simard JM, 2010, J NEUROSURG, V113, P622, DOI 10.3171/2009.11.JNS081052; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Soustiel JF, 2008, NEUROPATH APPL NEURO, V34, P412, DOI 10.1111/j.1365-2990.2007.00906.x; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Tisdall MM, 2008, J NEUROSURG, V109, P424, DOI 10.3171/JNS/2008/109/9/0424; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vigue B, 1999, INTENS CARE MED, V25, P445, DOI 10.1007/s001340050878; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Vlodavsky E, 2005, ACTA NEUROPATHOL, V110, P120, DOI 10.1007/s00401-004-0946-8; Wada K, 2001, NEUROSURGERY, V49, P160; Wada K, 1996, BRAIN RES, V740, P15; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zhang T, 2010, BRAIN INJURY, V24, P1350, DOI 10.3109/02699052.2010.504525; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	65	85	98	0	13	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2013	118	6					1317	1328		10.3171/2013.2.JNS121468			12	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	150BY	WOS:000319366400032	23510092	Bronze			2022-02-06	
J	Whittaker, B; Christiaans, SC; Altice, JL; Chen, MK; Bartolucci, AA; Morgan, CJ; Kerby, JD; Pittet, JF				Whittaker, Brent; Christiaans, Sarah C.; Altice, Jessica L.; Chen, Mike K.; Bartolucci, Alfred A.; Morgan, Charity J.; Kerby, Jeffrey D.; Pittet, Jean-Francois			EARLY COAGULOPATHY IS AN INDEPENDENT PREDICTOR OF MORTALITY IN CHILDREN AFTER SEVERE TRAUMA	SHOCK			English	Article						Pediatric trauma; coagulopathy; traumatic brain injury; tissue hypoperfusion; mortality	ACTIVATED PROTEIN-C; BRAIN-INJURY; RISK; DEFINITION; ADMISSION; SCALE	To determine whether early coagulopathy affects the mortality associated with severe civilian pediatric trauma, trauma patients younger than 18 years admitted to a pediatric intensive care unit from 2001 to 2010 were evaluated. Patients with burns, primary asphyxiation, preexisting bleeding diathesis, lack of coagulation studies, or transferred from other hospitals more than 24 h after injury were excluded. Age, sex, race, mechanism of injury, initial systolic blood pressure, Glasgow Coma Scale score, Injury Severity Score, prothrombin time, partial thromboplastin time, platelet count, and international normalized ratio were recorded. An arterial or venous blood gas was performed, if clinically indicated. Coagulopathy was defined as an international normalized ratio greater than 1.2. The primary outcome was in-hospital mortality. Secondary outcomes were lengths of intensive care unit and hospital stay. Eight hundred three patients were included in the study. Overall mortality was 13.4%. The incidence of age-adjusted hypotension was 5.4%. Early coagulopathy was observed in 37.9% of patients. High Injury Severity Score and/or hypotension were associated with early coagulopathy and higher mortality. Early coagulopathy was associated with a modest increase in mortality in pediatric trauma patients without traumatic brain injury (TBI). In contrast, the combination of TBI and early coagulopathy was associated with a fourfold increase in mortality in this patient population. Early coagulopathy is an independent predictor of mortality in civilian pediatric patients with severe trauma. The increase in mortality was particularly significant in patients with TBI either isolated or combined with other injuries, suggesting that a rapid correction of this coagulopathy could substantially decrease the mortality after TBI in pediatric trauma patients.	[Whittaker, Brent] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35249 USA; [Christiaans, Sarah C.; Altice, Jessica L.; Pittet, Jean-Francois] Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35249 USA; [Chen, Mike K.; Kerby, Jeffrey D.; Pittet, Jean-Francois] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35249 USA; [Bartolucci, Alfred A.; Morgan, Charity J.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35249 USA		Pittet, JF (corresponding author), Univ Alabama Birmingham, Dept Anesthesiol, 619 S 19th St,JT926, Birmingham, AL 35249 USA.	pittetj@uab.edu		Morgan, Charity J/0000-0003-0693-4739	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 GM086416]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM086416] Funding Source: NIH RePORTER	Funding support was received from the National Institutes of Health (RO1 GM086416 [to J.-F.P.]).	Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Chesebro BB, 2009, SHOCK, V32, P659, DOI 10.1097/SHK.0b013e3181a5a632; CIAVARELLA D, 1987, BRIT J HAEMATOL, V67, P365, DOI 10.1111/j.1365-2141.1987.tb02359.x; Cohen MJ, 2012, ANN SURG, V255, P379, DOI 10.1097/SLA.0b013e318235d9e6; COUNTS RB, 1979, ANN SURG, V190, P91, DOI 10.1097/00000658-197907000-00020; Davenport R, 2011, CRIT CARE MED, V39, P2652, DOI 10.1097/CCM.0b013e3182281af5; Davis JW, 1996, J TRAUMA, V41, P769, DOI 10.1097/00005373-199611000-00001; Eberhard LW, 2000, CRIT CARE MED, V28, P125, DOI 10.1097/00003246-200001000-00021; Frith D, 2010, J THROMB HAEMOST, V8, P1919, DOI 10.1111/j.1538-7836.2010.03945.x; Gruen RL, 2012, LANCET, V380, P1099, DOI 10.1016/S0140-6736(12)61224-0; Hendrickson JE, 2012, J PEDIATR-US, V160, P204, DOI 10.1016/j.jpeds.2011.08.019; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; Maegele M, 2012, SHOCK, V38, P450, DOI 10.1097/SHK.0b013e31826dbd23; Matos RI, 2008, PEDIATRICS, V122, pE959, DOI 10.1542/peds.2008-1244; Mitra B, 2012, INJURY, V43, P22, DOI 10.1016/j.injury.2010.10.015; MURRAY DJ, 1995, ANESTH ANALG, V80, P336, DOI 10.1097/00000539-199502000-00022; Patregnani JT, 2012, PEDIATR CRIT CARE ME, V13, P273, DOI 10.1097/PCC.0b013e31822f1727; Peiniger S, 2012, PEDIATR CRIT CARE ME, V13, P455, DOI 10.1097/PCC.0b013e31823893c5; RUTHERFORD EJ, 1992, J TRAUMA, V33, P417, DOI 10.1097/00005373-199209000-00014; Stewart TC, 2011, J TRAUMA, V71, P1801, DOI 10.1097/TA.0b013e31823c484a; Talving P, 2011, J TRAUMA, V71, P1205, DOI 10.1097/TA.0b013e31820d151d; Melo JRT, 2010, NEUROSURGERY, V67, P1542, DOI 10.1227/NEU.0b013e3181fa7049; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003	24	85	86	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1073-2322			SHOCK	Shock	MAY	2013	39	5					421	426		10.1097/SHK.0b013e31828e08cb			6	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	127XE	WOS:000317731400004	23591559	Green Accepted			2022-02-06	
J	Bachstetter, AD; Rowe, RK; Kaneko, M; Goulding, D; Lifshitz, J; Van Eldik, LJ				Bachstetter, Adam D.; Rowe, Rachel K.; Kaneko, Machi; Goulding, Danielle; Lifshitz, Jonathan; Van Eldik, Linda J.			The p38 alpha MAPK Regulates Microglial Responsiveness to Diffuse Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article							PROINFLAMMATORY CYTOKINE PRODUCTION; ATTENUATES SYNAPTIC DYSFUNCTION; PROTEIN-KINASE INHIBITOR; MACROSIALIN MOUSE CD68; UP-REGULATION; NEURON DEGENERATION; AXONAL INJURY; IN-VIVO; ACTIVATION; RECEPTOR	Neuropathology after traumatic brain injury (TBI) is the result of both the immediate impact injury and secondary injury mechanisms. Unresolved post-traumatic glial activation is a secondary injury mechanism that contributes to a chronic state of neuroinflammation in both animal models of TBI and human head injury patients. We recently demonstrated, using in vitro models, that p38 alpha MAPK signaling in microglia is a key event in promoting cytokine production in response to diverse disease-relevant stressors and subsequent inflammatory neuronal dysfunction. From these findings, we hypothesized that the p38 alpha signaling pathway in microglia could be contributing to the secondary neuropathologic sequelae after a diffuse TBI. Mice where microglia were p38 alpha-deficient (p38 alpha KO) were protected against TBI-induced motor deficits and synaptic protein loss. In wild-type (WT) mice, diffuse TBI produced microglia morphological activation that lasted for at least 7 d; however, p38 alpha KO mice failed to activate this response. Unexpectedly, we found that the peak of the early, acute phase cytokine and chemokine levels was increased in injured p38 alpha KO mice compared with injured WT mice. The increased cytokine levels in the p38 alpha KO mice could not be accounted for by more infiltration of macrophages or neutrophils, or increased astrogliosis. By 7 d after injury, the cytokine and chemokine levels remained elevated in injured WT mice but not in p38 alpha KO mice. Together, these data suggest that p38 alpha balances the inflammatory response by acutely attenuating the early proinflammatory cytokine surge while perpetuating the chronic microglia activation after TBI.	[Bachstetter, Adam D.; Kaneko, Machi; Goulding, Danielle; Van Eldik, Linda J.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Rowe, Rachel K.; Van Eldik, Linda J.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Rowe, Rachel K.; Van Eldik, Linda J.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 85004 USA; [Lifshitz, Jonathan] Univ Arizona, Coll Med, Dept Child Hlth, Phoenix, AZ 85004 USA; [Lifshitz, Jonathan] Phoenix Vet Affairs Healthcare Syst, Phoenix, AZ 85004 USA		Van Eldik, LJ (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 800 S Limestone, Lexington, KY 40536 USA.	linda.vaneldik@uky.edu		Rowe, Rachel/0000-0002-9034-3159; Bachstetter, Adam/0000-0003-4646-6757	Alzheimer's Association Zenith awardAlzheimer's Association; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS064247, R01 NS065052, R21 NS072611, R01 NS065052-S, F32 AG037280]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072611, R01NS064247, R01NS065052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [F32AG037280] Funding Source: NIH RePORTER	This work was supported in part by the Alzheimer's Association Zenith award to L.J.V.E. and National Institutes of Health Grant R01 NS064247 to L.J.V.E., Grants R01 NS065052, R21 NS072611, and R01 NS065052-S to J.L., and Grant F32 AG037280 to A. D. B. We thank Dr. Huiping Jiang (Boehringer Ingelheim Pharmaceuticals) and Dr. Jiahuai Han (Scripps Research Institute) for the kind gifts of the knock-out mice; and Edgardo Dimayuga, Jordan Harrison, Janna Neltner, and Bin Xing for assistance with various aspects of this work.	Bachstetter AD, 2012, J NEUROSCI, V32, P10201, DOI 10.1523/JNEUROSCI.1496-12.2012; Bachstetter AD, 2010, AGING DIS, V1, P199; Bachstetter AD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-79; Barone FC, 2001, J PHARMACOL EXP THER, V296, P312; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Clarke S, 1996, P NATL ACAD SCI USA, V93, P1434, DOI 10.1073/pnas.93.4.1434; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Culbert AA, 2006, J BIOL CHEM, V281, P23658, DOI 10.1074/jbc.M513646200; da Silva RP, 1999, BIOCHEM J, V338, P687, DOI 10.1042/bj3380687; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Ferreira R, 2012, J NEUROCHEM, V120, P93, DOI 10.1111/j.1471-4159.2011.07541.x; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Ghasemlou N, 2010, J NEUROSCI, V30, P13750, DOI 10.1523/JNEUROSCI.2998-10.2010; Giunta B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-185; Gorska MM, 2007, J EXP MED, V204, P1637, DOI 10.1084/jem.20062621; Greer JE, 2012, J NEUROSCI, V32, P6682, DOI 10.1523/JNEUROSCI.0881-12.2012; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Heinrichsdorff J, 2008, EMBO REP, V9, P1048, DOI 10.1038/embor.2008.149; Heit B, 2002, J CELL BIOL, V159, P91, DOI 10.1083/jcb.200202114; Heit B, 2008, NAT IMMUNOL, V9, P743, DOI 10.1038/ni.1623; Hosmane S, 2012, J NEUROSCI, V32, P7745, DOI 10.1523/JNEUROSCI.0203-12.2012; Huang GH, 2012, NAT IMMUNOL, V13, P152, DOI 10.1038/ni.2207; Hume DA, 2011, J LEUKOCYTE BIOL, V89, P525, DOI 10.1189/jlb.0810472; Isfort K, 2011, J BIOL CHEM, V286, P44776, DOI 10.1074/jbc.M111.289793; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kang YJ, 2008, J IMMUNOL, V180, P5075, DOI 10.4049/jimmunol.180.7.5075; Katayama T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040813; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kim C, 2008, NAT IMMUNOL, V9, P1019, DOI 10.1038/ni.1640; Kurushima H, 2000, J LEUKOCYTE BIOL, V67, P104, DOI 10.1002/jlb.67.1.104; Legos JJ, 2001, BRAIN RES, V892, P70, DOI 10.1016/S0006-8993(00)03228-5; Lifshitz Jonathan, 2009, P369, DOI 10.1007/978-1-60327-185-1_32; Liu YS, 2007, NAT REV IMMUNOL, V7, P202, DOI 10.1038/nri2035; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lucas T, 2010, J IMMUNOL, V184, P3964, DOI 10.4049/jimmunol.0903356; Mathur RK, 2004, NAT MED, V10, P540, DOI 10.1038/nm1045; Mizutani M, 2012, J IMMUNOL, V188, P29, DOI 10.4049/jimmunol.1100421; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Munoz L, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-21; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Penninger JM, 2001, NAT IMMUNOL, V2, P389, DOI 10.1038/87687; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ravichandran KS, 2011, IMMUNITY, V35, P445, DOI 10.1016/j.immuni.2011.09.004; Reed-Geaghan EG, 2009, J NEUROSCI, V29, P11982, DOI 10.1523/JNEUROSCI.3158-09.2009; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Soehnlein O, 2010, NAT REV IMMUNOL, V10, P427, DOI 10.1038/nri2779; Sommer A, 2000, FEBS LETT, V474, P146, DOI 10.1016/S0014-5793(00)01566-0; Stirling DP, 2008, NEUROSCIENCE, V155, P128, DOI 10.1016/j.neuroscience.2008.05.007; Sudduth TL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031993; Tanaka T, 2009, J BIOL CHEM, V284, P21626, DOI 10.1074/jbc.M109.005603; Thomas T, 2008, J NEUROCHEM, V105, P2039, DOI 10.1111/j.1471-4159.2008.05310.x; Thuraisingam T, 2010, J INVEST DERMATOL, V130, P278, DOI 10.1038/jid.2009.209; Trang T, 2009, J NEUROSCI, V29, P3518, DOI 10.1523/JNEUROSCI.5714-08.2009; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009; Wang XK, 2002, J BIOL CHEM, V277, P43968, DOI 10.1074/jbc.M206837200; Xing B, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-84; Xu Z, 2006, LIFE SCI, V79, P1895, DOI 10.1016/j.lfs.2006.06.023; Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247	72	85	90	0	17	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	APR 3	2013	33	14					6143	6153		10.1523/JNEUROSCI.5399-12.2013			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	120QP	WOS:000317186800027	23554495	Bronze, Green Accepted, Green Published			2022-02-06	
J	McCauley, SR; Wilde, EA; Miller, ER; Frisby, ML; Garza, HM; Varghese, R; Levin, HS; Robertson, CS; McCarthy, JJ				McCauley, Stephen R.; Wilde, Elisabeth A.; Miller, Emmy R.; Frisby, Melissa L.; Garza, Hector M.; Varghese, Reni; Levin, Harvey S.; Robertson, Claudia S.; McCarthy, James J.			Preinjury Resilience and Mood as Predictors of Early Outcome following Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						anxiety; mood; outcome; postconcussion symptoms; resilience; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; POST-CONCUSSION SYMPTOMS; COMPREHENSIVE-SOLDIER-FITNESS; OPERATIONS ENDURING FREEDOM; EMOTIONAL RISK-FACTORS; MINOR HEAD-INJURY; DSM-IV CRITERIA; POSTCONCUSSIONAL DISORDER; PSYCHOLOGICAL-RESILIENCE; PSYCHOMETRIC PROPERTIES	There is significant heterogeneity in outcomes following mild traumatic brain injury (mTBI). While several host factors (age, gender, and preinjury psychiatric history) have been investigated, the influence of preinjury psychological resilience and mood status in conjunction with mild TBI remains relatively unexplored. Euthymic mood and high resilience are potentially protective against anxiety and postconcussion symptoms, but their relative contributions are currently unknown. This prospective study obtained preinjury estimates of resilience and mood measures in addition to measures of anxiety (Acute Stress Disorder Scale and PTSD-Checklist-Civilian form) and postconcussion symptom severity (Rivermead Post Concussion Symptoms Questionnaire) < 24 hours (Baseline), 1 week, and 1 month postinjury in patients with either mTBI (n = 46) or a comparison group with orthopedic injuries not involving the head (OI, n = 29). The groups did not differ on preinjury resilience or mood status at baseline, but differed significantly on measures of anxiety and postconcussion symptom severity at each subsequent study occasion. Multivariate linear regression analyses were conducted to determine if preinjury resilience and mood were significant contributors to anxiety and postconcussion symptoms during the first month postinjury after accounting for other known host factors (e. g., age at injury, gender, and education). Injury group and preinjury mood status were significant predictors for all three dependent variables at each study occasion (all p < 0.007). Preinjury resilience showed a positive trend only for acute stress severity at baseline, but demonstrated significant prediction of all three dependent measures at one week and one month postinjury. These results suggest that preinjury depressed mood and resilience are significant contributors to the severity of postinjury anxiety and postconcussion symptoms, even after accounting for effects of other specific host factors.	[McCauley, Stephen R.; Wilde, Elisabeth A.; Frisby, Melissa L.; Garza, Hector M.; Varghese, Reni; Levin, Harvey S.] Baylor Coll Med, Phys Med & Rehabil Alliance, Houston, TX 77030 USA; [McCauley, Stephen R.; Wilde, Elisabeth A.; Frisby, Melissa L.; Garza, Hector M.; Varghese, Reni; Levin, Harvey S.] Univ Texas Houston, Sch Med, Houston, TX USA; [McCauley, Stephen R.; Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [McCauley, Stephen R.; Levin, Harvey S.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Pediat Radiol, Houston, TX 77030 USA; [Miller, Emmy R.; Levin, Harvey S.; Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [McCauley, Stephen R.; Wilde, Elisabeth A.; Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [McCarthy, James J.] Univ Texas Houston, Sch Med, Dept Emergency Med, Houston, TX USA; [McCarthy, James J.] Mem Hermann Hosp, Dept Emergency Med, Houston, TX USA		McCauley, SR (corresponding author), Baylor Coll Med, Dept Neurol, 1709 Dryden Rd,Suite 1200, Houston, TX 77030 USA.	mccauley@bcm.edu			Congressionally Directed Medical Research ProgramsUnited States Department of Defense [W81XWH-08-2-0131, W81XWH-08-0132, W81XWH-08-2-0133]; Department of DefenseUnited States Department of Defense	We sincerely thank the participants for their interest and willingness to take part in this research. This work was supported by W81XWH-08-2-0131 (McCarthy-PI), W81XWH-08-0132 (Robertson-PI), and W81XWH-08-2-0133 (Levin-PI) from the Congressionally Directed Medical Research Programs and the Department of Defense. The information in this article and the article itself have never been published either electronically or in print. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Department of Defense.	Adler AB, 2009, MIL MED, V174, P21, DOI 10.7205/MILMED-D-00-2208; Adler AB, 2009, J CONSULT CLIN PSYCH, V77, P928, DOI 10.1037/a0016877; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Assistant Secretary of Defense for Health Affairs, 2007, HLTH AFF MEM OCT 1 2; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bohn M., 1991, PROBLEMS DRUG DEPEND, V119, P233; BOHN MJ, 1995, J STUD ALCOHOL, V56, P423, DOI 10.15288/jsa.1995.56.423; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; Bonanno GA, 2004, AM PSYCHOL, V59, P20, DOI 10.1037/0003-066X.59.1.20; Brailey K, 2007, J TRAUMA STRESS, V20, P495, DOI 10.1002/jts.20234; BRESLAU N, 1995, AM J PSYCHIAT, V152, P529; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Bryant RA, 2000, PSYCHOL ASSESSMENT, V12, P61, DOI 10.1037/1040-3590.12.1.61; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Casey GW, 2011, AM PSYCHOL, V66, P1, DOI 10.1037/a0021930; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cato MA, 2002, CLIN NEUROPSYCHOL, V16, P524, DOI 10.1076/clin.16.4.524.13901; Cattelani R, 1996, BRAIN INJURY, V10, P187, DOI 10.1080/026990596124502; Committee on Injury Scaling, 1998, ABBR INJ SCAL; Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113; Cornum R, 2011, AM PSYCHOL, V66, P4, DOI 10.1037/a0021420; Creamer M, 2005, BEHAV RES THER, V43, P1383, DOI 10.1016/j.brat.2004.11.001; Dickstein BD, 2010, MIL MED, V175, P482, DOI 10.7205/MILMED-D-09-00178; DIKMEN SS, 1989, MILD HEAD INJURY, P229; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Dolan CA, 2006, MIL MED, V171, P93, DOI 10.7205/MILMED.171.2.93; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Frappell-Cooke W, 2010, OCCUP MED-OXFORD, V60, P645, DOI 10.1093/occmed/kqq149; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Green KT, 2010, J CLIN PSYCHIAT, V71, P823, DOI 10.4088/JCP.09m05780blu; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Iversen AC, 2008, PSYCHOL MED, V38, P511, DOI 10.1017/S0033291708002778; Iversen AC, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-68; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; KOBASA SC, 1979, J PERS SOC PSYCHOL, V37, P1, DOI 10.1037/0022-3514.37.1.1; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Kozlovsky N, 2008, EUR NEUROPSYCHOPHARM, V18, P107, DOI 10.1016/j.euroneuro.2007.04.009; Kremen WS, 2007, ARCH GEN PSYCHIAT, V64, P361, DOI 10.1001/archpsyc.64.3.361; Larrabee, 1997, Semin Clin Neuropsychiatry, V2, P196; Lester PB, 2011, AM PSYCHOL, V66, P77, DOI 10.1037/a0022083; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Lyons J.A., 1991, J TRAUMA STRESS, V4, P93, DOI [DOI 10.1007/BF00976011, 10.1002/jts.2490040108, DOI 10.1002/JTS.2490040108]; Maguen S, 2008, MIL MED, V173, P1; McCauley SR, 2006, BRAIN INJURY, V20, P519, DOI 10.1080/02699050600676651; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; MCCLELLAND RJ, 1994, J ROY SOC MED, V87, P508; McLeod DS, 2001, J TRAUMA STRESS, V14, P259, DOI 10.1023/A:1011157800050; McNeil J E, 1996, Cogn Neuropsychiatry, V1, P239, DOI 10.1080/135468096396532; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Miller L, 2001, NEUROREHABILITATION, V16, P109; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Parker RS, 2002, NEUROREHABILITATION, V17, P131; Phillips CJ, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-52; Pietrzak RH, 2011, J AFFECT DISORDERS, V133, P560, DOI 10.1016/j.jad.2011.04.028; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Pietrzak RH, 2009, DEPRESS ANXIETY, V26, P745, DOI 10.1002/da.20558; Polusny MA, 2011, PSYCHOL MED, V41, P687, DOI 10.1017/S0033291710002047; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Reivich KJ, 2011, AM PSYCHOL, V66, P25, DOI 10.1037/a0021897; Richardson JD, 2007, CAN J PSYCHIAT, V52, P510, DOI 10.1177/070674370705200809; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; RUSSELL RW, 1971, TRAUMATIC AMNESIAS; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; RUTTER M, 1985, BRIT J PSYCHIAT, V147, P598, DOI 10.1192/bjp.147.6.598; Sandweiss DA, 2011, ARCH GEN PSYCHIAT, V68, P496, DOI 10.1001/archgenpsychiatry.2011.44; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Sbordone RJ, 2010, PSYCHOL INJ LAW, V3, P63, DOI 10.1007/s12207-010-9066-z; Scherrer JF, 2008, COMPR PSYCHIAT, V49, P297, DOI 10.1016/j.comppsych.2007.11.001; Schok ML, 2010, AGING MENT HEALTH, V14, P328, DOI 10.1080/13607860903228812; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Seligman MEP, 2011, AM PSYCHOL, V66, P82, DOI 10.1037/a0021898; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Slick D.J., 1997, VICTORIA SYMPTOM VAL; Smith TC, 2008, EPIDEMIOLOGY, V19, P505, DOI 10.1097/EDE.0b013e31816a9dff; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Sosin DM, 1996, BRAIN INJURY, V10, P47; STOGNER BL, 2000, DISS ABSTR INT B, V61, P550; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; TEASDALE G, 1974, LANCET, V2, P81; Tedeschi RG, 2011, AM PSYCHOL, V66, P19, DOI 10.1037/a0021896; THURMAN D, 2001, HEAD TRAUMA BASIC PR; van Zuiden M, 2011, AM J PSYCHIAT, V168, P89, DOI 10.1176/appi.ajp.2010.10050706; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Weathers F. W., 1993, 9 ANN CONV INT SOC T; Wells TS, 2011, INT REV PSYCHIATR, V23, P144, DOI 10.3109/09540261.2011.558833; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; World Health Organization, 1993, ICD 10 CLASS MENT BE; World Health Organization, 1992, ICD 10 CLASSIFICATIO; Young RM, 2002, ALCOHOL ALCOHOLISM, V37, P451, DOI 10.1093/alcalc/37.5.451; Yudko E, 2007, J SUBST ABUSE TREAT, V32, P189, DOI 10.1016/j.jsat.2006.08.002; Zlotnick C, 2001, AM J PSYCHIAT, V158, P1923, DOI 10.1176/appi.ajp.158.11.1923	132	85	87	1	32	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2013	30	8			SI		642	652		10.1089/neu.2012.2393			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	133PO	WOS:000318151500006	23046394				2022-02-06	
J	Meeker, RB; Williams, K; Killebrew, DA; Hudson, LC				Meeker, Rick B.; Williams, Kimberly; Killebrew, Deirdre A.; Hudson, Lola C.			Cell trafficking through the choroid plexus	CELL ADHESION & MIGRATION			English	Article						cerebrospinal fluid; pleocytosis; monocytes; macrophages; dendritic cells; T cells; inflammation; adhesion molecules; chemokines	CENTRAL-NERVOUS-SYSTEM; FELINE IMMUNODEFICIENCY VIRUS; CEREBROSPINAL-FLUID PRODUCTION; TRAUMATIC BRAIN-INJURY; CD4(+) T-CELLS; ADHESION MOLECULES; DIFFERENTIAL EXPRESSION; IMMUNE SURVEILLANCE; EPIPLEXUS CELLS; DENDRITIC CELLS	The choroid plexus is a multifunctional organ that sits at the interface between the blood and cerebrospinal fluid (CSF). It serves as a gateway for immune cell trafficking into the CSF and is in an excellent position to provide continuous immune surveillance by CD4(+) T cells, macrophages and dendritic cells and to regulate immune cell trafficking in response to disease and trauma. However, little is known about the mechanisms that control trafficking through this structure. Three cell types within the choroid plexus, in particular, may play prominent roles in controlling the development of immune responses within the nervous system: the epithelial cells, which form the blood-CSF barrier, and resident macrophages and dendritic cells in the stromal matrix. Adhesion molecule and chemokine expression by the epithelial cells allows substantial control over the selection of cells that transmigrate. Macrophages and dendritic cells can present antigen within the choroid plexus and/or transmigrate into the cerebral ventricles to serve a variety of possible immune functions. Studies to better understand the diverse functions of these cells are likely to reveal new insights that foster the development of novel pharmacological and macrophage-based interventions for the control of CNS immune responses.	[Meeker, Rick B.; Williams, Kimberly; Killebrew, Deirdre A.] Univ N Carolina, Dept Neurol, Chapel Hill, NC 27515 USA; [Meeker, Rick B.; Williams, Kimberly] Univ N Carolina, Curriculum Neurobiol, Chapel Hill, NC USA; [Hudson, Lola C.] N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, Raleigh, NC USA		Meeker, RB (corresponding author), Univ N Carolina, Dept Neurol, Chapel Hill, NC 27515 USA.	meekerr@neurology.unc.edu			NIH GrantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-MH063646]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH085606, R01MH063646, F31MH101019] Funding Source: NIH RePORTER	This work was supported by NIH Grant R01-MH063646.	Adam P, 2007, FOLIA MICROBIOL, V52, P529, DOI 10.1007/BF02932115; Brown PD, 2004, NEUROSCIENCE, V129, P957, DOI 10.1016/j.neuroscience.2004.07.003; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Carrithers MD, 2000, BRAIN, V123, P1092, DOI 10.1093/brain/123.6.1092; Chinnery HR, 2010, J NEUROPATH EXP NEUR, V69, P896, DOI 10.1097/NEN.0b013e3181edbc1a; de Graaf MT, 2011, CYTOM PART B-CLIN CY, V80B, P43, DOI 10.1002/cyto.b.20542; DECKERTSCHLUTER M, 1994, J NEUROPATH EXP NEUR, V53, P457, DOI 10.1097/00005072-199409000-00005; Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534; Engelhardt B, 2001, MICROSC RES TECHNIQ, V52, P112, DOI 10.1002/1097-0029(20010101)52:1<112::AID-JEMT13>3.0.CO;2-5; FIGARELLABRANGER D, 1995, ACTA NEUROPATHOL, V89, P248; GORDON LB, 1992, J NEUROIMMUNOL, V40, P81, DOI 10.1016/0165-5728(92)90215-7; Gras G, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-30; Hanly A, 1998, HUM PATHOL, V29, P88, DOI 10.1016/S0046-8177(98)90395-1; Ichiyama T, 2009, J INFECTION, V58, P28, DOI 10.1016/j.jinf.2008.10.012; Johanson C, 2011, TOXICOL PATHOL, V39, P186, DOI 10.1177/0192623310394214; Johanson CE, 2008, FLUIDS BARRIERS CNS, V5, DOI 10.1186/1743-8454-5-10; Kivisakk P, 2003, P NATL ACAD SCI USA, V100, P8389, DOI 10.1073/pnas.1433000100; Kleine TO, 2006, CYTOM PART A, V69A, P147, DOI 10.1002/cyto.a.20225; LING EA, 1979, J ANAT, V129, P479; Ling EA, 1998, MICROSC RES TECHNIQ, V41, P43, DOI 10.1002/(SICI)1097-0029(19980401)41:1<43::AID-JEMT5>3.0.CO;2-V; Liu P, 2006, J NEUROVIROL, V12, P294, DOI 10.1080/13550280600889567; McMenamin PG, 1999, J COMP NEUROL, V405, P553, DOI 10.1002/(SICI)1096-9861(19990322)405:4<553::AID-CNE8>3.0.CO;2-6; Meeker RB, 2012, CELL TISSUE RES, V347, P443, DOI 10.1007/s00441-011-1301-8; Meeker RB, 2011, J NEUROVIROL, V17, P258, DOI 10.1007/s13365-011-0034-5; NATHANSON JA, 1989, P NATL ACAD SCI USA, V86, P1684, DOI 10.1073/pnas.86.5.1684; Neuenburg JK, 2005, AIDS, V19, P1351, DOI 10.1097/01.aids.0000181008.39514.ee; Provencio JJ, 2005, J NEUROIMMUNOL, V163, P179, DOI 10.1016/j.jneuroim.2005.03.003; Rezai-Zadeh K, 2009, J NEUROIMMUNE PHARM, V4, P462, DOI 10.1007/s11481-009-9166-2; Ryan G, 2005, J NEUROVIROL, V11, P337, DOI 10.1080/13550280500186445; Silverberg GD, 2001, NEUROLOGY, V57, P1763, DOI 10.1212/WNL.57.10.1763; Steffen BJ, 1996, AM J PATHOL, V148, P1819; Szmydynger-Chodobska J, 2009, J CEREBR BLOOD F MET, V29, P1503, DOI 10.1038/jcbfm.2009.71; Vercellino M, 2008, J NEUROIMMUNOL, V199, P133, DOI 10.1016/j.jneuroim.2008.04.035; Wilson EH, 2010, J CLIN INVEST, V120, P1368, DOI 10.1172/JCI41911; Wolburg K, 1999, CELL TISSUE RES, V296, P259, DOI 10.1007/s004410051287	35	85	88	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA		1933-6926		CELL ADHES MIGR	Celll Adhes. Migr.	SEP-OCT	2012	6	5					390	396		10.4161/cam.21054			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	032IW	WOS:000310711000002	22902764	Green Published, Green Submitted, gold			2022-02-06	
J	Sundaramurthy, A; Alai, A; Ganpule, S; Holmberg, A; Plougonven, E; Chandra, N				Sundaramurthy, Aravind; Alai, Aaron; Ganpule, Shailesh; Holmberg, Aaron; Plougonven, Erwan; Chandra, Namas			Blast-Induced Biomechanical Loading of the Rat: An Experimental and Anatomically Accurate Computational Blast Injury Model	JOURNAL OF NEUROTRAUMA			English	Article						animal studies; Finite element model; military injury; rat	TRAUMATIC BRAIN-INJURY; INTRACRANIAL-PRESSURE; INDUCED NEUROTRAUMA; SHOCK-WAVES; MECHANISMS; TUBE; OVERPRESSURE; RESPONSES; EXPOSURE; IMPACTS	Blast waves generated by improvised explosive devices (IEDs) cause traumatic brain injury (TBI) in soldiers and civilians. In vivo animal models that use shock tubes are extensively used in laboratories to simulate field conditions, to identify mechanisms of injury, and to develop injury thresholds. In this article, we place rats in different locations along the length of the shock tube (i.e., inside, outside, and near the exit), to examine the role of animal placement location (APL) in the biomechanical load experienced by the animal. We found that the biomechanical load on the brain and internal organs in the thoracic cavity (lungs and heart) varied significantly depending on the APL. When the specimen is positioned outside, organs in the thoracic cavity experience a higher pressure for a longer duration, in contrast to APL inside the shock tube. This in turn will possibly alter the injury type, severity, and lethality. We found that the optimal APL is where the Friedlander waveform is first formed inside the shock tube. Once the optimal APL was determined, the effect of the incident blast intensity on the surface and intracranial pressure was measured and analyzed. Noticeably, surface and intracranial pressure increases linearly with the incident peak overpressures, though surface pressures are significantly higher than the other two. Further, we developed and validated an anatomically accurate finite element model of the rat head. With this model, we determined that the main pathway of pressure transmission to the brain was through the skull and not through the snout; however, the snout plays a secondary role in diffracting the incoming blast wave towards the skull.	[Sundaramurthy, Aravind; Alai, Aaron; Ganpule, Shailesh; Holmberg, Aaron; Plougonven, Erwan; Chandra, Namas] Univ Nebraska, Dept Mech & Mat Engn, Lincoln, NE 68588 USA		Chandra, N (corresponding author), Univ Nebraska, Dept Mech & Mat Engn, W328-1 NW Nebraska Hall H, Lincoln, NE 68588 USA.	nchandra2@unl.edu	Sundaramurthy, Aravind/O-2047-2019	Sundaramurthy, Aravind/0000-0002-0359-8680	U.S. Army Research Office project "Army-UNL Center of Trauma Mechanics" [W911NF-08-10483]	The authors gratefully acknowledge the financial support under the U.S. Army Research Office project "Army-UNL Center of Trauma Mechanics" (contract no. W911NF-08-10483, Project Manager: Larry Russell, P.I: Namas Chandra). We are grateful to Dr. Maciej Skotak and Dr. Fang Wang for helpful comments on the manuscript.	Abdul-Wahab R., 2011, BIOENG C NEBEC 2011, P1; Ahlers S. T., 2012, FRONT NEUROL, P3; Alley MD, 2011, NEUROIMAGE, V54, pS45, DOI 10.1016/j.neuroimage.2010.05.030; Anderson JD., 2001, FUNDAMENTALS AERODYN, V3; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Bolander R., 2011, ANN BIOMED ENG, P1; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chandra N., 2011, CONTROLLING SHAPE SH; CHANG KS, 1995, SHOCK WAVES, V5, P33, DOI 10.1007/BF02425034; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Desmoulin GT, 2009, J TRAUMA, V67, P1113, DOI 10.1097/TA.0b013e3181bb8e84; Ganpule S, 2012, COMPUT METHOD BIOMEC, V15, P1233, DOI 10.1080/10255842.2011.597353; Grujicic M, 2011, J MATER ENG PERFORM, V20, P877, DOI 10.1007/s11665-010-9724-z; Haselbacher A, 2007, AIAA J, V45, P1917, DOI 10.2514/1.23081; Honma H, 2003, SHOCK WAVES, V13, P179, DOI 10.1007/s00193-003-0206-1; Jiang Z, 1999, SHOCK WAVES, V9, P1, DOI 10.1007/s001930050133; Jiang Z, 1998, PHYS FLUIDS, V10, P277, DOI 10.1063/1.869566; Kleinschmit N.N., 2011, THESIS U NEBRASKA LI; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Moore DF, 2008, FUTUR NEUROL, V3, P243, DOI 10.2217/14796708.3.3.243; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Nyein MK, 2011, P NATL ACAD SCI USA, V108, P433, DOI 10.1073/pnas.1018365108; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pena A, 2005, ACT NEUR S, V95, P333; Rafaels K., 2010, THESIS U VIRGINIA; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Saljo A, 2011, NEUROIMAGE, V54, pS83, DOI 10.1016/j.neuroimage.2010.05.050; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Teasdale G., 1974, J GERONTOL B-PSYCHOL, V304, P81, DOI DOI 10.1016/S0140-6736(74)91639-0; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zhu Feng, 2010, Stapp Car Crash J, V54, P211	41	85	87	3	34	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2012	29	13					2352	+		10.1089/neu.2012.2413			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	000PU	WOS:000308399900011	22620716	Green Submitted			2022-02-06	
J	McDonald, BC; Saykin, AJ; McAllister, TW				McDonald, Brenna C.; Saykin, Andrew J.; McAllister, Thomas W.			Functional MRI of mild traumatic brain injury (mTBI): progress and perspectives from the first decade of studies	BRAIN IMAGING AND BEHAVIOR			English	Article						Episodic memory; Frontal lobes; Functional connectivity; Functional MRI; Mild traumatic brain injury; Working memory	ALTERED WORKING-MEMORY; BOLD RESPONSE; HEAD-INJURY; CONCUSSION; FMRI; ABNORMALITIES; ACTIVATION; SYMPTOMS; RECOVERY; CORTEX	Mild traumatic brain injury (mTBI) represents the great majority of traumatic brain injuries, and is a common medical problem affecting cognitive and vocational functioning as well as quality of life in some individuals. Functional MRI (fMRI) is an important research method for investigating the neuroanatomic substrates of cognitive disorders and their treatment. Surprisingly, however, relatively little research has utilized fMRI to examine alterations in brain functioning after mTBI. This article provides a critical overview of the published fMRI research on mTBI to date. These topics include examination of frontal lobe/executive functions such as working memory, as well as episodic memory and resting state/functional connectivity. mTBI has also been investigated in military populations where studies have focused on effects of blast injury and comorbid conditions such as post-traumatic stress disorder and major depressive disorder. Finally, we address fMRI evaluations of response to behavioral or pharmacological challenges and interventions targeting cognitive and behavioral sequelae of mTBI. The review concludes with identification and discussion of gaps in current knowledge and future directions for fMRI studies of mTBI. The authors conclude that fMRI in combination with related methods can be expected to play an increasing role in research related to studies of pathophysiological mechanisms of the sequelae of mTBI as well as in diagnosis and treatment monitoring.	[McDonald, Brenna C.; Saykin, Andrew J.] Indiana Univ Sch Med, IU Ctr Neuroimaging, Dept Radiol & Imaging Sci, Indianapolis, IN 46202 USA; [McDonald, Brenna C.; Saykin, Andrew J.; McAllister, Thomas W.] Dartmouth Med Sch, Sect Neuropsychiat, Dept Psychiat, Lebanon, NH USA		McDonald, BC (corresponding author), Indiana Univ Sch Med, IU Ctr Neuroimaging, Dept Radiol & Imaging Sci, 950 W Walnut St,R2 E124, Indianapolis, IN 46202 USA.	mcdonalb@iupui.edu; asaykin@iupui.edu; thomas.w.mcallister@dartmouth.edu	Saykin, Andrew/A-1318-2007	Saykin, Andrew/0000-0002-1376-8532	National Institute on Disability and Rehabilitation Research [H133G70031, H133000136]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS040472]; Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD048176]; US Department of DefenseUnited States Department of Defense; Indiana Spinal Cord and Traumatic Brain Injury Fund; Indiana Economic Development Corporation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD047242, R01HD048176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010133, R01AG019771] Funding Source: NIH RePORTER	This research was supported in part by grants from the National Institute on Disability and Rehabilitation Research (H133G70031 and H133000136), the National Institute of Neurological Disorders and Stroke (R01 NS040472), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01 HD048176), the US Department of Defense to the Alzheimer's Disease Neuroimaging Initiative to investigate AD risk after TBI and PTSD, the Indiana Spinal Cord and Traumatic Brain Injury Fund, and the Indiana Economic Development Corporation.	Arnsten A F, 1998, Adv Pharmacol, V42, P764; Arnsten AFT, 2011, BIOL PSYCHIAT, V69, pE89, DOI 10.1016/j.biopsych.2011.01.027; Baugh C. M., 2012, BRAIN IMAGING BEHAV; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Breedlove E. L., 2012, J BIOMECHANICS; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Deco G, 2011, NAT REV NEUROSCI, V12, P43, DOI 10.1038/nrn2961; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Gamo NJ, 2011, BEHAV NEUROSCI, V125, P282, DOI 10.1037/a0023165; Gosselin N, 2011, J NEUROTRAUM, V28, P329, DOI 10.1089/neu.2010.1493; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Krivitzky LS, 2011, J INT NEUROPSYCH SOC, V17, P1143, DOI 10.1017/S1355617711001226; Laatsch LK, 2004, BRAIN INJURY, V18, P957, DOI 10.1080/02699050410001672369; Lipsky R. H., 2002, J NEUROPSYCHIATRY CL; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Matthews S, 2011, PSYCHIAT RES-NEUROIM, V191, P76, DOI 10.1016/j.pscychresns.2010.09.013; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Mayer A. R., 2012, BRAIN IMAGING BEHAV; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; McAllister T., 2001, J NEUROPSYCHIATRY CL, V13, P141; McAllister T. W., 2004, J NEUROPSYCHIATRY CL, V16, P240; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2011, INT J PSYCHOPHYSIOL, V82, P107, DOI 10.1016/j.ijpsycho.2011.06.022; McAllister TW, 2011, J NEUROPSYCH CLIN N, V23, P277, DOI 10.1176/appi.neuropsych.23.3.277; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McAllister TW., 2002, J NEUROPSYCHIATRY CL, V14, P116; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Pardini JE, 2010, NEUROSURGERY, V67, P1020, DOI 10.1227/NEU.0b013e3181ee33e2; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041; Rosenbaum S. B., 2012, BRAIN IMAGING BEHAV; Roy MJ, 2010, ANN NY ACAD SCI, V1208, P142, DOI 10.1111/j.1749-6632.2010.05689.x; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saykin AJ, 1999, BRAIN, V122, P1963, DOI 10.1093/brain/122.10.1963; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Slobounov S. M., 2012, BRAIN IMAGING BEHAV; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Stevens MC, 2012, BRAIN IMAGING BEHAV; Stulemeijer M, 2010, J NEUROTRAUM, V27, P1585, DOI 10.1089/neu.2010.1298; Talavage TM, 2010, J NEUROTRAUMA; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	58	85	87	0	46	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2012	6	2			SI		193	207		10.1007/s11682-012-9173-4			15	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	967LI	WOS:000305908900004	22618832	Green Accepted			2022-02-06	
J	Mondello, S; Jeromin, A; Buki, A; Bullock, R; Czeiter, E; Kovacs, N; Barzo, P; Schmid, K; Tortella, F; Wang, KK; Hayes, RL				Mondello, Stefania; Jeromin, Andreas; Buki, Andras; Bullock, Ross; Czeiter, Endre; Kovacs, Noemi; Barzo, Pal; Schmid, Kara; Tortella, Frank; Wang, Kevin K.; Hayes, Ronald L.			Glial Neuronal Ratio: A Novel Index for Differentiating Injury Type in Patients with Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; computed tomography; diagnostic; glial neuronal ratio; traumatic brain injury	COMPUTED-TOMOGRAPHY FINDINGS; FIBRILLARY ACIDIC PROTEIN; C-TERMINAL HYDROLASE; CEREBRAL-ISCHEMIA; AXONAL INJURY; MARKERS; BIOMARKERS; PROGNOSIS; DAMAGE; AREAS	Neurobiochemical marker levels in blood after traumatic brain injury (TBI) may reflect structural changes detected by neuroimaging. This study evaluates whether correlations between neuronal (ubiquitin carboxyterminal hydrolase-L1 [UCH-L1]) and glial (glial fibrillary acidic protein [GFAP]) biomarkers may be used as an indicator for differing intracranial pathologies after brain trauma. In 59 patients with severe TBI (Glasgow Coma Scale [GCS] score <= 8) serum samples were obtained at the time of hospital admission and analyzed for UCH-L1 and GFAP. Glial neuronal ratio (GNR) was evaluated as the ratio between GFAP and UCH-L1 concentrations. A logistic regression analysis was used to identify variables associated with type of injury. GNR had a median of 0.85 and was positively correlated with age (R = 0.45, p = 0.003). Twenty-nine patients presented with diffuse injury and 30 with focal mass lesions as assessed by CT scan at admission and classified according to the Marshall Classification. GNR was significantly higher in the focal mass lesion group compared with the diffuse injury group (1.77 versus 0.48, respectively; p = 0.003). Receiver operating characteristic curve analysis showed that GNR discriminated between types of injury (area under the curve [AUC] = 0.72; p = 0.003). GNR was more accurate earlier (<= 12 h after injury) than later (AUC = 0.80; p = 0.002). Increased GNR was independently associated with type of injury, but not age, gender, GCS score, or mechanism of injury. GNR was significantly higher in patients who died, but was not an independent predictor of death. The data from the present study indicate that GNR provides valuable information about different injury pathways, which may be of diagnostic significance. In addition, GNR may help to identify different pathophysiological mechanisms following different types of brain trauma, with implications for therapeutic interventions.	[Mondello, Stefania] Univ Florida, Dept Anesthesiol, Gainesville, FL USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Innovat Res, Dept Clin Programs, Alachua, FL 32615 USA; [Buki, Andras; Czeiter, Endre; Kovacs, Noemi] Univ Pecs, Dept Neurosurg, Pecs, Hungary; [Bullock, Ross] Univ Miami, Dept Neurosurg, Miami, FL USA; [Barzo, Pal] Univ Szeged, Dept Neurosurg, Szeged, Hungary; [Schmid, Kara; Tortella, Frank] Walter Reed Army Inst Res, Div Psychiat & Neurosci, Dept Appl Neurobiol, Silver Spring, MD USA; [Wang, Kevin K.] Banyan Biomarkers Inc, Ctr Innovat Res, Diagnost Res & Dev Dept, Alachua, FL USA		Mondello, S (corresponding author), Univ Florida, Dept Anesthesiol, 12085 Res Dr, Alachua, FL 32615 USA.	smondello@banyanbio.com	Czeiter, Endre/B-1404-2009; Mondello, Stefania/A-1813-2012	Mondello, Stefania/0000-0002-8587-3614; Wang, Kevin/0000-0002-9343-6473	Department of DefenseUnited States Department of Defense [DAMD17-03-1-0772, DAMD17-03-1-0066]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS049175-01, R01-NS052831-01, R01 NS051431-01]; University of FloridaUniversity of Florida [N00014-06-1-1029]; Developing Competitiveness of Universities in the South Transdanubian Region [SROP-4.2.1.B-10/2/KONV-2010-0002]; Banyan Biomarkers, Inc.; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS051431, R01NS049175, R01NS052831] Funding Source: NIH RePORTER	This study was primarily sponsored by Department of Defense Award numbers DAMD17-03-1-0772 and DAMD17-03-1-0066, but we also acknowledge additional fund support from National Institutes of Health grants R01 NS049175-01, R01-NS052831-01, and R01 NS051431-01, Navy grant N00014-06-1-1029 (University of Florida), and Developing Competitiveness of Universities in the South Transdanubian Region grant SROP-4.2.1.B-10/2/KONV-2010-0002.; Drs. Mondello, Buki, Bullock, Czeiter, and Barzo, are consultants of and received consulting fees from Banyan Biomarkers, Inc. Dr. Jeromin is an employee and received salary from Banyan Biomarkers, Inc. Drs. Wang and Hayes own stock and receive royalties and salaries from, and are officers of, Banyan Biomarkers Inc., and as such may benefit financially as a result of the outcomes of this research. Banyan Biomarkers, Inc. filed patent applications based upon the disclosure of this publication. Drs. Tortella, Kovacs, and Schmid report no disclosures.	Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; CHEN H, 1993, J NEUROL SCI, V118, P109, DOI 10.1016/0022-510X(93)90099-K; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; FOULKES MA, 1991, J NEUROSURG, V75, pS1, DOI 10.3171/sup.1991.75.1s.00s1; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gong B, 2007, DRUG NEWS PERSPECT, V20, P365, DOI 10.1358/dnp.2007.20.6.1138160; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; JACKSON P, 1981, J NEUROL SCI, V49, P429, DOI 10.1016/0022-510X(81)90032-0; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Lee DR, 2003, BRAIN RES, V989, P221, DOI 10.1016/S0006-8993(03)03373-0; LI Y, 1995, J NEUROL SCI, V128, P134, DOI 10.1016/0022-510X(94)00228-G; Liu D, 1999, MOL BRAIN RES, V68, P29, DOI 10.1016/S0169-328X(99)00063-7; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; ROSENGREN LE, 1994, J NEUROSCI METH, V51, P197, DOI 10.1016/0165-0270(94)90011-6; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; Setsuie R, 2007, NEUROCHEM INT, V51, P105, DOI 10.1016/j.neuint.2007.05.007; Tongaonkar P, 2000, MOL CELL BIOL, V20, P4691, DOI 10.1128/MCB.20.13.4691-4698.2000; Tsacopoulos M, 1996, J NEUROSCI, V16, P877; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2	32	85	86	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1096	1104		10.1089/neu.2011.2092			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100009	22165978	Green Published			2022-02-06	
J	Hunter, JV; Wilde, EA; Tong, KA; Holshouser, BA				Hunter, Jill V.; Wilde, Elisabeth A.; Tong, Karen A.; Holshouser, Barbara A.			Emerging Imaging Tools for Use with Traumatic Brain Injury Research	JOURNAL OF NEUROTRAUMA			English	Article						adults; children; CT; MRI; neuroimaging; TBI	DIFFUSE AXONAL INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; CEREBRAL-BLOOD-FLOW; CONTROLLED CORTICAL IMPACT; PROTON MR SPECTROSCOPY; COMMON DATA ELEMENTS; WHITE-MATTER INJURY; CENTRAL-NERVOUS-SYSTEM; WORKING-MEMORY LOAD; SEVERE HEAD TRAUMA	This article identifies emerging neuroimaging measures considered by the inter-agency Pediatric Traumatic Brain Injury (TBI) Neuroimaging Workgroup. This article attempts to address some of the potential uses of more advanced forms of imaging in TBI as well as highlight some of the current considerations and unresolved challenges of using them. We summarize emerging elements likely to gain more widespread use in the coming years, because of 1) their utility in diagnosis, prognosis, and understanding the natural course of degeneration or recovery following TBI, and potential for evaluating treatment strategies; 2) the ability of many centers to acquire these data with scanners and equipment that are readily available in existing clinical and research settings; and 3) advances in software that provide more automated, readily available, and cost-effective analysis methods for large scale data image analysis. These include multi-slice CT, volumetric MRI analysis, susceptibility-weighted imaging (SWI), diffusion tensor imaging (DTI), magnetization transfer imaging (MTI), arterial spin tag labeling (ASL), functional MRI (fMRI), including resting state and connectivity MRI, MR spectroscopy (MRS), and hyperpolarization scanning. However, we also include brief introductions to other specialized forms of advanced imaging that currently do require specialized equipment, for example, single photon emission computed tomography (SPECT), positron emission tomography (PET), encephalography (EEG), and magnetoencephalography (MEG)/magnetic source imaging (MSI). Finally, we identify some of the challenges that users of the emerging imaging CDEs may wish to consider, including quality control, performing multi-site and longitudinal imaging studies, and MR scanning in infants and children.	[Hunter, Jill V.] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA; [Hunter, Jill V.; Wilde, Elisabeth A.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Hunter, Jill V.; Wilde, Elisabeth A.] Baylor Coll Med, Dept Phys Med Rehabil & Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA; [Tong, Karen A.; Holshouser, Barbara A.] Loma Linda Univ, Sch Med, Dept Radiol, Loma Linda, CA USA		Hunter, JV (corresponding author), Texas Childrens Hosp, Dept Pediat Radiol, 6621 Fannin St,W1120, Houston, TX 77030 USA.	jhunter@bcm.edu			National Institutes of Health (National Institute of Neurological Disorders and Stroke; NIH/NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); United States Department of Education/National Institute on Disability and Rehabilitation Research (DOE/NIDRR); Department of Veterans' AffairsUS Department of Veterans Affairs; United States Department of DefenseUnited States Department of Defense	This project was jointly supported by the National Institutes of Health (National Institute of Neurological Disorders and Stroke; NIH/NINDS), the United States Department of Education/National Institute on Disability and Rehabilitation Research (DOE/NIDRR), the Department of Veterans' Affairs, and the United States Department of Defense.	Aaen GS, 2010, PEDIATRICS, V125, P295, DOI 10.1542/peds.2008-3312; Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; Alessandri B, 2000, J CLIN NEUROSCI, V7, P47, DOI 10.1054/jocn.1998.0139; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/0897715042441756; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; BARKER PB, 1993, NMR BIOMED, V6, P89, DOI 10.1002/nbm.1940060114; Barker PB, 2010, CLIN MR SPECTROSCOPY, P39; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beauchamp MH, 2011, INT J DEV NEUROSCI, V29, P137, DOI 10.1016/j.ijdevneu.2010.12.003; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI [10.1089/neu.2009.0885, 10.1089/neu.2009-0885]; Bergeson AG, 2004, CLIN NEUROPSYCHOL, V18, P509, DOI 10.1080/1385404049052414; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Bigler ED, 2010, BRAIN IMAGING BEHAV, V4, P270, DOI 10.1007/s11682-010-9105-0; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Bonte FJ, 2006, CLIN NUCL MED, V31, P376, DOI 10.1097/01.rlu.0000222736.81365.63; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Buxton RB, 2005, J MAGN RESON IMAGING, V22, P723, DOI 10.1002/jmri.20462; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Calhoun VD, 2002, MAGNET RESON MED, V48, P180, DOI 10.1002/mrm.10202; Cazalis F, 2006, BRAIN INJURY, V20, P1019, DOI 10.1080/02699050600664384; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chou YY, 2010, NEUROBIOL AGING, V31, P1386, DOI 10.1016/j.neurobiolaging.2010.05.001; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Coles JP, 2007, BRIT J ANAESTH, V99, P49, DOI 10.1093/bja/aem141; DANIELSEN ER, 1994, NMR BIOMED, V7, P311, DOI 10.1002/nbm.1940070704; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Detre JA, 1999, EUR J RADIOL, V30, P115, DOI 10.1016/S0720-048X(99)00050-9; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; DOUSSET V, 1992, RADIOLOGY, V182, P483, DOI 10.1148/radiology.182.2.1732968; Duckworth JL, 2010, CURR OPIN CRIT CARE, V16, P92, DOI 10.1097/MCC.0b013e3283374900; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Duhaime A.C., 2011, J NEUROTRAU IN PRESS; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fearing MA, 2008, J CHILD NEUROL, V23, P729, DOI 10.1177/0883073808314159; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; Forbes ML, 1997, ADV EXP MED BIOL, V411, P7; FRAHM J, 1989, MAGNET RESON MED, V11, P47, DOI 10.1002/mrm.1910110105; Friedman L, 2006, J MAGN RESON IMAGING, V23, P827, DOI 10.1002/jmri.20583; Friedman L, 2008, HUM BRAIN MAPP, V29, P958, DOI 10.1002/hbm.20440; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gale SD, 2010, J HEAD TRAUMA REHAB, V25, P15, DOI 10.1097/HTR.0b013e3181c39960; Gallagher CN, 2007, CURR OPIN NEUROL, V20, P403, DOI 10.1097/WCO.0b013e32821b987b; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Gerber DJ, 2004, BRAIN INJURY, V18, P1083, DOI 10.1080/02699050410001672341; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Groen WB, 2011, J PSYCHIATR NEUROSCI, V36, P32, DOI 10.1503/jpn.090100; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Hattingen E, 2008, NEURORADIOLOGY, V50, P759, DOI 10.1007/s00234-008-0409-3; Hattori N, 2004, J NUCL MED, V45, P775; Hattori N, 2003, J NUCL MED, V44, P1709; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; Hillary FG, 2002, J HEAD TRAUMA REHAB, V17, P411, DOI 10.1097/00001199-200210000-00004; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Hua X, 2010, NEUROBIOL AGING, V31, P1463, DOI 10.1016/j.neurobiolaging.2010.04.033; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hunter JV, 2005, AM J NEURORADIOL, V26, P482; HUPPI PS, 1991, PEDIATR RES, V30, P574; Hutchinson E, 2010, EPILEPSY RES, V88, P208, DOI 10.1016/j.eplepsyres.2009.11.011; Inglese M, 2003, MAGNET RESON MED, V50, P190, DOI 10.1002/mrm.10481; James GA, 2009, NEUROIMAGE, V45, P778, DOI 10.1016/j.neuroimage.2008.12.049; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Kaushik SS, 2011, MAGN RESON MED, V65, P1155, DOI 10.1002/mrm.22697; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; Kochanek PM, 2005, J CEREBR BLOOD F MET, V25, P1596, DOI 10.1038/sj.jcbfm.9600154; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; KREIS R, 1993, J MAGN RESON SER B, V102, P9, DOI 10.1006/jmrb.1993.1056; Kumar R, 2003, MAGN RESON IMAGING, V21, P893, DOI 10.1016/S0730-725X(03)00189-9; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Laatsch L, 2004, REHABIL PSYCHOL, V49, P262, DOI 10.1037/0090-5550.49.3.262; Laatsch LK, 2004, BRAIN INJURY, V18, P957, DOI 10.1080/02699050410001672369; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Makoroff KL, 2005, PEDIATR RADIOL, V35, P668, DOI 10.1007/s00247-005-1441-7; Mamere AE, 2009, AM J NEURORADIOL, V30, P947, DOI 10.3174/ajnr.A1477; Maniega SM, 2008, STROKE, V39, P2467, DOI 10.1161/STROKEAHA.107.507020; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; Maudsley AA, 2006, NMR BIOMED, V19, P492, DOI 10.1002/nbm.1025; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer A.R., 2011, HUM BRAIN MAPP; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCauley SR, 2011, J NEUROTRAUM, V28, P503, DOI 10.1089/neu.2010.1555; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; McLean MA, 2000, MAGNET RESON MED, V44, P401, DOI 10.1002/1522-2594(200009)44:3<401::AID-MRM10>3.0.CO;2-W; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Metting Z, 2010, J NEUROTRAUM, V27, P2183, DOI 10.1089/neu.2010.1395; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mueller Susanne G, 2005, Alzheimers Dement, V1, P55, DOI 10.1016/j.jalz.2005.06.003; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Newcombe VFJ, 2008, ACTA NEUROCHIR SUPPL, V102, P247, DOI 10.1007/978-3-211-85578-2_47; Newsome MR, 2007, NEUROCASE, V13, P16, DOI 10.1080/13554790601186629; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Pagani E, 2008, NEUROL SCI, V29, pS290, DOI 10.1007/s10072-008-1001-7; Panigrahy A, 2010, PEDIATR RADIOL, V40, P3, DOI 10.1007/s00247-009-1450-z; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Pouwels PJW, 1999, PEDIATR RES, V46, P474, DOI 10.1203/00006450-199910000-00019; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Rademacher J, 1999, NEUROIMAGE, V9, P393, DOI 10.1006/nimg.1998.0416; Rasmussen IA, 2008, J NEUROTRAUM, V25, P1057, DOI 10.1089/neu.2008.0520; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Risacher SL, 2010, NEUROBIOL AGING, V31, P1401, DOI 10.1016/j.neurobiolaging.2010.04.029; Robertson CL, 2000, ACT NEUR S, V76, P187; Rocca MA, 2002, ANN NEUROL, V51, P330, DOI 10.1002/ana.10120; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Scheibel RS, 2003, BRAIN INJURY, V17, P919, DOI 10.1080/0269905031000110472; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schmitz TW, 2006, NEUROPSYCHOLOGIA, V44, P762, DOI 10.1016/j.neuropsychologia.2005.07.012; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Schuff N, 2001, MAGN RESON MED, V45, P899, DOI 10.1002/mrm.1119; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Sherer M, 2006, BRAIN INJURY, V20, P997, DOI 10.1080/02699050600677055; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Simmons A, 2011, INT J GERIATR PSYCH, V26, P75, DOI 10.1002/gps.2491; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Soustiel JF, 2008, NEURORADIOLOGY, V50, P189, DOI 10.1007/s00234-007-0337-7; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; Strangman G, 2005, AM J PHYS MED REHAB, V84, P62, DOI 10.1097/01.PHM.0000150787.26860.12; Strangman GE, 2008, ARCH PHYS MED REHAB, V89, P974, DOI 10.1016/j.apmr.2008.02.011; Strangman GE, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00182; Suskauer SJ, 2009, DEV DISABIL RES REV, V15, P117, DOI 10.1002/ddrr.62; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Tomkins O, 2011, CARDIOVASC PSYCHIAT; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Tshibanda L, 2009, PROG BRAIN RES, V177, P215, DOI 10.1016/S0079-6123(09)17715-4; Van Boven RW, 2009, J REHABIL RES DEV, V46, P717, DOI 10.1682/JRRD.2008.12.0161; Vannorsdall TD, 2010, J NEUROPSYCH CLIN N, V22, P173, DOI 10.1176/appi.neuropsych.22.2.173; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Weisskoff RM, 1996, MAGNET RESON MED, V36, P643, DOI 10.1002/mrm.1910360422; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2006, BRAIN INJURY, V20, P695, DOI 10.1080/02699050600744079; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Wintermark M, 2005, STROKE, V36, pE83, DOI 10.1161/01.STR.0000177884.72657.8b; Wintermark M, 2004, CRIT CARE MED, V32, P1579, DOI 10.1097/01.CCM.0000130171.08842.72; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; WOLFF SD, 1989, MAGNET RESON MED, V10, P135, DOI 10.1002/mrm.1910100113; Wong EC, 2006, MAGN RESON MED, V55, P1334, DOI 10.1002/mrm.20906; Wong SBC, 2006, PROG BRAIN RES, V157, P173, DOI 10.1016/S0079-6123(06)57011-6; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Wu Z, 2010, AM J NEURORADIOL, V31, P1302, DOI 10.3174/ajnr.A2022; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013; Yeo RA, 2006, J NEUROTRAUM, V23, P1427, DOI 10.1089/neu.2006.23.1427; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	195	85	88	1	50	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	4					654	671		10.1089/neu.2011.1906			18	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	901SQ	WOS:000300987500005	21787167	Green Published			2022-02-06	
J	Zurek, J; Fedora, M				Zurek, Jiri; Fedora, Michal			The usefulness of S100B, NSE, GFAP, NF-H, secretagogin and Hsp70 as a predictive biomarker of outcome in children with traumatic brain injury	ACTA NEUROCHIRURGICA			English	Article						Biomarker; Brain injury; Outcome; Children	NEURON-SPECIFIC-ENOLASE; ANEURYSMAL SUBARACHNOID HEMORRHAGE; BILATERAL FEMUR FRACTURE; HEAT-SHOCK PROTEINS; PRACTICAL SCALE; GROWTH-FACTOR; IN-VITRO; SERUM; DAMAGE; BLOOD	Predicting the long-term outcome after traumatic brain injury (TBI) is an important component of treatment strategy. Despite dramatically improved emergency management of TBI and apparent clinical recovery, most patients with TBI still may have long-term central nervous system (CNS) impairment. Sixty-three patients with TBI were enrolled into the prospective study. Venous blood samples were taken at admission and every 24 h for a maximum of 6 consecutive days. Serum concentrations of the biomarkers S100B, neuron-specific enolase (NSE), GFAP, NF-H, secretagogin and Hsp70 were quantified immuno-luminometrically or by enzyme-linked immunosorbent assay. The outcome was evaluated 6 months after TBI using the Glasgow Outcome Scale (GOS) in all patients. The S100B levels in patients with worse outcome (GOS 4 or death) were already significantly higher at D0 (p < 0.001; p = 0.002). NSE levels were significantly higher in patients who died or had worse outcomes (p < 0.001; p = 0.003). Patients who had worse outcomes (GOS) or died had higher GFAP values (p < 0.001; p < 0.001), but their dynamics were similar over the same period. NF-H grew significantly faster in patients who had a worse GOS or died (p < 0.001; p = 0.001). Although further prospective study is warranted, these findings suggest that levels of biomarkers correlate with mortality and may be useful as predictors of outcome in children with TBI.	[Zurek, Jiri; Fedora, Michal] Univ Childrens Hosp, Dept Anesthesia & Intens Care, Brno 62500, Czech Republic		Zurek, J (corresponding author), Univ Childrens Hosp, Dept Anesthesia & Intens Care, Cernopolni 9, Brno 62500, Czech Republic.	jzurek@fnbrno.cz; mfedora@fnbrno.cz		Zurek, Jiri/0000-0002-6409-2560			Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Ciccarelli R, 1999, GLIA, V27, P275, DOI 10.1002/(SICI)1098-1136(199909)27:3<275::AID-GLIA9>3.3.CO;2-S; Cooper E. H., 1994, International Journal of Biological Markers, V9, P205; Da Rocha AB, 2005, J NEUROTRAUM, V22, P966, DOI 10.1089/neu.2005.22.966; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; GALEA E, 1995, J NEUROSCI RES, V41, P452, DOI 10.1002/jnr.490410404; Gartner W, 2001, CEREB CORTEX, V11, P1161, DOI 10.1093/cercor/11.12.1161; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Guzhova I, 2001, BRAIN RES, V914, P66, DOI 10.1016/S0006-8993(01)02774-3; Haqqani AS, 2007, J NEUROTRAUM, V24, P54, DOI 10.1089/neu.2006.0079; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Herrmann M, 2003, RESTOR NEUROL NEUROS, V21, P177; Herrmann M, 2003, RESTOR NEUROL NEUROS, V21, P75; JENNETT B, 1975, LANCET, V1, P480; Lewis SB, 2008, J CEREBR BLOOD F MET, V28, P1261, DOI 10.1038/jcbfm.2008.12; LI GC, 1983, J CELL PHYSIOL, V115, P116, DOI 10.1002/jcp.1041150203; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Nahlovsky J, 2006, NEUROCHIRURGIE; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelinka LE, 2004, SHOCK, V22, P88, DOI 10.1097/01.shk.0000130157.34382.3f; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Pockley AG, 2003, LANCET, V362, P469, DOI 10.1016/S0140-6736(03)14075-5; Rogstam A, 2007, BIOCHEM J, V401, P353, DOI 10.1042/BJ20060918; Rustandi RR, 1998, BIOCHEMISTRY-US, V37, P1951, DOI 10.1021/bi972701n; Sarto C, 2000, ELECTROPHORESIS, V21, P1218, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1218::AID-ELPS1218>3.3.CO;2-8; Shaw G, 2007, BIOCHEM BIOPH RES CO, V325, P619; Strong MJ, 2001, J NEUROCHEM, V76, P1315, DOI 10.1046/j.1471-4159.2001.00094.x; TEASDALE G, 1974, LANCET, V2, P81; TEPAS JJ, 1987, J PEDIATR SURG, V22, P14, DOI 10.1016/S0022-3468(87)80006-4; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; Unden J, 2004, SCAND J INFECT DIS, V36, P10, DOI 10.1080/00365540310017294; USUI A, 1989, CLIN CHEM, V35, P1942; WHITAKERAZMITIA PM, 1990, BRAIN RES, V528, P155, DOI 10.1016/0006-8993(90)90210-3; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; Zylicz M, 2001, EMBO J, V20, P4634, DOI 10.1093/emboj/20.17.4634	41	85	94	0	13	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	JAN	2012	154	1					93	103		10.1007/s00701-011-1175-2			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	870BE	WOS:000298643300016	21976236				2022-02-06	
J	Cottler, LB; Ben Abdallah, A; Cummings, SM; Barr, J; Banks, R; Forchheimer, R				Cottler, Linda B.; Ben Abdallah, Arbi; Cummings, Simone M.; Barr, John; Banks, Rayna; Forchheimer, Ronnie			Injury, pain, and prescription opioid use among former National Football League (NFL) players	DRUG AND ALCOHOL DEPENDENCE			English	Article						Opioid use; Opioid misuse; Prescription pain pills; NFL players; Concussions	DRUG-USERS; RELIABILITY; CONCUSSION; BEHAVIORS; MISUSE; ABUSE	Background: Athletes with injury-related pain, especially National Football League (NFL) players, are at increased risk for opioid use and misuse which may result in medical, psychiatric and social problems. This is the first study to evaluate the intersection of sports pain and opioid use and misuse among former NFL players. Methods: A telephone survey of 644 retired NFL players from the 2009 Retired Players Association Directory was conducted (53.4% completion rate) from March to August 2010. Results: Over half (52%) used opioids during their NFL career with 71% reporting misuse. Additionally, 15% of NFL misusers currently misused vs. 5% among players who used just as prescribed during their NFL career. Prevalence of current opioid use was 7%-3 times the rate of the general population. Multivariate analyses indicated that significant NFL pain increased the adjusted odds (AOR) of any current opioid use vs. non-use (AOR 6.76, 95%CI 2.88-15.87), as did moderate to severe mental impairment (AOR 1.88, 95%CI 1.19-2.98) and heavy drinking in the past week (AOR 2.15, 95%CI 1.17-3.98). Undiagnosed concussions singly predicted current misuse vs. use just as prescribed (AOR 4.25, 95%CI 1.12-16.22). Three variables predicted current misuse vs. non-use: significant pain (AOR 8.33, 95%CI 1.98-35.04), undiagnosed concussions (AOR 3.51, 95%CI 1.98-35.04) and heavy drinking (AOR 3.48, 95%CI 1.63-7.41). Conclusions: Players who misused during their NFL career were most likely to misuse currently compared to others. Current misuse was associated with more NFL pain, undiagnosed concussions and heavy drinking. Longitudinal studies are needed to determine the long term effects of opioid misuse among athletes. (C) 2011 Elsevier Ireland Ltd. All rights reserved.	[Cottler, Linda B.; Ben Abdallah, Arbi; Cummings, Simone M.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63108 USA; [Barr, John; Banks, Rayna; Forchheimer, Ronnie] ESPN Prod Inc, ESPN Enterprise Unit, Bristol, CT 06010 USA		Cottler, LB (corresponding author), Washington Univ, Sch Med, Dept Psychiat, 40 N Kingshighway,Suite 4, St Louis, MO 63108 USA.	cottler@epi.wustl.edu			ESPN (Entertainment and Sports Programming Network); National Institute on Drug Abuse of the National Institutes of Health (NIDA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA); NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA020791] Funding Source: NIH RePORTER	This study (Survey of Retired NFL Football Players; LB Cottler, PI) was funded by ESPN (Entertainment and Sports Programming Network). Additional funding was provided by the National Institute on Drug Abuse of the National Institutes of Health (NIDA; Research Supplement for Retired Professional NFL Football Players; Prescription Drug Misuse, Abuse and Dependence, DA020791-04S2; LB Cottler, PI). ESPN staff Barr, Banks and Forchheimer contributed to the study concept and participated in revisions of the manuscript. They had no role in the collection, analysis or interpretation of data. NIDA had no role in the study design, in the collection, analysis or interpretation of data, in the writing of the report, or in the decision to submit the paper for publication.	Alaranta A, 2008, SPORTS MED, V38, P449, DOI 10.2165/00007256-200838060-00002; Casson IR, 2009, PHYS MED REH CLIN N, V20, P195, DOI 10.1016/j.pmr.2008.10.006; Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009; Denisco RA, 2008, EXP CLIN PSYCHOPHARM, V16, P417, DOI 10.1037/a0013636; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; HALCHIN LE, 2008, C RES SERV REP C APR; Ives TJ, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-46; National Institute on Alcohol Abuse and Alcoholism, 2010, RETH DRINK ALC YOUR; NEEDLE R, 1995, PSYCHOL ADDICT BEHAV, V9, P242, DOI 10.1037/0893-164X.9.4.242; *NIDA, 2001, NIH PUBL; Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512; Orchard J, 2002, BRIT J SPORT MED, V36, P39, DOI 10.1136/bjsm.36.1.39; Schwenk TL, 2007, MED SCI SPORT EXER, V39, P599, DOI 10.1249/mss.0b013e31802fa679; Selden MA, 2009, AM J MED, V122, P811, DOI 10.1016/j.amjmed.2009.03.027; Shacham E, 2010, ARCH SEX BEHAV, V39, P1331, DOI 10.1007/s10508-009-9539-x; Simoni-Wastila L, 2004, AM J PUBLIC HEALTH, V94, P266, DOI 10.2105/AJPH.94.2.266; Substance Abuse and Mental Health Services Administration (Office of Applied Studies), 2009, NSDUH SER H; Zacny J, 2003, DRUG ALCOHOL DEPEN, V69, P215, DOI 10.1016/S0376-8716(03)00003-6	18	85	85	3	41	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716			DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	JUL 1	2011	116	1-3					188	194		10.1016/j.drugalcdep.2010.12.003			7	Substance Abuse; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Substance Abuse; Psychiatry	784SY	WOS:000292179700028	21277121	Green Accepted			2022-02-06	
J	Creed, JA; DiLeonardi, AM; Fox, DP; Tessler, AR; Raghupathi, R				Creed, Jennifer A.; DiLeonardi, Ann Mae; Fox, Douglas P.; Tessler, Alan R.; Raghupathi, Ramesh			Concussive Brain Trauma in the Mouse Results in Acute Cognitive Deficits and Sustained Impairment of Axonal Function	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; axonal transport; compound action potential; concussion; spatial learning; traumatic brain injury; working memory	AMYLOID PRECURSOR PROTEIN; FLUID PERCUSSION INJURY; LONG-TERM POTENTIATION; MINOR HEAD-INJURY; POSTCONCUSSION SYNDROME; NEURONAL DEGENERATION; CORPUS-CALLOSUM; WORKING-MEMORY; CORTEX LESIONS; ADULT-RAT	Concussive brain injury (CBI) accounts for approximately 75% of all brain-injured people in the United States each year and is particularly prevalent in contact sports. Concussion is the mildest form of diffuse traumatic brain injury (TBI) and results in transient cognitive dysfunction, the neuropathologic basis for which is traumatic axonal injury (TAI). To evaluate the structural and functional changes associated with concussion-induced cognitive deficits, adult mice were subjected to an impact on the intact skull over the midline suture that resulted in a brief apneic period and loss of the righting reflex. Closed head injury also resulted in an increase in the wet weight: dry weight ratio in the cortex suggestive of edema in the first 24 h, and the appearance of Fluoro-Jade-B-labeled degenerating neurons in the cortex and dentate gyrus of the hippocampus within the first 3 days post-injury. Compared to sham-injured mice, brain-injured mice exhibited significant deficits in spatial acquisition and working memory as measured using the Morris water maze over the first 3 days (p < 0.001), but not after the fourth day post-injury. At 1 and 3 days post-injury, intra-axonal accumulation of amyloid precursor protein in the corpus callosum and cingulum was accompanied by neurofilament dephosphorylation, impaired transport of Fluoro-Gold and synaptophysin, and deficits in axonal conductance. Importantly, deficits in retrograde transport and in action potential of myelinated axons continued to be observed until 14 days post-injury, at which time axonal degeneration was apparent. These data suggest that despite recovery from acute cognitive deficits, concussive brain trauma leads to axonal degeneration and a sustained perturbation of axonal function.	[Fox, Douglas P.; Tessler, Alan R.; Raghupathi, Ramesh] Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19129 USA; [Creed, Jennifer A.; DiLeonardi, Ann Mae; Raghupathi, Ramesh] Drexel Univ, Coll Med, Program Neurosci, Philadelphia, PA 19129 USA; [Tessler, Alan R.] Vet Adm Med Ctr, Philadelphia, PA 19104 USA		Raghupathi, R (corresponding author), Drexel Univ, Coll Med, Dept Neurobiol & Anat, 2900 Queen Lane,Room 277, Philadelphia, PA 19129 USA.	RRamesh@drexelmed.edu	Raghupathi, Ramesh/AAX-5538-2021	DiLeonardi, Ann Mae/0000-0002-1476-7726	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD41699, NS065017]; VA Merit Review grantUS Department of Veterans Affairs; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD041699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065017] Funding Source: NIH RePORTER	We would like acknowledge the efforts of Ms. Rachel Tang for the analysis of the electrophysiology data. These studies were supported in part by grants from the NIH (no. HD41699 and NS065017 to R. R.), and a VA Merit Review grant to R.R. and A.T.	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buxbaum JD, 1998, J NEUROSCI, V18, P9629; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Goda M, 2002, J NEUROTRAUM, V19, P1445, DOI 10.1089/089771502320914679; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Hoane MR, 2003, BRAIN RES BULL, V60, P105, DOI 10.1016/S0361-9230(03)00022-4; HOVDA DA, 1990, ACT NEUR S, V51, P331; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; KATAYAMA Y, 1990, ACT NEUR S, V51, P271; Keene CS, 2009, NEUROBIOL LEARN MEM, V91, P408, DOI 10.1016/j.nlm.2008.10.009; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Ohlsson M, 2004, RESTOR NEUROL NEUROS, V22, P1; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Papp H, 2002, NEUROCHEM INT, V41, P429, DOI 10.1016/S0197-0186(02)00014-1; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; Pothuizen HHJ, 2010, BEHAV BRAIN RES, V208, P566, DOI 10.1016/j.bbr.2010.01.001; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Reeves TM, 1997, NEUROSCIENCE, V77, P431, DOI 10.1016/S0306-4522(96)00486-1; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; SCHALOMON PM, 1995, PHYSIOL BEHAV, V57, P1199; SCHMUED LC, 1986, BRAIN RES, V377, P147, DOI 10.1016/0006-8993(86)91199-6; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Shojo H, 2006, BRAIN RES, V1078, P198, DOI 10.1016/j.brainres.2006.01.063; Smits M., 2010, NEURORADIOLOGY; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; YAMAKI T, 1994, J NEUROTRAUM, V11, P613, DOI 10.1089/neu.1994.11.613; Yamaki T, 1997, BRAIN RES, V752, P151, DOI 10.1016/S0006-8993(96)01469-2; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	75	85	85	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2011	28	4					547	563		10.1089/neu.2010.1729			17	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	746IW	WOS:000289240200006	21299360	Green Published			2022-02-06	
J	Lin, MS; Lee, YH; Chiu, WT; Hung, KS				Lin, Muh-Shi; Lee, Yi-Hsuan; Chiu, Wen-Ta; Hung, Kuo-Sheng			Curcumin Provides Neuroprotection After Spinal Cord Injury	JOURNAL OF SURGICAL RESEARCH			English	Article						curcumin; spinal cord injury; hemisection; BBB scale; astrocyte primary culture; functional outcome; apoptosis; GFAP; astrocyte reactivation; neuroprotection	ASTROCYTES PROTECT NEURONS; TRAUMATIC BRAIN-INJURY; INFLAMMATORY RESPONSE; INDUCED APOPTOSIS; OXIDATIVE STRESS; GENE-EXPRESSION; METHYLPREDNISOLONE; PROLIFERATION; REGENERATION; ACTIVATION	Background. Traumatic spinal cord injury (SCI) is a major cause of long-term disability. However, therapeutic agents targeting SCI are sorely lacking. The aim of this study was to investigate whether curcumin has neuroprotective effects after SCI in rats. Materials and methods. Studies were performed in 39 male Sprague-Dawley rats after spinal cord hemisection. The animals were randomly divided into three groups: sham, vehicle, and curcumin. The Basso, Beattie, and Bresnahan (BBB) scale was used to evaluate functional outcome. Specimens were tested for histologic, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL), and immunohistochemical staining. Primary cultured astrocytes were used to test the inhibitory effect of curcumin on glial reactivation. Results. The BBB scores for the affected hindlimb after hemisection were significantly improved in the curcumin-treated group compared with the vehicle group (on d 3 and 7; P < 0.001). Immunohistochemistry of NeuN revealed remarkable neuronal loss in the vehicle group after hemisection. In comparison, curcumin significantly protected neurons after SCI (curcumin compared with vehicle; P < 0.001). Furthermore, curcumin significantly attenuated apoptosis after SCI (curcumin compared with vehicle; P < 0.001). RT-PCR demonstrated that the expression of glial fibrillary acidic protein (GFAP) was significantly inhibited by curcumin. Conclusions. Curcumin inhibited apoptosis and neuron loss, quenched astrocyte activation, and significantly improved neurologic deficit 7 d after spinal cord hemisection. By down-regulating GFAP expression, curcumin seems to attenuate astrocyte reactivation, which may be beneficial for neuronal survival. This is the first report demonstrating the successful treatment of SCI by curcumin. (C) 2011 Elsevier Inc. All rights reserved.	[Lin, Muh-Shi; Chiu, Wen-Ta; Hung, Kuo-Sheng] Taipei Med Univ, Dept Neurosurg, Wan Fang Hosp, Taipei 116, Taiwan; [Lin, Muh-Shi] Taipei Cty Hosp, Dept Surg, Div Neurosurg, Taipei, Taiwan; [Lin, Muh-Shi; Chiu, Wen-Ta] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei 116, Taiwan; [Lee, Yi-Hsuan] Taipei Med Univ, Coll Med, Dept Physiol, Taipei 116, Taiwan; [Hung, Kuo-Sheng] Taipei Med Univ, Dept Neurosurg, Wan Fang Med Ctr, Grad Inst Injury Prevent & Control, Taipei 116, Taiwan		Hung, KS (corresponding author), Taipei Med Univ, Dept Neurosurg, Wan Fang Med Ctr, Grad Inst Injury Prevent & Control, 111 Sect 3,Hsin Long Rd, Taipei 116, Taiwan.	kshung25@gmail.com	Lin, 林牧熹 醫學博士 法學碩士 Muh-Shi/U-7004-2019	Lin, 林牧熹 醫學博士 法學碩士 Muh-Shi/0000-0002-9798-8160	National Science CouncilMinistry of Science and Technology, Taiwan [NSC 96-2314-B-010387-MY3, NSC 97-2323-B-038-004]; Department of Health, Taiwan [DOH-TD-B-111-002]	The authors acknowledge support for this work by the National Science Council (grant no. NSC 96-2314-B-010387-MY3, NSC 97-2323-B-038-004), and the Department of Health, Taiwan (grant no. DOH-TD-B-111-002).	Ambegaokar SS, 2003, NEUROENDOCRINOL LETT, V24, P469; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Benarroch EE, 2005, MAYO CLIN PROC, V80, P1326, DOI 10.4065/80.10.1326; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Chen J, 2006, APOPTOSIS, V11, P943, DOI 10.1007/s10495-006-6715-5; Chen YM, 2001, J NEUROCHEM, V77, P1601, DOI 10.1046/j.1471-4159.2001.00374.x; Davies SJA, 1996, EXP NEUROL, V142, P203, DOI 10.1006/exnr.1996.0192; Desagher S, 1996, J NEUROSCI, V16, P2553; Ersayli DT, 2006, SPINE, V31, P2221, DOI 10.1097/01.brs.0000232801.19965.a0; Fu YM, 2008, MOL PHARMACOL, V73, P399, DOI 10.1124/mol.107.039818; Hellmich HL, 2005, ANESTHESIOLOGY, V102, P806, DOI 10.1097/00000542-200504000-00017; Houle JD, 2003, EXP NEUROL, V182, P247, DOI 10.1016/S0014-4886(03)00029-3; Hung KS, 2005, J NEUROPATH EXP NEUR, V64, P15, DOI 10.1093/jnen/64.1.15; Hung KS, 2007, J NEUROSURG-SPINE, V6, P35, DOI 10.3171/spi.2007.6.1.7; Hurlbert RJ, 2006, SPINE, V31, pS16, DOI 10.1097/01.brs.0000218264.37914.2c; Jaruga E, 1998, BIOCHEM PHARMACOL, V56, P961, DOI 10.1016/S0006-2952(98)00144-0; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; Lin CH, 2008, J NEUROCHEM, V104, P1415, DOI 10.1111/j.1471-4159.2007.05098.x; Liu WL, 2008, GLIA, V56, P1390, DOI 10.1002/glia.20706; Mattson MP, 2006, TRENDS NEUROSCI, V29, P632, DOI 10.1016/j.tins.2006.09.001; Mattson Mark P, 2007, Dose Response, V5, P174, DOI 10.2203/dose-response.07-004.Mattson; Morino T, 2003, NEUROSCI RES, V46, P309, DOI 10.1016/S0168-0102(03)00095-6; PANCHAL HD, 2008, NEUROCHEM RES, V47, P24; Ransom B, 2003, TRENDS NEUROSCI, V26, P520, DOI 10.1016/j.tins.2003.08.006; Shapiro H, 2006, J GASTROEN HEPATOL, V21, P358, DOI 10.1111/j.1440-1746.2005.03984.x; Shin HJ, 2007, NEUROSCI LETT, V416, P49, DOI 10.1016/j.neulet.2007.01.060; Shishodia S, 2005, ANN NY ACAD SCI, V1056, P206, DOI 10.1196/annals.1352.010; Somasundaram S, 2002, CANCER RES, V62, P3868; Stichel CC, 1998, CELL TISSUE RES, V294, P1, DOI 10.1007/s004410051151; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Wang HH, 2009, GLIA, V57, P24, DOI 10.1002/glia.20732; Weber WM, 2006, BIOORGAN MED CHEM, V14, P2450, DOI 10.1016/j.bmc.2005.11.035; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Xu J, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-01-j0001.2001; Yazawa K, 2006, FEBS LETT, V580, P6623, DOI 10.1016/j.febslet.2006.11.011; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	37	85	96	4	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	APR	2011	166	2					280	289		10.1016/j.jss.2009.07.001			10	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	732ER	WOS:000288168300034	20018302				2022-02-06	
J	Gao, XA; Chen, JH				Gao, Xiang; Chen, Jinhui			Mild Traumatic Brain Injury Results in Extensive Neuronal Degeneration in the Cerebral Cortex	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Dendrite; mTBI; Neural degeneration; Spine; Synapse	CONTROLLED CORTICAL IMPACT; MINOR HEAD-INJURY; MEDIAL PREFRONTAL CORTEX; PYRAMIDAL NEURONS; DENDRITIC SPINES; FUNCTIONAL MRI; FLUORO-JADE; TIME-COURSE; RAT; HIPPOCAMPUS	Mild traumatic brain injury (mTBI) leads to long-term cognitive and emotional difficulties and behavioral disturbances, but the diagnosis and treatment of mTBI have historically been hampered by a lack of evidence-based correlates of these clinical manifestations. Unlike moderate and severe TBI, mTBI does not show significant tissue lesions or cavities in the cortex. Moreover, neuroimaging by magnetic resonance imaging or computed tomography is usually negative, suggesting that the damage is beyond the resolution of current structure-based scanning technologies. Therefore, we investigated the morphologies of spared neurons in the mouse cortex after mTBI in a controlled cortical impact injury model. Our results indicate that, although mTBI caused only a mild extent of cell death, it led to extensive dendrite degeneration and synapse reduction in the cortex in this model. This study sheds light on the neuropathologic consequences of mTBI in humans and suggests that neurodegeneration may be a novel target for developing diagnostic methods and therapeutic approaches for mTBI.	[Chen, Jinhui] Indiana Univ, Dept Neurosurg, Indianapolis, IN 46204 USA; [Gao, Xiang; Chen, Jinhui] Indiana Univ, Cord & Brain Injury Res Grp, Indianapolis, IN 46204 USA; [Chen, Jinhui] Indiana Univ, Stark Neurosci Res Inst, Indianapolis, IN 46204 USA		Chen, JH (corresponding author), Indiana Univ Sch Med, Dept Neurosurg, 980 W Walnut St, Indianapolis, IN 46202 USA.	chen204@iupui.edu	Chen, Jinhui/A-7138-2009	Chen, Jinhui/0000-0002-6864-7121	Indiana Spinal Cord & Brain Injury Research Grants [SCBI 200-12]; Ralph W. and Grace M. Showalter Research Award; Indiana University; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072631, R21NS075733] Funding Source: NIH RePORTER	This work was supported by grants from the Indiana Spinal Cord & Brain Injury Research Grants (SCBI 200-12), the Ralph W. and Grace M. Showalter Research Award, and Indiana University Biological Research Grant to J. Chen.	Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Bruns JJ, 2009, MT SINAI J MED, V76, P129, DOI 10.1002/msj.20101; Calhoun ME, 1996, J NEUROCYTOL, V25, P821, DOI 10.1007/BF02284844; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cassidy JD, 2004, J REHABIL MED, V36, P15, DOI 10.1080/16501960410023688; Cerqueira JJ, 2007, CEREB CORTEX, V17, P1998, DOI 10.1093/cercor/bhl108; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; CLINE DM, 1988, ANN EMERG MED, V17, P127, DOI 10.1016/S0196-0644(88)80297-X; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dunaevsky A, 1999, P NATL ACAD SCI USA, V96, P13438, DOI 10.1073/pnas.96.23.13438; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gao X, 2008, J NEUROTRAUM, V25, P985, DOI 10.1089/neu.2008.0460; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2009, EXP NEUROL, V219, P516, DOI 10.1016/j.expneurol.2009.07.007; Gao X, 2009, J NEUROTRAUM, V26, P1325, DOI [10.1089/neu.2008.0744, 10.1089/neu.2008-0744]; GARRAWAY M, 1995, LANCET, V345, P1485; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HARRIS KM, 1992, J NEUROSCI, V12, P2685; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P313, DOI 10.1097/HTR.0b013e3181d6f9bd; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Jagoda AS, 2009, J EMERG NURS, V35, P5; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; Lidvall H F, 1974, Acta Neurol Scand Suppl, V56, P3; LIDVALL HF, 1974, LANCET, V2, P1150; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LOWDON IMR, 1989, INJURY, V20, P193, DOI 10.1016/0020-1383(89)90109-5; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Minino Arialdi M, 2006, Natl Vital Stat Rep, V54, P1; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Petchprapai Nutthita, 2007, J Neurosci Nurs, V39, P260; Petrak LJ, 2005, J COMP NEUROL, V484, P183, DOI 10.1002/cne.20468; Portera-Cailliau C, 2003, J NEUROSCI, V23, P7129, DOI 10.1523/JNEUROSCI.23-18-07129.2003; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Radley JJ, 2004, NEUROSCIENCE, V125, P1, DOI 10.1016/j.neuroscience.2004.01.006; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; SHOLL D A, 1956, Prog Neurobiol, P324; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Tada T, 2006, CURR OPIN NEUROBIOL, V16, P95, DOI 10.1016/j.conb.2005.12.001; UYLINGS HBM, 1994, PROG BRAIN RES, V102, P109; UYLINGS HBM, 1986, J NEUROSCI METH, V18, P127, DOI 10.1016/0165-0270(86)90116-0; Uylings HBM, 2002, NETWORK-COMP NEURAL, V13, P397, DOI 10.1088/0954-898X/13/3/309; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	66	85	85	0	9	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAR	2011	70	3					183	191		10.1097/NEN.0b013e31820c6878			9	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	723BT	WOS:000287481900003	21293299	Green Accepted, Bronze			2022-02-06	
J	Hellewell, SC; Yan, EB; Agyapomaa, DA; Bye, N; Morganti-Kossmann, MC				Hellewell, Sarah C.; Yan, Edwin B.; Agyapomaa, Doreen A.; Bye, Nicole; Morganti-Kossmann, M. Cristina			Post-Traumatic Hypoxia Exacerbates Brain Tissue Damage: Analysis of Axonal Injury and Glial Responses	JOURNAL OF NEUROTRAUMA			English	Article						astrocytes; hypoxia; inflammation; macrophages; microglia; traumatic axonal injury	AMYLOID PRECURSOR PROTEIN; INTRAAXONAL NEUROFILAMENT COMPACTION; CENTRAL-NERVOUS-SYSTEM; CLOSED-HEAD INJURY; INFLAMMATORY RESPONSE; ULTRASTRUCTURAL-CHANGES; AXOLEMMAL PERMEABILITY; MICROGLIAL ACTIVATION; REACTIVE ASTROCYTES; SECONDARY INSULTS	Traumatic brain injury (TBI) resulting in poor neurological outcome is predominantly associated with diffuse brain damage and secondary hypoxic insults. Post-traumatic hypoxia is known to exacerbate primary brain injury; however, the underlying pathological mechanisms require further elucidation. Using a rat model of diffuse traumatic axonal injury (TAI) followed by a post-traumatic hypoxic insult, we characterized axonal pathology, macrophage/microglia accumulation, and astrocyte responses over 14 days. Rats underwent TAI alone, TAI followed by 30 min of hypoxia (TAI+Hx), hypoxia alone, or sham-operation (n=6/group). Systemic hypoxia was induced by ventilating rats with 12% oxygen in nitrogen, resulting in a similar to 50% reduction in arterial blood oxygen saturation. Brains were assessed for axonal damage, macrophage/microglia accumulation, and astrocyte activation at 1,7, and 14 days post-treatment. Immunohistochemistry with axonal damage markers (beta-amyloid precursor protein [beta-APP] and neurofilament) showed strong positive staining in TAI+Hx rats, which was most prominent in the corpus callosum (retraction bulbs 69.8 +/- 18.67; swollen axons 14.2 +/- 5.25), and brainstem (retraction bulbs 294 +/- 118.3; swollen axons 50.3 +/- 20.45) at 1 day post-injury. Extensive microglia/macrophage accumulation detected with the CD68 antibody was maximal at 14 days post-injury in the corpus callosum (macrophages 157.5 +/- 55.48; microglia 72.71 +/- 20.75), and coincided with regions of axonal damage. Astrocytosis assessed with glial fibrillary acidic protein (GFAP) antibody was also abundant in the corpus callosum and maximal at 14 days, with a trend toward an increase in TAI+Hx animals (18.99 +/- 2.45 versus 13.56 +/- 0.81; p=0.0617). This study demonstrates for the first time that a hypoxic insult following TAI perpetuates axonal pathology and cellular inflammation, which may account for the poor neurological outcomes seen in TBI patients who experience post-traumatic hypoxia.	[Hellewell, Sarah C.; Yan, Edwin B.; Agyapomaa, Doreen A.; Bye, Nicole; Morganti-Kossmann, M. Cristina] Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Hellewell, Sarah C.; Yan, Edwin B.; Agyapomaa, Doreen A.; Bye, Nicole; Morganti-Kossmann, M. Cristina] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia		Morganti-Kossmann, MC (corresponding author), Alfred Hosp, Natl Trauma Res Inst, 89 Commercial Rd, Melbourne, Vic 3004, Australia.	cristina.morganti-kossmann@monash.edu		Morganti-Kossmann, Cristina/0000-0002-0807-2063; Hellewell, Sarah/0000-0002-2179-2209	Victorian Neurotrauma Initiative; National Health and Medical Research CouncilNational Health and Medical Research Council of Australia	We acknowledge the generous support of the Victorian Neurotrauma Initiative and the National Health and Medical Research Council in funding this project.	Adamides AA, 2009, ACTA NEUROCHIR, V151, P1399, DOI 10.1007/s00701-009-0398-y; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; ALLEN A, 1989, ACTA NEUROPATHOL, V78, P637, DOI 10.1007/BF00691291; Bauman RA, 2000, J NEUROTRAUM, V17, P679, DOI 10.1089/089771500415427; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; Chesnut R M, 1995, New Horiz, V3, P366; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Czigner A, 2007, ACTA NEUROCHIR, V149, P281, DOI 10.1007/s00701-006-1095-8; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Geeraerts T, 2006, J NEUROTRAUM, V23, P1059, DOI 10.1089/neu.2006.23.1059; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN D, 1990, LANCET, V335, P330, DOI 10.1016/0140-6736(90)90615-C; GIULIAN D, 1993, J NEUROSCI, V13, P29; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Graham DI, 1996, NEUROPATH APPL NEURO, V22, P505, DOI 10.1111/j.1365-2990.1996.tb01125.x; GUO G, 2010, J CEREB BLOOD FLOW M, V30, P628; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184, DOI 10.1097/00004647-199902000-00010; Hausmann R, 1999, INT J LEGAL MED, V112, P227, DOI 10.1007/s004140050241; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; Hortobagyi T, 2007, NEUROPATH APPL NEURO, V33, P226, DOI 10.1111/j.1365-2990.2006.00794.x; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Iwadate Kimiharu, 2005, Legal Medicine, V7, P117, DOI 10.1016/j.legalmed.2004.10.003; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kallakuri S, 2003, EXP BRAIN RES, V148, P419, DOI 10.1007/s00221-002-1307-2; Kaur B, 1999, J CLIN PATHOL, V52, P203, DOI 10.1136/jcp.52.3.203; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Koob AO, 2006, J NEUROSCI RES, V83, P1558, DOI 10.1002/jnr.20837; Kuchta J, 2009, CENT EUR NEUROSURG, V70, P125, DOI 10.1055/s-0029-1214384; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Li BY, 2009, ACTA CRYSTALLOGR E, V65, pM1, DOI 10.1107/S1600536808039846; LIEM RKH, 1978, J CELL BIOL, V79, P637, DOI 10.1083/jcb.79.3.637; Lovasik D, 2001, Crit Care Nurs Q, V23, P24; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Mahmutyazicioglu Kamran, 2005, Diagn Interv Radiol, V11, P19; Maiti P, 2006, NEUROCHEM INT, V49, P709, DOI 10.1016/j.neuint.2006.06.002; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Mikrogianakis A, 2007, J NEUROTRAUM, V24, P338, DOI 10.1089/neu.2006.003615; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; Oehmichen M, 1999, ACTA NEUROPATHOL, V97, P491, DOI 10.1007/s004010051018; Okonkwo DO, 2003, CLIN SPORT MED, V22, P467, DOI 10.1016/S0278-5919(02)00107-2; Perunovic B, 2001, J NEUROL SCI, V185, P55, DOI 10.1016/S0022-510X(01)00463-4; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Puka-Sundvall M, 2000, DEV BRAIN RES, V125, P31, DOI 10.1016/S0165-3806(00)00110-3; Ramanathan L, 2005, J NEUROCHEM, V93, P47, DOI 10.1111/j.1471-4159.2004.02988.x; Reichard RR, 2005, NEUROPATH APPL NEURO, V31, P304, DOI 10.1111/j.1365-2990.2005.00645.x; Robertson CL, 2000, CRIT CARE MED, V28, P3218, DOI 10.1097/00003246-200009000-00017; Rosenzweig HL, 2004, STROKE, V35, P2576, DOI 10.1161/01.STR.0000143450.04438.ae; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; SABATES NR, 1991, J CLIN NEURO-OPHTHAL, V11, P273; Satoh JI, 2002, NEUROPATH APPL NEURO, V28, P95, DOI 10.1046/j.1365-2990.2002.00375.x; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Stahel PF, 2008, INTENS CARE MED, V34, P402, DOI 10.1007/s00134-007-0889-3; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Stiefel MF, 2005, J NEUROSURG, V103, P707, DOI 10.3171/jns.2005.103.4.0707; STOLL G, 2002, DETRIMENTAL BENEFICI; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; Utagawa A, 2008, BRAIN RES, V1207, P155, DOI 10.1016/j.brainres.2008.02.057; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	101	85	91	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2010	27	11					1997	2010		10.1089/neu.2009.1245			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	682BZ	WOS:000284375500007	20822466				2022-02-06	
J	Semple, BD; Bye, N; Ziebell, JM; Morganti-Kossmann, MC				Semple, Bridgette D.; Bye, Nicole; Ziebell, Jenna M.; Morganti-Kossmann, M. Cristina			Deficiency of the chemokine receptor CXCR2 attenuates neutrophil infiltration and cortical damage following closed head injury	NEUROBIOLOGY OF DISEASE			English	Article						Traumatic brain injury; Chemokine; Inflammation; CXCR2; Neutrophils	TRAUMATIC BRAIN-INJURY; COLONY-STIMULATING FACTOR; BARRIER PERMEABILITY; LEUKOCYTE INFILTRATION; NEURONAL DEGENERATION; GROWTH-FACTOR; WEIGHT-DROP; CELL-DEATH; EXPRESSION; ISCHEMIA	The contribution of infiltrated neutrophils to secondary damage following traumatic brain injury remains controversial. Chemokines that regulate neutrophil migration by signaling through the CXCR2 receptor are markedly elevated by brain injury and are associated with the propagation of secondary damage. This study thus investigated the function of CXCR2 in posttraumatic inflammation and secondary degeneration by examining Cxcr2-deficient (Cxcr2(-/-)) mice over 14 days following closed head injury (CHI). We demonstrate a significant attenuation of neutrophil infiltration in Cxcr2(-/-) mice at 12 hours and 7 days after CHI, despite increased levels of CXC neutrophil-attracting chemokines in the lesioned cortex. This coincides with reduced tissue damage, neuronal loss, and cell death in Cxcr2(-/-) mice compared to wild-type controls, with heterozygotes showing intermediate responses. In contrast, blood-brain barrier permeability and functional recovery did not appear to be affected by Cxcr2 deletion. This study highlights the deleterious contribution of neutrophils to posttraumatic neurodegeneration and demonstrates the importance of CXC chemokine signaling in this process. Therefore, CXCR2 antagonistic therapeutics currently in development for other inflammatory conditions may also be of benefit in posttraumatic neuroinflammation. Crown Copyright (c) 2010 Published by Elsevier Inc. All rights reserved.	[Semple, Bridgette D.] Monash Univ, Natl Trauma Res Inst, Dept Med, Melbourne, Vic 3004, Australia; [Semple, Bridgette D.; Bye, Nicole; Morganti-Kossmann, M. Cristina] Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia		Semple, BD (corresponding author), Monash Univ, Natl Trauma Res Inst, Dept Med, 4th Floor Burnet Tower,89 Commercial Rd, Melbourne, Vic 3004, Australia.	Bridgette.Semple@monash.edu; Nicole.Bye@monash.edu; Jenna.Ziebell@adelaide.edu.au; Cristina.Morganti-Kossmann@monash.edu	Ziebell, Jenna/Y-4496-2019	Morganti-Kossmann, Cristina/0000-0002-0807-2063; Ziebell, Jenna/0000-0003-2497-4347	Victorian Neurotrauma Initiative (VNI), Australian Government; Transport Accident Commission (TAC)	This study was supported by the Victorian Neurotrauma Initiative (VNI), Australian Government (Australian Postgraduate Award for B.D. Semple), and Transport Accident Commission (TAC). Technical assistance was provided by Ms. Nakisa Malakooti and Dr. Tom Woodcock.	Barsante MM, 2008, BRIT J PHARMACOL, V153, P992, DOI 10.1038/sj.bjp.0707462; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Beray-Berthat V, 2003, BRAIN RES, V987, P32, DOI 10.1016/S0006-8993(03)03224-4; Betsuyaku T, 1999, J CLIN INVEST, V103, P825, DOI 10.1172/JCI5191; Bhatia M, 2007, REGUL PEPTIDES, V138, P40, DOI 10.1016/j.regpep.2006.08.006; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; Cardona AE, 2008, BLOOD, V112, P256, DOI 10.1182/blood-2007-10-118497; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; CHAPMAN RW, 2008, PHARMACOL THERAPEUT, V121, P55; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Conti AC, 1998, J NEUROSCI, V18, P5663; Coughlan CM, 2000, NEUROSCIENCE, V97, P591, DOI 10.1016/S0306-4522(00)00024-5; Cowburn AS, 2008, CHEST, V134, P606, DOI 10.1378/chest.08-0422; Devalaraja RM, 2000, J INVEST DERMATOL, V115, P234, DOI 10.1046/j.1523-1747.2000.00034.x; Dinkel K, 2004, P NATL ACAD SCI USA, V101, P331, DOI 10.1073/pnas.0303510101; Emerich DF, 2002, EXP NEUROL, V173, P168, DOI 10.1006/exnr.2001.7835; Ertel W, 1999, J TRAUMA, V46, P784, DOI 10.1097/00005373-199905000-00005; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Garau A, 2005, CYTOKINE, V30, P125, DOI 10.1016/j.cyto.2004.12.014; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Harris AK, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-49; HEINEL LA, 1994, BRAIN RES BULL, V34, P137, DOI 10.1016/0361-9230(94)90010-8; Joice SL, 2009, BRAIN RES, V1298, P13, DOI 10.1016/j.brainres.2009.08.076; Kobayashi Y, 2008, FRONT BIOSCI-LANDMRK, V13, P2400, DOI 10.2741/2853; Koedel U, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000461; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Lindner M, 2009, GLIA, V57, P465, DOI 10.1002/glia.20833; LLOYD AR, 1995, J BIOL CHEM, V270, P28188; LOPEZ AF, 1984, BRIT J HAEMATOL, V57, P489, DOI 10.1111/j.1365-2141.1984.tb02923.x; Luan J, 2001, CYTOKINE, V14, P253, DOI 10.1006/cyto.2001.0882; LUI L, 2010, NAT NEUROSCI, V13, P319; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Matsumoto T, 1997, LAB INVEST, V77, P119; Mihara K, 2005, EUR J IMMUNOL, V35, P2573, DOI 10.1002/eji.200526021; Milatovic S, 2003, WOUND REPAIR REGEN, V11, P213, DOI 10.1046/j.1524-475X.2003.11310.x; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885; Nguyen HX, 2007, J NEUROCHEM, V102, P900, DOI 10.1111/j.1471-4159.2007.04643.x; Omari KM, 2006, GLIA, V53, P24, DOI 10.1002/glia.20246; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Palmer C, 2004, PEDIATR RES, V55, P549, DOI 10.1203/01.PDR.0000113546.03897.FC; Pham CTN, 2006, NAT REV IMMUNOL, V6, P541, DOI 10.1038/nri1841; Reutershan J, 2006, DRUG NEWS PERSPECT, V19, P615, DOI 10.1358/dnp.2006.19.10.1068009; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; Rose JJ, 2004, J BIOL CHEM, V279, P24372, DOI 10.1074/jbc.M401364200; Ryu JK, 2007, GLIA, V55, P439, DOI 10.1002/glia.20479; Schmidt O.I., 2004, EUR J TRAUMA, V30, P135, DOI DOI 10.1007/S00068-004-1394-9; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Scholz M, 2007, MED RES REV, V27, P401, DOI 10.1002/med.20064; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P459, DOI 10.1038/jcbfm.2009.240; Shaftel SS, 2007, J NEUROSCI, V27, P9301, DOI 10.1523/JNEUROSCI.1418-07.2007; Soares HD, 1995, J NEUROSCI, V15, P8223; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Tanimoto N, 2007, BIOCHEM BIOPH RES CO, V361, P533, DOI 10.1016/j.bbrc.2007.07.060; Nguyen TT, 2008, J BIONIC ENG, V5, P1, DOI 10.1016/S1672-6529(08)60001-3; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Valles A, 2006, NEUROBIOL DIS, V22, P312, DOI 10.1016/j.nbd.2005.11.015; Wengner AM, 2008, BLOOD, V111, P42, DOI 10.1182/blood-2007-07-099648; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; YAMASAKI Y, 1995, STROKE, V26, P318, DOI 10.1161/01.STR.26.2.318; Yang W, 1999, J BIOL CHEM, V274, P11328, DOI 10.1074/jbc.274.16.11328; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	69	85	86	0	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	NOV	2010	40	2					394	403		10.1016/j.nbd.2010.06.015			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	652WJ	WOS:000282041300005	20621186				2022-02-06	
J	Pham, N; Fazio, V; Cucullo, L; Teng, QS; Biberthaler, P; Bazarian, JJ; Janigro, D				Pham, Nancy; Fazio, Vincent; Cucullo, Luca; Teng, Qingshan; Biberthaler, Peter; Bazarian, Jeffrey J.; Janigro, Damir			Extracranial Sources of S100B Do Not Affect Serum Levels	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; NEURON-SPECIFIC ENOLASE; MINOR HEAD TRAUMA; ACUTE ISCHEMIC-STROKE; S-100B PROTEIN; BARRIER DISRUPTION; CARDIAC-SURGERY; PERIPHERAL MARKERS; BLOOD; DAMAGE	S100B, established as prevalent protein of the central nervous system, is a peripheral biomarker for blood-brain barrier disruption and often also a marker of brain injury. However, reports of extracranial sources of S100B, especially from adipose tissue, may confound its interpretation in the clinical setting. The objective of this study was to characterize the tissue specificity of S100B and assess how extracranial sources of S100B affect serum levels. The extracranial sources of S100B were determined by analyzing nine different types of human tissues by ELISA and Western blot. In addition, brain and adipose tissue were further analyzed by mass spectrometry. A study of 200 subjects was undertaken to determine the relationship between body mass index (BMI) and S100B serum levels. We also measured the levels of S100B homo- and heterodimers in serum quantitatively after blood-brain barrier disruption. Analysis of human tissues by ELISA and Western blot revealed variable levels of S100B expression. By ELISA, brain tissue expressed the highest S100B levels. Similarly, Western blot measurements revealed that brain tissue expressed high levels of S100B but comparable levels were found in skeletal muscle. Mass spectrometry of brain and adipose tissue confirmed the presence of S100B but also revealed the presence of S100A1. The analysis of 200 subjects revealed no statistically significant relationship between BMI and S100B levels. The main species of S100B released from the brain was the B-B homodimer. Our results show that extracranial sources of S100B do not affect serum levels. Thus, the diagnostic value of S100B and its negative predictive value in neurological diseases in intact subjects (without traumatic brain or bodily injury from accident or surgery) are not compromised in the clinical setting.	[Pham, Nancy; Janigro, Damir] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland Clin Fdn, Cleveland, OH 44106 USA; [Fazio, Vincent; Cucullo, Luca] Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; [Biberthaler, Peter] Univ Munich, Surg Dept Munich Cent, Munich, Germany; [Bazarian, Jeffrey J.] Univ Rochester, Sch Med, Dept Emergency Med, Rochester, NY USA		Pham, N (corresponding author), Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland Clin Fdn, Cleveland, OH 44106 USA.	janigrd@ccf.org	Cucullo, Luca/X-2765-2019	Cucullo, Luca/0000-0002-2827-7162; Janigro, Damir/0000-0003-2165-5826	Roche Diagnostics [RO1 NS43284, RO1 NS38195, R21 HD057256]; Cleveland Clinic- Swedish Satellite Laboratory Feasibility Project, Federal Appropriation Washington State; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD057256] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038195, R01NS043284] Funding Source: NIH RePORTER	This study was supported by RO1 NS43284, RO1 NS38195, R21 HD057256 to Damir Janigro. It was also supported by "A Prospective Pilot Study on S100B in TBI" funded by Roche Diagnostics and by the Cleveland Clinic- Swedish Satellite Laboratory Feasibility Project, Federal Appropriation Washington State. None of the funding agencies had role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdul-Khaliq H, 2000, CLIN CHEM LAB MED, V38, P1173, DOI 10.1515/CCLM.2000.181; Abdul-Khaliq H, 2000, CLIN CHEM LAB MED, V38, P1169, DOI 10.1515/CCLM.2000.180; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; BAUDIER J, 1986, J BIOL CHEM, V261, P8204; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Biberthaler P, 2002, EUR J MED RES, V7, P164; Biberthaler P, 2000, ACT NEUR S, V76, P177; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI 10.1089/neu.2008-0738; Dassan P, 2009, CEREBROVASC DIS, V27, P295, DOI 10.1159/000199468; DONATO R, 2001, INT J BIOCHEM CELL B, V637, P668; Fazio V, 2004, ANN THORAC SURG, V78, P46, DOI 10.1016/j.athoracsur.2003.11.042; Foerch C, 2007, STROKE, V38, P2491, DOI 10.1161/STROKEAHA.106.480111; Geyer C, 2009, J NEUROS-PEDIATR, V4, P339, DOI 10.3171/2009.5.PEDS08481; Goncalves CA, 2008, CLIN BIOCHEM, V41, P755, DOI 10.1016/j.clinbiochem.2008.04.003; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Hasselblatt M, 2004, NEUROLOGY, V62, P1634, DOI 10.1212/01.WNL.0000123092.97047.B1; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Korfias S, 2006, CURR MED CHEM, V13, P3719, DOI 10.2174/092986706779026129; Mann M, 2008, J PROTEOME RES, V7, P3065, DOI 10.1021/pr800463v; Marchi N, 2004, CLIN CHIM ACTA, V342, P1, DOI 10.1016/j.cccn.2003.12.008; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; Marchi N, 2003, J NEUROSCI, V23, P1949; Marchi N, 2007, EPILEPSIA, V48, P732, DOI 10.1111/j.1528-1167.2007.00988.x; Mazzone PJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007242; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Mussack T, 2000, ACT NEUR S, V76, P393; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Pineau JC, 2007, ANN NUTR METAB, V51, P421, DOI 10.1159/000111161; Portela LVC, 2002, CLIN CHEM, V48, P950; Raabe A, 1998, J NEUROL NEUROSUR PS, V65, P930, DOI 10.1136/jnnp.65.6.930; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Rothermundt M, 2004, INT REV NEUROBIOL, V59, P445; Ruan S, 2009, J NEUROTRAUM, V26, P1655, DOI 10.1089/neu.2009-0928; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; Steiner J, 2010, PSYCHONEUROENDOCRINO, V35, P321, DOI 10.1016/j.psyneuen.2009.07.012; Vogelbaum MA, 2005, CANCER-AM CANCER SOC, V104, P817, DOI 10.1002/cncr.21220; Watson P, 2005, AM J PHYSIOL-REG I, V288, pR1689, DOI 10.1152/ajpregu.00676.2004	48	85	89	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 10	2010	5	9							e12691	10.1371/journal.pone.0012691			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	648IX	WOS:000281687300022	20844757	gold, Green Submitted, Green Published			2022-02-06	
J	Le Brocque, RM; Hendrikz, J; Kenardy, JA				Le Brocque, Robyne M.; Hendrikz, Joan; Kenardy, Justin A.			The Course of Posttraumatic Stress in Children: Examination of Recovery Trajectories Following Traumatic Injury	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						children; posttraumatic stress; statistical applications	ROAD TRAFFIC ACCIDENTS; DEVELOPMENTAL TRAJECTORIES; PEDIATRIC INJURY; BRAIN-INJURY; EVENT SCALE; DISORDER; PTSD; SYMPTOMS; WAR; HOSPITALIZATION	Objective Group-based trajectory modeling was used to identify patterns of posttraumatic stress symptom (PTSS) in children 6-16 years following accidental injury. The aims were to: (a) identify probable groups of children following distinct trajectories, and (b) identify risk factors affecting the probability of group membership. Method Children's Impact of Events Scale (n = 190) was used to assess PTSS up to 2 years post injury. Age, gender, type of injury, and preinjury behavior were assessed as risk factors. Results Three distinct trajectory groups were identified: resilient (57%), elevated stress symptoms which recovered quickly (33%), and chronic (10%). Younger children were more likely to be in the recovery group. Those with serious injuries were more likely to be in the chronic group. Preinjury child behavior problems were predictive of recovery and high chronic symptoms. Conclusion Identification of distinct PTSS trajectory groups has implications for understanding the course and treatment of PTSS in children.	[Le Brocque, Robyne M.; Hendrikz, Joan; Kenardy, Justin A.] Univ Queensland, Ctr Natl Res Disabil & Rehabil Med, Mayne Med Sch, Herston, Qld 4006, Australia		Le Brocque, RM (corresponding author), Univ Queensland, Ctr Natl Res Disabil & Rehabil, Sch Med, Herston Rd, Herston, Qld 4006, Australia.	r.lebrocque@uq.edu.au	Le Brocque, Robyne/F-4848-2010; Kenardy, Justin A/H-6603-2014; Kenardy, Justin/F-2085-2010	Le Brocque, Robyne/0000-0002-4574-1254; Kenardy, Justin A/0000-0001-9475-8450; 			Achenbach TM, 1991, MANUAL CHILD BEHAV C; Bonanno GA, 2005, CURR DIR PSYCHOL SCI, V14, P135, DOI 10.1111/j.0963-7214.2005.00347.x; DALLOW N, 2007, QUEENSLAND TRAUMA RE; Daviss WB, 2000, J AM ACAD CHILD PSY, V39, P576, DOI 10.1097/00004583-200005000-00011; de Vries APJ, 1999, PEDIATRICS, V104, P1293, DOI 10.1542/peds.104.6.1293; DiGallo A, 1997, BRIT J PSYCHIAT, V170, P358, DOI 10.1192/bjp.170.4.358; Drotar, 2006, TRAUMATOLOGY, V12, P148, DOI [DOI 10.1177/1534765606294562, 10.77/1534765606294562]; Dyregrov A, 1996, SCAND J PSYCHOL, V37, P339, DOI 10.1111/j.1467-9450.1996.tb00667.x; Gillies ML, 2003, J TRAUMA STRESS, V16, P523, DOI 10.1023/A:1025774915005; Jones BL, 2001, SOCIOL METHOD RES, V29, P374, DOI 10.1177/0049124101029003005; Kassam-Adams N, 2004, J AM ACAD CHILD PSY, V43, P403, DOI 10.1097/00004583-200404000-00006; Kenardy JA, 2006, PEDIATRICS, V118, P1002, DOI 10.1542/peds.2006-0406; King LA, 2006, J TRAUMA STRESS, V19, P771, DOI 10.1002/jts.20188; Landolt MA, 2003, J CHILD PSYCHOL PSYC, V44, P1199, DOI 10.1111/1469-7610.00201; Langeland W, 2008, NEUROSCI BIOBEHAV R, V32, P161, DOI 10.1016/j.neubiorev.2007.07.002; Layne CM, 2009, TREATING TRAUMATIZED, P13; Mather FJ, 2003, BRAIN INJURY, V17, P1077, DOI 10.1080/0269905031000114045; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; Meiser-Stedman R, 2005, AM J PSYCHIAT, V162, P1381, DOI 10.1176/appi.ajp.162.7.1381; Nagin DS, 1999, PSYCHOL METHODS, V4, P139, DOI 10.1037/1082-989X.4.2.139; O'Donnell ML, 2007, BEHAV RES THER, V45, P601, DOI 10.1016/j.brat.2006.03.015; Olsson KA, 2008, J ANXIETY DISORD, V22, P1447, DOI 10.1016/j.janxdis.2008.02.007; Orcutt HK, 2004, J TRAUMA STRESS, V17, P195, DOI 10.1023/B:JOTS.0000029262.42865.c2; Perrin S, 2005, BEHAV COGN PSYCHOTH, V33, P487, DOI 10.1017/S1352465805002419; Pine DS, 2005, NEUROPSYCHOPHARMACOL, V30, P1781, DOI 10.1038/sj.npp.1300814; STALLARD P, 1999, INT HDB ROAD TRAFFIC, P117; Sturms LM, 2005, CLIN REHABIL, V19, P312, DOI 10.1191/0269215505cr867oa; Udwin O, 2000, J CHILD PSYCHOL PSYC, V41, P969, DOI 10.1111/1469-7610.00685; World Health Organization, 2006, CHILD AD INJ PREV WH; Yule W, 2000, J CHILD PSYCHOL PSYC, V41, P503, DOI 10.1017/S0021963099005570; YULE W, 1997, NFER CHILD PORTFOLIO	31	85	85	0	13	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693			J PEDIATR PSYCHOL	J. Pediatr. Psychol.	JUL	2010	35	6					637	645		10.1093/jpepsy/jsp050			9	Psychology, Developmental	Social Science Citation Index (SSCI)	Psychology	616EN	WOS:000279191700007	19541598	Bronze, Green Published			2022-02-06	
S	Greden, JF; Valenstein, M; Spinner, J; Blow, A; Gorman, LA; Dalack, GW; Marcus, S; Kees, M		Barchas, JD; Difede, J		Greden, John F.; Valenstein, Marcia; Spinner, Jane; Blow, Adrian; Gorman, Lisa A.; Dalack, Gregory W.; Marcus, Sheila; Kees, Michelle			Buddy-to-Buddy, a citizen soldier peer support program to counteract stigma, PTSD, depression, and suicide	PSYCHIATRIC AND NEUROLOGIC ASPECTS OF WAR	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	89th Annual Conference of the Association for Research in Nervous and Mental Disease	DEC 16, 2009	Rockefeller Univ, New York, NY		Rockefeller Univ	citizen soldiers; peer-to-peer; PTSD; depression; suicide	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROBLEMS; RISK PERIODS; VA PATIENTS; MILITARY; IRAQ; SERVICE; DISEASE; CARE	Citizen soldiers (National Guard and Reserves) represent approximately 40% of the two million armed forces deployed to Afghanistan and Iraq. Twenty-five to forty percent of them develop PTSD, clinical depression, sleep disturbances, or suicidal thoughts. Upon returning home, many encounter additional stresses and hurdles to obtaining care: specifically, many civilian communities lack military medical/psychiatric facilities; financial, job, home, and relationship stresses have evolved or have been exacerbated during deployment; uncertainty has increased related to future deployment; there is loss of contact with military peers; and there is reluctance to recognize and acknowledge mental health needs that interfere with treatment entry and adherence. Approximately half of those needing help are not receiving it. To address this constellation of issues, a private public partnership was formed under the auspices of the Welcome Back Veterans Initiative. In Michigan, the Army National Guard teamed with the University of Michigan and Michigan State University to develop innovative peer-to-peer programs for soldiers (Buddy-to-Buddy) and augmented programs for military families. Goals are to improve treatment entry, adherence, clinical outcomes, and to reduce suicides. This manuscript describes training approaches, preliminary results, and explores future national dissemination.	[Greden, John F.; Valenstein, Marcia; Spinner, Jane; Dalack, Gregory W.; Marcus, Sheila; Kees, Michelle] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA; [Greden, John F.; Valenstein, Marcia; Spinner, Jane; Dalack, Gregory W.; Marcus, Sheila; Kees, Michelle] Univ Michigan, Comprehens Depress Ctr, Ann Arbor, MI 48109 USA; [Valenstein, Marcia] Univ Michigan, Ann Arbor Vet Adm Hosp, Ann Arbor, MI 48109 USA; [Greden, John F.] Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA; [Blow, Adrian; Gorman, Lisa A.] Michigan State Univ, Lansing, MI USA		Greden, JF (corresponding author), Univ Michigan Hlth Syst, 4250 Plymouth Rd, Ann Arbor, MI 48109 USA.	gredenj@umich.edu	Blow, Adrian/U-1647-2019				*ASPPS, 2009, SHOULD SHOULD NO SOL; BASU S, 2009, US MED           MAR; DALACK GW, 2010, PSYCHIAT SE IN PRESS; *DEP VET AFF, 2009, ACE SUIC PREV VET TH; EMMANUEL LO, 2009, VA HIRES VETS GO FIN; Greden JF, 2001, J CLIN PSYCHIAT, V62, pS26; Hettema J, 2005, ANNU REV CLIN PSYCHO, V1, P91, DOI 10.1146/annurev.clinpsy.1.102803.143833; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hunkeler EM, 2000, ARCH FAM MED, V9, P700, DOI 10.1001/archfami.9.8.700; Jacobson IG, 2008, JAMA-J AM MED ASSOC, V300, P663, DOI 10.1001/jama.300.6.663; Joiner T.E., 2005, WHY PEOPLE DIE SUICI; Keane TM, 2006, ANNU REV CLIN PSYCHO, V2, P161, DOI 10.1146/annurev.clinpsy.2.022305.095305; Kilpatrick DG, 2007, AM J PSYCHIAT, V164, P1693, DOI 10.1176/appi.ajp.2007.06122007; Kuehn BM, 2009, JAMA-J AM MED ASSOC, V301, P1111, DOI 10.1001/jama.2009.342; Ludman EJ, 2007, PSYCHIAT SERV, V58, P1065, DOI 10.1176/appi.ps.58.8.1065; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; O'Bryant J., 2008, NATL GUARD PERSONNEL; Oquendo MA, 2006, ACTA PSYCHIAT SCAND, V114, P151, DOI 10.1111/j.1600-0447.2006.00829.x; Riddle JR, 2007, J CLIN EPIDEMIOL, V60, P192, DOI 10.1016/j.jclinepi.2006.04.008; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; SHINSHEKI E, 2010, DEP DEF VA SUIC PREV; TANIELIAN T, 2008, INVISIBLE WOUNDS WAR, V3, pR3; *US MAR CORPS, 2010, NEV LEAV MAR BEH; Valenstein M, 2009, PSYCHIAT SERV, V60, P439, DOI 10.1176/appi.ps.60.4.439; Valenstein M, 2009, J AFFECT DISORDERS, V112, P50, DOI 10.1016/j.jad.2008.08.020	26	85	85	1	29	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA	0077-8923		978-1-57331-804-4	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2010	1208						90	97		10.1111/j.1749-6632.2010.05719.x			8	Neurosciences; Psychiatry	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	BSK28	WOS:000284742000012	20955330	Green Submitted			2022-02-06	
J	Maerlender, A; Flashman, L; Kessler, A; Kumbhani, S; Greenwald, R; Tosteson, T; McAllister, T				Maerlender, A.; Flashman, L.; Kessler, A.; Kumbhani, S.; Greenwald, R.; Tosteson, T.; McAllister, T.			Examination of the Construct Validity of Impact Computerized Test, Traditional, and Experimental Neuropsychological Measures	CLINICAL NEUROPSYCHOLOGIST			English	Article						ImPACT; Mild TBI; Construct validity; Sports concussion; Computerized neuropsychological testing	TRAUMATIC BRAIN-INJURY; MEMORY; MILD; DYSFUNCTION; VALIDATION; SPORT	Although computerized neuropsychological screening is becoming a standard for sports concussion identification and management, convergent validity studies are limited. Such studies are important for several reasons: reference to established measures is needed to establish validity; examination of the computerized battery relative to a more traditional comprehensive battery will help understand the strengths and limitations of the computer battery; and such an examination will help inform the output of the computerized battery. We compared scores on the ImPACT battery to a comprehensive battery of traditional neuropsychological measures and several experimental measures used in the assessment of sports-related concussion in 54 healthy male athletes. Convergent validity was demonstrated for four of the five ImPACT domain scores. Two cognitive domains often compromised as a result of mild TBI were not directly identified by the ImPACT battery: sustained attention and auditory working memory. Affective symptoms correlated with performance on measures of attention and working memory. In this healthy sample the correlations between the domains covered by ImPACT and the neuropsychological battery supports ImPACT as a useful screening tool for assessing many of the cognitive factors related to mTBI. However, the data suggest other sources of data need to be considered when identifying and managing concussions.	[Maerlender, A.] Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Dept Psychiat, Lebanon, NH 03756 USA		Maerlender, A (corresponding author), Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Dept Psychiat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	maerlender@dartmouth.edu			National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [BRP R01HD048638, RO1NS055020]; National Center for Medical Rehabilitation Research; National Institute of Child Health and DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055020] Funding Source: NIH RePORTER	This work was supported by National Institute of Health BRP R01HD048638 National Center for Medical Rehabilitation Research, National Institute of Child Health and Development, and National Institute of Health RO1NS055020 National Institute of Health/National Institute of Neurological Disease and Stroke.	Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Benedict R., 1997, BRIEF VISUOSPATIAL M; Bishop SJ, 2009, NAT NEUROSCI, V12, P92, DOI 10.1038/nn.2242; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; Delis D.C., 2000, CALIFORNIA VERBAL LE; DELIS DC, 2001, DELISKALPAN EXECUTIV; Derakshan N, 1998, COGNITION EMOTION, V12, P697; Green P, 1995, MANUAL ORAL WORD MEM; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; IVERSON GL, 2003, CONSTRUCT VALIDITY I; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Mitrushina M., 2005, HDB NORMATIVE DATA N, V2nd; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2006, APPL NEUROPSYCHOL, V13, P151, DOI 10.1207/s15324826an1303_2; Smith A., 1991, SYMBOL DIGIT MODALIT; Spielberger CD, 1989, MANUAL STATE TRAIT A, V2nd; Swick D, 1999, NEUROPSYCHOLOGY, V13, P155, DOI 10.1037/0894-4105.13.2.155; Urbina S, 1997, PSYCHOL TESTING	27	85	85	0	40	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2010	24	8					1309	1325	PII 927588900	10.1080/13854046.2010.516072			17	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	685LA	WOS:000284629000005	20924979	Green Published, Green Submitted, Green Accepted			2022-02-06	
J	Truelle, JL; Koskinen, S; Hawthorne, G; Sarajuuri, J; Formisano, R; Von Wild, K; Neugebauer, E; Wilson, L; Gibbons, H; Powell, J; Bullinger, M; Hofer, S; Maas, A; Zitnay, G; Von Steinbuechel, N				Truelle, Jean-Luc; Koskinen, Sanna; Hawthorne, Graeme; Sarajuuri, Jaana; Formisano, Rita; Von Wild, Klaus; Neugebauer, Edmund; Wilson, Lindsay; Gibbons, Henning; Powell, Jane; Bullinger, Monika; Hoefer, Stefan; Maas, Andrew; Zitnay, George; Von Steinbuechel, Nicole		Qolibri Task Force	Quality of life after traumatic brain injury: The clinical use of the QOLIBRI, a novel disease-specific instrument	BRAIN INJURY			English	Article						Traumatic brain injury; health-related quality of life; assessment; international; multi-centre study; QOLIBRI	PSYCHIATRIC-DISORDERS; SUBJECTIVE EXPERIENCE; POPULATION NORMS; HOSPITAL ANXIETY; CLOSE RELATIVES; SOCIAL SUPPORT; HEALTH; SATISFACTION; REHABILITATION; QUESTIONNAIRE	Objective: To report the clinical use of the QOLIBRI, a disease-specific measure of health-related quality-of-life (HRQoL) after traumatic brain injury (TBI). Methods: The QOLIBRI, with 37 items in six scales (cognition, self, daily life and autonomy, social relationships, emotions and physical problems) was completed by 795 patients in six languages (Finnish, German, Italian, French, English and Dutch). QOLIBRI scores were examined by variables likely to be influenced by rehabilitation interventions and included socio-demographic, functional outcome, health status and mental health variables. Results: The QOLIBRI was self-completed by 73% of participants and 27% completed it in interview. It was sensitive to areas of life amenable to intervention, such as accommodation, work participation, health status (including mental health) and functional outcome. Conclusion: The QOLIBRI provides information about patient's subjective perception of his/her HRQoL which supplements clinical measures and measures of functional outcome. It can be applied across different populations and cultures. It allows the identification of personal needs, the prioritization of therapeutic goals and the evaluation of individual progress. It may also be useful in clinical trials and in longitudinal studies of TBI recovery.	[Truelle, Jean-Luc; Koskinen, Sanna; Hawthorne, Graeme; Sarajuuri, Jaana; Formisano, Rita; Von Wild, Klaus; Neugebauer, Edmund; Wilson, Lindsay; Gibbons, Henning; Powell, Jane; Bullinger, Monika; Hoefer, Stefan; Maas, Andrew; Zitnay, George; Von Steinbuechel, Nicole; Qolibri Task Force] Univ Hosp, Dept Phys Med & Rehabil, QOLIBRI Task Force TBI Qual Life, F-92380 Garches, France		Truelle, JL (corresponding author), Univ Hosp, Dept Phys Med & Rehabil, QOLIBRI Task Force TBI Qual Life, F-92380 Garches, France.	jean-luc.truelle@wanadoo.fr	Castro-Caldas, Alexandre/M-4156-2013; Wilson, Lindsay/A-3659-2009; Maas, Andrew IR/C-5584-2013; Hofer, Stefan/N-8253-2019; Hofer, Stefan/B-8393-2008; Mancuso, Mauro/J-6773-2018; Sarajuuri, Jaana/AAD-8665-2019; Wilson, Lindsay/O-8883-2019	Castro-Caldas, Alexandre/0000-0002-9148-3719; Wilson, Lindsay/0000-0003-4113-2328; Maas, Andrew IR/0000-0003-1612-1264; Hofer, Stefan/0000-0002-6128-3687; Hofer, Stefan/0000-0002-6128-3687; Mancuso, Mauro/0000-0002-8451-9277; Sarajuuri, Jaana/0000-0002-6432-0295; Wilson, Lindsay/0000-0003-4113-2328; Koskinen, Sanna/0000-0002-3453-5084	EMN (Euroacademia Multidisciplinaria Neurotraumatologica); EBIS (European Brain Injury Society); International Brain Research Foundation Inc; Les Gueules Cassees, France; MAAF Insurance Foundation, France; France Traumatisme Cranien, France; Hannelore Kohl Foundation, Germany; Cerebprotect e.V. Munster, Germany; Homerton Hospital, UK; Victorian Neurotrauma Initiative, Australia	We thank organizations who initiated, encouraged and supported our work in developing the QOLIBRI: the EMN (Euroacademia Multidisciplinaria Neurotraumatologica), the EBIS (European Brain Injury Society), the International Brain Research Foundation Inc, and in France Les Gueules Cassees, the MAAF Insurance Foundation, France Traumatisme Cranien, in Germany the Hannelore Kohl Foundation and Cerebprotect e.V. Munster, in the UK the Homerton Hospital and in Australia the Victorian Neurotrauma Initiative.	ABS, 1997, NAT HLTH SURV SF 36; Albrecht GL, 1999, SOC SCI MED, V48, P977, DOI 10.1016/S0277-9536(98)00411-0; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; AZOUVI P, 2005, ACTA NEUROPSYCHOLOGI, V3, P25; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Bivona U, 2008, J INT NEUROPSYCH SOC, V14, P862, DOI 10.1017/S1355617708081125; Branca B, 2004, J HEAD TRAUMA REHAB, V19, P40, DOI 10.1097/00001199-200401000-00005; Brown SA, 2004, APPL NEUROPSYCHOL, V11, P54, DOI 10.1207/s15324826an1101_7; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P93; Bush JW., 1982, HEALTH PSYCHOL, V1, P61, DOI [10.1037/0278-6133.1.1.61, DOI 10.1037/0278-6133.1.1.61]; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; CIURLI P, J INT NEURO IN PRESS; Coetzer R, 2005, INT J REHABIL RES, V28, P361, DOI 10.1097/00004356-200512000-00010; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; English TC, 1904, LANCET, V1, P485; Eriksson G, 2009, J REHABIL MED, V41, P187, DOI 10.2340/16501977-0307; Evans JJ, 2003, J INT NEUROPSYCH SOC, V9, P925, DOI 10.1017/S1355617703960127; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; Hawley CA, 2008, BRAIN INJURY, V22, P427, DOI 10.1080/02699050802064607; Hawthorne G, 2005, AUST NZ J PUBL HEAL, V29, P136, DOI 10.1111/j.1467-842X.2005.tb00063.x; Hawthorne G, 2006, SOC INDIC RES, V77, P37, DOI 10.1007/s11205-005-5552-1; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hillier SL, 1997, BRAIN INJURY, V11, P661; Hoffmann B, 2002, ACT NEUR S, V79, P33; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JENNETT B, 1975, LANCET, V1, P480; Johnstone B, 2009, BRAIN INJURY, V23, P411, DOI 10.1080/02699050902788501; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Klose M, 2007, J CLIN ENDOCR METAB, V92, P3861, DOI 10.1210/jc.2007-0901; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kozlowski O., 2002, Annales de Readaptation et de Medecine Physique, V45, P466, DOI 10.1016/S0168-6054(02)00297-0; Lowe SR, 2009, J TRAUMA STRESS, V22, P244, DOI 10.1002/jts.20403; Luo N, 2005, MED CARE, V43, P1078, DOI 10.1097/01.mlr.0000182493.57090.c1; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Malec J. F., 1994, J HEAD TRAUMA REHAB, V9, P1, DOI [10. 1097/ 00001199- 199412000- 00003, DOI 10.1097/00001199-199412000-00003]; Martin C, 2001, BRAIN INJURY, V15, P947, DOI 10.1080/02699050110065655; Mathiesen Birgit Bork, 2004, Cogn Neuropsychiatry, V9, P249, DOI 10.1080/13546800344000237; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; Nestvold K, 2009, BRAIN INJURY, V23, P15, DOI 10.1080/02699050802530540; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P161; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Oppermann JD, 2004, BRAIN INJURY, V18, P941, DOI 10.1080/02699050410001671919; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; PATRICK DL, 1984, QUALITY LIFE CARDIOV, V1, P53; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Sansoni J., 2007, FINAL REPORT DEMENTI; Schonberger M, 2006, NEUROPSYCHOL REHABIL, V16, P561, DOI 10.1080/09602010500263084; SCHONLE PW, 1995, NEUROL REHABIL, V2, P87; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Snaith R., 1994, HOSP ANXIETY DEPRESS; Sopena S, 2007, BRAIN INJURY, V21, P1063, DOI 10.1080/02699050701630342; *SPSS INC, 2006, STAT PACK SOC SCI V1; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Svendsen HA, 2004, NEUROPSYCHOL REHABIL, V14, P495, DOI 10.1080/09602010343000318; Svendsen HA, 2006, BRAIN INJURY, V20, P1295, DOI 10.1080/02699050601082123; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1978, ANESTHESIOLOGY, V49, P225, DOI 10.1097/00000542-197809000-00023; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Tedeschi RG, 2004, PSYCHOL INQ, V15, P1, DOI 10.1207/s15327965pli1501_01; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; Truelle JL, 2008, ACTA NEUROCHIR SUPPL, V101, P125; Truelle J-L, 2010, Asian J Neurosurg, V5, P24; TRUELLE JL, 2008, 5 C WORLD FED NEUR 2, P528; TRUELLE JL, 2005, ACTA NEUROPSYCHOLOGI, V3, P6; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; Vickery CD, 2005, BRAIN INJURY, V19, P657, DOI 10.1080/02699050400005218; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; VONSTEINBUECHEL N, 2010, J NEUROTRAU IN PRESS; VONSTEINBUECHEL N, NEUROTRAUMA IN PRESS; WAGNER AK, 1995, QUAL LIFE RES, V4, P169, DOI 10.1007/BF01833610; WARE JE, 1993, SF 36 HLTH SURV MAN; Wasserman L, 2008, BRAIN INJURY, V22, P811, DOI 10.1080/02699050802372166; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; *WHOQOL GROUP, 1993, QUAL LIFE RES, V2, P153, DOI DOI 10.1007/BF00435734; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; WINTER V, 2005, ACTA NEUROPSYCHOL, V3, P36; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; World Health Organization, 2007, INT CLASS FUNCT DIS; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zitnay GA, 2008, J NEUROTRAUM, V25, P1135, DOI 10.1089/neu.2008.0599; [No title captured]; [No title captured]	108	85	85	1	24	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	11					1272	1291		10.3109/02699052.2010.506865			20	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	667MY	WOS:000283198800002	20722501				2022-02-06	
J	Wolfe, PL; Millis, SR; Hanks, R; Fichtenberg, N; Larrabee, GJ; Sweet, JJ				Wolfe, Penny L.; Millis, Scott R.; Hanks, Robin; Fichtenberg, Norman; Larrabee, Glenn J.; Sweet, Jerry J.			Effort Indicators within the California Verbal Learning Test-II (CVLT-II)	CLINICAL NEUROPSYCHOLOGIST			English	Article						Effort indicators; CVLT-II; Malingering	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; ADULT INTELLIGENCE SCALE; RECOGNITION MEMORY TEST; MODEL SELECTION; PERFORMANCE PATTERNS; INCOMPLETE EFFORT; RESPONSE BIAS; IDENTIFICATION	This study determined whether performance patterns on the California Verbal Learning Test-II (CVLT-II) could differentiate participants with traumatic brain injury (TBI) showing adequate effort from those with mild TBI exhibiting poor effort using a case-control design. The TBI group consisted of 124 persons with moderate to severe traumatic brain injury (TBI). The poor effort group consisted of 77 persons with mild head injury who were involved in litigation (LG) and failed at least one stand-alone symptom validity measure (SVT) and also either a second SVT or an effort indicator embedded within a standard clinical test. A total of 18 CVLT-II variables were investigated using Bayesian model averaging (BMA) for logistic regression to determine which variables best differentiated the groups. The CVLT-II variables having the most support were Long-Delay Free Recall, Total Recognition Discriminability (d'), and Total Recall Discriminability.	[Wolfe, Penny L.; Millis, Scott R.; Hanks, Robin; Fichtenberg, Norman] Rehabil Inst Michigan, Detroit, MI USA; [Wolfe, Penny L.; Millis, Scott R.; Hanks, Robin; Fichtenberg, Norman] Wayne State Univ, Sch Med, Detroit, MI USA; [Sweet, Jerry J.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA		Wolfe, PL (corresponding author), Natl Rehabil Hosp, Dept Psychol, 102 Irving St NW, Washington, DC 20010 USA.	penny.wolfe@medstar.net					Ashendorf L, 2003, CLIN NEUROPSYCHOL, V17, P255, DOI 10.1076/clin.17.2.255.16502; Bauer L, 2005, APPL NEUROPSYCHOL, V12, P202, DOI 10.1207/s15324826an1204_3; BINDER LM, 1993, ARCH CLIN NEUROPSYCH, V8, P137, DOI 10.1016/0887-6177(93)90031-U; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; CONDOR R, 1992, COMPUTERIZED ASSESSM; Corwin J, 1994, NEUROPSYCHOLOGY, V8, P110, DOI 10.1037/0894-4105.8.1.110; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC, 1987, CALIFORNIA VERBAL LE; Forrest TJ, 2004, CLIN NEUROPSYCHOL, V18, P334, DOI 10.1080/13854040490501673; Green P., 2003, GREENS WORD MEMORY T; Green P., 1996, WORD MEMORY TEST MAN; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Harrell FE Jr, 2017, REGRESSION MODELING; Hoeting JA, 1999, STAT SCI, V14, P382, DOI 10.1214/ss/1009212519; Iverson GL, 2003, ARCH CLIN NEUROPSYCH, V18, P1, DOI 10.1016/S0887-6177(01)00176-7; KASS RE, 1995, J AM STAT ASSOC, V90, P773, DOI 10.1080/01621459.1995.10476572; Killgore WDS, 2000, J CLIN EXP NEUROPSYC, V22, P761; King JH, 2002, CLIN NEUROPSYCHOL, V16, P506, DOI 10.1076/clin.16.4.506.13912; Langeluddecke PM, 2003, ARCH CLIN NEUROPSYCH, V18, P181, DOI 10.1016/S0887-6177(01)00195-0; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P167, DOI 10.1080/13854040801968443; Lemeshow S, 2000, APPL LOGISTIC REGRES; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; MADIGAN D, 1994, J AM STAT ASSOC, V89, P1535, DOI 10.2307/2291017; Meyers JE, 1998, APPL NEUROPSYCHOL, V5, P120, DOI 10.1207/s15324826an0503_2; Millis S. R., 2004, PRINCIPLES PRACTICE, P1077; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; MILLIS SR, 1994, PERCEPT MOTOR SKILL, V79, P384, DOI 10.2466/pms.1994.79.1.384; Millis SR., 2001, J FORENSIC NEUROPSYC, V2, P1, DOI [10.1300/J151v02n01_01, DOI 10.1300/J151V02N01_]; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; R-Development Core Team, 2007, SER R LANG ENV STAT; Raftery AE, 1995, SOCIOL METHODOL, V25, P111, DOI 10.2307/271063; REITAN RM, 2002, J FORENSIC NEUROPSYC, V3, P275; Rey A., 1964, EXAMEN CLIN PSYCHOL; Reynolds CR, 1998, CRIT ISS NE, P261; Slick D.J., 1997, VICTORIA SYMPTOM VAL; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Sullivan K, 2002, ARCH CLIN NEUROPSYCH, V17, P223, DOI 10.1016/S0887-6177(01)00110-X; Sweet J. J., 2002, J FORENSIC NEUROPSYC, V3, P241; Sweet JJ, 1999, STUD NEUROPSYCHOL DE, P255; Sweet JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P105, DOI 10.1016/S0887-6177(98)00153-X; Tombaugh T.N., 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Viallefont V, 2001, STAT MED, V20, P3215, DOI 10.1002/sim.976; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Wang DL, 2004, STAT MED, V23, P3451, DOI 10.1002/sim.1930; Wasserman L, 2000, J MATH PSYCHOL, V44, P92, DOI 10.1006/jmps.1999.1278	57	85	86	1	18	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2010	24	1					153	168	PII 914741366	10.1080/13854040903107791			16	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	535MK	WOS:000272972300012	19750408				2022-02-06	
J	Hollis, SJ; Stevenson, MR; McIntosh, AS; Shores, EA; Collins, MW; Taylor, CB				Hollis, Stephanie J.; Stevenson, Mark R.; McIntosh, Andrew S.; Shores, E. Arthur; Collins, Michael W.; Taylor, Colman B.			Incidence, Risk, and Protective Factors of Mild Traumatic Brain Injury in a Cohort of Australian Nonprofessional Male Rugby Players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						brain concussion; incidence; risk factors; football; head injuries; athletic injuries	UNION FOOTBALL; PERFORMANCE PROJECT; NEUROCOGNITIVE PERFORMANCE; PROFESSIONAL FOOTBALL; CONCUSSION HISTORY; HEAD-INJURY; EPIDEMIOLOGY; MOUTHGUARDS; IMPACT	Background: Mild traumatic brain injury (mTBI) is an emerging public health issue in high-contact sports. Understanding the incidence along with the risk and protective factors of mTBI in high-contact sports such as rugby is paramount if appropriate preventive strategies are to be developed. Purpose: To estimate the incidence and identify the risk and protective factors of mTBI in Australian nonprofessional rugby players. Study Design: Cohort study; Level of evidence, 2. Methods: A cohort of 3207 male nonprofessional rugby players from Sydney, Australia, was recruited and followed over 1 or more playing seasons. Demographic information, history of recent concussion, and information on risk and protective factors were collected. The incidence of mTBI was estimated and the putative risk and protective factors were modeled in relation to mTBI. Results: The incidence of mTBI was 7.97 per 1000 player game hours, with 313 players (9.8%) sustaining 1 or more mTBIs during the study. Players who reported always wearing protective headgear during games were at a reduced risk (incident rate ratio [IRR], 0.57; 95% confidence interval [CI], 0.40-0.82) of sustaining an mTBI. In contrast, the likelihood of mTBI was almost 2 times higher among players who reported having sustained either 1 (IRR, 1.75; 95% CI, 1.11-2.76) or more mTBIs (IRR, 1.65; 95% CI, 1.11-2.45) within the 12 months before recruitment. Conclusion: Nonprofessional rugby has a high incidence of mTBI, with the absence of headgear and a recent history of mTBI associated with an increased risk of subsequent mTBI. These findings highlight that both use of headgear and the management of prior concussion would likely be beneficial in reducing the likelihood of mTBI among nonprofessional rugby players, who compose more than 99% of rugby union players in Australia.	[Hollis, Stephanie J.; Stevenson, Mark R.; Taylor, Colman B.] Univ Sydney, George Inst Int Hlth, Sydney, NSW 2050, Australia; [McIntosh, Andrew S.] Univ New S Wales, Sch Risk & Safety Sci, Sydney, NSW, Australia; [Shores, E. Arthur] Macquarie Univ, Dept Psychol, Sydney, NSW 2109, Australia; [Collins, Michael W.] Univ Pittsburgh, UPMC Ctr Sports Med, Pittsburgh, PA USA		Hollis, SJ (corresponding author), Univ Sydney, George Inst, POB M201,Missenden Rd, Sydney, NSW 2050, Australia.	shollis@george.org.au	Hollis, Stephanie J/B-5977-2011; stevenson, mark/AAE-9706-2019	stevenson, mark/0000-0003-3166-5876; Shores, Edwin A/0000-0003-1553-5131	U. S. Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [5R49CE323155]; Australian Government's National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE323155] Funding Source: NIH RePORTER	One or more authors has declared a potential conflict of interest: This study was supported by the U. S. Centers for Disease Control and Prevention grant 5R49CE323155 to the University of Pittsburgh Center for Injury Research and Control. Mark Stevenson is supported by funding from the Australian Government's National Health and Medical Research Council. Stephanie Hollis is supported by postgraduate scholarship funding from the Australian Government's National Health and Medical Research Council.	*AUSTR I HLTH WELF, 2003, AUSTR WELF, P65; BECKER DP, 1987, PHYSL BASIS MODERN S, P763; Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Blignaut J B, 1987, Br J Sports Med, V21, P5; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Brooks JHM, 2008, CLIN SPORT MED, V27, P51, DOI 10.1016/j.csm.2007.09.001; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chapman P., 1985, AUST J SCI MED SPORT, P23; CLARK DR, 1990, S AFR MED J, V77, P559; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Finch CF, 2001, BRIT J SPORT MED, V35, P89, DOI 10.1136/bjsm.35.2.89; Fuller CW, 2005, BRIT J SPORT MED, V39, pI3, DOI 10.1136/bjsm.2005.018937; GARRAWAY M, 1995, LANCET, V345, P1485; Garraway WM, 1999, BRIT J SPORT MED, V33, P37, DOI 10.1136/bjsm.33.1.37; Garraway WM, 2000, BRIT J SPORT MED, V34, P348, DOI 10.1136/bjsm.34.5.348; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; HICKEY JC, 1967, J AM DENT ASSOC, V74, P735, DOI 10.14219/jada.archive.1967.0145; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Kerr HA, 2008, BRIT J SPORT MED, V42, P595, DOI 10.1136/bjsm.2007.035881; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Makdissi M, 2009, AM J SPORT MED, V37, P877, DOI 10.1177/0363546508328118; Marshall SW, 2005, INT J EPIDEMIOL, V34, P113, DOI 10.1093/ije/dyh346; McCrory P, 2001, BRIT J SPORT MED, V35, P81, DOI 10.1136/bjsm.35.2.81; McIntosh AS, 2009, MED SCI SPORT EXER, V41, P306, DOI 10.1249/MSS.0b013e3181864bee; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2005, BRIT J SPORT MED, V39, P314, DOI 10.1136/bjsm.2005.018200; McIntosh AS, 2003, J SCI MED SPORT, V6, P355, DOI 10.1016/S1440-2440(03)80030-0; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; MCINTOSH AS, 2008, BR J SPORTS MED 0402; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Quarrie KL, 2001, BRIT J SPORT MED, V35, P157, DOI 10.1136/bjsm.35.3.157; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; STENGER JM, 1964, J AM DENT ASSOC, V69, P273, DOI 10.14219/jada.archive.1964.0290; WALLER AE, 1994, BRIT J SPORT MED, V28, P223, DOI 10.1136/bjsm.28.4.223; Woodward M, 1999, EPIDEMIOLOGY STUDY D; Zuckerman Marvin, 1983, BIOL BASES SENSATION, P37	44	85	88	0	30	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	DEC	2009	37	12					2328	2333		10.1177/0363546509341032			6	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	524YO	WOS:000272180500005	19789332				2022-02-06	
J	Pytel, P; Alexander, JJ				Pytel, Peter; Alexander, Jessy J.			Pathogenesis of septic encephalopathy	CURRENT OPINION IN NEUROLOGY			English	Article						brain; inflammation; sepsis	BLOOD-BRAIN-BARRIER; MAGNESIUM-SULFATE; NITRIC-OXIDE; COGNITIVE IMPAIRMENT; CRITICAL ILLNESS; TRAUMATIC BRAIN; SEPSIS SYNDROME; RAT MODEL; SHOCK; INJURY	Purpose of review Septic encephalopathy is a frequent complication in severe sepsis, the pathogenesis and mechanisms of which are not fully understood. Here, we review recent advances in our understanding of septic encephalopathy, from molecular mechanisms to behavioral alterations, from diagnostic tools to potential therapeutic agents. Recent findings Recent insights into septic encephalopathy include: microcirculatory failure precedes changes in evoked potential responses; blood-brain barrier alteration is prevented by reducing intercellular adhesion molecule expression and pericyte detachment; reducing infiltration of CD68 macrophages and inhibiting complement activation alleviates neuroinflammation in septic encephalopathy; and reducing mitochondrial dysfunction and inducible nitric oxide synthase expression can restore altered brain function. In addition, other factors such as the circulating levels of growth hormone are independent predictors for mortality and correlate with the severity of sepsis. Similar to humans, septic rats present recognition memory impairment and depressive-like symptoms but not anxiety-like behavior and will serve as efficient models to study the underlying mechanisms of septic encephalopathy. Summary Septic encephalopathy is a dynamic disease caused by a complex network of systems and pathways going awry. More insights into the pathogenesis of septic encephalopathy are expected to lead to new cellular and molecular targets, which in turn will permit design of specific septic encephalopathy-alleviating drugs and prevent its negative influence on survival.	[Alexander, Jessy J.] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Pytel, Peter] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA		Alexander, JJ (corresponding author), Univ Chicago, Dept Med, Chicago, IL 60637 USA.	jalexand@medicine.bsd.uchicago.edu	Alexander, Jessy/ABA-7664-2020				Alexander JJ, 2008, NEUROCHEM INT, V52, P447, DOI 10.1016/j.neuint.2007.08.006; Audoy-Remus J, 2008, J NEUROSCI, V28, P10187, DOI 10.1523/JNEUROSCI.3510-08.2008; Barichello T, 2007, CRIT CARE MED, V35, P2186, DOI 10.1097/01.CCM.0000281452.60683.96; Bartynski WS, 2006, AM J NEURORADIOL, V27, P2179; Baumgart K, 2009, INTENS CARE MED, V35, P344, DOI 10.1007/s00134-008-1319-x; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; Dubin A, 2007, INTENS CARE MED, V33, P485, DOI 10.1007/s00134-006-0519-5; Ebersoldt M, 2007, INTENS CARE MED, V33, P941, DOI 10.1007/s00134-007-0622-2; Eidelman LA, 1996, JAMA-J AM MED ASSOC, V275, P470, DOI 10.1001/jama.275.6.470; Esen F, 2005, CRIT CARE, V9, pR18, DOI 10.1186/cc3004; Euser AG, 2008, EXP PHYSIOL, V93, P254, DOI 10.1113/expphysiol.2007.039966; Fioretto JR, 2008, CYTOKINE, V43, P160, DOI 10.1016/j.cyto.2008.05.005; Fischer MB, 1997, J IMMUNOL, V159, P976; Flierl MA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002560; Flierl MA, 2008, FASEB J, V22, P3483, DOI 10.1096/fj.08-110595; Ghabriel MN, 2006, ACTA NEUROCHIR SUPPL, V96, P402; Gunther ML, 2007, MED HYPOTHESES, V69, P1179, DOI 10.1016/j.mehy.2007.03.039; Handa O, 2008, AM J PHYSIOL-HEART C, V295, pH1712, DOI 10.1152/ajpheart.00476.2008; Henry CJ, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-15; Hofer S, 2008, J SURG RES, V146, P276, DOI 10.1016/j.jss.2007.07.021; Hopkins RO, 2006, CURR OPIN CRIT CARE, V12, P388, DOI 10.1097/01.ccx.0000244115.24000.f5; Hopkins RO, 2006, CHEST, V130, P869, DOI 10.1378/chest.130.3.869; Hopkins RO, 2006, BRAIN INJURY, V20, P263, DOI 10.1080/02699050500488199; Hsu AA, 2008, PEDIATR CRIT CARE ME, V9, P245, DOI 10.1097/PCC.0b013e3181727b22; Huang YH, 2002, PROTEOMICS, V2, P1220, DOI 10.1002/1615-9861(200209)2:9<1220::AID-PROT1220>3.0.CO;2-3; Huber-Lang M, 2001, J IMMUNOL, V166, P1193, DOI 10.4049/jimmunol.166.2.1193; Jacob A, 2007, LAB INVEST, V87, P1186, DOI 10.1038/labinvest.3700686; Kadoi Y, 2004, ANESTH ANALG, V99, P212, DOI 10.1213/01.ANE.0000118111.94913.22; Kafa IM, 2007, NEUROPATHOLOGY, V27, P213, DOI 10.1111/j.1440-1789.2007.00757.x; Kunze K, 2002, J NEUROL, V249, P1150, DOI 10.1007/s00415-002-0869-z; Levy RJ, 2007, CRIT CARE MED, V35, pS468, DOI 10.1097/01.CCM.0000278604.93569.27; Lopez A, 2004, CRIT CARE MED, V32, P21, DOI 10.1097/01.CCM.0000105581.01815.C6; Maeda Shigeru, 2008, Neuropsychiatr Dis Treat, V4, P663; NAKAE H, 1994, RES COMMUN CHEM PATH, V84, P189; Nguyen DN, 2006, CRIT CARE MED, V34, P1967, DOI 10.1097/01.CCM.0000217218.51381.49; NISHIOKU T, 2008, CELL MOL NEUROBIOL; Pan W, 2008, J NEUROCHEM, V106, P313, DOI 10.1111/j.1471-4159.2008.05390.x; Pan WH, 2008, AM J PHYSIOL-CELL PH, V294, pC1436, DOI 10.1152/ajpcell.00489.2007; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Piazza O, 2007, BRIT J ANAESTH, V99, P518, DOI 10.1093/bja/aem201; Prodeus AP, 1997, NATURE, V390, P172, DOI 10.1038/36586; Riedemann NC, 2003, FASEB J, V17, P370, DOI 10.1096/fj.03-0708fje; Riedemann NC, 2003, J CLIN INVEST, V112, P460, DOI 10.1172/JCI200319523; Rittirsch D, 2008, NAT REV IMMUNOL, V8, P776, DOI 10.1038/nri2402; Rittirsch D, 2008, NAT MED, V14, P551, DOI 10.1038/nm1753; Rosengarten B, 2008, INFLAMM RES, V57, P479, DOI 10.1007/s00011-008-8042-5; Rosengarten B, 2007, CEREBROVASC DIS, V23, P140, DOI 10.1159/000097051; Semmler A, 2007, EXP NEUROL, V204, P733, DOI 10.1016/j.expneurol.2007.01.003; Sharshar T, 2004, BRAIN PATHOL, V14, P21, DOI 10.1111/j.1750-3639.2004.tb00494.x; Sharshar T, 2007, INTENS CARE MED, V33, P798, DOI 10.1007/s00134-007-0598-y; Siami S, 2008, CRIT CARE CLIN, V24, P67, DOI 10.1016/j.ccc.2007.10.001; SPRUNG CL, 1990, CRIT CARE MED, V18, P801, DOI 10.1097/00003246-199008000-00001; Streck EL, 2008, NEUROCHEM RES, V33, P2171, DOI 10.1007/s11064-008-9671-3; Toklu HZ, 2009, J SURG RES, V152, P238, DOI 10.1016/j.jss.2008.03.013; Turkoglu OF, 2008, J CLIN NEUROSCI, V15, P60, DOI 10.1016/j.jocn.2007.03.005; Umgelter A, 2008, BLOOD PURIFICAT, V26, P333, DOI 10.1159/000132464; Vissers JLM, 2006, CLIN CHIM ACTA, V366, P336, DOI 10.1016/j.cca.2005.11.017; Wratten ML, 2008, EUR J ANAESTH, V25, P1, DOI 10.1017/S0265021507003444; YOUNG GB, 1990, CLIN INVEST MED, V13, P297; YOUNG GB, 1992, J CLIN NEUROPHYSIOL, V9, P145, DOI 10.1097/00004691-199201000-00016	61	85	96	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	JUN	2009	22	3					283	287		10.1097/WCO.0b013e32832b3101			5	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	447KA	WOS:000266188800013	19387342				2022-02-06	
J	Le, TH; Gean, AD				Le, Tuong H.; Gean, Ahsa D.			Neuroimaging of Traumatic Brain Injury	MOUNT SINAI JOURNAL OF MEDICINE			English	Article						brain herniation; cerebral edema; diffuse axonal injury; epidural hematoma; intracerebral hematoma; intraventricular hemorrhage; subarachnoid hemorrhage; subdural hematoma; traumatic brain injury	DIFFUSE AXONAL INJURY; MINOR HEAD-INJURY; SUBARACHNOID HEMORRHAGE; CT; MR; SPECT; RULE; METHODOLOGY; FLAIR; TIME	In this article, the neuroradiological evaluation of traumatic brain injury is reviewed. Different imaging strategies in the assessment of traumatic brain injury are initially discussed, and this is followed by a review of the imaging characteristics of both primary and secondary brain injuries. Computed tomography remains the modality of choice for the initial assessment of acute head injury because it is fast, widely available, and highly accurate in the detection of skull fractures and acute intracranial hemorrhage. Magnetic resonance imaging is recommended for patients with acute traumatic brain injury when the neurological findings are unexplained by computed tomography. Magnetic resonance imaging also the modality of choice for the evaluation of subacute or chronic traumatic brain injury. Mild traumatic brain injury continues to be difficult to diagnose with current imaging technology. Advanced magnetic resonance techniques, such as diffusion-weighted imaging, magnetic resonance spectroscopy, and magnetization transfer imging, can improve the identification of traumatic brain injury, especially in the case of mild traumatic brain injury. Further research is needed for other advanced imaging method such as magnetic source imaging, single photon emission tomography, and positron emission tomography. Mt. Sinai J Med 76:145-162, 2009 (C) 2009 Mount Sinai School of Medicine	[Le, Tuong H.; Gean, Ahsa D.] San Francisco Gen Hosp, Brain & Spinal Cord Injury Ctr, Dept Radiol, San Francisco, CA 94110 USA		Gean, AD (corresponding author), San Francisco Gen Hosp, Brain & Spinal Cord Injury Ctr, Dept Radiol, San Francisco, CA 94110 USA.	alisa.gean@radiology.ucsf.edu					ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; Adams JH, 1991, NEUROIMAG CLIN N AM, V1, P397; Al-Nakshabandi NA, 2001, RADIOLOGY, V218, P433, DOI 10.1148/radiology.218.2.r01fe09433; Alavi A, 1989, J Neuropsychiatry Clin Neurosci, V1, pS45; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; BELL RS, 1971, NEW ENGL J MED, V284, P236, DOI 10.1056/NEJM197102042840504; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Frigon C, 2002, AM J ROENTGENOL, V179, DOI 10.2214/ajr.179.3.1790791; Gean A D, 1995, New Horiz, V3, P549; GEAN AD, 1994, IMAGING HEAD TRAUMA, P76; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; Gentry LR., 1996, MAGNETIC RESONANCE I, P611; GREENBERG J, 1985, NEUROSURGERY, V17, P48, DOI 10.1227/00006123-198507000-00008; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; HACKNEY DB, 1991, RADIOLOGY, V181, P711, DOI 10.1148/radiology.181.3.1947086; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; HESSELINK JR, 1988, AM J ROENTGENOL, V150, P1133; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI [10.1067/mem.2002.125782, 10.1016/j.jen.2008.12.010]; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; Le TH, 2006, SEMIN ROENTGENOL, V41, P177, DOI 10.1053/j.ro.2006.04.003; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Lorberboym M, 2002, AM J EMERG MED, V20, P310, DOI 10.1053/ajem.2002.34201; MASTERS SJ, 1980, AM J ROENTGENOL, V135, P539, DOI 10.2214/ajr.135.3.539; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Noguchi K, 1997, RADIOLOGY, V203, P257, DOI 10.1148/radiology.203.1.9122404; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Pruessmann KP, 1999, MAGNET RESON MED, V42, P952, DOI 10.1002/(SICI)1522-2594(199911)42:5<952::AID-MRM16>3.3.CO;2-J; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Sodickson DK, 1997, MAGNET RESON MED, V38, P591, DOI 10.1002/mrm.1910380414; Stiell IG, 2001, ANN EMERG MED, V38, P160, DOI 10.1067/mem.2001.116796; Stiell IG, 2001, ANN EMERG MED, V38, P317, DOI 10.1067/mem.2001.116795; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TEASDALE G, 1974, LANCET, V2, P81; Woodcock RJ, 2001, AM J NEURORADIOL, V22, P1698; Zee CS, 1998, NEUROIMAG CLIN N AM, V8, P525	45	85	92	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0027-2507	1931-7581		MT SINAI J MED	Mt. Sinai J. Med.	MAR-APR	2009	76	2					145	162		10.1002/msj.20102			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	427OE	WOS:000264787800008	19306377				2022-02-06	
J	Bayir, H; Adelson, PD; Wisniewski, SR; Shore, P; Lai, YC; Brown, D; Janesko-Feldman, KL; Kagan, VE; Kochanek, PM				Bayir, Huelya; Adelson, P. David; Wisniewski, Stephen R.; Shore, Paul; Lai, YiChen; Brown, Danielle; Janesko-Feldman, Keri L.; Kagan, Valerian E.; Kochanek, Patrick M.			Therapeutic hypothermia preserves antioxidant defenses after severe traumatic brain injury in infants and children	CRITICAL CARE MEDICINE			English	Article						pediatric head injury; biomarkers of oxidative stress; chemiluminescence; fluorescence	MODERATE HYPOTHERMIA; CEREBROSPINAL-FLUID; MILD HYPOTHERMIA; CARDIAC-ARREST; LIPID-PEROXIDATION; OXIDATIVE STRESS; POSTTRAUMATIC HYPOTHERMIA; EXTRACELLULAR LEVELS; IN-SITU; TEMPERATURE	Objective: Oxidative stress contributes to secondary damage after traumatic brain injury (TBI). Hypothermia decreases endogenous antioxidant consumption and lipid peroxidation after experimental cerebral injury. Our objective was to determine the effect of therapeutic hypothermia on oxidative damage after severe TBI in infants and children randomized to moderate hypothermia vs. normothermia. Design: Prospective randomized controlled study. Setting: Pediatric intensive care unit of Pittsburgh Children's Hospital. Patients: The study included 28 patients. Measurements and Main Results: We compared the effects of hypothermia (32 degrees C-33 degrees C) vs. normothermia in patients treated in a single center Involved in a multicentered randomized controlled trial of hypothermia in severe pediatric TBI (Glasgow Coma Scale score <= 8). The patients randomized to hypothermia (n = 13) were cooled to target temperature within -6 to 24 hours for 48 hours and then rewarmed. Antioxidant status was assessed by measurements of total antioxidant reserve and glutathione. Protein oxidation and lipid peroxidation were assessed by measurements of protein thiols and F2-isoprostane, respectively, in ventricular cerebrospinal fluid (CSF) samples (n = 76) obtained on day 1-3 after injury. The association between Glasgow Coma Scale score, age, gender, treatment, temperature, time after injury, and CSF antioxidant reserve, glutathi one, protein-thiol, F2-isoprostane levels were assessed by bivariate and multiple regression models. Demographic and clinical characteristics were similar between the two treatment groups. Mechanism of injury included both accidental injury and nonaccidental injury. Multiple regression models revealed preservation of CSF antioxidant reserve by hypothermia (p = 0.001). Similarly, a multiple regression model showed that glutathione levels were inversely associated with patient temperature at the time of sampling (p = 0.002). F2-isoprostane levels peaked on day 1 after injury and were progressively decreased thereafter. Although F2-isoprostane levels were approximately threefold lower in patients randomized to hypothermia vs. normothermia, this difference was not statistically significant. Conclusion: To our knowledge, this is the first study demonstrating that hypothermia attenuates oxidative stress after severe TBI in infants and children. Our data also support the concept that CSF represents a valuable tool for monitoring treatment effects on oxidative stress after TBI. (Crit Care Med 2009; 37:689-695)	[Bayir, Huelya; Janesko-Feldman, Keri L.; Kochanek, Patrick M.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Bayir, Huelya; Adelson, P. David; Brown, Danielle; Kochanek, Patrick M.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; [Bayir, Huelya; Kagan, Valerian E.] Univ Pittsburgh, Ctr Free Radical & Anfioxidant Hlth, Pittsburgh, PA 15213 USA; [Bayir, Huelya; Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA; [Bayir, Huelya; Kagan, Valerian E.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15213 USA; [Bayir, Huelya; Kagan, Valerian E.] Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15213 USA; [Adelson, P. David; Brown, Danielle] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15213 USA; [Wisniewski, Stephen R.] Univ Pittsburgh, Dept Epidemiol & Publ Hlth, Pittsburgh, PA 15213 USA; [Shore, Paul] Univ Texas SW Med Ctr Dallas, Childrens Med Ctr Dallas, Div Crit Care Serv, Dept Pediat, Dallas, TX 75390 USA; [Lai, YiChen] Baylor Coll Med, Div Crit Care, Dept Pediat, Houston, TX 77030 USA		Bayir, H (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.	bayihx@ccm.upmc.edu	Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860; Kagan, Valerian E./0000-0002-7245-1885	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS30318, NS38087, NS34884, NS052478, NS061817, HD057587, T32-HD40686]; Laerdal Foundation; CDC (University of Pittsburgh Centers for Injury Research and Control [CIRCL])United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; American Heart AssociationAmerican Heart Association [0535365N]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD057587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, R01NS038087, P01NS030318, R01NS061817, P50NS030318, U01NS052478] Funding Source: NIH RePORTER	Supported, in part, by grants NS30318, NS38087, NS34884, NS052478, NSO61817, HD057587, and T32-HD40686 (to PS and YCL) from NIH, Laerdal Foundation, CDC (University of Pittsburgh Centers for Injury Research and Control [CIRCL]) and 0535365N by American Heart Association.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS31; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Behringer W, 2002, J CEREBR BLOOD F MET, V22, P105, DOI 10.1097/00004647-200201000-00013; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Darwish RS, 2007, J TRAUMA, V63, P439, DOI 10.1097/TA.0b013e318069178a; DeKosky ST, 2004, J NEUROCHEM, V90, P998, DOI 10.1111/j.1471-4159.2004.02575.x; Erecinska M, 2003, J CEREBR BLOOD F MET, V23, P513, DOI 10.1097/01.WCB.0000066287.21705.21; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Gupta AK, 2002, BRIT J ANAESTH, V88, P188, DOI 10.1093/bja/88.2.188; Hall ED, 1997, J PHARMACOL EXP THER, V281, P895; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Holzer M, 2002, NEW ENGL J MED, V346, P549; HU BR, 1995, NEUROSCIENCE, V68, P1003, DOI 10.1016/0306-4522(95)00213-3; KARIBE H, 1994, BRAIN RES, V649, P12, DOI 10.1016/0006-8993(94)91043-X; Kasprzak HA, 2001, J NEUROTRAUM, V18, P793, DOI 10.1089/089771501316919157; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; Lee King-Teh, 1998, Kaohsiung Journal of Medical Sciences, V14, P6; LEI BP, 1994, STROKE, V25, P147, DOI 10.1161/01.STR.25.1.147; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; Maeda T, 1998, J NEUROTRAUM, V15, P655, DOI 10.1089/neu.1998.15.655; Maier CM, 2001, J NEUROSURG, V94, P90, DOI 10.3171/jns.2001.94.1.0090; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; McAnulty JF, 1997, CRYOBIOLOGY, V34, P406, DOI 10.1006/cryo.1997.2011; Merenda A, 2006, CURR OPIN CRIT CARE, V12, P90, DOI 10.1097/01.ccx.0000216573.26686.27; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; OCONNOR F, 1975, J CARDIOVASC SURG, V16, P493; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Pilitsis JG, 2003, NEUROSCI LETT, V349, P136, DOI 10.1016/S0304-3940(03)00803-6; Quinones-Hinojosa A, 2003, NEUROSURGERY, V52, P1178, DOI 10.1227/01.NEU.0000057836.64972.A0; Rainio P, 1998, SCAND CARDIOVASC J, V32, P353, DOI 10.1080/14017439850139807; Robertson CL, 2006, DEV NEUROSCI-BASEL, V28, P432, DOI 10.1159/000094169; ROSOMOFF HL, 1965, ARCH NEUROL-CHICAGO, V13, P337, DOI 10.1001/archneur.1965.00470040003001; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; SELDEN PD, 2003, PEDIATR CRIT CARE ME, V4, pS53; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; Simkhovich BZ, 2004, J CARDIOVASC PHARM T, V9, P83, DOI 10.1177/107424840400900203; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Takata T, 1997, NEUROSCI LETT, V227, P41, DOI 10.1016/S0304-3940(97)00296-6; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; YAGER J, 1993, PEDIATR RES, V34, P525, DOI 10.1203/00006450-199310000-00029; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538	63	85	85	1	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2009	37	2					689	695		10.1097/CCM.0b013e318194abf2			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	402LI	WOS:000263014800039	19114918	Green Accepted			2022-02-06	
J	Lange, B; Flynn, S; Rizzo, A				Lange, B.; Flynn, S.; Rizzo, A.			Initial usability assessment of off-the-shelf video game consoles for clinical game-based motor rehabilitation	PHYSICAL THERAPY REVIEWS			English	Article						Virtual reality; video games; rehabilitation; physical therapy; usability		Aims/background: Off-the-shelf games for consoles such as the Nintendo Wii, Nintendo WiiFit and Sony PlayStation 2 EyeToy have been developed and tested for the purpose of entertainment. Many clinics are adopting the use of these off-the-shelf devices for exercise, social interaction and rehabilitation because they are affordable, accessible and can be used within the clinic and home. Our group carried out initial usability evaluations for these off-the-shelf games and a prototype game (using an off-the-shelf device) specifically developed for people with disabilities. Methods: A series of studies have been undertaken through formative and summative evaluation and focus group research with a sample of people recovering from spinal cord injury, traumatic brain injury and stroke. Findings from two studies are presented. Following a demonstration and trial of the devices, observational and questionnaire data were collected to determine participants' perception of each system's usability, appeal and enjoyment. Results: The first study involved evaluation and focus group discussions of seven participants (two females, five males) with SCI (n=4) and CVA (n=3). Findings indicated that interaction with the EyeToy interface appeared to be more intuitive than the use of the Wii-mote interaction device, although some participants had difficulty navigating the menu of the PlayStation EyeToy. The second study involved evaluation of six participants (SCI=4 males, TBI=1 male, CVA=1 female), aged between 25 and 58 years. The investigator was able to increase or decrease the difficulty of a game (developed specifically for bimanual rehabilitation task), using an off-the-shelf haptic feedback device, for each participant, depending on their skill level so that each participant was able to work at a level that was challenging to them. In both studies, participants reported that they would be more motivated to exercise if playing these types of games in both the clinic and home setting. Conclusion: This series of usability tests is the first phase within a program of work using gaming for a range of physical disabilities. The use of virtual reality and video games for rehabilitation offers potential for motivating patients to perform specific therapy tasks.	[Lange, B.; Flynn, S.; Rizzo, A.] Univ Southern Calif, Inst Creat Technol, 13274 Fiji Way, Marina Del Rey, CA 90292 USA		Lange, B (corresponding author), Univ Southern Calif, Inst Creat Technol, 13274 Fiji Way, Marina Del Rey, CA 90292 USA.	lange@ict.usc.edu		Lange, Belinda/0000-0002-2330-2699			Adamovich SV, 2004, P ANN INT IEEE EMBS, V26, P4936; ALRECK PL, 1995, SURVEY RES HDB GUIDE; [Anonymous], 2007, SPIN CORD INJ INF NE; Baram Y, 2006, NEUROLOGY, V66, P178, DOI 10.1212/01.wnl.0000194255.82542.6b; Boian R, 2002, STUD HEALTH TECHNOL, V85, P64; Chuang TY, 2002, COMPUT METH PROG BIO, V69, P189, DOI 10.1016/S0169-2607(01)00190-0; Desurvire H, 2008, CHI C FLOR IT, P681; Deutsch JE, 2005, PRESENCE VIRTUAL REH, V14, P98; Deutsch JE, 2008, PHYS THER, V88, P1196, DOI 10.2522/ptj.20080062; Deutsch JE, 2007, IEEE T NEUR SYS REH, V15, P30, DOI 10.1109/TNSRE.2007.891384; Dumas Joseph S., 2008, MODERATING USABILITY; Dvorkin AY, 2006, CYBERPSYCHOL BEHAV, V9, P133, DOI 10.1089/cpb.2006.9.133; Finkelstein E., 2006, INCIDENCE EC BURDEN; Flynn Sheryl, 2007, J Neurol Phys Ther, V31, P180, DOI 10.1097/NPT.0b013e31815d00d5; Fulk George D, 2005, J Neurol Phys Ther, V29, P34; Fulton B, 2003, GAM DEV C 2003 P SAN; Fung J, 2006, CYBERPSYCHOL BEHAV, V9, P157, DOI 10.1089/cpb.2006.9.157; Fung J, 2004, P ANN INT IEEE EMBS, V26, P4859; Gerberding J.L., 2003, C MILD TRAUM BRAIN I; Hellweg S, 2008, BRAIN INJURY, V22, P365, DOI 10.1080/02699050801998250; Hix D, 2002, HUM FAC ER, P681; Juul J., 1998, THESIS; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kruger RA, 2008, FOCUS GROUPS PRACTIC, P3; Kuniavsky M., 2003, OBSERVING USER EXPER; Lewis JA, 2006, CYBERPSYCHOL BEHAV, V9, P142, DOI 10.1089/cpb.2006.9.142; Lewis JR, 1993, 54786 HUM FACT GROUP; Mirelman A, 2009, STROKE, V40, P169, DOI 10.1161/STROKEAHA.108.516328; Nielsen, 1993, USABILITY ENG; Nielsen J., 1990, SIGCHI Bulletin, P249; Oddsson LI, 2007, J NEUROENG REHABIL, V4, DOI 10.1186/1743-0003-4-25; Rand Debbie, 2008, J Neurol Phys Ther, V32, P155, DOI 10.1097/NPT.0b013e31818ee779; Rothi LJG, 2008, J SPEECH LANG HEAR R, V51, pS222, DOI 10.1044/1092-4388(2008/017); Subramanian S, 2007, J NEUROENG REHABIL, V4, DOI 10.1186/1743-0003-4-20; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Van Wyk E, 2008, P 2008 ANN RES C S A, P276; Winstein C. J., 2006, TXB NEURAL REPAIR RE, V2, P89, DOI DOI 10.1017/CBO9780511545078.009; Woollacott, 2007, MOTOR CONTROL TRANSL; Yang YR, 2008, GAIT POSTURE, V28, P201, DOI 10.1016/j.gaitpost.2007.11.007; Zhu HF, 2009, STROKE, V40, P18, DOI 10.1161/STROKEAHA.108.527606	40	85	86	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1083-3196	1743-288X		PHYS THER REV	Phys. Ther. Rev.		2009	14	5			SI		355	363		10.1179/108331909X12488667117258			9	Rehabilitation	Emerging Sources Citation Index (ESCI)	Rehabilitation	V72KR	WOS:000211641200007					2022-02-06	
J	Harting, MT; Jimenez, F; Adams, SD; Mercer, DW; Cox, CS				Harting, Matthew T.; Jimenez, Fernando; Adams, Sasha D.; Mercer, David W.; Cox, Charles S., Jr.			Acute, regional inflammatory response after traumatic brain injury: Implications for cellular therapy	SURGERY			English	Article							MESENCHYMAL STEM-CELLS; NECROSIS-FACTOR-ALPHA; MARROW STROMAL CELLS; CLOSED-HEAD INJURY; INTERFERON-GAMMA; RAT-BRAIN; TNF-ALPHA; CYTOKINES; INTERLEUKIN-6; RELEASE	Background. Although cellular therapy has shown promise in the management of traumatic brain injury (TBI), microenvironment interactions between the intracerebral milieu and therapeutic stem cells are poorly understood. We sought to characterize the acute, regional inflammatory response after TBI. Methods. Rats underwent a controlled cortical impact (CCI) injury or sham injury, penumbral, 24, 48, and 72 hours, and intracerebral fluid (IF) was isolated from the direct injury, penumbral, ipsilateral frontal, and contralateral regions. Cortical and hippocampal areas were also isolated. Regional cytokine levels were measured. Polymorphonuclear cell (PMN) oxidative burst and marker expression were assessed after incubation with the IF. Immunohistochemistry was used to identify intracerebral CD68(+) cells (microglia/macrophages). Results. The proinflammatory cytokines interleukin (IL)-1 alpha, IL-1 beta, and tumor necrosis factor-alpha were significantly elevated after CCI in the injury and penumbral regions. Increases in the same cytokines were localized to the cortex and the hippocampus. Increased PMN expression of CD11b and L-selectin was identified after incubation with injury or penumbral area IF, without change in PMN oxidative burst. CD68(+) cells were noted in the direct injury and penumbral areas. Conclusion. The local cerebral milieu in the first 48 hours after TBI is highly proinflammatory. This response is most pronounced in areas at a proximal to the direct injury. The local acute proinflammatory response after TBI may serve as a therapeutic target of early cell therapy or, conversely, may create on unfavorable local milieu, limiting the efficacy of early cellular therapy. (Surgery 2008; 144:803-13).	[Harting, Matthew T.; Jimenez, Fernando; Cox, Charles S., Jr.] Univ Texas Med Sch Houston, Dept Pediat Surg, Houston, TX 77030 USA; [Harting, Matthew T.; Jimenez, Fernando; Cox, Charles S., Jr.] Childrens Mem Hermann Hosp, Dept Pediat Surg, Houston, TX USA; [Harting, Matthew T.; Adams, Sasha D.; Mercer, David W.] Univ Texas Med Sch Houston, Dept Surg, Houston, TX 77030 USA; [Harting, Matthew T.; Adams, Sasha D.; Mercer, David W.] Univ Texas Med Sch Houston, Trauma Res Ctr, Houston, TX 77030 USA; [Cox, Charles S., Jr.] Texas A&M Univ, Michael E DeBakey Inst, College Stn, TX USA		Cox, CS (corresponding author), Univ Texas Med Sch Houston, Dept Pediat Surg, 6431 Fannin Street,MSB 5-254, Houston, TX 77030 USA.	charles.s.cox@uth.tmc.edu		Harting, Matthew/0000-0002-8929-8311	Children's Memorial Hermann Hospital Foundation [T32 GM008792-06, P50 GM38529, MO1 RR 02558, R21 HD 04 2659-01A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD042659] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P50GM038529, T32GM008792] Funding Source: NIH RePORTER	Supported by grant T32 GM008792-06, P50 GM38529, MO1 RR 02558, and R21 HD 04 2659-01A1, Children's Memorial Hermann Hospital Foundation, Texas Higher Education Coordinating Board.	Adams SD, 2008, J TRAUMA, V65, P170, DOI 10.1097/TA.0b013e31805824ca; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Allan SM, 2000, ANN NY ACAD SCI, V917, P84; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007-0197; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Konsman JP, 2007, CLIN SCI, V112, P1, DOI 10.1042/CS20060043; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Molcanyi M, 2007, J NEUROTRAUM, V24, P625, DOI 10.1089/neu.2006.0180; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Partrick DA, 1997, J TRAUMA, V43, P297, DOI 10.1097/00005373-199708000-00015; Penolazzi L, 2008, CELL BIOL INT, V32, P320, DOI 10.1016/j.cellbi.2007.08.030; Phinney DG, 2006, STEM CELLS DEV, V15, P437, DOI 10.1089/scd.2006.15.437; Shimonkevitz R, 1999, SHOCK, V12, P10, DOI 10.1097/00024382-199907000-00002; Shindo T, 2006, J MED INVESTIG, V53, P42, DOI 10.2152/jmi.53.42; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Streit WJ, 2000, TOXICOL PATHOL, V28, P28, DOI 10.1177/019262330002800104; Turrin NP, 2007, STEM CELLS, V25, P3165, DOI 10.1634/stemcells.2007-0508; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; WONG D, 1992, J NEUROIMMUNOL, V39, P11, DOI 10.1016/0165-5728(92)90170-P; Wong G, 2004, EXP NEUROL, V187, P171, DOI 10.1016/j.expneurol.2004.01.009; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	28	85	99	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	NOV	2008	144	5					803	813		10.1016/j.surg.2008.05.017			11	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	372NK	WOS:000260908100013	19081024	Green Accepted			2022-02-06	
J	Post, MWM; de Witte, LP; Reichrath, E; Verdonschot, MM; Wijlhuizen, GJ; Perenboom, RJM				Post, Marcel W. M.; de Witte, Luc P.; Reichrath, Enid; Verdonschot, Manon M.; Wijlhuizen, Gert Jan; Perenboom, Rom J. M.			Development and validation of IMPACT-S, an ICF-based questionnaire to measure activities and participation	JOURNAL OF REHABILITATION MEDICINE			English	Article						validation studies; disabled persons; questionnaires; reproducibility of results; outcome assessment	INTERNATIONAL CLASSIFICATION; HEALTH ICF; DISABILITY; CONSEQUENCES; AGREEMENT; HANDICAP; CARE	Objective: IMPACT-S is the screener part of the ICF Measure of Participation and ACTivities questionnaire. IMPACT-S consists of 33 items in 9 scales, reflecting the 9 activity and participation chapters of the International Classification of Functioning, Disability and Health (ICF). The reliability and validity of IMPACT-S as an independent brief measure of activities and participation was examined. Design: Repeated administration of a postal questionnaire. Patients: Road accident victims were recruited through several Dutch hospitals and rehabilitation centres. A total of 276 patients participated and 197 took part in both measurements. Methods: Examination of test-retest reliability, reproducibility and construct validity. The World Health Organization Disability Assessment Schedule II (WHODAS-II) was included as criterion measure for concurrent validity. Results: Types of main injury were fractures (38%), traumatic brain injury (37%), spinal cord injury (13%), whiplash (9%) and other (3%). Mean time after injury was 2.2 years. Internal consistency of IMPACT-S was satisfying for all 9 domains (0.75-0.89) and excellent for the total score (0.96). Test-retest reliability was good at item level (0.44-0.72), domain level (0.72-0.92) and total score (0.94). Strong correlations (0.61-0.88) between IMPACT-S and corresponding WHODAS-II scores were found. Conclusion: IMPACT-S is a reliable and valid generic measure of activity limitations and participation restrictions that fits the ICF.	[Post, Marcel W. M.] Rehabil Ctr De Hoogstr, NL-3583 TM Utrecht, Netherlands; [Post, Marcel W. M.] Rudolf Magnus Inst Neurosci, NL-3508 TA Utrecht, Netherlands; [Post, Marcel W. M.; de Witte, Luc P.; Reichrath, Enid; Verdonschot, Manon M.] iRv Inst Rehabil Res, Hoensbroek, Netherlands; [Wijlhuizen, Gert Jan; Perenboom, Rom J. M.] TNO Qual Life, Leiden, Netherlands		Post, MWM (corresponding author), Rehabil Ctr De Hoogstr, Rembrandtkade 10, NL-3583 TM Utrecht, Netherlands.	m.post@dehoogstraat.nl	Post, Marcel/AAS-2502-2021	de Witte, Luc/0000-0002-3013-2640			Australian Institute of Health and Welfare (AIHW), 2003, ICF AUSTR US GUID VE; Biering-Sorensen F, 2006, SPINAL CORD, V44, P541, DOI 10.1038/sj.sc.3101918; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Cardol M, 1999, CLIN REHABIL, V13, P411, DOI 10.1191/026921599668601325; Cieza A, 2005, QUAL LIFE RES, V14, P1225, DOI 10.1007/s11136-004-4773-0; Cieza A, 2004, J REHABIL MED, V36, P9, DOI 10.1080/16501960410015353; Cohen J., 2013, STAT POWER ANAL BEHA; de Vet HCW, 2006, J CLIN EPIDEMIOL, V59, P1033, DOI 10.1016/j.jclinepi.2005.10.015; Epping-Jordan J. E., 2000, WHO MENTAL HLTH B, V6, P5; Farin E, 2007, J REHABIL MED, V39, P537, DOI 10.2340/16501977-0083; Fleiss J.L., 1981, STAT METHODS RATES P; Fougeyrollas P, 1998, INT J REHABIL RES, V21, P127, DOI 10.1097/00004356-199806000-00002; Gandek B, 2007, AM J PHYS MED REHAB, V86, P57, DOI 10.1097/01.PHM.0000233200.43822.21; Geyh S, 2007, QUAL LIFE RES, V16, P833, DOI 10.1007/s11136-007-9174-8; Haley SM, 2004, ARCH PHYS MED REHAB, V85, P649, DOI 10.1016/j.apmr.2003.08.098; Harwood R H, 1994, Qual Health Care, V3, P11, DOI 10.1136/qshc.3.1.11; Jette AM, 2003, J REHABIL MED, V35, P145, DOI 10.1080/16501970310010501; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; Nunnally J., 1994, PSYCHOMETRIC THEORY; Perenboom R, 2006, NEWSLETTER WHO FAMIL, V4, P8; Perenboom RJM, 2003, DISABIL REHABIL, V25, P577, DOI 10.1080/0963828031000137081; Posl M, 2007, QUAL LIFE RES, V16, P1521, DOI 10.1007/s11136-007-9259-4; Reichrath E, 2005, KWALITEIT DOELMATIGH; Schepers VPM, 2007, DISABIL REHABIL, V29, P221, DOI 10.1080/09638280600756257; Soberg HL, 2007, J TRAUMA, V62, P461, DOI 10.1097/01.ta.0000222916.30253.ea; Stucki G, 2005, AM J PHYS MED REHAB, V84, P733, DOI 10.1097/01.phm.0000179521.70639.83; Stucki G, 2002, DISABIL REHABIL, V24, P281, DOI 10.1080/09638280110105222; Stucki G, 2007, J REHABIL MED, V39, P279, DOI 10.2340/16501977-0041; Van Brakel WH, 2006, DISABIL REHABIL, V28, P193, DOI 10.1080/09638280500192785; VANDERHOEKEN D, 2000, NEDERLANDSE WHODAS 2; Visser-Meily JMA, 2004, CLIN REHABIL, V18, P601, DOI 10.1191/0269215504cr776oa; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; *WHO, 1999, ICIDH 2 INT CLASS FU; *WHO, 1980, INT CLASS PAIRM DIS; *WHO, 2001, WHO DIS ASS SCH WHOD; World Health Organization, 2007, INT CLASS FUNCT DIS	36	85	87	1	16	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	SEP	2008	40	8					620	627		10.2340/16501977-0223			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	351FF	WOS:000259409200007	19020695	gold			2022-02-06	
J	Koskinen, S; Alaranta, H				Koskinen, Sanna; Alaranta, Hannu			Traumatic brain injury in Finland 1991-2005: A nationwide register study of hospitalized and fatal TBI	BRAIN INJURY			English	Article						traumatic brain injury; epidemiology; incidence	HEAD-INJURIES; OLDER-ADULTS; EPIDEMIOLOGY; REHABILITATION; MORTALITY; FUTURE; IMPACT	Primary objective: To examine the epidemiology of traumatic brain injury (TBI) in Finland in 1991-2005. Research design: Nationwide population based data of hospitalized and fatal TBI collected from the national registers of Finland. The incidence, age and gender distribution, aetiology, external causes, cursory outcome and mortality are presented. Methods and procedures: The data were collected from the National Hospital Discharge Register of Finland and from the official cause-of-death register of Statistics Finland. Main outcome and results: The average incidence of hospitalized TBI was 101/100 000 population and the mortality rate 18.1/100 000. The incidence increased by 59.4% in the patients aged 70 years or older while the incidence decreased by 2.4% in the younger age groups. The mortality rate decreased in men. The most common external causes were falls. The oldest patients needed 6.8-times longer stay in the hospital than the youngest. After discharge 54% of the patients needed at least occasional care. Conclusions: TBI prevention should be focused to the main groups at risk. The need for further care, rehabilitation and increasing the awareness of TBI is obvious.	[Koskinen, Sanna; Alaranta, Hannu] Kapyla Rehabil Ctr, FI-00251 Helsinki, Finland		Koskinen, S (corresponding author), Kapyla Rehabil Ctr, POB 103, FI-00251 Helsinki, Finland.	sannakos@gmail.com					Alaranta H, 2000, Wien Med Wochenschr, V150, P444; Alaranta H, 2002, SUOM LAAKARILEHTI, V47, P4801; Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; Binder S, 2005, J HEAD TRAUMA REHAB, V20, P189, DOI 10.1097/00001199-200505000-00002; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Engberg AW, 2007, J HEAD TRAUMA REHAB, V22, P221, DOI 10.1097/01.HTR.0000281837.62226.54; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Fletcher AE, 2007, BRAIN INJURY, V21, P691, DOI 10.1080/02699050701426873; HONKANEN R, 1990, HOSPITALIZATION DUE; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; Kannus P, 1999, JAMA-J AM MED ASSOC, V281, P1895, DOI 10.1001/jama.281.20.1895; Kannus P, 1999, AM J EPIDEMIOL, V149, P143; Kannus P, 2001, J CLIN EPIDEMIOL, V54, P597, DOI 10.1016/S0895-4356(00)00346-2; Keskimaki I, 1991, INT J HLTH SCI, V2, P15; Kleiven Svein, 2003, Inj Control Saf Promot, V10, P173, DOI 10.1076/icsp.10.3.173.14552; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Lexell J, 2007, J HEAD TRAUMA REHAB, V22, P229, DOI 10.1097/01.HTR.0000281838.00344.03; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Ragnarsson KT, 2002, RESTOR NEUROL NEUROS, V20, P103; Ribbers GM, 2007, J HEAD TRAUMA REHAB, V22, P234, DOI 10.1097/01.HTR.0000281839.07968.32; Servadei F, 2002, J Neurosurg Sci, V46, P111; Sosin DM, 1996, BRAIN INJURY, V10, P47; Steudel WI, 2005, ACTA NEUROCHIR, V147, P231, DOI 10.1007/s00701-004-0441-y; Sundstrom T, 2007, J NEUROTRAUM, V24, P147, DOI 10.1089/neu.2006.0099; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631	32	85	86	0	10	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2008	22	3					205	214		10.1080/02699050801938975			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	267LW	WOS:000253511500001	18297592				2022-02-06	
J	Shafi, S; de la Plata, CM; Diaz-Arrastia, R; Shipman, K; Carlile, M; Frankel, H; Parks, J; Gentilello, LM				Shafi, Shahid; de la Plata, Carlos Marquez; Diaz-Arrastia, Ramon; Shipman, Kristin; Carlile, Mao; Frankel, Heidi; Parks, Jennifer; Gentilello, Larry M.			Racial disparities in long-term functional outcome after traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	65th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 28-30, 2006	New Orleans, LA	Amer Assoc Surg Trauma		ethnic disparities; TBI	ACUTE MYOCARDIAL-INFARCTION; IMPACT; RACE; TRANSPLANTATION; EPIDEMIOLOGY; CHILDREN; SCALE; CARE	Objectives: Ethnic disparities have been demonstrated in several diseases, but not in trauma. We hypothesized that access to acute rehabilitation and long-term functional outcomes among traumatic brain injury (TBI) patients are influenced by patient race and ethnicity. Methods: Patients with severe TBI (Abbreviated Injury Scale [AIS] score, 3-5) who were discharged alive from initial hospitalization were recruited from an urban Level I trauma center (1998-2005). Functional outcome was measured 6 to 12 months after injury using the Glasgow Outcome Scale-Extended (GOSE) score, and classified as good recovery (GOSE score, and 8) or moderate to severe disability (GOSE score, 1-6). Ethnic minorities (n = 114) were compared with non-Hispanic Whites (NHW, n = 230). Logistic regression was used to measure the association between ethnicity and functional outcome while controlling for age, gender, Injury Severity Score (ISS), head AIS score, Glasgow Coma Scale (GCS) score, discharge disposition, and insurance. Results: Minority and NHW groups had similar ISS, GCS score, and head AIS score. Ethnic minorities were less likely to be insured (uninsured, 66 % vs. 31 %, p < 0.001), but were equally likely to be placed in a rehabilitation facility upon trauma center discharge (47% vs. 42%, p = 0.417). Minority patients were more likely to have moderate to severe disability at follow-up (74% vs. 61%; adjusted odds ratio [OR], 2.17; 95% confidence interval [CI], 1.27-3.69). The relationship between ethnicity and functional outcome became insignificant when insurance was taken into account (OR, 1.52; 95% CI, 0.81-2.72). Conclusion: Despite equal access to acute rehabilitation, ethnic minorities have significantly worse long-term functional outcomes after TBI, which is related to lack of health insurance.	[Shafi, Shahid; Shipman, Kristin; Frankel, Heidi; Parks, Jennifer; Gentilello, Larry M.] Univ Texas SW Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA; [de la Plata, Carlos Marquez; Diaz-Arrastia, Ramon; Carlile, Mao] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA		Shafi, S (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Surg, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	shahid.shafi@uthsouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD48179, U01 HD42652] Funding Source: Medline		BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; Barnato AE, 2005, MED CARE, V43, P308, DOI 10.1097/01.mlr.0000156848.62086.06; Barnhart JM, 2003, ARCH INTERN MED, V163, P461, DOI 10.1001/archinte.163.4.461; Bertoni AG, 2005, J NATL MED ASSOC, V97, P317; Betancourt JR, 2003, PUBLIC HEALTH REP, V118, P293, DOI 10.1093/phr/118.4.293; Carrasquillo O, 1999, J GEN INTERN MED, V14, P82, DOI 10.1046/j.1525-1497.1999.00293.x; Chan L, 2001, ARCH PHYS MED REHAB, V82, P1151, DOI 10.1053/apmr.2001.24892; COLLINS KS, 1999, US MINORITY HLTH CHA; Delano BG, 1997, ASAIO J, V43, pM861; Dubay LC, 1996, FUTURE CHILD, V6, P152, DOI 10.2307/1602499; Flattery Maureen P, 2004, J Cult Divers, V11, P25; FRANKOWSKI RAJ, 1985, DESCRIPTIVE EPIDEMIO; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; McAlearney JS, 2004, J HEALTH CARE POOR U, V15, P357, DOI 10.1353/hpu.2004.0044; Mochari Heidi, 2006, Prev Cardiol, V9, P8, DOI 10.1111/j.1520-037X.2005.3703.x; PERRY MJ, 1998, BARRIERS MED CAL ENR; Phillips RS, 1996, J GEN INTERN MED, V11, P387, DOI 10.1007/BF02600183; Reid AE, 2004, LIVER TRANSPLANT, V10, P834, DOI 10.1002/lt.20174; SHAFI S, IN PRESS J TRAUMA; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Syed M, 2000, AM HEART J, V140, P643, DOI 10.1067/mhj.2000.109644; Thrall Terese Hudson, 2002, Hosp Health Netw, V76, P30; *US DEP COMM EC ST, 2004, ADM INC POV HLTH INS; US Department of Health and Human Services, 2005, NAT HEALTHC DISP REP; US Department of Health and Human Services, 2000, HLTH PEOPL 2010; Venkat A, 2003, ACAD EMERG MED, V10, P1199, DOI 10.1197/S1069-6563(03)00490-1; Werner RM, 2005, CIRCULATION, V111, P1257, DOI 10.1161/01.CIR.0000157729.59754.09; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; 1998, GAOHEHS9893	34	85	85	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2007	63	6					1263	1268		10.1097/TA.0b013e31815b8f00			6	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	243AU	WOS:000251768100013	18212648				2022-02-06	
J	Schachtrup, C; Lu, P; Jones, LL; Lee, JK; Lu, J; Sachs, BD; Zhengt, B; Akassoglou, K				Schachtrup, Christian; Lu, Paul; Jones, Leonard L.; Lee, Jae K.; Lu, Jerry; Sachs, Ben D.; Zhengt, Binhai; Akassoglou, Katerina			Fibrinogen inhibits neurite outgrowth via beta 3 integrin-mediated phosphorylation of the EGF receptor	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						blood-brain barrier; regeneration; spinal cord injury; transactivation; scar	ACUTE INFLAMMATORY RESPONSES; AXONAL REGENERATION; SPINAL-CORD; CNS MYELIN; GROWTH; BRAIN; ACTIVATION; NERVE; BARRIER; ABNORMALITIES	Changes in the molecular and cellular composition of the CNS after injury or disease result in the formation of an inhibitory environment that inhibits the regeneration of adult mammalian CNS neurons. Although a dramatic change in the CNS environment after traumatic injury or disease is hemorrhage because of vascular rupture or leakage of the blood-brain barrier, the potential role for blood proteins in repair processes remains unknown. Here we show that the blood protein fibrinogen is an inhibitor of neurite outgrowth that is massively deposited in the spinal cord after injury. We show that fibrinogen acts as a ligand for beta 3 integrin and induces the transactivation of EGF receptor (EGFR) in neurons. Fibrinogen-mediated inhibition of neurite outgrowth is reversed by blocking either beta 3 integrin or phoshorylation of EGFR. Inhibition of Src family kinases that mediate the cross-talk between integrin and growth factor receptors rescue the fibrinogen-induced phosphorylation of EGFR. These results identify fibrinogen as the first blood-derived inhibitor of neurite outgrowth and suggest fibrinogen-induced EGFR transactivation on neuronal cells as a molecular link between vascular and neuronal damage in the CNS after injury.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA		Akassoglou, K (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.	akass@ucsd.edu		Akassoglou, Katerina/0000-0002-2632-1465	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052189, R01 NS051470, P30 NS047101, R01NS051470, R01 NS052189, R01 NS054734] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS051470, R01NS052189, R01NS054734, P30NS047101] Funding Source: NIH RePORTER		Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Adams RA, 2004, MOL INTERV, V4, P163; Adams RA, 2007, J EXP MED, V204, P571, DOI 10.1084/jem.20061931; Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066; Akassoglou K, 2000, J CELL BIOL, V149, P1157, DOI 10.1083/jcb.149.5.1157; Akassoglou K, 2004, P NATL ACAD SCI USA, V101, P6698, DOI 10.1073/pnas.0303859101; Akassoglou K, 2002, NEURON, V33, P861, DOI 10.1016/S0896-6273(02)00617-7; Akassoglou K, 2002, BIOL CHEM, V383, P37, DOI 10.1515/BC.2002.004; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; Busso N, 1998, J CLIN INVEST, V102, P41, DOI 10.1172/JCI2312; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875; Case LC, 2005, CURR BIOL, V15, pR749, DOI 10.1016/j.cub.2005.09.008; Chavis P, 2001, NATURE, V411, P317, DOI 10.1038/35077101; CLAUDIO L, 1995, ACTA NEUROPATHOL, V90, P228; Coller BS, 1997, J CLIN INVEST, V99, P1467, DOI 10.1172/JCI119307; Degen JL, 2001, ANN NY ACAD SCI, V936, P276; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Flick MJ, 2004, J CLIN INVEST, V113, P1596, DOI 10.1172/JCI200420741; Gay FW, 1997, BRAIN, V120, P1461, DOI 10.1093/brain/120.8.1461; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gveric D, 2003, BRAIN, V126, P1590, DOI 10.1093/brain/awg167; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hardy J, 2006, NAT MED, V12, P756, DOI 10.1038/nm0706-756; Herwald H, 2004, CELL, V116, P367, DOI 10.1016/S0092-8674(04)00057-1; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; Iadecola C, 2004, NAT REV NEUROSCI, V5, P347, DOI 10.1038/nrn1387; Jo M, 2007, ONCOGENE, V26, P2585, DOI 10.1038/sj.onc.1210066; Koprivica V, 2005, SCIENCE, V310, P106, DOI 10.1126/science.1115462; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Leyton L, 2001, CURR BIOL, V11, P1028, DOI 10.1016/S0960-9822(01)00262-7; Lipinski B, 2006, ALZ DIS ASSOC DIS, V20, P323, DOI 10.1097/01.wad.0000213844.21001.a2; Lluis F, 2001, BLOOD, V97, P1703, DOI 10.1182/blood.V97.6.1703; Lu P, 2004, J NEUROSCI, V24, P6402, DOI 10.1523/JNEUROSCI.1492-04.2004; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Mosesson MW, 2005, J THROMB HAEMOST, V3, P1894, DOI 10.1111/j.1538-7836.2005.01365.x; Niederost BP, 1999, J NEUROSCI, V19, P8979, DOI 10.1523/JNEUROSCI.19-20-08979.1999; NOBLE LJ, 1989, BRAIN RES, V482, P57, DOI 10.1016/0006-8993(89)90542-8; Petzelbauer P, 2005, NAT MED, V11, P298, DOI 10.1038/nm1198; Pinkstaff JK, 1999, J NEUROSCI, V19, P1541; Popovich PG, 1996, EXP NEUROL, V142, P258, DOI 10.1006/exnr.1996.0196; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; SCHWAB ME, 1988, J NEUROSCI, V8, P2381; Selnes OA, 2006, NAT CLIN PRACT NEURO, V2, P538, DOI 10.1038/ncpneuro0294; TANG LP, 1993, J EXP MED, V178, P2147, DOI 10.1084/jem.178.6.2147; Tang LP, 1996, J CLIN INVEST, V97, P1329, DOI 10.1172/JCI118549; Thompson RD, 2000, J IMMUNOL, V165, P426, DOI 10.4049/jimmunol.165.1.426; TOMA JG, 1992, J NEUROSCI, V12, P2504; Ugarova TP, 2001, ANN NY ACAD SCI, V936, P368; Vos CMP, 2005, NEUROBIOL DIS, V20, P953, DOI 10.1016/j.nbd.2005.06.012; Wang H, 2003, BIOL CHEM, V384, P193, DOI 10.1515/BC.2003.021; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Yamada KM, 2002, NAT CELL BIOL, V4, pE75, DOI 10.1038/ncb0402-e75; Zheng BH, 2003, NEURON, V38, P213, DOI 10.1016/S0896-6273(03)00225-3	56	85	88	0	7	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JUL 10	2007	104	28					11814	11819		10.1073/pnas.0704045104			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190MQ	WOS:000248063400054	17606926	Bronze, Green Published			2022-02-06	
J	Dawson, DR; Schwartz, ML; Winocur, G; Stuss, DT				Dawson, Deirdre R.; Schwartz, Michael L.; Winocur, Gordon; Stuss, Donald T.			Return to productivity following traumatic brain injury: Cognitive, psychological, physical, spiritual, and environmental correlates	DISABILITY AND REHABILITATION			English	Article						traumatic brain injury; productivity; coping	SEVERE HEAD-INJURY; CHRONIC PAIN; POSTTRAUMATIC AMNESIA; COPING STRATEGIES; EMPLOYMENT; RECOVERY; DEPRESSION; PREDICTORS; MODERATE; ADULTS	Purpose. The purpose of this study was to investigate the determinants and correlates of return to productivity (RTP) defined here as return to paid employment and/or school four years following traumatic brain injury (TBI). Method. Participants included 46 people with TBI, part of a prospective, cohort study, and 14 friend/family member controls all employed and/or in school at time of injury or inception into the study. Variables were selected for investigation based on two models of recovery. Demographic and injury severity data including time to recover free recall were collected at time of injury, on admission to a trauma unit. Data on other variables (neuropsychological, psychological, physical, spiritual, environmental) were collected concurrent with productivity status at a mean of 4.3 years post-TBI. Results. Time to recover free recall (measured acutely), neuropsychological status, pain severity, depression, and the use of maladaptive coping behaviours were all related to productivity status (p < 0.05). When these variables were entered into exploratory, planned hierarchical logistic regression models time to free recall, pain, and maladaptive coping remained in the models with depression only dropping out because of the high correlation with pain (r > 0.80). Conclusions. Injury severity (time to free recall), physical status (pain), and psychological status (depression, coping) are important to understanding differences in productivity outcomes. Addressing pain, depression and coping in rehabilitation programs may have a positive impact on outcomes.	Baycrest, Kunin Lunenfeld Appl Res Unit, Toronto, ON M6A 2E1, Canada; Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON, Canada; Univ Toronto, Dept Occupat Sci, Toronto, ON, Canada; Univ Toronto, Dept Occupat Therapy, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Psychol, Toronto, ON, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON, Canada; Baycrest, Rotman Res Inst, Toronto, ON, Canada		Dawson, DR (corresponding author), Baycrest, Kunin Lunenfeld Appl Res Unit, 2560 Bathurst St, Toronto, ON M6A 2E1, Canada.	ddawson@klaru-baycrest.on.ca	Dawson, Deirdre R/I-8882-2014	Dawson, Deirdre R/0000-0001-7517-6121			ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Antonak R. F., 1993, J HEAD TRAUMA REHAB, V8, P87, DOI DOI 10.1097/00001199-199312000-00009; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Beck, 1978, BECK DEPRESSION INVE; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BOSCHEN KA, 1995, VARIABLES AFFECTING; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; CODY RP, 1997, APPL STAT SAS PPROGR; Cohen S., 1985, SOCIAL SUPPORT THEOR, P73, DOI [10.1007/978-94-009-5115-0_5, DOI 10.1007/978-94-009-5115-0_5]; Coughlin AM, 2000, ARCH PHYS MED REHAB, V81, P739, DOI 10.1053/apmr.2000.5586; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dawson DR, 2006, BRAIN COGNITION, V60, P214; Dawson DR, 2004, BRAIN INJURY, V18, P221, DOI 10.1080/02699050310001617406; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Finset A, 2000, BRAIN INJURY, V14, P887; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Folkman S., 1998, MANUAL WAYS COPING Q; Frankl V.E., 1963, MANS SEARCH MEANING; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Judge TA, 2001, J APPL PSYCHOL, V86, P80, DOI 10.1037/0021-9010.86.1.80; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kennedy P, 2003, BRIT J CLIN PSYCHOL, V42, P41, DOI 10.1348/014466503762842002; KERNS RD, 1985, PAIN, V23, P345, DOI 10.1016/0304-3959(85)90004-1; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Khan-Bourne N, 2003, NEUROPSYCHOL REHABIL, V13, P89, DOI 10.1080/09602010244000318; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Levack W, 2004, DISABIL REHABIL, V26, P290, DOI 10.1080/09638280310001647615; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Logan M., 2000, DISS ABSTR INT, V61, P881; LUBUSKO AA, 1994, BRAIN INJURY, V8, P65, DOI 10.3109/02699059409150959; McColl MA, 2000, ARCH PHYS MED REHAB, V81, P817, DOI 10.1016/S0003-9993(00)90117-5; MCCOLL MA, 1995, INT J REHABIL RES, V18, P325, DOI 10.1097/00004356-199512000-00004; MCCOLL MA, 1995, DISABIL REHABIL, V17, P24, DOI 10.3109/09638289509166624; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; MOORE AD, 1994, BRAIN INJURY, V7, P193; NOMAN GR, 2000, BIOSTATISTICS BARE E; NOSEK MA, 1992, REHABIL COUNS BULL, V36, P21; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Oppermann JD, 2004, BRAIN INJURY, V18, P941, DOI 10.1080/02699050410001671919; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; REITAN RM, 1995, CLIN NEUROPSYCHOL, V9, P50, DOI 10.1080/13854049508402057; Reker GT, 1992, MANUAL LIFE ATTITUDE; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; *SAS I INC, 1999, SAS VERS 8 2; Schwartz ML, 1998, CAN J NEUROL SCI, V25, P108, DOI 10.1017/S0317167100033709; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; STROUP ES, 2000, DISS ABSTR INT, V60, P4913; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Stuss DT, 2001, PSYCHOL ASSESSMENT, V13, P230, DOI 10.1037//1040-3590.13.2.230; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; THOMPSON JL, 1986, METHODS OBSERVATIONA; Turner GR, 2004, SCI PRACT NEUROPSYCH, P224; TYRER S, 2003, NEUROPSYCHOL REHABIL, P189; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; Wechsler D, 1981, WECSLER ADULT INTELL; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P1, DOI [10.1016/S0960-9822(02)01374-X, 10.1080/09602010244000444]; WINOCUR G, J INT NEUROPSYCHOLOG; World Health Organization, 1976, INT CLASS IMP DIS HA; World Health Organization, 2007, INT CLASS FUNCT DIS	83	85	87	0	16	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.	FEB 28	2007	29	4					301	313		10.1080/09638280600756687			13	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	Rehabilitation	140SJ	WOS:000244526700004	17364780				2022-02-06	
J	McKay, C; Casey, JE; Wertheimer, J; Fichtenberg, NL				McKay, Cherisse; Casey, Joseph E.; Wertheimer, Jeffrey; Fichtenberg, Norman L.			Reliability and validity of the RBANS in a traumatic brain injured sample	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						brain injury; RBANS	NEUROPSYCHOLOGICAL STATUS; REPEATABLE BATTERY; SENSITIVITY	The RBANS has become increasingly utilized, in various populations since it reliably assesses individual neurocognitive domains in a rapid, efficient manner. The present study examined the convergent validity of the RBANS to frequently administered instruments in a moderate-severe traumatic brain injured (M-S TBI) sample. Fifty-seven individuals who sustained a M-S TBI were included in this study. The RBANS subtests showed moderate to strong internal reliability within the sample. Most of the subtests displayed moderate to strong correlations with the other neuropsychological tests, including the CVLT-II, COWAT, and WAIS-III subtests. The strongest correlations were within the RBANS Attention Index, with both the Digit Span and Coding subtests showing strong correlations with their WAIS-III counterparts. The RBANS measures distinct abilities that supplement other neuropsychological instruments that assess similar functions within a TBI sample. In addition to its administration advantages, the results of this study provide support for the use of the RBANS as a clinical valid and reliable tool in the brief screening of individuals with M-S TBI. (c) 2006 Published by Elsevier Ltd on behalf of National Academy of Neuropsychology.	Univ Windsor, Windsor, ON N9B 3P4, Canada; Rehabil Inst Michigan, Detroit, MI USA; Wayne State Univ, Detroit, MI USA		McKay, C (corresponding author), Univ Windsor, Windsor, ON N9B 3P4, Canada.	cherissemckay@hotmail.com					Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Beatty WW, 2004, ARCH CLIN NEUROPSYCH, V19, P825, DOI 10.1016/j.acn.2003.12.001; Benton A., 1978, MULTILINGUAL APHASIA; Benton A, 1983, JUDGMENT LINE ORIENT; Benton A. L., 1974, REVISED BENTON VISUA; CARONE, 2004, 32 M INT NEUR SOC; DELIS DC, 2000, CALIFORNIA VERBAL LE; Duff K, 2005, ARCH CLIN NEUROPSYCH, V20, P281, DOI 10.1016/j.acn.2004.07.007; Duff K, 2003, CLIN NEUROPSYCHOL, V17, P351, DOI 10.1076/clin.17.3.351.18082; Gold JM, 1999, AM J PSYCHIAT, V156, P1944; Gontkovsky ST, 2002, PSYCHOL REP, V90, P858, DOI 10.2466/PR0.90.3.858-860; Kaplan E, 1983, BOSTON NAMING TEST; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Larson EB, 2005, J CLIN EXP NEUROPSYC, V27, P16, DOI 10.1080/138033990513564; Larson Eric B, 2003, Top Stroke Rehabil, V9, P10; MCKAY CM, UNPUB REPEATABLE BAT; Meyers JE., 1995, REY COMPLEX FIGURE T; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; *PSYCH CORP, 1997, WECHSL AD INT SCAL; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; RANDOLPH C, 1997, CLIN GERIATRICS, V5, P77; Tombaugh T.N., 1996, TEST MEMORY MALINGER	23	85	90	1	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2007	22	1					91	98		10.1016/j.acn.2006.11.003			8	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	144RV	WOS:000244814700010	17141467	Bronze			2022-02-06	
J	Hilton, GD; Nunez, JL; Bambrick, L; Thompson, SM; McCarthy, MM				Hilton, Genell D.; Nunez, Joseph L.; Bambrick, Linda; Thompson, Scott M.; McCarthy, Margaret M.			Glutamate-mediated excitotoxicity in neonatal hippocampal neurons is mediated by mGluR-induced release of Ca++ from intracellular stores and is prevented by estradiol	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						excitatory amino acids; imaging; metabotropic receptors; neuroprotection; perinatal brain injury; steroids	ESTROGEN-RECEPTOR-ALPHA; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; GROUP-II; KAINIC ACID; CELL-DEATH; RAT-BRAIN; PERINATAL ASPHYXIA; SEX-DIFFERENCES; NERVOUS-SYSTEM	Hypoxic/ischernic (HI) brain injury in newborn full-term and premature infants is a common and pervasive source of life time disabilities in cognitive and locomotor function. In the adult, HI induces glutamate release and excitotoxic cell death dependent on NMDA receptor activation. In animal models of the premature human infant, glutamate is also released following HI, but neurons are largely insensitive to NMDA or AMPA/kainic acid (KA) receptor-mediated damage. Using primary cultured hippocampal neurons we have determined that glutamate increases intracellular calcium much more than kainic acid. Moreover, glutamate induces cell death by activating Type I metabotropic glutamate receptors (mGluRs). Pretreatment of neurons with the gonadal steroid estradiol reduces the level of the Type I metabotropic glutamate receptors and completely prevents cell death, suggesting a novel therapeutic approach to excitotoxic brain damage in the neonate.	Univ Maryland, Dept Physiol, Baltimore, MD 21201 USA; Univ Maryland, Neurosci Program, Baltimore, MD 21201 USA; Univ Maryland, Dept Anesthesiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA; Michigan State Univ, Neurosci Program, E Lansing, MI 48824 USA; Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA		Hilton, GD (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, 3970 Reservoir Rd NW,Room WG 03, Washington, DC 20057 USA.	Gdh4@georgetown.edu	McCarthy, Margaret/O-2059-2017; Thompson, Scott M/K-8921-2015	McCarthy, Margaret/0000-0003-2243-4726; 	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K01MH068347, R01MH052716] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040338] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH52716, K01 MH068347-01A1, R01 MH052716] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS040338, R01 NS40338] Funding Source: Medline		Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; Amateau SK, 2004, ENDOCRINOLOGY, V145, P2906, DOI 10.1210/en.2003-1363; AMIELTISON C, 1986, DEV MED CHILD NEUROL, V28, P671; Azcoitia I, 1998, NEUROREPORT, V9, P3075, DOI 10.1097/00001756-199809140-00029; Bao WL, 2001, BRAIN RES, V922, P173, DOI 10.1016/S0006-8993(01)03062-1; Baskys A, 2005, NEUROPHARMACOLOGY, V49, P146, DOI 10.1016/j.neuropharm.2005.04.029; BENARI Y, 1984, DEV BRAIN RES, V14, P284, DOI 10.1016/0165-3806(84)90314-6; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; Biagas Katherine, 1999, Current Opinion in Pediatrics, V11, P223, DOI 10.1097/00008480-199906000-00009; Bleakman D, 1998, NEUROPHARMACOLOGY, V37, P1187, DOI 10.1016/S0028-3908(98)00139-7; Boulware MI, 2005, J NEUROSCI, V25, P5066, DOI 10.1523/JNEUROSCI.1427-05.2005; Brazel CY, 2005, NEUROSCIENCE, V131, P55, DOI 10.1016/j.neuroscience.2004.10.038; Cai ZW, 1999, NEUROREPORT, V10, P3927, DOI 10.1097/00001756-199912160-00037; Cardona-Gomez P, 2004, MOL CELL NEUROSCI, V25, P363, DOI 10.1016/j.mcn.2003.10.008; Chen T, 2004, J NEUROTRAUM, V21, P271, DOI 10.1089/089771504322972068; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI DW, 1990, J NEUROSCI, V10, P2493; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; COOK TM, 1986, NEUROSCIENCE, V18, P79, DOI 10.1016/0306-4522(86)90180-6; Cozzi A, 2002, NEUROPHARMACOLOGY, V43, P119, DOI 10.1016/S0028-3908(02)00080-1; Culmsee C, 1999, J CEREBR BLOOD F MET, V19, P1263, DOI 10.1097/00004647-199911000-00011; Defagot MC, 2002, DEV NEUROSCI-BASEL, V24, P272, DOI 10.1159/000066741; Dobrev D, 1999, BRIT J PHARMACOL, V127, P576, DOI 10.1038/sj.bjp.0702574; Dubal DB, 1999, J NEUROSCI, V19, P6385; FAVIT A, 1991, BRAIN RES, V555, P65, DOI 10.1016/0006-8993(91)90860-X; Folbergrova J, 2005, EXP NEUROL, V192, P420, DOI 10.1016/j.expneurol.2004.12.019; Fotopoulos S, 2001, BIOL NEONATE, V79, P213; Gerevini VDD, 2004, DEV BRAIN RES, V150, P17, DOI 10.1016/j.devbrainres.2004.02.003; Harms C, 2001, J NEUROSCI, V21, P2600, DOI 10.1523/JNEUROSCI.21-08-02600.2001; Hilton GD, 2006, ENDOCRINOLOGY, V147, P1246, DOI 10.1210/en.2005-1258; Hilton GD, 2004, DEV BRAIN RES, V150, P191, DOI 10.1016/j.devbrainres.2004.03.006; Hilton GD, 2003, NEUROSCIENCE, V116, P383, DOI 10.1016/S0306-4522(02)00716-9; Kelly MJ, 1999, TRENDS ENDOCRIN MET, V10, P369, DOI 10.1016/S1043-2760(99)00190-3; Kingston AE, 1998, NEUROPHARMACOLOGY, V37, P1, DOI 10.1016/S0028-3908(97)00191-3; Kurata K, 2001, EUR J PHARMACOL, V416, P203, DOI 10.1016/S0014-2999(01)00880-9; Liu ZP, 2001, J COMP NEUROL, V441, P1, DOI 10.1002/cne.1393; Lopez-Bendito G, 2002, CEREB CORTEX, V12, P625, DOI 10.1093/cercor/12.6.625; Lou HC, 1996, ACTA PAEDIATR, V85, P1266, DOI 10.1111/j.1651-2227.1996.tb13909.x; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; MATTSON MP, 1992, EXP GERONTOL, V27, P29, DOI 10.1016/0531-5565(92)90027-W; McGeer E G, 1981, Int Rev Neurobiol, V22, P173, DOI 10.1016/S0074-7742(08)60293-7; Mermelstein PG, 1996, J NEUROSCI, V16, P595; Miller NR, 2005, ENDOCRINOLOGY, V146, P3070, DOI 10.1210/en.2004-1515; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; Nunez JL, 2005, EUR J NEUROSCI, V21, P3251, DOI 10.1111/j.1460-9568.2005.04175.x; Nunez JL, 2003, ENDOCRINOLOGY, V144, P2350, DOI 10.1210/en.2002-220840; Pivovarova NB, 2004, J NEUROSCI, V24, P5611, DOI 10.1523/JNEUROSCI.0531-04.2004; Prange-Kiel J, 2003, HIPPOCAMPUS, V13, P226, DOI 10.1002/hipo.10075; RHODA J, 1984, ENDOCRINOLOGY, V114, P1754, DOI 10.1210/endo-114-5-1754; Ritz MF, 2002, NEUROCHEM RES, V27, P1677, DOI 10.1023/A:1021695213099; ROBERTSON CMT, 1993, CLIN PERINATOL, V20, P483, DOI 10.1016/S0095-5108(18)30405-6; Romano C, 1996, J COMP NEUROL, V367, P403, DOI 10.1002/(SICI)1096-9861(19960408)367:3<403::AID-CNE6>3.0.CO;2-9; Sampei K, 2000, STROKE, V31, P738, DOI 10.1161/01.STR.31.3.738; Semyanov A, 2000, NEURON, V25, P663, DOI 10.1016/S0896-6273(00)81068-5; SIESJO BK, 1989, MAGNESIUM, V8, P223; Simon NP, 1999, CLIN PERINATOL, V26, P767, DOI 10.1016/S0095-5108(18)30050-2; THORNBERG E, 1995, ACTA PAEDIATR, V84, P927, DOI 10.1111/j.1651-2227.1995.tb13794.x; Toh VC, 2000, ACTA PAEDIATR, V89, P343, DOI 10.1080/080352500750028500; Vannucci RC, 1997, ANN NY ACAD SCI, V835, P234, DOI 10.1111/j.1749-6632.1997.tb48634.x; Wade CNB, 2003, ENDOCRINOLOGY, V144, P832, DOI 10.1210/en.2002-220899; Weaver CE, 1997, BRAIN RES, V761, P338, DOI 10.1016/S0006-8993(97)00449-6; WEISZ J, 1980, ENDOCRINOLOGY, V106, P306, DOI 10.1210/endo-106-1-306; WOLF G, 1984, DEV BRAIN RES, V14, P15, DOI 10.1016/0165-3806(84)90004-X; Wu JQ, 2004, NEUROPHARMACOLOGY, V46, P311, DOI 10.1016/j.neuropharm.2003.09.014; Zhang YM, 2003, BMC NEUROSCI, V4, DOI 10.1186/1471-2202-4-32; Zwienenberg M, 2001, NEUROSURGERY, V48, P1119, DOI 10.1097/00006123-200105000-00031	67	85	91	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	DEC	2006	24	11					3008	3016		10.1111/j.1460-9568.2006.05189.x			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	124IO	WOS:000243361700005	17156362	Green Accepted			2022-02-06	
J	Skoglund, TS; Eriksson-Ritzen, C; Jensen, C; Rydenhag, B				Skoglund, Thomas S.; Eriksson-Ritzen, Catherine; Jensen, Christer; Rydenhag, Bertil			Aspects on decompressive craniectomy in patients with traumatic head injuries	JOURNAL OF NEUROTRAUMA			English	Article						brain edema; decompressive craniectomy; intracranial pressure; outcome; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; BRAIN VOLUME REGULATION; INTRACRANIAL HYPERTENSION; MANAGEMENT; CHILDREN; THERAPY; EDEMA; GUIDELINES; SCALE; CRANIOTOMY	In patients with traumatic brain injury (TBI), intracranial hypertension secondary to cerebral edema is a major problem. A last-tier treatment in these cases is decompressive craniectomy. The aim of the present retrospective investigation was to (1) study the long-time outcome in patients with traumatic head injuries with intracranial hypertension treated with decompressive craniectomy; (2) examine the effects on intracranial pressure (ICP) by the craniectomy; and (3) investigate the possible relationship between the size of the removed bone-flap and the effects on ICP. Among the about 150 patients with severe TBI treated at our neurointensive care unit during 1997-2002, 19 patients were treated with decompressive craniectomy. All patients were young (mean 22 +/- 11 years, range 7-46 years), and 68% were male. The mean ICP was reduced from 29.2 +/- 3.5 before to 11.1 +/- 6.0 mm Hg immediately after the craniectomy; at 24 h after the craniectomy, the mean ICP was 13.9 +/- 9.7 mm Hg. Paired-samples t-test revealed a statistically significant decrease, both when comparing the preoperative values to the values immediately postoperative as well as to the values after 24 h (p < 0.01). A significant correlation between the size of the craniectomy and the decrease in ICP was found using Pearson regression analysis. The outcome of all patients could be assessed. The survival rate was 89%. Two patients died (both day 4 after the trauma); 68% of the patients had a favorable outcome (Glasgow Outcome Scale [GOS] score of 4 or 5); 16% were severely disabled (GOS score of 3); and one patient (5%) was left in a vegetative state.	Gothenburg Univ, Sahlgrens Hosp, Dept Neurosurg, S-41345 Gothenburg, Sweden; Gothenburg Univ, Sahlgrens Hosp, Dept Anesthesia & Intens Care Med, S-41345 Gothenburg, Sweden; Gothenburg Univ, Sahlgrens Hosp, Dept Radiol, S-41345 Gothenburg, Sweden		Skoglund, TS (corresponding author), Gothenburg Univ, Sahlgrens Hosp, Dept Neurosurg, S-41345 Gothenburg, Sweden.	thomas.skoglund@.vgregion.se					Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Cushing H, 1905, SURG GYNECOL OBSTET, V1, P297; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Elf K, 2005, NEUROSURGERY, V56, P962, DOI 10.1227/01.NEU.0000158317.00603.40; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hejazi N, 2002, EUR J PEDIATR, V161, P99, DOI 10.1007/s00431-001-0864-x; Hutchinson PJ, 2005, ACTA NEUROCHIR, V147, P1, DOI 10.1007/s00701-004-0400-7; JENNETT B, 1975, LANCET, V1, P480; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Meier U, 2003, ACTA NEUROCHIR SUPPL, V86, P367; Messing-Junger AM, 2003, ZBL NEUROCHIR, V64, P171; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Naredi S, 2001, ACTA ANAESTH SCAND, V45, P402, DOI 10.1034/j.1399-6576.2001.045004402.x; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Polin RS, 2003, CRIT CARE, V7, P409, DOI 10.1186/cc2370; POPLE IK, 1995, PEDIATR NEUROSURG, V23, P64, DOI 10.1159/000120938; Prat R, 1998, ACTA NEUROCHIR, V140, P1257, DOI 10.1007/s007010050247; RANSOHOFF J, 1971, J NEUROL NEUROSUR PS, V34, P106, DOI 10.1136/jnnp.34.1.106-a; ROSNER MJ, 1995, NEUROSURG CLIN N AM, V6, P761; Sahuquillo J, 2006, COCHRANE DB SYST REV, V1, P1; Schneider GH, 2002, ACT NEUR S, V81, P77; Simma B, 2002, INTENS CARE MED, V28, P1000, DOI 10.1007/s00134-002-1333-3; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; WIRTZ CR, 1997, NEUROSURG FOCUS, V15, pE3; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953	41	85	92	0	1	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2006	23	10					1502	1509		10.1089/neu.2006.23.1502			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	093XL	WOS:000241203500009	17020484				2022-02-06	
J	Kurca, E; Sivak, S; Kucera, P				Kurca, E.; Sivak, S.; Kucera, P.			Impaired cognitive functions in mild traumatic brain injury patients with normal and pathologic magnetic resonance imaging	NEURORADIOLOGY			English	Article						mild traumatic brain injury; cognitive impairment; magnetic resonance imaging; postconcussion syndrome	DIFFUSE AXONAL INJURY; SPORT-RELATED CONCUSSION; COMA SCALE SCORE; HEAD-INJURY; MRI; CT	Introduction: Mild traumatic brain injury (MTBI) is a common neurological (neurotraumatological) diagnosis. As well as different subjective symptoms, many patients develop neuropsychological dysfunction with objective impairment of attention, memory and certain executive functions. Magnetic resonance imaging (MRI) is not routinely used in MTBI patients despite its proven greater sensitivity and specificity in comparison with computed tomography (CT). Methods: The patient group consisted of 30 persons with MTBI and the control group consisted of 30 sex- and age-matched healthy volunteers. Both groups underwent neurological examination, neuropsychological testing (including the Postconcussion Symptoms Scale questionnaire, PCSS) and brain MRI (the patient group within 96 h after injury). Results: The analyzed groups did not differ significantly in terms of sex, age, or level or duration of education. MRI pathological findings (traumatic and nonspecific) were present in nine patients. Traumatic lesions were found in seven patients. Nonspecific white matter lesions were found in five healthy controls. There were significant differences between MTBI patients and controls in terms of subjective symptoms (PCSS) and selected neuropsychological tests. Statistically significant neuropsychological differences were found between MTBI patients with true traumatic lesions and MTBI patients with nonspecific lesions. Conclusion: There is evidence that MTBI patients with true traumatic MRI lesions are neuropsychologically different from MTBI patients with nonspecific MRI lesions or normal brain MRI. These results support the hypothesis that some acute MTBI signs and symptoms have a real organic basis which can be detected by selected new MRI modalities.	Comenius Univ, Jessenius Fac Med, Neurol Clin, Martin, Slovakia; Comenius Univ, Fac Med, Clin Neurol 1, Bratislava, Slovakia		Kurca, E (corresponding author), Comenius Univ, Jessenius Fac Med, Neurol Clin, Martin, Slovakia.	kurca@mfn.sk	Sivak, Stefan/O-4237-2018	Sivak, Stefan/0000-0002-0348-3082			Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GODERSKY JC, 1990, ACT NEUR S, V51, P311; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; KUEERA M, 1980, TEST KONCENTRACE POZ; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MORITANI T, 2004, DIFFUSION WEIGHTED M; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Sternberg RJ, 2002, KOGNITIVNI PSYCHOL; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Uchino Y, 2001, ACTA NEUROCHIR, V143, P1031, DOI 10.1007/s007010170008; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; VONKOMER J, 1992, DISJUNKENY REAKENY E; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wahlund LO, 2001, STROKE, V32, P1318, DOI 10.1161/01.STR.32.6.1318; Wechsler D, 1999, WECHSLER MEMORY SCAL; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013	26	85	86	0	11	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0028-3940	1432-1920		NEURORADIOLOGY	Neuroradiology	SEP	2006	48	9					661	669		10.1007/s00234-006-0109-9			9	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	082IF	WOS:000240379200009	16786351				2022-02-06	
J	Nakayama, N; Okumura, A; Shinoda, J; Nakashima, T; Iwama, T				Nakayama, N.; Okumura, A.; Shinoda, J.; Nakashima, T.; Iwama, T.			Relationship between regional cerebral metabolism and consciousness disturbance in traumatic diffuse brain injury without large focal lesions: an FDG-PET study with statistical parametric mapping analysis	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							POSITRON EMISSION TOMOGRAPHY; ANTERIOR CINGULATE CORTEX; CLOSED HEAD-INJURY; AXONAL INJURY; ALZHEIMERS-DISEASE; COMA; GYRUS; MILD	Background: The cerebral metabolism of patients in the chronic stage of traumatic diffuse brain injury (TDBI) has not been fully investigated. Aim: To study the relationship between regional cerebral metabolism (rCM) and consciousness disturbance in patients with TDBI. Methods: 52 patients with TDBI in the chronic stage without large focal lesions were enrolled, and rCM was evaluated by fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) with statistical parametric mapping (SPM). All the patients were found to have disturbed consciousness or cognitive function and were divided into the following three groups: group A (n=22), patients in a state with higher brain dysfunction; group B (n=13), patients in a minimally conscious state; and group C (n=17), patients in a vegetative state. rCM patterns on FDG-PET among these groups were evaluated and compared with those of normal control subjects on statistical parametric maps. Results: Hypometabolism was consistently indicated bilaterally in the medial prefrontal regions, the medial frontobasal regions, the cingulate gyrus and the thalamus. Hypometabolism in these regions was the most widespread and prominent in group C, and that in group B was more widespread and prominent than that in group A. Conclusions: Bilateral hypometabolism in the medial prefrontal regions, the medial frontobasal regions, the cingulate gyrus and the thalamus may reflect the clinical deterioration of TDBI, which is due to functional and structural disconnections of neural networks rather than due to direct cerebral focal contusion.	Kizawa Mem Hosp, Chubu Med Ctr Prolonged Traumat Brain Dysfunct, Minokamo City, Gifu 5050034, Japan; Gifu Prefectural Gifu Hosp, Dept Neurosurg, Gifu, Japan; Gifu Univ, Grad Sch Med, Dept Neurosurg, Gifu, Japan		Nakayama, N (corresponding author), Kizawa Mem Hosp, Chubu Med Ctr Prolonged Traumat Brain Dysfunct, 630 Shimokobi, Minokamo City, Gifu 5050034, Japan.	doctor.1@jasmine.ocn.ne.jp		Iwama, Toru/0000-0002-9426-284X			Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; CAVADA C, 1989, J COMP NEUROL, V287, P422, DOI 10.1002/cne.902870403; Chatfield C., 1980, INTRO MULTIVARIATE A; Dehaene S, 2001, COGNITION, V79, P1, DOI 10.1016/S0010-0277(00)00123-2; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; FRACKOWIAK RS, 1997, HUMAN BRAIN FUNCTION, V105; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Hirono N, 1998, J NEUROL NEUROSUR PS, V64, P552, DOI 10.1136/jnnp.64.4.552; Holmes A., 1997, HUMAN BRAIN FUNCTION, P67; Kjaer TW, 2001, CONSCIOUS COGN, V10, P356, DOI 10.1006/ccog.2001.0509; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; MINOSHIMA S, 1994, LANCET, V344, P895, DOI 10.1016/S0140-6736(94)92871-1; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; RAO N, 1984, ARCH PHYS MED REHAB, V65, P780; SRERIADE M, 1997, THALAMUS; Stamatakis EA, 2002, J NUCL MED, V43, P476; SUTHERLAND RJ, 1988, J NEUROSCI, V8, P1863; Talairach J., 1988, COPLANAR STEREOTACTI; Thompson C. J., 1986, Proceedings of the SPIE - The International Society for Optical Engineering, V671, P244; VOGT BA, 1992, CEREB CORTEX, V2, P435, DOI 10.1093/cercor/2.6.435-a; Whalen PJ, 1998, BIOL PSYCHIAT, V44, P1219, DOI 10.1016/S0006-3223(98)00251-0; Willis MW, 2002, PSYCHIAT RES-NEUROIM, V114, P23, DOI 10.1016/S0925-4927(01)00126-3; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263; Zeman AZJ, 1997, J NEUROL NEUROSUR PS, V62, P549, DOI 10.1136/jnnp.62.6.549	35	85	89	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUL	2006	77	7							856	10.1136/jnnp.2005.080523			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	054ZL	WOS:000238417900013	16549415	Green Published			2022-02-06	
J	Lu, J; Moochhala, S; Moore, XL; Ng, KC; Tan, MH; Lee, LKH; He, BP; Wong, MC; Ling, EA				Lu, J; Moochhala, S; Moore, XL; Ng, KC; Tan, MH; Lee, LKH; He, BP; Wong, MC; Ling, EA			Adult bone marrow cells differentiate into neural phenotypes and improve functional recovery in rats following traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						bone marrow cells; transplantation; neural differentiation; traumatic brain injury; functional recovery; rats	MESENCHYMAL STEM-CELLS; IN-VIVO; SYNAPTIC TRANSMISSION; HIPPOCAMPUS; DEFICITS; NEURONS	This study aims to investigate the therapeutic potential of adult bone marrow stromal cells (BMSCs). Exposed to a cocktail of induction medium, some BMSCs could differentiate into cell types with phenotypes of neural lineages in vitro. These cells expressed neural markers nestin, GFAP, 68-kDa neurofilament and beta-tubulin III as detected by immunohistochemistry and RT-PCR. Fluorescence-labeled cells were injected intravenously at 72 h after traumatic brain injury. Transplanted cells survived and migrated to the ipsilateral cerebral cortex at different time points after injection. They were immunopositive for neuronal marker MAP-2, oligodendrocyte marker CNPase, astrocytic maker GFAP or microglial marker OX-42 in vivo. In rats receiving BMSC transplants, there were significant improvements in motor and neurological functions when compared with the control groups. Hence, the therapeutic potential of BMSCs for traumatic brain injury is further amplified. (C) 2005 Elsevier Ireland Ltd. All fights reserved.	DSO Natl Labs, Def Med & Environm Res Inst, Singapore 117510, Singapore; Natl Canc Ctr, Brain Tumor Res Lab, Singapore, Singapore; Natl Univ Singapore, Dept Anat, Singapore 117548, Singapore		Lu, J (corresponding author), DSO Natl Labs, Def Med & Environm Res Inst, 27 Med Dr,09-01, Singapore 117510, Singapore.	ljia@dso.org.sg; mshabbir@dso.org.sg	Lee, Lionel/F-3394-2015	MOOCHHALA, SHABBIR/0000-0003-4521-3192			Arvanian VL, 2003, J NEUROSCI, V23, P8706; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Hess D, 2003, NAT BIOTECHNOL, V21, P763, DOI 10.1038/nbt841; Humpel Christian, 1995, Journal of Neural Transplantation and Plasticity, V5, P257; Ji JF, 2004, STEM CELLS, V22, P415, DOI 10.1634/stemcells.22-3-415; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kabos P, 2002, EXP NEUROL, V178, P288, DOI 10.1006/exnr.2002.8039; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KNIPPER M, 1994, NEUROREPORT, V5, P2433, DOI 10.1097/00001756-199412000-00007; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; NETTO CA, 1993, BEHAV BRAIN RES, V58, P107, DOI 10.1016/0166-4328(93)90095-8; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; SANCHEZRAMOS J, 2000, EXP NEUROL, V2, P47; Saporta S, 1999, NEUROSCIENCE, V91, P519, DOI 10.1016/S0306-4522(98)00610-1	21	85	104	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAY 1	2006	398	1-2					12	17		10.1016/j.neulet.2005.12.053			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	034FN	WOS:000236914500003	16455199				2022-02-06	
J	Harrison-Felix, C; Whiteneck, G; DeVivo, M; Hammond, FM; Jha, A				Harrison-Felix, C; Whiteneck, G; DeVivo, M; Hammond, FM; Jha, A			Causes of death following 1 year postinjury among individuals with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						causes of death; traumatic brain injury	LONG-TERM; LIFE EXPECTANCY; SYSTEMATIC BIAS; MORTALITY; EPILEPSY; ACCURACY; INDEX; ASCERTAINMENT; POPULATION; COMPLETION	Objective: To investigate causes of death in individuals with traumatic brain injury (TBI). Design: Retrospective cohort study Setting: Utilized data from the TBI Model Systems National Database, the Social Security Death Index, death certificates, and the US population age-race-gender-cause-specific mortality rates for 1994. Patients: Two thousand one hundred forty individuals with TBI completing inpatient rehabilitation in I of 15 National Institute on Disability and Rehabilitation Research-funded TBI Model Systems of Care between 1988 and 2001, and surviving past 1 year postinjury. Main Outcome Measures: Primary cause of death based on the International Classification of Diseases - 9th Revision - Clinical Modification-coded death certificates. Results: Individuals with TBI were about 37 times more likely to die of seizures, 12 times more likely to die of septicemia, 4 times more likely to die of pneumonia, and about 3 times more likely to die of other respiratory conditions (excluding pneumonia), digestive conditions, and all external causes of injury/poisoning than were individuals in the general population of similar age, gender, and race. Conclusion: Long-term follow-tip of individuals with TBI should increase vigilance for, and prevention of, diagnoses frequently causing death (circulatory disorders) and diagnoses with a high relative risk of causing death in this population (seizures, septicemia, respiratory and digestive conditions, and external causes of injury).	Craig Hosp, Dept Res, Englewood, CO 80113 USA; Univ Colorado, Hlth Sci Ctr, Dept Rehabil Med, Denver, CO 80202 USA; Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA; Charlotte Inst Rehabil, Charlotte, NC USA; Denver Hlth Med Ctr, Denver, CO USA		Harrison-Felix, C (corresponding author), Craig Hosp, Dept Res, 3425 S Clarkson Str, Englewood, CO 80113 USA.	charrison-felix@craighospital.org					Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Baguley I, 2000, BRAIN INJURY, V14, P505; BOYLE CA, 1990, AM J EPIDEMIOL, V131, P160, DOI 10.1093/oxfordjournals.aje.a115470; BRESLOW NE, 1987, INT AGENCY RES CANC, V82; Caplan B, 1996, J HEAD TRAUMA REHAB, V11, P1; Chan L, 2001, ARCH PHYS MED REHAB, V82, P1151, DOI 10.1053/apmr.2001.24892; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; CORKIN S, 1984, ARCH NEUROL-CHICAGO, V41, P975, DOI 10.1001/archneur.1984.04050200081022; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Cowper DC, 2002, ANN EPIDEMIOL, V12, P462, DOI 10.1016/S1047-2797(01)00285-X; DeVivo MJ, 2004, BRAIN INJURY, V18, P1155, DOI 10.1080/02699050410001672323; DEVIVO MJ, 1993, ARCH PHYS MED REHAB, V74, P248; DEVIVO MJ, 1995, CHEST, V108, P226, DOI 10.1378/chest.108.1.226; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Ficker DM, 1998, NEUROLOGY, V51, P1270, DOI 10.1212/WNL.51.5.1270; FISHER SG, 1995, AM J EPIDEMIOL, V141, P242, DOI 10.1093/oxfordjournals.aje.a117426; Gordis L, 2000, EPIDEMIOLOGY; HAMMOND F, 2000, ARCH PHYS MED REHAB, V81, P1259; Hammond F. M., 2000, ARCH PHYS MED REHAB, V81, P1260; Hanna N.J, 2002, NATL SENTINEL CLIN A; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; KIRCHER T, 1987, JAMA-J AM MED ASSOC, V258, P349, DOI 10.1001/jama.258.3.349; Leon-Carrion J, 2001, BRAIN INJURY, V15, P175, DOI 10.1080/026990501458407; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; Lhatoo SD, 2001, ANN NEUROL, V49, P336; Lloyd-Jones DM, 1998, ANN INTERN MED, V129, P1020, DOI 10.7326/0003-4819-129-12-199812150-00005; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; Messite J, 1996, JAMA-J AM MED ASSOC, V275, P794, DOI 10.1001/jama.275.10.794; Morgan CL, 2002, EPILEPSIA, V43, P1251, DOI 10.1046/j.1528-1157.2002.38701.x; *NAT CTR HLTH STAT, DEATHS 282 SEL CAUS; *NAT CTR HLTH STAT, DEATH RAT 72 SEL CAU; *NAT CTR HLTH STAT, DEATH RAT 113 SEL CA; *NAT CTR HLTH STAT, DEATH RAT 282 SEL CA; RICHEDWARDS JW, 1994, AM J EPIDEMIOL, V140, P1016, DOI 10.1093/oxfordjournals.aje.a117191; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; Roberts A.V., 1979, SEVERE ACCIDENTAL HE, P140; Rosenthal M, 1993, J HEAD TRAUMA REHAB, V8, P1; Schnorr TM, 1997, EPIDEMIOLOGY, V8, P321, DOI 10.1097/00001648-199705000-00017; Sesso HD, 2000, AM J EPIDEMIOL, V152, P107, DOI 10.1093/aje/152.2.107; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; Sperling MR, 1999, ANN NEUROL, V46, P45, DOI 10.1002/1531-8249(199907)46:1<45::AID-ANA8>3.0.CO;2-I; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Strauss DJ, 2003, NEUROLOGY, V60, P395, DOI 10.1212/WNL.60.3.395; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 2001, HEAD TRAUMA, P327; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; *US DEP COMM, 1994, CURR POP REP PROJ PO; *US DHHS, 1995, PHYS HDB MED CERT DE; Wagner AK, 2000, AM J PHYS MED REHAB, V79, P235, DOI 10.1097/00002060-200005000-00004; WALKER AE, 1989, ARCH NEUROL-CHICAGO, V46, P23, DOI 10.1001/archneur.1989.00520370025013; WEISS GH, 1982, ARCH NEUROL-CHICAGO, V39, P741, DOI 10.1001/archneur.1982.00510240003001; WENTWORTH DN, 1983, AM J PUBLIC HEALTH, V73, P1270, DOI 10.2105/AJPH.73.11.1270; Whiteneck G, 2001, COLORADO TRAUMATIC B; 1986, INT CLASSIFICATION D	62	85	85	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2006	21	1					22	33		10.1097/00001199-200601000-00003			12	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	004WW	WOS:000234784300003	16456389				2022-02-06	
J	Stalnacke, BM; Bjornstig, U; Karlsson, K; Sojka, P				Stalnacke, BM; Bjornstig, U; Karlsson, K; Sojka, P			One-year follow-up of mild traumatic brain injury: Post-concussion symptoms, disabilities and life satisfaction in relation to serum levels of S-100B and neurone-specific enolase in acute phase	JOURNAL OF REHABILITATION MEDICINE			English	Article						traumatic brain injury; head trauma; brain concussion; biochemical marker; S-100 proteins; life satisfaction; post-concussion symptoms	MINOR HEAD-INJURY; NEUROBIOCHEMICAL MARKERS; ELITE PLAYERS; DAMAGE; QUESTIONNAIRE; EPIDEMIOLOGY; POPULATION; PREDICTORS; SWEDEN; TRIAL	Objective: To investigate, in patients with mild traumatic brain injury, serum concentrations of S-100B and neurone-specific enolase in acute phase and post-concussion symptoms, disabilities and life satisfaction 1 year after the trauma. Design: Prospective study. Patients: Eighty-eight patients (age range 18-87 years). Methods: Blood samples were taken on admission and about 7 hours later. At follow-up 15 4 months later, the patients filled in questionnaires about symptoms (Rivermead Post Concussion Symptoms), disability (Rivermead Head Injury Follow-up) and life satisfaction (LiSat-11). Results: Concentrations of S-100B and neurone-specific enolase were regularly increased in the first blood sample. Of the 69 patients participating in the follow-up, 45% reported post-concussion symptom, 48% exhibited disability and 55% were satisfied with "life as a whole". In comparison with the "sick-leave" situation on admission to hospital, 3 patients were on sick-leave at the time of follow-up because of the head trauma. Stepwise forward logistic regression analysis revealed a statistically significant association (p<0.05) between disability and S-100B and dizziness. Conclusion: In spite of frequent persistent symptoms, disabilities and low levels of life satisfaction, the sick-leave frequency was low at follow-up. The association between S-100B and disability supports the notion that long-term consequences of a mild brain injury may partly be a result of brain tissue injury.	Umea Univ, Univ Umea Hosp, Dept Community Med & Rehabil, SE-90185 Umea, Sweden; Univ Umea Hosp, Dept Surg & Perioperat Sci, SE-90185 Umea, Sweden; Univ Umea Hosp, Sect Surg, SE-90185 Umea, Sweden; Univ Umea Hosp, Dept Med Biosci Clin Chem, SE-90185 Umea, Sweden		Stalnacke, BM (corresponding author), Umea Univ, Univ Umea Hosp, Dept Community Med & Rehabil, Bldg 9A, SE-90185 Umea, Sweden.	brittmarie.stalnacke@rehabmed.umu.se					*AB SANGT MED B, 2001, LIAIS SANGT 100 INST, P3; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Fugl-Meyer AR, 2002, J REHABIL MED, V34, P239, DOI 10.1080/165019702760279242; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kleiven Svein, 2003, Inj Control Saf Promot, V10, P173, DOI 10.1076/icsp.10.3.173.14552; KRAUS JF, 1989, MILD MODERATE HEAD I, P9; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Paniak C, 2000, BRAIN INJURY, V14, P219; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177	29	85	85	0	7	TAYLOR & FRANCIS AS	OSLO	PO BOX 12 POSTHUSET, NO-0051 OSLO, NORWAY	1650-1977			J REHABIL MED	J. Rehabil. Med.	SEP	2005	37	5					300	305		10.1080/16501970510032910			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	969HN	WOS:000232225300005	16208863	gold, Green Submitted			2022-02-06	
J	Meffre, D; Delespierre, B; Gouezou, M; Leclerc, P; Vinson, GP; Schumacher, M; Stein, DG; Guennoun, R				Meffre, D; Delespierre, B; Gouezou, M; Leclerc, P; Vinson, GP; Schumacher, M; Stein, DG; Guennoun, R			The membrane-associated progesterone-binding protein 25-Dx is expressed in brain regions involved in water homeostasis and is up-regulated after traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						circumventricular organs; 25-Dx; neuroprotection; progesterone; steroids; traumatic brain injury	INNER ZONE ANTIGEN; RAT-BRAIN; PRIMARY CULTURES; GLIAL-CELLS; RECEPTOR; VASOPRESSIN; ESTROGEN; DAMAGE; IDENTIFICATION; MODULATION	After traumatic brain injury, progesterone has important neuroprotective effects in the nervous system. There is better functional outcome and less oedema formation in pseudopregnant rat females (high levels of endogenous progesterone) than in males. In addition to intracellular progesterone receptors, membrane binding sites of the hormone such as 25-Dx may also be involved in neuroprotection. In the present study we investigated the distribution of the membrane-associated progesterone-binding protein 25-Dx in rat brain. Immunohistochemical analysis showed that 25-Dx is particularly abundant in the hypothalamic area, circumventricular organs, and ependymal cells of the lateral walls of the third and lateral ventricles. A strong signal was also detected in the meninges. Double immunofluorescence immunolabelling and confocal microscopy showed that 25-Dx is co-expressed with vasopressin in neurones of the paraventricular, supraoptic and retrochiasmatic nuclei. Levels of 25-Dx expression were higher in pseudopregnant females than in males. After traumatic brain injury, 25-Dx expression was up-regulated in neurones and induced in astrocytes, which play an important role in regulating water and ion homeostasis. The expression of 25-Dx in structures involved in CSF production (choroid plexus) and in osmoregulation (circumventricular organs, hypothalamus and meninges), and its up-regulation after brain damage, point to a novel and potentially important role of this progesterone-binding protein in the maintenance of water homeostasis after traumatic brain injury.	INSERM, U488, F-94276 Le Kremlin Bicetre, France; Queen Mary Univ London, Div Biomed Sci, London, England; Emory Univ, Dept Emergency Med, Brain Res Lab, Atlanta, GA 30322 USA		Guennoun, R (corresponding author), INSERM, U488, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	guen-noun@kb.inserm.fr	Guennoun, Rachida/F-2420-2011; Schumacher, Michael/G-3581-2013; Stein, Donald/AAJ-5139-2020	Guennoun, Rachida/0000-0002-9219-7300; Schumacher, Michael/0000-0001-6117-5371; MEFFRE, Delphine/0000-0002-9204-2245			Auger CJ, 2002, J NEUROENDOCRINOL, V14, P561, DOI 10.1046/j.1365-2826.2002.00809.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUKUSOGLU C, 1994, J NEUROCHEM, V63, P1434; CALDWELL JD, 1995, BRAIN RES, V693, P225, DOI 10.1016/0006-8993(95)00727-8; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; CROFTON JT, 1985, ENDOCRINOLOGY, V117, P1195, DOI 10.1210/endo-117-3-1195; De Nicola AF, 2003, ANN NY ACAD SCI, V1007, P317, DOI 10.1196/annals.1286.030; de Vries GJ, 1998, PROG BRAIN RES, V119, P3; Deniselle MCG, 2002, J STEROID BIOCHEM, V83, P199, DOI 10.1016/S0960-0760(02)00262-5; Etgen A.M., 2002, HORMONES BRAIN BEHAV, P643, DOI [10.1016/B978-012532104-4/50056-1, DOI 10.1016/B978-012532104-4/50056-1]; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Falkenstein E, 1999, ENDOCRINOLOGY, V140, P5999, DOI 10.1210/en.140.12.5999; Falkenstein E, 1996, BIOCHEM BIOPH RES CO, V229, P86, DOI 10.1006/bbrc.1996.1761; FORSLING ML, 1982, J ENDOCRINOL, V95, P147, DOI 10.1677/joe.0.0950147; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; GarciaSegura LM, 1996, FRONT NEUROENDOCRIN, V17, P180, DOI 10.1006/frne.1996.0005; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Guennoun R, 2003, CONTRO ISSU CLIM MED, P57; Hertz L, 2000, J NEUROSCI RES, V62, P480, DOI 10.1002/1097-4547(20001115)62:4<480::AID-JNR2>3.0.CO;2-K; Ibanez C, 2004, NEUROPATH APPL NEURO, V30, P80, DOI 10.1046/j.0305-1846.2003.00515.x; JUNGTESTAS I, 1991, EXP CELL RES, V193, P12, DOI 10.1016/0014-4827(91)90532-Y; JUNGTESTAS I, 1992, J STEROID BIOCHEM, V41, P621, DOI 10.1016/0960-0760(92)90394-X; JungTestas I, 1996, CELL MOL NEUROBIOL, V16, P439, DOI 10.1007/BF02088110; KE FC, 1990, J NEUROCHEM, V54, P467, DOI 10.1111/j.1471-4159.1990.tb01895.x; Krebs CJ, 2000, P NATL ACAD SCI USA, V97, P12816, DOI 10.1073/pnas.97.23.12816; Labombarda F, 2003, J NEUROCHEM, V87, P902, DOI 10.1046/j.1471-4159.2003.02055.x; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2000, J STEROID BIOCHEM, V73, P159, DOI 10.1016/S0960-0760(00)00064-9; LAIRD SM, 1988, ACTA ENDOCRINOL-COP, V119, P420, DOI 10.1530/acta.0.1190420; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088; MCEWEN BS, 1994, EXP GERONTOL, V29, P431, DOI 10.1016/0531-5565(94)90022-1; Meyer C, 1998, STEROIDS, V63, P111, DOI 10.1016/S0039-128X(97)00143-8; Meyer C, 1996, EUR J BIOCHEM, V239, P726, DOI 10.1111/j.1432-1033.1996.0726u.x; Micevych P, 2003, NEUROENDOCRINOLOGY, V78, P29, DOI 10.1159/000071703; Mifsud W, 2002, GENOME BIOL, V3; Min L, 2004, MOL CELL ENDOCRINOL, V215, P143, DOI 10.1016/j.mce.2003.11.025; Niermann H, 2001, J NEUROSCI, V21, P3045, DOI 10.1523/JNEUROSCI.21-09-03045.2001; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; RAINBOW TC, 1982, NATURE, V300, P648, DOI 10.1038/300648a0; Ramirez VD, 1996, CELL MOL NEUROBIOL, V16, P175, DOI 10.1007/BF02088175; Raza FS, 2001, EUR J BIOCHEM, V268, P2141, DOI 10.1046/j.1432-1327.2001.02096.x; Redzic ZB, 2004, ADV DRUG DELIVER REV, V56, P1695, DOI 10.1016/j.addr.2004.07.005; Sakamoto H, 2004, NEUROSCIENCE, V126, P325, DOI 10.1016/j.neuroscience.2004.04.003; Sakamoto H, 2001, J NEUROSCI, V21, P6221, DOI 10.1523/JNEUROSCI.21-16-06221.2001; SAVOURET JF, 1991, EMBO J, V10, P1875, DOI 10.1002/j.1460-2075.1991.tb07713.x; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Schumacher M, 2002, HORMONES BRAIN BEHAV, P683; Selmin O, 1996, CARCINOGENESIS, V17, P2609, DOI 10.1093/carcin/17.12.2609; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Simard M, 2004, NEUROSCIENCE, V129, P877, DOI 10.1016/j.neuroscience.2004.09.053; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; SUBRAHMANYAM CS, 1982, NUCLEIC ACIDS RES, V10, P3667, DOI 10.1093/nar/10.12.3667; Vongher JM, 1999, PHARMACOL BIOCHEM BE, V64, P777, DOI 10.1016/S0091-3057(99)00140-9; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100	57	85	87	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUN	2005	93	5					1314	1326		10.1111/j.1471-4159.2005.03127.x			13	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	927DP	WOS:000229172900024	15934950				2022-02-06	
J	Carrick, MM; Tyroch, AH; Youens, CA; Handley, T				Carrick, MM; Tyroch, AH; Youens, CA; Handley, T			Subsequent development of thrombocytopenia and coagulopathy in moderate and severe head injury: Support for serial laboratory examination	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	63rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma/Japanese-Association-for-Acute-Medicine	SEP 29-OCT 02, 2004	Maui, HI	Amer Assoc Surg Trauma, Japanese Assoc Acute Med		traumatic brain injury; secondary brain insult; thrombocytopenia; coagulopathy	DISSEMINATED INTRAVASCULAR COAGULATION; BRAIN-INJURY; TRAUMA; DISTURBANCES; FIBRINOLYSIS; ACTIVATION; HEMORRHAGE; SYSTEM	Background. Patients with moderate and severe traumatic brain injury (TBI) are at risk for secondary brain insults such as thrombocytopenia and coagulopathy. This study assessed the development of thrombocytopenia and coagulopathy at admission and within the subsequent 72 hours after TBI. Methods: Blunt trauma patients with moderate or severe TBI and an extracranial Abbreviated Injury Scale score less than 3 were reviewed. Data collection included initial and subsequent prothrombin time, partial thromboplastin time, and platelet values. Results: On initial evaluation, thrombocytopenia was present in 14% and coagulopathy in 21% of patients. By the third day, thrombocytopenia and coagulopathy increased to 46% and 41%, respectively. Of patients who died, 67% had thrombocytopenia and 62% had coagulopathy. Conclusion: Patients with moderate and severe TBI are at risk for thrombocytopenia and coagulopathy, not only at admission but also on subsequent laboratory examination. Repeat laboratory evaluation is warranted even if initial results are normal in this population.	Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; Texas Tech Univ, Hlth Sci Ctr, El Paso, TX USA		Carrick, MM (corresponding author), Baylor Coll Med, Michael E DeBakey Dept Surg, 1 Baylor Plaza, Houston, TX 77030 USA.	mcarrick@bcm.tmc.edu					AUER L, 1978, ACTA NEUROCHIR, V43, P51, DOI 10.1007/BF01809225; AUER LM, 1979, ACTA NEUROCHIR, V49, P219, DOI 10.1007/BF01808961; BULLOCK R, 1990, J NEUROSURG, V72, P9, DOI 10.3171/jns.1990.72.1.0009; Chesnut R M, 1995, New Horiz, V3, P366; CLARK JA, 1980, J NEUROSURG, V52, P266, DOI 10.3171/jns.1980.52.2.0266; Cortiana M, 1986, J Neurosurg Sci, V30, P133; CRONE KR, 1987, NEUROSURGERY, V21, P532, DOI 10.1227/00006123-198710000-00015; DAWODU ST, 2003, EMEDICINE, V6, P1; DRAYER BP, 1975, JAMA-J AM MED ASSOC, V231, P174, DOI 10.1001/jama.231.2.174; GANDO S, 1992, CRIT CARE MED, V20, P594, DOI 10.1097/00003246-199205000-00009; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; KAUFMAN HH, 1980, NEUROSURGERY, V7, P445, DOI 10.1227/00006123-198011000-00003; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; Keller M S, 2001, Semin Pediatr Surg, V10, P12, DOI 10.1053/spsu.2001.19381; Kushimoto S, 2003, J NEUROTRAUM, V20, P357, DOI 10.1089/089771503765172318; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; May AK, 1997, AM SURGEON, V63, P233; MINER ME, 1982, J PEDIATR-US, V100, P687, DOI 10.1016/S0022-3476(82)80565-9; Murshid WR, 2002, BRIT J NEUROSURG, V16, P362, DOI 10.1080/0268869021000007597; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Pondaag W, 1979, Acta Neurochir Suppl (Wien), V28, P98; PRESTON FE, 1974, J NEUROL NEUROSUR PS, V37, P241, DOI 10.1136/jnnp.37.3.241; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; Selladurai BM, 1997, BRIT J NEUROSURG, V11, P398; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; TOUHO H, 1986, NEUROSURGERY, V19, P523, DOI 10.1227/00006123-198610000-00005; VANDERSANDE JJ, 1981, J NEUROSURG, V55, P718, DOI 10.3171/jns.1981.55.5.0718; VANDERSANDE JJ, 1978, J NEUROSURG, V49, P357, DOI 10.3171/jns.1978.49.3.0357; VANDERSANDE JJ, 1981, J NEUROSURG, V54, P21, DOI 10.3171/jns.1981.54.1.0021	35	85	94	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2005	58	4					725	729		10.1097/01.TA.0000159249.68363.78			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	919VS	WOS:000228646300018	15824648				2022-02-06	
J	Shinoda, S; Schindler, CK; Meller, R; So, NK; Araki, T; Yamamoto, A; Lan, JQ; Taki, W; Simon, RP; Henshall, DC				Shinoda, S; Schindler, CK; Meller, R; So, NK; Araki, T; Yamamoto, A; Lan, JQ; Taki, W; Simon, RP; Henshall, DC			Bim regulation may determine hippocampal vulnerability after injurious seizures and in temporal lobe epilepsy	JOURNAL OF CLINICAL INVESTIGATION			English	Article							FORKHEAD TRANSCRIPTION FACTOR; INDUCED NEURONAL DEATH; BCL-2 FAMILY-MEMBER; TRANSIENT FOREBRAIN ISCHEMIA; TRAUMATIC BRAIN-INJURY; CELL-DEATH; STATUS EPILEPTICUS; NERVOUS-SYSTEM; CYTOCHROME-C; AKT	Programmed cell. death pathways have been implicated in the mechanism by which neurons die following brief and prolonged seizures, but the significance of proapoptotic Bcl-2 family proteins in the process remains poorly defined. Expression of the death agonist Bcl-2-interacting mediator of cell death (Bim) is under the control of the forkhead in rhabdomyosarcoma (FKHR) transcription factors. This prompted us to examine the response of this pathway to experimental seizures and in hippocampi from patients with intractable temporal lobe epilepsy. A short period of status epilepticus in rats that damaged the hippocampus activated FKHR/FKHRL-1 and induced a significant increase in expression of Bim. Blocking of FKHR/FKHRL-1 dephosphorylation after seizures improved hippocampal neuronal survival in vivo, and Bim antisense oligonucleotides were neuroprotective against seizures in vitro. Inhibition of Akt increased the FKHR/Bim response and DNA fragmentation within the normally resistant cortex. Analysis of hippocampi from patients with intractable epilepsy revealed that Bim levels were significantly lower than in controls and FKHR was inhibited; we were able to reproduce these results experimentally in rats by evoking multiple brief, noninjurious electroshock seizures. We conclude that Bim. expression maybe a critical determinant of whether seizures damage the brain, and that its control may be neuroprotective in status epilepticus and epilepsy.	Ctr Neurol Sci, Oregon Comprehens Epilepsy Program, Portland, OR USA; Mie Univ, Sch Med, Dept Neurosurg, Tsu, Mie 514, Japan; Legacy Res, Robert S Dow Neurobiol Labs, Portland, OR USA		Henshall, DC (corresponding author), Legacy Clin Res & Technol Ctr, Robert S Dow Neurol Labs, 1225 NE 2nd Ave, Portland, OR 97232 USA.	dhenshall@DowNeurobiolog.org	Henshall, David/C-3364-2012	Henshall, David/0000-0001-6237-9632	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS039016, R01 NS041935, NS39016, NS41935] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041935, R01NS039016] Funding Source: NIH RePORTER		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Aminoff MJ, 1998, ARCH NEUROL-CHICAGO, V55, P119, DOI 10.1001/archneur.55.1.119; Bengzon J, 2002, PROG BRAIN RES, V135, P111; Bouillet P, 2001, DEV CELL, V1, P645, DOI 10.1016/S1534-5807(01)00083-1; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Duncan JS, 2002, PROG BRAIN RES, V135, P253; Fannjiang Y, 2003, DEV CELL, V4, P575, DOI 10.1016/S1534-5807(03)00091-1; FURSHPAN EJ, 1989, NEURON, V3, P199, DOI 10.1016/0896-6273(89)90033-0; Gary DS, 2002, NEUROMOL MED, V2, P261, DOI 10.1385/NMM:2:3:261; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Henshall DC, 2002, J NEUROSCI, V22, P8458; Henshall DC, 2000, NEUROLOGY, V55, P250, DOI 10.1212/WNL.55.2.250; Henshall DC, 2001, NEUROBIOL DIS, V8, P568, DOI 10.1006/nbdi.2001.0415; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Jokeit H, 1999, J NEUROL, V246, P926, DOI 10.1007/s004150050484; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kawano T, 2001, J CEREBR BLOOD F MET, V21, P1268, DOI 10.1097/00004647-200111000-00003; Kawano T, 2002, J CEREBR BLOOD F MET, V22, P926, DOI 10.1097/00004647-200208000-00004; KELLY ME, 1994, BRAIN RES, V634, P245, DOI 10.1016/0006-8993(94)91927-5; KHAN A, 1995, CONVULSIVE THER, V11, P114; Kondratyev A, 2001, MOL BRAIN RES, V91, P1, DOI 10.1016/S0169-328X(01)00099-7; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kotloski R, 2002, PROG BRAIN RES, V135, P95; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Meldrum BS, 2002, PROG BRAIN RES, V135, P487; Meller R, 2003, CELL DEATH DIFFER, V10, P539, DOI 10.1038/sj.cdd.4401206; Mikati MA, 2003, EPILEPSIA, V44, P282, DOI 10.1046/j.1528-1157.2003.22502.x; Moriwaki A, 1998, NEUROSCIENCE, V86, P855, DOI 10.1016/S0306-4522(98)00071-2; Murphy JV, 2003, CNS DRUGS, V17, P101, DOI 10.2165/00023210-200317020-00003; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Narkilahti S, 2003, NEUROPHARMACOLOGY, V44, P1068, DOI 10.1016/S0028-3908(03)00115-1; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Ouyang YB, 1999, J CEREBR BLOOD F MET, V19, P1126, DOI 10.1097/00004647-199910000-00009; Paxinos P., 1997, RAT BRAIN STEREOTAXI; Pitkanen A, 2002, LANCET NEUROL, V1, P173, DOI 10.1016/S1474-4422(02)00073-X; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Roy M, 2002, GENE THER, V9, P214, DOI 10.1038/sj.gt.3301642; Sayin U, 2003, J NEUROSCI, V23, P2759; Shibata M, 2002, J CEREBR BLOOD F MET, V22, P810, DOI 10.1097/00004647-200207000-00006; Shinoda S, 2003, J NEUROCHEM, V86, P460, DOI 10.1046/j.1471-4159.2003.01860.x; Shinoda S, 2003, EUR J NEUROSCI, V17, P2065, DOI 10.1046/j.1460-9568.2003.02655.x; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Stoica BA, 2003, MOL CELL NEUROSCI, V22, P365, DOI 10.1016/S1044-7431(02)00028-3; Sutula TP, 2001, NEUROLOGY, V57, P169, DOI 10.1212/WNL.57.2.169; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wilson-Annan J, 2003, J CELL BIOL, V162, P877, DOI 10.1083/jcb.200302144; WOODBURY LA, 1952, ARCH INT PHARMACOD T, V92, P97; Zhang X, 2002, J NEUROSCI, V22, P6052	56	85	89	0	6	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA	0021-9738	1558-8238		J CLIN INVEST	J. Clin. Invest.	APR	2004	113	7					1059	1068		10.1172/JCI200419971			10	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	809QR	WOS:000220651700019	15057313	Bronze, Green Published			2022-02-06	
J	Coles, JP; Fryer, TD; Smielewski, P; Rice, K; Clark, JC; Pickard, JD; Menon, DK				Coles, JP; Fryer, TD; Smielewski, P; Rice, K; Clark, JC; Pickard, JD; Menon, DK			Defining ischemic burden after traumatic brain injury using O-15 PET imaging if cerebral physiology	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						trauma; head injury; positron emission tomography; cerebral ischemia; ischemic penumbra	STEADY-STATE TECHNIQUE; BLOOD-FLOW; OXYGEN UTILIZATION; ENERGY-METABOLISM; ACUTE STROKE; HYPERVENTILATION; TOMOGRAPHY; TISSUE; PENUMBRA; VOLUME	Whereas postmortem ischemic damage is common in head injury, antemortern demonstration of ischemia has proven to be elusive. Although O-15 positron emission tomography may be useful in this area, the technique has traditionally analyzed data within regions of interest (ROIs) to improve statistical accuracy. In head injury, such techniques are limited because of the lack of a priori knowledge regarding the location of ischemia, coexistence of hyperaemia, and difficulty in defining ischemic cerebral blood flow (CBF) and cerebral oxygen metabolism (CMRO2) levels. We report a novel method for defining disease pathophysiology following head injury. Voxel-based approaches are used to define the distribution of oxygen extraction fraction (OEF) across the entire brain; the standard deviation of this distribution provides a measure of the variability of OEF. These data are also used to integrate voxels above a threshold OEF value to produce an ROI based upon coherent physiology rather than spatial contiguity (the ischemic brain volume; IBV). However, such approaches may suffer from poor statistical accuracy, particularly in regions with low blood flow. The magnitude of these errors has been assessed in modeling experiments using the Hoffman brain phantom and modified control datasets. We conclude that this technique is a valid and useful tool for quantifying ischemic burden after traumatic brain injury.	Univ Cambridge, Addenbrookes Hosp, Div Anesthesia, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 2QQ, England; Inst Publ Hlth, MRC, Biostat Unit, Cambridge, England		Menon, DK (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Anesthesia, Box 93,Hills Rd, Cambridge CB2 2QQ, England.	dkm13@wbic.cam.ac.uk	Rice, Kenneth M/A-4150-2013	Rice, Kenneth M/0000-0001-5779-4495; Coles, Jonathan/0000-0003-4013-679X; Smielewski, Peter/0000-0001-5096-3938	MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390, G0001237] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G9439390] Funding Source: Medline		ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Baron JC, 1999, CEREBROVASC DIS, V9, P193, DOI 10.1159/000015955; BARON JC, 1989, J CEREBR BLOOD F MET, V9, P723, DOI 10.1038/jcbfm.1989.105; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; COLES JP, 2002, CLIN SCI, V103, P62; CORREIA JA, 1985, J CEREBR BLOOD F MET, V5, P591, DOI 10.1038/jcbfm.1985.88; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; FRACKOWIAK RSJ, 1980, J COMPUT ASSIST TOMO, V4, P727, DOI 10.1097/00004728-198012000-00001; HEISS WD, 1992, J CEREBR BLOOD F MET, V12, P193, DOI 10.1038/jcbfm.1992.29; HERSCOVITCH P, 1983, J CEREBR BLOOD F MET, V3, P407, DOI 10.1038/jcbfm.1983.66; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; HOFFMAN EJ, 1990, IEEE T NUCL SCI, V37, P616, DOI 10.1109/23.106686; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; KINAHAN PE, 1989, IEEE T NUCL SCI, V36, P964, DOI 10.1109/23.34585; LAMMERTSMA AA, 1982, J COMPUT ASSIST TOMO, V6, P566, DOI 10.1097/00004728-198206000-00022; LAMMERTSMA AA, 1981, J COMPUT ASSIST TOMO, V5, P544, DOI 10.1097/00004728-198108000-00016; LAMMERTSMA AA, 1992, J CEREBR BLOOD F MET, V12, P291, DOI 10.1038/jcbfm.1992.39; LAMMERTSMA AA, 1987, J CEREBR BLOOD F MET, V7, P372, DOI 10.1038/jcbfm.1987.75; LEBRUNGRANDIE P, 1983, ARCH NEUROL-CHICAGO, V40, P230, DOI 10.1001/archneur.1983.04050040060010; Marchal G, 1999, BRAIN, V122, P2387, DOI 10.1093/brain/122.12.2387; Marchal G, 1996, STROKE, V27, P599, DOI 10.1161/01.STR.27.4.599; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; PHELPS ME, 1979, J NUCL MED, V20, P328; POWERS WJ, 1985, J CEREBR BLOOD F MET, V5, P600, DOI 10.1038/jcbfm.1985.89; SMIELEWSKI P, 2003, IN PRESS J CLIN MONI; STEINER LA, 2003, IN PRESS J CEREB BLO; SUTTON LN, 1990, J NEUROSURG, V73, P927, DOI 10.3171/jns.1990.73.6.0927; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Yundt KD, 1997, CRIT CARE CLIN, V13, P163, DOI 10.1016/S0749-0704(05)70300-6	34	85	87	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2004	24	2					191	201		10.1097/01.WCB.0000100045.07481.DE			11	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	772CG	WOS:000188822600007	14747746	Bronze			2022-02-06	
J	Natale, JE; Ahmed, F; Cernak, I; Stoica, B; Faden, AI				Natale, JE; Ahmed, F; Cernak, I; Stoica, B; Faden, AI			Gene expression profile changes are commonly modulated across models and species after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; fluid percussion; gene expression; mRNA	TISSUE-PLASMINOGEN ACTIVATOR; SPINAL-CORD-INJURY; FOCAL CEREBRAL-ISCHEMIA; CALCIUM-BINDING PROTEINS; RAT-BRAIN; CORTICAL IMPACT; NEURONAL DEATH; MESSENGER-RNA; HEAT-SHOCK; PERIPHERAL BENZODIAZEPINE	Brain trauma is a major cause of morbidity and mortality, both in adult and pediatric populations. Much of the functional deficit derives from delayed cell death resulting from induction of neurotoxic factors that overwhelm endogenous neuroprotective responses. To identify the potential molecular mechanisms underlying such delayed responses, we compared gene expression patterns using high-density oligonucleotide arrays at 4, 8, 24, and 72 h after moderate levels of lateral fluid percussion-induced brain injury in rats and lateral controlled cortical impact injury in mice (a total of 47 profiles). Expression of 82 genes in 12 functional categories was significantly changed in both species after trauma. The largest number of gene expression changes were found in the functional groups related to inflammation (17%), transcription regulation (16%), and cell adhesion/extracellular matrix (15%). Fifty percent of genes similarly altered across models had not been previously implicated in traumatic brain injury. Of particular interest were expression changes in genes linked to neurodegeneration, such as ATF3 and lysosomal membrane glycoprotein 2, and to neuroprotection including lipocortin 1, calponin 3, gelsolin, Id-1, and p45 NF-E2. Gene expression profiling across species and models may help identify candidate molecular pathways induced by brain injury, some of which may provide novel targets for therapeutic intervention.	Childrens Natl Med Ctr, Med Genet Res Ctr, Washington, DC 20010 USA; Childrens Natl Med Ctr, Neurosci Res Ctr, Washington, DC 20010 USA; Georgetown Univ, Sch Med, Dept Neurosci, Washington, DC USA		Natale, JE (corresponding author), Childrens Natl Med Ctr, Med Genet Res Ctr, 111 Michigan Ave NW, Washington, DC 20010 USA.		STOICA, BOGDAN/H-9782-2013; Cernak, Ibolja/A-6399-2008	STOICA, BOGDAN/0000-0002-2501-6434; Ibolja, Cernak/0000-0003-3214-698X	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1P30HD40677-01] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1K08 NS41273, NS36537] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD040677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036537, K08NS041273] Funding Source: NIH RePORTER		Andrews GK, 2000, BIOCHEM PHARMACOL, V59, P95, DOI 10.1016/S0006-2952(99)00301-9; Bakay M, 2002, NEUROMUSCULAR DISORD, V12, pS125, DOI 10.1016/S0960-8966(02)00093-7; Banati RB, 1997, J NEUROCYTOL, V26, P77, DOI 10.1023/A:1018567510105; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; BRASSARD M, 1996, CONTROL CHART MEMORY, P288; Bruce-Keller AJ, 1999, J NEUROSCI RES, V58, P191, DOI 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO;2-E; Campagne MV, 1999, P NATL ACAD SCI USA, V96, P12870; CARRI NG, 1992, INT J DEV NEUROSCI, V10, P393, DOI 10.1016/0736-5748(92)90029-Y; Casellas P, 2002, NEUROCHEM INT, V40, P475, DOI 10.1016/S0197-0186(01)00118-8; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Chuaqui RF, 2002, NAT GENET, V32, P509, DOI 10.1038/ng1034; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Dutcher SA, 1998, J NEUROTRAUM, V15, P411, DOI 10.1089/neu.1998.15.411; Endres M, 1999, J CLIN INVEST, V103, P347, DOI 10.1172/JCI4953; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; FADEN AI, 1993, J NEUROTRAUM, V10, P101, DOI 10.1089/neu.1993.10.101; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Felbor U, 2002, P NATL ACAD SCI USA, V99, P7883, DOI 10.1073/pnas.112632299; Fox GB, 1998, J NEUROSCI RES, V53, P718, DOI 10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.3.CO;2-L; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Fujino I, 1997, NEUROSCI RES, V28, P243, DOI 10.1016/S0168-0102(97)00050-3; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; Gong PF, 2002, ANTIOXID REDOX SIGN, V4, P249, DOI 10.1089/152308602753666307; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; Hill IE, 1997, BRAIN RES, V751, P206, DOI 10.1016/S0006-8993(96)01403-5; Hussain S, 1996, NEUROCHEM INT, V29, P145, DOI 10.1016/0197-0186(95)00114-X; Iadecola C, 1999, J EXP MED, V189, P719, DOI 10.1084/jem.189.4.719; Jaworski DM, 2000, GLIA, V30, P199, DOI 10.1002/(SICI)1098-1136(200004)30:2<199::AID-GLIA9>3.0.CO;2-#; Jones LL, 2002, J NEUROSCI, V22, P4611, DOI 10.1523/JNEUROSCI.22-11-04611.2002; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Leist M, 2001, CELL DEATH DIFFER, V8, P324, DOI 10.1038/sj.cdd.4400859; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Marciano PG, 2002, NEUROCHEM RES, V27, P1147, DOI 10.1023/A:1020973308941; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCKANNA JA, 1993, J NEUROSCI RES, V36, P491, DOI 10.1002/jnr.490360415; Meyer G, 2002, J NEUROCHEM, V83, P490, DOI 10.1046/j.1471-4159.2002.01185.x; Miyachi T, 2001, NEUROSCI RES, V40, P53, DOI 10.1016/S0168-0102(01)00208-5; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Mori T, 2001, NEUROREPORT, V12, P4117, DOI 10.1097/00001756-200112210-00051; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; O'Keefe GM, 2001, J IMMUNOL, V166, P2260, DOI 10.4049/jimmunol.166.4.2260; Penkowa M, 2001, J NEUROTRAUM, V18, P447, DOI 10.1089/089771501750171056; Plantier M, 1999, EUR J NEUROSCI, V11, P2801, DOI 10.1046/j.1460-9568.1999.00702.x; Postler E, 1997, GLIA, V19, P27, DOI 10.1002/(SICI)1098-1136(199701)19:1<27::AID-GLIA3>3.0.CO;2-7; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rammes A, 1997, J BIOL CHEM, V272, P9496; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Rhodes DR, 2002, CANCER RES, V62, P4427; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/0968-0004(96)10020-7; Sharp FR, 1999, TRENDS NEUROSCI, V22, P97, DOI 10.1016/S0166-2236(98)01392-7; Tang Y, 2002, EUR J NEUROSCI, V15, P1937, DOI 10.1046/j.1460-9568.2002.02030.x; Tang Y, 2003, J CEREBR BLOOD F MET, V23, P310, DOI 10.1097/01.WCB.0000048518.34839.DE; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; Yakovlev AG, 2001, MOL MED, V7, P205, DOI 10.1007/BF03401955; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yenari MA, 1999, MOL MED TODAY, V5, P525, DOI 10.1016/S1357-4310(99)01599-3; YOUNG W, 1992, J NEUROTRAUMA S1, V9, P9	74	85	86	1	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2003	20	10					907	927		10.1089/089771503770195777			21	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	734RX	WOS:000186072300001	14588109				2022-02-06	
J	Logi, F; Fischer, C; Murri, L; Mauguiere, F				Logi, F; Fischer, C; Murri, L; Mauguiere, F			The prognostic value of evoked responses from primary somatosensory and auditory cortex in comatose patients	CLINICAL NEUROPHYSIOLOGY			English	Article						somatosensory evoked potentials; middle latency auditory evoked potentials; coma; post-anoxic coma; traumatic brain injury; outcome prediction	SEVERE HEAD-INJURY; EVENT-RELATED POTENTIALS; ANOXIC-ISCHEMIC COMA; SEVERE BRAIN-DAMAGE; OUTCOME PREDICTION; MIDDLE-LATENCY; CARDIAC-ARREST; BILATERAL LOSS; PARIETAL COMPONENTS; STEM	Objective: To evaluate somatosensory and auditory primary cortices using somatosensory evoked potentials (SEPs) and middle latency auditory evoked potentials (MLAEPs) in the prognosis of return to consciousness in comatose patients. Methods: SEPs and MLAEPs were recorded in 131 severe comatose patients. Latencies and amplitudes were measured. Coma had been caused by transient cardiac arrest (n = 49), traumatic brain injury (n = 22), stroke (n = 45), complications of neurosurgery (n = 12) and encephalitis (n = 3). One month after the onset of coma patients were classified as awake, still comatose or dead. Three months after (W), they were classified into one of the 5 categories of the Glasgow outcome scale (GOS). Results: At M3, 41.2% were dead, 47.3% were conscious (GOS 3-5) and 11.5% had not recovered consciousness. None of the patients in whom somatosensory N20 and auditory Pa were absent did return to consciousness and in the post-anoxic group, reduced cortical amplitude too was always associated with bad outcome. Conversely, N20 and Pa were present, respectively, in 33/69 and 34/69 patients who did not recover. Conclusions: The prognostic value of SEPs and MLAEPs in comatose patients depends on the cause of coma. Measurement of response amplitudes is informative. Abolition of cortical SEPs and/or cortical MLAEPs precludes post-anoxic comatose patients from returning to consciousness (100% specificity). In any case, the presence of short latency cortical somatosensory or auditory components is not a guarantee for return to consciousness. Late components should then be recorded. (C) 2003 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	Hop Neurol, EA1880, F-69003 Lyon, France; Univ Pisa, Inst Neurol, Dept Neurosci, I-56100 Pisa, Italy		Fischer, C (corresponding author), Hop Neurol, EA1880, 59 Blvd Pinel, F-69003 Lyon, France.	catherine.fischer@univ-lyon1.fr		MAUGUIERE, Francois/0000-0003-4291-4727			ANDERSON DC, 1984, ARCH NEUROL-CHICAGO, V41, P369, DOI 10.1001/archneur.1984.04050160031011; Attia J, 1998, CRIT CARE CLIN, V14, P497, DOI 10.1016/S0749-0704(05)70013-0; BARELLI A, 1991, CRIT CARE MED, V19, P1374, DOI 10.1097/00003246-199111000-00013; Bassetti C, 1996, J NEUROL NEUROSUR PS, V61, P610, DOI 10.1136/jnnp.61.6.610; BEREK K, 1995, STROKE, V26, P543, DOI 10.1161/01.STR.26.4.543; Berkhoff M, 2000, CLIN NEUROPHYSIOL, V111, P297, DOI 10.1016/S1388-2457(99)00246-1; BRUNKO E, 1987, ELECTROEN CLIN NEURO, V66, P15, DOI 10.1016/0013-4694(87)90133-7; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; Carter BG, 2001, CRIT CARE MED, V29, P178, DOI 10.1097/00003246-200101000-00036; Cheliou-Heraut F., 1992, Neurophysiologie Clinique, V22, P269, DOI 10.1016/S0987-7053(05)80259-X; Chen R, 1996, CRIT CARE MED, V24, P672, DOI 10.1097/00003246-199604000-00020; Chiappa KH, 1998, ELECTROEN CLIN NEURO, V106, P149, DOI 10.1016/S0013-4694(97)00118-1; Claassen J, 2001, CRIT CARE MED, V29, P494, DOI 10.1097/00003246-200103000-00005; CUSUMANO S, 1992, ELECTROEN CLIN NEURO, V84, P499, DOI 10.1016/0168-5597(92)90039-E; DEGIORGIO CM, 1993, ACTA NEUROL SCAND, V87, P423; DESMEDT JE, 1987, ELECTROEN CLIN NEURO, V68, P1, DOI 10.1016/0168-5597(87)90065-7; DRUMMOND JC, 1987, NEUROSURGERY, V20, P830, DOI 10.1227/00006123-198706000-00002; EDGREN E, 1994, LANCET, V343, P1055, DOI 10.1016/S0140-6736(94)90179-1; Facco E, 1998, ELECTROEN CLIN NEURO, V107, P332, DOI 10.1016/S0013-4694(98)00080-7; Facco E., 1993, Neurophysiologie Clinique, V23, P237, DOI 10.1016/S0987-7053(05)80233-3; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; Fischer C, 1999, CLIN NEUROPHYSIOL, V110, P1601, DOI 10.1016/S1388-2457(99)00131-5; FISCHER C, 1994, NEUROSURGERY, V35, P45, DOI 10.1227/00006123-199407000-00007; GANES T, 1988, ELECTROEN CLIN NEURO, V69, P6, DOI 10.1016/0013-4694(88)90030-2; Garcia-Larrea L., 1993, Neurophysiologie Clinique, V23, P141; Gendo A, 2001, INTENS CARE MED, V27, P1305, DOI 10.1007/s001340101008; GOTT PS, 1991, ARCH NEUROL-CHICAGO, V48, P1267, DOI 10.1001/archneur.1991.00530240071024; GREENBERG RP, 1981, J NEUROSURG, V55, P227, DOI 10.3171/jns.1981.55.2.0227; Guerit J. M., 1993, Neurophysiologie Clinique, V23, P209, DOI 10.1016/S0987-7053(05)80231-X; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; GUTLING E, 1994, ELECTROEN CLIN NEURO, V92, P568, DOI 10.1016/0168-5597(94)90141-4; GUTLING E, 1993, ELECTROEN CLIN NEURO, V88, P369, DOI 10.1016/0168-5597(93)90013-F; GUTLING E, 1995, NEUROLOGY, V45, P915, DOI 10.1212/WNL.45.5.915; Haupt WF, 2000, J CLIN NEUROPHYSIOL, V17, P326, DOI 10.1097/00004691-200005000-00010; HOULDEN DA, 1990, NEUROSURGERY, V27, P701, DOI 10.1227/00006123-199011000-00006; HUTCHINSON DO, 1991, ELECTROEN CLIN NEURO, V78, P228, DOI 10.1016/0013-4694(91)90037-5; JENNETT B, 1975, LANCET, V1, P480; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; LARREA LG, 1992, ELECTROEN CLIN NEURO, V84, P71, DOI 10.1016/0168-5597(92)90069-N; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; Litscher G, 1995, INT J NEUROSCI, V83, P253, DOI 10.3109/00207459508986342; Madl C, 2000, CRIT CARE MED, V28, P721, DOI 10.1097/00003246-200003000-00020; Madl C, 1996, ARCH NEUROL-CHICAGO, V53, P512, DOI 10.1001/archneur.1996.00550060054017; MAUGUIERE F, 1983, BRAIN, V106, P271, DOI 10.1093/brain/106.2.271; Mauguiere F, 1999, EEG CL N SU, V50, P31; Mazzini L, 2001, ARCH PHYS MED REHAB, V82, P57, DOI 10.1053/apmr.2001.18076; Morlet D, 1997, EVOKED POTENTIAL, V104, P437, DOI 10.1016/S0168-5597(97)00044-0; MORLET D, 2000, AUDIOL NEURO-OTOL, V5, P190; Nakabayashi M, 2001, INTENS CARE MED, V27, P1210, DOI 10.1007/s001340100984; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NEWLON PG, 1983, NEUROSURGERY, V12, P613, DOI 10.1227/00006123-198306000-00003; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; PFURTSCHELLER G, 1985, ELECTROEN CLIN NEURO, V62, P88, DOI 10.1016/0168-5597(85)90020-6; PohlmannEden B, 1997, INTENS CARE MED, V23, P301, DOI 10.1007/s001340050332; RAPPAPORT M, 1977, ARCH PHYS MED REHAB, V58, P333; ROSENBERG C, 1984, ARCH NEUROL-CHICAGO, V41, P835, DOI 10.1001/archneur.1984.04050190041012; ROSSINI PM, 1987, ELECTROEN CLIN NEURO, V68, P88, DOI 10.1016/0168-5597(87)90036-0; Rothstein TL, 2000, J CLIN NEUROPHYSIOL, V17, P486, DOI 10.1097/00004691-200009000-00007; ROTHSTEIN TL, 1991, ELECTROEN CLIN NEURO, V79, P101, DOI 10.1016/0013-4694(91)90046-7; Schwarz S, 1999, CRIT CARE MED, V27, P182, DOI 10.1097/00003246-199901000-00049; Sherman AL, 2000, NEUROLOGY, V54, P889, DOI 10.1212/WNL.54.4.889; Sleigh JW, 1999, J NEUROSURG, V91, P577, DOI 10.3171/jns.1999.91.4.0577; SNYDER BD, 1981, NEUROLOGY, V31, P1092, DOI 10.1212/WNL.31.9.1092; SYNEK VM, 1990, CLIN ELECTROENCEPHAL, V21, P25, DOI 10.1177/155005949002100111; WALSER H, 1985, ARCH NEUROL-CHICAGO, V42, P32, DOI 10.1001/archneur.1985.04060010038013; Wedekind C, 1999, J TRAUMA, V47, P44, DOI 10.1097/00005373-199907000-00010; Wijdicks EFM, 2001, AM J NEURORADIOL, V22, P1561; Wohlrab G, 2001, NEUROPEDIATRICS, V32, P271, DOI 10.1055/s-2001-19123; YING Z, 1992, J NEUROL NEUROSUR PS, V55, P470, DOI 10.1136/jnnp.55.6.470; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; YOUNG B, 1993, NEUROLOGY S2, V43, pA229; Yvert B, 2001, CEREB CORTEX, V11, P411, DOI 10.1093/cercor/11.5.411; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8; Zandbergen EGJ, 2001, INTENS CARE MED, V27, P1661, DOI 10.1007/s001340101076; ZENTNER J, 1992, NEUROSURGERY, V31, P429, DOI 10.1227/00006123-199209000-00007	76	85	101	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	SEP	2003	114	9					1615	1627		10.1016/S1388-2457(03)00086-5			13	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	722XJ	WOS:000185403100005	12948790				2022-02-06	
J	Naunheim, RS; Bayly, PV; Standeven, J; Neubauer, JS; Lewis, LM; Genin, GM				Naunheim, RS; Bayly, PV; Standeven, J; Neubauer, JS; Lewis, LM; Genin, GM			Linear and angular head accelerations during heading of a soccer ball	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						kinematic measurements; kinematic modeling; brain injury; impact modeling	PLAYERS; INJURY; BRAIN; CONCUSSION; CRITERION; FOOTBALL; IMPACT; DAMAGE	Purpose: Cognitive deficits observed in professional soccer players may be related to heading of a soccer ball. To assess the severity of a single instance of heading a soccer ball, this study experimentally and theoretically evaluated the linear and angular accelerations experienced by the human head during a frontal heading maneuver. Methods: Accelerations were measured using a set of three triaxial accelerometers mounted to the head of each of four adult male subjects. These measurements (nine signals) were used to estimate the linear acceleration of the mass center and the angular acceleration of the head. Results were obtained for ball speeds of 9 and 12 m(.)s(-1) (approximately 20 and 26 mph). A simple mathematical model was derived for comparison. Results: At 9 m(.)s(-1), peak linear acceleration of the head was 158 +/- 19 m(.)s(-2) (mean +/- standard deviation) and peak angular acceleration was 1302 +/- 324 rad-s(-2); at 12 m(.)s(-1), the values were 199 +/- 27 m(.)w(-2) and 1457 +/- 297 rad(.)s(-2), respectively. The initial acceleration pulses lasted approximately 25 ms. Measured head accelerations confirmed laboratory headform measurements reported in the literature and fell within the ranges predicted by the theoretical model. Conclusions: Linear and angular acceleration levels for a single heading maneuver were well below those thought to be associated with traumatic brain injury, as were computed values of the Gadd Severity Index and the Head Injury Criterion. However, the effect of repeated acceleration at this relatively low level is unknown.	Washington Univ, Henry Edwin Sever Sch Engn & Appl Sci, Dept Mech Engn, St Louis, MO 63130 USA; Washington Univ, Div Emergency Med, St Louis, MO USA; Washington Univ, Dept Biomed Engn, St Louis, MO USA		Genin, GM (corresponding author), Washington Univ, Henry Edwin Sever Sch Engn & Appl Sci, Dept Mech Engn, Campus Box 1185, St Louis, MO 63130 USA.	gmg@me.wustl.edu		Bayly, Philip/0000-0003-4303-0704			Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; Anderson SJ, 2000, PEDIATRICS, V105, P659, DOI 10.1542/peds.105.3.640; Bailey B. N., 1989, TXB HEAD INJURY, P308; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Baroff GS, 1998, J HEAD TRAUMA REHAB, V13, P45, DOI 10.1097/00001199-199804000-00007; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Gadd C, 1966, 660793 SAE; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GINSBERG G, 1995, DYNAMICS; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; KING AI, 1995, BIOMEDICAL ENG HDB, P357; KROSS R, 1983, EEG-EMG-Z ELEK ELEKT, V14, P209; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Naunheim RS, 2003, ACAD EMERG MED, V10, P85, DOI 10.1197/aemj.10.1.85; Newman J. A., 1980, 801317 SAE; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; ONUSIC H, 1995, INT J VEHICLE DES, V16, P194; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109	27	85	86	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	AUG	2003	35	8					1406	1412		10.1249/01.MSS.0000078933.84527.AE			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	707UE	WOS:000184527600023	12900697				2022-02-06	
J	Coleman, RD; Rapport, LJ; Ergh, TC; Hanks, RA; Ricker, JH; Millis, SR				Coleman, RD; Rapport, LJ; Ergh, TC; Hanks, RA; Ricker, JH; Millis, SR			Predictors of driving outcome after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	29th Annual Meeting of the International-Neuropsychological-Society	FEB 14-17, 2001	CHICAGO, ILLINOIS	Int Neuropsychol Soc		accidents; traffic; automobile driving; brain injuries; rehabilitation	ALZHEIMERS-DISEASE; CEREBRAL-DAMAGE; RATING-SCALE; REHABILITATION; PERFORMANCE; DRIVERS; DISABILITY; IMPAIRMENT; FITNESS; ABILITY	Objective: To examine predictors of driving status and fitness to drive after traumatic brain injury (TBI). Design: Retrospective and prospective follow-up of a cohort ranging from 4 months to 10 years post-TBI. Setting: A Midwestern, urban university-affiliated rehabilitation hospital. Participants: Seventy-one pairs of adults who had sustained a TBI and their significant others. Interventions: Not applicable. Main Outcome Measures: Driving status (whether the patient resumed driving), driving frequency (estimated miles driven per week), and postinjury driving records compiled by the Department of Motor Vehicles. Results: Logistic and hierarchical regression analyses indicated that the significant other's perceptions of the patient's fitness to drive were the strongest predictor of patients' driving status and driving frequency. However, years postinjury, disability at discharge, and current neuropsychologic functioning best predicted postinjury driving safety as measured by actual incidents. The relation between perception of patients' fitness and actual driving incidents, however, was modest. Conclusions: Neuropsychologic and medical information available by traditional methods showed unique value in predictive driving safety. However, caregiver perception of patients' fitness was the overwhelming determinant of whether and how much patients drive. The bases on which caregivers form their opinions affect the safety of patients and the public. The rehabilitation setting is a unique resource for family education regarding abilities essential to safe driving.	Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI 48202 USA; Rehabiol Inst Michigan, Detroit, MI USA		Rapport, LJ (corresponding author), Wayne State Univ, Dept Psychol, 71 W Warren, Detroit, MI 48202 USA.			Ricker, Joseph/0000-0003-3415-991X; Rapport, Lisa/0000-0001-8014-9523			Bieliauskas LA, 1998, CLIN NEUROPSYCHOL, V12, P206, DOI 10.1076/clin.12.2.206.1994; Boake C., 1998, J INT NEUROPSYCH SOC, V4, P75; BROOKE MM, 1992, AM J PHYS MED REHAB, V71, P177, DOI 10.1097/00002060-199206000-00009; Brouwer WH, 1997, NEUROPSYCHOL REHABIL, V7, P177, DOI 10.1080/713755536; BROUWER WH, 1990, TRAUMATIC BRAIN INJU, P89; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; Cutrona EC., 1987, ADV PERSONAL RELATIO, V1, P37, DOI DOI 10.1037/0882-7974.1.1.47; DElia LF, 1996, COLOR TRAILS TEST; Engum E. S., 1988, COGNITIVE REHABILITA, V6, P34; Fidell L.S., 2000, USING MULTIVARIATE S; Fisk GD, 1998, BRAIN INJURY, V12, P683; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Fox GK, 1998, ARCH PHYS MED REHAB, V79, P1288, DOI 10.1016/S0003-9993(98)90277-5; GALSKI T, 1993, AM J OCCUP THER, V47, P391, DOI 10.5014/ajot.47.5.391; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; GOUVIER WD, 1989, ARCH PHYS MED REHAB, V70, P745; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Haselkorn JK, 1998, ARCH PHYS MED REHAB, V79, P738, DOI 10.1016/S0003-9993(98)90349-5; JONES R, 1983, AM J OCCUP THER, V37, P754, DOI 10.5014/ajot.37.11.754; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; Lincoln N., 1992, CLIN REHABIL, V6, P275, DOI DOI 10.1177/026921559200600402; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; Meyers J E, 1999, Appl Neuropsychol, V6, P154, DOI 10.1207/s15324826an0603_3; Michon J. A, 1979, DEALING DANGER SUMMA; ODENHEIMER GL, 1994, J GERONTOL, V49, P153, DOI DOI 10.1093/GERONJ/49.4.M153; Ott BR, 2000, DEMENT GERIATR COGN, V11, P153, DOI 10.1159/000017229; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; PRIDDY D A, 1990, Brain Injury, V4, P267, DOI 10.3109/02699059009026176; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 1998, CLIN NEUROPSYCHOL, V12, P56, DOI 10.1076/clin.12.1.56.1721; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; RANNEY TA, 1994, ACCIDENT ANAL PREV, V26, P733, DOI 10.1016/0001-4575(94)90051-5; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RAPPORT LJ, 1993, ARCH PHYS MED REHAB, V74, P621, DOI 10.1016/0003-9993(93)90160-C; Rapport LJ, 1998, ARCH PHYS MED REHAB, V79, P629, DOI 10.1016/S0003-9993(98)90035-1; RAPPORT LJ, 1998, M AM PSYCH ASS AUG 1; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; ROTHKE S, 1989, INT J CLIN NEUROPSYC, V11, P134; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; SHORE D, 1980, ARCH PHYS MED REHAB, V61, P481; SHUTE GE, 1990, DEV NEUROPSYCHOL, V6, P1, DOI 10.1080/87565649009540445; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; Trobe JD, 1996, ARCH NEUROL-CHICAGO, V53, P411, DOI 10.1001/archneur.1996.00550050033021; VANWOLFFELAAR PC, 1990, DRIVING BEHAV SOCIAL, P564; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; WEBSTER JS, 1995, ARCH PHYS MED REHAB, V76, P924, DOI 10.1016/S0003-9993(95)80068-9; WEBSTER JS, 1994, J CLIN EXP NEUROPSYC, V16, P129, DOI 10.1080/01688639408402623; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Withaar FK, 2000, J INT NEUROPSYCH SOC, V6, P480, DOI 10.1017/S1355617700644065	55	85	88	1	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2002	83	10					1415	1422		10.1053/apmr.2002.35111			8	Rehabilitation; Sport Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	600NT	WOS:000178397800015	12370878				2022-02-06	
J	Ylvisaker, M; Hanks, R; Johnson-Greene, D				Ylvisaker, M; Hanks, R; Johnson-Greene, D			Perspectives on rehabilitation of individuals with cognitive impairment after brain injury: Rationale for reconsideration of theoretical paradigms	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive impairment; cognitive rebabilitation; neuropsychological rehabilitation; traumatic brain injury	EXPRESSIVE VOCABULARY DELAYS; EXECUTIVE FUNCTIONS; LONG-TERM; ATTENTION; BEHAVIOR; METAANALYSIS; CHILDHOOD; CHILDREN; TODDLERS; PROJECT	Background: The frequency of cognitive impairment associated with traumatic brain injury (TBI) has led to the widespread use of cognitive rehabilitation as a discrete rehabilitative service. This service has become controversial in part because of disagreements regarding its theoretical base and implementation procedures, and in part because of insufficient experimental support. Objective: We outline two paradigms for cognitive rehabilitation that are interestingly different, both theoretically and procedurally. These paradigms are defined in relation to the goals of intervention, orientation to assessment, modalities of treatment, organization of treatment, and logistics of service delivery (setting, content, and provider). A rationale for each paradigm is described. Conclusion: We conclude with a call for (a) additional research into the effectiveness of interventions for individuals with cognitive impairment after TBI and (b) clinicians' thoughtful reflection on the foundations of their service.	Coll St Rose, Dept Commun Disorders, Albany, NY USA; Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; Rehabil Inst Michigan, Detroit, MI USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI 48202 USA		Ylvisaker, M (corresponding author), 1171 Van Antwerp Rd, Schenectady, NY 12309 USA.	ylvisakm@mail.strose.edu					American Speech and Hearing Association, 1995, ASHA S14, V37, P23; Anderson, 1989, TRANSFER COGNITIVE S; Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; ASHMAN AF, 1989, COGNITIVE STRATEGIES; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Ben-Yishay Y., 1987, NEUROPSYCHOLOGICAL R, P165; BERK LE, 1995, NAEYC RES PRACTICE S, V0007; BJORKLUND DF, 1990, CHILDRENS STRATEGIES; BOAKE C, 1989, J HEAD TRAUMA REHAB, V41, P1; Bodrova E., 1996, TOOLS MIND VYGOTSKYA; BRAGA LW, 2000, INT HDB NEUROPSYCHOL; BROWN AL, 1992, INTERACTIVE LEARNING; CAMPIONE JC, 1990, DIAGNOSTIC MONITORING OF SKILL AND KNOWLEDGE ACQUISITION, P141; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Carnine D., 1991, THEORY INSTRUCTION P; Carr E. G., 1999, POSITIVE BEHAV SUPPO; Chesnut R, 1999, AHCPR PUBLICATION; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; CLANCEY WJ, 1997, SITUATED COGNITION H; Crepeau F, 1997, NEUROPSYCHOL REHABIL, V7, P147, DOI 10.1080/713755525; Curl RM, 1996, J HEAD TRAUMA REHAB, V11, P75, DOI 10.1097/00001199-199602000-00009; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; DESHLER DD, 1993, ELEM SCHOOL J, V94, P153, DOI 10.1086/461757; Detterman DL, 1993, TRANSFER TRIAL INTEL; Dywan J, 1996, J HEAD TRAUMA REHAB, V11, P79, DOI 10.1097/00001199-199604000-00008; EVANS P, 1993, CHARTING AGENDA ED A; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; Feeney TJ, 2001, J HEAD TRAUMA REHAB, V16, P61, DOI 10.1097/00001199-200102000-00008; Flavell J.H., 2001, COGNITIVE DEV, V4th ed.; Girolametto L, 1999, AM J SPEECH-LANG PAT, V8, P364, DOI 10.1044/1058-0360.0804.364; Girolametto L, 1996, J SPEECH HEAR RES, V39, P1274, DOI 10.1044/jshr.3906.1274; Grafman J, 1995, ANN NY ACAD SCI, V769, P337, DOI 10.1111/j.1749-6632.1995.tb38149.x; GRATTAN LM, 1991, DEV NEUROPSYCHOL, V7, P283, DOI 10.1080/87565649109540496; Harley J. P., 1992, NEUROREHABILITATION, V2, P62; Horner R. H., 1988, GEN MAINTENANCE LIFE; Kaiser AP, 1996, TOP EARLY CHILD SPEC, V16, P375, DOI 10.1177/027112149601600307; Kavale K. A., 1999, EFFICACY SPECIAL ED; Kazdin A. E., 1994, HDB PSYCHOTHERAPY BE, P19; KOEGEL LK, 1997, POSITIVE BEHAV SUPPO; LAVE J, 1991, PERSPECTIVES ON SOCIALLY SHARED COGNITION, P63, DOI 10.1037/10096-003; LeBlanc JM, 2000, J HEAD TRAUMA REHAB, V15, P1022, DOI 10.1097/00001199-200008000-00005; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; MALEC JF, 1996, NEUROLOGY TRAUMA, P231; Mann L, 1979, TRAIL PROCESS HIST P; Meichenbaum, 1977, COGNITIVE BEHAV MODI; MEICHENBAUM D, 1998, NURTURING INDEPENDEN; Merzenich MM, 1996, SCIENCE, V271, P77, DOI 10.1126/science.271.5245.77; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; PALINSCAR AS, 1989, TEACHING UNDERSTANDI, V1; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; PRESSLEY M, 1995, EDUC PSYCHOL, V30, P207, DOI 10.1207/s15326985ep3004_6; Robinson TR, 1999, J EDUC PSYCHOL, V91, P195, DOI 10.1037/0022-0663.91.2.195; Rogoff B., 1990, APPRENTICESHIP THINK; Sackett DL, 1995, J ROY SOC MED, V88, P620; Schacter Daniel L., 1996, SEARCHING MEMORY BRA; Schacter DL, 1986, CLIN NEUROPSYCHOLOGY, P257; Schneider P, 1996, LANG SPEECH HEAR SER, V27, P157, DOI 10.1044/0161-1461.2702.157; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; Stuss D. T., 1992, J HEAD TRAUMA REHAB, V7, P40; VANCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399; Varney NR., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI [10.1097/00001199-199303000-00005, DOI 10.1097/00001199-199303000-00005]; Vygotsky LS., 1978, MIND SOC DEV HIGHER; WEHMAN P, 1990, VOCATIONAL REHABILIT; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; Wertsch J. V., 1981, CONCEPT ACTIVITY SOV; Westby C. E., 1994, LANGUAGE LEARNING DI, P180; *WHO, 1998, COMM LANG FUNCT DIS; Wilson, 1993, APPL PREV PSYCHOL, V2, P209, DOI DOI 10.1016/S0962-1849(05)80091-5; World Health Organization, 1980, INT CLASS IMP DIS HA; Ylvisaker M., 1998, COLLABORATIVE BRAIN; Ylvisaker Mark, 1996, Seminars in Speech and Language, V17, P217, DOI 10.1055/s-2008-1064100; [No title captured]; [No title captured]	74	85	91	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	2002	17	3					191	209		10.1097/00001199-200206000-00002			19	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	552WE	WOS:000175642400002	12086574				2022-02-06	
J	Borgens, RB; Shi, RY; Bohnert, D				Borgens, RB; Shi, RY; Bohnert, D			Behavioral recovery from spinal cord injury following delayed application of polyethylene glycol	JOURNAL OF EXPERIMENTAL BIOLOGY			English	Article						spinal injury; neurotrauma; spinal cord; nerve injury; central nervous system injury; fusogen; polyethylene glycol; guinea pia	APPLIED ELECTRIC-FIELDS; GUINEA-PIG; MEMBRANE-FUSION; AXONS; 4-AMINOPYRIDINE; METHYLPREDNISOLONE; HEMISECTION; MECHANISM; GROWTH; REPAIR	Topical application of the hydrophilic polymer polyethylene glycol (PEG) to isolated adult guinea pig spinal cord injuries has been shown to lead to the recovery of both the anatomical integrity of the tissue and the conduction of nerve impulses through the lesion. Furthermore, a brief (2 min) application of the fusogen (M-r 1800, 50 % w/v aqueous solution) to the exposed spinal cord injury in vivo can also cause rapid recovery of nerve impulse conduction through the lesion in association with functional recovery. Behavioral recovery was demonstrated using a long-tract, spinal-cord-dependent behavior in rodents known as the cutaneus trunci muscle (CTM) reflex. This reflex is observed as a contraction of the skin of the back in response to tactile stimulation. Here, we confirm and extend these preliminary observations. A severe compression/contusion injury to the exposed thoracic spinal cord of the guinea pig was performed between thoracic vertebrae 10 and 11. Approximately 7 h later, a topical application of PEG was made to the injury (dura removed) for 2 min in 15 experimental animals, and levels of recovery were compared with those of 13 vehicle-treated control animals. In PEG-treated animals, 93 % recovered variable levels of CTM functioning and all recovered some level of conduction through the lesion, as measured by evoked potential techniques. The recovered reflex was relatively normal compared with the quantitative characteristics of the reflex prior to injury with respect to the direction, distance and velocity of skin contraction. Only 23 % of the control population showed any spontaneous CTM recovery (P=0.0003) and none recovered conduction through the lesion during the 1 month period of observation (P=0.0001). These results suggest that repair of nerve membranes by polymeric sealing can provide a novel means for the rapid restoration of function following spinal cord injury.	Purdue Univ, Sch Vet Med, Dept Basic Med Sci, Inst Appl Neurol,Ctr Paralysis Res, W Lafayette, IN 47907 USA		Borgens, RB (corresponding author), Purdue Univ, Sch Vet Med, Dept Basic Med Sci, Inst Appl Neurol,Ctr Paralysis Res, W Lafayette, IN 47907 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039288] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS39288-01] Funding Source: Medline		ASANO T, 1995, J NEUROTRAUM, V12, P993; Benowitz LI, 1999, P NATL ACAD SCI USA, V96, P13486, DOI 10.1073/pnas.96.23.13486; Blight A, 1988, J Am Paraplegia Soc, V11, P26; Blight AR, 1991, J NEUROTRAUM, V8, P103, DOI 10.1089/neu.1991.8.103; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; BLIGHT AR, 1990, J COMP NEUROL, V296, P614, DOI 10.1002/cne.902960408; Borgens RB, 2000, FASEB J, V14, P27, DOI 10.1096/fasebj.14.1.27; Borgens RB, 1999, J NEUROTRAUM, V16, P639, DOI 10.1089/neu.1999.16.639; BORGENS RB, 1986, J COMP NEUROL, V250, P168, DOI 10.1002/cne.902500204; BORGENS RB, 1987, SCIENCE, V238, P366, DOI 10.1126/science.3659920; BORGENS RB, 1990, J COMP NEUROL, V296, P634, DOI 10.1002/cne.902960409; BORGENS RB, 2001, IN PRESS NEUROSCI RE; BORGENS RB, 2001, IN PRESS J NEUROSURG; BORGENS RB, 1992, SPINAL CORD DYSFUNCT, V3, P110; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bregman B. S., 1996, Society for Neuroscience Abstracts, V22, P764; COLLINS WF, 1979, NEURAL TRAUMA, P273; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P271, DOI 10.1007/BF01538965; Duerstock BS, 2000, COMPUT MED IMAG GRAP, V24, P389, DOI 10.1016/S0895-6111(00)00034-3; Duerstock BS, 2002, J EXP BIOL, V205, P13; Griffin John W., 1995, P375; Hannig J, 1999, INT J RADIAT BIOL, V75, P379, DOI 10.1080/095530099140555; HANSEBOUT RR, 1993, J NEUROTRAUM, V10, P1, DOI 10.1089/neu.1993.10.1; HAYES KC, 1993, PARAPLEGIA, V31, P216, DOI 10.1038/sc.1993.40; Honmou Osamu, 1995, P480; KRAUSE TL, 1994, J NEUROSCI, V14, P6638; LazarovSpiegler O, 1996, FASEB J, V10, P1296, DOI 10.1096/fasebj.10.11.8836043; Lee J, 1997, BIOCHEMISTRY-US, V36, P6251, DOI 10.1021/bi970404c; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; LENTZ BR, 1994, CHEM PHYS LIPIDS, V73, P91, DOI 10.1016/0009-3084(94)90176-7; MALMGREN L, 1977, J HISTOCHEM CYTOCHEM, V25, P1280, DOI 10.1177/25.11.915248; MARKS JM, 2001, IN PRESS FASEB J; Merchant FA, 1998, J SURG RES, V74, P131, DOI 10.1006/jsre.1997.5252; Moriarty LJ, 1998, J NEUROL SCI, V155, P121, DOI 10.1016/S0022-510X(97)00203-7; NAKAJIMA N, 1994, J BIOMAT SCI-POLYM E, V6, P751, DOI 10.1163/156856295X00139; PADANLAM JT, 1994, ANN NY ACAD SCI, V92, P111; Palmer JS, 1998, J UROLOGY, V159, P2136, DOI 10.1016/S0022-5347(01)63295-6; Pointillart V, 2000, SPINAL CORD, V38, P71, DOI 10.1038/sj.sc.3100962; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; Shi R, 1999, J NEUROPHYSIOL, V81, P2406, DOI 10.1152/jn.1999.81.5.2406; Shi R, 1997, NEUROSCIENCE, V77, P553, DOI 10.1016/S0306-4522(96)00477-0; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; Shi RY, 2000, J NEUROPHYSIOL, V84, P1763, DOI 10.1152/jn.2000.84.4.1763; Short DJ, 2000, SPINAL CORD, V38, P273, DOI 10.1038/sj.sc.3100986; THIERAULT E, 1988, J NEUROPHYSIOL, V60, P446	46	85	88	0	10	COMPANY OF BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND	0022-0949			J EXP BIOL	J. Exp. Biol.	JAN	2002	205	1					1	12					12	Biology	Science Citation Index Expanded (SCI-EXPANDED)	Life Sciences & Biomedicine - Other Topics	516DH	WOS:000173536200001	11818407				2022-02-06	
J	McCullers, D; Sullivan, PG; Scheff, SW; Herman, JP				McCullers, D; Sullivan, PG; Scheff, SW; Herman, JP			Mifepristone protects CA1 hippocampal neurons following traumatic brain injury in rat	NEUROSCIENCE			English	Article						glucocorticoid receptor; mineralocorticoid receptor; spironolactone; bcl-2; bax; cortical impact	MESSENGER-RNA EXPRESSION; SEVERE HEAD-INJURY; CELL-DEATH; KAINIC ACID; GLUCOCORTICOID TOXICITY; GENE-EXPRESSION; IN-VIVO; MINERALOCORTICOID RECEPTOR; SELECTIVE VULNERABILITY; SUPPRESSOR GENE	The present study addresses mincralocorticoid receptor and glucocorticoid receptor effects on hippocampal neuron viability after experimental traumatic brain injury. Rats were pretreated for 48 h with vehicle, the mineralocorticoid receptor antagonist spironolactone, or the glucocorticoid receptor antagonist mifepristone (RU486) and subsequently subjected to sham operation or unilateral controlled cortical impact injury. To determine the effects of receptor antagonist pretreatments on cell survival, neurons in regions CA1, CA3, and dentate gyrus of the hippocampal formation were counted 24 h post-injury using the optical fractionator method. Injury decreased the number of viable neurons in CA1 and CA3 of vehicle-pretreated animals. Notably, this cell loss was prevented in CA1 by RU486 pretreatment. Neuronal loss was also observed in dentate gyros. The effects of receptor blockade and injury on the expression of viability-related genes were also assessed by comparing relative bel-2, bax, and p53 messenger RNA levels using in situ hybridization analysis. Spironolactone and RU486 decreased basal bel-2 messenger RNA levels in CA1 and dentate gyrus but did not affect basal bax or p53 levels. Injury decreased bel-2 messenger RNA levels in dentate gyrus but did not affect bax or p53 levels in vehicle-pretreated animals. These data demonstrate that RU486 pretreatment prevents the loss of CA1 pyramidal neurons 24 It after traumatic brain injury. RU486 modulation of bel-2, bux, or p53 messenger RNA expression does not predict neuronal viability at this time point, suggesting that RU486-mediated preservation of CA1 neurons does not involve transcriptional regulation of those cell death-related genes. (C) 2002 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45267 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA		McCullers, D (corresponding author), Univ Cincinnati, Coll Med, Dept Psychiat, POB 670559,231 Albert Sabin Way, Cincinnati, OH 45267 USA.		Herman, James P/D-4960-2015	Herman, James P/0000-0003-3571-2406	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG10836, AG12962, AG00242] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39828] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012962, P01AG010836] Funding Source: NIH RePORTER		Antonawich FJ, 1999, NEUROSCIENCE, V88, P319, DOI 10.1016/S0306-4522(98)00213-9; ARONSSON M, 1988, P NATL ACAD SCI USA, V85, P9331, DOI 10.1073/pnas.85.23.9331; ARRIZA JL, 1988, NEURON, V1, P887, DOI 10.1016/0896-6273(88)90136-5; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Behl C, 1997, ENDOCRINOLOGY, V138, P101, DOI 10.1210/en.138.1.101; Behl C, 1997, EUR J NEUROSCI, V9, P912, DOI 10.1111/j.1460-9568.1997.tb01442.x; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; Bullock MR, 1996, J NEUROTRAUM, V13, P715; Cadepond F, 1997, ANNU REV MED, V48, P129; Carpenter SEK, 1996, FERTIL STERIL, V66, P90, DOI 10.1016/S0015-0282(16)58392-7; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Clark RSB, 1997, J NEUROSCI, V17, P9172; COOPER PR, 1979, J NEUROSURG, V51, P307, DOI 10.3171/jns.1979.51.3.0307; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dong GX, 2001, BRAIN RES, V903, P45, DOI 10.1016/S0006-8993(01)02379-4; ELLIOTT EM, 1992, J NEUROCHEM, V59, P1033, DOI 10.1111/j.1471-4159.1992.tb08345.x; ELLIOTT EM, 1993, BRAIN RES, V602, P84, DOI 10.1016/0006-8993(93)90245-I; GIANNOTTA SL, 1984, NEUROSURGERY, V15, P497, DOI 10.1227/00006123-198410000-00004; GILLARDON F, 1995, NEUROSCI LETT, V192, P85, DOI 10.1016/0304-3940(95)11619-8; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Goodman YD, 1996, J NEUROCHEM, V66, P1836; GREENAMYRE JT, 1985, J PHARMACOL EXP THER, V233, P254; HALL ED, 1992, J NEUROTRAUMA, V9, P425; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HERMAN JP, 1993, CELL MOL NEUROBIOL, V13, P349, DOI 10.1007/BF00711577; Herman JP, 1998, J NEUROSCI, V18, P7462; HERMAN JP, 1989, MOL ENDOCRINOL, V3, P1886, DOI 10.1210/mend-3-11-1886; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HORNER HC, 1990, NEUROENDOCRINOLOGY, V52, P57; JOELS M, 1989, SCIENCE, V245, P1502, DOI 10.1126/science.2781292; Joels M, 1998, MOL NEUROBIOL, V17, P87, DOI 10.1007/BF02802026; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; KARST H, 1994, BRAIN RES, V649, P234, DOI 10.1016/0006-8993(94)91069-3; KATO J, 1994, HORM BEHAV, V28, P454, DOI 10.1006/hbeh.1994.1043; KERR DS, 1989, SCIENCE, V245, P1505, DOI 10.1126/science.2781293; KERR DS, 1992, P NATL ACAD SCI USA, V89, P8527, DOI 10.1073/pnas.89.18.8527; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KOHLER C, 1983, NEUROSCIENCE, V8, P819, DOI 10.1016/0306-4522(83)90013-1; McCullers DL, 1998, NEUROREPORT, V9, P3085, DOI 10.1097/00001756-199809140-00031; McCullers DL, 2001, J NEUROSCI RES, V64, P277; MCCULLERS DL, 2000, SOC NEUR ABSTR, V26, P419; MCEWEN BS, 1986, PHYSIOL REV, V66, P1121, DOI 10.1152/physrev.1986.66.4.1121; McIntosh LJ, 1996, EXP NEUROL, V141, P201, DOI 10.1006/exnr.1996.0154; McIntosh LJ, 1996, NEUROTOXICOLOGY, V17, P873; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; MORSE JK, 1990, EXP NEUROL, V110, P86, DOI 10.1016/0014-4886(90)90053-U; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; NADLER JV, 1978, NATURE, V271, P676, DOI 10.1038/271676a0; Nair SM, 1998, J NEUROSCI, V18, P2685; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; NORDEEN SK, 1995, STEROIDS, V60, P97, DOI 10.1016/0039-128X(94)00001-S; OKIYAMA K, 1994, J NEUROTRAUM, V11, P83, DOI 10.1089/neu.1994.11.83; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PARTHASARATHY S, 1994, J CLIN INVEST, V94, P1990, DOI 10.1172/JCI117551; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RATKA A, 1989, NEUROENDOCRINOLOGY, V50, P117, DOI 10.1159/000125210; Reagan LP, 1997, J CHEM NEUROANAT, V13, P149, DOI 10.1016/S0891-0618(97)00031-8; REUL JMHM, 1987, J ENDOCRINOL, V115, P459, DOI 10.1677/joe.0.1150459; REUL JMHM, 1989, MOL ENDOCRINOL, V3, P1674, DOI 10.1210/mend-3-10-1674; REUL JMHM, 1985, ENDOCRINOLOGY, V117, P2505, DOI 10.1210/endo-117-6-2505; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; SAPOLSKY RM, 1988, BRAIN RES, V453, P367, DOI 10.1016/0006-8993(88)90180-1; SAPOLSKY RM, 1986, NEUROENDOCRINOLOGY, V43, P440, DOI 10.1159/000124561; SAPOLSKY RM, 1986, J NEUROSCI, V6, P2240; SAPOLSKY RM, 1985, J NEUROSCI, V5, P1228; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; SEROOGY KB, 1996, NEUROCHEMISTRY PRACT, P121; SLOVITER RS, 1989, J COMP NEUROL, V280, P183, DOI 10.1002/cne.902800203; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SmithSwintosky VL, 1996, J CEREBR BLOOD F MET, V16, P585, DOI 10.1097/00004647-199607000-00008; STEIN BA, 1988, BRAIN RES, V473, P175, DOI 10.1016/0006-8993(88)90332-0; STEINBEHRENS BA, 1994, J NEUROCHEM, V63, P596; STEINBEHRENS BA, 1992, J NEUROCHEM, V58, P1730, DOI 10.1111/j.1471-4159.1992.tb10047.x; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Tarazi FI, 1996, PSYCHOPHARMACOLOGY, V128, P371, DOI 10.1007/s002130050147; TORNHEIM PA, 1978, J NEUROSURG, V48, P220, DOI 10.3171/jns.1978.48.2.0220; WAHL M, 1988, J CEREBR BLOOD F MET, V8, P621, DOI 10.1038/jcbfm.1988.109; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; YOUNG W, 1992, J NEUROTRAUMA S1, V9, P9	85	85	87	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2002	109	2					219	230	PII S0306-4522(01)00477-8	10.1016/S0306-4522(01)00477-8			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	525NV	WOS:000174078600002	11801359				2022-02-06	
J	Raghupathi, R; Conti, AC; Graham, DI; Krajewski, S; Reed, JC; Grady, MS; Trojanowskii, JQ; McIntosh, TK				Raghupathi, R; Conti, AC; Graham, DI; Krajewski, S; Reed, JC; Grady, MS; Trojanowskii, JQ; McIntosh, TK			Mild traumatic brain injury induces apoptotic cell death in the cortex that is preceded by decreases in cellular Bcl-2 immunoreactivity	NEUROSCIENCE			English	Article						head injury; apoptosis; Bcl-2; Bax. white matter; hippocampus	CORTICAL IMPACT INJURY; SPINAL-CORD INJURY; HEAD-INJURY; TRANSGENIC MICE; NEURONAL APOPTOSIS; DNA FRAGMENTATION; CEREBRAL-ISCHEMIA; IN-VIVO; RAT; OVEREXPRESSION	Although mild traumatic brain injury is associated with behavioral dysfunction and histopathological alterations. few studies have assessed the temporal pattern of regional apoptosis following mild brain injury. Anesthetized rats were subjected to mild lateral fluid-percussion brain injury (1.1-1.3 atm), and brains were evaluated for the presence of in situ DNA fragmentation (terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling, TUNEL) and morphologic characteristics of apoptotic cell death (nuclear and cytoplasmic condensation, presence of apoptotic bodies). Significant numbers of apoptotic TUNEL(+) cells were observed in the injured parietal cortex and underlying white matter up to 72 It post-injury (P < 0.05 compared to sham-injured-injured), with maximal numbers present at 24 h. Apoptosis was confirmed by the presence of 180-200 bp nuclear DNA fragments in tissue homogenates. The appearance of apoptotic TUNEL(+) cells in the injured cortex was preceded by a marked decrease in immunoreactivity for the anti-cell death protein, Bcl-2, as early as 2 h post-injury. This decrease in cellular Bcl-2 staining was not accompanied by a concomitant loss of staining for the pro-cell death Bax protein, suggesting that post-traumatic neuronal death in the cortex may be dependent on altered cellular ratios of Bcl-2:Bax. In the hippocampus, no significant increase in apoptotic TUNEL(+) cells was observed compared to sham-injured-injured animals. However, selective neuronal loss was evident in the CA3 region at 24 h post-injury, that was preceded by an overt loss of neuronal Bcl-2 immunoreactivity at 6 h. No changes in either cellular Bcl-2 or Bax expression were observed in the thalamus or white matter at any time post-injury. Taken together from these data, we suggest that apoptosis contributes to cell death in both gray and white matter, and that decreases in cellular Bcl-2 may, in part, be associated with both apoptotic and non-apoptotic cell death following mild brain trauma. (C) 2002 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; So Gen Hosp, Inst Neurol Sci, Glasgow G51 4TF, Lanark, Scotland; Burnham Inst Canc Res, La Jolla, CA USA		Raghupathi, R (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, Room 113,Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	rramesh@mail.med.upenn.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978, R01NS036821, P50NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010124] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG-10124, AG-09125] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM-34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS40978, P50-NS08803, NS36821] Funding Source: Medline		AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Beattie MS, 1998, NEUROSCIENTIST, V4, P163, DOI 10.1177/107385849800400312; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clark RSB, 1997, J NEUROSCI, V17, P9172; Conti AC, 1998, J NEUROSCI, V18, P5663; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Du C, 1996, J CEREBR BLOOD F MET, V16, P195, DOI 10.1097/00004647-199603000-00003; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; FUNG KM, 1995, AM J PATHOL, V146, P1376; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Gwag BJ, 1999, NEUROSCIENCE, V90, P1339, DOI 10.1016/S0306-4522(98)00508-9; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Lawrence MS, 1997, J CEREBR BLOOD F MET, V17, P740; Lawrence MS, 1996, J NEUROSCI, V16, P486; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Lewen A, 1999, ACTA NEUROCHIR, V141, P193, DOI 10.1007/s007010050286; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; Liu XZ, 1997, J NEUROSCI, V17, P5395; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PERINI S, 1984, NEUROL CLIN, V2, P719, DOI 10.1016/S0733-8619(18)31071-5; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RAGHUPATHI R, 1997, J CEREB BLOOD FLOW M, V17, pS494; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Regan RF, 1996, J NEUROTRAUM, V13, P223, DOI 10.1089/neu.1996.13.223; RINK A, 1995, AM J PATHOL, V147, P1575; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; STRUGAR J, 1993, J TRAUMA, V34, P555, DOI 10.1097/00005373-199304000-00012; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Tanaka M, 1997, CHIRALITY, V9, P17, DOI 10.1002/(SICI)1520-636X(1997)9:1<17::AID-CHIR4>3.0.CO;2-D; Tang SL, 1997, J CHART INST WATER E, V11, P14; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; Umile EM, 1998, BRAIN INJURY, V12, P577; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	63	85	87	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2002	110	4					605	616	PII S0306-4522(01)00461-4	10.1016/S0306-4522(01)00461-4			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	545YN	WOS:000175245300002	11934469				2022-02-06	
J	Goodman, D; Gaetz, M; Meichenbaum, D				Goodman, D; Gaetz, M; Meichenbaum, D			Concussions in hockey: there is cause for concern	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						demographics; treatment; prevention	ICE-HOCKEY; INJURIES; PLAYERS; CANADA; HEAD	Purpose: The purpose of the study A Lis to document various aspects of concussion in Canadian Amateur hockey including demographics, causes. treatment, and prevention in order to guide future recommendation,,, on how to reduce injury. Methods: A detailed prospective and retrospective concussion history was obtained from British Columbia Junior Hockey League players over the course of two seasons (1998-2000). Results: Higher rates of concussions occur in games versus practice, and there was an overrepresentation of forwards injured versus defensemen or goaltenders. There Aas between 4.63 and 5.95 concussions per 1000 player/game hours with the average age of the First hockey-related concussion in the 15th year. The greatest cause of Concussion was contact with the ice and/or the boards. Fighting was not a major cause of concussion, although other illegal actions such as elbowing were, Conclusions: The primary recommendation to reduce the number and severity of concussions is to eliminate plays where there is a demonstrable intent to injure another player. Concussions in hockey are of considerable concern: however, there is now encouraging information with respect to the treatment of these injuries.	Simon Fraser Univ, Sch Kinesiol, Human Motor Syst Lab, Burnaby, BC V5A 1S6, Canada; Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada		Goodman, D (corresponding author), Simon Fraser Univ, Sch Kinesiol, Human Motor Syst Lab, Burnaby, BC V5A 1S6, Canada.	goodman@sfu.ca					Barth J T, 2000, Dent Clin North Am, V44, P67; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; BIASCA N, 1995, UNFALLCHIRURG, V98, P283; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Jorgensen U, 1986, Br J Sports Med, V20, P7; Kelly JP, 1997, NEUROLOGY, V48, P581; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Molsa J, 1997, AM J SPORT MED, V25, P495, DOI 10.1177/036354659702500412; PATTERSSON M, 1993, BRIT J SPORT MED, V27, P251, DOI 10.1136/bjsm.27.4.251; Pinto M, 1999, CLIN J SPORT MED, V9, P70, DOI 10.1097/00042752-199904000-00005; Ruchinskas R A, 1997, Appl Neuropsychol, V4, P43, DOI 10.1207/s15324826an0401_5; SIM FH, 1987, AM J SPORTS MED, V15, pS86; STUART MJ, 1995, AM J SPORT MED, V23, P458, DOI 10.1177/036354659502300415; Tator CH, 2000, CAN MED ASSOC J, V162, P787; Tegner Y, 1991, Br J Sports Med, V25, P87; Tegner Y, 1996, BRIT J SPORT MED, V30, P251, DOI 10.1136/bjsm.30.3.251	19	85	85	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	DEC	2001	33	12					2004	2009		10.1097/00005768-200112000-00005			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	500CA	WOS:000172607300005	11740291				2022-02-06	
J	Singleton, RH; Stone, JR; Okonkwo, DO; Pellicane, AJ; Povlishock, JT				Singleton, RH; Stone, JR; Okonkwo, DO; Pellicane, AJ; Povlishock, JT			The immunophilin ligand FK506 attenuates axonal injury in an impact-acceleration model of traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						amyloid precursor protein; cytoskeleton; immunocytochemistry; immunophilin; rat; traumatic axonal injury; traumatic brain injury	MICROTUBULE-ASSOCIATED PROTEIN-2; CYCLOSPORINE-A; NEUROFILAMENT PROTEINS; PHOSPHORYLATION STATE; HEAD-INJURY; TAU-FACTOR; IN-VIVO; DAMAGE; CALCINEURIN; PERMEABILITY	The immunophilin ligand, cyclosporin A (CsA), is effective in reducing the axonal damage associated with traumatic brain injury (TBI). Based upon extensive ultrastructural and immunohistochemical studies, the neuroprotection afforded by CsA appeared to be mediated via mitochondrial protection, specifically, the prevention of mitochondrial swelling and inhibition of mitochondrial permeability transition (MPT). However, the potential that CsA could also be neuroprotective via the immunophilin-mediated inhibition of the protein phosphatase, calcineurin (CN) has not been directly assessed. To address this issue, the current study assessed the ability of FK506, another immunophilin ligand that inhibits CN with no effect on MPT, to attenuate axonal damage in a rat impact-acceleration model of TBI. Traumatic axonal injury (TAI), detected via an antibody against beta -amyloid precursor protein (APP), a specific marker of axonal injury, was significantly reduced at 24 hr postinjury in Sprague-Dawley rats receiving intravenous FK506 (2 mg/kg; n = 5) 30 min prior to injury compared to vehicle controls (n = 3). While not rejecting the established efficacy of CsA in providing neuroprotection via its targeting of MPT, this study does underscore the potential importance of CN in the progressive pathobiology of TAI, suggesting that CN may constitute another important therapeutic target.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA; Univ Virginia, Dept Neurosurg, Charlottesville, VA USA		Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, 1101 E Marshall St,Campus Virginia Commonwealth U, Richmond, VA 23298 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007288, R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20193, T32 NS7288] Funding Source: Medline		Bavetta S, 1999, EXP NEUROL, V158, P382, DOI 10.1006/exnr.1999.7119; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Butcher SP, 1997, J NEUROSCI, V17, P6939; CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; CONNERN CP, 1994, BIOCHEM J, V302, P321, DOI 10.1042/bj3020321; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; Drake M, 1996, ACTA PHYSIOL SCAND, V158, P155, DOI 10.1046/j.1365-201X.1996.535298000.x; EYER J, 1988, BIOCHEM J, V252, P655, DOI 10.1042/bj2520655; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GOTO S, 1985, J NEUROCHEM, V45, P276, DOI 10.1111/j.1471-4159.1985.tb05504.x; JOHNSON GVW, 1992, J NEUROCHEM, V59, P2056; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martin R, 1999, NEUROSCIENCE, V88, P327, DOI 10.1016/S0306-4522(98)00244-9; MATA M, 1992, J NEUROCYTOL, V21, P199, DOI 10.1007/BF01194978; Maxwell WL, 1997, J NEUROTRAUM, V14, P755; Morioka M, 1999, PROG NEUROBIOL, V58, P1, DOI 10.1016/S0301-0082(98)00073-2; NIXON RA, 1994, J CELL BIOL, V126, P1031, DOI 10.1083/jcb.126.4.1031; OCHIAI T, 1989, TRANSPLANT P, V21, P829; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pijak DS, 1996, J COMP NEUROL, V368, P569; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; TOYOSHIMA I, 1988, NEUROCHEM RES, V13, P621, DOI 10.1007/BF00973278; YAMAMOTO H, 1983, J NEUROCHEM, V41, P1119, DOI 10.1111/j.1471-4159.1983.tb09060.x; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	36	85	85	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2001	18	6					607	614		10.1089/089771501750291846			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	445ZQ	WOS:000169488800004	11437083				2022-02-06	
J	Puurunen, K; Jolkkonen, J; Sirvio, J; Haapalinna, A; Sivenius, J				Puurunen, K; Jolkkonen, J; Sirvio, J; Haapalinna, A; Sivenius, J			An alpha(2)-adrenergic antagonist, atipamezole, facilitates behavioral recovery after focal cerebral ischemia in rats	NEUROPHARMACOLOGY			English	Article						alpha(2)-adrenoceptor antagonist; behavior; cerebral ischemia, focal; rats; recovery	SENSORIMOTOR CORTEX INJURY; TRAUMATIC BRAIN INJURY; RELEASE IN-VIVO; MOTOR RECOVERY; ARTERY OCCLUSION; ALPHA-2-ADRENOCEPTOR ANTAGONIST; FUNCTIONAL RECOVERY; 5-HT1A RECEPTORS; CONTROLLED TRIAL; LOCUS-COERULEUS	Previous studies suggest that enhanced noradrenergic neurotransmission promotes functional recovery following cerebral lesions. The present study investigated whether systemic administration of an alpha (2)-adrenergic antagonist, atipamezole, facilitates recovery following transient focal cerebral ischemia in rats. The effect of atipamezole therapy on recovery from ischemia was compared with the effect of enriched-environment housing in rats. Ischemia was induced by occlusion of the right middle cerebral artery (MCA) for 120 min using the intraluminal filament model. Daily atipamezole treatment (1 mg/kg, subcutaneously) was started on day 2 after ischemia induction and drug administration stopped after 10 days. Another group of rats was housed in an enriched environment from day 2 following ischemia induction until the end of the experiment. Several different behavioral tests were used to measure functional recovery during the 26 days following the induction of focal cerebral ischemia. Thew was improved performance in the limb-placing test from the beginning of atipamezole treatment to day 8, and in wheel-running in the foot-slip test on days 2 and 4. Enriched-environment housing facilitated recovery in the foot-slip test in a later phase of the test period (days 8 to 10). Discovery of a hidden platform in a water-maze task was also facilitated in rats housed in the enriched environment, but this was probably due to the increased swimming speed of these rats. The present data suggest that, the alpha (2)-adrenergic antagonist, atipamezole, facilitates sensorimotor recovery after focal ischemia, but has no effect on subsequent water-maze tests assessing spatial learning and memory, when assessed 11 days after the cessation of drug administration. (C) 2001 Elsevier Science Ltd. All rights reserved.	Univ Kuopio, Dept Neurosci & Neurol, SF-70211 Kuopio, Finland; Univ Kuopio, AI Virtanen Inst, FIN-70211 Kuopio, Finland; Or Corp, Or Pharma, Turku, Finland; Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland; Brain Res & Rehabil Ctr Neuron, Kuopio, Finland		Puurunen, K (corresponding author), Univ Kuopio, Dept Neurosci & Neurol, POB 1627, SF-70211 Kuopio, Finland.	kirsi.puurunen@uku.fi					BIEGON A, 1992, EUR J PHARMACOL, V224, P27, DOI 10.1016/0014-2999(92)94814-C; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1994, AM J PHYS MED REHAB, V73, P76, DOI 10.1097/00002060-199404000-00002; Broderick J, 1998, STROKE, V29, P415, DOI 10.1161/01.STR.29.2.415; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; Corbett D, 1998, PROG NEUROBIOL, V54, P531, DOI 10.1016/S0301-0082(97)00078-6; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; DERYCK M, 1989, STROKE, V20, P1383, DOI 10.1161/01.STR.20.10.1383; Dombovy M L, 1988, Adv Neurol, V47, P265; Dunn-Meynell AA, 1998, BRAIN RES, V800, P245, DOI 10.1016/S0006-8993(98)00524-1; DunnMeynell AA, 1997, J NEUROTRAUM, V14, P43, DOI 10.1089/neu.1997.14.43; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1985, BRAIN RES, V342, P352, DOI 10.1016/0006-8993(85)91135-7; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GARCIA JH, 1993, AM J PATHOL, V142, P623; Gobert A, 1997, J NEUROCHEM, V69, P2616; GOLDSTEIN LB, 1993, J NEURAL TRANSP PLAS, V4, P175, DOI 10.1155/NP.1993.175; GRABOWSKI M, 1993, STROKE, V24, P889, DOI 10.1161/01.STR.24.6.889; GULATMARNAY C, 1989, J NEUROCHEM, V53, P519, DOI 10.1111/j.1471-4159.1989.tb07364.x; Haapalinna A, 1997, N-S ARCH PHARMACOL, V356, P570, DOI 10.1007/PL00005092; Haapalinna A, 1998, EUR J PHARMACOL, V347, P29, DOI 10.1016/S0014-2999(98)00077-6; HURWITZ BE, 1991, STROKE, V22, P648, DOI 10.1161/01.STR.22.5.648; Johansson BB, 1996, STROKE, V27, P324, DOI 10.1161/01.STR.27.2.324; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P399, DOI 10.1016/S0003-9993(95)80567-2; KARNI A, 1995, NATURE, V377, P155; Kawamata T, 1997, P NATL ACAD SCI USA, V94, P8179, DOI 10.1073/pnas.94.15.8179; KOTILA M, 1984, STROKE, V15, P1039, DOI 10.1161/01.STR.15.6.1039; LAITINEN KSM, 1995, EUR J PHARMACOL, V285, P255, DOI 10.1016/0014-2999(95)00410-M; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MALING HM, 1946, J NEUROPHYSIOL, V9, P379, DOI 10.1152/jn.1946.9.5.379; MARKGRAF CG, 1992, BRAIN RES, V575, P238, DOI 10.1016/0006-8993(92)90085-N; Mateo Y, 1999, EUR J PHARMACOL, V379, P53, DOI 10.1016/S0014-2999(99)00488-4; McCulloch J, 1996, J HYPERTENS, V14, pS131; Meana JJ, 1996, EUR J PHARMACOL, V312, P385, DOI 10.1016/0014-2999(96)00598-5; MINTZ M, 1986, PHARMACOL BIOCHEM BE, V25, P1307, DOI 10.1016/0091-3057(86)90127-9; NACHLAS MM, 1957, J HISTOCHEM CYTOCHEM, V5, P420, DOI 10.1177/5.4.420; Newman-Tancredi A, 1998, N-S ARCH PHARMACOL, V358, P197, DOI 10.1007/PL00005243; Nudo RJ, 1997, MOL PSYCHIATR, V2, P188, DOI 10.1038/sj.mp.4000188; OHLSSON AL, 1995, STROKE, V26, P644, DOI 10.1161/01.STR.26.4.644; Puurunen K, 1997, STROKE, V28, P623, DOI 10.1161/01.STR.28.3.623; RAITERI M, 1990, N-S ARCH PHARMACOL, V356, P570; RIEKKINEN P, 1990, BEHAV BRAIN RES, V37, P81, DOI 10.1016/0166-4328(90)90073-N; Ronning OM, 1998, STROKE, V29, P779, DOI 10.1161/01.STR.29.4.779; ROSE F D, 1988, Medical Science Research, V16, P257; SAVONTAUS E, 1997, EUROPEAN J PHARM, V28, P207; SCHEININ H, 1988, EUR J PHARMACOL, V151, P35, DOI 10.1016/0014-2999(88)90689-9; SIMSON PE, 1987, J NEUROSCI, V7, P1732; SIRVIO J, 1992, J NEURAL TRANSM-PARK, V4, P99, DOI 10.1007/BF02251473; SIVENIUS J, 1985, STROKE, V16, P928, DOI 10.1161/01.STR.16.6.928; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; TRENDELENBURG AU, 1994, N-S ARCH PHARMACOL, V350, P473; VIRTANEN R, 1989, ARCH INT PHARMACOD T, V297, P190; WADE DT, 1992, SCAND J REHABIL MED, P97; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; WINTER JC, 1998, J PHARM EXPT THERAPE, V263, P682; Wolf P, 1998, CEREBROVASC DIS, P834; Xerri C, 1996, J PHYSIOLOGY-PARIS, V90, P277, DOI 10.1016/S0928-4257(97)81438-6; Yonemori F, 1999, J CEREBR BLOOD F MET, V19, P483, DOI 10.1097/00004647-199905000-00002	59	85	91	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	MAR	2001	40	4					597	606		10.1016/S0028-3908(00)00182-9			10	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	411ZQ	WOS:000167529900015	11249969				2022-02-06	
J	Faden, AI; O'Leary, DM; Fan, L; Bao, WL; Mullins, PGM; Movsesyan, VA				Faden, AI; O'Leary, DM; Fan, L; Bao, WL; Mullins, PGM; Movsesyan, VA			Selective blockade of the mGluR1 receptor reduces traumatic neuronal injury in vitro and improves outcome after brain trauma	EXPERIMENTAL NEUROLOGY			English	Article						mGluR1 antagonists; brain trauma; neuronal death	METABOTROPIC GLUTAMATE RECEPTORS; IN-VITRO; NMDA-RECEPTORS; 1-AMINOINDAN-1,5-DICARBOXYLIC ACID; PHARMACOLOGICAL CHARACTERIZATION; AMINO-ACIDS; CELL-DEATH; ACTIVATION; RAT; ANTAGONIST	The effects of selective blockade of group I metabotropic glutamate receptor subtype 1 (mGluR1) on neuronal cell survival and post-traumatic recovery was examined using rat in vitro and in vivo trauma models. The selective mGluR1 antagonists (RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA), 7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylate ethyl ester (CPCCOEt), and (S)-(+)-alpha -amino-4-carboxy-2-methylbezeneacetic acid (LY367385) provided significant neuroprotection in rat cortical neuronal cultures subjected to mechanical injury, in both pretreatment or posttreatment paradigms. Administration of the antagonists also attenuated glutamate-induced neuronal cell death in the cultures. Coapplication of these antagonists with the N-methyl-D-aspartate (NMDA) receptor antagonist (5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10- imine (MK-801) had additive neuroprotective effects in glutamate injured cultures. Intracerebroventricular administration of AIDA to rats markedly improved recovery from motor dysfunction after lateral fluid percussion induced traumatic brain injury (TBI), Treatment with mGluR1 antagonists also significantly reduced lesion volumes in rats after TBI, as evaluated by MRI. It appears that these compounds mediate their neuroprotective effect through an mGluR1 antagonist action, as demonstrated by inhibition of agonist induced phosphoinositide hydrolysis in our in vitro system. Moreover, AIDA, CPCCOEt, and LY367385, at concentrations shown to be neuroprotective, had no significant effects on the steady state NMDA evoked whole cell current. Taken together, these data suggest that modulation of mGluR1 activity may have substantial therapeutic potential in brain injury. (C) 2001 Academic Press.	Georgetown Univ, Med Ctr, Dept Neurosci, Georgetown Inst Cognit & Computat Sci, Washington, DC 20007 USA		Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Georgetown Inst Cognit & Computat Sci, Washington, DC 20007 USA.			Mullins, Paul/0000-0002-1339-6361	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS37313] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313] Funding Source: NIH RePORTER		Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Allen JW, 1999, NEUROPHARMACOLOGY, V38, P1243, DOI 10.1016/S0028-3908(99)00044-1; Allen JW, 1999, J PHARMACOL EXP THER, V290, P112; Allen JW, 2000, CELL DEATH DIFFER, V7, P470, DOI 10.1038/sj.cdd.4400678; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BRUNO V, 1995, NEUROPHARMACOLOGY, V34, P1089, DOI 10.1016/0028-3908(95)00077-J; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; Clark BP, 1997, BIOORG MED CHEM LETT, V7, P2777, DOI 10.1016/S0960-894X(97)10071-3; COPANI A, 1995, J NEUROCHEM, V64, P101; COPANI A, 1995, MOL PHARMACOL, V47, P890; Faden A. I., 1999, Society for Neuroscience Abstracts, V25, P282; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1997, J NEUROTRAUM, V14, P885, DOI 10.1089/neu.1997.14.885; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; HOCKINGS PD, 1995, JMRI-J MAGN RESON IM, V5, P437, DOI 10.1002/jmri.1880050412; JOLY C, 1995, J NEUROSCI, V15, P3970; Kornhuber J, 1997, BIOL PSYCHIAT, V41, P135, DOI 10.1016/S0006-3223(96)00047-9; Litschig S, 1999, MOL PHARMACOL, V55, P453; Loubinoux I, 1997, STROKE, V28, P419, DOI 10.1161/01.STR.28.2.419; Maiese K, 1999, NEUROSCI LETT, V264, P17, DOI 10.1016/S0304-3940(99)00199-8; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moroni F, 1997, J PHARMACOL EXP THER, V281, P721; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Mukhin AG, 1997, NEUROREPORT, V8, P2561, DOI 10.1097/00001756-199707280-00028; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; MURASE K, 1989, NEUROSCI LETT, V103, P56, DOI 10.1016/0304-3940(89)90485-0; Nicoletti F, 1999, NEUROPHARMACOLOGY, V38, P1477, DOI 10.1016/S0028-3908(99)00102-1; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OPITZ T, 1994, NEUROPHARMACOLOGY, V33, P715, DOI 10.1016/0028-3908(94)90178-3; Pellegrini-Giampietro DE, 1999, EUR J NEUROSCI, V11, P3637, DOI 10.1046/j.1460-9568.1999.00786.x; Pellegrini-Giampietro DE, 1999, NEUROPHARMACOLOGY, V38, P1607, DOI 10.1016/S0028-3908(99)00097-0; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; SINENSKY MC, 1995, TOXICOL LETT, V75, P101; Strasser U, 1998, EUR J NEUROSCI, V10, P2848, DOI 10.1046/j.1460-9568.1998.00291.x; Vincent AM, 1999, EXP NEUROL, V155, P79, DOI 10.1006/exnr.1998.6966; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	41	85	98	0	4	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	FEB	2001	167	2					435	444		10.1006/exnr.2000.7577			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	400BG	WOS:000166848300024	11161632				2022-02-06	
J	Lane, PL; Skoretz, TG; Doig, G; Girotti, MJ				Lane, PL; Skoretz, TG; Doig, G; Girotti, MJ			Intracranial pressure monitoring and outcomes after traumatic brain injury	CANADIAN JOURNAL OF SURGERY			English	Article; Proceedings Paper	Joint Meeting of the Trauma-Association-of-Canada / Royal-College-of-Physicians-and-Surgeons-of-Canada	SEP 24-28, 1997	VANCOUVER, CANADA	Trauma Assoc Canada, Royal Coll Physicians & Surgeons Canada			GLASGOW-COMA-SCALE; SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; SEVERITY SCORE; MANAGEMENT; HEMATOMAS; CARE	OBJECTIVE: Uncontrolled intracranial hypertension after traumatic brain injury (TBI) contributes significantly to the death rate and to poor functional outcome. There is no evidence that intracranial pressure (ICP) monitoring alters the outcome of TBI. The objective of this study was to test the hypothesis that insertion of ICP monitors in patients who have TBI is not associated with a decrease in the death rate. DESIGN: Study of case records. METHODS: The data files from the Ontario Trauma Registry from 1989 to 1995 were examined. Included were all cases with an Injury Severity Score (ISS) greater than 12 from the 14 trauma centres in Ontario. Cases identifying a Maximum Abbreviated Injury Scale score in the head region (MAIS head) greater than 3 were selected for further analysis. Logistic regression analyses mere conducted to investigate the relationship between ICP and death. RESULTS: Of 9001 registered cases of TBI, an MAIS head greater than 3 was recorded in 5507. Of these patients, 541 (66.8% male, mean age 34.1 years) had an ICP monitor inserted. Their average ISS was 33.4 and 71.7% survived. There was wide variation among the institutions in the rate of insertion of ICP monitors in these patients (ranging from 0.4% to over 20%). Univariate logistic regression indicated that increased MAIS head, ISS, penetrating trauma and the insertion of an ICP monitor were each associated with an increased death rate. However, multivariate analyses controlling for MAIS head, ISS and injury mechanism indicated that ICP monitoring was associated with significantly improved survival (P < 0.015). CONCLUSIONS: ICP monitor insertion rates vary widely in Ontario's trauma hospitals. The insertion of an ICP monitor is associated with a statistically significant decrease in death rate among patients with severe TBI. This finding strongly supports the need for a prospective randomized trial of management protocols, including ICP monitoring, in patients with severe TBI.	Albert Einstein Med Ctr, Dept Emergency Med, Philadelphia, PA 19141 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD USA; Univ Western Ontario, Fac Med, Div Crit Care Med, London, ON, Canada; London Hlth Sci Ctr, Trauma Program, London, ON, Canada; Univ Western Ontario, Dept Surg, London, ON N6A 3K7, Canada		Lane, PL (corresponding author), Albert Einstein Med Ctr, Dept Emergency Med, 5501 Old York Rd, Philadelphia, PA 19141 USA.	lanep@aehn2.einstein.edu		Doig, Gordon/0000-0003-2141-7000			*AM ASS AUT MED, 1990, ABBR INJ SCAL 1990 R; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Brain Trauma Foundation, 1995, GUID MAN SEV HEAD IN; Buechler CM, 1998, J TRAUMA, V45, P429, DOI 10.1097/00005373-199809000-00001; Bullock R, 1995, GUIDELINES MANAGEMEN; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; EDDY VA, 1995, AM SURGEON, V61, P24; Fleischer A S, 1976, Surg Neurol, V6, P31; GUILLAUME J, 1951, REV NEUROL, V84, P131; GUTMAN MB, 1992, J NEUROSURG, V77, P9, DOI 10.3171/jns.1992.77.1.0009; Hosmer D, 1989, APPL LOGISTIC REGRES; JOHNSTON IH, 1973, ACTA NEUROCHIR, V29, P53, DOI 10.1007/BF01414616; KENNEDY F, 1993, J TRAUMA, V35, P75, DOI 10.1097/00005373-199307000-00013; KUDAY C, 1994, ACTA NEUROCHIR, V131, P203, DOI 10.1007/BF01808613; Lane PL, 1997, ACCIDENT ANAL PREV, V29, P53, DOI 10.1016/S0001-4575(96)00061-9; Lane PL, 1996, J TRAUMA, V41, P731, DOI 10.1097/00005373-199610000-00023; LEVY ML, 1994, NEUROSURGERY, V35, P77, DOI 10.1227/00006123-199407000-00012; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; MENDELOW AD, 1979, BRIT MED J, V1, P1240, DOI 10.1136/bmj.1.6173.1240; MIKROGIANAKIS A, 1995, UWO MED J, V64, P97; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; PUCKETT DC, 1990, ED ANNOTATION ICD 9; Rating the severity of tissue damage. I, 1971, JAMA-J AM MED ASSOC, V215, P277; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSS SE, 1992, ACCIDENT ANAL PREV, V24, P181, DOI 10.1016/0001-4575(92)90035-H; Rossi S, 1998, ACT NEUR S, V71, P91; *SAS I INC, 1990, SAS US GUID STAT VER; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Stewart TC, 1995, J TRAUMA, V39, P1036, DOI 10.1097/00005373-199512000-00003; STUART GG, 1983, J NEUROSURG, V59, P601, DOI 10.3171/jns.1983.59.4.0601; TEASDALE G, 1982, BRIT MED J, V285, P1695, DOI 10.1136/bmj.285.6356.1695; TEASDALE G, 1974, LANCET, V2, P81; *TRIAN INC, 1991, TRICODE 5 0 PERS COM; *TRIAN INC, 1991, COLLECTOR TRAUM REG; WALDER AD, 1995, INTENS CARE MED, V21, P606, DOI 10.1007/BF01700170; WARME PE, 1991, ACTA NEUROCHIR, V110, P57, DOI 10.1007/BF01402049	41	85	91	0	3	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	0008-428X	1488-2310		CAN J SURG	Can. J. Surg.	DEC	2000	43	6					442	448					7	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Surgery	381GD	WOS:000165753200011	11129833				2022-02-06	
J	Spell, LA; Frank, E				Spell, LA; Frank, E			Recognition of nonverbal communication of affect following traumatic brain injury	JOURNAL OF NONVERBAL BEHAVIOR			English	Article						nonverbal communication; facial expression; vocal prosody; traumatic brain injury; affect	HEMISPHERE; DISCRIMINATION; LESIONS	Recognition of facial expressions and vocal prosody was examined using the Diagnostic Assessment of Nonverbal Accuracy 2 (DANVA-2) and the Carolina Older Adult Test of Nonverbal Communication (COAT-NC) for 24 individuals with traumatic brain injury (TBI) and 24 matched controls. Results demonstrated that participants without TBI scored significantly higher than participants with TBI when presented with adult photo and voice stimuli. No significant group difference was noted with child photo and voice stimuli. Both groups scored significantly higher on photo subtests than on voice subtests for child and younger adult stimuli. For older adult stimuli, both groups scored significantly higher on the voice subtest than on the photo subtest. For the subjects with TBI, a significant relationship was found between scores on the voice subtests and a functional measure of cognition and communication.	Univ S Carolina, Dept Speech Language Pathol & Audiol, Columbia, SC 29208 USA		Spell, LA (corresponding author), Columbia Coll, Dept Educ, 1301 Columbia Coll Dr, Columbia, SC 29203 USA.						BENOWITZ LI, 1983, CORTEX, V19, P5, DOI 10.1016/S0010-9452(83)80046-X; BLONDER LX, 1991, BRAIN, V114, P1115, DOI 10.1093/brain/114.3.1115; BOWERS D, 1991, BRAIN, V114, P2593, DOI 10.1093/brain/114.6.2593; DEKOSKY ST, 1980, BRAIN LANG, V9, P206, DOI 10.1016/0093-934X(80)90141-8; DIXON WJ, 1988, BMDP STAT SOFTWARE M; Feldman R. S., 1991, FUNDAMENTALS NONVERB, P329, DOI DOI 10.1037/A0036052; Frattali C, 1995, FUNCTIONAL ASSESSMEN; HAGAN C, 1979, REHAB HEAD INJURED A; Helm-Estabrooks N., 1990, BRIEF TEST HEAD INJU; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; JENNETT B, 1974, LANCET, V1, P81; Kertesz A., 1982, W APHASIA BATTERY; Kowner R, 1996, J EXP PSYCHOL HUMAN, V22, P662, DOI 10.1037/0096-1523.22.3.662; LALANDE S, 1992, BRAIN LANG, V42, P165, DOI 10.1016/0093-934X(92)90123-V; Lehiste I., 1970, SUPRASEGMENTALS; MCCUTCHEON EP, 1992, HEAD SPINAL CORD INJ; Meredith W. H., 1967, BASIC MATH STAT TABL; NOWICKI S, 1993, J SOC PSYCHOL, V133, P749, DOI 10.1080/00224545.1993.9713934; NOWICKI S, 1994, J NONVERBAL BEHAV, V18, P9, DOI 10.1007/BF02169077; PAZGAN A, 1996, THESIS U S CAROLINA; PRIGATANO GP, 1982, J PERCEPTUAL MOTOR S, V54, P859; SHAVER M, 1996, THESIS U S CAROLINA; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; *SUNY RES FDN, 1993, GUID US UN DAT SET M; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WEATHERS M, 1996, THESIS U S CAROLINA; YLVISAKER M, 1987, COMMUNITY REENTRY HE	27	85	86	1	18	KLUWER ACADEMIC-HUMAN SCIENCES PRESS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013-1578 USA	0191-5886			J NONVERBAL BEHAV	J. Nonverbal Behav.	WIN	2000	24	4					285	300		10.1023/A:1006675230193			16	Psychology, Social	Social Science Citation Index (SSCI)	Psychology	368VC	WOS:000090137300003					2022-02-06	
J	Ownsworth, TL; McFarland, K; Young, RMD				Ownsworth, TL; McFarland, K; Young, RMD			Self-awareness and psychosocial functioning following acquired brain injury: An evaluation of a group support programme	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							CLOSED-HEAD-INJURY; REHABILITATION; PSYCHOTHERAPY; ADULTS	This study investigated a group support programme designed to improve self-awareness deficits and psychosocial functioning in a group of chronic patients (N = 21) with acquired brain injury (ABI). The participants were on average 8.6 years (range: 1-36 years) post-injury and were seen at the Brain Injury Association of Queensland, Australia. The assessment of participants involved two standardised measures of intellectual self-awareness with collateral reports from relatives. The present study introduced a new measure called the Self-Regulation Skills Interview (SRSI) which assessed higher levels of self awareness and self-regulation skills. Psychosocial functioning was assessed using a standardised self-report measure. At baseline the group had a relatively high level of intellectual self-awareness regarding their deficits, a low to moderate level of self-regulation skills, and significant psychosocial impairment. The participants were involved in a 16-week group programme which involved components of cognitive rehabilitation, cognitive-behavioural therapy, and social skills training. A post-intervention assessment indicated that participants had significantly improved levels of self-regulation skills and psychosocial functioning. A 6-month follow-up assessment indicated that overall, participants had maintained the gains made during the programme. The important role of self-regulation skills is emphasised as the principle factor contributing to the maintenance of the gains observed.	Univ Queensland, Sch Psychol, St Lucia, Qld 4072, Australia; Univ Queensland, Dept Psychiat, St Lucia, Qld, Australia		Ownsworth, TL (corresponding author), Univ Queensland, Sch Psychol, St Lucia, Qld 4072, Australia.		Young, Ross/AAF-2082-2021	Young, Ross/0000-0002-6806-6503; Ownsworth, Tamara/0000-0003-1835-7094			Armengol CG, 1999, J HEAD TRAUMA REHAB, V14, P233, DOI 10.1097/00001199-199906000-00004; Barco PP, 1991, COGNITIVE REHABILITA, P129; Bennett T L, 1997, Appl Neuropsychol, V4, P55, DOI 10.1207/s15324826an0401_7; Benson D.F., 1986, FRONTAL LOBES; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BERQUIST TF, 1993, BRAIN INJURY, V7, P275; BOAKE C, 1991, COGNITIVE REHABILITA, P181; BURKE JM, 1994, BRAIN INJURY, V8, P71, DOI 10.3109/02699059409150960; Carbery H, 1983, COGNITIVE REHABILITA, V1, P5; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [DOI 10.1097/00001199-198909000-00008, 10.1097/00001199-198909000-00008]; DEATON AV, 1986, REHABIL PSYCHOL, V31, P231, DOI 10.1037//0090-5550.31.4.231; DEATON AV, 1991, COGNITIVE REHABILITA, P191; Delmonico RL, 1998, J HEAD TRAUMA REHAB, V13, P10, DOI 10.1097/00001199-199812000-00004; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fleming JM, 1997, J HEAD TRAUMA REHAB, V12, P27, DOI 10.1097/00001199-199706000-00004; FLEMING JM, 1996, THESIS U QUEENSLAND; GARSKE GG, 1992, REHABIL COUNS BULL, V36, P44; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Klonoff PS, 1989, J HEAD TRAUMA REHAB, V4, P37; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; Lishman WA, 1998, ORGANIC PSYCHIAT; LONG DF, 1993, NEUROPSYCHOLOGICAL T, P3; McAllister TW, 1997, COMMUNITY MENT HLT J, V33, P341, DOI 10.1023/A:1025055426260; MILLER L, 1992, J COGNITIVE REHABILI, V10, P14; Morse P, 1992, CLIN SYNDROMES ADULT, P85; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; OWNSWORTH TL, IN PRESS CLIN NEUROP; Pepping M, 1991, NEUROPSYCHOLOGY EVER, P215; Pollens RD, 1988, COGNITIVE REHABILITA, V6, P26; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Schefft BK, 1997, CLIN NEUROPSYCHOLOGY, P237; Smith H.E., 1992, CLIN REHABIL, V6, P31; Tate RL, 1997, BRAIN INJURY, V11, P907, DOI 10.1080/026990597122972; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; YLVISAKER M, 1990, REHABILITATION ADULT, P558; [No title captured]	39	85	86	0	18	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	OCT	2000	10	5					465	484		10.1080/09602010050143559			20	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	358XX	WOS:000089583400001					2022-02-06	
J	Yu, CG; Jimenez, O; Marcillo, AE; Weider, B; Bangerter, K; Dietrich, WD; Castro, S; Yezierski, RP				Yu, CG; Jimenez, O; Marcillo, AE; Weider, B; Bangerter, K; Dietrich, WD; Castro, S; Yezierski, RP			Beneficial effects of modest systemic hypothermia on locomotor function and histopathological damage following contusion-induced spinal cord injury in rats	JOURNAL OF NEUROSURGERY			English	Article						spinal cord injury; spinal cord; locomotion; hypothermia; neuroprotection	TRAUMATIC BRAIN INJURY; POSTTRAUMATIC HYPOTHERMIA; MODERATE HYPOTHERMIA; TEMPERATURE; PROTECTION; METHYLPREDNISOLONE; ISCHEMIA; LACTATE; DEVICE; OXYGEN	Object. Local spinal cord cooling (LSCC) is associated with beneficial effects when applied following ischemic or traumatic spinal cord injury (SCI). However, the clinical application of LSCC is associated with many technical difficulties such as the requirement of special cooling devices, emergency surgery, and complicated postoperative management, if hypothermia is to be considered for future application in the treatment of SCI, alternative approaches must be developed. The objectives of the present study were to evaluate 1) the relationship between systemic and epidural temperature after SCI; 2) the effects of modest systemic hypothermia on histopathological damage at 7 and 44 days post-SCI; and 3) the effects of modest systemic hypothermia on locomotor outcome at 44 days post-SCI. Methods. A spinal cord contusion (12.5 mm at T-10) was produced in adult rats that had been randomly divided into two groups. Group 1 rats (seven in Experiment 1; 12 in Experiment 2) received hypothermic treatment (epidural temperature 32-33 degrees C) 30 minutes postinjury for 4 hours; Group 2 rats (nine in Experiment 1; eight in Experiment 2) received normothermic treatment (epidural temperature 37 degrees C) 30 minutes postinjury for 4 hours. Blood pressure, blood gas levels, and temperatures (epidural and rectal) were monitored throughout the 4-hour treatment period. Twice weekly assessment of locomotor function was performed over a 6-week survival period by using the Basso-Beattie-Bresnahan locomotor rating scale. Seven (Experiment 1) and 44 (Experiment 2) days after injury, animals were killed, perfused, and their spinal cords were serially sectioned. The area of tissue damage was quantitatively analyzed from 16 longitudinal sections selected from the central core of the spinal cord. Conclusions. The results showed that 1) modest changes in the epidural temperature of the spinal cord can be produced using systemic hypothermia; 2) modest systemic hypothermia (32-33(C degrees)) significantly protects against locomotor deficits following traumatic SCI; and 3) modest systemic hypothermia (32-33 degrees C) reduces the area of tissue damage at both 7 and 44 days postinjury. Although additional research is needed to study the therapeutic window and long-term benefits of systemic hypothermia, these data support the possible use of modest systemic hypothermia in the treatment of acute SCI.	Miami Project, Miami, FL 33136 USA; Univ Miami, Dept Neurol Surg, Miami, FL 33152 USA; Univ Miami, Dept Anat, Miami, FL 33152 USA; Univ Miami, Dept Cell Biol, Miami, FL 33152 USA; Univ Miami, Neurosci Program, Miami, FL 33152 USA		Yezierski, RP (corresponding author), Miami Project, 1600 NW 10th Ave,R-48, Miami, FL 33136 USA.	ryezierski@miami.edu	Yu, Chen Guang/C-6176-2011				ALBIN MS, 1967, ANESTH ANAL CURR RES, V46, P8; ARAKI N, 1991, J CEREB BLOOD FLO S2, V11, pS843; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BEHRMANN DL, 1992, J NEUROTRAUM, V9, P197, DOI 10.1089/neu.1992.9.197; BERNTMAN L, 1981, ANESTHESIOLOGY, V55, P495, DOI 10.1097/00000542-198111000-00003; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; BLACK P, 1971, Surgical Forum (Chicago), V22, P409; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; BRAIMBRIDGE MV, 1986, CARDIOPULMONARY BYPA, P385; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bresnahan JC, 1991, J NEUROTRAUM, V8, P91, DOI 10.1089/neu.1991.8.91; BRESNAHAN JC, 1987, EXP NEUROL, V95, P548, DOI 10.1016/0014-4886(87)90299-8; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Chatzipanteli K, 2000, J NEUROTRAUM, V17, P321, DOI 10.1089/neu.2000.17.321; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COOLEY DA, 1981, ANN THORAC SURG, V32, P260, DOI 10.1016/S0003-4975(10)61048-X; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1996, ADV NEUROL, V71, P177; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; DUCKER TB, 1969, J NEUROSURG, V30, P270, DOI 10.3171/jns.1969.30.3part1.0270; Eidelberg E, 1976, Surg Neurol, V6, P243; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; HAGERDAL M, 1978, ANESTHESIOLOGY, V49, P165, DOI 10.1097/00000542-197809000-00003; HAGERDAL M, 1975, J NEUROCHEM, V24, P311, DOI 10.1111/j.1471-4159.1975.tb11881.x; HANSEBOUT RR, 1992, SPINAL CORD DYSFUNCT, P59; KELLY DL, 1970, J NEUROSURG, V33, P554, DOI 10.3171/jns.1970.33.5.0554; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KRAMER RS, 1968, J THORAC CARDIOV SUR, V56, P699, DOI 10.1016/S0022-5223(19)42797-9; Liu SL, 1997, BRAIN RES, V756, P160, DOI 10.1016/S0006-8993(97)00137-6; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; MARSALA M, 1994, STROKE, V25, P2038, DOI 10.1161/01.STR.25.10.2038; MARTINEZARIZALA A, 1992, J NEUROTRAUM, V9, pS497; MEANS ED, 1981, J NEUROSURG, V55, P200, DOI 10.3171/jns.1981.55.2.0200; MICHENFELDER JD, 1970, ANESTHESIOLOGY, V33, P430, DOI 10.1097/00000542-197010000-00013; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; NATALE JE, 1989, STROKE, V20, P770, DOI 10.1161/01.STR.20.6.770; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; NOBLE LJ, 1989, EXP NEUROL, V103, P34, DOI 10.1016/0014-4886(89)90182-9; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85, DOI 10.1152/ajplegacy.1954.179.1.85; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TATOR CH, 1973, J NEUROSURG, V39, P52, DOI 10.3171/jns.1973.39.1.0052; Tuzgen S, 1998, SPINAL CORD, V36, P654, DOI 10.1038/sj.sc.3100660; Westergren H, 1998, J NEUROTRAUM, V15, P943, DOI 10.1089/neu.1998.15.943; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Yu C. G., 1999, Society for Neuroscience Abstracts, V25, P1443	52	85	89	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2000	93	1		S			85	93		10.3171/spi.2000.93.1.0085			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	328UD	WOS:000087867800013	10879763				2022-02-06	
J	Albensi, BC; Sullivan, PG; Thompson, MB; Scheff, SW; Mattson, MP				Albensi, BC; Sullivan, PG; Thompson, MB; Scheff, SW; Mattson, MP			Cyclosporin ameliorates traumatic brain-injury-induced alterations of hippocampal synaptic plasticity	EXPERIMENTAL NEUROLOGY			English	Article						Alzheimer's disease; apoptosis; learning and memory; long-term depression; long-term potentiation; mitochondrial permeability transition	LONG-TERM POTENTIATION; PERMEABILITY TRANSITION PORE; EXCITATORY AMINO-ACIDS; MITOCHONDRIAL DYSFUNCTION; RAT HIPPOCAMPUS; COGNITIVE DEFICITS; LIPID-PEROXIDATION; CORTICAL IMPACT; CYTOCHROME-C; CELL-DEATH	Although traumatic brain injury (TBI) often results in impaired learning and memory functions, the underlying mechanisms are unknown and there are currently no treatments that can preserve such functions. We studied plasticity at CA3-CA1 synapses in hippocampal slices from rats subjected to controlled cortical impact TBI. Long-term potentiation (LTP) of synaptic transmission was markedly impaired, whereas long-term depression (LTD) was enhanced, 48 h following TBI when compared to unoperated and sham control rats. Post-TBI administration of cyclosporin A, a compound that stabilizes mitochondrial function, resulted in a highly significant amelioration of the impairment of LTP and completely prevented the enhancement of LTD. Our data suggest that alterations in hippocampal synaptic plasticity may be responsible for learning and memory deficits resulting from TBI and that agents such as cyclosporin A that stabilize mitochondrial function may be effective treatments for TBI. (C) 2000 Academic Press.	Univ Kentucky, Sanders Brown Res Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; NIA, Neurosci Lab, Baltimore, MD 21224 USA		Albensi, BC (corresponding author), Univ Kentucky, Sanders Brown Res Ctr Aging, Lexington, KY 40536 USA.		Albensi, Benedict C/F-7304-2010; Mattson, Mark P/F-6038-2012; Albensi, Benedict Charles/AAJ-2359-2021	Albensi, Benedict Charles/0000-0002-7884-9261	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000317, Z01AG000317, Z01AG000312, Z01AG000313, ZIAAG000313, ZIAAG000312] Funding Source: NIH RePORTER		Albensi BC, 2000, SYNAPSE, V35, P151; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Baldwin SA, 1996, GLIA, V16, P266; Beal MF, 1998, BBA-BIOENERGETICS, V1366, P211, DOI 10.1124/jpet.112.192138; Bear MF, 1996, ANNU REV NEUROSCI, V19, P437, DOI 10.1146/annurev.ne.19.030196.002253; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; Bigler ED, 1996, J LEARN DISABIL-US, V29, P515, DOI 10.1177/002221949602900507; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS1; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Duan WZ, 1999, J NEUROCHEM, V72, P2312, DOI 10.1046/j.1471-4159.1999.0722312.x; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; Frei U, 1999, TRANSPLANT P, V31, P1669, DOI 10.1016/S0041-1345(99)00090-1; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Halestrap AP, 1997, MOL CELL BIOCHEM, V174, P167, DOI 10.1023/A:1006879618176; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hemenway Charles S., 1999, Cell Biochemistry and Biophysics, V30, P115, DOI 10.1007/BF02737887; Holtsberg FW, 1998, J NEUROCHEM, V70, P66; Ishida A, 1997, NEUROREPORT, V8, P2133, DOI 10.1097/00001756-199707070-00009; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Keller JN, 1998, J NEUROSCI, V18, P687; Lu YF, 1996, BRAIN RES, V729, P142, DOI 10.1016/S0006-8993(96)00568-9; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Mattson MP, 1996, RESTOR NEUROL NEUROS, V9, P191, DOI 10.3233/RNN-1996-9401; Mattson MP, 1998, TRENDS NEUROSCI, V21, P53, DOI 10.1016/S0166-2236(97)01188-0; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; Mattson MP, 1998, EXP NEUROL, V153, P35, DOI 10.1006/exnr.1998.6863; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Montal M, 1998, BBA-BIOENERGETICS, V1366, P113, DOI 10.1016/S0005-2728(98)00124-8; NATHAN T, 1990, BRAIN RES, V531, P55, DOI 10.1016/0006-8993(90)90757-3; Neame SJ, 1998, J CELL BIOL, V142, P1583, DOI 10.1083/jcb.142.6.1583; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; REEVES TM, 1995, EXP BRAIN RES, V106, P248; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Stanton PK, 1996, HIPPOCAMPUS, V6, P35, DOI 10.1002/(SICI)1098-1063(1996)6:1<35::AID-HIPO7>3.0.CO;2-6; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; TAKADA K, 1991, J PHARMACOBIO-DYNAM, V14, P34, DOI 10.1248/bpb1978.14.34; Tatton WG, 1998, ANN NEUROL, V44, pS134, DOI 10.1002/ana.410440720; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	56	85	87	0	3	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	APR	2000	162	2					385	389		10.1006/exnr.1999.7338			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	305EH	WOS:000086526100014	10739643				2022-02-06	
J	Kampfl, A; Franz, G; Aichner, F; Pfausler, B; Haring, HP; Felber, S; Luz, G; Schocke, M; Schmutzhard, E				Kampfl, A; Franz, G; Aichner, F; Pfausler, B; Haring, HP; Felber, S; Luz, G; Schocke, M; Schmutzhard, E			The persistent vegetative state after closed head injury: clinical and magnetic resonance imaging findings in 42 patients	JOURNAL OF NEUROSURGERY			English	Article						closed head injury; persistent vegetative state; magnetic resonance imaging	DIFFUSE AXONAL INJURY; ISCHEMIC BRAIN-DAMAGE; COMA DATA-BANK; TRAUMATIC COMA; WALLERIAN DEGENERATION; CORPUS-CALLOSUM; MR; FEATURES; LESIONS; NEUROPATHOLOGY	Object. In this retrospective study, the authors analyzed the frequency, anatomical distribution, and appearance of traumatic brain lesions in 42 patients in a posttraumatic persistent vegetative state. Methods. Cerebral magnetic resonance (MR) imaging was used to detect the number of lesions, which ranged from as few as five to as many as 19. with a mean of 11 lesions. In all 42 cases there was evidence on MR imaging of diffuse axonal injury, and injury to the corpus callosum was detected in all patients. The second most common area of diffuse axonal injury involved the dorsolateral aspect of the rostral brainstem (74% of patients). In addition, 65% of these patients exhibited white matter injury in the corona radiata and the frontal and temporal lobes. Lesions to the basal ganglia or thalamus were seen in 52% and 40% of patients, respectively, Magnetic resonance imaging showed some evidence of cortical contusion in 48% of patients in this study: the frontal and temporal lobes were most frequently involved. Injury to the parahippocampal gyrus was detected in 45% of patients; in this subgroup there was an 80% incidence of contralateral peduncular lesions in the midbrain. The most common pattern of injury (74% in this series) was the combination of focal lesions of the corpus callosum and the dorsolateral brainstem. In patients with no evidence of diffuse axonal injury in the upper brainstem (26% in this series), callosal lesions were most often associated with basal ganglia lesions. Lesions of the corona radiata and lobar white matter were equally distributed in patients with or without dorsolateral brainstem injury. Moreover, cortical contusions and thalamic, parahippocampal, and cerebral peduncular lesions were also similarly distributed in both groups. Conclusions. The: data indicate that diffuse axonal injury may be the major form of primary brain damage in the posttraumatic persistent vegetative state. In addition, the authors demonstrated in this study that MR imaging, in conjunction with a precise clinical correlation, may provide useful supportive information for the accurate diagnosis of a persistent vegetative state after traumatic brain injury.	Univ Innsbruck Hosp, Dept Neurol, Intens Care Unit, A-6020 Innsbruck, Austria; Univ Innsbruck Hosp, Dept Magnet Resonance & Spect, A-6020 Innsbruck, Austria; Univ Innsbruck Hosp, Dept Anesthesiol, A-6020 Innsbruck, Austria		Kampfl, A (corresponding author), Univ Innsbruck Hosp, Dept Neurol, Intens Care Unit, Anichstr 35, A-6020 Innsbruck, Austria.			Schmutzhard, Erich/0000-0003-3295-7491			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1986, J NEUROL NEUROSUR PS, V49, P1039, DOI 10.1136/jnnp.49.9.1039; Anderson CV, 1996, J NEUROTRAUM, V13, P35, DOI 10.1089/neu.1996.13.35; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; BIRBAMER G, 1993, J NEUROL, V240, P407, DOI 10.1007/BF00867352; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; CELESIA GG, 1993, NEUROLOGY, V43, P1457, DOI 10.1212/WNL.43.8.1457; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; CLIFTON GL, 1981, NEUROSURGERY, V8, P309, DOI 10.1227/00006123-198103000-00002; DOUGHTERY JH, 1998, NEUROLOGY, V31, P991; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FUJIOKA M, 1994, STROKE, V25, P2091, DOI 10.1161/01.STR.25.10.2091; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1994, RADIOLOGY, V191, P1; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Graham DI, 1997, GREENFIELDS NEUROPAT, P197; Grossman P, 1996, DISABIL REHABIL, V18, P1; JELLINGER K, 1970, J NEUROL SCI, V10, P51, DOI 10.1016/0022-510X(70)90091-2; JELLINGER K, 1977, APALLIC SYNDROME, P89; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; Katz D, 1992, J HEAD TRAUMA REHAB, V72, P1, DOI [10.1097/00001199-200501000-00008, DOI 10.1097/00001199-200501000-00008]; KENNARD C, 1995, J NEUROL NEUROSUR PS, V59, P347, DOI 10.1136/jnnp.59.4.347; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; KINNEY HC, 1994, NEW ENGL J MED, V330, P1469, DOI 10.1056/NEJM199405263302101; LEE JP, 1991, J TRAUMA, V31, P376, DOI 10.1097/00005373-199103000-00011; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; MACPHERSON P, 1986, J NEUROL NEUROSUR PS, V49, P29, DOI 10.1136/jnnp.49.1.29; MATSUO F, 1979, ANN NEUROL, V5, P72, DOI 10.1002/ana.410050111; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; ORITA T, 1994, J COMPUT ASSIST TOMO, V18, P943, DOI 10.1097/00004728-199411000-00019; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Payne K, 1996, ANN INTERN MED, V125, P104, DOI 10.7326/0003-4819-125-2-199607150-00004; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TEASDALE G, 1974, LANCET, V2, P81; UZZELL BP, 1987, NEUROSURGERY, V20, P396, DOI 10.1227/00006123-198703000-00007; WADE TD, 1996, BRIT MED J, V343, P943; WARAGAI M, 1994, NEURORADIOLOGY, V36, P402, DOI 10.1007/BF00612128; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; 1995, N ENGL J MED, V333, P130; [No title captured]	55	85	88	0	8	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	1998	88	5					809	816		10.3171/jns.1998.88.5.0809			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	ZJ709	WOS:000073244500003	9576247				2022-02-06	
J	Awasthi, D; Church, DF; Torbati, D; Carey, ME; Pryor, WA				Awasthi, D; Church, DF; Torbati, D; Carey, ME; Pryor, WA			Oxidative stress following traumatic brain injury in rats	SURGICAL NEUROLOGY			English	Article						ascorbic acid; ascorbyl radical; brain injury; ESR spectroscopy; free radicals; oxidative stress; spin trapping; trauma	CENTRAL NERVOUS-SYSTEM; HYDROXYL RADICAL GENERATION; LIPID-PEROXIDATION; ASCORBIC-ACID; METABOLIC-ACTIVATION; CARBON-TETRACHLORIDE; CEREBRAL-ISCHEMIA; ARACHIDONIC-ACID; SPINAL-CORD; OXYGEN	BACKGROUND Free radicals may be involved in the pathophysiology of traumatic brain injury (TBI) through oxidative damage of neurovascular structures. Endogenous antioxidants, such as ascorbate and alpha-tocopherol, may play a critical role in combating these oxidative reactions and their oxidized products can serve as an important index of oxidative stress. METHODS We used electron spin resonance (ESR) spectroscopy and in vivo spin trapping (reaction of an organic compound with free radical species) to detect the possible generation of free radicals after TBI. Injury was inflicted by a weight drop technique over the head (5.1 kg-cm). Rats were intravenously infused with either 1 mL, 0.1 M of the spin trap, alpha-phenyl-N-tert-butyl nitrone (PBN), or an equivalent volume of saline immediately before TBI or sham-injury. Animals were divided into four groups: (1) Group I: PBN-infused sham-injured, (2) Group II: PBN-infused injured, (3) Group III: saline-infused sham-injured, and (4) Group IV: saline-infused injured. Additional groups of saline-infused uninjured, salin-infused, and PBN-infused injured animals were used for histopathology. Sixty minutes after TBI or sham-injury, rats were again anesthetized and decapitated. The brains were removed within 1 minute, homogenized, and extracted for lipids. The extracts were analyzed by ESR spectroscopy. Brain ascorbic acid (AA) concentration was determined spectrophotometrically, using the ascorbate oxidase assay. RESULTS No PBN spin adduct signals (indicating trapped free radical species) were visible 60 minutes after TBI. All groups of rats showed an ascorbyl free radical signal. The ascorbyl signal intensity (AI) was, however, significantly higher in the injured rats, while the brain (AA) was significantly reduced. In addition, the ratio of AI/AA, which eliminates the effect of variable ascorbate concentrations in the brain, was also significantly higher in the injured animals. CONCLUSIONS We conclude that 60 minutes following TBI there was a significantly increased level of oxidative stress in the brain. This may reflect formation of free radical species with subsequent interaction with ascorbate (antioxidant) during the 60 minute period. The lack of PEN spin adduct signals 1 hour after TBI may indicate that free radical generation is time dependent and might be detectable earlier or later than the 60 minute period. (C) 1997 by Elsevier Science Inc.	UNIV MINNESOTA, MINNEAPOLIS, MN USA; LOUISIANA STATE UNIV, INST BIODYNAM, BATON ROUGE, LA 70803 USA		Awasthi, D (corresponding author), LOUISIANA STATE UNIV, MED CTR, DEPT NEUROSURG, 1542 TULANE AVE, NEW ORLEANS, LA 70112 USA.						ALBANO E, 1982, BIOCHEM J, V204, P593, DOI 10.1042/bj2040593; Allen AR., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; ANDERSON D K, 1985, Journal of Free Radicals in Biology and Medicine, V1, P59, DOI 10.1016/0748-5514(85)90030-3; BENDICH A, 1986, ADV FREE RADICAL BIO, V2, P419, DOI 10.1016/S8755-9668(86)80021-7; BODANNES RS, 1979, FEBS LETT, V105, P195, DOI 10.1016/0014-5793(79)80609-2; BRAY TM, 1985, ENVIRON HEALTH PERSP, V64, P61, DOI 10.2307/3429999; BUETTNER GR, 1993, FREE RADICAL BIO MED, V14, P49, DOI 10.1016/0891-5849(93)90508-R; CADET JL, 1988, INT J NEUROSCI, V40, P13, DOI 10.3109/00207458808985722; CHIUEH CC, 1992, FREE RADICAL BIO MED, V13, P581, DOI 10.1016/0891-5849(92)90151-6; CLOUGHHELFMAN C, 1991, FREE RADICAL RES COM, V15, P177, DOI 10.3109/10715769109049138; COHEN G, 1984, NEUROTOXICOLOGY, V5, P77; CONNOR HD, 1986, J BIOL CHEM, V261, P4542; DAS DK, 1989, BIOCHEM BIOPH RES CO, V165, P1004, DOI 10.1016/0006-291X(89)92702-2; DEMEDIUK P, 1985, PROG BRAIN RES, V63, P211; DEMOPOULOS HB, 1982, CAN J PHYSIOL PHARM, V60, P1415, DOI 10.1139/y82-210; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; DEMOPOULOS HB, 1982, PATHOLOGY OXYGEN, P127; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; FLAMM ES, 1978, STROKE, V9, P445, DOI 10.1161/01.STR.9.5.445; FLOYD RA, 1984, J BIOCHEM BIOPH METH, V10, P221, DOI 10.1016/0165-022X(84)90042-3; FOLCH J, 1957, J BIOL CHEM, V226, P497; Hall E D, 1986, Cent Nerv Syst Trauma, V3, P281; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HILLERED L, 1990, NEUROSCI LETT, V113, P328, DOI 10.1016/0304-3940(90)90606-A; IKEDA Y, 1990, NEUROSURGERY, V27, P1; KAGAN VE, 1990, ARCH BIOCHEM BIOPHYS, V280, P33, DOI 10.1016/0003-9861(90)90514-Y; KINUTA Y, 1989, J NEUROSURG, V71, P421, DOI 10.3171/jns.1989.71.3.0421; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KONTOS HA, 1984, CIRC RES, V55, P295, DOI 10.1161/01.RES.55.3.295; KUEHL FA, 1980, SCIENCE, V210, P978, DOI 10.1126/science.6254151; LAL EK, 1986, ARCH BIOCHEM BIOPHYS, V244, P156; LIEBLER DC, 1986, J BIOL CHEM, V261, P2114; MACHLIN LJ, 1987, FASEB J, V1, P441, DOI 10.1096/fasebj.1.6.3315807; MCCAY PB, 1984, J BIOL CHEM, V259, P2135; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Michael C., 1988, Nuclear Physics B, Proceedings Supplements, V4, P209, DOI 10.1016/0920-5632(88)90104-1; ORTEGA BD, 1972, STEROIDS BRAIN EDEMA, P167; PAPPIUS HM, 1983, NEUROCHEM RES, V8, P63, DOI 10.1007/BF00965654; PIETRI S, 1994, FREE RADICAL BIO MED, V16, P523, DOI 10.1016/0891-5849(94)90131-7; PIETRI S, 1989, EUR J BIOCHEM, V186, P163, DOI 10.1111/j.1432-1033.1989.tb15191.x; Pryor W., 1976, FREE RADICALS BIOLOG, P1; PRYOR WA, 1986, ANNU REV PHYSIOL, V48, P657, DOI 10.1146/annurev.ph.48.030186.003301; REHNCRONA S, 1980, J NEUROCHEM, V34, P1630, DOI 10.1111/j.1471-4159.1980.tb11254.x; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; Sen S., 1993, Society for Neuroscience Abstracts, V19, P636; SIESJO BK, 1985, J CEREBR BLOOD F MET, V5, P253, DOI 10.1038/jcbfm.1985.32; SPECTOR R, 1977, NEW ENGL J MED, V296, P1393, DOI 10.1056/NEJM197706162962409; TAUBER AI, 1985, ADV FREE RADICAL BIO, V1, P265; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; Yavorsky M, 1934, J BIOL CHEM, V106, P525; ZINI I, 1992, NEUROSCI LETT, V138, P279, DOI 10.1016/0304-3940(92)90933-X	54	85	87	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	JUN	1997	47	6					575	581		10.1016/S0090-3019(96)00461-2			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	XA470	WOS:A1997XA47000020	9167783				2022-02-06	
J	Kossmann, T; Stahel, PF; MorgantiKossmann, MC; Jones, JL; Barnum, SR				Kossmann, T; Stahel, PF; MorgantiKossmann, MC; Jones, JL; Barnum, SR			Elevated levels of the complement components C3 and factor B in ventricular cerebrospinal fluid of patients with traumatic brain injury	JOURNAL OF NEUROIMMUNOLOGY			English	Article						brain injury; cerebrospinal fluid; complement; blood-brain barrier	CENTRAL-NERVOUS-SYSTEM; RAT-BRAIN; ALZHEIMERS-DISEASE; HEAD-INJURY; GENE-EXPRESSION; SERUM; INTERLEUKIN-1; QUANTITATION; RESPONSES; PROTEINS	Immunological events occurring in the central nervous system (CNS) as a result of head trauma are largely unexplored. We report here that the levels of the alternative pathway complement proteins C3 and factor B are elevated in the cerebrospinal fluid (CSF) of head-injured patients. C3 and factor B indices suggest that changes in C3 and factor B levels in CSF are most likely due to altered blood-brain barrier integrity and not to intrathecal synthesis. These data demonstrate, for the first time, elevated levels of complement proteins in CSF of patients with severe traumatic brain injury. Elevated complement levels in brain injury may contribute to secondary damage.	UNIV ZURICH HOSP,DEPT SURG,DIV TRAMA SURG,CH-8091 ZURICH,SWITZERLAND; UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DIV CLIN IMMUNOL & RHEUMATOL,BIRMINGHAM,AL 35294					Morganti-Kossmann, Cristina/0000-0002-0807-2063	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS029719] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS29719] Funding Source: Medline		AISEN PS, 1994, AM J PSYCHIAT, V151, P1105; BARNUM SR, 1994, J IMMUNOL, V152, P765; BARNUM SR, 1995, CRIT REV ORAL BIOL M, V6, P132, DOI 10.1177/10454411950060020301; BECKER P, 1987, ANAESTHESIST, V36, P301; BROADWELL RD, 1993, EXP NEUROL, V120, P245, DOI 10.1006/exnr.1993.1059; DAVIS RE, 1993, CRIT REV NEUROBIOL, V7, P41; DUJARDIN BCG, 1985, J IMMUNOL METHODS, V80, P227, DOI 10.1016/0022-1759(85)90024-9; GAILLARD O, 1993, CLIN CHEM, V39, P309; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; HOYT DB, 1990, J TRAUMA, V30, P759, DOI 10.1097/00005373-199007000-00001; JENNETT B, 1975, LANCET, V1, P480; JOHNSON SA, 1992, NEUROBIOL AGING, V13, P641, DOI 10.1016/0197-4580(92)90086-D; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; KOSSMANN T, 1993, CIRC SHOCK S2, V62, P63; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MATHIESEN T, 1993, J NEUROSURG, V78, P562, DOI 10.3171/jns.1993.78.4.0562; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MAY PC, 1990, NEURON, V5, P831, DOI 10.1016/0896-6273(90)90342-D; MORGAN BP, 1993, COMPLEMENT HLTH DISE, P353; MORGANTIKOSSMAN.MC, 1995, IMMUNE RESPONSES NER, P158; NIETOSAMPEDRO M, 1987, J NEUROSCI RES, V17, P214, DOI 10.1002/jnr.490170303; OGLESBY TJ, 1988, J IMMUNOL METHODS, V110, P55, DOI 10.1016/0022-1759(88)90082-8; PASINETTI GM, 1992, EXP NEUROL, V118, P117, DOI 10.1016/0014-4886(92)90028-O; QUATTROCCHI K B, 1990, Journal of Neurotrauma, V7, P77, DOI 10.1089/neu.1990.7.77; QUATTROCCHI KB, 1991, J NEUROSURG, V75, P766, DOI 10.3171/jns.1991.75.5.0766; REBHUN J, 1991, ANN ALLERGY, V66, P335; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; Shin Moon Lee, 1992, P801; Takabayashi T, 1996, J IMMUNOL, V156, P3455; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TEASDALE G, 1974, LANCET, V2, P81; TIBBLING G, 1977, SCAND J CLIN LAB INV, V37, P385, DOI 10.3109/00365517709091496; TIBBLING G, 1977, SCAND J CLIN LAB INV, V37, P391; TIBBLING G, 1977, SCAND J CLIN LAB INV, V37, P397; WETSEL RA, 1995, CURR OPIN IMMUNOL, V7, P48, DOI 10.1016/0952-7915(95)80028-X; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	37	85	85	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728			J NEUROIMMUNOL	J. Neuroimmunol.	MAR	1997	73	1-2					63	69		10.1016/S0165-5728(96)00164-6			7	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	WM882	WOS:A1997WM88200008	9058760				2022-02-06	
J	Doppenberg, EMR; Bullock, R				Doppenberg, EMR; Bullock, R			Clinical neuro-protection trials in severe traumatic brain injury: Lessons from previous studies	JOURNAL OF NEUROTRAUMA			English	Article						clinical trials; end-points assessment; mechanism-driven; neuroprotection	SEVERE HEAD-INJURY; CONJUGATED SUPEROXIDE-DISMUTASE; KALLIKREIN-KININ SYSTEM; FLUID-PERCUSSION MODEL; THERAPEUTIC HYPOTHERMIA; INTRACRANIAL-PRESSURE; AXONAL CHANGE; OXYGEN; MEDIATOR; MODERATE	Major advances have been made in understanding the pathophysiological events after severe human traumatic brain injury, and consequently, many compounds have been tested in clinical trials, Thus far, no Phase III trials have been clearly successful, in human neurotrauma, although several Phase II studies have shown apparent benefit, This review is an attempt to identify factors that could be responsible for some of these failures, Recommendations are made that attempt to avoid these pitfalls in the future, Five criteria for future conduct of clinical trials are proposed, The usefulness of animal models for traumatic brain injury and their ability are discussed, Clearly, it is now becoming accepted that mechanism-driven trials, in which individual pathophysiological mechanisms are targeted, may be preferable in this heterogeneous patient population, The degree of brain penetration, the safety and tolerability of the compound, and end points used for outcome assessment are major influences upon the success of these trials, New approaches in developing, conducting, and analyzing these clinical trials should be considered in the future, if the costly failures of the past are not to be repeated, with the advent of newer ''neuroprotective agents'' and techniques.			Doppenberg, EMR (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DIV NEUROSURG, POB 980631, RICHMOND, VA 23298 USA.						ADAMS HP, 1994, STROKE, V25, P1901, DOI 10.1161/01.STR.25.9.1901; ADAMS JH, 1983, ACTA NEUROCHIR, V32, pS15; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BROADDUS WC, 1996, 46 ANN M MONTR; Bullock R., 1995, NEUROCHEMICAL MONITO, P64; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Di X, 1996, RESTOR NEUROL NEUROS, V9, P231, DOI 10.3233/RNN-1996-9406; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Drummond M., 1987, METHODS EC EVALUATIO, V4th; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GROSSET DG, 1993, J NEUROSURG, V78, P183; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; KHANDELWAL SR, 1993, AM J PHYSIOL, V265, pH1450, DOI 10.1152/ajpheart.1993.265.4.H1450; LANDOLT H, 1994, ACTA NEUROCHIR, P475; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MAIERHAUFF K, 1984, J NEUROSURG, V61, P97, DOI 10.3171/jns.1984.61.1.0097; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Marion DW, 1996, CRIT CARE MED, V24, pS81; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARMAROU A, 1996, ACTA NEUROCHIR S, V66, P188; MARMAROU A, 1993, J NEUROTRAUM, V10, pS61; MARSHALL LF, 1995, J NEUROTRAUM, V12, P929, DOI 10.1089/neu.1995.12.929; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; MUIZELAAR JP, 1994, ADV EXP MED BIOL, V366, P389; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PEERLESS SJ, 1981, STROKE, V12, P558, DOI 10.1161/01.STR.12.5.558; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; RANDAD RS, 1991, J MED CHEM, V34, P752, DOI 10.1021/jm00106a041; Sakas DE, 1996, CEREBROVAS BRAIN MET, V8, P209; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; STEIN SC, 1996, NEUROTRAUMA, P755; TEASDALE G, 1992, J NEUROTRAUM, V9, pS545; Tsuchida E, 1996, J NEUROSURG, V85, P104, DOI 10.3171/jns.1996.85.1.0104; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; UNTERBERG A, 1984, J NEUROSURG, V61, P87, DOI 10.3171/jns.1984.61.1.0087; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; WEI EP, 1993, AM J PHYSIOL, V265, pH1439; Whitehead J., 1983, DESIGN ANAL SEQUENTI; WOLF AL, 1993, J NEUROSURG, V78, P54, DOI 10.3171/jns.1993.78.1.0054; ZAUNER A, 1995, NEUROSURGERY, V37, P1168, DOI 10.1227/00006123-199512000-00017; ZAUNER A, 1997, UNPUB CONTINUOUS MUL	47	85	86	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	1997	14	2					71	80		10.1089/neu.1997.14.71			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	WN400	WOS:A1997WN40000001	9069438				2022-02-06	
J	Yablon, SA; Agana, BT; Ivanhoe, CB; Boake, C				Yablon, SA; Agana, BT; Ivanhoe, CB; Boake, C			Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: Am open-labeled trial	NEUROLOGY			English	Article							DOUBLE-BLIND	We studied the effect of botulinum toxin A (BTXA) among patients with traumatic brain injury (TBI) and severe spasticity unresponsive to conservative management. Twenty-one consecutive adult patients with severe spasticity involving the wrist and finger flexor musculature were treated with BTXA injection (20 to 40 units per muscle) under EMG guidance. After injection, patients received passive range of motion (ROM) exercise, with modalities and casting as clinically indicated. Outcome measures, including wrist ROM and the modified Ashworth Scale (MAS), were assessed 2 to 4 weeks after injection. Among the respective acute and chronic groups, mean ROM improved 42.9 (p = 0.001) and 36.2 degrees (p < 0.001). Mean MAS rating improved 1.5 (p = 0.01) and 1.47 (p = 0.002) points. There were no significant adverse effects. BTXA, in conjunction with conventional modalities, significantly improves spasticity and ROM in the distal upper extremity musculature of patients with TBI.	INST REHABIL & RES,BRAIN INJURY PROGRAM,HOUSTON,TX; UNIV TEXAS,HLTH SCI CTR HOUSTON,DEPT PHYS MED & REHABIL,HOUSTON,TX; BAYLOR COLL MED,DEPT PHYS MED & REHABIL,HOUSTON,TX 77030								AGANA BT, 1994, ARCH PHYS MED REHAB, V75, P1063; ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; BARBIERI S, 1994, MOVEMENT DISORDER S1, V9, P128; BIEDERMANN RE, 1993, ARCH PHYSICAL MED RE, V74, P1282; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BORGSTEIN J, 1993, AM J PHYS MED REHAB, V72, P364; BOWERS D N, 1991, Archives of Physical Medicine and Rehabilitation, V72, P816; BURGAR CG, 1994, ARCH PHYSICAL MED RE, V75, P1031; CHAN CH, 1990, NEUROLOGY, V40, P1427, DOI 10.1212/WNL.40.9.1427; DAS TK, 1989, BRIT J CLIN PRACT, V43, P401; DAS TK, 1989, POSTGRAD MED J, V65, P208, DOI 10.1136/pgmj.65.762.208; Delagi EF., 1980, ANATOMIC GUIDE ELECT, V2nd ed; DENGLER R, 1992, J NEUROL, V239, P375; DUNNE JW, 1995, J NEUROL NEUROSUR PS, V58, P232, DOI 10.1136/jnnp.58.2.232; GANS BM, 1990, PRACTICAL MANAGEMENT, P1; GRAZKO MA, 1995, NEUROLOGY, V45, P712, DOI 10.1212/WNL.45.4.712; Hesse S, 1992, J REHABIL SCI, V5, P98; JANKOVIC J, 1991, NEW ENGL J MED, V324, P1186, DOI 10.1056/nejm199104253241707; KASDON KL, 1990, PRACTICAL MANAGEMENT, P259; KATZ RT, 1988, AM J PHYS MED REHAB, V67, P108, DOI 10.1097/00002060-198806000-00004; KATZ RT, 1989, ARCH PHYS MED REHAB, V70, P144; KOMAN LA, 1993, J PEDIATR ORTHOPED, V13, P489, DOI 10.1097/01241398-199307000-00013; KOMAN LA, 1992, DEV MED CHILD NE S66, V34, P23; KOSTANZER A, 1992, MOVEMENT DISORDER S1, V7, P137; LEHMKUHL LD, 1990, J HEAD TRAUMA REHAB, V5, P23, DOI DOI 10.1097/00001199-199012000-00005; Lux Warren E., 1992, Archives of Physical Medicine and Rehabilitation, V73, P1008; MAYER NH, 1991, J NEURO REHAB, V5, pS1; MEMIN B, 1992, REV NEUROL, V148, P212; MEYTHALER JM, 1994, ARCH PHYSICAL MED RE, V75, P1036; OBRIEN CF, 1995, NEUROLOGY, V45, pA329; PIERSON SH, 1994, NEUROLOGY, V44, pA184; REEVES KD, 1992, AJPM, V2, P205; Robinson K. M., 1990, PRACTICAL MANAGEMENT, P201; SNOW BJ, 1990, ANN NEUROL, V28, P512, DOI 10.1002/ana.410280407; YARKONY GM, 1987, CLIN ORTHOP RELAT R, P93; YOUNG RR, 1987, CLIN ORTHOP RELAT R, V219, P50; [No title captured]; [No title captured]	38	85	87	0	2	LITTLE BROWN CO	BOSTON	34 BEACON STREET, BOSTON, MA 02108-1493	0028-3878			NEUROLOGY	Neurology	OCT	1996	47	4					939	944		10.1212/WNL.47.4.939			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	VN295	WOS:A1996VN29500015	8857723				2022-02-06	
J	BROWN, SJ; FANN, JR; GRANT, I				BROWN, SJ; FANN, JR; GRANT, I			POSTCONCUSSIONAL DISORDER - TIME TO ACKNOWLEDGE A COMMON SOURCE OF NEUROBEHAVIORAL MORBIDITY	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							MINOR HEAD-INJURY; MILD; SYMPTOMS; SEQUELAE; POPULATION; TRAUMA; CONCUSSION; DEFICITS		UNIV CALIF SAN DIEGO,SCH MED,DEPT PSYCHIAT,SAN DIEGO,CA 92093; UNIV WASHINGTON,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98195; VET AFFAIRS MED CTR,PSYCHIAT SERV,SAN DIEGO,CA						NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P50MH045294] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH45294] Funding Source: Medline		Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; BORNSTEIN RA, 1988, NEUROSURGERY, V23, P622, DOI 10.1227/00006123-198811000-00013; BROOKS N, 1984, NEUROBEHAVIORAL CONS; CARTLIDGE NEF, 1981, MAJOR PROBLEMS NEURO, V10, P95; DACEY RG, 1993, HEAD INJURY, P159; DIAMOND R, 1988, INT J CLIN NEUROPSYC, V10, P35; DIKMEN S, 1987, NEUROBEHAVIORAL RECO; Edna T H, 1987, J Oslo City Hosp, V37, P41; Eisenberg H.M., 1989, MILD HEAD INJURY, P133; ENOMOTO T, 1986, CHILD NERV SYST, V2, P72; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1974, LANCET, V2, P605; HALL S, 1991, PERCEPT MOTOR SKILL, V72, P1295, DOI 10.2466/PMS.72.4.1295-1298; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; JACOME DE, 1984, CLIN ELECTROENCEPHAL, V15, P214, DOI 10.1177/155005948401500406; JAKOBSEN J, 1987, ACTA NEUROL SCAND, V75, P341, DOI 10.1111/j.1600-0404.1987.tb05456.x; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Jennett B, 1981, MANAGEMENT HEAD INJU; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kay Thomas E., 1992, Archives of Physical Medicine and Rehabilitation, V73, P955; KELLY JP, 1991, JAMA-J AM MED ASSOC, V226, P2867; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEININGER B E, 1991, Brain Injury, V5, P199, DOI 10.3109/02699059109008090; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1989, MILD HEAT INJURY; LIDVALL H F, 1974, Acta Neurologica Scandinavica Supplementum, V50, P1; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P160; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; Mahon D, 1989, J Neurosci Nurs, V21, P382; MERSKEY H, 1972, BRAIN, V95, P521, DOI 10.1093/brain/95.3.521; MIDDELBOE T, 1992, J PERS DISORD, V6, P246, DOI 10.1521/pedi.1992.6.3.246; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; OMAYA AK, 1985, BIOMECHANICS TRAUMA, P245; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PARKER N, 1977, MED J AUSTRALIA, V2, P318, DOI 10.5694/j.1326-5377.1977.tb99164.x; POVLISHOCK J, 1983, J NEUROPATHOL EXP NE, V22, P225; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rutherford W. H., 1989, MILD HEAD INJURY, P217; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; TEASDALE G, 1974, LANCET, V2, P81; Thomsen I V, 1989, Brain Inj, V3, P157, DOI 10.3109/02699058909004547; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; UOMOTO JM, IN PRESS ARCH PHYS M; VERDUYN W H, 1992, Brain Injury, V6, P245, DOI 10.3109/02699059209029666; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; Yarnell P R, 1988, Brain Inj, V2, P255, DOI 10.3109/02699058809150950; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007	66	85	85	0	1	AMER PSYCHIATRIC ASSOCIATION	WASHINGTON	1400 K ST NW, WASHINGTON, DC 20005	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	1994	6	1					15	22					8	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	MV318	WOS:A1994MV31800003	8148632				2022-02-06	
J	BRUNO, VMG; GOLDBERG, MP; DUGAN, LL; GIFFARD, RG; CHOI, DW				BRUNO, VMG; GOLDBERG, MP; DUGAN, LL; GIFFARD, RG; CHOI, DW			NEUROPROTECTIVE EFFECT OF HYPOTHERMIA IN CORTICAL CULTURES EXPOSED TO OXYGEN-GLUCOSE DEPRIVATION OR EXCITATORY AMINO-ACIDS	JOURNAL OF NEUROCHEMISTRY			English	Article						GLUTAMATE; NMDA; KAINATE; S-ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID (AMPA); STROKE; HYPOXIA; ISCHEMIA; EXCITOTOXICITY	NMDA-RECEPTOR ACTIVATION; TRAUMATIC BRAIN INJURY; D-ASPARTATE RECEPTORS; NEURONAL INJURY; GLUTAMATE NEUROTOXICITY; CEREBRAL-ISCHEMIA; CELL-CULTURE; SPINAL-CORD; NEUROTRANSMITTER RELEASE; MODERATE HYPOTHERMIA	We examined the effect of moderate hypothermia (30 degrees C) on neuronal injury in murine cortical cell cultures. Lowering the temperature during and after a period of oxygen-glucose deprivation reduced both the release of glutamate to the bathing medium and accompanying neuronal degeneration. Hypothermia immediately after brief exposure to high concentrations of NMDA or glutamate also reduced the resulting neuronal degeneration. This protective effect was not eliminated when MK-801 and 6-cyano-7-nitroquinoxaline-2,3-dione were added immediately after washout of the exogenously added excitotoxin, suggesting that it was mediated by actions additional to reduction of endogenous late glutamate release. Hypothermia applied only during exposure to NMDA or glutamate, whether brief or prolonged, did not reduce subsequent cytosolic calcium accumulation or neuronal degeneration, suggesting that the postsynaptic induction of NMDA receptor-mediated excitotoxicity is not sensitive to temperature reduction. However, hypothermia during prolonged S-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid or kainate exposure did reduce neuronal degeneration.	WASHINGTON UNIV, SCH MED, DEPT NEUROL, ST LOUIS, MO 63110 USA; STANFORD UNIV, SCH MED, DEPT ANESTHESIA, STANFORD, CA 94305 USA; WASHINGTON UNIV, SCH MED, CTR STUDIES NERVOUS SYST INJURY, ST LOUIS, MO USA				bruno, Valeria/F-3146-2012	bruno, Valeria/0000-0003-4231-0739; Goldberg, Mark/0000-0003-3534-6979; Giffard, Rona/0000-0003-2173-4436	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026907, K08NS001425, K08NS001543] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 01543, NS 26907, NS 01425] Funding Source: Medline		ALBERS GW, 1992, ARCH NEUROL-CHICAGO, V49, P418, DOI 10.1001/archneur.1992.00530280112031; AMARA SG, 1992, NATURE, V360, P420, DOI 10.1038/360420d0; BAKER AJ, 1991, STROKE, V22, P666, DOI 10.1161/01.STR.22.5.666; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BUCHAN A, 1992, NEUROL CLIN, V10, P49, DOI 10.1016/S0733-8619(18)30233-0; BUCHAN A, 1990, J NEUROSCI, V10, P311; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CARDELL M, 1991, J NEUROCHEM, V57, P1814, DOI 10.1111/j.1471-4159.1991.tb06387.x; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1987, J NEUROSCI, V7, P357; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELLORY JC, 1976, BIOCHIM BIOPHYS ACTA, V443, P301, DOI 10.1016/0005-2736(76)90512-5; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GIFFARD RG, 1990, BRAIN RES, V506, P339, DOI 10.1016/0006-8993(90)91276-M; GINSBERG MD, 1990, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1990, P499; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; GOLDBERG MP, 1987, J PHARMACOL EXP THER, V243, P784; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; GOLDBERG MP, 1991, J CEREB BLOOD FLOW M, V11, pS422; GRODEN DL, 1991, CELL CALCIUM, V12, P279, DOI 10.1016/0143-4160(91)90002-V; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAIKALA H, 1986, BRAIN RES, V375, P313, DOI 10.1016/0006-8993(86)90751-1; HARTLEY DM, 1989, J PHARMACOL EXP THER, V250, P752; IKONOMIDOU C, 1989, BRAIN RES, V487, P184, DOI 10.1016/0006-8993(89)90956-6; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KAKU DA, 1991, BRAIN RES, V554, P344, DOI 10.1016/0006-8993(91)90214-G; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOH JY, 1991, P NATL ACAD SCI USA, V88, P9431, DOI 10.1073/pnas.88.21.9431; KOH JY, 1990, J NEUROSCI, V10, P693; KOONS D D, 1972, Cleveland Clinic Quarterly, V39, P109; KRANTIS A, 1983, ACTA NEUROPATHOL, V60, P61, DOI 10.1007/BF00685348; LANTOS J, 1986, ACTA PHYSIOL HUNG, V67, P141; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; LUST WD, 1981, ANAL BIOCHEM, V110, P258, DOI 10.1016/0003-2697(81)90144-5; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MARTINEZARIZALA A, 1992, J NEUROTRAUM, V9, pS497; MCDONALD JW, 1991, NEUROSCI LETT, V126, P83, DOI 10.1016/0304-3940(91)90377-6; MICHENFELDER JD, 1970, ANESTHESIOLOGY, V33, P430, DOI 10.1097/00000542-197010000-00013; MONYER H, 1992, NEURON, V8, P967, DOI 10.1016/0896-6273(92)90211-U; NASLUND TC, 1992, ANN SURG, V215, P409, DOI 10.1097/00000658-199205000-00002; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; NICHOLS RA, 1987, J NEUROCHEM, V48, P615, DOI 10.1111/j.1471-4159.1987.tb04137.x; NORWOOD WI, 1982, AM J PHYSIOL, V243, pC62, DOI 10.1152/ajpcell.1982.243.1.C62; OKADA Y, 1988, NEUROSCI LETT, V84, P277, DOI 10.1016/0304-3940(88)90520-4; PONTIUS RG, 1954, SURG FORUM, V5, P224; ROKKAS CK, 1991, SURG FORUM, V50, P265; RONG H, 1993, BRAIN RES, V618, P346, DOI 10.1016/0006-8993(93)91289-5; ROSE K, 1993, METHODS TOXICOLOGY, V1, P46; ROSOMOFF HL, 1957, ARCH NEURO PSYCHIATR, V78, P454, DOI 10.1001/archneurpsyc.1957.02330410018002; ROTHMAN SM, 1987, NEUROSCIENCE, V22, P471, DOI 10.1016/0306-4522(87)90347-2; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SACAAN AI, 1992, NEUROSCI LETT, V139, P77, DOI 10.1016/0304-3940(92)90862-2; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; SHUAIB A, 1993, NEUROCHEM RES, V18, P663, DOI 10.1007/BF00966779; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SIMPSON RE, 1991, NEUROSCI LETT, V124, P83, DOI 10.1016/0304-3940(91)90827-G; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; WEISS J, 1986, BRAIN RES, V380, P186, DOI 10.1016/0006-8993(86)91447-2; WELLS JD, 1978, SURG NEUROL, V10, P200; ZEEVALK GD, 1993, J NEUROCHEM, V61, P1445, DOI 10.1111/j.1471-4159.1993.tb13639.x	65	85	90	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	OCT	1994	63	4					1398	1406					9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	PH202	WOS:A1994PH20200026	7523591				2022-02-06	
J	OKIYAMA, K; SMITH, DH; THOMAS, MJ; MCINTOSH, TK				OKIYAMA, K; SMITH, DH; THOMAS, MJ; MCINTOSH, TK			EVALUATION OF A NOVEL CALCIUM-CHANNEL BLOCKER, (S)-EMOPAMIL, ON REGIONAL CEREBRAL EDEMA AND NEUROBEHAVIORAL FUNCTION AFTER EXPERIMENTAL BRAIN INJURY	JOURNAL OF NEUROSURGERY			English	Article						(S)-EMOPAMIL; CALCIUM CHANNEL BLOCKER; FLUID-PERCUSSION INJURY; CEREBRAL EDEMA; MEMORY; RAT	FLUID-PERCUSSION MODEL; SUBARACHNOID HEMORRHAGE; NMDA RECEPTORS; HEAD-INJURY; BLOOD-FLOW; CELL-DEATH; ISCHEMIA; RAT; NIMODIPINE; CATS	The authors investigated the effects of a novel calcium channel blocker, (S)-emopamil, on cerebral edema and neurobehavioral and memory function following experimental fluid-percussion brain injury in the rat. Two independent experiments were performed to evaluate the effects of this compound on cardiovascular variables and postinjury cerebral edema (increases in tissue water content), and on cognitive deficits and neurological motor function following brain injury. Treatment with (S)-emopamil significantly reduced focal brain edema at 48 hours after brain injury. Profound memory dysfunction induced by brain injury was significantly attenuated following (S)-emopamil treatment. In addition, (S)-emopamil also attenuated the deficits in motor function that were observed over a 2-week period following brain injury. These results suggest that changes in calcium homeostasis may play an important role in the pathogenesis of trauma to the central nervous system and that the calcium channel blocker (S)-emopamil might be a useful compound for the treatment of traumatic brain injury.	UNIV CONNECTICUT, CTR HLTH,DEPT SURG,SURG RES CTR, CENT NERVOUS SYST INJURY LAB, FARMINGTON, CT 06032 USA				smith, douglas/A-1321-2007		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, R55NS026818] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 26818] Funding Source: Medline		ALKON DL, 1989, SCI AM, V261, P42, DOI 10.1038/scientificamerican0789-42; BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; BETZ AL, 1989, STROKE, V20, P1253, DOI 10.1161/01.STR.20.9.1253; BIELENBERG GW, 1989, CEREBRAL ISCHEMIA CA, P274; BLISS T V P, 1988, P3; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CHAN PH, 1985, PROG BRAIN RES, V63, P227; CHEUNG JY, 1986, NEW ENGL J MED, V314, P1670; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI DW, 1987, J NEUROSCI, V7, P369; COMPTON J S, 1990, British Journal of Neurosurgery, V4, P9, DOI 10.3109/02688699009000676; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DECOURTENMYERS GM, 1985, STROKE, V16, P1016, DOI 10.1161/01.STR.16.6.1016; DEFEUDIS FV, 1989, TRENDS PHARMACOL SCI, V10, P215, DOI 10.1016/0165-6147(89)90262-9; DIETRICH WD, 1989, J CEREBR BLOOD F MET, V9, P812, DOI 10.1038/jcbfm.1989.115; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GREENBERG DA, 1987, ANN NEUROL, V21, P317, DOI 10.1002/ana.410210402; HOFFMEISTER F, 1985, NIMODIPINE PHARM CLI, P77; HOFMANN HP, 1989, ARZNEIMITTEL-FORSCH, V39-1, P304; IKEDA Y, 1990, NEUROSURGERY, V27, P1; JACEWICZ M, 1990, J CEREBR BLOOD F MET, V10, P903, DOI 10.1038/jcbfm.1990.147; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KATAYAMA Y, 1988, Society for Neuroscience Abstracts, V14, P1154; Kostron H, 1985, Neurochirurgia (Stuttg), V28 Suppl 1, P103; KUCHARCZYK J, 1989, STROKE, V20, P268, DOI 10.1161/01.STR.20.2.268; LEVERE TE, 1989, BEHAV NEUROSCI, V103, P561, DOI 10.1037/0735-7044.103.3.561; LEVIN HS, 1985, CENTRAL NERVOUS SYST, P281; LIU D, 1990, Journal of Neurotrauma, V7, P219, DOI 10.1089/neu.1990.7.219; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MATZEL LD, 1990, J NEUROSCI, V10, P2300; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MILLER JR, 1989, SOC NEUR ABSTR, V15, P534; MOSKOWITZ MA, 1984, SCIENCE, V224, P886, DOI 10.1126/science.6719118; NAKAYAMA H, 1988, NEUROLOGY, V38, P1667, DOI 10.1212/WNL.38.11.1667; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; PALMER GC, 1988, J NEUROSCI RES, V19, P252, DOI 10.1002/jnr.490190211; ROBINSON MJ, 1990, CEREBROVAS BRAIN MET, V2, P205; ROSS DT, 1989, BRAIN RES, V501, P129, DOI 10.1016/0006-8993(89)91034-2; SATO M, 1984, J CEREBR BLOOD F MET, V4, P173, DOI 10.1038/jcbfm.1984.25; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; SHIGENO T, 1989, STROKE, V20, P1260, DOI 10.1161/01.STR.20.9.1260; SIESJO BK, 1988, ANN NY ACAD SCI, V522, P638; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1985, CENTRAL NERVOUS SYST, P513; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Squire LR., 1987, MEMORY BRAIN; SZABO L, 1989, ARZNEIMITTEL-FORSCH, V39-1, P309; SZABO L, 1989, ARZNEIMITTELFORSCH, V39-1, P314; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YASUDA SU, 1989, DICP ANN PHARMAC, V23, P451, DOI 10.1177/106002808902300602; Young W, 1985, Cent Nerv Syst Trauma, V2, P109; Young W, 1986, Cent Nerv Syst Trauma, V3, P235; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	63	85	85	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	1992	77	4					607	615		10.3171/jns.1992.77.4.0607			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	JP648	WOS:A1992JP64800019	1527621				2022-02-06	
J	LEVIN, HS; GOLDSTEIN, FC				LEVIN, HS; GOLDSTEIN, FC			ORGANIZATION OF VERBAL MEMORY AFTER SEVERE CLOSED-HEAD INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article											LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 07377, NS 21889] Funding Source: Medline		BADDELEY AD, 1984, CLIN MANAGEMENT MEMO, P5; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BATTIG WF, 1969, J EXP PSYCHOL, V80, P1, DOI 10.1037/h0027577; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; Buschke H., 1984, NEUROPSYCHOLOGY MEMO, P33; BUTTERS N, 1973, NEUROPSYCHOLOGIA, V11, P291, DOI 10.1016/0028-3932(73)90040-7; CERMAK LS, 1973, NEUROPSYCHOLOGIA, V11, P85, DOI 10.1016/0028-3932(73)90068-7; COHEN BH, 1954, 10 U CONN TECH REP; CROVITZ HF, 1979, CORTEX, V15, P225, DOI 10.1016/S0010-9452(79)80027-1; FRANKEL MT, 1985, J EXP CHILD PSYCHOL, V40, P304, DOI 10.1016/0022-0965(85)90092-X; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; Jenkins J, 1970, NORMS WORD ASS, P1; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEWINSOHN PM, 1977, J CONSULT CLIN PSYCH, V45, P717, DOI 10.1037/0022-006X.45.5.717; Marshall G. R., 1970, NORMS WORD ASS, P321, DOI [10.1016/B978-0- 12-563050-4.50010-8, DOI 10.1016/B978-0-12-563050-4.50010-8]; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; SCHACTER DL, 1986, J CLIN EXP NEUROPSYC, V8, P727, DOI 10.1080/01688638608405192; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; Schacter DL, 1986, CLIN NEUROPSYCHOLOGY, P257; Squire LR, MEMORY BRAIN; STERNBERG RJ, 1977, PSYCHOL BULL, V84, P539, DOI 10.1037/0033-2909.84.3.539; TEASDALE G, 1974, LANCET, V2, P81; Thorndike E. L., 1944, TEACHERS WORD BOOK 3; Tulving E., 1972, ORG MEMORY, P381; Wechsler D., 1981, WAIS R MANUAL; WEINGARTNER H, 1983, SCIENCE, V221, P380, DOI 10.1126/science.6867715; WEINGARTNER H, 1981, J ABNORM PSYCHOL, V90, P187, DOI 10.1037/0021-843X.90.3.187; WEINGARTNER H, 1981, ARCH GEN PSYCHIAT, V38, P42; Weinstein E.A., 1955, DENIAL ILLNESS SYMBO; Wilson BA, 1984, CLIN MANAGEMENT MEMO; ZATORRE RJ, 1983, BRAIN COGNITION, V2, P331, DOI 10.1016/0278-2626(83)90017-9	34	85	85	1	5	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	1986	8	6					643	656		10.1080/01688638608405185			14	Psychology, Clinical; Clinical Neurology; Psychology	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Psychology; Neurosciences & Neurology	F0782	WOS:A1986F078200003	3782445				2022-02-06	
J	HAYES, RL; PECHURA, CM; KATAYAMA, Y; POVLISHOCK, JT; GIEBEL, ML; BECKER, DP				HAYES, RL; PECHURA, CM; KATAYAMA, Y; POVLISHOCK, JT; GIEBEL, ML; BECKER, DP			ACTIVATION OF PONTINE CHOLINERGIC SITES IMPLICATED IN UNCONSCIOUSNESS FOLLOWING CEREBRAL CONCUSSION IN THE CAT	SCIENCE			English	Article											HAYES, RL (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,RICHMOND,VA 23298, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587] Funding Source: Medline		AMATRUDA TT, 1975, BRAIN RES, V98, P501, DOI 10.1016/0006-8993(75)90369-8; BAXTER BL, 1969, EXP NEUROL, V23, P220, DOI 10.1016/0014-4886(69)90059-4; BORNSTEIN MB, 1946, J NEUROPHYSIOL, V9, P349, DOI 10.1152/jn.1946.9.5.349; BRIGGS TL, 1971, BRAIN RES, V29, P17, DOI 10.1016/0006-8993(71)90414-8; Bruyn, 1975, HDB CLIN NEUROLOGY, V23, P317; CARLTON S, 1982, SOC NEUR ABSTR, V8, P167; CHATRIAN GE, 1963, ELECTROEN CLIN NEURO, V15, P272, DOI 10.1016/0013-4694(63)90096-8; DEWITT DS, 1981, J CEREB BLOOD FLO S1, V1, pS579; GEORGE R, 1964, INT J NEUROPHARMACOL, V3, P541; GOOCHEE C, 1980, ANN NEUROL, V7, P359, DOI 10.1002/ana.410070414; HOSHINO K, 1976, ARCH ITAL BIOL, V114, P244; KATAYAMA Y, UNPUB; KIMURA H, 1981, J COMP NEUROL, V200, P151, DOI 10.1002/cne.902000202; MITLER MM, 1974, BRAIN RES, V68, P335, DOI 10.1016/0006-8993(74)90402-8; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PEON H, 1965, PROG BRAIN RES, V18, P96; PLUM F, 1980, DIAGNOSIS STUPOR COM, P11; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; PROUDFIT HK, 1980, BRAIN RES, V201, P459, DOI 10.1016/0006-8993(80)91053-7; RATCHESON RA, 1977, J NEUROCHEM, V28, P223, DOI 10.1111/j.1471-4159.1977.tb07730.x; ROSENBLUM W, 1980, NEUROSURGERY, V9, P613; RUGE D, 1948, J NEUROSURG, V11, P77; SHINOHARA M, 1979, SCIENCE, V203, P188, DOI 10.1126/science.758688; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SOKOLOFF L, 1978, CIBA F S, V56, P171, DOI DOI 10.1002/9780470720370.CH10; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Tarlov I.M., 1957, SPINAL CORD COMPRESS; TOWER DB, 1948, J CLIN INVEST, V27, P558; VANDONGEN PAM, 1980, EXP NEUROL, V67, P52, DOI 10.1016/0014-4886(80)90161-2; VANDONGEN PAM, 1977, PHARM BIOCH BEHAV, V8, P527; WARD A, 1950, J NEUROSURG, V7, P398, DOI 10.3171/jns.1950.7.5.0398	31	85	85	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science		1984	223	4633					301	303		10.1126/science.6701514			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY262	WOS:A1984RY26200040	6701514				2022-02-06	
J	BROOKS, DN				BROOKS, DN			WECHSLER MEMORY SCALE PERFORMANCE AND ITS RELATIONSHIP TO BRAIN-DAMAGE AFTER SEVERE CLOSED HEAD-INJURY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article									UNIV GLASGOW SO GEN HOSP,DEPT PSYCHOL MED,GLASGOW,SCOTLAND								BADDELEY AD, 1970, J VERB LEARN VERB BE, V9, P176, DOI 10.1016/S0022-5371(70)80048-2; BOND MR, 1975, OUTCOME SEVERE CNS D; BROOKS D N, 1974, Cortex, V10, P224; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; FAHY TJ, 1967, LANCET, V2, P476; HPAY H, 1971, HEAD INJURIES; KIRK RE, 1968, EXPT DESIGN PROCEDUR, P279; Klove H, 1972, Scand J Rehabil Med, V4, P55; LEVIN HS, IN PRESS; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; Ruesch J, 1943, ARCH NEURO PSYCHIATR, V50, P165, DOI 10.1001/archneurpsyc.1943.02290200065005; Talland G.A., 1965, DERANGED MEMORY; TOOTH G, 1947, J NEUROL NEUROSUR PS, V10, P1, DOI 10.1136/jnnp.10.1.1; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WILLIAMS M, 1952, J NEUROL NEUROSUR PS, V15, P54, DOI 10.1136/jnnp.15.1.54; [No title captured]	19	85	85	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry		1976	39	6					593	601		10.1136/jnnp.39.6.593			9	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	BV904	WOS:A1976BV90400013	950571	Green Published, Bronze			2022-02-06	
J	GROSS, AG				GROSS, AG			A NEW THEORY ON THE DYNAMICS OF BRAIN CONCUSSION AND BRAIN INJURY	JOURNAL OF NEUROSURGERY			English	Article																	BERGMANN L, 1954, ULTRASCHALL SEINE AN, V16; Courville CB, 1942, ARCH SURG-CHICAGO, V45, P19, DOI 10.1001/archsurg.1942.01220010022002; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296, DOI 10.1152/physrev.1945.25.2.296; Duret H, 1920, REV NEUROL-FRANCE, V36, P888; GAMA JP, 1835, TRAITE PLAIES TETE E, V24; Goggio AF, 1941, J NEUROL PSYCHIATRY, V4, P11, DOI 10.1136/jnnp.4.1.11; GURDJIAN ES, 1943, SURG GYNECOL OBSTET, V76, P623; Holbourn AHS, 1943, LANCET, V2, P438; MILES A, 1892, BRAIN, V15, P153; MUNRO D, 1938, CRANIO CEREBRAL INJU, V28; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; WARD JW, 1948, SCIENCE, V107, P349, DOI 10.1126/science.107.2779.349	14	85	86	1	5	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1958	15	5					548	561		10.3171/jns.1958.15.5.0548			14	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	WG964	WOS:A1958WG96400009	13576198				2022-02-06	
J	Chou, A; Krukowski, K; Jopson, T; Zhu, PJ; Costa-Mattioli, M; Walter, P; Rosi, S				Chou, Austin; Krukowski, Karen; Jopson, Timothy; Zhu, Ping Jun; Costa-Mattioli, Mauro; Walter, Peter; Rosi, Susanna			Inhibition of the integrated stress response reverses cognitive deficits after traumatic brain injury	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						brain trauma; memory deficits; translational control; eIF2 alpha; hippocampus	TERM SYNAPTIC PLASTICITY; ALZHEIMERS-DISEASE; TRANSLATIONAL CONTROL; MOUSE MODEL; HEAD TRAUMA; NEUROINFLAMMATORY RESPONSE; MEMORY STORAGE; UP-REGULATION; RISK-FACTOR; EIF2-ALPHA	Traumatic brain injury (TBI) is a leading cause of long-term neurological disability, yet the mechanisms underlying the chronic cognitive deficits associated with TBI remain unknown. Consequently, there are no effective treatments for patients suffering from the long-lasting symptoms of TBI. Here, we show that TBI persistently activates the integrated stress response (ISR), a universal intracellular signaling pathway that responds to a variety of cellular conditions and regulates protein translation via phosphorylation of the translation initiation factor eIF2 alpha. Treatment with ISRIB, a potent drug-like small-molecule inhibitor of the ISR, reversed the hippocampal-dependent cognitive deficits induced by TBI in two different injury mouse models-focal contusion and diffuse concussive injury. Surprisingly, ISRIB corrected TBI-induced memory deficits when administered weeks after the initial injury and maintained cognitive improvement after treatment was terminated. At the physiological level, TBI suppressed long-term potentiation in the hippocampus, which was fully restored with ISRIB treatment. Our results indicate that ISR inhibition at time points late after injury can reverse memory deficits associated with TBI. As such, pharmacological inhibition of the ISR emerges as a promising avenue to combat head trauma-induced chronic cognitive deficits.	[Chou, Austin; Krukowski, Karen; Jopson, Timothy; Rosi, Susanna] Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA; [Chou, Austin; Rosi, Susanna] Univ Calif San Francisco, Neurosci Grad Program, San Francisco, CA 94143 USA; [Krukowski, Karen; Jopson, Timothy; Rosi, Susanna] Univ Calif San Francisco, Dept Phys Therapy Rehabil Sci, San Francisco, CA 94143 USA; [Krukowski, Karen; Rosi, Susanna] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Zhu, Ping Jun; Costa-Mattioli, Mauro] Baylor Coll Med, Memory & Brain Res Ctr, Dept Neurosci, Houston, TX 77030 USA; [Walter, Peter] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; [Walter, Peter] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA		Rosi, S (corresponding author), Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Neurosci Grad Program, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Dept Phys Therapy Rehabil Sci, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.; Walter, P (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.; Walter, P (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.	peter@walterlab.ucsf.edu; Susanna.Rosi@ucsf.edu		Chou, Austin/0000-0003-4328-5811	Rogers Family Foundation; NIH/National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG042016]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS076708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG042016, F32AG054126] Funding Source: NIH RePORTER	We thank Dr. Nicole Day for technical expertise in conducting the initial injury and behavioral experiments; Dr. Carmela Sidrauski, Jordan Tsai, and Aditya Anand for help and advice with drug administration; and Dr. Regis Kelly for invaluable feedback on the manuscript. This work was supported by a generous grant from the Rogers Family Foundation (to S.R. and P.W.) and NIH/National Institute on Aging Grant R21AG042016 (to S.R.). P.W. is an Investigator of the Howard Hughes Medical Institute.	Acosta SA, 2017, J CELL PHYSIOL, V232, P665, DOI 10.1002/jcp.25629; Acosta SA, 2015, J CELL PHYSIOL, V230, P1024, DOI 10.1002/jcp.24830; Acosta SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090953; Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; Bachstetter AD, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0289-5; Batista G, 2016, ELIFE, V5, DOI 10.7554/eLife.17197; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Buffington SA, 2014, ANNU REV NEUROSCI, V37, P17, DOI 10.1146/annurev-neuro-071013-014100; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Chen A, 2003, NEURON, V39, P655, DOI 10.1016/S0896-6273(03)00501-4; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Committee on Care and Use of Laboratory Animals, 1996, GUIDE CARE USE LAB A, P85; Costa-Mattioli M, 2007, CELL, V129, P195, DOI 10.1016/j.cell.2007.01.050; Costa-Mattioli M, 2009, NEURON, V61, P10, DOI 10.1016/j.neuron.2008.10.055; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; Di Prisco GV, 2014, NAT NEUROSCI, V17, P1073, DOI 10.1038/nn.3754; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Donnelly N, 2013, CELL MOL LIFE SCI, V70, P3493, DOI 10.1007/s00018-012-1252-6; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Erturk A, 2016, J NEUROSCI, V36, P9962, DOI 10.1523/JNEUROSCI.1898-15.2016; Faizi M, 2012, BRAIN BEHAV, V2, P142, DOI 10.1002/brb3.41; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Freeman OJ, 2016, BRAIN RES, V1648, P530, DOI 10.1016/j.brainres.2016.03.029; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hinnebusch AG, 2016, SCIENCE, V352, P1413, DOI 10.1126/science.aad9868; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Huang W, 2016, ELIFE, V5, DOI 10.7554/eLife.12052; Huang W, 2013, NAT NEUROSCI, V16, P441, DOI 10.1038/nn.3351; Jacotte-Simancas A, 2015, J NEUROTRAUM, V32, P739, DOI 10.1089/neu.2014.3502; Jellinger KA, 2004, J NEUROL NEUROSUR PS, V75, P511; Jiang Z, 2010, J NEUROSCI, V30, P2582, DOI 10.1523/JNEUROSCI.3971-09.2010; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kelleher RJ, 2004, NEURON, V44, P59, DOI 10.1016/j.neuron.2004.09.013; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; Morganti JM, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0547-1; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Nadif K. N., 2011, NEURON, V72, P300, DOI DOI 10.1016/J.NEUR0N.2011.09.001; Neves G, 2008, NAT REV NEUROSCI, V9, P65, DOI 10.1038/nrn2303; Pasini S, 2015, CELL REP, V11, P183, DOI 10.1016/j.celrep.2015.03.025; Pearn ML, 2017, CELL MOL NEUROBIOL, V37, P571, DOI 10.1007/s10571-016-0400-1; Petrov T, 2001, J NEUROTRAUM, V18, P799, DOI 10.1089/089771501316919166; Placzek AN., 2016, ELIFE, V5, P5; Ron D, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a013177; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Scheper W, 2015, ACTA NEUROPATHOL, V130, P315, DOI 10.1007/s00401-015-1462-8; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Sekine Y, 2015, SCIENCE, V348, P1027, DOI 10.1126/science.aaa6986; Sidrauski C, 2015, ELIFE, V4, DOI 10.7554/eLife.07314; Sidrauski C, 2013, ELIFE, V2, DOI 10.7554/eLife.00498; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Song SJ, 2016, J NEUROSCI RES, V94, P409, DOI 10.1002/jnr.23714; Stern E, 2013, J NEUROSCI, V33, P2517, DOI 10.1523/JNEUROSCI.2322-12.2013; Stoica L, 2011, P NATL ACAD SCI USA, V108, P3791, DOI 10.1073/pnas.1014715108; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; Szmydynger-Chodobska J, 2009, J CEREBR BLOOD F MET, V29, P1503, DOI 10.1038/jcbfm.2009.71; Wang GH, 2011, J NEUROTRAUM, V28, P2123, DOI 10.1089/neu.2011.1939; Webster SJ, 2015, J NEUROSCI, V35, P6554, DOI 10.1523/JNEUROSCI.0291-15.2015; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203; Zhu PJ, 2011, CELL, V147, P1384, DOI 10.1016/j.cell.2011.11.029	72	84	85	0	12	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	AUG 1	2017	114	31					E6420	E6426		10.1073/pnas.1707661114			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC2FR	WOS:000406653300020	28696288	Bronze, Green Published			2022-02-06	
J	Schain, AJ; Melo-Carrillo, A; Strassman, AM; Burstein, R				Schain, Aaron J.; Melo-Carrillo, Agustin; Strassman, Andrew M.; Burstein, Rami			Cortical Spreading Depression Closes Paravascular Space and Impairs Glymphatic Flow: Implications for Migraine Headache	JOURNAL OF NEUROSCIENCE			English	Article						aura; glymph; interstitial fluid; lymph; neurodegeneration; trigeminovascular	BRAIN INTERSTITIAL FLUID; GENE-RELATED PEPTIDE; SENSORY NEURONS; RISK-FACTORS; SLEEP; AURA; ACTIVATION; CORTEX; INJURY; SENSITIZATION	Functioning of the glymphatic system, a network of paravascular tunnels through which cortical interstitial solutes are cleared from the brain, has recently been linked to sleep and traumatic brain injury, both of which can affect the progression of migraine. This led us to investigate the connection between migraine and the glymphatic system. Taking advantage of a novel in vivo method we developed using two- photon microscopy to visualize the paravascular space (PVS) in naive uninjected mice, we show that a single wave of cortical spreading depression (CSD), an animal model of migraine aura, induces a rapid and nearly complete closure of the PVS around surface as well as penetrating cortical arteries and veins lasting several minutes, and gradually recovering over 30 min. A temporal mismatch between the constriction or dilation of the blood vessel lumen and the closure of the PVS suggests that this closure is not likely to result from changes in vessel diameter. We also show that CSD impairs glymphatic flow, as indicated by the reduced rate at which intraparenchymally injected dye was cleared from the cortex to the PVS. This is the first observation of aPVSclosure in connection with an abnormal cortical event that underlies a neurological disorder. More specifically, the findings demonstrate a link between the glymphatic system and migraine, and suggest a novel mechanism for regulation of glymphatic flow.	[Schain, Aaron J.; Melo-Carrillo, Agustin; Strassman, Andrew M.; Burstein, Rami] Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02115 USA; [Schain, Aaron J.; Melo-Carrillo, Agustin; Strassman, Andrew M.; Burstein, Rami] Harvard Med Sch, Boston, MA 02215 USA		Burstein, R (corresponding author), CLS 649, 3 Blackfan Circle, Boston, MA 02215 USA.	rburstei@bidmc.harvard.edu		Burstein, Rami/0000-0003-3763-8916	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R37 NS079678, RO1 NS069847]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS069847, R37NS079678, R01NS094198] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grants R37 NS079678 and RO1 NS069847 (R.B.), and by a grant from R. Chemers Neustein (A.J.S.). We thank Dr. Rony Nir for assistance with statistical analyses.	Abbott NJ, 2004, NEUROCHEM INT, V45, P545, DOI 10.1016/j.neuint.2003.11.006; Anderson K, 2015, BEHAV NEUROL, V2015, DOI 10.1155/2015/693925; Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; Aurora SK, 1998, NEUROLOGY, V50, P1111, DOI 10.1212/WNL.50.4.1111; Ayata C, 2004, J CEREBR BLOOD F MET, V24, P1172, DOI 10.1097/01.WCB.0000137057.92786.F3; Ayata C, 2015, PHYSIOL REV, V95, P953, DOI 10.1152/physrev.00027.2014; Bakker ENTP, 2016, CELL MOL NEUROBIOL, V36, P181, DOI 10.1007/s10571-015-0273-8; BLAU JN, 1992, LANCET, V340, P355, DOI 10.1016/0140-6736(92)91415-5; Bolay H, 2002, NAT MED, V8, P136, DOI 10.1038/nm0202-136; Cairns BE, 2002, NEUROSCIENCE, V109, P389, DOI 10.1016/S0306-4522(01)00489-4; Carare RO, 2008, NEUROPATH APPL NEURO, V34, P131, DOI 10.1111/j.1365-2990.2007.00926.x; Charles A, 2009, CEPHALALGIA, V29, P1115, DOI 10.1111/j.1468-2982.2009.01983.x; Charles AC, 2013, NAT REV NEUROL, V9, P637, DOI 10.1038/nrneurol.2013.192; Cook SP, 2002, PAIN, V95, P41, DOI 10.1016/S0304-3959(01)00372-4; Coppola G, 2007, Cephalalgia, V27, P1427, DOI 10.1111/j.1468-2982.2007.01500.x; DaSilva AFM, 2007, NEUROLOGY, V69, P1990, DOI 10.1212/01.wnl.0000291618.32247.2d; Dodick DW, 2003, HEADACHE, V43, P282, DOI 10.1046/j.1526-4610.2003.03055.x; Du JH, 2001, PAIN, V89, P187, DOI 10.1016/S0304-3959(00)00362-6; Dussor G, 2008, J NEUROPHYSIOL, V99, P1581, DOI 10.1152/jn.01396.2007; EDVINSSON L, 1981, CEPHALALGIA, V1, P175, DOI 10.1046/j.1468-2982.1981.0104175.x; EDVINSSON L, 1987, J CEREBR BLOOD F MET, V7, P720, DOI 10.1038/jcbfm.1987.126; FABRICIUS M, 1993, BRAIN RES, V602, P350, DOI 10.1016/0006-8993(93)90701-N; GEHRMANN J, 1993, BRAIN PATHOL, V3, P11, DOI 10.1111/j.1750-3639.1993.tb00720.x; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Granziera C, 2006, PLOS MED, V3, P1915, DOI 10.1371/journal.pmed.0030402; Grutzendler J, 2002, NATURE, V420, P812, DOI 10.1038/nature01276; Gudmundsson LS, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3966; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; Hamming AM, 2016, J CEREBR BLOOD F MET, V36, P1224, DOI 10.1177/0271678X15619189; Hansen JM, 2012, NEUROLOGY, V79, P2044, DOI 10.1212/WNL.0b013e3182749eed; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Iliff JJ, 2013, J NEUROSCI, V33, P18190, DOI 10.1523/JNEUROSCI.1592-13.2013; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Jennum P, 2002, SLEEP MED REV, V6, P471, DOI 10.1053/smrv.2001.0223; Jessen NA, 2015, NEUROCHEM RES, V40, P2583, DOI 10.1007/s11064-015-1581-6; Ju YES, 2014, NAT REV NEUROL, V10, P115, DOI 10.1038/nrneurol.2013.269; Karatas H, 2013, SCIENCE, V339, P1092, DOI 10.1126/science.1231897; Kelman L, 2005, HEADACHE, V45, P904, DOI 10.1111/j.1526-4610.2005.05159.x; Kosaras B, 2009, J COMP NEUROL, V515, P331, DOI 10.1002/cne.22049; KRAIG RP, 1991, J NEUROSCI, V11, P2187; Kress BT, 2014, ANN NEUROL, V76, P845, DOI 10.1002/ana.24271; Kruit MC, 2010, CEPHALALGIA, V30, P129, DOI 10.1111/j.1468-2982.2009.01904.x; Kruit MC, 2006, STROKE, V37, P1109, DOI 10.1161/01.STR.0000206446.26702.e9; Kruit MC, 2004, JAMA-J AM MED ASSOC, V291, P427, DOI 10.1001/jama.291.4.427; Kurth T, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3659; Lateef T, 2011, CEPHALALGIA, V31, P648, DOI 10.1177/0333102410390395; Lauritzen M, 2016, J CEREB BLOOD FLOW M; Leao A A, 1986, Funct Neurol, V1, P363; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; Liman TG, 2012, CEPHALALGIA, V32, P459, DOI 10.1177/0333102412444014; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; LIVEING E, 1873, MEGRIM SICK HEADACHE; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Lucas S, 2014, CEPHALALGIA, V34, P93, DOI 10.1177/0333102413499645; MACIVER MB, 1993, J NEUROSCI, V13, P4511; Maleki N, 2013, BRAIN STRUCT FUNCT, V218, P903, DOI 10.1007/s00429-012-0437-y; Maleki N, 2012, CEPHALALGIA, V32, P607, DOI 10.1177/0333102412445622; Maleki N, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-71; Molchanova S, 2004, NEUROCHEM RES, V29, P1519, DOI 10.1023/B:NERE.0000029564.98905.5c; Molliver DC, 2002, EUR J NEUROSCI, V16, P1850, DOI 10.1046/j.1460-9568.2002.02253.x; Montagna P, 2003, LANCET NEUROL, V2, P167, DOI 10.1016/S1474-4422(03)00323-5; Moretti L, 2012, LANCET NEUROL, V11, P1103, DOI 10.1016/S1474-4422(12)70226-0; Nagelhus EA, 2013, PHYSIOL REV, V93, P1543, DOI 10.1152/physrev.00011.2013; OCONNOR TP, 1986, J NEUROSCI, V6, P2200; Ostergaard L, 2015, STROKE, V46, P1392, DOI 10.1161/STROKEAHA.114.008077; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Rains JC, 2008, CURR NEUROL NEUROSCI, V8, P167, DOI 10.1007/s11910-008-0027-9; Rains JC, 2006, HEADACHE, V46, P1344, DOI 10.1111/j.1526-4610.2006.00578.x; Saper CB, 2010, NEURON, V68, P1023, DOI 10.1016/j.neuron.2010.11.032; Scher AI, 2005, NEUROLOGY, V64, P614, DOI 10.1212/01.WNL.0000151857.43225.49; Schock SC, 2007, BRAIN RES, V1168, P129, DOI 10.1016/j.brainres.2007.06.070; Schurks M, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3914; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Strassman AM, 1996, NATURE, V384, P560, DOI 10.1038/384560a0; Sukhotinsky I, 2011, CEPHALALGIA, V31, P1601, DOI 10.1177/0333102411425865; SUZUKI N, 1989, NEUROSCIENCE, V31, P427, DOI 10.1016/0306-4522(89)90385-0; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; Theeler B, 2013, HEADACHE, V53, P881, DOI 10.1111/head.12123; Tietjen GE, 2001, NEUROLOGY, V57, P334, DOI 10.1212/WNL.57.2.334; Tietjen GE, 2009, STROKE, V40, P2977, DOI 10.1161/STROKEAHA.109.547901; Tomita M, 2011, NEUROIMAGE, V56, P1001, DOI 10.1016/j.neuroimage.2011.02.078; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; Toth P, 2016, AM J PHYSIOL-HEART C, V311, pH1118, DOI 10.1152/ajpheart.00267.2016; Unekawa M, 2015, J CEREBR BLOOD F MET, V35, P689, DOI 10.1038/jcbfm.2014.250; Vanmolkot FH, 2007, NEUROLOGY, V68, P1563, DOI 10.1212/01.wnl.0000260964.28393.ed; von Bornstadt D, 2015, NEURON, V85, P1117, DOI 10.1016/j.neuron.2015.02.007; VYSKOCIL F, 1972, BRAIN RES, V39, P255, DOI 10.1016/0006-8993(72)90802-5; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Xue JH, 2009, STROKE, V40, pE606, DOI 10.1161/STROKEAHA.109.560334; Yang G, 2010, NAT PROTOC, V5, P201, DOI 10.1038/nprot.2009.222; Zhang XC, 2011, ANN NEUROL, V69, P855, DOI 10.1002/ana.22329; Zhang XC, 2010, J NEUROSCI, V30, P8807, DOI 10.1523/JNEUROSCI.0511-10.2010; Zhao J, 2015, J NEUROPHYSIOL, V113, P2778, DOI 10.1152/jn.00991.2014	93	84	89	2	19	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	MAR 11	2017	37	11					2904	2915		10.1523/JNEUROSCI.3390-16.2017			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EQ1CX	WOS:000397808000011	28193695	Green Published, Bronze			2022-02-06	
J	Anzalone, AJ; Blueitt, D; Case, T; McGuffin, T; Pollard, K; Garrison, JC; Jones, MT; Pavur, R; Turner, S; Oliver, JM				Anzalone, Anthony J.; Blueitt, Damond; Case, Tami; McGuffin, Tiffany; Pollard, Kalyssa; Garrison, J. Craig; Jones, Margaret T.; Pavur, Robert; Turner, Stephanie; Oliver, Jonathan M.			A Positive Vestibular/Ocular Motor Screening (VOMS) Is Associated With Increased Recovery Time After Sports-Related Concussion in Youth and Adolescent Athletes	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; vestibular; ocular motor; symptoms	TRAUMATIC BRAIN-INJURY; STATES HIGH-SCHOOL; POSTCONCUSSION SYNDROME; EMERGENCY-DEPARTMENT; BALANCE DISORDERS; FOOTBALL PLAYERS; HEAD TRAUMA; EPIDEMIOLOGY; CONVERGENCE; SYMPTOMS	Background: Vestibular and ocular motor impairments are routinely reported in patients with sports-related concussion (SRC) and may result in delayed return to play (RTP). The Vestibular/Ocular Motor Screening (VOMS) assessment has been shown to be consistent and sensitive in identifying concussion when used as part of a comprehensive examination. To what extent these impairments or symptoms are associated with length of recovery is unknown. Purpose: To examine whether symptom provocation or clinical abnormality in specific domains of the VOMS results in protracted recovery (time from SRC to commencement of RTP protocol). Study Design: Cohort study (prognosis); Level of evidence, 2. Methods: A retrospective chart review was conducted of 167 patients (69 girls, 98 boys; mean SD age, 15 2 years [range, 11-19 years]) presenting with SRC in 2014. During the initial visit, VOMS was performed in which symptom provocation or clinical abnormality (eg, unsmooth eye movements) was documented by use of a dichotomous scale (0 = not present, 1 = present). The VOMS used in this clinic consisted of smooth pursuits (SMO_PUR), horizontal and vertical saccades (HOR_SAC and VER_SAC), horizontal and vertical vestibular ocular reflex (HOR_VOR and VER_VOR), near point of convergence (NPC), and accommodation (ACCOM). Domains were also categorized into ocular motor (SMO_PUR, HOR_SAC, VER_SAC, NPC, ACCOM) and vestibular (HOR_VOR, VER_VOR). Cox proportional hazard models were used to explore the relationship between the domains and recovery. Alpha was set at P .05. Results: Symptom provocation and/or clinical abnormality in all domains except NPC (P = .107) and ACCOM (P = .234) delayed recovery (domain, hazard ratio [95% CI]: SMO_PUR, 0.65 [0.47-0.90], P = .009; HOR_SAC, 0.68 [0.50-0.94], P = .018; VER_SAC, 0.55 [0.40-0.75], P < .001; HOR_VOR, 0.68 [0.49-0.94], P = .018; VER_VOR, 0.60 [0.44-0.83], P = .002). The lowest crude hazard ratio was for ocular motor category (0.45 [0.32-0.63], P < .001). Conclusion: These data suggest that symptom provocation/clinical abnormality associated with all domains except NPC and ACCOM can delay recovery after SRC in youth and adolescents. Thus, the VOMS not only may augment current diagnostic tools but also may serve as a predictor of recovery time in patients with SRC. The findings of this study may lead to more effective prognosis of concussion in youth and adolescents.	[Anzalone, Anthony J.; Blueitt, Damond; Case, Tami; McGuffin, Tiffany; Pollard, Kalyssa; Garrison, J. Craig; Jones, Margaret T.; Pavur, Robert; Turner, Stephanie; Oliver, Jonathan M.] Texas Hlth Ben Hogan Sports Med Concuss Ctr, Ft Worth, TX USA; [Anzalone, Anthony J.; Blueitt, Damond; Case, Tami; McGuffin, Tiffany; Pollard, Kalyssa; Garrison, J. Craig; Jones, Margaret T.; Pavur, Robert; Turner, Stephanie; Oliver, Jonathan M.] Texas Christian Univ, Dept Kinesiol, Sports Concuss Res Grp, POB 297730, Ft Worth, TX 76129 USA; [Anzalone, Anthony J.; Blueitt, Damond; Case, Tami; McGuffin, Tiffany; Pollard, Kalyssa; Garrison, J. Craig; Turner, Stephanie; Oliver, Jonathan M.] Texas Hlth Ben Hogan Sports Med Concuss Ctr, Ft Worth, TX USA; [Anzalone, Anthony J.; Blueitt, Damond; Case, Tami; McGuffin, Tiffany; Pollard, Kalyssa; Garrison, J. Craig; Turner, Stephanie; Oliver, Jonathan M.] Texas Hlth Ben Hogan Sports Med, Ft Worth, TX USA; [Jones, Margaret T.] George Mason Univ, Sch Recreat Hlth & Tourism, Manassas, VA USA; [Pavur, Robert] Univ North Texas, Coll Business, Denton, TX USA		Oliver, JM (corresponding author), Texas Christian Univ, Dept Kinesiol, Sports Concuss Res Grp, POB 297730, Ft Worth, TX 76129 USA.	jonathan.oliver@tcu.edu					Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Alvarez TL, 2012, OPTOMETRY VISION SCI, V89, P1740, DOI 10.1097/OPX.0b013e3182772dce; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Cohen M, 1989, Brain Inj, V3, P187, DOI 10.3109/02699058909004551; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Grubenhoff JA, 2014, PEDIATRICS, V134, P54, DOI 10.1542/peds.2013-2988; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Naguib MB, 2012, J LARYNGOL OTOL, V126, P26, DOI 10.1017/S002221511100291X; Pearce KL, 2015, AM J SPORT MED, V43, P3055, DOI 10.1177/0363546515606430; Scheiman M, 2003, OPTOMETRY VISION SCI, V80, P214, DOI 10.1097/00006324-200303000-00011; Schubert MC, 2004, PHYS THER, V84, P373, DOI 10.1093/ptj/84.4.373; Stone S, 2017, SPORTS HEALTH, V9, P41, DOI 10.1177/1941738116672184; Ventura RE, 2015, J NEURO-OPHTHALMOL, V35, P73, DOI 10.1097/WNO.0000000000000223; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	35	84	84	1	15	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	FEB	2017	45	2					474	479		10.1177/0363546516668624			6	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	EL7BU	WOS:000394776900028	27789472				2022-02-06	
J	Aziz, O; Musngi, M; Park, EJ; Mori, G; Robinovitch, SN				Aziz, Omar; Musngi, Magnus; Park, Edward J.; Mori, Greg; Robinovitch, Stephen N.			A comparison of accuracy of fall detection algorithms (threshold-based vs. machine learning) using waist-mounted tri-axial accelerometer signals from a comprehensive set of falls and non-fall trials	MEDICAL & BIOLOGICAL ENGINEERING & COMPUTING			English	Article						Older adults; Falls; Wearable sensors; Machine learning; Threshold-based algorithms	PRE-IMPACT DETECTION; WEARABLE SENSORS; OLD-PEOPLE	Falls are the leading cause of injury-related morbidity and mortality among older adults. Over 90 % of hip and wrist fractures and 60 % of traumatic brain injuries in older adults are due to falls. Another serious consequence of falls among older adults is the 'long lie' experienced by individuals who are unable to get up and remain on the ground for an extended period of time after a fall. Considerable research has been conducted over the past decade on the design of wearable sensor systems that can automatically detect falls and send an alert to care providers to reduce the frequency and severity of long lies. While most systems described to date incorporate threshold-based algorithms, machine learning algorithms may offer increased accuracy in detecting falls. In the current study, we compared the accuracy of these two approaches in detecting falls by conducting a comprehensive set of falling experiments with 10 young participants. Participants wore waist-mounted tri-axial accelerometers and simulated the most common causes of falls observed in older adults, along with near-falls and activities of daily living. The overall performance of five machine learning algorithms was greater than the performance of five threshold-based algorithms described in the literature, with support vector machines providing the highest combination of sensitivity and specificity.	[Aziz, Omar; Robinovitch, Stephen N.] Simon Fraser Univ, Injury Prevent & Mobil Lab, Burnaby, BC, Canada; [Robinovitch, Stephen N.] Simon Fraser Univ, Dept Biomed Physiol & Kinesiol, Burnaby, BC, Canada; [Aziz, Omar; Robinovitch, Stephen N.] Simon Fraser Univ, Sch Engn Sci, Burnaby, BC, Canada; [Mori, Greg] Simon Fraser Univ, Sch Comp Sci, Burnaby, BC, Canada; [Aziz, Omar; Musngi, Magnus; Park, Edward J.] Simon Fraser Univ, Sch Mech Syst Engn, Surrey, BC, Canada		Aziz, O (corresponding author), Simon Fraser Univ, Injury Prevent & Mobil Lab, Burnaby, BC, Canada.; Aziz, O (corresponding author), Simon Fraser Univ, Sch Engn Sci, Burnaby, BC, Canada.; Aziz, O (corresponding author), Simon Fraser Univ, Sch Mech Syst Engn, Surrey, BC, Canada.	oaziz@sfu.ca		Robinovitch, Stephen/0000-0003-3881-6227	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [AMG-100487, TIR-103945]; Canada Research Chairs programCanada Research Chairs	This work was supported by team grants from the Canadian Institutes of Health Research (Funding Reference Numbers: AMG-100487 and TIR-103945). SNR was also supported by the Canada Research Chairs program. The funding agency had no direct role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript.	Albert MV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036556; Arnold Catherine M, 2007, BMC Geriatr, V7, P17; Aziz O, 2014, GAIT POSTURE, V39, P506, DOI 10.1016/j.gaitpost.2013.08.034; Aziz O, 2012, IEEE ENG MED BIO, P5837, DOI 10.1109/EMBC.2012.6347321; Aziz O, 2011, IEEE T NEUR SYS REH, V19, P670, DOI 10.1109/TNSRE.2011.2162250; Bagala F, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0037062, 10.1371/journal.pone.0034473]; Bourke AK, 2008, MED ENG PHYS, V30, P937, DOI 10.1016/j.medengphy.2007.12.003; Bourke AK, 2007, GAIT POSTURE, V26, P194, DOI 10.1016/j.gaitpost.2006.09.012; Bourke AK, 2010, J BIOMECH, V43, P3051, DOI 10.1016/j.jbiomech.2010.07.005; Bourke AK, 2006, P 24 IASTED INT C BI; Bourke AK, 2008, IEEE ENG MED BIO, P2844, DOI 10.1109/IEMBS.2008.4649795; Boyle J, 2008, IEEE ENG MED BIO, P1274, DOI 10.1109/IEMBS.2008.4649396; Chao PK, 2009, PHYSIOL MEAS, V30, P1027, DOI 10.1088/0967-3334/30/10/004; Chen J, 2005, P ANN INT IEEE EMBS, P3551, DOI 10.1109/IEMBS.2005.1617246; Diaz A, 2004, P ANN INT IEEE EMBS, V26, P2180; Herman M, 2006, EVOLUTION SENIORS FA; Kangas M, 2008, GAIT POSTURE, V28, P285, DOI 10.1016/j.gaitpost.2008.01.003; Kau LJ, 2015, IEEE J BIOMED HEALTH, V19, P44, DOI 10.1109/JBHI.2014.2328593; Kern N, 2007, PERS UBIQUIT COMPUT, V11, P251, DOI 10.1007/s00779-006-0086-3; KING MB, 1995, J AM GERIATR SOC, V43, P1146, DOI 10.1111/j.1532-5415.1995.tb07017.x; Lee JK, 2015, IEEE T NEUR SYS REH, V23, P258, DOI 10.1109/TNSRE.2014.2357806; Lindemann U, 2005, MED BIOL ENG COMPUT, V43, P548, DOI 10.1007/BF02351026; MALLINSON WJW, 1985, AGE AGEING, V14, P174, DOI 10.1093/ageing/14.3.174; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; Noury N, 2008, IEEE ENG MED BIO, P2828, DOI 10.1109/IEMBS.2008.4649791; Noury N, 2008, IRBM, V29, P340, DOI 10.1016/j.irbm.2008.08.002; Robinovitch SN, 2013, LANCET, V381, P47, DOI 10.1016/S0140-6736(12)61263-X; Srygley JM, 2009, ARCH PHYS MED REHAB, V90, P786, DOI 10.1016/j.apmr.2008.11.007; Tinetti ME, 1998, J GERONTOL A-BIOL, V53, pM112, DOI 10.1093/gerona/53A.2.M112; VELLAS B, 1987, AGE AGEING, V16, P189, DOI 10.1093/ageing/16.3.189; Weiss Aner, 2010, BMC Res Notes, V3, P62, DOI 10.1186/1756-0500-3-62; Weiss GM, 2003, J ARTIF INTELL RES, V19, P315, DOI 10.1613/jair.1199; WILD D, 1981, BRIT MED J, V282, P266, DOI 10.1136/bmj.282.6260.266	33	84	87	3	45	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0140-0118	1741-0444		MED BIOL ENG COMPUT	Med. Biol. Eng. Comput.	JAN	2017	55	1					45	55		10.1007/s11517-016-1504-y			11	Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Mathematical & Computational Biology; Medical Informatics	Science Citation Index Expanded (SCI-EXPANDED)	Computer Science; Engineering; Mathematical & Computational Biology; Medical Informatics	EK0CH	WOS:000393593600004	27106749				2022-02-06	
J	Meabon, JS; Huber, BR; Cross, DJ; Richards, TL; Minoshima, S; Pagulayan, KF; Li, G; Meeker, KD; Kraemer, BC; Petrie, EC; Raskind, MA; Peskind, ER; Cook, DG				Meabon, James S.; Huber, Bertrand R.; Cross, Donna J.; Richards, Todd L.; Minoshima, Satoshi; Pagulayan, Kathleen F.; Li, Ge; Meeker, Kole D.; Kraemer, Brian C.; Petrie, Eric C.; Raskind, Murray A.; Peskind, Elaine R.; Cook, David G.			Repetitive blast exposure in mice and combat veterans causes persistent cerebellar dysfunction	SCIENCE TRANSLATIONAL MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; CEREBROSPINAL-FLUID; INDUCED NEUROTRAUMA; GLUCOSE-METABOLISM; COGNITIVE FUNCTION; HEAD-INJURY; DIFFUSION; CONCUSSION; INVOLVEMENT; DISEASE	m Blast exposure can cause mild traumatic brain injury (TBI) in mice and other mammals. However, there are important gaps in our understanding of the neuropathology underlying repetitive blast exposure in animal models compared to the neuroimaging abnormalities observed in blast-exposed veterans. Moreover, how an increase in the number of blast exposures affects neuroimaging endpoints in blast-exposed humans is not well understood. We asked whether there is a dose-response relationship between the number of blast-related mild TBIs and uptake of F-18-fluorodeoxyglucose (FDG), a commonly used indicator of neuronal activity, in the brains of blast-exposed veterans with mild TBI. We found that the number of blast exposures correlated with FDG uptake in the cerebellum of veterans. In mice, blast exposure produced microlesions in the blood-brain barrier (BBB) predominantly in the ventral cerebellum. Purkinje cells associated with these BBB microlesions displayed plasma membrane disruptions and aberrant expression of phosphorylated tau protein. Purkinje cell loss was most pronounced in the ventral cerebellar lobules, suggesting that early-stage breakdown of BBB integrity may be an important factor driving long-term brain changes. Blast exposure caused reactive gliosis in mouse cerebellum, particularly in the deep cerebellar nuclei. Diffusion tensor imaging tractography of the cerebellum of blast-exposed veterans revealed that mean diffusivity correlated negatively with the number of blast-related mild TBIs. Together, these results argue that the cerebellum is vulnerable to repetitive mild TBI in both mice and humans.	[Meabon, James S.; Pagulayan, Kathleen F.; Li, Ge; Petrie, Eric C.; Raskind, Murray A.; Peskind, Elaine R.] VA Puget Sound Hlth Care Syst VA Puget Sound, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA; [Meabon, James S.; Pagulayan, Kathleen F.; Li, Ge; Petrie, Eric C.; Raskind, Murray A.; Peskind, Elaine R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Huber, Bertrand R.] Boston Univ, Sch Med, VA Jama Plain, Dept Neurol, Jamaica Plain, MA 02130 USA; [Cross, Donna J.; Richards, Todd L.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA; [Minoshima, Satoshi] Univ Utah, Dept Radiol, Salt Lake City, UT 84132 USA; [Li, Ge; Meeker, Kole D.; Kraemer, Brian C.; Cook, David G.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA; [Kraemer, Brian C.; Cook, David G.] Univ Washington, Dept Med, Seattle, WA 98195 USA; [Cook, David G.] Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA		Cook, DG (corresponding author), VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.; Cook, DG (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.; Cook, DG (corresponding author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.	dgcook@u.washington.edu	Pagulayan, Kati/AAR-9225-2020	Minoshima, Satoshi/0000-0002-0043-3047; Cross, Donna/0000-0003-1918-2214; Petrie, Eric/0000-0003-1188-6321	Department of Veterans Affairs Office of Research and Development Medical Research ServiceUS Department of Veterans Affairs; VA Rehabilitation Research & Development Service; University of Washington Friends of Alzheimer's Research; University of Washington Royalty Research FundUniversity of Washington; Northwest Network Mental Illness Research, Education and Clinical Center; Office of Academic Affiliations Advanced Fellowship Program Mental Illness Research and Treatment, Department of Veterans Affairs; VA Clinical Science R&D Career Development Award Program [CX00516]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000258] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX002619, IK2CX000516, I01RX000521, I01BX002311, I01RX001612] Funding Source: NIH RePORTER	This work was supported by the Department of Veterans Affairs Office of Research and Development Medical Research Service (D.G.C. and B.C.K.); VA Rehabilitation Research & Development Service (E.R.P.); University of Washington Friends of Alzheimer's Research (D.G.C. and E.R.P.); University of Washington Royalty Research Fund (D.G.C.); Northwest Network Mental Illness Research, Education and Clinical Center (J.S.M., B.R.H., K.F.P., E.C.P., M.A.R., and E.R.P.); Office of Academic Affiliations Advanced Fellowship Program Mental Illness Research and Treatment, Department of Veterans Affairs (B.R.H.); NIH T32 AG000258 (J.S.M.); and VA Clinical Science R&D Career Development Award Program # CX00516 (K.F.P.). Author contributions: J.S.M. and B.R.H. conducted blast procedures, biochemistry experiments, and microscopy. K.D.M. conducted biochemistry experiments. J.S.M., B.R.H., D.J.C., T.L.R., S.M., G.L., E.C.P., M.A.R., E.R.P., and D.G.C. contributed to study design. J.S.M., D.J.C., E.R.P., G.L., E.R.P., M.A.R., and D.G.C. performed data analysis and data interpretation. J.S.M., D.J.C., T.L.R., K.F.P., G.L., B.C.K., E.C.P., M.A.R., E.R.P., and D.G.C. drafted the manuscript and/or edited it critically for important intellectual content.	Agosta F, 2010, AM J NEURORADIOL, V31, P1457, DOI 10.3174/ajnr.A2105; Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; Anderova M, 2011, J CEREBR BLOOD F MET, V31, P894, DOI 10.1038/jcbfm.2010.168; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Baugh CM, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0306-5; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Bernard JA, 2014, CEREB CORTEX, V24, P2151, DOI 10.1093/cercor/bht065; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Buckner RL, 2013, NEURON, V80, P807, DOI 10.1016/j.neuron.2013.10.044; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Caverzasi E, 2014, NEUROIMAGE-CLIN, V4, P426, DOI 10.1016/j.nicl.2014.01.011; Caverzasi E, 2014, BRAIN, V137, P3339, DOI 10.1093/brain/awu298; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 1997, Vojnosanit Pregl, V54, P91; Cernak I, 2000, MAGNESIUM RES, V13, P29; Cernak I, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00128; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; De Gasperi Rita, 2012, Front Neurol, V3, P177, DOI 10.3389/fneur.2012.00177; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Field A., 2005, DISCOVERING STAT USI, P777; Fischer BL, 2014, J NEUROTRAUM, V31, P169, DOI 10.1089/neu.2013.2877; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Jayadev S, 2013, GENET MED, V15, P673, DOI 10.1038/gim.2013.28; JONES BJ, 1968, J PHARM PHARMACOL, V20, P302, DOI 10.1111/j.2042-7158.1968.tb09743.x; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kamnaksh A, 2014, SCI REP-UK, V4, DOI 10.1038/srep04809; Karr JE, 2014, NEUROPSYCHOL REV, V24, P428, DOI 10.1007/s11065-014-9271-8; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Krave U, 2011, J NEUROTRAUM, V28, P57, DOI 10.1089/neu.2010.1431; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LAMPERT PW, 1984, JAMA-J AM MED ASSOC, V251, P2676, DOI 10.1001/jama.251.20.2676; Liu W, 2013, NMR BIOMED, V26, P651, DOI 10.1002/nbm.2910; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Meabon JS, 2012, J HISTOCHEM CYTOCHEM, V60, P139, DOI 10.1369/0022155411430095; Mendez MF, 2013, NEUROREHABILITATION, V32, P397, DOI 10.3233/NRE-130861; Mendez MF, 2013, BRAIN INJURY, V27, P10, DOI 10.3109/02699052.2012.722252; MINOSHIMA S, 1995, J NUCL MED, V36, P1238; MINOSHIMA S, 1994, J NUCL MED, V35, P949; MINOSHIMA S, 1994, J NUCL MED, V35, P1528; MINOSHIMA S, 1995, J COMPUT ASSIST TOMO, V19, P541, DOI 10.1097/00004728-199507000-00006; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; MURTHY JMK, 1979, J NEUROSURG, V50, P260, DOI 10.3171/jns.1979.50.2.0260; Nonaka H, 2002, ACTA NEUROPATHOL, V104, P608, DOI 10.1007/s00401-002-0592-y; Oguz I, 2014, FRONT NEUROINFORM, V8, DOI 10.3389/fninf.2014.00004; Oishi K., 2011, MRI ATLAS HUMAN WHIT, V2nd Edn.; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Petrie EC, 2009, ARCH NEUROL-CHICAGO, V66, P632, DOI 10.1001/archneurol.2009.59; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Rostami Elham, 2012, Front Neurol, V3, P115, DOI 10.3389/fneur.2012.00115; Ryan NS, 2013, BRAIN, V136, P1399, DOI 10.1093/brain/awt065; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Sarna JR, 2003, PROG NEUROBIOL, V70, P473, DOI 10.1016/S0301-0082(03)00114-X; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Stocker RPJ, 2014, NEUROIMAGE, V99, P207, DOI 10.1016/j.neuroimage.2014.05.067; Stoodley CJ, 2012, NEUROIMAGE, V59, P1560, DOI 10.1016/j.neuroimage.2011.08.065; Stoodley CJ, 2012, CEREBELLUM, V11, P352, DOI 10.1007/s12311-011-0260-7; Stoodley CJ, 2010, CORTEX, V46, P831, DOI 10.1016/j.cortex.2009.11.008; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Talairach J., 1988, COPLANAR STEREOTAXIC; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; THACH WT, 1972, BRAIN RES, V40, P89, DOI 10.1016/0006-8993(72)90112-6; Tonra James R, 2002, Cerebellum, V1, P57, DOI 10.1080/147342202753203096; Van Overwalle F, 2014, NEUROIMAGE, V86, P554, DOI 10.1016/j.neuroimage.2013.09.033; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Wang Y, 2011, BRAIN, V134, P3587, DOI 10.1093/brain/awr307; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; WINER BJ, 1991, STAT PRINCIPLES EXPT, P01057; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; Yang ZH, 2014, J CEREBR BLOOD F MET, V34, P1444, DOI 10.1038/jcbfm.2014.105; Yeh PH, 2014, HUM BRAIN MAPP, V35, P2652, DOI 10.1002/hbm.22358	99	84	84	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	1946-6234	1946-6242		SCI TRANSL MED	Sci. Transl. Med.	JAN 13	2016	8	321								10.1126/scitranslmed.aaa9585			15	Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Research & Experimental Medicine	DB4VD	WOS:000368510800004	26764157				2022-02-06	
J	Brotfain, E; Gruenbaum, SE; Boyko, M; Kutz, R; Zlotnik, A; Klein, M				Brotfain, Evgeni; Gruenbaum, Shaun E.; Boyko, Matthew; Kutz, Ruslan; Zlotnik, Alexander; Klein, Moti			Neuroprotection by Estrogen and Progesterone in Traumatic Brain Injury and Spinal Cord Injury	CURRENT NEUROPHARMACOLOGY			English	Article						Estrogen; neuroprotection; progesterone; spinal cord injury; traumatic brain injury	CORTICAL PERICONTUSIONAL ZONE; BLOOD GLUTAMATE LEVELS; PROGRAMMED CELL-DEATH; PLASMA GLUTAMATE; MENSTRUAL-CYCLE; CLINICAL-TRIAL; HORMONE-LEVELS; UP-REGULATION; RECOVERY; RECEPTOR	In recent years there has been a growing body of clinical and laboratory evidence demonstrating the neuroprotective effects of estrogen and progesterone after traumatic brain injury (TBI) and spinal cord injury (SCI). In humans, women have been shown to have a lower incidence of morbidity and mortality after TBI compared with age-matched men. Similarly, numerous laboratory studies have demonstrated that estrogen and progesterone administration is associated with a mortality reduction, improvement in neurological outcomes, and a reduction in neuronal apoptosis after TBI and SCI. Here, we review the evidence that supports hormone-related neuroprotection and discuss possible underlying mechanisms. Estrogen and progesterone-mediated neuroprotection are thought to be related to their effects on hormone receptors, signaling systems, direct antioxidant effects, effects on astrocytes and microglia, modulation of the inflammatory response, effects on cerebral blood flow and metabolism, and effects on mediating glutamate excitotoxicity. Future laboratory research is needed to better determine the mechanisms underlying the hormones' neuroprotective effects, which will allow for more clinical studies. Furthermore, large randomized clinical control trials are needed to better assess their role in human neurodegenerative conditions.	[Brotfain, Evgeni; Boyko, Matthew; Kutz, Ruslan; Zlotnik, Alexander; Klein, Moti] Ben Gurion Univ Negev, Soroka Med Ctr, Dept Anesthesia & Crit Care, Beer Sheva, Israel; [Gruenbaum, Shaun E.] Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06510 USA		Brotfain, E (corresponding author), Ben Gurion Univ Negev, Soroka Med Ctr, Dept Anesthesia & Crit Care, Beer Sheva, Israel.	bem1975@gmail.com	Boyko, Matthew/AAC-7341-2021; klein, moti/AAR-6552-2021	Boyko, Matthew/0000-0003-3116-1643; 			ABRAHAM GE, 1972, J CLIN ENDOCR METAB, V34, P312, DOI 10.1210/jcem-34-2-312; Allitt BJ, 2016, J NEUROTRAUM, V33, P375, DOI 10.1089/neu.2015.3946; Aminmansour Bahram, 2012, Adv Biomed Res, V1, P58, DOI 10.4103/2277-9175.100176; Andreadou E, 2008, IN VIVO, V22, P137; Arevalo MA, 2010, BBA-GEN SUBJECTS, V1800, P1106, DOI 10.1016/j.bbagen.2009.10.002; ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; Bao YJ, 2011, MOL CELL NEUROSCI, V48, P185, DOI 10.1016/j.mcn.2011.07.004; BARILE G, 1979, EUR J OBSTET GYN R B, V9, P243, DOI 10.1016/0028-2243(79)90062-5; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; Behl C, 2000, J NEUROCYTOL, V29, P351, DOI 10.1023/A:1007109222673; Lopez-Rodriguez AB, 2015, PSYCHONEUROENDOCRINO, V56, P1, DOI 10.1016/j.psyneuen.2015.02.018; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Beyer C., 1999, ESTROGEN DEV MAMMALI; Brann DW, 2007, STEROIDS, V72, P381, DOI 10.1016/j.steroids.2007.02.003; Bruce-Keller AJ, 2000, ENDOCRINOLOGY, V141, P3646, DOI 10.1210/en.141.10.3646; Bunting H, 2010, OPHTHAL RES, V43, P197, DOI 10.1159/000272024; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; Chen J, 2001, J Tongji Med Univ, V21, P62; Chen J., 2001, J TONGJI MED U, V21, P74; Cimarosti H, 2006, NEUROCHEM RES, V31, P483, DOI 10.1007/s11064-006-9043-9; Das A, 2011, J ENDOCRINOL, V208, P171, DOI 10.1677/JOE-10-0338; Day NL, 2013, J NEUROTRAUM, V30, P1531, DOI 10.1089/neu.2013.2854; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Dluzen DE, 2005, TRENDS PHARMACOL SCI, V26, P485, DOI 10.1016/j.tips.2005.08.001; Dubal DB, 1999, J NEUROSCI, V19, P6385; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Espey MG, 2002, NEUROLOGY, V58, P1439, DOI 10.1212/WNL.58.9.1439; Fernholm R, 2009, GROWTH HORM IGF RES, V19, P206, DOI 10.1016/j.ghir.2008.09.001; Garringer JA, 2013, J NEUROTRAUM, V30, P1415, DOI 10.1089/neu.2012.2565; Geddes RI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087252; GOEBELSMANN U, 1969, J CLIN ENDOCR METAB, V29, P1222, DOI 10.1210/jcem-29-9-1222; Green P S, 2000, Novartis Found Symp, V230, P202, DOI 10.1002/0470870818.ch15; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; Griffin GD, 2011, J NEUROENDOCRINOL, V23, P465, DOI 10.1111/j.1365-2826.2011.02143.x; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Guennoun R, 2008, BRAIN RES REV, V57, P493, DOI 10.1016/j.brainresrev.2007.05.009; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Hu R, 2012, CRIT CARE MED, V40, P3230, DOI 10.1097/CCM.0b013e3182657560; Johann S, 2013, J STEROID BIOCHEM, V137, P71, DOI 10.1016/j.jsbmb.2012.11.006; Johnston MV, 2001, PEDIATR RES, V49, P735, DOI 10.1203/00006450-200106000-00003; Kim H, 2015, J NEUROTRAUM, V32, P1210, DOI 10.1089/neu.2014.3771; Li LZ, 2011, NEUROCHEM INT, V58, P126, DOI 10.1016/j.neuint.2010.11.006; Lin C, 2015, SCI REP-UK, V5, DOI 10.1038/srep13442; Luoma JI, 2011, STEROIDS, V76, P845, DOI 10.1016/j.steroids.2011.02.013; McClean J, 2008, EXP NEUROL, V210, P41, DOI 10.1016/j.expneurol.2007.09.027; Meltser I, 2008, J CLIN INVEST, V118, P1563, DOI 10.1172/JCI32796; Moosmann B, 1999, P NATL ACAD SCI USA, V96, P8867, DOI 10.1073/pnas.96.16.8867; Naderi V, 2015, IRAN J BASIC MED SCI, V18, P138; Neese SL, 2010, BRAIN RES, V1362, P93, DOI 10.1016/j.brainres.2010.09.055; Nudi ET, 2015, J NEUROTRAUM, V32, P1117, DOI 10.1089/neu.2014.3618; Pascual JL, 2013, AM J SURG, V206, P840, DOI 10.1016/j.amjsurg.2013.07.016; Peterson TC, 2015, J NEUROTRAUM, V32, P765, DOI 10.1089/neu.2014.3530; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Punnonen R, 1976, Acta Obstet Gynecol Scand Suppl, V51, P63; ROGER M, 1975, NOUV PRESSE MED, V4, P2173; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Rusa R, 1999, STROKE, V30, P1665, DOI 10.1161/01.STR.30.8.1665; Samantaray S, 2011, NEUROCHEM RES, V36, P1809, DOI 10.1007/s11064-011-0498-y; Santarsieri M, 2014, J NEUROTRAUM, V31, P699, DOI 10.1089/neu.2013.3177; Schaible EV, 2014, J NEUROCHEM, V129, P940, DOI 10.1111/jnc.12708; Shakeri M, 2013, CLIN NEUROL NEUROSUR, V115, P2019, DOI 10.1016/j.clineuro.2013.06.013; SHERMAN BM, 1976, J CLIN ENDOCR METAB, V42, P629, DOI 10.1210/jcem-42-4-629; SHERMAN BM, 1975, J CLIN INVEST, V55, P699, DOI 10.1172/JCI107979; Si DW, 2014, EXP THER MED, V8, P1010, DOI 10.3892/etm.2014.1840; Simpkins JW, 2012, NEUROENDOCRINOLOGY, V96, P119, DOI 10.1159/000338409; Singh M, 2006, ENDOCRINE, V29, P271, DOI 10.1385/ENDO:29:2:271; Singh M, 2013, HORM BEHAV, V63, P284, DOI 10.1016/j.yhbeh.2012.06.003; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; Stein DG, 2013, HORM BEHAV, V63, P291, DOI 10.1016/j.yhbeh.2012.05.004; Stover JF, 2005, ACTA NEUROCHIR, V147, P847, DOI 10.1007/s00701-005-0562-y; Szydlowska K, 2010, CELL CALCIUM, V47, P122, DOI 10.1016/j.ceca.2010.01.003; Takano T, 2001, NAT MED, V7, P1010, DOI 10.1038/nm0901-1010; Teichberg VI, 2009, NEUROSCIENCE, V158, P301, DOI 10.1016/j.neuroscience.2008.02.075; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Tsesis S, 2013, GYNECOL ENDOCRINOL, V29, P912, DOI 10.3109/09513590.2013.813467; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vink R, 2004, EXPERT OPIN INV DRUG, V13, P1263, DOI 10.1517/13543784.13.10.1263; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Wise PM, 2002, RECENT PROG HORM RES, V57, P235, DOI 10.1210/rp.57.1.235; WOOLLEY CS, 1993, J COMP NEUROL, V336, P293, DOI 10.1002/cne.903360210; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Xu FF, 2014, BRAIN INJURY, V28, P1594, DOI 10.3109/02699052.2014.943289; Yang LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009851; Zauner A, 1996, ACT NEUR S, V67, P40; Zeng YH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140624; Zhang QG, 2008, J NEUROSCI, V28, P8430, DOI 10.1523/JNEUROSCI.2752-08.2008; Zlotnik A, 2007, EXP NEUROL, V203, P213, DOI 10.1016/j.expneurol.2006.08.021; Zlotnik A, 2012, INTENS CARE MED, V38, P137, DOI 10.1007/s00134-011-2401-3; Zlotnik A, 2011, BIOL REPROD, V84, P581, DOI 10.1095/biolreprod.110.088120; Zlotnik A, 2011, J NEUROSURG ANESTH, V23, P45, DOI 10.1097/ANA.0b013e3181f82a8f	102	84	88	2	15	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1570-159X	1875-6190		CURR NEUROPHARMACOL	Curr. Neuropharmacol.		2016	14	6					641	653		10.2174/1570159X14666160309123554			13	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	EE2YH	WOS:000389451600008	26955967	Green Published, Green Submitted			2022-02-06	
J	Kumar, RG; Boles, JA; Wagner, AK				Kumar, Raj G.; Boles, Jennifer A.; Wagner, Amy K.			Chronic Inflammation After Severe Traumatic Brain Injury: Characterization and Associations With Outcome at 6 and 12 Months Postinjury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cytokines; inflammation; interleukins; traumatic brain injury; Rehabilomics	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CEREBROSPINAL-FLUID; MICROGLIAL ACTIVATION; CYTOKINE PROFILE; IMMUNE-RESPONSE; HEAD TRAUMA; INTERLEUKIN-6; BIOMARKERS; SEX; MODULATION	Objective: Examine associations between chronic inflammatory profiles and outcome 6 to 12 months following severe traumatic brain injury (TBI). Setting: University-affiliated level 1 trauma center and community. Participants: Adults with severe TBI (n = 87); healthy controls (n = 7). Design: Prospective cohort study. Main Measures: Glasgow Outcome Scale; serum cytokines (interleukin [IL]-1 beta, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, tumor necrosis factor alpha), 2 weeks to 3 months, 4-to 6-month averages, 6-and 12-month levels. Results: Serum levels of IL-1 beta, IL-6, IL-8, IL-10, and tumor necrosis factor alpha were elevated over 3 months following TBI. Multivariate analysis showed that increased cytokine load score was associated with a 1.21 (95% confidence interval, 1.06-1.38) and 1.18 (95% confidence interval, 1.02-1.37) increase in odds of unfavorable Glasgow Outcome Scale score at 6 and 12 months, respectively. Also, elevated IL-6/IL-10 ratios were associated with increased odds of unfavorable outcomes at 6 months (adjusted odds ratio = 1.76; 95% confidence interval, 1.08-2.88). Conclusions: Chronic inflammation has not been well characterized following TBI. Our subacute cytokine load score classifies individuals at risk for unfavorable outcomes following injury. Higher proinflammatory burden with IL-6, relative to the antiinflammatory marker IL-10, is significantly associated with outcome. Further research should examine whether inflammatory genes and other inflammatory biomarkers affect risk for unfavorable outcomes and TBI complications.	[Kumar, Raj G.; Boles, Jennifer A.; Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave,Ste 202, Pittsburgh, PA 15213 USA; [Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Wagner, Amy K.] Univ Pittsburgh, Rehabil Res, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave,Ste 202, Pittsburgh, PA 15213 USA.; Wagner, AK (corresponding author), Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu			CDCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49 CCR 323155]; DODUnited States Department of Defense [W81XWH-071-0701]; NIDRR [H133A120087]; University of Pittsburgh Women's Studies Faculty Research Fund	This work was supported in part by CDC: R49 CCR 323155, DOD: W81XWH-071-0701, NIDRR H133A120087, University of Pittsburgh Women's Studies Faculty Research Fund.	Andaluz-Ojeda D, 2012, CYTOKINE, V57, P332, DOI 10.1016/j.cyto.2011.12.002; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bird MD, 2008, CELL IMMUNOL, V252, P57, DOI 10.1016/j.cellimm.2007.09.007; BJARNASON I, 1993, GASTROENTEROLOGY, V104, P1832, DOI 10.1016/0016-5085(93)90667-2; BOELEN A, 1995, J CLIN ENDOCR METAB, V80, P971, DOI 10.1210/jc.80.3.971; Browne KD, 2006, EXP NEUROL, V201, P301, DOI 10.1016/j.expneurol.2006.04.008; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Correia LCL, 2010, CLIN CHIM ACTA, V411, P540, DOI 10.1016/j.cca.2010.01.011; Curran JE, 2005, NAT GENET, V37, P1234, DOI 10.1038/ng1655; Deinzer R, 2004, BRAIN BEHAV IMMUN, V18, P458, DOI 10.1016/j.bbi.2003.11.008; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Diamond M, 2014, IL 1 BETA INFLUENCES; Dupuis J, 2005, ATHEROSCLEROSIS, V182, P307, DOI 10.1016/j.atherosclerosis.2005.02.015; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Faul M, 2010, TRAUMATIC BRAIN INJU; Feuerstein GZ, 1998, NEUROIMMUNOMODULAT, V5, P143, DOI 10.1159/000026331; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Gogos CA, 2000, J INFECT DIS, V181, P176, DOI 10.1086/315214; Hensler T, 2000, INFLAMM RES, V49, P524, DOI 10.1007/s000110050626; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; JENNETT B, 1975, LANCET, V1, P480; Jeong Hey-Kyeong, 2013, Exp Neurobiol, V22, P59, DOI 10.5607/en.2013.22.2.59; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kemper RHA, 2001, CEPHALALGIA, V21, P549, DOI 10.1046/j.1468-2982.2001.00196.x; Klimas NG, 2012, BRAIN BEHAV IMMUN, V26, P1202, DOI 10.1016/j.bbi.2012.06.006; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Maegele M, 2007, INFLAMM RES, V56, P318, DOI 10.1007/s00011-007-6141-3; Maiden L, 2007, CLIN GASTROENTEROL H, V5, P1040, DOI 10.1016/j.cgh.2007.04.031; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Maier SF, 2003, BRAIN BEHAV IMMUN, V17, P69, DOI 10.1016/S0889-1591(03)00032-1; Mayer CL, 2013, HEADACHE, V53, P1523, DOI 10.1111/head.12173; Mellergard P, 2011, NEUROSURGERY, V68, P12, DOI 10.1227/NEU.0b013e3181ef2a40; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; O'Connor KA, 2003, BRAIN RES, V991, P123, DOI 10.1016/j.brainres.2003.08.006; Oertelt-Prigione S, 2012, AUTOIMMUN REV, V11, pA479, DOI 10.1016/j.autrev.2011.11.022; Ong CKS, 2007, CLIN MED RES, V5, P17, DOI 10.3121/cmr.2007.698; Pankow JS, 2001, ATHEROSCLEROSIS, V154, P681, DOI 10.1016/S0021-9150(00)00586-4; Patel A, 2013, PSYCHIAT DANUB, V25, pS216; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; RINK A, 1995, AM J PATHOL, V147, P1575; Rothwell NJ, 1999, J PHYSIOL-LONDON, V514, P3, DOI 10.1111/j.1469-7793.1999.003af.x; Santarsieri M, 2014, J NEUROTRAUM, V31, P699, DOI 10.1089/neu.2013.3177; SAS Institute Inc, 2010, SAS 9 2 LANG REF CON; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schnabel R, 2008, HYPERTENSION, V51, P1651, DOI 10.1161/HYPERTENSIONAHA.107.105668; Schnabel RB, 2009, CIRC-CARDIOVASC GENE, V2, P229, DOI 10.1161/CIRCGENETICS.108.804245; Serafini G, 2013, EUR NEUROPSYCHOPHARM, V23, P1672, DOI 10.1016/j.euroneuro.2013.06.002; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Sorrells SF, 2007, BRAIN BEHAV IMMUN, V21, P259, DOI 10.1016/j.bbi.2006.11.006; Suleyman H, 2007, PHARMACOL REP, V59, P247; TEASDALE G, 1974, LANCET, V2, P81; Theeler B, 2013, HEADACHE, V53, P881, DOI 10.1111/head.12123; Thomale UW, 2007, IMMUNOBIOLOGY, V212, P567, DOI 10.1016/j.imbio.2007.01.007; Toyama H, 2008, ANN NUCL MED, V22, P417, DOI 10.1007/s12149-008-0136-1; Turnbull AV, 1999, PHYSIOL REV, V79, P1, DOI 10.1152/physrev.1999.79.1.1; Vezzani A, 2011, NAT REV NEUROL, V7, P31, DOI 10.1038/nrneurol.2010.178; Vitek MP, 2009, NEUROBIOL AGING, V30, P1350, DOI 10.1016/j.neurobiolaging.2007.11.014; Vogelzangs N, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.27; Wagner AK, 2012, BRAIN INJURY, V26, P1226, DOI 10.3109/02699052.2012.667594; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Wakelkamp IMMJ, 2003, CLIN ENDOCRINOL, V58, P280, DOI 10.1046/j.1365-2265.2003.01708.x; Wang HC, 2013, CLIN CHIM ACTA, V423, P122, DOI 10.1016/j.cca.2013.04.023; Waters RJ, 2013, J NEUROTRAUM, V30, P1710, DOI 10.1089/neu.2012.2792; Weckbach S, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/890816; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zou HC, 2013, NEUROREHAB NEURAL RE, V27, P878, DOI 10.1177/1545968313491007	79	84	86	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2015	30	6					369	381		10.1097/HTR.0000000000000067			13	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	DD0JN	WOS:000369606300009	24901329				2022-02-06	
J	Hinzman, JM; Andaluz, N; Shutter, LA; Okonkwo, DO; Pahl, C; Strong, AJ; Dreier, JP; Hartings, JA				Hinzman, Jason M.; Andaluz, Norberto; Shutter, Lori A.; Okonkwo, David O.; Pahl, Clemens; Strong, Anthony J.; Dreier, Jens P.; Hartings, Jed A.			Inverse neurovascular coupling to cortical spreading depolarizations in severe brain trauma	BRAIN			English	Article						spreading depression; peri-infarct depolarization; pressure reactivity index (PRx); hemedex	CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; RAT-BRAIN; RECEPTOR ACTIVATION; DEPRESSION; ISCHEMIA; CORTEX; AUTOREGULATION; OXYGEN	Cortical spreading depolarization causes a breakdown of electrochemical gradients following acute brain injury, and also elicits dynamic changes in regional cerebral blood flow that range from physiological neurovascular coupling (hyperaemia) to pathological inverse coupling (hypoperfusion). In this study, we determined whether pathological inverse neurovascular coupling occurred as a mechanism of secondary brain injury in 24 patients who underwent craniotomy for severe traumatic brain injury. After surgery, spreading depolarizations were monitored with subdural electrode strips and regional cerebral blood flow was measured with a parenchymal thermal diffusion probe. The status of cerebrovascular autoregulation was monitored as a correlation between blood pressure and regional cerebral blood flow. A total of 876 spreading depolarizations were recorded in 17 of 24 patients, but blood flow measurements were obtained for only 196 events because of technical limitations. Transient haemodynamic responses were observed in time-locked association with 82 of 196 (42%) spreading depolarizations in five patients. Spreading depolarizations induced only hyperaemic responses (794% increase) in one patient with intact cerebrovascular autoregulation; and only inverse responses (-24% decrease) in another patient with impaired autoregulation. In contrast, three patients exhibited dynamic changes in neurovascular coupling to depolarizations throughout the course of recordings. Severity of the pathological inverse response progressively increased (-14%, -29%, -79% decrease, P < 0.05) during progressive worsening of cerebrovascular autoregulation in one patient (Pearson coefficient 0.04, 0.14, 0.28, P < 0.05). A second patient showed transformation from physiological hyperaemic coupling (44% increase) to pathological inverse coupling (-30% decrease) (P < 0.05) coinciding with loss of autoregulation (Pearson coefficient 0.19 -> 0.32, P < 0.05). The third patient exhibited a similar transformation in brain tissue oxygenation, a surrogate of blood flow, from physiologic hyperoxic responses (20% increase) to pathological hypoxic responses (-14% decrease, P < 0.05). Pathological inverse coupling was only observed with electrodes placed in or adjacent to evolving lesions. Overall, 31% of the pathological inverse responses occurred during ischaemia (<18 ml/100 g/min) thus exacerbating perfusion deficits. Average perfusion was significantly higher in patients with good 6-month outcomes (46.8 +/- 6.5 ml/100 g/min) than those with poor outcomes (32.2 +/- 3.7 ml/100 g/min, P < 0.05). These results establish inverse neurovascular coupling to spreading depolarization as a novel mechanism of secondary brain injury and suggest that cortical spreading depolarization, the neurovascular response, cerebrovascular autoregulation, and ischaemia are critical processes to monitor and target therapeutically in the management of acute brain injury.	[Hinzman, Jason M.; Andaluz, Norberto; Hartings, Jed A.] Univ Cincinnati, Neurotrauma Ctr, Neurosci Inst, UC Coll Med,Dept Neurosurg, Cincinnati, OH 45267 USA; [Hinzman, Jason M.; Andaluz, Norberto; Hartings, Jed A.] Mayfield Clin, Cincinnati, OH 45267 USA; [Shutter, Lori A.; Okonkwo, David O.] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15260 USA; [Pahl, Clemens; Strong, Anthony J.] Kings Coll London, Dept Clin Neurosci, London, England; [Dreier, Jens P.] Charite, Dept Neurol, D-13353 Berlin, Germany		Hinzman, JM (corresponding author), Univ Cincinnati, 231 Albert Sabin Way,ML0517, Cincinnati, OH 45267 USA.	jmhinz2@gmail.com	Shutter, Lori A/G-2957-2013	Shutter, Lori/0000-0002-1390-0628; Dreier, Jens/0000-0001-7459-2828; Hartings, Jed/0000-0001-8583-3471	US Army CDMRP PH/TBI Research Program [W81XWH-08-2-0016]; DFGGerman Research Foundation (DFG)European Commission [323/5-1]; Era-Net Neuron [01EW1212]; BMBFFederal Ministry of Education & Research (BMBF) [CSB 01 EO 0801]; BCCN [01GQ1001C]	This work was funded by the US Army CDMRP PH/TBI Research Program (contract number W81XWH-08-2-0016), DFG 323/5-1, Era-Net Neuron 01EW1212, BMBF CSB 01 EO 0801, BCCN 01GQ1001C, and thermal diffusion probes were donated by Hemedex, Inc.	Aiba I, 2012, J PHYSIOL-LONDON, V590, P5877, DOI 10.1113/jphysiol.2012.234476; Attwell D, 2002, TRENDS NEUROSCI, V25, P621, DOI 10.1016/S0166-2236(02)02264-6; Bosche B, 2010, ANN NEUROL, V67, P607, DOI 10.1002/ana.21943; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Devor A, 2007, J NEUROSCI, V27, P4452, DOI 10.1523/JNEUROSCI.0134-07.2007; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Dreier JP, 1998, J CEREBR BLOOD F MET, V18, P978, DOI 10.1097/00004647-199809000-00007; Dreier JP, 2002, NEUROSURGERY, V51, P1457, DOI 10.1097/00006123-200212000-00017; Dreier JP, 2000, J NEUROSURG, V93, P658, DOI 10.3171/jns.2000.93.4.0658; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Feuerstein D, 2010, J CEREBR BLOOD F MET, V30, P1343, DOI 10.1038/jcbfm.2010.17; FLORENCE G, 1994, AM J PHYSIOL, V266, pR1136, DOI 10.1152/ajpregu.1994.266.4.R1136; GRAFSTEIN B, 1956, J NEUROPHYSIOL, V19, P154, DOI 10.1152/jn.1956.19.2.154; HABLITZ JJ, 1989, DEV BRAIN RES, V46, P243, DOI 10.1016/0165-3806(89)90288-5; HANSEN AJ, 1981, ACTA PHYSIOL SCAND, V113, P437, DOI 10.1111/j.1748-1716.1981.tb06920.x; Hartings JA, 2013, ACTA NEUROCHIR SUPPL, V115, P131, DOI 10.1007/978-3-7091-1192-5_27; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; Hartings JA, 2009, J NEUROTRAUM, V26, P1857, DOI [10.1089/neu.2009.0961, 10.1089/neu.2009-0961]; Hertle DN, 2012, BRAIN, V135, P2390, DOI 10.1093/brain/aws152; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KOCHER M, 1990, J CEREBR BLOOD F MET, V10, P564, DOI 10.1038/jcbfm.1990.99; Koide M, 2013, STROKE RES TREAT, V2013, DOI 10.1155/2013/819340; KRAIG RP, 1978, NEUROSCIENCE, V3, P1045, DOI 10.1016/0306-4522(78)90122-7; Lang EW, 2002, J NEUROL NEUROSUR PS, V72, P583, DOI 10.1136/jnnp.72.5.583; LAURITZEN M, 1982, ANN NEUROL, V12, P469, DOI 10.1002/ana.410120510; LAURITZEN M, 1984, J CEREBR BLOOD F MET, V4, P546, DOI 10.1038/jcbfm.1984.79; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; Lindquist BE, 2012, NEUROSCIENCE, V223, P365, DOI 10.1016/j.neuroscience.2012.07.053; Luckl J, 2009, J NEUROSCI RES, V87, P1219, DOI 10.1002/jnr.21933; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; Mayevsky A, 1996, BRAIN RES, V740, P268, DOI 10.1016/S0006-8993(96)00874-8; MAYEVSKY A, 1991, J CEREBR BLOOD F MET, V11, P829, DOI 10.1038/jcbfm.1991.142; MIES G, 1984, EXP NEUROL, V84, P249, DOI 10.1016/0014-4886(84)90222-X; MUIZELAAR JP, 1994, CAN J NEUROL SCI, V21, pS6, DOI 10.1017/S0084255900003685; Nakamura H, 2010, BRAIN, V133, P1994, DOI 10.1093/brain/awq117; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Offenhauser N, 2011, ACTA NEUROCHIR SUPPL, V110, P119, DOI [10.1007/978-3-7091-0353-1_21, 10.1007/978-3-7091-0353-1_2l]; PIPER RD, 1991, AM J PHYSIOL, V261, pH96, DOI 10.1152/ajpheart.1991.261.1.H96; Risher WC, 2012, GLIA, V60, P1709, DOI 10.1002/glia.22390; Schroder ML, 1996, J NEUROTRAUM, V13, P17, DOI 10.1089/neu.1996.13.17; Shin HK, 2006, J CEREBR BLOOD F MET, V26, P1018, DOI 10.1038/sj.jcbfm.9600252; Somjen GG, 2004, IONS BRAIN NORMAL FU; Strong AJ, 2005, J NEUROPHYSIOL, V94, P5, DOI 10.1152/classicessays.00032.2005; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; STRONG AJ, 1988, J CEREBR BLOOD F MET, V8, P79, DOI 10.1038/jcbfm.1988.10; Strong AJ, 2007, BRAIN, V130, P995, DOI 10.1093/brain/awl392; Sukhotinsky I, 2008, J CEREBR BLOOD F MET, V28, P1369, DOI 10.1038/jcbfm.2008.35; Vajkoczy P, 2003, J NEUROSURG, V98, P1227, DOI 10.3171/jns.2003.98.6.1227; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; Wilson JA, 2013, ACTA NEUROCHIR SUPPL, V115, P67, DOI 10.1007/978-3-7091-1192-5_15; Woitzik J, 2013, NEUROLOGY, V80, P1095, DOI 10.1212/WNL.0b013e3182886932; Zhou N, 2013, J CEREBR BLOOD F MET, V33, P1582, DOI 10.1038/jcbfm.2013.113; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	58	84	84	1	19	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	NOV	2014	137		11				2960	2972		10.1093/brain/awu241			13	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AX2GG	WOS:000346760900019	25154387	Bronze			2022-02-06	
J	Sekhon, MS; Griesdale, DE; Robba, C; McGlashan, N; Needham, E; Walland, K; Shook, AC; Smielewski, P; Czosnyka, M; Gupta, AK; Menon, DK				Sekhon, Mypinder S.; Griesdale, Donald E.; Robba, Chiara; McGlashan, Nick; Needham, Edward; Walland, Katherine; Shook, Alyssa C.; Smielewski, Peter; Czosnyka, Marek; Gupta, Arun K.; Menon, David K.			Optic nerve sheath diameter on computed tomography is correlated with simultaneously measured intracranial pressure in patients with severe traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						Optic nerve sheath diameter; Computed tomography; Traumatic brain injury; Intracranial pressure	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; NEUROCRITICAL CARE; HYPERTENSION; ULTRASONOGRAPHY; SCAN; AUTOREGULATION; EPIDEMIOLOGY; ULTRASOUND; SONOGRAPHY	Assess the relationship between optic nerve sheath diameter (ONSD) measured on bedside portable computed tomography (CT) scans and simultaneously measured intracranial pressure (ICP) in patients with severe traumatic brain injury. Retrospective cohort study of 57 patients admitted between 2009 and 2013. Linear and logistic regression were used to model the correlation and discrimination between ONSD and ICP or intracranial hypertension, respectively. The cohort had a mean age of 40 years (SD 16) and a median admission Glasgow coma score of 7 (IQR 4-10). The between-rater agreement by intraclass coefficient was 0.89 (95 % CI 0.83-0.93, P < 0.001). The mean ONSD was 6.7 mm (SD 0.75) and the mean ICP during CT was 21.3 mmHg (SD 8.4). Using linear regression, there was a strong correlation between ICP and ONSD (r = 0.74, P < 0.001). ONSD had an area under the curve to discriminate elevated ICP (a parts per thousand yen20 mmHg vs. < 20 mmHg) of 0.83 (95 % CI 0.73-0.94). Using a cutoff of 6.0 mm, ONSD had a sensitivity of 97 %, specificity of 42 %, positive predictive value of 67 %, and a negative predictive value of 92 %. Comparing linear regression models, ONSD was a much stronger predictor of ICP (R (2) of 0.56) compared to other CT features (R (2) of 0.21). Simultaneous measurement of ONSD on CT and ICP were strongly correlated and ONSD was discriminative for intracranial hypertension. ONSD was much more predictive of ICP than other CT features. There was excellent agreement between raters in measuring ONSD.	[Sekhon, Mypinder S.; Griesdale, Donald E.] Univ British Columbia, Vancouver Gen Hosp, Dept Med, Div Crit Care Med, Vancouver, BC V5Z 1M9, Canada; [Sekhon, Mypinder S.; Robba, Chiara; McGlashan, Nick; Needham, Edward; Walland, Katherine; Smielewski, Peter; Czosnyka, Marek; Gupta, Arun K.; Menon, David K.] Univ Cambridge, Cambridge Univ Hosp Trust, Addenbrookes Hosp, Neurocrit Care Unit, Cambridge CB2 0QQ, England; [Griesdale, Donald E.] Univ British Columbia, Vancouver Gen Hosp, Dept Anaesthesiol Pharmacol & Therapeut, Vancouver, BC V5Z 1M9, Canada; [Griesdale, Donald E.] Univ British Columbia, Vancouver Coastal Hlth Res Inst, Ctr Clin Epidemiol & Evaluat, Vancouver, BC V5Z 1M9, Canada; [Shook, Alyssa C.] St Pauls Hosp, Ctr Heart, Vancouver, BC V6Z 1Y6, Canada		Sekhon, MS (corresponding author), Univ British Columbia, Vancouver Gen Hosp, Dept Med, Div Crit Care Med, Room 2438,Jim Pattison Pavil,2nd Floor,855 West 1, Vancouver, BC V5Z 1M9, Canada.	mypindersekhon@gmail.com	Griesdale, Donald/AAT-7762-2021; Needham, EJ/AAM-7049-2020; Robba, Chiara/AAS-7421-2020	Griesdale, Donald/0000-0001-5985-8624; Needham, EJ/0000-0001-7042-7462; Smielewski, Peter/0000-0001-5096-3938	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001354, G0001237, G9439390, G0600986] Funding Source: Medline; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1000183B, G0001354B] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0001237, G0600986, G9439390] Funding Source: UKRI		Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Ballantyne S A, 2002, Eur J Ultrasound, V15, P145, DOI 10.1016/S0929-8266(02)00036-8; Blaivas M, 2003, ACAD EMERG MED, V10, P376, DOI 10.1197/aemj.10.4.376; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Cammarata G, 2011, J TRAUMA, V71, P779, DOI 10.1097/TA.0b013e3182220673; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Dubourg J, 2011, INTENS CARE MED, V37, P1059, DOI 10.1007/s00134-011-2224-2; FOUNDATION TB, 2007, J NEUROTRAUMA S1, V24, pS7, DOI DOI 10.1089/NEU.2007.9995; Geeraerts T, 2008, INTENS CARE MED, V34, P2062, DOI 10.1007/s00134-008-1149-x; Geeraerts T, 2007, INTENS CARE MED, V33, P1704, DOI 10.1007/s00134-007-0797-6; Geeraerts T, 2008, CRIT CARE, V12, DOI 10.1186/cc7006; Hansen HC, 1997, J NEUROSURG, V87, P34, DOI 10.3171/jns.1997.87.1.0034; Helmke K, 1996, PEDIATR RADIOL, V26, P701, DOI 10.1007/BF01383383; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kalantari H, 2013, AM J EMERG MED, V31, P1595, DOI 10.1016/j.ajem.2013.07.028; Kimberly HH, 2008, ACAD EMERG MED, V15, P201, DOI 10.1111/j.1553-2712.2007.00031.x; Kimberly HH, 2008, CRIT CARE, V12, DOI 10.1186/cc7008; Launey Y, 2014, J NEUROTRAUM, V31, P984, DOI 10.1089/neu.2012.2829; Legrand A, 2013, CRIT CARE, V17, DOI 10.1186/cc12589; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Miller MT, 2004, J TRAUMA, V56, P967, DOI 10.1097/01.TA.0000123699.16465.8B; Moretti R, 2011, ACTA ANAESTH SCAND, V55, P644, DOI 10.1111/j.1399-6576.2011.02432.x; Moretti R, 2009, NEUROCRIT CARE, V11, P406, DOI 10.1007/s12028-009-9250-8; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Radolovich DK, 2011, NEUROCRIT CARE, V15, P379, DOI 10.1007/s12028-011-9553-4; Rajajee V, 2011, NEUROCRIT CARE, V15, P506, DOI 10.1007/s12028-011-9606-8; Rumboldt Z, 2009, AM J NEURORADIOL, V30, P1630, DOI 10.3174/ajnr.A1603; Soldatos T, 2008, CRIT CARE, V12, DOI 10.1186/cc6897; Stocchetti N, 2014, ACTA NEUROCHIR, V156, P1615, DOI 10.1007/s00701-014-2127-4; Tayal VS, 2007, ANN EMERG MED, V49, P508, DOI 10.1016/j.annemergmed.2006.06.040; Treggiari MM, 2007, NEUROCRIT CARE, V6, P104, DOI 10.1007/s12028-007-0012-1; Vandenbroucke JP, 2007, EPIDEMIOLOGY, V18, P805, DOI 10.1097/EDE.0b013e3181577511; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678	37	84	90	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	SEP	2014	40	9					1267	1274		10.1007/s00134-014-3392-7			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AO5IK	WOS:000341377400007	25034476				2022-02-06	
J	Rincon, F; Kang, J; Vibbert, M; Urtecho, J; Athar, MK; Jallo, J				Rincon, Fred; Kang, Joon; Vibbert, Matthew; Urtecho, Jacqueline; Athar, M. Kamran; Jallo, Jack			Significance of arterial hyperoxia and relationship with case fatality in traumatic brain injury: a multicentre cohort study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							SEVERE HEAD-INJURY; NORMOBARIC HYPEROXIA; CEREBRAL METABOLISM; OXYGEN-TENSION; CARDIAC-ARREST; UNITED-STATES; RESUSCITATION; ASSOCIATION; EPIDEMIOLOGY; CONSUMPTION	Objective In this retrospective multi-centre cohort study, we tested the hypothesis that hyperoxia was not associated with higher in-hospital case fatality in ventilated traumatic brain injury TBI) patients admitted to the intensive care unit ICU). Methods Admissions of ventilated TBI patients who had arterial blood gases within 24 h of admission to the ICU at 61 US hospitals between 2003 and 2008 were identified. Hyperoxia was defined as PaO2 = 300 mm Hg 39.99 kPa), hypoxia as any PaO2 < 60 mm Hg 7.99 kPa) or PaO2/FiO(2) ratio = 300 and normoxia, not defined as hyperoxia or hypoxia. The primary outcome was in-hospital case fatality. Results Over the 5-year period, we identified 1212 ventilated TBI patients, of whom 403 33%) were normoxic, 553 46%) were hypoxic and 256 21%) were hyperoxic. The case-fatality was higher in the hypoxia group 224/ 553 [41%], crude OR 2.3, 95% CI 1.7-3.0, p<. 0001) followed by hyperoxia 80/ 256 [32%], crude OR 1.5, 95% CI 1.1-2.5, p=. 01) as compared to normoxia 87/ 403 [23%]). In a multivariate analysis adjusted for other potential confounders, the probability of being exposed to hyperoxia and hospital-specific characteristics, exposure to hyperoxia was independently associated with higher in-hospital case fatality adjusted OR 1.5, 95% CI 1.02-2.4, p= 0.04. Conclusions In ventilated TBI patients admitted to the ICU, arterial hyperoxia was independently associated with higher in-hospital case fatality. In the absence of results from clinical trials, unnecessary oxygen delivery should be avoided in critically ill ventilated TBI patients.	[Rincon, Fred; Kang, Joon; Vibbert, Matthew; Urtecho, Jacqueline] Dept Neurol, Div Crit Care, Philadelphia, PA USA; [Rincon, Fred; Kang, Joon; Vibbert, Matthew; Urtecho, Jacqueline] Dept Neurol, Div Neurotrauma, Philadelphia, PA USA; [Rincon, Fred; Vibbert, Matthew; Urtecho, Jacqueline; Athar, M. Kamran; Jallo, Jack] Dept Neurol Neurosurg, Div Crit Care, Philadelphia, PA USA; [Rincon, Fred; Vibbert, Matthew; Urtecho, Jacqueline; Athar, M. Kamran; Jallo, Jack] Dept Neurol Neurosurg, Div Neurotrauma, Philadelphia, PA USA; [Athar, M. Kamran] Dept Med Neurol, Philadelphia, PA USA		Rincon, F (corresponding author), Thomas Jefferson Univ, Div Crit Care & Neurotrauma, Dept Neurol Surg, 909 Walnut St,3rd Floor, Philadelphia, PA 19107 USA.	fred.rincon@jefferson.edu		Rincon, Fred/0000-0002-8510-118X; Jallo, Jack/0000-0002-5512-1729	American Heart AssociationAmerican Heart Association [AHA 12CRP12050342]; Department of Defense (DOD)United States Department of Defense [110398]	Dr Rincon has received salary support from the American Heart Association (AHA 12CRP12050342). Dr Jallo has received grant funding from the Department of Defense (DOD#110398).	Abelson-Mitchell N, 2008, J CLIN NURS, V17, P46, DOI 10.1111/j.1365-2702.2007.01941.x; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Brenner M, 2012, ARCH SURG-CHICAGO, V147, P1042, DOI 10.1001/archsurg.2012.1560; Bulte DP, 2007, J CEREBR BLOOD F MET, V27, P69, DOI 10.1038/sj.jcbfm.9600319; de Jonge E, 2008, CRIT CARE, V12, DOI 10.1186/cc7150; Dellinger RP, 2004, INTENS CARE MED, V30, P536, DOI [10.1007/s00134-004-2210-z, 10.1097/CCM.0b013e31827e83af, 10.1007/s00134-012-2769-8]; Diringer MN, 2007, J NEUROSURG, V106, P526, DOI 10.3171/jns.2007.106.4.526; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Douzinas EE, 2001, INTENS CARE MED, V27, P905, DOI 10.1007/s001340100932; Farquhar H, 2009, AM HEART J, V158, P371, DOI 10.1016/j.ahj.2009.05.037; Floyd TF, 2003, J APPL PHYSIOL, V95, P2453, DOI 10.1152/japplphysiol.00303.2003; Halpern NA, 2006, CRIT CARE MED, V34, P2105, DOI 10.1097/01.CCM.0000227174.30337.3E; Johnston AJ, 2003, BRIT J ANAESTH, V90, P774, DOI 10.1093/bja/aeg104; Kang J, 2012, NEUROLOGY, V78; Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707; Kumaria A, 2009, BRIT J NEUROSURG, V23, P576, DOI 10.3109/02688690903050352; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Localio AR, 2001, ANN INTERN MED, V135, P112, DOI 10.7326/0003-4819-135-2-200107170-00012; LODATO RF, 1989, J APPL PHYSIOL, V67, P1551, DOI 10.1152/jappl.1989.67.4.1551; Longhi L, 2002, ACT NEUR S, V81, P315; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; RAWLES JM, 1976, BMJ-BRIT MED J, V1, P1121, DOI 10.1136/bmj.1.6018.1121; Rincon F, 2010, NEUROCRIT CARE, V13, P75, DOI 10.1007/s12028-010-9347-0; Rossi S, 2001, J NEUROTRAUM, V18, P163, DOI 10.1089/08977150150502596; Rousseau A, 2010, J VASC RES, V47, P441, DOI 10.1159/000282667; Sacho RH, 2010, J NEUROTRAUM, V27, P2157, DOI 10.1089/neu.2010.1384; Seder DB, 2012, NEUROCRIT CARE, V17, P4, DOI 10.1007/s12028-012-9753-6; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Trzeciak S, 2009, CRIT CARE MED, V37, P2895, DOI 10.1097/CCM.0b013e3181b01d8c; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; von Elm E, 2007, LANCET, V370, P1453, DOI [10.1371/journal.pmed.0040297, 10.1371/journal.pmed.0040296, 10.1157/13119325, 10.1016/S0140-6736(07)61602-X]; Ziegler A, 2010, METHOD INFORM MED, V49, P421, DOI 10.3414/ME10-01-0026; ZWEMER CF, 1995, RESUSCITATION, V29, P225, DOI 10.1016/0300-9572(94)00848-A	40	84	88	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUL	2014	85	7					799	805		10.1136/jnnp-2013-305505			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	AJ7YX	WOS:000337919300017	23794718				2022-02-06	
J	Rivara, FP; Schiff, MA; Chrisman, SP; Chung, SK; Ellenbogen, RG; Herring, SA				Rivara, Frederick P.; Schiff, Melissa A.; Chrisman, Sara P.; Chung, Shana K.; Ellenbogen, Richard G.; Herring, Stanley A.			The Effect of Coach Education on Reporting of Concussions Among High School Athletes After Passage of a Concussion Law	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						sports concussion; injury incidence; soccer; concussive symptoms	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; FOOTBALL PLAYERS; UNITED-STATES; EPIDEMIOLOGY; COLLEGIATE; ZURICH	Background: Increasing attention has been paid to concussions and especially sports-related concussions in youth. To prevent an inappropriate return to play while symptomatic, nearly all states have now passed legislation on youth sports-related concussions. Purpose: To determine (1) the incidence of sports-related concussions in high school athletes using a unique system to collect reports on concussions, (2) the proportion of athletes with concussions who play with concussive symptoms, and (3) the effect of the type and modality of coach education on the likelihood of athletes reporting symptoms to the coach or playing with concussive symptoms. Study Design: Cohort study; Level of evidence, 2. Methods: This study was conducted with high school football and girls' soccer athletes playing in fall 2012 and their coaches and parents in 20 urban or rural high schools in Washington State. The main outcome was the incidence of concussions per 1000 athlete-exposures (AEs), the proportion of concussed athletes who played with concussive symptoms, and the association of coach concussion education with coach awareness of athletes with concussive symptoms. Results: Among the 778 athletes, the rate of concussions was 3.6 per 1000 AEs and was identical for the 2 sports studied. The cumulative concussion incidence over the course of the season was similar in girls' soccer (11.1%) and football (10.4%). Sixty-nine percent of concussed athletes reported playing with symptoms, and 40% reported that their coach was not aware of their concussion. Most measures of coach concussion education were not associated with coach awareness of concussions in their athletes, although the modalities of a video and quiz were associated with a lower likelihood of coach awareness. Conclusion: More objective and accurate methods are needed to identify concussions. Changes in athlete attitudes on reporting concussive symptoms will likely not be accomplished through legislation alone.	[Rivara, Frederick P.; Schiff, Melissa A.; Chrisman, Sara P.; Chung, Shana K.; Ellenbogen, Richard G.; Herring, Stanley A.] Univ Washington, Seattle, WA 98104 USA		Rivara, FP (corresponding author), Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, 325 Ninth Ave,Box 359960, Seattle, WA 98104 USA.	fpr@uw.edu	Meijer, Anna/K-5118-2016	Chrisman, Sara/0000-0001-5373-7223	Public Health Law Research Program of the Robert Wood Johnson Foundation	One or more of the authors has declared the following potential conflict of interest or source of funding: The study was supported by the Public Health Law Research Program of the Robert Wood Johnson Foundation. The grant went to the University of Washington and not to any of the individual authors.	Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Chrisman SP, 2011, CLIN PEDIATR, V50, P1031, DOI 10.1177/0009922811410970; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Finch CF, 2013, BRIT J SPORT MED, V47, P12, DOI 10.1136/bjsports-2012-091796; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Harvey HH, 2013, AM J PUBLIC HEALTH, V103, P1249, DOI 10.2105/AJPH.2012.301107; Institute of Medicine and National Research Council, 2013, SPORTS REL CONC YOUT; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Powell JW, 1999, J ATHL TRAINING, V34, P277; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; USA Football, 2013, SEE YOUR STAT STANDS; VanEenwyk J., 2009, GUIDELINES USING RUR; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	28	84	84	0	28	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAY	2014	42	5					1197	1203		10.1177/0363546514521774			7	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Sport Sciences	AG6ZM	WOS:000335567700023	24569704				2022-02-06	
J	James, LM; Strom, TQ; Leskela, J				James, Lisa M.; Strom, Thad Q.; Leskela, Jennie			Risk-Taking Behaviors and Impulsivity Among Veterans With and Without PTSD and Mild TBI	MILITARY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; PERSONALITY QUESTIONNAIRE; MAJOR DEPRESSION; SYMPTOM SEVERITY; WAR VETERANS; SUICIDE RISK; PREVALENCE; SOLDIERS	Military personnel commonly experience post-traumatic stress disorder (PTSD) and mild traumatic brain injury (mTBI), both of which are associated with premature mortality. The present study examined two factors that may play a role in premature mortality-impulsivity and risk-taking behaviors-in a sample of 234 veterans screening positive for PTSD, mTBI, PTSD + mTBI, and controls. Analyses of variance demonstrated that veterans with PTSD, regardless of mTBI status, reported engaging in more frequent risky behaviors and reported a greater tendency to engage in impulsive behaviors when in a negative affective state. They also reported more premilitary delinquent behaviors and more suicide-related behaviors than controls. The present study highlights associations between impulsivity, risk-taking behaviors, and PTSD, and suggests continuity across the lifespan in terms of a predisposition to engage in impulsive and/or risky behaviors. Thorough evaluation of impulsivity and potentially risky behaviors is important in clinical settings to guide interventions and reduce the mortality and public health impact of high-risk behaviors in veterans.	[James, Lisa M.; Strom, Thad Q.; Leskela, Jennie] Minneapolis Vet Affairs Hlth Care Syst, Minneapolis, MN 55417 USA; [James, Lisa M.; Strom, Thad Q.; Leskela, Jennie] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA; [James, Lisa M.; Strom, Thad Q.; Leskela, Jennie] Univ Minnesota, Ctr Cognit Sci, Minneapolis, MN 55455 USA		James, LM (corresponding author), Minneapolis Vet Affairs Hlth Care Syst, One Vet Dr, Minneapolis, MN 55417 USA.			Strom, Thad/0000-0001-6743-9999			Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Boscarino JA, 2006, ANN EPIDEMIOL, V16, P248, DOI 10.1016/j.annepidem.2005.03.009; Brenner LA, 2009, REHABIL PSYCHOL, V54, P390, DOI 10.1037/a0017802; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Cyders MA, 2007, PSYCHOL ASSESSMENT, V19, P107, DOI 10.1037/1040-3590.19.1.107; Donnellan MB, 2005, J RES PERS, V39, P458, DOI 10.1016/j.jrp.2004.05.004; Eisen SA, 2004, MIL MED, V169, P896, DOI 10.7205/MILMED.169.11.896; Freeman TW, 2003, SOUTH MED J, V96, P240, DOI 10.1097/01.SMJ.0000054421.36880.6E; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoyert DL, 2012, NATL VITAL STAT REPO, V2012, P6; Jakupcak M, 2007, J TRAUMA STRESS, V20, P945, DOI 10.1002/jts.20258; Joiner T.E., 2005, WHY PEOPLE DIE SUICI; Kang HK, 2003, AM J EPIDEMIOL, V157, P141, DOI 10.1093/aje/kwf187; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kehle SM, 2012, PSYCHOL ADDICT BEHAV, V26, P42, DOI 10.1037/a0024663; Kelley AM, 2012, J PSYCHIATR RES, V46, P582, DOI 10.1016/j.jpsychires.2012.01.017; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kilgore WDS, 2008, J PSYCHIATR RES, V42, P399; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kotler M, 2001, J NERV MENT DIS, V189, P162, DOI 10.1097/00005053-200103000-00004; Krueger RF, 2001, PERS INDIV DIFFER, V30, P1245, DOI 10.1016/S0191-8869(00)00106-9; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Mann JJ, 1999, AM J PSYCHIAT, V156, P181; Mathias CW, 2011, SUICIDE LIFE-THREAT, V41, P277, DOI 10.1111/j.1943-278X.2011.00027.x; Miller MW, 2004, J ABNORM PSYCHOL, V113, P636, DOI 10.1037/0021-843X.113.4.636; Miller MW, 2003, CLIN PSYCHOL-SCI PR, V10, P373, DOI 10.1093/clipsy/bpg040; Miller MW, 2003, PSYCHOL ASSESSMENT, V15, P205, DOI 10.1037/1040-3590.15.2.205; Newcombe VFJ, 2011, BRAIN, V134, P759, DOI 10.1093/brain/awq388; Nock MK, 2006, J ABNORM PSYCHOL, V115, P616, DOI 10.1037/0021-843X.115.3.616; O'Jile JR, 2004, APPL NEUROPSYCHOL, V11, P107, DOI 10.1207/s15324826an1102_7; Oquendo M, 2005, AM J PSYCHIAT, V162, P560, DOI 10.1176/appi.ajp.162.3.560; Orcutt HK, 2003, J TRAUMA STRESS, V16, P381, DOI 10.1023/A:1024470103325; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Pat-Horenczyk R, 2007, AM J PSYCHIAT, V164, P66, DOI 10.1176/appi.ajp.164.1.66; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Rao V, 2009, J NEUROPSYCH CLIN N, V21, P420, DOI 10.1176/appi.neuropsych.21.4.420; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Sacks MB, 2008, J PSYCHIATR RES, V42, P487, DOI 10.1016/j.jpsychires.2007.05.001; SCHLENGER WE, 1992, J TRAUMA STRESS, V5, P333, DOI 10.1002/jts.2490050303; Schwab KA, 2006, NEUROLOGY, V66, pA235; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Strom TQ, 2012, MIL MED, V177, P390, DOI 10.7205/MILMED-D-11-00133; Swick D, 2012, J INT NEUROPSYCH SOC, V18, P1, DOI DOI 10.1017/S13556177120000458; Tanelian T, 2004, INVISIBLE WOUNDS WAR; Tellier A, 2009, BRAIN INJURY, V23, P879, DOI 10.1080/02699050903200555; Teten AL, 2010, J INTERPERS VIOLENCE, V25, P1612, DOI 10.1177/0886260509354583; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Tull MT, 2007, J NERV MENT DIS, V195, P580, DOI 10.1097/NMD.0b013e318093ed5f; U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, US PTSD CHECKL; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Warden DL, 2005, J NEUROTRAUM, V22, P1178; Watanabe Kevin K., 1995, Annals of Epidemiology, V5, P407, DOI 10.1016/1047-2797(95)00039-A; Weathers F.W., 1993, ANN CONV INT SOC TRA; Whiteside SP, 2001, PERS INDIV DIFFER, V30, P669, DOI 10.1016/S0191-8869(00)00064-7; Zuckerman M., 1994, BEHAV EXPRESSION BIO	59	84	84	1	17	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	APR	2014	179	4					357	363		10.7205/MILMED-D-13-00241			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AN7UK	WOS:000340806300002	24690958	Bronze			2022-02-06	
J	Begum, G; Yan, HQ; Li, L; Singh, A; Dixon, CE; Sun, D				Begum, Gulnaz; Yan, Hong Q.; Li, Liaoliao; Singh, Amneet; Dixon, C. Edward; Sun, Dandan			Docosahexaenoic Acid Reduces ER Stress and Abnormal Protein Accumulation and Improves Neuronal Function Following Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article						amyloid precursor protein; controlled cortical impact injury; docosahexaenoic acid; phosphorylated tau; unfolded protein response	ENDOPLASMIC-RETICULUM STRESS; DIFFUSE AXONAL INJURY; AMYLOID PRECURSOR PROTEIN; CORTICAL IMPACT MODEL; CELL-DEATH; CHEMICAL CHAPERONES; ASTROCYTES; BETA; NA+; HOMEOSTASIS	In this study, we investigated the development of endoplasmic reticulum (ER) stress after traumatic brain injury (TBI) and the efficacy of post-TBI administration of docosahexaenoic acid (DHA) in reducing ER stress. TBI was induced by cortical contusion injury in Sprague-Dawley rats. Either DHA (16 mg/kg in DMSO) or vehicle DMSO (1 ml/kg) was administered intraperitoneally at 5 min after TBI, followed by a daily dose for 3-21 d. TBI triggered sustained expression of the ER stress marker proteins including phosphorylated eukaryotic initiation factor-2 alpha, activating transcription factor 4, inositol requiring kinase 1, and C/EBP homologous protein in the ipsilateral cortex at 3-21 d after TBI. The prolonged ER stress was accompanied with an accumulation of abnormal ubiquitin aggregates and increased expression of amyloid precursor protein (APP) and phosphorylated tau (p-Tau) in the frontal cortex after TBI. The ER stress marker proteins were colocalized with APP accumulation in the soma. Interestingly, administration of DHA attenuated all ER stress marker proteins and reduced the accumulation of both ubiquitinated proteins and APP/p-Tau proteins. In addition, the DHA-treated animals exhibited early recovery of their sensorimotor function after TBI. In summary, our study demonstrated that TBI induces a prolonged ER stress, which is positively correlated with abnormal APP accumulation. The sustained ER stress may play a role in chronic neuronal damage after TBI. Our findings illustrate that post-TBI administration of DHA has therapeutic potentials in reducing ER stress, abnormal protein accumulation, and neurological deficits.	[Begum, Gulnaz; Li, Liaoliao; Singh, Amneet; Sun, Dandan] Univ Pittsburgh, Brain Trauma Res Ctr, Dept Neurol, Pittsburgh, PA 15213 USA; [Yan, Hong Q.; Dixon, C. Edward] Univ Pittsburgh, Brain Trauma Res Ctr, Dept Neurosurg, Pittsburgh, PA 15213 USA; [Dixon, C. Edward; Sun, Dandan] Geriatr Res Educ & Clin Ctr, Vet Affairs Pittsburgh Hlth Care Syst, Pittsburgh, PA 15213 USA		Sun, D (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, S 598 S Biomedical Sci Tower,3500 Terrace St, Pittsburgh, PA 15213 USA.	sund@upmc.edu	soler, martha maricel m gomez/L-6025-2014	soler, martha maricel m gomez/0000-0002-4412-8108	University of Pittsburgh Neurology Departmental startup funds; University of Pittsburgh Medical Center endowed Chair Professorship on Brain Disorder Diseases; United States Department of Veterans Affairs VA RRD [B6761R]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038118] Funding Source: NIH RePORTER	This work was supported in part by University of Pittsburgh Neurology Departmental startup funds and University of Pittsburgh Medical Center endowed Chair Professorship on Brain Disorder Diseases (D.S.) and the United States Department of Veterans Affairs VA RR&D#B6761R Grant (C.E.D.).	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Bazan NG, 2009, J LIPID RES, V50, pS400, DOI 10.1194/jlr.R800068-JLR200; Begum G, 2012, J NEUROCHEM, V120, P622, DOI 10.1111/j.1471-4159.2011.07606.x; Belayev L, 2011, TRANSL STROKE RES, V2, P33, DOI 10.1007/s12975-010-0046-0; Berman DR, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.06.017; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XZ, 2008, J NEUROCHEM, V106, P1563, DOI 10.1111/j.1471-4159.2008.05501.x; Chen XZ, 2010, J NEUROCHEM, V112, P173, DOI 10.1111/j.1471-4159.2009.06438.x; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Colla E, 2012, J NEUROSCI, V32, P3301, DOI 10.1523/JNEUROSCI.5368-11.2012; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; DEWJI NN, 1995, MOL BRAIN RES, V33, P245, DOI 10.1016/0169-328X(95)00131-B; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donnelly N, 2013, CELL MOL LIFE SCI, V70, P3493, DOI 10.1007/s00018-012-1252-6; Drexler HCA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004161; Engin F, 2010, DIABETES OBES METAB, V12, P108, DOI 10.1111/j.1463-1326.2010.01282.x; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Groenendyk J, 2005, ACTA BIOCHIM POL, V52, P381; Hasadsri L, 2013, J NEUROTRAUM, V30, P897, DOI 10.1089/neu.2012.2672; Hoozemans JJM, 2012, NEURODEGENER DIS, V10, P212, DOI 10.1159/000334536; Hoozemans JJM, 2009, AM J PATHOL, V174, P1241, DOI 10.2353/ajpath.2009.080814; Hu BR, 2001, J CEREBR BLOOD F MET, V21, P865, DOI 10.1097/00004647-200107000-00012; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Ikonomovic MD, 2012, ACTA NEUROPATHOL, V123, P433, DOI 10.1007/s00401-012-0943-2; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Innis SM, 2007, J NUTR, V137, P855, DOI 10.1093/jn/137.4.855; Itoh T, 2009, NEUROL RES, V31, P103, DOI 10.1179/016164108X323771; Joseph MS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041288; Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755; Krajewska M, 2011, BRAIN RES, V1370, P227, DOI 10.1016/j.brainres.2010.11.015; Lai ED, 2007, PHYSIOLOGY, V22, P193, DOI 10.1152/physiol.00050.2006; Lai KO, 2008, P NATL ACAD SCI USA, V105, P17175, DOI 10.1073/pnas.0803906105; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Larner SF, 2006, J NEUROTRAUM, V23, P807, DOI 10.1089/neu.2006.23.807; Lenart B, 2004, J NEUROSCI, V24, P9585, DOI 10.1523/JNEUROSCI.2569-04.2004; Liu Y, 2010, J NEUROCHEM, V114, P1436, DOI 10.1111/j.1471-4159.2010.06862.x; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Pan HC, 2009, J NUTR BIOCHEM, V20, P715, DOI 10.1016/j.jnutbio.2008.06.014; Paschen W, 2003, CELL CALCIUM, V34, P365, DOI 10.1016/S0143-4160(03)00139-8; Paschen W, 1999, J CEREBR BLOOD F MET, V19, P1, DOI 10.1097/00004647-199901000-00001; Petraglia Anthony L, 2011, Surg Neurol Int, V2, P146, DOI 10.4103/2152-7806.85987; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Purkayastha S, 2011, P NATL ACAD SCI USA, V108, P2939, DOI 10.1073/pnas.1006875108; Sande A, 2010, J VET EMERG CRIT CAR, V20, P177, DOI 10.1111/j.1476-4431.2010.00527.x; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Sokka AL, 2007, J NEUROSCI, V27, P901, DOI 10.1523/JNEUROSCI.4289-06.2007; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Su G, 2002, AM J PHYSIOL-CELL PH, V282, pC1147, DOI 10.1152/ajpcell.00538.2001; Sun XT, 2013, J NEUROSCI, V33, P2398, DOI 10.1523/JNEUROSCI.2292-12.2013; Thorell WE, 2002, J NEUROTRAUM, V19, P335, DOI 10.1089/089771502753594909; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Wessa P, 2014, FREE STAT SOFTW; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Wu AG, 2011, J NEUROTRAUM, V28, P2113, DOI 10.1089/neu.2011.1872; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Young CN, 2012, J CLIN INVEST, V122, P3960, DOI 10.1172/JCI64583; Zhu Y, 2008, J NEUROSCI, V28, P2168, DOI 10.1523/JNEUROSCI.5232-07.2008; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	70	84	90	0	11	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 5	2014	34	10					3743	3755		10.1523/JNEUROSCI.2872-13.2014			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AC7HN	WOS:000332698900027	24599472	Green Published, Bronze			2022-02-06	
J	Fluiter, K; Opperhuizen, AL; Morgan, BP; Baas, F; Ramaglia, V				Fluiter, Kees; Opperhuizen, Anne Loes; Morgan, B. Paul; Baas, Frank; Ramaglia, Valeria			Inhibition of the Membrane Attack Complex of the Complement System Reduces Secondary Neuroaxonal Loss and Promotes Neurologic Recovery after Traumatic Brain Injury in Mice	JOURNAL OF IMMUNOLOGY			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; AXONAL INJURY; WALLERIAN DEGENERATION; MYELIN PHAGOCYTOSIS; ALTERNATIVE PATHWAY; HEAD-INJURY; DEFICIENCY; ACTIVATION; RECEPTOR; DEMYELINATION	Traumatic brain injury (TBI) is the leading cause of disability and death in young adults. The secondary neuroinflammation and neuronal damage that follows the primary mechanical injury is an important cause of disability in affected people. The membrane attack complex (MAC) of the complement system is detected in the traumatized brain early after TBI; however, its role in the pathology and neurologic outcome of TBI has not yet been investigated. We generated a C6 antisense oligonucleotide that blocks MAC formation by inhibiting C6, and we compared its therapeutic effect to that of Ornithodoros moubata complement inhibitor (OmCI), a known inhibitor of C5 activation that blocks generation of the anaphylatoxin C5a and C5b, an essential component of MAC. Severe closed head injury in mice induced abundant MAC deposition in the brain. Treatment with C6 antisense reduced C6 synthesis (85%) and serum levels (90%), and inhibited MAC deposition in the injured brain (91-96%). Treatment also reduced accumulation of microglia/macrophages (50-88%), neuronal apoptosis, axonal loss and weight loss (54-93%), and enhanced neurologic performance (84-92%) compared with placebo-treated controls after injury. These data provide the first evidence, to our knowledge, that inhibition of MAC formation in otherwise complement-sufficient animals reduces neuropathology and promotes neurologic recovery after TBI. Given the importance of maintaining a functional complement opsonization system to fight infections, a critical complication in TBI patients, inhibition of the MAC should be considered to reduce posttraumatic neurologic damage. This work identifies a novel therapeutic target for TBI and will guide the development of new therapy for patients.	[Fluiter, Kees; Opperhuizen, Anne Loes; Baas, Frank; Ramaglia, Valeria] Univ Amsterdam, Acad Med Ctr, Dept Genome Anal, NL-1105 AZ Amsterdam, Netherlands; [Morgan, B. Paul] Cardiff Univ, Inst Infect & Immun, Sch Med, Cardiff CF14 4YU, S Glam, Wales		Ramaglia, V (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Genome Anal, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	v.ramaglia@amc.nl	Opperhuizen, Anneloes/AAS-1902-2021; Opperhuizen, Anneloes/AAW-4823-2020; Baas, Frank/F-9574-2010; Fluiter, Kees/H-2828-2015	Opperhuizen, Anneloes/0000-0002-0995-7517; Baas, Frank/0000-0003-3912-5428; Fluiter, Kees/0000-0003-0898-7260; Morgan, Paul/0000-0003-4075-7676	Hersenstichting Nederlands Fellowship [F2010 (1)-05]	This work was supported by Hersenstichting Nederlands Fellowship F2010 (1)-05 (to V.R.).	Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Bijsterbosch MK, 1997, NUCLEIC ACIDS RES, V25, P3290, DOI 10.1093/nar/25.16.3290; BRAUER RB, 1994, J IMMUNOL, V153, P3168; Burk AM, 2012, SHOCK, V37, P348, DOI 10.1097/SHK.0b013e3182471795; Casarsa C, 2003, EUR J IMMUNOL, V33, P1260, DOI 10.1002/eji.200323574; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fluiter K, 2009, MOL BIOSYST, V5, P838, DOI 10.1039/b903922h; Graham MJ, 1998, J PHARMACOL EXP THER, V286, P447; GRAHAM MJ, 1993, NUCLEIC ACIDS RES, V21, P3737, DOI 10.1093/nar/21.16.3737; Hepburn NJ, 2007, J BIOL CHEM, V282, P8292, DOI 10.1074/jbc.M609858200; Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kurz MW, 2013, ACTA NEUROL SCAND, V127, P57, DOI 10.1111/ane.12051; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Li R, 2013, FASEB J, V27, P855, DOI 10.1096/fj.12-220509; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; Mead RJ, 2004, LAB INVEST, V84, P21, DOI 10.1038/labinvest.3700015; Mead RJ, 2002, J IMMUNOL, V168, P458, DOI 10.4049/jimmunol.168.1.458; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Orren A, 2012, CLIN EXP IMMUNOL, V167, P459, DOI 10.1111/j.1365-2249.2011.04525.x; PIDDLESDEN SJ, 1994, J IMMUNOL, V152, P5477; Plurad DS, 2010, AM SURGEON, V76, P43; Pratt JR, 2002, NAT MED, V8, P582, DOI 10.1038/nm0602-582; Ramaglia V, 2008, MOL IMMUNOL, V45, P3865, DOI 10.1016/j.molimm.2008.06.018; Ramaglia V, 2007, J NEUROSCI, V27, P7663, DOI 10.1523/JNEUROSCI.5623-06.2007; Ramaglia V, 2009, MOL IMMUNOL, V47, P302, DOI 10.1016/j.molimm.2009.09.019; Ramaglia V, 2009, MOL IMMUNOL, V46, P1892, DOI 10.1016/j.molimm.2009.01.017; Reichert F, 2003, NEUROBIOL DIS, V12, P65, DOI 10.1016/S0969-9961(02)00008-6; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Rostami E, 2013, J NEUROTRAUM, V30, P1954, DOI 10.1089/neu.2012.2583; Rotshenker S, 2003, J MOL NEUROSCI, V21, P65, DOI 10.1385/JMN:21:1:65; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Selassie AW, 2011, J TRAUMA, V71, P1226, DOI 10.1097/TA.0b013e318226ecfc; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel PF, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-2; Turnberg D, 2004, AM J PATHOL, V165, P825, DOI 10.1016/S0002-9440(10)63345-7; Wang Q, 2011, NAT MED, V17, P1674, DOI 10.1038/nm.2543; Woodruff TM, 2011, MOL IMMUNOL, V48, P1631, DOI 10.1016/j.molimm.2011.04.014; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Xiong ZQ, 2003, J NEUROSCI, V23, P955	47	84	84	0	7	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767	1550-6606		J IMMUNOL	J. Immunol.	MAR 1	2014	192	5					2339	2348		10.4049/jimmunol.1302793			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	AC7IL	WOS:000332701400038	24489093	Bronze			2022-02-06	
J	Dobryakova, E; DeLuca, J; Genova, HM; Wylie, GR				Dobryakova, Ekaterina; DeLuca, John; Genova, Helen M.; Wylie, Glenn R.			Neural Correlates of Cognitive Fatigue: Cortico-Striatal Circuitry and Effort-Reward Imbalance	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Cognitive fatigue; Basal ganglia; Reward network; Effort-reward relationship; MRI	VENTROMEDIAL PREFRONTAL CORTEX; MENTAL FATIGUE; BASAL GANGLIA; FRONTAL-CORTEX; MOTIVATION; RESPONSES; DOPAMINE; BEHAVIOR	Recently, there has been renewed interest in the study of cognitive fatigue. It is known that fatigue is one of the most disabling symptoms in numerous neurological populations, including stroke, multiple sclerosis, Parkinson's disease, and traumatic brain injury. Behavioral studies of cognitive fatigue are hampered by lack of correlation of self-report measures with objective performance. Neuroimaging studies provide new insight about cognitive fatigue and its neural correlates. Impairment within the cortico-striatal network, involved in effort-reward calculation, has been suggested to be critically related to fatigue. The current review surveys the recent neuroimaging literature, and suggests promising avenues for future research.	[Dobryakova, Ekaterina; DeLuca, John; Genova, Helen M.; Wylie, Glenn R.] Kessler Fdn Res Ctr, W Orange, NJ USA; [Dobryakova, Ekaterina; DeLuca, John; Genova, Helen M.; Wylie, Glenn R.] Rutgers State Univ, Newark, NJ 07102 USA; [Wylie, Glenn R.] War Related Illness & Injury Study Ctr, Dept Vet Affairs, E Orange, NJ USA		Dobryakova, E (corresponding author), Kessler Fdn Res Ctr, 300 Execut Dr,Suite 70, W Orange, NJ USA.	edobryakova@kesslerfoundation.org			National Institute on Disability and Rehabilitation Research [H133P070007]; National Multiple Sclerosis SocietyNational Multiple Sclerosis Society [RG 4232A1/1]; New Jersey Commission on Brain Injury Research [RG 10-3216-BIR-E-0]; Kessler Research Foundation Center	The authors acknowledge grant support from The National Institute on Disability and Rehabilitation Research (H133P070007), National Multiple Sclerosis Society RG 4232A1/1 to H.G. and New Jersey Commission on Brain Injury Research RG 10-3216-BIR-E-0 to G.W., and the Kessler Research Foundation Center. The authors declare no conflict of interest.	Boksem MAS, 2008, BRAIN RES REV, V59, P125, DOI 10.1016/j.brainresrev.2008.07.001; Boksem MAS, 2006, BIOL PSYCHOL, V72, P123, DOI 10.1016/j.biopsycho.2005.08.007; Boksem MAS, 2005, COGNITIVE BRAIN RES, V25, P107, DOI 10.1016/j.cogbrainres.2005.04.011; Bonelli Raphael M, 2007, Dialogues Clin Neurosci, V9, P141; Botvinick MM, 2009, PSYCHOL RES-PSYCH FO, V73, P835, DOI 10.1007/s00426-008-0197-8; Capuron L, 2012, ARCH GEN PSYCHIAT, V69, P1044, DOI 10.1001/archgenpsychiatry.2011.2094; CARVER CS, 1994, J PERS SOC PSYCHOL, V67, P319, DOI 10.1037/0022-3514.67.2.319; Chaudhuri A, 2000, J NEUROL SCI, V179, P34, DOI 10.1016/S0022-510X(00)00411-1; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; Claros-Salinas D, 2013, NEUROPSYCHOL REHABIL, V23, P182, DOI 10.1080/09602011.2012.726925; DeLuca J, 2005, ISS CLIN COGN NEUROP, P1; DeLuca J, 2008, J NEUROL SCI, V270, P28, DOI 10.1016/j.jns.2008.01.018; Haber SN, 2000, J NEUROSCI, V20, P2369; Haber SN, 2010, NEUROPSYCHOPHARMACOL, V35, P4, DOI 10.1038/npp.2009.129; Hollerman JR, 1998, J NEUROPHYSIOL, V80, P947, DOI 10.1152/jn.1998.80.2.947; Kluger BM, 2013, NEUROLOGY, V80, P409, DOI 10.1212/WNL.0b013e31827f07be; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; Leocani L, 2008, NEUROL SCI, V29, pS241, DOI 10.1007/s10072-008-0950-1; Lorist MM, 2009, BRAIN RES, V1270, P95, DOI 10.1016/j.brainres.2009.03.015; Middleton FA, 2000, BRAIN RES REV, V31, P236, DOI 10.1016/S0165-0173(99)00040-5; Moeller SJ, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.110; O'Doherty JP, 2011, ANN NY ACAD SCI, V1239, P118, DOI 10.1111/j.1749-6632.2011.06290.x; Pardini M, 2013, MULT SCLER J, V19, P233, DOI 10.1177/1352458512451509; Pardini M, 2010, BEHAV NEUROSCI, V124, P329, DOI 10.1037/a0019585; Pardini M, 2010, NEUROLOGY, V74, P749, DOI 10.1212/WNL.0b013e3181d25b6b; Roelcke U, 1997, NEUROLOGY, V48, P1566, DOI 10.1212/WNL.48.6.1566; Salamone JD, 2003, J PHARMACOL EXP THER, V305, P1, DOI 10.1124/jpet.102.035063; Strober L. D., 2013, SECONDARY INFLUENCES; Tang WK, 2013, J NEUROL SCI, V324, P131, DOI 10.1016/j.jns.2012.10.022; Tang WK, 2010, J NEUROL, V257, P178, DOI 10.1007/s00415-009-5284-2; Volkow ND, 2004, MOL PSYCHIATR, V9, P557, DOI 10.1038/sj.mp.4001507; Walton ME, 2003, J NEUROSCI, V23, P6475; Wylie G., 2012, INVESTIGATION COGNIT	33	84	84	0	36	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2013	19	8					849	853		10.1017/S1355617713000684			5	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	209AQ	WOS:000323725800001	23842042				2022-02-06	
J	Monti, JM; Voss, MW; Pence, A; McAuley, E; Kramer, AF; Cohen, NJ				Monti, Jim M.; Voss, Michelle W.; Pence, Ari; McAuley, Edward; Kramer, Arthur F.; Cohen, Neal J.			History of mild traumatic brain injury is associated with deficits in relational memory, reduced hippocampal volume, and less neural activity later in life	FRONTIERS IN AGING NEUROSCIENCE			English	Article						mTBI; hippocampus; aging; relational memory; fMRI	SYNAPTIC PLASTICITY; COGNITIVE DECLINE; EPISODIC MEMORY; DEFAULT NETWORK; OLDER-ADULTS; HEAD-INJURY; AMNESIA; CORTEX; NEUROPATHOLOGY; SEGMENTATION	Evidence suggests that a history of head trauma is associated with memory deficits later in life. The majority of previous research has focused on moderate-to-severe traumatic brain injury (TBI), but recent evidence suggests that even a mild TBI (mTBI) can interact with the aging process and produce reductions in memory performance. This study examined the association of mTBI with memory and the brain by comparing young and middle-aged adults who have had mTBI in their recent (several years ago) and remote (several decades ago) past, respectively, with control subjects on a face-scene relational memory paradigm while they underwent functional magnetic resonance imaging (fMRI). Hippocampal volumes were also examined from high-resolution structural images. Results indicated middle-aged adults with a head injury in their remote past had impaired memory compared to gender, age, and education matched control participants, consistent with previous results in the study of memory, aging, and TBI. The present findings extended previous results by demonstrating that these individuals also had smaller bilateral hippocampi, and had reduced neural activity during memory performance in cortical regions important for memory retrieval. These results indicate that a history of mTBI may be one of the many factors that negatively influence cognitive and brain health in aging.	[Monti, Jim M.; Kramer, Arthur F.; Cohen, Neal J.] Univ Illinois, Dept Psychol, Champaign, IL USA; [Monti, Jim M.; Pence, Ari; McAuley, Edward; Kramer, Arthur F.; Cohen, Neal J.] Univ Illinois, Beckman Inst, Urbana, IL 61801 USA; [Voss, Michelle W.] Univ Iowa, Dept Psychol, Iowa City, IA USA; [McAuley, Edward] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA; [Kramer, Arthur F.; Cohen, Neal J.] Univ Illinois, Neurosci Program, Urbana, IL 61801 USA		Monti, JM (corresponding author), Univ Illinois, Beckman Inst, 405 N Mathews Ave, Urbana, IL 61801 USA.	monti@illinois.edu	Kramer, Arthur/AAB-2937-2019	Kramer, Arthur/0000-0001-5870-2724	Health and Wellness Initiative from the College of Applied Health Sciences at the University of Illinois at Urbana-Champaign; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH062500] Funding Source: NIH RePORTER	This work was supported by funds from a Health and Wellness Initiative from the College of Applied Health Sciences at the University of Illinois at Urbana-Champaign. We thank Steve Broglio for his involvement in an earlier stage of this project, Rebecca Delgado for her assistance intesting participants, and Nancy Dodge and Holly Tracy for assisting in the imaging sessions.	Andrews-Hanna JR, 2007, NEURON, V56, P924, DOI 10.1016/j.neuron.2007.10.038; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Beauchamp MH, 2011, INT J DEV NEUROSCI, V29, P137, DOI 10.1016/j.ijdevneu.2010.12.003; Beckmann CF, 2003, NEUROIMAGE, V20, P1052, DOI 10.1016/S1053-8119(03)00435-X; Bennett DA, 2012, ANN NEUROL, V72, P599, DOI 10.1002/ana.23654; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bohbot VD, 1998, NEUROPSYCHOLOGIA, V36, P1217, DOI 10.1016/S0028-3932(97)00161-9; Buckner RL, 2004, NEUROIMAGE, V23, P724, DOI 10.1016/j.neuroimage.2004.06.018; Cabeza R, 2008, NAT REV NEUROSCI, V9, P613, DOI 10.1038/nrn2459; Centers for Disease Control and Prevention, 2003, C MILD TRAUM BRAIN I; Cohen, 2001, CONDITIONING CONSCIO; Cohen NJ, 1999, HIPPOCAMPUS, V9, P83, DOI 10.1002/(SICI)1098-1063(1999)9:1<83::AID-HIPO9>3.0.CO;2-7; Cohen NJ., 1993, MEMORY AMNESIA HIPPO; CORKIN S, 1989, J NEUROSCI, V9, P3876; Damoiseaux JS, 2008, CEREB CORTEX, V18, P1856, DOI 10.1093/cercor/bhm207; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Dobbins IG, 2002, NEURON, V35, P989, DOI 10.1016/S0896-6273(02)00858-9; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Erickson KI, 2009, HIPPOCAMPUS, V19, P1030, DOI 10.1002/hipo.20547; Faul M, 2010, TRAUMATIC BRAIN INJU; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fjell AM, 2013, NEUROBIOL AGING, V34, P2239, DOI 10.1016/j.neurobiolaging.2013.04.006; Foster TC, 2007, AGING CELL, V6, P319, DOI 10.1111/j.1474-9726.2007.00283.x; Fotuhi M, 2009, NAT REV NEUROL, V5, P649, DOI 10.1038/nrneurol.2009.175; Gatson JW, 2013, J TRAUMA ACUTE CARE, V74, P470, DOI 10.1097/TA.0b013e31827e1f51; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guillozet AL, 2003, ARCH NEUROL-CHICAGO, V60, P729, DOI 10.1001/archneur.60.5.729; Hannula DE, 2006, J NEUROSCI, V26, P8352, DOI 10.1523/JNEUROSCI.5222-05.2006; Hannula DE, 2007, J COGNITIVE NEUROSCI, V19, P1690, DOI 10.1162/jocn.2007.19.10.1690; Head D, 2008, NEUROPSYCHOLOGY, V22, P491, DOI 10.1037/0894-4105.22.4.491; Hirni DI, 2013, NEUROPSYCHOLOGIA, V51, P930, DOI 10.1016/j.neuropsychologia.2013.01.013; Hopkins RO, 2005, NEUROPSYCHOLOGY, V19, P233, DOI 10.1037/0894-4105.19.2.233; Jagust W, 2013, NEURON, V77, P219, DOI 10.1016/j.neuron.2013.01.002; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kennedy KM, 2012, NEUROIMAGE, V62, P1, DOI 10.1016/j.neuroimage.2012.03.077; Kobayashi Y, 2003, J COMP NEUROL, V466, P48, DOI 10.1002/cne.10883; Konkel A, 2008, FRONT HUM NEUROSCI, V2, DOI 10.3389/neuro.09.015.2008; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mesulam M. M., 2000, PRINCIPLES BEHAV COG, P439; Moretti L, 2012, LANCET NEUROL, V11, P1103, DOI 10.1016/S1474-4422(12)70226-0; Morey RA, 2009, NEUROIMAGE, V45, P855, DOI 10.1016/j.neuroimage.2008.12.033; Noble KG, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00307; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Price JL, 2009, NEUROBIOL AGING, V30, P1026, DOI 10.1016/j.neurobiolaging.2009.04.002; Raz N, 2005, CEREB CORTEX, V15, P1676, DOI 10.1093/cercor/bhi044; Raz N, 2010, NEUROIMAGE, V51, P501, DOI 10.1016/j.neuroimage.2010.03.020; Rentz DM, 2011, NEUROPSYCHOLOGIA, V49, P2776, DOI 10.1016/j.neuropsychologia.2011.06.006; Rockland KS, 1999, CEREB CORTEX, V9, P232, DOI 10.1093/cercor/9.3.232; Ryan JD, 2000, PSYCHOL SCI, V11, P454, DOI 10.1111/1467-9280.00288; Serrano F, 2004, AGEING RES REV, V3, P431, DOI 10.1016/j.arr.2004.05.002; Simons JS, 2003, NAT REV NEUROSCI, V4, P637, DOI 10.1038/nrn1178; Small SA, 2011, NAT REV NEUROSCI, V12, P585, DOI 10.1038/nrn3085; Spalding KL, 2013, CELL, V153, P1219, DOI 10.1016/j.cell.2013.05.002; Sperling RA, 2009, NEURON, V63, P178, DOI 10.1016/j.neuron.2009.07.003; Staresina BP, 2009, NEURON, V63, P267, DOI 10.1016/j.neuron.2009.06.024; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Wagner AD, 2005, TRENDS COGN SCI, V9, P445, DOI 10.1016/j.tics.2005.07.001; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Watson PD, 2013, HIPPOCAMPUS, V23, P570, DOI 10.1002/hipo.22115; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313	67	84	85	2	25	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1663-4365			FRONT AGING NEUROSCI	Front. Aging Neurosci.	AUG 22	2013	5								41	10.3389/fnagi.2013.00041			9	Geriatrics & Gerontology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Geriatrics & Gerontology; Neurosciences & Neurology	206JF	WOS:000323515400001	23986698	Green Published, gold			2022-02-06	
J	Messe, A; Caplain, S; Pelegrini-Issac, M; Blancho, S; Levy, R; Aghakhani, N; Montreuil, M; Benali, H; Lehericy, S				Messe, Arnaud; Caplain, Sophie; Pelegrini-Issac, Melanie; Blancho, Sophie; Levy, Richard; Aghakhani, Nozar; Montreuil, Michele; Benali, Habib; Lehericy, Stephane			Specific and Evolving Resting-State Network Alterations in Post-Concussion Syndrome Following Mild Traumatic Brain Injury	PLOS ONE			English	Article							GRAPH-THEORETICAL ANALYSIS; DEFAULT MODE NETWORK; FUNCTIONAL CONNECTIVITY; HEAD-INJURY; SYMPTOMS; SUBJECT; LEVEL; PHASE	Post-concussion syndrome has been related to axonal damage in patients with mild traumatic brain injury, but little is known about the consequences of injury on brain networks. In the present study, our aim was to characterize changes in functional brain networks following mild traumatic brain injury in patients with post-concussion syndrome using resting-state functional magnetic resonance imaging data. We investigated 17 injured patients with persistent post-concussion syndrome (under the DSM-IV criteria) at 6 months post-injury compared with 38 mild traumatic brain injury patients with no post-concussion syndrome and 34 healthy controls. All patients underwent magnetic resonance imaging examinations at the subacute (1-3 weeks) and late (6 months) phases after injury. Group-wise differences in functional brain networks were analyzed using graph theory measures. Patterns of long-range functional networks alterations were found in all mild traumatic brain injury patients. Mild traumatic brain injury patients with post-concussion syndrome had greater alterations than patients without post-concussion syndrome. In patients with post-concussion syndrome, changes specifically affected temporal and thalamic regions predominantly at the subacute stage and frontal regions at the late phase. Our results suggest that the post-concussion syndrome is associated with specific abnormalities in functional brain network that may contribute to explain deficits typically observed in PCS patients.	[Messe, Arnaud; Pelegrini-Issac, Melanie; Benali, Habib] Univ Paris 06, INSERM, Lab Imagerie Fonct, UMRS 678, Paris, France; [Messe, Arnaud; Pelegrini-Issac, Melanie; Benali, Habib; Lehericy, Stephane] Univ Paris 11, IFR49, DSV NeuroSpin I2BM, Gif Sur Yvette, France; [Caplain, Sophie; Montreuil, Michele] Univ Paris 08, EA 2027, St Denis, France; [Blancho, Sophie] Inst Rech Moelle Epiniere & Encephale, Paris, France; [Levy, Richard; Lehericy, Stephane] Univ Paris 06, INSERM, Grp Hosp Pitie Salpetriere, UMRS 975,CNRS UMR 7225,CRICM, Paris, France; [Levy, Richard] Hop St Antoine, Assistance Publ Hop Paris, F-75571 Paris, France; [Aghakhani, Nozar] Hop Univ Bicetre, Assistance Publ Hop Paris, Neurosurg Dept, Le Kremlin Bicetre, France; [Benali, Habib] Univ Montreal, MIC UNF, Montreal, PQ, Canada; [Lehericy, Stephane] Univ Paris 06, CHU Pitie Salpetriere, CENIR, Ctr Neuroimaging Res, Paris, France		Messe, A (corresponding author), Univ Paris 06, INSERM, Lab Imagerie Fonct, UMRS 678, Paris, France.	Arnaud.Messe@imed.jussieu.fr	aghakhani, nozar/ABF-7908-2021; Messe, Arnaud/I-1738-2019; Levy, Richard/D-8411-2011	Messe, Arnaud/0000-0001-9081-3088; aghakhani, nozar/0000-0001-8389-8167; Pelegrini-Issac, Melanie/0000-0003-3260-5795	IRME (Institut pour la Recherche sur la Moelle Epiniere et l'Encephale); GMF (Garantie Mutuelle des Fonctionnaires); program "Investissements d'avenir"French National Research Agency (ANR) [ANR-10-IAIHU-06]	This study was initiated by the IRME (Institut pour la Recherche sur la Moelle Epiniere et l'Encephale) and supported by a grant from the GMF (Garantie Mutuelle des Fonctionnaires). The research leading to these results has received funding from the program "Investissements d'avenir" ANR-10-IAIHU-06. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Achard S, 2006, J NEUROSCI, V26, P63, DOI 10.1523/JNEUROSCI.3874-05.2006; ACRM, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI 10.1097/00001199-199309000-00010; American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT; Azouvi P, 2001, REV NEUROPSYCHOL, V11, P383; Bassett DS, 2012, NEUROIMAGE, V59, P2196, DOI 10.1016/j.neuroimage.2011.10.002; Bassett DS, 2011, NEUROIMAGE, V54, P1262, DOI 10.1016/j.neuroimage.2010.09.006; Bassett DS, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000748; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Benjamini Y, 2001, ANN STAT, V29, P1165; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Biswal BB, 2010, P NATL ACAD SCI USA, V107, P4734, DOI 10.1073/pnas.0911855107; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Bressler SL, 2006, INT J PSYCHOPHYSIOL, V60, P139, DOI 10.1016/j.ijpsycho.2005.12.008; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; FitzGerald DB, 2011, INT J PSYCHOPHYSIOL, V82, P79, DOI 10.1016/j.ijpsycho.2011.02.011; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Fox MD, 2009, J NEUROPHYSIOL, V101, P3270, DOI 10.1152/jn.90777.2008; FREEMAN LC, 1977, SOCIOMETRY, V40, P35, DOI 10.2307/3033543; Ginestet CE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021570; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Hou R, 2011, J NEUROL NEUROSUR PS, V83, P217; Humphries MD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002051; Irimia A, 2012, NEUROIMAGE, V60, P1340, DOI 10.1016/j.neuroimage.2012.01.107; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kaiser M, 2006, PLOS COMPUT BIOL, V2, P805, DOI 10.1371/journal.pcbi.0020095; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Latora V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198701; Legome E, 2006, POSTCONCUSSION SYNDR; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Logothetis NK, 2004, ANNU REV PHYSIOL, V66, P735, DOI 10.1146/annurev.physiol.66.082602.092845; Lynall ME, 2010, J NEUROSCI, V30, P9477, DOI 10.1523/JNEUROSCI.0333-10.2010; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Newman MEJ, 2006, P NATL ACAD SCI USA, V103, P8577, DOI 10.1073/pnas.0601602103; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Raichle ME, 2011, BRAIN CONNECT, V1, P3, DOI 10.1089/brain.2011.0019; Ravasz E, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.026112; Reijneveld JC, 2007, CLIN NEUROPHYSIOL, V118, P2317, DOI 10.1016/j.clinph.2007.08.010; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Sandrone S, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00261; Sandrone S, 2012, J NEUROSCI, V32, P1915, DOI 10.1523/JNEUROSCI.5637-11.2012; Schwarz AJ, 2011, NEUROIMAGE, V55, P1132, DOI 10.1016/j.neuroimage.2010.12.047; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sporns O, 2005, PLOS COMPUT BIOL, V1, P245, DOI 10.1371/journal.pcbi.0010042; Sporns O., 2011, NETWORKS BRAIN; Sporns O, 2006, P NATL ACAD SCI USA, V103, P19219, DOI 10.1073/pnas.0609523103; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; van den Heuvel MP, 2011, J NEUROSCI, V31, P15775, DOI 10.1523/JNEUROSCI.3539-11.2011; Van Dijk KRA, 2010, J NEUROPHYSIOL, V103, P297, DOI 10.1152/jn.00783.2009; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Varela F, 2001, NAT REV NEUROSCI, V2, P229, DOI 10.1038/35067550; von Wild KRH, 2008, ACT NEUR S, V101, P55; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Xia M, 2011, P 17 INT C FUNCT MAP; Zalesky A, 2012, NEUROIMAGE, V60, P1055, DOI 10.1016/j.neuroimage.2012.01.068	69	84	86	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2013	8	6							e65470	10.1371/journal.pone.0065470			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173SK	WOS:000321099000072	23755237	gold, Green Published, Green Submitted			2022-02-06	
J	Duhaime, AC; Beckwith, JG; Maerlender, AC; McAllister, TW; Crisco, JJ; Duma, SM; Brolinson, PG; Rowson, S; Flashman, LA; Chu, JJ; Greenwald, RM				Duhaime, Ann-Christine; Beckwith, Jonathan G.; Maerlender, Arthur C.; McAllister, Thomas W.; Crisco, Joseph J.; Duma, Stefan M.; Brolinson, P. Gunnar; Rowson, Steven; Flashman, Laura A.; Chu, Jeffrey J.; Greenwald, Richard M.			Spectrum of acute clinical characteristics of diagnosed concussions in college athletes wearing instrumented helmets Clinical article	JOURNAL OF NEUROSURGERY			English	Article						concussion; traumatic brain injury; biomechanics; athletes; football; hockey	TRAUMATIC BRAIN-INJURY; HEAD IMPACT EXPOSURES; RECURRENT CONCUSSION; CEREBRAL CONCUSSION; FOOTBALL; MILD; RISK; ACCELERATION; KINEMATICS; DEPRESSION	Object. Concussive head injuries have received much attention in the medical and public arenas, as concerns have been raised about the potential short- and long-term consequences of injuries sustained in sports and other activities. While many student athletes have required evaluation after concussion, the exact definition of concussion has varied among disciplines and over time. The authors used data gathered as part of a multiinstitutional longitudinal study of the biomechanics of head impacts in helmeted collegiate athletes to characterize what signs, symptoms, and clinical histories were used to designate players as having sustained concussions. Methods. Players on 3 college football teams and 4 ice hockey teams (male and female) wore helmets instrumented with Head Impact Telemetry (HIT) technology during practices and games over 2-4 seasons of play. Preseason clinical screening batteries assessed baseline cognition and reported symptoms. If a concussion was diagnosed by the team medical staff, basic descriptive information was collected at presentation, and concussed players were reevaluated serially. The specific symptoms or findings associated with the diagnosis of acute concussion, relation to specific impact events, timing of symptom onset and diagnosis, and recorded biomechanical parameters were analyzed. Results. Data were collected from 450 athletes with 486,594 recorded head impacts. Forty-eight separate concussions were diagnosed in 44 individual players. Mental clouding, headache, and dizziness were the most common presenting symptoms. Thirty-one diagnosed cases were associated with an identified impact event; in 17 cases no specific impact event was identified. Onset of symptoms was immediate in 24 players, delayed in 11, and unspecified in 13. In 8 cases the diagnosis was made immediately after a head impact, but in most cases the diagnosis was delayed (median 17 hours). One diagnosed concussion involved a 30-second loss of consciousness; all other players retained alertness. Most diagnoses were based on self-reported symptoms. The mean peak angular and rotational acceleration values for those cases associated with a specific identified impact were 86.1 +/- 42.6g (range 16.5-177.9g) and 3620 +/- 2166 rad/sec(2) (range 183-7589 rad/sec(2)), respectively. Conclusions. Approximately two-thirds of diagnosed concussions were associated with a specific contact event. Half of all players diagnosed with concussions had delayed or unclear timing of onset of symptoms. Most had no externally observed findings. Diagnosis was usually based on a range of self-reported symptoms after a variable delay. Accelerations clustered in the higher percentiles for all impact events, but encompassed a wide range. These data highlight the heterogeneity of criteria for concussion diagnosis, and in this sports context, its heavy reliance on self-reported symptoms. More specific and standardized definitions of clinical and objective correlates of a "concussion spectrum" may be needed in future research efforts, as well as in the clinical diagnostic arena. (http://thejns.org/doi/abs/10.3171/2012.8.JNS112298)	[Duhaime, Ann-Christine] Harvard Univ, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA; [Beckwith, Jonathan G.; Chu, Jeffrey J.; Greenwald, Richard M.] Simbex, Lebanon, NH USA; [Maerlender, Arthur C.] Dartmouth Med Sch, Pediat Neuropsychol Serv, Lebanon, NH USA; [McAllister, Thomas W.; Flashman, Laura A.] Dartmouth Med Sch, Dept Psychiat, Lebanon, NH USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Crisco, Joseph J.] Brown Univ, Warren Alpert Med Sch, Dept Orthopaed, Bioengn Lab, Providence, RI 02912 USA; [Crisco, Joseph J.] Rhode Isl Hosp, Providence, RI USA; [Duma, Stefan M.; Rowson, Steven] Virginia Tech, Wake Forest Ctr Injury Biomech, Blacksburg, VA USA; [Brolinson, P. Gunnar] Edward Via Virginia Coll Osteopath Med, Blacksburg, VA USA		Duhaime, AC (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Dept Neurosurg, 15 Parkman St,Wang 331, Boston, MA 02114 USA.	aduhaime@partners.org	Duma, Stefan/A-8368-2012; Rowson, Steven/B-1270-2012	Rowson, Steven/0000-0002-3227-0596; Crisco, Joseph/0000-0002-8786-0905	National Institute for Child Health and Human Development at the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER	The research for this study is supported by the National Institute for Child Health and Human Development at the National Institutes of Health (Grant R01HD048638).	Alex BV, 1996, NEUROTRAUMA, P119; Alla S, 2012, BRIT J SPORT MED, V46, P562, DOI 10.1136/bjsm.2010.081299; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Beckwith JG, 2010, 8 WORLD C BRAIN INJ; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Cantu RC, 2003, NEUROSURGERY, V52, P846, DOI 10.1227/01.NEU.0000053210.76063.E4; Chu, 2006, J BIOMECH, V39, DOI https://doi.org/10.1016/s0021-9290(06)83518-9; Chu JJ, 2006, J BIOMECH S1, V39, pS534; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Duma S, 2004, 2004 ANN M AM SOC BI; FISHER CM, 1966, NEUROLOGY, V16, P826, DOI 10.1212/WNL.16.8.826; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Gwin J. T., 2009, J ASTM INT, V6, P1; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Marion DW, 2011, J NEUROTRAUM, V28, P517, DOI 10.1089/neu.2010.1638; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Takhounts EG, 2008, STAPP CAR C, V52, P1; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196	43	84	85	1	39	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2012	117	6					1092	1099		10.3171/2012.8.JNS112298			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	042IC	WOS:000311463900016	23030057	Green Published, Green Accepted, Bronze			2022-02-06	
J	Johansson, B; Bjuhr, H; Ronnback, L				Johansson, B.; Bjuhr, H.; Ronnback, L.			Mindfulness-based stress reduction (MBSR) improves long-term mental fatigue after stroke or traumatic brain injury	BRAIN INJURY			English	Article						Mental fatigue; TBI; stroke; MBSR; mindfulness; information processing speed; attention	ATTENTION; SYMPTOMS; MILD; DISORDERS; IMPACT	Objective: Patients who suffer from mental fatigue after a stroke or traumatic brain injury (TBI) have a drastically reduced capacity for work and for participating in social activities. Since no effective therapy exists, the aim was to implement a novel, non-pharmacological strategy aimed at improving the condition of these patients. Methods: This study tested a treatment with mindfulness-based stress reduction (MBSR). The results of the programme were evaluated using a self-assessment scale for mental fatigue and neuropsychological tests. Eighteen participants with stroke and 11 with TBI were included. All the subjects were well rehabilitated physically with no gross impairment to cognitive functions other than the symptom mental fatigue. Fifteen participants were randomized for inclusion in the MBSR programme for 8 weeks, while the other 14 served as controls and received no active treatment. Those who received no active treatment were offered MBSR during the next 8 weeks. Results: Statistically significant improvements were achieved in the primary end-point-the self-assessment for mental fatigue-and in the secondary end-point-neuropsychological tests; Digit Symbol-Coding and Trail Making Test. Conclusion: The results from the present study show that MBSR may be a promising non-pharmacological treatment for mental fatigue after a stroke or TBI.	[Johansson, B.; Bjuhr, H.; Ronnback, L.] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, SE-41345 Gothenburg, Sweden		Johansson, B (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, Dubbsgatan 14,1Tr, SE-41345 Gothenburg, Sweden.	birgitta.johansson2@vgregion.se		, Birgitta/0000-0003-0240-1142	AFA Insurance; Health & Medical Care Committee of the Region Vastra Gotaland	The authors report no conflicts of interest. This work was supported by grants from AFA Insurance and The Health & Medical Care Committee of the Region Vastra Gotaland.	Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Bedard M, 2003, DISABIL REHABIL, V25, P722, DOI 10.1080/0963828031000090489; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Carlson LE, 2005, INT J BEHAV MED, V12, P278, DOI 10.1207/s15327558ijbm1204_9; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; Colle F., 2006, Annales de Readaptation et de Medecine Physique, V49, P361, DOI 10.1016/j.annrmp.2006.04.010; Cullen M., 2011, MINDFULNESS BASED IN, V2, P186, DOI [DOI 10.1007/S12671-011-0058-1, 10.1007/s12671-011-0058-1]; de Groot MH, 2003, ARCH PHYS MED REHAB, V84, P1714, DOI 10.1053/S0003-9993(03)00346-0; DeLuca J, 2005, ISS CLIN COGN NEUROP, P1; Ellis DC, 2001, DELIS KAPLAN EXECUTI; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Grossman P, 2004, J PSYCHOSOM RES, V57, P35, DOI 10.1016/S0022-3999(03)00573-7; Ingles JL, 1999, ARCH PHYS MED REHAB, V80, P173, DOI 10.1016/S0003-9993(99)90116-8; Johansson B, 2010, BRAIN INJURY, V24, P2, DOI 10.3109/02699050903452961; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Kabat  Zinn J, 2001, FULL FULL CATASTROPH; KABATZINN J, 1985, J BEHAV MED, V8, P163, DOI 10.1007/BF00845519; Kilpatrick LA, 2011, NEUROIMAGE, V56, P290, DOI 10.1016/j.neuroimage.2011.02.034; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; LINDQVIST G, 1993, ACTA PSYCHIAT SCAND, V88, P5, DOI 10.1111/j.1600-0447.1993.tb05611.x; Lundin A, 2007, THESIS STOCKHOLM U S; Lutz A, 2008, TRENDS COGN SCI, V12, P163, DOI 10.1016/j.tics.2008.01.005; Madison S., 2003, LASDIAGNOS; McMillan T, 2002, NEUROPSYCHOL REHABIL, V12, P117, DOI 10.1080/09602010143000202; Moore A, 2009, CONSCIOUS COGN, V18, P176, DOI 10.1016/j.concog.2008.12.008; Naess H, 2005, CEREBROVASC DIS, V20, P245, DOI 10.1159/000087706; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Reitan R, 1985, HALSTEAD REITAN NEUR; Rodholm M, 2001, ACTA NEUROL SCAND, V103, P379, DOI 10.1034/j.1600-0404.2001.103006379.x; Ronnback L, 2012, LONG LASTING MENTAL; Ronnback L, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-22; Schepers VP, 2006, ARCH PHYS MED REHAB, V87, P184, DOI 10.1016/j.apmr.2005.10.005; Smith BW, 2008, J ALTERN COMPLEM MED, V14, P251, DOI 10.1089/acm.2007.0641; Staub F, 2001, CEREBROVASC DIS, V12, P75, DOI 10.1159/000047685; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Sundstrom A, 2007, BRAIN INJURY, V21, P1049, DOI 10.1080/02699050701630367; SVANBORG P, 1994, ACTA PSYCHIAT SCAND, V89, P21, DOI 10.1111/j.1600-0447.1994.tb01480.x; Wechsler D., 2003, WECHSLER ADULT INTEL; Winward C, 2009, STROKE, V40, P757, DOI 10.1161/STROKEAHA.108.527101; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	43	84	91	1	80	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2012	26	13-14					1621	1628		10.3109/02699052.2012.700082			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	041RU	WOS:000311419700008	22794665				2022-02-06	
J	Tamashiro, TT; Dalgard, CL; Byrnes, KR				Tamashiro, Tami T.; Dalgard, Clifton Lee; Byrnes, Kimberly R.			Primary Microglia Isolation from Mixed Glial Cell Cultures of Neonatal Rat Brain Tissue	JOVE-JOURNAL OF VISUALIZED EXPERIMENTS			English	Article						Immunology; Issue 66; Neuroscience; Physiology; Molecular Biology; Cell Culture; isolation; microglia; mixed glial cell; traumatic brain injury; neurodegenerative disease	ACTIVATION; GLUTAMATE; INFLAMMATION; MECHANISMS	Microglia account for approximately 12% of the total cellular population in the mammalian brain. While neurons and astrocytes are considered the major cell types of the nervous system, microglia play a significant role in normal brain physiology by monitoring tissue for debris and pathogens and maintaining homeostasis in the parenchyma via phagocytic activity 1,2. Microglia are activated during a number of injury and disease conditions, including neurodegenerative disease, traumatic brain injury, and nervous system infection (3). Under these activating conditions, microglia increase their phagocytic activity, undergo morpohological and proliferative change, and actively secrete reactive oxygen and nitrogen species, pro-inflammatory chemokines and cytokines, often activating a paracrine or autocrine loop (4-6). As these microglial responses contribute to disease pathogenesis in neurological conditions, research focused on microglia is warranted. Due to the cellular heterogeneity of the brain, it is technically difficult to obtain sufficient microglial sample material with high purity during in vivo experiments. Current research on the neuroprotective and neurotoxic functions of microglia require a routine technical method to consistently generate pure and healthy microglia with sufficient yield for study. We present, in text and video, a protocol to isolate pure primary microglia from mixed glia cultures for a variety of downstream applications. Briefly, this technique utilizes dissociated brain tissue from neonatal rat pups to produce mixed glial cell cultures. After the mixed glial cultures reach confluency, primary microglia are mechanically isolated from the culture by a brief duration of shaking. The microglia are then plated at high purity for experimental study. The principle and protocol of this methodology have been described in the literature (7,8). Additionally, alternate methodologies to isolate primary microglia are well described (9-12). Homogenized brain tissue may be separated by density gradient centrifugation to yield primary microglia (12). However, the centrifugation is of moderate length (45 min) and may cause cellular damage and activation, as well as, cause enriched microglia and other cellular populations. Another protocol has been utilized to isolate primary microglia in a variety of organisms by prolonged (16 hr) shaking while in culture (9-11). After shaking, the media supernatant is centrifuged to isolate microglia. This longer two-step isolation method may also perturb microglial function and activation. We chiefly utilize the following microglia isolation protocol in our laboratory for a number of reasons: (1) primary microglia simulate in vivo biology more faithfully than immortalized rodent microglia cell lines, (2) nominal mechanical disruption minimizes potential cellular dysfunction or activation, and (3) sufficient yield can be obtained without passage of the mixed glial cell cultures. It is important to note that this protocol uses brain tissue from neonatal rat pups to isolate microglia and that using older rats to isolate microglia can significantly impact the yield, activation status, and functional properties of isolated microglia. There is evidence that aging is linked with microglia dysfunction, increased neuroinflammation and neurodegenerative pathologies, so previous studies have used ex vivo adult microglia to better understand the role of microglia in neurodegenerative diseases where aging is important parameter. However, ex vivo microglia cannot be kept in culture for prolonged periods of time. Therefore, while this protocol extends the life of primary microglia in culture, it should be noted that the microglia behave differently from adult microglia and in vitro studies should be carefully considered when translated to an in vivo setting.	[Tamashiro, Tami T.; Dalgard, Clifton Lee] Uniformed Serv Univ Hlth Sci, Neurosci Program, Bethesda, MD USA; [Dalgard, Clifton Lee; Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD USA; [Dalgard, Clifton Lee] Uniformed Serv Univ Hlth Sci, Bethesda, MD USA		Byrnes, KR (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD USA.	kimberly.byrnes@usuhs.mil		Dalgard, Clifton/0000-0003-2025-8239; Byrnes, Kimberly/0000-0002-7501-7734	intramural program at the Uniformed Services University	Funded by the intramural program at the Uniformed Services University.	Barger SW, 2001, J NEUROCHEM, V76, P846, DOI 10.1046/j.1471-4159.2001.00075.x; Block ML, 2007, BIOCHEM SOC T, V35, P1127, DOI 10.1042/BST0351127; Byrnes KR, 2009, GLIA, V57, P550, DOI 10.1002/glia.20783; Frank MG, 2006, J NEUROSCI METH, V151, P121, DOI 10.1016/j.jneumeth.2005.06.026; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; HASSAN NF, 1991, CLIN IMMUNOL IMMUNOP, V59, P426, DOI 10.1016/0090-1229(91)90038-C; HASSAN NF, 1991, J LEUKOCYTE BIOL, V50, P86, DOI 10.1002/jlb.50.1.86; HASSAN NF, 1991, NEUROSCIENCE, V41, P149, DOI 10.1016/0306-4522(91)90205-3; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Loane DJ, 2009, J BIOL CHEM, V284, P15629, DOI 10.1074/jbc.M806139200; Ni Mingwei, 2010, Curr Protoc Toxicol, VChapter 12, DOI 10.1002/0471140856.tx1217s43; Pocock J M, 2001, Prog Brain Res, V132, P555; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528	14	84	86	1	18	JOURNAL OF VISUALIZED EXPERIMENTS	CAMBRIDGE	1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA	1940-087X			JOVE-J VIS EXP	J. Vis. Exp.	AUG	2012		66							e3814	10.3791/3814			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V36QC	WOS:000209225000009	22929966	Green Published			2022-02-06	
J	De Bonis, P; Frassanito, P; Mangiola, A; Nucci, CG; Anile, C; Pompucci, A				De Bonis, Pasquale; Frassanito, Paolo; Mangiola, Annunziato; Nucci, Carlotta Ginevra; Anile, Carmelo; Pompucci, Angelo			Cranial Repair: How Complicated Is Filling a "Hole''?	JOURNAL OF NEUROTRAUMA			English	Article						autologous bone flap; cranial repair; cranioplasty; custom-made skull prosthesis; decompressive craniectomy	TRAUMATIC BRAIN-INJURY; SINKING SKIN FLAP; DECOMPRESSIVE CRANIECTOMY; DELAYED CRANIOPLASTY; GRAFT INFECTION; BONE-GRAFTS; BLOOD-FLOW; PRESERVATION; DEFECTS; FROZEN	In general, cranioplasty is viewed as a straightforward surgical procedure, and for many years the complications associated with the procedure have been underestimated. We reviewed our 5-year experience consisting of 218 cranioplasties. Study outcomes focused specifically on the occurrence of complications after cranioplasty. Autologous bone-assisted and prosthetic cranioplasties were considered. Variables described by other authors to be associated with complications were studied, including history of previous cranioplasty, wider craniectomy size, bifrontal craniectomy, and delayed cranioplasty. We also analyzed the influence of material used for craniectomy on the occurrence of complications. The overall complication rate was 19.7%. Nineteen cases of infection (8.7%), 5 cases of postoperative wound dehiscence (2.3%), 6 cases of epidural hemorrhage (2.8%), and 13 cases of cranioplasty dislocation (5.9%) were observed. Bifrontal cranioplasties were more frequently associated with complications (p = 0.01; Fisher's exact test) and infection (p < 0.0001; Fisher's exact test). Postoperative wound dehiscence was more frequently observed with hand-made or custom-made cranioplasties compared with autologous cranioplasties (p = 0.02). Early cranioplasty (< 3 months from craniectomy) was significantly associated with cranioplasty dislocation (p = 0.03). Logistical regression analysis showed that the only factor independently associated with complication was the site of cranioplasty (p = 0.01). In particular, patients with a bifrontal cranioplasty had a 2-fold increased risk of complication (CI 95 1.1-3.6, p = 0.017) and a 2.5-fold increased risk of developing infection (CI 95 1.3-4.9, p = 0.009) compared with hemispheric/bihemispheric cranioplasty. Our analysis confirms that cranioplasty is burdened by a significant complication rate. In this context, bifrontal cranioplasty is related to a higher risk of complication and, in particular, infection.	[De Bonis, Pasquale; Frassanito, Paolo; Mangiola, Annunziato; Nucci, Carlotta Ginevra; Anile, Carmelo; Pompucci, Angelo] Catholic Univ, Sch Med, Inst Neurosurg, I-00168 Rome, Italy		Frassanito, P (corresponding author), Catholic Univ, Sch Med, Inst Neurosurg, Largo Agostino Gemelli 8, I-00168 Rome, Italy.	paolo.frassanito@gmail.com	de bonis, pasquale/K-8200-2016; Nucci, Carlotta Ginevra/AAE-4748-2019; FRASSANITO, Paolo/K-4099-2018	de bonis, pasquale/0000-0002-9879-8940; FRASSANITO, Paolo/0000-0003-0071-3126; Nucci, Carlotta Ginevra/0000-0002-9016-7503	Codman; Synthes	Pasquale De Bonis received grants from Codman and from Synthes in 2010.	AZIZ T Z, 1990, British Journal of Neurosurgery, V4, P417, DOI 10.3109/02688699008992764; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022; De Bonis P, 2011, J NEUROTRAUM, V28, P2043, DOI 10.1089/neu.2011.1889; De Bonis P, 2010, J NEUROTRAUM, V27, P1965, DOI 10.1089/neu.2010.1425; Ducic J, 2002, J ORAL MAXIL SURG, V60, P272, DOI 10.1053/joms.2002.30575; Dujovny M, 1997, SURG NEUROL, V47, P238, DOI 10.1016/S0090-3019(96)00013-4; Dujovny M, 1999, CRIT REV NEUROSURG, V9, P271, DOI 10.1007/s003290050143; Flannery T, 2001, BRIT J NEUROSURG, V15, P518, DOI 10.1080/02688690120097732; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grossman N., 2007, Cell and Tissue Banking, V8, P243, DOI 10.1007/s10561-006-9032-x; Horaczek JA, 2008, NEUROSURGERY, V63, P176, DOI 10.1227/01.NEU.0000312707.25073.CB; Isago T, 2004, ANN PLAS SURG, V53, P288, DOI 10.1097/01.sap.0000106433.89983.72; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Kuo JR, 2004, J CLIN NEUROSCI, V11, P486, DOI 10.1016/j.jocn.2003.06.005; Lee CH, 2007, CLIN NEUROL NEUROSUR, V109, P667, DOI 10.1016/j.clineuro.2007.05.015; Lee SC, 2009, J CLIN NEUROSCI, V16, P56, DOI 10.1016/j.jocn.2008.04.001; Li G, 2008, BRAIN INJURY, V22, P333, DOI 10.1080/02699050801958353; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; Movassaghi K, 2006, PLAST RECONSTR SURG, V117, P202, DOI 10.1097/01.prs.0000187152.48402.17; Neovius E, 2010, J PLAST RECONSTR AES, V63, P1615, DOI 10.1016/j.bjps.2009.06.003; Nievas MNCY, 2006, NEUROL RES, V28, P139, DOI 10.1179/016164106X98008; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; POSNICK JC, 1993, NEUROSURGERY, V32, P785, DOI 10.1227/00006123-199305000-00011; PROLO DJ, 1979, NEUROSURGERY, V4, P18, DOI 10.1227/00006123-197901000-00005; RISH BL, 1979, NEUROSURGERY, V4, P381, DOI 10.1227/00006123-197905000-00002; Sakamoto S, 2006, CLIN NEUROL NEUROSUR, V108, P583, DOI 10.1016/j.clineuro.2005.03.012; Sobani Zain A, 2011, Surg Neurol Int, V2, P123, DOI 10.4103/2152-7806.85055; Wen L, 2007, J CRANIOFAC SURG, V18, P526, DOI 10.1097/scs.0b013e3180534348; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470	34	84	84	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1071	1076		10.1089/neu.2011.2116			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100005	22059899				2022-02-06	
J	Berger, TW; Song, D; Chan, RHM; Marmarelis, VZ; LaCoss, J; Wills, J; Hampson, RE; Deadwyler, SA; Granacki, JJ				Berger, Theodore W.; Song, Dong; Chan, Rosa H. M.; Marmarelis, Vasilis Z.; LaCoss, Jeff; Wills, Jack; Hampson, Robert E.; Deadwyler, Sam A.; Granacki, John J.			A Hippocampal Cognitive Prosthesis: Multi-Input, Multi-Output Nonlinear Modeling and VLSI Implementation	IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING			English	Article						Hippocampus; multi-input/multi-output (MIMO) nonlinear model; neural prosthesis; spatio-temporal coding	TRAUMATIC BRAIN-INJURY; IDENTIFICATION; EXCITATION; AFFERENTS; SYSTEMS; MEMORY	This paper describes the development of a cognitive prosthesis designed to restore the ability to form new long-term memories typically lost after damage to the hippocampus. The animal model used is delayed nonmatch-to-sample (DNMS) behavior in the rat, and the "core" of the prosthesis is a biomimetic multi-input/multi-output (MIMO) nonlinear model that provides the capability for predicting spatio-temporal spike train output of hippocampus (CA1) based on spatio-temporal spike train inputs recorded presynaptically to CA1 (e.g., CA3). We demonstrate the capability of the MIMO model for highly accurate predictions of CA1 coded memories that can be made on a single-trial basis and in real-time. When hippocampal CA1 function is blocked and long-term memory formation is lost, successful DNMS behavior also is abolished. However, when MIMO model predictions are used to reinstate CA1 memory-related activity by driving spatio-temporal electrical stimulation of hippocampal output to mimic the patterns of activity observed in control conditions, successful DNMS behavior is restored. We also outline the design in very-large-scale integration for a hardware implementation of a 16-input, 16-output MIMO model, along with spike sorting, amplification, and other functions necessary for a total system, when coupled together with electrode arrays to record extracellularly from populations of hippocampal neurons, that can serve as a cognitive prosthesis in behaving animals.	[Berger, Theodore W.; Song, Dong; Chan, Rosa H. M.; Marmarelis, Vasilis Z.] Univ So Calif, Dept Biomed Engn, Ctr Neural Engn, Viterbi Sch Engn, Los Angeles, CA 90089 USA; [Marmarelis, Vasilis Z.] Univ So Calif, Dept Elect Engn, Ctr Neural Engn, Viterbi Sch Engn, Los Angeles, CA 90089 USA; [Hampson, Robert E.; Deadwyler, Sam A.] Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA; [LaCoss, Jeff; Wills, Jack; Granacki, John J.] Univ So Calif, Informat Sci Inst ISI, Viterbi Sch Engn, Los Angeles, CA 90089 USA; [Granacki, John J.] Univ So Calif, Viterbi Sch Engn, Dept Elect Engn & Biomed Engn, Los Angeles, CA 90089 USA		Berger, TW (corresponding author), Univ So Calif, Dept Biomed Engn, Ctr Neural Engn, Viterbi Sch Engn, Los Angeles, CA 90089 USA.	berger@bmsr.usc.edu; dsong@usc.edu; homchan@usc.edu; vzm@bmsrs.usc.edu; jlacoss@isi.edu; jackw@isi.edu; rhampson@wfubmc.edu; sdeadwyl@wfubmc.edu; granacki@usc.edu	Chan, Rosa/B-6662-2008; Song, Dong/A-8314-2010	Hampson, Robert/0000-0002-8648-9462; CHAN, Rosa/0000-0003-4808-2490; Song, Dong/0000-0002-6179-1120	Defense Advanced research Projects Agency (DARPA)United States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [N66601-09-C-2080, N66601-09-C-2081]; NSFNational Science Foundation (NSF) [EEC-0310723]; NIH/NIBIBUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41-EB001978]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01DA07625]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB001978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA007625] Funding Source: NIH RePORTER	Manuscript received May 22, 2011; revised December 08, 2011; accepted February 21, 2012. Date of current version March 16, 2012. This work was supported in part by Defense Advanced research Projects Agency (DARPA) contracts to S. A. Deadwyler N66601-09-C-2080 and to T. W. Berger N66601-09-C-2081 (Prog. Dir: COL G. Ling), and grants NSF EEC-0310723 to USC (T. W. Berger), NIH/NIBIB Grant P41-EB001978 to the Biomedical Simulations Resource at USC (to V. Z. Marmarelis and NIH R01DA07625 (to S. A. Deadwyler).	Berger T. W., 2007, NEURONANOTECHNOLOGY, P309; Berger T.W., 2005, REPLACEMENT PARTS BR; Berger TW, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046017; Berger TW, 2010, P IEEE, V98, P356, DOI 10.1109/JPROC.2009.2038804; Berger TW, 2001, P IEEE, V89, P993, DOI 10.1109/5.939806; BERGER TW, 1983, BEHAV BRAIN RES, V8, P49, DOI 10.1016/0166-4328(83)90171-7; Berger TW, 2005, IEEE ENG MED BIOL, V24, P30, DOI 10.1109/MEMB.2005.1511498; Berger TW, 2008, BRAIN COMPUTER INTER; Brown EN, 2002, NEURAL COMPUT, V14, P325, DOI 10.1162/08997660252741149; Carey ME, 1996, J TRAUMA, V40, pS165, DOI 10.1097/00005373-199603001-00036; Chiu-Hsien Chan, 2006, 2006 IEEE Biomedical Circuits and Systems Conference - Healthcare Technology (BioCas), P214, DOI 10.1109/BIOCAS.2006.4600346; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Deadwyler SA, 2007, BEHAV PHARMACOL, V18, P571, DOI 10.1097/FBP.0b013e3282ee2adb; EICHENBAUM H, 1988, BEHAV NEUROSCI, V102, P331, DOI 10.1037/0735-7044.102.3.331; Fang X, 2009, MIDWEST SYMP CIRCUIT, P180, DOI 10.1109/MWSCAS.2009.5236122; Fang X, 2008, MIDWEST SYMP CIRCUIT, P826, DOI 10.1109/MWSCAS.2008.4616927; Hampson R. E., 2012, IEEE T NEURAL SYST R, V20; Hsiao MC, 2008, IEEE ENG MED BIO, P5535, DOI 10.1109/IEMBS.2008.4650468; Kelper A., 2006, NEW ATLANTIS; Marmarelis VZ, 2005, MATH BIOSCI, V196, P1, DOI 10.1016/j.mbs.2005.04.002; MARMARELIS VZ, 1993, ANN BIOMED ENG, V21, P573, DOI 10.1007/BF02368639; McCullagh P., 1989, GEN LINEAR MODELS 2, V2; Milner B., 1970, MEMORY MEDIAL TEMPOR, P29; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Song D., 2009, STAT SIGNAL PROCESSI; Song D, 2007, IEEE T BIO-MED ENG, V54, P1053, DOI 10.1109/TBME.2007.891948; Song D, 2009, IEEE ENG MED BIO, P4555, DOI 10.1109/IEMBS.2009.5332719; Song Dong, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P6129; Song D, 2009, NEURAL NETWORKS, V22, P1340, DOI 10.1016/j.neunet.2009.05.004; Song D, 2009, J COMPUT NEUROSCI, V26, P1, DOI 10.1007/s10827-008-0097-3; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Truccolo W, 2005, J NEUROPHYSIOL, V93, P1074, DOI 10.1152/jn.00697.2004; YECKEL MF, 1995, HIPPOCAMPUS, V5, P108, DOI 10.1002/hipo.450050204; YECKEL MF, 1990, P NATL ACAD SCI USA, V87, P5832, DOI 10.1073/pnas.87.15.5832	34	84	84	1	31	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1534-4320	1558-0210		IEEE T NEUR SYS REH	IEEE Trans. Neural Syst. Rehabil. Eng.	MAR	2012	20	2					198	211		10.1109/TNSRE.2012.2189133			14	Engineering, Biomedical; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Rehabilitation	917MU	WOS:000302182500009	22438335	Green Accepted			2022-02-06	
J	Dalgard, CL; Cole, JT; Kean, WS; Lucky, JJ; Sukumar, G; McMullen, DC; Pollard, HB; Watson, WD				Dalgard, Clifton L.; Cole, Jeffrey T.; Kean, William S.; Lucky, Jessica J.; Sukumar, Gauthaman; McMullen, David C.; Pollard, Harvey B.; Watson, William D.			The cytokine temporal profile in rat cortex after controlled cortical impact	FRONTIERS IN MOLECULAR NEUROSCIENCE			English	Article						traumatic brain injury; cytokines; inflammation; IL-8; inflammatory response	TRAUMATIC BRAIN-INJURY; MACROPHAGE INFLAMMATORY PROTEIN-3-ALPHA/CCL20; MONOCYTE CHEMOATTRACTANT PROTEIN-1; TUMOR-NECROSIS-FACTOR; CLOSED-HEAD INJURY; INTERFERON-GAMMA; UP-REGULATION; NITRIC-OXIDE; METABOLISM; INTERLEUKIN-1-BETA	Cerebral inflammatory responses may initiate secondary cascades following traumatic brain injury (TBI). Changes in the expression of both cytokines and chemokines may activate, regulate, and recruit innate and adaptive immune cells associated with secondary degeneration, as well as alter a host of other cellular processes. In this study, we quantified the temporal expression of a large set of inflammatory mediators in rat cortical tissue after brain injury. Following a controlled cortical impact (CCI) on young adult male rats, cortical and hippocampal tissue of the injured hemisphere and matching contralateral material was harvested at early (4, 12, and 24 hours) and extended (3 and 7 days) time points post-procedure. Naive rats that received only anesthesia were used as controls. Processed brain homogenates were assayed for chemokine and cytokine levels utilizing an electrochemiluminescence-based multiplex ELISA platform. The temporal profile of cortical tissue samples revealed a multi phasic injury response following brain injury. CXCL1, IFN-y, TNF-cc levels significantly peaked at four hours post-injury compared to levels found in naive or contralateral tissue. CXCL1, IFN-y, and INF-ct levels were then observed to decrease at least 3-fold by 12 hours post-injury. IL-4, and IL-13 levels were also significantly elevated at four hours post injury although their expression did not decrease more than 3-fold for up to 24 hours post injury. Additionally, IL -1 and IL -4 levels displayed a biphasic temporal profile in response to injury, which may suggest their involvement in adaptive immune responses. Interestingly, peak levels of CCL2 and CCL20 were not observed until after four hours post-injury. CCL2 levels in injured cortical tissue were significantly higher than peak levels of any other inflammatory mediator measured, thus suggesting a possible use as a biomarker. Fully elucidating chemokine and cytokine signaling properties after brain injury may provide increased insight into a number of secondary cascade events that are initiated or regulated by inflammatory responses.	[Dalgard, Clifton L.; Sukumar, Gauthaman; Pollard, Harvey B.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Cole, Jeffrey T.; Kean, William S.; Lucky, Jessica J.; McMullen, David C.; Watson, William D.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA		Cole, JT (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Neurol, B-3012,4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	jeffrey.cole@usuhs.mil	Sukumar, Gauthaman/A-1697-2018	Sukumar, Gauthaman/0000-0003-3129-4171; Dalgard, Clifton/0000-0003-2025-8239	Comprehensive National Neuroscience Program (CNNP) [W81XWH-07-0679]	This work was supported in part by the Comprehensive National Neuroscience Program (CNNP, award number W81XWH-07-0679).	Adeleye A, 2010, EUR J PHARMACOL, V629, P25, DOI 10.1016/j.ejphar.2009.11.066; Alves OL, 2005, J NEUROTRAUM, V22, P733, DOI 10.1089/neu.2005.22.733; Ambrosini E, 2003, GLIA, V41, P290, DOI 10.1002/glia.10193; Arcure Jess, 2009, J Spec Oper Med, V9, P22; Bartnik BL, 2007, J NEUROTRAUM, V24, P1079, DOI 10.1089/neu.2006.0210; Bogdan C, 1997, J IMMUNOL, V159, P4506; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chowdhury F, 2009, J IMMUNOL METHODS, V340, P55, DOI 10.1016/j.jim.2008.10.002; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Cole JT, 2010, P NATL ACAD SCI USA, V107, P366, DOI 10.1073/pnas.0910280107; Deshpande LS, 2008, NEUROSCI LETT, V441, P115, DOI 10.1016/j.neulet.2008.05.113; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Finkelstein E., 2006, INCIDENCE EC BURDEN; Fu Q, 2010, CLIN CHEM, V56, P314, DOI 10.1373/clinchem.2009.135087; Faria MHG, 2007, ACTA CIR BRAS, V22, P125, DOI 10.1590/S0102-86502007000200009; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Helmy A, 2009, J NEUROTRAUM, V26, P549, DOI 10.1089/neu.2008.0719; Hulshof S, 2002, GLIA, V38, P24, DOI 10.1002/glia.10050; Karaoglan A, 2011, ULUS TRAVMA ACIL CER, V17, P298, DOI 10.5505/tjtes.2011.69077; Kawanokuchi J, 2006, MULT SCLER J, V12, P558, DOI 10.1177/1352458506070763; KIM KS, 1992, LYMPHOKINE CYTOK RES, V11, P293; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Krzysiek R, 2000, BLOOD, V96, P2338, DOI 10.1182/blood.V96.7.2338.h8002338_2338_2345; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Muessel MJ, 2000, BRAIN RES, V870, P211, DOI 10.1016/S0006-8993(00)02450-1; Mukherjee S, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00021; Paludan SR, 1997, FEBS LETT, V414, P61, DOI 10.1016/S0014-5793(97)00987-3; Ponomarev ED, 2007, J NEUROSCI, V27, P10714, DOI 10.1523/JNEUROSCI.1922-07.2007; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.3.CO;2-G; Rostworowski M, 1997, J NEUROSCI, V17, P3664; Scafidi S, 2009, J NEUROCHEM, V109, P189, DOI 10.1111/j.1471-4159.2009.05896.x; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Suzuki Y, 2005, INT J PARASITOL, V35, P83, DOI 10.1016/j.ijpara.2004.10.020; Takamiya M, 2007, J NEUROTRAUM, V24, P1833, DOI 10.1089/neu.2007.0336; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Wei HH, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-19; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Xiao-Sheng H, 2004, J CLIN NEUROSCI, V11, P402, DOI 10.1016/j.jocn.2004.01.001; Xing GQ, 2009, NEUROSCI LETT, V454, P38, DOI 10.1016/j.neulet.2009.01.047; Xiong Y, 2009, NEUROL RES, V31, P496, DOI 10.1179/174313208X353703; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zhao WH, 2006, J NEUROCHEM, V99, P1176, DOI 10.1111/j.1471-4159.2006.04172.x; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	49	84	87	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5099			FRONT MOL NEUROSCI	Front. Molec. Neurosci.		2012	5								6	10.3389/fnmol.2012.00006			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V36HD	WOS:000209202600006	22291617	Green Published, gold			2022-02-06	
J	Labib, N; Nouh, T; Winocour, S; Deckelbaum, D; Banici, L; Fata, P; Razek, T; Khwaja, K				Labib, Noura; Nouh, Thamer; Winocour, Sebastian; Deckelbaum, Dan; Banici, Laura; Fata, Paola; Razek, Tarek; Khwaja, Kosar			Severely Injured Geriatric Population: Morbidity, Mortality, and Risk Factors	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Elderly; Trauma; Geriatric; ISS; GCS; Complication; Morbidity; MVC; Intensive care; Fall; Traumatic brain injury; Outcomes; Mortality	ELDERLY TRAUMA PATIENTS; JUSTIFY AGGRESSIVE MANAGEMENT; HOST FACTORS; SEVERITY; OLDER; CARE; AGE; POLYTRAUMA; SURVIVAL; DEATH	Background: With an increasing life expectancy and more active elderly population, management of geriatric trauma patients continues to evolve. The aim was to describe the mechanism and injuries of severely injured geriatric patients and to identify risk factors associated with mortality. Methods: The Trauma Registry at a Canadian Level I trauma center was queried for all trauma patients older than 65 years and injury severity score >15 from 2004 to 2006, resulting in a retrospective chart review of 276 patients. The data were subsequently analyzed using univariate and multivariate analysis. Results: Average age was 81.5 years (mean injury severity score of 25). Most common comorbid illness was hypertension (57.3%) and most frequent mechanism of injury was falls (72.3%). The overall mortality was comparable with the US National Trauma Data Bank (26.8% vs. 32.0%, confidence interval, 0.00-0.10). Geriatric patients requiring intubation, blood transfusions, or suffering from head, C-spine, or chest trauma had an increased likelihood of death. In-hospital respiratory, gastrointestinal, or infectious complications also had higher likelihood of death. Conclusions: Falls continue to be the most frequent mechanism of injury in severely injured geriatric patients. Risk factors associated with a higher likelihood of death are identified. More research is needed to better understand this important and increasing group of trauma patients.	[Winocour, Sebastian; Deckelbaum, Dan; Banici, Laura; Khwaja, Kosar] McGill Univ, Ctr Hlth, Dept Surg, Montreal, PQ H3G 1A4, Canada; [Labib, Noura] McMaster Univ, Dept Emergency Med, Hamilton, ON, Canada		Khwaja, K (corresponding author), McGill Univ, Ctr Hlth, Dept Surg, 1650 Cedar Ave,L9-411, Montreal, PQ H3G 1A4, Canada.	kosar.khwaja@mcgill.ca	Nouh, Thamer/G-2655-2010	Nouh, Thamer/0000-0002-7118-7453			Aldrian S, 2005, WIEN KLIN WOCHENSCHR, V117, P145, DOI 10.1007/s00508-004-0290-y; [Anonymous], 2006, 2006 CENSUS PORTRAIT; Battistella FD, 1998, J TRAUMA, V44, P618, DOI 10.1097/00005373-199804000-00010; BROOS PLO, 1993, INJURY, V24, P365, DOI 10.1016/0020-1383(93)90096-O; Centers for Disease Control, 1999, CTR DIS CONTR 3 LEAD; CHAMPION HR, 1989, AM J PUBLIC HEALTH, V79, P1278, DOI 10.2105/AJPH.79.9.1278; DEMARIA EJ, 1987, ANN SURG, V206, P738, DOI 10.1097/00000658-198712000-00009; Gubler KD, 1997, ARCH SURG-CHICAGO, V132, P1010; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; KNUDSON MM, 1994, ARCH SURG-CHICAGO, V129, P448; Kuhne CA, 2005, WORLD J SURG, V29, P1476, DOI 10.1007/s00268-005-7796-y; LONNER JH, 1995, CLIN ORTHOP RELAT R, P136; Miller R, 1998, J TRAUMA, V44, P623; MILZMAN DP, 1992, J TRAUMA, V32, P236, DOI 10.1097/00005373-199202000-00021; Milzman DP, 1992, J TRAUMA, V32, P243; MORRIS JA, 1990, JAMA-J AM MED ASSOC, V263, P1942, DOI 10.1001/jama.263.14.1942; MORRIS JA, 1990, J TRAUMA, V30, P1476, DOI 10.1097/00005373-199012000-00006; OSLER T, 1988, AM J SURG, V156, P537, DOI 10.1016/S0002-9610(88)80548-8; PELLICANE JV, 1992, J TRAUMA, V33, P440, DOI 10.1097/00005373-199209000-00018; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; SHABOT MM, 1995, J TRAUMA, V39, P254, DOI 10.1097/00005373-199508000-00011; Shabot MM, 1995, J TRAUMA, V39, P259; Taylor MD, 2002, J TRAUMA, V53, P407, DOI 10.1097/00005373-200209000-00001; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Tornetta P, 1999, J TRAUMA, V46, P702, DOI 10.1097/00005373-199904000-00024; van der Sluis CK, 1997, INJURY, V28, P588, DOI 10.1016/S0020-1383(97)00094-6; Weigelt JA, 1997, TRAUMA ADV TRAUMA LI, P26; ZIETLOW SP, 1994, J TRAUMA, V37, P985, DOI 10.1097/00005373-199412000-00020	28	84	85	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2011	71	6					1908	1914		10.1097/TA.0b013e31820989ed			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	869RT	WOS:000298616400081	21537212				2022-02-06	
J	Erickson, JC				Erickson, Jay C.			Treatment Outcomes of Chronic Post-Traumatic Headaches After Mild Head Trauma in US Soldiers: An Observational Study	HEADACHE			English	Article						post-traumatic headache; concussion; mild head trauma; blast; migraine; triptan	BRAIN-INJURY; CHRONIC MIGRAINE; SUBCUTANEOUS SUMATRIPTAN; CONTROLLED-TRIALS; STRESS-DISORDER; DOUBLE-BLIND; TOPIRAMATE; GUIDELINES; SLEEP; PTSD	Background.- The effectiveness of medical therapies for chronic post-traumatic headaches (PTHs) attributable to mild head trauma in military troops has not been established. Objective.- To determine the treatment outcomes of acute and prophylactic medical therapies prescribed for chronic PTHs after mild head trauma in US Army soldiers. Methods.- A retrospective cohort study was conducted with 100 soldiers undergoing treatment for chronic PTH at a single US Army neurology clinic. Headache frequency and Migraine Disability Assessment (MIDAS) scores were determined at the initial clinic visit and then again by phone 3 months after starting headache prophylactic medication. Response rates of headache abortive medications were also determined. Treatment outcomes were compared between subjects with blast-related PTH and non-blast PTH. Results.- Ninety-nine of 100 subjects were male. Seventy-seven of 100 subjects had blast PTH and 23/100 subjects had non-blast PTH. Headache characteristics were similar for blast PTH and non-blast PTH with 96% and 95%, respectively, resembling migraine. Headache frequency among all PTH subjects decreased from 17.1 days/month at baseline to 14.5 days/month at follow-up (P = .009). Headache frequency decreased by 41% among non-blast PTH compared to 9% among blast PTH. Fifty-seven percent of non-blast PTH subjects had a 50% or greater decline in headache frequency compared to 29% of blast PTH subjects (P = .023). A significant decline in headache frequency occurred in subjects treated with topiramate (n = 29, -23%, P = .02) but not among those treated with a low-dose tricyclic antidepressant (n = 48, -12%, P = .23). Seventy percent of PTH subjects who used a triptan class medication experienced reliable headache relief within 2 hours compared to 42% of subjects using other headache abortive medications (P = .01). Triptan medications were effective for both blast PTH and non-blast PTH (66% response rate vs 86% response rate, respectively; P = .20). Headache-related disability, as measured by mean MIDAS scores, declined by 57% among all PTH subjects with no significant difference between blast PTH (-56%) and non-blast PTH (-61%). Conclusions.- Triptan class medications are usually effective for aborting headaches in military troops with chronic PTH attributed to a concussion from a blast injury or non-blast injury. Topiramate appears to be an effective headache prophylactic therapy in military troops with chronic PTH, whereas low doses of tricyclic antidepressants appear to have little efficacy. Chronic PTH triggered by a blast injury may be less responsive to commonly prescribed headache prophylactic medications compared to non-blast PTH. These conclusions require validation by prospective, controlled clinical trials.	[Erickson, Jay C.] Madigan Army Med Ctr, Neurol Serv, Tacoma, WA 98466 USA		Erickson, JC (corresponding author), Madigan Army Med Ctr, Neurol Serv, Tacoma, WA 98466 USA.	jay.erickson@us.army.mil			Uniformed Services University of Health Sciences, Bethesda, MD, USA	This study was supported by the Comprehensive National Neuroscience Program at the Uniformed Services University of Health Sciences, Bethesda, MD, USA. The author thanks Renee Mercer for her efforts in collecting the data.	Afari N, 2009, HEADACHE, V49, P1267, DOI 10.1111/j.1526-4610.2009.01517.x; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brennan KC, 2009, SEMIN NEUROL, V29, P406, DOI 10.1055/s-0029-1237113; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; COUCH JR, 1979, ARCH NEUROL-CHICAGO, V36, P695, DOI 10.1001/archneur.1979.00500470065013; Department ofVeterans Affairs/DepartmentofDefense (VA/ DoD), 2009, CLIN PRACT GUID MAN; Diener HC, 2007, CEPHALALGIA, V27, P814, DOI 10.1111/j.1468-2982.2007.01326.x; Diener HC, 2009, CEPHALALGIA, V29, P1021, DOI 10.1111/j.1468-2982.2009.01859.x; Erickson JC, 2008, NEUROLOGY, V70, pA152; Evans RW, 2004, NEUROL CLIN, V22, P237, DOI 10.1016/S0733-8619(03)00097-5; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; GAWEL MJ, 1993, HEADACHE, V33, P96, DOI 10.1111/j.1526-4610.1993.hed3302096.x; Giza CC, 2001, J ATHL TRAINING, V36, P228; Goadsby PJ, 2009, NEUROL CLIN, V27, P335, DOI 10.1016/j.ncl.2008.11.012; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Krymchantowski AV, 2002, HEADACHE, V42, P510, DOI 10.1046/j.1526-4610.2002.02125.x; Lampl C, 2009, EUR J NEUROL, V16, P943, DOI 10.1111/j.1468-1331.2009.02631.x; Lenaerts Marc E, 2004, Curr Treat Options Neurol, V6, P507, DOI 10.1007/s11940-004-0008-5; Leung Lai Yee, 2008, Molecular & Cellular Biomechanics, V5, P155; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; PACKARD RC, 1993, HEADACHE, V33, P133, DOI 10.1111/j.1526-4610.1993.hed3303133.x; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; Packard RC, 2000, HEADACHE, V40, P736, DOI 10.1046/j.1526-4610.2000.00128.x; Peterlin BL, 2008, HEADACHE, V48, P517, DOI 10.1111/j.1526-4610.2008.00917.x; Peterlin BL, 2009, HEADACHE, V49, P541, DOI 10.1111/j.1526-4610.2009.01368.x; Rains JC, 2008, CURR NEUROL NEUROSCI, V8, P167, DOI 10.1007/s11910-008-0027-9; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; SHEFTELL FD, 1994, HEADACHE, V34, P67, DOI 10.1111/j.1526-4610.1994.hed3402067.x; Silberstein S, 2008, CEPHALALGIA, V28, P484, DOI 10.1111/j.1468-2982.2008.01555.x; Silberstein SD, 2000, NEUROLOGY, V55, P754, DOI 10.1212/WNL.55.6.754; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Silberstein SD, 2007, HEADACHE, V47, P170, DOI 10.1111/j.1526-4610.2006.00684.x; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Stewart WF, 2001, NEUROLOGY, V56, pS20, DOI 10.1212/WNL.56.suppl_1.S20; Stovner LJ, 2009, EUR J NEUROL, V16, P112, DOI 10.1111/j.1468-1331.2008.02363.x; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tfelt-Hansen P, 2000, CEPHALALGIA, V20, P765; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x	45	84	87	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	JUN	2011	51	6					932	944		10.1111/j.1526-4610.2011.01909.x			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	772GH	WOS:000291221800011	21592097				2022-02-06	
J	Gosseries, O; Schnakers, C; Ledoux, D; Vanhaudenhuyse, A; Bruno, MA; Demertzi, A; Noirhomme, Q; Lehembre, R; Damas, P; Goldman, S; Peeters, E; Moonen, G; Laureys, S				Gosseries, Olivia; Schnakers, Caroline; Ledoux, Didier; Vanhaudenhuyse, Audrey; Bruno, Marie-Aurelie; Demertzi, Athena; Noirhomme, Quentin; Lehembre, Remy; Damas, Pierre; Goldman, Serge; Peeters, Erika; Moonen, Gustave; Laureys, Steven			Automated EEG entropy measurements in coma, vegetative state/unresponsive wakefulness syndrome and minimally conscious state	FUNCTIONAL NEUROLOGY			English	Article						coma; EEG entropy; electroencephalography; minimally conscious state; unresponsive wakefulness syndrome; vegetative state	BISPECTRAL INDEX; SPECTRAL ENTROPY; ELECTROENCEPHALOGRAM; REHABILITATION; RECOVERY; SEVOFLURANE; ACCURACY; PROPOFOL	Monitoring the level of consciousness in brain-injured patients with disorders of consciousness is crucial as it provides diagnostic and prognostic information. Behavioral assessment remains the gold standard for assessing consciousness but previous studies have shown a high rate of misdiagnosis. This study aimed to investigate the usefulness of electroencephalography (EEG) entropy measurements in differentiating unconscious (coma or vegetative) from minimally conscious patients. Left fronto-temporal EEG recordings (10-minute resting state epochs) were prospectively obtained in 56 patients and 16 age-matched healthy volunteers. Patients were assessed in the acute (<= 1 month post-injury; n=29) or chronic (>1 month post-injury; n=27) stage. The etiology was traumatic in 23 patients. Automated online EEG entropy calculations (providing an arbitrary value ranging from 0 to 91) were compared with behavioral assessments (Coma Recovery Scale-Revised) and outcome. EEG entropy correlated with Coma Recovery Scale total scores (r=0.49). Mean EEG entropy values were higher in minimally conscious (73 +/- 19; mean and standard deviation) than in vegetative/unresponsive wakefulness syndrome patients (45 +/- 28). Receiver operating characteristic analysis revealed an entropy cut-off value of 52 differentiating acute unconscious from minimally conscious patients (sensitivity 89% and specificity 90%). In chronic patients, entropy measurements offered no reliable diagnostic information. EEG entropy measurements did not allow prediction of outcome. User-independent time-frequency balanced spectral EEG entropy measurements seem to constitute an interesting diagnostic - albeit not prognostic - tool for assessing neural network complexity in disorders of consciousness in the acute setting. Future studies are needed before using this tool in routine clinical practice, and these should seek to improve automated EEG quantification paradigms in order to reduce the remaining false negative and false positive findings.	[Gosseries, Olivia; Schnakers, Caroline; Ledoux, Didier; Vanhaudenhuyse, Audrey; Bruno, Marie-Aurelie; Demertzi, Athena; Noirhomme, Quentin; Lehembre, Remy; Laureys, Steven] Univ Liege, Cyclotron Res Ctr, Coma Sci Grp, B-4000 Liege, Belgium; [Gosseries, Olivia; Schnakers, Caroline; Vanhaudenhuyse, Audrey; Bruno, Marie-Aurelie; Noirhomme, Quentin; Lehembre, Remy; Moonen, Gustave; Laureys, Steven] Sart Tilman Univ, Ctr Hosp, Dept Neurol, Liege, Belgium; [Ledoux, Didier; Damas, Pierre] Sart Tilman Univ, Ctr Hosp, Dept Intens Care, Liege, Belgium; [Goldman, Serge] Univ Brussels, Erasme Hosp, Dept Nucl Med, Brussels, Belgium; [Peeters, Erika] Inkendaal Hosp, Rehabil Ctr, Vlezenbeek, Belgium		Laureys, S (corresponding author), Univ Liege, Cyclotron Res Ctr, Coma Sci Grp, Sart Tilman B30, B-4000 Liege, Belgium.	steven.laureys@ulg.ac.be	Vanhaudenhuyse, Audrey/AAP-2455-2020; Demertzi, Athena/I-1251-2019; Gosseries, Olivia/AAB-6469-2020; Ledoux, Didier/ABA-8401-2021; Laureys, Steven/AAN-2097-2021; Laureys, Steven/A-3349-2011	Demertzi, Athena/0000-0001-8021-3759; Gosseries, Olivia/0000-0001-9011-7496; Ledoux, Didier/0000-0002-9314-6564; Laureys, Steven/0000-0002-3096-3807; Noirhomme, Quentin/0000-0001-8247-4493; Goldman, Serge/0000-0002-9917-8735	Belgian National Funds for Scientific Research (FNRS)Fonds de la Recherche Scientifique - FNRS; European CommissionEuropean CommissionEuropean Commission Joint Research Centre; James McDonnell Foundation; Mind Science Foundation; French Speaking Community Concerted Research Action; Foundation Medicale Reine Elisabeth; University and University Hospital of Liege	This research was funded by the Belgian National Funds for Scientific Research (FNRS), the European Commission (COST, DISCOS, MINDBRIDGE, DECODER), the James McDonnell Foundation, the Mind Science Foundation, the French Speaking Community Concerted Research Action, the Foundation Medicale Reine Elisabeth and the University and University Hospital of Liege.	Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; *ASP MED SYST, 2000, BISP IND MON SYST OP; Bein B, 2006, BEST PRACT RES-CLIN, V20, P101, DOI 10.1016/j.bpa.2005.07.009; Brenner RP, 2005, NEUROLOGIST, V11, P271, DOI 10.1097/01.nrl.0000178756.44055.f6; Bruhn J, 2001, ANESTHESIOLOGY, V95, P30, DOI 10.1097/00000542-200107000-00010; Bruhn J, 2000, ANESTHESIOLOGY, V92, P715, DOI 10.1097/00000542-200003000-00016; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Choi YS, 2009, IEEE ENG MED BIO, P4715, DOI 10.1109/IEMBS.2009.5334199; Drummond JC, 2000, ANESTHESIOLOGY, V93, P876, DOI 10.1097/00000542-200009000-00039; Giacino JT, 2006, ARCH PHYS MED REHAB, V87, pS67, DOI 10.1016/j.apmr.2006.07.272; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gilbert TT, 2001, CRIT CARE MED, V29, P1996, DOI 10.1097/00003246-200110000-00024; Gill M, 2003, ACAD EMERG MED, V10, P175, DOI 10.1197/aemj.10.2.175; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; Hans P, 2005, BRIT J ANAESTH, V94, P336, DOI 10.1093/bja/aei047; Husain AM, 2006, J CLIN NEUROPHYSIOL, V23, P208, DOI 10.1097/01.wnp.0000220094.60482.b5; INOUYE T, 1991, ELECTROEN CLIN NEURO, V79, P204, DOI 10.1016/0013-4694(91)90138-T; Kulkarni VP, 2007, J CLIN NEUROPHYSIOL, V24, P433, DOI 10.1097/WNP.0b013e31815c2810; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Lin MA, 2005, P ANN INT IEEE EMBS, P4580, DOI 10.1109/IEMBS.2005.1615489; Luccichenti G, 2009, FUNCT NEUROL, V24, P189; Martorano PP, 2006, J NEUROSURG ANESTH, V18, P205, DOI 10.1097/01.ana.0000206229.38883.d2; Monti MM, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3765; Navarro X, 2009, INT REV NEUROBIOL, V87, P483, DOI 10.1016/S0074-7742(09)87027-X; PALANCE BJ, 2009, CURR OPIN ANESTHESIO, V22, P533; PINCUS SM, 1991, J CLIN MONITOR, V7, P335, DOI 10.1007/BF01619355; Pistarini C, 2009, FUNCT NEUROL, V24, P169; Plum F., 1983, DIAGNOSIS STUPOR COM; Rezek IA, 1998, IEEE T BIO-MED ENG, V45, P1186, DOI 10.1109/10.709563; Sara M, 2010, NONLIN DYNAM PSYCHOL, V14, P1; Schnakers C, 2005, NEUROPSYCHOL REHABIL, V15, P381, DOI 10.1080/09602010443000524; Schnakers C, 2008, BRAIN INJURY, V22, P926, DOI 10.1080/02699050802530565; Schnakers C, 2004, REANIMATION, V13, DOI 10.1016/j.reaurg.2004.03.019; Schnakers C, 2008, BRAIN INJURY, V22, P786, DOI 10.1080/02699050802403557; Schnakers C, 2006, ANN NEUROL, V60, P744, DOI 10.1002/ana.20919; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; SHANNON CE, 1948, BELL SYST TECH J, V27, P623, DOI 10.1002/j.1538-7305.1948.tb00917.x; Vakkuri A, 2004, ACTA ANAESTH SCAND, V48, P145, DOI 10.1111/j.0001-5172.2004.00323.x; Viertio-Oja H, 2004, ACTA ANAESTH SCAND, V48, P154, DOI 10.1111/j.0001-5172.2004.00322.x; Vivien B, 2007, INTENS CARE MED, V33, P919, DOI 10.1007/s00134-007-0607-1; Wennervirta J, 2007, INTENS CARE MED, V33, P133, DOI 10.1007/s00134-006-0429-6; Wheeler P, 2005, J NEUROSURG ANESTH, V17, P86, DOI 10.1097/01.ana.0000151408.62650.b5; Wu DY, 2011, CLIN NEUROPHYSIOL, V122, P490, DOI 10.1016/j.clinph.2010.05.036; Young GB, 2000, J CLIN NEUROPHYSIOL, V17, P473, DOI 10.1097/00004691-200009000-00006; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8; ZWEIG MH, 1993, CLIN CHEM, V39, P561	48	84	91	0	14	C I C-EDIZIONI INT SRL	ROME	CORSO TRIESTE, 42, 00198 ROME, ITALY	0393-5264	1971-3274		FUNCT NEUROL	Funct. Neurol.	JAN-MAR	2011	26	1					25	30					6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	789OJ	WOS:000292524900004	21693085				2022-02-06	
J	Bagiella, E; Novack, TA; Ansel, B; Diaz-Arrastia, R; Dikmen, S; Hart, T; Temkin, N				Bagiella, Emilia; Novack, Thomas A.; Ansel, Beth; Diaz-Arrastia, Ramon; Dikmen, Sureyya; Hart, Tessa; Temkin, Nancy			Measuring Outcome in Traumatic Brain Injury Treatment Trials: Recommendations From the Traumatic Brain Injury Clinical Trials Network	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						clinical trial; global test procedure; outcome measures; traumatic brain injury	POSTTRAUMATIC SEIZURES; RANDOMIZED-TRIAL; SCALE; MISCLASSIFICATION; PREVENTION; PHENYTOIN; VALPROATE; 1-YEAR	Background: Traumatic brain injury (TBI) involves several aspects of a patient's condition, including physical, mental, emotional, cognitive, social, and functional changes. Therefore, a clinical trial with individuals with TBI should consider outcome measures that reflect their global status. Methods: We present the work of the National Institute of Child Health and Development-sponsored Traumatic Brain Injury Clinical Trials Network Outcome Measures subcommittee and its choice of outcome measures for a phase III clinical trial of patients with complicated mild to severe TBI. Results: Onthe basis of theoretical and practical considerations, the subcommittee recommended the adoption of a core of 9 measures that cover 2 different areas of recovery: functional and cognitive. These measures are the Extended Glasgow Outcome Scale; the Controlled Oral Word Association Test; the Trail Making Test, Parts A and B; the California Verbal Learning Test-II; the Wechsler Adult Intelligence Scale-III Digit Span subtest; the Wechsler Adult Intelligence Scale-III Processing Speed Index; and the Stroop Color-Word Matching Test, Parts 1 and 2. Conclusions: The statistical methods proposed to analyze these measures using a global test procedure, along with research and methodological and regulatory issues involved with the use of multiple outcomes in a clinical trial, are discussed.	[Bagiella, Emilia] Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, New York, NY 10032 USA; [Novack, Thomas A.] Univ Alabama Birmingham, Birmingham, AL USA; [Ansel, Beth] NICHHD, Natl Ctr Med Rehabil Res, Bethesda, MD 20892 USA; [Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Dikmen, Sureyya] Univ Washington, Sch Med, Dept Rehabil Med, Div Clin Psychol & Neuropsychol, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Hart, Tessa] Moss Rehabil Res Inst, Philadelphia, PA USA		Bagiella, E (corresponding author), Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, 722 W 168th St, New York, NY 10032 USA.	eb51@columbia.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	National Institute of Child Health and DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042823, U01HD042738, U01HD042687, U01HD042736, U01HD042678, U01HD042686, U01HD042653, U01HD042689, U01HD042652]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042678, U01HD042653, U01HD042823, U01HD042689, U01HD042736, U01HD042687, U01HD042738, U01HD042686] Funding Source: NIH RePORTER	The work of the Traumatic Brain Injury Clinical Trials Network Outcome Measures Subcommittee is supported by National Institute of Child Health and Development grants U01HD042823, U01HD042738, U01HD042687, U01HD042736, U01HD042678, U01HD042686, U01HD042653, U01HD042689, and U01HD042652 to 8 clinical sites and a data-coordinating center.	Benton A, 2000, MULTILINGUAL APHASIA; Benton A., 1994, CONTRIBUTIONS NEUROP; Choi SC, 2002, J NEUROTRAUM, V19, P17, DOI 10.1089/089771502753460204; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; Delis D.C., 2000, CALIFORNIA VERBAL LE; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; DODRILL CB, 1978, EPILEPSIA, V19, P611, DOI 10.1111/j.1528-1157.1978.tb05041.x; Fioravanti M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000269.pub3; Hart T, 2003, ARCH PHYS MED REHAB, V84, P221, DOI 10.1053/apmr.2003.50023; JENNETT B, 1975, LANCET, V1, P480; Jennett B., 1997, HEAD INJURY, P439; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; KREUTZER JS, 1993, J HEAD TRAUMA REHAB, V8, P47; LEHMACHER W, 1991, BIOMETRICS, V47, P511, DOI 10.2307/2532142; Leon-Carrion J, 2000, NEUROREHABILITATION, V14, P33; LEVIN HS, 1991, J NEUROL SCI, V103, pS39; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Lu J, 2008, J NEUROTRAUM, V25, P641, DOI 10.1089/neu.2007.0510; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Murray D. M., 1998, DESIGN ANAL GROUP RA; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Ragnarsson KT, 2006, J HEAD TRAUMA REHAB, V21, P379, DOI 10.1097/00001199-200609000-00002; Rapport LJ, 1998, ARCH PHYS MED REHAB, V79, P629, DOI 10.1016/S0003-9993(98)90035-1; Reitan RM, 2004, ARCH CLIN NEUROPSYCH, V19, P281, DOI 10.1016/S0887-6177(03)00042-8; Reitan RM, 1992, TRAIL MAKING TEST MA; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tilley BC, 1996, STROKE, V27, P2136, DOI 10.1161/01.STR.27.11.2136; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; WECHSLER D, 1997, ADULT INTELLIGENCE S, V21; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wilson JT, 2001, J NEUROL NEUROSUR PS, V70, P267; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wolfson, 1993, HALSTEAD REITAN NEUR; Zafonte R, 2009, J NEUROTRAUM, V26, P2207, DOI 10.1089/neu.2009.1015	43	84	84	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2010	25	5					375	382		10.1097/HTR.0b013e3181d27fe3			8	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	649JR	WOS:000281765400011	20216459	Green Accepted			2022-02-06	
